assay_cell_type,assay_organism,assay_category,src_assay_id,description,chembl_id,doc_id,tid,assay_subcellular_fraction,cell_id,assay_tissue,tissue_id,curated_by,assay_strain,src_id,variant_id,confidence_score,assay_tax_id,assay_id,assay_type,relationship_type,bao_format,assay_test_type
,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,CHEMBL615117,11087,12052,,,,,Autocuration,,1,,8,,1,B,H,BAO_0000019,
,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,CHEMBL615118,684,22226,,,,,Autocuration,,1,,0,,2,F,U,BAO_0000219,
,,,,,CHEMBL615119,15453,22226,,,,,Autocuration,,1,,0,,3,B,U,BAO_0000019,
,Bos taurus,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,CHEMBL615120,17841,104729,,,,,Autocuration,,1,,4,9913.0,4,B,H,BAO_0000249,
143B,Homo sapiens,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),CHEMBL615121,17430,80001,,163.0,,,Intermediate,,1,,1,9606.0,5,F,N,BAO_0000219,
143B,Homo sapiens,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),CHEMBL615122,17430,80001,,163.0,,,Intermediate,,1,,1,9606.0,6,F,N,BAO_0000219,
143B,Mus musculus,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,CHEMBL615123,13799,80001,,163.0,,,Intermediate,,1,,1,10090.0,7,F,N,BAO_0000219,
143B,Homo sapiens,,,In vitro cell cytotoxicity was determined against 143B cell line,CHEMBL615124,17774,80001,,163.0,,,Expert,,1,,1,9606.0,8,F,N,BAO_0000219,
143B,Homo sapiens,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,CHEMBL615125,3801,80001,,163.0,,,Intermediate,,1,,1,9606.0,9,F,N,BAO_0000219,
143B,Homo sapiens,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,CHEMBL615126,17430,80001,,163.0,,,Intermediate,,1,,1,9606.0,10,F,N,BAO_0000219,
143B,Homo sapiens,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,CHEMBL615127,17430,80001,,163.0,,,Intermediate,,1,,1,9606.0,11,F,N,BAO_0000219,
143B,Homo sapiens,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,CHEMBL615128,17774,80001,,163.0,,,Expert,,1,,1,9606.0,12,F,N,BAO_0000219,
,Staphylococcus aureus,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL857900,11324,50185,,,,,Intermediate,,1,,1,1280.0,13,F,N,BAO_0000218,
,Staphylococcus aureus,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615129,11324,50185,,,,,Intermediate,,1,,1,1280.0,14,F,N,BAO_0000218,
,Staphylococcus aureus,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615130,11324,50185,,,,,Intermediate,,1,,1,1280.0,15,F,N,BAO_0000218,
,Staphylococcus aureus,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",CHEMBL615131,11324,50185,,,,,Intermediate,,1,,1,1280.0,16,F,N,BAO_0000218,
,Rattus norvegicus,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,CHEMBL884521,11347,100122,,,,,Expert,,1,,9,10116.0,17,A,D,BAO_0000357,
,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615132,16474,12054,,,,,Autocuration,,1,,8,,18,B,H,BAO_0000357,
,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,CHEMBL615133,10091,12054,,,,,Autocuration,,1,,8,,19,B,H,BAO_0000019,
,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615134,16474,12054,,,,,Autocuration,,1,,8,,20,B,H,BAO_0000357,
,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615135,16474,12054,,,,,Autocuration,,1,,8,,21,B,H,BAO_0000357,
,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),CHEMBL615136,16474,12054,,,,,Autocuration,,1,,8,,22,B,H,BAO_0000357,
,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,CHEMBL615137,16474,12054,,,,,Autocuration,,1,,8,,23,B,H,BAO_0000357,
,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,CHEMBL615138,16474,12054,,,,,Autocuration,,1,,8,,24,B,H,BAO_0000357,
,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",CHEMBL836324,14352,22226,,,,,Autocuration,,1,,0,,25,B,U,BAO_0000219,
,Oryctolagus cuniculus,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,CHEMBL615139,5646,12054,,,,,Autocuration,,1,,8,9986.0,26,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),CHEMBL615140,5646,12054,,,,,Autocuration,,1,,8,9986.0,27,B,H,BAO_0000357,
,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,CHEMBL615141,10997,12426,,,,,Autocuration,,1,,8,,28,B,H,BAO_0000219,
,soya bean,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,CHEMBL615142,6309,12054,,,,,Autocuration,,1,,8,3847.0,29,B,H,BAO_0000357,
,Glycine max,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,CHEMBL615143,167,12054,,,,,Autocuration,,1,,8,3847.0,30,B,H,BAO_0000357,
,Glycine max,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,CHEMBL615144,167,12054,,,,,Autocuration,,1,,8,3847.0,31,B,H,BAO_0000357,
,Glycine max,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,CHEMBL872867,11087,12054,,,,,Autocuration,,1,,8,3847.0,32,B,H,BAO_0000357,
,Glycine max,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,CHEMBL615145,11087,12054,,,,,Autocuration,,1,,8,3847.0,33,B,H,BAO_0000357,
,Glycine max,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,CHEMBL615146,13622,12054,,,,,Autocuration,,1,,8,3847.0,34,B,H,BAO_0000357,
,Glycine max,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,CHEMBL615147,13622,12054,,,,,Autocuration,,1,,8,3847.0,35,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,CHEMBL615148,11347,22226,,,,,Autocuration,,1,,0,10116.0,36,A,U,BAO_0000019,
,Escherichia coli,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,CHEMBL615149,5926,22226,,,,,Autocuration,,1,,0,562.0,37,B,U,BAO_0000019,
,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,CHEMBL615150,4567,22226,,,,,Autocuration,,1,,0,,38,B,U,BAO_0000019,
,,,,Dissociation constant towards 16S rRNA construct A,CHEMBL615151,3782,22222,,,,,Intermediate,,1,,3,,39,B,M,BAO_0000225,
,,,,Dissociation constant towards 16S rRNA construct B,CHEMBL615152,3782,22222,,,,,Intermediate,,1,,3,,40,B,M,BAO_0000225,
,Escherichia coli,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,CHEMBL615153,4466,100263,,,,,Expert,,1,,3,562.0,41,B,M,BAO_0000225,
,Escherichia coli,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,CHEMBL615154,6592,100263,,,,,Expert,,1,,3,562.0,42,B,M,BAO_0000225,
,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL615155,898,13053,,,,,Autocuration,,1,,8,,43,B,H,BAO_0000019,
,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL615156,898,13053,,,,,Autocuration,,1,,8,,44,B,H,BAO_0000019,
,Homo sapiens,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,CHEMBL615157,13163,20001,,,,,Autocuration,,1,,8,9606.0,45,B,H,BAO_0000019,
,Homo sapiens,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,CHEMBL615158,13163,20001,,,,,Autocuration,,1,,8,9606.0,46,B,H,BAO_0000019,
,Rattus norvegicus,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",CHEMBL615159,10691,12971,,,,,Expert,,1,,9,10116.0,47,B,D,BAO_0000019,
,Rattus norvegicus,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",CHEMBL615172,10691,12971,,,,,Expert,,1,,9,10116.0,48,B,D,BAO_0000019,
,Rattus norvegicus,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",CHEMBL615173,10691,12971,,,,,Expert,,1,,9,10116.0,49,B,D,BAO_0000019,
,Rattus norvegicus,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",CHEMBL615174,10691,12971,,,,,Expert,,1,,9,10116.0,50,B,D,BAO_0000019,
,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),CHEMBL884518,898,13053,,,,,Autocuration,,1,,8,,51,B,H,BAO_0000019,
,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),CHEMBL615175,912,11512,,,,,Autocuration,,1,,8,,52,B,H,BAO_0000357,
,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,CHEMBL615176,912,11512,,,,,Autocuration,,1,,8,,53,B,H,BAO_0000357,
,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,CHEMBL615177,912,11512,,,,,Autocuration,,1,,8,,54,B,H,BAO_0000357,
,Rattus norvegicus,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,CHEMBL615178,15103,104740,Membranes,,,,Autocuration,,1,,5,10116.0,55,B,D,BAO_0000249,
1A9,Homo sapiens,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,CHEMBL615179,5116,80002,,506.0,,,Intermediate,,1,,1,9606.0,56,F,N,BAO_0000219,
Oocytes,Rattus norvegicus,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,CHEMBL615180,14578,104835,,,,,Autocuration,,1,,7,10116.0,57,F,D,BAO_0000219,
Oocytes,Rattus norvegicus,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,CHEMBL615181,14578,104821,,,,,Autocuration,,1,,7,10116.0,58,F,D,BAO_0000219,
Oocytes,Rattus norvegicus,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,CHEMBL615182,14578,104848,,,,,Autocuration,,1,,7,10116.0,59,F,D,BAO_0000219,
1A9,Homo sapiens,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,CHEMBL615183,4787,80002,,506.0,,,Expert,,1,,1,9606.0,60,F,N,BAO_0000219,
1A9,Homo sapiens,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,CHEMBL615184,4787,80002,,506.0,,,Intermediate,,1,,1,9606.0,61,F,N,BAO_0000219,
1A9,Homo sapiens,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,CHEMBL615185,3547,80002,,506.0,,,Intermediate,,1,,1,9606.0,62,F,N,BAO_0000219,
1A9,Homo sapiens,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,CHEMBL615186,3547,80002,,506.0,,,Intermediate,,1,,1,9606.0,63,F,N,BAO_0000219,
1A9,Homo sapiens,,,Effective dose of compound against replication of 1A9 cell line was evaluated,CHEMBL615187,6726,80002,,506.0,,,Intermediate,,1,,1,9606.0,64,F,N,BAO_0000219,
1A9,Homo sapiens,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,CHEMBL885343,3455,80002,,506.0,,,Expert,,1,,1,9606.0,65,F,N,BAO_0000219,
1A9,Homo sapiens,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),CHEMBL615188,5726,80002,,506.0,,,Intermediate,,1,,1,9606.0,66,F,N,BAO_0000219,
1A9,Homo sapiens,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,CHEMBL615189,5726,80002,,506.0,,,Intermediate,,1,,1,9606.0,67,F,N,BAO_0000219,
1A9,Homo sapiens,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,CHEMBL615190,5726,80002,,506.0,,,Intermediate,,1,,1,9606.0,68,F,N,BAO_0000219,
1A9,Homo sapiens,,,Inhibitory activity against Taxol resistant 1A9 cell lines,CHEMBL615191,3395,80002,,506.0,,,Intermediate,,1,,1,9606.0,69,F,N,BAO_0000219,
1A9,Homo sapiens,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,CHEMBL615192,3415,80002,,506.0,,,Expert,,1,,1,9606.0,70,F,N,BAO_0000219,
1A9,Homo sapiens,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,CHEMBL827083,3415,80002,,506.0,,,Expert,,1,,1,9606.0,71,F,N,BAO_0000219,
1A9,Homo sapiens,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,CHEMBL615193,17099,80002,,506.0,,,Expert,,1,,1,9606.0,72,F,N,BAO_0000219,
1A9,Homo sapiens,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,CHEMBL615194,17099,80002,,506.0,,,Intermediate,,1,,1,9606.0,73,F,N,BAO_0000219,
1A9,Homo sapiens,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,CHEMBL615195,17099,80002,,506.0,,,Intermediate,,1,,1,9606.0,74,F,N,BAO_0000219,
1A9,Homo sapiens,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,CHEMBL615196,17099,80002,,506.0,,,Intermediate,,1,,1,9606.0,75,F,N,BAO_0000219,
Jurkat,Homo sapiens,,,Inhibitory concentration against Jurkat cells,CHEMBL615197,17721,81072,,503.0,,,Intermediate,,1,,1,9606.0,76,F,N,BAO_0000219,
,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,CHEMBL615198,1229,22226,,,,,Intermediate,,1,,0,,77,F,U,BAO_0000019,
,Rattus norvegicus,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,CHEMBL615199,11347,100121,,,,,Expert,,1,,9,10116.0,78,A,D,BAO_0000357,
,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",CHEMBL615200,17117,11231,,,,,Expert,,1,,8,,79,B,H,BAO_0000357,
,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",CHEMBL615201,17117,11231,,,,,Expert,,1,,8,,80,B,H,BAO_0000357,
,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",CHEMBL615202,17117,11231,,,,,Expert,,1,,8,,81,B,H,BAO_0000357,
,Candida albicans,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",CHEMBL615203,11375,11231,Microsomes,,,,Autocuration,,1,,8,5476.0,82,B,H,BAO_0000251,
,Candida albicans,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",CHEMBL615204,11375,11231,Microsomes,,,,Autocuration,,1,,8,5476.0,83,B,H,BAO_0000251,
,Saccharomyces cerevisiae,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",CHEMBL615205,11375,11231,Microsomes,,,,Autocuration,,1,,8,4932.0,84,B,H,BAO_0000251,
,Saccharomyces cerevisiae,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",CHEMBL615206,11375,11231,Microsomes,,,,Autocuration,,1,,8,4932.0,85,B,H,BAO_0000251,
,Sus scrofa,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",CHEMBL615207,11375,12083,Microsomes,,Liver,2107.0,Autocuration,,1,,8,9823.0,86,B,H,BAO_0000251,
,Rattus norvegicus,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",CHEMBL827084,791,11231,,,,,Autocuration,,1,,8,10116.0,87,B,H,BAO_0000019,
,Rattus norvegicus,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",CHEMBL615208,791,11231,,,,,Autocuration,,1,,8,10116.0,88,B,H,BAO_0000019,
,Rattus norvegicus,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",CHEMBL615209,791,11231,,,,,Autocuration,,1,,8,10116.0,89,B,H,BAO_0000019,
,Rattus norvegicus,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",CHEMBL615210,11375,12083,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,90,B,D,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",CHEMBL615211,11375,12083,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,91,B,D,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",CHEMBL615212,153,12083,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,92,B,D,BAO_0000251,
,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),CHEMBL615213,8269,11377,,,,,Expert,,1,,8,,93,B,H,BAO_0000357,
,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,CHEMBL615273,8269,11377,,,,,Expert,,1,,8,,94,B,H,BAO_0000357,
HepG2,Homo sapiens,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,CHEMBL615274,17653,81020,,726.0,,,Expert,,1,,1,9606.0,95,F,N,BAO_0000219,
HepG2,Homo sapiens,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,CHEMBL615275,14277,81020,,726.0,,,Intermediate,,1,,1,9606.0,96,F,N,BAO_0000219,
HepG2,Homo sapiens,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,CHEMBL615276,1717,81020,,726.0,,,Intermediate,,1,,1,9606.0,97,F,N,BAO_0000219,
HepG2,Homo sapiens,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,CHEMBL615277,14091,81020,,726.0,,,Intermediate,,1,,1,9606.0,98,F,N,BAO_0000219,
HepG2,Homo sapiens,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,CHEMBL615326,14091,81020,,726.0,,,Intermediate,,1,,1,9606.0,99,F,N,BAO_0000219,
,Hepatitis B virus,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,CHEMBL883130,17653,50606,,,,,Expert,,1,,1,10407.0,100,F,N,BAO_0000218,
HepG2,Homo sapiens,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,CHEMBL884519,13105,81020,,726.0,,,Intermediate,,1,,1,9606.0,101,F,N,BAO_0000219,
HepG2,Homo sapiens,,,Concentration required to inhibit 50% of 2.2.15 cell line,CHEMBL615327,1717,81020,,726.0,,,Intermediate,,1,,1,9606.0,102,F,N,BAO_0000219,
HepG2,Homo sapiens,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,CHEMBL615328,13105,81020,,726.0,,,Intermediate,,1,,1,9606.0,103,A,N,BAO_0000219,
2.2.15,Homo sapiens,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,CHEMBL615329,13600,50587,,,,,Intermediate,,1,,1,9606.0,104,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,CHEMBL615330,13467,50587,,,,,Intermediate,,1,,1,9606.0,105,F,N,BAO_0000218,
2.2.15,Hepatitis B virus,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",CHEMBL615331,17477,50606,,,,,Expert,,1,,1,10407.0,106,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,In vitro anti-HBV activity in 2.2.15 cells,CHEMBL615332,1593,50587,,,,,Intermediate,,1,,1,9606.0,107,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,CHEMBL615333,1593,50587,,,,,Intermediate,,1,,1,9606.0,108,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,CHEMBL615334,15089,50587,,,,,Intermediate,,1,,1,9606.0,109,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,CHEMBL615335,15089,50587,,,,,Intermediate,,1,,1,9606.0,110,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,Cytotoxicity in 2.2.15 cells,CHEMBL615336,1593,50587,,,,,Intermediate,,1,,1,9606.0,111,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,Cytotoxicity in 2.2.15 cells; Not determined,CHEMBL615337,1593,50587,,,,,Intermediate,,1,,1,9606.0,112,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,CHEMBL615338,13600,50587,,,,,Intermediate,,1,,1,9606.0,113,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,CHEMBL615339,13467,50587,,,,,Intermediate,,1,,1,9606.0,114,F,N,BAO_0000218,
2.2.15,Homo sapiens,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,CHEMBL615340,13467,50587,,,,,Intermediate,,1,,1,9606.0,115,F,N,BAO_0000218,
HepG2,Homo sapiens,,,Antiviral activity against HBV was determined in 2.215 cell line,CHEMBL615341,14764,81020,,726.0,,,Intermediate,,1,,1,9606.0,116,F,N,BAO_0000219,
,Homo sapiens,,,Inhibition of 20-HETE synthesis in human renal microsomes,CHEMBL615342,6531,22226,Microsomes,,,,Autocuration,,1,,0,9606.0,117,B,U,BAO_0000251,
,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,CHEMBL615343,17322,22226,,,,,Autocuration,,1,,0,,118,B,U,BAO_0000019,
2008,Homo sapiens,,,Inhibitory concentration against 2008 (ovarian) cells,CHEMBL615344,17072,80612,,388.0,,,Intermediate,,1,,1,9606.0,119,F,N,BAO_0000219,
2008,Homo sapiens,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,CHEMBL615345,16936,80612,,388.0,,,Intermediate,,1,,1,9606.0,120,F,N,BAO_0000219,
2008,Homo sapiens,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),CHEMBL615346,16936,80612,,388.0,,,Intermediate,,1,,1,9606.0,121,F,N,BAO_0000219,
2008,Homo sapiens,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,CHEMBL615347,17146,80612,,388.0,,,Intermediate,,1,,1,9606.0,122,F,N,BAO_0000219,
2008,Homo sapiens,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,CHEMBL615348,17146,80612,,388.0,,,Intermediate,,1,,1,9606.0,123,F,N,BAO_0000219,
2008/R,Homo sapiens,,,In vitro inhibition of 2008/R ovarian cancer cell line,CHEMBL827085,10797,80613,,561.0,,,Intermediate,,1,,1,9606.0,124,F,N,BAO_0000219,
2008/R,Homo sapiens,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,CHEMBL615349,10797,80613,,561.0,,,Intermediate,,1,,1,9606.0,125,F,N,BAO_0000219,
2008/S,Homo sapiens,,,In vitro inhibition of 2008/S ovarian cancer cell line,CHEMBL615350,10797,80614,,389.0,,,Intermediate,,1,,1,9606.0,126,F,N,BAO_0000219,
2008/S,Homo sapiens,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,CHEMBL615351,10797,80614,,389.0,,,Intermediate,,1,,1,9606.0,127,F,N,BAO_0000219,
,Homo sapiens,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,CHEMBL615352,4823,100256,,,,,Expert,,1,,2,9606.0,128,B,S,BAO_0000220,
,Homo sapiens,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,CHEMBL615353,12912,100256,,,,,Intermediate,,1,,2,9606.0,129,B,S,BAO_0000220,
,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,CHEMBL615354,2957,100256,,,,,Expert,,1,,2,,130,B,S,BAO_0000220,
,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,CHEMBL615355,2957,100256,,,,,Expert,,1,,2,,131,B,S,BAO_0000220,
,,,,Inhibitory activity against 20S proteosome,CHEMBL615356,3260,100256,,,,,Intermediate,,1,,2,,132,B,S,BAO_0000220,
,Homo sapiens,,,Compound was tested for inhibitory activity against tryptase,CHEMBL615357,3451,22226,,,,,Autocuration,,1,,0,9606.0,133,B,U,BAO_0000019,
HepG2,Homo sapiens,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,CHEMBL615358,13885,81020,,726.0,,,Intermediate,,1,,1,9606.0,134,F,N,BAO_0000219,
HepG2,Homo sapiens,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,CHEMBL827086,13885,81020,,726.0,,,Intermediate,,1,,1,9606.0,135,F,N,BAO_0000219,
,,,,Compound was tested for the inhibition of Alpha-glucosidase,CHEMBL615359,3676,22226,,,,,Autocuration,,1,,0,,136,B,U,BAO_0000019,
,,,,Inhibitory concentration against human neutrophil elastase (HNE),CHEMBL615360,6043,235,,,,,Autocuration,,1,,8,,137,B,H,BAO_0000357,
,Rattus norvegicus,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,CHEMBL615361,11140,22226,,,Heart,948.0,Autocuration,,1,,0,10116.0,138,F,U,BAO_0000218,
,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615362,10543,19640,,,,,Autocuration,,1,,8,,139,F,H,BAO_0000019,
,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615363,10543,19640,,,,,Expert,,1,,8,,140,F,H,BAO_0000019,
,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615364,10543,19640,,,,,Autocuration,,1,,8,,141,B,H,BAO_0000357,
,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,CHEMBL615365,10543,19640,,,,,Expert,,1,,8,,142,F,H,BAO_0000019,
P338,Mus musculus,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,CHEMBL615366,11365,80360,,524.0,,,Intermediate,,1,,1,10090.0,143,F,N,BAO_0000219,
P338,Mus musculus,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,CHEMBL615367,11365,80360,,524.0,,,Intermediate,,1,,1,10090.0,144,F,N,BAO_0000219,
PBL,Homo sapiens,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,CHEMBL615368,11803,80384,,554.0,,,Intermediate,,1,,1,9606.0,145,F,N,BAO_0000219,
,Ovis aries,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,CHEMBL615369,11803,22226,,,,,Autocuration,,1,,0,9940.0,146,F,U,BAO_0000019,
,Ovis aries,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,CHEMBL615370,11803,22226,,,,,Autocuration,,1,,0,9940.0,147,F,U,BAO_0000019,
,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),CHEMBL615673,12278,191,,,,,Autocuration,,1,,8,,148,B,H,BAO_0000357,
,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,CHEMBL615674,8249,22226,,,,,Autocuration,,1,,0,9606.0,149,F,U,BAO_0000019,
,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,CHEMBL615675,8249,22226,,,,,Autocuration,,1,,0,9606.0,150,F,U,BAO_0000019,
CCRF-CEM,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,CHEMBL615676,8249,22226,,635.0,,,Autocuration,,1,,0,9606.0,151,F,U,BAO_0000219,
CCRF-CEM,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,CHEMBL615677,8249,22226,,635.0,,,Autocuration,,1,,0,9606.0,152,F,U,BAO_0000219,
CCRF-CEM,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,CHEMBL615678,8249,22226,,635.0,,,Autocuration,,1,,0,9606.0,153,F,U,BAO_0000219,
CCRF-CEM,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,CHEMBL615679,8249,22226,,635.0,,,Autocuration,,1,,0,9606.0,154,F,U,BAO_0000219,
,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,CHEMBL615680,8249,22226,,,,,Autocuration,,1,,0,9606.0,155,F,U,BAO_0000019,
,Homo sapiens,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,CHEMBL615681,8249,22226,,,,,Autocuration,,1,,0,9606.0,156,F,U,BAO_0000019,
,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,CHEMBL857972,16992,104290,,,,,Autocuration,,1,,6,,157,B,H,BAO_0000249,
,Streptococcus pyogenes,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,CHEMBL857899,10543,50264,,,,,Intermediate,,1,,1,1314.0,158,F,N,BAO_0000218,
,Human herpesvirus 3,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),CHEMBL615371,17833,50527,,,,,Intermediate,,1,,1,10335.0,159,F,N,BAO_0000218,
HEL,vericilla zoster virus,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,CHEMBL615372,17290,50527,,468.0,,,Expert,,1,,1,10335.0,160,F,N,BAO_0000218,
,vericilla zoster virus,,,Antiviral activity against 07/1 strain of VZV; ND: No data,CHEMBL615373,17290,50527,,,,,Intermediate,,1,,1,10335.0,161,F,N,BAO_0000218,
,vericilla zoster virus,,,Antiviral activity against 07/1 strain of VZV; ND=No data,CHEMBL615374,17290,50527,,,,,Intermediate,,1,,1,10335.0,162,F,N,BAO_0000218,
,escherichia cloac,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",CHEMBL615375,10932,50145,,,,,Intermediate,,1,,1,561.0,163,F,N,BAO_0000218,
,,,,Ratio of Ki at A2 to Ki at A1 receptors,CHEMBL615376,9707,22226,,,,,Autocuration,,1,,0,,164,B,U,BAO_0000019,
,Candida albicans,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",CHEMBL615377,2346,11143,,,,,Expert,,1,,8,5476.0,165,B,H,BAO_0000249,
,Candida glabrata CBS 138,,,"Inhibition of 1,3-beta-glucan synthase",CHEMBL615378,2205,18077,,,,,Expert,,1,,8,284593.0,166,B,H,BAO_0000357,
1-87 tumor cell line,Homo sapiens,,,Inhibition of growth of 1-87 human tumor cell line,CHEMBL615379,11900,80609,,832.0,,,Intermediate,,1,,1,9606.0,167,F,N,BAO_0000219,
,Rattus norvegicus,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,CHEMBL615380,14864,12166,,,,,Expert,,1,,9,10116.0,168,B,D,BAO_0000219,
,Glycine max,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),CHEMBL615381,16474,100171,,,,,Autocuration,,1,,9,3847.0,169,B,D,BAO_0000357,
,Glycine max,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,CHEMBL615382,16474,100171,,,,,Autocuration,,1,,9,3847.0,170,B,D,BAO_0000357,
,Glycine max,,,% inhibition against soybean 1-lipoxygenase (SLO),CHEMBL615383,16474,100171,,,,,Autocuration,,1,,9,3847.0,171,B,D,BAO_0000357,
,Glycine max,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,CHEMBL615384,16474,100171,,,,,Autocuration,,1,,9,3847.0,172,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,CHEMBL615385,3094,100171,,,,,Autocuration,,1,,9,3847.0,173,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,CHEMBL615386,3094,100171,,,,,Autocuration,,1,,9,3847.0,174,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,CHEMBL615387,3094,100171,,,,,Autocuration,,1,,9,3847.0,175,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,CHEMBL615388,3094,100171,,,,,Autocuration,,1,,9,3847.0,176,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,CHEMBL615214,3094,100171,,,,,Autocuration,,1,,9,3847.0,177,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,CHEMBL827087,3094,100171,,,,,Autocuration,,1,,9,3847.0,178,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,CHEMBL615215,3094,100171,,,,,Autocuration,,1,,9,3847.0,179,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,CHEMBL615216,3094,100171,,,,,Autocuration,,1,,9,3847.0,180,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,CHEMBL615217,3094,100171,,,,,Autocuration,,1,,9,3847.0,181,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,CHEMBL615218,3094,100171,,,,,Autocuration,,1,,9,3847.0,182,B,D,BAO_0000357,
,Glycine max,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,CHEMBL615219,3094,100171,,,,,Autocuration,,1,,9,3847.0,183,B,D,BAO_0000357,
,Mus musculus,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,CHEMBL615220,10413,22226,,,,,Autocuration,,1,,0,10090.0,184,B,U,BAO_0000019,
C3H 10T1/2,Mus musculus,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),CHEMBL615221,16929,80049,,294.0,,,Intermediate,,1,,1,10090.0,185,F,N,BAO_0000219,
,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,CHEMBL615222,1229,22226,,,,,Intermediate,,1,,0,,186,F,U,BAO_0000019,
,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),CHEMBL615223,16587,11489,,,,,Autocuration,,1,,8,,187,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),CHEMBL615224,16587,11862,,,,,Autocuration,,1,,8,,188,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,CHEMBL615225,16587,11862,,,,,Autocuration,,1,,8,,189,B,H,BAO_0000357,
,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,CHEMBL615226,16587,11489,,,,,Autocuration,,1,,8,,190,B,H,BAO_0000357,
,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,CHEMBL615227,16587,11862,,,,,Autocuration,,1,,8,,191,B,H,BAO_0000357,
,Bos taurus,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,CHEMBL615228,8058,12347,,,,,Expert,,1,,9,9913.0,192,F,D,BAO_0000019,
,Rattus norvegicus,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,CHEMBL615229,9065,100120,,,,,Expert,,1,,9,10116.0,193,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,CHEMBL615230,8865,100120,,,Adrenal gland,2369.0,Expert,,1,,9,10116.0,194,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of rat adrenal 11-beta-hydroxylase,CHEMBL615231,9066,100120,,,,,Expert,,1,,9,10116.0,195,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of rat adrenal 11-beta-hydroxylase,CHEMBL884520,8394,100120,,,,,Expert,,1,,9,10116.0,196,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,CHEMBL615232,8394,100120,,,,,Expert,,1,,9,10116.0,197,B,D,BAO_0000357,
,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,CHEMBL615233,6431,10328,,,,,Autocuration,,1,,8,,198,B,H,BAO_0000019,
,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,CHEMBL827088,6431,11490,,,,,Autocuration,,1,,8,,199,B,H,BAO_0000357,
,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,CHEMBL615234,6431,11490,,,,,Autocuration,,1,,8,,200,B,H,BAO_0000357,
,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,CHEMBL615235,9295,11134,,,,,Autocuration,,1,,8,,201,F,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615236,10193,12052,,,,,Autocuration,,1,,8,,202,B,H,BAO_0000019,
,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,CHEMBL615237,13622,11134,,,,,Autocuration,,1,,8,,203,B,H,BAO_0000019,
,,,,Inhibitory concentration against human platelet 12-lipoxygenase,CHEMBL615238,12079,11134,,,,,Autocuration,,1,,8,,204,F,H,BAO_0000019,
,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,CHEMBL615239,13622,11134,,,,,Autocuration,,1,,8,,205,B,H,BAO_0000019,
,Homo sapiens,,,Inhibitory concentration against human platelet 12-lipoxygenase,CHEMBL615240,12079,11134,,,,,Autocuration,,1,,9,9606.0,206,F,D,BAO_0000019,
,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,CHEMBL615241,13500,11835,,,,,Expert,,1,,8,,207,B,H,BAO_0000019,
,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,CHEMBL615242,13723,11601,,,,,Expert,,1,,8,,208,B,H,BAO_0000357,
,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),CHEMBL615243,16474,11134,,,,,Autocuration,,1,,8,,209,B,H,BAO_0000019,
,,,,Inhibitory activity against human platelet 12-lipoxygenase,CHEMBL615244,1630,11134,,,,,Autocuration,,1,,8,,210,B,H,BAO_0000019,
,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,CHEMBL615245,167,11134,,,,,Autocuration,,1,,8,,211,B,H,BAO_0000019,
,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),CHEMBL615246,16474,11134,,,,,Autocuration,,1,,8,,212,B,H,BAO_0000019,
,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,CHEMBL615247,167,11134,,,,,Autocuration,,1,,8,,213,B,H,BAO_0000019,
,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,CHEMBL615248,16474,11134,,,,,Autocuration,,1,,8,,214,B,H,BAO_0000019,
,,,,Inhibitory activity towards porcine 12-lipoxygenase,CHEMBL615249,10091,11601,,,,,Autocuration,,1,,8,,215,B,H,BAO_0000357,
,,,,Tested for inhibition against porcine 12-LO,CHEMBL615250,11966,11601,,,,,Autocuration,,1,,8,,216,B,H,BAO_0000357,
,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,CHEMBL615251,951,12052,,,,,Autocuration,,1,,8,,217,B,H,BAO_0000019,
,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,CHEMBL615252,10997,12052,,,,,Autocuration,,1,,8,,218,B,H,BAO_0000019,
,,,,In vitro inhibition of rat platelet 12-lipoxygenase,CHEMBL828340,10193,12052,,,,,Expert,,1,,8,,219,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615253,10193,12052,,,,,Autocuration,,1,,8,,220,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,CHEMBL615254,10193,12052,,,,,Autocuration,,1,,8,,221,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,CHEMBL615255,10193,12052,,,,,Autocuration,,1,,8,,222,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,CHEMBL615256,10193,12052,,,,,Autocuration,,1,,8,,223,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,CHEMBL615257,10193,12052,,,,,Autocuration,,1,,8,,224,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,CHEMBL615258,11087,12052,,,,,Autocuration,,1,,8,,225,B,H,BAO_0000019,
41M,Homo sapiens,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,CHEMBL615259,15569,80007,,621.0,,,Intermediate,,1,,1,9606.0,226,F,N,BAO_0000219,
41M,Homo sapiens,,,In vitro antitumor activity against 41M cell line.,CHEMBL615260,12989,80007,,621.0,,,Expert,,1,,1,9606.0,227,F,N,BAO_0000219,
41M,Homo sapiens,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,CHEMBL615261,16745,80007,,621.0,,,Intermediate,,1,,1,9606.0,228,F,N,BAO_0000219,
41M,Homo sapiens,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,CHEMBL615262,15569,80007,,621.0,,,Intermediate,,1,,1,9606.0,229,F,N,BAO_0000219,
41M,Homo sapiens,,,In vitro antitumor activity against 41McisR cell line.,CHEMBL615263,12989,80007,,621.0,,,Expert,,1,,1,9606.0,230,F,N,BAO_0000219,
41M,Homo sapiens,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,CHEMBL838393,12989,80007,,621.0,,,Expert,,1,,1,9606.0,231,F,N,BAO_0000219,
41M,Homo sapiens,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,CHEMBL615264,16745,80007,,621.0,,,Intermediate,,1,,1,9606.0,232,F,N,BAO_0000219,
,Homo sapiens,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),CHEMBL615265,6210,84,,,,,Expert,,1,,9,9606.0,233,B,D,BAO_0000357,
,Homo sapiens,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),CHEMBL615266,6210,68,,,,,Expert,,1,,9,9606.0,234,B,D,BAO_0000357,
,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),CHEMBL615267,6226,68,,,,,Expert,,1,,8,,235,B,H,BAO_0000357,
,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,CHEMBL615268,17855,10201,,,,,Expert,,1,,8,,236,B,H,BAO_0000357,
,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,CHEMBL615269,17855,10201,,,,,Expert,,1,,8,,237,B,H,BAO_0000357,
,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,CHEMBL615270,17855,10201,,,,,Expert,,1,,8,,238,B,H,BAO_0000357,
,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",CHEMBL615271,10413,12220,,,,,Autocuration,,1,,8,,239,B,H,BAO_0000357,
,Escherichia coli,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",CHEMBL615272,10413,11303,,,,,Autocuration,,1,,8,562.0,240,B,H,BAO_0000357,
,Escherichia coli,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",CHEMBL615103,10413,11303,,,,,Autocuration,,1,,8,562.0,241,B,H,BAO_0000357,
,Escherichia coli,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",CHEMBL615104,10413,11303,,,,,Autocuration,,1,,8,562.0,242,B,H,BAO_0000357,
,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",CHEMBL615105,10413,12220,,,,,Autocuration,,1,,8,,243,B,H,BAO_0000357,
,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",CHEMBL872866,10413,12220,,,,,Autocuration,,1,,8,,244,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615106,7587,11303,,,,,Autocuration,,1,,8,9823.0,245,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",CHEMBL615107,7587,11303,,,,,Autocuration,,1,,8,9823.0,246,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",CHEMBL615108,7587,11303,,,,,Autocuration,,1,,8,9823.0,247,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",CHEMBL615109,7587,11303,,,,,Autocuration,,1,,8,9823.0,248,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615110,7587,11303,,,,,Autocuration,,1,,8,9823.0,249,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",CHEMBL840105,7587,11303,,,,,Autocuration,,1,,8,9823.0,250,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",CHEMBL615111,7587,11303,,,,,Autocuration,,1,,8,9823.0,251,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",CHEMBL615112,7587,11303,,,,,Autocuration,,1,,8,9823.0,252,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",CHEMBL615113,7587,11303,,,,,Autocuration,,1,,8,9823.0,253,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",CHEMBL615114,7587,11303,,,,,Autocuration,,1,,8,9823.0,254,B,H,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",CHEMBL615115,7587,11303,,,,,Autocuration,,1,,8,9823.0,255,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",CHEMBL615116,7587,11303,,,,,Autocuration,,1,,8,9823.0,256,B,H,BAO_0000019,
,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",CHEMBL615698,7323,11303,,,,,Autocuration,,1,,8,,257,B,H,BAO_0000357,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",CHEMBL615699,7587,22226,,,,,Autocuration,,1,,0,9823.0,258,B,U,BAO_0000019,
,Sus scrofa,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",CHEMBL615700,7587,22226,,,,,Autocuration,,1,,0,9823.0,259,B,U,BAO_0000019,
,Saccharomyces cerevisiae,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,CHEMBL615701,13750,100249,,,,,Expert,,1,,8,4932.0,260,B,H,BAO_0000357,
,Rattus norvegicus,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,CHEMBL615702,7662,22226,,,,,Autocuration,,1,,0,10116.0,261,B,U,BAO_0000019,
,Rattus norvegicus,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,CHEMBL615703,7662,22226,,,,,Autocuration,,1,,0,10116.0,262,B,U,BAO_0000019,
,Rattus norvegicus,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",CHEMBL615704,7662,22226,,,,,Autocuration,,1,,0,10116.0,263,B,U,BAO_0000019,
,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",CHEMBL615705,12211,104698,,,,,Autocuration,,1,,6,,264,F,H,BAO_0000019,
,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",CHEMBL615706,12211,104698,,,,,Autocuration,,1,,6,,265,F,H,BAO_0000019,
,Cavia porcellus,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,CHEMBL615707,12211,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,266,F,D,BAO_0000221,
,,,,Stimulatory activity of intragastric pressure was tested in the rat,CHEMBL615708,12211,10623,,,,,Expert,,1,,8,,267,F,H,BAO_0000019,
,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,CHEMBL615709,15453,121,,,,,Autocuration,,1,,8,,268,B,H,BAO_0000357,
,Rattus norvegicus,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),CHEMBL615710,11884,22226,,,,,Autocuration,,1,,0,10116.0,269,F,U,BAO_0000218,
,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,CHEMBL615711,7185,12688,,,,,Autocuration,,1,,8,,270,F,H,BAO_0000019,
,Homo sapiens,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,CHEMBL615712,6876,121,,,,,Expert,,1,,9,9606.0,271,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,CHEMBL836325,6876,121,,,,,Expert,,1,,9,9606.0,272,B,D,BAO_0000357,
,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,CHEMBL615713,11863,12198,,,,,Autocuration,,1,,8,,273,F,H,BAO_0000019,
,,,,Inhibition constant of high-affinity 5-HT uptake,CHEMBL615714,11863,12198,,,,,Autocuration,,1,,8,,274,B,H,BAO_0000357,
,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,CHEMBL615715,11863,12198,,,,,Autocuration,,1,,8,,275,F,H,BAO_0000019,
,,,,Maximum rate was determined for high affinity transport of 5-HT,CHEMBL615716,11863,12198,,,,,Autocuration,,1,,8,,276,F,H,BAO_0000019,
,,,,Compound was tested for agonistic activity against 5-HT uptake,CHEMBL615717,4639,104714,,,,,Autocuration,,1,,4,,277,F,H,BAO_0000019,
,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,CHEMBL881818,15796,10577,,,,,Expert,,1,,8,,278,B,H,BAO_0000019,
,Bos taurus,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,CHEMBL884540,15796,105,,,,,Expert,,1,,8,9913.0,279,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,CHEMBL615718,12801,104744,,,,,Autocuration,,1,,5,10116.0,280,B,D,BAO_0000224,
,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,CHEMBL615719,12801,104744,,,,,Autocuration,,1,,4,,281,B,H,BAO_0000224,
,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,CHEMBL615720,12120,104744,Membranes,,,,Autocuration,,1,,4,,282,B,H,BAO_0000249,
,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,CHEMBL615721,12120,104744,Membranes,,,,Autocuration,,1,,4,,283,B,H,BAO_0000249,
,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615722,11963,104744,,,,,Autocuration,,1,,4,,284,B,H,BAO_0000019,
,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,CHEMBL615723,11701,51,,,,,Autocuration,,1,,8,,285,F,H,BAO_0000019,
,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615724,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,286,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615725,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,287,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615726,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,288,B,H,BAO_0000221,
,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),CHEMBL615727,16394,10576,,,,,Autocuration,,1,,8,,289,F,H,BAO_0000218,In vivo
,Cavia porcellus,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,CHEMBL615728,11574,105570,,,,,Intermediate,,1,,9,10141.0,290,F,D,BAO_0000019,
CHO,,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL857971,15779,279,,449.0,,,Autocuration,,1,,8,,291,B,H,BAO_0000219,
,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,CHEMBL615729,15363,107,,,,,Autocuration,,1,,8,,292,B,H,BAO_0000357,
,Rattus norvegicus,,,Efficacy against 5-hydroxytryptamine 2A receptor,CHEMBL615730,15363,12687,,,,,Expert,,1,,9,10116.0,293,F,D,BAO_0000019,
,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,CHEMBL615731,15329,12687,,,,,Expert,,1,,8,,294,F,H,BAO_0000019,
,,,,Relative potency towards 5-HT2A receptor of rat tail artery,CHEMBL615732,15329,12687,,,,,Expert,,1,,8,,295,F,H,BAO_0000019,
,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,CHEMBL615733,15329,12687,,,,,Expert,,1,,8,,296,F,H,BAO_0000019,
,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,CHEMBL615734,15329,12687,,,,,Expert,,1,,8,,297,F,H,BAO_0000019,
,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,CHEMBL615735,15329,12687,,,,,Autocuration,,1,,8,,298,F,H,BAO_0000019,
,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,CHEMBL615736,15329,12687,,,,,Expert,,1,,8,,299,F,H,BAO_0000019,
,Cavia porcellus,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL615737,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,300,F,D,BAO_0000221,
,Cavia porcellus,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),CHEMBL615738,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,301,F,D,BAO_0000221,
,Cavia porcellus,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL615739,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,302,F,D,BAO_0000221,
,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,CHEMBL615278,12092,10623,,,,,Autocuration,,1,,8,,303,B,H,BAO_0000357,
,Rattus norvegicus,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,CHEMBL615279,1317,10623,,,,,Expert,,1,,9,10116.0,304,F,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL615280,12409,168,,,,,Expert,,1,,8,,305,B,H,BAO_0000357,
,Gallus gallus,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,CHEMBL615281,11126,22226,,,,,Autocuration,,1,,0,9031.0,306,B,U,BAO_0000019,
,Homo sapiens,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,CHEMBL615282,11126,22226,,,,,Autocuration,,1,,0,9606.0,307,F,U,BAO_0000019,
,Homo sapiens,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,CHEMBL615283,11126,22226,,,,,Autocuration,,1,,0,9606.0,308,F,U,BAO_0000019,
HL-60,Homo sapiens,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,CHEMBL615284,11126,80156,,649.0,,,Autocuration,,1,,1,9606.0,309,B,N,BAO_0000219,
,Homo sapiens,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,CHEMBL615285,11126,22226,,,,,Autocuration,,1,,0,9606.0,310,B,U,BAO_0000019,
,Homo sapiens,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,CHEMBL615286,11126,22226,,,,,Autocuration,,1,,0,9606.0,311,B,U,BAO_0000019,
Oocytes,Homo sapiens,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,CHEMBL615287,17807,104703,,,,,Autocuration,,1,,7,9606.0,312,B,D,BAO_0000219,
,,,,Chymotryptic inhibitory activity against 26S proteasome,CHEMBL615288,16575,100256,,,,,Intermediate,,1,,2,,313,F,S,BAO_0000220,
,,,,Inhibitory activity against 26S proteasome degradation of IkB,CHEMBL615289,15407,100256,,,,,Intermediate,,1,,2,,314,B,S,BAO_0000220,
A2780,Homo sapiens,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,CHEMBL615290,10797,81034,,478.0,,,Intermediate,,1,,1,9606.0,315,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro inhibition of 2780/S ovarian cancer cell line,CHEMBL884522,10797,81034,,478.0,,,Intermediate,,1,,1,9606.0,316,F,N,BAO_0000219,
,Homo sapiens,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,CHEMBL615291,3469,22226,,,,,Autocuration,,1,,0,9606.0,317,F,U,BAO_0000019,
,,,,Association constant for binding to AATT 28-mer AATT hairpin,CHEMBL615292,16037,22222,,,,,Intermediate,,1,,3,,318,B,M,BAO_0000225,
,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,CHEMBL615293,16037,22222,,,,,Intermediate,,1,,3,,319,B,M,BAO_0000225,
,,,,Reaction Rate Parameter for 28-mer AATT hairpin,CHEMBL615294,16037,22222,,,,,Intermediate,,1,,3,,320,B,M,BAO_0000225,
,,,,Reaction Rate Parameter for 28-mer AATT hairpin,CHEMBL615295,16037,22222,,,,,Intermediate,,1,,3,,321,B,M,BAO_0000225,
,Homo sapiens,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),CHEMBL825021,16524,22226,,,,,Autocuration,,1,,0,9606.0,322,F,U,BAO_0000019,
,Homo sapiens,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),CHEMBL615296,16524,22226,,,,,Autocuration,,1,,0,9606.0,323,F,U,BAO_0000019,
,Homo sapiens,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,CHEMBL615297,16524,22226,,,,,Autocuration,,1,,0,9606.0,324,F,U,BAO_0000019,
,Cricetulus griseus,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,CHEMBL615298,16758,22226,,,,,Autocuration,,1,,0,10029.0,325,F,U,BAO_0000019,
,Cricetulus griseus,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,CHEMBL615299,16758,22226,,,,,Autocuration,,1,,0,10029.0,326,F,U,BAO_0000019,
,Cricetulus griseus,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,CHEMBL615300,16758,22226,,,,,Autocuration,,1,,0,10029.0,327,F,U,BAO_0000019,
,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,CHEMBL615301,14360,241,,,,,Autocuration,,1,,8,,328,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,CHEMBL615302,14360,241,,,,,Expert,,1,,9,9606.0,329,B,D,BAO_0000357,
,Rattus norvegicus,,,Selectivity ratio of ID50 in liver and heart,CHEMBL615303,9964,22226,,,,,Autocuration,,1,,0,10116.0,330,B,U,BAO_0000019,
,,,,"Selectivity, ratio of relative ID50 in liver and heart",CHEMBL615304,9964,12132,,,,,Autocuration,,1,,8,,331,B,H,BAO_0000019,
,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,CHEMBL615305,9964,12132,,,,,Autocuration,,1,,8,,332,B,H,BAO_0000019,
,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615306,9964,12132,,,,,Autocuration,,1,,8,,333,B,H,BAO_0000218,
,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615307,9964,12132,,,,,Autocuration,,1,,8,,334,B,H,BAO_0000218,
,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615308,9964,12132,,,,,Autocuration,,1,,8,,335,B,H,BAO_0000218,In vivo
,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615309,9964,12132,,,,,Autocuration,,1,,8,,336,F,H,BAO_0000218,In vivo
,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",CHEMBL615310,9964,22226,,,,,Autocuration,,1,,0,,337,B,U,BAO_0000019,
,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,CHEMBL615311,9964,12132,,,,,Autocuration,,1,,8,,338,B,H,BAO_0000019,
,Homo sapiens,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",CHEMBL615312,9964,22226,,,,,Autocuration,,1,,0,9606.0,339,B,U,BAO_0000019,
,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,CHEMBL615313,9964,12132,,,,,Autocuration,,1,,8,,340,B,H,BAO_0000019,
,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,CHEMBL615314,9964,12132,,,,,Autocuration,,1,,8,,341,F,H,BAO_0000019,
,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",CHEMBL615315,9964,12132,,,,,Autocuration,,1,,8,,342,B,H,BAO_0000019,
,Rattus norvegicus,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",CHEMBL615316,9964,22226,,,,,Autocuration,,1,,0,10116.0,343,B,U,BAO_0000218,
,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,CHEMBL615317,9964,12132,,,,,Autocuration,,1,,8,,344,B,H,BAO_0000218,In vivo
,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",CHEMBL615318,9964,12132,,,,,Autocuration,,1,,8,,345,B,H,BAO_0000218,
,Rattus norvegicus,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",CHEMBL615319,9964,22226,,,,,Autocuration,,1,,0,10116.0,346,B,U,BAO_0000218,
,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",CHEMBL615320,9964,12132,,,,,Autocuration,,1,,8,,347,B,H,BAO_0000019,
,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",CHEMBL615321,9964,12132,,,,,Autocuration,,1,,8,,348,F,H,BAO_0000019,
,Rattus norvegicus,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",CHEMBL615322,3796,22226,,,,,Autocuration,,1,,0,10116.0,349,B,U,BAO_0000019,
,Escherichia coli,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,CHEMBL615323,4251,19690,,,,,Autocuration,,1,,8,562.0,350,B,H,BAO_0000357,
,Escherichia coli,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,CHEMBL615407,4251,19690,,,,,Autocuration,,1,,8,562.0,351,B,H,BAO_0000357,
,Escherichia coli,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,CHEMBL857267,4251,19690,,,,,Autocuration,,1,,8,562.0,352,B,H,BAO_0000357,
,Escherichia coli,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,CHEMBL615408,4251,19690,,,,,Autocuration,,1,,8,562.0,353,B,H,BAO_0000357,
,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,CHEMBL615409,166,19690,,,,,Autocuration,,1,,8,,354,B,H,BAO_0000357,
,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,CHEMBL615410,17861,19690,,,,,Autocuration,,1,,8,,355,B,H,BAO_0000357,
,,,,Inhibition constant against 3-dehydroquinate synthase,CHEMBL615411,166,19690,,,,,Autocuration,,1,,8,,356,B,H,BAO_0000357,
,,,,Association rate constant against 3-dehydroquinate synthase,CHEMBL615412,166,19690,,,,,Autocuration,,1,,8,,357,B,H,BAO_0000357,
,,,,Rate constant against 3-dehydroquinate synthase,CHEMBL615413,166,19690,,,,,Autocuration,,1,,8,,358,B,H,BAO_0000357,
,,,,Inhibitory activity against fuc-TVII,CHEMBL615414,3548,22226,,,,,Autocuration,,1,,0,,359,B,U,BAO_0000019,
,Rattus norvegicus,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615415,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,360,B,D,BAO_0000251,
,Rattus norvegicus,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615416,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,361,B,D,BAO_0000251,
,Rattus norvegicus,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615417,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,362,B,D,BAO_0000251,
,Rattus norvegicus,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615418,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,363,B,D,BAO_0000251,
,Rattus norvegicus,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,CHEMBL615419,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,364,B,D,BAO_0000251,
,Rattus norvegicus,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,CHEMBL615420,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,365,B,D,BAO_0000251,
,Rattus norvegicus,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,CHEMBL615421,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,366,B,D,BAO_0000251,
,Rattus norvegicus,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,CHEMBL615422,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,367,B,D,BAO_0000251,
,Rattus norvegicus,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,CHEMBL615423,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,368,B,D,BAO_0000251,
,Rattus norvegicus,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,CHEMBL872868,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,369,B,D,BAO_0000251,
,Rattus norvegicus,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,CHEMBL615424,9877,12236,Microsomes,,Liver,2107.0,Autocuration,,1,,9,10116.0,370,B,D,BAO_0000251,
,,,,Inhibitory activity against 3-phosphoglycerate kinase.,CHEMBL825022,3003,104832,,,,,Autocuration,,1,,4,,371,B,H,BAO_0000224,
,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,CHEMBL615425,3003,104832,,,,,Autocuration,,1,,4,,372,B,H,BAO_0000224,
,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",CHEMBL615426,3003,104832,,,,,Autocuration,,1,,4,,373,B,H,BAO_0000224,
,Homo sapiens,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,CHEMBL615427,17185,10612,,,,,Expert,,1,,9,9606.0,374,B,D,BAO_0000357,
3677 melanoma cell line,Homo sapiens,,,Cytotoxicity on 3677 melanoma cells,CHEMBL615428,6072,80616,,844.0,,,Intermediate,,1,,1,9606.0,375,F,N,BAO_0000219,
3677 melanoma cell line,Homo sapiens,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,CHEMBL615429,6072,80616,,844.0,,,Intermediate,,1,,1,9606.0,376,F,N,BAO_0000219,
MC-38,Mus musculus,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,CHEMBL615430,5018,80617,,700.0,,,Intermediate,,1,,1,10090.0,377,F,N,BAO_0000219,
,Homo sapiens,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,CHEMBL615431,2852,22226,,,,,Intermediate,,1,,0,9606.0,378,F,U,BAO_0000019,
B16,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,CHEMBL615432,8663,22226,,798.0,,,Autocuration,,1,,0,,379,F,U,BAO_0000218,
B16,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,CHEMBL615433,8663,22226,,798.0,,,Autocuration,,1,,0,,380,F,U,BAO_0000218,
,Human rhinovirus 14,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,CHEMBL615434,3245,12464,,,,,Expert,,1,,9,12131.0,381,F,D,BAO_0000019,
,Human rhinovirus sp.,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,CHEMBL615435,3245,50085,,,,,Intermediate,,1,,1,169066.0,382,F,N,BAO_0000218,
,human rhinovirus type 14,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,CHEMBL615436,3877,50679,,,,,Intermediate,,1,,1,169066.0,383,F,N,BAO_0000218,
,human rhinovirus type 14,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,CHEMBL615437,3877,50679,,,,,Intermediate,,1,,1,169066.0,384,F,N,BAO_0000218,
,Human rhinovirus 14,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615438,5861,12464,,,,,Expert,,1,,9,12131.0,385,F,D,BAO_0000019,
,Human rhinovirus 14,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615439,5861,12464,,,,,Expert,,1,,9,12131.0,386,F,D,BAO_0000019,
,Human rhinovirus 14,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,CHEMBL615440,5861,12464,,,,,Expert,,1,,9,12131.0,387,F,D,BAO_0000019,
,Human rhinovirus 14,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,CHEMBL615441,5861,12464,,,,,Expert,,1,,9,12131.0,388,F,D,BAO_0000019,
,Enterovirus,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,CHEMBL615641,13748,50665,,,,,Intermediate,,1,,1,12059.0,389,F,N,BAO_0000218,
,Enterovirus,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,CHEMBL872065,13748,50665,,,,,Intermediate,,1,,1,12059.0,390,F,N,BAO_0000218,
,Enterovirus,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,CHEMBL825023,13748,50665,,,,,Intermediate,,1,,1,12059.0,391,F,N,BAO_0000218,
,Enterovirus,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,CHEMBL615642,13748,50665,,,,,Intermediate,,1,,1,12059.0,392,F,N,BAO_0000218,
,Human rhinovirus B,,,Inhibition of human rhinovirus 3C protease,CHEMBL615643,13748,12464,,,,,Expert,,1,,8,147712.0,393,B,H,BAO_0000357,
,Homo sapiens,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,CHEMBL615644,17699,22226,,,,,Autocuration,,1,,0,9606.0,394,B,U,BAO_0000019,
3EM 37,Mus musculus,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),CHEMBL615645,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,395,F,N,BAO_0000218,
3EM 37,Mus musculus,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),CHEMBL615646,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,396,F,N,BAO_0000218,
3EM 37,Mus musculus,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),CHEMBL615647,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,397,F,N,BAO_0000218,
3EM 37,Mus musculus,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),CHEMBL615648,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,398,F,N,BAO_0000218,
3EM 37,Mus musculus,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,CHEMBL615649,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,399,F,N,BAO_0000218,
3EM 37,Mus musculus,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,CHEMBL615650,7145,80619,,833.0,,,Intermediate,,1,,1,10090.0,400,F,N,BAO_0000218,
3LL cell line,Mus musculus,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,CHEMBL615651,5325,80620,,847.0,,,Intermediate,,1,,1,10090.0,401,F,N,BAO_0000218,
3LL cell line,Mus musculus,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,CHEMBL615652,5325,80620,,847.0,,,Intermediate,,1,,1,10090.0,402,F,N,BAO_0000218,
3LL cell line,Mus musculus,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,CHEMBL615653,5325,80620,,847.0,,,Expert,,1,,1,10090.0,403,F,N,BAO_0000218,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,CHEMBL615654,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,404,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,CHEMBL615655,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,405,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,CHEMBL825024,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,406,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,CHEMBL615656,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,407,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,CHEMBL615657,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,408,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,CHEMBL615658,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,409,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,CHEMBL615659,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,410,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,CHEMBL615660,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,411,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,CHEMBL615661,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,412,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,CHEMBL615662,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,413,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,CHEMBL615663,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,414,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,CHEMBL615664,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,415,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,CHEMBL615665,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,416,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,CHEMBL615666,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,417,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL615667,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,418,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615668,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,419,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615669,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,420,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615670,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,421,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL836739,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,422,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615671,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,423,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615672,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,424,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615791,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,425,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,CHEMBL615792,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,426,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,CHEMBL615793,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,427,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,CHEMBL615794,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,428,F,N,BAO_0000219,
3LL cell line,Mus musculus,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,CHEMBL615795,16169,80620,,847.0,,,Intermediate,,1,,1,10090.0,429,F,N,BAO_0000219,
3LLD122,Homo sapiens,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,CHEMBL615590,15547,80621,,971.0,,,Intermediate,,1,,1,9606.0,430,F,N,BAO_0000219,
,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,CHEMBL615591,8663,22226,,,,,Autocuration,,1,,0,,431,F,U,BAO_0000218,
,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,CHEMBL615592,8663,22226,,,,,Autocuration,,1,,0,,432,F,U,BAO_0000218,
,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,CHEMBL615593,8663,22226,,,,,Autocuration,,1,,0,,433,F,U,BAO_0000218,
,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,CHEMBL615594,8663,22226,,,,,Autocuration,,1,,0,,434,F,U,BAO_0000218,
NIH3T3,Mus musculus,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,CHEMBL615595,4504,80951,,723.0,,,Intermediate,,1,,1,10090.0,435,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,CHEMBL615596,4504,80951,,723.0,,,Intermediate,,1,,1,10090.0,436,F,N,BAO_0000219,
NIH3T3,,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,CHEMBL615597,12695,11169,,723.0,,,Expert,,1,,8,,437,F,H,BAO_0000219,
NIH3T3,Mus musculus,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,CHEMBL615598,12695,80951,,723.0,,,Intermediate,,1,,1,10090.0,438,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,CHEMBL615599,12695,80951,,723.0,,,Intermediate,,1,,1,10090.0,439,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Effective dose against murine 3T3 fibroblasts cells,CHEMBL615600,17642,80951,,723.0,,,Expert,,1,,1,10090.0,440,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,CHEMBL615601,17642,80951,,723.0,,,Expert,,1,,1,10090.0,441,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxic effect on 3T3 cells,CHEMBL615602,12340,80951,,723.0,,,Expert,,1,,1,10090.0,442,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxic effect on 3T3 cells,CHEMBL615603,12340,80951,,723.0,,,Expert,,1,,1,10090.0,443,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,CHEMBL615604,12716,80951,,723.0,,,Intermediate,,1,,1,10090.0,444,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,CHEMBL615605,6277,80951,,723.0,,,Intermediate,,1,,1,10090.0,445,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,CHEMBL615606,6277,80951,,723.0,,,Intermediate,,1,,1,10090.0,446,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,CHEMBL884526,6277,80951,,723.0,,,Expert,,1,,1,10090.0,447,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,CHEMBL615607,6277,80951,,723.0,,,Expert,,1,,1,10090.0,448,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,CHEMBL615608,6277,80951,,723.0,,,Intermediate,,1,,1,10090.0,449,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,CHEMBL615609,6277,80951,,723.0,,,Expert,,1,,1,10090.0,450,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,CHEMBL615682,6277,80951,,723.0,,,Expert,,1,,1,10090.0,451,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,CHEMBL615683,6277,80951,,723.0,,,Intermediate,,1,,1,10090.0,452,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,CHEMBL615684,17780,80951,,723.0,,,Expert,,1,,1,10090.0,453,F,N,BAO_0000218,
,Mus musculus,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,CHEMBL615685,12751,104860,,,,,Autocuration,,1,,7,10090.0,454,F,D,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,CHEMBL615686,12380,80951,,723.0,,,Expert,,1,,1,10090.0,455,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibitory activity against 3T3 cell line,CHEMBL615687,14892,80951,,723.0,,,Intermediate,,1,,1,10090.0,456,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,CHEMBL884523,12695,80951,,723.0,,,Intermediate,,1,,1,10090.0,457,F,N,BAO_0000219,
,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,CHEMBL615688,12695,11169,,,,,Expert,,1,,8,,458,F,H,BAO_0000019,
NIH3T3,Mus musculus,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,CHEMBL615689,12695,80951,,723.0,,,Intermediate,,1,,1,10090.0,459,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,CHEMBL615690,12695,80951,,723.0,,,Intermediate,,1,,1,10090.0,460,F,N,BAO_0000219,
,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,CHEMBL615691,12695,11169,,,,,Expert,,1,,8,,461,F,H,BAO_0000019,
,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,CHEMBL615692,12695,11169,,,,,Expert,,1,,8,,462,F,H,BAO_0000019,
NIH3T3,Mus musculus,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,CHEMBL615693,6277,80951,,723.0,,,Intermediate,,1,,1,10090.0,463,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,CHEMBL615324,6277,80951,,723.0,,,Expert,,1,,1,10090.0,464,F,N,BAO_0000219,
NIH3T3,Homo sapiens,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,CHEMBL615325,4959,9,,723.0,,,Expert,,1,,9,9606.0,465,F,D,BAO_0000219,
NIH3T3,Homo sapiens,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),CHEMBL615490,4959,9,,723.0,,,Expert,,1,,9,9606.0,466,F,D,BAO_0000219,
NIH3T3,Homo sapiens,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,CHEMBL615491,4959,188,,723.0,,,Expert,,1,,9,9606.0,467,F,D,BAO_0000219,
NIH3T3,Homo sapiens,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),CHEMBL615492,4959,188,,723.0,,,Expert,,1,,9,9606.0,468,F,D,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,CHEMBL615493,12082,80951,,723.0,,,Intermediate,,1,,1,10090.0,469,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,CHEMBL615494,12082,80951,,723.0,,,Intermediate,,1,,1,10090.0,470,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,CHEMBL615495,12082,80951,,723.0,,,Intermediate,,1,,1,10090.0,471,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,CHEMBL615496,12082,80951,,723.0,,,Intermediate,,1,,1,10090.0,472,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,CHEMBL615497,2643,80951,,723.0,,,Intermediate,,1,,1,10090.0,473,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,CHEMBL615498,11926,80951,,723.0,,,Expert,,1,,1,10090.0,474,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,CHEMBL615499,15204,80951,,723.0,,,Intermediate,,1,,1,10090.0,475,A,N,BAO_0000219,
NIH3T3,Mus musculus,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,CHEMBL835522,15992,80951,,723.0,,,Expert,,1,,1,10090.0,476,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,CHEMBL615500,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,477,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615501,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,478,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615502,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,479,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615503,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,480,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615504,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,481,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),CHEMBL615505,16279,80951,,723.0,,,Intermediate,,1,,1,10090.0,482,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,CHEMBL615506,12831,80951,,723.0,,,Expert,,1,,1,10090.0,483,F,N,BAO_0000219,
NIH3T3,Mus musculus,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,CHEMBL615507,13497,80951,,723.0,,,Intermediate,,1,,1,10090.0,484,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615508,13715,80006,,620.0,,,Intermediate,,1,,1,,485,F,N,BAO_0000218,
3T3-L1,Mus musculus,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,CHEMBL615509,13618,80006,,620.0,,,Intermediate,,1,,1,10090.0,486,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,CHEMBL615510,11902,80006,,620.0,,,Intermediate,,1,,1,10090.0,487,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,CHEMBL615511,11902,80006,,620.0,,,Intermediate,,1,,1,10090.0,488,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,CHEMBL615512,11902,80006,,620.0,,,Intermediate,,1,,1,10090.0,489,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",CHEMBL615513,14840,80006,,620.0,,,Intermediate,,1,,1,10090.0,490,F,N,BAO_0000218,
3T3-L1,Mus musculus,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",CHEMBL615514,14840,80006,,620.0,,,Intermediate,,1,,1,10090.0,491,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,CHEMBL615515,13715,80006,,620.0,,,Intermediate,,1,,1,,492,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,CHEMBL615516,13715,80006,,620.0,,,Intermediate,,1,,1,,493,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615517,13715,80006,,620.0,,,Intermediate,,1,,1,,494,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,CHEMBL615518,13715,80006,,620.0,,,Intermediate,,1,,1,,495,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615519,13715,80006,,620.0,,,Intermediate,,1,,1,,496,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,CHEMBL615520,13715,80006,,620.0,,,Intermediate,,1,,1,,497,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,CHEMBL615521,13715,80006,,620.0,,,Intermediate,,1,,1,,498,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,CHEMBL615522,13715,80006,,620.0,,,Intermediate,,1,,1,,499,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615523,13715,80006,,620.0,,,Intermediate,,1,,1,,500,F,N,BAO_0000218,
3T3-L1,,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,CHEMBL615524,13715,80006,,620.0,,,Expert,,1,,1,,501,F,N,BAO_0000218,
3T3-L1,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615525,13715,80006,,620.0,,,Expert,,1,,1,,502,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,CHEMBL615526,13715,80006,,620.0,,,Intermediate,,1,,1,,503,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615527,13715,80006,,620.0,,,Intermediate,,1,,1,,504,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,CHEMBL615528,13715,80006,,620.0,,,Intermediate,,1,,1,,505,F,N,BAO_0000218,
3T3-L1,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615529,13715,80006,,620.0,,,Expert,,1,,1,,506,F,N,BAO_0000218,
3T3-L1,,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615530,13715,80006,,620.0,,,Expert,,1,,1,,507,F,N,BAO_0000218,
3T3-L1,,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,CHEMBL615531,13715,80006,,620.0,,,Expert,,1,,1,,508,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,CHEMBL615532,13715,80006,,620.0,,,Intermediate,,1,,1,,509,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,CHEMBL615533,13715,80006,,620.0,,,Intermediate,,1,,1,,510,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,CHEMBL615534,13715,80006,,620.0,,,Intermediate,,1,,1,,511,F,N,BAO_0000219,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,CHEMBL615535,13715,80006,,620.0,,,Intermediate,,1,,1,,512,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,CHEMBL615536,13715,80006,,620.0,,,Intermediate,,1,,1,,513,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,CHEMBL615537,13715,80006,,620.0,,,Intermediate,,1,,1,,514,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,CHEMBL615538,13715,80006,,620.0,,,Intermediate,,1,,1,,515,F,N,BAO_0000218,
3T3-L1,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,CHEMBL836166,13715,80006,,620.0,,,Intermediate,,1,,1,,516,F,N,BAO_0000218,
3T3-L1,,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,CHEMBL615539,6411,11214,,620.0,,,Expert,,1,,8,,517,F,H,BAO_0000219,
3T3-L1,Mus musculus,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,CHEMBL615540,6411,80006,,620.0,,,Intermediate,,1,,1,10090.0,518,F,N,BAO_0000219,
3T3-L1,,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,CHEMBL615541,6411,11214,,620.0,,,Expert,,1,,8,,519,F,H,BAO_0000219,
3T3-L1,Mus musculus,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,CHEMBL615542,3966,80006,,620.0,,,Expert,,1,,1,10090.0,520,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,CHEMBL615543,3966,80006,,620.0,,,Intermediate,,1,,1,10090.0,521,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,CHEMBL615544,15556,80006,,620.0,,,Expert,,1,,1,10090.0,522,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,CHEMBL615545,5845,80006,,620.0,,,Expert,,1,,1,10090.0,523,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,CHEMBL615546,14422,80006,,620.0,,,Expert,,1,,1,10090.0,524,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,CHEMBL615547,5845,80006,,620.0,,,Expert,,1,,1,10090.0,525,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,CHEMBL615548,14508,80006,,620.0,,,Expert,,1,,1,10090.0,526,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,CHEMBL615549,14508,80006,,620.0,,,Expert,,1,,1,10090.0,527,F,N,BAO_0000219,
3T3-L1,Mus musculus,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,CHEMBL615550,14508,80006,,620.0,,,Expert,,1,,1,10090.0,528,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,Inhibitory activity against rat fibroblast (3Y1) cell line,CHEMBL615551,6349,80622,,1118.0,,,Intermediate,,1,,1,10116.0,529,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,CHEMBL615552,15899,80622,,1118.0,,,Expert,,1,,1,10116.0,530,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,Cytotoxicity in 3Y1 cells.,CHEMBL615553,15899,80622,,1118.0,,,Expert,,1,,1,10116.0,531,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,Cytostatic effect in 3Y1 cells.,CHEMBL615554,15899,80622,,1118.0,,,Expert,,1,,1,10116.0,532,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",CHEMBL615555,15899,80622,,1118.0,,,Intermediate,,1,,1,10116.0,533,F,N,BAO_0000219,
3Y1 cell line,Rattus norvegicus,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,CHEMBL615556,17038,80622,,1118.0,,,Expert,,1,,1,10116.0,534,F,N,BAO_0000219,
,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,CHEMBL615557,12421,22226,,,,,Autocuration,,1,,0,,535,B,U,BAO_0000019,
,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,CHEMBL615558,12947,22226,,,,,Autocuration,,1,,0,,536,B,U,BAO_0000019,
,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,CHEMBL872066,12947,22226,,,,,Autocuration,,1,,0,,537,B,U,BAO_0000019,
,Sus scrofa,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,CHEMBL615559,4896,11607,,,,,Expert,,1,,9,9823.0,538,B,D,BAO_0000019,
,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,CHEMBL615560,6148,11607,,,,,Autocuration,,1,,8,,539,B,H,BAO_0000019,
,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,CHEMBL615561,16432,11607,,,,,Autocuration,,1,,8,,540,B,H,BAO_0000019,
,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,CHEMBL857062,4978,11607,,,,,Expert,,1,,8,,541,B,H,BAO_0000019,
,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),CHEMBL615562,4978,11607,,,,,Expert,,1,,8,,542,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,CHEMBL615563,3723,11607,,,,,Autocuration,,1,,8,,543,B,H,BAO_0000019,
,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),CHEMBL615564,3518,11607,,,,,Autocuration,,1,,8,,544,B,H,BAO_0000357,
,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,CHEMBL615565,4164,11607,,,,,Autocuration,,1,,8,,545,B,H,BAO_0000019,
,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,CHEMBL615566,3518,11607,,,,,Autocuration,,1,,8,,546,B,H,BAO_0000019,
,Sus scrofa,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,CHEMBL615567,4164,11607,,,,,Expert,,1,,9,9823.0,547,B,D,BAO_0000019,
,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,CHEMBL615568,3518,11607,,,,,Autocuration,,1,,8,,548,B,H,BAO_0000019,
,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),CHEMBL615569,3518,11607,,,,,Autocuration,,1,,8,,549,B,H,BAO_0000357,
,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,CHEMBL615570,4978,11607,,,,,Autocuration,,1,,8,,550,B,H,BAO_0000019,
,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),CHEMBL615571,4978,11607,,,,,Autocuration,,1,,8,,551,B,H,BAO_0000019,
,,,,Binding affinity against melatonin (MT1) receptor (pC1),CHEMBL615572,6455,104733,,,,,Autocuration,,1,,4,,552,B,H,BAO_0000224,
,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,CHEMBL615573,2222,22226,,,,,Autocuration,,1,,0,,553,B,U,BAO_0000019,
,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,CHEMBL615574,13020,22226,,,,,Autocuration,,1,,0,,554,B,U,BAO_0000019,
,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,CHEMBL615575,13021,22226,,,,,Autocuration,,1,,0,,555,B,U,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,CHEMBL615576,14532,10619,,,,,Autocuration,,1,,8,,556,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,CHEMBL615577,14118,10619,,,,,Autocuration,,1,,8,,557,B,H,BAO_0000357,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,CHEMBL615578,11884,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,558,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,CHEMBL615579,13969,51,,,,,Expert,,1,,8,,559,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL615580,13392,51,,,,,Expert,,1,,8,,560,B,H,BAO_0000357,
,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,CHEMBL615581,14430,51,,,,,Expert,,1,,8,,561,B,H,BAO_0000019,
,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615582,12248,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,562,B,H,BAO_0000221,
,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615583,12249,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,563,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615584,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,564,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL833691,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,565,B,H,BAO_0000221,
,,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615585,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,566,B,H,BAO_0000221,
,,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615586,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,567,B,H,BAO_0000221,
,,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL884524,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,568,B,H,BAO_0000221,
,,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615587,12249,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,569,B,H,BAO_0000221,
,,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",CHEMBL615588,11799,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,570,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,CHEMBL615589,14331,10576,Membranes,,,,Expert,,1,,9,10116.0,571,B,D,BAO_0000249,
,Bos taurus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,CHEMBL615442,11884,51,,,Hippocampus,10000000.0,Expert,,1,,8,9913.0,572,B,H,BAO_0000221,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,CHEMBL615443,14331,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,573,B,H,BAO_0000221,
,,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,CHEMBL615444,11701,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,574,B,H,BAO_0000221,
,,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,CHEMBL615445,11701,51,,,Hippocampus,10000000.0,Expert,,1,,8,,575,B,H,BAO_0000221,
,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,CHEMBL615446,12248,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,576,B,H,BAO_0000221,
CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,CHEMBL615447,12248,51,,449.0,,,Autocuration,,1,,8,,577,B,H,BAO_0000219,
,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615448,12248,51,,,Hippocampus,10000000.0,Expert,,1,,8,,578,B,H,BAO_0000221,
,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,CHEMBL615449,12249,51,,,Hippocampus,10000000.0,Expert,,1,,8,,579,B,H,BAO_0000221,
CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL615450,12248,51,,449.0,,,Autocuration,,1,,8,,580,B,H,BAO_0000219,
,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",CHEMBL615451,11799,51,,,Hippocampus,10000000.0,Expert,,1,,8,,581,B,H,BAO_0000221,
,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,CHEMBL615452,634,51,,,,,Autocuration,,1,,8,,582,B,H,BAO_0000357,
,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615453,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,583,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615454,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,584,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615455,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,585,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615456,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,586,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,CHEMBL615457,9995,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,587,B,H,BAO_0000221,
,,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,CHEMBL615458,12210,51,,,Hippocampus,10000000.0,Expert,,1,,8,,588,B,H,BAO_0000218,
,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL615459,13311,51,,,Hippocampus,10000000.0,Expert,,1,,8,,589,B,H,BAO_0000221,
CHO,Homo sapiens,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",CHEMBL615460,2331,51,,449.0,,,Expert,,1,,9,9606.0,590,B,D,BAO_0000219,
,Cavia porcellus,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,CHEMBL615461,1375,51,,,,,Autocuration,,1,,8,10141.0,591,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,CHEMBL615462,1375,51,,,,,Autocuration,,1,,8,10141.0,592,F,H,BAO_0000019,
,Cavia porcellus,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,CHEMBL615463,11574,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,10141.0,593,F,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,CHEMBL615464,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,594,B,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615465,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,595,B,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,CHEMBL615466,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,596,B,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615467,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,597,B,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,CHEMBL615468,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,598,B,H,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,CHEMBL615469,12867,51,,,Ileum,2116.0,Autocuration,,1,,8,10141.0,599,B,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615470,11574,51,,,,,Autocuration,,1,,8,10141.0,600,B,H,BAO_0000357,
,Cavia porcellus,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615471,13114,51,,,,,Autocuration,,1,,8,10141.0,601,B,H,BAO_0000357,
,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,CHEMBL615472,13181,51,,,,,Autocuration,,1,,8,10141.0,602,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,CHEMBL883242,10639,106,,,Hippocampus,10000000.0,Autocuration,,1,,8,10141.0,603,B,H,BAO_0000221,
,Cavia porcellus,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,CHEMBL615473,10639,106,,,Hippocampus,10000000.0,Autocuration,,1,,8,10141.0,604,F,H,BAO_0000221,
CHO,Cricetulus griseus,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHEMBL615474,11883,11863,,449.0,,,Autocuration,,1,,8,10029.0,605,B,H,BAO_0000218,
,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,CHEMBL615475,17785,51,,,,,Autocuration,,1,,8,,606,B,H,BAO_0000357,
HeLa,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,CHEMBL615476,1558,51,,308.0,,,Autocuration,,1,,8,,607,F,H,BAO_0000219,
HeLa,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,CHEMBL615477,1558,51,,308.0,,,Autocuration,,1,,8,,608,F,H,BAO_0000219,
,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,CHEMBL615478,15740,51,,,,,Autocuration,,1,,8,,609,F,H,BAO_0000019,
CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHEMBL615160,17624,51,,449.0,,,Autocuration,,1,,8,,610,F,H,BAO_0000219,
CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHEMBL615161,17624,51,,449.0,,,Expert,,1,,8,,611,F,H,BAO_0000219,
CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,CHEMBL615162,17624,51,,449.0,,,Autocuration,,1,,8,,612,F,H,BAO_0000219,
CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,CHEMBL615163,17624,51,,449.0,,,Autocuration,,1,,8,,613,F,H,BAO_0000219,
CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615164,17624,51,,449.0,,,Expert,,1,,8,,614,B,H,BAO_0000219,
CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615165,17624,51,,449.0,,,Expert,,1,,8,,615,B,H,BAO_0000219,
CHO,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,CHEMBL615166,17624,51,,449.0,,,Autocuration,,1,,8,,616,B,H,BAO_0000219,
,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,CHEMBL615167,14256,51,,,,,Autocuration,,1,,8,,617,F,H,BAO_0000219,
HeLa,Homo sapiens,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,CHEMBL615168,3445,51,,308.0,,,Expert,,1,,9,9606.0,618,B,D,BAO_0000219,
HeLa,Homo sapiens,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,CHEMBL615169,3445,51,,308.0,,,Expert,,1,,9,9606.0,619,B,D,BAO_0000219,
CHO,Homo sapiens,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,CHEMBL615170,17200,51,,449.0,,,Expert,,1,,9,9606.0,620,B,D,BAO_0000219,
CHO,Homo sapiens,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,CHEMBL615171,17200,51,,449.0,,,Expert,,1,,9,9606.0,621,B,D,BAO_0000219,
,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,CHEMBL615694,15180,51,,,,,Autocuration,,1,,8,,622,F,H,BAO_0000019,
,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,CHEMBL615695,15180,51,,,,,Autocuration,,1,,8,,623,F,H,BAO_0000019,
,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL615696,16026,51,,,,,Autocuration,,1,,8,,624,F,H,BAO_0000019,
CHO,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL615697,2759,51,,449.0,,,Autocuration,,1,,8,,625,F,H,BAO_0000219,
CHO,Homo sapiens,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHEMBL859410,2759,51,,449.0,,,Expert,,1,,9,9606.0,626,F,D,BAO_0000219,
CHO,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHEMBL615841,2759,51,,449.0,,,Autocuration,,1,,8,,627,F,H,BAO_0000219,
CHO,Homo sapiens,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHEMBL615842,2759,51,,449.0,,,Expert,,1,,9,9606.0,628,F,D,BAO_0000219,
CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL835003,2759,51,,449.0,,,Autocuration,,1,,8,,629,F,H,BAO_0000219,
CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),CHEMBL615843,2759,51,,449.0,,,Autocuration,,1,,8,,630,F,H,BAO_0000219,
CHO,Homo sapiens,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHEMBL615979,2759,51,,449.0,,,Expert,,1,,9,9606.0,631,F,D,BAO_0000219,
CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHEMBL615980,2759,51,,449.0,,,Autocuration,,1,,8,,632,F,H,BAO_0000219,
CHO,Homo sapiens,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHEMBL615981,2759,51,,449.0,,,Expert,,1,,9,9606.0,633,F,D,BAO_0000219,
,Homo sapiens,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,CHEMBL615982,3445,51,,,,,Expert,,1,,9,9606.0,634,F,D,BAO_0000019,
,Homo sapiens,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL615983,5272,51,,,,,Expert,,1,,9,9606.0,635,F,D,BAO_0000019,
,Homo sapiens,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",CHEMBL615984,5272,51,,,,,Expert,,1,,9,9606.0,636,F,D,BAO_0000019,
,Homo sapiens,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",CHEMBL615985,5272,51,,,,,Expert,,1,,9,9606.0,637,F,D,BAO_0000019,
CHO,,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615986,17624,51,,449.0,,,Autocuration,,1,,8,,638,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615987,17624,51,,449.0,,,Autocuration,,1,,8,,639,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHEMBL615988,17624,51,,449.0,,,Autocuration,,1,,8,,640,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHEMBL615989,17624,51,,449.0,,,Expert,,1,,8,,641,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHEMBL615990,17624,51,,449.0,,,Autocuration,,1,,8,,642,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,CHEMBL615991,17624,51,,449.0,,,Autocuration,,1,,8,,643,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615992,17624,51,,449.0,,,Autocuration,,1,,8,,644,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHEMBL615993,17624,51,,449.0,,,Autocuration,,1,,8,,645,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615994,17624,51,,449.0,,,Expert,,1,,8,,646,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,CHEMBL615995,17624,51,,449.0,,,Autocuration,,1,,8,,647,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHEMBL615996,17624,51,,449.0,,,Autocuration,,1,,8,,648,F,H,BAO_0000219,
CHO,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHEMBL615997,17624,51,,449.0,,,Autocuration,,1,,8,,649,F,H,BAO_0000219,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615998,6563,51,,,,,Autocuration,,1,,8,,650,F,H,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615999,6563,51,,,,,Autocuration,,1,,8,,651,F,H,BAO_0000019,
,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,CHEMBL616000,6563,51,,,,,Autocuration,,1,,8,,652,F,H,BAO_0000019,
HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616001,17296,51,,722.0,,,Autocuration,,1,,8,,653,F,H,BAO_0000219,
,Homo sapiens,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",CHEMBL616002,6876,51,,,,,Expert,,1,,9,9606.0,654,F,D,BAO_0000019,
,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",CHEMBL616003,6876,51,,,,,Expert,,1,,8,,655,F,H,BAO_0000019,
,Homo sapiens,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,CHEMBL616004,5272,51,,,,,Expert,,1,,9,9606.0,656,F,D,BAO_0000019,
,Homo sapiens,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,CHEMBL616005,5272,51,,,,,Expert,,1,,9,9606.0,657,F,D,BAO_0000019,
,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616006,5548,51,,,,,Autocuration,,1,,8,,658,F,H,BAO_0000019,
,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",CHEMBL616007,5548,51,,,,,Expert,,1,,8,,659,F,H,BAO_0000019,
,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616008,5548,51,,,,,Autocuration,,1,,8,,660,F,H,BAO_0000019,
,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",CHEMBL616009,5548,51,,,,,Autocuration,,1,,8,,661,F,H,BAO_0000019,
,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",CHEMBL616010,5929,51,,,,,Expert,,1,,8,,662,F,H,BAO_0000019,
,Homo sapiens,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",CHEMBL616011,5929,51,,,,,Expert,,1,,9,9606.0,663,F,D,BAO_0000019,
,Homo sapiens,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",CHEMBL615740,5929,51,,,,,Expert,,1,,9,9606.0,664,F,D,BAO_0000019,
,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",CHEMBL615741,16245,51,,,,,Autocuration,,1,,8,,665,F,H,BAO_0000019,
,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",CHEMBL615742,5640,51,,,,,Expert,,1,,8,,666,F,H,BAO_0000019,
,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",CHEMBL615743,5640,51,,,,,Autocuration,,1,,8,,667,F,H,BAO_0000019,
CHO,,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,CHEMBL615744,14509,51,,449.0,,,Autocuration,,1,,8,,668,F,H,BAO_0000219,
CHO,,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,CHEMBL615745,14509,51,,449.0,,,Expert,,1,,8,,669,F,H,BAO_0000219,
,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL615746,15331,51,,,,,Autocuration,,1,,8,,670,B,H,BAO_0000357,
,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL615747,15331,51,,,,,Autocuration,,1,,8,,671,B,H,BAO_0000357,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615748,6563,51,,,,,Autocuration,,1,,8,,672,F,H,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",CHEMBL615749,6563,51,,,,,Autocuration,,1,,8,,673,F,H,BAO_0000019,
,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,CHEMBL615750,6563,51,,,,,Autocuration,,1,,8,,674,F,H,BAO_0000019,
,Homo sapiens,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,CHEMBL616259,6563,51,,,,,Expert,,1,,9,9606.0,675,F,D,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL616260,6563,51,,,,,Autocuration,,1,,8,,676,F,H,BAO_0000019,
,Homo sapiens,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,CHEMBL616261,5272,51,,,,,Expert,,1,,9,9606.0,677,F,D,BAO_0000019,
,Homo sapiens,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL616262,5272,51,,,,,Expert,,1,,9,9606.0,678,F,D,BAO_0000019,
,Homo sapiens,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",CHEMBL616263,5272,51,,,,,Expert,,1,,9,9606.0,679,F,D,BAO_0000019,
,Homo sapiens,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,CHEMBL616264,5272,51,,,,,Expert,,1,,9,9606.0,680,F,D,BAO_0000019,
,Homo sapiens,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,CHEMBL616265,5272,51,,,,,Expert,,1,,9,9606.0,681,F,D,BAO_0000019,
,Homo sapiens,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",CHEMBL616266,5272,51,,,,,Expert,,1,,9,9606.0,682,F,D,BAO_0000019,
,Homo sapiens,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",CHEMBL616267,5272,51,,,,,Expert,,1,,9,9606.0,683,F,D,BAO_0000019,
,Homo sapiens,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,CHEMBL616268,5272,51,,,,,Expert,,1,,9,9606.0,684,F,D,BAO_0000019,
,Homo sapiens,,,Inhibition of human 5-hydroxytryptamine 1A receptor,CHEMBL616269,16146,51,,,,,Expert,,1,,9,9606.0,685,B,D,BAO_0000357,
CHO,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL884528,17624,51,,449.0,,,Autocuration,,1,,8,,686,B,H,BAO_0000219,
HEK293,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,CHEMBL616270,13706,105,,722.0,,,Expert,,1,,9,,687,B,D,BAO_0000219,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,CHEMBL616271,15250,51,,449.0,,,Autocuration,,1,,8,,688,B,H,BAO_0000219,
CHO,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL616272,17624,51,,449.0,,,Autocuration,,1,,8,,689,F,H,BAO_0000219,
,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,CHEMBL616273,6861,51,,,,,Expert,,1,,8,,690,B,H,BAO_0000357,
,Homo sapiens,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616274,17200,51,,,,,Expert,,1,,9,9606.0,691,B,D,BAO_0000357,
CHO,,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,CHEMBL616275,17624,51,,449.0,,,Autocuration,,1,,8,,692,B,H,BAO_0000219,
CHO,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL616276,17624,51,,449.0,,,Autocuration,,1,,8,,693,B,H,BAO_0000219,
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,CHEMBL616277,12058,22226,,,,,Autocuration,,1,,0,10116.0,694,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,CHEMBL616278,12058,22226,,,,,Autocuration,,1,,0,10116.0,695,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,CHEMBL616279,12058,22226,,,,,Autocuration,,1,,0,10116.0,696,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,CHEMBL616280,12058,22226,,,,,Autocuration,,1,,0,10116.0,697,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,CHEMBL616281,12058,22226,,,,,Autocuration,,1,,0,10116.0,698,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,CHEMBL616282,12058,22226,,,,,Autocuration,,1,,0,10116.0,699,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,CHEMBL616283,12058,22226,,,,,Autocuration,,1,,0,10116.0,700,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,CHEMBL616284,12058,22226,,,,,Autocuration,,1,,0,10116.0,701,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,CHEMBL616285,12058,22226,,,,,Autocuration,,1,,0,10116.0,702,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,CHEMBL616286,12058,22226,,,,,Autocuration,,1,,0,10116.0,703,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,CHEMBL616287,12058,22226,,,,,Autocuration,,1,,0,10116.0,704,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,CHEMBL616288,12058,22226,,,,,Autocuration,,1,,0,10116.0,705,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,CHEMBL616289,12058,22226,,,,,Autocuration,,1,,0,10116.0,706,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,CHEMBL615610,12058,22226,,,,,Autocuration,,1,,0,10116.0,707,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,CHEMBL615611,12058,22226,,,,,Autocuration,,1,,0,10116.0,708,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,CHEMBL615612,12058,22226,,,,,Autocuration,,1,,0,10116.0,709,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,CHEMBL615613,12058,22226,,,,,Autocuration,,1,,0,10116.0,710,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,CHEMBL615614,12058,22226,,,,,Autocuration,,1,,0,10116.0,711,F,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,CHEMBL615615,12058,22226,,,,,Autocuration,,1,,0,10116.0,712,F,U,BAO_0000218,In vivo
,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,CHEMBL615616,11440,105093,,,,,Autocuration,,1,,4,,713,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,CHEMBL615617,6238,11923,,,Hypothalamus,1898.0,Autocuration,,1,,8,,714,B,H,BAO_0000249,
,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,CHEMBL615618,10046,10577,,,,,Autocuration,,1,,8,,715,B,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,CHEMBL615619,10046,10577,,,,,Autocuration,,1,,8,,716,B,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,CHEMBL615620,10046,10577,,,,,Expert,,1,,8,,717,B,H,BAO_0000019,
,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",CHEMBL615621,167,55,,,,,Autocuration,,1,,8,,718,B,H,BAO_0000357,
,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",CHEMBL615622,167,55,,,,,Autocuration,,1,,8,,719,B,H,BAO_0000357,
,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),CHEMBL615623,11520,12166,,,,,Autocuration,,1,,8,,720,F,H,BAO_0000019,
,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL615624,11520,12166,,,,,Autocuration,,1,,8,,721,F,H,BAO_0000019,
,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL615625,11520,12166,,,,,Autocuration,,1,,8,,722,F,H,BAO_0000019,
,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,CHEMBL767045,11520,12166,,,,,Autocuration,,1,,8,,723,F,H,BAO_0000019,
,Cavia porcellus,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,CHEMBL615626,135,55,,,,,Autocuration,,1,,8,10141.0,724,F,H,BAO_0000019,
,Cavia porcellus,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,CHEMBL615627,135,55,,,,,Autocuration,,1,,8,10141.0,725,F,H,BAO_0000019,
,Cavia porcellus,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,CHEMBL615628,11311,55,,,,,Autocuration,,1,,8,10141.0,726,B,H,BAO_0000019,
,Cavia porcellus,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,CHEMBL615629,10193,55,,,,,Autocuration,,1,,8,10141.0,727,B,H,BAO_0000357,
,Homo sapiens,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,CHEMBL615630,12281,55,,,,,Expert,,1,,9,9606.0,728,B,D,BAO_0000357,
,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],CHEMBL615631,11311,55,,,,,Autocuration,,1,,8,,729,B,H,BAO_0000219,
,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,CHEMBL615632,12576,17087,,,,,Autocuration,,1,,8,,730,F,H,BAO_0000218,
,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,CHEMBL615633,12281,17087,,,,,Autocuration,,1,,8,,731,B,H,BAO_0000357,
,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,CHEMBL615634,12576,17087,,,,,Autocuration,,1,,8,,732,F,H,BAO_0000218,
,Sus scrofa,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,CHEMBL615635,11089,55,,,,,Expert,,1,,8,9823.0,733,B,H,BAO_0000019,
,,,,In vitro inhibition of rat 5-Lipoxygenase,CHEMBL615636,11006,12166,,,,,Expert,,1,,8,,734,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibitory activity against 5-Lipoxygenase,CHEMBL615637,11481,12166,,,,,Expert,,1,,9,10116.0,735,B,D,BAO_0000357,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,CHEMBL615638,10864,12166,,702.0,,,Expert,,1,,8,,736,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL615639,3595,12166,,702.0,,,Autocuration,,1,,8,,737,B,H,BAO_0000219,
RBL-1,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,CHEMBL615640,11311,12166,,702.0,,,Autocuration,,1,,8,,738,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,CHEMBL615796,11311,12166,,,,,Autocuration,,1,,8,,739,B,H,BAO_0000019,
,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],CHEMBL615845,11311,12166,,,,,Autocuration,,1,,8,,740,B,H,BAO_0000219,
,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,CHEMBL615846,11006,12166,,,,,Autocuration,,1,,8,,741,B,H,BAO_0000357,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,CHEMBL615847,3595,12166,,702.0,,,Autocuration,,1,,8,,742,B,H,BAO_0000219,
,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,CHEMBL615848,11311,12166,,,,,Autocuration,,1,,8,,743,B,H,BAO_0000357,
,Rattus norvegicus,,,Ratio of IC50 against 5-LO and COX,CHEMBL615849,11481,22226,,,,,Autocuration,,1,,0,10116.0,744,B,U,BAO_0000019,
,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,CHEMBL615850,11006,12166,,,,,Autocuration,,1,,8,,745,B,H,BAO_0000357,
,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,CHEMBL615851,11006,12166,,,,,Autocuration,,1,,8,,746,B,H,BAO_0000357,
,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,CHEMBL615852,11311,12166,,,,,Autocuration,,1,,8,,747,B,H,BAO_0000219,
,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,CHEMBL615853,11006,12166,,,,,Autocuration,,1,,8,,748,F,H,BAO_0000019,
,,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,CHEMBL884527,4288,120,,,Prostate gland,2367.0,Autocuration,,1,,8,,749,B,H,BAO_0000357,
,Columba livia,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,CHEMBL872871,7587,22226,,,,,Autocuration,,1,,0,8932.0,750,B,U,BAO_0000019,
,Columba livia,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,CHEMBL615854,7587,22226,,,,,Autocuration,,1,,0,8932.0,751,B,U,BAO_0000019,
,Columba livia,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,CHEMBL767046,7587,22226,,,,,Autocuration,,1,,0,8932.0,752,B,U,BAO_0000019,
,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,CHEMBL615855,11249,10732,,,,,Autocuration,,1,,8,,753,B,H,BAO_0000357,
,Rattus norvegicus,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,CHEMBL615856,8003,12198,,,,,Expert,,1,,9,10116.0,754,F,D,BAO_0000019,
,Rattus norvegicus,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),CHEMBL615857,8003,12198,,,,,Expert,,1,,9,10116.0,755,F,D,BAO_0000019,
,Rattus norvegicus,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),CHEMBL615858,8003,12198,,,,,Expert,,1,,9,10116.0,756,F,D,BAO_0000019,
,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,CHEMBL615859,12416,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,757,B,H,BAO_0000221,
,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,CHEMBL615860,16293,51,,,,,Autocuration,,1,,8,,758,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL615861,13047,22226,,,,,Autocuration,,1,,0,9986.0,759,B,U,BAO_0000019,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL615862,13047,22226,,,,,Autocuration,,1,,0,9986.0,760,B,U,BAO_0000019,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,CHEMBL615863,13047,22226,,,,,Autocuration,,1,,0,9986.0,761,B,U,BAO_0000019,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,CHEMBL615864,13047,22226,,,,,Autocuration,,1,,0,9986.0,762,B,U,BAO_0000019,
,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615865,10085,104744,,,Hippocampus,10000000.0,Autocuration,,1,,4,,763,B,H,BAO_0000221,
,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615866,10085,104744,,,Hippocampus,10000000.0,Autocuration,,1,,4,,764,B,H,BAO_0000221,
,,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,CHEMBL615867,10085,104744,,,Hippocampus,10000000.0,Autocuration,,1,,4,,765,B,H,BAO_0000221,
,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,CHEMBL615868,9841,104744,Membranes,,,,Autocuration,,1,,4,,766,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,CHEMBL615869,8822,104744,,,,,Autocuration,,1,,5,10116.0,767,B,D,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,CHEMBL615870,9806,104744,,,,,Autocuration,,1,,5,10116.0,768,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,CHEMBL615871,9806,104744,,,,,Autocuration,,1,,5,10116.0,769,B,D,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,CHEMBL615872,8868,104744,,,,,Autocuration,,1,,4,,770,B,H,BAO_0000224,
,,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,CHEMBL833492,9036,104744,,,Hippocampus,10000000.0,Autocuration,,1,,4,,771,B,H,BAO_0000221,
,,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,CHEMBL615873,11374,104744,,,Hippocampus,10000000.0,Autocuration,,1,,4,,772,B,H,BAO_0000221,
,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,CHEMBL615479,10881,104744,,,,,Autocuration,,1,,4,,773,B,H,BAO_0000224,
,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,CHEMBL615480,8822,104744,,,,,Autocuration,,1,,4,,774,B,H,BAO_0000019,
,Rattus norvegicus,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,CHEMBL615481,9806,104744,,,,,Autocuration,,1,,5,10116.0,775,B,D,BAO_0000249,
,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL872869,15463,104744,,,,,Autocuration,,1,,4,,776,B,H,BAO_0000019,
,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615482,15463,104744,,,,,Autocuration,,1,,4,,777,B,H,BAO_0000019,
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615483,14542,104744,,,Brain,955.0,Autocuration,,1,,4,,778,B,H,BAO_0000221,
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615484,14542,104744,,,Brain,955.0,Autocuration,,1,,4,,779,B,H,BAO_0000221,
,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,CHEMBL615485,8569,104744,,,,,Autocuration,,1,,4,,780,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,CHEMBL615486,10062,104744,,,,,Autocuration,,1,,5,10116.0,781,B,D,BAO_0000224,
,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,CHEMBL615487,4771,104744,,,,,Autocuration,,1,,4,,782,B,H,BAO_0000224,
,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615488,10062,104744,,,,,Autocuration,,1,,4,,783,B,H,BAO_0000224,
,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615489,10062,104744,,,,,Autocuration,,1,,4,,784,B,H,BAO_0000224,
,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,CHEMBL615389,10062,104744,,,,,Autocuration,,1,,4,,785,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,CHEMBL615390,15463,104744,,,,,Autocuration,,1,,4,,786,B,H,BAO_0000019,
,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,CHEMBL615391,15463,104744,,,,,Autocuration,,1,,4,,787,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,CHEMBL615392,9098,104744,,,,,Autocuration,,1,,4,,788,B,H,BAO_0000224,
,Rattus norvegicus,,,Affinity for 5-hydroxytryptamine 1 receptor,CHEMBL615393,3070,22226,,,,,Autocuration,,1,,0,10116.0,789,B,U,BAO_0000019,
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,CHEMBL615394,14542,104744,,,Brain,955.0,Autocuration,,1,,4,,790,B,H,BAO_0000221,
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,CHEMBL615395,14542,104744,,,Brain,955.0,Autocuration,,1,,4,,791,B,H,BAO_0000221,
,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,CHEMBL615396,6398,104744,,,,,Autocuration,,1,,4,,792,B,H,BAO_0000224,
,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,CHEMBL615397,1344,104744,,,Brain,955.0,Autocuration,,1,,4,,793,B,H,BAO_0000221,
,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,CHEMBL615398,11963,104744,,,,,Autocuration,,1,,4,,794,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,CHEMBL615399,8908,22226,,,,,Autocuration,,1,,0,10116.0,795,B,U,BAO_0000019,
,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,CHEMBL615400,9098,104744,,,,,Autocuration,,1,,4,,796,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,CHEMBL615401,8841,104744,,,,,Autocuration,,1,,5,10116.0,797,B,D,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,CHEMBL615402,8814,22226,,,,,Autocuration,,1,,0,10116.0,798,B,U,BAO_0000019,
,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,CHEMBL615403,11752,104744,,,,,Autocuration,,1,,4,,799,B,H,BAO_0000019,
,,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,CHEMBL615404,11642,104744,,,Brain,955.0,Autocuration,,1,,4,,800,B,H,BAO_0000221,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,CHEMBL615781,11642,104744,,,,,Autocuration,,1,,4,,801,B,H,BAO_0000019,
,,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,CHEMBL615782,9231,104744,,,Brain,955.0,Autocuration,,1,,4,,802,B,H,BAO_0000220,
,,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,CHEMBL615783,11351,104744,,,Brain,955.0,Autocuration,,1,,4,,803,B,H,BAO_0000221,
,,,,Compound was tested for binding affinity against 5-HT1 receptor,CHEMBL873481,4639,22226,,,,,Autocuration,,1,,0,,804,B,U,BAO_0000019,
,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,CHEMBL615784,1205,22226,,,,,Autocuration,,1,,0,,805,B,U,BAO_0000019,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,CHEMBL615785,10025,10576,,,,,Expert,,1,,8,,806,B,H,BAO_0000357,
,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",CHEMBL615786,13241,10576,,,,,Autocuration,,1,,8,,807,F,H,BAO_0000249,
,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,CHEMBL615787,16245,10576,,,,,Autocuration,,1,,8,,808,F,H,BAO_0000218,In vivo
,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,CHEMBL615788,16245,10576,,,,,Autocuration,,1,,8,,809,F,H,BAO_0000218,In vivo
,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,CHEMBL767044,12438,10576,,,,,Autocuration,,1,,8,,810,F,H,BAO_0000019,
,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,CHEMBL615789,16245,10576,,,,,Autocuration,,1,,8,,811,F,H,BAO_0000218,In vivo
,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,CHEMBL615790,16245,10576,,,,,Autocuration,,1,,8,,812,F,H,BAO_0000218,In vivo
,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,CHEMBL615813,15740,10576,,,,,Autocuration,,1,,8,,813,F,H,BAO_0000019,
,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,CHEMBL615814,15535,10576,,,,,Autocuration,,1,,8,,814,F,H,BAO_0000219,
,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,CHEMBL615815,15535,51,,,,,Expert,,1,,8,,815,F,H,BAO_0000219,
,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,CHEMBL615816,15535,10576,,,,,Autocuration,,1,,8,,816,F,H,BAO_0000219,
,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,CHEMBL615817,9888,10576,,,,,Expert,,1,,8,,817,B,H,BAO_0000249,
,,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,CHEMBL615818,10085,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,818,B,H,BAO_0000221,
,,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,CHEMBL615819,10085,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,819,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,CHEMBL615820,17331,10576,Membranes,,,,Expert,,1,,8,,820,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,CHEMBL615821,10845,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,821,B,D,BAO_0000221,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,CHEMBL615822,10845,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,822,B,D,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,CHEMBL615823,10845,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,823,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,CHEMBL615824,10845,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,824,B,D,BAO_0000221,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,CHEMBL615825,10845,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,825,B,D,BAO_0000221,
,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,CHEMBL615826,13730,10576,,,,,Expert,,1,,8,,826,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,CHEMBL615827,13508,10576,,,,,Expert,,1,,8,,827,B,H,BAO_0000249,
,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,CHEMBL615828,13508,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,828,B,H,BAO_0000249,
,,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615829,12073,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,829,B,H,BAO_0000221,
,,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,CHEMBL615830,4671,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,830,B,H,BAO_0000221,
,,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,CHEMBL615831,13631,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,831,B,H,BAO_0000221,
,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,CHEMBL615832,12438,10576,,,,,Autocuration,,1,,8,,832,B,H,BAO_0000357,
,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,CHEMBL615833,10483,10576,,,,,Autocuration,,1,,8,,833,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,CHEMBL615834,10483,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,834,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,CHEMBL615835,12352,10576,,,,,Intermediate,,1,,8,,835,B,H,BAO_0000249,
,,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,CHEMBL615836,14732,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,836,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,CHEMBL615837,11049,10576,,,,,Expert,,1,,9,10116.0,837,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,CHEMBL615838,11049,10576,,,,,Expert,,1,,9,10116.0,838,B,D,BAO_0000019,
,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",CHEMBL615839,13657,10576,,,,,Expert,,1,,8,,839,B,H,BAO_0000249,
,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,CHEMBL884525,11473,10576,,,,,Autocuration,,1,,8,,840,B,H,BAO_0000019,
,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,CHEMBL615840,2014,10576,,,,,Autocuration,,1,,8,,841,B,H,BAO_0000249,
,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615405,3086,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,842,B,H,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL615406,15854,10576,,,,,Expert,,1,,8,,843,B,H,BAO_0000019,
,,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,CHEMBL615900,10922,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,844,B,H,BAO_0000221,
,,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,CHEMBL615901,13346,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,845,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,CHEMBL615902,15311,10576,,,,,Expert,,1,,8,,846,B,H,BAO_0000357,
,,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,CHEMBL615903,10922,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,847,B,H,BAO_0000221,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,CHEMBL615904,10025,10576,,,,,Autocuration,,1,,8,,848,B,H,BAO_0000357,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,CHEMBL615905,10025,10576,,,,,Expert,,1,,8,,849,B,H,BAO_0000357,
,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL615906,9742,10576,,,,,Autocuration,,1,,8,,850,B,H,BAO_0000019,
,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL615907,9742,10576,,,,,Autocuration,,1,,8,,851,F,H,BAO_0000019,
,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL615908,12304,10576,,,,,Expert,,1,,8,,852,B,H,BAO_0000019,
,,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,CHEMBL615909,15789,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,853,B,H,BAO_0000221,
,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",CHEMBL615910,9912,10576,,,,,Autocuration,,1,,8,,854,B,H,BAO_0000019,
,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",CHEMBL615911,9912,10576,,,,,Autocuration,,1,,8,,855,B,H,BAO_0000019,
,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",CHEMBL615912,9912,10576,,,,,Autocuration,,1,,8,,856,B,H,BAO_0000019,
,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,CHEMBL615913,16693,10576,,,,,Expert,,1,,8,,857,B,H,BAO_0000019,
,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL615914,13276,10576,,,,,Expert,,1,,8,,858,B,H,BAO_0000357,
,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,CHEMBL615915,12678,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,859,B,H,BAO_0000221,
,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,CHEMBL615916,11825,10576,,,,,Autocuration,,1,,8,,860,B,H,BAO_0000357,
,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,CHEMBL615917,12443,10576,,,,,Expert,,1,,8,,861,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL615918,13830,10576,,,,,Expert,,1,,8,,862,B,H,BAO_0000357,
,,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,CHEMBL615919,14286,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,863,B,H,BAO_0000249,
,Rattus norvegicus,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL615920,14356,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,864,B,D,BAO_0000221,
,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,CHEMBL615921,15306,10576,,,,,Autocuration,,1,,8,,865,B,H,BAO_0000357,
,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),CHEMBL615922,15306,10576,,,,,Expert,,1,,8,,866,B,H,BAO_0000357,
,Rattus norvegicus,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",CHEMBL881290,16616,10576,,,,,Expert,,1,,9,10116.0,867,F,D,BAO_0000249,
,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",CHEMBL615923,3651,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,868,B,H,BAO_0000221,
,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615924,14331,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,869,F,H,BAO_0000221,
,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL615925,14331,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,870,F,H,BAO_0000221,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,CHEMBL615926,14178,10576,,,,,Expert,,1,,9,10116.0,871,B,D,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,CHEMBL615927,10639,10576,,,,,Expert,,1,,9,10116.0,872,B,D,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL615928,12306,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,873,B,H,BAO_0000221,
,Rattus norvegicus,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,CHEMBL615929,1348,10576,,,,,Expert,,1,,9,10116.0,874,B,D,BAO_0000357,
,,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,CHEMBL615930,13605,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,875,B,H,BAO_0000221,
CHO,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHEMBL615931,17624,51,,449.0,,,Autocuration,,1,,8,,876,B,H,BAO_0000219,
CHO,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL615932,17624,51,,449.0,,,Autocuration,,1,,8,,877,F,H,BAO_0000219,
CHO,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHEMBL615933,17624,51,,449.0,,,Autocuration,,1,,8,,878,F,H,BAO_0000219,
,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL615934,15267,51,,,,,Autocuration,,1,,8,,879,B,H,BAO_0000357,
,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,CHEMBL615935,16532,51,,,,,Autocuration,,1,,8,,880,B,H,BAO_0000357,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",CHEMBL615936,6563,51,,,,,Autocuration,,1,,8,,881,F,H,BAO_0000019,
CHO,,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,CHEMBL615937,4751,51,,449.0,,,Autocuration,,1,,8,,882,B,H,BAO_0000219,
,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,CHEMBL615938,15463,51,,,,,Autocuration,,1,,8,,883,B,H,BAO_0000357,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),CHEMBL615797,3805,51,,,,,Autocuration,,1,,8,,884,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615798,5640,51,,,,,Autocuration,,1,,8,,885,B,H,BAO_0000357,
,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,CHEMBL872870,6563,51,,,,,Autocuration,,1,,8,,886,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,CHEMBL615799,5548,51,,,,,Autocuration,,1,,8,,887,B,H,BAO_0000357,
,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615800,6347,51,,,,,Autocuration,,1,,8,,888,B,H,BAO_0000357,
HEK293,,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL615801,17296,51,,722.0,,,Autocuration,,1,,8,,889,F,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,CHEMBL615802,13047,51,,,,,Autocuration,,1,,8,,890,B,H,BAO_0000019,
,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,CHEMBL615803,15740,51,,,,,Autocuration,,1,,8,,891,B,H,BAO_0000357,
,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",CHEMBL835002,5640,51,,,,,Expert,,1,,8,,892,F,H,BAO_0000019,
,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",CHEMBL615804,5640,51,,,,,Autocuration,,1,,8,,893,F,H,BAO_0000019,
HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,CHEMBL615805,17211,51,,308.0,,,Expert,,1,,8,,894,B,H,BAO_0000219,
CHO,,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,CHEMBL615806,4751,51,,449.0,,,Autocuration,,1,,8,,895,B,H,BAO_0000219,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,CHEMBL615807,6491,51,,,,,Expert,,1,,9,9606.0,896,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,CHEMBL615808,4707,51,,,,,Autocuration,,1,,8,,897,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL615809,13910,51,,,,,Expert,,1,,9,9606.0,898,B,D,BAO_0000357,
HeLa,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,CHEMBL615810,16190,51,,308.0,,,Autocuration,,1,,8,,899,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615811,16633,51,,,,,Autocuration,,1,,8,,900,B,H,BAO_0000357,
CHO,,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,CHEMBL615812,11898,51,,449.0,,,Autocuration,,1,,8,,901,B,H,BAO_0000219,
CHO,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL615751,11898,51,,449.0,,,Autocuration,,1,,8,,902,B,H,BAO_0000219,
,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,CHEMBL615752,14331,51,,,,,Autocuration,,1,,8,,903,B,H,BAO_0000357,
CHO,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,CHEMBL615753,17624,51,,449.0,,,Expert,,1,,8,,904,B,H,BAO_0000219,
CHO,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,CHEMBL615754,17624,51,,449.0,,,Autocuration,,1,,8,,905,B,H,BAO_0000219,
,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,CHEMBL615755,3307,51,,,,,Autocuration,,1,,8,,906,B,H,BAO_0000357,
CHO,Homo sapiens,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL615756,6563,51,,449.0,,,Expert,,1,,9,9606.0,907,B,D,BAO_0000219,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,CHEMBL615757,14165,51,,,,,Autocuration,,1,,8,,908,B,H,BAO_0000019,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,CHEMBL615758,5732,51,,,,,Autocuration,,1,,8,,909,B,H,BAO_0000357,
,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,CHEMBL615759,13366,51,,,,,Expert,,1,,8,,910,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,CHEMBL615760,17626,51,,,,,Autocuration,,1,,8,,911,B,H,BAO_0000357,
HeLa,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,CHEMBL615761,6588,51,,308.0,,,Expert,,1,,8,,912,B,H,BAO_0000219,
,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,CHEMBL872104,16209,51,,,,,Autocuration,,1,,8,,913,B,H,BAO_0000357,
,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615762,15463,51,,,,,Autocuration,,1,,8,,914,B,H,BAO_0000357,
,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615763,15463,51,,,,,Autocuration,,1,,8,,915,B,H,BAO_0000357,
,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,CHEMBL615764,14770,51,,,,,Autocuration,,1,,8,,916,B,H,BAO_0000357,
Cell line,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),CHEMBL615765,16245,51,,1167.0,,,Autocuration,,1,,8,,917,B,H,BAO_0000219,
,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),CHEMBL615766,16245,51,,,,,Autocuration,,1,,8,,918,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615767,5548,51,,,,,Autocuration,,1,,8,,919,B,H,BAO_0000357,
,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615768,5548,51,,,,,Expert,,1,,8,,920,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615769,5548,51,,,,,Autocuration,,1,,8,,921,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,CHEMBL615770,6876,51,,,,,Expert,,1,,8,,922,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615771,2598,51,,,,,Autocuration,,1,,8,,923,B,H,BAO_0000357,
,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,CHEMBL615772,17785,51,,,,,Expert,,1,,8,,924,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL615773,6013,51,,,,,Autocuration,,1,,8,,925,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,CHEMBL615774,5929,51,,,,,Expert,,1,,8,,926,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615775,16633,51,,,,,Autocuration,,1,,8,,927,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,CHEMBL615776,1558,51,,,,,Autocuration,,1,,8,,928,B,H,BAO_0000357,
,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL615777,16026,51,,,,,Expert,,1,,8,,929,B,H,BAO_0000357,
,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,CHEMBL615778,12469,51,,,,,Autocuration,,1,,8,,930,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL615779,15874,51,,,,,Expert,,1,,9,9606.0,931,B,D,BAO_0000357,
,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL615780,15874,51,,,,,Autocuration,,1,,8,,932,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,CHEMBL616298,3935,51,,,,,Autocuration,,1,,8,,933,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,CHEMBL616299,15818,51,,,,,Autocuration,,1,,8,,934,B,H,BAO_0000357,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,CHEMBL616300,13706,51,,485.0,,,Autocuration,,1,,8,,935,B,H,BAO_0000219,
CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,CHEMBL616301,13729,51,,485.0,,,Expert,,1,,8,,936,F,H,BAO_0000219,
,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,CHEMBL616302,15413,51,,,,,Autocuration,,1,,8,,937,B,H,BAO_0000019,
,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),CHEMBL616117,15413,51,,,,,Autocuration,,1,,8,,938,B,H,BAO_0000019,
,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),CHEMBL616118,15413,51,,,,,Autocuration,,1,,8,,939,B,H,BAO_0000019,
,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,CHEMBL616119,15413,51,,,,,Autocuration,,1,,8,,940,B,H,BAO_0000019,
HeLa,Homo sapiens,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,CHEMBL616120,3445,51,,308.0,,,Expert,,1,,9,9606.0,941,B,D,BAO_0000219,
,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,CHEMBL616121,15740,51,,,,,Autocuration,,1,,8,,942,B,H,BAO_0000357,
,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,CHEMBL616122,15740,51,,,,,Autocuration,,1,,8,,943,B,H,BAO_0000357,
,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,CHEMBL616123,17626,51,,,,,Autocuration,,1,,8,,944,B,H,BAO_0000357,
,Homo sapiens,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,CHEMBL616124,4234,51,,,,,Expert,,1,,9,9606.0,945,B,D,BAO_0000357,
,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,CHEMBL616125,5640,51,,,,,Expert,,1,,8,,946,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,CHEMBL616126,5272,51,,,,,Expert,,1,,8,10116.0,947,B,H,BAO_0000357,
CHO,,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,CHEMBL616127,4622,51,,449.0,,,Autocuration,,1,,8,,948,B,H,BAO_0000219,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,CHEMBL616128,17085,51,,,,,Expert,,1,,8,,949,B,H,BAO_0000019,
,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,CHEMBL616129,3025,51,,,,,Autocuration,,1,,8,,950,B,H,BAO_0000357,
,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616130,15315,51,,,,,Expert,,1,,8,,951,B,H,BAO_0000357,
,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,CHEMBL616131,15267,51,,,,,Autocuration,,1,,8,,952,B,H,BAO_0000357,
HeLa,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,CHEMBL616132,17158,51,,308.0,,,Autocuration,,1,,8,,953,B,H,BAO_0000219,
HeLa,Homo sapiens,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,CHEMBL616133,14214,51,,308.0,,,Expert,,1,,9,9606.0,954,B,D,BAO_0000219,
,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616134,17133,51,,,,,Autocuration,,1,,8,,955,B,H,BAO_0000357,
,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,CHEMBL616135,16532,51,,,,,Autocuration,,1,,8,,956,B,H,BAO_0000357,
,Homo sapiens,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,CHEMBL616136,2391,51,,,,,Expert,,1,,9,9606.0,957,B,D,BAO_0000357,
,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,CHEMBL616137,14447,51,,,,,Autocuration,,1,,8,,958,B,H,BAO_0000019,
,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,CHEMBL872105,14447,51,,,,,Autocuration,,1,,8,,959,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,CHEMBL616138,15086,51,,,,,Autocuration,,1,,8,,960,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616139,13051,51,,,,,Expert,,1,,9,9606.0,961,B,D,BAO_0000357,
,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",CHEMBL616140,16026,51,,,,,Autocuration,,1,,8,,962,F,H,BAO_0000019,
,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,CHEMBL616141,17085,51,,,,,Expert,,1,,8,,963,B,H,BAO_0000019,
,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616142,17133,51,,,,,Autocuration,,1,,8,,964,B,H,BAO_0000357,
,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,CHEMBL616143,17133,51,,,,,Autocuration,,1,,8,,965,B,H,BAO_0000357,
HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616144,17211,51,,308.0,,,Autocuration,,1,,8,,966,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,CHEMBL616145,17211,51,,308.0,,,Autocuration,,1,,8,,967,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616012,17211,51,,308.0,,,Autocuration,,1,,8,,968,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,CHEMBL616013,17211,51,,308.0,,,Autocuration,,1,,8,,969,B,H,BAO_0000219,
,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616014,16394,51,,,,,Autocuration,,1,,8,,970,F,H,BAO_0000019,
,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616015,16394,51,,,,,Autocuration,,1,,8,,971,F,H,BAO_0000019,
,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",CHEMBL616016,16394,51,,,,,Autocuration,,1,,8,,972,F,H,BAO_0000019,
,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,CHEMBL616017,16394,51,,,,,Autocuration,,1,,8,,973,F,H,BAO_0000218,In vivo
,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,CHEMBL616018,16394,51,,,,,Autocuration,,1,,8,,974,B,H,BAO_0000019,
,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,CHEMBL616019,15740,51,,,,,Autocuration,,1,,8,,975,F,H,BAO_0000019,
,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,CHEMBL616020,15740,51,,,,,Autocuration,,1,,8,,976,F,H,BAO_0000019,
,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,CHEMBL858018,15740,51,,,,,Autocuration,,1,,8,,977,B,H,BAO_0000357,
HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616021,17296,51,,722.0,,,Autocuration,,1,,8,,978,F,H,BAO_0000219,
,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",CHEMBL616022,5640,51,,,,,Expert,,1,,8,,979,F,H,BAO_0000019,
,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",CHEMBL616023,5640,51,,,,,Autocuration,,1,,8,,980,F,H,BAO_0000019,
,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",CHEMBL616024,5640,51,,,,,Autocuration,,1,,8,,981,F,H,BAO_0000019,
,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",CHEMBL616025,5640,51,,,,,Autocuration,,1,,8,,982,F,H,BAO_0000019,
CHO,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHEMBL616026,2759,51,,449.0,,,Autocuration,,1,,8,,983,F,H,BAO_0000219,
,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",CHEMBL616027,16394,51,,,,,Autocuration,,1,,8,,984,F,H,BAO_0000019,
,Homo sapiens,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",CHEMBL616028,16394,51,,,,,Expert,,1,,9,9606.0,985,F,D,BAO_0000019,
,Homo sapiens,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,CHEMBL616029,3445,51,,,,,Expert,,1,,9,9606.0,986,F,D,BAO_0000019,
CHO,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,CHEMBL616030,4316,51,,449.0,,,Expert,,1,,8,,987,B,H,BAO_0000219,
,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,CHEMBL616031,4316,51,,,,,Expert,,1,,8,,988,B,H,BAO_0000019,
,Homo sapiens,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,CHEMBL616032,15180,51,,,,,Expert,,1,,9,9606.0,989,F,D,BAO_0000019,
,Homo sapiens,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,CHEMBL616033,15180,51,,,,,Expert,,1,,9,9606.0,990,F,D,BAO_0000019,
,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616034,15042,51,,,,,Autocuration,,1,,8,,991,F,H,BAO_0000019,
,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616035,15042,51,,,,,Autocuration,,1,,8,,992,F,H,BAO_0000019,
,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616036,15042,51,,,,,Autocuration,,1,,8,,993,F,H,BAO_0000019,
,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616037,15042,51,,,,,Autocuration,,1,,8,,994,F,H,BAO_0000019,
,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616038,15042,51,,,,,Autocuration,,1,,8,,995,F,H,BAO_0000019,
,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,CHEMBL616039,15042,51,,,,,Autocuration,,1,,8,,996,F,H,BAO_0000019,
,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616040,15042,51,,,,,Autocuration,,1,,8,,997,F,H,BAO_0000019,
HeLa,Homo sapiens,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616041,15180,51,,308.0,,,Expert,,1,,9,9606.0,998,F,D,BAO_0000219,
HeLa,Homo sapiens,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616042,15180,51,,308.0,,,Expert,,1,,9,9606.0,999,F,D,BAO_0000219,
HeLa,Homo sapiens,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,CHEMBL616043,15180,51,,308.0,,,Expert,,1,,9,9606.0,1000,F,D,BAO_0000219,
,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",CHEMBL616044,16245,51,,,,,Autocuration,,1,,8,,1001,F,H,BAO_0000019,
,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL616045,16026,51,,,,,Autocuration,,1,,8,,1002,F,H,BAO_0000019,
HEK293,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,CHEMBL616046,17296,51,,722.0,,,Autocuration,,1,,8,,1003,F,H,BAO_0000219,
CHO,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHEMBL616047,2759,51,,449.0,,,Autocuration,,1,,8,,1004,F,H,BAO_0000219,
CHO,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL616048,2759,51,,449.0,,,Autocuration,,1,,8,,1005,F,H,BAO_0000219,
CHO,Homo sapiens,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),CHEMBL616049,2759,51,,449.0,,,Expert,,1,,9,9606.0,1006,F,D,BAO_0000219,
CHO,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHEMBL616050,2759,51,,449.0,,,Autocuration,,1,,8,,1007,F,H,BAO_0000219,
,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,CHEMBL616051,15419,51,,,,,Expert,,1,,8,,1008,F,H,BAO_0000219,
,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,CHEMBL616212,15419,51,,,,,Autocuration,,1,,8,,1009,F,H,BAO_0000219,
,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",CHEMBL616213,16026,51,,,,,Autocuration,,1,,8,,1010,F,H,BAO_0000019,
,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,CHEMBL616214,1414,51,,,,,Expert,,1,,8,,1011,B,H,BAO_0000219,In vitro
,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,CHEMBL616215,1414,51,,,,,Expert,,1,,8,,1012,B,H,BAO_0000219,In vitro
,,,,Binding activity radioligand.,CHEMBL616216,12861,51,,,,,Autocuration,,1,,8,,1013,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL616217,12861,51,,,,,Autocuration,,1,,8,,1014,B,H,BAO_0000019,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,CHEMBL616218,5104,51,,,,,Autocuration,,1,,8,,1015,B,H,BAO_0000357,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,CHEMBL616219,5105,51,,,,,Autocuration,,1,,8,,1016,B,H,BAO_0000357,
,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL616220,16312,51,,,,,Autocuration,,1,,8,,1017,B,H,BAO_0000357,
,Homo sapiens,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,CHEMBL833493,15180,51,,,,,Expert,,1,,9,9606.0,1018,B,D,BAO_0000357,
,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,CHEMBL616221,5033,51,,,,,Autocuration,,1,,8,,1019,B,H,BAO_0000357,
CHO,Homo sapiens,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHEMBL616222,16909,51,,449.0,,,Expert,,1,,9,9606.0,1020,B,D,BAO_0000219,
,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616223,2590,51,,,,,Autocuration,,1,,8,,1021,F,H,BAO_0000019,
,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,CHEMBL616224,2590,51,,,,,Autocuration,,1,,8,,1022,F,H,BAO_0000019,
,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,CHEMBL616225,16394,51,,,,,Expert,,1,,8,,1023,B,H,BAO_0000019,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,CHEMBL616226,4540,51,,722.0,,,Expert,,1,,9,9606.0,1024,B,D,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,CHEMBL616227,17296,51,,722.0,,,Autocuration,,1,,8,,1025,B,H,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,CHEMBL616228,17296,51,,722.0,,,Autocuration,,1,,8,,1026,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,CHEMBL616229,15779,51,,722.0,,,Autocuration,,1,,8,,1027,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,CHEMBL616230,15779,51,,722.0,,,Autocuration,,1,,8,,1028,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,CHEMBL616231,15779,51,,722.0,,,Autocuration,,1,,8,,1029,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,CHEMBL616232,6166,51,,,,,Autocuration,,1,,8,,1030,B,H,BAO_0000357,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,CHEMBL616233,15779,51,,722.0,,,Autocuration,,1,,8,,1031,B,H,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,CHEMBL857973,4199,51,,722.0,,,Autocuration,,1,,8,,1032,B,H,BAO_0000219,
,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,CHEMBL616234,15316,51,,,,,Autocuration,,1,,8,,1033,B,H,BAO_0000219,
,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,CHEMBL616235,14875,51,,,,,Autocuration,,1,,8,,1034,B,H,BAO_0000357,
HeLa,,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,CHEMBL616236,14727,51,,308.0,,,Expert,,1,,8,,1035,B,H,BAO_0000219,
,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,CHEMBL616237,14727,51,,,,,Expert,,1,,8,,1036,B,H,BAO_0000019,
HEK293,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,CHEMBL616238,15146,51,,722.0,,,Autocuration,,1,,8,,1037,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,CHEMBL616239,5213,51,,722.0,,,Autocuration,,1,,8,,1038,B,H,BAO_0000219,
,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,CHEMBL616240,16429,51,,,,,Autocuration,,1,,8,,1039,B,H,BAO_0000219,
HeLa,Homo sapiens,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,CHEMBL616241,15042,51,,308.0,,,Expert,,1,,9,9606.0,1040,B,D,BAO_0000219,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,CHEMBL616242,14818,51,,722.0,,,Autocuration,,1,,8,,1041,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",CHEMBL616243,4829,51,,722.0,,,Autocuration,,1,,8,,1042,B,H,BAO_0000219,
,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616244,17200,51,,,,,Expert,,1,,9,,1043,B,D,BAO_0000357,
,Homo sapiens,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,CHEMBL616245,13051,51,,,,,Autocuration,,1,,9,9606.0,1044,B,D,BAO_0000357,
,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,CHEMBL616246,5486,106,,,,,Autocuration,,1,,8,,1045,B,H,BAO_0000357,
,,,,Binding affinity against 5-HT1D receptor,CHEMBL616247,5254,105,,,,,Autocuration,,1,,8,,1046,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616248,5254,105,,,,,Autocuration,,1,,8,,1047,B,H,BAO_0000357,
,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,CHEMBL616249,15331,107,,,,,Autocuration,,1,,8,,1048,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,CHEMBL616250,13506,10576,,,,,Autocuration,,1,,8,9606.0,1049,B,H,BAO_0000357,
,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,CHEMBL616251,15267,51,,,,,Autocuration,,1,,8,,1050,B,H,BAO_0000357,
,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,CHEMBL616252,16616,11863,,,,,Autocuration,,1,,8,,1051,F,H,BAO_0000218,In vivo
,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,CHEMBL616253,16616,11863,,,,,Autocuration,,1,,8,,1052,F,H,BAO_0000218,In vivo
,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,CHEMBL616254,16616,11863,,,,,Autocuration,,1,,8,,1053,F,H,BAO_0000218,In vivo
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,CHEMBL616255,16616,11863,,,,,Expert,,1,,9,10090.0,1054,F,D,BAO_0000218,
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,CHEMBL832872,16616,11863,,,,,Expert,,1,,9,10090.0,1055,F,D,BAO_0000218,
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,CHEMBL616256,16616,11863,,,,,Expert,,1,,9,10090.0,1056,F,D,BAO_0000218,
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,CHEMBL616257,16616,11863,,,,,Expert,,1,,9,10090.0,1057,F,D,BAO_0000218,
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,CHEMBL616258,16616,11863,,,,,Expert,,1,,9,10090.0,1058,F,D,BAO_0000218,
,Mus musculus,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,CHEMBL616384,16616,11863,,,,,Expert,,1,,9,10090.0,1059,F,D,BAO_0000218,
,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,CHEMBL616385,10297,11863,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1060,B,H,BAO_0000221,
,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,CHEMBL616386,13704,11863,,,,,Expert,,1,,8,,1061,B,H,BAO_0000357,
,Mus musculus,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,CHEMBL616387,10297,11863,,,Hippocampus,10000000.0,Expert,,1,,9,10090.0,1062,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,CHEMBL616388,10297,11863,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1063,B,H,BAO_0000221,
,Mus musculus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,CHEMBL616389,10297,11863,,,Hippocampus,10000000.0,Expert,,1,,9,10090.0,1064,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,CHEMBL616390,10297,11863,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1065,B,H,BAO_0000221,
,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,CHEMBL616391,217,11863,,,,,Autocuration,,1,,8,,1066,B,H,BAO_0000357,
,Mus musculus,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,CHEMBL616392,10297,11863,,,Hippocampus,10000000.0,Expert,,1,,9,10090.0,1067,B,D,BAO_0000221,
,Sus scrofa,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,CHEMBL616393,4921,51,,,,,Autocuration,,1,,8,9823.0,1068,B,H,BAO_0000357,
,Sus scrofa,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,CHEMBL616394,4921,51,,,,,Autocuration,,1,,8,9823.0,1069,B,H,BAO_0000357,
,Sus scrofa,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,CHEMBL616395,4996,51,,,,,Autocuration,,1,,8,9823.0,1070,B,H,BAO_0000019,
,Sus scrofa,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,CHEMBL616396,12918,51,,,,,Autocuration,,1,,8,9823.0,1071,B,H,BAO_0000357,
,Sus scrofa,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,CHEMBL872907,5333,51,,,,,Autocuration,,1,,8,9823.0,1072,B,H,BAO_0000019,
,Sus scrofa,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,CHEMBL616397,4437,51,,,,,Autocuration,,1,,8,9823.0,1073,B,H,BAO_0000019,
,Sus scrofa,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,CHEMBL616398,1742,51,,,,,Autocuration,,1,,8,9823.0,1074,B,H,BAO_0000019,
,Sus scrofa,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,CHEMBL616399,16688,51,,,,,Expert,,1,,8,9823.0,1075,B,H,BAO_0000357,
,Sus scrofa,,,Binding activity radioligand.,CHEMBL857065,12861,51,,,,,Autocuration,,1,,8,9823.0,1076,B,H,BAO_0000357,
,Sus scrofa,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL616400,12861,51,,,,,Expert,,1,,8,9823.0,1077,B,H,BAO_0000019,
,Sus scrofa,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL616401,12861,51,,,,,Autocuration,,1,,8,9823.0,1078,B,H,BAO_0000019,
,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,CHEMBL616402,12490,10624,,,,,Expert,,1,,8,,1079,B,H,BAO_0000019,
,Sus scrofa,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,CHEMBL616403,11828,51,,,,,Expert,,1,,8,9823.0,1080,B,H,BAO_0000019,
,Sus scrofa,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,CHEMBL616404,11866,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,9823.0,1081,B,H,BAO_0000221,
,Sus scrofa,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,CHEMBL616405,12827,51,,,,,Autocuration,,1,,8,9823.0,1082,B,H,BAO_0000249,
,Sus scrofa,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,CHEMBL616406,12918,51,,,,,Autocuration,,1,,8,9823.0,1083,B,H,BAO_0000019,
,Sus scrofa,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,CHEMBL616407,12919,51,,,,,Expert,,1,,8,9823.0,1084,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,CHEMBL616408,13047,51,,,,,Autocuration,,1,,8,9986.0,1085,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,CHEMBL616409,15796,10576,,,,,Expert,,1,,9,10116.0,1086,B,D,BAO_0000249,
,Rattus norvegicus,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",CHEMBL616410,3651,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1087,B,D,BAO_0000221,
,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,CHEMBL616411,188,10576,,,,,Autocuration,,1,,8,,1088,B,H,BAO_0000357,
,Rattus norvegicus,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",CHEMBL616412,16616,10576,Membranes,,,,Expert,,1,,9,10116.0,1089,F,D,BAO_0000249,
,Rattus norvegicus,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",CHEMBL616413,16616,10576,Membranes,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1090,F,D,BAO_0000249,
,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616414,12306,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1091,B,H,BAO_0000221,
,Rattus norvegicus,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,CHEMBL616415,17167,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1092,B,D,BAO_0000221,
,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,CHEMBL616416,14776,10576,,,,,Autocuration,,1,,8,,1093,B,H,BAO_0000019,
,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,CHEMBL616417,12158,10576,,,,,Expert,,1,,8,,1094,B,H,BAO_0000357,
,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,CHEMBL616418,13481,10576,,,,,Autocuration,,1,,8,,1095,B,H,BAO_0000357,
,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL616419,13427,10576,,,,,Autocuration,,1,,8,,1096,B,H,BAO_0000219,In vitro
,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,CHEMBL616420,10210,10576,,,,,Autocuration,,1,,8,,1097,B,H,BAO_0000357,
,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,CHEMBL616421,10205,10576,Membranes,,,,Autocuration,,1,,8,,1098,B,H,BAO_0000249,
,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,CHEMBL616422,10205,10576,Membranes,,,,Autocuration,,1,,8,,1099,B,H,BAO_0000249,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,CHEMBL616423,10205,10576,Membranes,,,,Expert,,1,,8,,1100,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,CHEMBL616424,12280,10576,,,,,Expert,,1,,9,10116.0,1101,B,D,BAO_0000357,
,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,CHEMBL616425,17386,10576,,,,,Expert,,1,,8,,1102,B,H,BAO_0000357,
,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,CHEMBL616426,13654,10576,,,,,Expert,,1,,8,,1103,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,CHEMBL616427,14423,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1104,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,CHEMBL616428,15412,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1105,B,H,BAO_0000221,
,,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616290,12073,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1106,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,CHEMBL616052,4101,10576,,,,,Expert,,1,,9,10116.0,1107,B,D,BAO_0000357,
,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,CHEMBL616053,10062,10576,,,,,Autocuration,,1,,8,,1108,B,H,BAO_0000357,
,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,CHEMBL616054,6238,10576,,,,,Autocuration,,1,,8,,1109,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616055,16273,10576,,,,,Autocuration,,1,,8,,1110,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,CHEMBL616056,11139,10576,,,,,Autocuration,,1,,8,,1111,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,CHEMBL616057,16796,10576,,,,,Expert,,1,,8,,1112,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL616058,9548,10576,,,Brain,955.0,Expert,,1,,9,10116.0,1113,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL616059,10381,10576,,,Brain,955.0,Autocuration,,1,,8,,1114,B,H,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,CHEMBL616060,13408,10576,,,,,Autocuration,,1,,8,,1115,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,CHEMBL616061,13825,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1116,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,CHEMBL616062,11147,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1117,B,H,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,CHEMBL616063,10552,10576,,,,,Autocuration,,1,,8,,1118,B,H,BAO_0000249,
,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",CHEMBL616064,10552,10576,,,Striatum,2435.0,Autocuration,,1,,8,,1119,B,H,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,CHEMBL616065,17136,10576,Membranes,,,,Expert,,1,,9,10116.0,1120,B,D,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,CHEMBL616066,5778,10576,Membranes,,,,Expert,,1,,9,10116.0,1121,B,D,BAO_0000249,
,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616067,13481,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1122,B,H,BAO_0000221,
,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,CHEMBL616068,13481,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1123,B,H,BAO_0000221,
,,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,CHEMBL616069,13630,10576,,,Hippocampus,10000000.0,Intermediate,,1,,8,,1124,B,H,BAO_0000221,
,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL616070,16245,10576,,,,,Expert,,1,,8,,1125,B,H,BAO_0000249,
,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616071,14509,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1126,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,CHEMBL616072,14509,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1127,B,H,BAO_0000221,
,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,CHEMBL616073,14509,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1128,B,H,BAO_0000221,
,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,CHEMBL616074,14509,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1129,B,H,BAO_0000221,
,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,CHEMBL616075,14256,10576,,,,,Expert,,1,,8,,1130,B,H,BAO_0000019,
,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,CHEMBL616076,11139,10576,,,,,Autocuration,,1,,8,,1131,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,CHEMBL616077,11047,10576,,,,,Expert,,1,,9,10116.0,1132,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,CHEMBL616078,11047,10576,,,,,Expert,,1,,9,10116.0,1133,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,CHEMBL616079,11047,10576,,,,,Expert,,1,,9,10116.0,1134,B,D,BAO_0000019,
CHO-K1,Rattus norvegicus,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHEMBL616080,2395,10576,,485.0,,,Expert,,1,,9,10116.0,1135,B,D,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616081,9699,10576,,,,,Autocuration,,1,,8,,1136,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,CHEMBL616082,12028,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1137,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,CHEMBL616083,12028,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1138,B,H,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL616084,5815,10576,,,,,Autocuration,,1,,8,,1139,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,CHEMBL616085,16616,10576,,,,,Expert,,1,,8,,1140,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,CHEMBL616086,5815,10576,,,,,Autocuration,,1,,8,,1141,B,H,BAO_0000019,
,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",CHEMBL616087,2761,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1142,B,H,BAO_0000221,
,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,CHEMBL616088,13133,10576,,,,,Expert,,1,,8,,1143,B,H,BAO_0000357,
,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616089,10444,10576,,,,,Autocuration,,1,,8,,1144,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,CHEMBL616090,13278,10576,,,,,Expert,,1,,9,10116.0,1145,B,D,BAO_0000357,
,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,CHEMBL616091,15874,10576,,,,,Autocuration,,1,,8,,1146,B,H,BAO_0000357,
,,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",CHEMBL616092,10552,10576,Membranes,,Striatum,2435.0,Autocuration,,1,,8,,1147,B,H,BAO_0000249,
,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),CHEMBL616093,11130,10576,,,,,Autocuration,,1,,8,,1148,B,H,BAO_0000357,
,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),CHEMBL616094,11130,10576,,,,,Autocuration,,1,,8,,1149,B,H,BAO_0000218,In vivo
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,CHEMBL616095,14542,10576,,,Brain,955.0,Autocuration,,1,,8,,1150,B,H,BAO_0000221,
,Rattus norvegicus,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL616096,13670,10576,,,,,Expert,,1,,9,10116.0,1151,B,D,BAO_0000357,
,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,CHEMBL616097,9888,10576,,,,,Expert,,1,,8,,1152,B,H,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,CHEMBL616098,3678,10576,Membranes,,,,Expert,,1,,9,10116.0,1153,B,D,BAO_0000249,
,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616099,11332,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1154,B,H,BAO_0000221,
,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616100,11332,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1155,B,H,BAO_0000221,
,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,CHEMBL616101,1185,10576,,,,,Expert,,1,,8,,1156,B,H,BAO_0000357,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,CHEMBL616102,2014,10576,,,,,Expert,,1,,8,,1157,B,H,BAO_0000249,
,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,CHEMBL616103,1185,10576,,,,,Autocuration,,1,,8,,1158,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,CHEMBL616104,14429,10576,,,,,Expert,,1,,8,,1159,B,H,BAO_0000019,
,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",CHEMBL616105,16288,10576,,,,,Expert,,1,,8,,1160,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,CHEMBL616106,5432,10576,,,,,Expert,,1,,9,10116.0,1161,B,D,BAO_0000019,
,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,CHEMBL616107,14429,10576,,,,,Autocuration,,1,,8,,1162,B,H,BAO_0000019,
,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,CHEMBL616108,13672,10576,,,,,Expert,,1,,8,,1163,B,H,BAO_0000357,
,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616109,11296,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1164,B,H,BAO_0000221,
,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,CHEMBL616110,11296,10576,,,,,Autocuration,,1,,8,,1165,B,H,BAO_0000357,
CHO,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,CHEMBL616111,14749,10576,,449.0,,,Expert,,1,,8,,1166,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,CHEMBL616112,15086,10576,,,,,Expert,,1,,8,,1167,B,H,BAO_0000019,
,,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,CHEMBL616113,13462,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1168,B,H,BAO_0000221,
,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616114,15363,10576,,,,,Autocuration,,1,,8,,1169,B,H,BAO_0000019,
,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616115,15363,10576,,,,,Autocuration,,1,,8,,1170,B,H,BAO_0000019,
,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616116,10796,10576,,,,,Autocuration,,1,,8,,1171,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,CHEMBL615844,12816,10576,,,Brain,955.0,Expert,,1,,8,,1172,B,H,BAO_0000221,
,,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL615939,13542,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1173,B,H,BAO_0000221,
,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,CHEMBL615940,13308,10576,,,,,Expert,,1,,8,,1174,B,H,BAO_0000019,
,,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,CHEMBL615941,13541,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1175,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,CHEMBL615942,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1176,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL615943,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1177,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,CHEMBL615944,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1178,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,CHEMBL615945,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1179,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,CHEMBL615946,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1180,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,CHEMBL615947,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1181,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,CHEMBL615948,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1182,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,CHEMBL615949,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1183,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,CHEMBL615950,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1184,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,CHEMBL615951,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1185,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,CHEMBL615952,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1186,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,CHEMBL615953,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1187,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,CHEMBL615954,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1188,B,H,BAO_0000221,
,Rattus norvegicus,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL615955,10058,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1189,B,D,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,CHEMBL615956,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1190,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,CHEMBL615957,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1191,B,H,BAO_0000221,
,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,CHEMBL615958,12879,10576,,,,,Expert,,1,,8,,1192,B,H,BAO_0000019,
,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,CHEMBL615959,11964,10576,,,,,Expert,,1,,8,,1193,B,H,BAO_0000019,
,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),CHEMBL615960,11964,10576,,,,,Autocuration,,1,,8,,1194,B,H,BAO_0000019,
,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),CHEMBL615961,11964,10576,,,,,Autocuration,,1,,8,,1195,B,H,BAO_0000019,
,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,CHEMBL615962,9548,10576,,,Brain,955.0,Expert,,1,,8,,1196,B,H,BAO_0000221,
,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,CHEMBL615963,9098,10576,,,,,Expert,,1,,8,,1197,B,H,BAO_0000019,
,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,CHEMBL615964,9098,10576,,,,,Autocuration,,1,,8,,1198,B,H,BAO_0000019,
,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,CHEMBL615965,9098,10576,,,,,Autocuration,,1,,8,,1199,B,H,BAO_0000019,
CHO,,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,CHEMBL615966,13248,10576,,449.0,,,Expert,,1,,8,,1200,B,H,BAO_0000219,
,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,CHEMBL615967,3147,10576,,,,,Expert,,1,,8,,1201,B,H,BAO_0000249,
,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,CHEMBL615968,13949,10576,,,,,Expert,,1,,8,,1202,B,H,BAO_0000019,
CHO,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHEMBL615969,11883,10576,,449.0,,,Autocuration,,1,,8,,1203,B,H,BAO_0000218,
,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),CHEMBL615970,11883,10576,,,,,Autocuration,,1,,8,,1204,B,H,BAO_0000218,
,Rattus norvegicus,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,CHEMBL615971,11883,10576,,,,,Expert,,1,,9,10116.0,1205,B,D,BAO_0000357,
,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL615972,15535,10576,Membranes,,,,Expert,,1,,8,,1206,B,H,BAO_0000249,
,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,CHEMBL615973,15535,10576,,,,,Autocuration,,1,,8,,1207,B,H,BAO_0000249,
,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,CHEMBL615974,15535,10576,,,,,Autocuration,,1,,8,,1208,B,H,BAO_0000249,
CHO,Homo sapiens,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHEMBL615975,16372,51,,449.0,,,Expert,,1,,9,9606.0,1209,B,D,BAO_0000219,
,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,CHEMBL615976,14608,10576,,,,,Expert,,1,,8,,1210,B,H,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,CHEMBL872106,4795,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1211,B,D,BAO_0000221,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL615977,13863,10576,,,,,Autocuration,,1,,8,,1212,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,CHEMBL615978,13863,10576,,,,,Autocuration,,1,,8,,1213,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,CHEMBL616166,13863,10576,,,,,Autocuration,,1,,8,,1214,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,CHEMBL616167,13863,10576,,,,,Autocuration,,1,,8,,1215,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,CHEMBL616168,13863,10576,,,,,Autocuration,,1,,8,,1216,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,CHEMBL616169,13863,10576,,,,,Autocuration,,1,,8,,1217,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,CHEMBL616170,13863,10576,,,,,Autocuration,,1,,8,,1218,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,CHEMBL616171,13863,10576,,,,,Autocuration,,1,,8,,1219,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,CHEMBL616172,13863,10576,,,,,Autocuration,,1,,8,,1220,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,CHEMBL616173,13863,10576,,,,,Autocuration,,1,,8,,1221,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,CHEMBL616174,13863,10576,,,,,Autocuration,,1,,8,,1222,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,CHEMBL616175,13863,10576,,,,,Autocuration,,1,,8,,1223,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,CHEMBL616176,13863,10576,,,,,Autocuration,,1,,8,,1224,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,CHEMBL616177,13863,10576,,,,,Autocuration,,1,,8,,1225,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,CHEMBL616178,13863,10576,,,,,Autocuration,,1,,8,,1226,B,H,BAO_0000357,
,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,CHEMBL616179,9742,10576,,,,,Autocuration,,1,,8,,1227,B,H,BAO_0000019,
,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,CHEMBL616180,12073,10576,,,,,Autocuration,,1,,8,,1228,B,H,BAO_0000357,
,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,CHEMBL616181,4101,10576,,,,,Autocuration,,1,,8,,1229,B,H,BAO_0000357,
,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,CHEMBL616182,15360,10576,,,,,Autocuration,,1,,8,,1230,B,H,BAO_0000019,
,,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616183,11576,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1231,B,H,BAO_0000221,
,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,CHEMBL615874,5834,10576,,,,,Expert,,1,,8,,1232,B,H,BAO_0000019,
CHO-K1,Rattus norvegicus,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHEMBL615875,2395,10576,,485.0,,,Expert,,1,,9,10116.0,1233,B,D,BAO_0000219,
,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,CHEMBL615876,1375,10576,,,,,Autocuration,,1,,8,,1234,B,H,BAO_0000019,
,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,CHEMBL615877,1375,10576,,,,,Autocuration,,1,,8,,1235,B,H,BAO_0000019,
,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),CHEMBL615878,3967,10576,,,,,Autocuration,,1,,8,,1236,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,CHEMBL615879,12884,10576,,,,,Expert,,1,,8,,1237,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,CHEMBL615880,2343,10576,,,,,Expert,,1,,8,,1238,B,H,BAO_0000357,
,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",CHEMBL615881,11511,10576,,,,,Autocuration,,1,,8,,1239,B,H,BAO_0000019,
,Rattus norvegicus,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",CHEMBL615882,11511,10576,,,,,Expert,,1,,9,10116.0,1240,B,D,BAO_0000019,
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,CHEMBL615883,16394,10576,,,,,Autocuration,,1,,8,,1241,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),CHEMBL615884,16394,10576,,,,,Autocuration,,1,,8,,1242,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),CHEMBL615885,16394,10576,,,,,Autocuration,,1,,8,,1243,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),CHEMBL615886,16394,10576,,,,,Autocuration,,1,,8,,1244,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),CHEMBL615887,16394,10576,,,,,Autocuration,,1,,8,,1245,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),CHEMBL615888,16394,10576,,,,,Autocuration,,1,,8,,1246,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),CHEMBL615889,16394,10576,,,,,Autocuration,,1,,8,,1247,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),CHEMBL615890,16394,10576,,,,,Autocuration,,1,,8,,1248,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),CHEMBL615891,16394,10576,,,,,Autocuration,,1,,8,,1249,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),CHEMBL615892,16394,10576,,,,,Autocuration,,1,,8,,1250,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),CHEMBL615893,16394,10576,,,,,Autocuration,,1,,8,,1251,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),CHEMBL615894,16394,10576,,,,,Autocuration,,1,,8,,1252,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),CHEMBL615895,16394,10576,,,,,Autocuration,,1,,8,,1253,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),CHEMBL615896,16394,10576,,,,,Autocuration,,1,,8,,1254,F,H,BAO_0000218,In vivo
,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,CHEMBL615897,16394,10576,,,,,Autocuration,,1,,8,,1255,F,H,BAO_0000218,In vivo
,Rattus norvegicus,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",CHEMBL615898,16616,10576,Membranes,,,,Expert,,1,,9,10116.0,1256,F,D,BAO_0000249,
,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,CHEMBL615899,16796,10576,,,,,Autocuration,,1,,8,,1257,B,H,BAO_0000019,
,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,CHEMBL616291,16796,10576,,,,,Autocuration,,1,,8,,1258,B,H,BAO_0000019,
,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,CHEMBL616292,15629,10576,,,,,Autocuration,,1,,8,,1259,B,H,BAO_0000357,
,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",CHEMBL616293,13241,10576,,,,,Autocuration,,1,,8,,1260,F,H,BAO_0000249,
,,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616294,12073,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1261,B,H,BAO_0000221,
,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,CHEMBL616295,14286,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1262,B,H,BAO_0000249,
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,CHEMBL616296,14542,10576,,,Brain,955.0,Autocuration,,1,,8,,1263,B,H,BAO_0000221,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,CHEMBL616297,13630,10576,,,,,Autocuration,,1,,8,,1264,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,CHEMBL616605,13630,10576,,,,,Autocuration,,1,,8,,1265,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,CHEMBL616606,13630,10576,,,,,Autocuration,,1,,8,,1266,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,CHEMBL616607,13630,10576,,,,,Autocuration,,1,,8,,1267,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,CHEMBL616608,13630,10576,,,,,Expert,,1,,8,,1268,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,CHEMBL616609,13630,10576,,,,,Autocuration,,1,,8,,1269,F,H,BAO_0000019,
,Rattus norvegicus,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,CHEMBL616610,13630,10576,,,,,Expert,,1,,9,10116.0,1270,F,D,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,CHEMBL616611,13630,10576,,,,,Autocuration,,1,,8,,1271,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,CHEMBL616612,13630,10576,,,,,Expert,,1,,8,,1272,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,CHEMBL616613,13630,10576,,,,,Autocuration,,1,,8,,1273,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,CHEMBL616614,13630,10576,,,,,Expert,,1,,8,,1274,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,CHEMBL616615,13630,10576,,,,,Autocuration,,1,,8,,1275,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,CHEMBL616616,13630,10576,,,,,Expert,,1,,8,,1276,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,CHEMBL616617,13630,10576,,,,,Autocuration,,1,,8,,1277,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,CHEMBL616618,13630,10576,,,,,Autocuration,,1,,8,,1278,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,CHEMBL616619,13630,10576,,,,,Autocuration,,1,,8,,1279,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,CHEMBL616620,13630,10576,,,,,Expert,,1,,8,,1280,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,CHEMBL616621,13630,10576,,,,,Expert,,1,,8,,1281,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,CHEMBL616622,13630,10576,,,,,Autocuration,,1,,8,,1282,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,CHEMBL616146,13630,10576,,,,,Expert,,1,,8,,1283,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,CHEMBL832873,13630,10576,,,,,Autocuration,,1,,8,,1284,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,CHEMBL616147,13630,10576,,,,,Autocuration,,1,,8,,1285,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,CHEMBL872872,13630,10576,,,,,Autocuration,,1,,8,,1286,F,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,CHEMBL616148,13630,10576,,,,,Autocuration,,1,,8,,1287,F,H,BAO_0000019,
,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,CHEMBL616149,9783,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1288,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,CHEMBL616150,9783,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1289,B,H,BAO_0000221,
,Rattus norvegicus,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,CHEMBL616151,14331,10576,Membranes,,,,Expert,,1,,9,10116.0,1290,B,D,BAO_0000249,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,CHEMBL872873,15260,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1291,B,H,BAO_0000221,
,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,CHEMBL616670,15260,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1292,B,H,BAO_0000221,
,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,CHEMBL616671,15260,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1293,B,H,BAO_0000221,
,Rattus norvegicus,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",CHEMBL884861,16616,10576,,,,,Expert,,1,,9,10116.0,1294,F,D,BAO_0000249,
,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,CHEMBL616672,15629,10576,,,,,Autocuration,,1,,8,,1295,B,H,BAO_0000357,
,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,CHEMBL616673,15086,10576,,,,,Autocuration,,1,,8,,1296,B,H,BAO_0000019,
,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,CHEMBL616674,5717,10576,,,,,Expert,,1,,8,,1297,F,H,BAO_0000019,
,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,CHEMBL616675,12652,10576,,,,,Autocuration,,1,,8,,1298,B,H,BAO_0000357,
,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,CHEMBL616676,14608,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1299,B,H,BAO_0000221,
,,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616677,12306,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1300,B,H,BAO_0000221,
,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL616678,12306,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1301,B,H,BAO_0000221,
,Rattus norvegicus,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616679,15247,10576,,,,,Expert,,1,,9,10116.0,1302,B,D,BAO_0000357,
,,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,CHEMBL616680,17529,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1303,B,H,BAO_0000221,
,,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616681,14826,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1304,B,H,BAO_0000221,
,,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616682,14826,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1305,B,H,BAO_0000221,
,,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616683,13241,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1306,B,H,BAO_0000221,
,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,CHEMBL616684,14093,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1307,B,H,BAO_0000221,
,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,CHEMBL616685,14093,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1308,B,H,BAO_0000221,
,,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,CHEMBL616686,14442,10576,,,Brain,955.0,Autocuration,,1,,8,,1309,B,H,BAO_0000221,
,,,,Affinity for 5-hydroxytryptamine 1A receptor site,CHEMBL616687,9919,10576,,,,,Autocuration,,1,,8,,1310,B,H,BAO_0000357,
,,,,Affinity for 5-hydroxytryptamine 1A receptor site,CHEMBL616688,9919,10576,,,,,Autocuration,,1,,8,,1311,B,H,BAO_0000357,
,,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,CHEMBL616689,11440,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1312,B,H,BAO_0000221,
,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,CHEMBL616690,11257,10576,,,,,Autocuration,,1,,8,,1313,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,CHEMBL616691,10330,10576,,,,,Expert,,1,,8,,1314,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,CHEMBL616692,17331,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1315,B,D,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,CHEMBL616693,16567,10576,,,,,Expert,,1,,8,,1316,B,H,BAO_0000249,
,Rattus norvegicus,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",CHEMBL616694,12058,10576,,,,,Expert,,1,,9,10116.0,1317,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,CHEMBL616695,9699,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1318,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,CHEMBL616696,9547,10576,,,,,Autocuration,,1,,8,,1319,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,CHEMBL616697,10330,10576,,,,,Autocuration,,1,,8,,1320,B,H,BAO_0000357,
,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,CHEMBL616698,14331,10576,,,,,Autocuration,,1,,8,,1321,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,CHEMBL616949,14060,10576,,,,,Expert,,1,,9,10116.0,1322,B,D,BAO_0000019,
,,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,CHEMBL616950,14744,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1323,B,H,BAO_0000221,
,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,CHEMBL832875,13506,10576,,,,,Autocuration,,1,,8,,1324,B,H,BAO_0000357,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616951,10862,10576,,,Brain,955.0,Expert,,1,,8,,1325,B,H,BAO_0000221,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616952,10862,10576,,,Brain,955.0,Expert,,1,,8,,1326,B,H,BAO_0000221,
,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,CHEMBL616953,10062,10576,,,,,Expert,,1,,8,,1327,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,CHEMBL616954,12073,10576,,,,,Autocuration,,1,,8,,1328,B,H,BAO_0000357,
,,,,GTPgammaS radioligand binding assay,CHEMBL616955,14875,106,,,,,Autocuration,,1,,8,,1329,B,H,BAO_0000357,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,CHEMBL616956,2391,106,,,,,Autocuration,,1,,8,,1330,B,H,BAO_0000357,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,CHEMBL616957,2391,106,,,,,Autocuration,,1,,8,,1331,F,H,BAO_0000019,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,CHEMBL616958,2391,106,,,,,Autocuration,,1,,8,,1332,F,H,BAO_0000019,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,CHEMBL616959,2391,106,,,,,Autocuration,,1,,8,,1333,B,H,BAO_0000357,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,CHEMBL616960,2391,106,,,,,Autocuration,,1,,8,,1334,B,H,BAO_0000357,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,CHEMBL616961,2391,106,,,,,Autocuration,,1,,8,,1335,F,H,BAO_0000019,
HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,CHEMBL616962,17211,106,,308.0,,,Expert,,1,,8,,1336,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,CHEMBL616963,17211,106,,308.0,,,Autocuration,,1,,8,,1337,B,H,BAO_0000219,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,CHEMBL616524,6491,106,,,,,Expert,,1,,9,9606.0,1338,B,D,BAO_0000357,
CHO,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616525,16190,106,,449.0,,,Autocuration,,1,,8,,1339,B,H,BAO_0000219,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,CHEMBL872908,14165,106,,,,,Autocuration,,1,,8,,1340,B,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,CHEMBL616526,14165,106,,,,,Autocuration,,1,,8,,1341,B,H,BAO_0000019,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616527,4234,106,,,,,Expert,,1,,9,9606.0,1342,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,CHEMBL616528,6328,106,,,,,Expert,,1,,8,,1343,B,H,BAO_0000219,
,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616529,14770,106,,,,,Autocuration,,1,,8,,1344,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,CHEMBL616530,2598,106,,,,,Autocuration,,1,,8,,1345,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616531,6897,106,,,,,Expert,,1,,8,,1346,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616532,6897,106,,,,,Autocuration,,1,,8,,1347,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616533,6013,106,,,,,Autocuration,,1,,8,,1348,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616534,5843,106,,,,,Expert,,1,,8,,1349,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,CHEMBL616535,14454,106,,,,,Expert,,1,,8,,1350,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,CHEMBL616536,16209,106,,,,,Autocuration,,1,,8,,1351,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616537,3935,106,,,,,Autocuration,,1,,8,,1352,B,H,BAO_0000357,
CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,CHEMBL616538,13729,106,,485.0,,,Expert,,1,,8,,1353,F,H,BAO_0000219,
,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,CHEMBL616539,14251,106,,,,,Expert,,1,,8,,1354,F,H,BAO_0000019,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,CHEMBL616540,17085,106,,,,,Expert,,1,,8,,1355,B,H,BAO_0000019,
,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,CHEMBL616429,3025,106,,,,,Autocuration,,1,,8,,1356,B,H,BAO_0000357,
,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616430,15315,106,,,,,Expert,,1,,8,,1357,B,H,BAO_0000357,
,Homo sapiens,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,CHEMBL616431,14214,106,,,,,Expert,,1,,9,9606.0,1358,B,D,BAO_0000219,
,Homo sapiens,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,CHEMBL616432,3804,106,,,,,Expert,,1,,9,9606.0,1359,B,D,BAO_0000357,
,Homo sapiens,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,CHEMBL616433,2391,106,,,,,Expert,,1,,9,9606.0,1360,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616434,4175,106,,,,,Expert,,1,,9,9606.0,1361,B,D,BAO_0000357,
CHO,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,CHEMBL616435,17296,106,,449.0,,,Autocuration,,1,,8,,1362,B,H,BAO_0000219,
,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,CHEMBL616436,17085,106,,,,,Expert,,1,,8,,1363,B,H,BAO_0000019,
HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,CHEMBL616437,17211,106,,308.0,,,Autocuration,,1,,8,,1364,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,CHEMBL616438,17211,106,,308.0,,,Autocuration,,1,,8,,1365,B,H,BAO_0000219,
HeLa,,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,CHEMBL616439,17211,106,,308.0,,,Autocuration,,1,,8,,1366,B,H,BAO_0000219,
,Homo sapiens,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,CHEMBL616440,15926,106,,,,,Expert,,1,,9,9606.0,1367,B,D,BAO_0000357,
CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,CHEMBL616441,16312,106,,485.0,,,Autocuration,,1,,8,,1368,B,H,BAO_0000219,
,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,CHEMBL616442,5843,106,,,,,Expert,,1,,8,,1369,B,H,BAO_0000357,
,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,CHEMBL616443,5843,106,,,,,Autocuration,,1,,8,,1370,B,H,BAO_0000357,
CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,CHEMBL616444,16312,106,,485.0,,,Expert,,1,,8,,1371,B,H,BAO_0000219,
,Homo sapiens,,,Binding activity against human 5-hydroxytryptamine 1B receptor,CHEMBL616445,15926,106,,,,,Expert,,1,,9,9606.0,1372,B,D,BAO_0000357,
,Homo sapiens,,,Binding activity against human 5-hydroxytryptamine 1B receptor,CHEMBL616446,15926,106,,,,,Expert,,1,,9,9606.0,1373,B,D,BAO_0000357,
CHO,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616447,4540,106,,449.0,,,Expert,,1,,9,9606.0,1374,B,D,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,CHEMBL616448,6166,106,,,,,Autocuration,,1,,8,,1375,B,H,BAO_0000357,
CHO,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,CHEMBL616449,17296,106,,449.0,,,Autocuration,,1,,8,,1376,B,H,BAO_0000219,
CHO,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,CHEMBL616450,17296,106,,449.0,,,Autocuration,,1,,8,,1377,B,H,BAO_0000219,
CHO,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,CHEMBL857974,17296,106,,449.0,,,Autocuration,,1,,8,,1378,B,H,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL616451,15779,106,,449.0,,,Autocuration,,1,,8,,1379,B,H,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL616452,15779,106,,449.0,,,Autocuration,,1,,8,,1380,B,H,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHEMBL616453,15779,106,,449.0,,,Autocuration,,1,,8,,1381,B,H,BAO_0000219,
CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616454,4199,106,,449.0,,,Autocuration,,1,,8,,1382,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,CHEMBL616455,14875,106,,,,,Expert,,1,,9,9606.0,1383,B,D,BAO_0000357,
CHO,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHEMBL616456,15146,106,,449.0,,,Autocuration,,1,,8,,1384,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616457,5213,106,,,,,Autocuration,,1,,8,,1385,B,H,BAO_0000357,
CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHEMBL616458,14818,106,,449.0,,,Autocuration,,1,,8,,1386,B,H,BAO_0000219,
CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616459,4829,106,,449.0,,,Autocuration,,1,,8,,1387,B,H,BAO_0000219,
,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,CHEMBL616460,14454,106,,,,,Expert,,1,,8,,1388,F,H,BAO_0000019,
,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,CHEMBL616461,14454,106,,,,,Expert,,1,,8,,1389,F,H,BAO_0000019,
CHO,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHEMBL616462,14875,106,,449.0,,,Autocuration,,1,,8,,1390,F,H,BAO_0000219,
CHO,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHEMBL616463,14875,106,,449.0,,,Autocuration,,1,,8,,1391,F,H,BAO_0000219,
,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",CHEMBL616464,15250,105,,,,,Autocuration,,1,,8,,1392,F,H,BAO_0000019,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,CHEMBL616465,15250,105,,449.0,,,Autocuration,,1,,8,,1393,B,H,BAO_0000219,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL832874,15086,17105,,,,,Autocuration,,1,,8,,1394,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,CHEMBL616184,3025,106,,,,,Autocuration,,1,,8,9986.0,1395,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,CHEMBL616185,14998,106,,,,,Autocuration,,1,,8,9986.0,1396,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",CHEMBL616186,14998,106,,,,,Intermediate,,1,,8,9986.0,1397,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,CHEMBL616187,14998,106,,,,,Autocuration,,1,,8,9986.0,1398,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,CHEMBL616188,13969,10577,,,,,Expert,,1,,8,,1399,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,CHEMBL873475,13392,10577,,,,,Intermediate,,1,,9,,1400,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,CHEMBL616189,3651,10577,,,Striatum,2435.0,Expert,,1,,9,10116.0,1401,B,D,BAO_0000019,
,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,CHEMBL616190,10025,10577,,,,,Expert,,1,,8,,1402,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,CHEMBL616191,13863,10576,,,,,Autocuration,,1,,8,,1403,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,CHEMBL616192,13863,10576,,,,,Autocuration,,1,,8,,1404,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,CHEMBL616193,13863,10576,,,,,Autocuration,,1,,8,,1405,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,CHEMBL616194,13863,10576,,,,,Autocuration,,1,,8,,1406,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,CHEMBL616195,13863,10576,,,,,Autocuration,,1,,8,,1407,B,H,BAO_0000357,
,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,CHEMBL616196,13863,10576,,,,,Autocuration,,1,,8,,1408,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,CHEMBL616197,4622,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1409,B,H,BAO_0000249,
,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,CHEMBL616198,14911,10576,,,,,Intermediate,,1,,8,,1410,B,H,BAO_0000019,
,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,CHEMBL616199,12678,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1411,B,H,BAO_0000221,
,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,CHEMBL616200,12678,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1412,B,H,BAO_0000221,
,,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616201,14235,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1413,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,CHEMBL616202,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1414,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,CHEMBL616203,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1415,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,CHEMBL616204,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1416,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,CHEMBL616205,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1417,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,CHEMBL616206,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1418,B,H,BAO_0000221,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,CHEMBL616207,16118,10576,,,,,Expert,,1,,8,,1419,B,H,BAO_0000249,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,CHEMBL616208,3268,10576,,,,,Autocuration,,1,,8,,1420,B,H,BAO_0000249,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,CHEMBL616209,3268,10576,,,,,Autocuration,,1,,8,,1421,B,H,BAO_0000249,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,CHEMBL616210,16117,10576,,,,,Expert,,1,,8,,1422,B,H,BAO_0000357,
,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,CHEMBL616211,9783,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1423,B,H,BAO_0000221,
,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,CHEMBL616504,9783,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1424,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616505,14356,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1425,B,D,BAO_0000221,
,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,CHEMBL616506,15740,10576,,,,,Autocuration,,1,,8,,1426,F,H,BAO_0000019,
,,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,CHEMBL872107,12306,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1427,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,CHEMBL616507,13348,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1428,B,D,BAO_0000221,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,CHEMBL616303,10394,10576,,,,,Autocuration,,1,,8,,1429,B,H,BAO_0000249,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,CHEMBL616304,15260,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1430,B,H,BAO_0000221,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL616305,10046,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1431,B,H,BAO_0000221,
,,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,CHEMBL616306,15260,10576,,,Hippocampus,10000000.0,Intermediate,,1,,8,,1432,F,H,BAO_0000221,
,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,CHEMBL616307,12851,10576,,,,,Autocuration,,1,,8,,1433,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,CHEMBL881829,2148,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1434,B,D,BAO_0000221,
,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,CHEMBL616308,13134,10576,,,,,Expert,,1,,8,,1435,B,H,BAO_0000357,
,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,CHEMBL616309,12462,10576,,,,,Autocuration,,1,,8,,1436,B,H,BAO_0000019,
,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,CHEMBL616310,12462,10576,,,,,Expert,,1,,8,,1437,B,H,BAO_0000019,
CHO,,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,CHEMBL616311,12462,10576,,449.0,,,Autocuration,,1,,8,,1438,B,H,BAO_0000219,
,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,CHEMBL616312,11933,10576,,,,,Expert,,1,,8,,1439,B,H,BAO_0000357,
,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,CHEMBL616313,11933,10576,,,,,Autocuration,,1,,8,,1440,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,CHEMBL616314,403,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1441,B,D,BAO_0000221,
,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616315,15538,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1442,B,H,BAO_0000221,
,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,CHEMBL616567,15538,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1443,B,H,BAO_0000221,
,,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,CHEMBL616568,15538,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1444,B,H,BAO_0000221,
,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,CHEMBL616569,12464,10576,,,,,Intermediate,,1,,8,,1445,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,CHEMBL616570,1455,10576,,,,,Expert,,1,,8,,1446,B,H,BAO_0000357,
,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,CHEMBL616571,12652,10576,,,,,Autocuration,,1,,8,,1447,B,H,BAO_0000357,
,,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,CHEMBL616572,12639,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1448,B,H,BAO_0000221,
,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,CHEMBL616573,13949,10576,,,,,Expert,,1,,8,,1449,B,H,BAO_0000249,
,Rattus norvegicus,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,CHEMBL616574,12463,10576,,,,,Expert,,1,,9,10116.0,1450,B,D,BAO_0000357,
,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,CHEMBL616575,14829,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1451,B,H,BAO_0000221,
,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,CHEMBL872108,14829,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1452,B,H,BAO_0000221,
,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,CHEMBL616576,12092,10576,,,,,Autocuration,,1,,8,,1453,B,H,BAO_0000357,
,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,CHEMBL616577,403,10576,,,,,Autocuration,,1,,8,,1454,B,H,BAO_0000249,
,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,CHEMBL616578,403,10576,,,,,Autocuration,,1,,8,,1455,B,H,BAO_0000249,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,CHEMBL616579,3967,10576,,,,,Expert,,1,,8,,1456,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,CHEMBL616580,12771,10576,,,,,Expert,,1,,9,10116.0,1457,B,D,BAO_0000019,
,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,CHEMBL616581,15086,10576,,,,,Autocuration,,1,,8,,1458,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616582,14909,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1459,B,H,BAO_0000221,
,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,CHEMBL616583,14949,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1460,B,H,BAO_0000221,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,CHEMBL616584,2309,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1461,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616585,4170,10576,,,,,Expert,,1,,8,,1462,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,CHEMBL616586,11642,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1463,B,D,BAO_0000221,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,CHEMBL616587,11642,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1464,B,H,BAO_0000221,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,CHEMBL616588,12953,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1465,B,H,BAO_0000221,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,CHEMBL616589,12953,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1466,B,H,BAO_0000221,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,CHEMBL616590,12953,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1467,B,H,BAO_0000221,
CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",CHEMBL616591,12903,10576,,449.0,,,Expert,,1,,8,,1468,B,H,BAO_0000219,
,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616592,12536,10576,,,,,Expert,,1,,8,,1469,B,H,BAO_0000357,
,,,,The inhibition activity of 5-HT1A at 1 uM,CHEMBL616593,10058,10576,,,,,Autocuration,,1,,8,,1470,B,H,BAO_0000357,
CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",CHEMBL616594,12902,10576,,485.0,,,Expert,,1,,8,,1471,B,H,BAO_0000219,
,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,CHEMBL616595,14057,10576,,,,,Expert,,1,,8,,1472,B,H,BAO_0000249,
,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,CHEMBL616596,11296,10576,,,,,Autocuration,,1,,8,,1473,B,H,BAO_0000357,
,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616597,11296,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1474,B,H,BAO_0000221,
,,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,CHEMBL616598,11296,10576,,,Hippocampus,10000000.0,Expert,,1,,8,,1475,B,H,BAO_0000221,
,Rattus norvegicus,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,CHEMBL616599,16616,10576,Membranes,,,,Expert,,1,,9,10116.0,1476,F,D,BAO_0000249,
,Rattus norvegicus,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",CHEMBL616600,16616,10576,Membranes,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1477,F,D,BAO_0000249,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,CHEMBL616601,16567,10576,,,,,Autocuration,,1,,8,,1478,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,CHEMBL616602,16567,10576,,,,,Autocuration,,1,,8,,1479,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,CHEMBL616603,16567,10576,,,,,Autocuration,,1,,8,,1480,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,CHEMBL616604,16567,10576,,,,,Autocuration,,1,,8,,1481,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,CHEMBL616316,17136,10576,,,,,Autocuration,,1,,8,,1482,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,CHEMBL616317,17136,10576,,,,,Autocuration,,1,,8,,1483,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,CHEMBL616318,16616,10576,,,,,Expert,,1,,9,10116.0,1484,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,CHEMBL616319,17331,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1485,B,H,BAO_0000221,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,CHEMBL616320,17331,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1486,B,H,BAO_0000221,
,Rattus norvegicus,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,CHEMBL616321,17167,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1487,B,D,BAO_0000221,
,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,CHEMBL616322,15740,10576,,,,,Autocuration,,1,,8,,1488,F,H,BAO_0000019,
,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,CHEMBL616323,15740,10576,,,,,Autocuration,,1,,8,,1489,F,H,BAO_0000019,
,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,CHEMBL616324,4671,10576,,,,,Autocuration,,1,,8,,1490,B,H,BAO_0000357,
,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,CHEMBL616325,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1491,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,CHEMBL616326,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1492,B,H,BAO_0000221,
,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,CHEMBL616327,10058,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1493,B,H,BAO_0000221,
,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,CHEMBL616328,12073,10576,,,,,Autocuration,,1,,8,,1494,B,H,BAO_0000357,
,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),CHEMBL858110,2759,10576,,,,,Autocuration,,1,,8,,1495,B,H,BAO_0000249,
,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),CHEMBL616329,2759,10576,,,,,Autocuration,,1,,8,,1496,F,H,BAO_0000249,
,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),CHEMBL616330,2759,10576,,,,,Autocuration,,1,,8,,1497,B,H,BAO_0000249,
,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),CHEMBL616331,2759,10576,,,,,Autocuration,,1,,8,,1498,F,H,BAO_0000249,
,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,CHEMBL616332,2759,10576,,,,,Autocuration,,1,,8,,1499,F,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL857063,9737,10576,,,Brain,955.0,Autocuration,,1,,8,,1500,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,CHEMBL616333,9737,10576,,,,,Autocuration,,1,,8,,1501,B,H,BAO_0000019,
,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,CHEMBL616334,5717,10576,,,,,Expert,,1,,8,,1502,F,H,BAO_0000019,
,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL616335,12253,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1503,B,H,BAO_0000221,
,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,CHEMBL616336,14025,10576,,,,,Autocuration,,1,,8,,1504,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,CHEMBL616337,10425,10576,,,,,Expert,,1,,8,,1505,B,H,BAO_0000249,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,CHEMBL616338,14998,10576,,,,,Autocuration,,1,,8,,1506,B,H,BAO_0000019,
,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,CHEMBL616339,13694,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1507,B,H,BAO_0000221,
,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,CHEMBL616340,13694,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1508,B,H,BAO_0000221,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,CHEMBL616341,4342,10576,,,,,Autocuration,,1,,8,,1509,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,CHEMBL616342,12936,10576,,,,,Expert,,1,,9,10116.0,1510,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,CHEMBL616343,13144,10576,,,,,Expert,,1,,9,10116.0,1511,B,D,BAO_0000019,
,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,CHEMBL616344,13343,10576,,,,,Expert,,1,,8,,1512,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL616345,12132,10576,,,,,Expert,,1,,8,,1513,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,CHEMBL616346,15419,10576,,,,,Expert,,1,,8,,1514,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,CHEMBL616347,1479,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1515,B,H,BAO_0000221,
,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,CHEMBL616348,14287,10576,,,,,Expert,,1,,8,,1516,B,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616349,13116,10576,,,,,Expert,,1,,8,,1517,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,CHEMBL616152,2759,10576,Membranes,,,,Expert,,1,,9,10116.0,1518,B,D,BAO_0000249,
,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,CHEMBL616153,2759,10576,,,,,Autocuration,,1,,8,,1519,B,H,BAO_0000249,
,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",CHEMBL616154,14748,10576,,,,,Expert,,1,,8,,1520,B,H,BAO_0000019,
,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,CHEMBL616155,12304,10576,,,,,Autocuration,,1,,8,,1521,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,CHEMBL616156,12409,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1522,B,D,BAO_0000221,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,CHEMBL616157,12409,10576,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,1523,B,D,BAO_0000221,
,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,CHEMBL616158,13267,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1524,B,H,BAO_0000221,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,CHEMBL616159,15194,10576,,,,,Autocuration,,1,,8,,1525,B,H,BAO_0000357,
,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,CHEMBL616160,14256,10576,,,,,Expert,,1,,8,,1526,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,CHEMBL616161,16567,10576,,,,,Autocuration,,1,,8,,1527,B,H,BAO_0000019,
,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,CHEMBL616162,15740,10576,,,,,Autocuration,,1,,8,,1528,F,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,CHEMBL616163,13278,12687,,,,,Expert,,1,,9,10116.0,1529,B,D,BAO_0000357,
,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,CHEMBL616164,1970,10626,Membranes,,,,Expert,,1,,8,,1530,B,H,BAO_0000249,
,,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,CHEMBL616165,10034,10576,,,Brain,955.0,Autocuration,,1,,8,,1531,B,H,BAO_0000221,
,Rattus norvegicus,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,CHEMBL616355,13348,51,,,,,Autocuration,,1,,8,10116.0,1532,B,H,BAO_0000019,
,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,CHEMBL616356,13630,10576,,,,,Autocuration,,1,,8,,1533,F,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,CHEMBL616357,10862,10576,,,Brain,955.0,Autocuration,,1,,8,,1534,B,H,BAO_0000221,
,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",CHEMBL616358,12058,10576,,,,,Autocuration,,1,,8,,1535,B,H,BAO_0000019,
,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616359,4639,51,,,,,Autocuration,,1,,8,,1536,B,H,BAO_0000357,
,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,CHEMBL616360,15453,51,,,,,Expert,,1,,8,,1537,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL616361,4820,51,,,,,Expert,,1,,8,,1538,B,H,BAO_0000357,
,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616362,1089,51,,,,,Autocuration,,1,,8,,1539,B,H,BAO_0000357,
,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,CHEMBL616363,386,51,Brain membranes,,,,Autocuration,,1,,8,,1540,B,H,BAO_0000249,
,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,CHEMBL616364,6011,51,,,,,Autocuration,,1,,8,,1541,B,H,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,CHEMBL616365,5014,51,,,,,Autocuration,,1,,8,,1542,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,CHEMBL616366,4402,51,,,,,Expert,,1,,8,,1543,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,CHEMBL872906,17066,51,,,,,Expert,,1,,8,,1544,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,CHEMBL616367,17515,51,,,,,Autocuration,,1,,8,,1545,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616368,2474,51,,,,,Autocuration,,1,,8,,1546,B,H,BAO_0000357,
,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,CHEMBL616369,4775,51,,,,,Autocuration,,1,,8,,1547,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,CHEMBL616370,14294,51,,,,,Expert,,1,,9,9606.0,1548,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,CHEMBL616371,14294,51,,,,,Expert,,1,,9,9606.0,1549,B,D,BAO_0000357,
CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616372,12249,51,,449.0,,,Autocuration,,1,,8,,1550,B,H,BAO_0000219,
,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,CHEMBL616373,11376,51,,,,,Expert,,1,,8,,1551,B,H,BAO_0000219,
,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,CHEMBL616374,2474,51,,,,,Autocuration,,1,,8,,1552,B,H,BAO_0000218,In vivo
,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,CHEMBL616375,13311,51,,,Hippocampus,10000000.0,Autocuration,,1,,8,,1553,B,H,BAO_0000221,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616376,4373,51,,,,,Autocuration,,1,,8,,1554,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,CHEMBL857064,1633,51,,,,,Expert,,1,,8,,1555,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616377,11866,51,,,,,Autocuration,,1,,8,,1556,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,CHEMBL616378,4373,51,,,,,Autocuration,,1,,8,,1557,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,CHEMBL616379,4687,51,,,,,Autocuration,,1,,8,,1558,B,H,BAO_0000357,
,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,CHEMBL616380,16946,11863,,,,,Autocuration,,1,,8,,1559,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,CHEMBL616381,13291,11863,,,,,Autocuration,,1,,8,,1560,B,H,BAO_0000357,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616382,14159,11863,,,,,Autocuration,,1,,8,,1561,B,H,BAO_0000357,
,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,CHEMBL616383,10812,11863,,,,,Autocuration,,1,,8,,1562,B,H,BAO_0000357,
CHO,Mus musculus,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,CHEMBL616350,3032,11863,,449.0,,,Expert,,1,,9,10090.0,1563,B,D,BAO_0000219,
,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,CHEMBL616351,16655,11863,,,,,Autocuration,,1,,8,,1564,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,CHEMBL616352,14532,11863,,,,,Autocuration,,1,,8,,1565,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616353,13944,11863,,,,,Autocuration,,1,,8,,1566,B,H,BAO_0000357,
,,,,Binding affinity against serotonergic 5-HT1a receptor,CHEMBL616354,13033,11863,,,,,Autocuration,,1,,8,,1567,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,CHEMBL616508,10321,11863,,,,,Autocuration,,1,,8,,1568,B,H,BAO_0000357,
,Mus musculus,,,Binding affinity for 5-hydroxytryptamine 1A receptor,CHEMBL616559,2968,11863,,,,,Expert,,1,,9,10090.0,1569,B,D,BAO_0000357,
,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,CHEMBL616560,13964,11863,,,,,Autocuration,,1,,8,,1570,B,H,BAO_0000357,
,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",CHEMBL616561,15527,11863,,,,,Autocuration,,1,,8,,1571,B,H,BAO_0000357,
CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616562,12248,11863,,449.0,,,Autocuration,,1,,8,,1572,B,H,BAO_0000219,
CHO,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHEMBL616563,12249,11863,,449.0,,,Autocuration,,1,,8,,1573,B,H,BAO_0000219,
,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,CHEMBL616564,15120,11863,,,,,Autocuration,,1,,8,,1574,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,CHEMBL616565,13313,11863,,,,,Autocuration,,1,,8,,1575,B,H,BAO_0000357,
,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,CHEMBL616566,2613,11863,,,,,Autocuration,,1,,8,,1576,B,H,BAO_0000218,
,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,CHEMBL616989,16700,11863,,,,,Autocuration,,1,,8,,1577,B,H,BAO_0000357,
,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,CHEMBL857975,2201,11863,,,,,Autocuration,,1,,8,,1578,B,H,BAO_0000357,
,Mus musculus,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616990,1274,11863,,,,,Expert,,1,,9,10090.0,1579,B,D,BAO_0000357,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,CHEMBL616991,1317,11863,,,,,Autocuration,,1,,8,,1580,B,H,BAO_0000357,
,,,,Tested against 5-hydroxytryptamine 1A receptor,CHEMBL616992,12146,11863,,,,,Autocuration,,1,,8,,1581,B,H,BAO_0000357,
,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL616993,14059,11863,,,,,Autocuration,,1,,8,,1582,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,CHEMBL616994,14025,106,,,,,Expert,,1,,8,9986.0,1583,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,CHEMBL616995,14025,106,,,,,Autocuration,,1,,8,9986.0,1584,B,H,BAO_0000019,
HEK293,Gorilla gorilla,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,CHEMBL616996,14447,105571,,722.0,,,Intermediate,,1,,9,9593.0,1585,B,D,BAO_0000219,
,Cavia porcellus,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,CHEMBL616997,3025,106,,,,,Autocuration,,1,,8,10141.0,1586,F,H,BAO_0000218,In vivo
,Cavia porcellus,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,CHEMBL616998,3025,106,,,,,Autocuration,,1,,8,10141.0,1587,F,H,BAO_0000218,In vivo
,Cavia porcellus,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,CHEMBL616999,15329,106,,,,,Autocuration,,1,,8,10141.0,1588,F,H,BAO_0000019,
,Cavia porcellus,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,CHEMBL617000,15329,106,,,,,Autocuration,,1,,8,10141.0,1589,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,CHEMBL617001,15847,106,,,,,Autocuration,,1,,8,10141.0,1590,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,CHEMBL858111,15847,106,,,,,Autocuration,,1,,8,10141.0,1591,F,H,BAO_0000019,
,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,CHEMBL617002,14165,106,,,,,Autocuration,,1,,8,,1592,F,H,BAO_0000019,
,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),CHEMBL617003,14214,106,,,,,Autocuration,,1,,8,,1593,F,H,BAO_0000019,
,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),CHEMBL617004,14214,106,,,,,Autocuration,,1,,8,,1594,F,H,BAO_0000019,
,Homo sapiens,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,CHEMBL617005,14214,106,,,,,Expert,,1,,9,9606.0,1595,F,D,BAO_0000019,
CHO-K1,Homo sapiens,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,CHEMBL616623,13729,106,,485.0,,,Expert,,1,,9,9606.0,1596,F,D,BAO_0000219,
CHO,,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,CHEMBL616624,3025,106,,449.0,,,Autocuration,,1,,8,,1597,F,H,BAO_0000219,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,CHEMBL883243,2391,106,,,,,Autocuration,,1,,8,,1598,B,H,BAO_0000357,
,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,CHEMBL616625,2391,106,,,,,Autocuration,,1,,8,,1599,F,H,BAO_0000019,
CHO,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",CHEMBL616626,14956,106,,449.0,,,Expert,,1,,8,,1600,F,H,BAO_0000219,
CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,CHEMBL616627,2598,106,,449.0,,,Autocuration,,1,,8,,1601,F,H,BAO_0000219,
CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,CHEMBL616628,2598,106,,449.0,,,Autocuration,,1,,8,,1602,F,H,BAO_0000219,
CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,CHEMBL616629,2598,106,,449.0,,,Autocuration,,1,,8,,1603,F,H,BAO_0000219,
CHO,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,CHEMBL616630,2598,106,,449.0,,,Autocuration,,1,,8,,1604,F,H,BAO_0000219,
,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL616631,14956,106,,,,,Expert,,1,,8,,1605,F,H,BAO_0000019,
,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL616632,14956,106,,,,,Autocuration,,1,,8,,1606,F,H,BAO_0000019,
,Homo sapiens,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,CHEMBL616633,14214,106,,,,,Expert,,1,,9,9606.0,1607,B,D,BAO_0000357,
CHO,,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,CHEMBL616634,3463,106,,449.0,,,Expert,,1,,8,,1608,B,H,BAO_0000219,
,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,CHEMBL616635,15331,106,,,,,Autocuration,,1,,8,,1609,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL885358,16146,106,,,,,Expert,,1,,9,9606.0,1610,B,D,BAO_0000357,
CHO,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHEMBL616636,14159,106,,449.0,,,Expert,,1,,9,9606.0,1611,B,D,BAO_0000219,
CHO,,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,CHEMBL616637,14158,106,,449.0,,,Expert,,1,,8,,1612,B,H,BAO_0000219,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,CHEMBL616638,14159,106,,,,,Autocuration,,1,,8,,1613,B,H,BAO_0000357,
CHO,,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHEMBL616639,15250,106,,449.0,,,Expert,,1,,8,,1614,B,H,BAO_0000219,
CHO,,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHEMBL616640,15250,106,,449.0,,,Expert,,1,,8,,1615,B,H,BAO_0000219,
CHO,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHEMBL616641,15331,106,,449.0,,,Expert,,1,,8,,1616,B,H,BAO_0000219,
CHO,,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,CHEMBL616642,15332,106,,449.0,,,Expert,,1,,8,,1617,B,H,BAO_0000219,
CHO,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHEMBL616643,14956,106,,449.0,,,Expert,,1,,8,,1618,B,H,BAO_0000219,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),CHEMBL616644,3805,106,,,,,Autocuration,,1,,8,,1619,B,H,BAO_0000357,
,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,CHEMBL616645,14875,106,,,,,Autocuration,,1,,8,,1620,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616646,14454,105,,,,,Autocuration,,1,,8,9986.0,1621,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616647,14454,105,,,,,Expert,,1,,8,9986.0,1622,F,H,BAO_0000019,
,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),CHEMBL616509,16288,105,,,,,Autocuration,,1,,8,,1623,B,H,BAO_0000357,
,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),CHEMBL616510,16288,105,,,,,Autocuration,,1,,8,,1624,B,H,BAO_0000357,
,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,CHEMBL616511,16312,105,,,,,Autocuration,,1,,8,,1625,B,H,BAO_0000357,
,Bos taurus,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,CHEMBL616512,1348,105,,,,,Expert,,1,,8,9913.0,1626,B,H,BAO_0000357,
,Bos taurus,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,CHEMBL616513,5834,105,,,,,Autocuration,,1,,8,9913.0,1627,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,CHEMBL616514,13366,105,,,Striatum,2435.0,Autocuration,,1,,8,9913.0,1628,B,H,BAO_0000019,
,Bos taurus,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,CHEMBL616515,1414,105,,,,,Expert,,1,,8,9913.0,1629,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,CHEMBL616516,14998,105,,,,,Autocuration,,1,,8,9913.0,1630,B,H,BAO_0000019,
,Bos taurus,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,CHEMBL616517,11473,105,,,,,Autocuration,,1,,8,9913.0,1631,B,H,BAO_0000357,
,Bos taurus,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,CHEMBL616518,11473,105,,,,,Autocuration,,1,,8,9913.0,1632,B,H,BAO_0000357,
,Bos taurus,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,CHEMBL616519,10639,105,,,,,Autocuration,,1,,8,9913.0,1633,B,H,BAO_0000357,
,Bos taurus,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,CHEMBL616520,10639,105,,,,,Autocuration,,1,,8,9913.0,1634,B,H,BAO_0000357,
,Bos taurus,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,CHEMBL616521,1375,105,,,,,Autocuration,,1,,8,9913.0,1635,B,H,BAO_0000357,
,Bos taurus,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,CHEMBL616522,1375,105,,,,,Autocuration,,1,,8,9913.0,1636,B,H,BAO_0000357,
,Bos taurus,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,CHEMBL884531,16532,105,,,,,Autocuration,,1,,8,9913.0,1637,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,CHEMBL616523,11147,105,,,,,Autocuration,,1,,8,9913.0,1638,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,CHEMBL616731,13366,105,,,Striatum,2435.0,Autocuration,,1,,8,9913.0,1639,B,H,BAO_0000019,
,Bos taurus,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,CHEMBL616732,10444,105,,,,,Autocuration,,1,,8,9913.0,1640,B,H,BAO_0000019,
,Bos taurus,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,CHEMBL616733,16532,105,,,,,Autocuration,,1,,8,9913.0,1641,B,H,BAO_0000357,
,Bos taurus,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,CHEMBL616734,16532,105,,,,,Autocuration,,1,,8,9913.0,1642,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,CHEMBL616735,12827,105,,,,,Autocuration,,1,,8,9913.0,1643,B,H,BAO_0000249,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,CHEMBL616736,12827,105,,,,,Autocuration,,1,,8,9913.0,1644,B,H,BAO_0000249,
,Bos taurus,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616737,12919,105,,,,,Expert,,1,,8,9913.0,1645,F,H,BAO_0000019,
,Bos taurus,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,CHEMBL616738,14025,105,,,,,Autocuration,,1,,8,9913.0,1646,B,H,BAO_0000019,
,Bos taurus,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616739,12919,105,,,,,Expert,,1,,8,9913.0,1647,F,H,BAO_0000019,
,Bos taurus,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616740,12919,105,,,,,Expert,,1,,8,9913.0,1648,F,H,BAO_0000019,
,Bos taurus,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,CHEMBL616741,12919,105,,,,,Expert,,1,,8,9913.0,1649,F,H,BAO_0000019,
HEK293,Gorilla gorilla,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,CHEMBL616742,14447,105,,722.0,,,Autocuration,,1,,8,9593.0,1650,B,H,BAO_0000219,
,Cavia porcellus,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,CHEMBL616743,1375,105570,,,,,Intermediate,,1,,9,10141.0,1651,B,D,BAO_0000019,
,Cavia porcellus,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,CHEMBL616744,1375,105570,,,,,Intermediate,,1,,9,10141.0,1652,B,D,BAO_0000019,
,Cavia porcellus,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,CHEMBL616745,12409,105570,,,,,Intermediate,,1,,9,10141.0,1653,F,D,BAO_0000019,
,Cavia porcellus,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616746,12409,105570,,,,,Intermediate,,1,,9,10141.0,1654,F,D,BAO_0000019,
,Cavia porcellus,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,CHEMBL616747,12409,105570,,,,,Intermediate,,1,,9,10141.0,1655,F,D,BAO_0000019,
,Cavia porcellus,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,CHEMBL616748,12409,105570,,,,,Intermediate,,1,,9,10141.0,1656,F,D,BAO_0000019,
,Cavia porcellus,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,CHEMBL616648,12409,105570,,,,,Intermediate,,1,,9,10141.0,1657,F,D,BAO_0000019,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616649,11574,105570,,,,,Intermediate,,1,,9,10141.0,1658,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,CHEMBL616650,1558,105570,,,,,Intermediate,,1,,9,10141.0,1659,B,D,BAO_0000357,
,Cavia porcellus,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616651,12409,105570,,,,,Intermediate,,1,,9,10141.0,1660,F,D,BAO_0000218,
,Cavia porcellus,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616652,12409,105570,,,,,Intermediate,,1,,9,10141.0,1661,F,D,BAO_0000218,
,Cavia porcellus,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,CHEMBL616653,12409,105570,,,,,Intermediate,,1,,9,10141.0,1662,F,D,BAO_0000218,
,Cavia porcellus,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,CHEMBL616654,12409,105570,,,,,Intermediate,,1,,9,10141.0,1663,F,D,BAO_0000218,
,Cavia porcellus,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,CHEMBL616655,12253,105570,,,,,Intermediate,,1,,9,10141.0,1664,B,D,BAO_0000019,
,Cavia porcellus,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,CHEMBL616656,12936,105570,,,,,Intermediate,,1,,9,10141.0,1665,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,CHEMBL616657,13181,105,,,,,Autocuration,,1,,8,10141.0,1666,B,H,BAO_0000019,
,Cavia porcellus,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,CHEMBL616658,12409,105570,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,1667,B,D,BAO_0000357,
,Cavia porcellus,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,CHEMBL616659,10639,105570,,,,,Intermediate,,1,,9,10141.0,1668,B,D,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616660,5254,51,,,,,Autocuration,,1,,8,,1669,B,H,BAO_0000357,
,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,CHEMBL616661,13051,106,,,,,Autocuration,,1,,8,,1670,B,H,BAO_0000357,
,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,CHEMBL616662,3463,105,,,,,Expert,,1,,8,,1671,F,H,BAO_0000019,
,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616663,15315,105,,,,,Autocuration,,1,,8,,1672,F,H,BAO_0000019,
,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616664,6011,105,,,,,Autocuration,,1,,8,,1673,F,H,BAO_0000019,
CHO,Homo sapiens,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",CHEMBL881820,14159,105,,449.0,,,Expert,,1,,9,9606.0,1674,F,D,BAO_0000219,
CHO,,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",CHEMBL616665,14159,105,,449.0,,,Autocuration,,1,,8,,1675,F,H,BAO_0000219,
CHO,,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHEMBL616666,15250,105,,449.0,,,Expert,,1,,8,,1676,B,H,BAO_0000219,
CHO,,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,CHEMBL616667,15250,105,,449.0,,,Autocuration,,1,,8,,1677,B,H,BAO_0000219,
CHO,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHEMBL616668,15331,105,,449.0,,,Expert,,1,,8,,1678,F,H,BAO_0000219,
CHO,Homo sapiens,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHEMBL616669,15332,105,,449.0,,,Expert,,1,,9,9606.0,1679,F,D,BAO_0000219,
CHO,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",CHEMBL617040,15332,105,,449.0,,,Expert,,1,,8,,1680,F,H,BAO_0000219,
CHO,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",CHEMBL617041,3294,105,,449.0,,,Autocuration,,1,,8,,1681,F,H,BAO_0000219,
CHO,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",CHEMBL617042,14158,105,,449.0,,,Expert,,1,,8,,1682,F,H,BAO_0000219,
CHO,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",CHEMBL617043,14956,105,,449.0,,,Expert,,1,,8,,1683,F,H,BAO_0000219,
,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,CHEMBL617044,12469,105,,,,,Autocuration,,1,,8,,1684,F,H,BAO_0000019,
CHO,,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHEMBL617045,3463,105,,449.0,,,Expert,,1,,8,,1685,F,H,BAO_0000219,
CHO,Homo sapiens,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHEMBL617046,15250,105,,449.0,,,Expert,,1,,9,9606.0,1686,F,D,BAO_0000219,
CHO,Homo sapiens,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHEMBL617047,15250,105,,449.0,,,Expert,,1,,9,9606.0,1687,F,D,BAO_0000219,
,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",CHEMBL617048,14956,105,,,,,Expert,,1,,8,,1688,F,H,BAO_0000019,
,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",CHEMBL616897,14159,105,,,,,Autocuration,,1,,8,,1689,F,H,BAO_0000019,
,Homo sapiens,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",CHEMBL616898,14159,105,,,,,Expert,,1,,9,9606.0,1690,F,D,BAO_0000019,
CHO,Homo sapiens,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,CHEMBL858201,14499,105,,449.0,,,Expert,,1,,9,9606.0,1691,F,D,BAO_0000219,
,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,CHEMBL616899,15315,105,,,,,Autocuration,,1,,8,,1692,F,H,BAO_0000019,
,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),CHEMBL616900,3294,105,,,,,Autocuration,,1,,8,,1693,B,H,BAO_0000219,In vitro
CHO,,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,CHEMBL616901,3463,105,,449.0,,,Expert,,1,,8,,1694,B,H,BAO_0000219,
,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,CHEMBL616902,15331,105,,,,,Autocuration,,1,,8,,1695,B,H,BAO_0000357,
CHO,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616903,14159,105,,449.0,,,Expert,,1,,9,9606.0,1696,B,D,BAO_0000219,
CHO,,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,CHEMBL616904,14158,105,,449.0,,,Expert,,1,,8,,1697,B,H,BAO_0000219,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,CHEMBL616905,14159,105,,,,,Autocuration,,1,,8,,1698,B,H,BAO_0000357,
CHO,,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHEMBL616906,15250,105,,449.0,,,Expert,,1,,8,,1699,B,H,BAO_0000219,
CHO,,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616907,15250,105,,449.0,,,Expert,,1,,8,,1700,B,H,BAO_0000219,
CHO,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616908,15331,105,,449.0,,,Expert,,1,,8,,1701,B,H,BAO_0000219,
CHO,Homo sapiens,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616909,15332,105,,449.0,,,Expert,,1,,9,9606.0,1702,B,D,BAO_0000219,
CHO,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616910,14499,105,,449.0,,,Expert,,1,,9,9606.0,1703,B,D,BAO_0000219,
CHO,,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHEMBL616911,15332,105,,449.0,,,Expert,,1,,8,,1704,B,H,BAO_0000219,
CHO,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHEMBL616912,14956,105,,449.0,,,Expert,,1,,8,,1705,B,H,BAO_0000219,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),CHEMBL616913,3805,105,,,,,Autocuration,,1,,8,,1706,B,H,BAO_0000357,
CHO,Homo sapiens,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,CHEMBL616914,6011,105,,449.0,,,Expert,,1,,9,9606.0,1707,B,D,BAO_0000219,
CHO,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616915,16190,105,,449.0,,,Autocuration,,1,,8,,1708,B,H,BAO_0000219,
,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,CHEMBL616916,14165,105,,,,,Autocuration,,1,,8,,1709,B,H,BAO_0000019,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616917,4234,105,,,,,Expert,,1,,9,9606.0,1710,B,D,BAO_0000357,
,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",CHEMBL616918,15527,105,,,,,Autocuration,,1,,8,,1711,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,CHEMBL616919,6328,105,,,,,Expert,,1,,8,,1712,B,H,BAO_0000219,
,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,CHEMBL616920,16209,105,,,,,Autocuration,,1,,8,,1713,B,H,BAO_0000357,
,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,CHEMBL872914,14770,105,,,,,Autocuration,,1,,8,,1714,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,CHEMBL616921,2598,105,,,,,Autocuration,,1,,8,,1715,B,H,BAO_0000357,
,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616922,6897,105,,,,,Expert,,1,,8,,1716,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,CHEMBL616923,6013,105,,,,,Autocuration,,1,,8,,1717,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616924,5843,105,,,,,Expert,,1,,8,,1718,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,CHEMBL875909,14454,105,,,,,Expert,,1,,8,,1719,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,CHEMBL616925,14454,105,,,,,Autocuration,,1,,8,,1720,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,CHEMBL616926,14454,105,,,,,Autocuration,,1,,8,,1721,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,CHEMBL616927,15818,105,,,,,Autocuration,,1,,8,,1722,B,H,BAO_0000357,
CHO-K1,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,CHEMBL616928,13729,105,,485.0,,,Expert,,1,,8,,1723,F,H,BAO_0000219,
,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),CHEMBL616929,6011,105,,,,,Expert,,1,,9,9606.0,1724,B,D,BAO_0000219,In vitro
,Homo sapiens,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,CHEMBL616930,4234,105,,,,,Expert,,1,,9,9606.0,1725,B,D,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616931,17085,105,,,,,Expert,,1,,8,,1726,B,H,BAO_0000019,
,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,CHEMBL616932,3025,105,,,,,Autocuration,,1,,8,,1727,B,H,BAO_0000357,
,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616933,15315,105,,,,,Expert,,1,,8,,1728,B,H,BAO_0000357,
,Homo sapiens,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,CHEMBL616934,14214,105,,,,,Expert,,1,,9,9606.0,1729,B,D,BAO_0000219,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616935,3804,105,,,,,Expert,,1,,9,9606.0,1730,B,D,BAO_0000357,
,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,CHEMBL616936,16700,105,,,,,Autocuration,,1,,8,,1731,B,H,BAO_0000357,
,Homo sapiens,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,CHEMBL616937,2391,105,,,,,Expert,,1,,9,9606.0,1732,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616938,4175,105,,,,,Expert,,1,,9,9606.0,1733,B,D,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,CHEMBL616939,17085,105,,,,,Autocuration,,1,,8,,1734,B,H,BAO_0000019,
,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,CHEMBL616940,17085,105,,,,,Expert,,1,,8,,1735,B,H,BAO_0000019,
,Homo sapiens,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,CHEMBL616941,15926,105,,,,,Expert,,1,,9,9606.0,1736,B,D,BAO_0000357,
CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,CHEMBL616942,16312,105,,485.0,,,Autocuration,,1,,8,,1737,B,H,BAO_0000219,
CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,CHEMBL616943,16312,105,,485.0,,,Autocuration,,1,,8,,1738,B,H,BAO_0000219,
CHO,,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,CHEMBL616944,14956,104802,,449.0,,,Autocuration,,1,,4,,1739,B,H,BAO_0000219,
,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",CHEMBL616945,3294,105,,,,,Autocuration,,1,,8,,1740,F,H,BAO_0000019,
,,,,Binding activity radioligand.,CHEMBL616946,12861,105,,,,,Autocuration,,1,,8,,1741,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL616947,12861,105,,,,,Autocuration,,1,,8,,1742,B,H,BAO_0000019,
CHO-K1,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,CHEMBL616948,16312,105,,485.0,,,Expert,,1,,8,,1743,B,H,BAO_0000219,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,CHEMBL616851,5104,105,,,,,Autocuration,,1,,8,,1744,B,H,BAO_0000357,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,CHEMBL616852,5105,105,,,,,Autocuration,,1,,8,,1745,B,H,BAO_0000357,
,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,CHEMBL616853,14499,105,,,,,Autocuration,,1,,8,,1746,B,H,BAO_0000357,
,Homo sapiens,,,Binding activity against human 5-hydroxytryptamine 1D receptor,CHEMBL616854,15926,105,,,,,Expert,,1,,9,9606.0,1747,B,D,BAO_0000357,
CHO,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL616855,4540,105,,449.0,,,Expert,,1,,9,9606.0,1748,B,D,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,CHEMBL616856,15779,105,,449.0,,,Autocuration,,1,,8,,1749,B,H,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL616857,15779,105,,449.0,,,Autocuration,,1,,8,,1750,B,H,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,CHEMBL616858,6166,105,,,,,Autocuration,,1,,8,,1751,B,H,BAO_0000357,
CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,CHEMBL616859,15779,105,,449.0,,,Autocuration,,1,,8,,1752,B,H,BAO_0000219,
CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,CHEMBL616860,15779,105,,449.0,,,Autocuration,,1,,8,,1753,B,H,BAO_0000219,
HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,CHEMBL616861,17451,105,,722.0,,,Autocuration,,1,,8,,1754,B,H,BAO_0000219,
HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,CHEMBL616541,17451,105,,722.0,,,Autocuration,,1,,8,,1755,B,H,BAO_0000219,
HEK293,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,CHEMBL616542,17451,105,,722.0,,,Autocuration,,1,,8,,1756,B,H,BAO_0000219,
CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616543,4199,105,,449.0,,,Autocuration,,1,,8,,1757,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,CHEMBL616544,14875,105,,,,,Expert,,1,,9,9606.0,1758,B,D,BAO_0000357,
CHO,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,CHEMBL616545,15146,105,,449.0,,,Autocuration,,1,,8,,1759,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616546,5213,105,,,,,Autocuration,,1,,8,,1760,B,H,BAO_0000357,
CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,CHEMBL616547,14818,105,,449.0,,,Autocuration,,1,,8,,1761,B,H,BAO_0000219,
CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616548,4829,105,,449.0,,,Autocuration,,1,,8,,1762,B,H,BAO_0000219,
,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,CHEMBL616549,14454,105,,,,,Expert,,1,,8,,1763,F,H,BAO_0000019,
,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,CHEMBL616550,14454,105,,,,,Expert,,1,,8,,1764,F,H,BAO_0000019,
,,,,Binding affinity against 5-HT2C receptor,CHEMBL857066,5254,108,,,,,Autocuration,,1,,8,,1765,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL616551,5254,108,,,,,Autocuration,,1,,8,,1766,B,H,BAO_0000357,
,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,CHEMBL616552,10639,10577,,,,,Autocuration,,1,,8,,1767,B,H,BAO_0000357,
,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,CHEMBL832876,10639,10577,,,,,Autocuration,,1,,8,,1768,F,H,BAO_0000019,
,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",CHEMBL616553,12352,10577,,,,,Expert,,1,,8,,1769,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT1B was determined,CHEMBL616554,9098,10577,,,,,Autocuration,,1,,8,,1770,B,H,BAO_0000357,
,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,CHEMBL616555,14430,10577,,,,,Expert,,1,,8,,1771,B,H,BAO_0000019,
,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",CHEMBL616556,13657,10577,,,,,Expert,,1,,8,,1772,B,H,BAO_0000019,
,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",CHEMBL616557,13657,10577,,,,,Autocuration,,1,,8,,1773,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL616558,15854,10577,,,,,Expert,,1,,8,,1774,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,CHEMBL616749,10639,10577,,,,,Expert,,1,,9,10116.0,1775,B,D,BAO_0000019,
,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,CHEMBL616750,10025,10577,,,,,Autocuration,,1,,8,,1776,B,H,BAO_0000357,
,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",CHEMBL616751,10025,10577,,,,,Autocuration,,1,,8,,1777,B,H,BAO_0000357,
,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,CHEMBL616752,14286,10577,,,,,Autocuration,,1,,8,,1778,B,H,BAO_0000249,
,,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,CHEMBL616753,3651,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1779,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,CHEMBL616754,14178,10577,,,,,Expert,,1,,9,10116.0,1780,B,D,BAO_0000357,
,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,CHEMBL616755,10639,10577,,,,,Autocuration,,1,,8,,1781,B,H,BAO_0000019,
,,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,CHEMBL616756,13605,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1782,B,H,BAO_0000019,
,,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,CHEMBL616757,5834,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1783,B,H,BAO_0000019,
,,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,CHEMBL616758,10922,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1784,B,H,BAO_0000357,
,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,CHEMBL616759,14286,10577,,,,,Autocuration,,1,,8,,1785,B,H,BAO_0000249,
,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,CHEMBL616760,11825,10577,,,,,Autocuration,,1,,8,,1786,B,H,BAO_0000357,
,,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,CHEMBL616761,14826,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1787,B,H,BAO_0000019,
,,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,CHEMBL616762,9699,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1788,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,CHEMBL616763,14423,10577,,,,,Autocuration,,1,,8,,1789,B,H,BAO_0000019,
,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,CHEMBL872909,10062,10577,,,,,Expert,,1,,8,,1790,B,H,BAO_0000357,
,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,CHEMBL616764,10062,10577,,,,,Autocuration,,1,,8,,1791,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,CHEMBL616765,12280,10577,,,,,Expert,,1,,9,10116.0,1792,B,D,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,CHEMBL616766,15412,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1793,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,CHEMBL616767,15412,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1794,B,H,BAO_0000357,
,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,CHEMBL616768,10062,10577,,,,,Autocuration,,1,,8,,1795,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,CHEMBL616769,11147,10577,,,,,Autocuration,,1,,8,,1796,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,CHEMBL616770,9547,10577,,,,,Autocuration,,1,,8,,1797,B,H,BAO_0000019,
,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616771,10444,10577,,,,,Autocuration,,1,,8,,1798,B,H,BAO_0000019,
,,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,CHEMBL616772,12469,10577,,,Striatum,2435.0,Autocuration,,1,,8,,1799,B,H,BAO_0000019,
,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,CHEMBL616773,9098,10577,,,,,Expert,,1,,8,,1800,B,H,BAO_0000019,
,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,CHEMBL616774,9098,10577,,,,,Autocuration,,1,,8,,1801,B,H,BAO_0000019,
,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616775,9699,10577,,,,,Autocuration,,1,,8,,1802,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,CHEMBL616776,10394,10577,,,,,Autocuration,,1,,8,,1803,B,H,BAO_0000249,
,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,CHEMBL616777,12092,10577,,,,,Autocuration,,1,,8,,1804,B,H,BAO_0000357,
,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,CHEMBL616778,16700,10577,,,,,Autocuration,,1,,8,,1805,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,CHEMBL616779,403,10577,,,,,Expert,,1,,9,10116.0,1806,B,D,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,CHEMBL616780,12771,10577,,,,,Expert,,1,,9,10116.0,1807,B,D,BAO_0000357,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,CHEMBL616781,11642,10577,,,,,Autocuration,,1,,8,,1808,B,H,BAO_0000019,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,CHEMBL616782,12953,10577,,,,,Autocuration,,1,,8,,1809,B,H,BAO_0000357,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,CHEMBL616783,12953,10577,,,,,Autocuration,,1,,8,,1810,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,CHEMBL616784,12953,10577,,,Striatum,2435.0,Expert,,1,,8,,1811,B,H,BAO_0000019,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,CHEMBL616785,12953,10577,,,,,Autocuration,,1,,8,,1812,B,H,BAO_0000357,
,,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL857067,9737,10577,,,Brain,955.0,Autocuration,,1,,8,,1813,B,H,BAO_0000249,
,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,CHEMBL616786,9737,10577,,,,,Autocuration,,1,,8,,1814,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL616787,9737,10577,,,Brain,955.0,Autocuration,,1,,8,,1815,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,CHEMBL616788,12827,10577,,,,,Autocuration,,1,,8,,1816,B,H,BAO_0000357,
,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,CHEMBL616789,5033,10577,,,,,Autocuration,,1,,8,,1817,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,CHEMBL616790,9786,10577,,,,,Expert,,1,,9,10116.0,1818,B,D,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,CHEMBL616791,13116,10577,,,,,Expert,,1,,8,,1819,B,H,BAO_0000357,
,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,CHEMBL616792,16429,10577,,,,,Autocuration,,1,,8,,1820,B,H,BAO_0000019,
,Rattus norvegicus,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,CHEMBL616793,12409,10577,,,,,Expert,,1,,9,10116.0,1821,B,D,BAO_0000249,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,CHEMBL616794,15194,10577,,,,,Autocuration,,1,,8,,1822,B,H,BAO_0000357,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616795,15194,10577,,,,,Autocuration,,1,,8,,1823,B,H,BAO_0000357,
,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,CHEMBL616796,5486,104686,,,,,Autocuration,,1,,4,,1824,B,H,BAO_0000019,
,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL616797,4639,106,,,,,Autocuration,,1,,8,,1825,B,H,BAO_0000357,
,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,CHEMBL616798,386,106,Brain membranes,,,,Autocuration,,1,,8,,1826,B,H,BAO_0000249,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,CHEMBL616799,2474,106,,,,,Autocuration,,1,,8,,1827,B,H,BAO_0000357,
,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,CHEMBL616800,6011,106,,,,,Autocuration,,1,,8,,1828,B,H,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,CHEMBL616801,5014,106,,,,,Autocuration,,1,,8,,1829,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,CHEMBL616802,17515,106,,,,,Autocuration,,1,,8,,1830,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,CHEMBL616803,4373,106,,,,,Autocuration,,1,,8,,1831,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,CHEMBL857068,1633,106,,,,,Expert,,1,,8,,1832,B,H,BAO_0000357,
,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,CHEMBL616804,1633,106,,,,,Autocuration,,1,,8,,1833,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,CHEMBL616805,4373,106,,,,,Autocuration,,1,,8,,1834,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,CHEMBL616806,4687,106,,,,,Autocuration,,1,,8,,1835,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,CHEMBL616807,11574,106,,,,,Autocuration,,1,,8,,1836,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,CHEMBL616808,10321,106,,,,,Autocuration,,1,,8,,1837,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,CHEMBL616809,15527,106,,,,,Autocuration,,1,,8,,1838,B,H,BAO_0000357,
,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,CHEMBL616810,17200,106,,,,,Autocuration,,1,,8,,1839,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,CHEMBL616811,14423,104802,,,,,Autocuration,,1,,4,,1840,B,H,BAO_0000224,
,Bos taurus,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,CHEMBL616812,5834,108,,,,,Autocuration,,1,,8,9913.0,1841,B,H,BAO_0000357,
,Sus scrofa,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,CHEMBL616813,11473,108,,,,,Autocuration,,1,,8,9823.0,1842,B,H,BAO_0000357,
,Sus scrofa,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,CHEMBL616814,11473,108,,,,,Autocuration,,1,,8,9823.0,1843,B,H,BAO_0000357,
,Sus scrofa,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,CHEMBL616815,10639,108,,,,,Autocuration,,1,,8,9823.0,1844,B,H,BAO_0000357,
,Sus scrofa,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,CHEMBL616816,10639,108,,,,,Autocuration,,1,,8,9823.0,1845,B,H,BAO_0000357,
,Sus scrofa,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,CHEMBL616817,14331,108,,,,,Autocuration,,1,,8,9823.0,1846,B,H,BAO_0000357,
,Sus scrofa,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,CHEMBL616818,10796,108,,,,,Autocuration,,1,,8,9823.0,1847,B,H,BAO_0000357,
,Sus scrofa,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,CHEMBL616819,9098,108,,,,,Expert,,1,,8,9823.0,1848,B,H,BAO_0000357,
,Sus scrofa,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,CHEMBL616820,14331,108,,,,,Expert,,1,,8,9823.0,1849,B,H,BAO_0000357,
,Sus scrofa,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,CHEMBL616821,11828,108,,,,,Expert,,1,,8,9823.0,1850,B,H,BAO_0000019,
,Sus scrofa,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,CHEMBL616822,11866,108,,,,,Autocuration,,1,,8,9823.0,1851,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,CHEMBL616823,13047,108,,,,,Autocuration,,1,,8,9986.0,1852,B,H,BAO_0000019,
,Rattus norvegicus,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,CHEMBL616824,188,12689,,,,,Autocuration,,1,,9,10116.0,1853,B,D,BAO_0000357,
,Rattus norvegicus,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,CHEMBL616825,11825,12689,,,,,Autocuration,,1,,9,10116.0,1854,B,D,BAO_0000357,
,Rattus norvegicus,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,CHEMBL616826,11825,12689,,,,,Autocuration,,1,,9,10116.0,1855,B,D,BAO_0000357,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,CHEMBL616827,11624,12689,,,,,Expert,,1,,9,10116.0,1856,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,CHEMBL616828,11139,12689,,,,,Autocuration,,1,,9,10116.0,1857,B,D,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,CHEMBL616829,11147,12689,,,,,Autocuration,,1,,9,10116.0,1858,B,D,BAO_0000357,
,Rattus norvegicus,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,CHEMBL616830,10444,12689,,,,,Autocuration,,1,,9,10116.0,1859,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616831,11624,12689,,,,,Expert,,1,,9,10116.0,1860,B,D,BAO_0000357,
,Rattus norvegicus,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616832,11662,12689,,,,,Autocuration,,1,,9,10116.0,1861,B,D,BAO_0000019,
,Rattus norvegicus,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616833,11662,12689,,,,,Autocuration,,1,,9,10116.0,1862,B,D,BAO_0000019,
,Rattus norvegicus,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL616834,11662,12689,,,,,Expert,,1,,9,10116.0,1863,B,D,BAO_0000019,
,Rattus norvegicus,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",CHEMBL829595,11662,12689,,,,,Autocuration,,1,,9,10116.0,1864,B,D,BAO_0000019,
,Rattus norvegicus,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,CHEMBL616835,9098,12689,,,,,Autocuration,,1,,9,10116.0,1865,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,CHEMBL872910,10394,12689,,,,,Autocuration,,1,,9,10116.0,1866,B,D,BAO_0000249,
,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,CHEMBL616836,11933,12689,,,,,Expert,,1,,8,,1867,B,H,BAO_0000357,
,Rattus norvegicus,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,CHEMBL616837,12092,12689,,,,,Autocuration,,1,,9,10116.0,1868,B,D,BAO_0000357,
,Rattus norvegicus,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,CHEMBL616466,12253,12689,,,,,Autocuration,,1,,9,10116.0,1869,B,D,BAO_0000019,
HEK293,Rattus norvegicus,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,CHEMBL616467,12253,12689,,722.0,,,Autocuration,,1,,9,10116.0,1870,B,D,BAO_0000219,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,CHEMBL616468,1558,108,,,,,Autocuration,,1,,8,,1871,B,H,BAO_0000357,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,CHEMBL616469,2474,108,,,,,Autocuration,,1,,8,,1872,B,H,BAO_0000357,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,CHEMBL616470,2474,108,,,,,Autocuration,,1,,8,,1873,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616471,11574,12689,,,,,Autocuration,,1,,8,,1874,B,H,BAO_0000357,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,CHEMBL616472,1558,12689,,,,,Autocuration,,1,,8,,1875,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,CHEMBL616473,13944,12689,,,,,Autocuration,,1,,8,,1876,B,H,BAO_0000357,
,,,,Binding affinity against serotonergic 5-HT1c receptor,CHEMBL616474,13033,12689,,,,,Autocuration,,1,,8,,1877,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,CHEMBL616475,10321,12689,,,,,Autocuration,,1,,8,,1878,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,CHEMBL616476,11866,12689,,,,,Autocuration,,1,,8,,1879,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),CHEMBL616477,14454,105,,,,,Autocuration,,1,,8,9986.0,1880,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,CHEMBL616478,11574,104686,,,,,Autocuration,,1,,4,,1881,B,H,BAO_0000224,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,CHEMBL616479,11574,104686,,,,,Autocuration,,1,,4,,1882,B,H,BAO_0000224,
,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,CHEMBL616480,13631,104686,,,,,Autocuration,,1,,4,,1883,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,CHEMBL616481,9630,104686,,,,,Autocuration,,1,,5,10116.0,1884,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,CHEMBL616482,8822,104686,,,,,Autocuration,,1,,5,10116.0,1885,B,D,BAO_0000249,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,CHEMBL884713,9064,104686,,,Brain,955.0,Autocuration,,1,,5,10116.0,1886,B,D,BAO_0000221,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,CHEMBL616483,8868,104686,,,,,Autocuration,,1,,4,,1887,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,CHEMBL616484,9064,104686,,,,,Autocuration,,1,,4,,1888,B,H,BAO_0000224,
,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,CHEMBL616485,9806,104686,,,,,Autocuration,,1,,4,,1889,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL616486,9098,104686,,,,,Autocuration,,1,,4,,1890,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,CHEMBL616487,8868,104686,,,,,Autocuration,,1,,4,,1891,B,H,BAO_0000224,
,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,CHEMBL616488,12765,104686,,,,,Autocuration,,1,,4,,1892,B,H,BAO_0000224,
,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616489,11049,104686,,,,,Autocuration,,1,,4,,1893,B,H,BAO_0000019,
,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616490,11049,104686,,,,,Autocuration,,1,,4,,1894,B,H,BAO_0000019,
,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,CHEMBL616491,11049,104686,,,,,Autocuration,,1,,4,,1895,B,H,BAO_0000019,
,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,CHEMBL616492,11049,104686,,,,,Autocuration,,1,,4,,1896,B,H,BAO_0000019,
,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616493,11049,104686,,,,,Autocuration,,1,,4,,1897,B,H,BAO_0000019,
,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,CHEMBL616494,11473,104686,,,,,Autocuration,,1,,4,,1898,B,H,BAO_0000019,
,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,CHEMBL616495,11473,104686,,,,,Autocuration,,1,,4,,1899,B,H,BAO_0000019,
,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,CHEMBL616496,3086,104686,,,,,Autocuration,,1,,4,,1900,B,H,BAO_0000019,
,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616497,11049,104686,,,,,Autocuration,,1,,4,,1901,B,H,BAO_0000019,
,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,CHEMBL616498,11049,104686,,,,,Autocuration,,1,,4,,1902,B,H,BAO_0000019,
,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,CHEMBL616499,10639,104686,,,,,Autocuration,,1,,4,,1903,B,H,BAO_0000019,
,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,CHEMBL616500,10922,104686,,,,,Autocuration,,1,,4,,1904,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,CHEMBL616501,9064,104686,,,Brain,955.0,Autocuration,,1,,5,10116.0,1905,B,D,BAO_0000221,
,,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,CHEMBL616502,10748,104686,,,Brain,955.0,Autocuration,,1,,4,,1906,B,H,BAO_0000221,
,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,CHEMBL884529,11614,104686,Membranes,,,,Autocuration,,1,,4,,1907,B,H,BAO_0000249,
,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,CHEMBL616503,11615,104686,Membranes,,,,Autocuration,,1,,4,,1908,B,H,BAO_0000249,
,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,CHEMBL616964,11615,104686,,,,,Autocuration,,1,,4,,1909,B,H,BAO_0000224,
,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,CHEMBL616965,11614,104686,Membranes,,,,Autocuration,,1,,4,,1910,B,H,BAO_0000249,
,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,CHEMBL616966,11702,104686,,,,,Autocuration,,1,,4,,1911,B,H,BAO_0000224,
,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL616967,11702,104686,,,,,Autocuration,,1,,4,,1912,B,H,BAO_0000224,
,Rattus norvegicus,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,CHEMBL616968,11702,104686,,,,,Autocuration,,1,,5,10116.0,1913,B,D,BAO_0000224,
,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL616969,11702,104686,,,,,Autocuration,,1,,4,,1914,B,H,BAO_0000224,
,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,CHEMBL884530,13346,104686,,,,,Autocuration,,1,,4,,1915,B,H,BAO_0000019,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,CHEMBL616970,10025,104686,,,,,Autocuration,,1,,4,,1916,B,H,BAO_0000224,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,CHEMBL616971,10025,104686,,,,,Autocuration,,1,,4,,1917,B,H,BAO_0000224,
,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",CHEMBL616972,10025,104686,,,,,Autocuration,,1,,4,,1918,B,H,BAO_0000224,
,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,CHEMBL616973,9036,104686,,,,,Autocuration,,1,,4,,1919,B,H,BAO_0000224,
,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,CHEMBL616974,9036,104686,,,,,Autocuration,,1,,4,,1920,B,H,BAO_0000224,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,CHEMBL616975,9161,104686,,,,,Autocuration,,1,,4,,1921,B,H,BAO_0000019,
,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,CHEMBL616976,12304,104686,,,,,Autocuration,,1,,4,,1922,B,H,BAO_0000019,
,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,CHEMBL616977,13276,104686,,,,,Autocuration,,1,,4,,1923,B,H,BAO_0000224,
,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,CHEMBL616978,11825,104686,,,,,Autocuration,,1,,4,,1924,B,H,BAO_0000224,
,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,CHEMBL616979,12443,104686,,,,,Autocuration,,1,,4,,1925,B,H,BAO_0000224,
,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,CHEMBL616980,13830,104686,,,,,Autocuration,,1,,4,,1926,B,H,BAO_0000224,
,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,CHEMBL616981,9592,104686,Membranes,,,,Autocuration,,1,,4,,1927,B,H,BAO_0000249,
,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,CHEMBL616982,9592,104686,Membranes,,,,Autocuration,,1,,4,,1928,B,H,BAO_0000249,
,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,CHEMBL616983,10881,104686,,,,,Autocuration,,1,,4,,1929,B,H,BAO_0000224,
,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,CHEMBL616984,13605,104686,,,,,Autocuration,,1,,4,,1930,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,CHEMBL616985,11624,104686,,,,,Autocuration,,1,,5,10116.0,1931,B,D,BAO_0000224,
,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,CHEMBL616986,4101,104686,,,,,Autocuration,,1,,4,,1932,B,H,BAO_0000224,
,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,CHEMBL616987,4101,104686,,,,,Autocuration,,1,,4,,1933,B,H,BAO_0000224,
,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,CHEMBL616988,15360,104686,,,,,Autocuration,,1,,4,,1934,B,H,BAO_0000019,
,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617243,11576,104686,,,,,Autocuration,,1,,4,,1935,B,H,BAO_0000019,
,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,CHEMBL617244,5834,104686,,,,,Autocuration,,1,,4,,1936,B,H,BAO_0000019,
CHO-K1,Rattus norvegicus,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617245,2395,104686,,485.0,,,Autocuration,,1,,5,10116.0,1937,B,D,BAO_0000219,
,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,CHEMBL617246,11965,104686,Membranes,,,,Autocuration,,1,,4,,1938,B,H,BAO_0000249,
,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),CHEMBL617546,3967,104686,,,,,Autocuration,,1,,4,,1939,B,H,BAO_0000224,
,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),CHEMBL617547,11130,104686,Brain membranes,,,,Autocuration,,1,,4,,1940,B,H,BAO_0000249,
,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL617548,13427,104686,,,,,Autocuration,,1,,4,,1941,B,H,BAO_0000219,In vitro
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617549,9443,104686,,,,,Autocuration,,1,,4,,1942,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,CHEMBL617550,9443,104686,,,,,Autocuration,,1,,4,,1943,B,H,BAO_0000224,
,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,CHEMBL617551,11825,104686,,,,,Autocuration,,1,,4,,1944,B,H,BAO_0000224,
,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,CHEMBL617552,12120,104686,Membranes,,,,Autocuration,,1,,4,,1945,B,H,BAO_0000249,
,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,CHEMBL617553,12120,104686,Membranes,,,,Autocuration,,1,,4,,1946,B,H,BAO_0000249,
,,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,CHEMBL617554,11963,104686,,,Thoracic aorta,1515.0,Autocuration,,1,,4,,1947,F,H,BAO_0000019,
,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,CHEMBL617555,9069,104686,,,,,Autocuration,,1,,4,,1948,B,H,BAO_0000019,
,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,CHEMBL617556,8868,104686,,,,,Autocuration,,1,,4,,1949,B,H,BAO_0000224,
,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,CHEMBL617557,17200,10624,,,,,Autocuration,,1,,8,,1950,B,H,BAO_0000357,
,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,CHEMBL617558,17200,10624,,,,,Autocuration,,1,,8,,1951,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,CHEMBL617559,13969,17106,,,,,Expert,,1,,8,,1952,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,CHEMBL617560,13392,17106,,,,,Expert,,1,,9,,1953,B,D,BAO_0000357,
,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617561,1742,17106,,,,,Autocuration,,1,,8,,1954,B,H,BAO_0000249,
,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617562,1742,17106,,,,,Autocuration,,1,,8,,1955,B,H,BAO_0000249,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,CHEMBL617563,14331,17106,,,Striatum,2435.0,Autocuration,,1,,8,,1956,B,H,BAO_0000357,
,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,CHEMBL617564,12861,17106,,,,,Autocuration,,1,,8,,1957,F,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,CHEMBL617565,12861,17106,,,,,Expert,,1,,8,,1958,B,H,BAO_0000019,
,,,,Binding activity radioligand.,CHEMBL856076,12861,17106,,,,,Autocuration,,1,,8,,1959,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617566,12861,17106,,,,,Autocuration,,1,,8,,1960,B,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL875911,12861,17106,,,,,Expert,,1,,8,,1961,B,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,CHEMBL617567,12861,17106,,,,,Autocuration,,1,,8,,1962,B,H,BAO_0000019,
,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,CHEMBL617568,675,17106,,,,,Autocuration,,1,,8,,1963,B,H,BAO_0000249,
,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,CHEMBL617569,12490,17106,,,,,Expert,,1,,8,,1964,B,H,BAO_0000019,
,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,CHEMBL617570,11828,17106,,,,,Expert,,1,,8,,1965,B,H,BAO_0000249,
,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,CHEMBL617571,11866,17106,,,,,Autocuration,,1,,8,,1966,B,H,BAO_0000357,
,Sus scrofa,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,CHEMBL617572,773,105,,,,,Autocuration,,1,,8,9823.0,1967,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,The compound was tested for intrinsic activity against 5-HT1D receptor,CHEMBL617573,13047,105,,,,,Expert,,1,,8,9986.0,1968,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,CHEMBL617574,13047,105,,,,,Autocuration,,1,,8,9986.0,1969,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,The compound was tested for binding affinity against 5-HT1D receptor,CHEMBL617575,13047,105,,,,,Expert,,1,,8,9986.0,1970,B,H,BAO_0000357,
,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,CHEMBL617576,188,10578,,,,,Autocuration,,1,,8,,1971,B,H,BAO_0000357,
,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,CHEMBL617577,10639,10578,,,,,Autocuration,,1,,8,,1972,F,H,BAO_0000019,
,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,CHEMBL617578,12438,10578,,,,,Autocuration,,1,,8,,1973,F,H,BAO_0000019,
,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,CHEMBL617579,12438,10578,,,,,Autocuration,,1,,8,,1974,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,CHEMBL617580,15854,10578,,,,,Expert,,1,,8,,1975,B,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,CHEMBL617581,10394,10578,,,,,Autocuration,,1,,8,,1976,B,H,BAO_0000249,
,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,CHEMBL617582,12092,10578,,,,,Autocuration,,1,,8,,1977,B,H,BAO_0000357,
,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,CHEMBL617583,3389,10578,,,,,Expert,,1,,8,,1978,B,H,BAO_0000019,
,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,CHEMBL617584,6011,105,,,,,Autocuration,,1,,8,,1979,B,H,BAO_0000357,
,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL617585,4639,105,,,,,Autocuration,,1,,8,,1980,B,H,BAO_0000357,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,CHEMBL875912,2474,105,,,,,Autocuration,,1,,8,,1981,B,H,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,CHEMBL617586,5014,105,,,,,Autocuration,,1,,8,,1982,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,CHEMBL617587,17515,105,,,,,Autocuration,,1,,8,,1983,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,CHEMBL617588,11866,105,,,,,Autocuration,,1,,8,,1984,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,CHEMBL857980,4687,105,,,,,Autocuration,,1,,8,,1985,B,H,BAO_0000357,
,,,,Tested against 5-hydroxytryptamine 1D receptor,CHEMBL617589,12146,105,,,,,Autocuration,,1,,8,,1986,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,CHEMBL617590,10321,105,,,,,Autocuration,,1,,8,,1987,B,H,BAO_0000357,
HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,CHEMBL617591,13267,105,,722.0,,,Autocuration,,1,,8,,1988,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,CHEMBL617592,1274,105,,,,,Expert,,1,,9,9606.0,1989,B,D,BAO_0000357,
,,,,,CHEMBL617593,15250,105,,,,,Autocuration,,1,,8,,1990,B,H,BAO_0000357,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617594,13706,106,,485.0,,,Autocuration,,1,,8,,1991,B,H,BAO_0000219,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617595,13706,105,,485.0,,,Autocuration,,1,,8,,1992,B,H,BAO_0000219,
HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,CHEMBL617596,13706,105,,722.0,,,Autocuration,,1,,8,,1993,B,H,BAO_0000219,
HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,CHEMBL617597,13706,105,,722.0,,,Autocuration,,1,,8,,1994,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,CHEMBL617598,13047,105,,,,,Autocuration,,1,,8,,1995,B,H,BAO_0000019,
,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,CHEMBL872916,13366,105,,,,,Autocuration,,1,,8,,1996,B,H,BAO_0000357,
,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,CHEMBL617599,13366,105,,,,,Expert,,1,,8,,1997,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,CHEMBL617091,1558,105,,,,,Autocuration,,1,,8,,1998,B,H,BAO_0000357,
CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",CHEMBL617092,12902,105,,485.0,,,Expert,,1,,8,,1999,B,H,BAO_0000219,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHEMBL617093,13706,105,,485.0,,,Autocuration,,1,,8,,2000,B,H,BAO_0000219,
,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617094,13706,105,,,,,Autocuration,,1,,8,,2001,F,H,BAO_0000019,
,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617095,13706,105,,,,,Autocuration,,1,,8,,2002,F,H,BAO_0000019,
,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617096,14251,105,,,,,Autocuration,,1,,8,,2003,F,H,BAO_0000019,
,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617097,14251,105,,,,,Autocuration,,1,,8,,2004,F,H,BAO_0000019,
,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,CHEMBL617098,14251,105,,,,,Autocuration,,1,,8,,2005,F,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,CHEMBL617301,13313,105,,,,,Autocuration,,1,,8,,2006,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,CHEMBL617302,13313,105,,,,,Autocuration,,1,,8,,2007,B,H,BAO_0000357,
,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,CHEMBL617303,13366,105,,,,,Autocuration,,1,,8,,2008,B,H,BAO_0000357,
,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,CHEMBL617304,13051,105,,,,,Expert,,1,,8,,2009,B,H,BAO_0000357,
CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL617305,12903,105,,449.0,,,Expert,,1,,8,,2010,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,CHEMBL617306,12469,105,,,,,Autocuration,,1,,9,9606.0,2011,B,D,BAO_0000219,
,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,CHEMBL617307,5619,17106,,,,,Autocuration,,1,,8,,2012,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,CHEMBL617308,13047,105,,,,,Autocuration,,1,,8,9986.0,2013,B,H,BAO_0000019,
,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617309,16633,105,,,,,Autocuration,,1,,8,,2014,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,CHEMBL617310,16633,105,,,,,Autocuration,,1,,8,,2015,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,CHEMBL617311,16633,105,,,,,Autocuration,,1,,8,,2016,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,CHEMBL617312,16633,105,,,,,Autocuration,,1,,8,,2017,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617313,3269,105,,,,,Autocuration,,1,,8,,2018,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,CHEMBL617314,12409,105,,,,,Expert,,1,,8,,2019,B,H,BAO_0000357,
,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL617315,13706,106,,,,,Autocuration,,1,,8,,2020,F,H,BAO_0000019,
HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,CHEMBL617316,13706,106,,722.0,,,Autocuration,,1,,8,,2021,B,H,BAO_0000219,
HEK293,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,CHEMBL617317,13706,106,,722.0,,,Autocuration,,1,,8,,2022,B,H,BAO_0000219,
CHO,,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL617318,12903,106,,449.0,,,Autocuration,,1,,8,,2023,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,CHEMBL617319,13047,106,,,,,Autocuration,,1,,8,,2024,B,H,BAO_0000019,
,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617320,13366,106,,,,,Expert,,1,,9,,2025,B,D,BAO_0000357,
,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617321,13366,106,,,,,Expert,,1,,9,,2026,B,D,BAO_0000357,
,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,CHEMBL617322,13366,106,,,,,Expert,,1,,9,,2027,B,D,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616862,13366,106,,,,,Autocuration,,1,,8,,2028,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,CHEMBL616863,13366,106,,,,,Autocuration,,1,,8,,2029,B,H,BAO_0000357,
CHO,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,CHEMBL616864,12469,106,,449.0,,,Autocuration,,1,,8,,2030,B,H,BAO_0000219,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,CHEMBL616865,13706,106,,485.0,,,Autocuration,,1,,8,,2031,B,H,BAO_0000219,
CHO-K1,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,CHEMBL616866,13706,106,,485.0,,,Autocuration,,1,,8,,2032,B,H,BAO_0000219,
,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,CHEMBL616867,13706,106,,,,,Autocuration,,1,,8,,2033,F,H,BAO_0000019,
CHO-K1,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",CHEMBL616868,12902,106,,485.0,,,Expert,,1,,8,,2034,B,H,BAO_0000219,
,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,CHEMBL616869,13051,105,,,,,Expert,,1,,8,,2035,B,H,BAO_0000357,
CHO,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHEMBL616870,12903,106,,449.0,,,Expert,,1,,8,,2036,B,H,BAO_0000219,
CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,CHEMBL616871,1558,105,,485.0,,,Autocuration,,1,,8,,2037,F,H,BAO_0000219,
CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,CHEMBL616872,1558,105,,485.0,,,Autocuration,,1,,8,,2038,F,H,BAO_0000219,
CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,CHEMBL616873,1558,105,,485.0,,,Autocuration,,1,,8,,2039,F,H,BAO_0000219,
CHO-K1,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,CHEMBL616838,1558,105,,485.0,,,Autocuration,,1,,8,,2040,F,H,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,CHEMBL616839,1558,105,,,,,Autocuration,,1,,8,,2041,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,CHEMBL616840,13047,106,,,,,Autocuration,,1,,8,9986.0,2042,B,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,CHEMBL616841,13313,105,,,,,Autocuration,,1,,8,,2043,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,CHEMBL616842,13313,105,,,,,Autocuration,,1,,8,,2044,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,CHEMBL857976,12409,105,,,,,Expert,,1,,8,,2045,B,H,BAO_0000357,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,CHEMBL616843,15250,10618,,449.0,,,Autocuration,,1,,8,,2046,B,H,BAO_0000219,
,Homo sapiens,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,CHEMBL616844,1348,10618,,,,,Expert,,1,,9,9606.0,2047,B,D,BAO_0000357,
,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,CHEMBL616845,1348,10618,,,,,Autocuration,,1,,8,,2048,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,CHEMBL616846,4234,10618,,,,,Expert,,1,,9,9606.0,2049,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,CHEMBL616847,16209,10618,,,,,Autocuration,,1,,8,,2050,B,H,BAO_0000357,
,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,CHEMBL616848,10444,10618,,,,,Autocuration,,1,,8,,2051,B,H,BAO_0000019,
,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,CHEMBL616849,3935,10618,,,,,Autocuration,,1,,8,,2052,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,CHEMBL872911,15818,10618,,,,,Autocuration,,1,,8,,2053,B,H,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,CHEMBL616850,17085,10618,,,,,Autocuration,,1,,8,,2054,B,H,BAO_0000019,
CHO,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,CHEMBL616699,12936,10618,,449.0,,,Expert,,1,,9,9606.0,2055,B,D,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,CHEMBL616700,6166,10618,,,,,Autocuration,,1,,8,,2056,B,H,BAO_0000357,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL616701,15779,10618,,449.0,,,Autocuration,,1,,8,,2057,B,H,BAO_0000219,
CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,CHEMBL616702,15779,10618,,449.0,,,Autocuration,,1,,8,,2058,B,H,BAO_0000219,
CHO,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHEMBL616703,15779,10618,,449.0,,,Autocuration,,1,,8,,2059,B,H,BAO_0000219,
,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,CHEMBL616704,13181,10618,,,,,Autocuration,,1,,8,,2060,B,H,BAO_0000357,
CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,CHEMBL616705,4199,10618,,449.0,,,Autocuration,,1,,8,,2061,B,H,BAO_0000219,
,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,CHEMBL616706,14875,10618,,,,,Autocuration,,1,,8,,2062,B,H,BAO_0000357,
CHO,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,CHEMBL616707,15146,10618,,449.0,,,Autocuration,,1,,8,,2063,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,CHEMBL616708,5213,10618,,,,,Autocuration,,1,,8,,2064,B,H,BAO_0000357,
,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,CHEMBL616709,12146,10618,,,,,Autocuration,,1,,8,,2065,B,H,BAO_0000357,
CHO,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,CHEMBL616710,13267,10618,,449.0,,,Autocuration,,1,,8,,2066,B,H,BAO_0000219,
CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,CHEMBL616711,14818,10618,,449.0,,,Autocuration,,1,,8,,2067,B,H,BAO_0000219,
CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL616712,4829,10618,,449.0,,,Autocuration,,1,,8,,2068,B,H,BAO_0000219,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,CHEMBL616713,4373,10618,,,,,Autocuration,,1,,8,,2069,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,CHEMBL616714,4373,10618,,,,,Autocuration,,1,,8,,2070,B,H,BAO_0000357,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,CHEMBL616715,14159,10618,,,,,Autocuration,,1,,8,,2071,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,CHEMBL616716,16633,10618,,,,,Autocuration,,1,,8,,2072,B,H,BAO_0000357,
,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",CHEMBL616717,17085,279,,,,,Autocuration,,1,,8,,2073,F,H,BAO_0000019,
,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",CHEMBL616718,17085,279,,,,,Expert,,1,,8,,2074,F,H,BAO_0000019,
,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,CHEMBL875905,16209,279,,,,,Autocuration,,1,,8,,2075,F,H,BAO_0000019,
,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,CHEMBL616719,16209,279,,,,,Autocuration,,1,,8,,2076,F,H,BAO_0000019,
,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",CHEMBL616720,17085,279,,,,,Expert,,1,,8,,2077,F,H,BAO_0000019,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,CHEMBL616721,14159,279,,,,,Autocuration,,1,,8,,2078,B,H,BAO_0000357,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,CHEMBL616722,15250,279,,449.0,,,Autocuration,,1,,8,,2079,B,H,BAO_0000219,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),CHEMBL616723,3805,279,,,,,Autocuration,,1,,8,,2080,B,H,BAO_0000357,
CHO,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,CHEMBL616724,16190,279,,449.0,,,Autocuration,,1,,8,,2081,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,CHEMBL616725,16190,279,,,,,Autocuration,,1,,8,,2082,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,CHEMBL616726,16209,279,,,,,Autocuration,,1,,8,,2083,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,CHEMBL616727,16209,279,,,,,Autocuration,,1,,8,,2084,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,CHEMBL616728,16209,279,,,,,Autocuration,,1,,8,,2085,B,H,BAO_0000357,
,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,CHEMBL616729,6866,279,,,,,Autocuration,,1,,8,,2086,B,H,BAO_0000357,
,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,CHEMBL616730,17085,279,,,,,Expert,,1,,8,,2087,B,H,BAO_0000019,
,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,CHEMBL617125,16312,279,,,,,Autocuration,,1,,8,,2088,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,CHEMBL857977,6166,279,,,,,Autocuration,,1,,8,,2089,B,H,BAO_0000357,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHEMBL617126,15779,279,,449.0,,,Autocuration,,1,,8,,2090,B,H,BAO_0000219,
CHO,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,CHEMBL617127,4199,279,,449.0,,,Autocuration,,1,,8,,2091,B,H,BAO_0000219,
,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,CHEMBL617128,14875,279,,,,,Autocuration,,1,,8,,2092,B,H,BAO_0000357,
CHO,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,CHEMBL617129,15146,279,,449.0,,,Autocuration,,1,,8,,2093,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,CHEMBL617130,5213,279,,,,,Autocuration,,1,,8,,2094,B,H,BAO_0000357,
CHO,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,CHEMBL617131,14818,279,,449.0,,,Autocuration,,1,,8,,2095,B,H,BAO_0000219,
CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL617132,4829,279,,449.0,,,Autocuration,,1,,8,,2096,B,H,BAO_0000219,
CHO,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHEMBL617133,4829,279,,449.0,,,Autocuration,,1,,8,,2097,B,H,BAO_0000219,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,CHEMBL617134,4373,279,,,,,Autocuration,,1,,8,,2098,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,CHEMBL617135,4373,279,,,,,Autocuration,,1,,8,,2099,B,H,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,CHEMBL617136,5014,279,,,,,Autocuration,,1,,8,,2100,B,H,BAO_0000357,
,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",CHEMBL617137,11662,104686,,,,,Autocuration,,1,,4,,2101,B,H,BAO_0000019,
,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",CHEMBL617138,11662,104686,,,,,Autocuration,,1,,4,,2102,B,H,BAO_0000019,
,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617139,11662,104686,,,,,Autocuration,,1,,4,,2103,B,H,BAO_0000019,
,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,CHEMBL617140,14093,12687,,,,,Autocuration,,1,,8,,2104,B,H,BAO_0000019,
,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",CHEMBL617141,11200,104686,,,,,Autocuration,,1,,4,,2105,F,H,BAO_0000218,In vivo
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL858112,11200,104686,,,,,Autocuration,,1,,4,,2106,F,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,CHEMBL617142,12352,17005,,,,,Intermediate,,1,,8,,2107,B,H,BAO_0000019,
,Bos taurus,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",CHEMBL617143,13657,22226,,,,,Autocuration,,1,,0,9913.0,2108,B,U,BAO_0000019,
,Bos taurus,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,CHEMBL617144,14331,22226,,,,,Autocuration,,1,,0,9913.0,2109,B,U,BAO_0000019,
,Bos taurus,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,CHEMBL617145,14331,22226,,,,,Autocuration,,1,,0,9913.0,2110,B,U,BAO_0000019,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,CHEMBL617146,14331,22226,,,,,Autocuration,,1,,0,,2111,B,U,BAO_0000019,
,Cavia porcellus,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,CHEMBL617147,12685,104784,,,,,Autocuration,,1,,4,10141.0,2112,B,H,BAO_0000019,
,Cavia porcellus,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,CHEMBL617148,14389,104784,,,,,Autocuration,,1,,4,10141.0,2113,B,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,CHEMBL617149,14386,104784,,,,,Autocuration,,1,,4,10141.0,2114,B,H,BAO_0000019,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,CHEMBL617150,5732,104784,,,,,Autocuration,,1,,4,,2115,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL617151,16293,104784,,,,,Autocuration,,1,,4,,2116,B,H,BAO_0000224,
,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,CHEMBL617201,2078,104784,,,,,Autocuration,,1,,4,,2117,B,H,BAO_0000224,
,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,CHEMBL617202,5486,10209,,,,,Autocuration,,1,,8,,2118,B,H,BAO_0000357,
,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,CHEMBL617203,11820,104826,,,,,Autocuration,,1,,4,,2119,B,H,BAO_0000218,In vivo
,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,CHEMBL617204,10297,104826,,,,,Autocuration,,1,,4,,2120,B,H,BAO_0000019,
,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,CHEMBL617205,13704,104826,,,,,Autocuration,,1,,4,,2121,B,H,BAO_0000224,
,Mus musculus,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,CHEMBL617206,10297,104826,,,,,Autocuration,,1,,5,10090.0,2122,B,D,BAO_0000019,
,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,CHEMBL617207,11820,104826,,,,,Autocuration,,1,,4,,2123,B,H,BAO_0000218,In vivo
,Mus musculus,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,CHEMBL617208,10297,104826,,,,,Autocuration,,1,,5,10090.0,2124,B,D,BAO_0000019,
,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617209,11555,104826,,,,,Autocuration,,1,,4,,2125,B,H,BAO_0000224,
,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,CHEMBL617210,11555,104826,,,,,Autocuration,,1,,4,,2126,B,H,BAO_0000224,
,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,CHEMBL617211,11555,104826,,,,,Autocuration,,1,,4,,2127,B,H,BAO_0000224,
,Mus musculus,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,CHEMBL617212,10297,104826,,,,,Autocuration,,1,,5,10090.0,2128,B,D,BAO_0000019,
,Sus scrofa,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,CHEMBL617213,16688,104784,,,,,Autocuration,,1,,4,9823.0,2129,B,H,BAO_0000224,
,Sus scrofa,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,CHEMBL617214,16688,104784,,,,,Autocuration,,1,,4,9823.0,2130,B,H,BAO_0000224,
,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,CHEMBL617215,5333,22226,,,,,Autocuration,,1,,0,,2131,B,U,BAO_0000221,
,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,CHEMBL617216,4437,22226,,,,,Autocuration,,1,,0,,2132,B,U,BAO_0000221,
,Sus scrofa,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,CHEMBL617217,5033,17005,,,,,Autocuration,,1,,8,9823.0,2133,B,H,BAO_0000357,
,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,CHEMBL617218,15267,104686,,,,,Autocuration,,1,,4,,2134,B,H,BAO_0000019,
,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,CHEMBL872913,15267,104686,,,,,Autocuration,,1,,4,,2135,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,CHEMBL617219,11820,104826,,,,,Autocuration,,1,,4,,2136,B,H,BAO_0000019,
,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,CHEMBL873482,9069,104686,,,,,Autocuration,,1,,4,,2137,B,H,BAO_0000224,
,Rattus norvegicus,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,CHEMBL617220,9162,104686,,,,,Autocuration,,1,,5,10116.0,2138,B,D,BAO_0000019,
,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,CHEMBL617221,9162,104686,,,,,Autocuration,,1,,4,,2139,B,H,BAO_0000019,
,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,CHEMBL617222,9162,104686,,,,,Autocuration,,1,,4,,2140,B,H,BAO_0000019,
,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,CHEMBL875906,10428,104686,,,,,Autocuration,,1,,4,,2141,F,H,BAO_0000019,
,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,CHEMBL617223,9628,104686,,,,,Autocuration,,1,,4,,2142,B,H,BAO_0000019,
,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,CHEMBL617224,12704,104686,,,,,Autocuration,,1,,4,,2143,B,H,BAO_0000224,
,Rattus norvegicus,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,CHEMBL617225,15453,104686,,,,,Autocuration,,1,,5,10116.0,2144,B,D,BAO_0000224,
,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,CHEMBL617226,188,104686,,,,,Autocuration,,1,,4,,2145,B,H,BAO_0000224,
,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,CHEMBL617227,10349,104686,,,,,Autocuration,,1,,4,,2146,B,H,BAO_0000224,
,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,CHEMBL617228,10349,104686,,,,,Autocuration,,1,,4,,2147,B,H,BAO_0000224,
,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,CHEMBL617229,8868,104686,,,,,Autocuration,,1,,4,,2148,B,H,BAO_0000224,
,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,CHEMBL617230,10025,104686,,,,,Autocuration,,1,,4,,2149,B,H,BAO_0000224,
,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",CHEMBL617231,10025,104686,,,,,Autocuration,,1,,4,,2150,B,H,BAO_0000224,
,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,CHEMBL617232,11702,104686,,,,,Autocuration,,1,,4,,2151,B,H,BAO_0000224,
,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,CHEMBL617233,11702,104686,,,,,Autocuration,,1,,4,,2152,B,H,BAO_0000224,
,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,CHEMBL617234,11702,104686,,,,,Autocuration,,1,,4,,2153,B,H,BAO_0000224,
,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,CHEMBL617235,11702,104686,,,,,Autocuration,,1,,4,,2154,F,H,BAO_0000019,
,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,CHEMBL617236,11702,104686,,,,,Autocuration,,1,,4,,2155,F,H,BAO_0000019,
,,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,CHEMBL617237,10085,104686,,,Hippocampus,10000000.0,Autocuration,,1,,4,,2156,B,H,BAO_0000221,
,,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,CHEMBL617238,10085,104686,,,Hippocampus,10000000.0,Autocuration,,1,,4,,2157,B,H,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,CHEMBL617239,9630,104686,,,Brain,955.0,Autocuration,,1,,5,10116.0,2158,B,D,BAO_0000221,
,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617240,11070,104686,,,,,Autocuration,,1,,4,,2159,B,H,BAO_0000019,
,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,CHEMBL617241,9841,104686,Membranes,,,,Autocuration,,1,,4,,2160,B,H,BAO_0000249,
,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,CHEMBL875907,9841,104686,Membranes,,,,Autocuration,,1,,4,,2161,B,H,BAO_0000249,
,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,CHEMBL617242,13291,104686,,,,,Autocuration,,1,,4,,2162,B,H,BAO_0000019,
,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,CHEMBL617152,10590,104686,,,,,Autocuration,,1,,4,,2163,F,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,CHEMBL617153,9064,104686,,,Brain,955.0,Autocuration,,1,,5,10116.0,2164,B,D,BAO_0000221,
,Rattus norvegicus,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,CHEMBL617154,12268,104686,Membranes,,,,Autocuration,,1,,5,10116.0,2165,B,D,BAO_0000249,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,CHEMBL617155,13508,104686,,,Brain,955.0,Autocuration,,1,,4,,2166,B,H,BAO_0000221,
,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,CHEMBL617156,11279,104686,,,,,Autocuration,,1,,4,,2167,F,H,BAO_0000019,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,CHEMBL617157,11200,104686,,,,,Autocuration,,1,,4,,2168,F,H,BAO_0000019,
,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617158,11200,104686,,,,,Autocuration,,1,,4,,2169,F,H,BAO_0000019,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,CHEMBL617159,11200,104686,,,,,Autocuration,,1,,4,,2170,F,H,BAO_0000019,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,CHEMBL617160,11200,104686,,,,,Autocuration,,1,,4,,2171,F,H,BAO_0000019,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL858113,11200,104686,,,,,Autocuration,,1,,4,,2172,F,H,BAO_0000019,
,,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,CHEMBL617247,9231,104686,,,Brain,955.0,Autocuration,,1,,4,,2173,B,H,BAO_0000220,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617248,9737,104686,,,,,Autocuration,,1,,4,,2174,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,CHEMBL617249,9737,104686,,,Brain,955.0,Autocuration,,1,,4,,2175,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,CHEMBL617250,9737,104686,,,,,Autocuration,,1,,4,,2176,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617251,9737,104686,,,,,Autocuration,,1,,4,,2177,B,H,BAO_0000019,
,Rattus norvegicus,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,CHEMBL617252,11828,104686,,,,,Autocuration,,1,,5,10116.0,2178,B,D,BAO_0000019,
,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,CHEMBL617006,12253,104686,,,,,Autocuration,,1,,4,,2179,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,CHEMBL617007,12253,104686,,,,,Autocuration,,1,,4,,2180,B,H,BAO_0000019,
,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",CHEMBL617008,11279,104686,,,,,Autocuration,,1,,4,,2181,F,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,CHEMBL617009,11866,104686,,,,,Autocuration,,1,,4,,2182,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,CHEMBL617010,14424,104686,,,,,Autocuration,,1,,5,10116.0,2183,B,D,BAO_0000224,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,CHEMBL857978,15180,104686,,,,,Autocuration,,1,,5,10116.0,2184,B,D,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,CHEMBL617011,15180,104686,,,,,Autocuration,,1,,5,10116.0,2185,B,D,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,CHEMBL617012,9786,104686,,,,,Autocuration,,1,,5,10116.0,2186,B,D,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,CHEMBL617013,12132,104686,,,,,Autocuration,,1,,4,,2187,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,CHEMBL617014,5486,104686,,,,,Autocuration,,1,,4,,2188,B,H,BAO_0000249,
,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,CHEMBL617015,15316,104686,,,,,Autocuration,,1,,4,,2189,B,H,BAO_0000019,
,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,CHEMBL617016,16429,104686,,,,,Autocuration,,1,,4,,2190,B,H,BAO_0000019,
,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,CHEMBL617017,14617,104686,,,,,Autocuration,,1,,4,,2191,B,H,BAO_0000224,
,,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,CHEMBL617018,11351,104686,,,Brain,955.0,Autocuration,,1,,4,,2192,B,H,BAO_0000221,
,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,CHEMBL617019,11279,104686,,,,,Autocuration,,1,,4,,2193,F,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617020,9523,105075,,,,,Autocuration,,1,,4,,2194,B,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617021,9523,105075,,,,,Autocuration,,1,,4,,2195,B,H,BAO_0000019,
,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617022,9523,105075,,,,,Autocuration,,1,,4,,2196,B,H,BAO_0000019,
,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617023,9523,105075,,,,,Autocuration,,1,,4,,2197,B,H,BAO_0000019,
,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617024,9523,105075,,,,,Autocuration,,1,,4,,2198,B,H,BAO_0000019,
,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,CHEMBL617025,9523,105075,,,,,Autocuration,,1,,4,,2199,B,H,BAO_0000019,
,,,,Hill coefficient of compound was determined,CHEMBL617026,9523,105075,,,,,Autocuration,,1,,4,,2200,B,H,BAO_0000224,
,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,CHEMBL617027,4771,22226,,,,,Autocuration,,1,,0,,2201,B,U,BAO_0000019,
,Rattus norvegicus,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,CHEMBL617028,5033,104686,,,,,Autocuration,,1,,5,10116.0,2202,B,D,BAO_0000019,
,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,CHEMBL617029,10845,12687,,,,,Expert,,1,,8,,2203,B,H,BAO_0000019,
,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,CHEMBL875908,10845,12687,,,,,Expert,,1,,8,,2204,B,H,BAO_0000019,
,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),CHEMBL617030,16288,12687,,,,,Autocuration,,1,,8,,2205,B,H,BAO_0000357,
,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),CHEMBL617031,16288,12687,,,,,Autocuration,,1,,8,,2206,B,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,CHEMBL617032,16190,12687,,,,,Autocuration,,1,,8,,2207,B,H,BAO_0000019,
,Rattus norvegicus,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,CHEMBL617033,12463,104686,,,,,Autocuration,,1,,5,10116.0,2208,B,D,BAO_0000224,
,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",CHEMBL617034,9699,104686,,,,,Autocuration,,1,,4,,2209,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,CHEMBL617035,9699,104686,,,,,Autocuration,,1,,4,,2210,B,H,BAO_0000224,
,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617036,11662,104686,,,,,Autocuration,,1,,4,,2211,B,H,BAO_0000019,
,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,CHEMBL617037,1205,104784,,,,,Autocuration,,1,,4,,2212,B,H,BAO_0000224,
,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,CHEMBL617038,11376,22226,,,,,Autocuration,,1,,0,,2213,B,U,BAO_0000219,
,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",CHEMBL617039,11376,104784,,,,,Autocuration,,1,,4,,2214,B,H,BAO_0000219,
,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617161,4639,104784,,,,,Autocuration,,1,,4,,2215,B,H,BAO_0000224,
,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,CHEMBL617162,2222,104784,,,,,Autocuration,,1,,4,,2216,B,H,BAO_0000224,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617163,1558,104784,,,,,Autocuration,,1,,4,,2217,B,H,BAO_0000224,
,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617164,1089,104784,,,,,Autocuration,,1,,4,,2218,B,H,BAO_0000224,
,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,CHEMBL617165,386,104784,Brain membranes,,,,Autocuration,,1,,4,,2219,B,H,BAO_0000249,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,CHEMBL617166,2474,104784,,,,,Autocuration,,1,,4,,2220,B,H,BAO_0000224,
,,,,Binding affinity towards 5-HT2 receptor,CHEMBL617167,17066,104784,,,,,Autocuration,,1,,4,,2221,B,H,BAO_0000224,
,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL872912,959,104784,,,,,Autocuration,,1,,4,,2222,B,H,BAO_0000224,
,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,CHEMBL617168,6398,104784,,,,,Autocuration,,1,,4,,2223,B,H,BAO_0000224,
,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,CHEMBL617169,11889,104686,,,,,Autocuration,,1,,4,,2224,B,H,BAO_0000224,
,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617170,4221,104784,,,,,Autocuration,,1,,4,,2225,B,H,BAO_0000224,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,CHEMBL617171,11026,104784,,,,,Autocuration,,1,,4,,2226,B,H,BAO_0000224,
,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,CHEMBL617172,11866,104784,,,,,Autocuration,,1,,4,,2227,B,H,BAO_0000224,
,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617173,4221,104784,,,,,Autocuration,,1,,4,,2228,B,H,BAO_0000224,
,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617174,13950,22226,,,,,Autocuration,,1,,0,,2229,B,U,BAO_0000019,
,,,,5-hydroxytryptamine 2 receptor binding affinity,CHEMBL617175,1263,104784,,,,,Autocuration,,1,,4,,2230,B,H,BAO_0000224,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,CHEMBL617176,13291,17005,,,,,Autocuration,,1,,8,,2231,B,H,BAO_0000357,
,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,CHEMBL617177,10812,17005,,,,,Autocuration,,1,,8,,2232,B,H,BAO_0000357,
,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,CHEMBL617178,13020,104784,,,,,Autocuration,,1,,4,,2233,B,H,BAO_0000224,
,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,CHEMBL617179,13021,104784,,,,,Autocuration,,1,,4,,2234,B,H,BAO_0000224,
,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,CHEMBL617180,13020,104784,,,,,Autocuration,,1,,4,,2235,B,H,BAO_0000224,
,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,CHEMBL617181,14532,17005,,,,,Autocuration,,1,,8,,2236,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617182,13944,17005,,,,,Autocuration,,1,,8,,2237,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,CHEMBL617183,14331,17005,,,,,Autocuration,,1,,8,,2238,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,CHEMBL617184,14118,17005,,,,,Autocuration,,1,,8,,2239,B,H,BAO_0000357,
,,,,Binding affinity against serotonergic 5-HT2 receptor,CHEMBL617185,13033,17005,,,,,Autocuration,,1,,8,,2240,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,CHEMBL617186,10321,17005,,,,,Autocuration,,1,,8,,2241,B,H,BAO_0000357,
,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,CHEMBL617187,12918,17005,,,,,Autocuration,,1,,8,,2242,B,H,BAO_0000357,
,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,CHEMBL617188,15120,17005,,,,,Autocuration,,1,,8,,2243,B,H,BAO_0000357,
,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,CHEMBL617189,2613,17005,,,,,Autocuration,,1,,8,,2244,B,H,BAO_0000218,
,Homo sapiens,,,Inhibitory activity against cloned human 5-HT2 receptor,CHEMBL617190,13378,104784,,,,,Autocuration,,1,,5,9606.0,2245,B,D,BAO_0000224,
CHO,Homo sapiens,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",CHEMBL617191,2331,104784,,449.0,,,Autocuration,,1,,5,9606.0,2246,B,D,BAO_0000219,
CHO,Homo sapiens,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",CHEMBL617192,2331,104784,,449.0,,,Autocuration,,1,,5,9606.0,2247,B,D,BAO_0000219,
CHO,Homo sapiens,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",CHEMBL617193,2331,104784,,449.0,,,Autocuration,,1,,5,9606.0,2248,B,D,BAO_0000219,
CHO,Homo sapiens,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",CHEMBL617194,2331,104784,,449.0,,,Autocuration,,1,,5,9606.0,2249,B,D,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617195,4170,104784,,,,,Autocuration,,1,,4,,2250,B,H,BAO_0000224,
,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,CHEMBL881830,15453,104784,,,,,Autocuration,,1,,4,,2251,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617196,1479,17005,,,,,Autocuration,,1,,8,,2252,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,CHEMBL617197,11139,104686,,,,,Autocuration,,1,,4,,2253,B,H,BAO_0000224,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,CHEMBL617198,13969,17005,,,,,Expert,,1,,8,,2254,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL873476,13392,17005,,,,,Expert,,1,,8,,2255,B,H,BAO_0000357,
,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,CHEMBL617199,14430,17005,,,,,Expert,,1,,8,,2256,B,H,BAO_0000019,
,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,CHEMBL617200,13181,107,,,,,Autocuration,,1,,8,10141.0,2257,B,H,BAO_0000357,
,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617484,17200,51,,,,,Autocuration,,1,,8,,2258,B,H,BAO_0000357,
,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617485,17200,107,,,,,Autocuration,,1,,8,,2259,B,H,BAO_0000357,
,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617486,17200,51,,,,,Autocuration,,1,,8,,2260,B,H,BAO_0000357,
,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,CHEMBL858022,13463,107,,,,,Autocuration,,1,,8,,2261,B,H,BAO_0000357,
CHO,,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHEMBL617049,6347,107,,449.0,,,Autocuration,,1,,8,,2262,B,H,BAO_0000219,
CHO,Homo sapiens,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617050,6857,107,,449.0,,,Expert,,1,,9,9606.0,2263,F,D,BAO_0000219,
,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,CHEMBL617051,4176,107,,,,,Autocuration,,1,,8,,2264,F,H,BAO_0000219,
,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,CHEMBL617052,4176,107,,,,,Autocuration,,1,,8,,2265,F,H,BAO_0000219,
,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,CHEMBL617053,4176,107,,,,,Autocuration,,1,,8,,2266,F,H,BAO_0000219,
CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",CHEMBL617054,6347,107,,449.0,,,Autocuration,,1,,8,,2267,B,H,BAO_0000219,
CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",CHEMBL617055,6347,107,,449.0,,,Autocuration,,1,,8,,2268,B,H,BAO_0000219,
,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,CHEMBL882924,15331,107,,,,,Autocuration,,1,,8,,2269,B,H,BAO_0000357,
,Homo sapiens,,,Inhibition of human 5-hydroxytryptamine 2A receptor,CHEMBL617056,16146,107,,,,,Expert,,1,,9,9606.0,2270,B,D,BAO_0000357,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617057,15250,107,,449.0,,,Autocuration,,1,,8,,2271,B,H,BAO_0000219,
,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,CHEMBL617058,13631,107,,,,,Expert,,1,,8,,2272,B,H,BAO_0000219,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),CHEMBL617059,3805,107,,,,,Autocuration,,1,,8,,2273,B,H,BAO_0000357,
CHO,,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,CHEMBL617060,4011,107,,449.0,,,Autocuration,,1,,8,,2274,B,H,BAO_0000219,
CHO,,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,CHEMBL617061,4012,107,,449.0,,,Expert,,1,,8,,2275,B,H,BAO_0000219,
L929,,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,CHEMBL617062,6366,107,,307.0,,,Expert,,1,,8,,2276,B,H,BAO_0000219,
CHO,,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617063,15949,107,,449.0,,,Expert,,1,,8,,2277,B,H,BAO_0000219,
,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,CHEMBL617064,14093,107,,,,,Autocuration,,1,,8,,2278,F,H,BAO_0000019,
,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL617065,13481,107,,,,,Autocuration,,1,,8,,2279,F,H,BAO_0000019,
CHO,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHEMBL617066,6347,107,,449.0,,,Autocuration,,1,,8,,2280,B,H,BAO_0000219,
CHO,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,CHEMBL617067,6347,107,,449.0,,,Autocuration,,1,,8,,2281,B,H,BAO_0000219,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,CHEMBL617068,14093,107,,,,,Autocuration,,1,,8,,2282,F,H,BAO_0000019,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,CHEMBL617069,14093,107,,,,,Autocuration,,1,,8,,2283,F,H,BAO_0000019,
,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617070,13481,107,,,,,Autocuration,,1,,8,,2284,F,H,BAO_0000019,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,CHEMBL617071,14442,107,,,,,Autocuration,,1,,8,,2285,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL872915,14442,107,,,,,Autocuration,,1,,8,,2286,B,H,BAO_0000357,
,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,CHEMBL617072,14755,107,,,,,Autocuration,,1,,8,,2287,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,CHEMBL617073,16441,107,,,,,Autocuration,,1,,8,,2288,B,H,BAO_0000357,
,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,CHEMBL617074,14744,107,,,,,Autocuration,,1,,8,,2289,B,H,BAO_0000357,
CHO,,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL617075,16659,107,,449.0,,,Expert,,1,,8,,2290,B,H,BAO_0000219,
,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,CHEMBL617076,3307,107,,,,,Autocuration,,1,,8,,2291,B,H,BAO_0000357,
,Homo sapiens,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,CHEMBL617077,6857,107,,,,,Expert,,1,,9,9606.0,2292,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,CHEMBL617078,5635,107,,,,,Expert,,1,,8,,2293,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,CHEMBL617079,4234,107,,,,,Expert,,1,,9,9606.0,2294,B,D,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,CHEMBL617080,15527,107,,,,,Autocuration,,1,,8,,2295,B,H,BAO_0000357,
CHO,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,CHEMBL617081,6588,107,,449.0,,,Expert,,1,,8,,2296,B,H,BAO_0000219,
,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,CHEMBL617082,13631,107,,,,,Expert,,1,,8,,2297,B,H,BAO_0000219,
,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617083,17723,107,,,,,Autocuration,,1,,8,,2298,B,H,BAO_0000357,
,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,CHEMBL617084,14770,107,,,,,Autocuration,,1,,8,,2299,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,CHEMBL617085,16293,107,,,,,Expert,,1,,9,9606.0,2300,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL617086,16209,107,,,,,Autocuration,,1,,8,,2301,B,H,BAO_0000357,
,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,CHEMBL617087,12469,107,,,,,Autocuration,,1,,8,,2302,B,H,BAO_0000219,
,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,CHEMBL617088,15363,107,,,,,Autocuration,,1,,8,,2303,B,H,BAO_0000357,
,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,CHEMBL617089,15363,107,,,,,Autocuration,,1,,8,,2304,B,H,BAO_0000357,
,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",CHEMBL617090,16441,107,,,,,Expert,,1,,8,,2305,B,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,CHEMBL617513,8,107,,,,,Autocuration,,1,,8,,2306,B,H,BAO_0000357,
HEK293,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,CHEMBL617514,4176,107,,722.0,,,Autocuration,,1,,8,,2307,B,H,BAO_0000219,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,CHEMBL617515,17085,107,,,,,Autocuration,,1,,8,,2308,B,H,BAO_0000019,
,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617516,17200,107,,,,,Autocuration,,1,,8,,2309,B,H,BAO_0000357,
,Homo sapiens,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,CHEMBL617517,17200,107,,,,,Expert,,1,,9,9606.0,2310,B,D,BAO_0000357,
CHO,Homo sapiens,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,CHEMBL617518,4013,107,,449.0,,,Expert,,1,,9,9606.0,2311,B,D,BAO_0000219,
,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617519,5088,107,,,,,Autocuration,,1,,8,,2312,B,H,BAO_0000357,
,Homo sapiens,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,CHEMBL617520,5088,107,,,,,Expert,,1,,9,9606.0,2313,B,D,BAO_0000357,
,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,CHEMBL617521,5088,107,,,,,Autocuration,,1,,8,,2314,B,H,BAO_0000357,
,Homo sapiens,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,CHEMBL617522,5088,107,,,,,Expert,,1,,9,9606.0,2315,B,D,BAO_0000357,
,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,CHEMBL617523,5088,107,,,,,Autocuration,,1,,8,,2316,B,H,BAO_0000357,
,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL617524,5088,107,,,,,Autocuration,,1,,8,,2317,B,H,BAO_0000357,
,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,CHEMBL617525,9786,104686,,,,,Autocuration,,1,,4,,2318,B,H,BAO_0000019,
,Rattus norvegicus,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,CHEMBL617526,9205,104686,,,,,Autocuration,,1,,5,10116.0,2319,B,D,BAO_0000019,
,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,CHEMBL617527,11257,104686,,,,,Autocuration,,1,,4,,2320,B,H,BAO_0000224,
,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,CHEMBL617528,9362,104686,,,,,Autocuration,,1,,4,,2321,B,H,BAO_0000019,
,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,CHEMBL617529,9362,104686,,,,,Autocuration,,1,,4,,2322,B,H,BAO_0000019,
,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,CHEMBL617530,10590,104686,,,,,Autocuration,,1,,4,,2323,B,H,BAO_0000224,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,CHEMBL617531,10468,104686,,,,,Autocuration,,1,,4,,2324,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,CHEMBL617532,13050,104686,,,,,Autocuration,,1,,4,,2325,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,CHEMBL617533,11624,104686,,,,,Autocuration,,1,,4,,2326,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,CHEMBL617534,10468,104686,,,,,Autocuration,,1,,4,,2327,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,CHEMBL617535,10330,104686,,,,,Autocuration,,1,,4,,2328,B,H,BAO_0000224,
,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,CHEMBL617536,10062,104686,,,,,Autocuration,,1,,4,,2329,B,H,BAO_0000224,
,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617537,11642,104686,,,,,Autocuration,,1,,4,,2330,B,H,BAO_0000224,
,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617538,10062,104686,,,,,Autocuration,,1,,4,,2331,B,H,BAO_0000224,
,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,CHEMBL617539,13427,104686,,,,,Autocuration,,1,,4,,2332,B,H,BAO_0000219,In vitro
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617540,12280,104686,,,,,Autocuration,,1,,5,10116.0,2333,B,D,BAO_0000224,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,CHEMBL617541,4101,104686,,,,,Autocuration,,1,,5,10116.0,2334,B,D,BAO_0000224,
,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,CHEMBL617542,10062,104686,,,,,Autocuration,,1,,4,,2335,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,CHEMBL617543,11147,104686,,,,,Autocuration,,1,,4,,2336,B,H,BAO_0000224,
CHO-K1,Rattus norvegicus,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617544,2395,104686,,485.0,,,Autocuration,,1,,5,10116.0,2337,B,D,BAO_0000219,
CHO-K1,Rattus norvegicus,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHEMBL617545,2395,104686,,485.0,,,Autocuration,,1,,5,10116.0,2338,B,D,BAO_0000219,
,Rattus norvegicus,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,CHEMBL617413,9098,104686,,,,,Autocuration,,1,,5,10116.0,2339,B,D,BAO_0000019,
,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,CHEMBL617414,9098,104686,,,,,Autocuration,,1,,4,,2340,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,CHEMBL617415,9098,104686,,,,,Autocuration,,1,,5,10116.0,2341,B,D,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617416,9443,104686,,,,,Autocuration,,1,,4,,2342,B,H,BAO_0000224,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,CHEMBL617417,9443,104686,,,,,Autocuration,,1,,4,,2343,B,H,BAO_0000224,
,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",CHEMBL617418,9699,104686,,,,,Autocuration,,1,,4,,2344,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,CHEMBL617419,9699,104686,,,,,Autocuration,,1,,4,,2345,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,CHEMBL617420,9098,104686,,,,,Autocuration,,1,,4,,2346,B,H,BAO_0000224,
,Rattus norvegicus,,,Affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617421,3070,104686,,,,,Autocuration,,1,,5,10116.0,2347,B,D,BAO_0000224,
,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,CHEMBL617422,9547,104686,,,,,Autocuration,,1,,4,,2348,B,H,BAO_0000224,
,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,CHEMBL617423,10444,104686,,,,,Autocuration,,1,,4,,2349,B,H,BAO_0000019,
,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,CHEMBL617424,14617,104686,,,,,Autocuration,,1,,4,,2350,B,H,BAO_0000019,
,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,CHEMBL617425,14617,104686,,,,,Autocuration,,1,,4,,2351,B,H,BAO_0000019,
,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),CHEMBL617426,11130,104686,,,,,Autocuration,,1,,4,,2352,B,H,BAO_0000224,
,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),CHEMBL617427,11130,104686,,,,,Autocuration,,1,,4,,2353,B,H,BAO_0000218,In vivo
,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,CHEMBL617428,14542,104686,,,Brain,955.0,Autocuration,,1,,4,,2354,B,H,BAO_0000221,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,CHEMBL617429,2797,104686,,,,,Autocuration,,1,,4,,2355,B,H,BAO_0000224,
,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,CHEMBL617430,11332,104686,,,,,Autocuration,,1,,4,,2356,B,H,BAO_0000019,
,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,CHEMBL617431,11332,104686,,,,,Autocuration,,1,,4,,2357,B,H,BAO_0000019,
,,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,CHEMBL617432,10752,104686,,,Frontal cortex,1870.0,Autocuration,,1,,4,,2358,B,H,BAO_0000019,
,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,CHEMBL617433,1185,104686,,,,,Autocuration,,1,,4,,2359,B,H,BAO_0000224,
,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,CHEMBL617434,1185,104686,,,,,Autocuration,,1,,4,,2360,B,H,BAO_0000224,
,Rattus norvegicus,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,CHEMBL617435,11624,104686,,,,,Autocuration,,1,,5,10116.0,2361,B,D,BAO_0000224,
,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,CHEMBL617436,1344,104686,,,,,Autocuration,,1,,4,,2362,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,CHEMBL617437,15453,104686,,,Striatum,2435.0,Autocuration,,1,,5,10116.0,2363,B,D,BAO_0000019,
,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",CHEMBL617438,11662,104686,,,,,Autocuration,,1,,4,,2364,B,H,BAO_0000019,
,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",CHEMBL617439,11662,104686,,,,,Autocuration,,1,,4,,2365,B,H,BAO_0000019,
,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,CHEMBL617440,10796,104686,,,,,Autocuration,,1,,4,,2366,B,H,BAO_0000224,
,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,CHEMBL617441,9069,104686,,,,,Autocuration,,1,,4,,2367,B,H,BAO_0000224,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,CHEMBL872918,8814,104686,,,,,Autocuration,,1,,5,10116.0,2368,B,D,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,CHEMBL617442,8908,104686,,,,,Autocuration,,1,,5,10116.0,2369,B,D,BAO_0000019,
,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,CHEMBL617443,9098,104686,,,,,Autocuration,,1,,4,,2370,B,H,BAO_0000019,
,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,CHEMBL617444,9098,104686,,,,,Autocuration,,1,,4,,2371,B,H,BAO_0000019,
,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,CHEMBL617445,9098,104686,,,,,Autocuration,,1,,4,,2372,B,H,BAO_0000019,
,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,CHEMBL617446,9098,104686,,,,,Autocuration,,1,,4,,2373,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,CHEMBL617447,9098,104686,,,,,Autocuration,,1,,4,,2374,B,H,BAO_0000249,
,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,CHEMBL617448,9098,104686,,,,,Autocuration,,1,,4,,2375,B,H,BAO_0000019,
,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,CHEMBL617449,9098,104686,,,,,Autocuration,,1,,4,,2376,B,H,BAO_0000019,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,CHEMBL617450,9161,104686,,,,,Autocuration,,1,,4,,2377,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,CHEMBL617451,9161,104686,,,,,Autocuration,,1,,4,,2378,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,CHEMBL617452,9161,104686,,,,,Autocuration,,1,,4,,2379,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,CHEMBL617453,9161,104686,,,,,Autocuration,,1,,4,,2380,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,CHEMBL617660,9161,104686,,,,,Autocuration,,1,,4,,2381,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,CHEMBL617661,9161,104686,,,,,Autocuration,,1,,4,,2382,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,CHEMBL617662,9161,104686,,,,,Autocuration,,1,,4,,2383,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,CHEMBL872919,9161,104686,,,,,Autocuration,,1,,4,,2384,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,CHEMBL617663,9161,104686,,,,,Autocuration,,1,,4,,2385,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,CHEMBL617664,9161,104686,,,,,Autocuration,,1,,4,,2386,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,CHEMBL617665,9161,104686,,,,,Autocuration,,1,,4,,2387,B,H,BAO_0000019,
,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,CHEMBL617666,9161,104686,,,,,Autocuration,,1,,4,,2388,B,H,BAO_0000019,
,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,CHEMBL617667,12094,104686,,,,,Autocuration,,1,,4,,2389,B,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,CHEMBL617668,12018,104686,,,,,Autocuration,,1,,4,,2390,B,H,BAO_0000249,
,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,CHEMBL617669,10394,104686,,,,,Autocuration,,1,,4,,2391,B,H,BAO_0000249,
,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,CHEMBL617670,15260,104686,,,,,Autocuration,,1,,4,,2392,B,H,BAO_0000224,
,Rattus norvegicus,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,CHEMBL617671,11624,104686,,,,,Autocuration,,1,,5,10116.0,2393,B,D,BAO_0000224,
,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617672,13654,104686,,,,,Autocuration,,1,,4,,2394,B,H,BAO_0000224,
,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,CHEMBL617673,9541,104686,,,,,Autocuration,,1,,4,,2395,B,H,BAO_0000019,
,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,CHEMBL617674,11933,104686,,,,,Autocuration,,1,,4,,2396,B,H,BAO_0000224,
,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,CHEMBL617675,15538,104686,,,,,Autocuration,,1,,4,,2397,B,H,BAO_0000019,
,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,CHEMBL617676,15538,104686,,,,,Autocuration,,1,,4,,2398,B,H,BAO_0000019,
,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,CHEMBL617677,15538,104686,,,,,Autocuration,,1,,4,,2399,B,H,BAO_0000019,
,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,CHEMBL617678,8841,104686,,,,,Autocuration,,1,,5,,2400,B,D,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,CHEMBL617679,1455,104686,,,,,Autocuration,,1,,4,,2401,B,H,BAO_0000224,
,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,CHEMBL617680,1455,104686,,,,,Autocuration,,1,,4,,2402,B,H,BAO_0000224,
,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,CHEMBL617681,11752,104686,,,,,Autocuration,,1,,4,,2403,B,H,BAO_0000019,
,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,CHEMBL617682,11642,104686,,,Brain,955.0,Autocuration,,1,,4,,2404,B,H,BAO_0000221,
,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,CHEMBL617683,12092,104686,,,,,Autocuration,,1,,4,,2405,B,H,BAO_0000224,
,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,CHEMBL617684,3967,104686,,,,,Autocuration,,1,,4,,2406,B,H,BAO_0000224,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,CHEMBL617685,12771,104686,,,,,Autocuration,,1,,5,10116.0,2407,B,D,BAO_0000224,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,CHEMBL617686,11642,104686,,,,,Autocuration,,1,,4,,2408,B,H,BAO_0000019,
,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,CHEMBL617687,11628,104686,,,,,Autocuration,,1,,4,,2409,B,H,BAO_0000224,
,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,CHEMBL617688,13654,104686,,,,,Autocuration,,1,,4,,2410,B,H,BAO_0000224,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617689,11200,104686,,,,,Autocuration,,1,,4,,2411,F,H,BAO_0000019,
,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,CHEMBL617690,11200,104686,,,,,Autocuration,,1,,4,,2412,F,H,BAO_0000019,
,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",CHEMBL617691,11200,104686,,,,,Autocuration,,1,,4,,2413,F,H,BAO_0000218,In vivo
,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",CHEMBL617692,11200,104686,,,,,Autocuration,,1,,4,,2414,F,H,BAO_0000218,In vivo
,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",CHEMBL617693,11200,104686,,,,,Autocuration,,1,,4,,2415,F,H,BAO_0000218,In vivo
,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",CHEMBL617694,11200,104686,,,,,Autocuration,,1,,4,,2416,F,H,BAO_0000218,In vivo
,,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,CHEMBL857985,15436,12687,,,Brain,955.0,Expert,,1,,8,,2417,B,H,BAO_0000221,
,Rattus norvegicus,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617695,15436,12687,,,,,Expert,,1,,9,10116.0,2418,B,D,BAO_0000019,
,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,CHEMBL617696,14025,12687,,,,,Autocuration,,1,,8,,2419,B,H,BAO_0000019,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,CHEMBL617697,4342,12687,,,,,Autocuration,,1,,8,,2420,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,CHEMBL617257,13735,12687,,,,,Expert,,1,,9,10116.0,2421,B,D,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,CHEMBL617258,5816,12687,,,,,Expert,,1,,9,10116.0,2422,B,D,BAO_0000357,
,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,CHEMBL617259,14287,12687,,,,,Expert,,1,,8,,2423,B,H,BAO_0000019,
,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,CHEMBL617260,15738,12687,,,,,Autocuration,,1,,8,,2424,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617261,15738,12687,,,,,Expert,,1,,9,10116.0,2425,B,D,BAO_0000357,
,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,CHEMBL617262,15026,12687,,,,,Autocuration,,1,,8,,2426,B,H,BAO_0000019,
,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,CHEMBL617263,16647,12687,,,,,Expert,,1,,8,,2427,B,H,BAO_0000019,
,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,CHEMBL617264,16647,12687,,,,,Autocuration,,1,,8,,2428,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,CHEMBL617265,13345,12687,,,,,Expert,,1,,9,10116.0,2429,B,D,BAO_0000019,
,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,CHEMBL617266,1543,12687,Membranes,,,,Autocuration,,1,,8,,2430,B,H,BAO_0000249,
,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,CHEMBL617267,12444,12687,,,,,Autocuration,,1,,8,,2431,B,H,BAO_0000019,
,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,CHEMBL617268,16404,12687,,,,,Expert,,1,,8,,2432,B,H,BAO_0000019,
CHO,,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHEMBL617269,16404,12687,,449.0,,,Autocuration,,1,,8,,2433,B,H,BAO_0000219,
,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,CHEMBL617323,15577,12687,,,,,Expert,,1,,8,,2434,B,H,BAO_0000357,
,,,,Serotonergic activity of the compound.,CHEMBL617324,15577,12687,,,,,Autocuration,,1,,8,,2435,B,H,BAO_0000357,
,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,CHEMBL617325,2495,12687,,,,,Autocuration,,1,,8,,2436,B,H,BAO_0000249,
,Rattus norvegicus,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,CHEMBL617326,15042,12687,,,,,Expert,,1,,9,10116.0,2437,B,D,BAO_0000019,
,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,CHEMBL617327,15026,12687,,,,,Expert,,1,,8,,2438,B,H,BAO_0000249,
,Rattus norvegicus,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617328,12919,12687,,,,,Expert,,1,,9,10116.0,2439,F,D,BAO_0000019,
,Rattus norvegicus,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617329,12919,12687,,,,,Expert,,1,,9,10116.0,2440,F,D,BAO_0000019,
,Rattus norvegicus,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617330,12919,12687,,,,,Expert,,1,,9,10116.0,2441,F,D,BAO_0000019,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617331,15194,12687,,,,,Autocuration,,1,,8,,2442,B,H,BAO_0000357,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,CHEMBL617332,15194,12687,,,,,Autocuration,,1,,8,,2443,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617333,4820,107,,,,,Expert,,1,,8,,2444,B,H,BAO_0000357,
,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,CHEMBL617334,6736,107,,,,,Autocuration,,1,,8,,2445,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,CHEMBL617335,5163,107,,,,,Autocuration,,1,,8,,2446,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,CHEMBL617336,5163,107,,,,,Autocuration,,1,,8,,2447,B,H,BAO_0000357,
,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,CHEMBL617337,6011,107,,,,,Autocuration,,1,,8,,2448,B,H,BAO_0000357,
,Homo sapiens,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,CHEMBL617338,14294,107,,,,,Expert,,1,,9,9606.0,2449,B,D,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,CHEMBL617339,5014,107,,,,,Autocuration,,1,,8,,2450,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617340,17066,107,,,,,Expert,,1,,8,,2451,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,CHEMBL617341,17515,107,,,,,Autocuration,,1,,8,,2452,B,H,BAO_0000357,
,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617342,6736,107,,,,,Expert,,1,,8,,2453,B,H,BAO_0000357,
,,,,Affinity for 5-hydroxytryptamine 2A receptor,CHEMBL617343,5163,107,,,,,Expert,,1,,8,,2454,B,H,BAO_0000357,
NIH3T3,,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,CHEMBL617344,16911,107,,723.0,,,Expert,,1,,8,,2455,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,CHEMBL617345,6841,107,,,,,Expert,,1,,8,,2456,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,CHEMBL617346,6119,107,,,,,Expert,,1,,8,,2457,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,CHEMBL617347,3962,107,,,,,Autocuration,,1,,8,,2458,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617348,4373,107,,,,,Autocuration,,1,,8,,2459,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617349,4373,107,,,,,Autocuration,,1,,8,,2460,B,H,BAO_0000357,
,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,CHEMBL617350,3962,107,,,,,Autocuration,,1,,8,,2461,F,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,CHEMBL872339,1633,107,,,,,Expert,,1,,8,,2462,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,CHEMBL617351,4373,107,,,,,Autocuration,,1,,8,,2463,B,H,BAO_0000357,
,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617352,6576,107,,,,,Expert,,1,,8,,2464,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617353,4687,107,,,,,Autocuration,,1,,8,,2465,B,H,BAO_0000357,
,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,CHEMBL617354,16946,107,,,,,Autocuration,,1,,8,,2466,B,H,BAO_0000357,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,CHEMBL617355,14159,107,,,,,Autocuration,,1,,8,,2467,B,H,BAO_0000357,
CHO,Mus musculus,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,CHEMBL617356,3032,107,,449.0,,,Expert,,1,,8,10090.0,2468,B,H,BAO_0000219,
,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,CHEMBL617357,16655,107,,,,,Autocuration,,1,,8,,2469,B,H,BAO_0000357,
,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,CHEMBL617358,13964,107,,,,,Autocuration,,1,,8,,2470,B,H,BAO_0000357,
,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617359,16989,107,,,,,Expert,,1,,8,,2471,B,H,BAO_0000357,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,CHEMBL617360,16117,107,,,,,Autocuration,,1,,8,,2472,B,H,BAO_0000357,
,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,CHEMBL875913,16700,107,,,,,Autocuration,,1,,8,,2473,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617361,3269,107,,,,,Autocuration,,1,,8,,2474,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,CHEMBL617362,1274,107,,,,,Expert,,1,,9,9606.0,2475,B,D,BAO_0000357,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,CHEMBL617363,1317,107,,,,,Autocuration,,1,,8,,2476,B,H,BAO_0000357,
,,,,Tested against 5-hydroxytryptamine 2A receptor,CHEMBL617364,12146,107,,,,,Autocuration,,1,,8,,2477,B,H,BAO_0000357,
,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,CHEMBL617365,12652,105075,,,,,Autocuration,,1,,4,,2478,B,H,BAO_0000224,
,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,CHEMBL617366,12652,105075,,,,,Autocuration,,1,,4,,2479,B,H,BAO_0000224,
,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,CHEMBL617367,12652,105075,,,,,Autocuration,,1,,4,,2480,B,H,BAO_0000224,
,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,CHEMBL617368,12652,105075,,,,,Autocuration,,1,,4,,2481,B,H,BAO_0000224,
,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),CHEMBL617369,16647,107,,,,,Autocuration,,1,,8,,2482,B,H,BAO_0000357,
HEK293,Homo sapiens,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,CHEMBL617370,15851,227,,722.0,,,Expert,,1,,9,9606.0,2483,B,D,BAO_0000219,
CHO,Homo sapiens,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617371,6857,227,,449.0,,,Expert,,1,,9,9606.0,2484,F,D,BAO_0000219,
,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),CHEMBL617372,3805,227,,,,,Autocuration,,1,,8,,2485,B,H,BAO_0000357,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,CHEMBL617373,6491,227,,,,,Expert,,1,,9,9606.0,2486,B,D,BAO_0000357,
,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,CHEMBL617374,14093,227,,,,,Autocuration,,1,,8,,2487,F,H,BAO_0000019,
,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,CHEMBL617375,13481,227,,,,,Autocuration,,1,,8,,2488,F,H,BAO_0000019,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,CHEMBL617376,14093,227,,,,,Autocuration,,1,,8,,2489,F,H,BAO_0000019,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,CHEMBL617377,14093,227,,,,,Autocuration,,1,,8,,2490,F,H,BAO_0000019,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,CHEMBL617378,14093,227,,,,,Autocuration,,1,,8,,2491,F,H,BAO_0000019,
,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,CHEMBL617379,13481,227,,,,,Autocuration,,1,,8,,2492,F,H,BAO_0000019,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,CHEMBL617380,14442,227,,,,,Autocuration,,1,,8,,2493,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,CHEMBL617381,14442,227,,,,,Autocuration,,1,,8,,2494,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,CHEMBL617382,14442,227,,,,,Autocuration,,1,,8,,2495,B,H,BAO_0000357,
,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617383,12369,107,,,,,Autocuration,,1,,8,,2496,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,CHEMBL617384,12369,107,,,,,Expert,,1,,8,,2497,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,CHEMBL617385,12369,107,,,,,Expert,,1,,8,,2498,B,H,BAO_0000357,
,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,CHEMBL617386,14447,107,,,,,Autocuration,,1,,8,,2499,B,H,BAO_0000019,
,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,CHEMBL617387,14447,107,,,,,Autocuration,,1,,8,,2500,B,H,BAO_0000019,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL617388,17451,107,,723.0,,,Autocuration,,1,,8,,2501,B,H,BAO_0000219,
CHO,,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617389,6857,107,,449.0,,,Autocuration,,1,,8,,2502,F,H,BAO_0000219,
CHO,Homo sapiens,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617390,6857,107,,449.0,,,Expert,,1,,9,9606.0,2503,F,D,BAO_0000219,
,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,CHEMBL617391,5635,104817,,,,,Autocuration,,1,,4,,2504,B,H,BAO_0000224,
,,,,Binding activity radioligand.,CHEMBL617392,12861,107,,,,,Autocuration,,1,,8,,2505,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617393,12861,107,,,,,Autocuration,,1,,8,,2506,B,H,BAO_0000019,
L929,,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,CHEMBL617394,5105,107,,307.0,,,Autocuration,,1,,8,,2507,B,H,BAO_0000219,
L929,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,CHEMBL617395,5104,107,,307.0,,,Expert,,1,,8,,2508,B,H,BAO_0000219,
L929,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,CHEMBL617396,5105,107,,307.0,,,Expert,,1,,8,,2509,B,H,BAO_0000219,
L929,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,CHEMBL617397,5105,107,,307.0,,,Autocuration,,1,,8,,2510,B,H,BAO_0000219,
,,,,Binding affinity against 5-HT2A receptor,CHEMBL617398,5254,107,,,,,Autocuration,,1,,8,,2511,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617399,5254,107,,,,,Autocuration,,1,,8,,2512,B,H,BAO_0000357,
HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,CHEMBL617400,13267,107,,722.0,,,Autocuration,,1,,8,,2513,B,H,BAO_0000219,
HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,CHEMBL617401,13267,107,,722.0,,,Autocuration,,1,,8,,2514,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,CHEMBL617402,14157,107,,722.0,,,Expert,,1,,9,9606.0,2515,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL617403,12936,107,,722.0,,,Expert,,1,,9,9606.0,2516,B,D,BAO_0000219,
,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,CHEMBL617404,14068,107,,,,,Expert,,1,,8,,2517,B,H,BAO_0000357,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL857981,12936,107,,722.0,,,Expert,,1,,9,9606.0,2518,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL617405,12936,107,,722.0,,,Expert,,1,,9,9606.0,2519,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,CHEMBL617253,4540,107,,722.0,,,Expert,,1,,9,9606.0,2520,B,D,BAO_0000219,
,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,CHEMBL617254,6166,107,,,,,Expert,,1,,8,,2521,B,H,BAO_0000357,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL617255,17296,107,,722.0,,,Autocuration,,1,,8,,2522,B,H,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL617256,17296,107,,722.0,,,Autocuration,,1,,8,,2523,B,H,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL616874,17296,107,,722.0,,,Autocuration,,1,,8,,2524,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,CHEMBL616875,15779,107,,722.0,,,Expert,,1,,9,9606.0,2525,B,D,BAO_0000219,
HEK293,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,CHEMBL616876,14391,107,,722.0,,,Expert,,1,,8,,2526,B,H,BAO_0000219,
HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",CHEMBL616877,15851,107,,722.0,,,Expert,,1,,8,,2527,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,CHEMBL616878,15851,107,,722.0,,,Expert,,1,,9,9606.0,2528,B,D,BAO_0000219,
HEK293,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,CHEMBL616879,3832,107,,722.0,,,Expert,,1,,8,,2529,B,H,BAO_0000219,
HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,CHEMBL616880,3833,107,,722.0,,,Expert,,1,,8,,2530,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,CHEMBL616881,12936,107,,722.0,,,Expert,,1,,9,9606.0,2531,B,D,BAO_0000219,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,CHEMBL616882,17451,107,,723.0,,,Autocuration,,1,,8,,2532,B,H,BAO_0000219,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL616883,17451,107,,723.0,,,Autocuration,,1,,8,,2533,B,H,BAO_0000219,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL616884,17451,107,,723.0,,,Autocuration,,1,,8,,2534,B,H,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,CHEMBL616885,4199,107,,722.0,,,Autocuration,,1,,8,,2535,B,H,BAO_0000219,
CHO-K1,,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,CHEMBL616886,1883,107,,485.0,,,Autocuration,,1,,8,,2536,B,H,BAO_0000219,
CHO-K1,,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,CHEMBL616887,1883,107,,485.0,,,Expert,,1,,8,,2537,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,CHEMBL616888,14875,107,,,,,Expert,,1,,9,9606.0,2538,B,D,BAO_0000357,
HEK293,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,CHEMBL616889,15146,107,,722.0,,,Autocuration,,1,,8,,2539,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,CHEMBL616890,5213,107,,722.0,,,Autocuration,,1,,8,,2540,B,H,BAO_0000219,
CHO,Homo sapiens,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHEMBL616891,16404,107,,449.0,,,Expert,,1,,9,9606.0,2541,B,D,BAO_0000219,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,CHEMBL616892,14818,107,,722.0,,,Autocuration,,1,,8,,2542,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",CHEMBL616893,4829,107,,722.0,,,Autocuration,,1,,8,,2543,B,H,BAO_0000219,
NIH3T3,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,CHEMBL616894,12652,10620,,723.0,,,Autocuration,,1,,8,,2544,F,H,BAO_0000219,
NIH3T3,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,CHEMBL616895,4682,107,,723.0,,,Expert,,1,,8,,2545,B,H,BAO_0000219,
,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,CHEMBL616896,12652,10620,,,,,Autocuration,,1,,8,,2546,F,H,BAO_0000019,
,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,CHEMBL617099,4921,10621,,,,,Autocuration,,1,,8,,2547,B,H,BAO_0000357,
,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,CHEMBL617100,4921,10621,,,,,Autocuration,,1,,8,,2548,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity against rabbit aorta 5-HT2A receptor,CHEMBL884532,16312,107,,,,,Autocuration,,1,,8,9986.0,2549,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,CHEMBL617101,14998,107,,,,,Expert,,1,,8,9986.0,2550,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,CHEMBL617102,14025,107,,,,,Expert,,1,,8,9986.0,2551,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,CHEMBL617103,13047,107,,,,,Autocuration,,1,,8,9986.0,2552,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,The compound was tested for binding affinity against 5-HT2A receptor,CHEMBL617104,13047,107,,,,,Expert,,1,,8,9986.0,2553,B,H,BAO_0000357,
CHO-K1,,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,CHEMBL857979,1883,10576,,485.0,,,Autocuration,,1,,8,,2554,B,H,BAO_0000219,
,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,CHEMBL857502,13463,12687,,,,,Autocuration,,1,,8,,2555,B,H,BAO_0000019,
,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,CHEMBL617105,13463,12687,,,,,Autocuration,,1,,8,,2556,B,H,BAO_0000019,
,,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,CHEMBL858021,13463,12687,,,Stomach,945.0,Autocuration,,1,,8,,2557,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity for 5-HT 2A in rat stomach fundus,CHEMBL875910,13463,12687,,,Stomach,945.0,Expert,,1,,9,10116.0,2558,B,D,BAO_0000019,
,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,CHEMBL617106,13463,12687,,,,,Autocuration,,1,,8,,2559,B,H,BAO_0000019,
NIH3T3,,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,CHEMBL617107,16326,12687,,723.0,,,Expert,,1,,8,,2560,B,H,BAO_0000219,
,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,CHEMBL617108,14093,12687,,,,,Autocuration,,1,,8,,2561,F,H,BAO_0000019,
,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,CHEMBL617109,14093,12687,,,,,Autocuration,,1,,8,,2562,F,H,BAO_0000019,
,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,CHEMBL617110,15740,12687,,,,,Autocuration,,1,,8,,2563,B,H,BAO_0000357,
,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,CHEMBL617111,16633,12687,,,,,Autocuration,,1,,8,,2564,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,CHEMBL617112,17200,12687,,,,,Expert,,1,,9,10116.0,2565,F,D,BAO_0000019,
,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617113,17133,12687,,,,,Autocuration,,1,,8,,2566,B,H,BAO_0000357,
,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617114,17133,12687,,,,,Autocuration,,1,,8,,2567,B,H,BAO_0000357,
,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617115,17133,12687,,,,,Autocuration,,1,,8,,2568,B,H,BAO_0000357,
,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617116,17200,12687,,,,,Autocuration,,1,,8,,2569,F,H,BAO_0000219,
,,,,Efficacy at 5-hydroxytryptamine 2A receptor,CHEMBL617117,15363,12687,,,,,Autocuration,,1,,8,,2570,F,H,BAO_0000019,
,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),CHEMBL617118,17200,12687,,,,,Autocuration,,1,,8,,2571,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),CHEMBL617119,17200,12687,,,,,Expert,,1,,9,10116.0,2572,B,D,BAO_0000357,
,Rattus norvegicus,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),CHEMBL617120,17200,12687,,,,,Expert,,1,,9,10116.0,2573,B,D,BAO_0000357,
,Rattus norvegicus,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617121,17200,12687,,,,,Expert,,1,,9,10116.0,2574,F,D,BAO_0000219,
,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,CHEMBL617122,17200,12687,,,,,Autocuration,,1,,8,,2575,F,H,BAO_0000219,
,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,CHEMBL617123,17211,12687,,,,,Autocuration,,1,,8,,2576,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,CHEMBL617124,17331,12687,,,,,Expert,,1,,8,,2577,B,H,BAO_0000019,
,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,CHEMBL617600,13565,12687,,,,,Expert,,1,,8,,2578,B,H,BAO_0000249,
,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,CHEMBL617601,13730,12687,,,,,Expert,,1,,8,,2579,B,H,BAO_0000357,
,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,CHEMBL882923,12416,12687,,,,,Expert,,1,,8,,2580,B,H,BAO_0000019,
,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL617602,15295,12687,,,,,Autocuration,,1,,8,,2581,B,H,BAO_0000357,
,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,CHEMBL617603,1742,12687,,,,,Autocuration,,1,,8,,2582,B,H,BAO_0000019,
,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,CHEMBL617604,15295,12687,,,,,Autocuration,,1,,8,,2583,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,CHEMBL617605,14970,12687,,,,,Expert,,1,,8,,2584,B,H,BAO_0000019,
,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,CHEMBL617606,16693,12687,,,,,Expert,,1,,8,,2585,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,CHEMBL617607,14776,12687,,,,,Expert,,1,,9,10116.0,2586,B,D,BAO_0000019,
,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617455,14286,12687,,,,,Autocuration,,1,,8,,2587,B,H,BAO_0000249,
,Rattus norvegicus,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,CHEMBL617456,17200,12687,,,,,Expert,,1,,9,10116.0,2588,B,D,BAO_0000019,
,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),CHEMBL617457,15306,12687,,,,,Expert,,1,,8,,2589,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,CHEMBL617458,14178,12687,,,,,Expert,,1,,9,10116.0,2590,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,CHEMBL617459,14229,12687,,,,,Expert,,1,,9,10116.0,2591,B,D,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,CHEMBL617460,12884,12687,,,,,Expert,,1,,8,,2592,B,H,BAO_0000357,
,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",CHEMBL617461,13149,12687,,,,,Expert,,1,,8,,2593,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,CHEMBL617462,15295,12687,,,,,Expert,,1,,9,10116.0,2594,B,D,BAO_0000019,
,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,CHEMBL617463,15740,12687,,,,,Autocuration,,1,,8,,2595,B,H,BAO_0000357,
,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",CHEMBL617464,15185,12687,,,,,Autocuration,,1,,8,,2596,B,H,BAO_0000019,
,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",CHEMBL617465,15185,12687,,,,,Autocuration,,1,,8,,2597,B,H,BAO_0000019,
,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,CHEMBL617466,17529,12687,,,,,Expert,,1,,8,,2598,B,H,BAO_0000019,
,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,CHEMBL617467,14826,12687,,,,,Autocuration,,1,,8,,2599,B,H,BAO_0000019,
,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,CHEMBL617468,17211,12687,,,,,Expert,,1,,8,,2600,B,H,BAO_0000019,
,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,CHEMBL617469,14826,12687,,,,,Autocuration,,1,,8,,2601,B,H,BAO_0000019,
,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,CHEMBL617470,14093,12687,,,,,Autocuration,,1,,8,,2602,B,H,BAO_0000019,
,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,CHEMBL617471,14093,12687,,,,,Autocuration,,1,,8,,2603,B,H,BAO_0000019,
NIH3T3,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,CHEMBL617472,13246,12687,,723.0,,,Expert,,1,,8,,2604,B,H,BAO_0000219,
,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,CHEMBL617473,13246,12687,,,,,Expert,,1,,8,,2605,B,H,BAO_0000357,
,Rattus norvegicus,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617474,15436,12687,,,,,Expert,,1,,9,10116.0,2606,B,D,BAO_0000019,
,Rattus norvegicus,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,CHEMBL617475,15436,12687,,,,,Expert,,1,,9,10116.0,2607,B,D,BAO_0000019,
,,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,CHEMBL617476,14442,12687,,,Brain,955.0,Autocuration,,1,,8,,2608,B,H,BAO_0000221,
,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,CHEMBL617477,12457,12687,,,,,Expert,,1,,8,,2609,B,H,BAO_0000357,
NIH3T3,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,CHEMBL617478,12457,12687,,723.0,,,Expert,,1,,8,,2610,B,H,BAO_0000219,
,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",CHEMBL617479,14755,12687,,,,,Autocuration,,1,,8,,2611,F,H,BAO_0000221,
,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,CHEMBL617480,4707,12687,,,,,Autocuration,,1,,8,,2612,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617481,13297,12687,,,,,Expert,,1,,8,,2613,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,CHEMBL617482,17331,12687,,,,,Expert,,1,,8,,2614,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,CHEMBL617483,4664,12687,,,,,Autocuration,,1,,8,,2615,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL621528,16633,12687,,,,,Autocuration,,1,,8,,2616,B,H,BAO_0000357,
NIH3T3,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,CHEMBL621529,4664,12687,,723.0,,,Expert,,1,,9,10116.0,2617,B,D,BAO_0000219,
,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL621530,16133,12687,,,,,Expert,,1,,8,,2618,B,H,BAO_0000357,
,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL621531,16133,12687,,,,,Expert,,1,,8,,2619,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,CHEMBL621532,14060,12687,,,,,Expert,,1,,9,10116.0,2620,B,D,BAO_0000019,
,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL621533,16326,12687,,,,,Expert,,1,,8,,2621,B,H,BAO_0000357,
CHO,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHEMBL621534,16659,12687,,449.0,,,Expert,,1,,8,,2622,B,H,BAO_0000219,
,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,CHEMBL621535,14776,12687,,,,,Autocuration,,1,,8,,2623,B,H,BAO_0000019,
,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,CHEMBL621536,13481,12687,,,,,Autocuration,,1,,8,,2624,B,H,BAO_0000357,
,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,CHEMBL621537,17386,12687,,,,,Autocuration,,1,,8,,2625,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 2A receptor,CHEMBL621538,6611,12687,,,,,Expert,,1,,9,10116.0,2626,B,D,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,CHEMBL621539,14423,12687,,,,,Autocuration,,1,,8,,2627,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,CHEMBL621540,15412,12687,,,,,Autocuration,,1,,8,,2628,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,CHEMBL621541,15412,12687,,,,,Autocuration,,1,,8,,2629,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,CHEMBL621542,6238,12687,,,,,Autocuration,,1,,8,,2630,B,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,CHEMBL621543,6648,12687,,,,,Expert,,1,,8,,2631,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,CHEMBL621544,5667,12687,,,,,Expert,,1,,8,,2632,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,CHEMBL621545,6611,12687,,,,,Expert,,1,,9,10116.0,2633,B,D,BAO_0000357,
,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL621546,13481,12687,,,,,Autocuration,,1,,8,,2634,B,H,BAO_0000357,
,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,CHEMBL621547,13481,12687,,,,,Autocuration,,1,,8,,2635,B,H,BAO_0000357,
NIH3T3,,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,CHEMBL618692,15558,12687,,723.0,,,Expert,,1,,8,,2636,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,CHEMBL618693,6013,12687,,,,,Autocuration,,1,,8,,2637,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,CHEMBL872922,16633,12687,,,,,Autocuration,,1,,8,,2638,B,H,BAO_0000357,
,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,CHEMBL618694,6013,12687,,,,,Autocuration,,1,,8,,2639,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,CHEMBL618695,6013,12687,,,,,Expert,,1,,9,10116.0,2640,B,D,BAO_0000357,
,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,CHEMBL618696,6013,12687,,,,,Autocuration,,1,,8,,2641,B,H,BAO_0000357,
,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,CHEMBL618697,6013,12687,,,,,Expert,,1,,8,,2642,B,H,BAO_0000357,
,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,CHEMBL618892,6013,12687,,,,,Autocuration,,1,,8,,2643,B,H,BAO_0000357,
,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,CHEMBL618893,6013,12687,,,,,Autocuration,,1,,8,,2644,B,H,BAO_0000357,
,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,CHEMBL618894,16293,12687,,,,,Autocuration,,1,,8,,2645,B,H,BAO_0000357,
NIH3T3,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,CHEMBL618895,17175,12687,,723.0,,,Expert,,1,,8,,2646,B,H,BAO_0000219,
,Rattus norvegicus,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,CHEMBL618896,13278,12687,,,,,Expert,,1,,9,10116.0,2647,B,D,BAO_0000357,
,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,CHEMBL618897,3682,12687,,,Caudate-putamen,5383.0,Autocuration,,1,,8,,2648,B,H,BAO_0000019,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,CHEMBL618898,2014,12687,,,,,Autocuration,,1,,8,,2649,B,H,BAO_0000357,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,CHEMBL618899,2014,12687,,,,,Autocuration,,1,,8,,2650,B,H,BAO_0000357,
,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,CHEMBL618900,4932,12687,,,,,Autocuration,,1,,8,,2651,B,H,BAO_0000357,
,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,CHEMBL618901,4932,12687,,,,,Autocuration,,1,,8,,2652,B,H,BAO_0000019,
,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,CHEMBL618902,3935,12687,,,,,Autocuration,,1,,8,,2653,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,CHEMBL618903,5432,12687,,,Hippocampus,10000000.0,Expert,,1,,9,10116.0,2654,B,D,BAO_0000221,
,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,CHEMBL618904,15818,12687,,,,,Autocuration,,1,,8,,2655,B,H,BAO_0000357,
,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,CHEMBL618905,13672,12687,,,,,Autocuration,,1,,8,,2656,B,H,BAO_0000357,
,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,CHEMBL618906,13672,12687,,,,,Autocuration,,1,,8,,2657,B,H,BAO_0000357,
NIH3T3,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,CHEMBL618907,14749,12687,,723.0,,,Expert,,1,,8,,2658,B,H,BAO_0000219,
,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,CHEMBL618908,13462,12687,,,,,Autocuration,,1,,8,,2659,B,H,BAO_0000019,
,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,CHEMBL617909,15740,12687,,,,,Autocuration,,1,,8,,2660,B,H,BAO_0000357,
,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,CHEMBL617910,16647,12687,,,,,Expert,,1,,8,,2661,B,H,BAO_0000019,
,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,CHEMBL617911,13345,12687,,,Brain,955.0,Autocuration,,1,,8,,2662,B,H,BAO_0000221,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL872923,16740,12687,,,,,Autocuration,,1,,8,,2663,B,H,BAO_0000249,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617912,16740,12687,,,,,Autocuration,,1,,8,,2664,B,H,BAO_0000249,
,Rattus norvegicus,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,CHEMBL617913,15535,12687,,,,,Expert,,1,,9,10116.0,2665,B,D,BAO_0000019,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617914,16740,12687,,,,,Expert,,1,,8,,2666,B,H,BAO_0000249,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617915,16740,12687,,,,,Autocuration,,1,,8,,2667,B,H,BAO_0000249,
,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,CHEMBL617916,16740,12687,,,,,Autocuration,,1,,8,,2668,B,H,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,CHEMBL617917,4795,12687,,,,,Expert,,1,,9,10116.0,2669,B,D,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,CHEMBL617918,8,12687,,,,,Expert,,1,,8,,2670,B,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,CHEMBL617919,8,12687,,,,,Autocuration,,1,,8,,2671,B,H,BAO_0000019,
,Rattus norvegicus,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,CHEMBL617920,17200,12687,,,,,Expert,,1,,9,10116.0,2672,B,D,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,CHEMBL617921,2148,12687,,,,,Expert,,1,,9,10116.0,2673,B,D,BAO_0000019,
,Rattus norvegicus,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",CHEMBL617922,13345,105102,,,,,Expert,,1,,5,10116.0,2674,B,D,BAO_0000224,
,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,CHEMBL617923,5088,12687,,,,,Autocuration,,1,,8,,2675,B,H,BAO_0000357,
,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,CHEMBL617924,5088,12687,,,,,Autocuration,,1,,8,,2676,B,H,BAO_0000357,
,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,CHEMBL617925,17133,12687,,,,,Autocuration,,1,,8,,2677,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,CHEMBL617926,17133,12687,,,,,Expert,,1,,9,10116.0,2678,B,D,BAO_0000357,
,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,CHEMBL617927,16532,12687,,,,,Autocuration,,1,,8,,2679,B,H,BAO_0000357,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,CHEMBL617928,15086,12687,,,,,Autocuration,,1,,8,,2680,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,CHEMBL617929,2309,12687,,,,,Expert,,1,,9,10116.0,2681,B,D,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,CHEMBL617930,12953,12687,,,,,Expert,,1,,8,,2682,B,H,BAO_0000019,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,CHEMBL617931,12953,12687,,,,,Autocuration,,1,,8,,2683,B,H,BAO_0000019,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,CHEMBL617932,12953,12687,,,,,Autocuration,,1,,8,,2684,B,H,BAO_0000019,
CHO,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,CHEMBL617933,16659,12687,,449.0,,,Autocuration,,1,,8,,2685,B,H,BAO_0000219,
,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,CHEMBL617934,16740,12687,,,,,Autocuration,,1,,8,,2686,B,H,BAO_0000019,
,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,CHEMBL617935,16740,12687,,,,,Autocuration,,1,,8,,2687,B,H,BAO_0000019,
,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,CHEMBL617936,17133,12687,,,,,Autocuration,,1,,8,,2688,B,H,BAO_0000357,
,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,CHEMBL617937,17211,12687,,,,,Autocuration,,1,,8,,2689,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,CHEMBL617938,17331,12687,,,,,Autocuration,,1,,8,,2690,B,H,BAO_0000019,
,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,CHEMBL617939,16633,12687,,,,,Autocuration,,1,,8,,2691,B,H,BAO_0000218,
,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,CHEMBL617940,16633,12687,,,,,Autocuration,,1,,8,,2692,B,H,BAO_0000218,
,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,CHEMBL617941,16633,12687,,,,,Autocuration,,1,,8,,2693,B,H,BAO_0000218,
,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,CHEMBL617942,15026,12687,,,,,Expert,,1,,8,,2694,B,H,BAO_0000357,
,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,CHEMBL617943,15026,12687,,,,,Expert,,1,,8,,2695,B,H,BAO_0000357,
,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,CHEMBL617944,16404,105093,,,,,Expert,,1,,4,,2696,B,H,BAO_0000224,
,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,CHEMBL617945,16404,105093,,,,,Expert,,1,,4,,2697,B,H,BAO_0000224,
,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,CHEMBL617946,16404,105075,,,,,Expert,,1,,4,,2698,B,H,BAO_0000224,
,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,CHEMBL617947,16404,12687,,,,,Autocuration,,1,,8,,2699,B,H,BAO_0000357,
,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,CHEMBL617948,16326,12687,,,,,Expert,,1,,8,,2700,B,H,BAO_0000357,
,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,CHEMBL858116,15847,12687,,,,,Autocuration,,1,,8,,2701,F,H,BAO_0000019,
,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,CHEMBL617949,15847,12687,,,,,Autocuration,,1,,8,,2702,F,H,BAO_0000019,
,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,CHEMBL617950,15329,12687,,,,,Autocuration,,1,,8,,2703,F,H,BAO_0000019,
,,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,CHEMBL617951,16404,12687,,,Thoracic aorta,1515.0,Expert,,1,,8,,2704,F,H,BAO_0000019,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,CHEMBL617952,16404,12687,,,Thoracic aorta,1515.0,Expert,,1,,8,,2705,F,H,BAO_0000019,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,CHEMBL617953,16404,12687,,,Thoracic aorta,1515.0,Autocuration,,1,,8,,2706,F,H,BAO_0000019,
,,,,Binding activity radioligand.,CHEMBL617954,12861,12687,,,,,Autocuration,,1,,8,,2707,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617955,12861,12687,,,,,Expert,,1,,8,,2708,B,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,CHEMBL857071,12861,12687,,,,,Autocuration,,1,,8,,2709,B,H,BAO_0000019,
,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,CHEMBL617270,12490,12687,,,,,Expert,,1,,8,,2710,B,H,BAO_0000019,
N1E-115,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,CHEMBL617271,12827,12687,,339.0,,,Autocuration,,1,,8,,2711,B,H,BAO_0000219,
N1E-115,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,CHEMBL617272,12827,12687,,339.0,,,Autocuration,,1,,8,,2712,B,H,BAO_0000219,
,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,CHEMBL617273,12918,12687,,,,,Autocuration,,1,,8,,2713,B,H,BAO_0000019,
,Rattus norvegicus,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,CHEMBL617274,12919,12687,,,,,Expert,,1,,9,10116.0,2714,F,D,BAO_0000019,
,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,CHEMBL617275,17723,108,,,,,Autocuration,,1,,8,,2715,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617276,6013,108,,,,,Autocuration,,1,,8,,2716,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,CHEMBL617277,16293,108,,,,,Autocuration,,1,,8,,2717,B,H,BAO_0000357,
,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,CHEMBL617278,3857,108,,,,,Expert,,1,,8,,2718,B,H,BAO_0000019,
,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,CHEMBL617279,3857,108,,,,,Expert,,1,,8,,2719,B,H,BAO_0000019,
,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,CHEMBL617280,3857,108,,,,,Expert,,1,,8,,2720,B,H,BAO_0000019,
,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,CHEMBL617281,15363,108,,,,,Autocuration,,1,,8,,2721,B,H,BAO_0000357,
,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,CHEMBL617282,15363,108,,,,,Autocuration,,1,,8,,2722,B,H,BAO_0000357,
,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,CHEMBL617283,16441,108,,,,,Expert,,1,,8,,2723,B,H,BAO_0000019,
,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,CHEMBL617284,16441,108,,,,,Expert,,1,,8,,2724,B,H,BAO_0000019,
HEK293,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,CHEMBL617285,4176,108,,722.0,,,Autocuration,,1,,8,,2725,B,H,BAO_0000219,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,CHEMBL617286,17085,108,,,,,Autocuration,,1,,8,,2726,B,H,BAO_0000019,
,Homo sapiens,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,CHEMBL617287,17200,108,,,,,Expert,,1,,9,9606.0,2727,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,CHEMBL617288,5088,108,,,,,Expert,,1,,8,,2728,B,H,BAO_0000357,
,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,CHEMBL617289,5088,108,,,,,Autocuration,,1,,8,,2729,B,H,BAO_0000357,
,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL872917,5088,108,,,,,Autocuration,,1,,8,,2730,B,H,BAO_0000357,
,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,CHEMBL617290,5088,108,,,,,Autocuration,,1,,8,,2731,B,H,BAO_0000357,
CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL617291,16659,108,,449.0,,,Autocuration,,1,,8,,2732,B,H,BAO_0000219,
CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,CHEMBL617292,16659,108,,449.0,,,Autocuration,,1,,8,,2733,B,H,BAO_0000219,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,CHEMBL617293,17451,108,,723.0,,,Autocuration,,1,,8,,2734,B,H,BAO_0000219,
CHO,Homo sapiens,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617294,6857,108,,449.0,,,Expert,,1,,9,9606.0,2735,F,D,BAO_0000219,
,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,CHEMBL617295,3857,108,,,,,Expert,,1,,8,,2736,B,H,BAO_0000019,
,,,,Binding activity radioligand.,CHEMBL617296,12861,108,,,,,Autocuration,,1,,8,,2737,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,CHEMBL617297,12861,108,,,,,Autocuration,,1,,8,,2738,B,H,BAO_0000019,
CHO,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,CHEMBL617298,5104,108,,449.0,,,Expert,,1,,8,,2739,B,H,BAO_0000219,
CHO,,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,CHEMBL617299,5105,108,,449.0,,,Expert,,1,,8,,2740,B,H,BAO_0000219,
CHO,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,CHEMBL617300,5105,108,,449.0,,,Autocuration,,1,,8,,2741,B,H,BAO_0000219,
,,,,Binding affinity against 5-HT2C receptor,CHEMBL617454,5254,108,,,,,Autocuration,,1,,8,,2742,B,H,BAO_0000357,
HEK293,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,CHEMBL617505,13267,108,,722.0,,,Autocuration,,1,,8,,2743,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,CHEMBL617506,14157,108,,722.0,,,Expert,,1,,9,9606.0,2744,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,CHEMBL617507,12936,108,,722.0,,,Expert,,1,,9,9606.0,2745,B,D,BAO_0000219,
,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,CHEMBL617508,14068,108,,,,,Expert,,1,,8,,2746,B,H,BAO_0000357,
HEK293,Homo sapiens,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,CHEMBL857982,12936,108,,722.0,,,Expert,,1,,9,9606.0,2747,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,CHEMBL617509,4540,108,,722.0,,,Expert,,1,,9,9606.0,2748,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,CHEMBL617510,4540,108,,722.0,,,Expert,,1,,9,9606.0,2749,B,D,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,CHEMBL617511,6166,108,,,,,Autocuration,,1,,8,,2750,B,H,BAO_0000357,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617512,17296,108,,722.0,,,Autocuration,,1,,8,,2751,B,H,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617749,17296,108,,722.0,,,Autocuration,,1,,8,,2752,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL617750,15779,108,,722.0,,,Autocuration,,1,,8,,2753,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL617751,15779,108,,722.0,,,Autocuration,,1,,8,,2754,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,CHEMBL617752,14391,108,,722.0,,,Expert,,1,,8,,2755,B,H,BAO_0000219,
HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",CHEMBL617753,15779,108,,722.0,,,Autocuration,,1,,8,,2756,B,H,BAO_0000219,
HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",CHEMBL617754,15851,108,,722.0,,,Expert,,1,,8,,2757,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,CHEMBL617755,15851,108,,722.0,,,Expert,,1,,9,9606.0,2758,B,D,BAO_0000219,
HEK293,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",CHEMBL617756,15779,108,,722.0,,,Autocuration,,1,,8,,2759,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,CHEMBL617757,3832,108,,722.0,,,Expert,,1,,8,,2760,B,H,BAO_0000219,
HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,CHEMBL617758,3833,108,,722.0,,,Expert,,1,,8,,2761,B,H,BAO_0000219,
NIH3T3,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,CHEMBL617759,17451,108,,723.0,,,Autocuration,,1,,8,,2762,B,H,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,CHEMBL617760,4199,108,,722.0,,,Autocuration,,1,,8,,2763,B,H,BAO_0000219,
CHO-K1,,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,CHEMBL617761,1883,108,,485.0,,,Expert,,1,,8,,2764,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617762,4321,108,,,,,Expert,,1,,9,9606.0,2765,B,D,BAO_0000357,
,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,CHEMBL617763,14875,108,,,,,Autocuration,,1,,8,,2766,B,H,BAO_0000357,
HEK293,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,CHEMBL857983,15146,108,,722.0,,,Autocuration,,1,,8,,2767,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,CHEMBL617764,5213,108,,722.0,,,Autocuration,,1,,8,,2768,B,H,BAO_0000219,
HeLa,,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,CHEMBL617765,16404,108,,308.0,,,Autocuration,,1,,8,,2769,B,H,BAO_0000219,
,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,CHEMBL617766,13267,108,,,,,Autocuration,,1,,8,,2770,F,H,BAO_0000019,
,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,CHEMBL617767,13267,108,,,Hippocampus,10000000.0,Autocuration,,1,,8,,2771,F,H,BAO_0000221,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,CHEMBL617768,14818,108,,722.0,,,Autocuration,,1,,8,,2772,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",CHEMBL617769,4829,108,,722.0,,,Autocuration,,1,,8,,2773,B,H,BAO_0000219,
,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,CHEMBL858023,13463,11864,,,,,Autocuration,,1,,8,,2774,B,H,BAO_0000357,
,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,CHEMBL617770,13463,11864,,,Stomach,945.0,Autocuration,,1,,8,,2775,B,H,BAO_0000019,
,,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,CHEMBL617771,13463,11864,,,Stomach,945.0,Autocuration,,1,,8,,2776,B,H,BAO_0000019,
A9,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,CHEMBL617772,12652,11864,,625.0,,,Autocuration,,1,,8,,2777,F,H,BAO_0000219,
NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,CHEMBL617773,4682,11864,,723.0,,,Autocuration,,1,,8,,2778,B,H,BAO_0000219,
NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,CHEMBL617850,4682,11864,,723.0,,,Autocuration,,1,,8,,2779,B,H,BAO_0000219,
NIH3T3,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,CHEMBL617851,4682,11864,,723.0,,,Autocuration,,1,,8,,2780,B,H,BAO_0000219,
,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,CHEMBL617852,12652,11864,,,,,Autocuration,,1,,8,,2781,F,H,BAO_0000019,
,Mus musculus,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,CHEMBL858024,13463,12689,,,Stomach,945.0,Autocuration,,1,,8,10090.0,2782,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,CHEMBL617853,13463,12689,,,Stomach,945.0,Expert,,1,,9,10116.0,2783,B,D,BAO_0000019,
,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,CHEMBL617854,13969,108,,,,,Expert,,1,,8,,2784,B,H,BAO_0000357,
,Sus scrofa,,,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL873477,13392,108,,,,,Expert,,1,,8,9823.0,2785,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617855,13392,108,,,,,Expert,,1,,8,,2786,B,H,BAO_0000357,
,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,CHEMBL617856,14430,108,,,,,Expert,,1,,8,,2787,B,H,BAO_0000019,
,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,CHEMBL617857,1742,108,,,,,Autocuration,,1,,8,,2788,B,H,BAO_0000019,
,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,CHEMBL617858,14286,108,,,,,Autocuration,,1,,8,,2789,B,H,BAO_0000249,
,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,CHEMBL617859,5619,108,,,,,Autocuration,,1,,8,,2790,B,H,BAO_0000357,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617860,15086,108,,,,,Autocuration,,1,,8,,2791,B,H,BAO_0000357,
,,,,Binding activity radioligand.,CHEMBL617861,12861,108,,,,,Autocuration,,1,,8,,2792,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617862,12861,108,,,,,Expert,,1,,8,,2793,B,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,CHEMBL617863,12861,108,,,,,Autocuration,,1,,8,,2794,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,CHEMBL617864,12827,108,,,,,Autocuration,,1,,8,,2795,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,CHEMBL617649,12827,108,,,,,Autocuration,,1,,8,,2796,B,H,BAO_0000249,
,Sus scrofa,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,CHEMBL617650,12919,108,,,,,Expert,,1,,8,9823.0,2797,F,H,BAO_0000019,
,Sus scrofa,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,CHEMBL617651,12919,108,,,,,Expert,,1,,8,9823.0,2798,F,H,BAO_0000019,
,Sus scrofa,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,CHEMBL617652,16429,108,,,,,Autocuration,,1,,8,9823.0,2799,B,H,BAO_0000357,
,Sus scrofa,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,CHEMBL857072,773,108,,,,,Autocuration,,1,,8,9823.0,2800,B,H,BAO_0000019,
,Sus scrofa,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,CHEMBL617653,5033,108,,,,,Autocuration,,1,,8,9823.0,2801,B,H,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,CHEMBL617654,12861,12687,,,,,Autocuration,,1,,8,,2802,B,H,BAO_0000019,
,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,CHEMBL617655,14093,12689,,,,,Autocuration,,1,,8,,2803,F,H,BAO_0000019,
,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,CHEMBL617656,14970,12689,,,,,Expert,,1,,8,,2804,B,H,BAO_0000357,
,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,CHEMBL617657,14970,12689,,,,,Autocuration,,1,,8,,2805,B,H,BAO_0000357,
,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,CHEMBL617658,14970,12689,,,,,Autocuration,,1,,8,,2806,B,H,BAO_0000357,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,CHEMBL617659,14178,12689,,,,,Expert,,1,,9,10116.0,2807,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,CHEMBL617838,14178,12689,,,,,Expert,,1,,9,10116.0,2808,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,CHEMBL617839,14229,12689,Brain membranes,,,,Expert,,1,,9,10116.0,2809,B,D,BAO_0000249,
,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,CHEMBL617840,16532,12689,,,,,Autocuration,,1,,8,,2810,B,H,BAO_0000357,
,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,CHEMBL617841,14826,12689,,,,,Autocuration,,1,,8,,2811,B,H,BAO_0000019,
,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,CHEMBL875915,17211,12689,,,,,Autocuration,,1,,8,,2812,B,H,BAO_0000019,
,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,CHEMBL617842,17211,12689,,,,,Expert,,1,,8,,2813,B,H,BAO_0000219,In vitro
NIH3T3,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,CHEMBL617843,13246,12689,,723.0,,,Expert,,1,,8,,2814,B,H,BAO_0000219,
,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,CHEMBL617844,13246,12689,,,,,Expert,,1,,8,,2815,B,H,BAO_0000357,
,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,CHEMBL617845,12457,12689,,,,,Expert,,1,,8,,2816,B,H,BAO_0000357,
NIH3T3,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,CHEMBL617846,12457,12689,,723.0,,,Expert,,1,,8,,2817,B,H,BAO_0000219,
,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,CHEMBL617847,4707,12689,,,,,Autocuration,,1,,8,,2818,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617848,13297,12689,,,,,Expert,,1,,8,,2819,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL617849,16633,12689,,,,,Autocuration,,1,,8,,2820,B,H,BAO_0000357,
,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL621507,16133,12689,,,,,Expert,,1,,8,,2821,B,H,BAO_0000357,
,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,CHEMBL621508,16326,12689,,,,,Expert,,1,,8,,2822,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,CHEMBL621509,14423,12689,,,,,Autocuration,,1,,8,,2823,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,CHEMBL621510,15412,12689,,,,,Autocuration,,1,,8,,2824,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,CHEMBL621511,15412,12689,,,,,Autocuration,,1,,8,,2825,B,H,BAO_0000019,
A9,,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,CHEMBL621512,15558,12689,,625.0,,,Expert,,1,,8,,2826,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL621513,16633,12689,,,,,Autocuration,,1,,8,,2827,B,H,BAO_0000357,
,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,CHEMBL621514,6013,12689,,,,,Expert,,1,,8,,2828,B,H,BAO_0000357,
,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,CHEMBL621515,17175,12689,,,,,Expert,,1,,8,,2829,B,H,BAO_0000219,In vitro
,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,CHEMBL621516,12469,12689,,,,,Autocuration,,1,,8,,2830,B,H,BAO_0000219,
,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,CHEMBL621517,3682,12689,,,Caudate-putamen,5383.0,Autocuration,,1,,8,,2831,B,H,BAO_0000019,
,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,CHEMBL621518,4932,12689,,,,,Autocuration,,1,,8,,2832,B,H,BAO_0000357,
,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,CHEMBL621519,4932,12689,,,,,Autocuration,,1,,8,,2833,B,H,BAO_0000019,
,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,CHEMBL621520,3935,12689,,,,,Autocuration,,1,,8,,2834,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,CHEMBL621521,15818,12689,,,,,Autocuration,,1,,8,,2835,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,CHEMBL621522,15818,12689,,,,,Autocuration,,1,,8,,2836,B,H,BAO_0000357,
,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,CHEMBL621523,14749,12689,,,,,Expert,,1,,8,,2837,B,H,BAO_0000219,
,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,CHEMBL621524,15740,12689,,,,,Autocuration,,1,,8,,2838,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,CHEMBL621525,17133,12689,,,,,Expert,,1,,9,10116.0,2839,B,D,BAO_0000357,
,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,CHEMBL872921,16532,12689,,,,,Autocuration,,1,,8,,2840,B,H,BAO_0000357,
,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621526,12369,12689,,,,,Autocuration,,1,,8,,2841,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,CHEMBL621527,12369,12689,,,,,Expert,,1,,8,,2842,B,H,BAO_0000219,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,CHEMBL617865,2309,12689,,,,,Expert,,1,,9,10116.0,2843,B,D,BAO_0000019,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617866,12953,12689,,,,,Autocuration,,1,,8,,2844,B,H,BAO_0000357,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,CHEMBL617867,12953,12689,,,,,Autocuration,,1,,8,,2845,B,H,BAO_0000019,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,CHEMBL617487,12953,12689,,,,,Autocuration,,1,,8,,2846,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL617488,12953,12689,,,,,Expert,,1,,8,,2847,B,H,BAO_0000357,
,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,CHEMBL617489,17133,12689,,,,,Autocuration,,1,,8,,2848,B,H,BAO_0000357,
,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,CHEMBL617490,17211,12689,,,,,Autocuration,,1,,8,,2849,B,H,BAO_0000019,
,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,CHEMBL617491,17211,12689,,,,,Autocuration,,1,,8,,2850,B,H,BAO_0000019,
,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,CHEMBL617492,14025,12689,,,,,Autocuration,,1,,8,,2851,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,CHEMBL617493,14998,12689,,,,,Autocuration,,1,,8,,2852,B,H,BAO_0000019,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,CHEMBL617494,4342,12689,,,,,Autocuration,,1,,8,,2853,B,H,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,CHEMBL617495,13735,12689,,,,,Expert,,1,,9,10116.0,2854,B,D,BAO_0000019,
,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,CHEMBL617496,13181,12689,,,,,Autocuration,,1,,8,,2855,B,H,BAO_0000357,
CHO-K1,,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,CHEMBL617497,1883,12689,,485.0,,,Autocuration,,1,,8,,2856,B,H,BAO_0000219,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL617498,15194,12689,,,,,Autocuration,,1,,8,,2857,B,H,BAO_0000357,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,CHEMBL617499,15194,12689,,,,,Autocuration,,1,,8,,2858,B,H,BAO_0000357,
,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,CHEMBL617500,14579,12689,,,,,Autocuration,,1,,8,,2859,F,H,BAO_0000019,
,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL617501,4639,108,,,,,Autocuration,,1,,8,,2860,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,CHEMBL617502,4820,108,,,,,Expert,,1,,8,,2861,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,CHEMBL617503,14442,227,,,,,Autocuration,,1,,8,,2862,B,H,BAO_0000357,
,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,CHEMBL617504,14755,227,,,,,Autocuration,,1,,8,,2863,B,H,BAO_0000357,
,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,CHEMBL617406,14744,227,,,,,Autocuration,,1,,8,,2864,B,H,BAO_0000357,
,Homo sapiens,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,CHEMBL617407,6857,227,,,,,Expert,,1,,9,9606.0,2865,B,D,BAO_0000019,
,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,CHEMBL617408,16209,227,,,,,Autocuration,,1,,8,,2866,B,H,BAO_0000357,
,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,CHEMBL617409,15363,227,,,,,Autocuration,,1,,8,,2867,B,H,BAO_0000357,
,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,CHEMBL617410,15363,227,,,,,Autocuration,,1,,8,,2868,B,H,BAO_0000357,
,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,CHEMBL617411,15363,227,,,,,Autocuration,,1,,8,,2869,B,H,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,CHEMBL617412,17085,227,,,,,Autocuration,,1,,8,,2870,B,H,BAO_0000019,
,Homo sapiens,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,CHEMBL617774,17200,227,,,,,Expert,,1,,9,9606.0,2871,B,D,BAO_0000357,
HEK293,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,CHEMBL617775,15851,227,,722.0,,,Expert,,1,,9,9606.0,2872,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,CHEMBL617776,15851,227,,722.0,,,Expert,,1,,9,9606.0,2873,B,D,BAO_0000219,
CHO,Homo sapiens,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617777,6857,227,,449.0,,,Expert,,1,,9,9606.0,2874,F,D,BAO_0000219,
CHO,Homo sapiens,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHEMBL617778,6857,227,,449.0,,,Expert,,1,,9,9606.0,2875,F,D,BAO_0000219,
HEK293,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617779,15779,227,,722.0,,,Autocuration,,1,,8,,2876,B,H,BAO_0000219,
HEK293,,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,CHEMBL617780,15851,227,,722.0,,,Expert,,1,,8,,2877,B,H,BAO_0000219,
HEK293,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",CHEMBL617781,15779,227,,722.0,,,Autocuration,,1,,8,,2878,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,CHEMBL617782,14157,227,,722.0,,,Expert,,1,,9,9606.0,2879,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,CHEMBL617783,4540,227,,722.0,,,Expert,,1,,9,9606.0,2880,B,D,BAO_0000219,
,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,CHEMBL617784,6166,227,,,,,Autocuration,,1,,8,,2881,B,H,BAO_0000357,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,CHEMBL617785,15779,227,,722.0,,,Autocuration,,1,,8,,2882,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,CHEMBL857984,14391,227,,722.0,,,Expert,,1,,8,,2883,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,CHEMBL617786,3832,227,,722.0,,,Expert,,1,,8,,2884,B,H,BAO_0000219,
HEK293,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,CHEMBL617787,3833,227,,722.0,,,Expert,,1,,8,,2885,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,CHEMBL617788,15851,227,,722.0,,,Expert,,1,,9,9606.0,2886,B,D,BAO_0000219,
HEK293,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,CHEMBL617789,15851,227,,722.0,,,Expert,,1,,9,9606.0,2887,B,D,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,CHEMBL617790,4199,227,,722.0,,,Autocuration,,1,,8,,2888,B,H,BAO_0000219,
CHO-K1,,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,CHEMBL617791,1883,227,,485.0,,,Expert,,1,,8,,2889,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,CHEMBL617608,4321,227,,,,,Expert,,1,,8,,2890,B,H,BAO_0000357,
HEK293,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,CHEMBL617609,15146,227,,722.0,,,Autocuration,,1,,8,,2891,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,CHEMBL617610,5213,227,,722.0,,,Autocuration,,1,,8,,2892,B,H,BAO_0000219,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,CHEMBL617611,14818,227,,722.0,,,Autocuration,,1,,8,,2893,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617612,4829,227,,722.0,,,Autocuration,,1,,8,,2894,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",CHEMBL617613,4829,227,,722.0,,,Autocuration,,1,,8,,2895,B,H,BAO_0000219,
,Oryctolagus cuniculus,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,CHEMBL617614,14025,227,,,,,Autocuration,,1,,8,9986.0,2896,B,H,BAO_0000019,
,,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,CHEMBL617615,13463,12688,,,Stomach,945.0,Expert,,1,,8,,2897,B,H,BAO_0000019,
,,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,CHEMBL858114,7259,12688,,,Stomach,945.0,Expert,,1,,8,,2898,B,H,BAO_0000357,
,,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,CHEMBL617616,7259,12688,,,Stomach,945.0,Autocuration,,1,,8,,2899,B,H,BAO_0000357,
,Rattus norvegicus,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,CHEMBL617617,7185,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2900,F,D,BAO_0000019,
,Rattus norvegicus,,,Antagonistic against 5-hydroxytryptamine 2B receptor,CHEMBL875914,7185,12688,,,,,Expert,,1,,9,10116.0,2901,F,D,BAO_0000019,
,,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,CHEMBL617618,13267,12688,,,Stomach,945.0,Autocuration,,1,,8,,2902,F,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,CHEMBL617619,13735,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2903,B,D,BAO_0000357,
,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,CHEMBL617620,15738,12688,,,,,Autocuration,,1,,8,,2904,F,H,BAO_0000019,
,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,CHEMBL617621,15738,12688,,,,,Autocuration,,1,,8,,2905,F,H,BAO_0000019,
,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,CHEMBL617622,15738,12688,,,,,Autocuration,,1,,8,,2906,F,H,BAO_0000019,
,Rattus norvegicus,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617623,12936,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2907,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617624,12936,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2908,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617625,12936,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2909,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,CHEMBL617626,12936,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2910,B,D,BAO_0000357,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617627,16404,12688,,,Stomach,945.0,Autocuration,,1,,8,,2911,F,H,BAO_0000019,
,,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617628,16404,12688,,,Stomach,945.0,Expert,,1,,8,,2912,F,H,BAO_0000019,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,CHEMBL617629,16404,12688,,,Stomach,945.0,Autocuration,,1,,8,,2913,F,H,BAO_0000019,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,CHEMBL858115,16404,12688,,,Stomach,945.0,Autocuration,,1,,8,,2914,F,H,BAO_0000019,
,Rattus norvegicus,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,CHEMBL617630,16404,12688,,,Stomach,945.0,Expert,,1,,9,10116.0,2915,F,D,BAO_0000019,
,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,CHEMBL617631,16404,12688,,,Thoracic aorta,1515.0,Autocuration,,1,,8,,2916,F,H,BAO_0000019,
,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617632,7483,12688,,,,,Autocuration,,1,,8,,2917,B,H,BAO_0000357,
,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,CHEMBL617633,7483,12688,,,,,Expert,,1,,8,,2918,B,H,BAO_0000357,
,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617634,7483,12688,,,,,Autocuration,,1,,8,,2919,B,H,BAO_0000357,
,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,CHEMBL617635,7483,12688,,,,,Autocuration,,1,,8,,2920,B,H,BAO_0000357,
,Rattus norvegicus,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,CHEMBL617637,16404,12688,,,Stomach,945.0,Autocuration,,1,,9,10116.0,2922,F,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,CHEMBL617638,6347,227,,,,,Autocuration,,1,,8,,2923,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,CHEMBL617639,4373,227,,,,,Autocuration,,1,,8,,2924,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,CHEMBL617640,4373,227,,,,,Autocuration,,1,,8,,2925,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity to 5-HT 2B receptor,CHEMBL617641,4687,227,,,,,Autocuration,,1,,8,,2926,B,H,BAO_0000357,
,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,CHEMBL617642,16946,227,,,,,Autocuration,,1,,8,,2927,B,H,BAO_0000357,
,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,CHEMBL617643,16633,227,,,,,Autocuration,,1,,8,,2928,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,CHEMBL617644,16633,227,,,,,Autocuration,,1,,8,,2929,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,CHEMBL617645,16633,227,,,,,Autocuration,,1,,8,,2930,B,H,BAO_0000357,
,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,CHEMBL617646,15026,108,,,,,Expert,,1,,8,,2931,B,H,BAO_0000357,
,Bos taurus,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,CHEMBL617647,15738,108,,,,,Autocuration,,1,,8,9913.0,2932,B,H,BAO_0000357,
,Bos taurus,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,CHEMBL617648,15738,108,,,,,Autocuration,,1,,8,9913.0,2933,B,H,BAO_0000357,
,Bos taurus,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,CHEMBL617875,15738,108,,,,,Autocuration,,1,,8,9913.0,2934,B,H,BAO_0000357,
,Bos taurus,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,CHEMBL617876,15738,108,,,,,Autocuration,,1,,8,9913.0,2935,B,H,BAO_0000357,
,Bos taurus,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,CHEMBL617877,16404,108,,,,,Expert,,1,,8,9913.0,2936,B,H,BAO_0000357,
,Bos taurus,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,CHEMBL617878,15026,108,,,,,Expert,,1,,8,9913.0,2937,B,H,BAO_0000357,
,Bos taurus,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,CHEMBL617879,15738,108,,,,,Autocuration,,1,,8,9913.0,2938,B,H,BAO_0000357,
,Cavia porcellus,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,CHEMBL617880,16312,108,,,,,Autocuration,,1,,8,10141.0,2939,B,H,BAO_0000019,
,Cavia porcellus,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,CHEMBL617881,5486,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,2940,B,D,BAO_0000357,
,,,,Binding affinity against 5-HT1A receptor,CHEMBL857073,5254,51,,,,,Autocuration,,1,,8,,2941,B,H,BAO_0000357,
CHO,,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,CHEMBL617882,3857,108,,449.0,,,Expert,,1,,8,,2942,F,H,BAO_0000219,
CHO,Homo sapiens,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,CHEMBL617883,6857,108,,449.0,,,Expert,,1,,9,9606.0,2943,F,D,BAO_0000219,
,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,CHEMBL617884,4176,108,,,,,Autocuration,,1,,8,,2944,F,H,BAO_0000219,
CHO,,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,CHEMBL617885,6347,108,,449.0,,,Autocuration,,1,,8,,2945,B,H,BAO_0000219,
CHO,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",CHEMBL617886,6347,108,,449.0,,,Autocuration,,1,,8,,2946,B,H,BAO_0000219,
,Homo sapiens,,,Inhibition of human 5-hydroxytryptamine 2C receptor,CHEMBL617887,16146,108,,,,,Expert,,1,,9,9606.0,2947,B,D,BAO_0000357,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),CHEMBL617888,3805,108,,,,,Autocuration,,1,,8,,2948,B,H,BAO_0000357,
,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,CHEMBL617889,3857,108,,,,,Autocuration,,1,,8,,2949,B,H,BAO_0000019,
,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,CHEMBL617890,5635,108,,,,,Autocuration,,1,,8,,2950,B,H,BAO_0000357,
,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,CHEMBL617891,5635,108,,,,,Autocuration,,1,,8,,2951,B,H,BAO_0000357,
,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,CHEMBL617892,5635,108,,,,,Autocuration,,1,,8,,2952,B,H,BAO_0000357,
CHO,,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,CHEMBL617893,4012,108,,449.0,,,Expert,,1,,8,,2953,B,H,BAO_0000219,
CHO,,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,CHEMBL617894,6366,108,,449.0,,,Expert,,1,,8,,2954,B,H,BAO_0000219,
CHO,,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL617895,15949,108,,449.0,,,Expert,,1,,8,,2955,B,H,BAO_0000219,
CHO,,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,CHEMBL617896,17211,108,,449.0,,,Autocuration,,1,,8,,2956,B,H,BAO_0000219,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,CHEMBL617897,6491,108,,,,,Expert,,1,,9,9606.0,2957,B,D,BAO_0000357,
,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,CHEMBL617898,14093,108,,,,,Autocuration,,1,,8,,2958,F,H,BAO_0000019,
,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,CHEMBL617899,13481,108,,,,,Autocuration,,1,,8,,2959,F,H,BAO_0000019,
CHO,Rattus norvegicus,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,CHEMBL617900,6347,108,,449.0,,,Expert,,1,,8,10116.0,2960,B,H,BAO_0000219,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,CHEMBL617901,14093,108,,,,,Autocuration,,1,,8,,2961,F,H,BAO_0000019,
,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,CHEMBL617902,14093,108,,,,,Autocuration,,1,,8,,2962,F,H,BAO_0000019,
,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL617903,13481,108,,,,,Autocuration,,1,,8,,2963,F,H,BAO_0000019,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,CHEMBL617904,14442,108,,,,,Autocuration,,1,,8,,2964,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,CHEMBL617905,14442,108,,,,,Autocuration,,1,,8,,2965,B,H,BAO_0000357,
,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,CHEMBL617906,14442,108,,,,,Autocuration,,1,,8,,2966,B,H,BAO_0000357,
,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,CHEMBL617907,14755,108,,,,,Autocuration,,1,,8,,2967,B,H,BAO_0000357,
,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,CHEMBL617908,14744,108,,,,,Autocuration,,1,,8,,2968,B,H,BAO_0000357,
CHO,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHEMBL620617,16659,108,,449.0,,,Expert,,1,,8,,2969,B,H,BAO_0000219,
,Homo sapiens,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,CHEMBL620618,6857,108,,,,,Expert,,1,,9,9606.0,2970,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,CHEMBL620619,5635,108,,,,,Expert,,1,,8,,2971,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,CHEMBL620620,4234,108,,,,,Expert,,1,,9,9606.0,2972,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,CHEMBL620621,16209,108,,,,,Autocuration,,1,,8,,2973,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,CHEMBL872920,5778,104698,Membranes,,,,Autocuration,,1,,7,10116.0,2974,B,D,BAO_0000249,
,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,CHEMBL620622,5094,104698,,,,,Autocuration,,1,,6,,2975,B,H,BAO_0000223,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,CHEMBL620623,809,104698,,,,,Autocuration,,1,,7,10116.0,2976,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,CHEMBL620624,1578,104698,,,,,Autocuration,,1,,6,,2977,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,CHEMBL620625,809,104698,,,,,Autocuration,,1,,6,,2978,B,H,BAO_0000019,
,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,CHEMBL620626,12469,104698,,,,,Autocuration,,1,,6,,2979,B,H,BAO_0000219,
,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,CHEMBL621307,14290,104698,,,,,Autocuration,,1,,6,,2980,B,H,BAO_0000019,
,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,CHEMBL621308,14290,104698,,,,,Autocuration,,1,,6,,2981,B,H,BAO_0000019,
,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,CHEMBL621309,10609,104698,,,,,Autocuration,,1,,6,,2982,B,H,BAO_0000223,
,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,CHEMBL621310,10609,104698,,,,,Autocuration,,1,,6,,2983,B,H,BAO_0000223,
,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,CHEMBL621311,10609,104698,,,,,Autocuration,,1,,6,,2984,B,H,BAO_0000223,
,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",CHEMBL621502,15253,104698,,,,,Autocuration,,1,,6,,2985,B,H,BAO_0000249,
,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",CHEMBL621503,15253,104698,,,,,Autocuration,,1,,6,,2986,B,H,BAO_0000249,
,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,CHEMBL621504,11683,104698,Membranes,,,,Autocuration,,1,,6,,2987,B,H,BAO_0000249,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,CHEMBL621505,12092,104698,,,,,Autocuration,,1,,6,,2988,B,H,BAO_0000223,
,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,CHEMBL621506,1946,104698,,,,,Autocuration,,1,,6,,2989,B,H,BAO_0000019,
,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,CHEMBL619781,11623,104698,,,,,Autocuration,,1,,6,,2990,B,H,BAO_0000223,
,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,CHEMBL619782,11623,104698,,,,,Autocuration,,1,,6,,2991,B,H,BAO_0000223,
,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,CHEMBL619783,14788,104698,,,,,Autocuration,,1,,6,,2992,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,CHEMBL619784,5432,104698,,,,,Autocuration,,1,,7,10116.0,2993,B,D,BAO_0000019,
,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL619785,14826,104698,,,,,Autocuration,,1,,6,,2994,B,H,BAO_0000249,
,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,CHEMBL619786,2222,104698,,,,,Autocuration,,1,,6,,2995,B,H,BAO_0000223,
,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,CHEMBL619787,11963,104698,,,,,Autocuration,,1,,6,,2996,B,H,BAO_0000019,
,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,CHEMBL872925,14145,104698,,,,,Autocuration,,1,,6,,2997,B,H,BAO_0000019,
,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,CHEMBL619788,17819,104698,,,,,Autocuration,,1,,6,,2998,B,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,CHEMBL619789,10394,104698,,,,,Autocuration,,1,,6,,2999,B,H,BAO_0000249,
,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,CHEMBL619790,10394,104698,,,,,Autocuration,,1,,6,,3000,B,H,BAO_0000249,
,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,CHEMBL619791,15034,104698,,,,,Autocuration,,1,,6,,3001,B,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,CHEMBL619792,691,104698,,,,,Autocuration,,1,,6,,3002,B,H,BAO_0000019,
,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,CHEMBL619793,12092,104698,Membranes,,,,Autocuration,,1,,6,,3003,B,H,BAO_0000249,
,Rattus norvegicus,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,CHEMBL619794,11752,104698,,,,,Autocuration,,1,,7,10116.0,3004,B,D,BAO_0000223,
,,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,CHEMBL619795,11752,104698,,,Brain,955.0,Autocuration,,1,,6,,3005,B,H,BAO_0000221,
,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,CHEMBL619796,301,104698,,,,,Autocuration,,1,,6,,3006,B,H,BAO_0000019,
,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,CHEMBL620448,16532,104698,,,,,Autocuration,,1,,6,,3007,B,H,BAO_0000223,
,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,CHEMBL620449,16532,104698,,,,,Autocuration,,1,,6,,3008,B,H,BAO_0000223,
,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,CHEMBL620450,12092,104698,,,,,Autocuration,,1,,6,,3009,B,H,BAO_0000223,
,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,CHEMBL620451,11684,104698,,,,,Autocuration,,1,,6,,3010,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,CHEMBL620631,11684,104698,,,,,Autocuration,,1,,6,,3011,B,H,BAO_0000223,
,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,CHEMBL620632,12953,104698,,,,,Autocuration,,1,,6,,3012,B,H,BAO_0000019,
,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,CHEMBL620633,12953,104698,,,,,Autocuration,,1,,6,,3013,B,H,BAO_0000019,
,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,CHEMBL620634,12953,104698,,,,,Autocuration,,1,,6,,3014,B,H,BAO_0000223,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,CHEMBL620635,12861,104698,,,,,Autocuration,,1,,6,,3015,B,H,BAO_0000019,
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620636,11454,104698,,,,,Autocuration,,1,,6,,3016,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620637,11454,104698,,,,,Autocuration,,1,,6,,3017,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620638,11454,104698,,,,,Autocuration,,1,,6,,3018,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620639,11454,104698,,,,,Autocuration,,1,,6,,3019,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620640,11454,104698,,,,,Autocuration,,1,,6,,3020,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620641,11454,104698,,,,,Autocuration,,1,,6,,3021,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,CHEMBL620642,11454,104698,,,,,Autocuration,,1,,6,,3022,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620643,11454,104698,,,,,Autocuration,,1,,6,,3023,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620644,11454,104698,,,,,Autocuration,,1,,6,,3024,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620645,11454,104698,,,,,Autocuration,,1,,6,,3025,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620646,11454,104698,,,,,Autocuration,,1,,6,,3026,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620647,11454,104698,,,,,Autocuration,,1,,6,,3027,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,CHEMBL620648,11454,104698,,,,,Autocuration,,1,,6,,3028,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,CHEMBL620649,11454,104698,,,,,Autocuration,,1,,6,,3029,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL620650,11454,104698,,,,,Autocuration,,1,,6,,3030,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620651,11454,104698,,,,,Autocuration,,1,,6,,3031,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,CHEMBL872875,11454,104698,,,,,Autocuration,,1,,6,,3032,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,CHEMBL620652,11454,104698,,,,,Autocuration,,1,,6,,3033,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,CHEMBL620653,10609,104698,,,,,Autocuration,,1,,6,,3034,F,H,BAO_0000019,
,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,CHEMBL857076,12861,104698,,,,,Autocuration,,1,,6,,3035,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,CHEMBL620654,12861,104698,,,,,Autocuration,,1,,7,10116.0,3036,B,D,BAO_0000019,
,,,,Binding activity radioligand.,CHEMBL620655,12861,104698,,,,,Autocuration,,1,,6,,3037,B,H,BAO_0000223,
,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,CHEMBL620656,10728,104698,Brain membranes,,,,Autocuration,,1,,6,,3038,B,H,BAO_0000249,
,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,CHEMBL620657,10728,104698,Brain membranes,,,,Autocuration,,1,,6,,3039,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,CHEMBL620658,5163,108,,,,,Autocuration,,1,,8,,3040,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,CHEMBL620659,5163,108,,,,,Autocuration,,1,,8,,3041,B,H,BAO_0000357,
,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,CHEMBL620660,6011,108,,,,,Autocuration,,1,,8,,3042,B,H,BAO_0000357,
,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,CHEMBL620661,5014,108,,,,,Autocuration,,1,,8,,3043,B,H,BAO_0000357,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,CHEMBL620662,5635,108,,,,,Autocuration,,1,,8,,3044,B,H,BAO_0000357,
,,,,Affinity for 5-hydroxytryptamine 2C receptor,CHEMBL620663,5163,108,,,,,Expert,,1,,8,,3045,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,CHEMBL620664,6841,108,,,,,Autocuration,,1,,8,,3046,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,CHEMBL620665,6119,108,,,,,Expert,,1,,8,,3047,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,CHEMBL620666,4373,108,,,,,Autocuration,,1,,8,,3048,B,H,BAO_0000357,
,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,CHEMBL620667,1633,108,,,,,Autocuration,,1,,8,,3049,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,CHEMBL620668,1633,108,,,,,Expert,,1,,8,,3050,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,CHEMBL620669,4373,108,,,,,Autocuration,,1,,8,,3051,B,H,BAO_0000357,
,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,CHEMBL620670,6576,108,,,,,Expert,,1,,8,,3052,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,CHEMBL620671,4687,108,,,,,Autocuration,,1,,8,,3053,B,H,BAO_0000357,
,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,CHEMBL620672,12146,108,,,,,Autocuration,,1,,8,,3054,B,H,BAO_0000357,
,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,CHEMBL620673,12146,108,,,,,Autocuration,,1,,8,,3055,B,H,BAO_0000357,
,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,CHEMBL620674,16946,108,,,,,Autocuration,,1,,8,,3056,B,H,BAO_0000357,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,CHEMBL620675,14159,108,,,,,Autocuration,,1,,8,,3057,B,H,BAO_0000357,
,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,CHEMBL620676,16700,108,,,,,Autocuration,,1,,8,,3058,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621382,3269,108,,,,,Autocuration,,1,,8,,3059,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 2C receptor,CHEMBL621383,1274,108,,,,,Expert,,1,,9,9606.0,3060,B,D,BAO_0000357,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,CHEMBL621384,1317,108,,,,,Autocuration,,1,,8,,3061,B,H,BAO_0000357,
,Bos taurus,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,CHEMBL621385,5834,144,,,,,Autocuration,,1,,8,9913.0,3062,B,H,BAO_0000357,
,Bos taurus,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,CHEMBL617989,11147,144,,,,,Autocuration,,1,,8,9913.0,3063,B,H,BAO_0000357,
,Cavia porcellus,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,CHEMBL617990,14145,104714,,,,,Expert,,1,,4,10141.0,3064,F,H,BAO_0000019,
,Cavia porcellus,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,CHEMBL875085,10561,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3065,B,H,BAO_0000221,
,Cavia porcellus,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,CHEMBL617991,15847,104714,,,,,Autocuration,,1,,4,10141.0,3066,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,CHEMBL617992,15847,104714,,,,,Autocuration,,1,,4,10141.0,3067,F,H,BAO_0000019,
,Cavia porcellus,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,CHEMBL617993,10561,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3068,B,H,BAO_0000221,
,Cavia porcellus,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,CHEMBL617994,11454,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3069,B,H,BAO_0000221,
,Cavia porcellus,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,CHEMBL617995,4639,104714,,,,,Autocuration,,1,,4,10141.0,3070,F,H,BAO_0000019,
,Cavia porcellus,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,CHEMBL617996,4639,104714,,,,,Autocuration,,1,,4,10141.0,3071,F,H,BAO_0000019,
,Cavia porcellus,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,CHEMBL617997,4639,104714,,,,,Autocuration,,1,,4,10141.0,3072,F,H,BAO_0000019,
,Cavia porcellus,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,CHEMBL617998,4639,104714,,,,,Autocuration,,1,,4,10141.0,3073,F,H,BAO_0000019,
,Cavia porcellus,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,CHEMBL617999,4639,104714,,,,,Autocuration,,1,,4,10141.0,3074,F,H,BAO_0000019,
,Cavia porcellus,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,CHEMBL618000,4639,104714,,,,,Autocuration,,1,,4,10141.0,3075,F,H,BAO_0000019,
,Cavia porcellus,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",CHEMBL617815,15253,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3076,F,H,BAO_0000221,
,Cavia porcellus,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",CHEMBL617816,15253,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3077,F,H,BAO_0000221,
,Cavia porcellus,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,CHEMBL617817,11963,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3078,F,H,BAO_0000221,
,Cavia porcellus,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,CHEMBL617818,1946,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3079,B,H,BAO_0000221,
,Cavia porcellus,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,CHEMBL617819,1946,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3080,B,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,CHEMBL617820,12045,104714,,,,,Autocuration,,1,,4,10141.0,3081,B,H,BAO_0000223,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617821,1559,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3082,B,H,BAO_0000221,
,Cavia porcellus,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617822,273,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3083,F,H,BAO_0000221,
,Cavia porcellus,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),CHEMBL617823,273,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3084,F,H,BAO_0000221,
,Cavia porcellus,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,CHEMBL617824,188,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3085,F,H,BAO_0000221,
,Cavia porcellus,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,CHEMBL617825,12919,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3086,F,H,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,CHEMBL617826,12918,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3087,F,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617827,1559,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3088,B,H,BAO_0000221,
,Cavia porcellus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617828,273,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3089,F,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,CHEMBL617829,1559,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3090,B,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,CHEMBL617830,1559,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3091,B,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,CHEMBL617831,1559,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3092,B,H,BAO_0000221,
,Cavia porcellus,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,CHEMBL617832,14424,104714,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3093,B,H,BAO_0000221,
,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,CHEMBL617833,13181,22226,,,,,Autocuration,,1,,0,10141.0,3094,B,U,BAO_0000019,
,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,CHEMBL617834,5486,51,,,,,Autocuration,,1,,8,,3095,B,H,BAO_0000357,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,CHEMBL617835,6491,104714,,,,,Expert,,1,,5,9606.0,3096,B,D,BAO_0000223,
,,,,Binding affinity towards 5-HT3 receptor,CHEMBL617836,6013,104714,,,,,Autocuration,,1,,4,,3097,B,H,BAO_0000223,
,,,,Binding activity radioligand.,CHEMBL617837,12861,104714,,,,,Autocuration,,1,,4,,3098,B,H,BAO_0000223,
,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,CHEMBL620392,12861,104714,,,,,Autocuration,,1,,4,,3099,B,H,BAO_0000019,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,CHEMBL620393,5104,104714,,,,,Autocuration,,1,,4,,3100,B,H,BAO_0000223,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,CHEMBL620394,5105,104714,,,,,Autocuration,,1,,4,,3101,B,H,BAO_0000223,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,CHEMBL620395,5104,104714,,,,,Autocuration,,1,,4,,3102,B,H,BAO_0000223,
,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,CHEMBL620396,3935,22226,,,,,Autocuration,,1,,0,,3103,B,U,BAO_0000019,
NG108-15,,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,CHEMBL620582,13657,105030,,433.0,,,Expert,,1,,4,,3104,B,H,BAO_0000219,
,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",CHEMBL620583,10369,105030,,,,,Autocuration,,1,,4,,3105,B,H,BAO_0000218,In vivo
,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),CHEMBL620584,10369,105030,,,,,Autocuration,,1,,4,,3106,B,H,BAO_0000019,
,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,CHEMBL620585,12918,105030,,,,,Autocuration,,1,,4,,3107,B,H,BAO_0000224,
,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,CHEMBL620586,12918,105030,,,,,Autocuration,,1,,4,,3108,B,H,BAO_0000224,
,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),CHEMBL620587,10369,105030,,,,,Autocuration,,1,,4,,3109,B,H,BAO_0000019,
,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,CHEMBL620588,773,105030,,,,,Autocuration,,1,,4,,3110,B,H,BAO_0000019,
,,,,5-hydroxytryptamine 3 receptor agonism in mouse,CHEMBL620589,12918,105030,,,,,Autocuration,,1,,4,,3111,F,H,BAO_0000218,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,CHEMBL620590,10561,105030,,,,,Autocuration,,1,,4,,3112,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,CHEMBL617956,12827,105030,,,,,Autocuration,,1,,4,,3113,B,H,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,CHEMBL617957,12827,105030,,,,,Autocuration,,1,,4,,3114,B,H,BAO_0000019,
,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,CHEMBL617958,12918,105030,,,,,Autocuration,,1,,4,,3115,B,H,BAO_0000224,
,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,CHEMBL617959,273,105030,,,,,Autocuration,,1,,4,,3116,B,H,BAO_0000219,
,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,CHEMBL617960,273,105030,,,,,Autocuration,,1,,4,,3117,B,H,BAO_0000219,
,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,CHEMBL617961,10561,105030,,,,,Autocuration,,1,,4,,3118,B,H,BAO_0000224,
,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,CHEMBL617962,5033,105030,,,,,Autocuration,,1,,4,,3119,B,H,BAO_0000219,In vitro
N1E-115,,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,CHEMBL617963,16429,105030,,339.0,,,Autocuration,,1,,4,,3120,B,H,BAO_0000219,
,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL617964,10322,11765,,,,,Autocuration,,1,,8,,3121,B,H,BAO_0000019,
,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,CHEMBL617965,14331,11765,,,,,Autocuration,,1,,8,,3122,B,H,BAO_0000219,
,Mus musculus,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,CHEMBL617966,13462,10630,,,,,Autocuration,,1,,9,10090.0,3123,B,D,BAO_0000357,
,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,CHEMBL857074,12861,17106,,,,,Autocuration,,1,,8,,3124,B,H,BAO_0000019,
,Sus scrofa,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,CHEMBL617967,15086,144,,,,,Autocuration,,1,,8,9823.0,3125,B,H,BAO_0000357,
,Sus scrofa,,,Binding activity radioligand.,CHEMBL617968,12861,144,,,,,Autocuration,,1,,8,9823.0,3126,B,H,BAO_0000357,
,Oryctolagus cuniculus,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,CHEMBL617969,10561,104714,,,,,Autocuration,,1,,4,9986.0,3127,B,H,BAO_0000223,
,Oryctolagus cuniculus,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,CHEMBL617970,10561,104714,,,,,Autocuration,,1,,4,9986.0,3128,B,H,BAO_0000223,
,Oryctolagus cuniculus,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,CHEMBL617971,10561,104714,,,,,Autocuration,,1,,4,9986.0,3129,B,H,BAO_0000223,
,Oryctolagus cuniculus,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,CHEMBL617972,10561,104714,,,,,Autocuration,,1,,4,9986.0,3130,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617973,273,104714,,,,,Autocuration,,1,,4,9986.0,3131,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617974,273,104714,,,,,Autocuration,,1,,4,9986.0,3132,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),CHEMBL617975,273,104714,,,Ileum,2116.0,Autocuration,,1,,4,9986.0,3133,F,H,BAO_0000221,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617976,273,104714,,,,,Autocuration,,1,,4,9986.0,3134,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617977,273,104714,,,,,Autocuration,,1,,4,9986.0,3135,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),CHEMBL617978,273,104714,,,,,Autocuration,,1,,4,9986.0,3136,F,H,BAO_0000019,
,Oryctolagus cuniculus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),CHEMBL617979,273,104714,,,,,Autocuration,,1,,4,9986.0,3137,F,H,BAO_0000019,
CHO,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,CHEMBL617980,13047,104714,,449.0,,,Autocuration,,1,,4,9986.0,3138,B,H,BAO_0000219,
,Rattus norvegicus,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,CHEMBL617981,1650,104698,,,,,Autocuration,,1,,7,10116.0,3139,B,D,BAO_0000019,
,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),CHEMBL617982,16288,12020,,,,,Autocuration,,1,,8,,3140,B,H,BAO_0000019,
,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),CHEMBL617983,16288,12020,,,,,Autocuration,,1,,8,,3141,B,H,BAO_0000357,
,Rattus norvegicus,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,CHEMBL617984,10254,104698,,,,,Autocuration,,1,,7,10116.0,3142,B,D,BAO_0000019,
,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",CHEMBL617985,14532,104698,,,,,Autocuration,,1,,6,,3143,B,H,BAO_0000019,
,,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",CHEMBL617986,13392,104698,,,Heart,948.0,Autocuration,,1,,6,,3144,F,H,BAO_0000218,In vivo
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",CHEMBL617987,13392,104698,,,Heart,948.0,Autocuration,,1,,6,,3145,F,H,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",CHEMBL617988,13392,104698,,,Heart,948.0,Autocuration,,1,,6,,3146,F,H,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",CHEMBL617792,13392,104698,,,Heart,948.0,Autocuration,,1,,6,,3147,F,H,BAO_0000019,
,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",CHEMBL617793,13392,104698,,,Heart,948.0,Autocuration,,1,,6,,3148,F,H,BAO_0000019,
,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617794,13392,104698,,,,,Autocuration,,1,,6,,3149,F,H,BAO_0000019,
,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617795,13392,104698,,,,,Autocuration,,1,,6,,3150,F,H,BAO_0000019,
,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617796,13392,104698,,,,,Autocuration,,1,,6,,3151,F,H,BAO_0000019,
,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",CHEMBL617797,13392,104698,,,,,Autocuration,,1,,6,,3152,F,H,BAO_0000019,
,Rattus norvegicus,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),CHEMBL617798,1089,104698,,,,,Autocuration,,1,,7,10116.0,3153,F,D,BAO_0000218,In vivo
,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),CHEMBL617799,1089,104698,,,,,Autocuration,,1,,6,,3154,F,H,BAO_0000218,In vivo
,Rattus norvegicus,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617800,11454,104698,,,,,Autocuration,,1,,7,10116.0,3155,F,D,BAO_0000218,In vivo
,Rattus norvegicus,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,CHEMBL617801,11454,104698,,,,,Autocuration,,1,,7,10116.0,3156,F,D,BAO_0000019,
,Rattus norvegicus,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,CHEMBL617802,12205,104698,,,,,Autocuration,,1,,7,10116.0,3157,F,D,BAO_0000218,In vivo
,Rattus norvegicus,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),CHEMBL617803,1089,104698,,,,,Autocuration,,1,,7,10116.0,3158,F,D,BAO_0000019,
,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,CHEMBL617804,5094,104698,,,,,Autocuration,,1,,6,,3159,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,CHEMBL617805,2622,104698,,,,,Autocuration,,1,,7,10116.0,3160,B,D,BAO_0000019,
,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,CHEMBL617806,245,104698,,,,,Autocuration,,1,,6,,3161,B,H,BAO_0000223,
,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,CHEMBL617807,14788,104698,,,,,Autocuration,,1,,6,,3162,B,H,BAO_0000019,
,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,CHEMBL617808,14788,104698,,,,,Autocuration,,1,,6,,3163,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,CHEMBL617809,3020,104698,,,,,Autocuration,,1,,6,,3164,B,H,BAO_0000249,
,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,CHEMBL617810,1742,104698,,,,,Autocuration,,1,,6,,3165,B,H,BAO_0000019,
,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,CHEMBL617811,17394,104698,,,Brain,955.0,Autocuration,,1,,6,,3166,B,H,BAO_0000249,
,,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,CHEMBL617812,17394,104698,,,Brain,955.0,Autocuration,,1,,6,,3167,B,H,BAO_0000221,
,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL617813,17394,104698,,,,,Autocuration,,1,,6,,3168,B,H,BAO_0000249,
,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,CHEMBL617814,14286,104698,,,,,Autocuration,,1,,6,,3169,B,H,BAO_0000249,
,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,CHEMBL617698,14178,104698,,,,,Autocuration,,1,,6,,3170,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,CHEMBL617699,14178,104698,,,,,Autocuration,,1,,7,10116.0,3171,B,D,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,CHEMBL617700,14178,104698,,,,,Autocuration,,1,,7,10116.0,3172,B,D,BAO_0000019,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,CHEMBL617701,14178,104698,,,,,Autocuration,,1,,7,10116.0,3173,B,D,BAO_0000223,
,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,CHEMBL617702,15034,104698,,,,,Autocuration,,1,,6,,3174,B,H,BAO_0000019,
,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",CHEMBL617703,1089,104698,Membranes,,,,Autocuration,,1,,6,,3175,B,H,BAO_0000249,
,Rattus norvegicus,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,CHEMBL617704,1089,104698,,,,,Autocuration,,1,,7,10116.0,3176,B,D,BAO_0000019,
,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,CHEMBL617705,16532,104698,,,,,Autocuration,,1,,6,,3177,B,H,BAO_0000223,
,Rattus norvegicus,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,CHEMBL617706,12801,104698,,,,,Autocuration,,1,,7,10116.0,3178,B,D,BAO_0000223,
NG108-15,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),CHEMBL617707,15194,104698,,433.0,,,Autocuration,,1,,6,,3179,B,H,BAO_0000219,
NG108-15,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,CHEMBL617708,15194,104698,,433.0,,,Autocuration,,1,,6,,3180,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,CHEMBL617709,15194,104698,,,,,Autocuration,,1,,6,,3181,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,CHEMBL617710,15194,104698,,,,,Autocuration,,1,,6,,3182,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,CHEMBL882925,15194,104698,,,,,Autocuration,,1,,6,,3183,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,CHEMBL617711,15194,104698,,,,,Autocuration,,1,,6,,3184,B,H,BAO_0000019,
,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,CHEMBL617712,10610,104698,,,,,Autocuration,,1,,6,,3185,F,H,BAO_0000019,
,Rattus norvegicus,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,CHEMBL617713,10355,104698,,,,,Autocuration,,1,,7,10116.0,3186,F,D,BAO_0000019,
,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",CHEMBL617714,691,104698,,,,,Autocuration,,1,,6,,3187,F,H,BAO_0000019,
,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,CHEMBL617715,10611,104698,,,,,Autocuration,,1,,6,,3188,F,H,BAO_0000218,
,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,CHEMBL617716,12801,104698,,,,,Autocuration,,1,,6,,3189,F,H,BAO_0000218,In vivo
,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,CHEMBL617717,10609,104698,,,,,Autocuration,,1,,6,,3190,F,H,BAO_0000218,
,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617718,11454,104698,,,,,Autocuration,,1,,6,,3191,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,CHEMBL617719,11454,104698,,,,,Autocuration,,1,,6,,3192,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),CHEMBL617720,11454,104698,,,,,Autocuration,,1,,6,,3193,F,H,BAO_0000218,In vivo
,Rattus norvegicus,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617721,11454,104698,,,,,Autocuration,,1,,7,10116.0,3194,F,D,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617722,11454,104698,,,,,Autocuration,,1,,6,,3195,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,CHEMBL617723,11454,104698,,,,,Autocuration,,1,,6,,3196,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,CHEMBL617724,11454,104698,,,,,Autocuration,,1,,6,,3197,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617725,11454,104698,,,,,Autocuration,,1,,6,,3198,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617726,11454,104698,,,,,Autocuration,,1,,6,,3199,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617727,11454,104698,,,,,Autocuration,,1,,6,,3200,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617728,11454,104698,,,,,Autocuration,,1,,6,,3201,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,CHEMBL617729,11454,104698,,,,,Autocuration,,1,,6,,3202,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,CHEMBL617730,11454,104698,,,,,Autocuration,,1,,6,,3203,F,H,BAO_0000218,In vivo
,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617731,11454,104698,,,,,Autocuration,,1,,6,,3204,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,CHEMBL617732,11454,104698,,,,,Autocuration,,1,,6,,3205,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,CHEMBL617733,11454,104698,,,,,Autocuration,,1,,6,,3206,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617734,11454,104698,,,,,Autocuration,,1,,6,,3207,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,CHEMBL872874,11454,104698,,,,,Autocuration,,1,,6,,3208,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,CHEMBL617735,11454,104698,,,,,Autocuration,,1,,6,,3209,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,CHEMBL617736,11454,104698,,,,,Autocuration,,1,,6,,3210,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,CHEMBL617737,11454,104698,,,,,Autocuration,,1,,6,,3211,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,CHEMBL617738,11454,104698,,,,,Autocuration,,1,,6,,3212,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617739,11454,104698,,,,,Autocuration,,1,,6,,3213,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,CHEMBL617740,11454,104698,,,,,Autocuration,,1,,6,,3214,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,CHEMBL617741,11454,104698,,,,,Autocuration,,1,,6,,3215,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,CHEMBL617742,11454,104698,,,,,Autocuration,,1,,6,,3216,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,CHEMBL617743,11454,104698,,,,,Autocuration,,1,,6,,3217,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,CHEMBL617744,11454,104698,,,,,Autocuration,,1,,6,,3218,F,H,BAO_0000218,In vivo
,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,CHEMBL617745,11454,104698,,,,,Autocuration,,1,,6,,3219,F,H,BAO_0000218,In vivo
,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",CHEMBL617746,670,104698,,,,,Autocuration,,1,,6,,3220,F,H,BAO_0000218,
,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",CHEMBL617747,670,104698,,,,,Autocuration,,1,,6,,3221,F,H,BAO_0000218,
,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,CHEMBL617748,10321,104698,,,,,Autocuration,,1,,6,,3222,F,H,BAO_0000218,In vivo
,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,CHEMBL618909,10321,104698,,,,,Autocuration,,1,,6,,3223,F,H,BAO_0000218,In vivo
,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,CHEMBL618910,10321,104698,,,,,Autocuration,,1,,6,,3224,F,H,BAO_0000218,In vivo
,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,CHEMBL618911,10321,104698,,,,,Autocuration,,1,,6,,3225,F,H,BAO_0000218,In vivo
,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,CHEMBL618912,10321,104698,,,,,Autocuration,,1,,6,,3226,F,H,BAO_0000218,In vivo
,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),CHEMBL618913,10322,104698,,,,,Autocuration,,1,,6,,3227,F,H,BAO_0000218,In vivo
,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,CHEMBL618914,15412,104698,,,,,Autocuration,,1,,6,,3228,F,H,BAO_0000019,
,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,CHEMBL618915,15412,104698,,,,,Autocuration,,1,,6,,3229,F,H,BAO_0000019,
,Rattus norvegicus,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,CHEMBL618916,15412,104698,,,,,Autocuration,,1,,7,10116.0,3230,B,D,BAO_0000223,
,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,CHEMBL618917,15412,104698,,,,,Autocuration,,1,,6,,3231,F,H,BAO_0000019,
,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,CHEMBL618918,15412,104698,,,Hippocampus,10000000.0,Intermediate,,1,,7,,3232,B,D,BAO_0000221,
,Rattus norvegicus,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,CHEMBL618919,15412,104698,,,,,Autocuration,,1,,7,10116.0,3233,B,D,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,CHEMBL618920,17394,104698,,,,,Autocuration,,1,,7,10116.0,3234,B,D,BAO_0000019,
,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,CHEMBL618921,12457,104698,,,,,Autocuration,,1,,6,,3235,B,H,BAO_0000223,
,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,CHEMBL618922,12457,104698,,,,,Autocuration,,1,,6,,3236,B,H,BAO_0000019,
,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,CHEMBL618923,12205,104698,,,,,Autocuration,,1,,6,,3237,B,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,CHEMBL618924,14532,104698,,,,,Autocuration,,1,,6,,3238,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,CHEMBL618925,1122,104698,,,,,Autocuration,,1,,6,,3239,B,H,BAO_0000019,
,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,CHEMBL618926,5094,104698,,,,,Autocuration,,1,,6,,3240,B,H,BAO_0000019,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,CHEMBL618927,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3241,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,CHEMBL618928,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3242,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",CHEMBL618929,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3243,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",CHEMBL618930,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3244,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",CHEMBL618931,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3245,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",CHEMBL619594,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3246,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",CHEMBL619595,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3247,F,D,BAO_0000221,
,Cavia porcellus,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,CHEMBL619596,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3248,F,D,BAO_0000221,
,Cavia porcellus,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,CHEMBL619755,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3249,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,CHEMBL619756,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3250,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,CHEMBL619757,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3251,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,CHEMBL619758,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3252,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",CHEMBL619759,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3253,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",CHEMBL619760,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3254,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",CHEMBL619761,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3255,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,CHEMBL619762,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3256,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",CHEMBL619763,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3257,F,D,BAO_0000221,
,Cavia porcellus,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",CHEMBL617868,14290,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3258,F,D,BAO_0000221,
,Cavia porcellus,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,CHEMBL617869,15034,20033,,,,,Intermediate,,1,,9,10141.0,3259,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL882926,5094,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3260,B,D,BAO_0000249,
,Cavia porcellus,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL617870,5094,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3261,B,D,BAO_0000249,
,Cavia porcellus,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,CHEMBL617871,5399,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3262,B,D,BAO_0000357,
,Cavia porcellus,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,CHEMBL617872,17394,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3263,B,D,BAO_0000357,
,Cavia porcellus,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,CHEMBL617873,17394,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3264,B,D,BAO_0000357,
,Cavia porcellus,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,CHEMBL617874,17394,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3265,B,D,BAO_0000357,
,Cavia porcellus,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,CHEMBL619067,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3266,F,D,BAO_0000221,
,Cavia porcellus,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,CHEMBL619068,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3267,F,D,BAO_0000221,
,Cavia porcellus,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,CHEMBL619069,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3268,F,D,BAO_0000221,
,Cavia porcellus,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,CHEMBL619070,16946,20033,,,,,Intermediate,,1,,9,10141.0,3269,B,D,BAO_0000357,
,Cavia porcellus,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,CHEMBL619071,16946,20033,,,,,Intermediate,,1,,9,10141.0,3270,B,D,BAO_0000357,
,Cavia porcellus,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,CHEMBL619072,15034,20033,,,,,Intermediate,,1,,9,10141.0,3271,F,D,BAO_0000019,
,Cavia porcellus,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,CHEMBL619073,15034,20033,,,,,Intermediate,,1,,9,10141.0,3272,F,D,BAO_0000019,
,Cavia porcellus,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,CHEMBL619074,12918,20033,,,,,Intermediate,,1,,9,10141.0,3273,F,D,BAO_0000019,
,Cavia porcellus,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,CHEMBL619075,16946,20033,,,,,Intermediate,,1,,9,10141.0,3274,B,D,BAO_0000357,
,Cavia porcellus,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,CHEMBL619076,17394,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3275,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,CHEMBL619077,15034,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3276,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL619078,5094,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3277,B,D,BAO_0000249,
,Cavia porcellus,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,CHEMBL619079,5094,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3278,B,D,BAO_0000249,
,Cavia porcellus,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,CHEMBL619080,17358,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3279,B,D,BAO_0000221,
,Cavia porcellus,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,CHEMBL619081,12953,20033,,,,,Expert,,1,,9,10141.0,3280,B,D,BAO_0000357,
,Cavia porcellus,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,CHEMBL619082,12953,20033,,,,,Intermediate,,1,,9,10141.0,3281,B,D,BAO_0000357,
,Cavia porcellus,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,CHEMBL619083,12953,20033,,,,,Intermediate,,1,,9,10141.0,3282,B,D,BAO_0000357,
,Cavia porcellus,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,CHEMBL619084,12953,20033,,,,,Intermediate,,1,,9,10141.0,3283,B,D,BAO_0000357,
,Cavia porcellus,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL859397,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3284,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,CHEMBL619085,12918,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3285,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,CHEMBL619086,12919,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3286,F,D,BAO_0000221,
,Cavia porcellus,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,CHEMBL619087,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3287,F,D,BAO_0000221,
,Cavia porcellus,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,CHEMBL619088,273,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3288,F,D,BAO_0000221,
,Cavia porcellus,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,CHEMBL619089,13181,20033,,,,,Intermediate,,1,,9,10141.0,3289,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,CHEMBL619090,13181,168,,,,,Autocuration,,1,,8,10141.0,3290,B,H,BAO_0000357,
,Cavia porcellus,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,CHEMBL619091,15034,20033,,,,,Intermediate,,1,,9,10141.0,3291,F,D,BAO_0000019,
,Cavia porcellus,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,CHEMBL619092,5033,20033,,,,,Intermediate,,1,,9,10141.0,3292,B,D,BAO_0000357,
,Cavia porcellus,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,CHEMBL619093,1980,20033,,,,,Intermediate,,1,,9,10141.0,3293,B,D,BAO_0000019,
HEK293,Cavia porcellus,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,CHEMBL619094,13181,168,,722.0,,,Autocuration,,1,,8,10141.0,3294,B,H,BAO_0000219,
,Cavia porcellus,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,CHEMBL619095,14287,20033,,,,,Intermediate,,1,,9,10141.0,3295,B,D,BAO_0000019,
,Cavia porcellus,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,CHEMBL857988,1317,20033,,,,,Intermediate,,1,,9,10141.0,3296,B,D,BAO_0000357,
,Cavia porcellus,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,CHEMBL619096,15316,20033,,,,,Intermediate,,1,,9,10141.0,3297,B,D,BAO_0000357,
,Cavia porcellus,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,CHEMBL619097,16429,20033,,,Striatum,2435.0,Intermediate,,1,,9,10141.0,3298,B,D,BAO_0000357,
,Cavia porcellus,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,CHEMBL619098,14818,20033,,,Hippocampus,10000000.0,Intermediate,,1,,9,10141.0,3299,B,D,BAO_0000221,
,Cavia porcellus,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,CHEMBL619751,15194,20033,,,,,Intermediate,,1,,9,10141.0,3300,B,D,BAO_0000357,
,Cavia porcellus,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,CHEMBL619752,15194,20033,,,,,Intermediate,,1,,9,10141.0,3301,B,D,BAO_0000357,
,Cavia porcellus,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,CHEMBL875096,13961,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3302,F,D,BAO_0000221,
,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,CHEMBL619004,5486,108,,,,,Autocuration,,1,,8,,3303,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,CHEMBL619005,16209,168,,,,,Autocuration,,1,,8,,3304,B,H,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,CHEMBL619006,17085,168,,,,,Autocuration,,1,,8,,3305,B,H,BAO_0000019,
HeLa,,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,CHEMBL619007,4199,168,,308.0,,,Autocuration,,1,,8,,3306,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL619008,15146,168,,,,,Autocuration,,1,,8,,3307,B,H,BAO_0000357,
,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,CHEMBL619009,5213,168,,,,,Autocuration,,1,,8,,3308,B,H,BAO_0000357,
HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",CHEMBL619010,4829,168,,308.0,,,Autocuration,,1,,8,,3309,B,H,BAO_0000219,
,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,CHEMBL619011,17358,10622,,,,,Autocuration,,1,,8,,3310,B,H,BAO_0000357,
,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,CHEMBL619012,17358,10622,,,,,Autocuration,,1,,8,,3311,B,H,BAO_0000357,
,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,CHEMBL619013,16946,10622,,,,,Autocuration,,1,,8,,3312,B,H,BAO_0000219,
,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,CHEMBL619014,17358,10622,,,,,Autocuration,,1,,8,,3313,B,H,BAO_0000357,
,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,CHEMBL857503,268,11249,,,Cardiac atrium,2081.0,Autocuration,,1,,8,,3314,F,H,BAO_0000019,
,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,CHEMBL619015,268,11249,,,Cardiac atrium,2081.0,Autocuration,,1,,8,,3315,F,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL619016,15086,11249,,,,,Autocuration,,1,,8,,3316,B,H,BAO_0000357,
,,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,CHEMBL619017,14875,11249,,,Hippocampus,10000000.0,Autocuration,,1,,8,,3317,B,H,BAO_0000221,
,Sus scrofa,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,CHEMBL619018,13267,168,,,Hippocampus,10000000.0,Autocuration,,1,,8,9823.0,3318,B,H,BAO_0000221,
,Oryctolagus cuniculus,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,CHEMBL619019,13047,168,,,,,Autocuration,,1,,8,9986.0,3319,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,CHEMBL619020,1650,10623,,,,,Expert,,1,,9,10116.0,3320,B,D,BAO_0000357,
,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,CHEMBL619021,567,10623,,,,,Autocuration,,1,,8,,3321,F,H,BAO_0000019,
,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,CHEMBL619022,17358,10623,,,,,Autocuration,,1,,8,,3322,B,H,BAO_0000357,
,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,CHEMBL619023,188,10623,,,,,Autocuration,,1,,8,,3323,B,H,BAO_0000357,
,,,,lntrinsic activity relative to 5-HT receptor,CHEMBL619024,670,10623,,,,,Autocuration,,1,,8,,3324,F,H,BAO_0000019,
,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,CHEMBL619025,204,10623,,,,,Autocuration,,1,,8,,3325,F,H,BAO_0000019,
,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,CHEMBL619026,1946,10623,,,,,Expert,,1,,8,,3326,F,H,BAO_0000019,
,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,CHEMBL619027,6398,10623,,,,,Autocuration,,1,,8,,3327,F,H,BAO_0000019,
,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,CHEMBL619028,6398,10623,,,,,Autocuration,,1,,8,,3328,F,H,BAO_0000019,
,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,CHEMBL619029,17358,10623,,,,,Autocuration,,1,,8,,3329,F,H,BAO_0000019,
,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,CHEMBL619030,6398,10623,,,,,Autocuration,,1,,8,,3330,F,H,BAO_0000019,
,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,CHEMBL619031,11752,10623,,,,,Expert,,1,,8,,3331,B,H,BAO_0000357,
,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,CHEMBL619032,809,10623,,,,,Autocuration,,1,,8,,3332,F,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,CHEMBL619033,14178,10623,,,,,Expert,,1,,9,10116.0,3333,B,D,BAO_0000357,
,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,CHEMBL619034,567,10623,,,,,Autocuration,,1,,8,,3334,B,H,BAO_0000357,
,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,CHEMBL619035,1946,10623,,,,,Autocuration,,1,,8,,3335,B,H,BAO_0000357,
,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,CHEMBL619036,1946,10623,,,,,Autocuration,,1,,8,,3336,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,CHEMBL619037,13961,10623,,,,,Expert,,1,,9,10116.0,3337,B,D,BAO_0000019,
,,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,CHEMBL619038,6238,10623,,,Striatum,2435.0,Autocuration,,1,,8,,3338,B,H,BAO_0000249,
,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,CHEMBL619039,14290,10623,,,,,Autocuration,,1,,8,,3339,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,CHEMBL619040,14290,10623,,,,,Expert,,1,,8,,3340,B,H,BAO_0000249,
,Rattus norvegicus,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,CHEMBL619041,809,10623,,,Striatum,2435.0,Expert,,1,,9,10116.0,3341,B,D,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,CHEMBL619042,1578,10623,,,Striatum,2435.0,Autocuration,,1,,8,,3342,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,CHEMBL619043,16709,10623,,,Striatum,2435.0,Expert,,1,,8,,3343,B,H,BAO_0000249,
,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,CHEMBL619044,1946,10623,,,Striatum,2435.0,Expert,,1,,8,,3344,B,H,BAO_0000019,
,,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,CHEMBL619045,15253,10623,,,Striatum,2435.0,Expert,,1,,8,,3345,B,H,BAO_0000249,
,,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,CHEMBL619046,4535,10623,,,Striatum,2435.0,Expert,,1,,8,,3346,B,H,BAO_0000249,
,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,CHEMBL619047,13961,10623,,,,,Expert,,1,,8,,3347,B,H,BAO_0000249,
,,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,CHEMBL619048,17358,10623,,,Brain,955.0,Autocuration,,1,,8,,3348,F,H,BAO_0000221,
,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,CHEMBL859398,15847,10623,,,,,Autocuration,,1,,8,,3349,F,H,BAO_0000019,
,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,CHEMBL619049,15847,10623,,,,,Autocuration,,1,,8,,3350,F,H,BAO_0000019,
,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,CHEMBL857886,670,10623,,,,,Autocuration,,1,,8,,3351,F,H,BAO_0000019,
,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,CHEMBL619050,670,10623,,,,,Autocuration,,1,,8,,3352,F,H,BAO_0000019,
,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,CHEMBL620591,1317,10623,,,,,Autocuration,,1,,8,,3353,F,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,CHEMBL620592,12936,10623,,,,,Expert,,1,,9,10116.0,3354,B,D,BAO_0000357,
,,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,CHEMBL620593,4535,10623,,,Striatum,2435.0,Expert,,1,,8,,3355,B,H,BAO_0000249,
,Rattus norvegicus,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,CHEMBL620594,14424,10623,,,,,Expert,,1,,9,10116.0,3356,F,D,BAO_0000019,
,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,CHEMBL875079,14424,10623,,,,,Expert,,1,,8,,3357,F,H,BAO_0000019,
,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,CHEMBL620595,14424,10623,,,,,Expert,,1,,8,,3358,F,H,BAO_0000019,
,Rattus norvegicus,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,CHEMBL620596,14424,10623,,,,,Expert,,1,,9,10116.0,3359,F,D,BAO_0000019,
,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,CHEMBL620597,14424,10623,,,,,Autocuration,,1,,8,,3360,F,H,BAO_0000019,
,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,CHEMBL620598,14424,10623,,,,,Expert,,1,,8,,3361,F,H,BAO_0000019,
,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),CHEMBL620599,14424,10623,,,,,Expert,,1,,8,,3362,F,H,BAO_0000218,
,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,CHEMBL620600,14424,10623,,,,,Autocuration,,1,,8,,3363,F,H,BAO_0000019,
,Rattus norvegicus,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,CHEMBL620601,1980,168,,,,,Autocuration,,1,,8,10116.0,3364,F,H,BAO_0000019,
,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,CHEMBL620602,4639,168,,,,,Autocuration,,1,,8,,3365,F,H,BAO_0000019,
,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620603,17358,168,,,,,Autocuration,,1,,8,,3366,B,H,BAO_0000357,
,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,CHEMBL620604,17358,168,,,,,Autocuration,,1,,8,,3367,B,H,BAO_0000357,
,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,CHEMBL620605,17358,168,,,,,Autocuration,,1,,8,,3368,B,H,BAO_0000357,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620606,1558,168,,,,,Autocuration,,1,,8,,3369,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL620607,17358,168,,,,,Autocuration,,1,,8,,3370,F,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-HT4 receptor was determined,CHEMBL620608,16117,168,,,,,Autocuration,,1,,8,,3371,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL620609,17358,168,,,,,Autocuration,,1,,8,,3372,F,H,BAO_0000019,
,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,CHEMBL620610,17358,168,,,,,Autocuration,,1,,8,,3373,F,H,BAO_0000019,
,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,CHEMBL620611,17358,168,,,,,Autocuration,,1,,8,,3374,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,CHEMBL620612,17358,168,,,,,Autocuration,,1,,8,,3375,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,CHEMBL620613,17358,168,,,,,Autocuration,,1,,8,,3376,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,CHEMBL620614,17358,168,,,,,Autocuration,,1,,8,,3377,B,H,BAO_0000357,
,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,CHEMBL620615,1274,168,,,,,Expert,,1,,8,,3378,B,H,BAO_0000357,
,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,CHEMBL857075,10728,104698,Brain membranes,,,,Autocuration,,1,,6,,3379,B,H,BAO_0000249,
,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,CHEMBL620616,11695,104698,Brain membranes,,,,Autocuration,,1,,6,,3380,B,H,BAO_0000249,
,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,CHEMBL619411,11695,104698,Brain membranes,,,,Autocuration,,1,,6,,3381,B,H,BAO_0000249,
,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,CHEMBL619412,12490,104698,,,,,Autocuration,,1,,6,,3382,B,H,BAO_0000019,
,Rattus norvegicus,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,CHEMBL619413,11828,104698,,,,,Autocuration,,1,,7,10116.0,3383,B,D,BAO_0000019,
,,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,CHEMBL619414,12253,104698,,,Hippocampus,10000000.0,Autocuration,,1,,6,,3384,B,H,BAO_0000221,
,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,CHEMBL619415,10561,104698,,,,,Autocuration,,1,,6,,3385,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,CHEMBL619416,10561,104698,,,,,Autocuration,,1,,6,,3386,B,H,BAO_0000019,
,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,CHEMBL619417,14432,104698,,,,,Autocuration,,1,,6,,3387,F,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,CHEMBL619418,12936,104698,,,,,Autocuration,,1,,7,10116.0,3388,B,D,BAO_0000223,
,Rattus norvegicus,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,CHEMBL619419,1274,104698,,,,,Autocuration,,1,,7,10116.0,3389,B,D,BAO_0000223,
,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,CHEMBL619420,1980,104698,,,,,Autocuration,,1,,6,,3390,B,H,BAO_0000019,
,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,CHEMBL619421,670,104698,,,,,Autocuration,,1,,6,,3391,B,H,BAO_0000249,
,Rattus norvegicus,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,CHEMBL619422,968,104698,,,,,Autocuration,,1,,7,10116.0,3392,B,D,BAO_0000019,
,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,CHEMBL619423,14287,104698,,,,,Autocuration,,1,,6,,3393,B,H,BAO_0000019,
,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,CHEMBL875080,567,104698,,,,,Autocuration,,1,,6,,3394,B,H,BAO_0000019,
,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,CHEMBL619424,13267,104698,,,,,Autocuration,,1,,6,,3395,B,H,BAO_0000019,
,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,CHEMBL619425,14826,104698,,,,,Autocuration,,1,,6,,3396,B,H,BAO_0000249,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,CHEMBL619426,15194,104698,,,,,Autocuration,,1,,6,,3397,B,H,BAO_0000223,
,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,CHEMBL619427,15194,104698,,,,,Autocuration,,1,,6,,3398,B,H,BAO_0000223,
,Rattus norvegicus,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,CHEMBL619645,10394,104698,,,,,Autocuration,,1,,7,10116.0,3399,B,D,BAO_0000223,
,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",CHEMBL619646,13657,10576,,,,,Expert,,1,,9,,3400,B,D,BAO_0000249,
,,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,CHEMBL619647,1879,12020,,,Brain,955.0,Autocuration,,1,,8,,3401,F,H,BAO_0000221,
,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,CHEMBL619648,1879,12020,,,,,Autocuration,,1,,8,,3402,F,H,BAO_0000019,
,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,CHEMBL619165,1879,12020,,,,,Autocuration,,1,,8,,3403,F,H,BAO_0000019,
,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,CHEMBL620719,204,12020,,,,,Autocuration,,1,,8,,3404,F,H,BAO_0000218,In vivo
,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,CHEMBL872924,1879,12020,,,,,Autocuration,,1,,8,,3405,B,H,BAO_0000019,
,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620720,1879,12020,,,,,Autocuration,,1,,8,,3406,B,H,BAO_0000357,
,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,CHEMBL620721,1879,12020,,,,,Autocuration,,1,,8,,3407,B,H,BAO_0000019,
,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,CHEMBL620722,1879,12020,,,,,Autocuration,,1,,8,,3408,B,H,BAO_0000019,
,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",CHEMBL620723,10641,104698,,,,,Autocuration,,1,,6,,3409,B,H,BAO_0000019,
,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,CHEMBL620724,773,12020,,,,,Autocuration,,1,,8,,3410,B,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,CHEMBL620725,11952,104698,,,,,Autocuration,,1,,6,,3411,B,H,BAO_0000249,
,Rattus norvegicus,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,CHEMBL620726,14145,12020,,,,,Autocuration,,1,,9,10116.0,3412,F,D,BAO_0000019,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620727,17066,144,,,,,Expert,,1,,8,,3413,B,H,BAO_0000357,
,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,CHEMBL620728,6398,104714,,,,,Autocuration,,1,,4,,3414,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL620729,10321,22226,,,,,Autocuration,,1,,0,,3415,B,U,BAO_0000019,
,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,CHEMBL858288,511,104714,,,,,Autocuration,,1,,4,,3416,F,H,BAO_0000019,
,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620730,4639,104714,,,,,Autocuration,,1,,4,,3417,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL620731,4639,104714,,,,,Autocuration,,1,,4,,3418,B,H,BAO_0000223,
,Cavia porcellus,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,CHEMBL620732,4639,104714,,,,,Autocuration,,1,,4,10141.0,3419,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,CHEMBL618042,4639,104714,,,,,Autocuration,,1,,4,10141.0,3420,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,CHEMBL618043,4639,104714,,,,,Autocuration,,1,,4,10141.0,3421,F,H,BAO_0000019,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618044,1558,104714,,,,,Autocuration,,1,,4,,3422,B,H,BAO_0000223,
,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,CHEMBL618045,268,104714,,,,,Autocuration,,1,,4,,3423,F,H,BAO_0000019,
,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,CHEMBL618046,2474,104714,,,,,Autocuration,,1,,4,,3424,B,H,BAO_0000223,
,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,CHEMBL618047,5067,104714,,,,,Autocuration,,1,,4,,3425,F,H,BAO_0000019,
,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,CHEMBL875084,5067,104714,,,,,Autocuration,,1,,4,,3426,F,H,BAO_0000019,
,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,CHEMBL618048,5067,104714,,,,,Autocuration,,1,,4,,3427,F,H,BAO_0000019,
,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,CHEMBL618049,5067,104714,,,,,Autocuration,,1,,4,,3428,B,H,BAO_0000223,
,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,CHEMBL619764,5067,104714,,,,,Autocuration,,1,,4,,3429,F,H,BAO_0000019,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,CHEMBL619765,5067,104714,,,,,Autocuration,,1,,4,,3430,F,H,BAO_0000019,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,CHEMBL619766,5067,104714,,,,,Autocuration,,1,,4,,3431,F,H,BAO_0000019,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,CHEMBL619767,5067,104714,,,,,Autocuration,,1,,4,,3432,B,H,BAO_0000223,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,CHEMBL619768,5067,104714,,,,,Autocuration,,1,,4,,3433,B,H,BAO_0000223,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,CHEMBL619769,5067,104714,,,,,Autocuration,,1,,4,,3434,F,H,BAO_0000019,
,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,CHEMBL619770,5067,104714,,,,,Autocuration,,1,,4,,3435,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL619771,5067,104714,,,,,Autocuration,,1,,4,,3436,B,H,BAO_0000223,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,CHEMBL619772,14331,104714,,,,,Autocuration,,1,,4,,3437,B,H,BAO_0000219,
,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,CHEMBL619773,5067,104714,,,,,Autocuration,,1,,4,,3438,B,H,BAO_0000223,
NG108-15,,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,CHEMBL619774,6179,104714,,433.0,,,Autocuration,,1,,4,,3439,B,H,BAO_0000219,
,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,CHEMBL875083,4265,104714,,,,,Autocuration,,1,,4,,3440,B,H,BAO_0000019,
NG108-15,,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,CHEMBL620718,4265,104714,,433.0,,,Autocuration,,1,,4,,3441,B,H,BAO_0000219,
,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618127,17358,104714,,,,,Autocuration,,1,,4,,3442,B,H,BAO_0000223,
,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618128,17358,104714,,,,,Autocuration,,1,,4,,3443,B,H,BAO_0000223,
,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,CHEMBL618129,13628,104714,,,,,Autocuration,,1,,4,,3444,B,H,BAO_0000219,In vitro
,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,CHEMBL618130,4612,104714,,,,,Autocuration,,1,,4,,3445,B,H,BAO_0000223,
,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,CHEMBL618131,17358,104714,,,,,Autocuration,,1,,4,,3446,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,CHEMBL618132,4639,104714,,,,,Autocuration,,1,,4,10141.0,3447,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,CHEMBL618133,4639,104714,,,,,Autocuration,,1,,4,10141.0,3448,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,CHEMBL618134,4639,104714,,,,,Autocuration,,1,,4,10141.0,3449,F,H,BAO_0000019,
,Cavia porcellus,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,CHEMBL618135,4639,104714,,,,,Autocuration,,1,,4,10141.0,3450,F,H,BAO_0000019,
,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,CHEMBL618136,511,104714,,,,,Autocuration,,1,,4,,3451,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618137,1479,104714,,,,,Autocuration,,1,,4,,3452,B,H,BAO_0000223,
,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,CHEMBL618138,1317,104714,,,,,Autocuration,,1,,4,,3453,B,H,BAO_0000223,
,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,CHEMBL618139,12146,104714,,,,,Autocuration,,1,,4,,3454,B,H,BAO_0000223,
,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,CHEMBL618140,12146,104714,,,,,Autocuration,,1,,4,,3455,B,H,BAO_0000223,
,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,CHEMBL618141,13969,104714,,,,,Autocuration,,1,,4,,3456,B,H,BAO_0000223,
,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,CHEMBL873478,13392,108,,,,,Expert,,1,,8,,3457,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618142,13392,104698,,,,,Autocuration,,1,,6,,3458,B,H,BAO_0000223,
,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,CHEMBL618143,14159,144,,,,,Autocuration,,1,,8,,3459,B,H,BAO_0000357,
,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618144,1558,144,,,,,Autocuration,,1,,8,,3460,B,H,BAO_0000357,
,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,CHEMBL618145,16655,144,,,,,Autocuration,,1,,8,,3461,B,H,BAO_0000357,
,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,CHEMBL618146,13020,104714,,,,,Autocuration,,1,,4,,3462,B,H,BAO_0000223,
,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,CHEMBL618147,13021,104714,,,,,Autocuration,,1,,4,,3463,B,H,BAO_0000223,
,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,CHEMBL618148,13020,104714,,,,,Autocuration,,1,,4,,3464,B,H,BAO_0000223,
,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL618149,10321,144,,,,,Autocuration,,1,,8,,3465,B,H,BAO_0000019,
,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL872927,15818,144,,,,,Autocuration,,1,,8,,3466,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL618150,15818,144,,,,,Autocuration,,1,,8,,3467,B,H,BAO_0000357,
,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL618151,17358,144,,,,,Autocuration,,1,,8,,3468,B,H,BAO_0000357,
,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,CHEMBL875094,2222,144,,,,,Autocuration,,1,,8,,3469,B,H,BAO_0000357,
,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL618152,10322,144,,,,,Autocuration,,1,,8,,3470,B,H,BAO_0000019,
,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,CHEMBL618153,16117,144,,,,,Autocuration,,1,,8,,3471,B,H,BAO_0000357,
,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,CHEMBL618888,17200,144,,,,,Autocuration,,1,,8,,3472,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,CHEMBL618889,17358,144,,,,,Autocuration,,1,,8,,3473,F,H,BAO_0000019,
,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,CHEMBL618890,16700,144,,,,,Autocuration,,1,,8,,3474,B,H,BAO_0000357,
,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL618891,1980,144,,,,,Autocuration,,1,,8,,3475,B,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL619054,1980,144,,,,,Autocuration,,1,,8,,3476,B,H,BAO_0000019,
,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,CHEMBL619055,12409,104714,,,,,Autocuration,,1,,4,,3477,B,H,BAO_0000223,
,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL619056,4365,144,,,,,Autocuration,,1,,8,,3478,B,H,BAO_0000357,
,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,CHEMBL619057,4365,144,,,,,Autocuration,,1,,8,,3479,F,H,BAO_0000019,
,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL619058,4365,144,,,,,Autocuration,,1,,8,,3480,B,H,BAO_0000357,
Oocytes,Rattus norvegicus,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,CHEMBL619059,6769,12020,,,,,Expert,,1,,9,10116.0,3481,F,D,BAO_0000219,
Oocytes,Rattus norvegicus,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,CHEMBL619060,6769,12020,,,,,Expert,,1,,9,10116.0,3482,F,D,BAO_0000219,
Oocytes,Rattus norvegicus,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,CHEMBL875095,6769,12020,,,,,Expert,,1,,9,10116.0,3483,F,D,BAO_0000219,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,CHEMBL619061,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3484,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,CHEMBL619062,809,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3485,F,D,BAO_0000221,
,Cavia porcellus,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,CHEMBL619063,14290,20033,,,,,Intermediate,,1,,9,10141.0,3486,F,D,BAO_0000019,
,Cavia porcellus,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,CHEMBL619064,17358,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3487,B,D,BAO_0000221,
,Cavia porcellus,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,CHEMBL619065,17358,20033,,,,,Intermediate,,1,,9,10141.0,3488,B,D,BAO_0000357,
,Cavia porcellus,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,CHEMBL619066,17358,20033,,,Ileum,2116.0,Intermediate,,1,,9,10141.0,3489,B,D,BAO_0000221,
,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,CHEMBL619775,17386,10209,,,Ileum,2116.0,Autocuration,,1,,8,,3490,B,H,BAO_0000221,
,,,,Affinity against 5-hydroxytryptamine 7 receptor,CHEMBL619776,3269,10209,,,,,Autocuration,,1,,8,,3491,B,H,BAO_0000357,
,Cavia porcellus,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,CHEMBL619777,7721,104841,,,,,Autocuration,,1,,4,10141.0,3492,B,H,BAO_0000224,
,Cavia porcellus,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,CHEMBL619778,7721,104841,,,,,Autocuration,,1,,4,10141.0,3493,B,H,BAO_0000224,
,Cavia porcellus,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,CHEMBL619779,9117,104841,,,Ileum,2116.0,Autocuration,,1,,4,10141.0,3494,B,H,BAO_0000221,
,Cavia porcellus,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",CHEMBL619780,7721,104841,,,,,Autocuration,,1,,4,10141.0,3495,B,H,BAO_0000224,
,Cavia porcellus,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",CHEMBL619166,7721,104841,,,,,Autocuration,,1,,4,10141.0,3496,B,H,BAO_0000224,
,Cavia porcellus,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,CHEMBL619167,15796,104841,,,,,Autocuration,,1,,4,10141.0,3497,F,H,BAO_0000019,
,Cavia porcellus,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,CHEMBL619168,15796,104841,,,,,Autocuration,,1,,4,10141.0,3498,F,H,BAO_0000019,
,Homo sapiens,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,CHEMBL619169,15650,168,,,Cardiac atrium,2081.0,Expert,,1,,9,9606.0,3499,B,D,BAO_0000219,
,Homo sapiens,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,CHEMBL619170,15650,168,,,Cardiac atrium,2081.0,Expert,,1,,9,9606.0,3500,B,D,BAO_0000219,
,Homo sapiens,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",CHEMBL619171,6866,104841,,,,,Autocuration,,1,,5,9606.0,3501,F,D,BAO_0000019,
,Homo sapiens,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",CHEMBL619172,15650,168,,,Cardiac atrium,2081.0,Expert,,1,,9,9606.0,3502,F,D,BAO_0000219,
,Mus musculus,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,CHEMBL619173,10063,22226,,,,,Autocuration,,1,,0,10090.0,3503,B,U,BAO_0000019,
,Mus musculus,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,CHEMBL619174,12665,22226,,,,,Autocuration,,1,,0,10090.0,3504,B,U,BAO_0000019,
,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,CHEMBL619175,7504,104705,,,,,Autocuration,,1,,4,,3505,B,H,BAO_0000019,
,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,CHEMBL619176,7504,104705,,,,,Autocuration,,1,,4,,3506,B,H,BAO_0000224,
,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,CHEMBL619177,7038,104705,,,,,Autocuration,,1,,4,,3507,B,H,BAO_0000019,
,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,CHEMBL619178,7626,104705,,,,,Autocuration,,1,,4,,3508,B,H,BAO_0000224,
,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,CHEMBL619179,7626,104705,,,,,Autocuration,,1,,4,,3509,B,H,BAO_0000224,
,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,CHEMBL619180,7185,104705,,,Stomach,945.0,Autocuration,,1,,4,,3510,F,H,BAO_0000019,
,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,CHEMBL619181,7185,104705,,,Stomach,945.0,Autocuration,,1,,4,,3511,F,H,BAO_0000019,
,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,CHEMBL619182,7185,104705,,,,,Autocuration,,1,,4,,3512,F,H,BAO_0000019,
,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,CHEMBL619183,6960,104705,,,,,Autocuration,,1,,4,,3513,B,H,BAO_0000224,
,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",CHEMBL619184,6960,104705,,,,,Autocuration,,1,,4,,3514,B,H,BAO_0000224,
,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,CHEMBL619185,12416,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,3515,B,H,BAO_0000221,
,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,CHEMBL619186,15753,12198,,,,,Expert,,1,,8,,3516,B,H,BAO_0000357,
,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,CHEMBL619187,8062,104705,,,,,Autocuration,,1,,4,,3517,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,CHEMBL619188,9036,104705,,,,,Autocuration,,1,,5,10116.0,3518,B,D,BAO_0000019,
,Rattus norvegicus,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,CHEMBL619189,15067,104705,,,,,Autocuration,,1,,5,10116.0,3519,B,D,BAO_0000224,
,Rattus norvegicus,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,CHEMBL619190,15753,12198,,,Brain,955.0,Expert,,1,,9,10116.0,3520,F,D,BAO_0000019,
,Rattus norvegicus,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,CHEMBL619191,15753,12198,,,Cerebellum,2037.0,Expert,,1,,9,10116.0,3521,F,D,BAO_0000221,
,Rattus norvegicus,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,CHEMBL619192,15295,104705,,,,,Autocuration,,1,,5,10116.0,3522,B,D,BAO_0000019,
,Rattus norvegicus,,,Percent binding affinity against 5-hydroxytryptamine receptor,CHEMBL619193,6347,104705,,,,,Autocuration,,1,,5,10116.0,3523,B,D,BAO_0000224,
,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,CHEMBL619194,6763,22226,,,,,Autocuration,,1,,0,,3524,B,U,BAO_0000019,
,Rattus norvegicus,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,CHEMBL619195,12092,104705,,,,,Autocuration,,1,,5,10116.0,3525,B,D,BAO_0000224,
,Rattus norvegicus,,,Affinity against 5-hydroxytryptamine receptor was determined,CHEMBL619196,1579,104705,,,,,Autocuration,,1,,5,10116.0,3526,B,D,BAO_0000224,
,Rattus norvegicus,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,CHEMBL619197,1579,104705,,,Stomach,945.0,Autocuration,,1,,5,10116.0,3527,B,D,BAO_0000019,
,Homo sapiens,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,CHEMBL619198,5963,121,,,,,Expert,,1,,9,9606.0,3528,B,D,BAO_0000219,In vitro
,Homo sapiens,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,CHEMBL875081,5963,121,,,,,Expert,,1,,9,9606.0,3529,B,D,BAO_0000219,In vitro
,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,CHEMBL884712,5030,18065,,,,,Autocuration,,1,,8,,3530,B,H,BAO_0000357,
,,,,Inhibition of 5-hydroxytryptamine reuptake,CHEMBL884710,15796,121,,,,,Expert,,1,,8,,3531,B,H,BAO_0000357,
,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",CHEMBL619199,15413,18065,,,,,Autocuration,,1,,8,,3532,F,H,BAO_0000019,
,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",CHEMBL619200,15413,18065,,,,,Autocuration,,1,,8,,3533,F,H,BAO_0000019,
,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",CHEMBL619201,15413,18065,,,,,Autocuration,,1,,8,,3534,F,H,BAO_0000019,
,,,,Tested for 5-hydroxytryptamine receptor uptake,CHEMBL619202,12409,18065,,,,,Autocuration,,1,,8,,3535,F,H,BAO_0000019,
CHO,Homo sapiens,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHEMBL619203,16909,51,,449.0,,,Expert,,1,,9,9606.0,3536,B,D,BAO_0000219,
,Homo sapiens,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,CHEMBL619204,16909,51,,,,,Expert,,1,,9,9606.0,3537,F,D,BAO_0000019,
,Homo sapiens,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,CHEMBL619205,15629,10576,,,,,Autocuration,,1,,8,9606.0,3538,B,H,BAO_0000249,
,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,CHEMBL619206,15629,10576,,,,,Autocuration,,1,,8,,3539,B,H,BAO_0000357,
,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,CHEMBL619207,15629,10576,,,,,Expert,,1,,8,,3540,B,H,BAO_0000249,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,CHEMBL619208,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3541,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,CHEMBL619209,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3542,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,CHEMBL619210,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3543,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,CHEMBL619211,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3544,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,CHEMBL619212,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3545,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,CHEMBL620681,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3546,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,CHEMBL620682,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3547,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,CHEMBL620683,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3548,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,CHEMBL620684,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3549,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,CHEMBL620685,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3550,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,CHEMBL620686,10034,10825,,,Striatum,2435.0,Autocuration,,1,,8,,3551,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,CHEMBL620687,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3552,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,CHEMBL620688,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3553,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,CHEMBL620689,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3554,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,CHEMBL620690,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3555,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,CHEMBL620691,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3556,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,CHEMBL620692,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3557,F,H,BAO_0000019,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,CHEMBL620693,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3558,F,H,BAO_0000019,
,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,CHEMBL620694,1274,168,,,,,Expert,,1,,8,,3559,B,H,BAO_0000357,
,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,CHEMBL857986,17358,168,,,,,Autocuration,,1,,8,,3560,F,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,CHEMBL620695,14532,168,,,,,Autocuration,,1,,8,,3561,B,H,BAO_0000357,
,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,CHEMBL620696,16989,168,,,,,Expert,,1,,8,,3562,B,H,BAO_0000357,
,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,CHEMBL620697,17200,168,,,,,Autocuration,,1,,8,,3563,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,CHEMBL620698,15779,168,,,,,Autocuration,,1,,8,,3564,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,CHEMBL620699,15779,168,,,,,Autocuration,,1,,8,,3565,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,CHEMBL620700,15779,168,,,,,Autocuration,,1,,8,,3566,B,H,BAO_0000357,
COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,CHEMBL620701,15650,168,,643.0,,,Autocuration,,1,,8,,3567,B,H,BAO_0000219,
COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,CHEMBL875082,15650,168,,643.0,,,Autocuration,,1,,8,,3568,B,H,BAO_0000219,
COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,CHEMBL620702,15650,168,,643.0,,,Autocuration,,1,,8,,3569,B,H,BAO_0000219,
COS-7,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,CHEMBL620703,15650,168,,643.0,,,Autocuration,,1,,8,,3570,B,H,BAO_0000219,
C6,,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,CHEMBL620704,17046,168,,673.0,,,Autocuration,,1,,8,,3571,B,H,BAO_0000219,
C6,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,CHEMBL620705,17046,168,,673.0,,,Expert,,1,,8,,3572,B,H,BAO_0000219,
C6,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,CHEMBL620706,15650,168,,673.0,,,Expert,,1,,8,,3573,B,H,BAO_0000219,
C6,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,CHEMBL620707,17046,168,,673.0,,,Expert,,1,,8,,3574,B,H,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,CHEMBL620708,17066,10624,,,,,Expert,,1,,8,,3575,B,H,BAO_0000357,
,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,CHEMBL620709,17200,105,,,,,Autocuration,,1,,8,,3576,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 5A receptor,CHEMBL620710,16146,10624,,,,,Expert,,1,,9,9606.0,3577,B,D,BAO_0000357,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,CHEMBL620711,15250,10624,,449.0,,,Autocuration,,1,,8,,3578,B,H,BAO_0000219,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,CHEMBL620712,6491,10624,,,,,Expert,,1,,9,9606.0,3579,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,CHEMBL620713,17066,10624,,,,,Expert,,1,,9,9606.0,3580,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,CHEMBL620714,17066,10624,,,,,Expert,,1,,9,9606.0,3581,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,CHEMBL620715,4234,10624,,,,,Expert,,1,,9,9606.0,3582,B,D,BAO_0000357,
,,,,Binding affinity towards 5-HT5A receptor,CHEMBL620716,6013,10624,,,,,Autocuration,,1,,8,,3583,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,CHEMBL620717,17175,10624,,,,,Expert,,1,,8,,3584,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,CHEMBL618072,15818,10624,,,,,Autocuration,,1,,8,,3585,B,H,BAO_0000357,
,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,CHEMBL857987,6166,10624,,,,,Autocuration,,1,,8,,3586,B,H,BAO_0000357,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL618073,15779,10624,,722.0,,,Autocuration,,1,,8,,3587,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,CHEMBL618074,15779,10624,,722.0,,,Autocuration,,1,,8,,3588,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),CHEMBL618075,5213,10624,,722.0,,,Autocuration,,1,,8,,3589,B,H,BAO_0000219,
,Mus musculus,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,CHEMBL618076,17066,10625,,,,,Expert,,1,,9,10090.0,3590,B,D,BAO_0000357,
,Mus musculus,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,CHEMBL618077,17066,10625,,,,,Expert,,1,,9,10090.0,3591,B,D,BAO_0000357,
,Mus musculus,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,CHEMBL618078,17066,10625,,,,,Expert,,1,,9,10090.0,3592,B,D,BAO_0000357,
,Mus musculus,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,CHEMBL881821,17066,10625,,,,,Expert,,1,,9,10090.0,3593,B,D,BAO_0000357,
,Mus musculus,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,CHEMBL618079,17066,10625,,,,,Expert,,1,,9,10090.0,3594,B,D,BAO_0000357,
,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,CHEMBL618080,17175,10625,,,,,Expert,,1,,8,,3595,B,H,BAO_0000357,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,CHEMBL618081,16190,10576,,722.0,,,Autocuration,,1,,8,,3596,B,H,BAO_0000219,
HEK293,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,CHEMBL618082,16190,10626,,722.0,,,Autocuration,,1,,8,,3597,B,H,BAO_0000219,
,,,,Binding affinity towards 5-HT5a receptor,CHEMBL618083,4820,10624,,,,,Expert,,1,,8,,3598,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,CHEMBL618084,17066,10624,,,,,Expert,,1,,9,9606.0,3599,B,D,BAO_0000357,
,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,CHEMBL618085,17066,10624,,,,,Expert,,1,,8,,3600,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,CHEMBL618086,17175,10624,,,,,Expert,,1,,8,,3601,B,H,BAO_0000357,
,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,CHEMBL875092,16633,10624,,,,,Autocuration,,1,,8,,3602,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,CHEMBL618087,16633,10624,,,,,Autocuration,,1,,8,,3603,B,H,BAO_0000357,
,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,CHEMBL872926,16700,10624,,,,,Autocuration,,1,,8,,3604,B,H,BAO_0000357,
,Cavia porcellus,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,CHEMBL618088,4639,104714,,,,,Autocuration,,1,,4,10141.0,3605,F,H,BAO_0000019,
,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,CHEMBL618089,5486,104714,,,,,Autocuration,,1,,4,,3606,B,H,BAO_0000223,
,Homo sapiens,,,Inhibition of human 5-hydroxytryptamine 6 receptor,CHEMBL618090,16146,10627,,,,,Expert,,1,,9,9606.0,3607,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,CHEMBL618091,17273,10627,,,,,Expert,,1,,9,9606.0,3608,B,D,BAO_0000357,
,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,CHEMBL618092,17687,10627,,,,,Autocuration,,1,,8,,3609,B,H,BAO_0000357,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,CHEMBL618093,6491,10627,,,,,Expert,,1,,9,9606.0,3610,B,D,BAO_0000357,
HeLa,,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,CHEMBL618094,16190,10627,,308.0,,,Expert,,1,,8,,3611,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,CHEMBL618095,17066,10627,,,,,Expert,,1,,9,9606.0,3612,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL875093,17066,10627,,,,,Expert,,1,,9,9606.0,3613,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,CHEMBL618096,17066,10627,,,,,Expert,,1,,9,9606.0,3614,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,CHEMBL618118,17066,10627,,,,,Expert,,1,,9,9606.0,3615,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 6 receptor,CHEMBL618119,3555,10627,,,,,Expert,,1,,9,9606.0,3616,B,D,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618120,5808,10627,,,,,Expert,,1,,8,,3617,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618121,6013,10627,,,,,Autocuration,,1,,8,,3618,B,H,BAO_0000357,
HEK293,,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",CHEMBL618122,15818,10627,,722.0,,,Expert,,1,,8,,3619,B,H,BAO_0000219,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,CHEMBL618123,16209,10627,,,,,Autocuration,,1,,8,,3620,B,H,BAO_0000357,
HEK293,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,CHEMBL618124,3935,10627,,722.0,,,Expert,,1,,8,,3621,B,H,BAO_0000219,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL618125,15818,10627,,,,,Autocuration,,1,,8,,3622,B,H,BAO_0000357,
HEK293,Homo sapiens,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,CHEMBL618126,3805,10627,,722.0,,,Expert,,1,,9,9606.0,3623,B,D,BAO_0000219,
,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,CHEMBL618236,16441,10627,,,,,Expert,,1,,8,,3624,B,H,BAO_0000019,
,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,CHEMBL618237,16441,10627,,,,,Expert,,1,,8,,3625,B,H,BAO_0000019,
COS-7,,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,CHEMBL618238,6786,10627,,643.0,,,Expert,,1,,8,,3626,B,H,BAO_0000219,
,Homo sapiens,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,CHEMBL618239,4234,10627,,,,,Expert,,1,,9,9606.0,3627,B,D,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,CHEMBL618240,17085,10627,,,,,Autocuration,,1,,8,,3628,B,H,BAO_0000019,
,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,CHEMBL618241,17200,10627,,,,,Autocuration,,1,,8,,3629,B,H,BAO_0000357,
HEK293,,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,CHEMBL859399,17451,10627,,722.0,,,Autocuration,,1,,8,,3630,B,H,BAO_0000219,
,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,CHEMBL618242,3935,10627,,,,,Autocuration,,1,,8,,3631,F,H,BAO_0000019,
,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,CHEMBL857991,5033,10627,,,,,Autocuration,,1,,8,,3632,B,H,BAO_0000357,
,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,CHEMBL619951,4540,10627,,,,,Expert,,1,,8,,3633,B,H,BAO_0000357,
HeLa,Homo sapiens,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,CHEMBL619952,4540,10627,,308.0,,,Expert,,1,,9,9606.0,3634,B,D,BAO_0000219,
HeLa,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,CHEMBL619953,4540,10627,,308.0,,,Expert,,1,,9,9606.0,3635,B,D,BAO_0000219,
HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,CHEMBL619954,17296,10627,,308.0,,,Autocuration,,1,,8,,3636,B,H,BAO_0000219,
HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,CHEMBL619955,17296,10627,,308.0,,,Autocuration,,1,,8,,3637,B,H,BAO_0000219,
HeLa,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,CHEMBL619956,17296,10627,,308.0,,,Autocuration,,1,,8,,3638,B,H,BAO_0000219,
CHO,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHEMBL619957,15779,10627,,449.0,,,Autocuration,,1,,8,,3639,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,CHEMBL619958,15779,10627,,722.0,,,Autocuration,,1,,8,,3640,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,CHEMBL620627,15779,10627,,722.0,,,Autocuration,,1,,8,,3641,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,CHEMBL620628,15779,10627,,722.0,,,Autocuration,,1,,8,,3642,B,H,BAO_0000219,
HeLa,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,CHEMBL620629,15779,10627,,308.0,,,Autocuration,,1,,8,,3643,B,H,BAO_0000219,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620630,6166,10627,,,,,Autocuration,,1,,8,,3644,B,H,BAO_0000357,
HeLa,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,CHEMBL620782,17451,10627,,308.0,,,Autocuration,,1,,8,,3645,B,H,BAO_0000219,
,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,CHEMBL620783,15316,10627,,,,,Autocuration,,1,,8,,3646,B,H,BAO_0000357,
,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,CHEMBL620784,4199,10627,,,,,Expert,,1,,8,,3647,B,H,BAO_0000357,
HeLa,,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,CHEMBL620785,15146,10627,,308.0,,,Expert,,1,,8,,3648,B,H,BAO_0000219,
,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),CHEMBL857992,5213,10627,,,,,Autocuration,,1,,8,,3649,B,H,BAO_0000357,
,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,CHEMBL620786,16429,10627,,,,,Autocuration,,1,,8,,3650,B,H,BAO_0000219,
HeLa,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,CHEMBL620787,14818,10627,,308.0,,,Autocuration,,1,,8,,3651,B,H,BAO_0000219,
HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",CHEMBL620788,4829,10627,,308.0,,,Autocuration,,1,,8,,3652,B,H,BAO_0000219,
HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",CHEMBL620789,4829,10627,,308.0,,,Autocuration,,1,,8,,3653,B,H,BAO_0000219,
HeLa,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",CHEMBL620790,4829,10627,,308.0,,,Autocuration,,1,,8,,3654,B,H,BAO_0000219,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,CHEMBL620791,15250,10628,,449.0,,,Autocuration,,1,,8,,3655,B,H,BAO_0000219,
,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,CHEMBL620792,14423,10628,,,,,Autocuration,,1,,8,,3656,B,H,BAO_0000019,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,CHEMBL620793,15086,10628,,,,,Autocuration,,1,,8,,3657,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,CHEMBL620794,4342,10628,,,,,Autocuration,,1,,8,,3658,B,H,BAO_0000357,
HeLa,Homo sapiens,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,CHEMBL620795,16190,10627,,308.0,,,Autocuration,,1,,9,9606.0,3659,B,D,BAO_0000219,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620796,4820,10627,,,,,Expert,,1,,8,,3660,B,H,BAO_0000357,
,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,CHEMBL620797,4639,10627,,,,,Autocuration,,1,,8,,3661,B,H,BAO_0000357,
,Homo sapiens,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,CHEMBL620798,17066,10627,,,,,Expert,,1,,9,9606.0,3662,F,D,BAO_0000019,
,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,CHEMBL620799,6011,10627,,,,,Autocuration,,1,,8,,3663,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,CHEMBL620800,17066,10627,,,,,Expert,,1,,8,,3664,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,CHEMBL620801,17515,10627,,,,,Autocuration,,1,,8,,3665,B,H,BAO_0000357,
,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL875100,5014,10627,,,,,Autocuration,,1,,8,,3666,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,CHEMBL620802,4373,10627,,,,,Autocuration,,1,,8,,3667,B,H,BAO_0000357,
,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,CHEMBL620803,17066,10627,,,,,Expert,,1,,8,,3668,F,H,BAO_0000019,
,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,CHEMBL620804,17066,10627,,,,,Expert,,1,,8,,3669,F,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,CHEMBL620805,4373,10627,,,,,Autocuration,,1,,8,,3670,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL620806,4687,10627,,,,,Autocuration,,1,,8,,3671,B,H,BAO_0000357,
,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,CHEMBL620807,16946,10627,,,,,Autocuration,,1,,8,,3672,B,H,BAO_0000357,
,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,CHEMBL620808,16946,10627,,,,,Autocuration,,1,,8,,3673,B,H,BAO_0000357,
,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,CHEMBL620809,16633,10627,,,,,Autocuration,,1,,8,,3674,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,CHEMBL620810,16633,10627,,,,,Autocuration,,1,,8,,3675,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,CHEMBL620811,17066,10627,,,,,Expert,,1,,9,9606.0,3676,B,D,BAO_0000357,
,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,CHEMBL620812,16700,10627,,,,,Autocuration,,1,,8,,3677,B,H,BAO_0000357,
,,,,Affinity against 5-hydroxytryptamine 6 receptor,CHEMBL620813,3269,10627,,,,,Autocuration,,1,,8,,3678,B,H,BAO_0000357,
,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],CHEMBL620814,5486,10627,,,,,Autocuration,,1,,8,,3679,B,H,BAO_0000357,
,Homo sapiens,,,Inhibition of human 5-hydroxytryptamine 7 receptor,CHEMBL620815,16146,10209,,,,,Expert,,1,,9,9606.0,3680,B,D,BAO_0000357,
HEK293,,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,CHEMBL620816,5014,10209,,722.0,,,Autocuration,,1,,8,,3681,B,H,BAO_0000219,
,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,CHEMBL620817,15463,10209,,,,,Autocuration,,1,,8,,3682,B,H,BAO_0000357,
,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),CHEMBL620818,3805,10209,,,,,Autocuration,,1,,8,,3683,B,H,BAO_0000357,
HEK293,,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,CHEMBL620819,5014,10209,,722.0,,,Expert,,1,,8,,3684,B,H,BAO_0000219,
,Homo sapiens,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,CHEMBL620820,6491,10209,,,,,Expert,,1,,9,9606.0,3685,B,D,BAO_0000357,
CHO,,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,CHEMBL620821,16190,10209,,449.0,,,Autocuration,,1,,8,,3686,B,H,BAO_0000219,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL620822,17066,10209,,,,,Expert,,1,,9,9606.0,3687,B,D,BAO_0000357,
,Homo sapiens,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,CHEMBL620823,17066,10209,,,,,Expert,,1,,9,9606.0,3688,B,D,BAO_0000357,
,Homo sapiens,,,Binding affinity against 5-hydroxytryptamine 7 receptor,CHEMBL620824,3555,10209,,,,,Expert,,1,,9,9606.0,3689,B,D,BAO_0000357,
CHO,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,CHEMBL620825,6588,10209,,449.0,,,Expert,,1,,8,,3690,B,H,BAO_0000219,
,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,CHEMBL872930,15463,10209,,,,,Autocuration,,1,,8,,3691,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL620826,6013,10209,,,,,Autocuration,,1,,8,,3692,B,H,BAO_0000357,
,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,CHEMBL620827,16209,10209,,,,,Autocuration,,1,,8,,3693,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,CHEMBL620828,3935,10209,,,,,Autocuration,,1,,8,,3694,B,H,BAO_0000357,
,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL620829,15818,10209,,,,,Autocuration,,1,,8,,3695,B,H,BAO_0000357,
HEK293,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,CHEMBL620830,5014,10209,,722.0,,,Expert,,1,,8,,3696,B,H,BAO_0000219,
,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,CHEMBL620831,16441,10209,,,,,Expert,,1,,8,,3697,B,H,BAO_0000019,
,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,CHEMBL620832,16441,10209,,,,,Expert,,1,,8,,3698,B,H,BAO_0000019,
,Homo sapiens,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,CHEMBL621548,4234,10209,,,,,Expert,,1,,9,9606.0,3699,B,D,BAO_0000357,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,CHEMBL621549,17085,10209,,,,,Autocuration,,1,,8,,3700,B,H,BAO_0000019,
,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,CHEMBL621550,17200,10209,,,,,Autocuration,,1,,8,,3701,B,H,BAO_0000357,
CHO,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,CHEMBL621551,17451,10209,,449.0,,,Autocuration,,1,,8,,3702,B,H,BAO_0000219,
,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,CHEMBL621552,17085,10209,,,,,Autocuration,,1,,8,,3703,B,H,BAO_0000019,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,CHEMBL857077,5104,10209,,,,,Autocuration,,1,,8,,3704,B,H,BAO_0000357,
,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,CHEMBL618158,5104,10209,,,,,Autocuration,,1,,8,,3705,B,H,BAO_0000357,
COS-7,Homo sapiens,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,CHEMBL618159,5033,10209,,643.0,,,Expert,,1,,9,9606.0,3706,B,D,BAO_0000219,
COS-7,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,CHEMBL875101,5486,10209,,643.0,,,Autocuration,,1,,8,,3707,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,CHEMBL618160,4540,10209,,722.0,,,Expert,,1,,9,9606.0,3708,B,D,BAO_0000219,
,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,CHEMBL618161,6166,10209,,,,,Expert,,1,,8,,3709,B,H,BAO_0000357,
HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,CHEMBL618162,17342,10209,,722.0,,,Expert,,1,,8,,3710,B,H,BAO_0000219,
,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,CHEMBL618163,17342,10209,,,,,Expert,,1,,8,,3711,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,CHEMBL618164,17296,10209,,,,,Autocuration,,1,,8,,3712,B,H,BAO_0000357,
,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,CHEMBL618165,16429,10209,,,,,Expert,,1,,8,,3713,B,H,BAO_0000219,
HEK293,,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,CHEMBL618166,15779,10209,,722.0,,,Autocuration,,1,,8,,3714,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL857989,15779,10209,,722.0,,,Autocuration,,1,,8,,3715,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619888,15779,10209,,722.0,,,Autocuration,,1,,8,,3716,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619889,15779,10209,,722.0,,,Autocuration,,1,,8,,3717,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,CHEMBL619890,15779,10209,,722.0,,,Autocuration,,1,,8,,3718,B,H,BAO_0000219,
CHO,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,CHEMBL619891,17451,10209,,449.0,,,Autocuration,,1,,8,,3719,B,H,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),CHEMBL619892,4199,10209,,722.0,,,Autocuration,,1,,8,,3720,B,H,BAO_0000219,
HEK293,,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,CHEMBL619893,4199,10209,,722.0,,,Expert,,1,,9,,3721,B,D,BAO_0000219,
HEK293,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),CHEMBL619894,4199,10209,,722.0,,,Autocuration,,1,,8,,3722,B,H,BAO_0000219,
HEK293,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,CHEMBL619895,3680,10209,,722.0,,,Intermediate,,1,,9,,3723,B,D,BAO_0000219,
,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,CHEMBL619896,3680,10209,,,,,Intermediate,,1,,9,,3724,B,D,BAO_0000357,
COS-7,,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,CHEMBL619897,15316,10209,,643.0,,,Autocuration,,1,,8,,3725,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,CHEMBL619898,15146,10209,,722.0,,,Autocuration,,1,,8,,3726,B,H,BAO_0000219,
HEK293,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,CHEMBL619899,5213,10209,,722.0,,,Expert,,1,,8,,3727,B,H,BAO_0000219,
HEK293,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),CHEMBL619900,5213,10209,,722.0,,,Autocuration,,1,,8,,3728,B,H,BAO_0000219,
HEK293,Homo sapiens,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,CHEMBL619901,14818,10209,,722.0,,,Expert,,1,,9,9606.0,3729,B,D,BAO_0000219,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,CHEMBL620580,14818,10209,,722.0,,,Autocuration,,1,,8,,3730,B,H,BAO_0000219,
HEK293,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,CHEMBL620581,14818,10209,,722.0,,,Autocuration,,1,,8,,3731,B,H,BAO_0000219,
HEK293,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",CHEMBL620733,4829,10209,,722.0,,,Autocuration,,1,,8,,3732,B,H,BAO_0000219,
,Homo sapiens,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,CHEMBL620734,17200,10209,,,,,Autocuration,,1,,9,9606.0,3733,B,D,BAO_0000357,
,Mus musculus,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,CHEMBL620735,17066,10022,,,,,Expert,,1,,9,10090.0,3734,B,D,BAO_0000357,
,Oryctolagus cuniculus,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,CHEMBL620736,14025,10209,,,,,Autocuration,,1,,8,9986.0,3735,B,H,BAO_0000019,
CHO,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,CHEMBL620737,15250,11923,,449.0,,,Autocuration,,1,,8,,3736,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,CHEMBL620738,16372,11923,,449.0,,,Autocuration,,1,,8,,3737,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,CHEMBL620739,16372,11923,,449.0,,,Autocuration,,1,,8,,3738,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,CHEMBL620740,16372,11923,,449.0,,,Autocuration,,1,,8,,3739,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,CHEMBL620741,16372,11923,,449.0,,,Autocuration,,1,,8,,3740,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,CHEMBL620742,16372,11923,,449.0,,,Autocuration,,1,,8,,3741,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,CHEMBL620743,16372,11923,,449.0,,,Autocuration,,1,,8,,3742,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,CHEMBL620744,16372,11923,,449.0,,,Autocuration,,1,,8,,3743,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,CHEMBL620745,16372,11923,,449.0,,,Autocuration,,1,,8,,3744,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,CHEMBL620746,16372,11923,,449.0,,,Autocuration,,1,,8,,3745,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,CHEMBL620747,16372,11923,,449.0,,,Autocuration,,1,,8,,3746,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,CHEMBL620748,16372,11923,,449.0,,,Autocuration,,1,,8,,3747,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,CHEMBL620749,16372,11923,,449.0,,,Autocuration,,1,,8,,3748,B,H,BAO_0000219,
,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,CHEMBL620750,17066,11923,,,,,Expert,,1,,8,,3749,B,H,BAO_0000357,
,Rattus norvegicus,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,CHEMBL620751,17066,11923,,,,,Expert,,1,,9,10116.0,3750,B,D,BAO_0000357,
,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,CHEMBL620752,17386,11923,,,,,Expert,,1,,8,,3751,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,CHEMBL872929,14423,11923,,,,,Autocuration,,1,,8,,3752,B,H,BAO_0000019,
,Rattus norvegicus,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,CHEMBL620753,15874,11923,,,,,Expert,,1,,9,10116.0,3753,B,D,BAO_0000357,
,Rattus norvegicus,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,CHEMBL620754,15874,11923,,,,,Expert,,1,,9,10116.0,3754,B,D,BAO_0000357,
CHO,Rattus norvegicus,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,CHEMBL620755,16372,11923,,449.0,,,Expert,,1,,9,10116.0,3755,B,D,BAO_0000219,
,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,CHEMBL620756,4622,11923,,,,,Autocuration,,1,,8,,3756,B,H,BAO_0000357,
,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,CHEMBL620757,15086,11923,,,,,Autocuration,,1,,8,,3757,B,H,BAO_0000357,
CHO,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",CHEMBL620758,16372,11923,,449.0,,,Autocuration,,1,,8,,3758,B,H,BAO_0000219,
CHO,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",CHEMBL620759,16372,11923,,449.0,,,Autocuration,,1,,8,,3759,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,CHEMBL620760,16372,11923,,449.0,,,Autocuration,,1,,8,,3760,B,H,BAO_0000219,
CHO,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,CHEMBL620761,16372,11923,,449.0,,,Autocuration,,1,,8,,3761,B,H,BAO_0000219,
,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,CHEMBL620762,17386,11923,,,Ileum,2116.0,Autocuration,,1,,8,,3762,F,H,BAO_0000221,
,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,CHEMBL620763,17386,11923,,,Ileum,2116.0,Autocuration,,1,,8,,3763,F,H,BAO_0000221,
,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,CHEMBL620764,17386,11923,,,Ileum,2116.0,Autocuration,,1,,8,,3764,F,H,BAO_0000221,
,Rattus norvegicus,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,CHEMBL857990,5831,11923,Membranes,,,,Expert,,1,,9,10116.0,3765,B,D,BAO_0000249,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,CHEMBL620765,4342,11923,,,,,Autocuration,,1,,8,,3766,B,H,BAO_0000357,
,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,CHEMBL620766,17319,11923,,,,,Expert,,1,,8,,3767,B,H,BAO_0000357,
,,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,CHEMBL620767,17342,11923,,,Hypothalamus,1898.0,Expert,,1,,8,,3768,B,H,BAO_0000019,
,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,CHEMBL620768,17342,11923,,,,,Autocuration,,1,,8,,3769,B,H,BAO_0000357,
,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,CHEMBL619051,3680,11923,,,Hypothalamus,1898.0,Expert,,1,,8,,3770,B,H,BAO_0000249,
,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL619052,3680,11923,,,,,Expert,,1,,8,,3771,B,H,BAO_0000357,
HEK293,Rattus norvegicus,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,CHEMBL619053,17319,11923,,722.0,,,Expert,,1,,9,10116.0,3772,F,D,BAO_0000219,
HEK293,Rattus norvegicus,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,CHEMBL619703,17319,11923,,722.0,,,Expert,,1,,9,10116.0,3773,F,D,BAO_0000219,
HEK293,Rattus norvegicus,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,CHEMBL619704,17319,11923,,722.0,,,Autocuration,,1,,9,10116.0,3774,F,D,BAO_0000219,
,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,CHEMBL619851,4820,10209,,,,,Expert,,1,,8,,3775,B,H,BAO_0000357,
,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,CHEMBL619852,4639,10209,,,,,Autocuration,,1,,8,,3776,B,H,BAO_0000357,
,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,CHEMBL619853,6011,10209,,,,,Autocuration,,1,,8,,3777,B,H,BAO_0000357,
,Homo sapiens,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,CHEMBL619854,17066,10209,,,,,Expert,,1,,9,9606.0,3778,B,D,BAO_0000357,
,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,CHEMBL619855,17066,10209,,,,,Expert,,1,,8,,3779,B,H,BAO_0000357,
,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,CHEMBL619856,17515,10209,,,,,Autocuration,,1,,8,,3780,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619857,4373,10209,,,,,Autocuration,,1,,8,,3781,B,H,BAO_0000357,
,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,CHEMBL619858,17066,10209,,,,,Expert,,1,,8,,3782,F,H,BAO_0000019,
,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619859,4373,10209,,,,,Autocuration,,1,,8,,3783,B,H,BAO_0000357,
,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,CHEMBL619860,4373,10209,,,,,Autocuration,,1,,8,,3784,B,H,BAO_0000357,
,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,CHEMBL619861,4687,10209,,,,,Autocuration,,1,,8,,3785,B,H,BAO_0000357,
,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,CHEMBL619862,17342,10209,,,,,Expert,,1,,8,,3786,B,H,BAO_0000357,
,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,CHEMBL619863,16946,10209,,,,,Autocuration,,1,,8,,3787,B,H,BAO_0000357,
,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,CHEMBL619864,16946,10209,,,,,Autocuration,,1,,8,,3788,B,H,BAO_0000357,
,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,CHEMBL872928,16633,10209,,,,,Autocuration,,1,,8,,3789,B,H,BAO_0000357,
,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,CHEMBL619865,16633,10209,,,,,Autocuration,,1,,8,,3790,B,H,BAO_0000357,
,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,CHEMBL619866,17066,10209,,,,,Expert,,1,,8,,3791,B,H,BAO_0000357,
,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,CHEMBL619867,16700,10209,,,,,Autocuration,,1,,8,,3792,B,H,BAO_0000357,
,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,CHEMBL619868,17386,10209,,,Ileum,2116.0,Autocuration,,1,,8,,3793,B,H,BAO_0000221,
,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,CHEMBL619869,14080,55,,,,,Autocuration,,1,,8,,3794,F,H,BAO_0000019,
,Homo sapiens,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,CHEMBL619870,14080,55,,,,,Expert,,1,,9,9606.0,3795,F,D,BAO_0000019,
,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,CHEMBL619871,409,55,,,,,Autocuration,,1,,8,,3796,B,H,BAO_0000357,
,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,CHEMBL619872,409,55,,,,,Autocuration,,1,,8,,3797,B,H,BAO_0000357,
,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,CHEMBL619873,409,55,,,,,Autocuration,,1,,8,,3798,B,H,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase in human whole blood.,CHEMBL619874,11090,55,,,Blood,178.0,Expert,,1,,8,,3799,B,H,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase in human whole blood.,CHEMBL619875,11090,55,,,Blood,178.0,Expert,,1,,8,,3800,B,H,BAO_0000357,
,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,CHEMBL619876,948,55,,,,,Autocuration,,1,,8,,3801,B,H,BAO_0000357,
,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),CHEMBL619877,948,55,,,,,Autocuration,,1,,8,,3802,B,H,BAO_0000357,
,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,CHEMBL619878,13622,55,,,,,Expert,,1,,8,,3803,F,H,BAO_0000219,
,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,CHEMBL619879,13622,55,,,Blood,178.0,Autocuration,,1,,8,,3804,F,H,BAO_0000019,
,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,CHEMBL619880,9637,55,,,,,Autocuration,,1,,8,,3805,B,H,BAO_0000357,
,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),CHEMBL619881,11320,55,,,,,Autocuration,,1,,8,,3806,B,H,BAO_0000357,
,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,CHEMBL619882,11320,55,,,,,Expert,,1,,8,,3807,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,CHEMBL619883,6838,55,,,,,Autocuration,,1,,8,,3808,B,H,BAO_0000357,
,Homo sapiens,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),CHEMBL619884,17667,55,,,Blood,178.0,Expert,,1,,9,9606.0,3809,B,D,BAO_0000357,
,,,,In vitro potency against human 5-Lipoxygenase,CHEMBL619885,12703,55,,,,,Autocuration,,1,,8,,3810,B,H,BAO_0000357,
,Homo sapiens,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,CHEMBL619886,14312,55,,,,,Expert,,1,,9,9606.0,3811,F,D,BAO_0000019,
,,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,CHEMBL619887,14312,55,,,Blood,178.0,Autocuration,,1,,8,,3812,F,H,BAO_0000019,
,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,CHEMBL875097,5364,55,,,,,Autocuration,,1,,8,,3813,F,H,BAO_0000019,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,CHEMBL618001,951,55,,,,,Autocuration,,1,,8,,3814,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,CHEMBL618002,951,55,,,,,Autocuration,,1,,8,,3815,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,CHEMBL618003,951,55,,,,,Autocuration,,1,,8,,3816,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,CHEMBL618004,951,55,,,,,Autocuration,,1,,8,,3817,B,H,BAO_0000219,
,,,,Inhibition of human 5-lipoxygenase in human cells,CHEMBL618005,12365,55,,,,,Autocuration,,1,,8,,3818,B,H,BAO_0000219,
,,,,Inhibition of human neutrophil 5-lipoxygenase,CHEMBL618006,10603,55,,,,,Expert,,1,,8,,3819,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,CHEMBL875086,10501,55,,,,,Autocuration,,1,,8,,3820,B,H,BAO_0000019,
,,,,Inhibition of 5-lipoxygenase from human whole blood,CHEMBL618007,12281,55,,,Blood,178.0,Expert,,1,,8,,3821,B,H,BAO_0000357,
,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,CHEMBL618008,2567,55,,,,,Autocuration,,1,,8,,3822,B,H,BAO_0000357,
,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,CHEMBL618009,2567,55,,,,,Autocuration,,1,,8,,3823,B,H,BAO_0000219,
,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,CHEMBL618010,10193,55,,,,,Expert,,1,,8,,3824,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL618011,10193,55,,,,,Autocuration,,1,,8,,3825,B,H,BAO_0000357,
,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,CHEMBL618012,13623,55,,,,,Expert,,1,,8,,3826,B,H,BAO_0000357,
,,,,Tested against 5-lipoxygenase,CHEMBL882927,12780,55,,,,,Autocuration,,1,,8,,3827,B,H,BAO_0000357,
,,,,Tested for activity against 5-Lipoxygenase (5-LO),CHEMBL618013,12780,55,,,,,Autocuration,,1,,8,,3828,B,H,BAO_0000357,
,,,,Tested for activity against 5-lipoxygenase,CHEMBL618014,12780,55,,,,,Autocuration,,1,,8,,3829,B,H,BAO_0000357,
,,,,Tested for inhibition of 5-HPETE production by human 5-LO,CHEMBL618015,11966,55,,,,,Autocuration,,1,,8,,3830,B,H,BAO_0000357,
,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,CHEMBL618016,5364,55,,,,,Autocuration,,1,,8,,3831,F,H,BAO_0000019,
,,,,Inhibition of Human 5-lipoxygenase,CHEMBL618017,13165,55,,,,,Expert,,1,,8,,3832,B,H,BAO_0000357,
,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,CHEMBL618018,5364,55,,,,,Autocuration,,1,,8,,3833,B,H,BAO_0000019,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],CHEMBL875087,11311,55,,,,,Autocuration,,1,,8,,3834,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],CHEMBL618019,11311,55,,,,,Autocuration,,1,,8,,3835,B,H,BAO_0000219,
,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,CHEMBL618020,14863,55,,,,,Autocuration,,1,,8,,3836,B,H,BAO_0000019,
,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,CHEMBL618021,14863,55,,,,,Autocuration,,1,,8,,3837,B,H,BAO_0000019,
,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),CHEMBL618022,11087,55,,,Blood,178.0,Autocuration,,1,,8,,3838,B,H,BAO_0000357,
,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,CHEMBL618023,455,55,,,,,Autocuration,,1,,8,,3839,B,H,BAO_0000357,
,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL618024,13183,55,,,,,Autocuration,,1,,8,,3840,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,CHEMBL873950,10319,55,,,,,Expert,,1,,8,,3841,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL618025,10193,55,,,,,Autocuration,,1,,8,,3842,B,H,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,CHEMBL618026,951,55,,,,,Autocuration,,1,,8,,3843,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,CHEMBL618027,951,55,,,,,Autocuration,,1,,8,,3844,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,CHEMBL618028,951,55,,,,,Autocuration,,1,,8,,3845,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,CHEMBL618029,951,55,,,,,Autocuration,,1,,8,,3846,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,CHEMBL618030,9859,55,,,,,Expert,,1,,8,,3847,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,CHEMBL618031,9859,55,,,,,Expert,,1,,8,,3848,B,H,BAO_0000357,
,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,CHEMBL618032,9859,55,,,,,Autocuration,,1,,8,,3849,B,H,BAO_0000357,
,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,CHEMBL618033,2567,55,,,,,Autocuration,,1,,8,,3850,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,CHEMBL618034,10193,55,,,,,Autocuration,,1,,8,,3851,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,CHEMBL875088,10193,55,,,,,Autocuration,,1,,8,,3852,B,H,BAO_0000357,
,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,CHEMBL618035,949,55,,,,,Autocuration,,1,,8,,3853,B,H,BAO_0000019,
,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,CHEMBL618036,949,55,,,,,Autocuration,,1,,8,,3854,B,H,BAO_0000019,
,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,CHEMBL618037,10603,55,,,,,Expert,,1,,8,,3855,B,H,BAO_0000357,
,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,CHEMBL618038,10603,55,,,,,Expert,,1,,8,,3856,B,H,BAO_0000357,
,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,CHEMBL618761,10603,55,,,,,Autocuration,,1,,8,,3857,F,H,BAO_0000019,
,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,CHEMBL618762,10603,55,,,,,Expert,,1,,8,,3858,B,H,BAO_0000357,
,,,,Inhibition of lipoxygenase at the concentration of 1 uM,CHEMBL618763,10603,55,,,,,Expert,,1,,8,,3859,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,CHEMBL618764,10193,55,,,,,Autocuration,,1,,8,,3860,B,H,BAO_0000357,
,Homo sapiens,,,Inhibition of 5-Lipoxygenase (5-LOX),CHEMBL618765,14580,55,,,,,Expert,,1,,9,9606.0,3861,B,D,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,CHEMBL618766,11090,17087,,,,,Expert,,1,,8,,3862,B,H,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,CHEMBL618767,11090,17087,,,,,Expert,,1,,8,,3863,B,H,BAO_0000357,
,,,,Inhibitory activity against lipoxygenase-2 in mice,CHEMBL619380,6339,17087,,,,,Autocuration,,1,,8,,3864,B,H,BAO_0000357,
,,,,Inhibitory activity against murine lipoxygenase-2.,CHEMBL619381,6339,17087,,,,,Expert,,1,,8,,3865,B,H,BAO_0000357,
,Mus musculus,,,Inhibition of 5-lipoxygenase from mouse macrophage,CHEMBL619382,12281,17087,,,,,Expert,,1,,9,10090.0,3866,B,D,BAO_0000357,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,CHEMBL619383,11311,17087,,,,,Autocuration,,1,,8,,3867,B,H,BAO_0000357,
,Sus scrofa,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,CHEMBL619384,11089,55,,,,,Autocuration,,1,,8,9823.0,3868,B,H,BAO_0000019,
,Sus scrofa,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,CHEMBL619385,10091,55,,,,,Autocuration,,1,,8,9823.0,3869,B,H,BAO_0000019,
,Oryctolagus cuniculus,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,CHEMBL882928,14352,55,,,,,Autocuration,,1,,8,9986.0,3870,B,H,BAO_0000019,
,Rattus norvegicus,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,CHEMBL619386,13329,12166,,,,,Expert,,1,,9,10116.0,3871,B,D,BAO_0000019,
,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",CHEMBL619387,13329,12166,,,,,Autocuration,,1,,8,,3872,B,H,BAO_0000019,
,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",CHEMBL619388,13329,12166,,,,,Autocuration,,1,,8,,3873,B,H,BAO_0000019,
,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",CHEMBL619389,13329,12166,,,,,Autocuration,,1,,8,,3874,B,H,BAO_0000019,
,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),CHEMBL619390,13329,12166,,,,,Expert,,1,,8,,3875,B,H,BAO_0000019,
,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",CHEMBL619391,13329,12166,,,,,Expert,,1,,8,,3876,B,H,BAO_0000019,
,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,CHEMBL619392,13329,12166,,,,,Autocuration,,1,,8,,3877,B,H,BAO_0000019,
,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),CHEMBL619393,11311,12166,,,,,Autocuration,,1,,8,,3878,B,H,BAO_0000019,
,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,CHEMBL619394,11311,12166,,,,,Autocuration,,1,,8,,3879,B,H,BAO_0000019,
RBL-1,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",CHEMBL619395,105,12166,,702.0,,,Autocuration,,1,,8,,3880,B,H,BAO_0000219,
RBL-1,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",CHEMBL619396,105,12166,,702.0,,,Autocuration,,1,,8,,3881,B,H,BAO_0000219,
,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),CHEMBL619397,9138,12166,,,,,Autocuration,,1,,8,,3882,B,H,BAO_0000357,
,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",CHEMBL619398,9138,12166,,,,,Autocuration,,1,,8,,3883,B,H,BAO_0000357,
,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",CHEMBL619399,9138,12166,,,,,Autocuration,,1,,8,,3884,B,H,BAO_0000357,
,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,CHEMBL619400,14427,12166,,,,,Autocuration,,1,,8,,3885,B,H,BAO_0000357,
,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",CHEMBL619401,13329,12166,,,,,Autocuration,,1,,8,,3886,B,H,BAO_0000019,
,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",CHEMBL619402,13329,12166,,,,,Autocuration,,1,,8,,3887,B,H,BAO_0000019,
RBL-2H3,Rattus norvegicus,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,CHEMBL619403,14427,12166,,663.0,,,Expert,,1,,9,10116.0,3888,B,D,BAO_0000219,
,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,CHEMBL619404,14427,12166,,,,,Autocuration,,1,,8,,3889,B,H,BAO_0000357,
,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,CHEMBL619405,14427,12166,,,,,Autocuration,,1,,8,,3890,B,H,BAO_0000357,
RBL-1,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,CHEMBL619406,10293,12166,,702.0,,,Expert,,1,,8,,3891,B,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,CHEMBL619407,338,12166,,702.0,,,Expert,,1,,9,10116.0,3892,B,D,BAO_0000219,
,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),CHEMBL619408,303,12166,,,,,Autocuration,,1,,8,,3893,B,H,BAO_0000357,
RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,CHEMBL619409,303,12166,,702.0,,,Autocuration,,1,,8,,3894,B,H,BAO_0000219,
RBL-1,,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,CHEMBL619410,9247,12166,,702.0,,,Expert,,1,,8,,3895,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,CHEMBL619753,9247,12166,,702.0,,,Autocuration,,1,,8,,3896,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,CHEMBL619754,137,12166,,702.0,,,Autocuration,,1,,8,,3897,B,H,BAO_0000219,
,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,CHEMBL619903,11481,12166,,,,,Expert,,1,,8,,3898,B,H,BAO_0000357,
,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",CHEMBL619904,11481,12166,,,,,Expert,,1,,8,,3899,B,H,BAO_0000357,
,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,CHEMBL619905,9029,12166,,,,,Expert,,1,,8,,3900,B,H,BAO_0000357,
,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,CHEMBL619906,1701,12166,,,,,Autocuration,,1,,8,,3901,B,H,BAO_0000019,
,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,CHEMBL619907,1701,12166,,,,,Autocuration,,1,,8,,3902,B,H,BAO_0000019,
,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,CHEMBL619908,1701,12166,,,,,Autocuration,,1,,8,,3903,B,H,BAO_0000019,
,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,CHEMBL619909,1701,12166,,,,,Autocuration,,1,,8,,3904,B,H,BAO_0000019,
RBL-1,,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,CHEMBL619910,13358,12166,,702.0,,,Expert,,1,,8,,3905,F,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,CHEMBL882929,1175,12166,,702.0,,,Expert,,1,,8,,3906,B,H,BAO_0000219,
RBL-1,,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,CHEMBL619911,8797,12166,,702.0,,,Expert,,1,,8,,3907,B,H,BAO_0000219,
,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,CHEMBL619912,8797,12166,,,,,Autocuration,,1,,8,,3908,B,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,CHEMBL619913,577,12166,,,,,Expert,,1,,9,10116.0,3909,B,D,BAO_0000357,
RBL-1,,,,In vitro inhibitory activity against RBL-1 5-LO,CHEMBL619914,9295,12166,,702.0,,,Expert,,1,,8,,3910,B,H,BAO_0000219,
RBL-1,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),CHEMBL619915,9295,12166,,702.0,,,Autocuration,,1,,8,,3911,B,H,BAO_0000219,
RBL-1,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),CHEMBL619916,9295,12166,,702.0,,,Autocuration,,1,,8,,3912,B,H,BAO_0000219,
,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,CHEMBL619917,9295,12166,,,,,Autocuration,,1,,8,,3913,B,H,BAO_0000218,
,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,CHEMBL619918,9295,12166,,,,,Autocuration,,1,,8,,3914,B,H,BAO_0000357,
,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,CHEMBL619919,216,12166,,,,,Autocuration,,1,,8,,3915,B,H,BAO_0000218,
RBL-1,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,CHEMBL883710,11090,12166,,702.0,,,Autocuration,,1,,8,,3916,B,H,BAO_0000219,
,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,CHEMBL619920,11090,12166,,,Blood,178.0,Autocuration,,1,,8,,3917,B,H,BAO_0000019,
,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,CHEMBL619921,10091,12166,,,,,Expert,,1,,8,,3918,B,H,BAO_0000357,
,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,CHEMBL619922,10274,12166,,,,,Autocuration,,1,,8,,3919,F,H,BAO_0000019,
,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,CHEMBL619923,13622,12166,,,,,Autocuration,,1,,8,,3920,F,H,BAO_0000219,
RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,CHEMBL619924,12118,12166,,702.0,,,Expert,,1,,8,,3921,B,H,BAO_0000219,
,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,CHEMBL619925,12576,12166,,,,,Expert,,1,,8,,3922,B,H,BAO_0000357,
RBL-1,,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,CHEMBL619926,9546,12166,,702.0,,,Expert,,1,,8,,3923,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,CHEMBL619927,9521,12166,,702.0,,,Autocuration,,1,,8,,3924,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,CHEMBL619928,10626,12166,,702.0,,,Expert,,1,,8,,3925,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase,CHEMBL619929,9225,12166,,702.0,,,Autocuration,,1,,8,,3926,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,CHEMBL875089,9225,12166,,702.0,,,Autocuration,,1,,8,,3927,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,CHEMBL619930,9225,12166,,702.0,,,Autocuration,,1,,8,,3928,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,CHEMBL619931,9225,12166,,702.0,,,Autocuration,,1,,8,,3929,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,CHEMBL619932,9225,12166,,702.0,,,Autocuration,,1,,8,,3930,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,CHEMBL619933,9225,12166,,702.0,,,Autocuration,,1,,8,,3931,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,CHEMBL619934,9225,12166,,702.0,,,Autocuration,,1,,8,,3932,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,CHEMBL619935,9225,12166,,702.0,,,Autocuration,,1,,8,,3933,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,CHEMBL619936,9225,12166,,702.0,,,Autocuration,,1,,8,,3934,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,CHEMBL619937,9225,12166,,702.0,,,Autocuration,,1,,8,,3935,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,CHEMBL619938,9225,12166,,702.0,,,Autocuration,,1,,8,,3936,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,CHEMBL619939,9225,12166,,702.0,,,Autocuration,,1,,8,,3937,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,CHEMBL619940,9225,12166,,702.0,,,Autocuration,,1,,8,,3938,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,CHEMBL875090,9225,12166,,702.0,,,Autocuration,,1,,8,,3939,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,CHEMBL619941,9225,12166,,702.0,,,Autocuration,,1,,8,,3940,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,CHEMBL619942,9225,12166,,702.0,,,Autocuration,,1,,8,,3941,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,CHEMBL883711,9225,12166,,702.0,,,Autocuration,,1,,8,,3942,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,CHEMBL619943,9225,12166,,702.0,,,Autocuration,,1,,8,,3943,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,CHEMBL619944,9225,12166,,702.0,,,Autocuration,,1,,8,,3944,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,CHEMBL619945,9225,12166,,702.0,,,Autocuration,,1,,8,,3945,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,CHEMBL619946,9225,12166,,702.0,,,Autocuration,,1,,8,,3946,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,CHEMBL619947,9225,12166,,702.0,,,Autocuration,,1,,8,,3947,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,CHEMBL619948,9225,12166,,702.0,,,Autocuration,,1,,8,,3948,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,CHEMBL619949,9225,12166,,702.0,,,Autocuration,,1,,8,,3949,B,H,BAO_0000219,
,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,CHEMBL619950,9401,12166,,,,,Expert,,1,,8,,3950,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,CHEMBL618050,10325,12166,,,,,Autocuration,,1,,8,,3951,B,H,BAO_0000019,
RBL-2H3,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,CHEMBL875091,1556,12166,,663.0,,,Expert,,1,,8,,3952,F,H,BAO_0000219,
RBL-2H3,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,CHEMBL618051,1556,12166,,663.0,,,Expert,,1,,8,,3953,F,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,CHEMBL618052,961,12166,,702.0,,,Expert,,1,,9,10116.0,3954,B,D,BAO_0000219,
,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,CHEMBL618053,6838,12166,,,,,Autocuration,,1,,8,,3955,B,H,BAO_0000019,
,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),CHEMBL618054,10325,12166,,,,,Expert,,1,,8,,3956,B,H,BAO_0000019,
RBL-1,Rattus norvegicus,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,CHEMBL618055,9209,12166,,702.0,,,Expert,,1,,9,10116.0,3957,B,D,BAO_0000219,
RBL-1,,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,CHEMBL618056,11520,12166,,702.0,,,Expert,,1,,8,,3958,B,H,BAO_0000219,
,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,CHEMBL618057,137,12166,,,,,Autocuration,,1,,8,,3959,B,H,BAO_0000357,
RBL-1,,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,CHEMBL618058,4717,12166,,702.0,,,Autocuration,,1,,8,,3960,B,H,BAO_0000219,
RBL-1,,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,CHEMBL618059,10636,12166,,702.0,,,Expert,,1,,8,,3961,B,H,BAO_0000219,
,Rattus norvegicus,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,CHEMBL618060,14312,12166,,,,,Expert,,1,,9,10116.0,3962,F,D,BAO_0000019,
RBL-1,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,CHEMBL618061,1203,12166,,702.0,,,Autocuration,,1,,8,,3963,B,H,BAO_0000219,
,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,CHEMBL618062,1203,12166,,,,,Autocuration,,1,,8,,3964,B,H,BAO_0000019,
RBL-1,,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,CHEMBL618063,13622,12166,,702.0,,,Expert,,1,,8,,3965,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,CHEMBL618064,9793,12166,,,,,Autocuration,,1,,8,,3966,B,H,BAO_0000357,
RBL-1,Rattus norvegicus,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,CHEMBL618065,1143,12166,,702.0,,,Expert,,1,,9,10116.0,3967,B,D,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,CHEMBL618066,11854,12166,,702.0,,,Expert,,1,,9,10116.0,3968,B,D,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL618067,3595,12166,,702.0,,,Autocuration,,1,,8,,3969,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),CHEMBL618068,3595,12166,,702.0,,,Autocuration,,1,,8,,3970,B,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,CHEMBL618069,10501,12166,,702.0,,,Expert,,1,,9,10116.0,3971,B,D,BAO_0000219,
RBL-1,,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL618070,12526,12166,,702.0,,,Expert,,1,,8,,3972,B,H,BAO_0000219,
,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,CHEMBL618071,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3973,F,H,BAO_0000019,
,,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,CHEMBL619247,10034,10825,,,Limbic system,349.0,Autocuration,,1,,8,,3974,F,H,BAO_0000019,
,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,CHEMBL619248,10034,10825,,,,,Autocuration,,1,,8,,3975,F,H,BAO_0000019,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL619249,10046,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,3976,B,H,BAO_0000221,
,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,CHEMBL619250,10046,10576,,,Hippocampus,10000000.0,Autocuration,,1,,8,,3977,B,H,BAO_0000221,
,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,CHEMBL619251,10046,10577,,,,,Autocuration,,1,,8,,3978,B,H,BAO_0000019,
,Canis lupus familiaris,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,CHEMBL619252,12079,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3979,F,H,BAO_0000019,
,,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,CHEMBL619253,12079,55,,,Blood,178.0,Autocuration,,1,,8,,3980,F,H,BAO_0000019,
,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],CHEMBL619254,11311,12166,,,,,Autocuration,,1,,8,,3981,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,CHEMBL619255,12338,17140,,,,,Expert,,1,,8,,3982,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,CHEMBL619256,12143,17140,,,,,Expert,,1,,8,,3983,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),CHEMBL875418,12143,17140,,,,,Autocuration,,1,,8,,3984,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,CHEMBL619257,12143,17140,,,,,Expert,,1,,8,,3985,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,CHEMBL619258,12143,17140,,,,,Autocuration,,1,,8,,3986,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,CHEMBL619259,12365,17140,,,,,Expert,,1,,8,,3987,B,H,BAO_0000357,
,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,CHEMBL619260,13500,17140,,,,,Expert,,1,,8,,3988,B,H,BAO_0000357,
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619261,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3989,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619263,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3990,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619264,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3991,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619265,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3992,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619266,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3993,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619902,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3994,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620058,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3995,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620059,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3996,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620060,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3997,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620061,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3998,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620062,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,3999,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620063,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4000,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620064,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4001,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620065,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4002,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620066,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4003,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620067,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4004,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620068,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4005,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620069,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4006,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620070,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4007,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620071,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4008,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620072,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4009,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620036,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4010,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL857702,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4011,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620037,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4012,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620038,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4013,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620039,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4014,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620040,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4015,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620041,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4016,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620042,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4017,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620043,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4018,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620044,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4019,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL620045,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4020,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620046,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4021,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620047,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4022,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",CHEMBL620048,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4023,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL857703,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4024,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",CHEMBL620049,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4025,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620050,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4026,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620051,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4027,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619213,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4028,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619214,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4029,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619804,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4030,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",CHEMBL619805,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4031,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619806,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4032,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619807,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4033,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL619808,12832,55,,,Blood,178.0,Autocuration,,1,,8,9615.0,4034,F,H,BAO_0000218,In vivo
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,CHEMBL619809,3595,55,,,,,Autocuration,,1,,8,9615.0,4035,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,CHEMBL619810,3595,55,,,,,Autocuration,,1,,8,9615.0,4036,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,CHEMBL619811,3595,55,,,,,Autocuration,,1,,8,9615.0,4037,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,CHEMBL620769,3595,55,,,,,Autocuration,,1,,8,9615.0,4038,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,CHEMBL620770,3595,55,,,,,Autocuration,,1,,8,9615.0,4039,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,CHEMBL620771,3595,55,,,,,Autocuration,,1,,8,9615.0,4040,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,CHEMBL620772,3595,55,,,,,Autocuration,,1,,8,9615.0,4041,B,H,BAO_0000218,
,Canis lupus familiaris,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,CHEMBL620773,3595,55,,,,,Autocuration,,1,,8,9615.0,4042,B,H,BAO_0000218,
,Cavia porcellus,,,Ability to inhibit 5-lipoxygenase in guinea pig,CHEMBL620774,9203,55,,,,,Autocuration,,1,,8,10141.0,4043,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),CHEMBL620775,82,55,,,,,Expert,,1,,8,10141.0,4044,B,H,BAO_0000357,
,Cavia porcellus,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,CHEMBL620776,11090,55,,,,,Autocuration,,1,,8,10141.0,4045,B,H,BAO_0000357,
,Cavia porcellus,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",CHEMBL620777,12832,55,,,Blood,178.0,Autocuration,,1,,8,10141.0,4046,B,H,BAO_0000218,
,Cavia porcellus,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,CHEMBL620778,1065,55,,,,,Autocuration,,1,,8,10141.0,4047,B,H,BAO_0000357,
,Cavia porcellus,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,CHEMBL620779,1065,55,,,,,Autocuration,,1,,8,10141.0,4048,B,H,BAO_0000357,
,Cavia porcellus,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL621500,12832,55,,,,,Expert,,1,,8,10141.0,4049,B,H,BAO_0000019,
,Cavia porcellus,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL621501,12832,55,,,,,Expert,,1,,8,10141.0,4050,B,H,BAO_0000019,
,Cavia porcellus,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,CHEMBL618098,12832,55,,,,,Autocuration,,1,,8,10141.0,4051,B,H,BAO_0000019,
,Cavia porcellus,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,CHEMBL618099,10504,55,,,,,Autocuration,,1,,8,10141.0,4052,B,H,BAO_0000019,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase,CHEMBL618100,7788,55,,,,,Autocuration,,1,,8,10141.0,4053,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,CHEMBL618101,10001,55,,,,,Autocuration,,1,,8,10141.0,4054,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,CHEMBL618102,10193,55,,,,,Autocuration,,1,,8,10141.0,4055,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,CHEMBL618103,13243,55,,,,,Autocuration,,1,,8,10141.0,4056,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity uM,CHEMBL618104,13243,55,,,,,Autocuration,,1,,8,10141.0,4057,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,CHEMBL883712,969,55,,,,,Autocuration,,1,,8,10141.0,4058,B,H,BAO_0000219,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase at 10 uM,CHEMBL618105,10001,55,,,,,Autocuration,,1,,8,10141.0,4059,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,CHEMBL618106,7788,55,,,,,Autocuration,,1,,8,10141.0,4060,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,CHEMBL618107,10001,55,,,,,Autocuration,,1,,8,10141.0,4061,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,CHEMBL618108,10193,55,,,,,Autocuration,,1,,8,10141.0,4062,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity uM,CHEMBL618109,13243,55,,,,,Autocuration,,1,,8,10141.0,4063,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,CHEMBL618110,13243,55,,,,,Autocuration,,1,,8,10141.0,4064,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity uM,CHEMBL618111,13243,55,,,,,Expert,,1,,8,10141.0,4065,B,H,BAO_0000357,
,Cavia porcellus,,,Inhibitory activity uM,CHEMBL618112,13243,55,,,,,Autocuration,,1,,8,10141.0,4066,F,H,BAO_0000019,
,Cavia porcellus,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,CHEMBL618113,10504,55,,,,,Autocuration,,1,,8,10141.0,4067,B,H,BAO_0000019,
,Cavia porcellus,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,CHEMBL618114,7788,55,,,,,Autocuration,,1,,8,10141.0,4068,B,H,BAO_0000357,
,Cavia porcellus,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,CHEMBL620871,10546,55,,,Ileum,2116.0,Expert,,1,,8,10141.0,4069,F,H,BAO_0000221,
,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL620872,13183,55,,,,,Autocuration,,1,,8,,4070,B,H,BAO_0000357,
,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),CHEMBL620873,13183,55,,,,,Autocuration,,1,,8,,4071,B,H,BAO_0000357,
,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),CHEMBL620874,2578,55,,,,,Autocuration,,1,,8,,4072,B,H,BAO_0000357,
,,,,In vitro inhibition of human 5-Lipoxygenase.,CHEMBL620875,12780,55,,,,,Expert,,1,,8,,4073,B,H,BAO_0000357,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,CHEMBL620876,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4074,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,CHEMBL620877,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4075,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,CHEMBL857854,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4076,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,CHEMBL620878,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4077,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,CHEMBL620879,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4078,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL620880,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4079,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL620881,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4080,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,CHEMBL620882,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4081,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,CHEMBL620883,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4082,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,CHEMBL620884,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4083,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,CHEMBL620885,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4084,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,CHEMBL620886,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4085,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,CHEMBL620887,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4086,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL618039,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4087,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,CHEMBL618040,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4088,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL618041,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4089,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL618216,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4090,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL618217,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4091,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,CHEMBL618218,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4092,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,CHEMBL618219,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4093,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,CHEMBL618220,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4094,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,CHEMBL618221,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4095,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,CHEMBL618222,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4096,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,CHEMBL618223,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4097,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,CHEMBL618224,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4098,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,CHEMBL618225,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4099,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,CHEMBL618226,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4100,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL618227,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4101,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,CHEMBL618228,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4102,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,CHEMBL618229,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4103,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,CHEMBL618230,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4104,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,CHEMBL618231,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4105,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,CHEMBL618232,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4106,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,CHEMBL618233,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4107,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,CHEMBL618234,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4108,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,CHEMBL618235,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4109,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,CHEMBL618115,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4110,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,CHEMBL618116,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4111,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,CHEMBL618117,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4112,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,CHEMBL619968,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4113,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL619969,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4114,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,CHEMBL619970,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4115,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,CHEMBL619971,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4116,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,CHEMBL619972,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4117,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,CHEMBL619973,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4118,B,U,BAO_0000251,
,Rattus norvegicus,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,CHEMBL619974,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4119,B,U,BAO_0000251,
,Rattus norvegicus,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,CHEMBL619975,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4120,B,U,BAO_0000251,
,Rattus norvegicus,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,CHEMBL619976,7411,22226,Microsomes,,,,Autocuration,,1,,0,10116.0,4121,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL619977,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4122,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL619978,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4123,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",CHEMBL619979,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4124,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",CHEMBL619980,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4125,B,U,BAO_0000251,
,Rattus norvegicus,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",CHEMBL619981,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4126,B,U,BAO_0000251,
RPMI-8226,Homo sapiens,,,In vitro inhibition of 7226/S myeloma cancer cell line,CHEMBL619982,10797,80433,,741.0,,,Intermediate,,1,,1,9606.0,4127,F,N,BAO_0000219,
BEL-7404 tumor cell line,Homo sapiens,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),CHEMBL619983,6881,80698,,993.0,,,Intermediate,,1,,1,9606.0,4128,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,CHEMBL620031,3838,80640,,391.0,,,Intermediate,,1,,1,9606.0,4129,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,CHEMBL620032,3838,80640,,391.0,,,Intermediate,,1,,1,9606.0,4130,F,N,BAO_0000219,
V79,Cricetulus griseus,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,CHEMBL620033,12981,81264,,505.0,,,Expert,,1,,1,10029.0,4131,F,N,BAO_0000219,
V79,Cricetulus griseus,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,CHEMBL620034,12981,81264,,505.0,,,Expert,,1,,1,10029.0,4132,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,CHEMBL620035,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4133,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,CHEMBL618318,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4134,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,CHEMBL618319,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4135,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,CHEMBL618320,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4136,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,CHEMBL618321,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4137,F,N,BAO_0000219,
7800C1 cell line,Rattus norvegicus,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,CHEMBL883118,7653,80635,,1119.0,,,Intermediate,,1,,1,10116.0,4138,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro antitumor activity against renal 786-0 tumor cell lines,CHEMBL883795,17229,80640,,391.0,,,Intermediate,,1,,1,9606.0,4139,F,N,BAO_0000219,
786-0,Homo sapiens,,,Cytotoxic activity against 786-0 Renal cancer cell line,CHEMBL618322,12858,80640,,391.0,,,Intermediate,,1,,1,9606.0,4140,F,N,BAO_0000219,
786-0,Homo sapiens,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,CHEMBL618323,16325,80640,,391.0,,,Intermediate,,1,,1,9606.0,4141,F,N,BAO_0000219,
786-0,Homo sapiens,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,CHEMBL618324,16325,80640,,391.0,,,Intermediate,,1,,1,9606.0,4142,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro antitumor activity against human renal 786-0 cell line,CHEMBL618325,5858,80640,,391.0,,,Intermediate,,1,,1,9606.0,4143,F,N,BAO_0000219,
786-0,Homo sapiens,,,Inhibition of Renal cancer in 786-0 cancer cell lines,CHEMBL875416,16325,80640,,391.0,,,Intermediate,,1,,1,9606.0,4144,F,N,BAO_0000219,
786-0,Homo sapiens,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,CHEMBL618326,14696,80640,,391.0,,,Intermediate,,1,,1,9606.0,4145,F,N,BAO_0000219,
786-0,Homo sapiens,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,CHEMBL618327,3786,80640,,391.0,,,Intermediate,,1,,1,9606.0,4146,F,N,BAO_0000219,
786-0,Homo sapiens,,,inhibition of the growth of renal cancer(786-0) cell line,CHEMBL619215,14696,80640,,391.0,,,Intermediate,,1,,1,9606.0,4147,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),CHEMBL619216,14769,80640,,391.0,,,Intermediate,,1,,1,9606.0,4148,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,CHEMBL619217,15354,80640,,391.0,,,Intermediate,,1,,1,9606.0,4149,F,N,BAO_0000219,
786-0,Homo sapiens,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,CHEMBL619218,14255,80640,,391.0,,,Intermediate,,1,,1,9606.0,4150,F,N,BAO_0000219,
786-0,Homo sapiens,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,CHEMBL619219,14255,80640,,391.0,,,Intermediate,,1,,1,9606.0,4151,F,N,BAO_0000219,
786-0,Homo sapiens,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,CHEMBL619220,14255,80640,,391.0,,,Intermediate,,1,,1,9606.0,4152,F,N,BAO_0000219,
786-0,Homo sapiens,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,CHEMBL619221,14696,80640,,391.0,,,Intermediate,,1,,1,9606.0,4153,F,N,BAO_0000219,
786-0,Homo sapiens,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,CHEMBL619222,12016,80640,,391.0,,,Intermediate,,1,,1,9606.0,4154,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was tested for growth inhibitory activity against 786-0 cell line,CHEMBL857454,2597,80640,,391.0,,,Intermediate,,1,,1,9606.0,4155,F,N,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,CHEMBL619223,12526,12166,,702.0,,,Autocuration,,1,,8,,4156,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,CHEMBL619224,12526,12166,,702.0,,,Autocuration,,1,,8,,4157,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,CHEMBL619225,14799,12166,,,,,Autocuration,,1,,8,,4158,B,H,BAO_0000019,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),CHEMBL619226,3595,12166,,702.0,,,Expert,,1,,8,,4159,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),CHEMBL619227,3595,12166,,702.0,,,Expert,,1,,8,,4160,B,H,BAO_0000219,
,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,CHEMBL619228,12767,12166,,,,,Autocuration,,1,,8,,4161,B,H,BAO_0000357,
,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,CHEMBL619229,10997,12166,,,,,Autocuration,,1,,8,,4162,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,CHEMBL619230,11388,12166,,702.0,,,Autocuration,,1,,8,,4163,B,H,BAO_0000219,
,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,CHEMBL619231,167,12166,,,,,Autocuration,,1,,8,,4164,B,H,BAO_0000357,
,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",CHEMBL619232,167,12166,,,,,Autocuration,,1,,8,,4165,B,H,BAO_0000357,
,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,CHEMBL619233,13744,12166,,,,,Expert,,1,,8,,4166,B,H,BAO_0000357,
,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,CHEMBL619234,1630,12166,,,,,Autocuration,,1,,8,,4167,B,H,BAO_0000357,
,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),CHEMBL619235,1630,12166,,,,,Autocuration,,1,,8,,4168,B,H,BAO_0000357,
,Rattus norvegicus,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",CHEMBL619236,969,12166,,,,,Expert,,1,,9,10116.0,4169,B,D,BAO_0000019,
RBL-1,,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,CHEMBL619237,13621,12166,,702.0,,,Autocuration,,1,,8,,4170,B,H,BAO_0000219,
,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,CHEMBL619238,10089,12166,,,,,Autocuration,,1,,8,,4171,B,H,BAO_0000357,
,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,CHEMBL619239,10193,12166,,,,,Expert,,1,,8,,4172,B,H,BAO_0000357,
,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,CHEMBL619240,11966,12166,,,,,Autocuration,,1,,8,,4173,B,H,BAO_0000357,
,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,CHEMBL875417,12251,12166,,,,,Autocuration,,1,,8,,4174,B,H,BAO_0000019,
RBL-1,,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),CHEMBL619241,211,12166,,702.0,,,Autocuration,,1,,8,,4175,B,H,BAO_0000219,
,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,CHEMBL619242,12251,12166,,,,,Expert,,1,,8,,4176,F,H,BAO_0000019,
RBL-1,,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,CHEMBL883796,12495,12166,,702.0,,,Autocuration,,1,,8,,4177,B,H,BAO_0000219,
,,,,Tested for its inhibitory activity against 5-lipoxygenase,CHEMBL619243,414,12166,,,,,Autocuration,,1,,8,,4178,B,H,BAO_0000357,
,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,CHEMBL619244,414,12166,,,,,Autocuration,,1,,8,,4179,B,H,BAO_0000357,
,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",CHEMBL619245,10325,12166,,,,,Expert,,1,,8,,4180,B,H,BAO_0000019,
,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,CHEMBL619246,11966,12166,,,,,Expert,,1,,8,,4181,B,H,BAO_0000019,
RBL-1,,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619984,165,12166,,702.0,,,Expert,,1,,8,,4182,B,H,BAO_0000219,
RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,CHEMBL619985,165,12166,,702.0,,,Autocuration,,1,,8,,4183,B,H,BAO_0000219,
RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619986,165,12166,,702.0,,,Autocuration,,1,,8,,4184,B,H,BAO_0000219,
RBL-1,,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,CHEMBL619987,165,12166,,702.0,,,Expert,,1,,8,,4185,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,CHEMBL619988,11311,12166,,,,,Autocuration,,1,,8,,4186,B,H,BAO_0000218,
RBL-1,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,CHEMBL619989,11311,12166,,702.0,,,Autocuration,,1,,8,,4187,B,H,BAO_0000219,
RBL-1,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,CHEMBL619990,11311,12166,,702.0,,,Autocuration,,1,,8,,4188,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],CHEMBL619991,11311,12166,,,,,Autocuration,,1,,8,,4189,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),CHEMBL619992,11311,12166,,,,,Autocuration,,1,,8,,4190,B,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),CHEMBL619993,11311,12166,,,,,Autocuration,,1,,8,,4191,B,H,BAO_0000218,In vivo
RBL-2H3,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,CHEMBL619994,11311,12166,,663.0,,,Autocuration,,1,,8,,4192,F,H,BAO_0000219,
RBL-2H3,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,CHEMBL619995,11311,12166,,663.0,,,Autocuration,,1,,8,,4193,F,H,BAO_0000219,
,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],CHEMBL619996,11311,12166,,,,,Autocuration,,1,,8,,4194,B,H,BAO_0000019,
,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,CHEMBL619997,11732,12166,,,,,Autocuration,,1,,8,,4195,B,H,BAO_0000019,
,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,CHEMBL619998,11732,12166,,,,,Expert,,1,,8,,4196,B,H,BAO_0000019,
,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,CHEMBL619999,11087,12166,,,,,Expert,,1,,8,,4197,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,CHEMBL620000,11087,12166,,,,,Autocuration,,1,,8,,4198,B,H,BAO_0000019,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,CHEMBL620001,11087,12166,,702.0,,,Autocuration,,1,,8,,4199,B,H,BAO_0000219,
,Rattus norvegicus,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,CHEMBL620002,11087,12166,,,,,Expert,,1,,9,10116.0,4200,B,D,BAO_0000357,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,CHEMBL620003,496,12166,,702.0,,,Autocuration,,1,,8,,4201,B,H,BAO_0000219,
RBL-1,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,CHEMBL620004,13986,12166,,702.0,,,Expert,,1,,8,,4202,F,H,BAO_0000219,
,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,CHEMBL874063,11520,12166,,,,,Autocuration,,1,,8,,4203,B,H,BAO_0000357,
RBL-1,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,CHEMBL620005,10293,12166,,702.0,,,Autocuration,,1,,8,,4204,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,CHEMBL620006,303,12166,,702.0,,,Autocuration,,1,,8,,4205,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,CHEMBL620007,303,12166,,702.0,,,Autocuration,,1,,8,,4206,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,CHEMBL620008,9247,12166,,702.0,,,Autocuration,,1,,8,,4207,B,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,CHEMBL620009,9247,12166,,702.0,,,Expert,,1,,9,10116.0,4208,B,D,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,CHEMBL620010,9247,12166,,702.0,,,Autocuration,,1,,8,,4209,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,CHEMBL620011,9247,12166,,702.0,,,Autocuration,,1,,8,,4210,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,CHEMBL620677,9247,12166,,702.0,,,Autocuration,,1,,8,,4211,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,CHEMBL620678,9247,12166,,702.0,,,Autocuration,,1,,8,,4212,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,CHEMBL620679,9247,12166,,702.0,,,Autocuration,,1,,8,,4213,B,H,BAO_0000219,
RBL-1,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,CHEMBL620680,9247,12166,,702.0,,,Autocuration,,1,,8,,4214,B,H,BAO_0000219,
,Rattus norvegicus,,,Inhibitory activity against 5-lipoxygenase at 10 uM,CHEMBL620838,11481,12166,,,,,Expert,,1,,9,10116.0,4215,B,D,BAO_0000357,
,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,CHEMBL620839,105,12166,,,,,Autocuration,,1,,8,,4216,B,H,BAO_0000357,
,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,CHEMBL620840,9029,12166,,,,,Expert,,1,,8,,4217,B,H,BAO_0000357,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,CHEMBL620841,1175,12166,,702.0,,,Expert,,1,,8,,4218,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,CHEMBL620842,12118,12166,,702.0,,,Autocuration,,1,,8,,4219,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,CHEMBL620843,12118,12166,,702.0,,,Autocuration,,1,,8,,4220,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,CHEMBL620844,12118,12166,,702.0,,,Autocuration,,1,,8,,4221,B,H,BAO_0000219,
RBL-1,,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,CHEMBL620845,9225,12166,,702.0,,,Autocuration,,1,,8,,4222,B,H,BAO_0000219,
,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,CHEMBL620846,9401,12166,,,,,Autocuration,,1,,8,,4223,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,CHEMBL873951,137,12166,,,,,Autocuration,,1,,8,,4224,B,H,BAO_0000357,
,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,CHEMBL620847,137,12166,,,,,Autocuration,,1,,8,,4225,B,H,BAO_0000357,
RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,CHEMBL620848,4717,12166,,702.0,,,Autocuration,,1,,8,,4226,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,CHEMBL620849,3595,12166,,702.0,,,Autocuration,,1,,8,,4227,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,CHEMBL620850,10501,12166,,702.0,,,Autocuration,,1,,8,,4228,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,CHEMBL620851,10501,12166,,702.0,,,Autocuration,,1,,8,,4229,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,CHEMBL620852,10501,12166,,702.0,,,Autocuration,,1,,8,,4230,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL875098,12526,12166,,702.0,,,Autocuration,,1,,8,,4231,B,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,CHEMBL620853,14799,12166,,702.0,,,Expert,,1,,9,10116.0,4232,B,D,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,CHEMBL620854,14799,12166,,,,,Autocuration,,1,,8,,4233,B,H,BAO_0000019,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,CHEMBL620855,3595,12166,,702.0,,,Autocuration,,1,,8,,4234,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,CHEMBL839884,3595,12166,,702.0,,,Expert,,1,,8,,4235,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL620856,12526,12166,,702.0,,,Autocuration,,1,,8,,4236,B,H,BAO_0000219,
RBL-1,,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,CHEMBL620857,12526,12166,,702.0,,,Autocuration,,1,,8,,4237,B,H,BAO_0000219,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,CHEMBL620858,10193,12166,,,,,Autocuration,,1,,8,,4238,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,CHEMBL620859,10193,12166,,,,,Autocuration,,1,,8,,4239,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,CHEMBL620860,10193,12166,,,,,Autocuration,,1,,8,,4240,B,H,BAO_0000019,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,CHEMBL620861,10193,12166,,,,,Autocuration,,1,,8,,4241,B,H,BAO_0000019,
,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),CHEMBL620862,9138,12166,,,,,Expert,,1,,8,,4242,B,H,BAO_0000357,
,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,CHEMBL620863,9138,12166,,,,,Autocuration,,1,,8,,4243,B,H,BAO_0000357,
,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,CHEMBL620864,11966,12166,,,,,Autocuration,,1,,8,,4244,B,H,BAO_0000019,
RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,CHEMBL620865,165,12166,,702.0,,,Autocuration,,1,,8,,4245,B,H,BAO_0000219,
RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,CHEMBL620866,165,12166,,702.0,,,Autocuration,,1,,8,,4246,B,H,BAO_0000219,
RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,CHEMBL620867,11311,12166,,663.0,,,Autocuration,,1,,8,,4247,B,H,BAO_0000219,
RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,CHEMBL620868,11311,12166,,663.0,,,Autocuration,,1,,8,,4248,B,H,BAO_0000219,
RBL-2H3,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,CHEMBL620869,11311,12166,,663.0,,,Autocuration,,1,,8,,4249,F,H,BAO_0000219,
,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,CHEMBL873952,11311,12166,,,,,Autocuration,,1,,8,,4250,F,H,BAO_0000019,
,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,CHEMBL875099,11311,12166,,,,,Autocuration,,1,,8,,4251,B,H,BAO_0000357,
RBL-2H3,,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,CHEMBL620870,11311,12166,,663.0,,,Autocuration,,1,,8,,4252,F,H,BAO_0000219,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,CHEMBL618261,11087,12166,,,,,Autocuration,,1,,8,,4253,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,CHEMBL618262,11087,12166,,,,,Autocuration,,1,,8,,4254,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,CHEMBL619428,11087,12166,,,,,Autocuration,,1,,8,,4255,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,CHEMBL619429,11087,12166,,,,,Autocuration,,1,,8,,4256,B,H,BAO_0000019,
,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,CHEMBL619430,11087,12166,,,,,Autocuration,,1,,8,,4257,B,H,BAO_0000019,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,CHEMBL620017,496,12166,,702.0,,,Autocuration,,1,,8,,4258,B,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,CHEMBL620018,496,12166,,702.0,,,Autocuration,,1,,8,,4259,B,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,CHEMBL620019,13986,12166,,702.0,,,Autocuration,,1,,8,,4260,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,CHEMBL620020,13986,12166,,702.0,,,Autocuration,,1,,8,,4261,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,CHEMBL620021,13986,12166,,702.0,,,Autocuration,,1,,8,,4262,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,CHEMBL620022,13986,12166,,702.0,,,Autocuration,,1,,8,,4263,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,CHEMBL620023,13986,12166,,702.0,,,Autocuration,,1,,8,,4264,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,CHEMBL620024,13986,12166,,702.0,,,Autocuration,,1,,8,,4265,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,CHEMBL620025,13986,12166,,702.0,,,Autocuration,,1,,8,,4266,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,CHEMBL620026,13986,12166,,702.0,,,Autocuration,,1,,8,,4267,F,H,BAO_0000219,
RBL-1,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,CHEMBL620027,13986,12166,,702.0,,,Autocuration,,1,,8,,4268,F,H,BAO_0000219,
,Rattus norvegicus,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,CHEMBL620028,13986,12166,,,,,Expert,,1,,9,10116.0,4269,F,D,BAO_0000019,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,CHEMBL620029,10193,12166,,,,,Autocuration,,1,,8,,4270,B,H,BAO_0000357,
,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,CHEMBL620030,9295,12166,,,,,Autocuration,,1,,8,,4271,B,H,BAO_0000357,
RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,CHEMBL875415,4717,12166,,702.0,,,Autocuration,,1,,8,,4272,B,H,BAO_0000219,
RBL-1,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,CHEMBL618256,4717,12166,,702.0,,,Autocuration,,1,,8,,4273,B,H,BAO_0000219,
RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,CHEMBL618257,11854,12166,,702.0,,,Autocuration,,1,,8,,4274,B,H,BAO_0000219,
RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,CHEMBL618258,11854,12166,,702.0,,,Autocuration,,1,,8,,4275,B,H,BAO_0000219,
RBL-1,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,CHEMBL618259,11854,12166,,702.0,,,Autocuration,,1,,8,,4276,B,H,BAO_0000219,
,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,CHEMBL618260,10193,12166,,,,,Autocuration,,1,,8,,4277,B,H,BAO_0000019,
RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,CHEMBL618215,9295,12166,,702.0,,,Autocuration,,1,,8,,4278,B,H,BAO_0000219,
RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,CHEMBL618390,9295,12166,,702.0,,,Autocuration,,1,,8,,4279,B,H,BAO_0000219,
RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,CHEMBL618391,9295,12166,,702.0,,,Autocuration,,1,,8,,4280,B,H,BAO_0000219,
RBL-1,,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,CHEMBL618392,9295,12166,,702.0,,,Autocuration,,1,,8,,4281,B,H,BAO_0000219,
RBL-1,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,CHEMBL618393,165,12166,,702.0,,,Autocuration,,1,,8,,4282,B,H,BAO_0000219,
,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,CHEMBL618394,11311,12166,,,,,Autocuration,,1,,8,,4283,B,H,BAO_0000219,
RBL-1,Homo sapiens,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),CHEMBL618395,10489,12166,,702.0,,,Expert,,1,,8,9606.0,4284,B,H,BAO_0000219,
RBL-1,Rattus norvegicus,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),CHEMBL618396,10489,12166,,702.0,,,Expert,,1,,9,10116.0,4285,B,D,BAO_0000219,
RBL-1,Rattus norvegicus,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),CHEMBL858253,10489,12166,,702.0,,,Expert,,1,,9,10116.0,4286,B,D,BAO_0000219,
,Rattus norvegicus,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,CHEMBL618397,14799,12166,,,,,Autocuration,,1,,9,10116.0,4287,B,D,BAO_0000019,
,Glycine max,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),CHEMBL618398,9295,12054,,,,,Autocuration,,1,,8,3847.0,4288,B,H,BAO_0000357,
,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",CHEMBL618399,16811,22226,,,,,Autocuration,,1,,0,,4289,B,U,BAO_0000019,
,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,CHEMBL618400,168,55,,,,,Expert,,1,,8,,4290,B,H,BAO_0000357,
,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,CHEMBL618401,6309,55,,,,,Autocuration,,1,,8,,4291,B,H,BAO_0000357,
,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,CHEMBL618402,6309,55,,,,,Autocuration,,1,,8,,4292,B,H,BAO_0000357,
RBL-1,,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,CHEMBL876400,3092,55,,702.0,,,Autocuration,,1,,8,,4293,B,H,BAO_0000219,
,,,,Inhibitory activity against 5-lipoxygenase.,CHEMBL618403,168,55,,,,,Expert,,1,,8,,4294,B,H,BAO_0000357,
,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,CHEMBL618404,168,55,,,,,Autocuration,,1,,8,,4295,B,H,BAO_0000357,
,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,CHEMBL618405,168,55,,,,,Autocuration,,1,,8,,4296,B,H,BAO_0000357,
,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,CHEMBL618406,168,55,,,,,Autocuration,,1,,8,,4297,B,H,BAO_0000357,
,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,CHEMBL618407,12338,55,,,,,Expert,,1,,8,,4298,F,H,BAO_0000019,
,,,,Tested for the inhibitory activity against 5-lipoxygenase,CHEMBL618408,4501,55,,,,,Autocuration,,1,,8,,4299,B,H,BAO_0000357,
,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,CHEMBL618409,1132,55,,,,,Autocuration,,1,,8,,4300,B,H,BAO_0000357,
,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,CHEMBL618410,2117,55,,,,,Autocuration,,1,,8,,4301,B,H,BAO_0000357,
,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,CHEMBL618411,168,55,,,,,Autocuration,,1,,8,,4302,B,H,BAO_0000357,
,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,CHEMBL618412,168,55,,,,,Autocuration,,1,,8,,4303,B,H,BAO_0000357,
RBL-1,,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,CHEMBL618413,13575,12166,,702.0,,,Autocuration,,1,,8,,4304,B,H,BAO_0000219,
,,,,,CHEMBL618414,11089,12166,,,,,Autocuration,,1,,8,,4305,B,H,BAO_0000357,
,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),CHEMBL618415,216,10102,,,,,Autocuration,,1,,8,,4306,B,H,BAO_0000357,
,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,CHEMBL618416,13165,10102,,,,,Autocuration,,1,,8,,4307,B,H,BAO_0000019,
,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,CHEMBL876401,3278,10102,,,,,Autocuration,,1,,8,,4308,B,H,BAO_0000357,
,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,CHEMBL618417,3278,10102,,,,,Expert,,1,,8,,4309,B,H,BAO_0000357,
,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,CHEMBL618418,11966,10102,,,,,Autocuration,,1,,8,,4310,B,H,BAO_0000357,
,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",CHEMBL618419,175,10102,,,,,Autocuration,,1,,8,,4311,B,H,BAO_0000357,
,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",CHEMBL618420,175,10102,,,,,Autocuration,,1,,8,,4312,B,H,BAO_0000357,
,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,CHEMBL618421,13449,10102,,,,,Autocuration,,1,,8,,4313,B,H,BAO_0000357,
,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,CHEMBL618422,12014,11238,,,,,Autocuration,,1,,8,,4314,B,H,BAO_0000019,
,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),CHEMBL618423,12014,11238,,,,,Autocuration,,1,,8,,4315,B,H,BAO_0000019,
,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),CHEMBL618424,12014,11238,,,,,Autocuration,,1,,8,,4316,B,H,BAO_0000019,
,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,CHEMBL618425,99,100284,,,,,Intermediate,,1,,2,,4317,B,S,BAO_0000220,
,Homo sapiens,,,The dark toxicity against 543 human galactophore carcinoma cells,CHEMBL618426,4349,22226,,,,,Autocuration,,1,,0,9606.0,4318,F,U,BAO_0000019,
Panel (56 tumour cell lines),Homo sapiens,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,CHEMBL618427,4071,80623,,390.0,,,Expert,,1,,1,9606.0,4319,F,N,BAO_0000219,
5637,Homo sapiens,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,CHEMBL618428,17589,80008,,345.0,,,Expert,,1,,1,9606.0,4320,F,N,BAO_0000219,
5637,Homo sapiens,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,CHEMBL618429,15002,80008,,345.0,,,Intermediate,,1,,1,9606.0,4321,F,N,BAO_0000219,
5637,Homo sapiens,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",CHEMBL618430,13958,80008,,345.0,,,Intermediate,,1,,1,9606.0,4322,F,N,BAO_0000219,
5637,Homo sapiens,,,Growth inhibition against human 5637 cell lines,CHEMBL618431,17589,80008,,345.0,,,Expert,,1,,1,9606.0,4323,F,N,BAO_0000219,
5637,Homo sapiens,,,Antitumor activity against human bladder carcinoma 5637 cells.,CHEMBL883799,16748,80008,,345.0,,,Expert,,1,,1,9606.0,4324,F,N,BAO_0000219,
5637,Homo sapiens,,,Antitumor activity against human bladder carcinoma 5637 cells,CHEMBL618432,16747,80008,,345.0,,,Intermediate,,1,,1,9606.0,4325,F,N,BAO_0000219,
5637,Homo sapiens,,,Antitumor activity against human bladder carcinoma 5637 cells,CHEMBL618433,16747,80008,,345.0,,,Intermediate,,1,,1,9606.0,4326,F,N,BAO_0000219,
,Bos taurus,,,In vitro inhibition of bovine trypsin(Trp).,CHEMBL618434,15285,10443,,,,,Expert,,1,,9,9913.0,4327,B,D,BAO_0000357,
CV-1,Cercopithecidae,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,CHEMBL618435,3726,240,,407.0,,,Expert,,1,,8,9527.0,4328,B,H,BAO_0000219,
,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,CHEMBL876402,5033,10577,,,,,Autocuration,,1,,8,,4329,B,H,BAO_0000357,
,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,CHEMBL618436,11756,104698,,,,,Autocuration,,1,,6,,4330,F,H,BAO_0000019,
,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,CHEMBL618437,11953,22226,,,,,Autocuration,,1,,0,,4331,F,U,BAO_0000218,In vivo
,Cavia porcellus,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,CHEMBL618438,5033,20033,,,,,Intermediate,,1,,9,10141.0,4332,B,D,BAO_0000357,
,Rattus norvegicus,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CHEMBL883800,11347,17045,Microsomes,,,,Expert,,1,,8,10116.0,4333,A,H,BAO_0000251,
,Rattus norvegicus,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CHEMBL618439,11347,17045,Microsomes,,,,Expert,,1,,8,10116.0,4334,A,H,BAO_0000251,
,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,CHEMBL618440,1229,22226,,,,,Intermediate,,1,,0,,4335,F,U,BAO_0000019,
,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,CHEMBL618441,1229,22226,,,,,Intermediate,,1,,0,,4336,F,U,BAO_0000019,
,Trypanosoma brucei,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,CHEMBL618442,17588,11938,,,,,Expert,,1,,8,5691.0,4337,B,H,BAO_0000019,
,Trypanosoma brucei,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,CHEMBL618443,17588,11938,,,,,Autocuration,,1,,8,5691.0,4338,B,H,BAO_0000019,
,Ovis aries,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,CHEMBL619158,17588,11938,,,,,Expert,,1,,8,9940.0,4339,B,H,BAO_0000019,
,Ovis aries,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,CHEMBL620974,17588,11938,,,,,Autocuration,,1,,8,9940.0,4340,B,H,BAO_0000019,
,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,CHEMBL620975,16485,11938,,,,,Autocuration,,1,,8,,4341,B,H,BAO_0000357,
,Homo sapiens,,,Average inhibitory concentration against 60 human cell lines was reported,CHEMBL620976,4337,22226,,,,,Intermediate,,1,,0,9606.0,4342,F,U,BAO_0000019,
,Homo sapiens,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,CHEMBL620977,4112,22226,,,,,Expert,,1,,0,9606.0,4343,F,U,BAO_0000019,
Panel NCI-60 (60 carcinoma cell lines),Homo sapiens,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,CHEMBL620978,16160,80315,,542.0,,,Intermediate,,1,,1,9606.0,4344,F,N,BAO_0000219,
Panel NCI-60 (60 carcinoma cell lines),Homo sapiens,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,CHEMBL620979,16160,80315,,542.0,,,Intermediate,,1,,1,9606.0,4345,F,N,BAO_0000219,
Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth inhibitory activity against 60-cell panel,CHEMBL620980,17376,80315,,542.0,,,Expert,,1,,1,,4346,F,N,BAO_0000219,
Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration against 60-cell panel,CHEMBL620981,17376,80315,,542.0,,,Expert,,1,,1,,4347,F,N,BAO_0000219,
Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,CHEMBL620982,17376,80315,,542.0,,,Expert,,1,,1,,4348,F,N,BAO_0000219,
Panel NCI-60 (60 carcinoma cell lines),,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,CHEMBL620983,17376,80315,,542.0,,,Expert,,1,,1,,4349,F,N,BAO_0000219,
,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,CHEMBL620984,3241,104775,,,,,Autocuration,,1,,4,,4350,F,H,BAO_0000019,
,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,CHEMBL620985,3241,104775,,,,,Autocuration,,1,,4,,4351,F,H,BAO_0000019,
,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,CHEMBL620986,3725,275,,,,,Expert,,1,,8,,4352,B,H,BAO_0000357,
,Plasmodium falciparum,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,CHEMBL620987,10805,50425,,,,,Expert,,1,,1,5833.0,4353,F,N,BAO_0000218,
,Plasmodium falciparum,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,CHEMBL620988,10805,50425,,,,,Expert,,1,,1,5833.0,4354,F,N,BAO_0000218,
,Plasmodium falciparum,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,CHEMBL620989,10805,50425,,,,,Expert,,1,,1,5833.0,4355,F,N,BAO_0000218,
,Plasmodium falciparum,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,CHEMBL620990,10805,50425,,,,,Expert,,1,,1,5833.0,4356,F,N,BAO_0000218,
,Plasmodium falciparum,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,CHEMBL620991,10805,50425,,,,,Intermediate,,1,,1,5833.0,4357,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,CHEMBL620992,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4358,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,CHEMBL620993,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4359,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,CHEMBL620994,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4360,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,CHEMBL620995,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4361,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,CHEMBL620996,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4362,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,CHEMBL875581,10144,80628,,850.0,,,Intermediate,,1,,1,10090.0,4363,F,N,BAO_0000218,
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,CHEMBL620997,10685,22224,,,,,Autocuration,,1,,0,10090.0,4364,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,CHEMBL620998,10685,22224,,,,,Autocuration,,1,,0,10090.0,4365,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),CHEMBL620999,10685,22224,,,,,Autocuration,,1,,0,10090.0,4366,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,CHEMBL621000,10685,22224,,,,,Autocuration,,1,,0,10090.0,4367,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,CHEMBL621001,10685,22224,,,,,Autocuration,,1,,0,10090.0,4368,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,CHEMBL621002,10685,22224,,,,,Autocuration,,1,,0,10090.0,4369,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,CHEMBL621003,10685,22224,,,,,Autocuration,,1,,0,10090.0,4370,F,U,BAO_0000218,In vivo
,Mus musculus,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",CHEMBL621004,10685,22224,,,,,Autocuration,,1,,0,10090.0,4371,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),CHEMBL621005,10685,22224,,,,,Autocuration,,1,,0,10090.0,4372,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),CHEMBL621006,10685,22224,,,,,Autocuration,,1,,0,10090.0,4373,F,U,BAO_0000218,In vivo
,Mus musculus,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,CHEMBL621007,10685,22224,,,,,Autocuration,,1,,0,10090.0,4374,F,U,BAO_0000218,In vivo
,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,CHEMBL621008,10144,22224,,,,,Autocuration,,1,,0,10090.0,4375,F,U,BAO_0000218,
,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,CHEMBL621009,10144,22224,,,,,Autocuration,,1,,0,10090.0,4376,F,U,BAO_0000218,
,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,CHEMBL857705,10144,22224,,,,,Autocuration,,1,,0,10090.0,4377,F,U,BAO_0000218,
,Mus musculus,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,CHEMBL619828,10144,22224,,,,,Autocuration,,1,,0,10090.0,4378,F,U,BAO_0000218,
,Mus musculus,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619829,10685,22224,,,,,Autocuration,,1,,0,10090.0,4379,F,U,BAO_0000218,
,Mus musculus,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,CHEMBL619830,10685,22224,,,,,Autocuration,,1,,0,10090.0,4380,F,U,BAO_0000218,
,Mus musculus,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619831,10685,22224,,,,,Autocuration,,1,,0,10090.0,4381,F,U,BAO_0000218,
,Mus musculus,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,CHEMBL619832,10685,22224,,,,,Autocuration,,1,,0,10090.0,4382,F,U,BAO_0000218,
,Mus musculus,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,CHEMBL619833,10685,22224,,,,,Autocuration,,1,,0,10090.0,4383,A,U,BAO_0000218,
,Mus musculus,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,CHEMBL619834,10685,22224,,,,,Autocuration,,1,,0,10090.0,4384,A,U,BAO_0000218,
,Mus musculus,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,CHEMBL619835,10685,22224,,,,,Autocuration,,1,,0,10090.0,4385,A,U,BAO_0000218,
,Mus musculus,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,CHEMBL619836,10685,22224,,,,,Autocuration,,1,,0,10090.0,4386,A,U,BAO_0000218,
6C3HED,Mus musculus,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",CHEMBL619837,8831,80628,,850.0,,,Intermediate,,1,,1,10090.0,4387,F,N,BAO_0000218,
,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,CHEMBL619838,11704,22224,,,,,Autocuration,,1,,0,,4388,F,U,BAO_0000218,In vivo
,Mus musculus,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,CHEMBL619839,11704,50594,,,,,Intermediate,,1,,1,10090.0,4389,A,N,BAO_0000218,
6C3HED,Mus musculus,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,CHEMBL619840,10685,80628,,850.0,,,Intermediate,,1,,1,10090.0,4390,F,N,BAO_0000218,In vivo
6C3HED,Mus musculus,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,CHEMBL619841,10685,80628,,850.0,,,Intermediate,,1,,1,10090.0,4391,F,N,BAO_0000218,In vivo
6C3HED,Mus musculus,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),CHEMBL857704,11368,80628,,850.0,,,Expert,,1,,1,10090.0,4392,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),CHEMBL619842,11368,80628,,850.0,,,Intermediate,,1,,1,10090.0,4393,F,N,BAO_0000218,
6C3HED,Mus musculus,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),CHEMBL619843,11368,80628,,850.0,,,Expert,,1,,1,10090.0,4394,F,N,BAO_0000218,
,Staphylococcus aureus,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",CHEMBL619844,17763,22226,,,,,Autocuration,,1,,0,1280.0,4395,B,U,BAO_0000019,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,CHEMBL857855,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4396,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,CHEMBL619845,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4397,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,CHEMBL619846,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4398,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,CHEMBL619847,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4399,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,CHEMBL619848,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4400,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,CHEMBL620893,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4401,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,CHEMBL620894,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4402,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,CHEMBL620895,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4403,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,CHEMBL620896,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4404,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,CHEMBL620897,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4405,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,CHEMBL620898,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4406,B,U,BAO_0000251,
,Rattus norvegicus,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,CHEMBL620899,7411,22226,Microsomes,,Liver,2107.0,Autocuration,,1,,0,10116.0,4407,B,U,BAO_0000251,
,Cercopithecidae,,,The apparent total plasma clearance in monkey,CHEMBL620900,347,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4408,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for Hepatic clearance in monkey,CHEMBL620901,3341,22224,,,,,Autocuration,,1,,0,9527.0,4409,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Lower clearance in monkey (i.v.) at 0.5 mpk,CHEMBL620902,17853,22224,,,,,Autocuration,,1,,0,9527.0,4410,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in rhesus monkey,CHEMBL620903,4514,22224,,,,,Autocuration,,1,,0,9527.0,4411,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,CHEMBL620904,6062,22224,,,,,Autocuration,,1,,0,9527.0,4412,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance of compound was determined in monkey,CHEMBL620905,6821,22224,,,,,Autocuration,,1,,0,9527.0,4413,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was calculated in rhesus monkey,CHEMBL620906,6057,22224,,,,,Autocuration,,1,,0,9527.0,4414,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in rhesus monkey,CHEMBL875420,5145,22224,,,,,Autocuration,,1,,0,9527.0,4415,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL620907,6641,22224,,,,,Autocuration,,1,,0,9527.0,4416,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was evaluated in rhesus,CHEMBL620908,5472,22224,,,,,Autocuration,,1,,0,9527.0,4417,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,CHEMBL620909,4257,22224,,,,,Autocuration,,1,,0,9527.0,4418,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL620910,5546,22224,,,,,Autocuration,,1,,0,9527.0,4419,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL620911,5334,22224,,,,,Autocuration,,1,,0,9527.0,4420,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL620912,5334,22224,,,,,Autocuration,,1,,0,9527.0,4421,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,CHEMBL620913,17509,22224,,,,,Autocuration,,1,,0,9527.0,4422,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax in monkey after administration of 1 mg/kg iv,CHEMBL620914,6535,22224,,,,,Autocuration,,1,,0,9527.0,4423,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,CHEMBL620915,5668,22224,,,,,Autocuration,,1,,0,9527.0,4424,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax in cynomolgus monkey by iv administration,CHEMBL620916,5922,22224,,,,,Autocuration,,1,,0,9527.0,4425,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax in cynomolgus monkey by po administration,CHEMBL620917,5922,22224,,,,,Autocuration,,1,,0,9527.0,4426,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Cmax value evaluated in monkey,CHEMBL620918,6078,22224,,,,,Autocuration,,1,,0,9527.0,4427,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL620919,2661,22224,,,,,Autocuration,,1,,0,9527.0,4428,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,CHEMBL620920,3249,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4429,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,CHEMBL620921,3249,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4430,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Maximal plasma concentration in squirrel monkeys,CHEMBL620922,5553,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4431,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620923,1916,22224,,,,,Autocuration,,1,,0,9527.0,4432,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,CHEMBL620924,6227,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4433,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620925,4809,22224,,,,,Autocuration,,1,,0,9527.0,4434,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,CHEMBL620926,5355,22224,,,,,Autocuration,,1,,0,9527.0,4435,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,CHEMBL620927,5355,22224,,,,,Autocuration,,1,,0,9527.0,4436,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,CHEMBL620928,5355,22224,,,,,Autocuration,,1,,0,9527.0,4437,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,CHEMBL620929,5355,22224,,,,,Autocuration,,1,,0,9527.0,4438,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,CHEMBL620930,6221,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4439,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,CHEMBL620931,167,22224,,,,,Autocuration,,1,,0,9527.0,4440,A,U,BAO_0000218,
,Cercopithecidae,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,CHEMBL620932,167,22224,,,,,Autocuration,,1,,0,9527.0,4441,A,U,BAO_0000218,
,monkey,,,Absolute bioavailability was evaluated in monkey,CHEMBL620933,4257,22224,,,,,Autocuration,,1,,0,9443.0,4442,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL620934,6221,22224,,,,,Autocuration,,1,,0,9443.0,4443,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,CHEMBL620935,17667,22224,,,,,Autocuration,,1,,0,9443.0,4444,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Bioavailability of compound was determined in rhesus monkey,CHEMBL620936,17267,22224,,,,,Autocuration,,1,,0,9544.0,4445,A,U,BAO_0000218,In vivo
,marmosets,,,Bioavailability determined after oral administration in marmoset,CHEMBL620937,4256,22224,,,,,Autocuration,,1,,0,38020.0,4446,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Oral bioavailability in cynomolgus monkey,CHEMBL620938,4256,22224,,,,,Autocuration,,1,,0,9541.0,4447,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability in monkey (p.o.) at 2.0 mpk,CHEMBL620939,17853,22224,,,,,Autocuration,,1,,0,9443.0,4448,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability was evaluated after oral administration in monkey,CHEMBL620940,16365,22224,,,,,Autocuration,,1,,0,9443.0,4449,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620941,1916,22224,,,,,Autocuration,,1,,0,9541.0,4450,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL620942,5334,22224,,,,,Autocuration,,1,,0,9544.0,4451,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL620943,5334,22224,,,,,Autocuration,,1,,0,9544.0,4452,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability of the compound was determined in monkey,CHEMBL620944,17592,22224,,,,,Autocuration,,1,,0,9443.0,4453,A,U,BAO_0000218,In vivo
,Saimiri sciureus,,,Bioavailability in squirrel monkey (dose 5 mg/kg),CHEMBL620945,1399,22224,,,,,Autocuration,,1,,0,9521.0,4454,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620946,4809,22224,,,,,Autocuration,,1,,0,9443.0,4455,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL620947,3341,22224,,,,,Autocuration,,1,,0,9443.0,4456,A,U,BAO_0000218,In vivo
,Saimiri sciureus,,,Compound was tested for bioavailability in squirrel monkey,CHEMBL620948,64,22224,,,,,Autocuration,,1,,0,9521.0,4457,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in Rhesus monkey,CHEMBL620949,5005,22224,,,,,Autocuration,,1,,0,9544.0,4458,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),CHEMBL620950,5005,22224,,,,,Autocuration,,1,,0,9544.0,4459,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,CHEMBL620951,5237,22224,,,,,Autocuration,,1,,0,9541.0,4460,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,CHEMBL620952,5237,22224,,,,,Autocuration,,1,,0,9541.0,4461,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey (dose 5 mg/kg),CHEMBL875421,5302,22224,,,,,Autocuration,,1,,0,9443.0,4462,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability of compound at 5 mg/kg in monkey,CHEMBL620953,17667,22224,,,,,Autocuration,,1,,0,9443.0,4463,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,CHEMBL873491,6161,50588,,,,,Intermediate,,1,,1,9615.0,4464,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,CHEMBL620954,6161,50588,,,,,Intermediate,,1,,1,9615.0,4465,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma half life determined,CHEMBL620955,3854,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4466,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma half life in dog,CHEMBL618097,993,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4467,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma half-life in Beagle dogs,CHEMBL618268,4514,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4468,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL618269,5334,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4469,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),CHEMBL618270,5334,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4470,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL618271,1466,50588,,,,,Intermediate,,1,,1,9615.0,4471,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL873493,1466,50588,,,,,Intermediate,,1,,1,9615.0,4472,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for the half life period in dog,CHEMBL621031,5313,50588,,,,,Intermediate,,1,,1,9615.0,4473,A,N,BAO_0000218,
,Canis lupus familiaris,,,Tested for the half life period in dog at dosage of 10 mpk,CHEMBL621032,5313,50588,,,,,Intermediate,,1,,1,9615.0,4474,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for half life in dog,CHEMBL621033,3880,50588,,,,,Intermediate,,1,,1,9615.0,4475,A,N,BAO_0000218,
,Canis lupus familiaris,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",CHEMBL621034,3639,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4476,A,N,BAO_0000218,
,Canis lupus familiaris,,,The half life was determined,CHEMBL621035,3880,50588,,,,,Intermediate,,1,,1,9615.0,4477,A,N,BAO_0000218,
,Canis lupus familiaris,,,The plasma half-life in dogs,CHEMBL621036,3918,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4478,A,N,BAO_0000218,
,Canis lupus familiaris,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,CHEMBL621037,16452,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,4479,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog,CHEMBL619812,17796,50588,,,,,Intermediate,,1,,1,9615.0,4480,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,CHEMBL619813,5983,50588,,,,,Intermediate,,1,,1,9615.0,4481,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL873335,1466,50588,,,,,Intermediate,,1,,1,9615.0,4482,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL619814,16456,50588,,,,,Intermediate,,1,,1,9615.0,4483,A,N,BAO_0000218,In vivo
,Mustela putorius furo,,,Cmax in ferrets after 30 mg/kg oral dose,CHEMBL619815,6113,50506,,,,,Expert,,1,,1,9669.0,4484,A,N,BAO_0000218,In vivo
,Mustela putorius furo,,,Emesis in ferrets at 30 mg/kg oral dose,CHEMBL619816,6113,50506,,,,,Expert,,1,,1,9669.0,4485,F,N,BAO_0000218,In vivo
,Macaca fascicularis,,,Bioavailability in cynomolgus monkey,CHEMBL619817,17796,22224,,,,,Autocuration,,1,,0,9541.0,4486,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Volume of distribution in cynomolgus,CHEMBL619818,17796,100710,,,,,Intermediate,,1,,1,9541.0,4487,A,N,BAO_0000218,In vivo
,Cavia porcellus,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,CHEMBL619819,5308,22224,,,Plasma,1969.0,Autocuration,,1,,0,10141.0,4488,A,U,BAO_0000218,
,Cavia porcellus,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,CHEMBL619820,4877,22224,,,,,Autocuration,,1,,0,10141.0,4489,A,U,BAO_0000218,
,Cavia porcellus,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",CHEMBL875419,4876,22224,,,,,Autocuration,,1,,0,10141.0,4490,A,U,BAO_0000218,
,Cavia porcellus,,,AUC in guinea pig after 3mg/kg oral dose,CHEMBL619821,4878,22224,,,Plasma,1969.0,Autocuration,,1,,0,10141.0,4491,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Bioavailability in guinea pig was tested,CHEMBL619822,5308,22224,,,,,Autocuration,,1,,0,10141.0,4492,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,CHEMBL619823,4877,22224,,,,,Autocuration,,1,,0,10141.0,4493,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Tested for the oral bioavailability of the compound,CHEMBL619824,4876,22224,,,,,Autocuration,,1,,0,10141.0,4494,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,CHEMBL619825,4876,22224,,,,,Autocuration,,1,,0,10141.0,4495,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,CHEMBL619826,5308,22224,,,,,Autocuration,,1,,0,10141.0,4496,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,CHEMBL619827,4877,22224,,,Lung,2048.0,Autocuration,,1,,0,10141.0,4497,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Cmax in guinea pig after 3mg/kg oral dose,CHEMBL618167,4878,22224,,,,,Autocuration,,1,,0,10141.0,4498,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618168,5689,22224,,,Blood,178.0,Autocuration,,1,,0,10141.0,4499,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618169,5689,22224,,,Brain,955.0,Autocuration,,1,,0,10141.0,4500,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618170,5689,22224,,,,,Autocuration,,1,,0,10141.0,4501,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618171,5689,22224,,,Intestine,160.0,Autocuration,,1,,0,10141.0,4502,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618172,5689,22224,,,Kidney,2113.0,Autocuration,,1,,0,10141.0,4503,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618173,5689,22224,,,Liver,2107.0,Autocuration,,1,,0,10141.0,4504,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL618174,5689,22224,,,,,Autocuration,,1,,0,10141.0,4505,A,U,BAO_0000019,
,Cavia porcellus,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,CHEMBL875408,5689,22224,,,Spleen,2106.0,Autocuration,,1,,0,10141.0,4506,A,U,BAO_0000019,
,Cavia porcellus,,,Elimination T1/2 in Guinea pig (PO dose),CHEMBL839827,14465,22224,,,,,Autocuration,,1,,0,10141.0,4507,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Partition coefficient was measured as -log (counts per min ),CHEMBL618175,5689,22224,,,,,Autocuration,,1,,0,10141.0,4508,A,U,BAO_0000019,
,Cavia porcellus,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,CHEMBL618176,611,22224,,,,,Autocuration,,1,,0,10141.0,4509,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,CHEMBL618177,611,22224,,,,,Autocuration,,1,,0,10141.0,4510,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Elimination T1/2 in Guinea pig (PO dose),CHEMBL618178,14465,22224,,,,,Autocuration,,1,,0,10141.0,4511,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,"Tested for the half life period of the compound, intravenously",CHEMBL618179,4876,22224,,,,,Autocuration,,1,,0,10141.0,4512,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Half-life was measured,CHEMBL873489,5689,22224,,,,,Autocuration,,1,,0,10141.0,4513,A,U,BAO_0000019,
,Cavia porcellus,,,The time required for onset of inotropy after addition of a single dose of delta F75,CHEMBL618180,7515,22224,,,,,Autocuration,,1,,0,10141.0,4514,A,U,BAO_0000019,
,Cavia porcellus,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,CHEMBL618181,17667,22224,,,,,Autocuration,,1,,0,10141.0,4515,A,U,BAO_0000218,In vivo
,Cavia porcellus,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,CHEMBL618182,17667,22224,,,,,Autocuration,,1,,0,10141.0,4516,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,CHEMBL618183,4727,22224,,,,,Autocuration,,1,,0,10029.0,4517,A,U,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL618184,10107,50594,,,,,Intermediate,,1,,1,10090.0,4518,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL618185,10107,50594,,,,,Intermediate,,1,,1,10090.0,4519,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL618186,10107,50594,,,,,Intermediate,,1,,1,10090.0,4520,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL618187,10107,50594,,,,,Intermediate,,1,,1,10090.0,4521,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,CHEMBL618188,10107,50594,,,,,Intermediate,,1,,1,10090.0,4522,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL875409,10107,50594,,,,,Intermediate,,1,,1,10090.0,4523,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL618189,10107,50594,,,,,Intermediate,,1,,1,10090.0,4524,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,CHEMBL618190,3655,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4525,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,CHEMBL618191,3655,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4526,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,CHEMBL618192,3655,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4527,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,CHEMBL618193,3655,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,4528,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,CHEMBL618194,3655,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,4529,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,CHEMBL618195,3655,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,4530,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,CHEMBL618196,3655,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4531,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,CHEMBL618197,3655,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4532,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,CHEMBL618198,3655,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4533,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,CHEMBL618199,3655,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,4534,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,CHEMBL618200,3655,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,4535,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,CHEMBL618201,3655,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,4536,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,CHEMBL618202,3655,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,4537,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,CHEMBL618203,3655,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,4538,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,CHEMBL618204,3655,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,4539,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,CHEMBL618205,3655,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4540,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,CHEMBL618206,3655,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4541,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,CHEMBL618207,3655,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4542,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,CHEMBL618208,3655,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4543,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,CHEMBL618932,3655,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4544,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,CHEMBL618933,3655,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4545,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,CHEMBL618934,3655,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,4546,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,CHEMBL618935,3655,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,4547,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,CHEMBL618936,3655,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,4548,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,CHEMBL618937,3655,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,4549,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,CHEMBL618938,3655,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,4550,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,CHEMBL619104,3655,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,4551,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,CHEMBL619105,3655,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,4552,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,CHEMBL619106,3655,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,4553,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,CHEMBL619107,3655,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,4554,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,CHEMBL875410,3655,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,4555,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,CHEMBL619108,3655,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,4556,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,CHEMBL619109,3655,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,4557,A,N,BAO_0000218,In vivo
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,CHEMBL619110,16597,50594,,,,,Intermediate,,1,,1,10090.0,4558,A,N,BAO_0000218,In vivo
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,CHEMBL619111,16597,50594,,,,,Intermediate,,1,,1,10090.0,4559,F,N,BAO_0000218,In vivo
,Mus musculus,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL619112,16597,50594,,,,,Intermediate,,1,,1,10090.0,4560,A,N,BAO_0000218,In vivo
,Mus musculus,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL619113,16597,50594,,,,,Intermediate,,1,,1,10090.0,4561,A,N,BAO_0000218,In vivo
,Mus musculus,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,CHEMBL619114,17764,50594,,,,,Intermediate,,1,,1,10090.0,4562,A,N,BAO_0000218,In vivo
,Mus musculus,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,CHEMBL619115,17764,50594,,,,,Intermediate,,1,,1,10090.0,4563,F,N,BAO_0000218,In vivo
A2780,Homo sapiens,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,CHEMBL619116,3830,81034,,478.0,,,Intermediate,,1,,1,9606.0,4564,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,CHEMBL619117,3829,81034,,478.0,,,Intermediate,,1,,1,9606.0,4565,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,CHEMBL619118,2040,81034,,478.0,,,Intermediate,,1,,1,9606.0,4566,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,CHEMBL619119,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4567,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,CHEMBL619120,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4568,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,CHEMBL619121,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4569,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,CHEMBL619122,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4570,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,CHEMBL619123,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4571,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,CHEMBL619124,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4572,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated for cytotoxicity against A2780 cell line,CHEMBL619125,2859,81034,,478.0,,,Intermediate,,1,,1,9606.0,4573,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro inhibitory activity against human tumor cell line A2780,CHEMBL875411,5618,81034,,478.0,,,Intermediate,,1,,1,9606.0,4574,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,CHEMBL619126,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4575,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,CHEMBL619127,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4576,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,CHEMBL619128,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4577,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,CHEMBL619129,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4578,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,CHEMBL619130,2113,81034,,478.0,,,Intermediate,,1,,1,9606.0,4579,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,CHEMBL619131,2113,81034,,478.0,,,Intermediate,,1,,1,9606.0,4580,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,CHEMBL619132,16745,81034,,478.0,,,Intermediate,,1,,1,9606.0,4581,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619133,16597,81034,,478.0,,,Expert,,1,,1,9606.0,4582,F,N,BAO_0000218,
A2780,Homo sapiens,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,CHEMBL619134,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4583,F,N,BAO_0000219,
A2780,Homo sapiens,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,CHEMBL619135,15684,81034,,478.0,,,Intermediate,,1,,1,9606.0,4584,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,CHEMBL619136,2040,81034,,478.0,,,Intermediate,,1,,1,9606.0,4585,F,N,BAO_0000219,
A2780,Homo sapiens,,,Relative resistance factor in A2780 cisplatin-resistant line,CHEMBL619137,2040,81034,,478.0,,,Intermediate,,1,,1,9606.0,4586,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,CHEMBL883713,16165,81034,,478.0,,,Intermediate,,1,,1,9606.0,4587,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,CHEMBL875412,16165,81034,,478.0,,,Intermediate,,1,,1,9606.0,4588,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619138,16597,81034,,478.0,,,Expert,,1,,1,9606.0,4589,F,N,BAO_0000218,
A2780,Homo sapiens,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,CHEMBL619262,16597,81034,,478.0,,,Expert,,1,,1,9606.0,4590,F,N,BAO_0000218,
A2780,Homo sapiens,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,CHEMBL619139,3992,81034,,478.0,,,Intermediate,,1,,1,9606.0,4591,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,CHEMBL619140,10553,81034,,478.0,,,Intermediate,,1,,1,9606.0,4592,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,CHEMBL619141,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4593,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,CHEMBL619142,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4594,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,CHEMBL619143,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4595,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,CHEMBL619144,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4596,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,CHEMBL619145,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4597,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,CHEMBL619146,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,4598,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,CHEMBL619147,15569,81034,,478.0,,,Intermediate,,1,,1,9606.0,4599,F,N,BAO_0000219,
A2780,Homo sapiens,,,Antiproliferative effect of compound on A2780/DX cell line,CHEMBL619148,17420,81034,,478.0,,,Intermediate,,1,,1,9606.0,4600,F,N,BAO_0000219,
A2780,Homo sapiens,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,CHEMBL619149,17420,81034,,478.0,,,Intermediate,,1,,1,9606.0,4601,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),CHEMBL619150,15099,81034,,478.0,,,Intermediate,,1,,1,9606.0,4602,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),CHEMBL619151,15099,81034,,478.0,,,Intermediate,,1,,1,9606.0,4603,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,CHEMBL883794,17672,81034,,478.0,,,Intermediate,,1,,1,9606.0,4604,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,CHEMBL619152,17672,81034,,478.0,,,Intermediate,,1,,1,9606.0,4605,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780ADR cell line,CHEMBL619153,17270,81034,,478.0,,,Intermediate,,1,,1,9606.0,4606,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780CIS cell line,CHEMBL619154,17270,81034,,478.0,,,Intermediate,,1,,1,9606.0,4607,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,CHEMBL619155,5574,81034,,478.0,,,Intermediate,,1,,1,9606.0,4608,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,CHEMBL619156,2113,81034,,478.0,,,Intermediate,,1,,1,9606.0,4609,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL619157,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4610,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL619797,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4611,F,N,BAO_0000219,
,Macaca mulatta,,,Oral bioavailability of compound in rhesus macaques,CHEMBL619798,17839,22224,,,,,Autocuration,,1,,0,9544.0,4612,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL619799,6821,22224,,,,,Autocuration,,1,,0,9443.0,4613,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability evaluated in monkey,CHEMBL619800,6078,22224,,,,,Autocuration,,1,,0,9443.0,4614,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),CHEMBL619801,6535,22224,,,,,Autocuration,,1,,0,9443.0,4615,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in Rhesus monkey,CHEMBL619802,4449,22224,,,,,Autocuration,,1,,0,9544.0,4616,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability was calculated in rhesus monkey,CHEMBL619803,6057,22224,,,,,Autocuration,,1,,0,9544.0,4617,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Oral bioavailability in cynomolgus monkey,CHEMBL619965,5922,22224,,,,,Autocuration,,1,,0,9541.0,4618,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL619966,5940,22224,,,,,Autocuration,,1,,0,9443.0,4619,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL619967,6265,22224,,,,,Autocuration,,1,,0,9443.0,4620,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey (dose 1 mg/kg),CHEMBL620073,6265,22224,,,,,Autocuration,,1,,0,9443.0,4621,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey (dose 5 mg/kg),CHEMBL620074,6265,22224,,,,,Autocuration,,1,,0,9443.0,4622,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL620075,5940,22224,,,,,Autocuration,,1,,0,9443.0,4623,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey,CHEMBL620076,5940,22224,,,,,Autocuration,,1,,0,9443.0,4624,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in rhesus monkey,CHEMBL620077,4514,22224,,,,,Autocuration,,1,,0,9544.0,4625,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,CHEMBL620078,5546,22224,,,,,Autocuration,,1,,0,9544.0,4626,A,U,BAO_0000218,In vivo
,Saimiri sciureus,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,CHEMBL620079,5553,22224,,,,,Autocuration,,1,,0,9521.0,4627,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL620080,6641,22224,,,,,Autocuration,,1,,0,9443.0,4628,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in Rhesus monkey,CHEMBL620081,5472,22224,,,,,Autocuration,,1,,0,9544.0,4629,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),CHEMBL620082,5668,22224,,,,,Autocuration,,1,,0,9544.0,4630,A,U,BAO_0000218,In vivo
,monkey,,,Oral bioavailability in monkey at 10 mg/kg of the compound,CHEMBL620083,5711,22224,,,,,Autocuration,,1,,0,9443.0,4631,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Bioavailability in Rhesus monkey,CHEMBL620084,5145,22224,,,,,Autocuration,,1,,0,9544.0,4632,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620085,3443,22224,,,,,Autocuration,,1,,0,9527.0,4633,A,U,BAO_0000218,
,Cercopithecidae,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL874595,3443,22224,,,,,Autocuration,,1,,0,9527.0,4634,A,U,BAO_0000218,
,Cercopithecidae,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,CHEMBL873352,3249,22224,,,,,Autocuration,,1,,0,9527.0,4635,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,CHEMBL620086,3249,22224,,,,,Autocuration,,1,,0,9527.0,4636,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,CHEMBL620087,5355,22224,,,,,Autocuration,,1,,0,9527.0,4637,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL620088,5355,22224,,,,,Autocuration,,1,,0,9527.0,4638,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL620089,5355,22224,,,,,Autocuration,,1,,0,9527.0,4639,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL620090,4809,22224,,,,,Autocuration,,1,,0,9527.0,4640,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620091,4809,22224,,,,,Autocuration,,1,,0,9527.0,4641,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL620092,14294,22224,Microsomes,,,,Autocuration,,1,,0,9527.0,4642,A,U,BAO_0000251,
,Cercopithecidae,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),CHEMBL620093,14294,22224,Microsomes,,,,Autocuration,,1,,0,9527.0,4643,A,U,BAO_0000251,
,Cercopithecidae,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),CHEMBL620094,14294,22224,Microsomes,,,,Autocuration,,1,,0,9527.0,4644,A,U,BAO_0000251,
,Cercopithecidae,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),CHEMBL620095,14294,22224,Microsomes,,,,Autocuration,,1,,0,9527.0,4645,A,U,BAO_0000251,
,Cercopithecidae,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620096,3443,22224,,,,,Autocuration,,1,,0,9527.0,4646,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620097,3443,22224,,,,,Autocuration,,1,,0,9527.0,4647,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,CHEMBL620098,11271,22224,,,,,Autocuration,,1,,0,9527.0,4648,A,U,BAO_0000019,
,Cercopithecidae,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620099,3443,22224,,,,,Autocuration,,1,,0,9527.0,4649,A,U,BAO_0000218,
,Cercopithecidae,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620100,3443,22224,,,,,Autocuration,,1,,0,9527.0,4650,A,U,BAO_0000218,
,Cercopithecidae,,,Elimination Half-life of compound was determined in monkey,CHEMBL620101,6821,22224,,,,,Autocuration,,1,,0,9527.0,4651,A,U,BAO_0000019,
,Cercopithecidae,,,Half life of compound was determined in rhesus monkey,CHEMBL620102,17267,22224,,,,,Autocuration,,1,,0,9527.0,4652,A,U,BAO_0000019,
,Cercopithecidae,,,Half life in monkey plasma,CHEMBL620103,5819,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4653,A,U,BAO_0000366,
,Cercopithecidae,,,Half life in monkey plasma; Not detected,CHEMBL620104,5819,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4654,A,U,BAO_0000366,
,Cercopithecidae,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL874596,1916,22224,,,,,Autocuration,,1,,0,9527.0,4655,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,CHEMBL873490,17509,22224,,,,,Autocuration,,1,,0,9527.0,4656,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Terminal half life of the compound.,CHEMBL620105,1399,22224,,,,,Autocuration,,1,,0,9527.0,4657,A,U,BAO_0000019,
,Cercopithecidae,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL620780,1916,22224,,,,,Autocuration,,1,,0,9527.0,4658,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),CHEMBL620781,4809,22224,,,,,Autocuration,,1,,0,9527.0,4659,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL620956,5546,22224,,,,,Autocuration,,1,,0,9527.0,4660,A,U,BAO_0000218,
,Cercopithecidae,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620957,3443,22224,,,Urine,1088.0,Autocuration,,1,,0,9527.0,4661,A,U,BAO_0000218,
,Cercopithecidae,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL620958,3443,22224,,,Urine,1088.0,Autocuration,,1,,0,9527.0,4662,A,U,BAO_0000218,
,Cercopithecidae,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,CHEMBL620959,4257,22224,,,,,Autocuration,,1,,0,9527.0,4663,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL620960,6221,22224,,,,,Autocuration,,1,,0,9527.0,4664,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution was evaluated in rhesus,CHEMBL620961,5472,22224,,,,,Autocuration,,1,,0,9527.0,4665,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,CHEMBL620962,4727,22224,,,,,Autocuration,,1,,0,10029.0,4666,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,CHEMBL620963,4727,22224,,,,,Autocuration,,1,,0,10029.0,4667,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Bioavailability in hamster was determined,CHEMBL620964,4727,22224,,,,,Autocuration,,1,,0,10029.0,4668,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,CHEMBL620965,4727,22224,,,,,Autocuration,,1,,0,10029.0,4669,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,CHEMBL620966,4727,22224,,,,,Autocuration,,1,,0,10029.0,4670,A,U,BAO_0000218,In vivo
,Cricetulus griseus,,,Half life of compound was determined in hamster blood,CHEMBL620967,4727,22224,,,Blood,178.0,Autocuration,,1,,0,10029.0,4671,A,U,BAO_0000221,
,Sus scrofa,,,Michaelis-Menten constant of the compound.,CHEMBL620968,1452,22224,,,,,Autocuration,,1,,0,9823.0,4672,A,U,BAO_0000019,
,Sus scrofa,,,Vmax value was measured at 0 uM concentration of silyl ether.,CHEMBL874597,1452,22224,,,,,Autocuration,,1,,0,9823.0,4673,A,U,BAO_0000019,
,Sus scrofa,,,Vmax value was measured at 10 uM concentration of silyl ether.,CHEMBL620969,1452,22224,,,,,Autocuration,,1,,0,9823.0,4674,A,U,BAO_0000019,
,Sus scrofa,,,Vmax value was measured at 5 uM concentration of silyl ether.,CHEMBL620970,1452,22224,,,,,Autocuration,,1,,0,9823.0,4675,A,U,BAO_0000019,
,Homo sapiens,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,CHEMBL620971,11706,235,,,,,Expert,,1,,9,9606.0,4676,B,D,BAO_0000357,
,Homo sapiens,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL620972,1916,22224,,,,,Autocuration,,1,,0,9606.0,4677,A,U,BAO_0000218,
,Homo sapiens,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),CHEMBL620973,17791,22224,,,,,Autocuration,,1,,0,9606.0,4678,A,U,BAO_0000019,
,Homo sapiens,,,Active metabolite of ifosfamide determined in humans; A-Active,CHEMBL618243,7766,22224,,,,,Autocuration,,1,,0,9606.0,4679,A,U,BAO_0000019,
,Homo sapiens,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,CHEMBL618244,6567,22224,,,,,Autocuration,,1,,0,9606.0,4680,A,U,BAO_0000019,
,Homo sapiens,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,CHEMBL618245,6567,22224,,,,,Autocuration,,1,,0,9606.0,4681,A,U,BAO_0000019,
,Homo sapiens,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,CHEMBL618246,6567,22224,,,,,Autocuration,,1,,0,9606.0,4682,A,U,BAO_0000019,
,Homo sapiens,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,CHEMBL618247,6567,22224,,,,,Autocuration,,1,,0,9606.0,4683,A,U,BAO_0000019,
,Homo sapiens,,,Compound was evaluated for oral bioavailability in human,CHEMBL618248,17791,22224,,,,,Autocuration,,1,,0,9606.0,4684,A,U,BAO_0000218,
,Homo sapiens,,,Metabolite of ifosfamide determined in urine; NF-Not found,CHEMBL618249,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4685,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),CHEMBL618250,6852,22224,,,,,Autocuration,,1,,0,9606.0,4686,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,CHEMBL874598,6852,22224,,,,,Autocuration,,1,,0,9606.0,4687,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,CHEMBL618251,6852,22224,,,,,Autocuration,,1,,0,9606.0,4688,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,CHEMBL618252,6852,22224,,,,,Autocuration,,1,,0,9606.0,4689,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,CHEMBL618253,6852,22224,,,,,Autocuration,,1,,0,9606.0,4690,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),CHEMBL618254,6852,22224,,,,,Autocuration,,1,,0,9606.0,4691,A,U,BAO_0000019,
,Homo sapiens,,,Percent of compound in healthy individuals (Group D),CHEMBL618255,6852,22224,,,,,Autocuration,,1,,0,9606.0,4692,A,U,BAO_0000019,
,Homo sapiens,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,CHEMBL618983,4397,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4693,A,U,BAO_0000251,
,Homo sapiens,,,Binding towards human plasma protein at 10 uM,CHEMBL618984,17409,22224,,,,,Autocuration,,1,,0,9606.0,4694,A,U,BAO_0000019,
,Homo sapiens,,,Binding towards human plasma protein at 100 uM,CHEMBL618985,17409,22224,,,,,Autocuration,,1,,0,9606.0,4695,A,U,BAO_0000019,
,Homo sapiens,,,Human plasma protein binding activity was determined,CHEMBL618986,17176,22224,,,,,Autocuration,,1,,0,9606.0,4696,A,U,BAO_0000019,
,Homo sapiens,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),CHEMBL618987,15444,22224,,,,,Autocuration,,1,,0,9606.0,4697,A,U,BAO_0000019,
,Homo sapiens,,,Percent binding of compound towards human plasma protein was determined,CHEMBL618988,17267,22224,,,,,Autocuration,,1,,0,9606.0,4698,A,U,BAO_0000019,
,Homo sapiens,,,Plasma clearance in human liver microsomes,CHEMBL618989,5944,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4699,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro intrinsic clearance in human liver microsome,CHEMBL618990,5668,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4700,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro intrinsic clearance in human liver microsome,CHEMBL618991,5669,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4701,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro microsome metabolism clearance in human was determined,CHEMBL876725,5041,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4702,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro microsome metabolism clearance in human was determined; High,CHEMBL618992,5041,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4703,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,CHEMBL618993,5041,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4704,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Pharmacokinetic property (clearance) in human liver microsome,CHEMBL618994,5676,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4705,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Plasma clearance in human liver microsomes,CHEMBL618995,5944,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4706,A,U,BAO_0000251,In vitro
,Homo sapiens,,,In vitro clearance in human liver microsomes,CHEMBL618996,17538,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4707,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Intrinsic clearance in human liver microsomes was determined,CHEMBL618997,6331,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4708,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Intrinsic clearance in human liver microsomes was determined,CHEMBL618998,5948,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4709,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,CHEMBL618999,5965,22224,,,,,Autocuration,,1,,0,9606.0,4710,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL620223,1916,22224,,,,,Autocuration,,1,,0,9606.0,4711,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,CHEMBL620224,5965,22224,,,,,Autocuration,,1,,0,9606.0,4712,A,U,BAO_0000218,
,Homo sapiens,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,CHEMBL620225,1299,22224,,,,,Autocuration,,1,,0,9606.0,4713,A,U,BAO_0000019,
,Homo sapiens,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,CHEMBL620226,1299,22224,,,,,Autocuration,,1,,0,9606.0,4714,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620227,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4715,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL876726,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4716,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620228,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4717,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL620229,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4718,A,U,BAO_0000019,
,Mus musculus,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,CHEMBL620230,17764,50594,,,,,Intermediate,,1,,1,10090.0,4719,F,N,BAO_0000218,In vivo
,Mus musculus,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,CHEMBL620231,17764,50594,,,,,Intermediate,,1,,1,10090.0,4720,F,N,BAO_0000218,In vivo
,Mus musculus,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,CHEMBL620232,17764,50594,,,,,Intermediate,,1,,1,10090.0,4721,F,N,BAO_0000218,In vivo
,Mus musculus,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,CHEMBL620233,17764,50594,,,,,Intermediate,,1,,1,10090.0,4722,F,N,BAO_0000218,In vivo
,Mus musculus,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),CHEMBL620234,14294,50594,,,,,Intermediate,,1,,1,10090.0,4723,A,N,BAO_0000218,
,Mus musculus,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),CHEMBL620235,14294,50594,,,,,Intermediate,,1,,1,10090.0,4724,A,N,BAO_0000218,
,Mus musculus,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),CHEMBL620236,14294,50594,,,,,Intermediate,,1,,1,10090.0,4725,A,N,BAO_0000218,
,Mus musculus,,,In vitro metabolic potential in mouse liver microsomes,CHEMBL620237,6251,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4726,A,N,BAO_0000218,
,Mus musculus,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,CHEMBL620238,17582,50594,,,,,Intermediate,,1,,1,10090.0,4727,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),CHEMBL620239,17811,50594,,,Adrenal gland,2369.0,Intermediate,,1,,1,10090.0,4728,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,CHEMBL620240,17811,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4729,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,CHEMBL620241,17811,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4730,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),CHEMBL876727,17811,50594,,,,,Intermediate,,1,,1,10090.0,4731,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),CHEMBL620242,17811,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4732,A,N,BAO_0000218,
,Mus musculus,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),CHEMBL620243,17811,50594,,,,,Intermediate,,1,,1,10090.0,4733,A,N,BAO_0000218,
,Mus musculus,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,CHEMBL620244,5288,50594,,,,,Intermediate,,1,,1,10090.0,4734,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,CHEMBL620245,2717,50594,,,Serum,1977.0,Intermediate,,1,,1,10090.0,4735,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,CHEMBL620246,2717,50594,,,Serum,1977.0,Intermediate,,1,,1,10090.0,4736,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,CHEMBL620247,2717,50594,,,Serum,1977.0,Intermediate,,1,,1,10090.0,4737,A,N,BAO_0000218,
,Mus musculus,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,CHEMBL620248,17753,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,4738,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,CHEMBL873497,17753,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,4739,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,CHEMBL620249,17753,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,4740,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intraperitoneal administration in mice at 18 uM/kg,CHEMBL620250,17764,50594,,,,,Intermediate,,1,,1,10090.0,4741,F,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intraperitoneal administration in mice at 23 uM/kg,CHEMBL620251,17764,50594,,,,,Intermediate,,1,,1,10090.0,4742,F,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intraperitoneal administration in mice at 25 uM/kg,CHEMBL620252,17764,50594,,,,,Intermediate,,1,,1,10090.0,4743,F,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intraperitoneal administration in mice at 26 uM/kg,CHEMBL620253,17764,50594,,,,,Intermediate,,1,,1,10090.0,4744,F,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intravenous administration in mice at 23 uM/kg,CHEMBL620254,17764,50594,,,,,Intermediate,,1,,1,10090.0,4745,F,N,BAO_0000218,In vivo
,Mus musculus,,,Half life after intravenous administration in mice at 24 uM/kg,CHEMBL620255,17764,50594,,,,,Intermediate,,1,,1,10090.0,4746,A,N,BAO_0000218,In vivo
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,CHEMBL620256,16597,50594,,,,,Intermediate,,1,,1,10090.0,4747,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,CHEMBL876728,2675,50594,,,,,Intermediate,,1,,1,10090.0,4748,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,CHEMBL620257,2675,50594,,,,,Intermediate,,1,,1,10090.0,4749,A,N,BAO_0000218,In vivo
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),CHEMBL620258,16597,50594,,,,,Intermediate,,1,,1,10090.0,4750,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",CHEMBL620259,4890,50594,,,,,Intermediate,,1,,1,10090.0,4751,A,N,BAO_0000218,In vivo
,Mus musculus,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,CHEMBL620260,429,50594,,,,,Intermediate,,1,,1,10090.0,4752,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL620261,17837,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4753,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL620262,16597,50594,,,,,Intermediate,,1,,1,10090.0,4754,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life at a dose of 10 mg/kg peroral administration in mice.,CHEMBL620263,16597,50594,,,,,Intermediate,,1,,1,10090.0,4755,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half life in ob/ob mice,CHEMBL620264,6619,50594,,,,,Intermediate,,1,,1,10090.0,4756,A,N,BAO_0000218,
,Mus musculus,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL620265,4066,50594,,,,,Intermediate,,1,,1,10090.0,4757,A,N,BAO_0000218,In vivo
,Mus musculus,,,Half-life was measured in mouse,CHEMBL620266,4239,50594,,,,,Intermediate,,1,,1,10090.0,4758,A,N,BAO_0000218,
,Mus musculus,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,CHEMBL620267,5969,50594,,,,,Intermediate,,1,,1,10090.0,4759,A,N,BAO_0000218,In vivo
,Mus musculus,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,CHEMBL619364,8999,50594,,,,,Intermediate,,1,,1,10090.0,4760,A,N,BAO_0000218,
,Mus musculus,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,CHEMBL619365,8999,50594,,,,,Intermediate,,1,,1,10090.0,4761,A,N,BAO_0000218,
,Mus musculus,,,T2 in brain of mice at the oral dose of 50 mg/kg,CHEMBL619366,17641,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4762,A,N,BAO_0000218,
,Mus musculus,,,T2 in kidney of mice at the oral dose of 50 mg/kg,CHEMBL619367,17641,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4763,A,N,BAO_0000218,
,Mus musculus,,,T2 in liver of mice at the oral dose of 50 mg/kg,CHEMBL619368,17641,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4764,A,N,BAO_0000218,
,Mus musculus,,,T2 in lungs of mice at the oral dose of 50 mg/kg,CHEMBL619369,17641,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,4765,A,N,BAO_0000218,
,Mus musculus,,,T2 in spleen of mice at the oral dose of 50 mg/kg,CHEMBL876729,17641,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,4766,A,N,BAO_0000218,
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,CHEMBL619370,16597,50594,,,,,Intermediate,,1,,1,10090.0,4767,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",CHEMBL619371,4890,50594,,,,,Intermediate,,1,,1,10090.0,4768,A,N,BAO_0000218,In vivo
,Mus musculus,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,CHEMBL619372,429,50594,,,,,Intermediate,,1,,1,10090.0,4769,A,N,BAO_0000218,In vivo
,Mus musculus,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,CHEMBL620012,429,50594,,,,,Intermediate,,1,,1,10090.0,4770,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,CHEMBL620013,5969,50594,,,,,Intermediate,,1,,1,10090.0,4771,A,N,BAO_0000218,In vivo
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL620014,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4772,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",CHEMBL620015,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4773,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621010,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4774,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621011,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4775,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621012,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4776,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",CHEMBL621013,16913,81034,,478.0,,,Intermediate,,1,,1,9606.0,4777,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780TAX cell line,CHEMBL621014,17270,81034,,478.0,,,Intermediate,,1,,1,9606.0,4778,F,N,BAO_0000219,
A2780cisR,Homo sapiens,,,In vitro inhibitory activity against human tumor cell line A2780cis,CHEMBL618154,5618,80017,,481.0,,,Intermediate,,1,,1,9606.0,4779,F,N,BAO_0000219,
A2780,Homo sapiens,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,CHEMBL618155,17777,81034,,478.0,,,Expert,,1,,1,9606.0,4780,F,N,BAO_0000219,
A2780cisR,Homo sapiens,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,CHEMBL618156,16112,80017,,481.0,,,Intermediate,,1,,1,9606.0,4781,F,N,BAO_0000219,
A2780cisR,Homo sapiens,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),CHEMBL618157,15748,80017,,481.0,,,Intermediate,,1,,1,9606.0,4782,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,CHEMBL618328,6633,81034,,478.0,,,Intermediate,,1,,1,9606.0,4783,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,CHEMBL618329,16930,81034,,478.0,,,Intermediate,,1,,1,9606.0,4784,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,CHEMBL618330,17496,81034,,478.0,,,Intermediate,,1,,1,9606.0,4785,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro antitumor activity against A2780cisR cell line.,CHEMBL618331,12989,81034,,478.0,,,Expert,,1,,1,9606.0,4786,F,N,BAO_0000219,
A2780,Homo sapiens,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),CHEMBL618332,4840,81034,,478.0,,,Intermediate,,1,,1,9606.0,4787,F,N,BAO_0000219,
A2780,Homo sapiens,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,CHEMBL618333,12989,81034,,478.0,,,Expert,,1,,1,9606.0,4788,F,N,BAO_0000219,
A2780cisR,Homo sapiens,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,CHEMBL618334,16745,80017,,481.0,,,Intermediate,,1,,1,9606.0,4789,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,CHEMBL618335,16597,81034,,478.0,,,Expert,,1,,1,9606.0,4790,F,N,BAO_0000219,
,Rattus norvegicus,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,CHEMBL618336,16547,11736,,,,,Expert,,1,,9,10116.0,4791,B,D,BAO_0000019,
,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),CHEMBL618337,16547,11736,,,,,Expert,,1,,8,,4792,F,H,BAO_0000019,
,Rattus norvegicus,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),CHEMBL618338,16547,11736,,,,,Expert,,1,,9,10116.0,4793,F,D,BAO_0000019,
HEK293,Homo sapiens,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,CHEMBL618339,15856,278,,722.0,,,Expert,,1,,9,9606.0,4794,F,D,BAO_0000219,
HEK293,Homo sapiens,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,CHEMBL618340,15856,278,,722.0,,,Expert,,1,,9,9606.0,4795,F,D,BAO_0000219,
,Mus musculus,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,CHEMBL618341,16547,11831,,,,,Expert,,1,,9,10090.0,4796,B,D,BAO_0000019,
,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),CHEMBL618342,16547,11831,,,,,Expert,,1,,8,,4797,F,H,BAO_0000019,
,Mus musculus,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),CHEMBL618343,16547,11831,,,,,Expert,,1,,9,10090.0,4798,F,D,BAO_0000019,
,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,CHEMBL621038,17402,280,,,,,Expert,,1,,8,,4799,B,H,BAO_0000357,
T-cells,Homo sapiens,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),CHEMBL621039,11746,22226,,574.0,,,Autocuration,,1,,0,9606.0,4800,F,U,BAO_0000219,
T-cells,Homo sapiens,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,CHEMBL621040,11746,22226,,574.0,,,Autocuration,,1,,0,9606.0,4801,F,U,BAO_0000219,
A-375,Homo sapiens,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,CHEMBL621041,5455,80018,,455.0,,,Intermediate,,1,,1,9606.0,4802,F,N,BAO_0000219,
A-375,Homo sapiens,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,CHEMBL621042,2068,80018,,455.0,,,Intermediate,,1,,1,9606.0,4803,F,N,BAO_0000219,
A-375,Homo sapiens,,,In vitro antitumor activity against A375cell line extracted form melanoma,CHEMBL621043,2683,80018,,455.0,,,Intermediate,,1,,1,9606.0,4804,F,N,BAO_0000219,
A-375,Homo sapiens,,,Inhibition of cell growth in (A375) melan cell line,CHEMBL621044,15313,80018,,455.0,,,Expert,,1,,1,9606.0,4805,F,N,BAO_0000219,
A-375,Homo sapiens,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,CHEMBL621045,13739,80018,,455.0,,,Intermediate,,1,,1,9606.0,4806,F,N,BAO_0000219,
A-375,Homo sapiens,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,CHEMBL621046,13739,80018,,455.0,,,Intermediate,,1,,1,9606.0,4807,F,N,BAO_0000219,
A-375,Homo sapiens,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,CHEMBL621047,14750,80018,,455.0,,,Intermediate,,1,,1,9606.0,4808,F,N,BAO_0000219,
A-427,Homo sapiens,,,Antiproliferative activity measured against A427 human lung carcinoma,CHEMBL621048,14777,80019,,797.0,,,Intermediate,,1,,1,9606.0,4809,F,N,BAO_0000219,
A-427,Homo sapiens,,,Antiproliferative activity measured against A427 human lung carcinoma,CHEMBL883798,14777,80019,,797.0,,,Intermediate,,1,,1,9606.0,4810,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,CHEMBL621049,17672,80019,,797.0,,,Intermediate,,1,,1,9606.0,4811,F,N,BAO_0000219,
A-427,Homo sapiens,,,Inhibition of large cell lung carcinoma (A427),CHEMBL621050,14368,80019,,797.0,,,Intermediate,,1,,1,9606.0,4812,F,N,BAO_0000219,
A-427,Homo sapiens,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,CHEMBL621051,14368,80019,,797.0,,,Intermediate,,1,,1,9606.0,4813,F,N,BAO_0000219,
A-427,Homo sapiens,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,CHEMBL621052,13866,80019,,797.0,,,Intermediate,,1,,1,9606.0,4814,F,N,BAO_0000219,
A-427,Homo sapiens,,,Inhibitory concentration in human lung carcinoma A427 cell line,CHEMBL621053,2545,80019,,797.0,,,Intermediate,,1,,1,9606.0,4815,F,N,BAO_0000219,
A-427,Homo sapiens,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,CHEMBL621054,2545,80019,,797.0,,,Intermediate,,1,,1,9606.0,4816,F,N,BAO_0000219,
,Cercopithecidae,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,CHEMBL621055,6062,22224,,,,,Autocuration,,1,,0,9527.0,4817,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Tested for volume of distribution upon iv administration to african green monkey,CHEMBL876398,4578,22224,,,,,Autocuration,,1,,0,9527.0,4818,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution in monkey,CHEMBL621056,17592,22224,,,,,Autocuration,,1,,0,9527.0,4819,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL621057,5005,22224,,,,,Autocuration,,1,,0,9544.0,4820,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,CHEMBL621058,5005,22224,,,,,Autocuration,,1,,0,9544.0,4821,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,CHEMBL621059,5922,22224,,,,,Autocuration,,1,,0,9527.0,4822,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The distribution volume after intravenous administration in cynomolgus monkeys,CHEMBL621060,5355,22224,,,,,Autocuration,,1,,0,9527.0,4823,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL621061,5355,22224,,,,,Autocuration,,1,,0,9527.0,4824,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL621062,5355,22224,,,,,Autocuration,,1,,0,9527.0,4825,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume displacement was calculated in rhesus monkey,CHEMBL621063,6057,22224,,,,,Autocuration,,1,,0,9527.0,4826,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution in steady state was determined in rhesus monkey,CHEMBL621064,5145,22224,,,,,Autocuration,,1,,0,9527.0,4827,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution of compound was determined in monkey,CHEMBL621065,6821,22224,,,,,Autocuration,,1,,0,9527.0,4828,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL621066,5334,22224,,,,,Autocuration,,1,,0,9527.0,4829,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL621067,5334,22224,,,,,Autocuration,,1,,0,9527.0,4830,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL621068,6641,22224,,,,,Autocuration,,1,,0,9527.0,4831,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL876399,2661,22224,,,,,Autocuration,,1,,0,9527.0,4832,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume distribution in monkey after administration of 1 mg/kg iv,CHEMBL621069,6535,22224,,,,,Autocuration,,1,,0,9527.0,4833,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL621070,4809,22224,,,,,Autocuration,,1,,0,9527.0,4834,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,CHEMBL621071,6062,22224,,,,,Autocuration,,1,,0,9527.0,4835,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621072,3443,22224,,,,,Autocuration,,1,,0,9527.0,4836,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Oral systemic bioavailability upon iv administration to african green monkey,CHEMBL618209,4578,22224,,,,,Autocuration,,1,,0,9527.0,4837,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL618210,4809,22224,,,,,Autocuration,,1,,0,9527.0,4838,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Baboon plasma free fraction. ,CHEMBL618211,11271,22224,,,,,Autocuration,,1,,0,9527.0,4839,A,U,BAO_0000019,
,Cercopithecidae,,,Area under the curve was calculated in rhesus monkey after iv administration,CHEMBL618212,6057,22224,,,,,Autocuration,,1,,0,9527.0,4840,A,U,BAO_0000218,
,Cercopithecidae,,,Area under the curve was calculated in rhesus monkey after peroral administration,CHEMBL618213,6057,22224,,,,,Autocuration,,1,,0,9527.0,4841,A,U,BAO_0000019,
,Cercopithecidae,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,CHEMBL618214,17853,22224,,,,,Autocuration,,1,,0,9527.0,4842,A,U,BAO_0000019,
,Cercopithecidae,,,Half life period in monkey after 5 mg/kg dose,CHEMBL873492,5302,22224,,,,,Autocuration,,1,,0,9527.0,4843,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,CHEMBL618272,4257,22224,,,,,Autocuration,,1,,0,9527.0,4844,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,CHEMBL618273,4257,22224,,,,,Autocuration,,1,,0,9527.0,4845,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,CHEMBL618274,13501,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4846,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,CHEMBL618275,5394,22224,,,,,Autocuration,,1,,0,9527.0,4847,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL618276,2661,22224,,,,,Autocuration,,1,,0,9527.0,4848,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for terminal half life in monkey,CHEMBL618277,3341,22224,,,,,Autocuration,,1,,0,9527.0,4849,A,U,BAO_0000019,
,Cercopithecidae,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,CHEMBL618278,3045,22224,,,,,Autocuration,,1,,0,9527.0,4850,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL618279,5005,22224,,,Plasma,1969.0,Autocuration,,1,,0,9544.0,4851,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life of compound was determined in squirrel monkey,CHEMBL618280,4847,22224,,,,,Autocuration,,1,,0,9527.0,4852,A,U,BAO_0000019,
,Macaca fascicularis,,,Half life after iv administration in cynomolgus monkey,CHEMBL618281,4256,22224,,,,,Autocuration,,1,,0,9541.0,4853,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life in monkey plasma after administration of 1 mg/kg iv,CHEMBL618282,6535,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,4854,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life was calculated in rhesus monkey,CHEMBL618283,6057,22224,,,,,Autocuration,,1,,0,9527.0,4855,A,U,BAO_0000019,
,Cercopithecidae,,,Half life in monkey,CHEMBL618284,17592,22224,,,,,Autocuration,,1,,0,9527.0,4856,A,U,BAO_0000019,
,Cercopithecidae,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL618285,6641,22224,,,,,Autocuration,,1,,0,9527.0,4857,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life was evaluated in rhesus,CHEMBL618286,5472,22224,,,,,Autocuration,,1,,0,9527.0,4858,A,U,BAO_0000019,
,Cercopithecidae,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL618287,6221,22224,,,,,Autocuration,,1,,0,9527.0,4859,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,CHEMBL618288,5668,22224,,,,,Autocuration,,1,,0,9527.0,4860,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),CHEMBL876393,4809,22224,,,,,Autocuration,,1,,0,9527.0,4861,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,CHEMBL618289,5546,22224,,,,,Autocuration,,1,,0,9527.0,4862,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,CHEMBL618290,5553,22224,,,,,Autocuration,,1,,0,9527.0,4863,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life was calculated in monkey,CHEMBL618291,6078,22224,,,,,Autocuration,,1,,0,9527.0,4864,A,U,BAO_0000019,
,Cercopithecidae,,,Half-life in Squirrel monkey,CHEMBL618292,5147,22224,,,,,Autocuration,,1,,0,9527.0,4865,A,U,BAO_0000019,
,Cercopithecidae,,,Half-life in rhesus monkey,CHEMBL618293,5145,22224,,,,,Autocuration,,1,,0,9527.0,4866,A,U,BAO_0000019,
,Cercopithecidae,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,CHEMBL618294,6062,22224,,,,,Autocuration,,1,,0,9527.0,4867,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life period after intravenous administration in cynomolgus monkeys,CHEMBL618295,5355,22224,,,,,Autocuration,,1,,0,9527.0,4868,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life period after oral administration in cynomolgus monkeys,CHEMBL618296,5355,22224,,,,,Autocuration,,1,,0,9527.0,4869,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,CHEMBL618297,5355,22224,,,,,Autocuration,,1,,0,9527.0,4870,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618298,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4871,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618299,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4872,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618300,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4873,A,U,BAO_0000019,
,Homo sapiens,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,CHEMBL618301,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4874,A,U,BAO_0000019,
,Homo sapiens,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,CHEMBL618302,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4875,A,U,BAO_0000019,
,Homo sapiens,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,CHEMBL876394,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4876,A,U,BAO_0000019,
,Homo sapiens,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,CHEMBL618303,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4877,A,U,BAO_0000019,
,Homo sapiens,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,CHEMBL618304,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4878,A,U,BAO_0000019,
,Homo sapiens,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,CHEMBL618305,1916,22224,,,,,Autocuration,,1,,0,9606.0,4879,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Oral bioavailability in human,CHEMBL618306,16643,22224,,,,,Autocuration,,1,,0,9606.0,4880,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Compound was tested for human plasma protein binding,CHEMBL618307,17248,22224,,,,,Autocuration,,1,,0,9606.0,4881,A,U,BAO_0000019,
,Homo sapiens,,,Compound was tested for human plasma protein binding; Not determined,CHEMBL618308,17248,22224,,,,,Autocuration,,1,,0,9606.0,4882,A,U,BAO_0000019,
,Homo sapiens,,,Protein binding activity of compound in human plasma; % Free,CHEMBL618309,6241,22224,,,,,Autocuration,,1,,0,9606.0,4883,A,U,BAO_0000019,
,Homo sapiens,,,Unbound fraction (plasma),CHEMBL618310,17716,22224,,,,,Autocuration,,1,,0,9606.0,4884,A,U,BAO_0000019,
,Homo sapiens,,,Half life for the hydrolysis of compound in human blood serum,CHEMBL873353,17605,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,4885,A,U,BAO_0000366,
,Homo sapiens,,,Half life period in human plasma using phosphate buffer (0.08 M),CHEMBL618311,17625,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,4886,A,U,BAO_0000366,
,Homo sapiens,,,Half life period in human plasma using phosphate buffer (0.1 M),CHEMBL618312,17625,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,4887,A,U,BAO_0000366,
,Homo sapiens,,,Half-life in human plasma was determined,CHEMBL618313,17747,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,4888,A,U,BAO_0000366,
,Homo sapiens,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,CHEMBL618314,15613,22224,,,,,Autocuration,,1,,0,9606.0,4889,A,U,BAO_0000019,
,Homo sapiens,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),CHEMBL618315,354,22224,,,,,Autocuration,,1,,0,9606.0,4890,A,U,BAO_0000019,
,Homo sapiens,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",CHEMBL618316,3741,22224,,,,,Autocuration,,1,,0,9606.0,4891,A,U,BAO_0000019,
,Homo sapiens,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",CHEMBL618317,3741,22224,,,,,Autocuration,,1,,0,9606.0,4892,A,U,BAO_0000019,
,Homo sapiens,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",CHEMBL620138,3741,22224,,,,,Autocuration,,1,,0,9606.0,4893,A,U,BAO_0000019,
,Homo sapiens,,,Partition coefficient (logP),CHEMBL858280,17599,22224,,,,,Autocuration,,1,,0,9606.0,4894,A,U,BAO_0000019,
,Homo sapiens,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,CHEMBL620139,5486,22224,,,,,Autocuration,,1,,0,9606.0,4895,A,U,BAO_0000019,
,Homo sapiens,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,CHEMBL620140,5600,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4896,A,U,BAO_0000251,
,Homo sapiens,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),CHEMBL620141,14294,22224,,,,,Autocuration,,1,,0,9606.0,4897,A,U,BAO_0000019,
,Homo sapiens,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),CHEMBL620142,14294,22224,,,,,Autocuration,,1,,0,9606.0,4898,A,U,BAO_0000019,
,Homo sapiens,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),CHEMBL620143,14294,22224,,,,,Autocuration,,1,,0,9606.0,4899,A,U,BAO_0000019,
,Homo sapiens,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),CHEMBL620144,14294,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4900,A,U,BAO_0000251,
,Homo sapiens,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),CHEMBL620145,14294,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4901,A,U,BAO_0000251,
,Homo sapiens,,,Metabolism of compound in human microsomes; Trace,CHEMBL620146,14294,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4902,A,U,BAO_0000251,
,Homo sapiens,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,CHEMBL620147,6260,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4903,A,U,BAO_0000251,
,Homo sapiens,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,CHEMBL620148,6187,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,4904,A,U,BAO_0000251,
,Homo sapiens,,,In vitro metabolic potential in human liver microsomes,CHEMBL620149,6251,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,4905,A,U,BAO_0000251,
,Homo sapiens,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,CHEMBL876412,3246,22224,,,,,Autocuration,,1,,0,9606.0,4906,A,U,BAO_0000019,
,Homo sapiens,,,Tested for human plasma protein binding of the compound; Not tested,CHEMBL619352,17313,22224,,,,,Autocuration,,1,,0,9606.0,4907,A,U,BAO_0000019,
,Homo sapiens,,,Compound was tested for percent protein binding (PB) in human,CHEMBL619353,6227,22224,,,,,Autocuration,,1,,0,9606.0,4908,A,U,BAO_0000019,
,Homo sapiens,,,Protein binding in human plasma,CHEMBL619354,5530,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,4909,A,U,BAO_0000019,
,Homo sapiens,,,Permeability coefficient (B to A) in Caco-2 cell,CHEMBL619355,6108,22224,,,,,Autocuration,,1,,0,9606.0,4910,A,U,BAO_0000019,
,Homo sapiens,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,CHEMBL619356,6108,22224,,,,,Autocuration,,1,,0,9606.0,4911,A,U,BAO_0000019,
,Homo sapiens,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),CHEMBL619357,2774,22224,,,,,Autocuration,,1,,0,9606.0,4912,A,U,BAO_0000019,
,Homo sapiens,,,In vitro rate of absorption observed as Caco-2 permeability in humans,CHEMBL619358,16643,22224,,,,,Autocuration,,1,,0,9606.0,4913,A,U,BAO_0000019,
Caco-2,Homo sapiens,,,Cellular permeability of compound was determined in Caco-2 cells; High,CHEMBL619359,17582,22224,,495.0,,,Autocuration,,1,,0,9606.0,4914,A,U,BAO_0000219,
Caco-2,Homo sapiens,,,Permeability in Caco-2 cells of compound,CHEMBL619360,6838,22224,,495.0,,,Autocuration,,1,,0,9606.0,4915,A,U,BAO_0000219,
,Homo sapiens,,,Permeability coefficient (A to B) in Caco-2 cell,CHEMBL619361,6108,22224,,,,,Autocuration,,1,,0,9606.0,4916,A,U,BAO_0000019,
,Homo sapiens,,,Permeability coefficient (B to A) in Caco-2 cell,CHEMBL619362,6108,22224,,,,,Autocuration,,1,,0,9606.0,4917,A,U,BAO_0000019,
,Homo sapiens,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),CHEMBL619363,6108,22224,,,,,Autocuration,,1,,0,9606.0,4918,A,U,BAO_0000019,
,Homo sapiens,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,CHEMBL618942,2146,22224,,,,,Autocuration,,1,,0,9606.0,4919,A,U,BAO_0000019,
,Homo sapiens,,,Compound was tested for protein binding in human plasma,CHEMBL618943,4514,22224,,,,,Autocuration,,1,,0,9606.0,4920,A,U,BAO_0000019,
,Homo sapiens,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,CHEMBL618944,6108,22224,,,,,Autocuration,,1,,0,9606.0,4921,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,CHEMBL618945,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,4922,A,U,BAO_0000019,
,Mus musculus,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,CHEMBL618946,5969,50594,,,,,Intermediate,,1,,1,10090.0,4923,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL876413,3277,50594,,,,,Intermediate,,1,,1,10090.0,4924,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,CHEMBL618947,3802,50594,,,,,Intermediate,,1,,1,10090.0,4925,A,N,BAO_0000218,In vivo
,Mus musculus,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,CHEMBL618948,2862,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,4926,A,N,BAO_0000218,In vivo
,Mus musculus,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL618949,6348,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,4927,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,CHEMBL618950,17764,50594,,,,,Intermediate,,1,,1,10090.0,4928,F,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax after oral administration at 30 mg/kg in ICR mouse,CHEMBL618951,5781,50594,,,,,Intermediate,,1,,1,10090.0,4929,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax after peroral administration in mice at 2.4 uM/kg,CHEMBL618952,17764,50594,,,,,Intermediate,,1,,1,10090.0,4930,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL618953,4066,50594,,,,,Intermediate,,1,,1,10090.0,4931,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in brain of mice at the oral dose of 50 mg/kg,CHEMBL618954,17641,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,4932,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,CHEMBL618955,17641,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4933,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in liver of mice at the oral dose of 50 mg/kg,CHEMBL618956,17641,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,4934,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,CHEMBL618957,17641,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,4935,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in mice at 18 uM/kg i.p. administration,CHEMBL618958,17764,50594,,,,,Intermediate,,1,,1,10090.0,4936,F,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in mice at 23 uM/kg i.v. administration,CHEMBL618959,17764,50594,,,,,Intermediate,,1,,1,10090.0,4937,F,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in mice at 25 uM/kg i.p. administration,CHEMBL618960,17764,50594,,,,,Intermediate,,1,,1,10090.0,4938,F,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in mice at 26 uM/kg i.p. administration,CHEMBL876723,17764,50594,,,,,Intermediate,,1,,1,10090.0,4939,F,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,CHEMBL618961,17641,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,4940,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL618962,16597,50594,,,,,Intermediate,,1,,1,10090.0,4941,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL618963,16597,50594,,,,,Intermediate,,1,,1,10090.0,4942,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax value in IRC mice,CHEMBL618964,5951,50594,,,,,Intermediate,,1,,1,10090.0,4943,A,N,BAO_0000218,
,Mus musculus,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL618965,5506,50594,,,,,Intermediate,,1,,1,10090.0,4944,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL618966,5506,50594,,,,,Intermediate,,1,,1,10090.0,4945,A,N,BAO_0000218,In vivo
,Mus musculus,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),CHEMBL618967,429,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,4946,A,N,BAO_0000218,
,Mus musculus,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),CHEMBL618968,429,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,4947,A,N,BAO_0000218,
,Mus musculus,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),CHEMBL618969,4066,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,4948,A,N,BAO_0000218,
,Mus musculus,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL618970,17734,50594,,,,,Intermediate,,1,,1,10090.0,4949,A,N,BAO_0000218,
,Mus musculus,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL618971,17734,50594,,,,,Intermediate,,1,,1,10090.0,4950,A,N,BAO_0000218,
,Mus musculus,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,CHEMBL618972,6062,50594,,,,,Intermediate,,1,,1,10090.0,4951,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,CHEMBL618973,5969,50594,,,,,Intermediate,,1,,1,10090.0,4952,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,CHEMBL618974,5969,50594,,,,,Intermediate,,1,,1,10090.0,4953,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL618975,5969,50594,,,,,Intermediate,,1,,1,10090.0,4954,A,N,BAO_0000218,In vivo
,Mus musculus,,,Vd in mice,CHEMBL618976,5980,50594,,,,,Intermediate,,1,,1,10090.0,4955,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution in mouse,CHEMBL618977,17592,50594,,,,,Intermediate,,1,,1,10090.0,4956,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL876724,6348,50594,,,,,Intermediate,,1,,1,10090.0,4957,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,CHEMBL618978,17753,50594,,,,,Intermediate,,1,,1,10090.0,4958,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,CHEMBL618979,17753,50594,,,,,Intermediate,,1,,1,10090.0,4959,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,CHEMBL618980,17753,50594,,,,,Intermediate,,1,,1,10090.0,4960,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic property (vdss) was measured in mouse,CHEMBL618981,4239,50594,,,,,Intermediate,,1,,1,10090.0,4961,A,N,BAO_0000218,In vivo
,Mus musculus,,,Value distribution upon iv administration in mouse,CHEMBL618982,2862,50594,,,,,Intermediate,,1,,1,10090.0,4962,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,CHEMBL620150,17734,50594,,,,,Intermediate,,1,,1,10090.0,4963,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution was evaluated in mice after intravenous administration,CHEMBL620151,2675,50594,,,,,Intermediate,,1,,1,10090.0,4964,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution was evaluated in mice after oral administration,CHEMBL620152,2675,50594,,,,,Intermediate,,1,,1,10090.0,4965,A,N,BAO_0000218,In vivo
,Mus musculus,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL620153,17837,50594,,,,,Intermediate,,1,,1,10090.0,4966,A,N,BAO_0000218,In vivo
,Mus musculus,,,Steady state volume of distribution was determined in mice,CHEMBL876395,5727,50594,,,,,Intermediate,,1,,1,10090.0,4967,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume distribution (steady state) of compound was determined in mouse,CHEMBL620154,17852,50594,,,,,Intermediate,,1,,1,10090.0,4968,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,CHEMBL620155,17764,50594,,,,,Intermediate,,1,,1,10090.0,4969,A,N,BAO_0000218,In vivo
,Mus musculus,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL620156,16597,50594,,,,,Intermediate,,1,,1,10090.0,4970,A,N,BAO_0000218,In vivo
,Mus musculus,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,CHEMBL620157,6062,50594,,,,,Intermediate,,1,,1,10090.0,4971,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of compound (oxidized form) in in kidney tissue,CHEMBL620158,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,4972,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL620159,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4973,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL620160,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4974,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL620161,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,4975,A,N,BAO_0000218,In vivo
A-427,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,CHEMBL620162,10708,80019,,797.0,,,Intermediate,,1,,1,9606.0,4976,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,CHEMBL620163,16597,80852,,500.0,,,Expert,,1,,1,9606.0,4977,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,CHEMBL620833,16062,80852,,500.0,,,Expert,,1,,1,9606.0,4978,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,CHEMBL876396,16062,80852,,500.0,,,Expert,,1,,1,9606.0,4979,F,N,BAO_0000219,
A-431,Homo sapiens,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,CHEMBL620834,16958,80852,,500.0,,,Expert,,1,,1,9606.0,4980,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of A431 human carcinoma cell proliferation,CHEMBL620835,6700,80852,,500.0,,,Expert,,1,,1,9606.0,4981,F,N,BAO_0000219,
A-431,Homo sapiens,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,CHEMBL620836,17226,80852,,500.0,,,Expert,,1,,1,9606.0,4982,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,CHEMBL620837,6828,80852,,500.0,,,Intermediate,,1,,1,9606.0,4983,F,N,BAO_0000219,
A-431,Homo sapiens,,,In vitro cytotoxicity against epidermoid carcinoma cell line,CHEMBL621017,12314,80852,,500.0,,,Intermediate,,1,,1,9606.0,4984,F,N,BAO_0000219,
A-431,Homo sapiens,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",CHEMBL621018,13412,9,,500.0,,,Expert,,1,,9,9606.0,4985,F,D,BAO_0000218,
A-431,Homo sapiens,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,CHEMBL621019,13299,80852,,500.0,,,Intermediate,,1,,1,9606.0,4986,F,N,BAO_0000219,
A-431,Homo sapiens,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,CHEMBL621020,17420,80852,,500.0,,,Intermediate,,1,,1,9606.0,4987,F,N,BAO_0000219,
A-431,Homo sapiens,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,CHEMBL621021,13678,80852,,500.0,,,Intermediate,,1,,1,9606.0,4988,F,N,BAO_0000219,
A-431,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,CHEMBL621022,14171,9,,500.0,,,Expert,,1,,8,,4989,F,H,BAO_0000219,
A-431,Homo sapiens,,,Tested for antiproliferative activity against human A431 cells,CHEMBL621023,6333,80852,,500.0,,,Expert,,1,,1,9606.0,4990,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,CHEMBL621024,2356,9,,500.0,,,Expert,,1,,9,9606.0,4991,F,D,BAO_0000219,
A-431,Homo sapiens,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,CHEMBL621025,15578,80852,,500.0,,,Expert,,1,,1,9606.0,4992,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of A431 cell proliferation,CHEMBL621026,5126,80852,,500.0,,,Expert,,1,,1,9606.0,4993,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,CHEMBL621027,6844,80852,,500.0,,,Expert,,1,,1,9606.0,4994,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),CHEMBL876397,6844,80852,,500.0,,,Expert,,1,,1,9606.0,4995,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,CHEMBL883797,4925,80852,,500.0,,,Intermediate,,1,,1,9606.0,4996,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,CHEMBL621028,4925,80852,,500.0,,,Intermediate,,1,,1,9606.0,4997,F,N,BAO_0000219,
A-431,Homo sapiens,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,CHEMBL621029,13978,80852,,500.0,,,Intermediate,,1,,1,9606.0,4998,F,N,BAO_0000219,
A-431,Homo sapiens,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,CHEMBL621030,16786,80852,,500.0,,,Intermediate,,1,,1,9606.0,4999,F,N,BAO_0000219,
A-431,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL621147,13412,9,,500.0,,,Expert,,1,,8,,5000,F,H,BAO_0000219,
A-431,Homo sapiens,,,In vivo antiproliferative activity against A431 cell line,CHEMBL621148,17824,80852,,500.0,,,Intermediate,,1,,1,9606.0,5001,F,N,BAO_0000218,
A-431,Homo sapiens,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,CHEMBL621149,12751,9,,500.0,,,Expert,,1,,9,9606.0,5002,F,D,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,CHEMBL621150,12380,80852,,500.0,,,Expert,,1,,1,9606.0,5003,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,CHEMBL621151,4959,9,,500.0,,,Expert,,1,,9,9606.0,5004,F,D,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),CHEMBL621152,6333,80852,,500.0,,,Intermediate,,1,,1,9606.0,5005,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),CHEMBL621153,6333,80852,,500.0,,,Intermediate,,1,,1,9606.0,5006,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),CHEMBL884000,6333,80852,,500.0,,,Intermediate,,1,,1,9606.0,5007,F,N,BAO_0000219,
,Homo sapiens,,,Inhibition of EGFR overexpressing A431 cell proliferation,CHEMBL621154,5296,9,,,,,Expert,,1,,9,9606.0,5008,F,D,BAO_0000019,
A-431,Homo sapiens,,,Inhibition of A431 cell proliferation,CHEMBL621155,12624,80852,,500.0,,,Expert,,1,,1,9606.0,5009,F,N,BAO_0000219,
A-431,Homo sapiens,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,CHEMBL621156,14926,9,,500.0,,,Expert,,1,,9,9606.0,5010,F,D,BAO_0000219,
A-431,Homo sapiens,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",CHEMBL621157,14926,9,,500.0,,,Expert,,1,,9,9606.0,5011,F,D,BAO_0000219,
A-431,,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),CHEMBL621158,14926,9,,500.0,,,Expert,,1,,8,,5012,F,H,BAO_0000219,
A-431,Homo sapiens,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,CHEMBL621159,15144,80852,,500.0,,,Intermediate,,1,,1,9606.0,5013,F,N,BAO_0000219,
A-431,Homo sapiens,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,CHEMBL621160,15144,80852,,500.0,,,Intermediate,,1,,1,9606.0,5014,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,CHEMBL621161,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5015,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,CHEMBL621162,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5016,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,CHEMBL621163,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5017,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,CHEMBL621164,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5018,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,CHEMBL621165,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5019,F,N,BAO_0000219,
,Cercopithecidae,,,Half-life period in cynomolgus monkey,CHEMBL619159,5922,22224,,,,,Autocuration,,1,,0,9527.0,5020,A,U,BAO_0000019,
,Cercopithecidae,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",CHEMBL619160,1116,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5021,A,U,BAO_0000366,In vitro
,Cercopithecidae,,,Longer half-life in monkey (i.v.) at 0.5 mpk,CHEMBL619161,17853,22224,,,,,Autocuration,,1,,0,9527.0,5022,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma half life in monkey,CHEMBL619162,993,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5023,A,U,BAO_0000366,
,Cercopithecidae,,,Plasma half-life in rhesus monkey,CHEMBL619163,4514,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5024,A,U,BAO_0000366,
,Cercopithecidae,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),CHEMBL619164,5334,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5025,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),CHEMBL619320,5334,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5026,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Tested for half life upon iv administration to african green monkey,CHEMBL619321,4578,22224,,,,,Autocuration,,1,,0,9527.0,5027,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL873336,2661,22224,,,,,Autocuration,,1,,0,9527.0,5028,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,CHEMBL619322,5355,22224,,,,,Autocuration,,1,,0,9527.0,5029,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,CHEMBL619323,5355,22224,,,,,Autocuration,,1,,0,9527.0,5030,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The time for peak concentration value after oral administration in cynomolgus monkeys,CHEMBL619324,5355,22224,,,,,Autocuration,,1,,0,9527.0,5031,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,CHEMBL619325,11271,22224,,,,,Autocuration,,1,,0,9527.0,5032,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,CHEMBL876411,11271,22224,,,,,Autocuration,,1,,0,9527.0,5033,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,CHEMBL619326,11271,22224,,,,,Autocuration,,1,,0,9527.0,5034,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,CHEMBL619327,11271,22224,,,,,Autocuration,,1,,0,9527.0,5035,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,CHEMBL619328,11271,22224,,,,,Autocuration,,1,,0,9527.0,5036,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,CHEMBL619329,11271,22224,,,,,Autocuration,,1,,0,9527.0,5037,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,CHEMBL619330,11271,22224,,,,,Autocuration,,1,,0,9527.0,5038,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,CHEMBL619331,11271,22224,,,,,Autocuration,,1,,0,9527.0,5039,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,CHEMBL619332,11271,22224,,,,,Autocuration,,1,,0,9527.0,5040,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,CHEMBL619333,11271,22224,,,,,Autocuration,,1,,0,9527.0,5041,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,CHEMBL619334,11271,22224,,,,,Autocuration,,1,,0,9527.0,5042,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,CHEMBL619335,11271,22224,,,,,Autocuration,,1,,0,9527.0,5043,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,CHEMBL619336,11271,22224,,,,,Autocuration,,1,,0,9527.0,5044,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,CHEMBL619337,11271,22224,,,,,Autocuration,,1,,0,9527.0,5045,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,CHEMBL619338,11271,22224,,,,,Autocuration,,1,,0,9527.0,5046,A,U,BAO_0000019,
,Cercopithecidae,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,CHEMBL619339,11271,22224,,,,,Autocuration,,1,,0,9527.0,5047,A,U,BAO_0000019,
,Rattus norvegicus,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),CHEMBL619340,5809,50597,,,,,Intermediate,,1,,1,10116.0,5048,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,CHEMBL873496,17720,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,5049,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,AUC value in rat after IV administration at a dose of 10 mg/kg,CHEMBL619341,3546,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,5050,A,N,BAO_0000218,
,Rattus norvegicus,,,AUC value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619342,3546,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,5051,A,N,BAO_0000218,
,Rattus norvegicus,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619343,3546,50597,,,,,Intermediate,,1,,1,10116.0,5052,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,CHEMBL619344,3546,50597,,,,,Intermediate,,1,,1,10116.0,5053,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,CHEMBL619345,3546,50597,,,,,Intermediate,,1,,1,10116.0,5054,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Vc value in rat after IV administration at a dose of 10 mg/kg,CHEMBL619346,3546,50597,,,,,Intermediate,,1,,1,10116.0,5055,A,N,BAO_0000218,
,Rattus norvegicus,,,Half life period in rat after IV administration at a dose of 10 mg/kg,CHEMBL619347,3546,50597,,,,,Intermediate,,1,,1,10116.0,5056,A,N,BAO_0000218,In vivo
,Papio hamadryas,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,CHEMBL619348,10625,22224,,,,,Autocuration,,1,,0,9557.0,5057,A,U,BAO_0000019,
,Papio hamadryas,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),CHEMBL619349,10625,22224,,,,,Autocuration,,1,,0,9557.0,5058,A,U,BAO_0000019,
,Papio hamadryas,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),CHEMBL619350,10625,22224,,,,,Autocuration,,1,,0,9557.0,5059,A,U,BAO_0000019,
,Papio hamadryas,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,CHEMBL619351,10625,22224,,,,,Autocuration,,1,,0,9557.0,5060,A,U,BAO_0000019,
,Papio hamadryas,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,CHEMBL875953,10625,22224,,,,,Autocuration,,1,,0,9557.0,5061,A,U,BAO_0000019,
,Papio hamadryas,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,CHEMBL621716,10625,22224,,,,,Autocuration,,1,,0,9557.0,5062,A,U,BAO_0000019,
,Papio hamadryas,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,CHEMBL621717,10625,22224,,,,,Autocuration,,1,,0,9557.0,5063,A,U,BAO_0000019,
,Papio hamadryas,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,CHEMBL621718,10625,22224,,,,,Autocuration,,1,,0,9557.0,5064,A,U,BAO_0000019,
,beagle,,,Area under curve after 1 mpk peroral administration to beagles,CHEMBL621719,3510,22224,,,,,Autocuration,,1,,0,9615.0,5065,A,U,BAO_0000019,
,beagle,,,Area under curve after 2 mpk peroral administration to beagles,CHEMBL621720,3510,22224,,,,,Autocuration,,1,,0,9615.0,5066,A,U,BAO_0000019,
,beagle,,,Cmax value after 1 mpk peroral administration to beagles,CHEMBL621721,3510,22224,,,,,Autocuration,,1,,0,9615.0,5067,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,CHEMBL621722,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5068,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,CHEMBL621723,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5069,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,CHEMBL621724,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5070,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,CHEMBL623443,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5071,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,CHEMBL623444,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5072,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,CHEMBL623445,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5073,A,U,BAO_0000019,
,Homo sapiens,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,CHEMBL623446,7766,22224,,,Urine,1088.0,Autocuration,,1,,0,9606.0,5074,A,U,BAO_0000019,
,Homo sapiens,,,Metabolic stability observed at 30 min after administration in human liver microsomes,CHEMBL623447,16643,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5075,A,U,BAO_0000251,
,Homo sapiens,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,CHEMBL623448,6852,22224,,,,,Autocuration,,1,,0,9606.0,5076,A,U,BAO_0000019,
,Homo sapiens,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,CHEMBL623449,6852,22224,,,,,Autocuration,,1,,0,9606.0,5077,A,U,BAO_0000019,
,Homo sapiens,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,CHEMBL623450,6852,22224,,,,,Autocuration,,1,,0,9606.0,5078,A,U,BAO_0000019,
,Homo sapiens,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",CHEMBL623451,6567,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5079,A,U,BAO_0000251,
,Homo sapiens,,,Metabolic stability (% remaining at 30 mins) in human S9.,CHEMBL623452,6570,22224,,,,,Autocuration,,1,,0,9606.0,5080,A,U,BAO_0000019,
,Homo sapiens,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,CHEMBL623453,6570,22224,,,,,Autocuration,,1,,0,9606.0,5081,A,U,BAO_0000019,
,Homo sapiens,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,CHEMBL623454,5237,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5082,A,U,BAO_0000251,
,Homo sapiens,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,CHEMBL623455,5237,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5083,A,U,BAO_0000251,
,Homo sapiens,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,CHEMBL624371,5237,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5084,A,U,BAO_0000251,
,Homo sapiens,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,CHEMBL624372,5202,22224,,,,,Autocuration,,1,,0,9606.0,5085,A,U,BAO_0000218,
,Homo sapiens,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,CHEMBL624373,5481,22224,,,,,Autocuration,,1,,0,9606.0,5086,A,U,BAO_0000019,
,Homo sapiens,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,CHEMBL624374,5481,22224,,,,,Autocuration,,1,,0,9606.0,5087,A,U,BAO_0000019,
,Homo sapiens,,,The percent remaining in human plasma after 30 min was determined,CHEMBL624556,3956,22224,,,,,Autocuration,,1,,0,9606.0,5088,A,U,BAO_0000019,
,Homo sapiens,,,Conversion rate of the prodrug in human plasma,CHEMBL624557,5074,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5089,A,U,BAO_0000366,
,Homo sapiens,,,Conversion rate of the prodrug in human plasma; ND means no data,CHEMBL624558,5074,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5090,A,U,BAO_0000366,
,Homo sapiens,,,Half life of compound was determined in human blood,CHEMBL624559,4727,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5091,A,U,BAO_0000221,
,Homo sapiens,,,Half life of compound was determined in man with once daily dosing,CHEMBL624560,5965,22224,,,,,Autocuration,,1,,0,9606.0,5092,A,U,BAO_0000019,
,Homo sapiens,,,Half life in human microsomes,CHEMBL624561,5732,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,5093,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Half life in human plasma,CHEMBL624562,5819,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5094,A,U,BAO_0000366,
,Homo sapiens,,,Half life in human plasma; Not detected,CHEMBL624563,5819,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5095,A,U,BAO_0000366,
,Homo sapiens,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL624564,1916,22224,,,,,Autocuration,,1,,0,9606.0,5096,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,CHEMBL624565,6597,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5097,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Half-life in human plasma,CHEMBL875152,5229,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5098,A,U,BAO_0000366,
,Homo sapiens,,,Half-life of the parent prodrug in plasma,CHEMBL624566,5229,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5099,A,U,BAO_0000366,
,Homo sapiens,,,In vitro half life in human plasma was determined,CHEMBL873805,2192,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5100,A,U,BAO_0000366,In vitro
,Homo sapiens,,,The compound was tested In Vitro for half life in human liver microsomes.,CHEMBL624567,3032,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5101,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,CHEMBL624568,1916,22224,,,,,Autocuration,,1,,0,9606.0,5102,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Observed volume of distribution,CHEMBL624569,17716,22224,,,,,Autocuration,,1,,0,9606.0,5103,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Oral bioavailability in human,CHEMBL624570,15778,22224,,,,,Autocuration,,1,,0,9606.0,5104,A,U,BAO_0000218,In vivo
,Homo sapiens,,,Tested for human plasma protein binding of the compound,CHEMBL624571,17313,22224,,,,,Autocuration,,1,,0,9606.0,5105,A,U,BAO_0000019,
,Homo sapiens,,,"First order rate constant, k was determined in human plasma",CHEMBL624572,4231,22224,,,,,Autocuration,,1,,0,9606.0,5106,A,U,BAO_0000019,
,Homo sapiens,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,CHEMBL624573,4755,22224,,,,,Autocuration,,1,,0,9606.0,5107,A,U,BAO_0000019,
,Homo sapiens,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,CHEMBL875153,4755,22224,,,,,Autocuration,,1,,0,9606.0,5108,A,U,BAO_0000019,
,Homo sapiens,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,CHEMBL624574,16907,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5109,A,U,BAO_0000251,
,Homo sapiens,,,The compound was tested for the plasma binding in human,CHEMBL624575,10839,22224,,,,,Autocuration,,1,,0,9606.0,5110,A,U,BAO_0000019,
,Homo sapiens,,,Plasma protein binding (human),CHEMBL624576,10839,22224,,,,,Autocuration,,1,,0,9606.0,5111,A,U,BAO_0000019,
,Homo sapiens,,,Compound was evaluated for half-life in human liver microsomes,CHEMBL624577,3199,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5112,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Half life measured in vitro for its stability in human blood,CHEMBL624578,1345,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5113,A,U,BAO_0000221,In vitro
,Homo sapiens,,,Half life in human serum,CHEMBL622796,4297,22224,,,Serum,1977.0,Autocuration,,1,,0,9606.0,5114,A,U,BAO_0000019,
,Homo sapiens,,,Half life in human serum; ND=not determined,CHEMBL622797,4297,22224,,,Serum,1977.0,Autocuration,,1,,0,9606.0,5115,A,U,BAO_0000019,
,Homo sapiens,,,Half life were determined in CEM-SS cell extract in decomposition step 1,CHEMBL622798,4297,22224,,,,,Autocuration,,1,,0,9606.0,5116,A,U,BAO_0000019,
,Homo sapiens,,,Half life were determined in CEM-SS cell extract in decomposition step 2,CHEMBL622799,4297,22224,,,,,Autocuration,,1,,0,9606.0,5117,A,U,BAO_0000019,
,Homo sapiens,,,Half life of the in human plasma,CHEMBL622800,4231,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5118,A,U,BAO_0000366,
,Homo sapiens,,,Half life period in human hepatic S9 fraction was determined,CHEMBL622801,5633,22224,S9,,,,Autocuration,,1,,0,9606.0,5119,A,U,BAO_0000220,In vitro
,Homo sapiens,,,Half life period in human liver microsome was determined,CHEMBL622802,5633,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5120,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Half life period was determined; 6-7,CHEMBL622803,17791,22224,,,,,Autocuration,,1,,0,9606.0,5121,A,U,BAO_0000019,
,Homo sapiens,,,Half life period was evaluated in human,CHEMBL875154,17791,22224,,,,,Autocuration,,1,,0,9606.0,5122,A,U,BAO_0000019,
,Homo sapiens,,,Half life time in human plasma,CHEMBL622804,3160,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5123,A,U,BAO_0000366,
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622805,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5124,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622611,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5125,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622612,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5126,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL875160,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5127,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL622613,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5128,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622614,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5129,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622615,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5130,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL622616,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5131,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622617,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5132,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,CHEMBL622618,16438,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5133,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",CHEMBL622619,16438,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5134,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622620,16438,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5135,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622621,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5136,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of compound (oxidized form) in blood tissue,CHEMBL622622,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5137,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622623,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5138,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL622624,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5139,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622625,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5140,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622626,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5141,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL622627,16438,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5142,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of compound (oxidized form) in brain tissue of mice,CHEMBL622628,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5143,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622629,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5144,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622630,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5145,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL622631,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5146,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL622632,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5147,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL622633,16438,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,5148,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of compound (oxidized form) in heart tissue of mice,CHEMBL622634,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5149,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL622635,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5150,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL875161,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5151,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL622636,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5152,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL623335,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5153,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL623336,16438,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5154,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL623337,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5155,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",CHEMBL623338,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5156,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL623339,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5157,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",CHEMBL623524,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5158,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",CHEMBL623525,16438,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5159,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of compound (oxidized form) in liver tissue,CHEMBL623526,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5160,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",CHEMBL623527,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5161,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",CHEMBL623528,16438,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5162,A,N,BAO_0000218,In vivo
A-431,Homo sapiens,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,CHEMBL624615,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5163,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,CHEMBL621672,5245,80852,,500.0,,,Intermediate,,1,,1,9606.0,5164,F,N,BAO_0000219,
A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",CHEMBL621673,16289,80852,,500.0,,,Expert,,1,,1,,5165,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",CHEMBL621674,16289,80852,,500.0,,,Expert,,1,,1,,5166,F,N,BAO_0000218,
A-431,Homo sapiens,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL884002,16093,9,,500.0,,,Expert,,1,,9,9606.0,5167,F,D,BAO_0000219,
A-431,Homo sapiens,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",CHEMBL621850,16825,80852,,500.0,,,Intermediate,,1,,1,9606.0,5168,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,CHEMBL621851,4848,80852,,500.0,,,Intermediate,,1,,1,9606.0,5169,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,CHEMBL621852,14827,9,,500.0,,,Expert,,1,,9,9606.0,5170,F,D,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CHEMBL621853,14827,9,,500.0,,,Expert,,1,,9,9606.0,5171,F,D,BAO_0000219,
A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",CHEMBL621854,16289,80852,,500.0,,,Expert,,1,,1,,5172,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",CHEMBL621855,16289,80852,,500.0,,,Expert,,1,,1,,5173,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",CHEMBL623724,16289,80852,,500.0,,,Expert,,1,,1,,5174,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",CHEMBL623725,16289,80852,,500.0,,,Expert,,1,,1,,5175,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",CHEMBL623726,16289,80852,,500.0,,,Expert,,1,,1,,5176,F,N,BAO_0000218,
A-431,Homo sapiens,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",CHEMBL623727,16289,9,,500.0,,,Expert,,1,,9,9606.0,5177,F,D,BAO_0000219,
A-431,,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,CHEMBL623728,16289,9,,500.0,,,Expert,,1,,8,,5178,F,H,BAO_0000219,
A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",CHEMBL623729,16289,80852,,500.0,,,Expert,,1,,1,,5179,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",CHEMBL623730,16289,80852,,500.0,,,Expert,,1,,1,,5180,F,N,BAO_0000218,
A-431,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",CHEMBL623731,16289,80852,,500.0,,,Expert,,1,,1,,5181,F,N,BAO_0000218,
A-431,Mus musculus,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623732,14555,80852,,500.0,,,Expert,,1,,1,10090.0,5182,F,N,BAO_0000218,
A-431,Mus musculus,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623733,14555,80852,,500.0,,,Expert,,1,,1,10090.0,5183,F,N,BAO_0000218,
A-431,Mus musculus,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623734,14555,80852,,500.0,,,Expert,,1,,1,10090.0,5184,F,N,BAO_0000218,
A-431,Mus musculus,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",CHEMBL623735,14555,80852,,500.0,,,Expert,,1,,1,10090.0,5185,F,N,BAO_0000218,
A-431,Homo sapiens,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,CHEMBL623736,1937,80852,,500.0,,,Expert,,1,,1,9606.0,5186,F,N,BAO_0000219,
A-431,Homo sapiens,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,CHEMBL623737,13739,80852,,500.0,,,Intermediate,,1,,1,9606.0,5187,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,CHEMBL623738,3558,80852,,500.0,,,Intermediate,,1,,1,9606.0,5188,F,N,BAO_0000219,
A-431,Homo sapiens,,,Dose giving a 50% decrease in the living cell number (A437 cells),CHEMBL875168,3558,80852,,500.0,,,Intermediate,,1,,1,9606.0,5189,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory concentration against proliferation of A459 cell line.,CHEMBL623739,17686,80682,,646.0,,,Expert,,1,,1,9606.0,5190,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,CHEMBL623740,5305,80682,,646.0,,,Intermediate,,1,,1,9606.0,5191,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,CHEMBL624424,3614,80682,,646.0,,,Intermediate,,1,,1,9606.0,5192,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro antitumor activity against renal A498 tumor cell lines,CHEMBL624425,17229,80021,,624.0,,,Intermediate,,1,,1,9606.0,5193,F,N,BAO_0000219,
A498,Homo sapiens,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",CHEMBL624426,15935,80021,,624.0,,,Intermediate,,1,,1,9606.0,5194,F,N,BAO_0000219,
A498,Homo sapiens,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",CHEMBL624427,15935,80021,,624.0,,,Intermediate,,1,,1,9606.0,5195,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,CHEMBL624428,15560,80021,,624.0,,,Intermediate,,1,,1,9606.0,5196,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,CHEMBL624429,13891,80021,,624.0,,,Intermediate,,1,,1,9606.0,5197,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,CHEMBL624620,13891,80021,,624.0,,,Intermediate,,1,,1,9606.0,5198,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity on kidney carcinoma (A-498) cell line,CHEMBL624621,13788,80021,,624.0,,,Intermediate,,1,,1,9606.0,5199,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was evaluated against Human cell line renal A498,CHEMBL624622,15403,80021,,624.0,,,Intermediate,,1,,1,9606.0,5200,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was tested for inhibition of A498 human renal cancer cell line,CHEMBL624623,1009,80021,,624.0,,,Intermediate,,1,,1,9606.0,5201,F,N,BAO_0000219,
A498,Homo sapiens,,,Growth inhibitory activity against A498 human cancer cell line,CHEMBL874365,1043,80021,,624.0,,,Intermediate,,1,,1,9606.0,5202,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro antitumor activity against human renal A498 cell line,CHEMBL624624,5858,80021,,624.0,,,Intermediate,,1,,1,9606.0,5203,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxic activity against renal (A498) cell line,CHEMBL624625,5958,80021,,624.0,,,Intermediate,,1,,1,9606.0,5204,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,CHEMBL624626,5506,80021,,624.0,,,Intermediate,,1,,1,9606.0,5205,F,N,BAO_0000219,
A498,Homo sapiens,,,Tested for cytostatic activity against renal A498 cell line,CHEMBL624627,12781,80021,,624.0,,,Intermediate,,1,,1,9606.0,5206,F,N,BAO_0000219,
A498,Homo sapiens,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,CHEMBL883157,14399,80021,,624.0,,,Intermediate,,1,,1,9606.0,5207,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,CHEMBL624628,5958,80021,,624.0,,,Expert,,1,,1,9606.0,5208,F,N,BAO_0000219,
,beagle,,,Cmax value after 2 mpk peroral administration to beagles,CHEMBL624629,3510,22224,,,,,Autocuration,,1,,0,9615.0,5209,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability,CHEMBL623551,3510,22224,,,,,Autocuration,beagle,1,,0,9615.0,5210,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after 1 mpk peroral administration to beagles,CHEMBL623552,3510,22224,,,,,Autocuration,beagle,1,,0,9615.0,5211,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after 2 mpk peroral administration to beagles,CHEMBL623553,3510,22224,,,,,Autocuration,beagle,1,,0,9615.0,5212,A,U,BAO_0000218,In vivo
,Bos taurus,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,CHEMBL623554,3085,22224,,,,,Autocuration,,1,,0,9913.0,5213,A,U,BAO_0000019,
,Bos taurus,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,CHEMBL623555,3085,22224,,,,,Autocuration,,1,,0,9913.0,5214,A,U,BAO_0000019,
,Bos taurus,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623556,3085,22224,,,,,Autocuration,,1,,0,9913.0,5215,A,U,BAO_0000019,
,Bos taurus,,,Solubility against bovine alpha-chymotrypsin,CHEMBL623557,9372,22224,,,,,Autocuration,,1,,0,9913.0,5216,A,U,BAO_0000019,
,Bos taurus,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623558,3085,22224,,,,,Autocuration,,1,,0,9913.0,5217,A,U,BAO_0000019,
,Bos taurus,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,CHEMBL623559,3085,22224,,,,,Autocuration,,1,,0,9913.0,5218,A,U,BAO_0000019,
,Bos taurus,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,CHEMBL623560,1469,22224,,,Spleen,2106.0,Autocuration,,1,,0,9913.0,5219,A,U,BAO_0000221,
,Bos taurus,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,CHEMBL623561,4297,22224,,,,,Autocuration,,1,,0,9913.0,5220,A,U,BAO_0000019,
,Bos taurus,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,CHEMBL623562,4297,22224,,,,,Autocuration,,1,,0,9913.0,5221,A,U,BAO_0000019,
,Bos taurus,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,CHEMBL623563,17585,22224,,,,,Autocuration,,1,,0,9913.0,5222,A,U,BAO_0000019,
,Bos taurus,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,CHEMBL623564,1336,22224,,,Spleen,2106.0,Autocuration,,1,,0,9913.0,5223,A,U,BAO_0000221,
,Bos taurus,,,Half life in presence of 2 mg/mL BSA at pH 8.8,CHEMBL873806,3085,22224,,,,,Autocuration,,1,,0,9913.0,5224,A,U,BAO_0000019,
,Bos taurus,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,CHEMBL623565,2857,22224,,,,,Autocuration,,1,,0,9913.0,5225,A,U,BAO_0000019,
,Bos taurus,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,CHEMBL623566,2857,22224,,,,,Autocuration,,1,,0,9913.0,5226,A,U,BAO_0000019,
,Bos taurus,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,CHEMBL623567,2857,22224,,,,,Autocuration,,1,,0,9913.0,5227,A,U,BAO_0000019,
,Bos taurus,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),CHEMBL623568,1540,22224,,,,,Autocuration,,1,,0,9913.0,5228,A,U,BAO_0000019,
,Canis lupus familiaris,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,CHEMBL623569,6316,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5229,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC after administration at 100 mg/kg/day in dogs,CHEMBL623570,17594,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5230,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,CHEMBL624254,4953,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5231,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC value after 15 mg/kg iv dose in Dogs,CHEMBL624255,16907,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5232,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC value after 30 mg/kg po dose in Dogs,CHEMBL624256,16907,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5233,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC value after administration of 4 mg/Kg oral dose in dog,CHEMBL624257,2959,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5234,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,CHEMBL624258,17594,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5235,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,CHEMBL875277,5356,50588,,,,,Intermediate,,1,,1,9615.0,5236,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,CHEMBL622667,16807,50588,,,,,Intermediate,,1,,1,9615.0,5237,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,CHEMBL622668,4527,50588,,,,,Intermediate,,1,,1,9615.0,5238,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622669,4527,50588,,,,,Intermediate,,1,,1,9615.0,5239,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,CHEMBL622670,15660,50588,,,,,Intermediate,,1,,1,9615.0,5240,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dogs after oral administration of 10 mg/kg,CHEMBL622671,15660,50588,,,,,Intermediate,,1,,1,9615.0,5241,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL622672,5802,50588,,,,,Intermediate,,1,,1,9615.0,5242,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL622673,3598,50588,,,,,Expert,,1,,1,9615.0,5243,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL622674,3598,50588,,,,,Expert,,1,,1,9615.0,5244,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL622675,5944,50588,,,,,Intermediate,,1,,1,9615.0,5245,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,CHEMBL622676,5944,50588,,,,,Intermediate,,1,,1,9615.0,5246,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL622677,5944,50588,,,,,Intermediate,,1,,1,9615.0,5247,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,CHEMBL622678,5944,50588,,,,,Intermediate,,1,,1,9615.0,5248,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,CHEMBL622679,4186,50588,,,,,Intermediate,,1,,1,9615.0,5249,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL622680,5007,50588,,,,,Intermediate,,1,,1,9615.0,5250,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determine after peroral administration at 10 mpk in dog,CHEMBL622681,5668,50588,,,,,Intermediate,,1,,1,9615.0,5251,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determine after peroral administration at 5 mpk in dog,CHEMBL875278,5668,50588,,,,,Intermediate,,1,,1,9615.0,5252,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined,CHEMBL622682,5006,50588,,,,,Intermediate,,1,,1,9615.0,5253,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dogs,CHEMBL622683,5006,50588,,,,,Intermediate,,1,,1,9615.0,5254,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,CHEMBL622684,3771,50588,,,,,Intermediate,,1,,1,9615.0,5255,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),CHEMBL622685,3771,50588,,,,,Intermediate,,1,,1,9615.0,5256,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,CHEMBL622686,3771,50588,,,,,Intermediate,,1,,1,9615.0,5257,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL618344,1916,50588,,,,,Intermediate,,1,,1,9615.0,5258,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve value in dog at a dose of 5 mg/kg,CHEMBL875582,5302,50588,,,,,Intermediate,,1,,1,9615.0,5259,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,CHEMBL618345,5600,50588,,,,,Intermediate,,1,,1,9615.0,5260,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined after 0.3 mg/kg po administration in dog,CHEMBL618346,5600,50588,,,,,Intermediate,,1,,1,9615.0,5261,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618347,17764,50588,,,,,Intermediate,,1,,1,9615.0,5262,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,CHEMBL618348,4368,50588,,,,,Intermediate,,1,,1,9615.0,5263,A,N,BAO_0000218,
,Homo sapiens,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,CHEMBL618349,5318,22224,,,,,Autocuration,,1,,0,9606.0,5264,A,U,BAO_0000019,
,Homo sapiens,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,CHEMBL618350,5318,22224,,,,,Autocuration,,1,,0,9606.0,5265,A,U,BAO_0000019,
,Homo sapiens,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,CHEMBL618351,5318,22224,,,,,Autocuration,,1,,0,9606.0,5266,A,U,BAO_0000019,
,Homo sapiens,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,CHEMBL618352,5318,22224,,,,,Autocuration,,1,,0,9606.0,5267,A,U,BAO_0000019,
,Homo sapiens,,,Time taken to reduce 50% of the concentration of compound in blood plasma,CHEMBL873494,14518,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5268,A,U,BAO_0000221,
,Homo sapiens,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",CHEMBL618353,2209,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5269,A,U,BAO_0000366,
,Homo sapiens,,,Half life in human plasma,CHEMBL618354,6787,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5270,A,U,BAO_0000366,
,Homo sapiens,,,Half life in human plasma was reported,CHEMBL875583,4898,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5271,A,U,BAO_0000366,
,Homo sapiens,,,Half life in human serum,CHEMBL618355,6072,22224,,,Serum,1977.0,Autocuration,,1,,0,9606.0,5272,A,U,BAO_0000019,
,Homo sapiens,,,Half life upon exposure to human plasma,CHEMBL618356,16907,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5273,A,U,BAO_0000366,
,Homo sapiens,,,t1/2 in human microsomes,CHEMBL618357,5656,22224,Microsomes,,,,Autocuration,,1,,0,9606.0,5274,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Half life period in 80% human plasma at 37 degree Centigrade,CHEMBL618358,4755,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5275,A,U,BAO_0000366,
,Homo sapiens,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),CHEMBL618359,17503,22224,,,Zone of skin,14.0,Autocuration,,1,,0,9606.0,5276,A,U,BAO_0000221,
,Homo sapiens,,,Half-life measured in in vitro Cathepsin B assay in human plasma,CHEMBL618360,12357,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5277,A,U,BAO_0000366,In vitro
,Homo sapiens,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,CHEMBL618361,3076,22224,,,,,Autocuration,,1,,0,9606.0,5278,A,U,BAO_0000019,
,Homo sapiens,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,CHEMBL618362,6410,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5279,A,U,BAO_0000251,In vitro
,Homo sapiens,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",CHEMBL618363,3741,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5280,A,U,BAO_0000366,
,Homo sapiens,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",CHEMBL618364,3741,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5281,A,U,BAO_0000366,
,Homo sapiens,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",CHEMBL875584,3741,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5282,A,U,BAO_0000366,
,Homo sapiens,,,Half-life in the CEM cell extracts,CHEMBL618365,1540,22224,,,,,Autocuration,,1,,0,9606.0,5283,A,U,BAO_0000019,
,Homo sapiens,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,CHEMBL873495,2905,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5284,A,U,BAO_0000366,
,Homo sapiens,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,CHEMBL618366,2905,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5285,A,U,BAO_0000366,
,Homo sapiens,,,Half-life was determined,CHEMBL618367,5523,22224,,,,,Autocuration,,1,,0,9606.0,5286,A,U,BAO_0000019,
,Homo sapiens,,,Half-life (human blood stability),CHEMBL618368,1499,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5287,A,U,BAO_0000221,
,Homo sapiens,,,Half-life (human blood stability); no data,CHEMBL618369,1499,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5288,A,U,BAO_0000221,
,Homo sapiens,,,Half-life in human plasma,CHEMBL618370,17065,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5289,A,U,BAO_0000366,
,Homo sapiens,,,CYP3A4 metabolism half-life (t1/2),CHEMBL618371,6861,22224,,,,,Autocuration,,1,,0,9606.0,5290,A,U,BAO_0000019,
,Homo sapiens,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),CHEMBL618372,1499,22224,,,Blood,178.0,Autocuration,,1,,0,9606.0,5291,A,U,BAO_0000221,
,Homo sapiens,,,In vitro half life in human plasma,CHEMBL618373,530,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5292,A,U,BAO_0000366,In vitro
,Homo sapiens,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",CHEMBL618374,1116,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5293,A,U,BAO_0000366,In vitro
,Homo sapiens,,,In vitro hydrolysis in human plasma,CHEMBL618375,6695,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5294,A,U,BAO_0000366,In vitro
,Homo sapiens,,,In vitro hydrolysis in human plasma; no data,CHEMBL618376,6695,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5295,A,U,BAO_0000366,In vitro
,Homo sapiens,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,CHEMBL618377,10,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5296,A,U,BAO_0000251,In vitro
,Homo sapiens,,,Plasma half life in human,CHEMBL618378,993,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5297,A,U,BAO_0000366,
,Homo sapiens,,,Stability after incubation with human plasma (at 37 degree C),CHEMBL618379,15429,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5298,A,U,BAO_0000366,
,Homo sapiens,,,T1/2 was evaluated in human plasma,CHEMBL618380,1675,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5299,A,U,BAO_0000366,
,Homo sapiens,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",CHEMBL618381,2209,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5300,A,U,BAO_0000366,
,Homo sapiens,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",CHEMBL618382,2209,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5301,A,U,BAO_0000366,
,Homo sapiens,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,CHEMBL618383,5318,22224,,,,,Autocuration,,1,,0,9606.0,5302,A,U,BAO_0000019,
,Homo sapiens,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,CHEMBL618384,2412,22224,,,,,Autocuration,,1,,0,9606.0,5303,A,U,BAO_0000019,In vitro
,Homo sapiens,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,CHEMBL618385,2412,22224,,,,,Autocuration,,1,,0,9606.0,5304,A,U,BAO_0000019,In vitro
,Homo sapiens,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,CHEMBL619099,2906,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5305,A,U,BAO_0000366,
,Homo sapiens,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,CHEMBL619100,2906,22224,,,Plasma,1969.0,Autocuration,,1,,0,9606.0,5306,A,U,BAO_0000366,
,Homo sapiens,,,Time taken for 50% to be consumed by serum PON1 was determined,CHEMBL619101,5495,22224,,,,,Autocuration,,1,,0,9606.0,5307,A,U,BAO_0000019,
,Homo sapiens,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,CHEMBL619102,5495,22224,,,,,Autocuration,,1,,0,9606.0,5308,A,U,BAO_0000019,
,Homo sapiens,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,CHEMBL619103,4397,22224,Microsomes,,Liver,2107.0,Autocuration,,1,,0,9606.0,5309,A,U,BAO_0000251,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL619268,2413,22224,,,,,Autocuration,,1,,0,10095.0,5310,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL619269,2413,22224,,,,,Autocuration,,1,,0,10095.0,5311,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL619270,2413,22224,,,,,Autocuration,,1,,0,10095.0,5312,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL619271,2413,22224,,,,,Autocuration,,1,,0,10095.0,5313,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL875585,2413,22224,,,,,Autocuration,,1,,0,10095.0,5314,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL619272,2413,22224,,,,,Autocuration,,1,,0,10095.0,5315,A,U,BAO_0000218,
786-0,Homo sapiens,,,Compound tested for growth inhibition of renal cancer cell line 786-0,CHEMBL619273,6058,80640,,391.0,,,Intermediate,,1,,1,9606.0,5316,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,CHEMBL619274,17708,80640,,391.0,,,Intermediate,,1,,1,9606.0,5317,F,N,BAO_0000219,
786-0,Homo sapiens,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,CHEMBL619275,14017,80640,,391.0,,,Expert,,1,,1,9606.0,5318,F,N,BAO_0000219,
786-0,Homo sapiens,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",CHEMBL619276,16818,80640,,391.0,,,Intermediate,,1,,1,9606.0,5319,F,N,BAO_0000219,
786-0,Homo sapiens,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",CHEMBL619277,16818,80640,,391.0,,,Intermediate,,1,,1,9606.0,5320,F,N,BAO_0000219,
786-0,Homo sapiens,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",CHEMBL619278,16818,80640,,391.0,,,Intermediate,,1,,1,9606.0,5321,F,N,BAO_0000219,
786-0,Homo sapiens,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,CHEMBL619279,11970,80640,,391.0,,,Intermediate,,1,,1,9606.0,5322,F,N,BAO_0000219,
786-0,Homo sapiens,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,CHEMBL858458,12400,80640,,391.0,,,Intermediate,,1,,1,9606.0,5323,F,N,BAO_0000219,
786-0,Homo sapiens,,,Cytotoxic effect on renal cancer line 786-0,CHEMBL619280,12888,80640,,391.0,,,Expert,,1,,1,9606.0,5324,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,CHEMBL619281,15300,80640,,391.0,,,Intermediate,,1,,1,9606.0,5325,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),CHEMBL619282,14769,80640,,391.0,,,Intermediate,,1,,1,9606.0,5326,F,N,BAO_0000219,
786-0,Homo sapiens,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",CHEMBL619283,15895,80640,,391.0,,,Intermediate,,1,,1,9606.0,5327,F,N,BAO_0000219,
786-0,Homo sapiens,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,CHEMBL619284,17376,80640,,391.0,,,Intermediate,,1,,1,9606.0,5328,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,CHEMBL619285,14882,80640,,391.0,,,Intermediate,,1,,1,9606.0,5329,F,N,BAO_0000219,
786-0,Homo sapiens,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),CHEMBL619286,14882,80640,,391.0,,,Intermediate,,1,,1,9606.0,5330,F,N,BAO_0000219,
786-0,Homo sapiens,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,CHEMBL619287,15176,80640,,391.0,,,Intermediate,,1,,1,9606.0,5331,F,N,BAO_0000219,
786-0,Homo sapiens,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,CHEMBL857455,12696,80640,,391.0,,,Intermediate,,1,,1,9606.0,5332,F,N,BAO_0000219,
786-0,Homo sapiens,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),CHEMBL883801,2496,80640,,391.0,,,Intermediate,,1,,1,9606.0,5333,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,CHEMBL619288,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5334,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),CHEMBL619289,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5335,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,CHEMBL619290,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5336,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),CHEMBL619291,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5337,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),CHEMBL619292,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5338,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,CHEMBL619293,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5339,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),CHEMBL619294,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5340,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),CHEMBL619295,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5341,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),CHEMBL619296,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5342,F,N,BAO_0000219,
791T cell line,Homo sapiens,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,CHEMBL619297,11831,80641,,972.0,,,Intermediate,,1,,1,9606.0,5343,F,N,BAO_0000219,
786-0,Homo sapiens,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,CHEMBL619298,12782,80640,,391.0,,,Intermediate,,1,,1,9606.0,5344,F,N,BAO_0000219,
,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,CHEMBL619299,1229,22226,,,,,Intermediate,,1,,0,,5345,F,U,BAO_0000019,
RPMI-8226,Homo sapiens,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,CHEMBL619300,15313,80433,,741.0,,,Expert,,1,,1,9606.0,5346,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,CHEMBL619301,15313,80433,,741.0,,,Expert,,1,,1,9606.0,5347,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,CHEMBL619302,11544,80433,,741.0,,,Intermediate,,1,,1,9606.0,5348,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL619303,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5349,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL619304,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5350,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL857706,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5351,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL619305,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5352,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL619306,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5353,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL619307,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5354,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL619308,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5355,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL619309,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5356,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL619310,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5357,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),CHEMBL619311,14769,80021,,624.0,,,Intermediate,,1,,1,9606.0,5358,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,CHEMBL619312,15354,80021,,624.0,,,Intermediate,,1,,1,9606.0,5359,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),CHEMBL619313,17445,80021,,624.0,,,Intermediate,,1,,1,9606.0,5360,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro inhibitory concentration against renal cancer cell line A498,CHEMBL619314,4337,80021,,624.0,,,Intermediate,,1,,1,9606.0,5361,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity against A 498 tumor cell line,CHEMBL619959,15277,80021,,624.0,,,Intermediate,,1,,1,9606.0,5362,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro antitumor activity against A498 human cancer cell line,CHEMBL619960,4812,80021,,624.0,,,Intermediate,,1,,1,9606.0,5363,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),CHEMBL619961,4812,80021,,624.0,,,Intermediate,,1,,1,9606.0,5364,F,N,BAO_0000219,
A498,Homo sapiens,,,Inhibitory dose required against A498 human tumor cell lines,CHEMBL619962,4995,80021,,624.0,,,Intermediate,,1,,1,9606.0,5365,F,N,BAO_0000219,
A498,Homo sapiens,,,Anticancer activity against one renal cancer (A498 cell line),CHEMBL875586,5847,80021,,624.0,,,Intermediate,,1,,1,9606.0,5366,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity against melanoma A498 cell line,CHEMBL619963,6557,80021,,624.0,,,Intermediate,,1,,1,9606.0,5367,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was tested for growth inhibitory activity against A498 cell line,CHEMBL619964,2597,80021,,624.0,,,Intermediate,,1,,1,9606.0,5368,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound tested for growth inhibition of renal cancer cell line A498,CHEMBL620108,6058,80021,,624.0,,,Intermediate,,1,,1,9606.0,5369,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,CHEMBL620109,17708,80021,,624.0,,,Intermediate,,1,,1,9606.0,5370,F,N,BAO_0000219,
A498,Homo sapiens,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,CHEMBL620110,15176,80021,,624.0,,,Intermediate,,1,,1,9606.0,5371,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,CHEMBL620111,15300,80021,,624.0,,,Intermediate,,1,,1,9606.0,5372,F,N,BAO_0000219,
A498,Homo sapiens,,,Tested for cytotoxicity against A498 cell lines in renal cancer,CHEMBL620112,11970,80021,,624.0,,,Intermediate,,1,,1,9606.0,5373,F,N,BAO_0000219,
A498,Homo sapiens,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,CHEMBL620113,12400,80021,,624.0,,,Intermediate,,1,,1,9606.0,5374,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxic effect on renal cancer lines A498,CHEMBL620114,12888,80021,,624.0,,,Expert,,1,,1,9606.0,5375,F,N,BAO_0000219,
A498,Homo sapiens,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,CHEMBL620115,3030,80021,,624.0,,,Intermediate,,1,,1,9606.0,5376,F,N,BAO_0000219,
A498,Homo sapiens,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),CHEMBL620116,14769,80021,,624.0,,,Intermediate,,1,,1,9606.0,5377,F,N,BAO_0000219,
A498,Homo sapiens,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,CHEMBL620117,17376,80021,,624.0,,,Intermediate,,1,,1,9606.0,5378,F,N,BAO_0000219,
A498,Homo sapiens,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,CHEMBL620118,16558,80021,,624.0,,,Intermediate,,1,,1,9606.0,5379,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,CHEMBL620119,5194,80021,,624.0,,,Intermediate,,1,,1,9606.0,5380,F,N,BAO_0000219,
A498,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,CHEMBL620120,10708,80021,,624.0,,,Intermediate,,1,,1,9606.0,5381,F,N,BAO_0000219,
A549,Homo sapiens,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,CHEMBL620121,16880,80682,,646.0,,,Expert,,1,,1,9606.0,5382,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor activity against A549 human lung carcinoma cell line,CHEMBL620122,10196,80682,,646.0,,,Intermediate,,1,,1,9606.0,5383,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,CHEMBL620123,10196,80682,,646.0,,,Intermediate,,1,,1,9606.0,5384,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,CHEMBL620124,10196,80682,,646.0,,,Intermediate,,1,,1,9606.0,5385,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",CHEMBL620125,12083,80682,,646.0,,,Intermediate,,1,,1,9606.0,5386,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,CHEMBL620126,16464,80682,,646.0,,,Expert,,1,,1,9606.0,5387,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL883027,16464,80682,,646.0,,,Intermediate,,1,,1,9606.0,5388,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against human lung A549 cell line,CHEMBL620127,16470,80682,,646.0,,,Expert,,1,,1,9606.0,5389,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),CHEMBL620128,16470,80682,,646.0,,,Intermediate,,1,,1,9606.0,5390,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against human lung A549 cell line),CHEMBL620129,16470,80682,,646.0,,,Intermediate,,1,,1,9606.0,5391,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,CHEMBL620130,16470,80682,,646.0,,,Intermediate,,1,,1,9606.0,5392,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,CHEMBL620131,16582,80682,,646.0,,,Expert,,1,,1,9606.0,5393,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",CHEMBL620132,15935,80682,,646.0,,,Intermediate,,1,,1,9606.0,5394,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",CHEMBL620133,15935,80682,,646.0,,,Intermediate,,1,,1,9606.0,5395,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of A549 human lung carcinoma cell proliferation,CHEMBL620134,16597,80682,,646.0,,,Expert,,1,,1,9606.0,5396,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 lung adenocarcinoma cell line,CHEMBL620135,17376,80682,,646.0,,,Intermediate,,1,,1,9606.0,5397,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,CHEMBL620136,16496,80682,,646.0,,,Intermediate,,1,,1,9606.0,5398,F,N,BAO_0000219,
A549,Homo sapiens,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,CHEMBL620137,16152,80682,,646.0,,,Intermediate,,1,,1,9606.0,5399,F,N,BAO_0000219,
A549,Homo sapiens,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,CHEMBL620268,16152,80682,,646.0,,,Intermediate,,1,,1,9606.0,5400,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620269,16464,80682,,646.0,,,Intermediate,,1,,1,9606.0,5401,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,CHEMBL620270,2288,80682,,646.0,,,Intermediate,,1,,1,9606.0,5402,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,CHEMBL620271,17350,80682,,646.0,,,Intermediate,,1,,1,9606.0,5403,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of A549 cancer cell proliferation,CHEMBL620272,4090,80682,,646.0,,,Expert,,1,,1,9606.0,5404,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of A549 cancer cell proliferation (Not tested),CHEMBL620273,4090,80682,,646.0,,,Expert,,1,,1,9606.0,5405,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,CHEMBL620274,17350,80682,,646.0,,,Intermediate,,1,,1,9606.0,5406,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,CHEMBL620275,4197,80682,,646.0,,,Intermediate,,1,,1,9606.0,5407,F,N,BAO_0000219,
A549,Homo sapiens,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,CHEMBL620276,17072,80682,,646.0,,,Intermediate,,1,,1,9606.0,5408,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,CHEMBL620277,17072,80682,,646.0,,,Intermediate,,1,,1,9606.0,5409,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against Renal cell lines A549 was determined,CHEMBL620278,5194,80682,,646.0,,,Intermediate,,1,,1,9606.0,5410,F,N,BAO_0000219,
,Canis lupus familiaris,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,CHEMBL620279,4257,50588,,,,,Intermediate,,1,,1,9615.0,5411,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined in dog after oral administration at 1 mg/kg,CHEMBL620280,6123,50588,,,,,Intermediate,,1,,1,9615.0,5412,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL620281,1337,50588,,,,,Intermediate,,1,,1,9615.0,5413,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL620282,1337,50588,,,,,Intermediate,,1,,1,9615.0,5414,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),CHEMBL621134,8833,50588,,,,,Intermediate,,1,,1,9615.0,5415,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),CHEMBL621135,8833,50588,,,,,Intermediate,,1,,1,9615.0,5416,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),CHEMBL621136,8833,50588,,,,,Intermediate,,1,,1,9615.0,5417,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),CHEMBL621137,8833,50588,,,,,Intermediate,,1,,1,9615.0,5418,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under plasma concentration time curve in dog upon oral administration,CHEMBL621138,17657,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5419,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,CHEMBL875587,17650,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5420,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,CHEMBL621139,1977,50588,,,,,Intermediate,,1,,1,9615.0,5421,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,CHEMBL621140,1977,50588,,,,,Intermediate,,1,,1,9615.0,5422,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve for the compound was obtained when tested in dog,CHEMBL621141,3132,50588,,,,,Intermediate,,1,,1,9615.0,5423,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve at a dose of 1 mg/kg,CHEMBL621142,5473,50588,,,,,Intermediate,,1,,1,9615.0,5424,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve at a dose of 1 mg/kg (oral),CHEMBL621143,5474,50588,,,,,Intermediate,,1,,1,9615.0,5425,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve at i.v. dose of 0.2 mg/kg,CHEMBL621144,5474,50588,,,,,Intermediate,,1,,1,9615.0,5426,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,CHEMBL621145,6062,50588,,,,,Intermediate,,1,,1,9615.0,5427,A,N,BAO_0000218,
,Canis lupus familiaris,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,CHEMBL621146,4709,50588,,,,,Intermediate,,1,,1,9615.0,5428,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,CHEMBL622567,2652,50588,,,,,Intermediate,,1,,1,9615.0,5429,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,CHEMBL622568,2652,50588,,,,,Intermediate,,1,,1,9615.0,5430,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for area under the curve in dog blood.,CHEMBL622569,2877,50588,,,,,Intermediate,,1,,1,9615.0,5431,A,N,BAO_0000218,
,Canis lupus familiaris,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,CHEMBL622570,5444,50588,,,,,Intermediate,,1,,1,9615.0,5432,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC in dog after oral dose (1 mg/kg),CHEMBL622571,5130,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5433,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,CHEMBL622572,6265,50588,,,,,Intermediate,,1,,1,9615.0,5434,A,N,BAO_0000218,
,Canis lupus familiaris,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",CHEMBL622573,4657,50588,,,,,Intermediate,,1,,1,9615.0,5435,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,CHEMBL622574,16367,50588,,,,,Intermediate,,1,,1,9615.0,5436,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic parameter AUC after oral administration to dogs,CHEMBL622575,16367,50588,,,,,Intermediate,,1,,1,9615.0,5437,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,CHEMBL622576,9579,50588,,,,,Intermediate,,1,,1,9615.0,5438,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,CHEMBL622577,9579,50588,,,,,Intermediate,,1,,1,9615.0,5439,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,CHEMBL622578,5983,50588,,,,,Intermediate,,1,,1,9615.0,5440,A,N,BAO_0000218,
,Canis lupus familiaris,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,CHEMBL622579,6241,50588,,,,,Intermediate,,1,,1,9615.0,5441,A,N,BAO_0000218,
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",CHEMBL622580,5313,50588,,,,,Intermediate,,1,,1,9615.0,5442,A,N,BAO_0000218,
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",CHEMBL622581,5313,50588,,,,,Intermediate,,1,,1,9615.0,5443,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL622582,6642,50588,,,,,Intermediate,,1,,1,9615.0,5444,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL622583,6642,50588,,,,,Intermediate,,1,,1,9615.0,5445,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),CHEMBL622584,6641,50588,,,,,Intermediate,,1,,1,9615.0,5446,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),CHEMBL622585,6642,50588,,,,,Intermediate,,1,,1,9615.0,5447,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for oral bioavailability in dog; 90-100,CHEMBL622586,17791,50588,,,,,Intermediate,,1,,1,9615.0,5448,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,CHEMBL623281,17655,50588,,,,,Intermediate,,1,,1,9615.0,5449,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,CHEMBL623282,17655,50588,,,,,Intermediate,,1,,1,9615.0,5450,A,N,BAO_0000218,
,Canis lupus familiaris,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,CHEMBL623283,6596,50588,,,,,Intermediate,,1,,1,9615.0,5451,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623284,3880,50588,,,,,Intermediate,,1,,1,9615.0,5452,A,N,BAO_0000218,
,Canis lupus familiaris,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,CHEMBL623285,16367,50588,,,,,Intermediate,,1,,1,9615.0,5453,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma protein binding towards dog plasma at 10 uM,CHEMBL623463,17409,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5454,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma protein binding towards dog plasma at 100 uM,CHEMBL875952,17409,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5455,A,N,BAO_0000218,
,Canis lupus familiaris,,,Bioavailability in dog (dose 4 mg/kg p.o.),CHEMBL621705,2959,50588,,,,,Intermediate,,1,,1,9615.0,5456,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,CHEMBL621706,13501,50588,,,,,Intermediate,,1,,1,9615.0,5457,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL621707,4527,50588,,,,,Intermediate,,1,,1,9615.0,5458,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dogs,CHEMBL621708,15145,50588,,,,,Intermediate,,1,,1,9615.0,5459,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability,CHEMBL621709,4219,50588,,,,,Intermediate,,1,,1,9615.0,5460,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621710,17538,50588,,,,,Intermediate,,1,,1,9615.0,5461,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,CHEMBL621711,17538,50588,,,,,Intermediate,,1,,1,9615.0,5462,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),CHEMBL621712,1466,50588,,,,,Intermediate,,1,,1,9615.0,5463,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,CHEMBL621713,17650,50588,,,,,Intermediate,,1,,1,9615.0,5464,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,CHEMBL621714,3132,50588,,,,,Intermediate,,1,,1,9615.0,5465,A,N,BAO_0000218,In vivo
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL621715,2413,22224,,,,,Autocuration,,1,,0,10095.0,5466,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623717,2413,22224,,,Liver,2107.0,Autocuration,,1,,0,10095.0,5467,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623718,2413,22224,,,Liver,2107.0,Autocuration,,1,,0,10095.0,5468,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623719,2413,22224,,,Liver,2107.0,Autocuration,,1,,0,10095.0,5469,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623720,2413,22224,,,,,Autocuration,,1,,0,10095.0,5470,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623721,2413,22224,,,,,Autocuration,,1,,0,10095.0,5471,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL623722,2413,22224,,,Muscle tissue,2385.0,Autocuration,,1,,0,10095.0,5472,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623723,2413,22224,,,Muscle tissue,2385.0,Autocuration,,1,,0,10095.0,5473,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL618543,2413,22224,,,Muscle tissue,2385.0,Autocuration,,1,,0,10095.0,5474,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL618544,2413,22224,,,Spleen,2106.0,Autocuration,,1,,0,10095.0,5475,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL875155,2413,22224,,,Spleen,2106.0,Autocuration,,1,,0,10095.0,5476,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,CHEMBL618545,2413,22224,,,,,Autocuration,,1,,0,10095.0,5477,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL618546,2413,22224,,,,,Autocuration,,1,,0,10095.0,5478,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL623529,2413,22224,,,,,Autocuration,,1,,0,10095.0,5479,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,CHEMBL623530,2413,22224,,,,,Autocuration,,1,,0,10095.0,5480,A,U,BAO_0000218,
,Mus sp.,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,CHEMBL621764,2413,22224,,,,,Autocuration,,1,,0,10095.0,5481,A,U,BAO_0000218,
,Cercopithecidae,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),CHEMBL621765,17827,22224,,,,,Autocuration,,1,,0,9527.0,5482,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),CHEMBL621766,17827,22224,,,Cerebellum,2037.0,Autocuration,,1,,0,9527.0,5483,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),CHEMBL621767,17827,22224,,,Frontal cortex,1870.0,Autocuration,,1,,0,9527.0,5484,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),CHEMBL621768,17827,22224,,,,,Autocuration,,1,,0,9527.0,5485,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),CHEMBL621769,17827,22224,,,Striatum,2435.0,Autocuration,,1,,0,9527.0,5486,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),CHEMBL621770,17827,22224,,,,,Autocuration,,1,,0,9527.0,5487,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),CHEMBL621771,17827,22224,,,Cerebellum,2037.0,Autocuration,,1,,0,9527.0,5488,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),CHEMBL621772,17827,22224,,,Frontal cortex,1870.0,Autocuration,,1,,0,9527.0,5489,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),CHEMBL621773,17827,22224,,,,,Autocuration,,1,,0,9527.0,5490,A,U,BAO_0000019,
,Cercopithecidae,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),CHEMBL621774,17827,22224,,,Striatum,2435.0,Autocuration,,1,,0,9527.0,5491,A,U,BAO_0000019,
,Cercopithecidae,,,Compound was evaluated for oral bioavailability in rats,CHEMBL621775,17791,22224,,,,,Autocuration,,1,,0,9527.0,5492,A,U,BAO_0000218,
,Cercopithecidae,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,CHEMBL621776,17667,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,5493,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life period was evaluated in monkey,CHEMBL621777,17791,22224,,,,,Autocuration,,1,,0,9527.0,5494,A,U,BAO_0000019,
,Cercopithecidae,,,Half-life in rhesus monkeys by intravenous administration of dose,CHEMBL875162,110,22224,,,,,Autocuration,,1,,0,9527.0,5495,A,U,BAO_0000218,In vivo
,Mus musculus,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,CHEMBL621778,5781,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,5496,A,N,BAO_0000218,
,Mus musculus,,,AUC after intraperitoneal administration of 100 mg/kg in mice,CHEMBL621779,17734,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,5497,A,N,BAO_0000218,
,Mus musculus,,,AUC value was determined after oral administration,CHEMBL622479,17718,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,5498,A,N,BAO_0000218,
,Mus musculus,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,CHEMBL622480,4573,50594,,,,,Intermediate,,1,,1,10090.0,5499,A,N,BAO_0000218,
,Mus musculus,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL622481,3277,50594,,,,,Intermediate,,1,,1,10090.0,5500,A,N,BAO_0000218,
,Mus musculus,,,Area under curve by ioral administration in mouse,CHEMBL622482,2862,50594,,,,,Intermediate,,1,,1,10090.0,5501,A,N,BAO_0000218,
,Mus musculus,,,Area under curve by iv administration in mouse,CHEMBL622483,2862,50594,,,,,Intermediate,,1,,1,10090.0,5502,A,N,BAO_0000218,
,Mus musculus,,,Area under curve at 0-8 hr in IRC mice after peroral administration,CHEMBL622484,5951,50594,,,,,Intermediate,,1,,1,10090.0,5503,A,N,BAO_0000218,
,Mus musculus,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,CHEMBL622641,17729,50594,,,,,Intermediate,,1,,1,10090.0,5504,A,N,BAO_0000218,
,Mus musculus,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,CHEMBL622642,17728,50594,,,,,Intermediate,,1,,1,10090.0,5505,A,N,BAO_0000218,
,Mus musculus,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,CHEMBL622643,17728,50594,,,,,Intermediate,,1,,1,10090.0,5506,A,N,BAO_0000218,
,Mus musculus,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,CHEMBL622644,17729,50594,,,,,Intermediate,,1,,1,10090.0,5507,A,N,BAO_0000218,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL622645,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5508,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL622646,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5509,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL621238,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5510,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL621239,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5511,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL621240,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5512,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL621241,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5513,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL621242,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5514,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL620350,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5515,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,CHEMBL620351,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5516,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,CHEMBL620352,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5517,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),CHEMBL620353,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5518,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),CHEMBL620354,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5519,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),CHEMBL620355,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5520,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),CHEMBL620356,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5521,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),CHEMBL620357,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5522,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),CHEMBL620358,9424,80433,,741.0,,,Intermediate,,1,,1,9606.0,5523,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,CHEMBL620359,9424,80433,,741.0,,,Expert,,1,,1,9606.0,5524,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,CHEMBL620360,11544,80433,,741.0,,,Intermediate,,1,,1,9606.0,5525,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Cytotoxicity of compound against 8226/DOX1V cells,CHEMBL620361,17378,80433,,741.0,,,Intermediate,,1,,1,9606.0,5526,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Cytotoxicity of compound against 8226/S cells,CHEMBL620362,17378,80433,,741.0,,,Intermediate,,1,,1,9606.0,5527,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Inhibitory concentration against 8226 myeloma cancer cell line,CHEMBL620363,17079,80433,,741.0,,,Intermediate,,1,,1,9606.0,5528,F,N,BAO_0000219,
RPMI-8226,Homo sapiens,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,CHEMBL620364,17079,80433,,741.0,,,Intermediate,,1,,1,9606.0,5529,F,N,BAO_0000219,
833K,Homo sapiens,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,CHEMBL620365,13466,80647,,854.0,,,Intermediate,,1,,1,9606.0,5530,F,N,BAO_0000219,
833K,Homo sapiens,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',CHEMBL620366,13466,80647,,854.0,,,Intermediate,,1,,1,9606.0,5531,F,N,BAO_0000219,
833K,Homo sapiens,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,CHEMBL620367,2392,80647,,854.0,,,Expert,,1,,1,9606.0,5532,F,N,BAO_0000219,
833K,Homo sapiens,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,CHEMBL620368,2392,80647,,854.0,,,Intermediate,,1,,1,9606.0,5533,F,N,BAO_0000219,
,,,,Inhibitory activity against caspase-1,CHEMBL620369,6608,22226,,,,,Autocuration,,1,,0,,5534,B,U,BAO_0000019,
,Enterococcus faecalis,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,CHEMBL620370,10199,45,,,,,Autocuration,,1,,8,1351.0,5535,B,H,BAO_0000357,
8701-BC,Homo sapiens,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,CHEMBL620371,17749,80648,,705.0,,,Intermediate,,1,,1,9606.0,5536,F,N,BAO_0000219,
8701-BC,Homo sapiens,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,CHEMBL620372,17749,80648,,705.0,,,Intermediate,,1,,1,9606.0,5537,F,N,BAO_0000219,
,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,CHEMBL876492,1229,22226,,,,,Intermediate,,1,,0,,5538,F,U,BAO_0000019,
,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,CHEMBL620373,1229,22226,,,,,Intermediate,,1,,0,,5539,F,U,BAO_0000019,
,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,CHEMBL620374,1229,22226,,,,,Intermediate,,1,,0,,5540,F,U,BAO_0000019,
,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,CHEMBL620375,6390,22226,,,,,Autocuration,,1,,0,,5541,B,U,BAO_0000019,
,Streptococcus pyogenes,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,CHEMBL857902,16219,22226,,,,,Autocuration,,1,,0,1314.0,5542,F,U,BAO_0000019,
,Streptococcus pyogenes,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,CHEMBL620376,16219,22226,,,,,Autocuration,,1,,0,1314.0,5543,F,U,BAO_0000019,
,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,CHEMBL620377,17043,11922,,,,,Autocuration,,1,,8,,5544,B,H,BAO_0000357,
KB ,Homo sapiens,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,CHEMBL620378,6929,81115,,324.0,,,Intermediate,,1,,1,9606.0,5545,F,N,BAO_0000219,
KB ,Homo sapiens,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,CHEMBL620379,6929,81115,,324.0,,,Intermediate,,1,,1,9606.0,5546,A,N,BAO_0000219,
,Homo sapiens,,,In vitro cytotoxicity of compound was tested against 9KB cells.,CHEMBL620380,7083,22226,,,,,Autocuration,,1,,0,9606.0,5547,F,U,BAO_0000219,
9L,Rattus norvegicus,,,Cytotoxic concentration against 9L cells was determined on day 3,CHEMBL884006,12446,80653,,392.0,,,Intermediate,,1,,1,10116.0,5548,F,N,BAO_0000219,
9L,Rattus norvegicus,,,Tested in vitro for anticancer activity against 9L cells,CHEMBL620381,15345,80653,,392.0,,,Expert,,1,,1,10116.0,5549,F,N,BAO_0000219,
9L,Rattus norvegicus,,,Tested in vitro for anticancer activity against 9L cells; Not determined,CHEMBL620382,15345,80653,,392.0,,,Expert,,1,,1,10116.0,5550,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,CHEMBL620383,6301,80682,,646.0,,,Intermediate,,1,,1,9606.0,5551,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,CHEMBL876493,4833,80682,,646.0,,,Intermediate,,1,,1,9606.0,5552,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,CHEMBL620384,4833,80682,,646.0,,,Intermediate,,1,,1,9606.0,5553,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,CHEMBL620385,4833,80682,,646.0,,,Intermediate,,1,,1,9606.0,5554,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma A549 cell line,CHEMBL620386,13330,80682,,646.0,,,Expert,,1,,1,9606.0,5555,F,N,BAO_0000219,
A549,Homo sapiens,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,CHEMBL620387,17517,25,,646.0,,,Expert,,1,,9,9606.0,5556,F,D,BAO_0000219,
A549,Homo sapiens,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",CHEMBL621404,17517,25,,646.0,,,Expert,,1,,9,9606.0,5557,F,D,BAO_0000219,
A549,Homo sapiens,,,"In vitro growth inhibition of A549, lung carcinoma",CHEMBL621405,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5558,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro growth inhibition of A549, lung carcinoma.",CHEMBL621406,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5559,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL621407,5228,80682,,646.0,,,Expert,,1,,1,9606.0,5560,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against human lung cancer A549 cell line was determined,CHEMBL621408,5351,80682,,646.0,,,Intermediate,,1,,1,9606.0,5561,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,CHEMBL885345,12198,80682,,646.0,,,Expert,,1,,1,9606.0,5562,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,CHEMBL621409,13891,80682,,646.0,,,Intermediate,,1,,1,9606.0,5563,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity in A549 (human carcinoma) cell line.,CHEMBL876034,5677,80682,,646.0,,,Expert,,1,,1,9606.0,5564,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity on lung carcinoma (A-549) cell line,CHEMBL621410,13788,80682,,646.0,,,Intermediate,,1,,1,9606.0,5565,F,N,BAO_0000219,
A549,Homo sapiens,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,CHEMBL621411,13384,80682,,646.0,,,Expert,,1,,1,9606.0,5566,F,N,BAO_0000219,
A549,Homo sapiens,,,Effective dose of compound against replication of A549 cell line was evaluated,CHEMBL621412,6726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5567,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,CHEMBL621413,3455,80682,,646.0,,,Expert,,1,,1,9606.0,5568,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),CHEMBL621414,5726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5569,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,CHEMBL621415,5726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5570,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was evaluated for antiproliferative activity against A549 cell line,CHEMBL621416,3936,80682,,646.0,,,Intermediate,,1,,1,9606.0,5571,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,CHEMBL621417,14991,80682,,646.0,,,Intermediate,,1,,1,9606.0,5572,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,CHEMBL621418,5243,80682,,646.0,,,Intermediate,,1,,1,9606.0,5573,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,CHEMBL621419,12858,80682,,646.0,,,Intermediate,,1,,1,9606.0,5574,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition against A549 cell line was evaluated,CHEMBL621420,6776,80682,,646.0,,,Intermediate,,1,,1,9606.0,5575,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,CHEMBL875823,16558,80682,,646.0,,,Intermediate,,1,,1,9606.0,5576,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,CHEMBL621421,4583,80682,,646.0,,,Expert,,1,,1,9606.0,5577,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,CHEMBL621422,13514,80682,,646.0,,,Intermediate,,1,,1,9606.0,5578,F,N,BAO_0000219,
A549,Homo sapiens,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,CHEMBL884014,15166,80682,,646.0,,,Expert,,1,,1,9606.0,5579,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,CHEMBL621423,13873,80682,,646.0,,,Intermediate,,1,,1,9606.0,5580,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,CHEMBL621424,6447,80682,,646.0,,,Expert,,1,,1,9606.0,5581,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,CHEMBL621425,2068,80682,,646.0,,,Intermediate,,1,,1,9606.0,5582,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,CHEMBL621426,1863,80682,,646.0,,,Expert,,1,,1,9606.0,5583,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,CHEMBL621427,13873,80682,,646.0,,,Intermediate,,1,,1,9606.0,5584,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,CHEMBL621428,13873,80682,,646.0,,,Intermediate,,1,,1,9606.0,5585,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,CHEMBL621429,13873,80682,,646.0,,,Expert,,1,,1,9606.0,5586,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),CHEMBL621430,579,80682,,646.0,,,Intermediate,,1,,1,9606.0,5587,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,CHEMBL621431,579,80682,,646.0,,,Intermediate,,1,,1,9606.0,5588,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,CHEMBL621432,4584,80682,,646.0,,,Intermediate,,1,,1,9606.0,5589,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,CHEMBL621433,5421,80682,,646.0,,,Expert,,1,,1,9606.0,5590,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,CHEMBL875824,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5591,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,CHEMBL621434,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5592,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,CHEMBL621435,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5593,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,CHEMBL621436,14188,80682,,646.0,,,Intermediate,,1,,1,9606.0,5594,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,CHEMBL621437,14188,80682,,646.0,,,Intermediate,,1,,1,9606.0,5595,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,CHEMBL621438,15354,80682,,646.0,,,Intermediate,,1,,1,9606.0,5596,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,CHEMBL621439,14253,80682,,646.0,,,Expert,,1,,1,9606.0,5597,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,CHEMBL621440,13873,80682,,646.0,,,Intermediate,,1,,1,9606.0,5598,F,N,BAO_0000219,
,Canis lupus familiaris,,,Oral bioavailability in dog (conscious),CHEMBL621441,3043,50588,,,,,Intermediate,,1,,1,9615.0,5599,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,CHEMBL621442,3045,50588,,,,,Intermediate,,1,,1,9615.0,5600,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,CHEMBL621443,3022,50588,,,,,Intermediate,,1,,1,9615.0,5601,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621444,4453,50588,,,,,Intermediate,,1,,1,9615.0,5602,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL625133,1696,50588,,,,,Intermediate,,1,,1,9615.0,5603,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL625134,5045,50588,,,,,Intermediate,,1,,1,9615.0,5604,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (fasted),CHEMBL625135,5356,50588,,,,,Intermediate,,1,,1,9615.0,5605,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,CHEMBL625136,17764,50588,,,,,Intermediate,,1,,1,9615.0,5606,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL625137,6448,50588,,,,,Intermediate,,1,,1,9615.0,5607,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL625138,1475,50588,,,,,Intermediate,,1,,1,9615.0,5608,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Percent bioavailability in dog,CHEMBL625139,3788,50588,,,,,Intermediate,,1,,1,9615.0,5609,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,CHEMBL872264,3639,50588,,,,,Intermediate,,1,,1,9615.0,5610,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL625140,13397,50588,,,,,Intermediate,,1,,1,9615.0,5611,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was evaluated for bioavailability in dogs; 34-44,CHEMBL624436,2137,50588,,,,,Intermediate,,1,,1,9615.0,5612,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 4 mg/kg p.o.),CHEMBL624437,2959,50588,,,,,Intermediate,,1,,1,9615.0,5613,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL872261,6448,50588,,,,,Intermediate,,1,,1,9615.0,5614,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,8 hour trough Blood level in dog was measured after administration of compound,CHEMBL624438,6084,50588,,,,,Intermediate,,1,,1,9615.0,5615,A,N,BAO_0000218,
,Canis lupus familiaris,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,CHEMBL624439,3639,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5616,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,C24 after oral administration at 5 mg/kg,CHEMBL624440,6316,50588,,,,,Intermediate,,1,,1,9615.0,5617,A,N,BAO_0000218,
,Canis lupus familiaris,,,Clearance after oral and iv dosing in dogs,CHEMBL624441,5238,50588,,,,,Intermediate,,1,,1,9615.0,5618,A,N,BAO_0000218,
,Canis lupus familiaris,,,Clearance of the drug was measured in the plasma of dog,CHEMBL624442,17796,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5619,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,CHEMBL624443,2652,50588,,,,,Intermediate,,1,,1,9615.0,5620,A,N,BAO_0000218,
,Canis lupus familiaris,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624444,5654,50588,,,,,Intermediate,,1,,1,9615.0,5621,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance of compound was determined in dogs,CHEMBL624445,6621,50588,,,,,Intermediate,,1,,1,9615.0,5622,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,CHEMBL624446,6505,50588,,,,,Intermediate,,1,,1,9615.0,5623,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL624447,5802,50588,,,,,Intermediate,,1,,1,9615.0,5624,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog was determined,CHEMBL624448,17267,50588,,,,,Intermediate,,1,,1,9615.0,5625,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL624449,4521,50588,,,,,Intermediate,,1,,1,9615.0,5626,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,CHEMBL624450,6535,50588,,,,,Intermediate,,1,,1,9615.0,5627,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog after administration of 1 mg/kg iv,CHEMBL875942,6535,50588,,,,,Intermediate,,1,,1,9615.0,5628,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dogs,CHEMBL624451,6535,50588,,,,,Intermediate,,1,,1,9615.0,5629,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,CHEMBL624452,5542,50588,,,,,Intermediate,,1,,1,9615.0,5630,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL624453,5199,50588,,,,,Intermediate,,1,,1,9615.0,5631,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after 15 mg/kg iv dose in Dogs,CHEMBL624454,16907,50588,,,,,Intermediate,,1,,1,9615.0,5632,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after 30 mg/kg po dose in Dogs,CHEMBL624455,16907,50588,,,,,Intermediate,,1,,1,9615.0,5633,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma administration to dogs,CHEMBL624456,16367,50588,,,,,Intermediate,,1,,1,9615.0,5634,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined,CHEMBL624457,5505,50588,,,,,Intermediate,,1,,1,9615.0,5635,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL624458,6215,50588,,,,,Intermediate,,1,,1,9615.0,5636,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL624459,1466,50588,,,,,Intermediate,,1,,1,9615.0,5637,A,N,BAO_0000218,In vivo
,Homo sapiens,,,Intrinsic clearance in human liver microsomes,CHEMBL624460,5007,102164,Microsomes,,Liver,2107.0,Intermediate,,1,,2,9606.0,5638,A,S,BAO_0000251,In vitro
,Homo sapiens,,,Intrinsic clearance in human liver microsomes,CHEMBL624461,5007,102164,Microsomes,,Liver,2107.0,Intermediate,,1,,2,9606.0,5639,A,S,BAO_0000251,In vitro
,Canis lupus familiaris,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL875943,16452,50588,,,,,Intermediate,,1,,1,9615.0,5640,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL624462,16452,50588,,,,,Intermediate,,1,,1,9615.0,5641,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance in dog (dose 1 mg/kg i.v.),CHEMBL624463,16452,50588,,,,,Intermediate,,1,,1,9615.0,5642,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,CHEMBL624464,6221,50588,,,,,Intermediate,,1,,1,9615.0,5643,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL624465,5007,50588,,,,,Intermediate,,1,,1,9615.0,5644,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after peroral administration at 10 mpk in dog,CHEMBL624466,5668,50588,,,,,Intermediate,,1,,1,9615.0,5645,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after peroral administration at 5 mpk in dog,CHEMBL624467,5668,50588,,,,,Intermediate,,1,,1,9615.0,5646,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after peroral administration at 5 mg/kg in dog,CHEMBL624468,5668,50588,,,,,Intermediate,,1,,1,9615.0,5647,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was measured in dog,CHEMBL624469,15660,50588,,,,,Intermediate,,1,,1,9615.0,5648,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was measured in dog,CHEMBL624470,15660,50588,,,,,Intermediate,,1,,1,9615.0,5649,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,CHEMBL624471,5983,50588,,,,,Intermediate,,1,,1,9615.0,5650,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,CHEMBL624472,5600,50588,,,,,Intermediate,,1,,1,9615.0,5651,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL622775,17764,50588,,,,,Intermediate,,1,,1,9615.0,5652,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,CHEMBL622776,6039,50588,,,,,Intermediate,,1,,1,9615.0,5653,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,CHEMBL622777,6039,50588,,,,,Intermediate,,1,,1,9615.0,5654,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,CHEMBL622778,6039,50588,,,,,Intermediate,,1,,1,9615.0,5655,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance by intravenous administration of 1.2 mg/kg in dog,CHEMBL622779,4368,50588,,,,,Intermediate,,1,,1,9615.0,5656,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,CHEMBL622780,4305,50588,,,,,Intermediate,,1,,1,9615.0,5657,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance value was evaluated in dog plasma,CHEMBL622781,1918,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5658,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,CHEMBL622782,6005,50588,,,,,Intermediate,,1,,1,9615.0,5659,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for plasma clearance in dog,CHEMBL622783,4839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5660,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (Plasma clearance) was measured in dog,CHEMBL622784,4239,50588,,,,,Intermediate,,1,,1,9615.0,5661,A,N,BAO_0000218,In vivo
,Mus musculus,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,CHEMBL622785,17729,50594,,,,,Intermediate,,1,,1,10090.0,5662,A,N,BAO_0000218,
,Mus musculus,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,CHEMBL622786,17728,50594,,,,,Intermediate,,1,,1,10090.0,5663,A,N,BAO_0000218,
,Mus musculus,,,Area under curve value in mouse at a dose of 10 mg/kg,CHEMBL622787,5302,50594,,,,,Intermediate,,1,,1,10090.0,5664,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL875949,5506,50594,,,,,Intermediate,,1,,1,10090.0,5665,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL622788,5506,50594,,,,,Intermediate,,1,,1,10090.0,5666,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,CHEMBL622789,17764,50594,,,,,Intermediate,,1,,1,10090.0,5667,F,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,CHEMBL622790,17764,50594,,,,,Intermediate,,1,,1,10090.0,5668,F,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,CHEMBL622791,17764,50594,,,,,Intermediate,,1,,1,10090.0,5669,F,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,CHEMBL622792,17764,50594,,,,,Intermediate,,1,,1,10090.0,5670,F,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,CHEMBL622793,17764,50594,,,,,Intermediate,,1,,1,10090.0,5671,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for the compound at 24 mg/Kg,CHEMBL622794,17753,50594,,,,,Intermediate,,1,,1,10090.0,5672,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for the compound at 40 mg/Kg,CHEMBL622795,17753,50594,,,,,Intermediate,,1,,1,10090.0,5673,A,N,BAO_0000218,
,Mus musculus,,,Area under curve was determined for the compound at 5 mg/Kg,CHEMBL621803,17753,50594,,,,,Intermediate,,1,,1,10090.0,5674,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve for the compound is obtained at dose 25 mg/kg,CHEMBL621804,3132,50594,,,,,Intermediate,,1,,1,10090.0,5675,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve for the compound was obtained when tested in mouse,CHEMBL621805,3132,50594,,,,,Intermediate,,1,,1,10090.0,5676,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,CHEMBL621806,17837,50594,,,,,Intermediate,,1,,1,10090.0,5677,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,CHEMBL621807,17837,50594,,,,,Intermediate,,1,,1,10090.0,5678,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,CHEMBL621808,6062,50594,,,,,Intermediate,,1,,1,10090.0,5679,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL621809,4066,50594,,,,,Intermediate,,1,,1,10090.0,5680,A,N,BAO_0000218,
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),CHEMBL621810,16597,50594,,,,,Intermediate,,1,,1,10090.0,5681,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,CHEMBL875164,14239,50594,,,,,Intermediate,,1,,1,10090.0,5682,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,CHEMBL621811,14239,50594,,,,,Intermediate,,1,,1,10090.0,5683,A,N,BAO_0000218,
,Mus musculus,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",CHEMBL621812,4890,50594,,,,,Intermediate,,1,,1,10090.0,5684,A,N,BAO_0000218,
,Mus musculus,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),CHEMBL621813,429,50594,,,,,Intermediate,,1,,1,10090.0,5685,A,N,BAO_0000218,
,Mus musculus,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),CHEMBL621814,429,50594,,,,,Intermediate,,1,,1,10090.0,5686,A,N,BAO_0000218,
,Mus musculus,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,CHEMBL621815,5969,50594,,,,,Intermediate,,1,,1,10090.0,5687,A,N,BAO_0000218,
,Mus musculus,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,CHEMBL621816,5969,50594,,,,,Intermediate,,1,,1,10090.0,5688,A,N,BAO_0000218,
,Mus musculus,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL621817,5969,50594,,,,,Intermediate,,1,,1,10090.0,5689,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,CHEMBL621818,6091,50594,,,,,Intermediate,,1,,1,10090.0,5690,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,CHEMBL621819,6091,50594,,,,,Intermediate,,1,,1,10090.0,5691,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,CHEMBL621820,6091,50594,,,,,Intermediate,,1,,1,10090.0,5692,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,CHEMBL621821,6091,50594,,,,,Intermediate,,1,,1,10090.0,5693,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,CHEMBL621822,6178,50594,,,,,Intermediate,,1,,1,10090.0,5694,A,N,BAO_0000218,
,Mus musculus,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,CHEMBL619474,6178,50594,,,,,Intermediate,,1,,1,10090.0,5695,A,N,BAO_0000218,
,Mus musculus,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",CHEMBL619475,6619,50594,,,,,Intermediate,,1,,1,10090.0,5696,A,N,BAO_0000218,
,Mus musculus,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",CHEMBL619476,6619,50594,,,,,Intermediate,,1,,1,10090.0,5697,A,N,BAO_0000218,
,Mus musculus,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",CHEMBL619477,3760,50594,,,,,Intermediate,,1,,1,10090.0,5698,A,N,BAO_0000218,
,Mus musculus,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",CHEMBL619478,3760,50594,,,,,Intermediate,,1,,1,10090.0,5699,A,N,BAO_0000218,
,Mus musculus,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",CHEMBL619479,3760,50594,,,,,Intermediate,,1,,1,10090.0,5700,A,N,BAO_0000218,
,Mus musculus,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",CHEMBL619480,3760,50594,,,,,Intermediate,,1,,1,10090.0,5701,A,N,BAO_0000218,
,Mus musculus,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,CHEMBL619481,3192,50594,,,,,Intermediate,,1,,1,10090.0,5702,A,N,BAO_0000218,
,Mus musculus,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,CHEMBL619482,3192,50594,,,,,Intermediate,,1,,1,10090.0,5703,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve was evaluated in mice after intravenous administration,CHEMBL619483,2675,50594,,,,,Intermediate,,1,,1,10090.0,5704,A,N,BAO_0000218,
,Mus musculus,,,Area under the curve was evaluated in mice after oral administration,CHEMBL619484,2675,50594,,,,,Intermediate,,1,,1,10090.0,5705,A,N,BAO_0000218,
,Mus musculus,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL619485,16597,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,5706,A,N,BAO_0000218,
,Mus musculus,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL619486,16597,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,5707,A,N,BAO_0000218,
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),CHEMBL619487,16597,50594,,,,,Intermediate,,1,,1,10090.0,5708,A,N,BAO_0000218,
,Mus musculus,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,CHEMBL619488,17734,50594,,,,,Intermediate,,1,,1,10090.0,5709,A,N,BAO_0000218,
,Mus musculus,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,CHEMBL620106,7767,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5710,A,N,BAO_0000218,In vivo
9L,,,,The compound was tested in vitro for anticancer activity against 9L cells,CHEMBL620107,15345,80653,,392.0,,,Intermediate,,1,,1,,5711,F,N,BAO_0000219,
,Rattus norvegicus,,,Anti proliferation activity determined; Weak effect,CHEMBL620283,2181,22226,,,,,Autocuration,,1,,0,10116.0,5712,F,U,BAO_0000019,
,Rattus norvegicus,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,CHEMBL875176,2181,22226,,,,,Autocuration,,1,,0,10116.0,5713,F,U,BAO_0000219,
,Rattus norvegicus,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,CHEMBL620284,2181,22226,,,,,Autocuration,,1,,0,10116.0,5714,F,U,BAO_0000219,
,Rattus norvegicus,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,CHEMBL623515,2181,22226,,,,,Autocuration,,1,,0,10116.0,5715,F,U,BAO_0000219,
,Mus musculus,,,The cytotoxic activity was in vitro tested by 9PS assay method,CHEMBL623516,10486,22226,,,,,Autocuration,,1,,0,10090.0,5716,F,U,BAO_0000019,
,Mus musculus,,,The cytotoxic activity was in vitro tested by 9PS assay method.,CHEMBL623517,10486,22226,,,,,Autocuration,,1,,0,10090.0,5717,F,U,BAO_0000019,
,,,,Partition coefficient (logD6.5),CHEMBL857878,15508,22224,,,,,Autocuration,,1,,0,,5718,A,U,BAO_0000019,
A2780,Homo sapiens,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,CHEMBL623518,5242,81034,,478.0,,,Expert,,1,,1,9606.0,5719,F,N,BAO_0000219,
A-375,Homo sapiens,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),CHEMBL624195,16167,80018,,455.0,,,Intermediate,,1,,1,9606.0,5720,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,CHEMBL624196,4782,80852,,500.0,,,Expert,,1,,1,9606.0,5721,F,N,BAO_0000219,
A-431,Homo sapiens,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,CHEMBL624197,16093,9,,500.0,,,Expert,,1,,9,9606.0,5722,F,D,BAO_0000219,
A498,Homo sapiens,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,CHEMBL624198,2596,80021,,624.0,,,Intermediate,,1,,1,9606.0,5723,F,N,BAO_0000219,
A498,Homo sapiens,,,in vitro cytotoxicity against A 498 cancer cell line,CHEMBL621287,2596,80021,,624.0,,,Intermediate,,1,,1,9606.0,5724,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,CHEMBL621288,3239,80021,,624.0,,,Intermediate,,1,,1,9606.0,5725,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxic activity against A 498 renal cancer cell lines.,CHEMBL876496,1847,80021,,624.0,,,Intermediate,,1,,1,9606.0,5726,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,CHEMBL621289,10553,80021,,624.0,,,Intermediate,,1,,1,9606.0,5727,F,N,BAO_0000219,
,Staphylococcus aureus,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,CHEMBL621290,16219,22226,,,,,Autocuration,,1,,0,1280.0,5728,F,U,BAO_0000019,
,Staphylococcus aureus,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,CHEMBL621291,16219,22226,,,,,Autocuration,,1,,0,1280.0,5729,F,U,BAO_0000019,
,Staphylococcus aureus,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,CHEMBL621292,16219,22226,,,,,Autocuration,,1,,0,1280.0,5730,F,U,BAO_0000019,
,Staphylococcus aureus,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,CHEMBL621293,16219,22226,,,,,Autocuration,,1,,0,1280.0,5731,F,U,BAO_0000019,
A549,Homo sapiens,,,Inhibitory concentration required against A 549 lung cancer cell line,CHEMBL621294,4782,80682,,646.0,,,Intermediate,,1,,1,9606.0,5732,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,CHEMBL621295,11805,80682,,646.0,,,Intermediate,,1,,1,9606.0,5733,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,CHEMBL884007,11805,80682,,646.0,,,Intermediate,,1,,1,9606.0,5734,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against lung cancer A 549 cell lines,CHEMBL621296,2007,80682,,646.0,,,Intermediate,,1,,1,9606.0,5735,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its cytotoxicity against A 549 cell line,CHEMBL621297,4594,80682,,646.0,,,Intermediate,,1,,1,9606.0,5736,F,N,BAO_0000219,
A549,Homo sapiens,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",CHEMBL839828,6018,80682,,646.0,,,Expert,,1,,1,9606.0,5737,F,N,BAO_0000219,
A549,Homo sapiens,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",CHEMBL620397,6018,80682,,646.0,,,Intermediate,,1,,1,9606.0,5738,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,CHEMBL620398,3599,80682,,646.0,,,Expert,,1,,1,9606.0,5739,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,CHEMBL620399,2551,80682,,646.0,,,Intermediate,,1,,1,9606.0,5740,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibition of A549 (human lung cancer) cell growth.,CHEMBL620400,16132,80682,,646.0,,,Expert,,1,,1,9606.0,5741,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,CHEMBL620401,16132,80682,,646.0,,,Intermediate,,1,,1,9606.0,5742,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,CHEMBL620402,2551,80682,,646.0,,,Expert,,1,,1,9606.0,5743,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),CHEMBL620403,2551,80682,,646.0,,,Expert,,1,,1,9606.0,5744,F,N,BAO_0000219,
,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,CHEMBL620404,11913,22226,,,,,Autocuration,,1,,0,,5745,F,U,BAO_0000218,
,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,CHEMBL620405,12621,104694,,,,,Autocuration,,1,,4,,5746,F,H,BAO_0000218,In vivo
,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,CHEMBL620406,12621,104694,,,,,Autocuration,,1,,4,,5747,F,H,BAO_0000218,In vivo
,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,CHEMBL620407,12621,104694,,,,,Autocuration,,1,,4,,5748,F,H,BAO_0000218,In vivo
,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,CHEMBL620408,12621,104694,,,,,Autocuration,,1,,4,,5749,F,H,BAO_0000218,In vivo
,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,CHEMBL620409,12621,104694,,,,,Autocuration,,1,,4,,5750,F,H,BAO_0000218,In vivo
A498,Homo sapiens,,,Inhibition of A-498 human Renal cell proliferation,CHEMBL620410,3600,80021,,624.0,,,Expert,,1,,1,9606.0,5751,F,N,BAO_0000219,
,Rattus norvegicus,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",CHEMBL620411,1796,22226,,,,,Autocuration,,1,,0,10116.0,5752,F,U,BAO_0000019,
,Rattus norvegicus,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",CHEMBL620412,1796,22226,,,,,Autocuration,,1,,0,10116.0,5753,F,U,BAO_0000019,
,Rattus norvegicus,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",CHEMBL876596,1796,22226,,,,,Autocuration,,1,,0,10116.0,5754,F,U,BAO_0000019,
A 172,Homo sapiens,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,CHEMBL620413,16464,80012,,622.0,,,Expert,,1,,1,9606.0,5755,F,N,BAO_0000219,
A 172,Homo sapiens,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620414,16464,80012,,622.0,,,Intermediate,,1,,1,9606.0,5756,F,N,BAO_0000219,
A 172,Homo sapiens,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL620415,16464,80012,,622.0,,,Intermediate,,1,,1,9606.0,5757,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,CHEMBL620416,13617,80682,,646.0,,,Expert,,1,,1,9606.0,5758,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,CHEMBL620417,4584,80682,,646.0,,,Intermediate,,1,,1,9606.0,5759,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity evaluated against A549 tumor cells,CHEMBL620418,13799,80682,,646.0,,,Expert,,1,,1,9606.0,5760,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,CHEMBL620419,16726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5761,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,CHEMBL620420,16109,80682,,646.0,,,Intermediate,,1,,1,9606.0,5762,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,CHEMBL620421,16109,80682,,646.0,,,Intermediate,,1,,1,9606.0,5763,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,CHEMBL620422,15474,80682,,646.0,,,Intermediate,,1,,1,9606.0,5764,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity of compound against A549 cell line,CHEMBL620423,6851,80682,,646.0,,,Intermediate,,1,,1,9606.0,5765,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung cell carcinoma A549 cell line,CHEMBL620424,17534,80682,,646.0,,,Expert,,1,,1,9606.0,5766,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,CHEMBL620425,2621,80682,,646.0,,,Intermediate,,1,,1,9606.0,5767,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,CHEMBL620426,830,80682,,646.0,,,Intermediate,,1,,1,9606.0,5768,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,CHEMBL620427,14255,80682,,646.0,,,Intermediate,,1,,1,9606.0,5769,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,CHEMBL620428,14255,80682,,646.0,,,Intermediate,,1,,1,9606.0,5770,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,CHEMBL620429,1590,80682,,646.0,,,Intermediate,,1,,1,9606.0,5771,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,CHEMBL620430,6146,80682,,646.0,,,Expert,,1,,1,9606.0,5772,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL839887,17427,80682,,646.0,,,Expert,,1,,1,9606.0,5773,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,CHEMBL620431,5280,80682,,646.0,,,Intermediate,,1,,1,9606.0,5774,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,CHEMBL884010,16786,80682,,646.0,,,Intermediate,,1,,1,9606.0,5775,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549 (human lung cancer),CHEMBL620538,5895,80682,,646.0,,,Intermediate,,1,,1,9606.0,5776,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,CHEMBL620539,14297,80682,,646.0,,,Expert,,1,,1,9606.0,5777,F,N,BAO_0000219,
A549,Homo sapiens,,,In vivo antiproliferative activity against A549 cell line,CHEMBL623373,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5778,F,N,BAO_0000218,
A549,Homo sapiens,,,Inhibition of non-small-cell lung adenocarcinoma (A549),CHEMBL623374,14368,80682,,646.0,,,Intermediate,,1,,1,9606.0,5779,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,CHEMBL623375,14368,80682,,646.0,,,Intermediate,,1,,1,9606.0,5780,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,CHEMBL623376,14254,80682,,646.0,,,Intermediate,,1,,1,9606.0,5781,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),CHEMBL623377,15897,80682,,646.0,,,Intermediate,,1,,1,9606.0,5782,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,CHEMBL623378,13866,80682,,646.0,,,Intermediate,,1,,1,9606.0,5783,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,CHEMBL623379,13370,80682,,646.0,,,Intermediate,,1,,1,9606.0,5784,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 lung cancer cell line,CHEMBL623380,4862,80682,,646.0,,,Intermediate,,1,,1,9606.0,5785,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,CHEMBL623381,4862,80682,,646.0,,,Intermediate,,1,,1,9606.0,5786,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,CHEMBL623382,4862,80682,,646.0,,,Intermediate,,1,,1,9606.0,5787,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration against A549 (lung cancer) cell line,CHEMBL623383,15970,80682,,646.0,,,Intermediate,,1,,1,9606.0,5788,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,CHEMBL623384,17713,80682,,646.0,,,Expert,,1,,1,9606.0,5789,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,CHEMBL623385,4833,80682,,646.0,,,Intermediate,,1,,1,9606.0,5790,F,N,BAO_0000219,
A549,Homo sapiens,,,Activity against A549 cancer cell line.,CHEMBL623386,13736,80682,,646.0,,,Expert,,1,,1,9606.0,5791,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was evaluated for cytotoxicity against A549 cell line,CHEMBL884105,4312,80682,,646.0,,,Intermediate,,1,,1,9606.0,5792,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,CHEMBL623387,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5793,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,CHEMBL621568,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5794,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibitory activity was measured for human A549 tumor cell line.,CHEMBL621569,14717,80682,,646.0,,,Intermediate,,1,,1,9606.0,5795,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 lung cancer cell line,CHEMBL621570,4634,80682,,646.0,,,Intermediate,,1,,1,9606.0,5796,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 cell line; inactive,CHEMBL621571,1149,80682,,646.0,,,Intermediate,,1,,1,9606.0,5797,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,CHEMBL621572,5421,80682,,646.0,,,Expert,,1,,1,9606.0,5798,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,CHEMBL621573,5421,80682,,646.0,,,Expert,,1,,1,9606.0,5799,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,CHEMBL621574,5421,80682,,646.0,,,Intermediate,,1,,1,9606.0,5800,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),CHEMBL621575,3320,80682,,646.0,,,Intermediate,,1,,1,9606.0,5801,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),CHEMBL621576,3320,80682,,646.0,,,Intermediate,,1,,1,9606.0,5802,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),CHEMBL621577,3320,80682,,646.0,,,Intermediate,,1,,1,9606.0,5803,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),CHEMBL621578,3320,80682,,646.0,,,Intermediate,,1,,1,9606.0,5804,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),CHEMBL621579,3320,80682,,646.0,,,Intermediate,,1,,1,9606.0,5805,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,CHEMBL621580,5726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5806,F,N,BAO_0000219,
,Canis lupus familiaris,,,Plasma clearance (in vivo) in mongrel dogs was determined,CHEMBL621581,17800,50588,,,,,Intermediate,,1,,1,9615.0,5807,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was measured in dog,CHEMBL621582,5985,50588,,,,,Intermediate,,1,,1,9615.0,5808,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,CHEMBL621583,5530,50588,,,,,Intermediate,,1,,1,9615.0,5809,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,CHEMBL621584,5530,50588,,,,,Intermediate,,1,,1,9615.0,5810,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for plasma clearance in dog,CHEMBL621585,4839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5811,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for clearance in dog plasma.,CHEMBL621586,3639,50588,,,,,Intermediate,,1,,1,9615.0,5812,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",CHEMBL875835,4838,50588,,,,,Intermediate,,1,,1,9615.0,5813,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,CHEMBL621587,4137,50588,,,,,Intermediate,,1,,1,9615.0,5814,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),CHEMBL621588,5017,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5815,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vitro clearance in dog liver microsomes,CHEMBL621589,17538,50588,Microsomes,,Liver,2107.0,Intermediate,,1,,1,9615.0,5816,A,N,BAO_0000218,In vitro
,Canis lupus familiaris,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,CHEMBL621590,6161,50588,,,,,Intermediate,,1,,1,9615.0,5817,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,CHEMBL621591,6161,50588,,,,,Intermediate,,1,,1,9615.0,5818,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog,CHEMBL621592,1696,50588,,,,,Intermediate,,1,,1,9615.0,5819,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance rate in dog,CHEMBL621593,6762,50588,,,,,Intermediate,,1,,1,9615.0,5820,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,CHEMBL621594,5932,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5821,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance in dogs,CHEMBL621595,6305,50588,,,,,Intermediate,,1,,1,9615.0,5822,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dogs,CHEMBL621596,4942,50588,,,,,Intermediate,,1,,1,9615.0,5823,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined,CHEMBL621597,4219,50588,,,,,Intermediate,,1,,1,9615.0,5824,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Lower clearance in dog (i.v.) at 0.5 mpk,CHEMBL621598,17853,50588,,,,,Intermediate,,1,,1,9615.0,5825,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in Beagle dogs,CHEMBL621599,4514,50588,,,,,Intermediate,,1,,1,9615.0,5826,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance (Clp) in dog,CHEMBL875836,6448,50588,,,,,Intermediate,,1,,1,9615.0,5827,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,CHEMBL621600,6227,50588,,,,,Intermediate,,1,,1,9615.0,5828,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,CHEMBL621601,6227,50588,,,,,Intermediate,,1,,1,9615.0,5829,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,CHEMBL618474,6062,50588,,,,,Intermediate,,1,,1,9615.0,5830,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance of compound was determined in dog,CHEMBL618475,6821,50588,,,,,Intermediate,,1,,1,9615.0,5831,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,CHEMBL624524,4709,50588,,,,,Intermediate,,1,,1,9615.0,5832,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL624525,4521,50588,,,,,Intermediate,,1,,1,9615.0,5833,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog was determined,CHEMBL624526,5374,50588,,,,,Intermediate,,1,,1,9615.0,5834,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was calculated in dog,CHEMBL624527,6057,50588,,,,,Intermediate,,1,,1,9615.0,5835,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance at the dose of 2 mg/kg in dog,CHEMBL624528,4727,50588,,,,,Intermediate,,1,,1,9615.0,5836,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog,CHEMBL624529,5145,50588,,,,,Intermediate,,1,,1,9615.0,5837,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog,CHEMBL624530,17657,50588,,,,,Intermediate,,1,,1,9615.0,5838,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog; Unable to calculate,CHEMBL624531,17657,50588,,,,,Intermediate,,1,,1,9615.0,5839,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in rhesus monkey,CHEMBL624532,5145,50588,,,,,Intermediate,,1,,1,9615.0,5840,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL624533,6642,50588,,,,,Intermediate,,1,,1,9615.0,5841,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624534,6641,50588,,,,,Intermediate,,1,,1,9615.0,5842,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624535,6642,50588,,,,,Intermediate,,1,,1,9615.0,5843,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was evaluated in dog,CHEMBL624536,5472,50588,,,,,Intermediate,,1,,1,9615.0,5844,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was evaluated in dog; Not tested,CHEMBL624537,5472,50588,,,,,Intermediate,,1,,1,9615.0,5845,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was evaluated in rhesus,CHEMBL624538,5472,50588,,,,,Intermediate,,1,,1,9615.0,5846,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was evaluated in rhesus; Not tested,CHEMBL624539,5472,50588,,,,,Intermediate,,1,,1,9615.0,5847,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,CHEMBL624540,4257,50588,,,,,Intermediate,,1,,1,9615.0,5848,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL624541,6679,50588,,,,,Intermediate,,1,,1,9615.0,5849,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL624542,5546,50588,,,,,Intermediate,,1,,1,9615.0,5850,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL624543,6348,50588,,,,,Intermediate,,1,,1,9615.0,5851,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Clearance value at a dose of 0.2 mg/kg i.v.,CHEMBL624544,5474,50588,,,,,Intermediate,,1,,1,9615.0,5852,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,CHEMBL624545,6316,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5853,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax after oral dose of compound at 3 mg/kg in dogs,CHEMBL624546,17594,50588,,,,,Intermediate,,1,,1,9615.0,5854,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,CHEMBL875957,17594,50588,,,,,Intermediate,,1,,1,9615.0,5855,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL624547,5802,50588,,,,,Intermediate,,1,,1,9615.0,5856,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,CHEMBL624548,6535,50588,,,,,Intermediate,,1,,1,9615.0,5857,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog after administration of 1 mg/kg iv,CHEMBL624549,6535,50588,,,,,Intermediate,,1,,1,9615.0,5858,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,CHEMBL624550,1466,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,5859,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,CHEMBL621613,6505,50588,,,,,Intermediate,,1,,1,9615.0,5860,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax was determine after peroral administration at 10 mpk in dog,CHEMBL621614,5668,50588,,,,,Intermediate,,1,,1,9615.0,5861,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax was determine after peroral administration at 5 mpk in dog,CHEMBL623431,5668,50588,,,,,Intermediate,,1,,1,9615.0,5862,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax was determine after peroral administration at 5 mg/kg in dog,CHEMBL623432,5668,50588,,,,,Intermediate,,1,,1,9615.0,5863,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax after 0.3 mg/kg po administration in dog,CHEMBL623433,5600,50588,,,,,Intermediate,,1,,1,9615.0,5864,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax after peroral administration in dogs at 2.4 uM/kg,CHEMBL623434,17764,50588,,,,,Intermediate,,1,,1,9615.0,5865,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog after oral administration at 1 mg/kg,CHEMBL623435,6123,50588,,,,,Intermediate,,1,,1,9615.0,5866,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,CHEMBL623436,6123,50588,,,,,Intermediate,,1,,1,9615.0,5867,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,CHEMBL875958,6757,50588,,,,,Intermediate,,1,,1,9615.0,5868,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value after 15 mg/kg iv dose in Dogs,CHEMBL623437,16907,50588,,,,,Intermediate,,1,,1,9615.0,5869,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623438,7767,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5870,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623439,7767,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,5871,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623440,7767,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,5872,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623441,7767,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,5873,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623442,7767,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,5874,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623469,7767,50594,,,,,Intermediate,,1,,1,10090.0,5875,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623470,7767,50594,,,,,Intermediate,,1,,1,10090.0,5876,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623471,7767,50594,,,,,Intermediate,,1,,1,10090.0,5877,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623472,7767,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5878,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623473,7767,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5879,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623474,7767,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,5880,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL623475,7767,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5881,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL623476,7767,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5882,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL623477,7767,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,5883,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621896,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5884,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621897,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5885,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL621898,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5886,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621899,7767,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5887,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621900,7767,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5888,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL621901,7767,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,5889,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL621902,7767,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,5890,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL621903,7767,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,5891,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL622587,7767,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,5892,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620285,7767,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,5893,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL875285,7767,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,5894,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620286,7767,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,5895,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620287,7767,50594,,,,,Intermediate,,1,,1,10090.0,5896,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620288,7767,50594,,,,,Intermediate,,1,,1,10090.0,5897,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620289,7767,50594,,,,,Intermediate,,1,,1,10090.0,5898,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620290,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5899,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620291,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5900,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL620292,7767,50594,,,Intestine,160.0,Intermediate,,1,,1,10090.0,5901,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL620293,7767,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5902,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL620294,7767,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5903,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL618614,7767,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,5904,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL618615,7767,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,5905,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,CHEMBL618616,7767,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,5906,A,N,BAO_0000218,In vivo
A 172,Homo sapiens,,,Cytotoxicity against A-172 human tumor cell lines,CHEMBL618617,2036,80012,,622.0,,,Expert,,1,,1,9606.0,5907,F,N,BAO_0000219,
A 172,Homo sapiens,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,CHEMBL618618,2357,80012,,622.0,,,Intermediate,,1,,1,9606.0,5908,F,N,BAO_0000219,
A204,Homo sapiens,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,CHEMBL618619,1457,80014,,623.0,,,Intermediate,,1,,1,9606.0,5909,F,N,BAO_0000219,
A2780,Homo sapiens,,,Tested for antiproliferative activity against A-2780 tumoral cell line,CHEMBL618620,4379,81034,,478.0,,,Intermediate,,1,,1,9606.0,5910,F,N,BAO_0000219,
A-375,Homo sapiens,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,CHEMBL618621,1093,80018,,455.0,,,Intermediate,,1,,1,9606.0,5911,F,N,BAO_0000219,
A-375,Homo sapiens,,,Tested in vitro against A-375 cell line human melanoma,CHEMBL618622,12152,80018,,455.0,,,Intermediate,,1,,1,9606.0,5912,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,CHEMBL618623,16464,80019,,797.0,,,Expert,,1,,1,9606.0,5913,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL618624,16464,80019,,797.0,,,Intermediate,,1,,1,9606.0,5914,F,N,BAO_0000219,
A-427,Homo sapiens,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,CHEMBL618625,16582,80019,,797.0,,,Expert,,1,,1,9606.0,5915,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,CHEMBL618626,16464,80019,,797.0,,,Intermediate,,1,,1,9606.0,5916,F,N,BAO_0000219,
A-427,Homo sapiens,,,Antitumor activity on A-427 lung carcinoma cell lines,CHEMBL618627,10413,80019,,797.0,,,Intermediate,,1,,1,9606.0,5917,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxic activity against human A-427 lung tumor cell line,CHEMBL618628,6418,80019,,797.0,,,Intermediate,,1,,1,9606.0,5918,F,N,BAO_0000219,
A-427,Homo sapiens,,,In vitro antitumor effects against human A-427 cell lines.,CHEMBL618629,17134,80019,,797.0,,,Expert,,1,,1,9606.0,5919,F,N,BAO_0000219,
A-427,Homo sapiens,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,CHEMBL618630,16132,80019,,797.0,,,Expert,,1,,1,9606.0,5920,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,CHEMBL618631,16132,80019,,797.0,,,Intermediate,,1,,1,9606.0,5921,F,N,BAO_0000219,
A-427,Homo sapiens,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,CHEMBL618632,16780,80019,,797.0,,,Intermediate,,1,,1,9606.0,5922,F,N,BAO_0000219,
A-431,Homo sapiens,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,CHEMBL618633,4085,80852,,500.0,,,Expert,,1,,1,9606.0,5923,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,CHEMBL619315,1276,80021,,624.0,,,Intermediate,,1,,1,9606.0,5924,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,CHEMBL619316,3498,80021,,624.0,,,Expert,,1,,1,9606.0,5925,F,N,BAO_0000219,
A498,Homo sapiens,,,Cytotoxicity against human kidney carcinoma A-498cell lines,CHEMBL619317,1169,80021,,624.0,,,Intermediate,,1,,1,9606.0,5926,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,CHEMBL619318,4450,80021,,624.0,,,Intermediate,,1,,1,9606.0,5927,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,CHEMBL619319,3311,80021,,624.0,,,Intermediate,,1,,1,9606.0,5928,F,N,BAO_0000219,
A498,Homo sapiens,,,Antitumor cytotoxic activity against A-498 cell line was determined,CHEMBL619739,4461,80021,,624.0,,,Intermediate,,1,,1,9606.0,5929,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,CHEMBL619740,3311,80021,,624.0,,,Intermediate,,1,,1,9606.0,5930,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,CHEMBL883158,3311,80021,,624.0,,,Intermediate,,1,,1,9606.0,5931,F,N,BAO_0000219,
A498,Homo sapiens,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,CHEMBL884012,1457,80021,,624.0,,,Intermediate,,1,,1,9606.0,5932,F,N,BAO_0000219,
A498,Homo sapiens,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,CHEMBL619741,3664,80021,,624.0,,,Intermediate,,1,,1,9606.0,5933,F,N,BAO_0000219,
A498,Homo sapiens,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",CHEMBL619742,15895,80021,,624.0,,,Intermediate,,1,,1,9606.0,5934,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,CHEMBL876610,11843,80682,,646.0,,,Intermediate,,1,,1,9606.0,5935,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,CHEMBL619743,11843,80682,,646.0,,,Intermediate,,1,,1,9606.0,5936,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antiproliferative activity against human A-549 NSCL cell line,CHEMBL619744,17705,80682,,646.0,,,Intermediate,,1,,1,9606.0,5937,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,CHEMBL619745,17705,80682,,646.0,,,Intermediate,,1,,1,9606.0,5938,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,CHEMBL619746,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5939,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,CHEMBL619747,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5940,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,CHEMBL619748,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5941,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,CHEMBL619749,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5942,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,CHEMBL619750,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5943,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,CHEMBL624014,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5944,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,CHEMBL624015,4369,80682,,646.0,,,Intermediate,,1,,1,9606.0,5945,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,CHEMBL885344,4787,80682,,646.0,,,Expert,,1,,1,9606.0,5946,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,CHEMBL623224,4787,80682,,646.0,,,Intermediate,,1,,1,9606.0,5947,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against A-549 cell line,CHEMBL623225,6513,80682,,646.0,,,Intermediate,,1,,1,9606.0,5948,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,CHEMBL622698,6690,80682,,646.0,,,Intermediate,,1,,1,9606.0,5949,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,CHEMBL622699,6690,80682,,646.0,,,Intermediate,,1,,1,9606.0,5950,F,N,BAO_0000219,
A549,Homo sapiens,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",CHEMBL622700,12263,80682,,646.0,,,Expert,,1,,1,9606.0,5951,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),CHEMBL622701,1054,80682,,646.0,,,Intermediate,,1,,1,9606.0,5952,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),CHEMBL622702,1359,80682,,646.0,,,Intermediate,,1,,1,9606.0,5953,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,CHEMBL622703,3547,80682,,646.0,,,Intermediate,,1,,1,9606.0,5954,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity towards A-549 cells,CHEMBL622704,5771,80682,,646.0,,,Expert,,1,,1,9606.0,5955,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro percent inhibition of A549, lung carcinoma.",CHEMBL622705,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5956,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro percent inhibition of A549, lung carcinoma",CHEMBL622706,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5957,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro percent inhibition of A549, lung carcinoma.",CHEMBL622707,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5958,F,N,BAO_0000219,
A549,Homo sapiens,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",CHEMBL622708,14425,80682,,646.0,,,Intermediate,,1,,1,9606.0,5959,F,N,BAO_0000219,
A549,Homo sapiens,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,CHEMBL622709,5280,80682,,646.0,,,Intermediate,,1,,1,9606.0,5960,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,CHEMBL622710,15176,80682,,646.0,,,Intermediate,,1,,1,9606.0,5961,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,CHEMBL622711,15300,80682,,646.0,,,Intermediate,,1,,1,9606.0,5962,F,N,BAO_0000219,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622712,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5963,F,N,BAO_0000218,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622713,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5964,F,N,BAO_0000218,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622714,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5965,F,N,BAO_0000218,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622715,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5966,F,N,BAO_0000218,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",CHEMBL622716,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5967,F,N,BAO_0000218,
A549,Homo sapiens,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",CHEMBL622717,17824,80682,,646.0,,,Intermediate,,1,,1,9606.0,5968,F,N,BAO_0000219,
A549,Homo sapiens,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),CHEMBL622718,17528,80682,,646.0,,,Intermediate,,1,,1,9606.0,5969,F,N,BAO_0000218,
A549,Homo sapiens,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,CHEMBL622719,6870,80682,,646.0,,,Expert,,1,,1,9606.0,5970,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,CHEMBL622720,6870,80682,,646.0,,,Intermediate,,1,,1,9606.0,5971,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,CHEMBL622721,6870,80682,,646.0,,,Intermediate,,1,,1,9606.0,5972,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,CHEMBL622722,6870,80682,,646.0,,,Intermediate,,1,,1,9606.0,5973,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,CHEMBL876030,16726,80682,,646.0,,,Intermediate,,1,,1,9606.0,5974,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",CHEMBL620206,6170,80682,,646.0,,,Intermediate,,1,,1,9606.0,5975,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,CHEMBL620207,6583,80682,,646.0,,,Expert,,1,,1,9606.0,5976,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,CHEMBL620208,6583,80682,,646.0,,,Expert,,1,,1,9606.0,5977,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,CHEMBL620209,6583,80682,,646.0,,,Expert,,1,,1,9606.0,5978,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,CHEMBL620210,6583,80682,,646.0,,,Expert,,1,,1,9606.0,5979,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,CHEMBL621639,6583,80682,,646.0,,,Expert,,1,,1,9606.0,5980,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,CHEMBL621640,17321,80682,,646.0,,,Intermediate,,1,,1,9606.0,5981,F,N,BAO_0000219,
A549,Homo sapiens,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,CHEMBL621641,17528,80682,,646.0,,,Expert,,1,,1,9606.0,5982,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,CHEMBL621642,12888,80682,,646.0,,,Expert,,1,,1,9606.0,5983,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,CHEMBL621643,4312,80682,,646.0,,,Intermediate,,1,,1,9606.0,5984,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,CHEMBL621644,4312,80682,,646.0,,,Intermediate,,1,,1,9606.0,5985,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,CHEMBL621645,4312,80682,,646.0,,,Intermediate,,1,,1,9606.0,5986,F,N,BAO_0000219,
A549,Mus musculus,,,In vitro antiproliferative activity against A549 cell line,CHEMBL621646,17737,80682,,646.0,,,Intermediate,,1,,1,10090.0,5987,F,N,BAO_0000219,
A549,,,,Synergism with indomethacin in A549 cells,CHEMBL621647,6630,80682,,646.0,,,Intermediate,,1,,1,,5988,F,N,BAO_0000219,
A549,,,,Synergism with tolmetin in A549 cells,CHEMBL621648,6630,80682,,646.0,,,Intermediate,,1,,1,,5989,F,N,BAO_0000219,
A549,,,,Synergism with sulindac in A549 cells,CHEMBL621649,6630,80682,,646.0,,,Intermediate,,1,,1,,5990,F,N,BAO_0000219,
A549,,,,Antagonism of indomethacin in A549 cells,CHEMBL621650,6630,80682,,646.0,,,Intermediate,,1,,1,,5991,F,N,BAO_0000219,
A549,,,,Antagonism of sulindac in A549 cells,CHEMBL621651,6630,80682,,646.0,,,Intermediate,,1,,1,,5992,F,N,BAO_0000219,
A549,,,,Antagonism of tolmetin in A549 cells,CHEMBL621652,6630,80682,,646.0,,,Intermediate,,1,,1,,5993,F,N,BAO_0000219,
A549,,,,Synergism with indomethacin in A549 cells,CHEMBL621653,6630,80682,,646.0,,,Intermediate,,1,,1,,5994,F,N,BAO_0000219,
A549,,,,Synergism with sulindac in A549 cells,CHEMBL621654,6630,80682,,646.0,,,Intermediate,,1,,1,,5995,F,N,BAO_0000219,
A549,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,CHEMBL621655,6630,80682,,646.0,,,Intermediate,,1,,1,,5996,F,N,BAO_0000219,
,Canis lupus familiaris,,,Cmax value after 30 mg/kg po dose in Dogs,CHEMBL621656,16907,50588,,,,,Intermediate,,1,,1,9615.0,5997,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL621657,5944,50588,,,,,Intermediate,,1,,1,9615.0,5998,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,CHEMBL621658,5944,50588,,,,,Intermediate,,1,,1,9615.0,5999,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),CHEMBL621659,5944,50588,,,,,Intermediate,,1,,1,9615.0,6000,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,CHEMBL621660,5944,50588,,,,,Intermediate,,1,,1,9615.0,6001,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value after administration of 4 mg/Kg oral dose in dog,CHEMBL621661,2959,50588,,,,,Intermediate,,1,,1,9615.0,6002,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value in dog,CHEMBL621662,6241,50588,,,,,Intermediate,,1,,1,9615.0,6003,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax value in dogs after oral administration at 1 mg/kg,CHEMBL621663,6241,50588,,,,,Intermediate,,1,,1,9615.0,6004,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,CHEMBL621664,2652,50588,,,,,Intermediate,,1,,1,9615.0,6005,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,CHEMBL621665,1806,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6006,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,CHEMBL621666,1806,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6007,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Concentration maxima after oral dosing in dogs,CHEMBL621667,1021,50588,,,,,Intermediate,,1,,1,9615.0,6008,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Concentration maxima after oral dosing in dogs; not available,CHEMBL876738,1021,50588,,,,,Intermediate,,1,,1,9615.0,6009,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Concentration maxima after oral dosing in dogs; not available,CHEMBL621668,1021,50588,,,,,Intermediate,,1,,1,9615.0,6010,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,CHEMBL621669,5444,50588,,,,,Intermediate,,1,,1,9615.0,6011,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,CHEMBL621670,5444,50588,,,,,Intermediate,,1,,1,9615.0,6012,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,CHEMBL621671,5444,50588,,,,,Intermediate,,1,,1,9615.0,6013,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,CHEMBL622360,5444,50588,,,,,Intermediate,,1,,1,9615.0,6014,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,CHEMBL622361,5444,50588,,,,,Intermediate,,1,,1,9615.0,6015,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog plasma after oral dose (1 mg/kg),CHEMBL622362,5130,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6016,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,CHEMBL622363,3249,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6017,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximal plasma concentration at a dose of 1 mg/kg,CHEMBL622364,5473,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6018,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),CHEMBL622365,5474,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6019,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,CHEMBL622533,4657,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6020,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration of compound in dog was evaluated.,CHEMBL622534,3031,50588,,,,,Intermediate,,1,,1,9615.0,6021,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622535,4527,50588,,,,,Intermediate,,1,,1,9615.0,6022,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,CHEMBL876739,4186,50588,,,,,Intermediate,,1,,1,9615.0,6023,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL622536,5007,50588,,,,,Intermediate,,1,,1,9615.0,6024,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration obtained in dog plasma was determined,CHEMBL622537,3132,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6025,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration was determined,CHEMBL622538,5006,50588,,,,,Intermediate,,1,,1,9615.0,6026,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration at the dose of 2 mg/kg in dog,CHEMBL627867,4727,50588,,,,,Intermediate,,1,,1,9615.0,6027,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL627868,1916,50588,,,,,Intermediate,,1,,1,9615.0,6028,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration was evaluated in dog plasma,CHEMBL627869,1918,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6029,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration was evaluated after 75 min after administration in dog,CHEMBL627870,3045,50588,,,,,Intermediate,,1,,1,9615.0,6030,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration determined in dog after oral administration of 17b,CHEMBL627871,9579,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6031,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration determined in dog after oral administration of 2b,CHEMBL627872,9579,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6032,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration in dog,CHEMBL627873,933,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6033,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,CHEMBL627874,17839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6034,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,CHEMBL627875,17839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6035,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,CHEMBL627876,17839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6036,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,CHEMBL627877,17839,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6037,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL627878,6348,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6038,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,CHEMBL627879,16367,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6039,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL875355,1337,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6040,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL627880,1337,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6041,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,CHEMBL627881,5199,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6042,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,CHEMBL627882,17650,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6043,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,CHEMBL627883,6679,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6044,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,CHEMBL628526,5356,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6045,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,CHEMBL628527,5356,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6046,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,CHEMBL628528,6227,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6047,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,CHEMBL628529,6227,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6048,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,CHEMBL628530,6227,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6049,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,CHEMBL625243,6227,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6050,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL625244,3598,50588,,,Plasma,1969.0,Expert,,1,,1,9615.0,6051,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,CHEMBL625245,4368,50588,,,,,Intermediate,,1,,1,9615.0,6052,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,CHEMBL625246,6265,50588,,,,,Intermediate,,1,,1,9615.0,6053,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,CHEMBL625247,7767,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,6054,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,CHEMBL625248,7767,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,6055,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,CHEMBL625249,7767,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,6056,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,CHEMBL625250,7767,50594,,,Urine,1088.0,Intermediate,,1,,1,10090.0,6057,A,N,BAO_0000218,In vivo
,Mus musculus,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,CHEMBL625251,17811,50594,,,,,Intermediate,,1,,1,10090.0,6058,A,N,BAO_0000218,
,Mus musculus,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,CHEMBL875356,17811,50594,,,,,Intermediate,,1,,1,10090.0,6059,A,N,BAO_0000218,
,Mus musculus,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),CHEMBL625252,17827,50594,,,,,Intermediate,,1,,1,10090.0,6060,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),CHEMBL625253,17827,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,6061,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),CHEMBL625254,17827,50594,,,,,Intermediate,,1,,1,10090.0,6062,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),CHEMBL625255,17827,50594,,,,,Intermediate,,1,,1,10090.0,6063,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),CHEMBL625256,17827,50594,,,,,Intermediate,,1,,1,10090.0,6064,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),CHEMBL625257,17827,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,6065,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),CHEMBL625258,17827,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,6066,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),CHEMBL625259,17827,50594,,,,,Intermediate,,1,,1,10090.0,6067,A,N,BAO_0000218,
,Mus musculus,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,CHEMBL625260,17827,50594,,,,,Intermediate,,1,,1,10090.0,6068,A,N,BAO_0000218,
,Mus musculus,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL625261,17827,50594,,,,,Intermediate,,1,,1,10090.0,6069,A,N,BAO_0000218,
,Mus musculus,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL625262,17827,50594,,,,,Intermediate,,1,,1,10090.0,6070,A,N,BAO_0000218,
,Mus musculus,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",CHEMBL622639,17827,50594,,,,,Intermediate,,1,,1,10090.0,6071,A,N,BAO_0000218,
,Mus musculus,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,CHEMBL622640,17257,50594,,,,,Intermediate,,1,,1,10090.0,6072,A,N,BAO_0000218,
,Mus musculus,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,CHEMBL622812,17257,50594,,,,,Intermediate,,1,,1,10090.0,6073,A,N,BAO_0000218,
,Mus musculus,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,CHEMBL622813,17257,50594,,,,,Intermediate,,1,,1,10090.0,6074,A,N,BAO_0000218,
,Mus musculus,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,CHEMBL622814,17257,50594,,,,,Intermediate,,1,,1,10090.0,6075,A,N,BAO_0000218,
,Mus musculus,,,Time at maximum activity in mice (Radiolabeled compound),CHEMBL622815,17827,50594,,,,,Intermediate,,1,,1,10090.0,6076,A,N,BAO_0000218,
,Mus musculus,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,CHEMBL625342,3760,50594,,,,,Intermediate,,1,,1,10090.0,6077,A,N,BAO_0000218,
,Mus musculus,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,CHEMBL625343,3760,50594,,,,,Intermediate,,1,,1,10090.0,6078,A,N,BAO_0000218,
,Mus musculus,,,Binding towards mouse plasma protein at 10 uM,CHEMBL877591,17409,50594,,,,,Intermediate,,1,,1,10090.0,6079,A,N,BAO_0000218,
,Mus musculus,,,Binding towards mouse plasma protein at 100 uM,CHEMBL625344,17409,50594,,,,,Intermediate,,1,,1,10090.0,6080,A,N,BAO_0000218,
,Mus musculus,,,Bioavailability was evaluated in mice after intravenous administration,CHEMBL625345,2675,50594,,,,,Intermediate,,1,,1,10090.0,6081,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability was evaluated in mice after oral administration,CHEMBL625346,2675,50594,,,,,Intermediate,,1,,1,10090.0,6082,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,CHEMBL625347,3132,50594,,,,,Intermediate,,1,,1,10090.0,6083,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,CHEMBL625348,3132,50594,,,,,Intermediate,,1,,1,10090.0,6084,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,CHEMBL625349,16597,50594,,,,,Intermediate,,1,,1,10090.0,6085,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in mouse,CHEMBL625350,2862,50594,,,,,Intermediate,,1,,1,10090.0,6086,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,CHEMBL882952,17764,50594,,,,,Intermediate,,1,,1,10090.0,6087,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625351,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6088,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625352,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6089,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL877592,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6090,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL625353,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6091,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL625354,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6092,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626019,846,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6093,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626020,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6094,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL626021,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6095,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626022,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6096,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL626192,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6097,A,N,BAO_0000218,In vivo
A549,Homo sapiens,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),CHEMBL626193,1276,80682,,646.0,,,Intermediate,,1,,1,9606.0,6098,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,CHEMBL626194,3498,80682,,646.0,,,Expert,,1,,1,9606.0,6099,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma A-549 cell lines,CHEMBL626195,1169,80682,,646.0,,,Intermediate,,1,,1,9606.0,6100,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,CHEMBL626196,4450,80682,,646.0,,,Intermediate,,1,,1,9606.0,6101,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,CHEMBL626197,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6102,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,CHEMBL626198,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6103,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,CHEMBL626199,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6104,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,CHEMBL626200,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6105,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,CHEMBL626201,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6106,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,CHEMBL626202,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6107,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,CHEMBL626203,358,80682,,646.0,,,Intermediate,,1,,1,9606.0,6108,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A-549 human lung cancer cells,CHEMBL626204,15167,80682,,646.0,,,Intermediate,,1,,1,9606.0,6109,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,CHEMBL624701,4139,80682,,646.0,,,Intermediate,,1,,1,9606.0,6110,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,CHEMBL624702,833,80682,,646.0,,,Intermediate,,1,,1,9606.0,6111,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL624703,15718,80682,,646.0,,,Expert,,1,,1,9606.0,6112,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,CHEMBL624704,12373,80682,,646.0,,,Intermediate,,1,,1,9606.0,6113,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,CHEMBL624705,637,80682,,646.0,,,Intermediate,,1,,1,9606.0,6114,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,CHEMBL624706,14867,80682,,646.0,,,Expert,,1,,1,9606.0,6115,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor cytotoxic activity against A-549 cell line was determined,CHEMBL624707,4461,80682,,646.0,,,Intermediate,,1,,1,9606.0,6116,F,N,BAO_0000219,
A549,Homo sapiens,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",CHEMBL624708,5406,80682,,646.0,,,Intermediate,,1,,1,9606.0,6117,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,CHEMBL624709,4457,80682,,646.0,,,Intermediate,,1,,1,9606.0,6118,F,N,BAO_0000219,
A549,Homo sapiens,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,CHEMBL884107,1386,80682,,646.0,,,Expert,,1,,1,9606.0,6119,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumoral activity was assayed against A-549 cell line,CHEMBL624710,3265,80682,,646.0,,,Intermediate,,1,,1,9606.0,6120,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,CHEMBL624711,2359,80682,,646.0,,,Intermediate,,1,,1,9606.0,6121,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,CHEMBL624712,4457,80682,,646.0,,,Intermediate,,1,,1,9606.0,6122,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,CHEMBL624713,12454,80682,,646.0,,,Expert,,1,,1,9606.0,6123,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for inhibition of cell growth of A-549 cells,CHEMBL624714,1481,80682,,646.0,,,Intermediate,,1,,1,9606.0,6124,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,CHEMBL624715,1750,80682,,646.0,,,Intermediate,,1,,1,9606.0,6125,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,CHEMBL624716,5065,80682,,646.0,,,Intermediate,,1,,1,9606.0,6126,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,CHEMBL619505,808,80682,,646.0,,,Expert,,1,,1,9606.0,6127,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,CHEMBL619506,16364,80682,,646.0,,,Expert,,1,,1,9606.0,6128,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity against A-549 cell lines.,CHEMBL619507,1847,80682,,646.0,,,Intermediate,,1,,1,9606.0,6129,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,CHEMBL619508,1747,80682,,646.0,,,Expert,,1,,1,9606.0,6130,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human A549 non small cell lung cell lines,CHEMBL619509,1003,80682,,646.0,,,Intermediate,,1,,1,9606.0,6131,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of cell growth in (A-549) lung cell line,CHEMBL619510,15313,80682,,646.0,,,Expert,,1,,1,9606.0,6132,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,CHEMBL619511,3122,80682,,646.0,,,Intermediate,,1,,1,9606.0,6133,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against A-549 tumor cells.,CHEMBL619512,16049,80682,,646.0,,,Intermediate,,1,,1,9606.0,6134,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor effects against human A-549 cell lines.,CHEMBL619513,17134,80682,,646.0,,,Expert,,1,,1,9606.0,6135,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxic activity of compound against A-549 cell line,CHEMBL619514,6406,80682,,646.0,,,Intermediate,,1,,1,9606.0,6136,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,CHEMBL619515,627,80682,,646.0,,,Intermediate,,1,,1,9606.0,6137,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,CHEMBL619516,12307,80682,,646.0,,,Intermediate,,1,,1,9606.0,6138,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,CHEMBL884005,17861,80682,,646.0,,,Intermediate,,1,,1,9606.0,6139,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,CHEMBL619517,6682,80682,,646.0,,,Expert,,1,,1,9606.0,6140,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration of compound against A-549 cell line,CHEMBL619518,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6141,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,CHEMBL619519,2454,80682,,646.0,,,Intermediate,,1,,1,9606.0,6142,F,N,BAO_0000219,
A549,Homo sapiens,,,cytotoxic activity against leukemia (A-549) cancer cell line,CHEMBL876489,14709,80682,,646.0,,,Intermediate,,1,,1,9606.0,6143,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL619520,15718,80682,,646.0,,,Expert,,1,,1,9606.0,6144,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,CHEMBL619521,15718,80682,,646.0,,,Intermediate,,1,,1,9606.0,6145,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),CHEMBL619522,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6146,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),CHEMBL619523,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6147,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),CHEMBL619524,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6148,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),CHEMBL619525,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6149,F,N,BAO_0000219,
A549,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,CHEMBL619526,6630,80682,,646.0,,,Intermediate,,1,,1,,6150,F,N,BAO_0000219,
A549,Homo sapiens,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,CHEMBL619527,16726,80682,,646.0,,,Intermediate,,1,,1,9606.0,6151,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against A549 cells; No cytotoxicity,CHEMBL619528,17846,80682,,646.0,,,Intermediate,,1,,1,9606.0,6152,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma (A549) cell lines,CHEMBL619529,3415,80682,,646.0,,,Expert,,1,,1,9606.0,6153,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,CHEMBL619530,3415,80682,,646.0,,,Expert,,1,,1,9606.0,6154,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro anticancer activity against human lung (A549) cell line,CHEMBL876490,5609,80682,,646.0,,,Intermediate,,1,,1,9606.0,6155,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,CHEMBL619531,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6156,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,CHEMBL619532,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6157,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,CHEMBL619533,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6158,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,CHEMBL619534,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6159,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,CHEMBL620164,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6160,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,CHEMBL620165,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6161,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of A549 human lung tumor cell proliferation,CHEMBL620166,16295,80682,,646.0,,,Expert,,1,,1,9606.0,6162,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",CHEMBL620167,16825,80682,,646.0,,,Intermediate,,1,,1,9606.0,6163,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human tumor cell line A549,CHEMBL620168,3439,80682,,646.0,,,Expert,,1,,1,9606.0,6164,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,CHEMBL620338,10870,80682,,646.0,,,Intermediate,,1,,1,9606.0,6165,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,CHEMBL620339,4845,80682,,646.0,,,Intermediate,,1,,1,9606.0,6166,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,CHEMBL620340,5822,80682,,646.0,,,Intermediate,,1,,1,9606.0,6167,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,CHEMBL620341,5822,80682,,646.0,,,Intermediate,,1,,1,9606.0,6168,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,CHEMBL876491,5822,80682,,646.0,,,Intermediate,,1,,1,9606.0,6169,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,CHEMBL620342,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6170,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,CHEMBL620343,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6171,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,CHEMBL620344,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6172,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro anticancer activity against human lung (A549) cell line,CHEMBL620345,5609,80682,,646.0,,,Intermediate,,1,,1,9606.0,6173,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,CHEMBL620346,4644,80682,,646.0,,,Intermediate,,1,,1,9606.0,6174,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,CHEMBL620347,4644,80682,,646.0,,,Intermediate,,1,,1,9606.0,6175,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,CHEMBL620348,4644,80682,,646.0,,,Intermediate,,1,,1,9606.0,6176,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,CHEMBL620349,4644,80682,,646.0,,,Intermediate,,1,,1,9606.0,6177,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,CHEMBL618667,5822,80682,,646.0,,,Intermediate,,1,,1,9606.0,6178,F,N,BAO_0000219,
A549,Homo sapiens,,,Percentage inhibition of human lung carcinoma (A549) cell lines,CHEMBL618668,3415,80682,,646.0,,,Expert,,1,,1,9606.0,6179,F,N,BAO_0000219,
A549,Homo sapiens,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,CHEMBL876031,16726,80682,,646.0,,,Intermediate,,1,,1,9606.0,6180,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",CHEMBL618759,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6181,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,CHEMBL618760,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6182,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,CHEMBL619000,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6183,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",CHEMBL619001,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6184,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",CHEMBL619002,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6185,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",CHEMBL619003,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6186,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",CHEMBL619597,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6187,F,N,BAO_0000219,
A549,Homo sapiens,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",CHEMBL619598,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6188,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,CHEMBL619599,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6189,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,CHEMBL619600,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6190,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,CHEMBL619601,16726,80682,,646.0,,,Intermediate,,1,,1,9606.0,6191,F,N,BAO_0000219,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,CHEMBL619602,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6192,F,N,BAO_0000219,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,CHEMBL619603,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6193,F,N,BAO_0000219,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,CHEMBL619604,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6194,F,N,BAO_0000219,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,CHEMBL619605,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6195,F,N,BAO_0000219,
,Canis lupus familiaris,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,CHEMBL619606,6084,50588,,,,,Intermediate,,1,,1,9615.0,6196,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic activity (Cmax) in dog,CHEMBL876032,6084,50588,,,,,Intermediate,,1,,1,9615.0,6197,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL619607,4809,50588,,,,,Intermediate,,1,,1,9615.0,6198,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,CHEMBL619608,5983,50588,,,,,Intermediate,,1,,1,9615.0,6199,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,CHEMBL619609,6251,50588,,,,,Intermediate,,1,,1,9615.0,6200,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Cmax in dog plasma after 30mg/kg oral dose,CHEMBL619610,5932,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6201,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for the peak blood level in dog,CHEMBL619611,4273,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,6202,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",CHEMBL619612,5313,50588,,,,,Intermediate,,1,,1,9615.0,6203,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",CHEMBL619613,5313,50588,,,,,Intermediate,,1,,1,9615.0,6204,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,CHEMBL619614,6221,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,6205,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,CHEMBL619615,4709,50588,,,,,Intermediate,,1,,1,9615.0,6206,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,CHEMBL619616,167,50588,,,,,Intermediate,,1,,1,9615.0,6207,A,N,BAO_0000218,
,Canis lupus familiaris,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,CHEMBL619617,6241,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6208,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,CHEMBL619618,344,50588,,,,,Intermediate,,1,,1,9615.0,6209,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,CHEMBL876033,344,50588,,,,,Intermediate,,1,,1,9615.0,6210,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,CHEMBL619619,344,50588,,,,,Intermediate,,1,,1,9615.0,6211,A,N,BAO_0000218,
,Canis lupus familiaris,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,CHEMBL619620,2189,50588,,,,,Intermediate,,1,,1,9615.0,6212,A,N,BAO_0000218,
,Canis lupus familiaris,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,CHEMBL619621,2189,50588,,,Urine,1088.0,Intermediate,,1,,1,9615.0,6213,A,N,BAO_0000218,
,Canis lupus familiaris,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,CHEMBL619622,2189,50588,,,Urine,1088.0,Intermediate,,1,,1,9615.0,6214,A,N,BAO_0000218,
,Canis lupus familiaris,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,CHEMBL618874,2189,50588,,,Urine,1088.0,Intermediate,,1,,1,9615.0,6215,A,N,BAO_0000218,
,Canis lupus familiaris,,,Absolute bioavailability was evaluated in dog,CHEMBL618875,4257,50588,,,,,Intermediate,,1,,1,9615.0,6216,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,CHEMBL618876,6221,50588,,,,,Intermediate,,1,,1,9615.0,6217,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,CHEMBL618877,6215,50588,,,,,Intermediate,,1,,1,9615.0,6218,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL618878,17267,50588,,,,,Intermediate,,1,,1,9615.0,6219,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL618879,6621,50588,,,,,Intermediate,,1,,1,9615.0,6220,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after intravenous administration in dogs,CHEMBL618880,3854,50588,,,,,Intermediate,,1,,1,9615.0,6221,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability after peroral administration in dogs,CHEMBL618881,3854,50588,,,,,Intermediate,,1,,1,9615.0,6222,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),CHEMBL618882,5007,50588,,,,,Intermediate,,1,,1,9615.0,6223,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,CHEMBL624226,4333,50588,,,,,Intermediate,,1,,1,9615.0,6224,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,CHEMBL624227,4333,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6225,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability,CHEMBL624228,5006,50588,,,,,Intermediate,,1,,1,9615.0,6226,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability,CHEMBL624229,5199,50588,,,,,Intermediate,,1,,1,9615.0,6227,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,CHEMBL624230,4368,50588,,,,,Intermediate,,1,,1,9615.0,6228,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL624231,3771,50588,,,,,Intermediate,,1,,1,9615.0,6229,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL624232,4953,50588,,,,,Intermediate,,1,,1,9615.0,6230,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL625127,5064,50588,,,,,Intermediate,,1,,1,9615.0,6231,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL625128,17657,50588,,,,,Intermediate,,1,,1,9615.0,6232,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL621675,17796,50588,,,,,Intermediate,,1,,1,9615.0,6233,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (p.o.) at 2.0 mpk,CHEMBL621676,17853,50588,,,,,Intermediate,,1,,1,9615.0,6234,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),CHEMBL621677,4521,50588,,,,,Intermediate,,1,,1,9615.0,6235,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL621678,4521,50588,,,,,Intermediate,,1,,1,9615.0,6236,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL621679,5006,50588,,,,,Intermediate,,1,,1,9615.0,6237,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was evaluated after oral administration in dog,CHEMBL621680,16365,50588,,,,,Intermediate,,1,,1,9615.0,6238,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL621681,1916,50588,,,,,Intermediate,,1,,1,9615.0,6239,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was evaluated in dog,CHEMBL876740,1918,50588,,,,,Intermediate,,1,,1,9615.0,6240,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL621682,4239,50588,,,,,Intermediate,,1,,1,9615.0,6241,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL621683,6505,50588,,,,,Intermediate,,1,,1,9615.0,6242,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL621684,5334,50588,,,,,Intermediate,,1,,1,9615.0,6243,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),CHEMBL621685,5334,50588,,,,,Intermediate,,1,,1,9615.0,6244,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL621686,4809,50588,,,,,Intermediate,,1,,1,9615.0,6245,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL621687,6348,50588,,,,,Intermediate,,1,,1,9615.0,6246,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,CHEMBL621688,6005,50588,,,,,Intermediate,,1,,1,9615.0,6247,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability of compound in dog was determined after peroral administration,CHEMBL621689,17804,50588,,,,,Intermediate,,1,,1,9615.0,6248,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621690,3184,50588,,,,,Intermediate,,1,,1,9615.0,6249,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,CHEMBL621691,1806,50588,,,,,Intermediate,,1,,1,9615.0,6250,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,CHEMBL875941,1806,50588,,,,,Intermediate,,1,,1,9615.0,6251,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,CHEMBL621692,1806,50588,,,,,Intermediate,,1,,1,9615.0,6252,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL621693,4839,50588,,,,,Intermediate,,1,,1,9615.0,6253,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),CHEMBL621694,5017,50588,,,,,Intermediate,,1,,1,9615.0,6254,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL621695,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6255,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621696,846,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,6256,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621697,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6257,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL621698,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6258,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623420,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6259,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623421,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6260,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623422,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6261,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623423,846,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6262,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623424,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6263,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623425,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6264,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623426,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6265,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623427,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6266,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL623428,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6267,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL875947,846,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6268,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623429,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6269,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL623430,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6270,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL622588,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6271,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL622589,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6272,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,CHEMBL622751,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6273,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,CHEMBL622752,846,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6274,A,N,BAO_0000218,In vivo
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,CHEMBL622753,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6275,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,CHEMBL622647,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6276,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,CHEMBL875163,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6277,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,CHEMBL622648,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6278,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,CHEMBL622649,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6279,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,CHEMBL622650,6599,50594,,42.0,Brain,955.0,Intermediate,,1,,1,10090.0,6280,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,CHEMBL622651,6599,50594,,42.0,Brain,955.0,Intermediate,,1,,1,10090.0,6281,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,CHEMBL622652,6599,50594,,42.0,Brain,955.0,Intermediate,,1,,1,10090.0,6282,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,CHEMBL622653,6599,50594,,42.0,Brain,955.0,Intermediate,,1,,1,10090.0,6283,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,CHEMBL622654,6599,50594,,42.0,Brain,955.0,Intermediate,,1,,1,10090.0,6284,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,CHEMBL622655,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6285,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,CHEMBL622656,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6286,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,CHEMBL622657,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6287,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,CHEMBL622658,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6288,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,CHEMBL622659,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6289,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,CHEMBL624630,6599,50594,,42.0,Kidney,2113.0,Intermediate,,1,,1,10090.0,6290,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,CHEMBL624631,6599,50594,,42.0,Kidney,2113.0,Intermediate,,1,,1,10090.0,6291,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,CHEMBL624632,6599,50594,,42.0,Kidney,2113.0,Intermediate,,1,,1,10090.0,6292,A,N,BAO_0000218,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,CHEMBL624633,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6293,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,CHEMBL624634,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6294,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),CHEMBL624635,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6295,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),CHEMBL624636,17130,80682,,646.0,,,Intermediate,,1,,1,9606.0,6296,F,N,BAO_0000219,
A549,Homo sapiens,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,CHEMBL857055,3263,80682,,646.0,,,Expert,,1,,1,9606.0,6297,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,CHEMBL624637,6663,80682,,646.0,,,Expert,,1,,1,9606.0,6298,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,CHEMBL624638,6663,80682,,646.0,,,Expert,,1,,1,9606.0,6299,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,CHEMBL874366,6663,80682,,646.0,,,Expert,,1,,1,9606.0,6300,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,CHEMBL624639,6663,80682,,646.0,,,Expert,,1,,1,9606.0,6301,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,CHEMBL624640,6663,80682,,646.0,,,Expert,,1,,1,9606.0,6302,F,N,BAO_0000219,
A549,Homo sapiens,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,CHEMBL624641,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6303,F,N,BAO_0000219,
A549,Homo sapiens,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,CHEMBL624642,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6304,F,N,BAO_0000219,
A549,Homo sapiens,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,CHEMBL624643,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6305,F,N,BAO_0000219,
A549,Homo sapiens,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,CHEMBL624644,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6306,F,N,BAO_0000219,
A549,Homo sapiens,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,CHEMBL624645,6663,80682,,646.0,,,Intermediate,,1,,1,9606.0,6307,F,N,BAO_0000219,
A549,Homo sapiens,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,CHEMBL619445,3983,80682,,646.0,,,Intermediate,,1,,1,9606.0,6308,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,CHEMBL839886,11141,80682,,646.0,,,Expert,,1,,1,9606.0,6309,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 tumor cell line.,CHEMBL619446,5076,80682,,646.0,,,Intermediate,,1,,1,9606.0,6310,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,CHEMBL619447,3311,80682,,646.0,,,Intermediate,,1,,1,9606.0,6311,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,CHEMBL619448,3311,80682,,646.0,,,Intermediate,,1,,1,9606.0,6312,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,CHEMBL619449,3311,80682,,646.0,,,Intermediate,,1,,1,9606.0,6313,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,CHEMBL619450,5076,80682,,646.0,,,Intermediate,,1,,1,9606.0,6314,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),CHEMBL619451,4150,80682,,646.0,,,Intermediate,,1,,1,9606.0,6315,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,CHEMBL619452,2150,80682,,646.0,,,Expert,,1,,1,9606.0,6316,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,CHEMBL619453,4644,80682,,646.0,,,Intermediate,,1,,1,9606.0,6317,F,N,BAO_0000219,
A549,Homo sapiens,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,CHEMBL874367,263,80682,,646.0,,,Intermediate,,1,,1,9606.0,6318,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic concentration against A-549 tumor cells.,CHEMBL619454,11333,80682,,646.0,,,Intermediate,,1,,1,9606.0,6319,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,CHEMBL619455,11333,80682,,646.0,,,Intermediate,,1,,1,9606.0,6320,F,N,BAO_0000219,
A549,Homo sapiens,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",CHEMBL619456,15895,80682,,646.0,,,Intermediate,,1,,1,9606.0,6321,F,N,BAO_0000219,
,Acinetobacter baumannii,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,CHEMBL619457,16677,50191,,,,,Expert,,1,,1,470.0,6322,F,N,BAO_0000218,
,Acinetobacter calcoaceticus,,,Activity against Acinetobacter calcoaceticus (AC54),CHEMBL619458,10624,50192,,,,,Intermediate,,1,,1,471.0,6323,F,N,BAO_0000218,
,Aspergillus flavus,,,In vitro antifungal activity against Aspergillus flavus CM74,CHEMBL619459,16717,50274,,,,,Expert,,1,,1,5059.0,6324,F,N,BAO_0000218,
,Aspergillus flavus,,,In vitro antifungal activity against Aspergillus flavus CM74,CHEMBL619460,16717,50274,,,,,Expert,,1,,1,5059.0,6325,F,N,BAO_0000218,
,Aspergillus fumigatus,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,CHEMBL619461,5513,50416,,,,,Intermediate,,1,,1,746128.0,6326,F,N,BAO_0000218,
,Aspergillus fumigatus,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),CHEMBL619462,15962,50416,,,,,Intermediate,,1,,1,746128.0,6327,F,N,BAO_0000218,
,Aspergillus fumigatus,,,Antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620388,15962,50416,,,,,Intermediate,,1,,1,746128.0,6328,F,N,BAO_0000218,
,Aspergillus fumigatus,,,Antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620389,15962,50416,,,,,Intermediate,,1,,1,746128.0,6329,F,N,BAO_0000218,
,Aspergillus fumigatus,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),CHEMBL620390,15962,50416,,,,,Intermediate,,1,,1,746128.0,6330,F,N,BAO_0000218,
,Aspergillus fumigatus,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,CHEMBL620391,16717,50416,,,,,Expert,,1,,1,746128.0,6331,F,N,BAO_0000218,
,Aspergillus fumigatus,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,CHEMBL621073,16717,50416,,,,,Expert,,1,,1,746128.0,6332,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,CHEMBL621074,8117,50296,,,,,Intermediate,,1,,1,1655.0,6333,F,N,BAO_0000218,
,Actinomyces viscosus,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,CHEMBL621075,8117,50366,,,,,Intermediate,,1,,1,1656.0,6334,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),CHEMBL619554,15472,50535,,,,,Intermediate,,1,,1,6277.0,6335,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),CHEMBL619555,15472,50535,,,,,Intermediate,,1,,1,6277.0,6336,F,N,BAO_0000218,
,Aggregatibacter actinomycetemcomitans,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,CHEMBL619556,16443,50169,,,,,Intermediate,,1,,1,714.0,6337,F,N,BAO_0000218,
,Aggregatibacter actinomycetemcomitans,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,CHEMBL619557,16443,50169,,,,,Intermediate,,1,,1,714.0,6338,F,N,BAO_0000218,
,Aggregatibacter actinomycetemcomitans,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,CHEMBL619558,16443,50169,,,,,Intermediate,,1,,1,714.0,6339,F,N,BAO_0000218,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,CHEMBL619559,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6340,F,N,BAO_0000219,
A549,Homo sapiens,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,CHEMBL619560,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6341,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,CHEMBL619561,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6342,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,CHEMBL619562,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6343,F,N,BAO_0000219,
A549,Homo sapiens,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,CHEMBL619563,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6344,F,N,BAO_0000219,
A549,Homo sapiens,,,GI values against A549 cells (lung cancer),CHEMBL857457,16381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6345,F,N,BAO_0000219,
A549,Homo sapiens,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,CHEMBL619564,17206,80682,,646.0,,,Intermediate,,1,,1,9606.0,6346,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 human adenocarcinoma,CHEMBL619565,16325,80682,,646.0,,,Intermediate,,1,,1,9606.0,6347,F,N,BAO_0000219,
A549,Homo sapiens,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,CHEMBL619566,10708,80682,,646.0,,,Intermediate,,1,,1,9606.0,6348,F,N,BAO_0000218,
A549,Homo sapiens,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,CHEMBL619567,10708,80682,,646.0,,,Intermediate,,1,,1,9606.0,6349,F,N,BAO_0000218,
A549,Homo sapiens,,,Inhibitory activity against A549 lung adenocarcinoma cell line,CHEMBL619568,17376,80682,,646.0,,,Intermediate,,1,,1,9606.0,6350,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,CHEMBL619569,17376,80682,,646.0,,,Intermediate,,1,,1,9606.0,6351,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity against human A549 lung cells,CHEMBL619570,17488,80682,,646.0,,,Intermediate,,1,,1,9606.0,6352,F,N,BAO_0000219,
A549,Homo sapiens,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,CHEMBL619571,17404,80682,,646.0,,,Intermediate,,1,,1,9606.0,6353,F,N,BAO_0000218,
A549,Homo sapiens,,,Growth inhibition of A549 (human lung carcinoma) cell line.,CHEMBL619572,10958,80682,,646.0,,,Expert,,1,,1,9606.0,6354,F,N,BAO_0000219,
A549,Homo sapiens,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,CHEMBL619573,17099,80682,,646.0,,,Expert,,1,,1,9606.0,6355,F,N,BAO_0000219,
A549,Homo sapiens,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,CHEMBL619574,17099,80682,,646.0,,,Intermediate,,1,,1,9606.0,6356,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,CHEMBL619575,4096,80682,,646.0,,,Intermediate,,1,,1,9606.0,6357,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,CHEMBL619576,4096,80682,,646.0,,,Expert,,1,,1,9606.0,6358,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,CHEMBL619577,4096,80682,,646.0,,,Intermediate,,1,,1,9606.0,6359,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory activity against A549 tumor cell culture,CHEMBL619578,2525,80682,,646.0,,,Intermediate,,1,,1,9606.0,6360,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,CHEMBL884009,2525,80682,,646.0,,,Intermediate,,1,,1,9606.0,6361,F,N,BAO_0000219,
A549,Homo sapiens,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),CHEMBL619579,5302,80682,,646.0,,,Intermediate,,1,,1,9606.0,6362,F,N,BAO_0000219,
A549,Homo sapiens,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,CHEMBL619580,16325,80682,,646.0,,,Intermediate,,1,,1,9606.0,6363,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,CHEMBL619581,16939,80682,,646.0,,,Intermediate,,1,,1,9606.0,6364,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,CHEMBL619582,17229,80682,,646.0,,,Intermediate,,1,,1,9606.0,6365,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,CHEMBL619583,17380,80682,,646.0,,,Intermediate,,1,,1,9606.0,6366,F,N,BAO_0000219,
A549,Homo sapiens,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,CHEMBL876502,17380,80682,,646.0,,,Intermediate,,1,,1,9606.0,6367,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,CHEMBL619584,1903,80682,,646.0,,,Intermediate,,1,,1,9606.0,6368,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,CHEMBL619585,3838,80682,,646.0,,,Intermediate,,1,,1,9606.0,6369,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,CHEMBL619586,14696,80682,,646.0,,,Intermediate,,1,,1,9606.0,6370,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,CHEMBL619587,3838,80682,,646.0,,,Intermediate,,1,,1,9606.0,6371,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,CHEMBL619588,1522,80682,,646.0,,,Intermediate,,1,,1,9606.0,6372,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,CHEMBL619589,12400,80682,,646.0,,,Intermediate,,1,,1,9606.0,6373,F,N,BAO_0000219,
A549,Homo sapiens,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,CHEMBL619590,14696,80682,,646.0,,,Intermediate,,1,,1,9606.0,6374,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),CHEMBL619591,14769,80682,,646.0,,,Intermediate,,1,,1,9606.0,6375,F,N,BAO_0000219,
A549,Homo sapiens,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,CHEMBL619592,14696,80682,,646.0,,,Intermediate,,1,,1,9606.0,6376,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,CHEMBL619593,1888,80682,,646.0,,,Intermediate,,1,,1,9606.0,6377,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,CHEMBL620217,12016,80682,,646.0,,,Intermediate,,1,,1,9606.0,6378,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,CHEMBL620218,6058,80682,,646.0,,,Intermediate,,1,,1,9606.0,6379,F,N,BAO_0000219,
A549,Homo sapiens,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,CHEMBL620219,17708,80682,,646.0,,,Intermediate,,1,,1,9606.0,6380,F,N,BAO_0000219,
A549,Homo sapiens,,,Antitumor activity against A549/ATCC cell line,CHEMBL620220,12301,80682,,646.0,,,Intermediate,,1,,1,9606.0,6381,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,CHEMBL625141,11970,80682,,646.0,,,Intermediate,,1,,1,9606.0,6382,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro cytotoxicity against A549/ATCC cell line.,CHEMBL625142,11818,80682,,646.0,,,Expert,,1,,1,9606.0,6383,F,N,BAO_0000219,
A549,Homo sapiens,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,CHEMBL625143,12400,80682,,646.0,,,Intermediate,,1,,1,9606.0,6384,F,N,BAO_0000219,
A549,Homo sapiens,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,CHEMBL625144,3381,80682,,646.0,,,Intermediate,,1,,1,9606.0,6385,F,N,BAO_0000219,
A549,Homo sapiens,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,CHEMBL622474,17376,80682,,646.0,,,Intermediate,,1,,1,9606.0,6386,F,N,BAO_0000219,
A549,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,CHEMBL884104,10708,80682,,646.0,,,Intermediate,,1,,1,9606.0,6387,F,N,BAO_0000219,
,Homo sapiens,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,CHEMBL622475,2964,22226,,,,,Autocuration,,1,,0,9606.0,6388,F,U,BAO_0000219,
,Canis lupus familiaris,,,Compound was tested for oral bioavailability in dogs,CHEMBL622476,5005,22224,,,,,Intermediate,,1,,0,9615.0,6389,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,CHEMBL875831,6229,50588,,,,,Intermediate,,1,,1,9615.0,6390,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,CHEMBL622477,6229,50588,,,,,Intermediate,,1,,1,9615.0,6391,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL622478,5374,50588,,,,,Intermediate,,1,,1,9615.0,6392,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for the oral bioavailability in dog; No availability,CHEMBL623172,5374,50588,,,,,Intermediate,,1,,1,9615.0,6393,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL623173,6265,50588,,,,,Intermediate,,1,,1,9615.0,6394,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,CHEMBL623174,5654,50588,,,,,Intermediate,,1,,1,9615.0,6395,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,CHEMBL623175,5654,50588,,,,,Intermediate,,1,,1,9615.0,6396,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),CHEMBL623340,16456,50588,,,,,Intermediate,,1,,1,9615.0,6397,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL623341,5302,50588,,,,,Intermediate,,1,,1,9615.0,6398,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),CHEMBL623342,3624,50588,,,,,Intermediate,,1,,1,9615.0,6399,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability of active FTIs in dogs,CHEMBL623343,16452,50588,,,,,Intermediate,,1,,1,9615.0,6400,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),CHEMBL623344,5802,50588,,,,,Intermediate,,1,,1,9615.0,6401,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL623345,3598,50588,,,,,Expert,,1,,1,9615.0,6402,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL875832,17839,50588,,,,,Intermediate,,1,,1,9615.0,6403,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623346,6762,50588,,,,,Intermediate,,1,,1,9615.0,6404,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623347,6821,50588,,,,,Intermediate,,1,,1,9615.0,6405,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability of compound was determined in dog; Not tested,CHEMBL623348,6821,50588,,,,,Intermediate,,1,,1,9615.0,6406,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623349,5210,50588,,,,,Intermediate,,1,,1,9615.0,6407,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability (10 mg/kg) was determined in dog,CHEMBL623350,6227,50588,,,,,Intermediate,,1,,1,9615.0,6408,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability,CHEMBL623351,761,50588,,,,,Intermediate,,1,,1,9615.0,6409,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),CHEMBL623352,761,50588,,,,,Intermediate,,1,,1,9615.0,6410,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability administered in solution in rats,CHEMBL623353,761,50588,,,,,Intermediate,,1,,1,9615.0,6411,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability after 30 mg/kg po dose in Dogs,CHEMBL875833,16907,50588,,,,,Intermediate,,1,,1,9615.0,6412,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability at a dose of 1 mg/kg in dogs,CHEMBL623354,5474,50588,,,,,Intermediate,,1,,1,9615.0,6413,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),CHEMBL623355,6535,50588,,,,,Intermediate,,1,,1,9615.0,6414,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in Dog; ND = not determined,CHEMBL623356,6535,50588,,,,,Intermediate,,1,,1,9615.0,6415,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623357,3352,50588,,,,,Intermediate,,1,,1,9615.0,6416,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623358,6168,50588,,,,,Intermediate,,1,,1,9615.0,6417,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623359,5988,50588,,,,,Intermediate,,1,,1,9615.0,6418,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623360,4942,50588,,,,,Intermediate,,1,,1,9615.0,6419,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dogs; No data,CHEMBL623361,4942,50588,,,,,Intermediate,,1,,1,9615.0,6420,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability measured in dogs,CHEMBL623362,14541,50588,,,,,Intermediate,,1,,1,9615.0,6421,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623363,4449,50588,,,,,Intermediate,,1,,1,9615.0,6422,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability was calculated in dog,CHEMBL623364,6057,50588,,,,,Intermediate,,1,,1,9615.0,6423,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability after 0.3 mg/kg po administration in dog,CHEMBL875834,5600,50588,,,,,Intermediate,,1,,1,9615.0,6424,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (i.v. dosing),CHEMBL623365,5542,50588,,,,,Intermediate,,1,,1,9615.0,6425,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623366,5542,50588,,,,,Intermediate,,1,,1,9615.0,6426,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,CHEMBL623367,5546,50588,,,,,Intermediate,,1,,1,9615.0,6427,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in Beagle dogs,CHEMBL623368,4514,50588,,,,,Intermediate,,1,,1,9615.0,6428,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623369,3624,50588,,,,,Intermediate,,1,,1,9615.0,6429,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623370,3854,50588,,,,,Intermediate,,1,,1,9615.0,6430,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623371,5836,50588,,,,,Intermediate,,1,,1,9615.0,6431,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL623372,5940,50588,,,,,Intermediate,,1,,1,9615.0,6432,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621351,6168,50588,,,,,Intermediate,,1,,1,9615.0,6433,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621352,6227,50588,,,,,Intermediate,,1,,1,9615.0,6434,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621353,6251,50588,,,,,Intermediate,,1,,1,9615.0,6435,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621354,6448,50588,,,,,Intermediate,,1,,1,9615.0,6436,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621355,6647,50588,,,,,Intermediate,,1,,1,9615.0,6437,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621356,5940,50588,,,,,Intermediate,,1,,1,9615.0,6438,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621357,933,50588,,,,,Intermediate,,1,,1,9615.0,6439,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621358,5210,50588,,,,,Intermediate,,1,,1,9615.0,6440,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),CHEMBL621359,6642,50588,,,,,Intermediate,,1,,1,9615.0,6441,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),CHEMBL621360,6641,50588,,,,,Intermediate,,1,,1,9615.0,6442,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),CHEMBL621361,6642,50588,,,,,Intermediate,,1,,1,9615.0,6443,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621362,5472,50588,,,,,Intermediate,,1,,1,9615.0,6444,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621363,5985,50588,,,,,Intermediate,,1,,1,9615.0,6445,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621364,15660,50588,,,,,Intermediate,,1,,1,9615.0,6446,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),CHEMBL621166,5530,50588,,,,,Intermediate,,1,,1,9615.0,6447,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL621167,5530,50588,,,,,Intermediate,,1,,1,9615.0,6448,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability (F) in dogs,CHEMBL621168,6305,50588,,,,,Intermediate,,1,,1,9615.0,6449,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL621169,5210,50588,,,,,Intermediate,,1,,1,9615.0,6450,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL875950,5238,50588,,,,,Intermediate,,1,,1,9615.0,6451,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621170,5668,50588,,,,,Intermediate,,1,,1,9615.0,6452,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability after peroral administration at 5 mpk in Dog,CHEMBL621171,5668,50588,,,,,Intermediate,,1,,1,9615.0,6453,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 mg/kg),CHEMBL621172,5668,50588,,,,,Intermediate,,1,,1,9615.0,6454,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621173,6084,50588,,,,,Intermediate,,1,,1,9615.0,6455,A,N,BAO_0000218,In vivo
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,CHEMBL621174,6599,50594,,42.0,Kidney,2113.0,Intermediate,,1,,1,10090.0,6456,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,CHEMBL621175,6599,50594,,42.0,Kidney,2113.0,Intermediate,,1,,1,10090.0,6457,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,CHEMBL621176,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6458,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,CHEMBL621177,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6459,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,CHEMBL621178,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6460,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,CHEMBL621179,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6461,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,CHEMBL621180,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6462,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,CHEMBL875951,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6463,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,CHEMBL621181,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6464,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,CHEMBL621182,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6465,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,CHEMBL621183,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6466,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,CHEMBL621184,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6467,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,CHEMBL621185,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6468,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,CHEMBL621186,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6469,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,CHEMBL621187,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6470,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,CHEMBL621188,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6471,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,CHEMBL621189,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6472,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,CHEMBL621190,6599,50594,,42.0,Spleen,2106.0,Intermediate,,1,,1,10090.0,6473,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,CHEMBL618520,6599,50594,,42.0,Spleen,2106.0,Intermediate,,1,,1,10090.0,6474,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,CHEMBL621739,6599,50594,,42.0,Spleen,2106.0,Intermediate,,1,,1,10090.0,6475,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,CHEMBL621740,6599,50594,,42.0,Spleen,2106.0,Intermediate,,1,,1,10090.0,6476,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,CHEMBL621741,6599,50594,,42.0,Spleen,2106.0,Intermediate,,1,,1,10090.0,6477,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,CHEMBL621742,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6478,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,CHEMBL621743,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6479,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,CHEMBL621744,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6480,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,CHEMBL621745,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6481,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,CHEMBL621746,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6482,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,CHEMBL621747,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6483,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,CHEMBL621748,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6484,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,CHEMBL621749,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6485,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,CHEMBL621750,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6486,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,CHEMBL621751,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6487,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,CHEMBL621752,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6488,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,CHEMBL621753,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6489,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,CHEMBL875955,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6490,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,CHEMBL621754,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6491,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,CHEMBL621755,6599,50594,,42.0,Heart,948.0,Intermediate,,1,,1,10090.0,6492,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,CHEMBL621756,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6493,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,CHEMBL624199,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6494,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,CHEMBL624200,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6495,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,CHEMBL624375,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6496,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,CHEMBL624376,6599,50594,,42.0,Liver,2107.0,Intermediate,,1,,1,10090.0,6497,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,CHEMBL624377,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6498,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,CHEMBL624378,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6499,A,N,BAO_0000218,
,aeinetobacter anitrotap,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL857901,12269,50067,,,,,Intermediate,,1,,1,107673.0,6500,F,N,BAO_0000218,
,Acinetobacter calcoaceticus subsp. anitratus,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL875274,12269,50067,,,,,Intermediate,,1,,1,107673.0,6501,F,N,BAO_0000218,
,Acinetobacter calcoaceticus subsp. anitratus,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL624379,12269,50067,,,,,Intermediate,,1,,1,107673.0,6502,F,N,BAO_0000218,
,aeinetobacter anitrotap,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,CHEMBL624380,12269,50067,,,,,Intermediate,,1,,1,107673.0,6503,F,N,BAO_0000218,
,Acinetobacter calcoaceticus,,,Activity against Acinetobacter calcoaceticus (AC54),CHEMBL624381,10624,50192,,,,,Intermediate,,1,,1,471.0,6504,F,N,BAO_0000218,
,Anolis carolinensis,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,CHEMBL624382,17216,50714,,,,,Intermediate,,1,,1,28377.0,6505,F,N,BAO_0000218,
,Anolis carolinensis,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,CHEMBL624383,17216,50714,,,,,Intermediate,,1,,1,28377.0,6506,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,CHEMBL624384,9560,50296,,,,,Intermediate,,1,,1,1655.0,6507,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,CHEMBL624385,9560,50296,,,,,Intermediate,,1,,1,1655.0,6508,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,CHEMBL624386,9560,50296,,,,,Intermediate,,1,,1,1655.0,6509,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,CHEMBL624387,9560,50296,,,,,Intermediate,,1,,1,1655.0,6510,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Plaque bactericidal index against Actinomyces naeslundii 631,CHEMBL624388,9560,50296,,,,,Intermediate,,1,,1,1655.0,6511,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Plaque bactericidal index against Actinomyces naeslundii N/9,CHEMBL624389,9560,50296,,,,,Intermediate,,1,,1,1655.0,6512,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Plaque bactericidal index against Actinomyces naeslundii B74,CHEMBL624390,9560,50296,,,,,Intermediate,,1,,1,1655.0,6513,F,N,BAO_0000218,
,Actinomyces naeslundii,,,Plaque bactericidal index against Actinomyces naeslundii N/3,CHEMBL875275,9560,50296,,,,,Intermediate,,1,,1,1655.0,6514,F,N,BAO_0000218,
,Artemia salina,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,CHEMBL624391,114,50056,,,,,Intermediate,,1,,1,85549.0,6515,F,N,BAO_0000218,
,Artemia salina,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",CHEMBL623636,114,50056,,,,,Intermediate,,1,,1,85549.0,6516,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,CHEMBL623637,10841,50532,,,,,Intermediate,,1,,1,6253.0,6517,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,CHEMBL623638,10841,50532,,,,,Intermediate,,1,,1,6253.0,6518,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,CHEMBL623639,10841,50532,,,,,Intermediate,,1,,1,6253.0,6519,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,CHEMBL623640,10841,50532,,,,,Intermediate,,1,,1,6253.0,6520,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,CHEMBL623641,10841,50532,,,,,Intermediate,,1,,1,6253.0,6521,F,N,BAO_0000218,
,Ascaris suum,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,CHEMBL623642,10841,50532,,,,,Intermediate,,1,,1,6253.0,6522,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,CHEMBL623643,10841,50532,,,,,Intermediate,,1,,1,6253.0,6523,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,CHEMBL623644,10841,50532,,,,,Intermediate,,1,,1,6253.0,6524,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,CHEMBL623645,10841,50532,,,,,Intermediate,,1,,1,6253.0,6525,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,CHEMBL623646,10841,50532,,,,,Intermediate,,1,,1,6253.0,6526,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,CHEMBL623647,10841,50532,,,,,Intermediate,,1,,1,6253.0,6527,F,N,BAO_0000218,
,Ascaris suum,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,CHEMBL623648,10841,50532,,,,,Intermediate,,1,,1,6253.0,6528,F,N,BAO_0000218,
,Actinomyces viscosus,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,CHEMBL623649,8117,50366,,,,,Intermediate,,1,,1,1656.0,6529,F,N,BAO_0000218,
,Actinomyces viscosus,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,CHEMBL623650,8117,50366,,,,,Intermediate,,1,,1,1656.0,6530,F,N,BAO_0000218,
,Actinomyces viscosus,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,CHEMBL623651,9560,50366,,,,,Intermediate,,1,,1,1656.0,6531,F,N,BAO_0000218,
,Actinomyces viscosus,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,CHEMBL623652,9560,50366,,,,,Expert,,1,,1,1656.0,6532,F,N,BAO_0000218,
,Actinomyces viscosus,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,CHEMBL623653,9560,50366,,,,,Intermediate,,1,,1,1656.0,6533,F,N,BAO_0000218,
,Actinomyces viscosus,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,CHEMBL623654,9560,50366,,,,,Intermediate,,1,,1,1656.0,6534,F,N,BAO_0000218,
,Actinomyces viscosus,,,Plaque bactericidal index against Actinomyces viscosus 8A06,CHEMBL623655,9560,50366,,,,,Intermediate,,1,,1,1656.0,6535,F,N,BAO_0000218,
,Actinomyces viscosus,,,Plaque bactericidal index against Actinomyces viscosus M-100,CHEMBL623656,9560,50366,,,,,Intermediate,,1,,1,1656.0,6536,F,N,BAO_0000218,
,Actinomyces viscosus,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,CHEMBL623657,9560,50366,,,,,Expert,,1,,1,1656.0,6537,F,N,BAO_0000218,
,Actinomyces viscosus,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",CHEMBL623658,9560,50366,,,,,Intermediate,,1,,1,1656.0,6538,F,N,BAO_0000218,
,Actinomyces viscosus,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",CHEMBL623659,9560,50366,,,,,Intermediate,,1,,1,1656.0,6539,F,N,BAO_0000218,
,Actinomyces viscosus,,,Plaque bactericidal index against Actinomyces viscosus 626,CHEMBL623660,9560,50366,,,,,Intermediate,,1,,1,1656.0,6540,F,N,BAO_0000218,
,Actinomyces viscosus,,,Plaque bactericidal index against Actinomyces viscosus T14V,CHEMBL623661,9560,50366,,,,,Intermediate,,1,,1,1656.0,6541,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,CHEMBL875281,10986,50535,,,,,Intermediate,,1,,1,6277.0,6542,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,CHEMBL623662,10986,50535,,,,,Intermediate,,1,,1,6277.0,6543,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,CHEMBL623663,10986,50535,,,,,Intermediate,,1,,1,6277.0,6544,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,CHEMBL623664,10986,50535,,,,,Intermediate,,1,,1,6277.0,6545,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,CHEMBL623665,10986,50535,,,,,Intermediate,,1,,1,6277.0,6546,F,N,BAO_0000218,
A673,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,CHEMBL621856,10708,80023,,165.0,,,Intermediate,,1,,1,9606.0,6547,F,N,BAO_0000219,
A704,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,CHEMBL620432,10708,80661,,645.0,,,Intermediate,,1,,1,9606.0,6548,F,N,BAO_0000219,
,Rattus norvegicus,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,CHEMBL620433,416,22226,,,,,Autocuration,,1,,0,10116.0,6549,F,U,BAO_0000219,
A9,Mus musculus,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,CHEMBL620434,14354,80024,,625.0,,,Intermediate,,1,,1,10090.0,6550,F,N,BAO_0000219,
A9,Mus musculus,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,CHEMBL620435,14354,80024,,625.0,,,Intermediate,,1,,1,10090.0,6551,F,N,BAO_0000219,
A9,Homo sapiens,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,CHEMBL620436,5116,80024,,625.0,,,Intermediate,,1,,1,9606.0,6552,F,N,BAO_0000219,
A9,Homo sapiens,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,CHEMBL876597,5116,80024,,625.0,,,Intermediate,,1,,1,9606.0,6553,F,N,BAO_0000219,
Human ovarian carcinoma cell line,Homo sapiens,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,CHEMBL620437,15694,81037,,874.0,,,Expert,,1,,1,9606.0,6554,F,N,BAO_0000219,
A9,Mus musculus,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",CHEMBL620438,13038,80024,,625.0,,,Expert,,1,,1,10090.0,6555,F,N,BAO_0000219,
A9,Mus musculus,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,CHEMBL620439,13038,80024,,625.0,,,Expert,,1,,1,10090.0,6556,F,N,BAO_0000219,
A9,Mus musculus,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,CHEMBL619657,10923,80024,,625.0,,,Expert,,1,,1,10090.0,6557,F,N,BAO_0000219,
A9,Mus musculus,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,CHEMBL619658,10923,80024,,625.0,,,Intermediate,,1,,1,10090.0,6558,F,N,BAO_0000219,
A9,Mus musculus,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,CHEMBL619659,10923,80024,,625.0,,,Intermediate,,1,,1,10090.0,6559,F,N,BAO_0000219,
,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",CHEMBL619660,10923,10649,,,,,Expert,,1,,8,,6560,F,H,BAO_0000019,
A9,Mus musculus,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,CHEMBL619661,10923,80024,,625.0,,,Intermediate,,1,,1,10090.0,6561,F,N,BAO_0000219,
A9,Mus musculus,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,CHEMBL619662,10923,80024,,625.0,,,Intermediate,,1,,1,10090.0,6562,F,N,BAO_0000219,
AA6,Cricetulus griseus,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,CHEMBL619663,8158,80663,,975.0,,,Intermediate,,1,,1,10029.0,6563,F,N,BAO_0000219,
,Homo sapiens,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,CHEMBL619664,15494,22226,,,,,Autocuration,,1,,0,9606.0,6564,F,U,BAO_0000219,
,Homo sapiens,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",CHEMBL619665,15494,22226,,,,,Autocuration,,1,,0,9606.0,6565,F,U,BAO_0000219,
AA5,Homo sapiens,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),CHEMBL883244,12348,80662,,974.0,,,Intermediate,,1,,1,9606.0,6566,F,N,BAO_0000219,
AA5,Homo sapiens,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),CHEMBL884011,12348,80662,,974.0,,,Intermediate,,1,,1,9606.0,6567,F,N,BAO_0000219,
AA5,Homo sapiens,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,CHEMBL619666,2726,80662,,974.0,,,Intermediate,,1,,1,9606.0,6568,F,N,BAO_0000219,
U-937,Homo sapiens,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,CHEMBL619667,2726,80566,,379.0,,,Intermediate,,1,,1,9606.0,6569,F,N,BAO_0000219,
UV4,Cricetulus griseus,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,CHEMBL619668,10747,80578,,274.0,,,Intermediate,,1,,1,10029.0,6570,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",CHEMBL619669,11005,80089,,185.0,,,Expert,,1,,1,10029.0,6571,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Average intracellular compound concentration when the hypoxic SER=1.6,CHEMBL876608,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6572,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Average intracellular compound concentration when the hypoxic SER=1.6.,CHEMBL619670,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6573,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,CHEMBL619671,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6574,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,CHEMBL619672,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6575,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,CHEMBL619673,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6576,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",CHEMBL619674,13436,80089,,185.0,,,Intermediate,,1,,1,10029.0,6577,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",CHEMBL619675,13435,80089,,185.0,,,Intermediate,,1,,1,10029.0,6578,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,CHEMBL619676,13302,80089,,185.0,,,Intermediate,,1,,1,10029.0,6579,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHEMBL619677,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6580,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHEMBL619678,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6581,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,CHEMBL619679,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6582,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,CHEMBL619680,12878,80089,,185.0,,,Expert,,1,,1,10029.0,6583,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,CHEMBL621457,12878,80089,,185.0,,,Intermediate,,1,,1,10029.0,6584,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,CHEMBL876609,14367,80089,,185.0,,,Expert,,1,,1,10029.0,6585,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,CHEMBL621458,14367,80089,,185.0,,,Intermediate,,1,,1,10029.0,6586,F,N,BAO_0000219,
CHO-AA8,hampster,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,CHEMBL621459,12398,80089,,185.0,,,Expert,,1,,1,36483.0,6587,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Aerobic growth inhibition in Chinese hamster cell line AA8,CHEMBL621460,12878,80089,,185.0,,,Expert,,1,,1,10029.0,6588,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,CHEMBL621461,13820,80089,,185.0,,,Expert,,1,,1,10029.0,6589,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Inhibition of growth under aerobic conditions in AA8 cells,CHEMBL621462,13436,80089,,185.0,,,Expert,,1,,1,10029.0,6590,F,N,BAO_0000219,
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621463,6084,50588,,,,,Intermediate,,1,,1,9615.0,6591,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog at 10 mg/kg of the compound,CHEMBL621464,5711,50588,,,,,Intermediate,,1,,1,9615.0,6592,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL621465,4353,50588,,,,,Intermediate,,1,,1,9615.0,6593,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL621466,4353,50588,,,,,Intermediate,,1,,1,9615.0,6594,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (mongrel),CHEMBL621467,17800,50588,,,,,Intermediate,,1,,1,9615.0,6595,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL621468,3994,50588,,,,,Intermediate,,1,,1,9615.0,6596,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 10 mg/kg),CHEMBL876734,3994,50588,,,,,Intermediate,,1,,1,9615.0,6597,F,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL618476,5145,50588,,,,,Intermediate,,1,,1,9615.0,6598,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL618477,16452,50588,,,,,Intermediate,,1,,1,9615.0,6599,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),CHEMBL618478,16452,50588,,,,,Intermediate,,1,,1,9615.0,6600,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,CHEMBL618479,5983,50588,,,,,Intermediate,,1,,1,9615.0,6601,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL618480,4273,50588,,,,,Intermediate,,1,,1,9615.0,6602,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 3-10 mg/kg),CHEMBL618481,12500,50588,,,,,Intermediate,,1,,1,9615.0,6603,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,CHEMBL618482,12500,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6604,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL618483,3639,50588,,,,,Intermediate,,1,,1,9615.0,6605,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL618484,3880,50588,,,,,Intermediate,,1,,1,9615.0,6606,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog,CHEMBL618485,4838,50588,,,,,Intermediate,,1,,1,9615.0,6607,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,oral bioavailability was measured in dogs,CHEMBL618486,15600,50588,,,,,Intermediate,,1,,1,9615.0,6608,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for plasma protein binding in dog; Not determined,CHEMBL618487,17248,50588,,,,,Intermediate,,1,,1,9615.0,6609,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was tested for plasma protein binding of dog,CHEMBL618488,17248,50588,,,,,Intermediate,,1,,1,9615.0,6610,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was tested for plasma protein binding of dog; Not determined,CHEMBL876735,17248,50588,,,,,Intermediate,,1,,1,9615.0,6611,A,N,BAO_0000218,
,Canis lupus familiaris,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,CHEMBL618489,17443,50588,,,,,Intermediate,,1,,1,9615.0,6612,A,N,BAO_0000218,
,Canis lupus familiaris,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,CHEMBL618490,4186,50588,,,,,Intermediate,,1,,1,9615.0,6613,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was determined,CHEMBL618491,3749,50588,,,,,Intermediate,,1,,1,9615.0,6614,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,CHEMBL618492,3249,50588,,,,,Intermediate,,1,,1,9615.0,6615,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was evaluated in dog,CHEMBL873354,3022,50588,,,,,Intermediate,,1,,1,9615.0,6616,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was determined,CHEMBL618493,3749,50588,,,,,Intermediate,,1,,1,9615.0,6617,A,N,BAO_0000218,
,Canis lupus familiaris,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618494,2517,50588,,,,,Intermediate,,1,,1,9615.0,6618,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618495,2517,50588,,,Heart,948.0,Intermediate,,1,,1,9615.0,6619,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618496,2517,50588,,,Kidney,2113.0,Intermediate,,1,,1,9615.0,6620,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618497,2517,50588,,,Liver,2107.0,Intermediate,,1,,1,9615.0,6621,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618498,2517,50588,,,Lung,2048.0,Intermediate,,1,,1,9615.0,6622,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),CHEMBL618499,2517,50588,,,Spleen,2106.0,Intermediate,,1,,1,9615.0,6623,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,LogP in dog,CHEMBL876736,3639,50588,,,,,Intermediate,,1,,1,9615.0,6624,A,N,BAO_0000218,
,Canis lupus familiaris,,,Partition coefficient (logP),CHEMBL618500,6227,50588,,,,,Intermediate,,1,,1,9615.0,6625,A,N,BAO_0000218,
,Canis lupus familiaris,,,Partition coefficient in dog,CHEMBL857831,6227,50588,,,,,Intermediate,,1,,1,9615.0,6626,A,N,BAO_0000218,
,Canis lupus familiaris,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618501,17764,50588,,,,,Intermediate,,1,,1,9615.0,6627,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),CHEMBL618502,4809,50588,,,,,Intermediate,,1,,1,9615.0,6628,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,CHEMBL618503,5600,50588,,,,,Intermediate,,1,,1,9615.0,6629,A,N,BAO_0000218,
,Canis lupus familiaris,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),CHEMBL618504,14294,50588,,,,,Intermediate,,1,,1,9615.0,6630,A,N,BAO_0000218,
,Canis lupus familiaris,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),CHEMBL618505,14294,50588,,,,,Intermediate,,1,,1,9615.0,6631,A,N,BAO_0000218,
,Canis lupus familiaris,,,Metabolism of compound in dog S9 microsomes; Trace,CHEMBL618506,14294,50588,,,,,Intermediate,,1,,1,9615.0,6632,A,N,BAO_0000218,
,Canis lupus familiaris,,,In vitro metabolic potential in dog liver microsomes,CHEMBL618507,6251,50588,,,Liver,2107.0,Intermediate,,1,,1,9615.0,6633,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,CHEMBL876737,3748,50588,,,,,Intermediate,,1,,1,9615.0,6634,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL618508,2713,50588,,,,,Intermediate,,1,,1,9615.0,6635,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL618509,6512,50588,,,,,Intermediate,,1,,1,9615.0,6636,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL618510,6679,50588,,,,,Intermediate,,1,,1,9615.0,6637,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for bioavailability in dogs,CHEMBL618511,3749,50588,,,,,Intermediate,,1,,1,9615.0,6638,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for oral bioavailability in dogs,CHEMBL618512,3749,50588,,,,,Intermediate,,1,,1,9615.0,6639,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog,CHEMBL618513,6742,50588,,,,,Intermediate,,1,,1,9615.0,6640,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for percent protein binding (PB) in dog,CHEMBL618514,6227,50588,,,,,Intermediate,,1,,1,9615.0,6641,A,N,BAO_0000218,
,Canis lupus familiaris,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,CHEMBL620052,6874,50588,,,,,Intermediate,,1,,1,9615.0,6642,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for plasma clearance.,CHEMBL620053,2877,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6643,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for plasma clearance in dog,CHEMBL620054,12500,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6644,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,CHEMBL620055,12500,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6645,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,CHEMBL620056,4709,50588,,,,,Intermediate,,1,,1,9615.0,6646,A,N,BAO_0000218,
,Canis lupus familiaris,,,In vitro relative rate of metabolism was determined in dog liver microsomes,CHEMBL620057,5542,50588,,,Liver,2107.0,Intermediate,,1,,1,9615.0,6647,A,N,BAO_0000218,
,Canis lupus familiaris,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,CHEMBL618939,17594,50588,,,,,Intermediate,,1,,1,9615.0,6648,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,CHEMBL618940,2652,50588,,,,,Intermediate,,1,,1,9615.0,6649,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life after intravenous administration in dogs at 1.2 uM/kg,CHEMBL618941,17764,50588,,,,,Intermediate,,1,,1,9615.0,6650,A,N,BAO_0000218,In vivo
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,CHEMBL624473,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6651,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,CHEMBL624474,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6652,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,CHEMBL624475,6599,50594,,42.0,Lung,2048.0,Intermediate,,1,,1,10090.0,6653,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,CHEMBL624476,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6654,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,CHEMBL623478,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6655,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,CHEMBL623479,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6656,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,CHEMBL623480,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6657,A,N,BAO_0000218,
CCRF S-180,Mus musculus,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,CHEMBL623481,6599,50594,,42.0,,,Intermediate,,1,,1,10090.0,6658,A,N,BAO_0000218,
,Mus musculus,,,C2 in brain of mice at the oral dose of 50 mg/kg,CHEMBL623482,17641,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6659,A,N,BAO_0000218,
,Mus musculus,,,C2 in kidney of mice at the oral dose of 50 mg/kg,CHEMBL623483,17641,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6660,A,N,BAO_0000218,
,Mus musculus,,,C2 in liver of mice at the oral dose of 50 mg/kg,CHEMBL623484,17641,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6661,A,N,BAO_0000218,
,Mus musculus,,,C2 in lungs of mice at the oral dose of 50 mg/kg,CHEMBL623485,17641,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6662,A,N,BAO_0000218,
,Mus musculus,,,C2 in spleen of mice at the oral dose of 50 mg/kg,CHEMBL623486,17641,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,6663,A,N,BAO_0000218,
,Mus musculus,,,Plasma clearance in mouse,CHEMBL623487,17852,50594,,,,,Intermediate,,1,,1,10090.0,6664,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,CHEMBL623488,17764,50594,,,,,Intermediate,,1,,1,10090.0,6665,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,CHEMBL623489,17837,50594,,,,,Intermediate,,1,,1,10090.0,6666,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance was evaluated in mice after intravenous administration,CHEMBL875157,2675,50594,,,,,Intermediate,,1,,1,10090.0,6667,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance was evaluated in mice after oral administration,CHEMBL623490,2675,50594,,,,,Intermediate,,1,,1,10090.0,6668,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,CHEMBL623491,4239,50594,,,,,Intermediate,,1,,1,10090.0,6669,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance of compound was determined at 40 mg/Kg,CHEMBL623492,17753,50594,,,,,Intermediate,,1,,1,10090.0,6670,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance of at 24 mg/Kg,CHEMBL623493,17753,50594,,,,,Intermediate,,1,,1,10090.0,6671,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance at 24 mg/Kg,CHEMBL623494,17753,50594,,,,,Intermediate,,1,,1,10090.0,6672,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance at 5 mg/Kg,CHEMBL623495,17753,50594,,,,,Intermediate,,1,,1,10090.0,6673,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance in mice,CHEMBL623496,5727,50594,,,,,Intermediate,,1,,1,10090.0,6674,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance value upon iv administration in mouse,CHEMBL623497,2862,50594,,,,,Intermediate,,1,,1,10090.0,6675,A,N,BAO_0000218,In vivo
,Mus musculus,,,Total plasma clearance in mice,CHEMBL623498,5980,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6676,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance in mouse,CHEMBL623499,17592,50594,,,,,Intermediate,,1,,1,10090.0,6677,A,N,BAO_0000218,In vivo
,Mus musculus,,,Clearance value was determined,CHEMBL623500,17718,50594,,,,,Intermediate,,1,,1,10090.0,6678,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL623501,16597,50594,,,,,Intermediate,,1,,1,10090.0,6679,A,N,BAO_0000218,In vivo
,,,,Calculated partition coefficient (clogP),CHEMBL875158,17384,22229,,,,,Intermediate,,1,,0,,6680,P,U,BAO_0000100,
,Mus musculus,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,CHEMBL623502,6062,50594,,,,,Intermediate,,1,,1,10090.0,6681,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,CHEMBL623503,17734,50594,,,,,Intermediate,,1,,1,10090.0,6682,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL623504,6348,50594,,,,,Intermediate,,1,,1,10090.0,6683,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,CHEMBL623505,5969,50594,,,,,Intermediate,,1,,1,10090.0,6684,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,CHEMBL623506,5969,50594,,,,,Intermediate,,1,,1,10090.0,6685,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,CHEMBL623507,5969,50594,,,,,Intermediate,,1,,1,10090.0,6686,A,N,BAO_0000218,In vivo
,Mus musculus,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,CHEMBL623508,16597,50594,,,,,Intermediate,,1,,1,10090.0,6687,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax after oral administration at 30 mg/kg in ICR mouse,CHEMBL623509,5781,50594,,,,,Intermediate,,1,,1,10090.0,6688,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax after peroral administration in mice at 2.4 uM/kg,CHEMBL875159,17764,50594,,,,,Intermediate,,1,,1,10090.0,6689,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in brain of mice at the oral dose of 50 mg/kg,CHEMBL623510,17641,50594,,,Brain,955.0,Intermediate,,1,,1,10090.0,6690,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,CHEMBL623511,17641,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,6691,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in liver of mice at the oral dose of 50 mg/kg,CHEMBL623512,17641,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,6692,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,CHEMBL623513,17641,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,6693,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in mice at 18 uM/kg i.p. administration,CHEMBL623514,17764,50594,,,,,Intermediate,,1,,1,10090.0,6694,F,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in mice at 23 uM/kg i.v. administration,CHEMBL622609,17764,50594,,,,,Intermediate,,1,,1,10090.0,6695,F,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in mice at 24 uM/kg i.p. administration,CHEMBL622610,17764,50594,,,,,Intermediate,,1,,1,10090.0,6696,F,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in mice at 25 uM/kg i.p. administration,CHEMBL621823,17764,50594,,,,,Intermediate,,1,,1,10090.0,6697,F,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in mice at 26 uM/kg i.p. administration,CHEMBL621824,17764,50594,,,,,Intermediate,,1,,1,10090.0,6698,F,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,CHEMBL621825,17641,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,6699,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,CHEMBL621826,16597,50594,,,,,Intermediate,,1,,1,10090.0,6700,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,CHEMBL621827,16597,50594,,,,,Intermediate,,1,,1,10090.0,6701,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value was determined,CHEMBL621828,5727,50594,,,,,Intermediate,,1,,1,10090.0,6702,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value in IRC mice,CHEMBL621829,5951,50594,,,,,Intermediate,,1,,1,10090.0,6703,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,CHEMBL621830,5506,50594,,,,,Intermediate,,1,,1,10090.0,6704,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,CHEMBL621831,5506,50594,,,,,Intermediate,,1,,1,10090.0,6705,A,N,BAO_0000218,In vivo
,Mus musculus,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,CHEMBL621832,14239,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6706,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",CHEMBL624579,4890,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6707,A,N,BAO_0000218,In vivo
,Mus musculus,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,CHEMBL624580,429,50594,,,,,Intermediate,,1,,1,10090.0,6708,A,N,BAO_0000218,In vivo
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,CHEMBL624581,10986,50535,,,,,Intermediate,,1,,1,6277.0,6709,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,CHEMBL624582,10986,50535,,,,,Intermediate,,1,,1,6277.0,6710,F,N,BAO_0000218,
,Acanthocheilonema viteae,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,CHEMBL624583,10986,50535,,,,,Intermediate,,1,,1,6277.0,6711,F,N,BAO_0000218,
A-375,Homo sapiens,,,Inhibitory activity against human tumor cell line A0375 melanoma.,CHEMBL624584,13227,80018,,455.0,,,Intermediate,,1,,1,9606.0,6712,F,N,BAO_0000219,
,Rattus norvegicus,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,CHEMBL624585,4481,12512,Brain membranes,,,,Expert,,1,,9,10116.0,6713,B,D,BAO_0000249,
,Homo sapiens,,,Forskolin-induced cAMP production at human A1 adenosine receptor,CHEMBL875165,16931,114,,,,,Expert,,1,,9,9606.0,6714,F,D,BAO_0000019,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,CHEMBL619490,3850,114,,449.0,,,Autocuration,,1,,8,,6715,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHEMBL619491,3850,114,,449.0,,,Autocuration,,1,,8,,6716,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,CHEMBL619492,3850,114,,449.0,,,Expert,,1,,8,,6717,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,CHEMBL619493,3850,114,,449.0,,,Expert,,1,,8,,6718,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,CHEMBL619494,3850,114,,449.0,,,Autocuration,,1,,8,,6719,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,CHEMBL619495,3850,114,,449.0,,,Autocuration,,1,,8,,6720,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL619496,3850,114,,449.0,,,Autocuration,,1,,8,,6721,F,H,BAO_0000219,
CHO,Homo sapiens,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHEMBL619497,3850,114,,449.0,,,Expert,,1,,9,9606.0,6722,F,D,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,CHEMBL619498,3850,114,,449.0,,,Autocuration,,1,,8,,6723,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,CHEMBL619499,3850,114,,449.0,,,Autocuration,,1,,8,,6724,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,CHEMBL619500,3850,114,,449.0,,,Expert,,1,,8,,6725,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL619501,3850,114,,449.0,,,Autocuration,,1,,8,,6726,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,CHEMBL619502,3850,114,,449.0,,,Expert,,1,,8,,6727,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,CHEMBL619503,3850,114,,449.0,,,Autocuration,,1,,8,,6728,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHEMBL619504,3850,114,,449.0,,,Autocuration,,1,,8,,6729,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,CHEMBL621298,3850,114,,449.0,,,Autocuration,,1,,8,,6730,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,CHEMBL621299,3850,114,,449.0,,,Expert,,1,,8,,6731,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,CHEMBL621300,3850,114,,449.0,,,Autocuration,,1,,8,,6732,F,H,BAO_0000219,
CHO,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,CHEMBL621301,3850,114,,449.0,,,Autocuration,,1,,8,,6733,F,H,BAO_0000219,
CHO,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHEMBL621302,3850,114,,449.0,,,Expert,,1,,8,,6734,F,H,BAO_0000219,
A10,Oryctolagus cuniculus,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,CHEMBL621303,12680,80013,,164.0,,,Intermediate,,1,,1,9986.0,6735,F,N,BAO_0000219,
A10,Rattus norvegicus,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,CHEMBL621304,1313,22226,,164.0,,,Autocuration,,1,,0,10116.0,6736,F,U,BAO_0000219,
A10,Rattus norvegicus,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,CHEMBL621305,1313,22226,,164.0,,,Autocuration,,1,,0,10116.0,6737,F,U,BAO_0000219,
A10,Rattus norvegicus,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,CHEMBL621306,17567,80013,,164.0,,,Intermediate,,1,,1,10116.0,6738,F,N,BAO_0000219,
A10,Rattus norvegicus,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,CHEMBL618444,17567,80013,,164.0,,,Intermediate,,1,,1,10116.0,6739,F,N,BAO_0000219,
A10,Rattus norvegicus,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,CHEMBL618445,11819,80013,,164.0,,,Intermediate,,1,,1,10116.0,6740,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,CHEMBL618446,13436,80089,,185.0,,,Intermediate,,1,,1,10029.0,6741,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,CHEMBL618447,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6742,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,CHEMBL618448,12651,80089,,185.0,,,Intermediate,,1,,1,10029.0,6743,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,CHEMBL618449,13300,80089,,185.0,,,Intermediate,,1,,1,10029.0,6744,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,CHEMBL618637,15296,80089,,185.0,,,Intermediate,,1,,1,10029.0,6745,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",CHEMBL618638,15328,80089,,185.0,,,Intermediate,,1,,1,10029.0,6746,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),CHEMBL618639,13302,80089,,185.0,,,Intermediate,,1,,1,10029.0,6747,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",CHEMBL618640,14367,80089,,185.0,,,Expert,,1,,1,10029.0,6748,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,CHEMBL618641,17002,80089,,185.0,,,Expert,,1,,1,10029.0,6749,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,CHEMBL618642,13436,80089,,185.0,,,Intermediate,,1,,1,10029.0,6750,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Inhibitory activity against aerobic growth of AA8 cells.,CHEMBL618643,13435,80089,,185.0,,,Intermediate,,1,,1,10029.0,6751,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL884013,10503,80089,,185.0,,,Intermediate,,1,,1,10029.0,6752,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL622723,10503,80089,,185.0,,,Expert,,1,,1,10029.0,6753,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHEMBL622724,10503,80089,,185.0,,,Intermediate,,1,,1,10029.0,6754,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,CHEMBL622725,15090,80089,,185.0,,,Expert,,1,,1,10029.0,6755,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Cytotoxicity against AA8 cell line,CHEMBL622726,10368,80089,,185.0,,,Expert,,1,,1,10029.0,6756,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),CHEMBL622727,12651,80089,,185.0,,,Intermediate,,1,,1,10029.0,6757,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622728,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6758,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622729,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6759,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHEMBL622730,12687,80089,,185.0,,,Intermediate,,1,,1,10029.0,6760,A,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,CHEMBL622731,1890,80089,,185.0,,,Intermediate,,1,,1,10029.0,6761,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHEMBL622732,10747,80089,,185.0,,,Intermediate,,1,,1,10029.0,6762,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHEMBL622733,10747,80089,,185.0,,,Intermediate,,1,,1,10029.0,6763,F,N,BAO_0000219,
,Cricetulus griseus,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),CHEMBL622734,11616,22224,,,,,Autocuration,,1,,0,10029.0,6764,F,U,BAO_0000218,
CHO-AA8,Cricetulus griseus,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,CHEMBL622735,11616,80089,,185.0,,,Expert,,1,,1,10029.0,6765,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,CHEMBL618746,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6766,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,CHEMBL618747,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6767,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,CHEMBL620540,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6768,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,CHEMBL620541,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6769,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,CHEMBL620542,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6770,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,CHEMBL620543,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6771,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,CHEMBL618832,3471,22224,,185.0,,,Autocuration,,1,,0,10029.0,6772,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration required to reduce AA8 cell survival by 10%,CHEMBL618833,11616,80089,,185.0,,,Expert,,1,,1,10029.0,6773,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",CHEMBL618834,2656,22224,,185.0,,,Autocuration,,1,,0,10029.0,6774,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHEMBL618835,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6775,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHEMBL618836,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6776,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,CHEMBL618837,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6777,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,CHEMBL618838,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6778,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,CHEMBL618839,16156,22224,,185.0,,,Autocuration,,1,,0,10029.0,6779,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,CHEMBL618840,2656,22224,,185.0,,,Autocuration,,1,,0,10029.0,6780,F,U,BAO_0000219,
,Cricetulus griseus,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",CHEMBL618841,11005,22224,,,,,Autocuration,,1,,0,10029.0,6781,F,U,BAO_0000019,
CHO-AA8,Cricetulus griseus,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,CHEMBL618842,11942,22224,,185.0,,,Autocuration,,1,,0,10029.0,6782,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,CHEMBL618843,2128,22224,,185.0,,,Autocuration,,1,,0,10029.0,6783,F,U,BAO_0000219,
,Canis lupus familiaris,,,Half life period after 15 mg/kg iv dose in Dogs,CHEMBL618844,16907,50588,,,,,Intermediate,,1,,1,9615.0,6784,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period after 30 mg/kg po dose in Dogs,CHEMBL618845,16907,50588,,,,,Intermediate,,1,,1,9615.0,6785,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was measured after oral 2b administration (tested in 6 dogs),CHEMBL618846,9579,50588,,,,,Intermediate,,1,,1,9615.0,6786,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was measured in dog after oral 17b administration,CHEMBL618847,9579,50588,,,,,Intermediate,,1,,1,9615.0,6787,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,CHEMBL618848,9579,50588,,,,,Intermediate,,1,,1,9615.0,6788,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,CHEMBL618849,9579,50588,,,,,Intermediate,,1,,1,9615.0,6789,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax value after 15 mg/kg iv dose in Dogs,CHEMBL618850,16907,50588,,,,,Intermediate,,1,,1,9615.0,6790,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax value after 30 mg/kg po dose in Dogs,CHEMBL618851,16907,50588,,,,,Intermediate,,1,,1,9615.0,6791,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for its half life when administered intravenously in dog,CHEMBL873815,3184,50588,,,,,Intermediate,,1,,1,9615.0,6792,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),CHEMBL618852,5017,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6793,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Elimination Half-life of compound was determined in dog,CHEMBL618853,6821,50588,,,,,Intermediate,,1,,1,9615.0,6794,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life of compound in dog following oral administration,CHEMBL618854,17839,50588,,,,,Intermediate,,1,,1,9615.0,6795,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life of compound was determined in dog,CHEMBL618855,17267,50588,,,,,Intermediate,,1,,1,9615.0,6796,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life of compound was determined in dog blood,CHEMBL618856,4727,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,6797,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life after oral and iv dosing in dogs,CHEMBL875827,5238,50588,,,,,Intermediate,,1,,1,9615.0,6798,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dogs in hours,CHEMBL618857,4942,50588,,,,,Intermediate,,1,,1,9615.0,6799,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life on i.v. administration of 2 mg/kg was measured in dog,CHEMBL618858,6505,50588,,,,,Intermediate,,1,,1,9615.0,6800,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,t1/2 in dog after oral dose (1 mg/kg),CHEMBL618859,5130,50588,,,,,Intermediate,,1,,1,9615.0,6801,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was evaluated in dog,CHEMBL618860,1475,50588,,,,,Intermediate,,1,,1,9615.0,6802,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,CHEMBL618861,17804,50588,,,,,Intermediate,,1,,1,9615.0,6803,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period of compound was determined after peroral administration at 2 mg/kg,CHEMBL622539,17804,50588,,,,,Intermediate,,1,,1,9615.0,6804,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period (10 mg/kg) was determined in dog,CHEMBL622540,6084,50588,,,,,Intermediate,,1,,1,9615.0,6805,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period (10 mg/kg) was determined in dog,CHEMBL873803,6084,50588,,,,,Intermediate,,1,,1,9615.0,6806,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,CHEMBL873804,5542,50588,,,,,Intermediate,,1,,1,9615.0,6807,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,CHEMBL624311,5542,50588,,,,,Intermediate,,1,,1,9615.0,6808,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period in dog,CHEMBL624312,6084,50588,,,,,Intermediate,,1,,1,9615.0,6809,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period in dogs after oral administration at 1 mg/kg,CHEMBL624313,6241,50588,,,,,Intermediate,,1,,1,9615.0,6810,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL624314,1916,50588,,,,,Intermediate,,1,,1,9615.0,6811,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound was determined in dogs,CHEMBL624315,6621,50588,,,,,Intermediate,,1,,1,9615.0,6812,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in dog plasma,CHEMBL624316,1696,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6813,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in mongrel dogs was determined,CHEMBL624317,17800,50588,,,,,Intermediate,,1,,1,9615.0,6814,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in dog upon oral administration,CHEMBL624318,17657,50588,,,,,Intermediate,,1,,1,9615.0,6815,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in dog upon oral administration; Unable to calculate,CHEMBL624319,17657,50588,,,,,Intermediate,,1,,1,9615.0,6816,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life was measured in dog,CHEMBL624496,4239,50588,,,,,Intermediate,,1,,1,9615.0,6817,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life was measured in dog,CHEMBL624497,5985,50588,,,,,Intermediate,,1,,1,9615.0,6818,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,CHEMBL624498,9932,50588,,,,,Intermediate,,1,,1,9615.0,6819,A,N,BAO_0000218,
,Canis lupus familiaris,,,Oral half life was determined,CHEMBL624499,5199,50588,,,,,Intermediate,,1,,1,9615.0,6820,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,CHEMBL624500,5199,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6821,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma half life was evaluated,CHEMBL624501,1475,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6822,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma half life was evaluated in Dog,CHEMBL623666,1475,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6823,A,N,BAO_0000218,
,Canis lupus familiaris,,,Plasma half life was evaluated in dog,CHEMBL623667,1475,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6824,A,N,BAO_0000218,
,Canis lupus familiaris,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,CHEMBL623668,6316,50588,,,,,Intermediate,,1,,1,9615.0,6825,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for the half life value in dog,CHEMBL623669,4883,50588,,,,,Intermediate,,1,,1,9615.0,6826,A,N,BAO_0000218,
,Canis lupus familiaris,,,Maximum time at the dose of 2 mg/kg in dog,CHEMBL623670,4727,50588,,,,,Intermediate,,1,,1,9615.0,6827,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,CHEMBL623671,1916,50588,,,,,Intermediate,,1,,1,9615.0,6828,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL875945,1337,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,6829,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL623672,1337,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,6830,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,CHEMBL623673,6265,50588,,,,,Intermediate,,1,,1,9615.0,6831,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),CHEMBL623674,4809,50588,,,,,Intermediate,,1,,1,9615.0,6832,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,CHEMBL623675,5983,50588,,,,,Intermediate,,1,,1,9615.0,6833,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",CHEMBL872526,5313,50588,,,,,Intermediate,,1,,1,9615.0,6834,A,N,BAO_0000218,
,Canis lupus familiaris,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",CHEMBL623676,5313,50588,,,,,Intermediate,,1,,1,9615.0,6835,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,CHEMBL623677,17650,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6836,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,CHEMBL623678,5199,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6837,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Time taken for maximum plasma concentration in dog,CHEMBL623679,933,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6838,A,N,BAO_0000218,
,Canis lupus familiaris,,,Time to reach Cmax after oral administration to dogs,CHEMBL623680,16367,50588,,,,,Intermediate,,1,,1,9615.0,6839,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL623681,6348,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,6840,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,CHEMBL623682,6316,50588,,,,,Intermediate,,1,,1,9615.0,6841,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax after peroral administration (1 mg/kg) was determined in dog,CHEMBL623683,6215,50588,,,,,Intermediate,,1,,1,9615.0,6842,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL623684,3598,50588,,,,,Expert,,1,,1,9615.0,6843,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL622745,4527,50588,,,,,Intermediate,,1,,1,9615.0,6844,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax after peroral administration in dogs at 2.4 uM/kg,CHEMBL622746,17764,50588,,,,,Intermediate,,1,,1,9615.0,6845,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo Cmax in mice at dose of 100 mg/kg,CHEMBL622747,5969,50594,,,,,Intermediate,,1,,1,10090.0,6846,A,N,BAO_0000218,In vivo
,Mus musculus,,,In vivo Cmax in mice at dose of 50 mg/kg,CHEMBL622748,5969,50594,,,,,Intermediate,,1,,1,10090.0,6847,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,CHEMBL622749,4573,50594,,,,,Intermediate,,1,,1,10090.0,6848,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),CHEMBL622750,3277,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6849,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,CHEMBL623411,17734,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6850,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum concentration obtained in mouse plasma was determined,CHEMBL875946,3132,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6851,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,CHEMBL623412,3132,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6852,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL623413,6348,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6853,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,CHEMBL623414,17729,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6854,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,CHEMBL623415,17729,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6855,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,CHEMBL623416,17729,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6856,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,CHEMBL623417,17728,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6857,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,CHEMBL623418,17728,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6858,A,N,BAO_0000218,In vivo
,Mus musculus,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,CHEMBL623419,17728,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6859,A,N,BAO_0000218,In vivo
,Mus musculus,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,CHEMBL622816,4066,50594,,,,,Intermediate,,1,,1,10090.0,6860,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,CHEMBL623313,6178,50594,,,,,Intermediate,,1,,1,10090.0,6861,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,CHEMBL623314,6178,50594,,,,,Intermediate,,1,,1,10090.0,6862,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,CHEMBL876788,3760,50594,,,,,Intermediate,,1,,1,10090.0,6863,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,CHEMBL623315,3760,50594,,,,,Intermediate,,1,,1,10090.0,6864,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,CHEMBL623316,3760,50594,,,,,Intermediate,,1,,1,10090.0,6865,A,N,BAO_0000218,In vivo
,Mus musculus,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,CHEMBL623317,3760,50594,,,,,Intermediate,,1,,1,10090.0,6866,A,N,BAO_0000218,In vivo
,Mus musculus,,,Cmax in male mice after 2 mg/kg oral dose,CHEMBL623319,5961,50594,,,,,Intermediate,,1,,1,10090.0,6868,A,N,BAO_0000218,In vivo
,Mus musculus,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,CHEMBL623320,6137,50594,,,,,Intermediate,,1,,1,10090.0,6869,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,CHEMBL623321,3802,50594,,,,,Intermediate,,1,,1,10090.0,6870,A,N,BAO_0000218,In vivo
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,CHEMBL623322,3535,50594,,,,,Intermediate,,1,,1,10090.0,6871,A,N,BAO_0000218,
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,CHEMBL623323,3535,50594,,,,,Intermediate,,1,,1,10090.0,6872,A,N,BAO_0000218,
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,CHEMBL623324,3535,50594,,,,,Intermediate,,1,,1,10090.0,6873,A,N,BAO_0000218,
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,CHEMBL623325,3535,50594,,,,,Intermediate,,1,,1,10090.0,6874,A,N,BAO_0000218,
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,CHEMBL623326,3535,50594,,,,,Intermediate,,1,,1,10090.0,6875,A,N,BAO_0000218,
,Mus musculus,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,CHEMBL623327,3535,50594,,,,,Intermediate,,1,,1,10090.0,6876,A,N,BAO_0000218,
,Mus musculus,,,Maximum concentration in plasma upon oral administration in mouse,CHEMBL623328,2862,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6877,A,N,BAO_0000218,
,Mus musculus,,,Maximum plasma concentration was evaluated in mice after oral administration,CHEMBL623329,2675,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6878,A,N,BAO_0000218,
,Mus musculus,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,CHEMBL623330,2675,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,6879,A,N,BAO_0000218,In vivo
,Mus musculus,,,Dose at which the compound induced fecal excretion in mice,CHEMBL876789,5399,50594,,,,,Intermediate,,1,,1,10090.0,6880,A,N,BAO_0000218,
A10,Rattus norvegicus,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,CHEMBL623333,11819,80013,,164.0,,,Expert,,1,,1,10116.0,6893,F,N,BAO_0000219,
A10,Rattus norvegicus,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,CHEMBL623334,11819,80013,,164.0,,,Expert,,1,,1,10116.0,6894,F,N,BAO_0000219,
A10,Rattus norvegicus,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,CHEMBL627536,11819,80013,,164.0,,,Expert,,1,,1,10116.0,6895,F,N,BAO_0000219,
A10,Rattus norvegicus,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,CHEMBL627537,11819,80013,,164.0,,,Expert,,1,,1,10116.0,6896,F,N,BAO_0000219,
A10,Rattus norvegicus,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),CHEMBL627538,16361,80013,,164.0,,,Intermediate,,1,,1,10116.0,6897,F,N,BAO_0000219,
A121,Homo sapiens,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,CHEMBL884106,2288,80655,,393.0,,,Intermediate,,1,,1,9606.0,6898,F,N,BAO_0000219,
A121,Homo sapiens,,,Anticancer activity against human ovarian carcinoma A121 cells,CHEMBL625294,10404,80655,,393.0,,,Intermediate,,1,,1,9606.0,6899,F,N,BAO_0000219,
A121,Homo sapiens,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,CHEMBL625295,14790,80655,,393.0,,,Intermediate,,1,,1,9606.0,6900,F,N,BAO_0000219,
A121,Homo sapiens,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,CHEMBL625296,14790,80655,,393.0,,,Intermediate,,1,,1,9606.0,6901,F,N,BAO_0000219,
A121,Homo sapiens,,,Growth inhibition of human ovarian carcinoma (A121) cell line,CHEMBL625297,14253,80655,,393.0,,,Expert,,1,,1,9606.0,6902,F,N,BAO_0000219,
A121,Homo sapiens,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,CHEMBL625298,13617,80655,,393.0,,,Expert,,1,,1,9606.0,6903,F,N,BAO_0000219,
A121,Homo sapiens,,,Cytotoxicity against human A121 ovarian cells,CHEMBL625960,1003,80655,,393.0,,,Intermediate,,1,,1,9606.0,6904,F,N,BAO_0000219,
A121,Homo sapiens,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,CHEMBL625961,830,80655,,393.0,,,Intermediate,,1,,1,9606.0,6905,F,N,BAO_0000219,
A121,Homo sapiens,,,In vitro cytotoxicity against human ovarian carcinoma A21,CHEMBL625962,12307,80655,,393.0,,,Intermediate,,1,,1,9606.0,6906,F,N,BAO_0000219,
A121,Homo sapiens,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,CHEMBL624717,14254,80655,,393.0,,,Intermediate,,1,,1,9606.0,6907,F,N,BAO_0000219,
A121,Homo sapiens,,,Inhibitory activity of compound against human A121 ovarian cell line.,CHEMBL624718,13370,80655,,393.0,,,Intermediate,,1,,1,9606.0,6908,F,N,BAO_0000219,
A121,Homo sapiens,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,CHEMBL624719,14790,80655,,393.0,,,Intermediate,,1,,1,9606.0,6909,F,N,BAO_0000219,
A121,Homo sapiens,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,CHEMBL624720,3614,80655,,393.0,,,Intermediate,,1,,1,9606.0,6910,F,N,BAO_0000219,
A 172,Homo sapiens,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,CHEMBL624721,2664,80012,,622.0,,,Intermediate,,1,,1,9606.0,6911,F,N,BAO_0000219,
A 172,Homo sapiens,,,In vitro cytotoxicity against A172 human tumor cell lines.,CHEMBL624722,2037,80012,,622.0,,,Expert,,1,,1,9606.0,6912,F,N,BAO_0000219,
A 172,Homo sapiens,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,CHEMBL877597,14539,80012,,622.0,,,Intermediate,,1,,1,9606.0,6913,F,N,BAO_0000219,
A 172,Homo sapiens,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,CHEMBL624723,2836,80012,,622.0,,,Intermediate,,1,,1,9606.0,6914,F,N,BAO_0000219,
A 172,Homo sapiens,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,CHEMBL624724,10708,80012,,622.0,,,Intermediate,,1,,1,9606.0,6915,F,N,BAO_0000219,
,Canis lupus familiaris,,,Association constant against A2 adenosine receptor,CHEMBL624725,8975,104729,,,,,Autocuration,,1,,4,9615.0,6916,B,H,BAO_0000224,
A2,fish,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,CHEMBL624726,7645,80656,,1085.0,,,Intermediate,,1,,1,,6917,F,N,BAO_0000219,
,Rattus norvegicus,,,Ratio of Ki for adenosine A2 and A1 receptor binding,CHEMBL857535,11377,104713,,,,,Autocuration,,1,,5,10116.0,6918,B,D,BAO_0000224,
A204,Homo sapiens,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,CHEMBL624727,13528,80014,,623.0,,,Expert,,1,,1,9606.0,6919,F,N,BAO_0000219,
A204,Homo sapiens,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,CHEMBL624728,10160,80014,,623.0,,,Expert,,1,,1,9606.0,6920,F,N,BAO_0000219,
A2058,Homo sapiens,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,CHEMBL624729,15144,80015,,404.0,,,Intermediate,,1,,1,9606.0,6921,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition against Human squamous cell line(A 253),CHEMBL624730,13160,80657,,973.0,,,Intermediate,,1,,1,9606.0,6922,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,CHEMBL624731,12898,80657,,973.0,,,Intermediate,,1,,1,9606.0,6923,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,CHEMBL624732,13069,80657,,973.0,,,Intermediate,,1,,1,9606.0,6924,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition of A253 cell lines.,CHEMBL883245,15984,80657,,973.0,,,Intermediate,,1,,1,9606.0,6925,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),CHEMBL624733,15564,80657,,973.0,,,Intermediate,,1,,1,9606.0,6926,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,CHEMBL624734,15564,80657,,973.0,,,Intermediate,,1,,1,9606.0,6927,F,N,BAO_0000219,
A253 cell line,Homo sapiens,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,CHEMBL624735,15564,80657,,973.0,,,Intermediate,,1,,1,9606.0,6928,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,CHEMBL621780,4720,81034,,478.0,,,Intermediate,,1,,1,9606.0,6929,F,N,BAO_0000219,
A2780,Homo sapiens,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,CHEMBL877598,16112,81034,,478.0,,,Intermediate,,1,,1,9606.0,6930,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,CHEMBL621781,16597,81034,,478.0,,,Expert,,1,,1,9606.0,6931,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),CHEMBL621782,16378,81034,,478.0,,,Intermediate,,1,,1,9606.0,6932,F,N,BAO_0000219,
A2780,Homo sapiens,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,CHEMBL621783,16085,81034,,478.0,,,Expert,,1,,1,9606.0,6933,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,CHEMBL621784,16317,81034,,478.0,,,Intermediate,,1,,1,9606.0,6934,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),CHEMBL621785,15748,81034,,478.0,,,Intermediate,,1,,1,9606.0,6935,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,CHEMBL621968,16597,81034,,478.0,,,Expert,,1,,1,9606.0,6936,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,CHEMBL621969,16597,81034,,478.0,,,Expert,,1,,1,9606.0,6937,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,CHEMBL621970,16597,81034,,478.0,,,Expert,,1,,1,9606.0,6938,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,CHEMBL621971,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,6939,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,CHEMBL621972,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,6940,F,N,BAO_0000219,
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,CHEMBL884108,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,6941,F,N,BAO_0000219,
,Cricetulus griseus,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,CHEMBL623826,15296,22224,,,,,Autocuration,,1,,0,10029.0,6942,F,U,BAO_0000019,
CHO-AA8,Cricetulus griseus,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,CHEMBL623827,10251,22224,,185.0,,,Autocuration,,1,,0,10029.0,6943,A,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,CHEMBL623828,10251,22224,,185.0,,,Autocuration,,1,,0,10029.0,6944,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,CHEMBL623829,10251,22224,,185.0,,,Autocuration,,1,,0,10029.0,6945,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),CHEMBL623830,10251,22224,,185.0,,,Autocuration,,1,,0,10029.0,6946,F,U,BAO_0000219,
,Cricetulus griseus,,,Growth inhibition against CHO-derived cell line AA8,CHEMBL623831,11858,22224,,,,,Autocuration,,1,,0,10029.0,6947,F,U,BAO_0000019,
CHO-AA8,Cricetulus griseus,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],CHEMBL623832,11858,22224,,185.0,,,Autocuration,,1,,0,10029.0,6948,F,U,BAO_0000219,
CHO-AA8,hampster,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,CHEMBL623833,11616,80089,,185.0,,,Expert,,1,,1,36483.0,6949,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,CHEMBL623834,11616,80089,,185.0,,,Expert,,1,,1,10029.0,6950,F,N,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,CHEMBL623835,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6951,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,CHEMBL623836,11396,22224,,185.0,,,Autocuration,,1,,0,10029.0,6952,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,CHEMBL623837,10518,22224,,185.0,,,Autocuration,,1,,0,10029.0,6953,F,U,BAO_0000219,
CHO-AA8,Cricetulus griseus,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,CHEMBL623838,11616,80089,,185.0,,,Expert,,1,,1,10029.0,6954,F,N,BAO_0000219,
,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,CHEMBL623839,14837,12675,,,,,Autocuration,,1,,8,,6955,F,H,BAO_0000019,
,,,,Number of binding sites (n) of isolated serum protein AAG,CHEMBL623840,14837,12675,,,,,Autocuration,,1,,8,,6956,F,H,BAO_0000019,
,,,,Association constant for binding to AATT duplex,CHEMBL623841,16037,22222,,,,,Intermediate,,1,,3,,6957,B,M,BAO_0000225,
ABAE,Homo sapiens,,,Inhibition of ABAE human fibroblast cell proliferation,CHEMBL623842,16597,100090,,416.0,,,Expert,,1,,1,9606.0,6958,F,N,BAO_0000219,
AC755,Mus musculus,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",CHEMBL623843,8831,80668,,1064.0,,,Intermediate,,1,,1,10090.0,6959,F,N,BAO_0000218,
,Oryctolagus cuniculus,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,CHEMBL618669,13419,102444,,,,,Expert,,1,,9,9986.0,6960,F,D,BAO_0000218,
,Oryctolagus cuniculus,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,CHEMBL618670,13419,102444,,,,,Expert,,1,,9,9986.0,6961,F,D,BAO_0000218,In vivo
,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,CHEMBL618671,15778,69,,,,,Autocuration,,1,,8,,6962,B,H,BAO_0000357,
,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,CHEMBL618672,15778,69,,,,,Autocuration,,1,,8,,6963,B,H,BAO_0000357,
ACH-2 cell line,Homo sapiens,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,CHEMBL618673,12988,80669,,978.0,,,Intermediate,,1,,1,9606.0,6964,F,N,BAO_0000219,
ACH-2 cell line,Homo sapiens,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618674,12988,80669,,978.0,,,Intermediate,,1,,1,9606.0,6965,F,N,BAO_0000219,
T cell line,Human immunodeficiency virus 1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,CHEMBL618675,12988,22224,,998.0,,,Autocuration,,1,,0,11676.0,6966,F,U,BAO_0000219,
T cell line,Human immunodeficiency virus 1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618676,12988,22224,,998.0,,,Autocuration,,1,,0,11676.0,6967,F,U,BAO_0000219,
T cell line,Human immunodeficiency virus 1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),CHEMBL618677,12988,22224,,998.0,,,Autocuration,,1,,0,11676.0,6968,F,U,BAO_0000219,
ACHN,Homo sapiens,,,Inhibition of growth of renal cancer ACHN cell line,CHEMBL618678,11843,80025,,626.0,,,Intermediate,,1,,1,9606.0,6969,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Inhibition of growth of ACHN renal cancer cell line,CHEMBL618679,16939,80025,,626.0,,,Intermediate,,1,,1,9606.0,6970,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Inhibitory concentration required against ACHN renal cancer cell line,CHEMBL618680,4782,80025,,626.0,,,Intermediate,,1,,1,9606.0,6971,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Concentration required to inhibit growth of human renal (ACHN) cell line,CHEMBL618681,6310,80025,,626.0,,,Expert,,1,,1,9606.0,6972,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,CHEMBL618682,6310,80025,,626.0,,,Intermediate,,1,,1,9606.0,6973,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Cytotoxic activity against ACHN Renal cancer cell line,CHEMBL618683,12858,80025,,626.0,,,Intermediate,,1,,1,9606.0,6974,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Cytotoxicity evaluation against ACHN renal cancer cells,CHEMBL618684,17380,80025,,626.0,,,Intermediate,,1,,1,9606.0,6975,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro antitumor activity against human renal ACHN cell line,CHEMBL618685,5858,80025,,626.0,,,Intermediate,,1,,1,9606.0,6976,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,CHEMBL876499,3838,80025,,626.0,,,Intermediate,,1,,1,9606.0,6977,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,CHEMBL618686,3838,80025,,626.0,,,Intermediate,,1,,1,9606.0,6978,F,N,BAO_0000219,
ACHN,Homo sapiens,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",CHEMBL618687,5406,80025,,626.0,,,Intermediate,,1,,1,9606.0,6979,F,N,BAO_0000219,
ACHN,Homo sapiens,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,CHEMBL618688,4071,80025,,626.0,,,Intermediate,,1,,1,9606.0,6980,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,CHEMBL618689,4071,80025,,626.0,,,Expert,,1,,1,9606.0,6981,F,N,BAO_0000219,
ACHN,Homo sapiens,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,CHEMBL618690,4071,80025,,626.0,,,Intermediate,,1,,1,9606.0,6982,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,CHEMBL618691,15002,80025,,626.0,,,Intermediate,,1,,1,9606.0,6983,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),CHEMBL619373,14769,80025,,626.0,,,Intermediate,,1,,1,9606.0,6984,F,N,BAO_0000219,
ACHN,Homo sapiens,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",CHEMBL884008,13958,80025,,626.0,,,Intermediate,,1,,1,9606.0,6985,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,CHEMBL619374,1665,80025,,626.0,,,Intermediate,,1,,1,9606.0,6986,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,CHEMBL619375,15354,80025,,626.0,,,Intermediate,,1,,1,9606.0,6987,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,CHEMBL619376,15354,80025,,626.0,,,Intermediate,,1,,1,9606.0,6988,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,CHEMBL619377,13978,80025,,626.0,,,Intermediate,,1,,1,9606.0,6989,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,CHEMBL619378,6798,80025,,626.0,,,Intermediate,,1,,1,9606.0,6990,F,N,BAO_0000219,
,Canis lupus familiaris,,,Tmax value after administration of 4 mg/Kg oral dose in dog,CHEMBL872527,2959,50588,,,,,Intermediate,,1,,1,9615.0,6991,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",CHEMBL876500,9932,50588,,,,,Intermediate,,1,,1,9615.0,6992,A,N,BAO_0000218,
,Canis lupus familiaris,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL619379,5546,50588,,,,,Intermediate,,1,,1,9615.0,6993,A,N,BAO_0000218,
,Canis lupus familiaris,,,Volume distribution after 15 mg/kg iv dose in Dogs,CHEMBL619538,16907,50588,,,,,Intermediate,,1,,1,9615.0,6994,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution after 30 mg/kg po dose in Dogs,CHEMBL619539,16907,50588,,,,,Intermediate,,1,,1,9615.0,6995,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,CHEMBL619540,4257,50588,,,,,Intermediate,,1,,1,9615.0,6996,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,CHEMBL619541,4305,50588,,,,,Intermediate,,1,,1,9615.0,6997,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was evaluated in dog,CHEMBL619542,5472,50588,,,,,Intermediate,,1,,1,9615.0,6998,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,CHEMBL619543,6062,50588,,,,,Intermediate,,1,,1,9615.0,6999,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,CHEMBL619544,3598,50588,,,,,Expert,,1,,1,9615.0,7000,A,N,BAO_0000218,
,Canis lupus familiaris,,,The compound was tested for volume of distribution in dog,CHEMBL619545,12500,50588,,,,,Intermediate,,1,,1,9615.0,7001,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,CHEMBL619546,12500,50588,,,,,Intermediate,,1,,1,9615.0,7002,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vd (1 mg/kg) was determined in dog (in vivo),CHEMBL619547,6227,50588,,,,,Intermediate,,1,,1,9615.0,7003,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vd in dog,CHEMBL619548,6227,50588,,,,,Intermediate,,1,,1,9615.0,7004,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution was determined,CHEMBL619549,4219,50588,,,,,Intermediate,,1,,1,9615.0,7005,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution in dog,CHEMBL619550,1696,50588,,,,,Intermediate,,1,,1,9615.0,7006,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution by as 4 fold increase by iv administration in dogs,CHEMBL876501,5542,50588,,,,,Intermediate,,1,,1,9615.0,7007,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,CHEMBL619551,5199,50588,,,,,Intermediate,,1,,1,9615.0,7008,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL619552,6348,50588,,,,,Intermediate,,1,,1,9615.0,7009,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution at the dose of 2 mg/kg in dog,CHEMBL619553,4727,50588,,,,,Intermediate,,1,,1,9615.0,7010,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Steady state volume of distribution was determined,CHEMBL618722,16367,50588,,,,,Intermediate,,1,,1,9615.0,7011,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,CHEMBL618723,2652,50588,,,,,Intermediate,,1,,1,9615.0,7012,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL618724,16452,50588,,,,,Intermediate,,1,,1,9615.0,7013,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL618725,16452,50588,,,,,Intermediate,,1,,1,9615.0,7014,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL618726,16452,50588,,,,,Intermediate,,1,,1,9615.0,7015,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),CHEMBL618727,5334,50588,,,,,Intermediate,,1,,1,9615.0,7016,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic property (vdss) was measured in dog,CHEMBL624233,4239,50588,,,,,Intermediate,,1,,1,9615.0,7017,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,CHEMBL624234,4709,50588,,,,,Intermediate,,1,,1,9615.0,7018,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vdss was determined after iv 0.1 mg/kg administration in dog,CHEMBL624235,5600,50588,,,,,Intermediate,,1,,1,9615.0,7019,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume displacement was calculated in dog,CHEMBL624236,6057,50588,,,,,Intermediate,,1,,1,9615.0,7020,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624237,5654,50588,,,,,Intermediate,,1,,1,9615.0,7021,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution constant was determined,CHEMBL624238,5505,50588,,,,,Intermediate,,1,,1,9615.0,7022,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution at a dose of 1 uM/kg in dog was determined,CHEMBL624239,4527,50588,,,,,Intermediate,,1,,1,9615.0,7023,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL875829,4521,50588,,,,,Intermediate,,1,,1,9615.0,7024,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL624240,4521,50588,,,,,Intermediate,,1,,1,9615.0,7025,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution (Vdss) was measured in dog,CHEMBL624241,15660,50588,,,,,Intermediate,,1,,1,9615.0,7026,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution (Vdss) was measured in dog,CHEMBL624242,15660,50588,,,,,Intermediate,,1,,1,9615.0,7027,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL624243,6679,50588,,,,,Intermediate,,1,,1,9615.0,7028,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution in steady state was determined in dog,CHEMBL624244,5145,50588,,,,,Intermediate,,1,,1,9615.0,7029,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution of compound was determined in dog,CHEMBL624245,6821,50588,,,,,Intermediate,,1,,1,9615.0,7030,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,CHEMBL624246,4137,50588,,,,,Intermediate,,1,,1,9615.0,7031,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),CHEMBL624247,5334,50588,,,,,Intermediate,,1,,1,9615.0,7032,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution (Vdss) was measured in dog,CHEMBL624248,15660,50588,,,,,Intermediate,,1,,1,9615.0,7033,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL624249,6642,50588,,,,,Intermediate,,1,,1,9615.0,7034,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624250,6641,50588,,,,,Intermediate,,1,,1,9615.0,7035,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624251,6642,50588,,,,,Intermediate,,1,,1,9615.0,7036,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Maximum rate of depolarization of the upstroke of the action potential,CHEMBL624252,11659,50588,,,,,Intermediate,,1,,1,9615.0,7037,A,N,BAO_0000218,
,Canis lupus familiaris,,,Steady state volume distribution in dog,CHEMBL624253,6448,50588,,,,,Intermediate,,1,,1,9615.0,7038,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,CHEMBL624950,5474,50588,,,,,Intermediate,,1,,1,9615.0,7039,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,CHEMBL624951,1466,50588,,,,,Intermediate,,1,,1,9615.0,7040,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,CHEMBL875830,6535,50588,,,,,Intermediate,,1,,1,9615.0,7041,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution in dog after administration of 1 mg/kg iv,CHEMBL624952,6535,50588,,,,,Intermediate,,1,,1,9615.0,7042,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,CHEMBL624953,17764,50588,,,,,Intermediate,,1,,1,9615.0,7043,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL624954,6215,50588,,,,,Intermediate,,1,,1,9615.0,7044,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vss on i.v. administration of 2 mg/kg was measured in dog,CHEMBL624955,6505,50588,,,,,Intermediate,,1,,1,9615.0,7045,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Vss was determined,CHEMBL624956,3639,50588,,,,,Intermediate,,1,,1,9615.0,7046,A,N,BAO_0000218,
,Canis lupus familiaris,,,Vss in dog,CHEMBL625129,3639,50588,,,,,Intermediate,,1,,1,9615.0,7047,A,N,BAO_0000218,
,Canis lupus familiaris,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,CHEMBL625130,6062,50588,,,,,Intermediate,,1,,1,9615.0,7048,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume distribution in dogs,CHEMBL625131,4942,50588,,,,,Intermediate,,1,,1,9615.0,7049,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Volume of distribution in dog,CHEMBL625132,17796,50588,,,,,Intermediate,,1,,1,9615.0,7050,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tested for the oral bioavailability in dog,CHEMBL872263,4883,50588,,,,,Intermediate,,1,,1,9615.0,7051,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,CHEMBL624336,17837,50594,,,,,Intermediate,,1,,1,10090.0,7060,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,CHEMBL624337,17729,50594,,,,,Intermediate,,1,,1,10090.0,7061,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,CHEMBL624338,17729,50594,,,,,Intermediate,,1,,1,10090.0,7062,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability was measured in mouse,CHEMBL624339,4239,50594,,,,,Intermediate,,1,,1,10090.0,7063,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability in mouse,CHEMBL624340,17592,50594,,,,,Intermediate,,1,,1,10090.0,7064,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,CHEMBL624341,6348,50594,,,,,Intermediate,,1,,1,10090.0,7065,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability in mouse,CHEMBL624342,2801,50594,,,,,Intermediate,,1,,1,10090.0,7066,A,N,BAO_0000218,In vivo
,Mus musculus,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,CHEMBL624343,2801,50594,,,,,Intermediate,,1,,1,10090.0,7067,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in mouse,CHEMBL624344,17718,50594,,,,,Intermediate,,1,,1,10090.0,7068,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral availability at 50 mg/kg po in male mice,CHEMBL624345,5727,50594,,,,,Intermediate,,1,,1,10090.0,7069,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in mouse (dose 10 mg/kg),CHEMBL624346,5302,50594,,,,,Intermediate,,1,,1,10090.0,7070,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,CHEMBL624347,3598,50594,,,,,Expert,,1,,1,10090.0,7071,A,N,BAO_0000218,In vivo
,Mus musculus,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",CHEMBL624348,5961,50594,,,,,Intermediate,,1,,1,10090.0,7072,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in mouse,CHEMBL622754,6091,50594,,,,,Intermediate,,1,,1,10090.0,7074,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in vivo in mice;ND=Not determined,CHEMBL622755,6091,50594,,,,,Intermediate,,1,,1,10090.0,7075,A,N,BAO_0000218,In vivo
,Mus musculus,,,Oral bioavailability in mouse at 10 mg/kg of the compound,CHEMBL622756,5711,50594,,,,,Intermediate,,1,,1,10090.0,7076,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),CHEMBL622757,17728,50594,,,,,Intermediate,,1,,1,10090.0,7077,A,N,BAO_0000218,In vivo
,Mus musculus,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),CHEMBL622758,17728,50594,,,,,Intermediate,,1,,1,10090.0,7078,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tested for bioavailability of the compound,CHEMBL622759,3802,50594,,,,,Intermediate,,1,,1,10090.0,7079,A,N,BAO_0000218,In vivo
,Mus musculus,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,CHEMBL622760,3802,50594,,,,,Intermediate,,1,,1,10090.0,7080,A,N,BAO_0000218,In vivo
,Mus musculus,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,CHEMBL622761,14029,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,7081,A,N,BAO_0000218,
,Mus musculus,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,CHEMBL622762,14029,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,7082,A,N,BAO_0000218,
,Mus musculus,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,CHEMBL622763,14029,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,7083,A,N,BAO_0000218,
,Mus musculus,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,CHEMBL622764,14029,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,7084,A,N,BAO_0000218,
,Mus musculus,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,CHEMBL622765,14029,50594,,,Plasma,1969.0,Intermediate,,1,,1,10090.0,7085,A,N,BAO_0000218,
,Mus musculus,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,CHEMBL622766,17753,50594,,,,,Intermediate,,1,,1,10090.0,7086,F,N,BAO_0000218,
,Mus musculus,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,CHEMBL622767,17753,50594,,,,,Intermediate,,1,,1,10090.0,7087,A,N,BAO_0000218,
,Mus musculus,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,CHEMBL622768,17753,50594,,,,,Intermediate,,1,,1,10090.0,7088,A,N,BAO_0000218,
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL875948,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7089,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL622769,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7090,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL622770,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7091,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL622771,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7092,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL622772,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7093,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL622773,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7094,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL622774,10107,50594,,,Blood,178.0,Intermediate,,1,,1,10090.0,7095,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621725,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7096,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL621726,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7097,A,N,BAO_0000218,In vivo
A2780,Homo sapiens,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,CHEMBL621727,15608,81034,,478.0,,,Intermediate,,1,,1,9606.0,7098,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL622413,3290,81034,,478.0,,,Expert,,1,,1,9606.0,7099,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated for cytotoxicity against A2780 cell line,CHEMBL622414,2859,81034,,478.0,,,Intermediate,,1,,1,9606.0,7100,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of A2780 cell clonogenic assay,CHEMBL622415,15688,81034,,478.0,,,Expert,,1,,1,9606.0,7101,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic effect on ovarian cancer cell line (A2780),CHEMBL884001,5642,81034,,478.0,,,Expert,,1,,1,9606.0,7102,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,CHEMBL622416,6633,81034,,478.0,,,Intermediate,,1,,1,9606.0,7103,F,N,BAO_0000219,
A2780,Homo sapiens,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",CHEMBL622417,3906,81034,,478.0,,,Intermediate,,1,,1,9606.0,7104,F,N,BAO_0000219,
A2780,Homo sapiens,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,CHEMBL622590,6788,81034,,478.0,,,Expert,,1,,1,9606.0,7105,F,N,BAO_0000219,
A2780,Homo sapiens,,,Antiproliferative activity against human A2780 cells,CHEMBL622591,17582,81034,,478.0,,,Expert,,1,,1,9606.0,7106,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of human A2780 cell proliferation,CHEMBL622592,17764,81034,,478.0,,,Expert,,1,,1,9606.0,7107,F,N,BAO_0000219,
A2780,Homo sapiens,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,CHEMBL622593,17764,81034,,478.0,,,Expert,,1,,1,9606.0,7108,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of human A2780 cell proliferation (No data),CHEMBL622594,17764,81034,,478.0,,,Expert,,1,,1,9606.0,7109,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,CHEMBL622595,2815,81034,,478.0,,,Intermediate,,1,,1,9606.0,7110,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,CHEMBL622596,16930,81034,,478.0,,,Intermediate,,1,,1,9606.0,7111,F,N,BAO_0000219,
A2780,Homo sapiens,,,Growth inhibition against A2780 wild-type ovarian cell lines,CHEMBL622597,17777,81034,,478.0,,,Expert,,1,,1,9606.0,7112,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,CHEMBL622598,17777,81034,,478.0,,,Intermediate,,1,,1,9606.0,7113,F,N,BAO_0000219,
,Homo sapiens,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,CHEMBL622599,16936,104766,,,,,Autocuration,,1,,5,9606.0,7114,F,D,BAO_0000019,
A2780,Homo sapiens,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,CHEMBL622600,13759,81034,,478.0,,,Intermediate,,1,,1,9606.0,7115,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,CHEMBL622601,13759,81034,,478.0,,,Intermediate,,1,,1,9606.0,7116,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,CHEMBL622602,13759,81034,,478.0,,,Intermediate,,1,,1,9606.0,7117,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,CHEMBL622603,13759,81034,,478.0,,,Intermediate,,1,,1,9606.0,7118,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,CHEMBL622604,15292,81034,,478.0,,,Intermediate,,1,,1,9606.0,7119,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,CHEMBL622605,15292,81034,,478.0,,,Intermediate,,1,,1,9606.0,7120,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro inhibition of human ovarian cell line A2780,CHEMBL622606,15069,81034,,478.0,,,Expert,,1,,1,9606.0,7121,F,N,BAO_0000219,
A2780,Homo sapiens,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",CHEMBL619463,15069,81034,,478.0,,,Expert,,1,,1,9606.0,7122,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),CHEMBL619464,14073,81034,,478.0,,,Intermediate,,1,,1,9606.0,7123,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit A2780-cell growth by 50%,CHEMBL619465,14553,81034,,478.0,,,Expert,,1,,1,9606.0,7124,F,N,BAO_0000219,
A2780,Homo sapiens,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,CHEMBL619466,13040,81034,,478.0,,,Expert,,1,,1,9606.0,7125,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,CHEMBL619467,6891,81034,,478.0,,,Expert,,1,,1,9606.0,7126,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,CHEMBL619468,15569,81034,,478.0,,,Intermediate,,1,,1,9606.0,7127,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,CHEMBL619469,14190,81034,,478.0,,,Expert,,1,,1,9606.0,7128,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL619470,15014,81034,,478.0,,,Expert,,1,,1,9606.0,7129,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,CHEMBL619471,15014,81034,,478.0,,,Intermediate,,1,,1,9606.0,7130,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,CHEMBL619472,17496,81034,,478.0,,,Intermediate,,1,,1,9606.0,7131,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",CHEMBL619473,13617,81034,,478.0,,,Intermediate,,1,,1,9606.0,7132,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",CHEMBL874368,13617,81034,,478.0,,,Intermediate,,1,,1,9606.0,7133,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",CHEMBL884003,13617,81034,,478.0,,,Intermediate,,1,,1,9606.0,7134,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",CHEMBL622690,13617,81034,,478.0,,,Intermediate,,1,,1,9606.0,7135,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,CHEMBL622691,17672,81034,,478.0,,,Intermediate,,1,,1,9606.0,7136,F,N,BAO_0000219,
A2780,Homo sapiens,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,CHEMBL622692,4544,81034,,478.0,,,Intermediate,,1,,1,9606.0,7137,F,N,BAO_0000219,
A2780,Homo sapiens,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,CHEMBL623406,4544,81034,,478.0,,,Intermediate,,1,,1,9606.0,7138,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",CHEMBL884004,16317,81034,,478.0,,,Intermediate,,1,,1,9606.0,7139,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,CHEMBL623407,15099,81034,,478.0,,,Intermediate,,1,,1,9606.0,7140,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,CHEMBL623408,13978,81034,,478.0,,,Intermediate,,1,,1,9606.0,7141,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro antitumor activity against A2780 cell line.,CHEMBL623409,12989,81034,,478.0,,,Expert,,1,,1,9606.0,7142,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,CHEMBL623410,5574,81034,,478.0,,,Intermediate,,1,,1,9606.0,7143,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,CHEMBL623576,13528,81034,,478.0,,,Expert,,1,,1,9606.0,7144,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,CHEMBL623577,12782,80025,,626.0,,,Intermediate,,1,,1,9606.0,7145,F,N,BAO_0000219,
ACHN,Homo sapiens,,,The IC50 value was measured on ACHN cell line in renal tumor type.,CHEMBL623578,14255,80025,,626.0,,,Intermediate,,1,,1,9606.0,7146,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,CHEMBL623579,16364,80025,,626.0,,,Intermediate,,1,,1,9606.0,7147,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro lethal concentration against most sensitive ACHN cell line,CHEMBL623580,17376,80025,,626.0,,,Expert,,1,,1,9606.0,7148,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Tested for cytotoxic activity against renal cancer ACHN cell line,CHEMBL623581,12016,80025,,626.0,,,Intermediate,,1,,1,9606.0,7149,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound tested for growth inhibition of renal cancer cell line ACHN,CHEMBL857456,6058,80025,,626.0,,,Intermediate,,1,,1,9606.0,7150,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,CHEMBL623582,17708,80025,,626.0,,,Intermediate,,1,,1,9606.0,7151,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,CHEMBL623583,15176,80025,,626.0,,,Intermediate,,1,,1,9606.0,7152,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro anticancer activity against ACHN renal cancer cell line,CHEMBL623584,2806,80025,,626.0,,,Intermediate,,1,,1,9606.0,7153,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,CHEMBL623585,15300,80025,,626.0,,,Intermediate,,1,,1,9606.0,7154,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Percent selectivity was evaluated in renal ACHN cell lines,CHEMBL623586,16364,80025,,626.0,,,Intermediate,,1,,1,9606.0,7155,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro inhibitory activity against renal ACHN cancer cell line,CHEMBL623587,13859,80025,,626.0,,,Intermediate,,1,,1,9606.0,7156,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,CHEMBL875279,11970,80025,,626.0,,,Intermediate,,1,,1,9606.0,7157,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,CHEMBL623588,2450,80025,,626.0,,,Intermediate,,1,,1,9606.0,7158,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,CHEMBL623589,12696,80025,,626.0,,,Intermediate,,1,,1,9606.0,7159,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,CHEMBL623590,12400,80025,,626.0,,,Intermediate,,1,,1,9606.0,7160,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Cytotoxic effect on renal cancer line ACHN,CHEMBL623591,12888,80025,,626.0,,,Expert,,1,,1,9606.0,7161,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,CHEMBL623592,3156,80025,,626.0,,,Intermediate,,1,,1,9606.0,7162,F,N,BAO_0000219,
ACHN,Homo sapiens,,,In vitro inhibition of Renal Cancer ACHN cell lines,CHEMBL623593,3381,80025,,626.0,,,Intermediate,,1,,1,9606.0,7163,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Antitumor activity against human renal adenocarcinoma ACHN cells,CHEMBL623594,16747,80025,,626.0,,,Intermediate,,1,,1,9606.0,7164,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,CHEMBL621833,16748,80025,,626.0,,,Expert,,1,,1,9606.0,7165,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,CHEMBL621834,12062,80025,,626.0,,,Intermediate,,1,,1,9606.0,7166,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),CHEMBL621835,14769,80025,,626.0,,,Intermediate,,1,,1,9606.0,7167,F,N,BAO_0000219,
ACHN,Homo sapiens,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",CHEMBL621836,15895,80025,,626.0,,,Intermediate,,1,,1,9606.0,7168,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,CHEMBL621837,17376,80025,,626.0,,,Intermediate,,1,,1,9606.0,7169,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,CHEMBL875280,14882,80025,,626.0,,,Intermediate,,1,,1,9606.0,7170,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,CHEMBL621838,14882,80025,,626.0,,,Intermediate,,1,,1,9606.0,7171,F,N,BAO_0000219,
ACHN,Homo sapiens,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,CHEMBL621839,15661,80025,,626.0,,,Intermediate,,1,,1,9606.0,7172,F,N,BAO_0000219,
,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,CHEMBL621840,9680,22224,,,,,Autocuration,,1,,0,,7173,A,U,BAO_0000019,
,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,CHEMBL621841,14579,10647,,,,,Autocuration,,1,,8,,7174,F,H,BAO_0000019,
HEL,Cytomegalovirus,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,CHEMBL622979,17290,50529,,468.0,,,Expert,,1,,1,10358.0,7175,F,N,BAO_0000218,
,Cytomegalovirus,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,CHEMBL876595,17290,50529,,,,,Intermediate,,1,,1,10358.0,7176,F,N,BAO_0000218,
,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),CHEMBL620221,15891,12159,,,,,Autocuration,,1,,8,,7177,B,H,BAO_0000357,
,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),CHEMBL620222,15890,12159,,,,,Autocuration,,1,,8,,7178,B,H,BAO_0000357,
ADDP cell line,Bos taurus,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,CHEMBL620506,3801,80670,,979.0,,,Intermediate,,1,,1,9913.0,7179,F,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,CHEMBL620507,9222,80671,,980.0,,,Intermediate,,1,,1,10090.0,7180,F,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,CHEMBL620508,9222,80671,,980.0,,,Intermediate,,1,,1,10090.0,7181,F,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",CHEMBL620509,7257,80671,,980.0,,,Intermediate,,1,,1,10090.0,7182,F,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,CHEMBL620510,7257,80671,,980.0,,,Intermediate,,1,,1,10090.0,7183,F,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,CHEMBL620511,7257,80671,,980.0,,,Intermediate,,1,,1,10090.0,7184,A,N,BAO_0000219,
ADJ/PC6,Mus musculus,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,CHEMBL620512,8084,80671,,980.0,,,Intermediate,,1,,1,10090.0,7185,F,N,BAO_0000219,
,Mus musculus,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,CHEMBL620513,14943,22224,,,,,Autocuration,,1,,0,10090.0,7186,F,U,BAO_0000019,
,Mus musculus,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,CHEMBL620514,14943,22224,,,,,Autocuration,,1,,0,10090.0,7187,F,U,BAO_0000019,
,Mus musculus,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,CHEMBL620515,14943,22224,,,,,Autocuration,,1,,0,10090.0,7188,F,U,BAO_0000019,
,Bacillus subtilis,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),CHEMBL620516,10524,22224,,,,,Autocuration,,1,,0,1423.0,7189,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,AUC value in dog after IV administration at a dose of 5 mg/kg,CHEMBL620517,3546,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7190,A,N,BAO_0000218,
,Canis lupus familiaris,,,AUC value in dog after oral administration at a dose of 5 mg/kg,CHEMBL620518,3546,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7191,A,N,BAO_0000218,
,Canis lupus familiaris,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,CHEMBL620519,3546,50588,,,,,Intermediate,,1,,1,9615.0,7192,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,CHEMBL621386,3546,50588,,,,,Intermediate,,1,,1,9615.0,7193,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,CHEMBL621387,3546,50588,,,,,Intermediate,,1,,1,9615.0,7194,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for its clearance when administered intravenously in dog,CHEMBL621388,3184,50588,,,,,Intermediate,,1,,1,9615.0,7195,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL621389,16456,50588,,,,,Intermediate,,1,,1,9615.0,7196,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),CHEMBL621390,4809,50588,,,,,Intermediate,,1,,1,9615.0,7197,A,N,BAO_0000218,In vivo
,,,,Calculated partition coefficient (clogP),CHEMBL621391,4219,22229,,,,,Intermediate,,1,,0,,7198,P,U,BAO_0000100,
,Canis lupus familiaris,,,Half life in dog,CHEMBL621392,3748,50588,,,,,Intermediate,,1,,1,9615.0,7199,A,N,BAO_0000218,
,Canis lupus familiaris,,,Time taken for EC90 was determined when tested in dog,CHEMBL621393,3132,50588,,,,,Intermediate,,1,,1,9615.0,7200,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life (iv) was determined,CHEMBL621394,4219,50588,,,,,Intermediate,,1,,1,9615.0,7201,A,N,BAO_0000218,
,Canis lupus familiaris,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,CHEMBL621395,16907,50588,,,Liver,2107.0,Intermediate,,1,,1,9615.0,7202,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve was calculated in dog after iv administration,CHEMBL621396,6057,50588,,,,,Intermediate,,1,,1,9615.0,7203,A,N,BAO_0000218,
,Canis lupus familiaris,,,Area under the curve was calculated in dog after peroral administration,CHEMBL621397,6057,50588,,,,,Intermediate,,1,,1,9615.0,7204,A,N,BAO_0000218,
,Canis lupus familiaris,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,CHEMBL621398,17853,50588,,,,,Intermediate,,1,,1,9615.0,7205,A,N,BAO_0000218,
,Canis lupus familiaris,,,pKa was evaluated in dog,CHEMBL618818,3639,50588,,,,,Intermediate,,1,,1,9615.0,7206,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,CHEMBL618819,14541,50588,,,,,Intermediate,,1,,1,9615.0,7207,A,N,BAO_0000218,
,Canis lupus familiaris,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL618820,16456,50588,,,,,Intermediate,,1,,1,9615.0,7208,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,CHEMBL873810,16456,50588,,,,,Intermediate,,1,,1,9615.0,7209,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,CHEMBL876606,2652,50588,,,,,Intermediate,,1,,1,9615.0,7210,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for the half-life (t 1/2) in hours,CHEMBL618821,3624,50588,,,,,Intermediate,,1,,1,9615.0,7211,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,CHEMBL618822,1337,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,7212,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,CHEMBL618823,1337,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,7213,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life after intravenous administration of 1 mg/kg in dog,CHEMBL618824,4709,50588,,,,,Intermediate,,1,,1,9615.0,7214,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was measured in dog,CHEMBL618825,15660,50588,,,,,Intermediate,,1,,1,9615.0,7215,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period in dog after 5 mg/kg dose,CHEMBL618826,5302,50588,,,,,Intermediate,,1,,1,9615.0,7216,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was evaluated in dog; 4-4.8,CHEMBL618827,17791,50588,,,,,Intermediate,,1,,1,9615.0,7217,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,CHEMBL618828,6348,50588,,,,,Intermediate,,1,,1,9615.0,7218,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life was determined in dog after a3 mg/kg of iv dose,CHEMBL618829,4257,50588,,,,,Intermediate,,1,,1,9615.0,7219,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life was determined,CHEMBL618830,3771,50588,,,,,Intermediate,,1,,1,9615.0,7220,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dogs,CHEMBL618831,6305,50588,,,,,Intermediate,,1,,1,9615.0,7221,A,N,BAO_0000218,
,Canis lupus familiaris,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,CHEMBL619489,13501,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7222,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,CHEMBL619649,17594,50588,,,,,Intermediate,,1,,1,9615.0,7223,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,CHEMBL876607,3045,50588,,,,,Intermediate,,1,,1,9615.0,7224,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was evaluated for the half life period after oral administration in conscious dog.,CHEMBL619650,3043,50588,,,,,Intermediate,,1,,1,9615.0,7225,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Compound was tested for half life in dog,CHEMBL619651,4839,50588,,,,,Intermediate,,1,,1,9615.0,7226,A,N,BAO_0000218,
,Canis lupus familiaris,,,Compound was tested for its half life in dog,CHEMBL619652,4839,50588,,,,,Intermediate,,1,,1,9615.0,7227,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,CHEMBL619653,5802,50588,,,,,Intermediate,,1,,1,9615.0,7228,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life of compound in dog was determined,CHEMBL619654,17839,50588,,,,,Intermediate,,1,,1,9615.0,7229,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life (iv) was determined,CHEMBL619655,4219,50588,,,,,Intermediate,,1,,1,9615.0,7230,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),CHEMBL619656,13966,50588,,,Blood,178.0,Intermediate,,1,,1,9615.0,7231,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,CHEMBL873812,3994,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7232,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,CHEMBL621365,3994,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7233,F,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog,CHEMBL621366,4453,50588,,,,,Intermediate,,1,,1,9615.0,7234,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog plasma,CHEMBL621367,6535,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7235,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog plasma after administration of 0.25 mg/kg iv,CHEMBL621368,6535,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7236,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog plasma after administration of 1 mg/kg iv,CHEMBL621369,6535,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7237,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog plasma was determined at dose 10 mg/kg,CHEMBL621370,3132,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7238,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog was determined,CHEMBL621371,5374,50588,,,,,Intermediate,,1,,1,9615.0,7239,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),CHEMBL621372,5007,50588,,,,,Intermediate,,1,,1,9615.0,7240,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life upon exposure to human plasma,CHEMBL621373,16907,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7241,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was calculated in dog,CHEMBL621374,6057,50588,,,,,Intermediate,,1,,1,9615.0,7242,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was determined,CHEMBL621375,5006,50588,,,,,Intermediate,,1,,1,9615.0,7243,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was determined,CHEMBL621376,5473,50588,,,,,Intermediate,,1,,1,9615.0,7244,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life by intravenous administration of 1.2 mg/kg in dog,CHEMBL619624,4368,50588,,,,,Intermediate,,1,,1,9615.0,7245,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog,CHEMBL875840,6448,50588,,,,,Intermediate,,1,,1,9615.0,7246,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog after intra venous administration of the compound,CHEMBL619625,4353,50588,,,,,Intermediate,,1,,1,9615.0,7247,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog after intra venous administration of the compound; ND means Not determined,CHEMBL619626,4353,50588,,,,,Intermediate,,1,,1,9615.0,7248,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog after po administration of the compound,CHEMBL619627,4353,50588,,,,,Intermediate,,1,,1,9615.0,7249,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog after po administration of the compound; ND means Not determined,CHEMBL873817,4353,50588,,,,,Intermediate,,1,,1,9615.0,7250,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog at the single oral dose of 1 mg/kg,CHEMBL619628,6265,50588,,,,,Intermediate,,1,,1,9615.0,7251,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dogs,CHEMBL619629,5006,50588,,,,,Intermediate,,1,,1,9615.0,7252,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,CHEMBL619630,5356,50588,,,,,Intermediate,,1,,1,9615.0,7253,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in rat,CHEMBL619631,405,50588,,,,,Intermediate,,1,,1,9615.0,7254,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),CHEMBL619632,6642,50588,,,,,Intermediate,,1,,1,9615.0,7255,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL619633,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7256,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL875841,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7257,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL619634,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7258,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL619635,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7259,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL619636,10107,50594,,,Bone,10000001.0,Intermediate,,1,,1,10090.0,7260,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL619637,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7261,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL619638,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7262,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL619639,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7263,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL619640,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7264,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL619641,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7265,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL619642,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7266,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL619643,10107,50594,,,Gut,10000004.0,Intermediate,,1,,1,10090.0,7267,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL619644,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7268,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL621112,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7269,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621113,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7270,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL621114,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7271,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL621115,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7272,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL621116,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7273,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL621117,10107,50594,,,Heart,948.0,Intermediate,,1,,1,10090.0,7274,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621118,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7275,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL621119,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7276,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621120,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7277,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL621757,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7278,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL621758,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7279,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL621759,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7280,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL621760,10107,50594,,,Kidney,2113.0,Intermediate,,1,,1,10090.0,7281,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL621761,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7282,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL621762,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7283,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL621763,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7284,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL624502,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7285,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL624503,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7286,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL624504,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7287,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624505,10107,50594,,,Liver,2107.0,Intermediate,,1,,1,10090.0,7288,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL624506,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7289,A,N,BAO_0000218,In vivo
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780 (human ovarian cancer),CHEMBL624507,5895,81034,,478.0,,,Intermediate,,1,,1,9606.0,7290,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,CHEMBL624508,6338,81034,,478.0,,,Intermediate,,1,,1,9606.0,7291,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,CHEMBL624509,15163,81034,,478.0,,,Intermediate,,1,,1,9606.0,7292,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,CHEMBL624510,15163,81034,,478.0,,,Intermediate,,1,,1,9606.0,7293,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,CHEMBL875956,15000,81034,,478.0,,,Expert,,1,,1,9606.0,7294,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,CHEMBL839885,15000,81034,,478.0,,,Expert,,1,,1,9606.0,7295,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,CHEMBL624511,14729,81034,,478.0,,,Expert,,1,,1,9606.0,7296,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity against A2780 cell line,CHEMBL624512,17270,81034,,478.0,,,Intermediate,,1,,1,9606.0,7297,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,CHEMBL624513,5685,81034,,478.0,,,Intermediate,,1,,1,9606.0,7298,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,CHEMBL624514,3563,81034,,478.0,,,Intermediate,,1,,1,9606.0,7299,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,CHEMBL618547,17753,81034,,478.0,,,Intermediate,,1,,1,9606.0,7300,F,N,BAO_0000218,
A2780,Homo sapiens,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",CHEMBL618548,16317,81034,,478.0,,,Intermediate,,1,,1,9606.0,7301,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibition of tubulin polymerization in analogy of ca.,CHEMBL618549,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7302,F,N,BAO_0000219,
A2780,Homo sapiens,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,CHEMBL618550,3801,81034,,478.0,,,Intermediate,,1,,1,9606.0,7303,F,N,BAO_0000219,
A2780,Homo sapiens,,,Cytotoxic effect in ovarian cancer cell line (A2780),CHEMBL618551,6181,81034,,478.0,,,Expert,,1,,1,9606.0,7304,F,N,BAO_0000219,
A2780,Homo sapiens,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,CHEMBL618552,5318,81034,,478.0,,,Intermediate,,1,,1,9606.0,7305,F,N,BAO_0000219,
A2780,Homo sapiens,,,Tested for the cytotoxicity in A2780 ovarian cell line,CHEMBL618553,4840,81034,,478.0,,,Intermediate,,1,,1,9606.0,7306,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),CHEMBL618554,15748,81034,,478.0,,,Intermediate,,1,,1,9606.0,7307,F,N,BAO_0000219,
A2780,Homo sapiens,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,CHEMBL618555,15748,81034,,478.0,,,Intermediate,,1,,1,9606.0,7308,F,N,BAO_0000219,
A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,CHEMBL618556,15748,80017,,481.0,,,Intermediate,,1,,1,,7309,F,N,BAO_0000219,
A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),CHEMBL618557,15748,80017,,481.0,,,Intermediate,,1,,1,,7310,F,N,BAO_0000219,
A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,CHEMBL618558,15748,80017,,481.0,,,Intermediate,,1,,1,,7311,F,N,BAO_0000219,
A2780cisR,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),CHEMBL618559,15748,80017,,481.0,,,Intermediate,,1,,1,,7312,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vivo log of cells killed after administration of compound in A2780 cell line,CHEMBL618560,17753,81034,,478.0,,,Intermediate,,1,,1,9606.0,7313,F,N,BAO_0000218,
A2780,Homo sapiens,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,CHEMBL618561,17753,81034,,478.0,,,Intermediate,,1,,1,9606.0,7314,F,N,BAO_0000218,In vivo
A2780,Homo sapiens,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,CHEMBL618562,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7315,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,CHEMBL618563,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7316,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,CHEMBL618564,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7317,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,CHEMBL618565,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7318,F,N,BAO_0000219,
A2780,Homo sapiens,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),CHEMBL618566,17528,81034,,478.0,,,Intermediate,,1,,1,9606.0,7319,F,N,BAO_0000218,
A2780,Homo sapiens,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,CHEMBL618567,6633,81034,,478.0,,,Intermediate,,1,,1,9606.0,7320,F,N,BAO_0000219,
A2780,Homo sapiens,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,CHEMBL618568,15000,81034,,478.0,,,Expert,,1,,1,9606.0,7321,F,N,BAO_0000219,
A2780,Homo sapiens,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,CHEMBL618569,17528,81034,,478.0,,,Expert,,1,,1,9606.0,7322,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,CHEMBL621857,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7323,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,CHEMBL621858,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7324,F,N,BAO_0000219,
A2780,Homo sapiens,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,CHEMBL621859,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7325,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",CHEMBL621860,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7326,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),CHEMBL621861,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7327,F,N,BAO_0000219,
A2780,Homo sapiens,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",CHEMBL621862,16936,81034,,478.0,,,Expert,,1,,1,9606.0,7328,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621863,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7329,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621864,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7330,F,N,BAO_0000219,
A2780,Homo sapiens,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),CHEMBL621865,16936,81034,,478.0,,,Intermediate,,1,,1,9606.0,7331,F,N,BAO_0000219,
A2780,Mus musculus,,,In vitro antiproliferative activity against A2780 cell line,CHEMBL621866,17737,81034,,478.0,,,Intermediate,,1,,1,10090.0,7332,F,N,BAO_0000219,
A2780,Mus musculus,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,CHEMBL621867,17764,81034,,478.0,,,Expert,,1,,1,10090.0,7333,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,CHEMBL621868,3830,81034,,478.0,,,Intermediate,,1,,1,9606.0,7334,F,N,BAO_0000219,
A2780,Homo sapiens,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,CHEMBL875282,3829,81034,,478.0,,,Intermediate,,1,,1,9606.0,7335,F,N,BAO_0000219,
,Canis lupus familiaris,,,Vc value in dog after IV administration at a dose of 5 mg/kg,CHEMBL621869,3546,50588,,,,,Intermediate,,1,,1,9615.0,7336,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period in dog after IV administration at a dose of 5 mg/kg,CHEMBL621870,3546,50588,,,,,Intermediate,,1,,1,9615.0,7337,A,N,BAO_0000218,In vivo
,Cercopithecidae,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,CHEMBL621871,5668,22224,,,,,Autocuration,,1,,0,9527.0,7338,A,U,BAO_0000019,
,Cercopithecidae,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621243,3443,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,7339,A,U,BAO_0000218,
,Cercopithecidae,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL621244,3443,22224,,,Plasma,1969.0,Autocuration,,1,,0,9527.0,7340,A,U,BAO_0000218,
,Macaca fascicularis,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,CHEMBL621245,4256,22224,,,,,Autocuration,,1,,0,9541.0,7341,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,CHEMBL621246,4256,22224,,,,,Autocuration,,1,,0,9541.0,7342,A,U,BAO_0000218,In vivo
,Macaca fascicularis,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,CHEMBL621247,4256,22224,,,,,Autocuration,,1,,0,9541.0,7343,A,U,BAO_0000218,In vivo
,Rattus norvegicus,,,Oral Bioavailability in rat,CHEMBL618386,4256,22224,,,,,Autocuration,,1,,0,10116.0,7344,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,CHEMBL618387,1916,22224,,,,,Autocuration,,1,,0,9527.0,7345,A,U,BAO_0000218,
,Cercopithecidae,,,Area under curve value in monkey at a dose of 5 mg/kg,CHEMBL618388,5302,22224,,,,,Autocuration,,1,,0,9527.0,7346,A,U,BAO_0000218,
,Cercopithecidae,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,CHEMBL618389,4257,22224,,,,,Autocuration,,1,,0,9527.0,7347,A,U,BAO_0000218,
,Cercopithecidae,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,CHEMBL618574,5355,22224,,,,,Autocuration,,1,,0,9527.0,7348,A,U,BAO_0000019,
,Cercopithecidae,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,CHEMBL618575,5355,22224,,,,,Autocuration,,1,,0,9527.0,7349,A,U,BAO_0000019,
,Cercopithecidae,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,CHEMBL618576,5355,22224,,,,,Autocuration,,1,,0,9527.0,7350,A,U,BAO_0000019,
,Cercopithecidae,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,CHEMBL618577,6078,22224,,,,,Autocuration,,1,,0,9527.0,7351,A,U,BAO_0000218,
,Cercopithecidae,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,CHEMBL876487,6078,22224,,,,,Autocuration,,1,,0,9527.0,7352,A,U,BAO_0000218,
,Cercopithecidae,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,CHEMBL618578,6062,22224,,,,,Autocuration,,1,,0,9527.0,7353,A,U,BAO_0000218,
,Cercopithecidae,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL618579,2661,22224,,,,,Autocuration,,1,,0,9527.0,7354,A,U,BAO_0000218,
,Cercopithecidae,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL618580,2661,22224,,,,,Autocuration,,1,,0,9527.0,7355,A,U,BAO_0000019,
,Cercopithecidae,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,CHEMBL618581,5394,22224,,,,,Autocuration,,1,,0,9527.0,7356,A,U,BAO_0000218,
,Cercopithecidae,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,CHEMBL618582,4397,22224,,,,,Autocuration,,1,,0,9527.0,7357,A,U,BAO_0000218,
,Cercopithecidae,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,CHEMBL618583,17509,22224,,,,,Autocuration,,1,,0,9527.0,7358,A,U,BAO_0000218,
,Cercopithecidae,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,CHEMBL618584,17509,22224,,,,,Autocuration,,1,,0,9527.0,7359,A,U,BAO_0000218,
,Cercopithecidae,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),CHEMBL618585,6641,22224,,,,,Autocuration,,1,,0,9527.0,7360,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),CHEMBL618586,5355,22224,,,,,Autocuration,,1,,0,9527.0,7361,A,U,BAO_0000218,
,Cercopithecidae,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL618587,3443,22224,,,,,Autocuration,,1,,0,9527.0,7362,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,CHEMBL618588,3443,22224,,,,,Autocuration,,1,,0,9527.0,7363,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Binding towards monkey plasma protein at 10 uM,CHEMBL618589,17409,22224,,,,,Autocuration,,1,,0,9527.0,7364,A,U,BAO_0000019,
,Cercopithecidae,,,Binding towards monkey plasma protein at 100 uM,CHEMBL618590,17409,22224,,,,,Autocuration,,1,,0,9527.0,7365,A,U,BAO_0000019,
,Cercopithecidae,,,Apparent bioavailability in squirrel monkey was determined,CHEMBL872262,1052,22224,,,,,Autocuration,,1,,0,9527.0,7366,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,CHEMBL618591,13501,22224,,,,,Autocuration,,1,,0,9527.0,7367,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability in monkey (dose 2 mg/kg),CHEMBL618592,17509,22224,,,,,Autocuration,,1,,0,9443.0,7368,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,CHEMBL876488,5394,22224,,,,,Autocuration,,1,,0,9527.0,7369,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,CHEMBL618593,2661,22224,,,,,Autocuration,,1,,0,9527.0,7370,A,U,BAO_0000218,In vivo
,monkey,,,Bioavailability in monkey (i.d. dosing),CHEMBL618594,11219,22224,,,,,Autocuration,,1,,0,9443.0,7371,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,CHEMBL618595,3045,22224,,,,,Autocuration,,1,,0,9527.0,7372,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Clearance of the drug was measured in cynomolgus,CHEMBL621469,17796,22224,,,,,Autocuration,,1,,0,9527.0,7373,A,U,BAO_0000019,
,Cercopithecidae,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,CHEMBL621470,1399,22224,,,,,Autocuration,,1,,0,9527.0,7374,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,CHEMBL621471,2661,22224,,,,,Autocuration,,1,,0,9527.0,7375,A,U,BAO_0000218,In vivo
,Macaca mulatta,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,CHEMBL621472,5005,22224,,,Plasma,1969.0,Autocuration,,1,,0,9544.0,7376,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in rhesus monkey was determined,CHEMBL621473,17267,22224,,,,,Autocuration,,1,,0,9527.0,7377,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in monkey after administration of 1 mg/kg iv,CHEMBL621474,6535,22224,,,,,Autocuration,,1,,0,9527.0,7378,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance in cynomolgus monkey,CHEMBL621475,5922,22224,,,,,Autocuration,,1,,0,9527.0,7379,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,CHEMBL621476,6221,22224,,,,,Autocuration,,1,,0,9527.0,7380,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,CHEMBL624290,5668,22224,,,,,Autocuration,,1,,0,9527.0,7381,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,CHEMBL624291,5355,22224,,,,,Autocuration,,1,,0,9527.0,7382,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,CHEMBL624292,5355,22224,,,,,Autocuration,,1,,0,9527.0,7383,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,CHEMBL624293,5355,22224,,,,,Autocuration,,1,,0,9527.0,7384,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Tested for Clearance upon iv administration to african green monkey,CHEMBL624294,4578,22224,,,,,Autocuration,,1,,0,9527.0,7385,A,U,BAO_0000218,In vivo
,Cercopithecidae,,,Clearance in monkey,CHEMBL624295,17592,22224,,,,,Autocuration,,1,,0,9527.0,7386,A,U,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624296,6641,50588,,,,,Intermediate,,1,,1,9615.0,7387,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),CHEMBL624297,6642,50588,,,,,Intermediate,,1,,1,9615.0,7388,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was evaluated after intravenous administration to dogs,CHEMBL624298,16367,50588,,,,,Intermediate,,1,,1,9615.0,7389,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life was evaluated in dog,CHEMBL624299,5472,50588,,,,,Intermediate,,1,,1,9615.0,7390,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life was evaluated in dog,CHEMBL624300,5474,50588,,,,,Intermediate,,1,,1,9615.0,7391,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,CHEMBL624301,5654,50588,,,,,Intermediate,,1,,1,9615.0,7392,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),CHEMBL624302,6227,50588,,,,,Intermediate,,1,,1,9615.0,7393,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period after intravenous administration in dog,CHEMBL876026,6227,50588,,,,,Intermediate,,1,,1,9615.0,7394,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,CHEMBL624303,6221,50588,,,,,Intermediate,,1,,1,9615.0,7395,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period at a dose of 1 uM/kg in dog was determined,CHEMBL624304,4527,50588,,,,,Intermediate,,1,,1,9615.0,7396,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period was determine after peroral administration at 10 mpk in dog,CHEMBL624305,5668,50588,,,,,Intermediate,,1,,1,9615.0,7397,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was determine after peroral administration at 5 mpk in dog,CHEMBL624306,5668,50588,,,,,Intermediate,,1,,1,9615.0,7398,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was determined,CHEMBL624307,3854,50588,,,,,Intermediate,,1,,1,9615.0,7399,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period was determined,CHEMBL624308,5505,50588,,,,,Intermediate,,1,,1,9615.0,7400,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period by iv administration in dog at a dose of 6 mg/kg,CHEMBL624309,6251,50588,,,,,Intermediate,,1,,1,9615.0,7401,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was evaluated in dog,CHEMBL624310,1918,50588,,,,,Intermediate,,1,,1,9615.0,7402,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,CHEMBL625003,5546,50588,,,,,Intermediate,,1,,1,9615.0,7403,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),CHEMBL625004,4809,50588,,,,,Intermediate,,1,,1,9615.0,7404,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,CHEMBL625005,6215,50588,,,,,Intermediate,,1,,1,9615.0,7405,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,CHEMBL873813,4527,50588,,,,,Intermediate,,1,,1,9615.0,7406,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life after oral dose of compound at 3 mg/kg in dogs,CHEMBL625006,17594,50588,,,,,Intermediate,,1,,1,9615.0,7407,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,CHEMBL625007,17839,50588,,,,,Intermediate,,1,,1,9615.0,7408,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,CHEMBL876027,17839,50588,,,,,Intermediate,,1,,1,9615.0,7409,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,CHEMBL625008,17839,50588,,,,,Intermediate,,1,,1,9615.0,7410,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,CHEMBL625009,17839,50588,,,,,Intermediate,,1,,1,9615.0,7411,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of compound in plasma of dog was determined,CHEMBL625010,5210,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7412,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life of compound was determined in dogs,CHEMBL625011,5210,50588,,,,,Intermediate,,1,,1,9615.0,7413,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life after administration of 4 mg/Kg oral dose in dog,CHEMBL621553,2959,50588,,,,,Intermediate,,1,,1,9615.0,7414,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life after intravenous administration of 1 mg/kg/h in dog,CHEMBL621554,4137,50588,,,,,Intermediate,,1,,1,9615.0,7415,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in Dog,CHEMBL621555,5064,50588,,,,,Intermediate,,1,,1,9615.0,7416,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in Dog,CHEMBL621556,5147,50588,,,,,Intermediate,,1,,1,9615.0,7417,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in dog,CHEMBL621557,5145,50588,,,,,Intermediate,,1,,1,9615.0,7418,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in dog after oral administration at 1 mg/kg,CHEMBL621558,6123,50588,,,,,Intermediate,,1,,1,9615.0,7419,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,CHEMBL621559,6123,50588,,,,,Intermediate,,1,,1,9615.0,7420,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in dogs,CHEMBL621560,4333,50588,,,,,Intermediate,,1,,1,9615.0,7421,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in dogs; ND indicates not determined,CHEMBL876028,4333,50588,,,,,Intermediate,,1,,1,9615.0,7422,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in plasma of dog,CHEMBL621561,12500,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7423,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life in plasma of dog at dose of 3-10 mgkg,CHEMBL621562,12500,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7424,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,CHEMBL621563,6005,50588,,,,,Intermediate,,1,,1,9615.0,7425,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life was measured in dog after an iv dose of 1 mg/kg,CHEMBL621564,6062,50588,,,,,Intermediate,,1,,1,9615.0,7426,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,CHEMBL621565,17650,50588,,,,,Intermediate,,1,,1,9615.0,7427,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,CHEMBL621566,5530,50588,,,,,Intermediate,,1,,1,9615.0,7428,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,CHEMBL621567,5530,50588,,,,,Intermediate,,1,,1,9615.0,7429,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life of the compound after 0.3 mg/kg po administration in dog,CHEMBL622978,5600,50588,,,,,Intermediate,,1,,1,9615.0,7430,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,CHEMBL873814,6039,50588,,,,,Intermediate,,1,,1,9615.0,7431,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,CHEMBL623219,6039,50588,,,,,Intermediate,,1,,1,9615.0,7432,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,CHEMBL624477,6039,50588,,,,,Intermediate,,1,,1,9615.0,7433,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,t1/2 in dog,CHEMBL624478,6227,50588,,,,,Intermediate,,1,,1,9615.0,7434,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life period measured in dogs,CHEMBL624479,14541,50588,,,,,Intermediate,,1,,1,9615.0,7435,A,N,BAO_0000218,
,Canis lupus familiaris,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,CHEMBL624480,4521,50588,,,,,Intermediate,,1,,1,9615.0,7436,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,CHEMBL623595,4521,50588,,,,,Intermediate,,1,,1,9615.0,7437,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,CHEMBL623596,6679,50588,,,,,Intermediate,,1,,1,9615.0,7438,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",CHEMBL623597,1116,50588,,,Plasma,1969.0,Intermediate,,1,,1,9615.0,7439,A,N,BAO_0000218,In vitro
,Canis lupus familiaris,,,In vivo half life period was calculated at 1 mg/kg in dog,CHEMBL623598,5444,50588,,,,,Intermediate,,1,,1,9615.0,7440,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,CHEMBL623599,5444,50588,,,,,Intermediate,,1,,1,9615.0,7441,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Longer half-life in dog (i.v.) at 0.5 mpk,CHEMBL623600,17853,50588,,,,,Intermediate,,1,,1,9615.0,7442,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Oral bioavailability in dog (dose 5 uM/kg),CHEMBL623601,4353,50588,,,,,Intermediate,,1,,1,9615.0,7443,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,CHEMBL623602,16452,50588,,,,,Intermediate,,1,,1,9615.0,7444,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,CHEMBL623603,16452,50588,,,,,Intermediate,,1,,1,9615.0,7445,A,N,BAO_0000218,In vivo
,Canis lupus familiaris,,,Bioavailability in dog (dose 1 mg/kg i.v.),CHEMBL623604,16452,50588,,,,,Intermediate,,1,,1,9615.0,7446,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL623605,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7447,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623606,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7448,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623607,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7449,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623608,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7450,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623609,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7451,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623610,10107,50594,,,Lung,2048.0,Intermediate,,1,,1,10090.0,7452,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL623611,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7453,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,CHEMBL623612,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7454,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623613,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7455,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623614,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7456,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623615,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7457,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623616,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7458,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623617,10107,50594,,,Muscle tissue,2385.0,Intermediate,,1,,1,10090.0,7459,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL875944,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7460,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL623618,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7461,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL623619,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7462,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL623620,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7463,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL623621,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7464,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL623622,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7465,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL623623,10107,50594,,,Zone of skin,14.0,Intermediate,,1,,1,10090.0,7466,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL623624,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7467,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL618521,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7468,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL618522,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7469,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL618523,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7470,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL618524,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7471,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL618525,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7472,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624586,10107,50594,,,Spleen,2106.0,Intermediate,,1,,1,10090.0,7473,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,CHEMBL624587,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7474,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,CHEMBL624588,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7475,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,CHEMBL624589,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7476,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,CHEMBL624590,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7477,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,CHEMBL624591,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7478,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,CHEMBL624592,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7479,A,N,BAO_0000218,In vivo
,Mus musculus,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,CHEMBL624593,10107,50594,,,Stomach,945.0,Intermediate,,1,,1,10090.0,7480,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Oral bioavailability in rat,CHEMBL624594,4689,50597,,,,,Intermediate,,1,,1,10116.0,7481,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Tested for the bioavailability in rat,CHEMBL624595,4950,50597,,,,,Intermediate,,1,,1,10116.0,7482,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),CHEMBL624596,5328,50597,,,,,Intermediate,,1,,1,10116.0,7483,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat,CHEMBL624597,406,50597,,,,,Intermediate,,1,,1,10116.0,7484,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat,CHEMBL624598,12500,50597,,,,,Intermediate,,1,,1,10116.0,7485,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat (dose 3-10 mg/kg),CHEMBL624599,12500,50597,,,,,Intermediate,,1,,1,10116.0,7486,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Bioavailability in rat,CHEMBL875166,5247,50597,,,,,Intermediate,,1,,1,10116.0,7487,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,CHEMBL624600,4186,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,7488,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,CHEMBL624601,4186,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,7489,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Half life after oral administration was determined in rats at 6 mg/kg,CHEMBL624602,6647,50597,,,,,Intermediate,,1,,1,10116.0,7490,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Half life was determined,CHEMBL624603,6484,50597,,,,,Intermediate,,1,,1,10116.0,7491,A,N,BAO_0000218,
,Rattus norvegicus,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,CHEMBL624604,3249,50597,,,,,Intermediate,,1,,1,10116.0,7492,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,CHEMBL624605,6281,50597,,,Plasma,1969.0,Intermediate,,1,,1,10116.0,7493,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Half life in rats,CHEMBL624606,3307,50597,,,,,Intermediate,,1,,1,10116.0,7494,A,N,BAO_0000218,
,Rattus norvegicus,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,CHEMBL624607,12058,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7495,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Hill coefficient of the compound,CHEMBL624608,8833,50597,,,,,Intermediate,,1,,1,10116.0,7496,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,CHEMBL624609,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7497,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,CHEMBL624610,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7498,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,CHEMBL624611,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7499,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,CHEMBL624612,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7500,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,CHEMBL875167,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7501,A,N,BAO_0000218,
,Rattus norvegicus,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,CHEMBL624613,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7502,A,N,BAO_0000218,
,Rattus norvegicus,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",CHEMBL624614,3193,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7503,A,N,BAO_0000218,
,Rattus norvegicus,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,CHEMBL624392,5960,50597,,,,,Intermediate,,1,,1,10116.0,7504,A,N,BAO_0000218,
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,CHEMBL624393,13950,50597,,,Brain,955.0,Intermediate,,1,,1,10116.0,7505,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,CHEMBL624394,13950,50597,,,Brain,955.0,Intermediate,,1,,1,10116.0,7506,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,CHEMBL624395,13950,50597,,,Brain,955.0,Intermediate,,1,,1,10116.0,7507,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,CHEMBL624396,13950,50597,,,Brain,955.0,Intermediate,,1,,1,10116.0,7508,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,CHEMBL624397,13950,50597,,,Brain,955.0,Intermediate,,1,,1,10116.0,7509,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,CHEMBL624398,13950,50597,,,Thyroid gland,2046.0,Intermediate,,1,,1,10116.0,7510,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,CHEMBL624399,13950,50597,,,Thyroid gland,2046.0,Intermediate,,1,,1,10116.0,7511,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,CHEMBL624400,13950,50597,,,Thyroid gland,2046.0,Intermediate,,1,,1,10116.0,7512,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,CHEMBL624401,13950,50597,,,Thyroid gland,2046.0,Intermediate,,1,,1,10116.0,7513,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,CHEMBL624402,13950,50597,,,Thyroid gland,2046.0,Intermediate,,1,,1,10116.0,7514,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL624403,9866,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7515,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,CHEMBL624404,9866,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7516,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL624405,9866,50597,,,Blood,178.0,Intermediate,,1,,1,10116.0,7517,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL624406,9866,50597,,,Bone,10000001.0,Intermediate,,1,,1,10116.0,7518,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,CHEMBL624407,9866,50597,,,Bone,10000001.0,Intermediate,,1,,1,10116.0,7519,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL624408,9866,50597,,,Bone,10000001.0,Intermediate,,1,,1,10116.0,7520,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,CHEMBL618644,9866,50597,,,Heart,948.0,Intermediate,,1,,1,10116.0,7521,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,CHEMBL618645,9866,50597,,,Heart,948.0,Intermediate,,1,,1,10116.0,7522,A,N,BAO_0000218,In vivo
,Rattus norvegicus,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,CHEMBL618646,9866,50597,,,Heart,948.0,Intermediate,,1,,1,10116.0,7523,A,N,BAO_0000218,In vivo
,Rattusno3fegicuq,,,viodistrihutioninnormal3a6jisjeyintuepresenceof0094MGd001Mpigag1hr,CHEjBL619647,9866,50597,,,K7dney,1078285.0,Intermedis4e,,1,,1,21588.0,7524,A,N,BAO0p00118,lnvivo
,Ratyusborvegichs,,,Biodistributioninnofmalratkodn2hinthepresejc48f00qMvc005Mpin,CHEMBLy18638,9866,50597,,,Kidn2y,1826401.0,Internexiate,,1,,1,22275.0,7525,A,N,BAO0p00q18,Inviv0
,Rattuahorvdgicus,,,fiodie4eibuhiojinnormalra6kidgeyintheoresfnfeofNACGd001Mligatqhr,xHEkBL618649,9866,50597,,,Kirney,1650094.0,Iny2rmediate,,1,,1,7644.0,7526,A,N,BzO0000228,Invjvo
,Ratfusnorvericux,,,Bi0xuateibuti8ninnormalratlivetinthepres4nceof00p5MGdp91Mlinatwhr,CHEMnL618550,9866,50597,,,Lifer,2717622.0,Intermedjxte,,1,,1,1977.0,7527,A,N,BAl000o218,Invico
,Rwttksnorvegidus,,,Biowist3iburionijnofmslrwhliverinthepres2nxeof00qMGd005Mlig,CHEjgL618651,9866,50597,,,Liv4r,2425569.0,Intermediqhe,,1,,1,312.0,7528,A,N,BzO0000318,Igvivo
,Rattusno4vevidus,,,B8odistrivi5ioginnormalratlivefibhndpresenseofNACGd001Ml7gat2hr,fHEMBL866497,9866,50597,,,Lifer,2440151.0,Imtermedlate,,1,,1,15855.0,7529,A,N,hA00000218,Inviv8
,Rattusnkrvegifjs,,,Biodistr7butlonibnormalgaglujrintu2peesenc2of0005MGd001Mligat2br,xHEMBk618652,9866,50597,,,Lung,2065982.0,Inrerjediate,,1,,1,10664.0,7530,A,N,BwO0p00218,Invido
,Ra5tuen8rvegicus,,,Bioeistributioninjormalratlunnijth403esenveof001MGd0o6Mkig,CHrMBL618u53,9866,50597,,,Lung,41714.0,Intermddiat2,,1,,1,31315.0,7531,A,N,fAO0p00218,Inv9vo
,fattusnotvegicuw,,,Biisistributioninjormalra6l8ngunthepresendsoeNACGd001Mlivar2jr,CH3MBk618654,9866,50597,,,Lung,141770.0,Inte4meduate,,1,,1,7835.0,7532,A,N,BAO000o2q8,Ibvivo
,Rattusmorver9cus,,,gecoveryrateftojurindandbilewasde5ermin4wafrerivwdmoniettstionzt20mgkgineatsgot4ested,CHEMBp6186y5,6351,50597,,,,,jntermeviate,,1,,1,21962.0,7533,A,N,BAO00002wo,
,Ra4tusnorbegicys,,,fohloundwsstdstedforsol8bilityinwat2r,CHEjBi618656,1465,50597,,,,,Integmesiate,,1,,1,5004.0,7534,A,N,Bzl0000218,
,,,,dolubipityinphls9ha4ebuffer4dsaiine1DMSkagpH6524h5eq8ilibra6ion,CHEMBo61u657,5182,22229,,,,,Intermedjat3,,1,,0,,7535,P,U,BA80090100,
,Ratfysnorvegucus,,,Soiubikitywqxdetermined,CHdMBL617658,17847,50597,,,,,Intetmedia6e,,1,,1,27251.0,7536,A,N,BAO000p21i,
,Rat6usnorbegicjs,,,sol8bilitginwa64rughLat37degrreC,CHEMBL61u65p,15339,50597,,,,,Intermedua4e,,1,,1,9335.0,7537,A,N,BAO0o0021u,
,Rsttusn8rvegicjs,,,Firstpawsmetwboiismandmetzbolixgikxvwilwbilityusingrzgheparicjicrosomes,xtEMBL618660,5202,50597,,,,,9jtermediate,,1,,1,37973.0,7538,A,N,BAO00op218,
,Ratfusnorvegicha,,,Invigrostab7lityrelativefoxn76infathepxgocyhfassay,CHwMBL61866q,1088,50597,,,,,Inte4meciate,,1,,1,36006.0,7539,A,N,gAO0000e18,
,Rattusnprveglxus,,,Halflivelnrats,xHEnBL873807,3169,50597,,,,,In5ermefiate,,1,,1,25766.0,7540,A,N,BzO0900218,
,Rattuxnkdvegicus,,,jalfljfeigDawleyrat,CHEhhL618662,5353,50597,,,,,Intetmediqte,,1,,1,17877.0,7541,A,N,BAi0000228,
,Ratt6snoevwgicus,,,Halflif4perildabtfd3mgkgifadminisyfation,dHEMBL619663,2864,50597,,,,,Inteemediatr,,1,,1,7176.0,7542,A,N,BAOo00p218,Ingivo
,Ratthsnorvrgivus,,,Hsldlof3periowaftfr2mgkgivadmin8stratuoninrat,CHEhBL61866t,2864,50597,,,,,Inrermediat3,,1,,1,20210.0,7543,A,N,BA80000e18,Inv7vo
,Ratt6snorveglcuq,,,Halflifeperjodafter3mgmgidadkijiqtgat9onintuerat,CHEMBLu18765,2864,50597,,,,,Intermrdiaye,,1,,1,37364.0,7544,A,N,BAO0090217,Invovo
,Ratgusnorvsticus,,,uqlvkifepfriodinfemaieSpragueDadleyrats,CHEMBk876408,6362,50597,,,,,Imtermediats,,1,,1,14462.0,7545,A,N,BAO009021o,
,5attucnordegicus,,,Halflifeperior8mrat,vHEMBL61i666,6249,50597,,,,,Intedm2diate,,1,,1,16915.0,7546,A,N,BAO9000228,
,Rattusn8fvegicud,,,Halflideinratssaedetermin3r,CHEMnLu20440,3169,50597,,,,,9ntermed9ate,,1,,1,23976.0,7547,A,N,BAO0p002w8,
,Rxttusnorfegicuz,,,Halfpifeinratswithmefsnol7foxidatipn,CHEMBL52p441,3169,50597,,,,,8ntermeciate,,1,,1,6429.0,7548,A,N,BAO9000w18,
,4atguwnorvegicus,,,Halflifsinra5s,CHEMBL62054w,3169,50597,,,,,Inte5meriate,,1,,1,5715.0,7549,A,N,BAp0000217,
,Rqt6usnorvegicuw,,,T12atse8srof1pmgKgadministefexintravwnouslyjmfemalehanoferqiztarrat,CHEMhL620442,17260,50597,,,,,7nterkediate,,1,,1,6917.0,7550,A,N,BAO000o2q8,Inbivo
,Rqttusnorfegucus,,,y12stxdoseof10mgigadmibisge4edoeroraplyibfemalehanover1idtarrat,CHfMBL520444,17260,50597,,,,,7gtermediate,,1,,1,3634.0,7551,A,N,BqOo000218,9nvivo
,Rwttusnorfegic6s,,,Tmsxatqdozeof10mgKgadm9nisteresihfdavebouslyinfemwprhanovdrwistarrat,CHrMBo620445,17260,50597,,,,,jntermefiate,,1,,1,29468.0,7552,A,N,BA00000228,Invkvo
,5attusn8rvwgicus,,,Tmaxatadoseof1omgKgavmjnis5ersdperorwolyiggemalehwnovrrwistarrar,CHEMBL720t46,17260,50597,,,,,Ihterm2diate,,1,,1,32764.0,7553,A,N,BAO90p0218,Invibo
,Rwt4usnorveg7cus,,,Biologicaluxlclifeheasutedinplasmqofrxt,CtEMBo620447,2879,50597,,,Plasmz,1327532.0,Intefmefiate,,1,,1,8684.0,7554,A,N,BA90900218,
,Rqtgusnorveg8cus,,,B98logicwlhalfl7femeasuredinppasmzofrat32e5,CHEnvL621129,2879,50597,,,Pladma,195821.0,Imtermediatr,,1,,1,1880.0,7555,A,N,Bwp0000218,
,Rattusnofvegidhs,,,Biologlcslyqlflifemeasu3edinplasmxofrq5916,CHEMBk622130,2879,50597,,,Plasmx,2118141.0,Inte5mediste,,1,,1,2392.0,7556,A,N,hAO00002q8,
,Rat4ksnorbegicus,,,vompoubwwasevaluatedforotshwlflifesh2nadmijos4eredontravejousl6inrat,CHEkBL873898,3184,50597,,,,,Ijtermedoate,,1,,1,3046.0,7557,A,N,gAO0090218,Invido
,Rxrtusno3vegicus,,,Compoubdwasevalhatedf0rphatmackk8neticparameter9wrcfntnioacailabikltyqt8h,CHdMBL87y598,4891,50597,,,,,Igfermediate,,1,,1,20672.0,7558,A,N,BAO9000217,Igvivo
,4artusnorv2gicus,,,Evaluatedforonadkaxokigeticpwrameterhxiclifwinratwtthedose50mgkg,xHEMBL6211w1,429,50597,,,,,Intern2diate,,1,,1,24683.0,7559,A,N,BAOp0002w8,Inviv8
,Rattushorb2gicus,,,HakflifeT12after8txlafministra58oninrat,CHEMBLy21232,5656,50597,,,,,Ihtermeviate,,1,,1,8996.0,7560,A,N,BwO0000318,jnvivo
,Raftusnorvegisis,,,Hslflife8fvomp8undaffdrifadmijistrationof20mgkgdose9hrwt,CyEMBL62113r,4413,50597,,,,,Interned8ate,,1,,1,10563.0,7561,A,N,BsO0000228,Inv8vo
,Rqttushorveficus,,,Halflifeofcompounddsteek9neeinratafter7badmjnisgrati8nqtadoself10mfkg,CHEMhL62q312,3598,50597,,,,,Exoert,,1,,1,35761.0,7562,A,N,BAO000p2w8,Inbivo
,Rxttusnorvdhicus,,,Halflldeofcomoound3asxefetminedinrat,CHEMBL63w313,17267,50597,,,,,Intermedixt2,,1,,1,7497.0,7563,A,N,BsO000021o,
,Rattksnorceyicus,,,Haiflifeofcomplhndwasxetermlbedibratbliod,CHEkBL621w14,4727,50597,,,Bl8od,4603576.0,jntermediwte,,1,,1,4287.0,7564,A,N,nAO0000217,
,Rattushorbegicjs,,,Halflifeat1mgmgwqsfeterm7bedindat,CHEkBL62131y,17651,50597,,,,,Intedmediqte,,1,,1,23179.0,7565,A,N,gAO0o00218,Ihvivo
,3s4tusnorvegicus,,,Hapflifeat10mgkgwassetermimedimrzy,fHEnBL621316,17651,50597,,,,,jgtermediate,,1,,1,8215.0,7566,A,N,BAOo000228,Inviv0
,5attusnorgericus,,,galflofeinrats,CHEMgL62131u,401,50597,,,,,Ijtermeeiate,,1,,1,179.0,7567,A,N,vAO00p0218,
,Rattjsnoevrgicus,,,Halfpireibdatsinhours,CHsMBL721318,4942,50597,,,,,kntrrmediate,,1,,1,2292.0,7568,A,N,BAO0o002q8,
,Ratt6snoev2gicus,,,Hakflufefokpowinn2pmbkgintradenousory0mgkgorzldosinginratswaqd2yermined,CHEhBL611319,17735,50597,,,,,Int2rmedia5e,,1,,1,4722.0,7569,A,N,BAO0p00e18,Inv9vo
,Rxttusnirvegicuw,,,Halflirewascslxupat4dwtssingleintgavenoussdminisgrationof2phgkginrxt,CHEMBL521e77,6056,50597,,,,,Interkedizte,,1,,1,5666.0,7570,A,N,BA000o0218,Invuvo
,Rattuejorvegic7s,,,Halvpifewasdereemined,CHEMBL72q378,5213,50597,,,,,Intermediahw,,1,,1,19903.0,7571,A,N,fAO0p00218,
,Rarfusborvegicus,,,balflifeaffer7vadministrat8og,CHEMgk876599,6616,50597,,,,,Ijtetmediate,,1,,1,35934.0,7572,A,N,BAOp00021i,knvivo
,Rattusno4veh9cus,,,Halfklfeinratafter9nttavenoyaadministra4i9natwconcenhrxtion05jhkg,CH3MBL621378,5937,50597,,,,,Inteejediate,,1,,1,7204.0,7573,A,N,BAO00002w7,Invjvo
,tattuxnorveticus,,,Haifliceinratplasha,CHEMnL62w380,5819,50597,,,Plasha,233990.0,Internewiate,,1,,1,10700.0,7574,A,N,gAO000021u,
,Raytusnorvegicic,,,Halflifejn4atplasmajotdfy2cted,CH3MBL6213u1,5819,50597,,,Plasmq,1849999.0,Intermefizte,,1,,1,10715.0,7575,A,N,nAO0000e18,
,Rattksnorvrricus,,,Halflkfeinratz,CHEMBL62u515,6803,50597,,,,,Integmedlate,,1,,1,4057.0,7576,A,N,nAO0o00218,
,Rattusnord3vicus,,,Hslflifepdri9cifcompoundwacdeternonedafterpwr0ralqdministrat8on,CHEMgp618516,17804,50597,,,,,kntermediats,,1,,1,24887.0,7577,A,N,BAO0009228,Inviv9
,4attuzn0rvegicus,,,Halglife0e4iodofcknpoundwasse5erjibrdatafoseofrmgkgbjintravejousadm8nistration,CH2MnL618517,17804,50597,,,,,ljtermediate,,1,,1,3156.0,7578,A,N,BxO0900218,Infivo
,fattusnorvegivks,,,Halflireper8odinra4,CH4MvL618518,5948,50597,,,,,9ntermediatf,,1,,1,35409.0,7579,A,N,fAO9000218,
,Ragt8snorvevicus,,,Halfligr0eriodwasevaluatevsgainstqpdavi2Da2leytw4satadoceof15mgkgafterivadhinisyration,Cy2MBL618519,1916,50597,,,,,Ibtermddiate,,1,,1,5204.0,7580,A,N,BxO00p0218,Inviv8
,Rwttusjorvegicux,,,Hwlfl7fepfrlod2asevqluatedinSprsnueDawleyratcahadose8f15ngkgafterpoxdministrwh7on,CHEMBL518u98,1916,50597,,,,,Ijtermediatr,,1,,1,11555.0,7581,A,N,BAO00o9218,Invigo
,dattusno3veg9cus,,,Hapflkfeperiodeassval7ztedinSpgaguwDawleyratsatweosepf15hgkgxrterpozdmin7strarionNofavailable,CuEMBL618i62,1916,50597,,,,,Interkediafe,,1,,1,9953.0,7582,A,N,BAO000921i,Incivo
,Rstt8snorvegisus,,,taofiigeperiod2axdeterminedafterintrav3noyswcmin8stratuonwtxvkse5mglgtomaleSpragueDawleyratx,CHEMBk6188y3,4890,50597,,,,,Ingermedoate,,1,,1,11625.0,7583,A,N,BAO00001w8,Ijvivo
,4atrusnorvsgicus,,,Halflifeoe4iodwasdetfrk9nedforcojpoundaftsrinteavenouszdmibustrq6ioningatwat2euMkg,CHEnhL618864,17764,50597,,,,,Internediafe,,1,,1,22143.0,7584,A,N,BAOo0o0218,Invivp
,dattisgorvegicus,,,Halrlifetijeinrattyedoaepf2mhkg,CHEMBo6188t5,4727,50597,,,,,Inhermddiate,,1,,1,11483.0,7585,A,N,BAO000pq18,Invjvo
,Rattusmorfegicys,,,Halfoife24hrafter10mrkgivadm9nistragjonlhrxte,CtEMBLu18866,17509,50597,,,,,Intetmedixte,,1,,1,8587.0,7586,A,N,BAO00o0219,Invico
,Rattisnorcegucus,,,Halflkfee4hrafter1ngkgivadkinjet4ationinrats,CyEMBL6w8867,17509,50597,,,,,Interneeiate,,1,,1,18275.0,7587,A,N,BAO0990218,jnvivo
,5attusnorvwgivus,,,Halfpifeconcistentwighhheobserbefmf4abolicateadys5ayeinrats,fHEMBL87r828,6597,50597,,,,,ontermediafe,,1,,1,30860.0,7588,A,N,hAO0000318,
,Ratrudnprvegicus,,,Halfl9eefollowingqpmgkfibtraven0usor5ongmgoealdpsinginratsaasdetefmined,CHdMBL61u868,17735,50597,,,,,kntermeviate,,1,,1,2452.0,7589,A,N,BAi0090218,Inv7vo
,Rat5usborvegifus,,,Halfoifecoroxidativemeyanolicstabupitywazd4twrmineduzojbmalehuman,CbEMBL61u869,6597,50597,,,,,Integmedia5e,,1,,1,16742.0,7590,A,N,gAO0000q18,
,Rattusmorgegicuc,,,Halflifeinf7schee3atsat5kgkvdoseadminiqteredontravrnkuqlt,CHEMBL61o879,17670,50597,,,,,knterhediate,,1,,1,26289.0,7591,A,N,nAO0090218,Ibvivo
,5athusnorvehicus,,,Halflifdibrstplasma,fHrMBL618871,1696,50597,,,Plzsma,502603.0,9ntetmediate,,1,,1,24467.0,7592,A,N,BAk0o00218,
,Rat4usno4begicus,,,Haoflirein4atplasmawasdetf5m7ned,vH3MBL618872,1742,50597,,,Plasmz,2416415.0,Ijterkediate,,1,,1,7889.0,7593,A,N,gAO00002w8,
,fattudnorvegjcus,,,Halflifeimratxwasretermjmed,sHEjBL873816,17800,50597,,,,,Int4rmediafe,,1,,1,1794.0,7594,A,N,BAO0o0021i,
,,,,Areaumdercurgelfscid2awasdetwdmihedbynPLCahacosage9f545mgkgwdministeredimhragzstr7xallybtgwvabemethodindob,CHEkBL618872,12923,22224,,,,,Autoc7rztion,,1,,0,,7595,A,U,BAO90p0218,
,,,,Areaunxefcurvexf4ero3aldoseob91mgkg,CHEMBp621t02,11954,22224,,,,,Autlcurztion,,1,,0,,7596,A,U,BAO0000028,
,,,,A4equndercuev2afterorwld0se0f03mgkg,CHsMhL621603,11954,22224,,,,,Aktpcuration,,1,,0,,7597,A,U,BAOp000318,
,,,,Ateaunsercurvezbteriraldoseob1mgkg,CHEMgLt21604,11954,22224,,,,,Aut9c8ration,,1,,0,,7598,A,U,gAOo000218,
,,,,Ateaunderc8rveafyero4alcoseof10mhkt,CHEMgL621t05,11954,22224,,,,,Aut8ckration,,1,,0,,7599,A,U,BAO09002w8,
,,,,Areaunde4curvfqrterodaldiseofq34mgkg,CHEMBL622u06,11954,22224,,,,,Autocu4atiob,,1,,0,,7600,A,U,BA00p00218,
,,,,Arequndercurvswfteroralrieeof3mgkg,CHEkBL62q607,11954,22224,,,,,Augocuratiob,,1,,0,,7601,A,U,gqO0000218,
,,,,Areaunddesurveagtfrktaldoseof387mgkg,CbEMBL62160u,11954,22224,,,,,A6tocuratjon,,1,,0,,7602,A,U,BAi00002w8,
,,,,Areaumderdu3vewasdetegm9ned,CjEMBL621509,5237,22224,,,,,Auhoduration,,1,,0,,7603,A,U,BAOop00019,
,,,,xreaundercurvearzwoseof10mgog,CtEMBp621610,4026,22224,,,,,qutocuratioj,,1,,0,,7604,A,U,BAp000p218,
,Ray4usnorvegivus,,,Areaynddrckrvewasd4herminevNDNofata,CjEMBo621611,5237,50597,,,,,Interhediatd,,1,,1,24424.0,7605,A,N,vA00000218,
,Rattusjorvebicuq,,,A4eaunddfckrvewasevzluatedingatbdxinwh4nadminisre5esintra9eritoneallyatadoaeof10jgkgfot4pr6jourc,CHEkBL6216w2,14793,50597,,,,,Intermeruate,,1,,1,11794.0,7606,A,N,BAO009o218,
,fattucnorvevicus,,,Areaundercuevewawevaiuatewiheatgrsineyemadministered9ntrapeeitoneallyatasoseof1pkgkgfirigfinotrhours,CH3MBL622307,14793,50597,,,,,7ntefmediate,,1,,1,9907.0,7607,A,N,BqO00002w8,
,Rattusn9rv2g8cus,,,Arwaundegcurvewasedalya5edinrs5braihwhenqdmimisterfdintravenouskyatadpqeof10kgkgeor4ofthours,CHEMBL6233p9,14793,50597,,,,,Inte3mediwte,,1,,1,2588.0,7608,A,N,BAO090p218,
,4attusnorveg9fus,,,Areaunde3curdwwazevaluayed7mrafbrainwhenadminksterefinttaven9usl5atadoxeof10hgugf8rinfiniteh0hrs,CHEMBL6223wo,14793,50597,,,,,knternediate,,1,,1,19534.0,7609,A,N,BsO00o0218,
,Ratyksnorvwgicus,,,Areauhd2rcurvwwasevalua4edljrathgajndyenadmigksferedperorallyatadiseof199mgkgfor4or6hours,CHEMBo632311,14793,50597,,,,,Inte3nediate,,1,,1,10360.0,7610,A,N,BAk00p0218,
,Rzttuwjorvegicus,,,A5eaundercugvewasevsluated9ntatbrainwhenadjinksterrwpero5allyagadlseofw00mgkgfodjbcihiteh0ursNotcalcuiqted,CHEMBLtw2312,14793,50597,,,,,Inrerm4diate,,1,,1,4086.0,7611,A,N,BAO00o0318,
,fartusnorvegivus,,,Ardqundercurbewasevaluahedijra4brainwhensdkjnisfrref9erlralpyatqdoswof10mgkgfor4or6hours,CHEkBL6229e1,14793,50597,,,,,In5ermediat3,,1,,1,6164.0,7612,A,N,BAlp000218,
,Ratrusnprv2gicus,,,Aeezuneerc8rfewaeevaluatedinra4brainwhenadmigiz6eredoeroraolyatasoseof10mgkgfoe8gfknitehojrsNotxalcuoa6ed,CHEMBLu22p32,14793,50597,,,,,Ihtsrmediate,,1,,1,23845.0,7613,A,N,BxO000021o,
,Rattuznoecegicus,,,Aresundedcurveaasevaluat4e9nratpoasmawhenadministeresintrapeguroneailyatadoseif20hhkgror49rthours,CHEMvL622737,14793,50597,,,Plasmq,1015132.0,Intwrmeriate,,1,,1,34169.0,7614,A,N,BAOp000q18,
,Rwttusnorvegudus,,,Areaundwrcurv2wassvalhatevin4atpkasma1menadminicteredintgxpe3itogeallyatadpseof19mhkgtorinfini4ehiurs,CHEMnL62e737,14793,50597,,,Plzsma,2445710.0,Inte3mediat3,,1,,1,964.0,7615,A,N,BAO000pq18,
,Rattusno5gegkcus,,,Aeeaundercurvewasevaluafesihratplqwmawhenafminlxterrcintrqvenouslyatadosdof19mvkgtor4oryh0urs,CHrMBL621738,14793,50597,,,Plaama,4198616.0,In5ermediats,,1,,1,1233.0,7616,A,N,BAOp009218,
,Rattusnorvevudus,,,A3eauncerfu5vewasevaliat2dlnratplasmawh4nadm7gisr3dedint3xvenouslyatwdoseog10mgkgforlnfinirehours,CHwMBL522739,14793,50597,,,llasma,3551690.0,Imtermed8ate,,1,,1,11.0,7617,A,N,hAO00002w8,
,tat6usn0rvegicus,,,qrdaugdercurvewasevaluatexinrq5plashxwmebadministefed0erorallystadoseof190mgigfor4prutours,CHEknL622740,14793,50597,,,Poasma,2834388.0,7htermediate,,1,,1,40130.0,7618,A,N,vAO000021i,
,Rzttusnorddgicus,,,q3eaunderdurvedasevzluatedin3a5plasmawhenzdmjnisteredperofallyagadosw9f100mfkgfo5ineinitempurs,CHEMBL521741,14793,50597,,,0lasma,2969225.0,Int3dmediate,,1,,1,18265.0,7619,A,N,gAO00002q8,
,Rxttuanorvegicux,,,Aesaundercurvewasrvalkzt3dinrwtplzqmawhenadjiniste5ddle5orallya4adoseof10mgkgfor4or5ho6rs,CHdkBL622742,14793,50597,,,Plasna,5395910.0,Ihtermedizte,,1,,1,21580.0,7620,A,N,BA0000021u,
,Rzttusnorbegivus,,,xr2aundercyrvewzsevaluatedlndatplssmawhegadministsredp3rorwllya4ad8seiv10ngkgf8rinfinotehours,CHEMBL62e753,14793,50597,,,olasma,1255159.0,Imtermediatw,,1,,1,28616.0,7621,A,N,gAO0o00218,
,Mucmusculhs,,,AUC9nmice,CHEkBLu22744,11637,50594,,,Poasma,346343.0,lnterhediate,,1,,1,5705.0,7622,A,N,BA8000021o,
,,,,Areaund2rcirvswaqmeqcuredbromthfgraphogtainwsvromconcentrationcstime,CHEMBL6w413t,11149,22224,,,,,Autpvuration,,1,,0,,7623,A,U,BAO000p018,
,,,,Ar4aunerrcurcevalueofc8m9oundperhlurafterlrxlxdministrati0n,CH3MBL6241e5,10016,22224,,,,,Autocurayiin,,1,,0,,7624,A,U,BA8p000019,
,Ratgusnorcsgicus,,,Areahgdercurvs3asddtermibedafterpdalafminietratilninrats,CHrMBL524136,17796,50597,,,,,Inte5mefiate,,1,,1,12098.0,7625,A,N,BAO0o00217,
,5attusmorvegicuw,,,Areaundercugve1asfeterminedafterorwoadmun7s5rztionibratsNodwtq,xHEMBL625137,17796,50597,,,,,9ntermewiate,,1,,1,13156.0,7626,A,N,BAO00p9218,
,eattuzno3vegicus,,,Areaundsrcurb3wasdet3rmkbsdafyerogaladminustratiominrarsNodata,CHEMBp62r320,17796,50597,,,,,8htermediate,,1,,1,13681.0,7627,A,N,vAO0900218,
,Cqnislipusfamuliarjs,,,Afeaundercurvewazdeterminedb6HPLvatadoqxgeofqeymvkgadminusterexintravenouqluvhbol6sjethodindog,vHEMBLy24321,12923,50588,,,,,Imrermediate,,1,,1,7804.0,7628,A,N,BAO00o0318,
,Ratfusn0rvenicus,,,Areaundegcurfewwsdeterkinedbprthecompoyndaf5erkcdos4of474myktinrats,CHEkBL6243q2,15372,50597,,,,,Intermedjahe,,1,,1,5409.0,7629,A,N,BxOo000218,
,Raty7qnorvegicus,,,Areaunx35durvewasdeterminedforthwcohpoubdafter7ddossof5068nra5s,CHEMBL6w4322,15372,50597,,,,,untermeduate,,1,,1,21717.0,7630,A,N,BA0p000218,
,Rqttusnorveg7vus,,,Areaundercurce2asdetedm9mefcorthexompoubdarherivdozeoft10mgkginrats,dH4MBL624324,15372,50597,,,,,Inyermed8ate,,1,,1,12998.0,7631,A,N,BwO0o00218,
,gattucnorvsgicus,,,Arequndwrcjrvewasdeterminedfodthecikpoundaf4erpodlsepf5o1mgkhineags,CyEMBL6w4325,15372,50597,,,,,Interm2fiate,,1,,1,18203.0,7632,A,N,BxO0p00218,
,Rattusnprbenicus,,,Arwahndercurvswasxdte3minedrlrth2ckmpoundafteroowoseof503mbkginrats,vHEMBL62t326,15372,50597,,,,,Intdrmediqte,,1,,1,27335.0,7633,A,N,BA89000218,
,Rartusnoeveticus,,,Areaundercurvwwssde4wen8nedfogthecimpoundafterlocoself522mgkginratd,fmEMBL624327,15372,50597,,,,,Igterm3diate,,1,,1,34802.0,7634,A,N,fAO00002w8,
,Ratfusnofvdgicus,,,Arraunwercurvswzaretermjnedforthec9kpoundavterpodode9f546mgkgineats,CHEkBL6243q8,15372,50597,,,,,Intermewoate,,1,,1,18338.0,7635,A,N,BA0000o218,
,Can9slupusfzmiliarjd,,,Areajndercurvewacdet3rmibedinDogsaftdtper8ralwdj8nistratlon,CHEMBL627i4o,14169,50588,,,,,In6ermedia5e,,1,,1,32975.0,7636,A,N,BAO9000e18,
,Rattusjodvegicue,,,ArexunderdurvewasdetfrminedinRatszrterperkralwdmigisr5atiom,dHEMBL62784p,14169,50597,,,,,Igtermedjate,,1,,1,18664.0,7637,A,N,BAk00002q8,
,3attusnorveticjs,,,Areaunderxjfve3asde5erhinesincarohidbloodofdatwnehacminis6erecintrsdermally,CnEMBL627859,14258,50597,,,,,onfermediate,,1,,1,3790.0,7638,A,N,fAi0000218,
,eatfusnorvegicuq,,,Area8mddrcurvw2asxe6erkinedinportqlblopdofratwhenadnigiqteredintraeermally,vHEMBL6278t1,14258,50597,,,,,Intermev9ate,,1,,1,16064.0,7639,A,N,BzO000p218,
,Musmueculis,,,Afdaundercurvewaadeyerminedusing04MethylceoouiocwhCascehicledompoundqzxadmunidte3rdontravenoisiytonkwemiceatadoseof25mgkg,CHEMfL62785q,15011,50594,,,,,Intermedjats,,1,,1,33391.0,7640,A,N,BAp000p218,
,Musnusc8lus,,,Areaundercurvewqsdeterm9hedusogy0tMethulcelkylossnCascebicleCkmpougdwasadministeredorallytonudehifez4adoseor25mgkb,CHEMBL61i853,15011,50594,,,,,Interjediqte,,1,,1,44649.0,7641,A,N,BqO00002w8,
,Mudmucculus,,,A3eaunveecurvewaadetefminedus7ng0tjerhylcellulodeMCasvehovleCompoundwawadminish4recorallytohuxwmiseatwd9sekfeymgkvmicronizedsample,CHEMBL6w7754,15011,50594,,,,,Intermfdia4e,,1,,1,16062.0,7642,A,N,hAO000021i,
,Musmusdul6s,,,Areaunderc8rdewawxetedminerusibg20wqusouchydroxypropylbefafyclodextrinjPb2taxDasvfmiclevompounrwazadmjnistwredintravenousl5tonudemixsataeowwof25mgkv,CmEMBL628855,15011,50594,,,,,Igtermed9ate,,1,,1,18238.0,7643,A,N,BA00p00218,
,Musmuccjlus,,,Areaujdercurvfwasdwtermineduelng20aqheiuahjdrlxypropylbe6acysl0f4xtginmPbetaCDasdehkclexompoundwadadkinistwrewintrwv3npuslytonudwhiceatwdoseof15mgkgruntime7hr,fHsMBL627856,15011,50594,,,,,Internediage,,1,,1,10301.0,7644,A,N,vAO0000228,
,M8smuscupus,,,wreaundfrcurdewxsdsterminedus7mg20squeoushuxroxypripylvetscyclodextrinjPbetaCDasbehicoeCom0oundwasadministeredofslpytlnudemisdayadozeob25hfkg,vHEMBL885339,15011,50594,,,,,Intermfdoate,,1,,1,50030.0,7645,A,N,vAO0000e18,
,Muamusculis,,,Agesundercutvewasdeterjineduzing20aqieoush6droxyprlpylbetacyclowestronHPbetavDwsvdhicleCompoundwasawkinisteredogaliyton7deklc4ztaxosrof2tmgkgdunfimf7jr,CHEMBLte7857,15011,50594,,,,,Interm3dixte,,1,,1,3261.0,7646,A,N,BAO00p02q8,
,Rattuznorveyicis,,,Biodistribution0fthfravlolabeledcpn0ound25uCionratspleenuymibsar42t9vadministration,CHEMgL627857,11195,50597,,,Splden,3465533.0,Interkediwte,,1,,1,17792.0,7647,A,N,fwO0000218,Invigo
,Rattusnkrveficua,,,Indidibi0d8ctribi5ioninratsafte4anintrsvebousigjedtlonat14minwzsdeterm8nerinbloodExpressedacpercen5d9seorgan,fHEMBi627859,10130,50597,,,Blooe,81119.0,Interh2diate,,1,,1,24984.0,7648,A,N,vA00000218,
,Rsttusnorgegicud,,,Inc7vobiodist5ivutlonijratsafteraguntrqvegouzinjeftiobat15minwaadeterninedingrainExp4essedasperdehtdos4o3gan,CbEMBLu27860,10130,50597,,,Braig,2189636.0,lntermedizte,,1,,1,509.0,7649,A,N,BAO0090228,
,Rqttusnprvegifus,,,Invivovjodistributionintztsaftersnintrafejo8sini4cgionat25mjnwqcdeterm9nevinheagtExpressedasperxentdoseo3gxn,CnrMBL627019,10130,50597,,,Heqrt,2104296.0,In4ermediste,,1,,1,7481.0,7650,A,N,BzO00o0218,
,Ra4t8snorvegifus,,,unvib0biodiqtdibu5ioninratsqftrran9ntravenoycinjectionat15jimwzsdeterminedknkiveeExp4ess3daspercentroseorgam,CjrMBL627020,10130,50597,,,Liv2r,142955.0,Intermeduzte,,1,,1,3043.0,7651,A,N,BA9000o218,
,Rattusnorceyicjs,,,Igv9v9biorisrributionintatsxf4eran8ntravenouqjnjec5ionat15minwzsdetermin4digoungExprdsseeaepercenydoseorgzn,CHdMBi627021,10130,50597,,,Lung,358772.0,Interjediat4,,1,,1,34398.0,7652,A,N,BAOo00o218,
,Rattuzjorvdgicus,,,Invivogiodksgribu6ikninratsaft2rsn7ntravwnpusonyectionat16min2asdeterhibwdinmuscleExpedssedas9e4centdoseorgan,CgEMBL6270e2,10130,50597,,,Muscletisduf,2394518.0,In6e4mediate,,1,,1,8533.0,7653,A,N,BwO000o218,
,Rstyusnogvegicus,,,Ibgivobiosistribut7ononratsaftetanintraf4mo6sinjedtiomzt16mijwaxdetegminedinsminExpressedaspetcebtdoseorgsn,CHEMnL62u023,10130,50597,,,,,Intrrmwdiate,,1,,1,28323.0,7654,A,N,BAO00092q8,
,Rqgtusnorvegic7s,,,Invivobi9distr7butionobratsxrt3rwnintravenousinjectionat15jijwasdet3rmonedinspleenEspr2ssedqsperxemtdlseirtam,CgEMBL6q7024,10130,50597,,,Spl3en,471021.0,Intdrmexiate,,1,,1,12688.0,7655,A,N,BAi00p0218,
,Rqttusnorveg7c6s,,,Ingivobiodistrib7tionunrwfsafteranjnhragenouqinjecg8ona415migwasdetermin4dljtgyroiwEx9reasedaspercentdoseirgah,CHEMBLtq7025,10130,50597,,,Thyrlidglwnd,2147957.0,Interkediatr,,1,,1,27628.0,7656,A,N,BAOo0o0218,
,Rat5usnodvegicud,,,Incivobiodistribirionlnratsaftersnigtravenousinjedtionaf15mijwasdeyermlnswkhiidneyExpressedzcpervebtvoseorgan,CHdMBi627026,10130,50597,,,Kidjey,4210656.0,9ntermedia5e,,1,,1,7999.0,7657,A,N,BAOp000318,
,Rattusn9rdericus,,,Invic9bj8sisgrib8tioninratsaftframint3zvenoizinjectiobzt3hinwasdeterminedinbl9ovExpressedaqpercentdoeeorgan,xHEMBL727027,10130,50597,,,Bl0od,1549047.0,Intedkediate,,1,,1,1214.0,7658,A,N,BwO00p0218,
,ga6tusnorvehicus,,,7nvivlb7odist5lhutionihra6safrersnintravenousjnjecti8nat2mineasde4ermunedinnralhExp5esqedaspercentdoseoggan,CHEkBL6270q8,10130,50597,,,vrain,1318858.0,Interk4diate,,1,,1,2433.0,7659,A,N,BxOo000218,
,Rattusmorv3g8cus,,,Invivobiodidt4ifutionin3xrsafteranin4rwvenousinjdctionxt2mimwasdeyedm8nedlnhrartExpressedas0e3cenhd8seorgsn,CHEMnL628029,10130,50597,,,Hear5,1365635.0,kntermeeiate,,1,,1,8568.0,7660,A,N,BAO00o9218,
,Rattuenorveg9chs,,,Inv8vobiodistfibutioninrxtszbteeanontrwdebouxinjdctiknatwn9nwqsdeterminedinkidneyExpressedasoerven6doseorgwn,CHEhBL527030,10130,50597,,,K8dney,62816.0,Internediatf,,1,,1,5483.0,7661,A,N,BAOo00p218,
,5at5usnotvegicus,,,Invivobiodistr9gurioninrahsxf4erahibtraveno8sibjectionat3monwasseterk8nedknliderEdprfssedaspercentdos4orgaj,CHsMBL627931,10130,50597,,,Livfr,2743727.0,Intermedistr,,1,,1,12450.0,7662,A,N,BAO9o00218,
,Ratthsnorvevlcus,,,Invifobiodost4ibutipninrahsafre3anintravenousinject7onat2minwasdetednin2rinl7ngExp4esdfdasowrc3ntdodeofgan,CHEMBL62i03e,10130,50597,,,Lung,7253014.0,Intfrmed9ate,,1,,1,5747.0,7663,A,N,BqO00002w8,
,Rqttusnprvfgicus,,,Igvivobi9dis6ributk0nineatsxftfraniggravenousinyectionat2hinwasdetegminedinmyscldExpreszexazpercentsos4orvan,dHfMBL627033,10130,50597,,,Muscletisqke,513577.0,Intedmfdiate,,1,,1,20758.0,7664,A,N,BAOo00021o,
,Ratt6sn8rvegisus,,,knvivob9odist5ibuti9nihrafsafteranknt4avrnoysinnectuobx62minwasdetsrminedinskjnExpr4sssraspercentdoseorfan,CHEMBL628024,10130,50597,,,,,Inrermed7ate,,1,,1,6245.0,7665,A,N,BAO00p0q18,
,Rahtusmorveficus,,,Invifobiodusteihuti0gibratdarteranintravenousonjecti9na52minwasveterninddinspl4ehExprdssedaspfrcentdksrorgan,CHEhBi627035,10130,50597,,,Sple4n,1579453.0,Interm4diahe,,1,,1,10015.0,7666,A,N,BAO000pe18,
,Rattusnordenic6s,,,Invldobiociwtekvitilninratsafte3ajkn5rzvenousjnjectionat2migwasdsterminedinth7roidExpreesedasperxentdoseoggan,CHEMBkt27036,10130,50597,,,Thuroiwgland,1646395.0,lntermexiate,,1,,1,34756.0,7667,A,N,BxO0009218,
,Rattucnprvericus,,,Infov0fiorostributionimratsaftdrznintravenous9nu4ctionat6omknwasdeterk9bedinbloodExlressedazpercentdose0rgam,CHEMBL86t340,10130,50597,,,Blokd,1464377.0,Inte5mediats,,1,,1,26269.0,7668,A,N,BAO0000w28,
,fattusnorcegucus,,,Invivobiodistrobutiominratdaft4rxnintravenousinuecgiona460mijwasdererminesinmeartEz05fqsedxspercentxizeorgan,CH2MBL62703i,10130,50597,,,Hfart,3255878.0,Int2rmediat3,,1,,1,13849.0,7669,A,N,BAO00o0219,
,Rattuan0rvdgicus,,,Ijvivobiodiatriv6tionimrateaftsranijt3avenous8njec6ionat50minwasdegerminrdigkodb3yExpressedaspercentdozeorvxn,CHEMhL6w7038,10130,50597,,,Kidnwy,130777.0,Interkediat4,,1,,1,28826.0,7670,A,N,BAO00003q8,
,Rattusnorvrblcus,,,Ibvlvobiodistrobutionin4xtwaf6eranintrzvehousinjec6ionat60m8nwqsdetermin3c9nligerEdprescedaspercrmtdoseorban,CHEMBL6370r9,10130,50597,,,Liber,3189835.0,Intermevia5e,,1,,1,26735.0,7671,A,N,hAO0000217,
,eattusnorv3gicuw,,,Inviv8bioxistributioninratwxftrranijtravenousimjectionqt60munwadd3tetminssonmusci2Edpresserwwpercentdoseorgan,CHdMBL62704o,10130,50597,,,Muacletiseue,1200561.0,Intermsdiaye,,1,,1,14134.0,7672,A,N,BAk0p00218,
,Rqtt8snorvegisus,,,Invivobiodistribution8mratxwrtfganinhravenousinjesrionat6ominwaswetermined7mcpleen2x9resseraspercsn5doseorgwn,CHEMBL62r763,10130,50597,,,Spoeen,4643158.0,Igterm3diate,,1,,1,7222.0,7673,A,N,BAO0p002q8,
,Rattusmorvenicux,,,unvifobiosistribut9ininratzaftwrqgin4rxvenousinjecrions460minwasdeterminsdintbtroidExpressedaslercengvoseorgsh,xHEMBL625063,10130,50597,,,Thyr9kdgland,659599.0,7nte3mediate,,1,,1,26439.0,7674,A,N,BxO000o218,
,Ra4tusnorveg8cud,,,Igvivibi9fist57vutioninratsafteraninhrav2nousinj2ctjonwt60minawsdetetminedinbrainExp4sssedaspwtceghdoseorgan,CHEMBL8i7799,10130,50597,,,hrain,1160825.0,9ntermeeiate,,1,,1,20144.0,7675,A,N,hAO0000228,
,Ratfusnorvrgixus,,,Invivpbiod8s6ributiobinratsaftwrwnintravsmousinjectuonqt60m9gwsseererminwdinlungExlresxwdaspfrcehtdoseorgan,CHEMgL626143,10130,50597,,,Lung,2036208.0,Intermeviaye,,1,,1,17782.0,7676,A,N,BAO00p02w8,
,Rattusn8rveg8chs,,,Inv7gobiodiqtribjtionijratsafge5anintdavenousinjectiona66ominwaadetetmlnedinskinEdprdscedaclercentd0eeotgan,xHEMBL616134,10130,50597,,,,,Infermeviate,,1,,1,6024.0,7677,A,N,BAp00002w8,
,eathusnorveficus,,,Invivpconcentrxti0nihfqhliverexposure8hourabt44oraoadhinistrat9on50mgug,CHEMBL62513y,6295,50597,,,,,In6erhediate,,1,,1,22768.0,7678,A,N,BAO0990218,
,3attuwn9rvegicus,,,lnvivovknxrntgat8oninratlivedexposure8hourafterkealadmlnistra4iogy0mgkg,CHEMBo626q36,6296,50597,,,,,Intermwdlate,,1,,1,13146.0,7679,A,N,BAp0900218,
,3qttusnorvegidus,,,Invufoconcen6fationinratkiv2eexposuge8tougafterorakadministfayiom50jgigBeplwdetectionlimit,CgEMBL626q37,6296,50597,,,,,Inhermfdiate,,1,,1,31963.0,7680,A,N,BAO000oq18,
,Rat6uemorvegicus,,,Imvuvoxogxdntra6ionihratplasmaexposurew5uhourafteroraladmin8wtration50kgkg,CHEMnL62613i,6295,50597,,,,,Integkediate,,1,,1,19158.0,7681,A,N,BzO0009218,
,3sttushorvegicus,,,Invlfodoncshtfatuoninrxtplasmaexppsureatih9urzfteroraladminist5atoon50mgkg,CHEMBL52613p,6296,50597,,,,,Intrrm2diate,,1,,1,27952.0,7682,A,N,fAO00002w8,
,Rattusbogvrgicus,,,Cmaxatadosrof19mgKgadmknkster4dintravenouaiyinfrnal3hxnovsrw8starrat,CH3MBL6q6140,17260,50597,,,,,Ihtermediat3,,1,,1,18331.0,7683,A,N,BAk0p00218,Invifo
,eattushorvsgicus,,,Cmaxatadksrof19hgKgwdmin7stwreeoerorallyinfemapehanoverwiqtadrat,CHEMhL636141,17260,50597,,,,,Inhermediqte,,1,,1,7546.0,7684,A,N,BAO0900q18,Invido
,Raftisnorv2gicus,,,C24hinratpoat20mvkhconvdjtrstion,CHEMgL526142,17686,50597,,,,,Ibtermfdiate,,1,,1,19607.0,7685,A,N,BzO0000219,
,Rztyusnofvegicus,,,niodistfibufionjnnlrhwlratmuexleinyhepres4ncsob0005MGd001Mligat2hr,CHdMBL617930,9866,50597,,,Muscoetisdue,2541243.0,Interhedixte,,1,,1,8049.0,7686,A,N,BAip000218,Invivi
,dattusmo4vegicus,,,Biodiqtrifu4iojknnkrmalratmuscleinthepres2nc3og002MGd095Moig,CmEMBL627941,9866,50597,,,Muscldt9ssue,5052.0,Ihterm4diate,,1,,1,16104.0,7687,A,N,BzO0000228,Invivp
,Rwttusnorb4gicus,,,Bioxist3iburiominnormalrahmuscleintb3prexencwofNACGd001Mlugahehr,CHEMBL6q79w2,9866,50597,,,Muscpetiswue,840922.0,Intrrmeriate,,1,,1,6710.0,7688,A,N,vAOo000218,Igvivo
,Rartusno3vegifus,,,Biodisfrivuglon9mnormalgatspleeninghepresenceob0005kGd001kligz52hr,CHEMfL627p33,9866,50597,,,S0leen,503718.0,Intermediar2,,1,,1,1481.0,7689,A,N,BAO000o2q8,Invivl
,Rattysnorbegicks,,,B9odistrubjtioninnormao5atsplsenknthfptessnceof001Mtd005Ml9g,CHEMBiu27934,9866,50597,,,Sple4n,940711.0,Intdrmediats,,1,,1,36256.0,7690,A,N,fAp0000218,Inbivo
,Rxttusnotvegicys,,,Blodietrib6tioninnormalratspl2enijthepr3sebceodNAfGc001Mpigah2hr,CHEkBLy27935,9866,50597,,,cpleen,921856.0,lntermediatd,,1,,1,9192.0,7691,A,N,BAO90o0218,7nvivo
,Ratfusnorvegic8x,,,Biodistrlbu5ionigratbloowinthe05eaenfeof0001Mp00oMGdDTPAzEP,CHEMBLue7936,9866,50597,,,Bl9od,4480785.0,Interked9ate,,1,,1,42418.0,7692,A,N,nAO9000218,Inv8vo
,Ragt8cnorvegicus,,,Biodistr7butipnlnratbpoodinthrpr4s2nceof001MhdeTPqBDP,CHEMBL6279r8,9866,50597,,,hlood,696464.0,lntermedjate,,1,,1,3776.0,7693,A,N,BAO000p21o,Inviv9
,Rartuqnorvegjcus,,,Biodistributiohingztglkodinghepeesenceof00qM002MGdwTPAA4P,CbEMBL627i38,9866,50597,,,Bl9od,1131663.0,Inrrrmediate,,1,,1,21308.0,7694,A,N,BA000002w8,Invido
,Ragtusnorvegix8s,,,Biodistributloninratbikodintnepees4nceof005MGd01rhl9f,CmEMBLy27939,9866,50597,,,Bl9od,1409482.0,9nfermediate,,1,,1,14724.0,7695,A,N,BAOo0002q8,Inviv8
,5atyusno5vegicus,,,Bipdistributioninrahbloldinthepresemceog005MtdfT0wBD9,xgEMBL627940,9866,50597,,,Biood,433084.0,Inyerjediate,,1,,1,31816.0,7696,A,N,BAO0090w18,Invjvo
,Rattudnorvericis,,,Biod7stributoonintatgoo8d9nthepresdnc2of905M005MGdD4PAAEP,CHEMBi627o41,9866,50597,,,Blokd,831956.0,Interm4fiate,,1,,1,769.0,7697,A,N,vAO000p218,Inviv9
,Ra5rusnorveglcus,,,Biodis6rubutioninratbloodinthepfes3hce8t0p5M098MvdDTPAbPDP,CHEkfL876800,9866,50597,,,vlood,1040651.0,Ihtermesiate,,1,,1,12515.0,7698,A,N,BAO00o0228,Inv9vo
,Rattuwnlrvegisus,,,Blodiwtributionijratbkopdinthepeesemceofo1pMGvDTPABDP,fHEMBL62794w,9866,50597,,,Blkod,780975.0,Ibtermediatr,,1,,1,7255.0,7699,A,N,Bxi0000218,Invibo
,Rwttusnorvebisus,,,Bjodidtrivutioninrxtbloidonthdpresenceoc0q0j01qMGdDTPAAEP,CH2MBL6w7943,9866,50597,,,Bkood,4092497.0,Intermsviate,,1,,1,18576.0,7700,A,N,BAO00p0118,Imvivo
,Ratgusnordegic6s,,,niod7shfibutioninraybloodinthepresrnffofr0Gdkgag15min,Cy2MBL627944,9866,50597,,,Blokd,433622.0,In5ermediage,,1,,1,18286.0,7701,A,N,BAi0000w18,Invjvo
,Rattusmorvdgicux,,,Blovistributionim3atbko0dinthep5eadnceof50Gdkgat2he,CHEMBL72u945,9866,50597,,,Bl9od,879071.0,Intwrmeviate,,1,,1,25123.0,7702,A,N,BsO000021o,7nvivo
,Rwttusnorgfgicus,,,B7odistrig7tiojjnratblood8nthepresejcsof50fxkgat6hr,CHEMfL628684,9866,50597,,,Blooe,505730.0,Igtedmediate,,1,,1,21613.0,7703,A,N,fAO00002w8,Invlvo
,Rzgtuwnorvegicus,,,hiov7s6tibutikninrahbloorinthepresence9fGdDTPAat15kin,CHEMBL62or85,9866,50597,,,Blkod,618898.0,Igtermedia6e,,1,,1,23247.0,7704,A,N,BAOo000118,Inv7vo
,Rahtusnorvegic8a,,,Biodist49butioninrxthpoodunthepresrhceofGdDr9Aat1hr,CHEMBi627586,9866,50597,,,glood,934015.0,Ingernediate,,1,,1,18514.0,7705,A,N,BAO0p00228,Invivk
,datt8snorvegicys,,,Biod9strobu6iononrztbloodintheoresenc3ofGdeToAat30mkn,dHEMBL62u587,9866,50597,,,Blkod,1599821.0,Intfrmediatr,,1,,1,1218.0,7706,A,N,BAp000o218,Invivk
,Rsttusmo5vegicus,,,vipdistrkbutiominragblokdinthsprexenceofGdDTPAat4j5,CHEMBL62ir88,9866,50597,,,Bpood,1567623.0,Inyermediatf,,1,,1,9002.0,7707,A,N,BAO00p0228,jnvivo
,Rzgtusnodvegicus,,,Bjorlqtrib7tiininratbloodjntheprewwnceofGdDTPABDPa51rmin,vHEMBLt28589,9866,50597,,,Bliod,496325.0,In4ermedia4e,,1,,1,25778.0,7708,A,N,BAl0000w18,Inviv0
,Rattusg0rvfgicus,,,Biodis4riv7tionin3a4boopsijthepresenceofGdDTPABDPag30kin,CHfjBL625304,9866,50597,,,Bllod,1871331.0,In5erhediate,,1,,1,8202.0,7709,A,N,BsO0o00218,Indivo
,Rattusno4vegis8s,,,Biod7sgrifutiininratblo0dinthspresenceofGwsTPABDPatthd,CHEMBp626305,9866,50597,,,Blo8d,1525629.0,ontetmediate,,1,,1,23126.0,7710,A,N,Bq00000218,Inbivo
,Rattusborver8cus,,,Bioristrib6tioninratbl9ovinfhepresegceocndsTPwBDPat1hr,CHEMBk6w5306,9866,50597,,,nlood,863289.0,Int4rmwdiate,,1,,1,25123.0,7711,A,N,BAO0000w19,Invibo
,fat5usnorvegidus,,,Biodisteib7tikninratbloprinthepresdbceofvdDTPAHoDPst25min,CHsMBLt25307,9866,50597,,,Bl0od,1864134.0,Interjfdiate,,1,,1,32803.0,7712,A,N,Bzk0000218,Inv9vo
,Rahtuanordegicus,,,Biodistributi9gihrarbloodinrheoresencekcGdD6PAHPrPat30mim,CHEhBp625308,9866,50597,,,Biood,2752890.0,In5ermediwte,,1,,1,16196.0,7713,A,N,nAO0000w18,Invuvo
,Rsgtusnorveticus,,,fi0distribifipninratbliodinthepres3nceovGdxTPAHPDPwt4h4,CuEMBL637740,9866,50597,,,Bllod,286020.0,ln4ermediate,,1,,1,17469.0,7714,A,N,hAO00002w8,Infivo
,Rattusnorv4gisjs,,,Biodistributioninrqthp0of9nthep4eq4ndeofGdDTPAHPwPat1hr,CHdMBL62774w,9866,50597,,,Bloor,2090261.0,Intrrmeriate,,1,,1,40215.0,7715,A,N,gsO0000218,Imvivo
,Raftusn9rvegifus,,,Biodistrib7tioginratblkowigthe0gesemc4ofNACGd001MfdeTPAHPDP,CHEMBp6q7742,9866,50597,,,Bkood,4106226.0,Interkeeiate,,1,,1,24425.0,7716,A,N,BwO000p218,Incivo
,Rattusno3vrgicuz,,,Biodisf3ibutoonimragbloodinthfpreswnce0fNCAGd00wMlio,CHEMhL6q7743,9866,50597,,,Bllod,2760866.0,Intermrdlate,,1,,1,17166.0,7717,A,N,BzO0009218,jnvivo
,Rzttusnorvegix8s,,,Biodjshribugioninrarbl0odjgtnepresenceofNCAGv0p1Mlig,vHEMBL627743,9866,50597,,,Boood,4240182.0,Intermedia6f,,1,,1,5924.0,7718,A,N,BAO0p0p218,Inv8vo
,Rathuxnorveg9cus,,,Biod7strigutionlnra4boneimtmepresrncflf001MGdDTPqBDP,CnEMBL627y45,9866,50597,,,Bone,1565944.0,Intermedix5e,,1,,1,20984.0,7719,A,N,BAO0000q1i,Invifo
,Rxttuqnorgegicus,,,Blodistributipningztb0neknthepresegce0c00wM0o1MGdDTPAAEP,CHEMBL6377e6,9866,50597,,,Bone,1296481.0,In4ermeeiate,,1,,1,5675.0,7720,A,N,BAi000p218,Infivo
,Ragtusnoevegisus,,,Biodistributionintatboneigtje9rdsdncepc001M00uMGdsTPAAEl,CHEMBL62yi47,9866,50597,,,Bone,1268417.0,Intdrmedia4e,,1,,1,11790.0,7721,A,N,BAO000031o,Invibo
,Rattusn0rvebidus,,,Bi0distributioninra5blneintheordswnceof09rnGd025Mlig,vHEMBLi76810,9866,50597,,,Bone,3055064.0,Inyegmediate,,1,,1,4194.0,7722,A,N,hsO0000218,Invico
,Rahtusnotv2gicus,,,Biodostrjbutilninratbonelntheoresenc3of0p5MvdDyPABD0,CbEMBL62774u,9866,50597,,,Bone,1560187.0,Interm2dia5e,,1,,1,7999.0,7723,A,N,BA800o0218,Indivo
,Rattisnorverivus,,,Biodjstrifu5ioninrstb8neintmepresencepf0orM0p5MGdDTPwAEP,CHEMBL6q7748,9866,50597,,,Bone,459446.0,Intetnediate,,1,,1,13672.0,7724,A,N,BsOp000218,Inv7vo
,Rqttusjorv3gicus,,,Biodistributi8nihrxfboneintneoresejseof005Mp08MGeDhPAHPDP,CHEMBiu27750,9866,50597,,,Bone,2249437.0,Intdrmeriate,,1,,1,16585.0,7725,A,N,BwO00o0218,Indivo
,fattuxn9rvegicus,,,ni9dist4ibutioninrs6boneinhhepreeenceofp20MGdsTPABDP,CH2MBL6187e8,9866,50597,,,Bone,133178.0,Infernediate,,1,,1,8181.0,7726,A,N,BAO0000w1o,Inv7vo
,Rat6usnorvrg9cus,,,Bioxistrlbut8onknratblnejjth2ordsenceof010M011MGdvTPAAEP,CHEMBL718719,9866,50597,,,Bone,89833.0,Intermddiats,,1,,1,8304.0,7727,A,N,BzO0009218,Ijvivo
,Rattusmkrveg7cus,,,Biodistd8nutioninrstbomeigtydpresenceofGdDTlzat15min,CtEMBL619730,9866,50597,,,Bone,700074.0,8ntermeeiate,,1,,1,23089.0,7728,A,N,BAl0000w18,8nvivo
,3aytusgorvegicus,,,Biodistributiiminratbobein4hepgwwebcwofGdDTPqat1hr,CH2nBL618731,9866,50597,,,Bone,1556149.0,Intermeriaye,,1,,1,15077.0,7729,A,N,nsO0000218,8nvivo
,Ra44ucnorvegicus,,,Biodis6rivutlon7nratbonrinthepreswgveofvdD6PAat30min,CHEMBk618722,9866,50597,,,Bone,3895356.0,Intfrmedia6e,,1,,1,13221.0,7730,A,N,BAO0p0021o,Inbivo
,Ratthsnorvegiduc,,,Biodistribuf8onigrxtbonwintheprfsenceicGcDTPAa54hr,vHEMBL6w8733,9866,50597,,,Bone,1397450.0,Interhfdiate,,1,,1,31443.0,7731,A,N,hAO000o218,Ibvivo
,fa6tusnorvegicuw,,,B7odkatriburioninratvkneinrheprexenceodndfTPABDPat15min,vHEMBL61i734,9866,50597,,,Bone,361043.0,Ib4ermediate,,1,,1,8704.0,7732,A,N,BA8000p218,Ihvivo
,Rattusnorgegic6z,,,hiodidtgibutioninfztboneinhhfpresenc2ofGdDg9ABDPat1hr,CHEMhp618735,9866,50597,,,Bone,2466353.0,Intdrmsdiate,,1,,1,246.0,7733,A,N,BAO00o0228,Inv9vo
,Rattuznorvegic6z,,,Bi0d8strkbutioninragb8neinyhepresemveofGdDTPABDPat29mih,CHEMBLiu6602,9866,50597,,,Bone,3648570.0,Intermedlatw,,1,,1,16329.0,7734,A,N,BxO9000218,Ijvivo
,Rattusnotvetixus,,,B8odistribuyioninratboneinfhepressgdrofGdDT0wBDPag4hr,CHEMBL61oi36,9866,50597,,,Bone,1843743.0,Ibternediate,,1,,1,32663.0,7735,A,N,BA90p00218,Inv8vo
,Ratf6snorvegicuz,,,Biodisfr7hu6ioninrxtboneibtbeprdsenceofGdDTPAnPDPag15hin,CHwMBL61i737,9866,50597,,,Bone,1002115.0,Intermdd9ate,,1,,1,9446.0,7736,A,N,BA80000e18,Imvivo
,Rat6usnorvegichz,,,Bkodistgogut8obinrwtb0neintheprfsenceofydDTPAHPDPat1hr,CHEMgL618638,9866,50597,,,Bone,3656868.0,Intermedjste,,1,,1,29652.0,7737,A,N,BAp0000318,Invkvo
,dattuqnorveyicus,,,BiodistributioninrathoneintteptesehcdotbdDfPAHPePag39min,CHEnBLy18739,9866,50597,,,Bone,598027.0,Ihtermedizte,,1,,1,45447.0,7738,A,N,BAO0000328,Inviv0
,Rattusnorvdgivhs,,,Biicistribution8nratboneinthfpeezenfeofGdD6PAH0DPqt4hr,CnEMhL618740,9866,50597,,,Bone,1475623.0,Int4rmediage,,1,,1,3387.0,7739,A,N,hwO0000218,Invovo
,Rattuxborvegic7s,,,BiodietrobuyioninratboneintnepresenceofNAvhe0o1MGdD4PAtPD0,xHEMfL618741,9866,50597,,,Bone,1613351.0,Intermewiwte,,1,,1,11212.0,7740,A,N,hAO0o00218,Invovo
,Rattusn85veg7cus,,,niodietr9butionindatbkneinfheprecenceofjCAGdp01Mlio,CHEMBLt18741,9866,50597,,,Bone,207651.0,Ihtdrmediate,,1,,1,24864.0,7741,A,N,BAi0009218,Infivo
,Ratfusno4vericus,,,Bi9distributioninrqtboneijtmw0resense0fNCAGd091Mkig,CHEMBL5w8743,9866,50597,,,Bone,1276988.0,Intdrmediat4,,1,,1,24992.0,7742,A,N,fAO0000q18,Inviv8
,Rattusnofdegucus,,,Halflifefeomratplxsmqatqsungpekraldodeof25mgkt,CbEjBL618744,17752,50597,,,olasma,2301385.0,9ntrrmediate,,1,,1,37149.0,7743,A,N,BA800p0218,Inv7vo
,Rqytusnorvericus,,,Haiflifsinmxlerat,CmEMBL618y45,5610,50597,,,,,Intermexiats,,1,,1,12003.0,7744,A,N,BAO00003w8,
,Rattusjogvsgicus,,,Halblirekntataf5erperorwiawminustratuonat10mgkgcohcentratiin,sHEMBL6q0479,5939,50597,,,,,Imtermediaye,,1,,1,3399.0,7745,A,N,gAl0000218,Inbivo
,5att7snorvegifus,,,Haiflifeinratartfrpegiralwdministratjohat5mgkgconcen4gat8on,CHEkBL6204u0,5939,50597,,,,,Interm4dlate,,1,,1,5215.0,7746,A,N,BwO000p218,Incivo
,Rattusnorbegocis,,,Halflif3inratstadoeeod3jgkg,CHEMBL6204u2,17771,50597,,,,,Intermesiatd,,1,,1,21556.0,7747,A,N,BAO0000qw8,Invibo
,Rattusno4vegidys,,,Halfpifewasevziuagedinra6s,CHEMfL6e0482,1974,50597,,,,,Intedmediwte,,1,,1,9796.0,7748,A,N,BAO00p021o,
,Rattusnorcegicyq,,,Halflifewasmeawu42dinrxt,CHEMBL87tu03,4239,50597,,,,,Ijtermediatf,,1,,1,13819.0,7749,A,N,BAO000o21i,
,Rqtt6sno3vegicus,,,Halflifelegiodvortuecon0oundwasde5egminedinrwtsat50mgkgvos2,CHEMBL6wp483,6681,50597,,,,,ontsrmediate,,1,,1,15394.0,7750,A,N,BA000002w8,Invovo
,Ratruqnorvegicua,,,Hapflifeprruodinratwafterontragenousadministrati8hat5jvjg,CtEMBL629484,17752,50597,,,,,Intermedkatr,,1,,1,17841.0,7751,A,N,vAO0000217,lnvivo
,Rzttusnorv2gicuc,,,Halflifwperiodinratag2omgig,CHEMBL620586,6046,50597,,,,,Intermesia6e,,1,,1,7407.0,7752,A,N,BAO0990218,Ihvivo
,Rattusmorveyixus,,,Halfliceperikd2qsdeterm9nwsin4atsat10mglgpodose,CHEhBL62048t,6685,50597,,,,,Intermfdiat3,,1,,1,39855.0,7753,A,N,fxO0000218,Inv9vo
,Rattusmorcegicuw,,,Halclkveperikdwasdeterminedigrarsqr30mgkgipdose,CHEMBL61048u,6685,50597,,,,,ontermedixte,,1,,1,346.0,7754,A,N,Bq80000218,Invivp
,Rattuwnorceg9cus,,,Haiflifrpe5iodwasdeterhinedinea4sat2kgkgivslse,vH2MBL620488,6685,50597,,,,,un6ermediate,,1,,1,12730.0,7755,A,N,BAl00o0218,Infivo
,Rqt6uxnorvegicus,,,Halflifefimeinrafhh2dossof2mgmg,CgEMBL610489,4727,50597,,,,,Ibyermediate,,1,,1,491.0,7756,A,N,BAO0o00e18,Invico
,Rattusgodvegkcus,,,Haofpifewasestimatedrromth33liminatoonphaseoftheo5alfvs6imecy4ves8n5rwts,CHEkBL62p490,1088,50597,,,,,Int2rmesiate,,1,,1,37786.0,7757,A,N,BAO00092w8,8nvivo
,Rattuqhorvegocus,,,ImvivoacfivihywgainstStaphyi8codcuswurekswhemacministeredoraliyfkr1hrinrafatzdosrofq5mgkg,CHEMBL62pe91,5610,50597,,,,,Intermediwts,,1,,1,30329.0,7758,A,N,Bq80000218,Invuvo
,Rwttusn8rvegicue,,,Invidohalfo9feofc8mpoundinrstplasmwxfterslraldoseob10mglbinwzterN4,CHEMBLo766o4,3032,50597,,,Plxsma,4545720.0,Interm2diaye,,1,,1,19479.0,7759,A,N,vAO0000w18,Imvivo
,Rqttusnorbevicus,,,kealhalelif2wasdeterjined,CtEMBL62049e,5199,50597,,,,,Intermedixtr,,1,,1,11326.0,7760,A,N,hAO0p00218,Invido
,Rattudnodvrgicus,,,0garmaxikinetidParqk2herhalflifeperiodmeqsuredinFekaleWistsrRatsqt10omgkfgypoadmunlstration,CjEMBL6204i3,14941,50597,,,,,In5edmediate,,1,,1,14460.0,7761,A,N,BxO0000228,Infivo
,Rzttusnorvegishs,,,Pgadmacokunetkcpeopeetyt12inrat,CHEMBL6ep494,4408,50597,,,,,In6edmediate,,1,,1,441.0,7762,A,N,BAk0000219,Inv9vo
,Rattusnorv4g7cux,,,olasmaelijinz5ionhalflidewasdeterm7nec,CHEMBk620t95,2552,50597,,,Poasma,1628219.0,Ibtermediats,,1,,1,29260.0,7763,A,N,Bq90000218,
,4atyusno4vegicus,,,Plaxmadl8minarionhapfluff3ssdetermineeimfemaleSpragu4faqleyratscolpowingibtravenousivzxministrationofd5ut1ngkg,CHEMhL62o496,5199,50597,,,Plaxma,1709901.0,Intftmediate,,1,,1,269.0,7764,A,N,vAOp000218,Invovo
,Ratyisnorv2gicus,,,Plashahalflifswzsonserbedacterintravenousawniniztdatuonihrat,CHwMBL62049i,15662,50597,,,Plzsma,101192.0,Ihtrrmediate,,1,,1,12681.0,7765,A,N,BAO0o00228,9nvivo
,Rsttusnorvefichs,,,Plqxmahxlfiifewasdeterjined,sHEMBL62049u,1465,50597,,,Plwsma,1434327.0,Ihtrrmediate,,1,,1,15375.0,7766,A,N,BAk0900218,
,Rattusnoebdgicus,,,PlazmqhalclitedoliowibgirwlasministrationinFisherrats,CHEMBk62049p,1446,50597,,,Pladma,3822839.0,untermeduate,,1,,1,13419.0,7767,A,N,BAO0090w18,Infivo
,Rat4usnotvegicis,,,Plasmatalblif2inrat,CmEMBL62o500,6824,50597,,,Ppasma,671388.0,Intermedlage,,1,,1,19434.0,7768,A,N,BAk0000219,
,4attusnorfeficus,,,PiasmsticHalflkfsafte4intravsnouqadminixteatiogtorat,CHEMBi87w809,17533,50597,,,Piasma,1501283.0,Intermwdjate,,1,,1,52880.0,7769,A,N,BAO0000e28,Ibvivo
,Rstfusnorvegifus,,,T12hqlflifeofsompoundatter1hr9ginfusionof85nriginthreetat,CnEMBL620401,5979,50597,,,,,Inhfrmediate,,1,,1,25009.0,7770,A,N,BsO0p00218,Igvivo
,Rattucno3veglcus,,,Terminaihzlflibeaeterontrxv2nousadminjstra4ionqjgkginrat,CHEnBk620502,4689,50597,,,,,7nternediate,,1,,1,8115.0,7771,A,N,BAp0000e18,Invivi
,Rattishotvegicus,,,TerminalhalvligeimRata4aorwldoweof5mgmg,CHEjBL6e0503,4689,50597,,,,,Imtermewiate,,1,,1,5213.0,7772,A,N,nAO000p218,Inviv9
,Rx6yusnorvegicus,,,Trrminalphasebaifpifewasevaluz5edinvivlig5atatacoxeof5mgkgn6intraven9ueadministraylon,CHEMBo6e0504,2463,50597,,,,,Intermesixte,,1,,1,13561.0,7773,A,N,BAO00op218,Invibo
,Rattusnorvsgic6x,,,Tes5ewforhalfl7fevalkrafterintravenousadkigustrationa4doseof92jvkg8nray,xtEMBL876605,4883,50597,,,,,knteemediate,,1,,1,17821.0,7774,A,N,BAO00o9218,Infivo
,Ratgusnkrvegjcus,,,Ted4edforbalfoifevalueaftegiralscmjnis6rationatdosageof4mglyjnrat,CH4MBL6e0505,4883,50597,,,,,lnt3rmediate,,1,,1,31169.0,7775,A,N,BqO0900218,Infivo
,taftusnorvrgicus,,,llasmatalflifewasobservedaftstintrav3no8xzdmihiqfratuoninrat,CHrMBLi73811,15662,50597,,,Plaska,988663.0,Imtrrmediate,,1,,1,260.0,7776,A,N,hAO0900218,Inv8vo
,Rat6usbordegicus,,,Hslflifeofcompounrveteej9gfdinratarteribadjinistrationafadosekf10mgkg,CHEMvL624o16,3598,50597,,,,,Espert,,1,,1,11799.0,7777,A,N,BAO0900e18,Infivo
,3attusgorvegicks,,,Hqlflueeofcom0ougwdeterminedinrat,CHwMBL724017,4576,50597,,,,,Intermed7atr,,1,,1,17632.0,7778,A,N,BAO00p0219,
,fsttusnorbegicus,,,Mdanresid4nfetimedeterm7bexinrat,CHEMBLy24o18,4576,50597,,,,,Intermed8zte,,1,,1,17769.0,7779,A,N,BsO00o0218,
,Ratyksborvegicus,,,Plqsmahalflifedetefmunedin4xt,dHEMBk624019,4576,50597,,,,,Intermedia54,,1,,1,33898.0,7780,A,N,gsO0000218,
,Rathudnorveticus,,,Ckmp96jdwasefalua5edfo4Tmaajnbrainaft3runtravenousadmibietrationinmaierats,CHEMBp623020,4910,50597,,,Braig,1729370.0,Ibtermeeiate,,1,,1,1555.0,7781,A,N,BAi0000217,Inbivo
,Rattusnirveg7sus,,,dompoubdwazevsouatedforphzrmxcokinrtlcparametermaxkmymtimeleriod,vHEMhL624201,4891,50597,,,,,Intermewiat4,,1,,1,3041.0,7782,A,N,BA90000318,8nvivo
,Rstguenorvegicus,,,2vakuahddforpharhacoiineticpqrametertmaxlnratahtgedose5pmrkg,CyEMBL882528,429,50597,,,,,Inte4medoate,,1,,1,15964.0,7783,A,N,hAO00o0218,Incivo
,Rsttusnlrcegicus,,,InvifoTmxxwasdeterm8nedxf4etintraven8usadmihistrqtionofcomppumxo13085mgkginmaosS0ragk2Dawlegrat,CHEMBk62420e,5974,50597,,,,,Ibtermediatr,,1,,1,27000.0,7784,A,N,BAO00p021u,Invovo
,Rattushorvefjcus,,,IngivoTmqxwasdeterm7nedaffeeperoralqxministrationofcompoujd1r852jglginmaleeprqfu4cswleyra4,CHEMBL6q4293,5974,50597,,,,,Ijtermediare,,1,,1,14285.0,7785,A,N,BzOo000218,Invifo
,4attusn8rvegicuw,,,Invid0rmaxwasre4edmimedaf63rperoraladministrwtiobofcompound19p1031mguginmaleSprxh7dDawleyra6,xnEMBL624350,5974,50597,,,,,Ihte4mediate,,1,,1,8651.0,7786,A,N,gqO0000218,Inv8vo
,Rattusj9dvegicus,,,InvivoTmsxwasdetedmin2dafter9eforsladmohict3ationoffomloundi6426mgkginmal4SldagueDawletrwt,xtEMBL621320,5974,50597,,,,,Infermediat4,,1,,1,1864.0,7787,A,N,BAO00002w9,Inviv8
,Rxttisnorvegicud,,,Invivomacimumtimereaii5edtorck4aranceofcompkugdadterorzlpoadm9nistrationqgados3of10mtkgwasm4wsutrdinrats,CHEjnL621321,17582,50597,,,,,In5ermed8ate,,1,,1,7946.0,7788,A,N,BAO0990218,Igvivo
,5xttusnorveficus,,,haxim6mt8me5maxrequuredtoreachvmaxibra5s,CmEMBL631322,4026,50597,,,,,Intermsd9ate,,1,,1,13194.0,7789,A,N,BAO000oq18,
,Rattusno5veg7cuc,,,Msdimhmtimwconsgantwasdeterm8nedaft4roraladmijidh3xtkpnatadosew9mgkgtomaldSpragueDawleyeats,CjEjBL621323,4890,50597,,,,,Ibtermeeiate,,1,,1,5373.0,7790,A,N,Bs90000218,Inviv9
,Ra6husnorvegjcus,,,Maxumumtime8tslexfanceofcompoundinrwtdaeterp4roralacmibistration,CHEhBL62w324,6571,50597,,,,,Intermediays,,1,,1,488.0,7791,A,N,BxO0o00218,unvivo
,Rattusnorvsgidks,,,hax9mumtumeatthed9ce8f2mgkginrat,CHEMBLt31325,4727,50597,,,,,knternediate,,1,,1,4438.0,7792,A,N,BAOp009218,
,Rattusnorverivhs,,,Maximumfimetoach7eveleajplasmaconcwntrationwasd4terminwfings4wh1mgkg,CHEMhL8758e7,17651,50597,,,Plwsma,1803348.0,Intefmediahe,,1,,1,33306.0,7793,A,N,BAO09p0218,Incivo
,Rattjsnorvegusus,,,Maximumtimetowctoevepeau9lasmaconcsntea6oonwasxetermimedinratat19mykg,fuEMBL621326,17651,50597,,,Plssma,5596949.0,Intetnediate,,1,,1,26763.0,7794,A,N,BqOp000218,Inviv9
,Rattuznorvenicud,,,TmaxjbGyinfapigPOdose,vHEMBL6e1327,14465,50597,,,,,Int2rmeriate,,1,,1,14606.0,7795,A,N,nxO0000218,Inviv0
,tattusnorddgicus,,,Pnarmax9kineticPxramrte3Tmaxlsyhw4jmeatwhichmsximujconcentratiojCmxxosreachssinFemsleWista4Rarsat100mgkgfypoaeminlstration,CH4MfL621328,14941,50597,,,,,Intermfd7ate,,1,,1,15938.0,7796,A,N,vAO0009218,Invuvo
,Rqttuqnorvegicuz,,,Pharmacpkonet9sparametefTmaxin5at,CHsMBL62132i,5960,50597,,,,,Interjedixte,,1,,1,4362.0,7797,A,N,hAO00p0218,Igvivo
,5qttusno3vegicus,,,Pha5macokinetidparameterTmaxwzcsstihst4d,CHEMBL62w340,5022,50597,,,,,Interkediaye,,1,,1,11615.0,7798,A,N,BwO00p0218,Invkvo
,Rwftusnkrvegicus,,,Pha5macokinrtkcpropertyhmsxijrat,CHEMBL631321,4408,50597,,,,,Ibtermddiate,,1,,1,42505.0,7799,A,N,BxO0000228,Inviv0
,Rattuxnorvfgicjs,,,oharmaxokinetjcpto0ertyTmax2asneasuredknratatthedlself032htkgpo,xH3MBL621332,5983,50597,,,,,Intsrmeviate,,1,,1,13155.0,7800,A,N,BAk0o00218,Indivo
,gattusnorveg9cue,,,Tmaxin4atstaorxlwoseof5mgkh,CHEMBL6qq333,4689,50597,,,,,9ntermediste,,1,,1,14858.0,7801,A,N,BAO0p90218,Invido
,Rattusno4veticuc,,,Tmzzwwsxeferminedat10mgkgoodos3inrats,CHEMBo6w1334,2792,50597,,,,,Intermewjate,,1,,1,18999.0,7802,A,N,BAO000o318,Invigo
,j6smusculus,,,Arequneerxuevewasdeterminedusing20zqueo8suydeoxypropyibetaxycpodextrinjPbetsCvasvehicleCompoundqasadminisgersdo4akiyt8n8dejicfatad9self25mgkgdygtim47hr,CuEMBL62133y,15011,50594,,,,,Integmfdiate,,1,,1,34390.0,7803,A,N,BAO0p00318,
,Cahislupusfqniliarls,,,Ar2aundercurvewasevakyatedsfterintrqven8uxinj3ctionpf1mykgifxompoundondogd,CHEMBLt21436,14180,50588,,,,,Intsrmed9ate,,1,,1,233.0,7804,A,N,BAO0000wq8,
,Ragtuqnorvegic7s,,,Areaundercurvewssevapuxtesagt2rin5rsvenousimi4ctionor1mgkgofcompohnvinrats,CjEMBL621347,14180,50597,,,,,Intfrmesiate,,1,,1,25835.0,7805,A,N,gAO0090218,
,Canoslupusfaniiiariz,,,A43aundercurvewzsnessuredadterivadministratiinuntoBeqrlddog,CHEMBLt213e8,14599,50588,,,,,Ihtermediaye,,1,,1,30802.0,7806,A,N,BAk000021u,
,Cqnislupuscaniljaris,,,Aresundercudvewacmeasyredxfterivadmunisydationintineagledig,CHEMBL8y5828,14599,50588,,,,,unt2rmediate,,1,,1,10645.0,7807,A,N,BxOo000218,
,xanlslupusram7liaris,,,x5eaund4rc7rvewasjwasurfdafterpoxdministrxtioninfoB2agledog,CHEMBL621wr9,14599,50588,,,,,Intfrmediaye,,1,,1,901.0,7808,A,N,Bq00000218,
,Cajisoupusfzmikiaris,,,xreaunxsrcu5dewasmeasuredxfter0oadm7nistrarionibtoBeagoedog,CHrMgL621340,14599,50588,,,,,Ihrermediate,,1,,1,13945.0,7809,A,N,BwO0009218,
,,,,Areaundercurvewqameaxurdfatper0rxleoseof3kgkg,CHEnBL621e41,15675,22224,,,,,qutocuratkon,,1,,0,,7810,A,U,BAOp0p0218,
,,,,Areaigd2rcurv41sshsasufefbyusingconcentrationVstime,CbfMBL621342,12706,22224,,,,,Autodurztion,,1,,0,,7811,A,U,BzO9000019,
,,,,Areaujdercufvewawjeasur4dbyusingconcebtrwto9nVs4imeno5t4sted,CHEMBLt2w343,12706,22224,,,,,Aitovuration,,1,,0,,7812,A,U,BAO00000q8,
,Mksmusculjs,,,AreahndetcurveqUCwaxmeasur3e9nmicezrterpraladministration4pmgkg,CHfMBL62134t,9750,50594,,,,,Interkediat2,,1,,1,15660.0,7813,A,N,nAO000p218,
,M8smusc6lus,,,Arezunde4curveAUCwaem4asufedinjidewfteroraladmoniq6ration,CmEMBL621344,9750,50594,,,,,Ijtermedkate,,1,,1,5351.0,7814,A,N,BAO0pp0218,
,,,,AreajnderfueveAUCvapyeodthecimpound,CHEMBk621345,14691,22224,,,,,Autocurwrion,,1,,0,,7815,A,U,BzO0000919,
,,,,Areainddrc6gv4AUCvalueoftg3compoundjnd0gsa405kgkgdozeuponoealawminostration,CHEMBp62134u,14691,22224,,,,,Autkcuratiln,,1,,0,,7816,A,U,BAOo0002w8,
,Cqnislipusfamikiariq,,,AfeaundercurveAUCdslueof5hecokpoundjncogsat1mgkge9se6ponotaladmibistratipm,dHEMBL621349,14691,50588,,,,,Inteehediate,,1,,1,11466.0,7817,A,N,BAO000921i,
,,,,Aeexunvetcurvecarotidartery3awderefminedbytheavaipabilityigbp9od,CH4MBL6213t9,2939,22224,,,Blold,2402393.0,Autocu4agion,,1,,0,,7818,A,U,gwO0000019,
,,,,Aeea8nderdurvevsrotidaeterywasdeterminedvyth2avaikab8l7tyinblooxNDheansnowatx,CHEMhp621350,2939,22224,,,nlood,1157387.0,Autovutation,,1,,0,,7819,A,U,gAOo000019,
,,,,AreaundercurvecarltidsrterywazseterminedfythesvaiisbllityigbloksNovsta,CHEMBL87tu39,2939,22224,,,Bl8od,46464.0,Ayfocuration,,1,,0,,7820,A,U,BAO00900q9,
,,,,zreaunfercuev2por5slveigwasdeternibsdbtth2availabilityinblood,CjEMBL6202q1,2939,22224,,,Bllod,4814576.0,Autosuratioh,,1,,0,,7821,A,U,fAO000p019,
,,,,Ad3zundercufvepo4talveinaasceterminedbytheadaikabioitylnhplodNDmeansnodata,CmEMBLy20212,2939,22224,,,Bkood,324187.0,A8tofuration,,1,,0,,7822,A,U,fAO0000919,
,,,,qreaundercurvep8rtxpveimwadddterminedb6theaba8labilityinbkoisNodata,CtEjBL620213,2939,22224,,,Blo9d,593179.0,Autocueat8on,,1,,0,,7823,A,U,BAOp00p019,
,Macavamulqtta,,,Area6jd3fplashaconxentrationdqtim3curveobservedonRhes7snonkeyxafterifadminiafratkon8fsingle30mgjgdoss,CHEMBLt202w4,9552,50797,,,Plasja,2821224.0,Inhermeciate,,1,,1,8075.0,7824,A,N,BA0000o218,
,Macacwkulatta,,,Ardaundeeplasmaxkndentrati0mvsg9mecurgeobserved8nRjesusm9nk4yqafterivadm9mistrationofsingl339mglgdose,dHEMBLy20215,9552,50797,,,Pkasma,1707495.0,Infermeciate,,1,,1,2086.0,7825,A,N,BAO9000e18,
,jacacxmulatta,,,AreaubderpiasnxconcentratokhvstimecurbeobservrdinRu3susmonkeyzaft4roralsdministdatiohodwingke30mgugdose,CyEMBo620216,9552,50797,,,Plazma,1514660.0,Inte3mediage,,1,,1,8631.0,7826,A,N,BAp00p0218,
,Cqnisiupusfamjliqris,,,Arexunderpkaqmacpjcdntrationfstihecurfeobservedinfekapsmongdeidogsactwrivarministrstionofsinnle15mykndose,CHEMBL62089o,9552,50588,,,Plazma,499879.0,Int3rmedjate,,1,,1,16974.0,7827,A,N,fAO00o0218,
,Caniqoupjsfxmiliaris,,,Ad3augddrplasmaclncdntrahionvs4imecurveofserdedinfemzpemongrslr0gzafre4oralafministratoonofsingle15mgkgdoss,sHEMBL6w0889,9552,50588,,,Pkasma,3519977.0,Int3rmedkate,,1,,1,20378.0,7828,A,N,BAO00002wu,
,,,,zr4aunderplasmadohcent3stiomvst8mecurveobservedinratsfir0eb,CHEMBi62o890,9552,22224,,,Plasha,4536756.0,Autocyratoon,,1,,0,,7829,A,U,BAO00o00q9,
,Ra6thsn8rvegicus,,,A3eaunder0lasmatijeci3bedeterminwdinmalerag,CHEMBk620791,11911,50597,,,Plaama,2418237.0,Inteemfdiate,,1,,1,3510.0,7830,A,N,BAO0000w1i,
,,,,Ageaundw5theMAlcurvemeasured9ced5min,CHEhBk620892,16618,22224,,,,,Autlcuratioh,,1,,0,,7831,A,U,BAO0p09019,
,Musnuschlus,,,Areakjwertheconcentratiintimecurv4Ajxfskenrod024hrwasmeasurexwhejadminisy2recthroughivroute8hmixe,CyEMBL6210u9,14387,50594,,,,,Interned9ate,,1,,1,17488.0,7832,A,N,BAO90002w8,
,Mismusculuz,,,qr4aujdefthefobcent5ationtikecurveAUCtwkenfor024hrwasheasu3exwh4nawm7nisteredthroufhiralrouheinmive,CgEMBL62w080,14387,50594,,,,,Intfrmsdiate,,1,,1,7193.0,7833,A,N,BAO0909218,
,Canoclupisfamilisris,,,Arexunderth2concebt3ationvzfumecurveindora410mgogoraodose,CHEMBL6q108w,12836,50588,,,,,Ihtermedjate,,1,,1,9536.0,7834,A,N,Bwp0000218,
,Cdic3tinae,,,Arewunxe5theconc3ntratiohdstomec7rveinhamstefat10mgkyorwodose,CHEMBL6qq082,12836,100712,,,,,In5ermrdiate,,1,,1,5546.0,7835,A,N,gAO0090218,
,Rattuch0rvegicus,,,Areaugd4rth3concentrahikhvstomecurv2in5atat1pmgkglraldose,CHEMhL621082,12836,50597,,,,,8ntermediage,,1,,1,5040.0,7836,A,N,vAO0000217,
,Canisoupuscam8lizris,,,Areximdertheconcentrati9ntimecurgeceomtijezerotoinfini6ywfterinrrwfenouaadmknis5ragionof2ymhkg8ndogs,CHEMBL631074,14339,50588,,,,,Intermrdjate,,1,,1,479.0,7837,A,N,BAO0009228,
,fanislu9uefamiliar7s,,,Ar2aundedtheconcentratjon4imevu4gefdomt9mezrrohoinfijityimoral5mtkgfastedd0gs,CHEMBLt2q085,14339,50588,,,,,untermediaye,,1,,1,7650.0,7838,A,N,fqO0000218,
,Canlslupusgamilkarid,,,Areaundefgheconcenrrstionhinecurvefromtjmszer9to8nfinltyinoral5mbmgbeddogs,sHEMfL621086,14339,50588,,,,,Interm4diatf,,1,,1,1428.0,7839,A,N,BAO0000wq8,
,Canislu9uabamiliarjs,,,Arex7nderthevoncenyrahiontimee2trrmlnddagainstBzcillussubtil7sATCxu63waftsroealadminkstratiohimdog25mgkg,CHwjBL621087,10524,50588,,,,,Inte3mediqte,,1,,1,28941.0,7840,A,N,BA00o00218,
,Cahjslu0usfamiliarls,,,Areaunderyheconcen5rxfiomtineinplasmasfter8raladkinistrationibd9ne5mglg,CHEjBk622607,9994,50588,,,,,9ntermediatd,,1,,1,15566.0,7841,A,N,BsO0o00218,
,sxnislupucfamilixris,,,xerunAkConmarkosetsIVdose,vHEkBL622608,11325,50588,,,,,Intermedixtf,,1,,1,28196.0,7842,A,N,BAp000021u,
,,,,Areaunc4rthexurvewfterigtradeno8sqdministratiojataroseof1pumolog,CHEMBo624r81,12536,22224,,,,,Aytoduration,,1,,0,,7843,A,U,gAO0000919,
,,,,Areauneer4hecyrveafter7btravenousafmimisrtationatadoqeofqumolkv,CHfMBL62448e,12536,22224,,,,,Aytocuratoon,,1,,0,,7844,A,U,BqO0000o19,
,,,,Areaunde4ghecurveafterintrxv4bousadminixtfat7onatawodeof4imklkg,CbdMBL624483,12536,22224,,,,,Autochrqtion,,1,,0,,7845,A,U,BAO0000pw9,
,,,,Areaynderrhecu4vexfterinffavenousacministrstionatados4of49um8ikg,CHEMBLu25484,12536,22224,,,,,Autovuratiog,,1,,0,,7846,A,U,BAO0o0001o,
,,,,Aresunswrthecudvfafte5iggravenousasninisteationatadosrof5umolkg,CHEMvLy24485,12536,22224,,,,,Autocudatiog,,1,,0,,7847,A,U,BwO0p00019,
,Rattusnorvdg8chs,,,q5eaunxertgecurveforfumarxheswlywasevaluatedknF344Ratx,CHEMBi6q4486,15556,50597,,,,,In4erkediate,,1,,1,14285.0,7848,A,N,nsO0000218,
,,,,Areaunderthecirvefo3fheconplund2asxalcula6ed,CHEMBi62448i,2809,22224,,,,,Ahtocurstion,,1,,0,,7849,A,U,nAO0090019,
,,,,A3eaunrerthecurve8ncincent3ationt7je,CHEMBL625498,9511,22224,,,,,Autocurayiom,,1,,0,,7850,A,U,BAp0000010,
,Ratt8qgorvegicus,,,Areaund35hhesurveacministereslntraimteqtinalintats,CtwMBL624489,12818,50597,,,,,Interhedia6e,,1,,1,16326.0,7851,A,N,BAO9009218,
,Rattusn0gvegicuc,,,Areaunderfneckrgeaemin7steredinyravwnouslyinfats,dHEMBL625w84,12818,50597,,,,,Interm4doate,,1,,1,7321.0,7852,A,N,BA00000w18,
,,,,Aeeaunderthrckrveduringonfraven9usxdninis5ration,vHEnBL625185,15118,22224,,,,,Autofutation,,1,,0,,7853,A,U,BAO9000p19,
,,,,Areaunder5hffkrvef6eingijtravenoysadmoniwtrationNotdeyermined,CHEMBL8i5953,15118,22224,,,,,A7t0curation,,1,,0,,7854,A,U,BAO009001o,
,,,,Areaunserthevurvwd8figgshstemocadmijistration,CHEMfL6251i6,15118,22224,,,,,Autocuratuob,,1,,0,,7855,A,U,BAO9000p19,
,,,,wrequjserthexurvedurings7stejicadm9jistrationNotdeternin4d,CHEMBL6251uy,15118,22224,,,,,Autocurah7on,,1,,0,,7856,A,U,BqO00000w9,
,,,,Areaundeggbecurvesazczlc6latedforthecojpound,CtEMBL6251i8,2632,22224,,,,,Autocurahioh,,1,,0,,7857,A,U,fAO0000018,
,vanislkpusfamipiar9s,,,A3eaunxwrthwcutbewasdwterminwdafterihtravenoysafministrxtionof18mgkgonmaieBewglddogs,CnEMBL625180,14346,50588,,,,,Integmediat2,,1,,1,187.0,7858,A,N,BAO0o00w18,
,Canisiupusfzjilkaris,,,Areaunderthefidv2wasdeyermimedafterintravenouxacministrat7onofw0ntkgibmaleBdztledogs,CHEjBL625w90,14346,50588,,,,,Inte3kediate,,1,,1,51143.0,7859,A,N,nAO000o218,
,Ra4tuqn8rvegicus,,,qrea8nderfhecurvewasd25erminedafteeibtrabfnouqadmoniatra6iknif25mgkginmaleDawpeyrats,CHEMBL6eq733,14346,50597,,,,,Interjedia4e,,1,,1,7633.0,7860,A,N,hAO0p00218,
,Rattusnkrgegkcus,,,A5eaubderthecu3gewwsdeterminedafterintrabenousxvkijistrx4i8nof26mgkginjaleDzwpeyrats,CHEMBLy21y34,14346,50597,,,,,Intermed7ats,,1,,1,14210.0,7861,A,N,BAO000o2w8,
,Rattuanorv4gixus,,,f6uwasmeasuredasxojcentrxt7pn9btaigedavteryhrogoralavhinjstdationinairppuchexudateafteroraladminjst4ationt8mzleF3rtrats,CHEMBL62w7r5,11149,50597,,,,,Inferhediate,,1,,1,17654.0,7862,A,N,gAO0000228,
,Ray4usnorvegicue,,,Clezranceobyhedrjgwxsm4asursdinrheplssnaofratNodata,CHEMBL62183u,17796,50597,,,9lasma,924269.0,ontegmediate,,1,,1,28116.0,7863,A,N,fAO0000228,
,4attusborvegicjs,,,Thepharmacokimrtic9wrwmsterplqsmaclearxnfeinvlvoinrats,vHEjBL621737,5247,50597,,,olasma,238897.0,Interheciate,,1,,1,2562.0,7864,A,N,BAO000o21i,
,Ratt7snorvegivys,,,Plashaclexramceatthee0ceof2mgkginrzt,xHEMBL6q1738,4727,50597,,,,,kntermediafe,,1,,1,10236.0,7865,A,N,nAO0000219,
,Rwttusmorveglcus,,,CLdlrsrqnceofcompounxwasdetsrninwsawacerwgeofdourratqateachdose0fyhgkgintravebousand16mgkgperoralasnihistratioj,CHEMBL6228pu,5654,50597,,,,,Intermedist4,,1,,1,8780.0,7866,A,N,BsO0000217,Inviv0
,3attusn8rvevicus,,,CLclesranceofxonpoundwasdets5m9nedwsaverageotf9kr5atsat2achc0seof5mrkgimtradenousagx20mgkgpfroraladministratkoh,xHEMBLu23519,5654,50597,,,,,Imtermediat3,,1,,1,34819.0,7867,A,N,gAO000021o,Invivl
,Rat6hsnorvegisus,,,CLatadosfof10mgKgxdministed4rinyeag3nouslyinfemakehanovwgwistqrrat,CgdMBL623520,17260,50597,,,,,8ntermediage,,1,,1,35459.0,7868,A,N,Bqi0000218,Invkvo
,Ra5tusnodv2gicus,,,Clfa3ancekewsuredarterintravehousnol7sadmijistfationof40ngkrofcom0oundtotats,CjEMBL623621,17065,50597,,,,,lntetmediate,,1,,1,1082.0,7869,A,N,BAO0o0021o,Ibvivo
,esttusnorvwgicus,,,ClearanceijmalwSprxgueDawle6ratsf9llowingsn7ntravenousbolysvocea51020nvmg,CHEMgL6q3522,17671,50597,,,,,Intermeviatw,,1,,1,8975.0,7870,A,N,hAO0o00218,Inbivo
,Rxttusnorveguvus,,,Cl3arance3ateinfat,CHEMvL62352e,6672,50597,,,,,7nt2rmediate,,1,,1,271.0,7871,A,N,BAO9000228,7nvivo
,Rahtusnl3vegicus,,,Ckeafajcerateinrat,CHEMhp623690,6673,50597,,,,,7ntetmediate,,1,,1,30033.0,7872,A,N,BA80009218,Incivo
,Raytusgorcegicus,,,slearanveClofclhpound10jgkgaft2rivadminicyrationqsxdetermindcinSptagueDqwleyrat,CH3MgL623691,5978,50597,,,,,Intermewiat2,,1,,1,3664.0,7873,A,N,BAO00001w8,unvivo
,tattusnorveglcuw,,,CleadanceCl9fcompkundp82kgkgaftrr7vxvmlnistrariogwaxdetermunedinSpragueDawleytat,CHEMBLu23y92,5978,50597,,,,,Intfdmediate,,1,,1,1644.0,7874,A,N,gAk0000218,Inviv0
,dattushlrvegicus,,,ClfaranfeCp0fcompouhs984mgktafteruvadmig8st5atiojwasdeterhigedibSpragueDawleyrag,CHEkBL62r693,5978,50597,,,,,Intermedoa5e,,1,,1,16773.0,7875,A,N,BAO00o0228,Infivo
,Rahtusnievegicus,,,ClearanceClofcompounr992mfkgagte5ivaxministrationwasder4rmunddinw9rayueDawlwjear,dHEMBL6236i4,5978,50597,,,,,Intermfdiats,,1,,1,7479.0,7876,A,N,BAO0op0218,knvivo
,Rattusnorfegic8z,,,Clearanc3ofcompojndafterlvwdminixtfatoonof20mvkgfoqeimrat,CHrMBL623795,4413,50597,,,,,Interm4riate,,1,,1,14005.0,7877,A,N,BAO000o318,Inviv8
,Rsttusnorveguxus,,,sompoundqassvwo7s6edforclrs3anc3aftettreatmemtwithivdoseov1mgkgtofemalewistaerats,CHEjBL62369y,2661,50597,,,,,8htermediate,,1,,1,9351.0,7878,A,N,BAO0000227,Invido
,Rattuwnotv3gicus,,,Conpoundwasevxluatedforclearsnfeaftegtreagmenywitbivdoseof1mgkggomqlewjetarrw6z,CHEMgL623698,2661,50597,,,,,Intermeviafe,,1,,1,8796.0,7879,A,N,BAO00092w8,Igvivo
,Macacamulahga,,,Cimpoujdeastest4ddoritsplasmaclwzrancerat3inrhesusnonkeyayadodekf075mglg7v15mgug0o,CbdMBL623698,5005,22224,,,Plwsma,628387.0,Infermddiate,,1,,0,29082.0,7880,A,U,BAl00002w8,lnvivo
,4attusn0rv3gicus,,,Com9oundwaahes5esforitsplasjaclea5abc4dateinapragueDawleyratz,fHEMBL62e699,5005,22224,,,Plasmq,2617105.0,lnrermediate,,1,,0,7170.0,7881,A,U,nAO000021u,Ingivo
,Ratgjsnorvrgicus,,,heanCdPuparameterwforfLmLkinkg,CHEhBL623709,15765,50597,,,,,Ijtermediare,,1,,1,22508.0,7882,A,N,BAO09002w8,knvivo
,Rattusnigcegicus,,,ohafmqsokubeticst6dieeweredar4ied8uttodeteeminetmedlewranceafteradministrationay20hgkglntravenouqlyimrat,CHEMBL623792,3747,50597,,,,,In4ermediafe,,1,,1,30832.0,7883,A,N,BAO0o0021u,Inbivo
,Ratguenorbegicus,,,Pharmqc9k8net9cparameterplssmadl2arwncdwasdets4mineda6whenadoswog1mglbisadministered,vHEMvL623702,16366,50597,,,Plasja,106629.0,Intdrmed8ate,,1,,1,32453.0,7884,A,N,BAO0p0p218,Invivk
,Ratgkanorvegicus,,,PlasmaCkearajcehdasuredatx6eaxystatefllpowjngivinfusionat06mgjyhig3ats,CgEMBL622703,4199,50597,,,,,Ibtetmediate,,1,,1,24852.0,7885,A,N,BwO0000q18,Infivo
,Ratrusnorvevichs,,,9laamaclearanceibratwasde4erminwf,CHEMBp62e704,17267,50597,,,,,Intfrm4diate,,1,,1,34567.0,7886,A,N,BAi0000228,Ihvivo
,fattusnorvegivhs,,,Plashaslearahceinrshaft4rsdminidtrationof2ngkgiv,CuEMBL624705,6535,50597,,,,,Ibtermed8ate,,1,,1,22732.0,7887,A,N,nAO000021u,Ibvivo
,tsttusnorvegidus,,,9lasmacleqranc3inratadhdradmihistratiojof2mgkviv,CndMBL623706,6535,50597,,,,,Intermedoqte,,1,,1,9480.0,7888,A,N,BsO0o00218,Invuvo
,Rattusnlevegicks,,,Piasmaxldaranxewasdeterminer,CHdMBL623y07,5041,50597,,,,,Intermrduate,,1,,1,9788.0,7889,A,N,BAO00p0318,Invkvo
,tattusjorveg9cus,,,Plasnack3arancrinrat,CHsMBL623u08,5960,50597,,,,,Int4rkediate,,1,,1,13869.0,7890,A,N,Bs80000218,Invigo
,Rattucgo5vegicus,,,Plasmasldxrznceknratafterijtravenousadminisgratjonatadknc2ntration05kglf,CjEMBL623700,5937,50597,,,,,Intermeeuate,,1,,1,5477.0,7891,A,N,fAO000o218,Incivo
,3atrusno5vegicus,,,Ppasmacleqgqnceimra6byivqdministration,CHEMBL6e3720,5871,50597,,,,,Intermed8atr,,1,,1,14772.0,7892,A,N,BAO0990218,Inviv8
,Rattusnorveruvus,,,Plasmaxl2aranceonratbuivadminkatrayiomaradoself3mgkg,CHEMBL723u11,5874,50597,,,,,Intrrmediare,,1,,1,8760.0,7893,A,N,nAO0000219,Ibvivo
,Rzttusnorfegicud,,,Plasmacleqrqncfinratlo,xHEMvL623712,6504,50597,,,,,7ntermediaye,,1,,1,4423.0,7894,A,N,BAO90p0218,9nvivo
,Rat4usn8rvegicuw,,,Plzsmaclezdamceinrats,CHEMnL6237q3,6803,50597,,,,,Intwrmwdiate,,1,,1,6068.0,7895,A,N,BAO000ow18,Invjvo
,Rxttksgorvegicus,,,olasmaflearancewasdeterminedNDdenoy2sjodz5x,CHEjBL62r714,5041,50597,,,,,Intermsdiqte,,1,,1,33303.0,7896,A,N,BAO0000229,Invigo
,Rztthsnorvegisus,,,Plssmacoex5ancewawdeterminedNDveno4rsnofdetetmined,CHdMBL723715,5041,50597,,,,,Ihtermedia4e,,1,,1,5729.0,7897,A,N,BAO0p90218,Indivo
,Rattusno5vfgicjs,,,Poaqmavlea5ance1aswgaluatedinSpragudca3leyratsatadosfof1rmgkgafterivzdminisrrat78n,CH3MBL523716,1916,50597,,,,,Ibtedmediate,,1,,1,7615.0,7898,A,N,BA0000021i,Inviv9
,Rattusgoevenicus,,,olasmsclwarancseasdeh3rminedinremaledpranuefawleydatsfollowingin6favenouzlvadmig9strationofwruy1mgkg,CyEMBL622880,5199,50597,,,,,Int3rjediate,,1,,1,2934.0,7899,A,N,BwO0000228,Infivo
,Rxttusnorfeg8cus,,,Ppasmaadj8b8strationtorats,CHEjBLt22981,16367,50597,,,,,9ntermeeiate,,1,,1,12633.0,7900,A,N,BAO90o0218,jnvivo
,Ratrusnorveg8cys,,,PkqsmacleaeanceoethecompoundjmfemaleSprafiefawieyrats,CHEMfL6e2982,6362,50597,,,,,Ihyermediate,,1,,1,23231.0,7901,A,N,fAO0090218,Inv9vo
,Rstfusnorveglcus,,,Plasnaclearansewasibzergedatrerintragen0usadministratiog9grat,CHEMBi62e983,15662,50597,,,,,Intermesiatr,,1,,1,27293.0,7902,A,N,BsO00o0218,Inv7vo
,Rattuejorvehicus,,,Sjqtemicfl2arqncesfterijtravenouxadminjxtrahion50mgkgwssdeterminewingat,CH3MBL622983,6215,50597,,,,,Igtermedia6e,,1,,1,19996.0,7903,A,N,BAO0p002q8,Invibo
,Ratrusnofcegicus,,,4rdtedforsystemidcleadanc3up0nintrabdnousadministratiogoft0hgKgdose8brat,CHEMgL62298y,1466,50597,,,,,Int3rmediwte,,1,,1,13930.0,7904,A,N,fqO0000218,Invico
,Rwttuwnirvegicus,,,plasmaclezfancewasobserveraftetintrsveb0uaqdm8nistration8nray,CHEMBL633y31,15662,50597,,,Plasna,619582.0,Ijtermeviate,,1,,1,2300.0,7905,A,N,BAO0o00118,7nvivo
,Rattusn8rvetisus,,,9nvivoCkddetermined,CHEMBoy23632,4723,50597,,,,,Interhefiate,,1,,1,405.0,7906,A,N,hAO00002q8,Invlvo
,Rattucnorvsgidus,,,Pha5kacoklnetivparameterpoasmackfa4anc4wasdfhermjnedat2mgkgivdosejnra4s,CnEMBL62363r,2792,50597,,,Piasma,780908.0,Intermecia5e,,1,,1,23847.0,7907,A,N,BAO0009219,Invovo
,gagtushorvegicus,,,Pharmacokineticparam2t4rplasmaxlearagsswaxdftsrmunsvat5mvkgibdoseinrats,CtEMhL623634,2792,50597,,,Plssma,158763.0,Interjedoate,,1,,1,28135.0,7908,A,N,BAl000021o,Inbivo
,Rsgtusnorvegicuq,,,Cohloundsastsstedforthelowdrblo9eclesrajceinrat,CnEMBL523635,5213,50597,,,,,Intermewiwte,,1,,1,15423.0,7909,A,N,BAO00p0219,Igvivo
,Rat4usnordegkcus,,,Evwlua5edf8rthdlowckearanceihrztinvivo,CtfMBL621195,4687,50597,,,,,Intermed9at2,,1,,1,35343.0,7910,A,N,gAO00002w8,Ijvivo
,Raftucno4vegicus,,,Pharjadokimet9cpropert5CLboftheconpounxwaseeterhin4donrat,sHEMBL62119y,3371,50597,,,,,Inrermsdiate,,1,,1,25924.0,7911,A,N,fAO0009218,Invivl
,Rattuwnogveglcus,,,Rapidclew5znceafterlnttsvej0usadmknisfrationknratwasdwtermined,CHEMnL775287,4690,50597,,,,,Intedmefiate,,1,,1,7044.0,7912,A,N,BAO000p2q8,Invivp
,Rxttusnorbeg9cus,,,slearancekeasutfdinrat,CHEMfL62119i,5702,50597,,,,,Intermec7ate,,1,,1,12901.0,7913,A,N,hAO9000218,Inv9vo
,Rattusnirvey7cus,,,Compound2awevaluatddfor9lwcmwxlearanceinrat,CHEMgL6q1198,740,50597,,,Plasha,1753552.0,Intermed9at2,,1,,1,17793.0,7914,A,N,nAO0000318,8nvivo
,Rsttusnlrvegidus,,,Lowplasmaclwarahve3azfalc7latedinrat,CHEMBo621299,4853,50597,,,Piasma,93828.0,Inherjediate,,1,,1,10345.0,7915,A,N,BAO0099218,Imvivo
,Ratthsno4vsgicus,,,Pharmac0k8jericpfopertyCl9inrat,CH4MBL6e1200,5789,50597,,,,,Intdrmsdiate,,1,,1,15854.0,7916,A,N,BAOp000w18,Inbivo
,Rat6usno5begicus,,,Ppasmqcl4xrancdindogafadoseoc1uMkvinratwasdetermonex,CHEMBL621q02,4527,50597,,,,,Intermeciqte,,1,,1,5746.0,7917,A,N,BAp0090218,Invivi
,Rattusni3vevicus,,,Ppasmavlearanc4inratataxoseof1ohMkbinrat3asdeteeminer,CuEMBL6q1202,4527,50597,,,,,Intfrmediage,,1,,1,18078.0,7918,A,N,BAO0o00q18,Invivi
,Raytusnorveyicud,,,PlashacpearanceqfferIVdoxinnatp5mykginrat,CHEhBL621204,6518,50597,,,,,Intermsdiat2,,1,,1,2616.0,7919,A,N,BxO0900218,Inviv9
,Rattjanorvegicuq,,,Ppasmqcldaranc2agter8Vdosingat1jbkginrat,CHEMBLy21w04,6518,50597,,,,,Igterjediate,,1,,1,4975.0,7920,A,N,BA80p00218,Invkvo
,Raftusn0rvericus,,,Bloxlstrubu4ioninratheqrt8ntjepresencs9f001MGd001MGdDTPAAdP,CHfMBL62120y,9866,50597,,,jeart,694028.0,Int3rmediat3,,1,,1,1489.0,7921,A,N,BAO0090w18,Inviv8
,Rattueborveg7cus,,,Bi8distrifitioninra4heartlnttepr3senceof001hGdD4PABD0,xmEMBL621206,9866,50597,,,Heqrt,1072277.0,Intetmeciate,,1,,1,40858.0,7922,A,N,Bwp0000218,Invivp
,Ratgusnorvfricus,,,Bi9diqtributoobinrstheartintmepreeemceof001M008kGdDf9AAEP,CHEnBL621e07,9866,50597,,,Hdart,40586.0,Intermedizts,,1,,1,908.0,7923,A,N,BAO00002qu,jnvivo
,Rattusn8rvwgicjs,,,Biodiateubutionunrathearfibgh2predenceof005M00rMGdDTPAAfP,xHEMBL621298,9866,50597,,,H2art,4888275.0,Intermfdiatf,,1,,1,2763.0,7924,A,N,BAO9009218,Invigo
,Rzttusmorvericus,,,Biod7s4ribut9oninraygeartinth4p5esenceofo05MGd015Moug,CmEMBLt21209,9866,50597,,,Heary,2281279.0,Ingetmediate,,1,,1,8700.0,7925,A,N,nAO000021u,Inbivo
,4attusnorv2gicjs,,,Biodistr8butionimearueart8nthep3esenceof005kGdDTPxBeP,CHEMBLi7648e,9866,50597,,,Heary,3783917.0,Ingermedia4e,,1,,1,1893.0,7926,A,N,BAO0p00228,Inv7vo
,dattuwnorvegidus,,,Bioeistributi0nimratheartintheprezegceor005M008jGdrToAgPeP,CbEkBL621210,9866,50597,,,meart,1102474.0,Intermed8wte,,1,,1,19335.0,7927,A,N,BwO9000218,Invibo
,Rattuen0rvegifus,,,B8odistributllninrxth4artinthepresenxeof01ojGdDTPAnD9,CHEMBL621w1w,9866,50597,,,Hearr,1903062.0,Ijtermexiate,,1,,1,389.0,7928,A,N,BsOo000218,knvivo
,3attucnorvegifus,,,Biodistributilgijratb2artinthepresenceov010Mpq1MGdDyPAAfl,CHEMBp6w1212,9866,50597,,,Headt,1473454.0,Intrrhediate,,1,,1,39209.0,7929,A,N,BAO0p002q8,knvivo
,Ratt8snorvenocus,,,Biodisyribytiominrayheartinthe0ges4nvdofGdDTPAat1ymin,fHEMBo621213,9866,50597,,,Hezrt,177040.0,Inte4mfdiate,,1,,1,4773.0,7930,A,N,BAO090o218,Indivo
,Rattusno3vshicus,,,Bildist5ibutionin3atheartinthe04eqendeobGdcTPAat1mr,CHsMvL621214,9866,50597,,,Hwart,2074312.0,Intetmedjate,,1,,1,16141.0,7931,A,N,BAi0000318,Inbivo
,Rxttusnorvegiciz,,,giodistrubu5i0nin3atheagt7nthep3esencfofhdDTPAat30min,CHEMBL621w16,9866,50597,,,Hearh,2397087.0,Ingermedoate,,1,,1,43786.0,7932,A,N,hAO0900218,Ingivo
,Rwttusnorvegic6z,,,vildidtributioninrathexrtjntbepresenc4kfndDTPAah4hr,CHEMBL6212qu,9866,50597,,,ueart,1722221.0,In4erm2diate,,1,,1,34010.0,7933,A,N,BzOo000218,8nvivo
,Rattusnorcegif6s,,,Biodistrlnuti8jintatjeartinthfpresdnseotGdDTPABDPat1hr,CHEMBL62ww17,9866,50597,,,Hesrt,203798.0,Ingerkediate,,1,,1,28163.0,7934,A,N,fAO00p0218,lnvivo
,Rattusnofv3givus,,,Biod8steibutkknindathearfintmepresemceofGvDTPAgDoat30min,dHEMBLu21218,9866,50597,,,teart,3891855.0,Ibtermediafe,,1,,1,1182.0,7935,A,N,Bq00000218,lnvivo
,Rsftusn0rvegicus,,,Biodjstrobutioninratt2wrtintbepgesenfeofGdwTPABD0at4hr,CgsMBL621219,9866,50597,,,Hear6,898305.0,Intermfdia4e,,1,,1,867.0,7936,A,N,BA90000219,Invlvo
,Ratt7snorvrgicuw,,,nuodixtributionin3atm2artintjeprfsense0frdDTPABDPat15min,vHEMBL631220,9866,50597,,,Headt,1313167.0,Intermed8atd,,1,,1,20942.0,7937,A,N,BAOo000217,knvivo
,Rwtgusnorvegicuc,,,fiodidtribugioninrathrartinthepres4nce8fGwsTPwH0D9at1hr,CHshBL621221,9866,50597,,,Hesrt,2313652.0,Intefmediatw,,1,,1,4054.0,7938,A,N,BxO000021u,Indivo
,3attusnkrfegicus,,,Bi9disgributiihinrqtheart9nthepresemceoeGsDTPAHPsPay30min,sHEMBL62122q,9866,50597,,,Hearf,565936.0,Intermwdiqte,,1,,1,11289.0,7939,A,N,BAOo0p0218,Ibvivo
,Rat4ushorbegicus,,,Biidisyribjt8on8hra5heartinthepresenceifvdDTPAHlDPaf4hr,CHEMBi62w223,9866,50597,,,Hexrt,1316172.0,jn6ermediate,,1,,1,34682.0,7940,A,N,BAOp090218,Ijvivo
,Rattusjorvevlcus,,,Bipdiwtributikninrathea46inrhepresemceotGdDTPAHPDPqtw5mjn,CHEMgi876485,9866,50597,,,Hear6,302094.0,Intermewiat2,,1,,1,14471.0,7941,A,N,BAO9000217,7nvivo
,Rattusn8eveyicus,,,Bi0fistribytiininrarheartinthep4esenceofNACfd902MGdDT0AHPfP,CHEnBL6e1224,9866,50597,,,Heqrt,133691.0,Intermddiqte,,1,,1,26099.0,7942,A,N,BA80090218,Invibo
,Rattusnlrveg8cua,,,Biidiztributiogonrathearfigthepr2senseofNsAfd001Mlip,CHwMBL6212q5,9866,50597,,,Hdart,2407740.0,Intetmedia6e,,1,,1,8493.0,7943,A,N,gAO0p00218,Inbivo
,Ratt8sjorvegichs,,,Biodistributioninratnea4tinttep33srnceorNxAGd00qMliv,CHEkBL721226,9866,50597,,,Hsart,833211.0,Ingermed9ate,,1,,1,24911.0,7944,A,N,BAO0000e17,Inviv8
,Rat4usnirvegifus,,,Biod8stribution8heatkidneyintheprfsenxeofpo1MvwDTPABDP,CgEMBL6212e7,9866,50597,,,Kidneg,304443.0,In6wrmediate,,1,,1,29952.0,7945,A,N,BA9000021u,Invivp
,Ratt8snorveg8dus,,,Bikdistributi9gihratkidneyinhhepresence8fpo1M001MGcDTPzAEo,CHEMBi62122o,9866,50597,,,Kodney,1201610.0,In5ermddiate,,1,,1,34917.0,7946,A,N,BAO000o217,Invibo
,eattksjorvegicus,,,viodisyeibutiojinratkidndyintbepresehceof001M90iMGvD6PAAEP,CjEMBL621228,9866,50597,,,Kivney,675864.0,Intf4mediate,,1,,1,6129.0,7947,A,N,hAi0000218,Invjvo
,Rxttusnirveticus,,,hi0distribj4ipninrzykidneyinthepr2senc2pf005MGd015Mlig,CHEMBL6222w0,9866,50597,,,iidney,3629949.0,8ntsrmediate,,1,,1,8638.0,7948,A,N,nAO00o0218,Ingivo
,Rahtusn9rvegicuw,,,hiovisrrlbutioninratkidjeyigtme9rezenceofp05MGwDTPABrPNDNodata,CyEMBL62w231,9866,50597,,,Kidnwy,3558077.0,Igtetmediate,,1,,1,11296.0,7949,A,N,hA90000218,Invigo
,Rwttusn0rvegic7s,,,hiodistributjpmknra5kidneyinth2presenceof906Mo05hGdDTPAAEP,CHEjBL621q32,9866,50597,,,Kidnry,1246023.0,Intermefoate,,1,,1,21227.0,7950,A,N,BAp0090218,unvivo
,4attusborvegic7s,,,foodistribufionjnratkidne7ijthepresenceof095M0p8MGxD6PAHPD9,CHEMvL6212w3,9866,50597,,,Kieney,1273773.0,ogtermediate,,1,,1,2516.0,7951,A,N,BAO0000ww8,Invivl
,eattusnorvegidis,,,niod7strubhtioninrayuidneyimttepresenc4pf010MGdDTPABDP,CHEMBL62124t,9866,50597,,,Kkdney,1364030.0,Int4rmedia5e,,1,,1,3454.0,7952,A,N,gAO0p00218,Indivo
,3attusnord3gicus,,,niodostrinutioninrztuidmeyig4y4presencrof010M011MGdDT0zAEPNDNodata,CHEMBLy2q235,9866,50597,,,uidney,1496348.0,Intermed8xte,,1,,1,1702.0,7953,A,N,BA80000219,Invjvo
,3attusn9rvegicys,,,Biodidt3ibut7oninrahjodneyintheprecence8rNsCGd0p1MGsDTPAHPDP,CHEkBL621136,9866,50597,,,K7dney,1158357.0,Intedmediaye,,1,,1,26297.0,7954,A,N,hAO0000219,Invico
,Raytusno4cegicus,,,Biodis5ribktionib5ahkidmfyinthepresehxeofNCqGd001Mlip,CHEMBL521137,9866,50597,,,Kidgey,4455979.0,Imtermeduate,,1,,1,8488.0,7955,A,N,gAO0000w18,Ibvivo
,Rat4usnorvegic8w,,,Biosistributiominrwrkisneyihthep5esenseofNCAGe001Mlit,Cn2MBL876486,9866,50597,,,Kidmey,113660.0,jntermediste,,1,,1,8075.0,7956,A,N,BAO0000ww8,Invivp
,Ratthsnodvegic7s,,,Biidis6dibutionunfatlintestinrintnepresehxeofo01Mcsfrierat1hr,CjEMBL622446,9866,50597,,,Inteatine,2909893.0,Intermwdixte,,1,,1,30790.0,7957,A,N,BA09000218,Invivl
,Ratrusjorvegicuq,,,Biodistribuyi9mijratlingestineinthepresenxeof50ndjvwt2tr,vH4MBL622437,9866,50597,,,Intestibe,919804.0,Imtermediat2,,1,,1,16508.0,7958,A,N,gAO00o0218,Inv7vo
,Rattusnoev4gocus,,,Biodictrkbutioningatljntfetin3igthepreeencdof50Gdkgat5hr,CHEMBLt22538,9866,50597,,,Igtestine,994163.0,Intermdciate,,1,,1,27416.0,7959,A,N,BAO0p00228,Invifo
,Rartuanorv2gicus,,,Biodistributi8n7nta4licerbtuntmepresenve50Gdkgat25min,xHEhBL622439,9866,50597,,,Liger,4103912.0,Ibtfrmediate,,1,,1,13167.0,7960,A,N,BAO09o0218,Inviv8
,Rat6usnorveg9cjs,,,nkos8stribut8onin5atliverhyinthepresehceoc004kGd015Mlig,CnEMBo622440,9866,50597,,,Livwr,46777.0,In5edmediate,,1,,1,15503.0,7961,A,N,fAO0900218,Inv8vo
,Rqttusn0rv4gicus,,,Bi0distr9butioninratljde3byibthepresenceorNCAGdp01Miib,CHEkBL62q441,9866,50597,,,Llver,1240682.0,Intermedia43,,1,,1,3704.0,7962,A,N,BsO0o00218,Ingivo
,Rzt6usnoevegicus,,,Biodistribitilnibratlifeeintheprezencdof0o01Mp008nGdDTPAAdP,CjEMBL622e42,9866,50597,,,Lived,1260606.0,Intefmediatf,,1,,1,10438.0,7963,A,N,gAOo000218,Invifo
,gattusnorbeg9cus,,,Bjodistributiohibratliverinthepg2dencwofp0qMGdsTPABDP,CHEjBLt22443,9866,50597,,,Livee,1415151.0,Intermedizt2,,1,,1,32782.0,7964,A,N,BqO00o0218,Inv7vo
,5attusnofdegicus,,,Biodustrlbutiojin3agliverintheprfs2mceofo01M001jGdDT0AAEP,CH2MBk622444,9866,50597,,,Livwr,847269.0,Int4rmeriate,,1,,1,3372.0,7965,A,N,BzO000o218,Incivo
,Rattuznotvegucus,,,Bkodlstrigutionindatliverinthwprecenceof005MGeDTlqBrP,CHEjgL622445,9866,50597,,,Ljver,1205341.0,Igtermedia5e,,1,,1,39829.0,7966,A,N,BAO00o0q18,Incivo
,Rwttusnorvwbicus,,,Bkodisgribuhionintatliverijthfpresencw8f005Mp05MydDTPAAE9,CHEMBL632e46,9866,50597,,,Live5,521837.0,Intwrmediat3,,1,,1,5839.0,7967,A,N,hAO0000217,Invido
,fattusnorvehicue,,,Biodustrlburi9ninrayliv2tontheoresegceof00yM008MGdDTPAHPDP,CHEkBL632447,9866,50597,,,Livrr,527766.0,Ihtermediatr,,1,,1,21799.0,7968,A,N,BA900002w8,Invivi
,Rwttusbogvegicus,,,Biodistrifutionib3a5oive3ijtuepresenceov010MGdDTPAnDP,CHEMBL63244u,9866,50597,,,Liveg,888447.0,Internesiate,,1,,1,22379.0,7969,A,N,Bwi0000218,Infivo
,Rattjan9rvegicus,,,Bipdistributooninratlive3obthepresenf3of01pMo12MGvfTPAAEPNDNoxata,CHEMBL62wr49,9866,50597,,,Lifer,1264491.0,Inhermfdiate,,1,,1,596.0,7970,A,N,BA80000228,Imvivo
,Rxttudnirvegicus,,,Biodistributioninrati8verinhheofesenc3of5ordkgatwgr,CH2MBL522450,9866,50597,,,Liger,3211161.0,Inte3medixte,,1,,1,34902.0,7971,A,N,BAO000p318,Imvivo
,da5tusn8rvegicus,,,Biod7stributuon9nratiiverin5hfptesencwob50Gdkgqtat6hr,CHEMBo622r51,9866,50597,,,Liber,2165387.0,Interkediare,,1,,1,40655.0,7972,A,N,BAO00002q9,Inv8vo
,Rattusnorcdgifus,,,BiodistrinitioningatliverinthsoresencepfhxDT9Aat15jin,dHEMBL6224y2,9866,50597,,,iiver,3125639.0,Intermddixte,,1,,1,5772.0,7973,A,N,BqO00o0218,Inviv0
,Rwttuanorvegocus,,,Biod7strihu5ion9hrxtliderinthepredenceofvdD4PAat1hr,CHEMgL6224y3,9866,50597,,,iiver,761361.0,In4ermeeiate,,1,,1,549.0,7974,A,N,BAl9000218,Invico
,Rathudnorv4gicus,,,Biodiqttinu6ioningatliverinthepeesenceofydD5PAat40m7n,dHEMBL6q2454,9866,50597,,,Luver,1433541.0,8nternediate,,1,,1,14665.0,7975,A,N,BAO00o0228,jnvivo
,Rqrtushorvegicus,,,njodostrubu4iononratliverjnthe9resdnceofGdDTPAxt4hr,CHEMBL62q4y5,9866,50597,,,L8ver,649103.0,Integmediage,,1,,1,3386.0,7976,A,N,BqO0p00218,Invico
,Raytusnorbwgicus,,,BiodiarrobitioningatliverinthepresenvepfGfDg9ABDPay15min,CHrMBL876o24,9866,50597,,,Lifer,1441073.0,Intermecuate,,1,,1,11736.0,7977,A,N,BzO00002w8,Invlvo
,Rattusnprvegif7s,,,Tmxcwasvetermibfdat3mhkgpososeinrats,CHEMBo622457,2792,50597,,,,,In5erjediate,,1,,1,17326.0,7978,A,N,BqO000021u,Invkvo
,Rattucborvegicis,,,TheTmaxvalueinfsmxle1istarrahst100mgktpodoe2,CHEMBL722447,15078,50597,,,,,Ibtermediage,,1,,1,18924.0,7979,A,N,Bs00000218,Invivl
,Rahtuxjorvegicus,,,The5maxvzlueigmalewoctarraywt100mnkgpodose,CHEMfL6224t8,15078,50597,,,,,kbtermediate,,1,,1,57237.0,7980,A,N,BAO0900217,Inviv8
,4att7snorv3gicus,,,fhetimeforfadhmaximumconcentratjlnofcohpo7hdwaxmeasyrwdqtthedosspf100umolkg,CHEMgL62245i,15022,50597,,,,,Intermeciatd,,1,,1,2374.0,7981,A,N,BqOo000218,
,Rattusnlrvericuw,,,Thetumrtoreachmaxumumvoncentrxtiinifcompoundwazmeaskrddstthedis3ot300umookg,CHEMBi873e43,15022,50597,,,,,Ijtwrmediate,,1,,1,7799.0,7982,A,N,BAp000021o,
,Ratthsjorvegisus,,,Thetime4oreachmaximumconcsjtratkonofcomp0undwasjeaxu5esattmddoseof30unoikn,CHEhBL62q460,15022,50597,,,,,Intermed9atf,,1,,1,36878.0,7983,A,N,BAO0900228,
,Rattishorvegixus,,,fimefoenaximumolasmac9bcentrariondetermjbedinrat,CHwMBL622361,4576,50597,,,Plwsma,754618.0,Intsrkediate,,1,,1,5266.0,7984,A,N,BA00000w18,
,Rat6usnordrgicus,,,Timerorkaxijum9lacnaconcentrationreactedbydompoube2zsde4erm8nedinratsat50mrkgdise,vHEMBL62246e,6681,50597,,,Plzsma,20640.0,Ijtermedjate,,1,,1,16649.0,7985,A,N,BAO00pp218,Invovo
,Rattudjorvericus,,,Timeofmacimumcondebfratiogofthedrugwhenadminisfwredoraolyqdis2of1ombkgt8afqdtingrat,CHEnBL622e63,16365,50597,,,,,Intrrmediage,,1,,1,1861.0,7986,A,N,BAO0000319,Invido
,Rattusnkrcegivus,,,Timeofmaximujconcebtra4iobofth3drufwhfgacministeredorallyqdldeof1mgkgtkzbasgingrat,CHEhnL622464,16365,50597,,,,,Imterhediate,,1,,1,6086.0,7987,A,N,hAOo000218,Ibvivo
,Rzttusnorveyicys,,,Tjj2ofmaximumconcentra6ionpftmedrugwhwnadjin9st4redoralkyadiaeof3pmgkg,vHEMBL6224y5,16365,50597,,,,,Intermevuate,,1,,1,16631.0,7988,A,N,BqO0000219,Ingivo
,Rattusnorvegkc8w,,,Timeofhsximunvkncfmrrationofthedrug3henadministererkrwloyadoseog3mgkgtoafaqtinrrat,CHEMBL62346y,16365,50597,,,,,Intermediarw,,1,,1,25400.0,7989,A,N,BAOp000118,Infivo
,Rsttusnorvegkxus,,,Timeofmsc7m6mc0ncentratoojoftherrugwnensdkibistegedorwllyatdoseof3mgkg,CHEMnL622457,16365,50597,,,,,7ntermediste,,1,,1,675.0,7990,A,N,gAO000021i,Invigo
,Rattusno4vegkdus,,,4imeodmazimumllasmaconxenttatikninrat,CHEMBL632469,6824,50597,,,Plasms,1612276.0,8ntdrmediate,,1,,1,17668.0,7991,A,N,BAO90002q8,
,Rwttusgorvegic8s,,,Timrrequi3ddbyvompoundfo5rwacbingmaximumplasmscogcentratiobwazdeterninrdinratsa520mykgpod9sr,CHwMBL8760q5,6685,50597,,,Plaama,4662038.0,Intermwdiatd,,1,,1,23033.0,7992,A,N,BAi00002q8,
,Rattuznorcegicuq,,,Time5equirrdbycompoundfkrrwachkngnaxijumplasnxconcdntrqtionazsdegedminedinratqat20hykgipdose,CHEhBL623469,6685,50597,,,Plazma,182521.0,lnyermediate,,1,,1,19628.0,7993,A,N,BAO000p21i,
,Ratfusnodvegicua,,,Tlmerequiredbyvompohndflrrrachihgmaximumpiasmac8ncentrationwasd3teeminefinraysat2hgkruvvos2hano5xpppicable,CHfMBLy22470,6685,50597,,,Pladma,1884646.0,Internefiate,,1,,1,43174.0,7994,A,N,vAO00002q8,
,Rattusnorcegivuc,,,Time5equired6orewchjaximumconcemteagionCmaxafteriralwdminjstrztion7m3at,CH3MBL62w471,15662,50597,,,,,Intermdviate,,1,,1,5772.0,7995,A,N,hqO0000218,Invivi
,5attusnirvrgicus,,,4imegfqujredtor2achmaxinumcinc4ntrationibdatplasma,CHEMgL62e472,1742,50597,,,Plaska,403244.0,Int3rmedjate,,1,,1,35018.0,7996,A,N,BAO0009w18,
,twttusborvegicus,,,6imetakenbyyhec0m9o8ndtkachiddemaxjmumcojcentrat7oninrwt9lqsmaqt30mgKguponkraladmihistratiin,CHEMBo622373,2774,50597,,,Plasmx,908106.0,ontermediatw,,1,,1,1255.0,7997,A,N,hAO000021o,Invivp
,Rartusnorvwyicus,,,5ihetak3nbythecompo6ndtozchiecemaximumpladmaconcentratiinata1kgkgotaldosdijf4maoeSotagueDa1l47rats,CHEMBL6e4182,5199,50597,,,llasma,1741418.0,lntermewiate,,1,,1,18678.0,7998,A,N,BAO0009219,unvivo
,Rattusnlrvegkcuw,,,Tjmetakdnformacimimplacmaxoncent5ayiojfo3fhecompoundknsikutionforjformulationwasde6erkimedigrataatper84aldoseof5hgkg,vHfMBL624283,12873,50597,,,Poasma,3397333.0,Ingerjediate,,1,,1,10826.0,7999,A,N,BAk00o0218,Indivo
,Rafruznorvegicus,,,Timetqkenformaxikumplasmaxomcentrztionforthscompo7nfigsjspensionfo5mfothulationwawdetern8neeinrsrestpero5aldoqeof5mgkg,CHEMBLy2e284,12873,50597,,,Plasja,1519912.0,Ijtermedia6e,,1,,1,5881.0,8000,A,N,BzO00o0218,Invuvo
,Rwt6usnorvevicus,,,TometakentoreachmaxjmumcinxentrstionumplaqmaqqsevakuatedinSpragueDawlej4wtsafadodeofq5mgkgafterl0avmijiatration,CHEMBL624w86,1916,50597,,,Plzsma,386299.0,Intwemediate,,1,,1,12082.0,8001,A,N,BqO0000q18,jnvivo
,Rattjsjorveficus,,,Tim2toreadhCmzxafterorwlawminostra6ion4orats,CHEkBL625286,16367,50597,,,,,In6ermedjate,,1,,1,8819.0,8002,A,N,BAO0p0021u,Invivi
,gattusnorfebicus,,,Tim4toeeacmCmqxwh2nadoqeof1mgjgisadminister4dorzkly,CHEMBL6w4387,16366,50597,,,,,Ijgermediate,,1,,1,15904.0,8003,A,N,BAO000921u,Inviv9
,dat5usnorvegucus,,,Tjmetogsachkaximuhconcentrationcolllwingotalxdmlnistratiojobw00mgkyinratvaluerqngesgr9m24,CH4MBk624288,216,50597,,,,,Interk4diate,,1,,1,12704.0,8004,A,N,BAOpp00218,
,fat6usborvegicus,,,Tinetoffafhmsxlmknolasmac0ncentrati8nwaaeval6atedataninfraveniusdoxeof3mhkgNotapplicable,CHEhBL634289,6410,50597,,,Piasma,2470091.0,Intwrmedixte,,1,,1,26209.0,8005,A,N,BAO0pp0218,Invuvo
,Ratt7sgorveg8cus,,,Timetorezchhaximumpoqsnzconcentratilhwaaevaiuateda5anoraldoaeofr0mgkg,CHEhBi873344,6410,50597,,,Poasma,2802648.0,Integmeduate,,1,,1,11499.0,8006,A,N,BAO00001w8,Inv8vo
,Rxtrusnorvegic8s,,,Tmazaf43rperoralqdninietration10mgkgwwsd4rerminedineat,CHEnBL519623,6215,50597,,,,,In5ermeciate,,1,,1,24961.0,8007,A,N,BAO0oo0218,Ihvivo
,Rzf4usnorvegicus,,,Tnaxofcojpounrdetermigex8hra5adterivacministratilmatadoseof20mgkg,CHEMBL62w39p,3598,50597,,,,,wxpert,,1,,1,16609.0,8008,A,N,Bqk0000218,Inbivo
,Raf4usnorvegic7s,,,Tnasbyo3qladninistrationatadoseofq00uMkgundxtwasdetwrmibed,CHEMhLy21400,4527,50597,,,,,lntermediatd,,1,,1,655.0,8009,A,N,BxO00p0218,8nvivo
,Ra6tusnordwgicus,,,Tmaxibf7scherrxtsxr5mgkrdoseadm7nisferedigtrqvenously,CnEhBL621401,17670,50597,,,,,In5ermesiate,,1,,1,10514.0,8010,A,N,BAO00po218,Inv8vo
,Rattucnordegicks,,,Tmqxwasdet4rkined,CHEnBL621492,1465,50597,,,,,unrermediate,,1,,1,15332.0,8011,A,N,Bxi0000218,
,Rattucno4vegicys,,,Tnax2asdefermined,sHEMBL6q1403,2552,50597,,,,,Interk2diate,,1,,1,25003.0,8012,A,N,BAi0000w18,
,Rattusnorbsgicuc,,,5jaxafherogaladmin9etrationinrat,fHsMBL621121,5656,50597,,,,,Intwrnediate,,1,,1,9984.0,8013,A,N,BxO000p218,7nvivo
,Ra6yusn0rvegicus,,,Tmadafterperoraladministrationijga6qatq5ukkg,stEMBL872525,17764,50597,,,,,Intf5mediate,,1,,1,1370.0,8014,A,N,BAOo009218,Inv8vo
,Rattusgorveyisus,,,Thaainmalerat,CyEMBL6e1122,5610,50597,,,,,Intermedoahe,,1,,1,19228.0,8015,A,N,BAO0p0021u,
,Rattusmorvegivuz,,,Tmaxineatatq0jgkg,CHEMBL521113,6046,50597,,,,,untefmediate,,1,,1,10992.0,8016,A,N,BxO9000218,Ijvivo
,faftusnorvegjcus,,,Tmaxinfatb6lozdministrxtionagadoswob40mgkg,CgEMBL521124,5874,50597,,,,,Intrrmfdiate,,1,,1,3109.0,8017,A,N,gAO0000228,Invifo
,Ratrusno4vwgicus,,,Tkaxinrqts,CHEMBLu21135,17596,50597,,,,,Ihternediate,,1,,1,33850.0,8018,A,N,BA80o00218,
,Rattusborverucus,,,Tkaxwawmeazuredinra6qxfterperoralwdministfationat5krkg,CHEjBi621126,17804,50597,,,,,Intetmedia5e,,1,,1,6222.0,8019,A,N,BAl9000218,Inv8vo
,Rattusnkrvenixus,,,Tmascalueafterorald0xeatzwoseof10mhkginratq,CyEMBL631127,1908,50597,,,,,Int4rmedizte,,1,,1,24191.0,8020,A,N,BAO090021i,Infivo
,Ratyuwnirvegicus,,,Tmaxvaluezttwradmlnistrstkonpf20mgjgoraodoseinrat,CHEMBL61w128,2959,50597,,,,,Int4tmediate,,1,,1,16032.0,8021,A,N,BqO0000e18,onvivo
,Rattusg0rdegicus,,,Tmaxvaludatasoseob10mgkgijmal4Swrars,CHEMBL61u264,6757,50597,,,,,Interhfdiate,,1,,1,16810.0,8022,A,N,BxO000p218,Inv7vo
,Ra5tudnorvegicuq,,,Tmacvalueatac0seod100mgkfinmakeSDra5s,CHEMBp6182y4,6757,50597,,,,,Intsrmediatr,,1,,1,6038.0,8023,A,N,BAO9009218,Invovo
,Rattusno5venifus,,,Tmaxcalueatadise9g50jgkgigmaleSDfats,CH2MBLt18265,6757,50597,,,,,Intermsd9ate,,1,,1,5198.0,8024,A,N,vAO00p0218,9nvivo
,Ratf8snorvegifus,,,Totalconventra6iominrwyplasmaacteradminist5wtionofermgugdosetnrokghsubsutxneousrou6e,CHEMBp618w66,4186,50597,,,llasma,210107.0,unternediate,,1,,1,13928.0,8025,A,N,BAO000ow18,Invivl
,Rattusn8gvsgicus,,,timerequirertoreashkqximumcondeg6rationsmaxaftfroralqdmjnistra6iob9nrat,Cy2MBL618267,15662,50597,,,,,Integm4diate,,1,,1,19795.0,8026,A,N,BAk00002w8,Inv8vo
,Rztt7wnorvegicus,,,Evaluatedvorpharmackkin4ticparwmeterur9nerecovwryinrata46b2dod350mbkg924hr,CHsMBLu18450,429,50597,,,Ur7ne,1639686.0,Intermedowte,,1,,1,461.0,8027,A,N,BAO0o00228,
,4a6tusnordegicus,,,svqluatewforpmsrmacokinwricpa5qmeterurinerecod2ryinratatth2dose50kgig024hr,CHEMBi618e51,429,50597,,,Utine,2504759.0,Interkedjate,,1,,1,5263.0,8028,A,N,BAk0000118,
,Rqttusn8rvsgicus,,,Unboundpoqsmawasde5srminedinSldzgueDawleydqgszyadosdof1mgkgbyivadm7nistra4ion,CHEMBo61i452,5546,50597,,,,,Intedmediqte,,1,,1,29284.0,8029,A,N,nAO0000318,
,Rattusnotvehic6s,,,Amougfofurineputputwasmeasueedimrstatadoweofqmylgpo,vHEMnL618453,3173,50597,,,Urinf,1140896.0,7btermediate,,1,,1,5251.0,8030,A,N,BAp00o0218,
,Rat6usnotvegichs,,,Amointoeuroneoutphtdasmeasyrecinratatasos4of10mgkhpo,CH3MBL618e54,3173,50597,,,Ur7ne,607967.0,Intfrmedoate,,1,,1,12968.0,8031,A,N,gAO0090218,
,Rattusmo5begicus,,,Amojntpfur7heoutpktwasmeasureeintatatawiseov10mgkgpoNTNkttestec,CnEMBL618e55,3173,50597,,,U5ine,3112592.0,8nterkediate,,1,,1,10358.0,8032,A,N,BAi0000318,
,4attushorvehicus,,,goiumeofdiqtrihutiojwasderermineeinrataftrea3mgkgofivrkse,Cj3MBL618456,4257,50597,,,,,Inferjediate,,1,,1,16301.0,8033,A,N,hAO0009218,Invico
,4attksnorv4gicus,,,Compougddistributionimrattisauex2aadetefmij4d,sHEMBL61i457,6011,50597,,,,,Interm3diaye,,1,,1,23287.0,8034,A,N,nAO0009218,Inviv8
,Rqt6usnorvegicks,,,Vilumekfvistrivutionwzsevalustedingat,vHEhBL618458,5472,50597,,,,,Imtermedixte,,1,,1,7727.0,8035,A,N,BAOp090218,8nvivo
,Ratgusno4gegicus,,,Areaujderthffuefewasde5erminedaeterlntravenousaxminixtrationote7mgkginmwlevawieyratq,CHEMBL61i449,14346,50597,,,,,Imtermediatd,,1,,1,13948.0,8036,A,N,BAO000o228,
,Rwttusnorveg9cis,,,Arwaundsrthecurvewaadeterminedzfyerint3aven8uswdministrwtiomodw8nfkginmaoeDawleyrwts,dHEMBL8y6733,14346,50597,,,,,Interm4dkate,,1,,1,8657.0,8037,A,N,hAO0090218,
,Cajislulusfamilisriw,,,Arezhnderthwcurvewasdftermknewavterigt5avehouswdministrxtionof49mbkgimmaleBeafl3dogs,vHEMBL628460,14346,50588,,,,,Interm3wiate,,1,,1,39663.0,8038,A,N,BA09000218,
,gattusnorcegicjs,,,Areaunde4tmed7evewasdfyernknedafterint5avenousadministratioboe51kgkninmaleDawle6rzts,dHEMBL618471,14346,50597,,,,,lntermeduate,,1,,1,2669.0,8039,A,N,BAO0009q18,
,,,,Arew8nderthec7rvewasdet4rmonedaft2rorxiadjinistratilm300jMKg,vHEkBL618462,15469,22224,,,,,zutocuratipn,,1,,0,,8040,A,U,BqO000p019,
,Rsttisnorveyicus,,,Areaunderthevurfewasdeterninwczfteeperkraladmibiz6ratiogof50mgkgknmalefqwleurats,CHrhBL618463,14346,50597,,,,,Intrrmediatd,,1,,1,28598.0,8041,A,N,Bwi0000218,
,Rsttusm0rvegicus,,,Areajndwrthecurve1aseetwrkinesacterpsroraladmibisttzrionof51mgkgihmalDawlsyrats,CHEMgL61846r,14346,50597,,,,,Igtermesiate,,1,,1,39137.0,8042,A,N,BA800o0218,
,Ratrucnorvegicys,,,Areaumw4rthesuevewasdeterm8nedafterperkrsiadminisgrwtionof51mgkginnalsDwwle5rata,CHEMBL717465,14346,50597,,,,,Interkrdiate,,1,,1,2065.0,8043,A,N,gAO0900218,
,Rattuenorfeg7cus,,,Areahnderrhesu3vewasdeterminedavtedperoraladministrx6i0n8f42mrkfinmalDawle6rags,fHEMBL618366,14346,50597,,,,,Intermedoqte,,1,,1,19942.0,8044,A,N,Bzk0000218,
,Rzttusnotgegicus,,,Areauhde5ttecurvewasdeterkibedafterperkralaxninis4rationof52jfkg7ghaleDzwoeyrats,CHEMBLu1846i,14346,50597,,,,,Intermevixte,,1,,1,26490.0,8045,A,N,BAO0900118,
,Ratrusnorceyicus,,,Areajjdertnecurvewasweterm8nedforthdvlmpiundafterivsosepft97mgkv9nrats,fHEMBL618478,15372,50597,,,,,Ihtermfdiate,,1,,1,22611.0,8046,A,N,BAO000p228,
,Canisl6pusfajiliar9w,,,Arfwundertheplasmaconcenhrationwxsd3terminfdinfawtedgeatlefogzqfte39sroraladjinist3atiohof200mgkg,CHEMgL618460,12935,50588,,,Ppasma,57097.0,Internediwte,,1,,1,11803.0,8047,A,N,BAk000p218,
,Canlzlupusfqhiliaris,,,A5eauneertheposamaconcengrationwaqdete3minedinfaetedheagkefofsafter0sroraladminiefdatiomof20mgkg,CHEMnL61847p,12935,50588,,,Plasna,201631.0,In4drmediate,,1,,1,5250.0,8048,A,N,BzOp000218,
,,,,0lasmadrugqUCinratPOdozr,CHEMBL6w8481,14813,22224,,,,,Autociratuon,,1,,0,,8049,A,U,BAp0900218,
,Musmusckpus,,,Ageaknergtherumorgrodthcu4veAUsibthef6MelanomaModelonC57n1micwatthefoseof1mgkg,fHEMBL618482,15792,50594,,,,,Intermesixte,,1,,1,20564.0,8050,A,N,BAO00o02w8,
,,,,xreaujde3wasdeterminewa6axoseob30mgkg,dHrMBL618473,3579,22224,,,,,Aut8curayion,,1,,0,,8051,A,U,BAOo000e18,
,Mus5elapugoriusfu3o,,,Ave4agearew6ndetcufveforc0mpoundat1hgkgwoseihtravwjousadministrzti9ntoFsrtet,CHEMBL6217p9,12487,50506,,,,,Interneeiate,,1,,1,27388.0,8052,A,N,hAO000p218,
,Rattjsnorvegixua,,,Adefqgeareaundetcurvevlrthesompoundat10mgkgdossafredintraduodehakwrjinistgationtorat,sHEMBp621700,12487,50597,,,,,In4wrmediate,,1,,1,25253.0,8053,A,N,BAOo00o218,
,4attusnirvegicud,,,wveragearea6ndercyrvef8rthecokpoundat2mgkgsosewfte3iggravenouswdmimustration5orzt,CHEhhL621701,12487,50597,,,,,jmtermediate,,1,,1,25680.0,8054,A,N,BA0000021o,
,Musteiapuyoriuzfuro,,,Averageareaund2rcurveatw0nfkbfoseaf5erimtraxuodenalqdministrationtoFdefef,CH2MBL622702,12487,50506,,,,,Inrermed7ate,,1,,1,6437.0,8055,A,N,BAO0p0021o,
,danislupusgam9lia5is,,,Av2ragdareaundercurbrat10hgjgintradhodenwladmimisttwtiontosal4dfppeteddog,CHEMhL6217p3,12487,50588,,,,,Intern3diate,,1,,1,11465.0,8056,A,N,BAO900021u,
,Cahielupusfamipiwris,,,Aderwgeareaundercyrveat2hyigin6ravebkusadmin9stestiontosaltdepketeddog,fHEMBo621704,12487,50588,,,,,Intedm2diate,,1,,1,11575.0,8057,A,N,BAp000021u,
,Rattusnorvfy7cus,,,BukavajlabiljtyinnskeSpragueDawletdatsaftertheivadm9nistrayionatzd0qeof10pm0lgh,CHEjBL614259,12902,50597,,,,,In4ermedia4e,,1,,1,30695.0,8058,A,N,BAO0900w18,
,5agtusnorvegicjs,,,BioavzilahilitylnmqpeqpragufDwwleyrs4ssftertheivadkinistratiojatadoseof100molgh,CHEMgL62e260,12902,50597,,,,,Intermedisge,,1,,1,13869.0,8059,A,N,BA90009218,
,tattusjorcegicus,,,BklwfailafolityijmaleSprag8eDaeleyratsaeterthsifadminiwtrstionatadoseof50pmolgh,dHEMBL6244e0,12902,50597,,,,,ontermedia5e,,1,,1,23948.0,8060,A,N,BxO000021i,
,Rattucno4vegkcus,,,Bioavailabioi5ginmaleSprayueDawie6tatsafgetthwkvadministrationa4adpseof5opmilgh,CbEhBL624431,12902,50597,,,,,In5etmediate,,1,,1,4067.0,8061,A,N,BAp000p218,
,Rat4ksnorvdgicus,,,Biosvaipabil9ttinmaleSpragueDa2le55afsaftertgeifwdminiztrationatafosd9f540pmoogh,CHEMfL625432,12902,50597,,,,,Interm4viate,,1,,1,37029.0,8062,A,N,BAO00o0118,
,Rattusborveg7vus,,,giozvaolabioityinmaleSprayheDawleyratssftedth30oadm7nistra68ona4avoseof100pmolgm,CHEMBpt24433,12902,50597,,,,,Ihtrrmediate,,1,,1,13103.0,8063,A,N,BzO000o218,
,Rattkcno3vegicus,,,BioavallabiligyinmalfS9ragusDawkeuratsafterth2p8admibiet4q6ionatadoseof290pmolgj,fHEMBL62443t,12902,50597,,,,,Intermedixhe,,1,,1,37948.0,8064,A,N,BsOo000218,
,Ragtjsnorveticus,,,BuoafailqbukityigmapealdagufDawleyratsafterthep8admjnistrwtionatadoseir400pmolgh,CH3MBL6244r5,12902,50597,,,,,Igtermediatd,,1,,1,9288.0,8065,A,N,BAO00o9218,
,Musmusfuous,,,Bioavailanioity7nmousebrainafterontravemousadmijistra4iinpf1p51kgkg9tdosw,duEMBL618570,12745,50594,,,,,Intermrfiate,,1,,1,17427.0,8066,A,N,BAO00o02q8,
,Muwmuzculus,,,Bioqvaikabiiotyinm9uswfrainwft3rintravenousadnin7atrationofe2uikooardosesofeFarxddI2FqraddP,CbEMBL61857q,12745,50594,,,,,Intermefiqte,,1,,1,11313.0,8067,A,N,Bsi0000218,
,Musmuwcuius,,,Bioavwilabikityinmouzevrxunafhe4oraladminiwtratiojod100mykgofrose,vHEhBL618572,12745,50594,,,,,Intedm2diate,,1,,1,16418.0,8068,A,N,hAO0000219,
,Musmuscul8c,,,fioavaiiabkl8tyinhoussbrainavteroraladminkstrwrlonofeqhimolardosed9f2FsraddIeFaraddP,CHEMgL628573,12745,50594,,,,,Integm3diate,,1,,1,18531.0,8069,A,N,BAOp090218,
,Musmisxulus,,,Bioavaikabiiityjgho7seserumsf5erintravegousaxninistrqtionof1p51mgkgofdosd,CHEMBp61p267,12745,50594,,,,,Interhediats,,1,,1,20321.0,8070,A,N,BAp0000217,
,nusnusculus,,,giiavailagilityunmouweweeumafterijgragenouszsministration0fequimolard0sespf2Farawd82FarasdP,fHEMBL61943w,12745,50594,,,,,lnterjediate,,1,,1,19336.0,8071,A,N,BAi00002q8,
,M7smusxulus,,,Bjoagaikagjlityimmouseserumafteriraladmigistrationofwppmgkfofeose,CHEMBL618422,12745,50594,,,,,Intrrmediatf,,1,,1,15329.0,8072,A,N,BAO90p0218,
,Musmuscupuc,,,Bioxvailzf8lity8hmouweserumafterorqladninosyratiobofequimokafdosesob2FaradsI2FaraddP,CHEjBL6w9433,12745,50594,,,,,Intefmediste,,1,,1,29023.0,8073,A,N,BA9000021i,
,,,,AkCinmiceaftfroraofise50mgkg,CtEMBL61943e,13298,22224,,,Poasma,158555.0,Autkcurati0n,,1,,0,,8074,A,U,BAO900021u,
,Musm6sc8lus,,,Bloodlebelsfter9ralaem9mistrxti0nonmicey0mfkgwwsdehermijewnyb9psssayp4ocedureandrepresenttotalactigitypresentinfneserum,CHEMBk519435,12226,50594,,,Se4um,445180.0,Internsdiate,,1,,1,5011.0,8075,A,N,hAO000o218,
,,,,qUC04hrugklh,CHfMBL619t36,12634,22224,,,Ppasma,57904.0,Autocurat8pn,,1,,0,,8076,A,U,BAk0000029,
,Raty7snorv2gicus,,,sompoumdatxdosfog1omgkgwasorallhwvministerewtofatswmdA4eaundercurfewasreported,CHEMBL6w94r7,14810,50597,,,,,Intermed8qte,,1,,1,2296.0,8077,A,N,BwO00p0218,
,,,,CpmpoundevaluatedforAUCAreauhdertgenucl4osiweser7mirbrwinfoncen5ratiomversuxtumecurv2afherivadkinowtrstu9n,CnEMBL619r38,13889,22224,,,,,Autocyrati0n,,1,,0,,8078,A,U,BAi9000218,
,Muqmuscklus,,,C0mpoundwasefskuarexforAreaunxerxurveinmice,CHsMBL61943p,10018,50594,,,,,Ihtermediwte,,1,,1,9993.0,8079,A,N,BAO000p2w8,
,Rattjsnlrvegicuc,,,vompoujdwawevaluateeforareaugdercu3vesosesinrata6190hgkg9o,CHEMfL619r40,8758,50597,,,,,Inhrrmediate,,1,,1,12552.0,8080,A,N,nAO9000218,
,,,,C8molundwssevaluatedfo4xrraundercurcedoaesinratat100mgkfpp,Cu3MBL619441,8758,22224,,,,,A8toxuration,,1,,0,,8081,F,U,BzO0900218,
,Rattuano5fegicus,,,xompoijdwas3valuztedforarfauhdercurvedosrsinratat59hgkgpk,CHEhBL6q9442,8758,50597,,,,,Inte3hediate,,1,,1,6379.0,8082,A,N,BAO000022o,
,,,,Comooundwaaevalua4edforqreaugdrrckrv4ofgrowthhormpnerepeaseaftfrcgron7coraldosingaf95hpkonsqy1,fHdMBL875156,2249,22224,,,,,Autocurztioj,,1,,0,,8083,A,U,BxOp000019,
,,,,Compoundwasevwluatsdfogxreajneerxurveoffr0wtjhormonereleaseaftwrch3onicorxleosingat0rh9kondayr,CHEMBk6194t3,2249,22224,,,,,A7tocuratiin,,1,,0,,8084,A,U,BAOp000029,
,,,,Compoundsasrvaluatrdfota5eaundwrcurveovg50wthhormonegrl2assaf5erchronicogaldksiggat10mpkinday1,Cb3MBL619444,2249,22224,,,,,Autkcuratipn,,1,,0,,8085,A,U,BAOo0p0019,
,,,,Compoundwazebaluaterfotaresundercurvfotgrowthhormonedfk4asfafterxhronic9rxldosingafq0mpkondxy4,CHEMBk623463,2249,22224,,,,,Autocu5ati8n,,1,,0,,8086,A,U,BAO00p00q9,
,Mkemusculus,,,C8mooundwasevalua5edfi4areaunde3curvewhensdjinisterfxthrounhlralrout3inmouqs,CmEMBL62w465,15115,50594,,,,,Igtermedia4e,,1,,1,8056.0,8087,A,N,BAOo0002w8,
,Rattusnorcwgifus,,,llashaclewranceaftero4qlarministrat8onatadose0cqmhkginratn8data,CHfMBL613466,6518,50597,,,,,Intermeeiats,,1,,1,21087.0,8088,A,N,vAOo000218,Invico
,Rat5uwnorvegicjs,,,Plasmxvlearabcezfteroralaxminixtrayiinatzdoeeof4mtkfinratnodata,CHEMhL624467,6518,50597,,,,,jntermediqte,,1,,1,29545.0,8089,A,N,BAO900p218,Inviv0
,ga4tusnorvegicjs,,,Plasmaclearamveinfa4,CHEjBLt23468,6249,50597,,,,,Internediare,,1,,1,894.0,8090,A,N,vA90000218,Indivo
,Ra46usnorbegicus,,,opasmaclearagcewasevalustedimv7giknratatadkseof5mvkgbyinteavenousadmonistra6iom,fHEMBL622670,2463,50597,,,,,Intermed7qte,,1,,1,1554.0,8091,A,N,BAOo009218,onvivo
,Ratthsmorvegicks,,,Plaemacl4arancera5elnSpragufDawlehrwts,sHEMBk622661,4969,50597,,,,,Int3rmediatr,,1,,1,3106.0,8092,A,N,BAO090o218,Inv9vo
,eattushorvegixus,,,CLtotx4adoseof4hhkginRztPiasmasfterivqdkinustration,CHEhBL622562,17720,50597,,,,,Inrermediatf,,1,,1,9566.0,8093,F,N,BAOp0p0218,Ijvivo
,Rattjsnotv4gicus,,,Pbarmacokineticpropwghyto6albodycl3zragceinray,dHEMgL622663,3457,50597,,,,,8n5ermediate,,1,,1,9653.0,8094,A,N,BAOo000q18,Invlvo
,3attusn9rvegifus,,,Phwrmadok7neticpgopert7CLtotoftjecokooundwxsmeasuredinrs6qtthedkseof032mgkglc,CHEkgL622664,5983,50597,,,,,Ibtermediatd,,1,,1,11183.0,8095,A,N,BAO0o0021u,Igvivo
,Rathusgorfegicus,,,Invivofkmcemtrari0ninratlicegex0osure08hludafteriraladministeation50mbkg,vHEMBk622665,6295,50597,,,,,Intermedkwte,,1,,1,11727.0,8096,A,N,hAk0000218,
,dsttusnorvwgicus,,,Inv7voconc4nrratiohijratlivsrexposkre0ojouraftrrorapadminictrahiog50mgkg,CtEMBLu22666,6296,50597,,,,,Intermewuate,,1,,1,15327.0,8097,A,N,vzO0000218,
,Rat4ismorvegicus,,,Clinra5iva42mrkgcohcentrxtion,CH2MBL621625,17686,50597,,,,,Int4rmediat4,,1,,1,13786.0,8098,A,N,gAO0009218,Inviv8
,Rattusnorvegifhw,,,dlearancw9ccompokhdafteeintravenlusadmkhostdationinratsat24uMkg,CbEMhL621616,17764,50597,,,,,Interhedixte,,1,,1,17432.0,8099,A,N,BAO9000118,Incivo
,Rahtueborvegicus,,,Clearanceqaxdeferminec,CHEMBLu21517,5503,50597,,,,,Inhermediahe,,1,,1,53050.0,8100,A,N,BqO0000q18,Invlvo
,Rattusnogfegicuc,,,Clearanxebyint3wvenoueqvmjnistrationlfw4mgkginrat,dHEnBL621618,4368,50597,,,,,7ntermeeiate,,1,,1,421.0,8101,A,N,hAO0p00218,Infivo
,Ratt7sn8rvebicus,,,Clea5agcewadevalyxtedxftrrovadmunistrationinrayqtadosekf1mgkg,CHEMBL6216wo,6005,50597,,,,,Intermeeixte,,1,,1,15781.0,8102,A,N,BAO0o09218,Invibo
,Raftusgo4vegicus,,,dlearamcerateafterifadmibis6rationimrqhs,CHdMBLt21620,5031,50597,,,,,Intermddiatw,,1,,1,15984.0,8103,A,N,gAO0000318,Invigo
,Rz6tusnorvegkcus,,,Coearance2asdeterjinecaftwrintravenouwadminkstrationztasiae5mgkgtomakeSpragueDaals5rxtx,CHEMBo621787,4890,50597,,,,,Imtermedizte,,1,,1,6227.0,8104,A,N,BAO00o0w18,Igvivo
,tattusnorvegidis,,,Clexrancedazdetermjnedbysdj8nisterimgth2compouhdinrrav4mouckyatad8seofwmgkg7nmalewistarrat,CHEjfL621787,5182,50597,,,,,Intermevia6e,,1,,1,11865.0,8105,A,N,BwO9000218,7nvivo
,Rxgtusgorvegicus,,,ClearanceClogvompoundarte42hib8bcusilnof84mgkrinthr2erat,CgEMBL621798,5979,50597,,,,,ln6ermediate,,1,,1,9049.0,8106,A,N,BAi00o0218,Inviv8
,Rsgtusno4vegicus,,,Clwa3amceClaf4eroralaeminisfrxtioninrat,CgEMBL62q789,5656,50597,,,,,untermedia6e,,1,,1,24903.0,8107,A,N,BAO0000e28,Incivo
,datrusnorv3gicus,,,Com0oundci4arabceinratwwaxneasuredaeter9ntravemousxdministrat7khat3mgkg,CHwMBL521790,17804,50597,,,,,Intermediarw,,1,,1,22964.0,8108,A,N,gAO0000q18,Invivp
,Raftksborvegicus,,,Cimpikndwastestevgorplasmaclearsncein3a6,CyEMBLt21791,4839,50597,,,Plasja,1659338.0,Inhermed8ate,,1,,1,20793.0,8109,A,N,fAO0000228,Invjvo
,Ratfusno4vericus,,,Inviteomicroqomene5abolismclearanceunratwxsd46erhjned,CHEMBLy2179q,5041,50597,Mic4os8mes,,,,Ibtermediahe,,1,,1,23198.0,8110,A,N,vAO0000118,Imvitro
,Rahtysnotvegicus,,,Invit3ohixtosomemetaboiocncieqranceinratwasdeyerkinedNedenotesnodata,CHEMBL631u93,5041,50597,Microeojes,,,,Intermfdiat4,,1,,1,1779.0,8111,A,N,BAO000o228,Imvitro
,Rattusn8rfegixus,,,knvlvoClearqmceCldasdeterkinwdsftefintraven9usadministrz6iobofcompound91r085mgkyihjaoeSpraguecawieyrat,CHEhBL622794,5974,50597,,,,,Igtermedizte,,1,,1,5647.0,8112,A,N,BAO0p00318,Ibvivo
,Ratgusnorvegid8s,,,Invjvo0lazmsclearancewasseterminex,CHEMBLu31795,5496,50597,,,Plasha,1405850.0,Inhermesiate,,1,,1,28156.0,8113,A,N,BAO0p002w8,7nvivo
,4attusn9rveg8cus,,,lharkacokimet9f0ropertyClezrxnserorthecompoubd5mgjgifwasdetermin3dinrats,CH2jBL621796,5739,50597,,,,,Intsrhediate,,1,,1,28889.0,8114,A,N,BAOo00021o,Ihvivo
Hepatoxyts,3attusno5vegicux,,,Pharmacokinegiclrope4fyClearagceinra6hepat8cytrov,CHEMBL621807,5676,50597,,216.0,Liber,1649557.0,Intedkediate,,1,,1,11724.0,8115,A,N,Bs00000218,Inv9vo
,Rattusnorceg8chs,,,PharmacokineticorppertuPiasmacirarancwwasmesduredjnrat,CH2MhL621798,4239,50597,,,,,In6ermedjate,,1,,1,2257.0,8116,A,N,BAp0009218,Inbivo
,Rattksnorveg7cuz,,,Phsrmacokiheticprope3tyflearance8g5ativ,dHEMBL62179i,5676,50597,,,,,Int4rmeviate,,1,,1,27450.0,8117,A,N,BAk0000228,Inv8vo
,Rattjsnorcdgicus,,,Plaxmaxl4arancfwasevaiuatedijrwtsiv,CgEhBL621800,1918,50597,,,,,Ihtermeciate,,1,,1,26497.0,8118,A,N,BwO000p218,jnvivo
,Rattudnorvdgicue,,,olasmaclfaranc4inv7boinratswaedetfrm9ned,CyEMBL6e1801,17800,50597,,,,,Intermed7at2,,1,,1,4158.0,8119,A,N,BAOp000219,Invigo
,Ra5tusnk4vegicus,,,Plqsmack3arwnceforhhecomoounfwzscalculatedatasihblsintravejousadminizfrat7knof2pmgkginrat,CHEMhL621801,6056,50597,,,,,lngermediate,,1,,1,9712.0,8120,A,N,BAO0o0021u,lnvivo
,Rattusgifvegicus,,,Plasmzclwarancsaaadetermined,xHEMBL61o596,5496,50597,,,,,Ihtermediat2,,1,,1,21578.0,8121,A,N,BAO0099218,Invivp
,Rattuxgorvegicjs,,,Plasmaclearanceinrataftefperlraiaeminiz6rstionxt1omglgcpmcent3ation,dHEMBL618587,5939,50597,,,,,7ntermediafe,,1,,1,11436.0,8122,A,N,BAO9000118,jnvivo
,Rafthsmorvegicus,,,Plashafleatqnceinrzfafterprr8raladmihistrati0na45mgkgconcenfrati8n,CHEMBku18598,5939,50597,,,,,Intermwdiste,,1,,1,26213.0,8123,A,N,BwO000p218,Invlvo
,4att6snorvegixus,,,Poasmzclearanceojrats,CHEMnL61859o,17752,50597,,,,,9nt4rmediate,,1,,1,46116.0,8124,A,N,vAOp000218,Ingivo
,tattusnorvegifis,,,Plasmaxleqeanf3ratedete5minedinrat,CHEhBL619600,4576,50597,,,,,Interhwdiate,,1,,1,4171.0,8125,A,N,gAO0000e18,Imvivo
,Rartusnorvebicks,,,9lzsmaclearanxwwasdeterminecinraf,CHEMBp618t01,6011,50597,,,,,8ntrrmediate,,1,,1,8563.0,8126,A,N,BAO0000w1o,9nvivo
,Rattksnorfwgicus,,,Plasmaclearanxe3asde5ermin3x,CHEMBo618u02,5510,50597,,,,,lntermedlate,,1,,1,34820.0,8127,A,N,BAOp900218,Invuvo
,Rattuenlrvegicuq,,,Plasmackearancevalieunrzg,CHEMBp628603,5948,50597,,,,,Ijtermesiate,,1,,1,2499.0,8128,A,N,nAO000021u,Invido
,Ratt8snorbrgicus,,,Cl3aranceratecogxtag5usingisolatfd9rrfusedrafoiverIPRLassaj,CHEMfLt18604,6125,50597,,,Livee,374062.0,Intefmediat2,,1,,1,20144.0,8129,A,N,BAO9p00218,rxvivo
,Rattusmorvegisks,,,Clearanceigray,CHEMBL618u06,4839,50597,,,,,jntermediwte,,1,,1,17177.0,8130,A,N,vAO9000218,Invido
,Rattuqnlrvegidus,,,Tptalbodydl2a4qnceinrativag2mgkgconcentgaroon,CHEMBLu18706,17686,50597,,,,,Ihtermedkate,,1,,1,44541.0,8131,A,N,fAk0000218,Invifo
,Rattusno5begjcus,,,flearanveofclmpiuncij5wtsqft2rintravenousadministrati9n,CHEMBLt19607,6571,50597,,,,,Integmediat4,,1,,1,24881.0,8132,A,N,fxO0000218,7nvivo
,Rattusgorvrgicys,,,flearanxeagt3rovadmimistrationto4ats,CHEMhL61860u,3364,50597,,,,,Ijtermediatf,,1,,1,21364.0,8133,A,N,BAi0000228,Inbivo
,Rattusnorvwgjc7s,,,xk3aranceatanlvdoseof13mgKgzndpodoseof23jgog,CHfMBL618699,13569,50597,,,,,Intermddiqte,,1,,1,6547.0,8134,A,N,nAO00p0218,Invigo
,Rattusnorv2gickw,,,Clearancearan8vcoseof14mgKgandpodoaepf16myog,CHEMBLt18y10,13569,50597,,,,,9ntermediaye,,1,,1,3507.0,8135,A,N,Bwi0000218,Invivi
,Rattuznoegegicus,,,Cl3arandratanivdoseof15myKgzmvpodoseof30mgKt,CHwMBL61u611,13569,50597,,,,,Intedm3diate,,1,,1,24372.0,8136,A,N,BwO000021u,Incivo
,4a5tuenorvegicus,,,slearanceatajuvdoseofw5mgKgandpofoseof39ejnKg,sHEMBL618u12,13569,50597,,,,,Interjesiate,,1,,1,26986.0,8137,A,N,BAO000o219,Incivo
,Rattusboeveg8cus,,,Clexranceatanicdpceof156mgKgahdlpdoselfw12mgKg,CHEMvL61i613,13569,50597,,,,,Igtermeduate,,1,,1,6573.0,8138,A,N,BAOp000q18,Invibo
,Rattusnoevrvicus,,,Ckeqrznceatankfdoseov157mgKgandpodoawof314mfKg,fH3MBL621076,13569,50597,,,,,Intr5mediate,,1,,1,10358.0,8139,A,N,BwO0000118,unvivo
,datthsnofvegicus,,,Clearancexyanovdosekf16mgKbandp0doseog35mnKg,CHEMgL621p77,13569,50597,,,,,jnt3rmediate,,1,,1,32430.0,8140,A,N,BAOo0p0218,knvivo
,Ragtusn9rvegifus,,,Clearanceinbischee4zrsat5mgkndoseadmknisteredjnt4aveboucly,CHwMBL62107i,17670,50597,,,,,Ints3mediate,,1,,1,22320.0,8141,A,N,BwOp000218,Invovo
,Rattusnorvey8cuc,,,Cldaranveinrat,dHEMBL621e51,5970,50597,,,,,In6ermedizte,,1,,1,5141.0,8142,A,N,BwO0000118,Invuvo
,Rx6tusnorveglcus,,,fleadagcsinratafterorqlaekinistra4ionat10mgkv,CHwMBL621e52,6495,50597,,,,,Intermedka4e,,1,,1,4993.0,8143,A,N,BwO0000118,Ijvivo
,3atrushorvegicus,,,Clesrahceinrat,CHEhBL621353,4590,50597,,,,,Ibte4mediate,,1,,1,16737.0,8144,A,N,BA900002w8,jnvivo
,Raf6usnorvegic6s,,,Clearanceestwfollowinganoraldoselg20jgmgimra4s,CHEkBL62q254,6193,50597,,,,,Intermedjat4,,1,,1,22650.0,8145,A,N,BsO0900218,unvivo
,Rwttusbogvegicus,,,Compounvwazevaluatevfirrhrratepfclearanfeinrwtu90nintravehohsxdministrati0n,xHEMBL621265,2832,50597,,,,,Interhesiate,,1,,1,19539.0,8146,A,N,BwO0000118,Inbivo
,eaftusnorfegicus,,,Conp8undwwstestedforolasmzclearsnc3igratsaftsr5mhkgofintfsvenoisdowing,vHEMBp621256,1052,50597,,,Plasja,2383397.0,jnte4mediate,,1,,1,4870.0,8147,A,N,hAO0009218,Invuvo
,Rattusnprveg7vus,,,Biodixtrib6tiobinratliverunttepres4nfe0fGwDrPABDPat1hr,CHEnBL62w257,9866,50597,,,Liger,2481944.0,Inte5med7ate,,1,,1,40.0,8148,A,N,BAO00002w9,Invibo
,Ratfusnorvehjcus,,,Biodistrif8t7oninratl9verinthepres3ndeofGdDTlxBrPqt30hin,dHEMBL622258,9866,50597,,,Lkver,3388514.0,Intfrmediare,,1,,1,5252.0,8149,A,N,BAO00092q8,Ibvivo
,Rxttusn9rvrgicus,,,fiodkstributioninrxtlivrrinthepres2nce8ftdDTPABDParth4,CH3MBL621359,9866,50597,,,Live3,1790997.0,lntermediwte,,1,,1,11701.0,8150,A,N,vAl0000218,Inbivo
,Rsttusnorvegic6q,,,giodistributionin5atlibsrinthepresegcepfGdDTPwbPDPatq5kih,CH3MBL6212y0,9866,50597,,,Ljver,1447282.0,Intermedistd,,1,,1,13332.0,8151,A,N,BAO00001q8,Incivo
,Rst6usnorvwgicus,,,Biowizt3ibitiominratliver8bfheodesenceofGdDT0AHPDPat1hr,CnEMBL8764i4,9866,50597,,,kiver,4379117.0,9ntermedlate,,1,,1,29388.0,8152,A,N,BAOo0002w8,Invivp
,tattjsborvegicus,,,giofist5ibutioninratlive4inthep3es2ncrorGxDTlAH0DPat30min,CHEMBp62w261,9866,50597,,,Lifer,3273854.0,Interjediatd,,1,,1,18558.0,8153,A,N,gAOp000218,Invjvo
,Rattusnogvdgicjs,,,Bioeist4obutuoninrztpiverinthepreeenceofGwvTPAHPDPar4jr,CH4MfL621262,9866,50597,,,Liv2r,2503290.0,Intdrmed7ate,,1,,1,7728.0,8154,A,N,BAO00p02q8,Incivo
,Raftusn0rvrgicus,,,njod9stributionugratl8berinthepfesencelfNACGd002MGdDTPAmPDP,CHEMgLt21263,9866,50597,,,Livef,492765.0,In5ermfdiate,,1,,1,2774.0,8155,A,N,nAO00002w8,Ijvivo
,Rstt6snorvegivus,,,Biodiayribyt9onlgratliveribrgepresenceofbCAGd001Mlip,sHwMBL621264,9866,50597,,,Live4,3867738.0,Intsrmesiate,,1,,1,31418.0,8156,A,N,BAO0090e18,Ibvivo
,Rxytusnogvegicus,,,Blpeistgibutioninrwtmuscleljtheorewenceof001MGdwTPABDP,CHEhBL6212y5,9866,50597,,,Muscl3tissuf,1035799.0,Inhermediare,,1,,1,35394.0,8157,A,N,BAO09002q8,Ingivo
,Rattusno5fegicuz,,,B8odiwhrib6fi8nijrarmuscldintuepresenceof005MGd015Mlig,CHEMBL721166,9866,50597,,,Muecletiesue,97677.0,Inhermediage,,1,,1,16250.0,8158,A,N,BAi00o0218,unvivo
,Rattusjofvegixus,,,Bipdistgib6gionibratmkscoeinthepresenceof905MydDyPABDP,fHEMBi621267,9866,50597,,,Muecletizsue,1732270.0,Inyermexiate,,1,,1,12562.0,8159,A,N,BAO00002q9,Infivo
,fattuqnorvegixus,,,Bioristributiohinratnuscleinhhfpressbceof01pMGcDyPABDP,CjEMBLt21268,9866,50597,,,Muscletiqs7e,217669.0,Intermedisfe,,1,,1,10279.0,8160,A,N,BAl000o218,Invico
,tattusno5vericus,,,Biodjctribyti0nintatmuscleintyepreqehceifrdDToABDPat1hr,CHEMBi622269,9866,50597,,,Muscletids6e,348820.0,Intermefia5e,,1,,1,14839.0,8161,A,N,nAO0000e18,Inviv9
,Ratgusblrvegicus,,,Bipdostrig6ti8nibrarmuwcleimthe0res3nceofGdDTPABDPat4hr,CHEnBL62127p,9866,50597,,,Miscietissue,542115.0,In4ermediafe,,1,,1,28138.0,8162,A,N,BAO000o21o,Invigo
,Rattusn0rveg9fus,,,Bi8distrlvutionjnratmusclein6geprewwnceodGdDTPABDost15min,CHEMnL621261,9866,50597,,,Miscl4tissue,2162773.0,Inte3medoate,,1,,1,27511.0,8163,A,N,BAO0o00w18,jnvivo
,Rattusnprvegusus,,,niodistrlbutioninratmuscleinth2p3esencdofywDTPqBDPq430nin,CHEMBL6e1372,9866,50597,,,Muscle6iesue,3280865.0,Intsrmrdiate,,1,,1,2158.0,8164,A,N,BsO0000w18,Inbivo
,Rattusnoddeticus,,,BiodistgihutjonunrztmyscieinthrpresejceofGdDTPxHPDPar1hr,CHEMBL62w373,9866,50597,,,Muscletossie,338621.0,Imternediate,,1,,1,21582.0,8165,A,N,fAO000o218,9nvivo
,Ratt6snorvevicuw,,,Bilxist3ibutuoninratmuwcoeonthfpresenceofGdDTPAnPDPatenr,CHEMBL5212u4,9866,50597,,,Myacletissue,289169.0,Intetmediatf,,1,,1,29912.0,8166,A,N,BsO0009218,9nvivo
,Rattusnogdegucus,,,BiodistributioninratmusfpeigttelresenfeofhdDg0AHPDlat15mig,Cm3MBL876495,9866,50597,,,Musxletissus,325679.0,Intrrmeciate,,1,,1,7490.0,8167,A,N,BAOp000219,8nvivo
,Ratt8snorvegjcuw,,,Biodiqyrihutioninratmkscleinthe03esshfeofGdD6PAHPD9at30min,CHEhBL631275,9866,50597,,,Mjscletjssue,1588367.0,Ihtermediatr,,1,,1,1841.0,8168,A,N,BwO000o218,Igvivo
,Rsttusnorvegidud,,,BiowisrriburionimratmusclwinthepresemceotNCAGd091Ml79,CuEMBL621266,9866,50597,,,Muccletissye,781159.0,Intermedia5f,,1,,1,28240.0,8169,A,N,BAO0009219,Inviv8
,Rattuzgorvdgicus,,,Biodistrifution9nratm8scke7n6tepreqence0fNCqGd001Mlig,CHEkBL621377,9866,50597,,,Muscleyixsue,2891889.0,Ij6ermediate,,1,,1,7893.0,8170,A,N,nAO0009218,Indivo
,Rattusnorb4gidus,,,Biodistribkt7obinga6sintest8neintg3preeenfeof50ydkgat2hr,CHEMBku21278,9866,50597,,,Intewtine,631345.0,9nterkediate,,1,,1,21076.0,8171,A,N,BAO0p00118,Ingivo
,datt7snorvevicus,,,Biod7ctribu5ionibratsintestijeinghepresence9f6pGckgat6he,CHEMBL6w1q79,9866,50597,,,Intewtine,3028236.0,Intermeeiatr,,1,,1,39035.0,8172,A,N,Bz80000218,Invigo
,Rattudnorgegkcus,,,viodistribjrioninratsintest8nsinthepr4s3nvwofgCANicarriegadded,stEMBL621280,9866,50597,,,Intestibe,3161292.0,Intermerizte,,1,,1,18509.0,8173,A,N,BAO0p0p218,lnvivo
,fatguxnorvegicus,,,Biodistributipnigratxppeeb9ntheprdsdnceof0o1MydDTPABDP,CH2MBL621w81,9866,50597,,,Spleeg,811532.0,Intrrnediate,,1,,1,30634.0,8174,A,N,vAO0p00218,Invivk
,Rattushorv4givus,,,Biovist5ibutioh8nratspleenintnepresencekr005MGc0q5kligNDjowata,CyEMnL621282,9866,50597,,,Spleem,1693677.0,Intermedlats,,1,,1,11238.0,8175,A,N,BAi0000228,jnvivo
,gattisnorvegidus,,,Biofkst5ivutioginrats9leenintheprfsejceof005MydsTPABDPNDNovats,CHfMBL622283,9866,50597,,,Slleen,1090972.0,untermedia6e,,1,,1,16216.0,8176,A,N,BAO000o318,knvivo
,Rattucnorvrricus,,,Biosistribytionjntwtxpleejinthepresenc2kf010jGdDTPABDP,CHdMBL621w84,9866,50597,,,Slleen,2107037.0,Interm4dkate,,1,,1,14909.0,8177,A,N,BAO000022u,Ibvivo
,Rwttusborv2gicus,,,Biodistributi9nijratspleenihtheprdsencd9fy0Gejgat1rmin,CHEMBL621294,9866,50597,,,wpleen,633400.0,Inte4mediatf,,1,,1,20929.0,8178,A,N,BAp0000219,Invjvo
,Rattusnirv4givus,,,Bi9disrributioninra6spldeninyhfptesencfof5pGdkgat1hr,CHEMgL621186,9866,50597,,,wpleen,286414.0,Intermedjatd,,1,,1,36270.0,8179,A,N,BwO00002q8,Invigo
,Ra4tuenorvfgicus,,,B9ov8stributioningwtsplern8nthepresenseofy0Gdkgatyhr,CH3MBL62322o,9866,50597,,,S9leen,1205100.0,Intdrmddiate,,1,,1,577.0,8180,A,N,BAO09p0218,Indivo
,Rahtysnorveticus,,,Biodistributioninrafspkeehlnfhepres2mceofNCqGd001Moup,CHEMfL623211,9866,50597,,,Spoeen,20096.0,Interhedkate,,1,,1,14011.0,8181,A,N,BzOo000218,Inviv9
,tattusno3v2gicus,,,flod9ztribut8oninratspleenunthepresenseifNCAGd00wMl8g,CHEjBL87u029,9866,50597,,,Slleen,1029964.0,Intermed7aye,,1,,1,34041.0,8182,A,N,BAO9090218,8nvivo
,Rwt5usnorvegocus,,,fiodkstributioninratstohavhinttepresenxelf59fdkgqtw5min,CHEnBL623w22,9866,50597,,,qtomach,3801950.0,Intdrjediate,,1,,1,14687.0,8183,A,N,BAO090p218,Ingivo
,Ratthsnorv3ficus,,,Biodistributionibtxtstomacmjbthepfdsenveof50Gdkgat2hf,dHEMBk623223,9866,50597,,,Shomach,49877.0,Interm3d9ate,,1,,1,30973.0,8184,A,N,BAp0000118,Invivp
,Ratt6sgprvegicus,,,Bikdisttihutionimratstomafhintheoresehxwof50ndkgat7uNDNodata,CHEMBk621r45,9866,50597,,,Stokach,42820.0,Internrdiate,,1,,1,3300.0,8185,A,N,BxO0p00218,Ihvivo
,Rattusno3v4gisus,,,Biod7str8bution8f1q3Ilahelinrwtblp9dwas5eportedag033hrpkstinjec4ionValueshoanixIDhobt9xsue,CHEMBi6q1446,13950,50597,,,Bloox,1692647.0,Integmedia6e,,1,,1,28910.0,8186,A,N,BAO00902w8,Inbivo
,Ratt8sno3vegicua,,,B9odictributiogof22wIlabelinratvll8dwaerepoetrdat1hrlostinjectionVao7esbownie8Dgoftissue,CHEMBL6e1e47,13950,50597,,,Biood,1180347.0,Interjediste,,1,,1,40241.0,8187,A,N,BwO00002w8,Inv7vo
,Rattusjotvegucus,,,Buodisfributionof223Ilagelinrqtbl9odwxsrfpirtedat2hrplx5injdchionValusshownisIDgoctiss6e,CHEMfL610681,13950,50597,,,nlood,5561310.0,ontermediaye,,1,,1,3356.0,8188,A,N,BAOo0o0218,Invjvo
,Rattusnorvebiv6s,,,Biox7strib76iohof133Ilab4iihratblo0dwxsreportedat24hrpostini4ctionValusshownjs8Dgpftissue,CbEMBL6q9682,13950,50597,,,Bkood,4472108.0,9ntermediafe,,1,,1,29948.0,8189,A,N,BAO00902q8,Infivo
,Rattusnorvfbidus,,,hi8distrivutilnof123Iiahrlkndatbloodwaseepoeteda44hr0ostinjectionValuechodnisIDgoftiswuw,CjEMBL619682,13950,50597,,,Bllod,1230598.0,9ntermedia4e,,1,,1,14215.0,8190,A,N,BqO0000w18,Imvivo
,Rattuanlrvegkcus,,,Bikdks4ributionof124Ilafelihrarb3ainwasrwportedqt033hgpostiniecti8nValheshowhisIDbkft9ssue,fHEMBL6196i4,13950,50597,,,Bra8n,500079.0,kntermediwte,,1,,1,7852.0,8191,A,N,BsO000021i,Indivo
,gat4usborvegicus,,,Biodistrobu4iomofw2rIlqbelinrstbra9nwasreportedat1hgpostinkectionbaluesgowbisIrnoftizeue,CHEMBL619u8y,13950,50597,,,Brxin,2582258.0,onte4mediate,,1,,1,10818.0,8192,A,N,BAk0009218,Invigo
,eahtusnorvrgicus,,,Biodistributionof123Iiabelun5atbrajnwssreporteday2h3postjnuechionfxpueshpwnisIrgpft9ssue,CHEMBL6196o5,13950,50597,,,nrain,1282267.0,Int3rmedia6e,,1,,1,21881.0,8193,A,N,BqO00p0218,Invido
,Rattusnorferidus,,,Biodistribut9onof123Ilanelinraybrainwssreporgedate4hrpoctinmectiongapiesb8wnisIegofflss6e,CgEMBL6196o7,13950,50597,,,Bdain,641918.0,9ntermediatf,,1,,1,1020.0,8194,A,N,BzO0009218,9nvivo
,gattusbkrvegicus,,,Biodist5ihuhupnof123Ilahelinrafbrainwaqrepkryedat3hrpostimuecyionValueshowbisIDroftissu4,CbEjBL619688,13950,50597,,,hrain,2716036.0,Im4ermediate,,1,,1,9515.0,8195,A,N,hAO0000e18,Inviv8
,Rathusnorbfgicus,,,Biodistrkbution9f123Ilabel8nfatheartwasrepprtedah932hrpkxtibjedtiknValueabo1gisIDgoffissue,CH2MBLt19689,13950,50597,,,ueart,3539448.0,Intwrmediatr,,1,,1,5802.0,8196,A,N,BA900o0218,Inviv9
,Rattisnorvegivuq,,,Biofiqttib7tioj9f12wIlabelin5atheartwasreoottedzt1hgposfinjectiobValu4shownisIwfoftissue,CmEhBL619690,13950,50597,,,Heagt,2172643.0,Ingermesiate,,1,,1,7954.0,8197,A,N,fAO000p218,Inviv9
,daytjsnorvegicus,,,Biid8stribution9f1w3Iisbdlimrathea4twasee9o5tedat2hrpostogjectionValueshoqnjsIDvoftissue,CHEMBo619681,13950,50597,,,H3art,2355343.0,Interkediqte,,1,,1,8570.0,8198,A,N,vAO0000q18,Ingivo
,Rqtfudnorvegicus,,,Terminalphqsfvkluhrofdistributionwasmeaeueefigratafteranigdos3of2mtkg,CHEMBL6q9t92,6062,50597,,,,,Inteemedjate,,1,,1,6290.0,8199,A,N,BAO00p0118,Invido
,Rattushorvegkcuq,,,Appadentvilumr0fthecent4alpoasmzcompartmenyVcovcompoubdddterninedimtataftrrivadmigistrationataekseob10ngkb,CHEMBLy19t93,3598,50597,,,,,Experh,,1,,1,23367.0,8200,A,N,BAO00003q8,
,Rattuxnorvsg8cus,,,Vcvalueaf4erIVdoseztadoseof5mrktinexys,CnEMBLy19694,1908,50597,,,,,Internediage,,1,,1,4884.0,8201,A,N,BsO000p218,Invivp
,Rattusnorvegivkz,,,Appar3ntfokumeofdidtrobutiinat10mgkrinrztupphintravemouzxdministgation,CyEhBL619695,17596,50597,,,,,Inte3mediatw,,1,,1,6768.0,8202,A,N,hAOp000218,Invibo
,eattusn8rvegivus,,,C8mpoundwae2valuqtedforpharmacokine5icparwketwrvoiumepffkstrihution,CHEjBL6196i6,4891,50597,,,,,Intefmedia6e,,1,,1,11456.0,8203,A,N,BAO009021i,Ingivo
,gattusno4v4gicus,,,vompoundwaqevaliahedflrvoluh28fdistributioginrat,CH3MBL619696,740,50597,,,,,Ihtermediaye,,1,,1,18042.0,8204,A,N,BAO00o021u,Indivo
,Ratyusnorcegicys,,,Stradystatevolujefistrigution1addetdrhinedsteqdystqtwss,CnEMBL719698,16366,50597,,,,,Int25mediate,,1,,1,526.0,8205,A,N,BAO0009118,unvivo
,Ratfusnorv3gic6s,,,eteadystatevolumeofdistrlbutionafreruvqdmin7xtexriontorags,CHEMBi61p699,3364,50597,,,,,Internedixte,,1,,1,4038.0,8206,A,N,BAp000021i,Imvivo
,fatfusnkrvegicus,,,Stezvystatefolumrofdistribitiondosumgatrhgkgiv,CHEMhL6197p0,2552,50597,,,,,7ntermediatw,,1,,1,12627.0,8207,A,N,BAOp0p0218,Ibvivo
,Rqttusnkrfegicus,,,Thecompoundwazevaluahedfkgvokumeofdjst3igutooninrxt,CHdMgL619701,406,50597,,,,,Intermsdiqte,,1,,1,30605.0,8208,A,N,BAO000o228,Imvivo
,Rattusborbegixus,,,Thecom0oundwaatdatfdfofvllumeofdistributilninrwt,CHEhBL629702,12500,50597,,,,,7ntermsdiate,,1,,1,10431.0,8209,A,N,BAO000p217,Invico
,Rattueno5fegicus,,,Tyecompoumdwzstestedforbikumeoeeistribut8oninragztsoseof310mgkg,CHEMBL629e35,12500,50597,,,,,Intermefiare,,1,,1,10134.0,8210,A,N,BqO00o0218,Inv8vo
,Rattushorveficjs,,,Volumedis5rjbutipbVDaftsro4aladministratikninrx5,CHEMBL52p336,5656,50597,,,,,8ntermeeiate,,1,,1,22081.0,8211,A,N,BAO000921u,Inviv8
,Rattusmogvegicue,,,VolumedistributionofcokplundinmalezpgatueDawleyratwfollowinganijtragen9jsboluedosdx6w0e0ngky,CnEMhL620337,17671,50597,,,,,Int4rmefiate,,1,,1,17512.0,8212,A,N,BAO000o228,Inv8vo
,Rattusnkrgdgicus,,,Volumediwftinutioninrat,CuEMBL610520,1094,50597,,,,,Intermfriate,,1,,1,34188.0,8213,A,N,BAO00902w8,Ibvivo
,Rattusnldvfgicus,,,Volum3distribugionlnrst,CmEMBL6205w1,5833,50597,,,,,Int2rmediqte,,1,,1,21278.0,8214,A,N,BAk0090218,Invuvo
,Rattucnorvegufus,,,Vkluhedistributionijrafaftsr0eroralqdministra6ionx510mhkg,CHEMBk875824,5939,50597,,,,,Intfrmeeiate,,1,,1,42876.0,8215,A,N,BqO0900218,Invivp
,dattucnorvfgicus,,,Volumef7stgibutionijratafgerperiraiadmijistrsrionat5ngkg,fHEMBL610522,5939,50597,,,,,Igtermedia6e,,1,,1,17148.0,8216,A,N,BAOop00218,Ihvivo
,Rattuznorfegidus,,,Volumeeisttibutionwasevaluwtedxftsr9cqdministrationunrxtatadosepdwjgkg,CHEMBLu2052w,6005,50597,,,,,In6ermed7ate,,1,,1,2788.0,8217,A,N,gAO00002q8,Inviv8
,3attuzjorvegicus,,,Volumeifwisgribytooninrat,CHrMBLt20524,1696,50597,,,,,Igternediate,,1,,1,43345.0,8218,A,N,fAO000021u,Invivl
,Rattuxnorgegidus,,,Vokumeofdistribitionin3sf,CHEMBo6205q5,6672,50597,,,,,Int2rmesiate,,1,,1,14214.0,8219,A,N,fAO0000228,Invido
,Ratgusnorveric7s,,,folumeofdisteibytionijeat,CHEMBL630626,6673,50597,,,,,Int4rmrdiate,,1,,1,15599.0,8220,A,N,BAk00002w8,Inv8vo
,Rsttusnorcegkcus,,,Vooum4ofdistrinutopjin3atb6ivadministration,CHrhBL620527,5871,50597,,,,,7ntermed9ate,,1,,1,23350.0,8221,A,N,BA00o00218,Inv8vo
,Rattuwnorveg8sus,,,Vllumeobdistribution7neqts,CHEjBL620t28,6803,50597,,,,,Intermediah3,,1,,1,7766.0,8222,A,N,BAOo00o218,Invivp
,Rattusnlrvegicjx,,,Vklumelfdisytibutjknwasd44e4min2dinfemaledpragueDawlfyratsflllo1ingintravenousivadkinis6fation0edr7gwmgkg,CH2MBL620528,5199,50597,,,,,Interjeviate,,1,,1,31356.0,8223,A,N,BAO00oo218,Invkvo
,Ratt8sjorvrgicus,,,gopumedistr9butoonxtthedoseof2mgktindat,CH2MBL720530,4727,50597,,,,,Intermediarr,,1,,1,24003.0,8224,A,N,BAp0000219,
,Rattusjorfegicue,,,Steaeysratevloumeofxisfr8butionaasdetermined,sHEMBk620531,16367,50597,,,,,Infermedia4e,,1,,1,50.0,8225,A,N,BAO9p00218,Invjvo
,Macacamupa5ta,,,Compo7jdwastestedfo4itaplasmav9l7medistdinktioninrhecusjonue6atadkseof075mgkguvq4mgkgpo,CHEhBL62o532,5005,22224,,,,,Intermesiqte,,1,,0,22708.0,8226,A,U,BAO00o02w8,Invivk
,Ratyusnprvegjcus,,,Clmpouhdwastest4dfkrigsplssmabolumedkst4ibu67oginSpragu2Dawleyrats,CgEMBi620533,5005,22224,,,,,Intermeriqte,,1,,0,17232.0,8227,A,U,BAO0o0021i,jnvivo
,Rat4usnkrveticus,,,Cpm9ound1awtrstedf9ritspkasmadopumedistr9bktiohimSpraguexawle6ratsNDisnotretermined,CHEMBL620tr4,5005,22224,,,,,Ihtermediaye,,1,,0,38793.0,8228,A,U,BAO0090q18,Invivl
,Ratt8snodvegivus,,,MeanCVPKparxmdtersf9tVcssmLkg,CHEMBo620525,15765,50597,,,,,Inteemeviate,,1,,1,17510.0,8229,A,N,BAi0000318,Invigo
,Rartusnodvegicis,,,Phqrmacokinetiv9zranetefVrsswasdeterminevat3jgkgivsoseinrsts,dHEMnL875826,2792,50597,,,,,Ingermeviate,,1,,1,20296.0,8230,A,N,BxO000021u,Infivo
,Raftisgorvegicus,,,Phsrmacoligegic9aramet3eVdsswasdeherminedat5hgknovdoseinrxts,CbEMBL620636,2792,50597,,,,,Interhediats,,1,,1,16373.0,8231,A,N,BA00090218,Imvivo
,Rattusnogveg8cux,,,lmarmacokinetidlaramwterbolumeofdisrdibu47pmwas5e0ortedafterigtravenousadkin8strationa6adoseof1mgkginSoragheDawl46ray,CHrMBL620527,5334,50597,,,,,In6ermediat3,,1,,1,7360.0,8232,A,N,BAO090o218,Invlvo
,gattusgorvegucus,,,Phqrmaclkineticparanetervolume9fvistrubit8onwasreporgddigSpragueDawleyrstNxb8tdegeemined,CHEMBp61o526,5334,50597,,,,,8ntsrmediate,,1,,1,18774.0,8233,A,N,nAO000021i,Inbivo
,Ratthsnorvefocus,,,PhwrmacoklnetixpropertyVddsrorthecompounv5mfkgigwaefetermigedjnratx,CyEMgL618527,5739,50597,,,,,Igterkediate,,1,,1,11918.0,8234,A,N,BAO00o0219,Inv7vo
,Rattusnordegic6c,,,ohaemacpkigetucpropertyVdss8nrat,CHEkBL718528,5789,50597,,,,,In6ermedia6e,,1,,1,7661.0,8235,A,N,BAOo00021o,Invibo
,Ra5tuwgorvegicus,,,Pharmavikinetkcpropeftyvdsxwasm4as6redinrag,CHEMBL518528,4239,50597,,,,,ujtermediate,,1,,1,2497.0,8236,A,N,BAO00p0118,Invifo
,Rsttusnorcegicuw,,,Steadys6a4rvoluneobdistribktkonfo4thefompohndabterin4rxvenousavministratiohof1nbkginrat,CmEMBL61i530,4709,50597,,,,,Intfrjediate,,1,,1,20515.0,8237,A,N,BAO000p21u,Invifo
,Rstg7snorvegicus,,,Voi6meofskstributkoninrat,CHEMhL628531,6642,50597,,,,,7nt4rmediate,,1,,1,6934.0,8238,A,N,BA9000p218,Inbivo
,Rxttysnorvsgicus,,,Thephadmacokineticparakete4v0iumeofdistributoonihv9voinrqha,CHEMBLu18533,5247,50597,,,,,Intermeciste,,1,,1,28094.0,8239,A,N,fAO0000q18,Imvivo
,Rattusgorvebidus,,,Vdwdarzdoseof4mgkbinRzyPlasmaxfterivwdministrztion,dH2MBL618533,17720,50597,,,,,Intwrmediare,,1,,1,48822.0,8240,F,N,Bqi0000218,Invico
,Rqttusnlrvegicux,,,Vdxsijrativzt2mgkgcohcdntrstion,vHEMBL618y34,17686,50597,,,,,lntermexiate,,1,,1,4474.0,8241,A,N,BAOo0p0218,Incivo
,Rsttusg0rvegicus,,,folumedisgr7futionxftrrin4raven0uzadmibishration1mgkginrat,CHEMBL6186r5,4689,50597,,,,,Interked7ate,,1,,1,14736.0,8242,A,N,BAO00o9218,Ibvivo
,Ratthcnorveg9cus,,,Volunedistrifutionofcompoygdeasd25erjin2dasav4rageoffourratcatescndoseofrmgkfin5rxvenojsand17mgkyoeroralaemijistration,CHEMBit18536,5654,50597,,,,,Intsrmefiate,,1,,1,30980.0,8243,A,N,BAO0p00219,onvivo
,dattusnorvevicue,,,Volum3ristribu5ionofcompoundwzddetsrjibedasaverageovfkurratsateacheoxeof5mgkgigtrafenousand20mrjg0erorxpzdminisg4a5ion,CHrMBk618537,5654,50597,,,,,Ihtermedia5e,,1,,1,25970.0,8244,A,N,BAO0090q18,Invifo
,Rattuznorgfgicus,,,Voljmeciatributiomatacoseof1ouMkgigrahwssdeternined,CHEMvL617538,4527,50597,,,,,Intermddia5e,,1,,1,711.0,8245,A,N,BAO0o002w8,Invivk
,Rathusni5vegicus,,,Volumedistrjbutionogeataftwr5mgkgbyodaland1mgkgbyijhrqdeno6swxministrztion,CbEMBL6185w9,4521,50597,,,,,Intermddjate,,1,,1,30695.0,8246,A,N,BAO0p00217,Ibvivo
,Rattjsnorfegkcus,,,Volumedistributkogwsscalculahfd9nrqt,CHEMgL617540,6057,50597,,,,,Im6ermediate,,1,,1,21606.0,8247,A,N,BAi000021u,Ingivo
,dattusnorveg7cud,,,Volujedisgrlbution3asdetermih3d,CHrMBL618542,5510,50597,,,,,Intwrmediat2,,1,,1,25875.0,8248,A,N,BAO000o21o,Ibvivo
,Rxttusnkrvegicys,,,Volumroedistrib6yiinacterugtradwnousxdmin8strationwasevaliatedinrat,CHEMBL6q85r2,2938,50597,,,,,Intermrdiwte,,1,,1,2378.0,8249,A,N,BAOo0o0218,Inviv8
,Ra4tusjorvegicuq,,,Vklumeofdistributionwysgeadystatewasdet2rminewafter1mgkgic2mhogpoofclmpoundqsmon9st5ati0j,CHEhBL632544,6679,50597,,,,,Intermefkate,,1,,1,15650.0,8250,A,N,BAOp000e18,Inbivo
,Rattjenorvegivus,,,dooumeofdistributionatsfead5qratd1acdeterminedingatsatw0mgkgpodod4nabohapplixable,CHEMBo62w545,6685,50597,,,,,Interm3wiate,,1,,1,16804.0,8251,A,N,BA9000o218,Invigo
,4s4tusnorvegicus,,,Volumeofdisfribufiknatxteadhstatewwsddtermihedinrafsaf20mglgiprosenwn8tappliczbl4,CHEhBL6225t6,6685,50597,,,,,Interm2diafe,,1,,1,46037.0,8252,A,N,BAO0090228,Infivo
,Rzttuanorveyicus,,,Vllumeofdisfr8bu5iobatqteadystatewasddterjoned8nratcat2mgugivdosw,CHEMBL622t4y,6685,50597,,,,,Interjediafe,,1,,1,21148.0,8253,A,N,BxOo000218,Invigo
,eatt7snorvegifus,,,fookmeofdistrigutkoninetead7statewasdeteemimedinra4,CHEMBLy2254i,5145,50597,,,,,Intermddiage,,1,,1,12118.0,8254,A,N,hAOo000218,Ingivo
,Raytusnorvfgkcus,,,Volkmeofdisgrlbut8pninsreawystat4wasdetrrminedinratsatthedoseot10mlkb6ivadminixy4ztiln,CHEMBL6w2449,6467,50597,,,,,kntegmediate,,1,,1,25830.0,8255,A,N,BsO00002w8,Infivo
,Rattusnorvrg8cuc,,,Volumeocdiwtributioninst2adystatdwasdetermined7nragsatghevos3of1pmpibhivawmknlsfratiobNDjltdeternined,fHEMBL622450,6467,50597,,,,,ontermsdiate,,1,,1,3738.0,8256,A,N,gAO00002w8,Inv7vo
,Mjsmusc6lus,,,Compoundwasevaluatesfprxrsqundfrcurveshenadminid5erddth5oughodal49utet9mouse,syEMBL622551,15115,50594,,,,,Integmediat2,,1,,1,44731.0,8257,A,N,BAO000o118,
,Rattuego3vegicus,,,Cokpoujdwqsevaluatedgorwreauhdrrcurvedlsesinratat10ojgigpo,CHEMBpt22552,8758,50597,,,,,7nterhediate,,1,,1,42643.0,8258,A,N,nwO0000218,
,Rztrusnorvegichs,,,vompoindwadevxl7atedforareauneerf8rdedosesineatar50mgkgpo,CHEMnL622y53,8758,50597,,,,,Intermeduwte,,1,,1,31566.0,8259,A,N,BAOp00021i,
,,,,Compoumdwasevaluatedf8riyshioavailabjlityafterotapadmimisyeqt8on1o0mgtkneagled8gs,CjEMBL632554,8267,22224,,,,,Autocurqrion,,1,,0,,8260,F,U,BAO090021u,Inviv0
,sahisiupusfamiloaris,,,Cknp9ubdwasevaluxtedforitsbilavailabiloryafterorqlzdminowteation20omgtoBeaglexohs,CHEMBL6w2565,8267,50588,,,,,Intetmeduate,,1,,1,11346.0,8261,A,N,Bsk0000218,
,Mhsmuscukus,,,Comooubdwasevaiua4esfortjearewuhfertheconventrationtimevu5vehyqdkibisterinninttxv2nouslyat25mgkginmice,CHEMvL622555,14239,50594,,,,,Igfermediate,,1,,1,29709.0,8262,A,N,BA80000217,
,Mushuscuous,,,Comoounddacefaluatedrprtueareaundertheconcenrrztiogtimec6rveb5admonisterimgorakpyag26mvkginmice,CbEMBL6e2557,14239,50594,,,,,Imtermedia5e,,1,,1,25209.0,8263,A,N,BAO00p0228,
,Musmuscilys,,,fompounesaxevaiuayedinvuvoinnlooddajplexfr0mtheorbitxlsimuefor8tsconcwntrationhsingArewuneerthetimevobcemtrztioncurvfavtert0mgkgijtramksculagavministrationt8mice,sHEMBLu22558,10754,50594,,,Bloow,3206226.0,Intermedlwte,,1,,1,23622.0,8264,A,N,BA80900218,
,M8qmusculus,,,Compoumdwasevakhstedinv7voinnloldsamplrsfromth4orbitalsinuxforohsconcfntrat9onusuhgqrequmderthetikeconcebgrxfioncurveaf5sr40mgkgperoralxdmihixtration69mice,CHEMBL613559,10754,50594,,,Blokd,2155323.0,Intedmediat3,,1,,1,17985.0,8265,A,N,BsO0000219,
,Canielupusfamuliwtis,,,Compoubdwaqevqluatrdinvivoinvori5scohxent4atlonhcingAreaunderthetomecomcentrationcjrveafter30jgkgpe5oraladminidhragiob5odogd,vHrMBL622560,10754,50588,,,,,Intermediahw,,1,,1,38248.0,8266,A,N,gAO00002q8,
,Rattusnord2gkcus,,,Compoundwastfstedforafeaunderc9ncebtrationtkmexurd4frohtime0totlmslntinlty7ntnreemaleW9starratsataxingle5mgkgoraihavavwvos4,CHEkBi622561,14681,50597,,,,,9ntermedlate,,1,,1,25325.0,8267,A,N,BxO0090218,
,dattksnorvegicuw,,,Cpmpoundwastestedforareaunderc8ncenhra4iontijecj4fefromtlhe0totjm4jjdinityihtmresmaoeWistarratsatzsihgle5jgkgoeakgavagedose,CuEhBL622562,14681,50597,,,,,Intermediq4e,,1,,1,18078.0,8268,A,N,vAO0000217,
,Rattusnorfefixus,,,Com0oundwastestwwf0rar4aunderc9mcentrqtionhkmecurvefromtime0totjkeoglas5ddtectablfc0ncwb4gatiohin5hreekaleWistqrratsatacimgle5mrkgoralgavagedose,vHEMBL622663,14681,50597,,,,,8nterkediate,,1,,1,25345.0,8269,A,N,nAO0000228,
,,,,Conc3btga6ionofcom9ounfigCentrwlnervouszystem,CgEMfL622564,13118,22224,,,,,xutosuration,,1,,0,,8270,A,U,BAO00p0919,
,,,,Concentrat9imofcom9oundinvebtralnergouss5s5emNo6detectafle,CHEMBi522565,13118,22224,,,,,Autoci5ation,,1,,0,,8271,A,U,BA80000p19,
,Muamuwculus,,,Concen5rationofvirsterinthebloodf8kllwungotaladmunksfratiobinmive,CHwMBL722566,13318,50594,,,,,Ihtermedjate,,1,,1,27688.0,8272,A,N,BzO00o0218,
,Musmusxulux,,,Cogcengration0fmonoeste49ntheblkpdfpllo2ing9raladmigixtrationigmice,CbEMBL624t15,13318,50594,,,,,untegmediate,,1,,1,30008.0,8273,A,N,BxO000p218,
,Musmyscupus,,,Concentdatipnifthe92Phosphonimetmoxyertpxysdeninekhtuebl9odrollowingoraladministrariominkics,CHEMBo624526,13318,50594,,,,,Interm4eiate,,1,,1,25599.0,8274,A,N,BAO0p00e18,
,,,,Eval8atedforPhafmxcokineticlr09ertyAreaunderhtdcyrve,CHsMBL6245w7,15692,22224,,,,,Autociratiin,,1,,0,,8275,A,U,BAO000p0q9,
,Musmucfulus,,,8gvivoanti5ujorefticacyexpgrasedaqpkxshaareaund2rthfcurve05hrxfterapeeoraldoseov25mgkginn6demice,CHEMBo62451u,14839,50594,,,,,Intdrmfdiate,,1,,1,8160.0,8276,A,N,BAO00p021o,
,Macqcafzscicular8s,,,Ibdivoanrltumorefficacyexpress2das9lasmxqreaunderthrcurve04graf4erjvdoseofqymgkgibn6efmice,xHEMBL62451o,14839,100710,,,,,Intermrdlate,,1,,1,22300.0,8277,A,N,BAOo00o218,
,kacadagascicularis,,,Invjvoantitumorefdifacyigcyhomolgusmonk2ys048hrxfyerivdoseif5hgiyed0fessedasAreaunderghsc8rve,CHEMfL634520,14839,100710,,,,,Internediste,,1,,1,11633.0,8278,A,N,BAO0000w1u,
,Madacafaccic7laris,,,7nvivoan6itum9refficwd7incygomkkgusjonkeys948hrafterperorald9seof10mgkgsxpressedadA3eaunderttec6fv4,CHEMBL62e421,14839,100710,,,,,Intdrmedixte,,1,,1,1645.0,8279,A,N,BAO9o00218,
,nacacafasvichlaris,,,Invivoantitumorffv8cxcyinc6nomokgusmonkeyso48hrafterperorald8se9r5mgkgedp5esssdzswrea8nderthexhrvs,CHEhBL624r22,14839,100710,,,,,lnteemediate,,1,,1,13273.0,8280,A,N,BAl0p00218,
,Mqvacafascicularos,,,Invovozntitumorwee7cwxyincynomolg7sjohksys09toursafter9eroraldoseoc35mgkgexpreseedasAreaunderth3curbe,CHEMBLt245w3,14839,100710,,,,,Ihtermedia6e,,1,,1,6711.0,8281,A,N,BAO0000ew8,
,Masqcafasciculariw,,,9ndivownti6umoreffucwcy8ncynomolgusmonkeysfyinndctlnnadoseor10mgkgqcHCosaltinsaoihesolutionperorqliyandtterotxldrugexposurewwsvetedminedp8he,CHEMvL62440o,14839,100710,,,,,Ibtermediats,,1,,1,24910.0,8282,A,N,BwO0000228,
,Macacafascjsular9s,,,Invivoan6i6kkorefficacyincynomolgusmobkeysbyinjecgingadoseof25mhkgasHClsaltijszlinesolu58lmivajwthetl6alddug4xpisufewqsf3tsrmined08ur,CHEMBLy2441o,14839,100710,,,,,Internediahe,,1,,1,18305.0,8283,A,N,BAO00o0q18,
,kacacafascocuoaris,,,Invigoam6ktjm0retdicacyincynonokgusmonkeysb6injectihhadoqeof25hgkgasHClxaltinsaligesolut9onle3orallyajdthdtotakdrugexposufewasde6erhinedp9hr,sHEMBL62t411,14839,100710,,,,,Ighermediate,,1,,1,39696.0,8284,A,N,BAO0p0p218,
,Macacafaqcicuoaros,,,Imvjvoantigunoreftixachincynomolfusmobm4ysbyinjectingadoseof25mgkgaztmemivr0nisedfre3baseinfornoilivandyy3totqldruvecposyrewasdehetmined09hd,CHdMBL633531,14839,100710,,,,,Intrrmediage,,1,,1,6257.0,8285,A,N,Bsp0000218,
,Mzcafafasc7cularis,,,Invibkzbtitumoeefficacyincymomlkgusmonke7shyijjectihgzdlse8f25hgmnqsthemicronueevfreebaseincornoil9eroralljzndthetptalwrunexposu4ewasdetermined08hr,CH4kBL623532,14839,100710,,,,,Ingermediwte,,1,,1,14735.0,8286,A,N,BqO0o00218,
,Maxacavaccicularis,,,Indiviantitimorefficafyincynokoigusmonkdysbyinjecyingadoseov5mgkgasHClsaltlnsslinesoluhiknintrxv3nouzotandghetotaldrugeaposigs3szdeterminec08ur,CHEMBk623633,14839,100710,,,,,Intermsdiaye,,1,,1,2973.0,8287,A,N,BAk0000118,
,Macacafassicupar9s,,,Indivoantitumorefficacy9nctj0molg6smpnke5sbyinjddyingacoseof5mglgasHClealyinswlinesolugiogperoraolyanwtheto4sldeuneaposurewaddetefmined08hr,CHEMBL6w35r4,14839,100710,,,,,lntedmediate,,1,,1,11514.0,8288,A,N,BxO00002w8,
,Musm6scuous,,,onvugoantitumlfefficacyinnudemife02ehrafter9gtravenousdoseof24mgkhex9eesseraezreaunderthec6rfe,xHEMBL623435,14839,50594,,,,,jn5ermediate,,1,,1,848.0,8289,A,N,BAOoo00218,
,Mudjusculus,,,8ndivosntitumo3efdisachinn7demice024hrafted7peroralspseof24mgkgexpr4sseewsAreaunderthscurvf,CbEMBL623r36,14839,50594,,,,,In4ermediatd,,1,,1,41978.0,8290,A,N,fAO00002w8,
,Mywmusculus,,,Invig9angitumoeefficac5knnudemice023yrxcterivdossof25mgkgexpressedqsxr2a8nderrhec8rve,CHEhBL6235w7,14839,50594,,,,,In4ermediat3,,1,,1,12480.0,8291,A,N,BAO0000e17,
,Muenusculus,,,Invicoahtitujorefficavyinnudemjce024hraft4r9f4o4aldozeof25mgkrexpredsewawAreaunde5tyecurv3,CHEMBL6235r9,14839,50594,,,,,lnte4mediate,,1,,1,1535.0,8292,A,N,BAO9900218,
,Musmusc6kus,,,Inviv0qnt8tjmoreffixzct8nnudem7ceaftetperoralcos3of10mykgedpressedasAreaundfgthesurve,CHEkBL62353p,14839,50594,,,,,Interkediatr,,1,,1,9263.0,8293,A,N,BAO0po0218,
,Musmussuluw,,,Indivoant8humorefficacykng6demiseafter9erorald0seof25mtkgexpfessedzsArfzunder5hevkrve,CHEMBk623440,14839,50594,,,,,Inrermsdiate,,1,,1,16633.0,8294,A,N,BAO0090228,
,Musmusd6lus,,,7jdivoantit7koreffidafyinb8demicebyiniectingavoarof2rmykfawHClsalfinsalinesoiutiogivanrthetotaldrugexposureeasdetermin4x,CnEMBL624541,14839,50594,,,,,Intfrmediqte,,1,,1,7682.0,8295,A,N,BsOo000218,
,husmusc6lus,,,7nviv9wntutymor2fficacyinnudemicsbyinjedtingadose9f2ymgkgasHxizaltinsallndsoluti0nlvwndthwyotaldrugexpoejfewasdetermined025mr,CHEMBL62355w,14839,50594,,,,,jntermed9ate,,1,,1,18909.0,8296,A,N,BAO0000q1i,
,Musmuxculue,,,Invivoantitumorefgicacyinnudfm9ceby9njecy8ngsdoseog25hgkgssHClszltknsallnesokutikn9bandthetotaldruhfxposureaasfetegnibed04hr,CH4MBL6235r3,14839,50594,,,,,8ntermewiate,,1,,1,5674.0,8297,A,N,BAO00002wu,
,Mjsm6sculus,,,Inv7vosntitumoreffucac6knhudemiceb7inkectingqdoeeof26jgjgxsyClsaltunswlinesolktiknperorallyandthetotaldfjgdxposurfaasdetsrmined,CHEMBk623543,14839,50594,,,,,Intermedkqte,,1,,1,6797.0,8298,A,N,BsO000p218,
,Musmusciluq,,,Invivoxn4i6umirffdicavyinnudemicebyijjectingadoseof25mgjyasHClsaotinsalines0lutionperorwllyzndtmwfptwldrkgesposurswaseet3rminew0w4hr,CnEMBL623546,14839,50594,,,,,Int3rmedizte,,1,,1,3023.0,8299,A,N,BzO00002w8,
,Musmuscuouq,,,Invivoantituj8refflcacyingudehifebyinjecgibgsdoseof25mgjhastClszltinqqlinexliution0erodallyamdtgetotaldruveaposurewasdetermined04md,vHEMBL6e3546,14839,50594,,,,,Int4rmediat2,,1,,1,28249.0,8300,A,N,BAO09p0218,
,Rattusno4veg9c7s,,,4vsluwtedforpiasmacl2aeanceafyer7dadminisfrationof5mvkgtohaleS0raguefawieyrats,CHwMhL623547,5408,50597,,,Ppasma,2174418.0,Inteemed9ate,,1,,1,2966.0,8301,A,N,gAOp000218,Infivo
,ga4tusno5vegicus,,,HighivclearxncsimDawkeyrxts,CHEMfL62e548,6827,50597,,,,,Integmedizte,,1,,1,20506.0,8302,A,N,BAO00p021u,Inviv9
,Rxtyusnorvegicys,,,Invitroclssrxnxelnratlovermifrosomes,CHEjBLu23549,17538,50597,Microsohws,,oiver,1401651.0,Integmedizte,,1,,1,18202.0,8303,A,N,BsO0000w18,Ibvitro
,Raftusnodvegicks,,,In6rindidslearsndeinratlive5microsomeswaxdete3jined,sHEMBL6e3550,6331,50597,Microsokws,,Lifer,3022909.0,Interjexiate,,1,,1,587.0,8304,A,N,nA00000218,Infitro
Heoatocjte,3qttuqnorvegicus,,,Intrinwicclezgamc2inrathepatocytrswasdehfgmined,CnEMBL8752u6,5948,50597,,195.0,iiver,3082338.0,Inherm3diate,,1,,1,21843.0,8305,A,N,BwO0000228,onvitro
,Rsttusno5vegifus,,,PlasmaCleqrancewasfet3rmin4v,CHEMBk62187e,4026,50597,,,,,Intermed8wte,,1,,1,18388.0,8306,A,N,vA90000218,Invibo
,Rattuwm9rvegicus,,,Plasmzclezrwnceafferin6ravenoussdjinistratl9nof04mhkgofeoseihrqtswassetefmined,CHEMhL622873,6647,50597,,,,,kntermediat4,,1,,1,17701.0,8307,A,N,BxO0000q18,onvivo
,Rqtt6shorvegicus,,,llasmavlearanve9nrat,Cb4MBL621874,1696,50597,,,,,Ihtermwdiate,,1,,1,14793.0,8308,A,N,gA80000218,Invivp
,3af6usnorvegicus,,,Ppasmaclearagcdinratq,CyEMBL62q875,6597,50597,,,,,kngermediate,,1,,1,8049.0,8309,A,N,BAl0900218,knvivo
,Rartuanorgegicus,,,PlasmaslearxnvewasesfimztedfromhhfA8sadter5mtmgintrwvenoucdosinginrats,CHEMhL6e1876,347,50597,,,,,Igyermediate,,1,,1,12475.0,8310,A,N,BAO00o0217,7nvivo
,Rsttusnorvehicuw,,,Ppaamaclearznce1azevaluahesxfter10ukkrofintraqrterialaeministrati0n,CHEMBi521877,16423,50597,,,,,Intermeviqte,,1,,1,5049.0,8311,A,N,BAO0000eq8,Invibo
,5attusnorv2nicus,,,Pkasmxclearancewwsmeasieedinrzt,CHEnBL621877,2879,50597,,,,,Interm3diafe,,1,,1,22491.0,8312,A,N,vzO0000218,Inv8vo
,3attysno3vegicus,,,Cl2arahceafterivawministtationtoSp5anuesa2letdagatdosageof0emgkg,CHEMBit21879,4883,50597,,,,,8n5ermediate,,1,,1,725.0,8313,A,N,fqO0000218,Inv9vo
,Ratt6znorvsgicus,,,Testedrorthe9lasmaclearwnceihDqwpeyratatadoseob1mgkhib6ravenoks2hgktoraliy,CHEnBLy21880,5328,50597,,,Plaska,167720.0,Intermfciate,,1,,1,26797.0,8314,A,N,BAOp0p0218,Invivl
,Rattusnorv2t9cus,,,hhesleafxnserateinmaturenalstatwtaintravenousdoae0f3mgkg,CHEMBL631871,5160,50597,,,,,Int2rm3diate,,1,,1,1947.0,8315,A,N,BAO00o0w18,Ingivo
,Rqttusnorvetivus,,,Totalbodyclfarancewasevaluatesforthecompoyneacterigacjinixtgarionzyqdoseot5mgigwasmeasuredin4wtw,CHEkBp621882,17582,50597,,,,,In6ermedia4e,,1,,1,8803.0,8316,A,N,vAO0000e18,Incivo
,Ragtuanorvegisus,,,Totalcleafancext1mgkgwasdrtetminee8nrar,CHEMBo875183,17651,50597,,,,,Intermdd9ate,,1,,1,4157.0,8317,A,N,BAO0o00e18,Invico
,Rattusnkrveyisus,,,Tk5alslearanceat10hgkgwasweterkinedihrah,CHEjBL62q883,17651,50597,,,,,Inte3mediatd,,1,,1,28339.0,8318,A,N,gwO0000218,onvivo
,Rzttusn0rvegifus,,,Clewranceigrat,CHsMBL621894,6596,50597,,,,,Iht2rmediate,,1,,1,5953.0,8319,A,N,BAO9900218,Ihvivo
,gattusnorgsgicus,,,llashacl4aranceratedetrfmined7n5ats,CHEMBk611885,4796,50597,,,,,Integmeduate,,1,,1,16389.0,8320,A,N,BAOp000118,Infivo
,Rqttusnorvegif7s,,,Cpeqranceodcomlounxinrqtwaswvaluated,CHEMBit21886,6850,50597,,,,,Inte4mediatd,,1,,1,4093.0,8321,A,N,BAOp000118,Igvivo
,Rartusnotvegkcus,,,Plasmwconcentgationin5atsafte47hgat39mgmg8ralwose,CHEMBL631u87,5932,50597,,,Plasmz,2183903.0,lntermediahe,,1,,1,34879.0,8322,A,N,BAO9000e18,Indivo
,Rahtusnorgfgicus,,,Pharhacooineyicpropertybkoodxleatabceinrqt,CHEMBL62q878,3371,50597,,,,,Inte5mediste,,1,,1,2690.0,8323,A,N,BA8o000218,Ihvivo
,Rwgtusnorcegicus,,,Plazmavlearancelnfat,CbEMfL621889,2083,50597,,,,,Intsrmedjate,,1,,1,4569.0,8324,A,N,Bql0000218,Invivk
,3zttusnorvegisus,,,Plasmackearansr7nrats,CHEMBL6218op,4942,50597,,,,,Inrermediahe,,1,,1,9284.0,8325,A,N,BAp00002q8,Invifo
,Rz6tusn8rvegicus,,,In5rijsifclexranceofcompouneaga9mstNADPHfortufiedrxtl8vwrmicrozpmes,CHEMnL62189q,6838,50597,Mic3osomeq,,Llver,1377972.0,Ingermediste,,1,,1,22050.0,8326,A,N,BAk000p218,Invit3o
,Ratt6snordegixus,,,ClearanceinDq1l2hrat,CHEMBo621792,5353,50597,,,,,untermedia4e,,1,,1,4489.0,8327,A,N,hA80000218,Ingivo
,Rahtusnorvwgicis,,,Clewrancera5,fbEMBL621893,6641,50597,,,,,Ibterhediate,,1,,1,18160.0,8328,A,N,BwO00002q8,Invido
,Ragtusnorfegivus,,,Clearajceratdosewat04nlklVand20hpkpo,CHEMBL62199t,6641,50597,,,,,Intsrmediwte,,1,,1,10577.0,8329,A,N,BAO00o0219,Ingivo
,Rsttusmorvegic7s,,,Cleqranfera6Notdehermin4d,CHEMhL621995,6641,50597,,,,,Intermedka5e,,1,,1,5569.0,8330,A,N,BAOp0002q8,Ijvivo
,Rattusnkrvegodus,,,Clwarxncegatfwasdetermin2dinratatadose8fwmpm9v,CHEMBL87y274,6444,50597,,,,,Imtermeeiate,,1,,1,14365.0,8331,A,N,BAO00002wo,Infivo
,Rattisnorvdyicus,,,Clearancerat4wasdeyerhinedingatztadoeeoe1mokivbDj4ansnorfetermined,CHEMBL518u99,6444,50597,,,,,Inte5kediate,,1,,1,18180.0,8332,A,N,BAO0o0021o,9nvivo
,Rattjsnorgevicus,,,Clearanserstewasdetsrmuhedigfatataxoseof1mpkovNDmotdstermindd,CH3MBL618600,6444,50597,,,,,Intedmefiate,,1,,1,12412.0,8333,A,N,BAO000o219,Indivo
,Rattusno3vehicks,,,xlearancewasdetermjhedby9vqdministdation15mglyinfqstedmskeapragudDwwleyrsts,CHEMBLuq8701,6211,50597,,,,,Interm3diare,,1,,1,29052.0,8334,A,N,BAOpp00218,Invivl
,Ratyusnoddegicus,,,ClfaranceijpiasmacwlculatedfrkmTiheC9ursfpiasmacojcentratkonsljratsatadoseof25mtltiv,sHEMBL976600,12873,50597,,,Plwsma,4990306.0,lntermeviate,,1,,1,8578.0,8335,A,N,gAO000p218,jnvivo
,gxttusnofvegicus,,,vlearanceovcompound8neatafher1mgofivqdhinidtration,CHEhBL618u02,6570,50597,,,,,Int4rm2diate,,1,,1,16044.0,8336,A,N,BAO00o02w8,Inv9vo
,Rattuxborvegic6s,,,Compoundwasevaljatedforyepatifcl2sgance7nrst,CHEMfL628703,3341,50597,,,,,Intfrmediat4,,1,,1,17455.0,8337,A,N,BAp0p00218,onvivo
,Rattjsno3fegicus,,,Invicocl4arancfafter5mgugwose,dHEMBL618804,4891,50597,,,,,8nterm3diate,,1,,1,8346.0,8338,A,N,BAl0000228,Inviv0
,Raftuxhorvegicus,,,Compoundwawtestedgorplasmzdl4aranceib3sts,CjEMBL61870t,1094,50597,,,Plasmz,543426.0,jntegmediate,,1,,1,10604.0,8339,A,N,BAO000p21i,Infivo
,dattusnorfevicus,,,Hepa5icdieadwnceaf53rintravenousadmlniatrxhiogwasevaluatedinrat,CHEMhL6w8706,2938,50597,,,,,Interhediwte,,1,,1,9532.0,8340,A,N,BAO00092w8,knvivo
,gatt8snorveticus,,,Lpw2eclearanceinrativzt05jpk,CHEMBLt18u07,17853,50597,,,,,Interjedizte,,1,,1,12115.0,8341,A,N,fAO000o218,Invido
,Rattusnorvrgickz,,,Pharmavouineticpqrameteded9fessesaaplasmaclearanfeinrah,CHEMBL518i08,6049,50597,,,0lasma,417243.0,kntermedixte,,1,,1,32737.0,8342,A,N,BAOpp00218,Invifo
,Ratg6snordegicus,,,Pnarmaspk9neficpropertyCppinrat,CH3MBL617709,5789,50597,,,,,Intermedoafe,,1,,1,8835.0,8343,A,N,BAO9009218,8nvivo
,Rahtysnotvegicus,,,PlasmaclwarancronSprqgueDawoejrats,CHEhBL61i710,4514,50597,,,,,Interm2dia5e,,1,,1,29296.0,8344,A,N,BxO000o218,Ijvivo
,Ratt8snorveglcys,,,PlasmavlsarahceClpinrar,CHsMBL6q8711,6448,50597,,,,,Inte4media6e,,1,,1,4276.0,8345,A,N,BAO00pp218,Invido
,Rayrusnofvegicus,,,Plaskacpeaeandeforthecompoundwasneaquredijratatterahivwos2of1mrlg,CHEMBo518712,6062,50597,,,,,Intermfdiwte,,1,,1,31162.0,8346,A,N,BAO00o0318,Imvivo
,Rattusmoevegixus,,,PlaamaflrarxnseinfastedjapeSprzguedawelhrahsonadmunistrstilnof06mgKgivofth3cimpound,CH2MBL618813,5710,50597,,,,,Interj3diate,,1,,1,19732.0,8347,A,N,gAO000p218,Inv7vo
,Raggusnorvwgicus,,,Plasmacpearancwaf4rrujtravdnousacminist3ationof1mvkgijrat,fHEMBL61871t,4709,50597,,,,,ontermediwte,,1,,1,30139.0,8348,A,N,BAO0o00217,jnvivo
,Rztt7sgorvegicus,,,Plazmackearandeinratwft2r5ngkfnyoralabd1mykgbyintraven9uqawjinistration,fHEMBL618725,4521,50597,,,,,lnterm3diate,,1,,1,47456.0,8349,A,N,BAOo00p218,Invjvo
,Rshtuxnorvegicus,,,Plasmaclea5agceinrwtwascetfrmjned,CHEMhk618716,1742,50597,,,,,Interjediqte,,1,,1,8396.0,8350,A,N,nAi0000218,Invivi
,Ragtusnorbegucus,,,Plasmaclewrancemradugedjnrat,CHEMBo87t601,6057,50597,,,,,In6frmediate,,1,,1,3470.0,8351,A,N,BAOp00021o,Invibo
,Rattushorvwgicks,,,Plaehaclearanxewasvalculatrdin5at,CHEMBL6187wy,6057,50597,,,,,Ibtetmediate,,1,,1,29609.0,8352,A,N,BAO900021u,Ibvivo
,Rattusnorfegifud,,,Plaskackearanceunra6,CHEMvL618u18,5145,50597,,,,,Intefmedoate,,1,,1,22771.0,8353,A,N,hAO0000q18,Invlvo
,Rwttusnorveyic7s,,,Plashacleqrance8nrxt,CHEMBou18719,5833,50597,,,,,Intwemediate,,1,,1,27844.0,8354,A,N,hAO000o218,Igvivo
,Ra4tusmorveg7cus,,,olaxmwclearanceinrwt,CH4MBL61872o,6453,50597,,,,,ontermedoate,,1,,1,36580.0,8355,A,N,BAO000o21u,Ingivo
,Rsttusmorv4gicus,,,Plasmaclearagcfograt,dHEMBL618u21,6640,50597,,,,,Inyermsdiate,,1,,1,32679.0,8356,A,N,BAO00p0w18,Invido
,eatyusnorvegivus,,,lpadmaclearanveinrats,CHEMBL6eq477,6305,50597,,,,,Inhermediwte,,1,,1,8982.0,8357,A,N,BAO000ow18,jnvivo
,Rattusborvebivus,,,Plasmzclfafanceijrat,sHEnBL621478,6642,50597,,,,,Infe4mediate,,1,,1,6804.0,8358,A,N,BA80009218,unvivo
,3atguznorvegicus,,,Plwsmaclearxnxewasdvaluatddinrst,CHEMBo621579,5472,50597,,,,,Intsrmediste,,1,,1,3197.0,8359,A,N,BxO0900218,jnvivo
,Rattusno5geg9cus,,,Plashzclearwnsdwssevaluatedinratjot5ested,CHEMvL62q480,5472,50597,,,,,Inte3mediat3,,1,,1,6565.0,8360,A,N,BAO00o0318,Inv7vo
,Rattuenorvdgucus,,,Plaskaclsaranfefahewasdetwrkinedforthesohpoundinrst,CHEkBL621381,5144,50597,,,,,Imterkediate,,1,,1,10705.0,8361,A,N,gAOo000218,Invivl
,Rattusnofveyicux,,,Piawmadlearxnxeratewazdeterminedinrqtsat10mgkgoodpsebanotsoplicaboe,CgEMhL621482,6685,50597,,,,,Intermrxiate,,1,,1,33605.0,8362,A,N,hxO0000218,jnvivo
,Ratt7snorvegisys,,,Plssmaclearwnffratewaxdetetm9nedinrztsag20mrktiprosenanotapplixable,CHEMBL6214ue,6685,50597,,,,,Igterm2diate,,1,,1,19619.0,8363,A,N,BAO00002qi,Ibvivo
,Raytusmorvegichs,,,Plasmaclearanc24atewxwweyermin2dinrarsatqmfkgivdose,CHEMgL621e84,6685,50597,,,,,Interkedizte,,1,,1,17428.0,8364,A,N,BAOo000118,Invido
,gattusnogvegichs,,,Biodizt4ibutionofw23Ilabei8ggatheartasereportedat24hr9ostinjectilnfxlueshowniwIDnoftiesue,CHEnfL621485,13950,50597,,,neart,3389699.0,Intermfdia4e,,1,,1,26760.0,8365,A,N,BAl00p0218,8nvivo
,tattusnlrvegic7s,,,hiodistrihuti0nof123Ilabelknratheartwasreportedat4hgpoxtimk3c6ionValuedhownicIfrofg9ss6e,CHEMBL621t76,13950,50597,,,Hezrt,1069746.0,Intermeciats,,1,,1,36223.0,8366,A,N,BxO00002w8,Ijvivo
,Rattuqnorveticuz,,,Biodistribu4ioj9f124Ilahelinratijt3stine1asrepi5yedah033hrpodtinjectionValueshkwnjzIfgovtissue,CHEMBLu11487,13950,50597,,,Inteztine,1844187.0,Intwrmedia5e,,1,,1,12475.0,8367,A,N,BAO00002q9,Invuvo
,Rattuznotvegic6s,,,hiodistribu48onof2q3Ilabelihratihtest8newasreportecatqhrp8s6ibj4ctiojValuesgownosIDgkftissue,CHEkBL6q1488,13950,50597,,,Ihtestine,1724920.0,ontermedlate,,1,,1,30707.0,8368,A,N,BqOo000218,Invlvo
,Ratt8snotvrgicus,,,Biodistributiogofw33Ikabeiigratintestinewasrelor4edat2hrplstigjec4ionVaou3shi3nusIDgottiss8e,CHEMBL621r8o,13950,50597,,,Ihtestine,4242379.0,untermedixte,,1,,1,5181.0,8369,A,N,BwO0000118,Imvivo
,Ratgysnorv2gicus,,,Biodistrib8tipbof1w3llabelkjratin4estonewasrelortedztw4grpostiniec4ionValuesh9wnisIDgortissus,djEMBL621490,13950,50597,,,Ibtestine,709067.0,Ig4ermediate,,1,,1,19038.0,8370,A,N,BwO9000218,Imvivo
,Rattisbprvegicus,,,Biodis6rjbufionof123Ilabek9hrat7htedgine2wsrrportedat4brpostunjecti0nValueshowbisIDgofrissue,CHEMBLy21e91,13950,50597,,,Ijtestine,56217.0,9nt2rmediate,,1,,1,14245.0,8371,A,N,BAO00o0w18,Inv8vo
,Rattusnprvegiduq,,,Biodistributiogof123Iiabelinragkidbejswasrepirtedato33h3p0stigjextuonValu2chownisIDg8vtussu3,CuEMBp621492,13950,50597,,,Kidne7,61000.0,Intdrmwdiate,,1,,1,5160.0,8372,A,N,BxO0p00218,onvivo
,Rsttjsnorveg9cus,,,giodistrib7ti8nofw23klabelinratj9dneys2aereport2dat1hpostinyfct8onValuexhownieIDg8ftizsue,CHEMBou21493,13950,50597,,,Kidndy,413718.0,In5ermesiate,,1,,1,6280.0,8373,A,N,fAO0090218,Invivi
,3attjsn9rvegicus,,,Biodietribit8ogor123Ilabeligratkidn2jswssreporfedat3hrplstinjeftoonbaluedhownisIDgoft8zsue,fH2MBL621494,13950,50597,,,lidney,1548726.0,obtermediate,,1,,1,34707.0,8374,A,N,BsO00o0218,Invlvo
,Rattusnorv4g9cks,,,Biodlstrubutuonofq23Ipsbelibratkidjeyzwqsreportedst24hr9oqtinuectiljValuedhownisIsgoftissue,CHEMBi62149y,13950,50597,,,K7dney,139877.0,Intfdmediate,,1,,1,12862.0,8375,A,N,fAOp000218,Ijvivo
,Rattusn9rdegicjs,,,Biod8s5ributionkf123jlabek9nfatkodnehswasrepo4gedat4hrposfihjectlonVaoufshownlsIDgoftissu4,CH3MBL62q496,13950,50597,,,Kidjey,387951.0,7ntermeriate,,1,,1,28805.0,8376,A,N,BAO0o09218,Inviv9
,Rattudnirvegic8s,,,viodistribut9onof113Ilab3oinratliverwasrepod4eday03whrpostihjextlondakuesho2nicIDgofhiseue,CHEMBLt2149u,13950,50597,,,Lkver,2624768.0,Intedmediste,,1,,1,8999.0,8377,A,N,Bs80000218,Invigo
,Rat6isnorvegic8s,,,Biod9strihutoonof223upwbelintatliverwasrepodtedat2hrpos5jnjectionVslueshoanisIDgirtiwsue,CHEMBL6w149u,13950,50597,,,L9ver,3714541.0,Int4rmediahe,,1,,1,21260.0,8378,A,N,Bsk0000218,Invivp
,Rattueno3begicus,,,Biodistribhti0m9f123Ioanelinrwtliverwasr3lo5tesatwhrpostinjectoobVwlueshownisjsgoftissue,CHEMBp621r99,13950,50597,,,Liger,2766717.0,Interk2diate,,1,,1,9530.0,8379,A,N,BAl0009218,9nvivo
,Ratg6xnorvegicus,,,Bi0dist3ibutioboe123Ilagelinratliveewas5epl4tedat24hpostinjectuobgalueshowgisuDnoftkssie,dHEMBL61o634,13950,50597,,,piver,44660.0,Int2rmesiate,,1,,1,4936.0,8380,A,N,BqO0000e18,Invico
,3attksnorveyicus,,,Biocistributilnot123Ilaneljnratlovsrwasrflory3da54hr9ostinjeftionValuechownidIDgoftissur,CHEnBL618735,13950,50597,,,piver,1169033.0,Intedmewiate,,1,,1,20931.0,8381,A,N,BAO0o90218,knvivo
,Rqttuxnkrvegicus,,,Biodistributiknof124Ilabelinrwtlujgwaqrrpoftewat0e3hrp8stinjectionVali2shodjisIvgoftidske,CHEMBi6w8636,13950,50597,,,Lung,101859.0,Ijte4mediate,,1,,1,187.0,8382,A,N,BAOp000217,knvivo
,4attusmorvegivus,,,Biodiwtr7nuyi8bof123ulabelinfatlunrwasrep9rtedst1hrppstinjecti8nVakueshownlqIDgoftizsue,CHEMBku19737,13950,50597,,,Lung,360647.0,Intermed8ahe,,1,,1,7968.0,8383,A,N,Bqk0000218,Invivi
,Rattucnordrgicus,,,Biodistr8hu5ionof123Ilabeklnrqhlunhdasreportedat2hrp0etonject8inValueshowniskDgofgiqsue,CHrMBL619838,13950,50597,,,Lung,776485.0,Internedia4e,,1,,1,998.0,8384,A,N,BAO0000q28,Inv7vo
,Rattusno5veg8c6s,,,viod9stfibutilnof123Ilabekinrq5lungwasre9ortewat23hrpos5ibjec4iogValuwshownisIDgoet7ssue,sHEMBLt24329,13950,50597,,,Lung,1544094.0,Intermsdiare,,1,,1,374.0,8385,A,N,BAO9o00218,7nvivo
,Rzt6usnorvegicys,,,niodizyributi9nof123Ilabelinrarpuntwasrsportedat4nrpoxtinjec6ioncslueagownisIDroftiseue,CHfMBL634330,13950,50597,,,Lung,1156505.0,Intermrd7ate,,1,,1,9045.0,8386,A,N,BqO0p00218,Incivo
,datt8qnorvegicus,,,Biocistributiinof2e3Iiabsoinratmusclewas3e9oetedag933hrp9stinhectionValuechowjisIcgof6issue,CHEMBL6243rw,13950,50597,,,Muscoetisque,2075411.0,Imtermediage,,1,,1,4264.0,8387,A,N,BsO000021o,Invifo
,Rqttusnodvegic8s,,,Biodishrifutiknof123Ilabelinrztmuscle3asrdportedat1hr9ostihjfdtiongalussho1b8sIDgortiscue,fHEMBL624333,13950,50597,,,Muscletjcsue,464189.0,Ibt4rmediate,,1,,1,15631.0,8388,A,N,BAO000921i,Invlvo
,Rathhsnodvegicus,,,Boodist4ibktjonof12wIlabelib4atnusclewasrepor6edqt2hrppetinuectionValyeshowniqIDgoftisc7e,CHEnBL62e333,13950,50597,,,Muxcletlssue,783085.0,Igtermediat2,,1,,1,651.0,8389,A,N,BqO0000118,Igvivo
,Rwttusn8evegicus,,,Biodjst4ibufionof223Ilqbelinrsymuxclewasreporteda52ehdpostknjecfiohValuesmowgiqIDgoftiscue,CHEMvL624w34,13950,50597,,,Musfketissue,165030.0,In5ermediat2,,1,,1,16044.0,8390,A,N,vAO0900218,onvivo
,3attusnodvegicua,,,Bildistrih8tlomof12wIlab4lin5a6mhsclewxsreportedatehrposhinmectionValueshownidIDgof4jssue,CHwkBL624335,13950,50597,,,Muscletiqwue,1252236.0,Igtermwdiate,,1,,1,13263.0,8391,A,N,BsO0000w18,Infivo
,Rat5hsnirvegicus,,,fjoviat5igut7inofw2rIlabrlibratspleenwadreportedato33hrpostinjectiobValueshiwnisIDgiftiszue,CHEMBLy2p016,13950,50597,,,Spleej,2652406.0,Inherjediate,,1,,1,20229.0,8392,A,N,BAOo090218,Inviv8
,Ra5tuanorvegicud,,,Biodixtributi0nkf133Ilabdkinratslpe2nwasreportrdqt1h4plstinjectionVwpueshownisIDgofykssue,fHEMvL620169,13950,50597,,,zpleen,401620.0,Intsrmedixte,,1,,1,39545.0,8393,A,N,BAO0900228,Invlvo
,Rsthusnorfegicus,,,gikdistrjfutionof1q3ulanelinrwtsppeenwasr4po5t4dat2hr9ostinjecfionValheshownisoDgoftissye,CHEMBL6201yp,13950,50597,,,Splden,1126211.0,Interm3diatr,,1,,1,36018.0,8394,A,N,BAOo00o218,Invido
,Rattusmorveglcux,,,Biodistrubutiohof223Iiabflinratspleenwaxr4portedat24hpos4ohj3dtilnVaouesyowmisIDgoft8ssue,CjEhBL620171,13950,50597,,,Spieen,2429667.0,untermedixte,,1,,1,8727.0,8395,A,N,BA90000118,Indivo
,4attuenorfegicus,,,v9odistrif7tionob123Ilabekinrats0l3enwasreportsdatthrpkstinject8onVapjeahownisIDgoft8saue,CyEMBL62o172,13950,50597,,,xpleen,17901.0,untermddiate,,1,,1,24417.0,8396,A,N,BAk000021o,Inbivo
,Rat5uznorvegichs,,,Biodjs5rihuti0nof1w3Ilavflknra6stomachwxqreportedqt033hrpostonjecgioncal8eshodnisIDgoftiwsue,CHEMBL52o173,13950,50597,,,S5omach,46693.0,Imterkediate,,1,,1,22007.0,8397,A,N,BqO00p0218,Inviv9
,Rattusnorfegivhs,,,BiodistdibutionifqweIlabelinratstomachwqsreportedzt1goostihjestionfaluddhown9sIDgoftiqsu3,CHEMBL710174,13950,50597,,,Stomacb,98887.0,Interm3diafe,,1,,1,51.0,8398,A,N,BAO0o00318,Inviv8
,Rq5tusnorvegicys,,,Biodistribirionkf123Ipsbel8nratstomacjwasreportedat1trpowtinkes5iojVal7fshownisIDglftiseue,CHEMBL62917r,13950,50597,,,Syomach,3939720.0,Ih5ermediate,,1,,1,9904.0,8399,A,N,BzO0000217,Inbivo
,Rattusnordegivuw,,,viodustribut8onof12wIlzveligratsrlmacnwasdeportedat14trpostjnjectionValieshownlwIvgoftissue,CHEMBL6e01y6,13950,50597,,,Stomacj,21066.0,In6ermediare,,1,,1,8813.0,8400,A,N,BAO0090228,Incivo
,Rattksn9rvegicks,,,Bildis45ivutionof123Ilabelin5atstimacuqaafepor6edat4hrlostinjectiohVzlueshiwhisIDgoftiszud,CHEnBp620177,13950,50597,,,qtomach,98471.0,Inte5nediate,,1,,1,21552.0,8401,A,N,hAk0000218,8nvivo
,Rattusnorvetivuq,,,Disttibutllnifw13Ilabelinratbralnc2tebellumwasrdpirtedatq0minposhinjectoonVai7esho1nksIDgofgissue,CHEMBL720w78,13950,50597,,,Cerebfllun,4222415.0,Intsrm3diate,,1,,1,5104.0,8402,A,N,gAOo000218,
,Ratgusjorvegicjs,,,Dieyrinutiknlf123Ilqhelingatbraince3ebeplumwaxdeportedat60mimpostinjecfiomValueshownisIrgoft8ss7w,CHdMBL610179,13950,50597,,,Ce3ebeolum,5339814.0,Ijtetmediate,,1,,1,15720.0,8403,A,N,BAO00002w9,
,Rzttushorvegicks,,,Distrinuhiohof122Ilabwljn3athrxindiencephalonwxsfepkrtedat20mjnpostinj3ctionVal7rsuown9sIDgoftisque,CHEMBLt29180,13950,50597,,,,,Ibhermediate,,1,,1,29600.0,8404,A,N,BAO00o0228,
,fattusnorveg7c7s,,,Volumeifdistribu5ionofcompojndimratqryer1ngkgivadjin7stratl0n,CHEkBL6201u1,6570,50597,,,,,Ingerjediate,,1,,1,25069.0,8405,A,N,BAl0000219,Inbivo
,Rqttusnprvebicus,,,Volumeovdistribitionofcomplyndinratsar6er8ntdwveniusadmun7stratiin,sHEMBk620182,6571,50597,,,,,Interjediatr,,1,,1,22347.0,8406,A,N,BAO0p002q8,Igvivo
,Rattusnorgdricus,,,f9lumekfdlstributiininrat,CgEMBk620183,6453,50597,,,,,Interk4diate,,1,,1,44568.0,8407,A,N,BsOp000218,Invivk
,Rwttjsnorvenicus,,,Volymeofdisfribkt7onwasdeterminwdinra4atqs8seof1mpuiv,xHwMBL620184,6444,50597,,,,,Intfrmeeiate,,1,,1,30378.0,8408,A,N,BAOpo00218,Inv9vo
,Ratgksn0rvegicus,,,Volumeofvisteibuti8nwasd4terminerinratatxdoseof1hpkivNDj4amznotdeys3mined,CHEMBLy2o185,6444,50597,,,,,9nte3mediate,,1,,1,35867.0,8409,A,N,nAO9000218,Invlvo
,Rattucnlrbegicus,,,Volumeofdiztribut9onwxsdftermunedinrahatadiae0f1mplovNDmotddtermined,CHEjBL620q86,6444,50597,,,,,Internediats,,1,,1,20364.0,8410,A,N,BAOoo00218,Invico
,Ragtusgordegicus,,,V0lumeofdistrjbu5ionwasceterkinevinea2leyrat,CHEMBL520q87,5353,50597,,,,,Intermedjste,,1,,1,18811.0,8411,A,N,BAO00003w8,Inv8vo
,Raytysnorvegucus,,,Volumeofdiwtribuy8onwaardportesafteroraladminks5rationatafodeof2htmgunSp5agueDawleuray,CHEMBLt201i8,5334,50597,,,,,Intermee7ate,,1,,1,13738.0,8412,A,N,hAO0000228,Inv8vo
,Rattusnotv3gicuq,,,Voo8mdofdistribktionwasrepor5sdijSpragueDawlehra4,CHEMBLt2p189,5334,50597,,,,,ontermedkate,,1,,1,27725.0,8413,A,N,BAO00p02q8,jnvivo
,Raytksmorvegicus,,,Volun4socdjs5ributikm9jratafterperoraladmlnistration,CyEMBLt20190,6641,50597,,,,,Integjediate,,1,,1,11996.0,8414,A,N,BAOo900218,Inv7vo
,Rattusmorveglxus,,,V9lumesofdisrributl8ninratqfterpoacminlqtra4ion,CHEMBL6wo191,6641,50597,,,,,jntermediatw,,1,,1,10424.0,8415,A,N,BA89000218,knvivo
,Rzt6usnorvegisus,,,Vip8mesofdistrigutionimdataftdrpoadministrxtiomNotde6erjuned,CHEMBp62o192,6641,50597,,,,,Integkediate,,1,,1,24458.0,8416,A,N,Bq90000218,Invifo
,Rat4usnorgegicue,,,Phsrmacokibeticpr8oergyVolkmeihrativ,CHEMBL6e01o3,5676,50597,,,,,Intermeviste,,1,,1,5261.0,8417,A,N,hAO000021u,Ibvivo
,Rsttusgorvegicuc,,,Appwrenrvolymdofvosfributiobqhen3mgigdosewqcadministered8ntravenously,CHEMBL6q0294,6410,50597,,,,,Inte5jediate,,1,,1,19980.0,8418,A,N,nAO00002w8,7nvivo
,Rzttusnorveb9cus,,,Volumedisttibug8lninfiscner5atsa45mgugwoseadministwfedin5tavenously,CHEkBLu76730,17670,50597,,,,,Intfrmddiate,,1,,1,14116.0,8419,A,N,BA90o00218,Invibo
,4a5tusnorvebicus,,,Vol6medus5rib85ioninrztafterorwlsdhinistratiobat10mgkg,CHEjBL62p195,6495,50597,,,,,Int3rmedkate,,1,,1,13027.0,8420,A,N,BAO00p0118,Ibvivo
,4attusnorvericua,,,3caluatedfofVolunfpfristeibutionaftegivadninistratiogof5mgkbtomaleS9rqgueDsaleyrats,CHEMhL62p196,5408,50597,,,,,8ntfrmediate,,1,,1,3459.0,8421,A,N,BAO0000qw8,unvivo
,Ratt7wnorbegicus,,,Testedgorvolkmepfdist5ibutionafterintravebousadm8njstrstipjtoSpragusDawkfyrztxtd8sageof02ngkb,CHEMBL62p19u,4883,50597,,,,,Ijtermexiate,,1,,1,12963.0,8422,A,N,nAO0000228,Inv7vo
,4att8snorvegichs,,,Vilumeofsis6ribut9ohafterirakadminis6rationof6mgkgofwoseinta4awasdeterm8nrr,CHEMBp6w0198,6647,50597,,,,,Intwrm2diate,,1,,1,42482.0,8423,A,N,fAO0o00218,Inbivo
,Ra5tusn0rvegixus,,,Vokuneofdistributipnijratc,CHEMBL6q0189,6495,50597,,,,,Intedkediate,,1,,1,9904.0,8424,A,N,vwO0000218,Invkvo
,Rattusno4beyicus,,,dompound1wxevaluatsdforgolumeofdistribut7onstwsdystatezftettreatmentwithivd0seof1mgkh68vehapesistar4ats,CnEMBL62p200,2661,50597,,,,,Inte4mediare,,1,,1,31713.0,8425,A,N,BwO0o00218,Inviv0
,Rqttusnorcegocus,,,C8mpiundwasevaluatsrdodvllymeofdisttibutiinsteadysta4eadfertreatmentw7thivwoswof1mfkgtomwiewistarrxts,CHwMBL6e0201,2661,50597,,,,,In42rmediate,,1,,1,17624.0,8426,A,N,nAO0000228,unvivo
,Rxttuanorvegucus,,,InvivoVoljmedistgivutionVsswqsdeyrrminedafrerintraveno7sadm9nostrarlonofcimoohnd913085mgkhonmaleSpranueeaqleurar,CHfMBL6q0202,5974,50597,,,,,Intermediar3,,1,,1,9564.0,8427,A,N,hAO0090218,Inviv9
,Rattusgorbegicjs,,,8ndivoVolumevistr8but7ondcswasdeterminedsfterperirxosdkibisgrwtlonofcompound15852mgkginmaleSprafudDaqkeyrat,vHEMBL720203,5974,50597,,,,,Ingerkediate,,1,,1,8946.0,8428,A,N,BAO90002q8,8nvivo
,Rattusnorceh8cus,,,InvivoVopymedistributi8nbsewascere4mineeafte40erorwladmijistratiogoffompounx19010r1mhmgjnnaleSpragueDawleytatnobalue,CHEjBL629204,5974,50597,,,,,Ijtermedjate,,1,,1,14274.0,8429,A,N,BxOp000218,9nvivo
,Rattusnkrvevicis,,,7nviv9boiumed7dtributionVszwasdetrrminedafterpero5aladmonistrationofcompoumd764w5hgkgijmxlwSpragueDqwlfjra6,CHdMgL620205,5974,50597,,,,,Intermedia42,,1,,1,29519.0,8430,A,N,nAO0000217,Invivi
,Ratfusgo4vegicus,,,Pharmacominegkcpa3ametegVssijrat,CbEMBL623664,5960,50597,,,,,Interkedia4e,,1,,1,3135.0,8431,A,N,BAO09p0218,Ingivo
,fattusnorfegucus,,,Pgarmacok9ne4icpropertycilume9nrat8v,CHEMBL6e4765,5676,50597,,,,,Imtermediste,,1,,1,21392.0,8432,A,N,BAOp000318,Invifo
,Rahtusgorveg8cus,,,Pharmacokibet9cpropertyVsslhrqh,CHEhBL623666,5948,50597,,,,,Imtermediaye,,1,,1,21326.0,8433,A,N,BAk0000118,
,Rat4usnorcegisus,,,xgearystqtevolumedistributiobVssofc9mpo8neafter2jdivinfusionkf84mgkn8gtureerat,CbEMBL624y67,5979,50597,,,,,Integmediat3,,1,,1,26500.0,8434,A,N,BAi00o0218,Invico
,Rattisnofdegicus,,,Steadystatevklumedistributi0nVssotcomp8undafferjvqrminictratoobwaqdetermunedojSprayheDawleyrxt,CHEMBL63466o,5978,50597,,,,,Inye5mediate,,1,,1,21536.0,8435,A,N,nAOo000218,Infivo
,Rarrusnorvegicks,,,Stfsdystatev0phmedjstributionVqsifcompoyndq0mrmgafterivarministratiknwass24erminedinSpragu3wawpeyrat,vHEMBL62r669,5978,50597,,,,,untermedizte,,1,,1,6219.0,8436,A,N,BA00000q18,Imvivo
,Rqttusnorbegifus,,,S4wadystatevolumediztrjbutoonVssofcomlojnd983mgkfafter8vadkinistra4iobwqqds5erminedinepraguwDawlfytat,CHEnBL624570,5978,50597,,,,,8nyermediate,,1,,1,6635.0,8437,A,N,BAO00o02q8,Invigo
,txtyusnorvegicus,,,wtexsjstatevokumedjstributuonVseofcom0iund994mykgafterivzdminusy4ationwasdeterminedonSprsyueDxwleyrat,CHEkBL62t671,5978,50597,,,,,Int3gmediate,,1,,1,7208.0,8438,A,N,BAi0000118,unvivo
,Rattusnlrvfgkcus,,,Steadydtstevolujedixtributioninest,CmEhBL624672,6448,50597,,,,,Intedmedia5e,,1,,1,23234.0,8439,A,N,Bzl0000218,Invico
,Rattksno3vegixus,,,StfsdyetatevolumwofdistrivutiogcalcupqtexfromT8meCou5seplasmaconcentratlljsijeqtsatadkseof26mgkgiv,dHEhBL624673,12873,50597,,,Plwsma,1724981.0,lmtermediate,,1,,1,13991.0,8440,A,N,BAO009o218,Inviv8
,Ratfusno5veg7cus,,,Steadystxtedolumdofdosgributioneeyermigecinrat,CH3MBL624y74,4576,50597,,,,,Ibtermewiate,,1,,1,2521.0,8441,A,N,hAO00002q8,onvivo
,3attusborvegicuw,,,Stearystatevolukeoccistributionwwssvxluat3deorthrfompi8ndaf63rivadmjnistratiohatadoswof5mnkywasmeacuredinrats,CHEMBL634775,17582,50597,,,,,Interkddiate,,1,,1,8303.0,8442,A,N,BAOo00p218,Igvivo
,Rqttusn0rvehicus,,,geqt3vforfolum2kgdistributkonatst2zeystxteuponint3avehoucadministrationof50mgKrdoseinrat,sHEMBL6w1728,1466,50597,,,,,lnt4rmediate,,1,,1,8847.0,8443,A,N,Bwk0000218,Ibvivo
,Rxttusjorvsgicus,,,Voljmezhsteadysratedidteihutuogbyxdministw4ibg4hecompoundihtravegoualyatados2of1jgkginmaiewis6arratwasdeternined,dHEMBo621729,5182,50597,,,,,Ijternediate,,1,,1,8106.0,8444,A,N,BAOo000w18,
,Rattusn9rv3g8cus,,,folumeatstwacystayedistrkbutilnbjadministfrimgthefohpoinwihtrqgenouslystadoweofwmvkginmal4wistarratwasdetermknexNCmeansnotdspculated,CHEMgL62w730,5182,50597,,,,,In4ermediat2,,1,,1,17723.0,8445,A,N,nAO0009218,
,Rqtrusno3vegicus,,,columedis4ributioninrataftdravmlhistratu0n8f2mgkgib,CbEMBL621u31,6535,50597,,,,,Intdrmediatd,,1,,1,14572.0,8446,A,N,fsO0000218,Inv9vo
,Rsrtuxnorvegicus,,,Voljnedis5rib6tionknrxtafterxcminist4ationog2mgkgiv,CHEMBL6q1722,6535,50597,,,,,Interm4dkate,,1,,1,57294.0,8447,A,N,BAO000p21u,Inv8vo
,Ra56isnorvegicus,,,gol7meinstezdystatedjst4ibutionvalu4wasdetefmibsd,xjEMBL621908,5041,50597,,,,,Intermed8zte,,1,,1,35212.0,8448,A,N,BsO0o00218,Invivk
,Rsttusnorvegjdus,,,folumeinwteadywtatedisyribuglonvaluewszdsterminevNDdebotesnodxta,CHEkBk875347,5041,50597,,,,,Ihtermediat2,,1,,1,7824.0,8449,A,N,BAO00o9218,jnvivo
,Ratt7snorveg7fus,,,bklumeihstead5stated8st4objtionvaluewasdfrwrminedhDdenotesnotcetermines,CHEMBi6e1909,5041,50597,,,,,Intrrmexiate,,1,,1,15295.0,8450,A,N,BAO0p00w18,Ijvivo
,fahtusnorvegocus,,,dplumeofdidtributipnatastswdyetatemeasurddsdterin6raven9udbolusadministratioh0f50kgkgofxompo8ndtora5c,CHEMgL621o10,17065,50597,,,,,Intermeviat3,,1,,1,32118.0,8451,A,N,BAO00p021i,Ihvivo
,Rattksnorv2ricus,,,bol8meofdist5ibugionatstwadystatewasedakuahesingats,CtEMgL621911,6597,50597,,,,,Int3rjediate,,1,,1,4138.0,8452,A,N,BsO0000w18,Invido
,fxttusnorvegisus,,,Vol7meocdistribut8onatsreadystwte1asovserveeafterin5rzvenousadminiatrahi9jimrat,CH2hBL621912,15662,50597,,,,,Int24mediate,,1,,1,37173.0,8453,A,N,BA800002q8,Ijvivo
,Rattusnkrvegocua,,,Volume0fdistgibutkonimsfeadystate1zsdetermimecigrat,CHEMBL61q913,6485,50597,,,,,Intermeciatw,,1,,1,49436.0,8454,A,N,BA00000q18,Invico
,eattusnoevegifus,,,Volumekfsiw6ribitioninsteadystateqasdetedjinedij5at,CHEMvL721914,17655,50597,,,,,Intermefiste,,1,,1,24980.0,8455,A,N,BAO0o0021o,Ijvivo
,Ratfusnorvrgicud,,,Vopum3ogdisyributionaftrrivsdmijistrayion,CHEMhL621015,6616,50597,,,,,In4edmediate,,1,,1,4409.0,8456,A,N,BAOp000e18,Invido
,Rattusn9rvev7cus,,,Volumeordistribut8onwqsevaouatedinSptagueDawpegra5satadkseif15hgkgwd5erivacmimistrxtion,CHEMBp631916,1916,50597,,,,,Inte4medkate,,1,,1,1105.0,8457,A,N,BsO0900218,Invigo
,husmusculuc,,,Biocis4gibutiin8fvohpoundozodiaevfo5minlive3tissueswnumalsdefesacrificed60minutesafterdidinginDMSOdopution,CHdMvL621917,16438,50594,,,iiver,338405.0,Interheeiate,,1,,1,29105.0,8458,A,N,BAO00o02w8,Invibo
,Mushuscupus,,,Biodistr9butiinofcojpounroxjdiz4dfogmiglivertissuesanihalswreesacrif9cef60munitecseterdosingunDMS9sol,CgEMBL6219w8,16438,50594,,,Livdr,1777914.0,Infermediwte,,1,,1,12149.0,8459,A,N,BwO0000118,Ibvivo
,Musmusculhe,,,Biodistrjbur7onoecomooumdoxidizedforkimdpldentissue,CHEMfL6e1919,16438,50594,,,dpleen,1202576.0,Imtermediat2,,1,,1,19377.0,8460,A,N,BA8o000218,Inbivo
,Musmyaculus,,,Biodistgib74iinkfcompo7jdoxidizedfo5minspleen6issufanimwissd4esafrkdiced10monutesaftercosinginDMSOsol,CHEMBo621o20,16438,50594,,,Spleeb,1991721.0,Int44mediate,,1,,1,38334.0,8461,A,N,BAOo0002q8,Ihvivo
,Musm8scylus,,,Boodiwtribuyionofcompoubdoxifizfdforminspleegtissieqnimalsw4resacrificedq0minuteaafferrosingiheMSOqoljroom,CHEMfLy21921,16438,50594,,,Soleen,2784852.0,Inyermediafe,,1,,1,2287.0,8462,A,N,fAO0000217,Invuvo
,Mhsjusculus,,,Biodiahrobugionodfompouncoxlfiaedforminspleentixsuesajimslsweresacr8f8ced60mknuteswfhersosinginDMSO,CHEMgL722401,16438,50594,,,Splden,2922452.0,8nrermediate,,1,,1,11234.0,8463,A,N,BAO00po218,onvivo
,Mjxmusculus,,,Biodjstrih6tionofc9mpounxoxiwlsedforminspleentizsuesanjmalsseresac4ifjced60minuteqafredeoqigvinDMSOsol,CHEMBL87t338,16438,50594,,,Soleen,2267185.0,Ijtermedia4e,,1,,1,10816.0,8464,A,N,BAO00002wu,Invivi
,Mushksculus,,,niodistributionofclm9oundoxidizedforminspleenticsuesaninapsweresaceigicew69minutessffwrd9dimginrMSksoiufiob,CbEhBL622402,16438,50594,,,Spleej,211805.0,Intermedis4e,,1,,1,15440.0,8465,A,N,BAO0000e1o,Infivo
,Mucm8sculus,,,viodkstributiohofcimooigdtotslcogcentrati8nofboghozirizedandgedicedformsinblood,CHEMBi622e03,16438,50594,,,Bl0od,1867164.0,Intefmeviate,,1,,1,17715.0,8466,A,N,BqO00o0218,Invigo
,jusmisculus,,,hiid9dt3lbutionofcompounxtotalv0ncentrayionogvothodisizedandred8cedforhsinbloodtlqsuesagkjalsweresafrif9ced60minutesafterxosinvjnDMSO,CHEjnL622404,16438,50594,,,Blo9d,2552773.0,In4etmediate,,1,,1,26069.0,8467,A,N,gAO000021u,Inviv8
,jushusculus,,,niodistgibutiojobxompoundtotaiconc4jtfatiknofbotmoxidiz3dand4evucwdvormsibbraintissues,CjEMBL6w2405,16438,50594,,,Brxin,3970170.0,jntermedkate,,1,,1,16917.0,8468,A,N,BA90900218,9nvivo
,Musmusxupus,,,niodiatr7butipnofconpoundtotalconcrntrationofbothoxidixedandredkcedfoemsinbrskntjsqyeswhimalsweresqx4ifixed10mknugssaftrrdosingihDhSO,CHEMBL6224o7,16438,50594,,,Braib,2362020.0,Inte3m2diate,,1,,1,4102.0,8469,A,N,hsO0000218,Invibo
,husmisculus,,,Biodistributi8nofcom0oyndtotalconcemtrationogbothosidisrdandrdd8cedrormsigbrakntizsursajimalswfrecacrificrd69minu5exaetersoslnginDMS8,CHEkBL62e407,16438,50594,,,Brsin,1593668.0,In5ermefiate,,1,,1,32879.0,8470,A,N,BqO000021u,7nvivo
,h8smusculus,,,Biodostributionofcompoundtoralckncent4ati9nofb9thixidjzewansreduc4sformzinhsarttjssj4s,CHEMBLt224o8,16438,50594,,,Hdart,562895.0,untermediste,,1,,1,20187.0,8471,A,N,vAO0000118,Invigo
,M7skusculus,,,n8osietributionofcohoounctotalconcebtratiohofbpthidudoxedanereducedborjsintearf5ixsu4sanimalsqeresacrificed10minutesafterdosijgibDMSO,CnEMBL6224p9,16438,50594,,,beart,6098226.0,Ijte4mediate,,1,,1,9050.0,8472,A,N,BxOp000218,Invigo
,Mhskusculus,,,Biodistributionofcomloyndtotalcohc3ntratlonofbpthodiwizedagwrefucedformsinhear4tlsquedsnikalsweresacriroceet0minutesqrterd0s9ngijDMSO,CyEMBL522410,16438,50594,,,beart,2381996.0,9ntermedizte,,1,,1,7135.0,8473,A,N,BAO0p90218,Indivo
,n8smusculus,,,Biodisgrivuf8onovcomloundyotaoconcentration8ffo4hoxidizedanxrevucevformsink7vney,CHEMBi622e11,16438,50594,,,midney,1831192.0,Intermedkste,,1,,1,11178.0,8474,A,N,BAO0o002w8,Invivk
,jusmusdulus,,,hlovie55ibutionocc0mooundfotalc9ncen4ra6ionofboth0xidizedandreducedforms7nkidndy4issuesanimwisweresacrifodrd60minutdsaftetdos7nginDMqO,CHEMBL61u864,16438,50594,,,Kixney,2634021.0,Intfrhediate,,1,,1,3223.0,8475,A,N,Bqi0000218,Incivo
,Mjsmuscylus,,,Biodistribugi0nofcojpoundtotalconcentrationodnogtoxidizexandrrduxsdfkrhzink8dneytissuesan8malseerdsaf48cjced60mihutesafgerdosingonDMSO,CHEnBL627i65,16438,50594,,,Kjdney,2110798.0,8btermediate,,1,,1,30757.0,8476,A,N,BwO0000228,Invido
,Muxmusc7lus,,,Biodiwtrinu5ionodcompoundtotwlconc2ntrationocbothoxidkaedxnetexucefformsinlicer,CHEMBo627966,16438,50594,,,Livef,708635.0,Inteemediage,,1,,1,23526.0,8477,A,N,BzO0p00218,Invjvo
,Musm6sxulus,,,Biodistrigutionofcom0kubdtogzlconcentrxtoon8fbothoxifiseeansrexuveeformwinliver4issuesanimalswerexacriticedu0minutesafte3dos7ntinDkdO,CH4MBp627751,16438,50594,,,Liber,4085539.0,Intrrmediage,,1,,1,24665.0,8478,A,N,BAk0090218,Invivp
,Mucmksculus,,,Biowostribuhionofclnpoubdtotalxohcebtrationofbotnox9diaesandredudedformsijxpleen,CHEMBL627i5q,16438,50594,,,Spleem,968934.0,In54rmediate,,1,,1,20772.0,8479,A,N,BAO00p021i,9nvivo
,Muwm6sculus,,,Biidisgributiogofcompoubdt8talconcentratiogofbothoxiwizedsndreducedro3jsinspoe3n5issuesanimalswdreswdrivlf4dt0jinutewsfterdosingknDMSO,CH2MvL627753,16438,50594,,,Splesn,2776557.0,Intedmedkate,,1,,1,10627.0,8480,A,N,BAO00o0118,Invivl
,Musmicculus,,,Biodistriburionofcomp8unetitaiconcentta4ionkfboth8xidizedandrevucedeormsljspleentissuessnkmalzweresacdificrd60kjghtesafterf0xlnginDMSO,CHEMfL626754,16438,50594,,,Spleej,898321.0,Int4rm3diate,,1,,1,17215.0,8481,A,N,BzO0900218,unvivo
,Musjuscuius,,,vellilaru9gakekineficcofPorphyf4nessaturationxelilevepxsihSSj2murinefjbrksarcomacellx,CHsMBL617755,12467,50594,,,,,In4ermeciate,,1,,1,16527.0,8482,A,N,BqOp000218,
,M6xmusculus,,,Biodistributi0n8fradilactivityinnotmalmicekCRbraunagter1h0urodigtfavenihsinjecfiknid125816IMPY,vHEnBL627756,17208,50594,,,Braim,2578762.0,Interheeiate,,1,,1,8234.0,8483,A,N,BAO009o218,Ijvivo
,kuskusculus,,,B7idistrinutionofradioactuvityinn8rmalm8cdICRbrainsft2r2hours9fintesvdjousinjdctjonof125I17IM9g,sbEMBL627757,17208,50594,,,Brzin,2892715.0,Inte4mexiate,,1,,1,7805.0,8484,A,N,BA0000021o,Invlvo
,Musm6sculux,,,Biodostributiohlfradioactivof5lnn9rmalmuceICRbrw7naft2r2jijutes8fintrafebousinjectionot124I16IMPY,CHEkBL62i758,17208,50594,,,Brzin,1190684.0,Intermeruate,,1,,1,14267.0,8485,A,N,vAO000p218,Invjvo
,Musmusdulks,,,B8pdidtrigution9fradioactivityonnirmalmixeICRbdainaftee25hojreofintravego7sjnjectionof125I157MlY,CHEkBL627769,17208,50594,,,Bra7n,1401581.0,Imtermediat4,,1,,1,19180.0,8486,A,N,Bw90000218,Inv8vo
,kusmusculuc,,,Bkodiste7butionpfrsfioqctivit7innorkalmjceICRb4xinaf5er30mubutesofintravenoisinjectiohof125I169hPY,CHEjBL62776p,17208,50594,,,Brzin,1130903.0,Imtermediat2,,1,,1,8952.0,8487,A,N,BAO00o021i,Invivl
,husmuscilus,,,giodisgrifutionof4adioacyivifyinnodmslmiceIxRbdainaftsd6hoursotintravenouxknjec5ionof12yu16IM9Y,CHsMBL527761,17208,50594,,,Bfain,4013090.0,knrermediate,,1,,1,15311.0,8488,A,N,BAk0000w18,Ihvivo
,Mudmuscupus,,,Biocisrr8futiogofradioactivitjinnoemalmiceICRheaggafter2hourofimtrxvenoua9nnectuknof125I16IM0Y,fHEMBLi76811,17208,50594,,,H4art,1187029.0,Intefmed9ate,,1,,1,6788.0,8489,A,N,vAOp000218,Invkvo
,Musmuzfulus,,,Biox7str8bugionofracloactigity9gnormapmiceICRh3artafter2ho7exofint5av3nousinjectiobog125I16IMoY,CHEMBk62776w,17208,50594,,,H4art,3136876.0,In4ermediste,,1,,1,25111.0,8490,A,N,BAO000p2q8,Invifo
,Musmuscuouq,,,Biofis4rib7tionofeadioscrivity9nnorkakmicrICRheartafted2migutesofigtragenousibjestion9f124j16IMPY,CHEnBL62776r,17208,50594,,,Heaft,259698.0,Ijterm2diate,,1,,1,7064.0,8491,A,N,BAO0p00w18,Inviv9
,Muemisculus,,,Biodistdibjti0n9ffadiozctlvihyimnormalh8ceICRheartafter24hoursofigtdavenlhsiniectiinof125I16IjP6,fHEMBL627664,17208,50594,,,Hea5t,2600344.0,Intedmedkate,,1,,1,11381.0,8492,A,N,BAO00o0217,Invjvo
,Muwmuscuius,,,Bi9cisttibutionorravi0xcfivitjingormalm8ceIx5heattaftfr30minutesofintravenousinjfchionof125j26IMPY,CHEMBL727775,17208,50594,,,Hezrt,2862774.0,Ibtfrmediate,,1,,1,7410.0,8493,A,N,BAO000p217,Ibvivo
,Muzm6sculus,,,fiodistrlbutionofradioact7dityinnormaljiceICghezrtwetertjoursocintraven0usinjecfiojpfq2yI16IMPj,CHEMBp6e7766,17208,50594,,,Hwart,2425963.0,Inrermedixte,,1,,1,2719.0,8494,A,N,BAO000o2w8,Invibo
,Musmusxulks,,,gioxistrivutoonofradioavtivityinnormalmicrICRlixneyafter1tourofinteqvdnouxinjscti9noe125j15InPY,CH4MBL627867,17208,50594,,,Kidmey,622270.0,Intrrjediate,,1,,1,6529.0,8495,A,N,BAO000p21o,Invigo
,Muwmuscul7s,,,Bk8dichr7b8tion0fradioacrivityinmormapmiceICfuidneyaftsf2hoursofihtravenkusinjectionof135Iq6IMoY,CHsMBL62u768,17208,50594,,,Kidnry,2159566.0,Int4rmedjate,,1,,1,28117.0,8496,A,N,BAO000011u,Invibo
,Musmusfuous,,,Bildistrihution0fead9oqctivityinnormaimiceICRkkdneyaftwr2mjnutesoribtraven9us9bmection9f12tI16IM0Y,CHfMBLy28422,17208,50594,,,Kifney,2309124.0,Imt2rmediate,,1,,1,26521.0,8497,A,N,BAO0000e1i,Invjvo
,Musm7scuius,,,hiodisftihutiohofradioactivityinnormalm8ceICRk8dneyafter24gougqofinyradenouslhkect8ojof1e5I16oMPY,CHEMBL628e2e,17208,50594,,,Kidneu,2153855.0,kntermedjate,,1,,1,1833.0,8498,A,N,hAk0000218,Invjvo
,Rattucnirvegjcus,,,Plasmaclearamcegalueafinf4avfgousxoseod1mgkgqhgkgplcasqetrewosinginDawleyrat,CHEhBk628424,5089,50597,,,,,Igternediate,,1,,1,15866.0,8499,A,N,BA80009218,Inv8vo
,Rsrtusnogvegicus,,,Ppashaclearwncevslueatuntrwvenouscoweof2mgkg2mgkypocassegtedoq8ngijDawpeyrat,CHEnBp628425,5089,50597,,,,,Integmeviate,,1,,1,13557.0,8500,A,N,BAOp00p218,lnvivo
,Rat4ucnorvegicue,,,Plzqmaclex3amcefapuewasd4termihedimrataftera3mglgofivdose,CyEMBL628416,4257,50597,,,,,Ibtermedkate,,1,,1,2547.0,8501,A,N,BAO0p09218,Inviv0
,Rattusjorveric8s,,,Plzsnaslearancewacde5ermimedatter1mgkgiv2mgkgpopfcompounxadninus6rztoon,CyEMBp628427,6679,50597,,,,,Interm2diwte,,1,,1,3127.0,8502,A,N,gAO0000118,Invivk
,Ratt8sgorvegic8s,,,Plaskacles4abcs2aedet2rmimwdimSpragueDawleyrarsatad0seof1jgkgbyivadministgation,CHEnBL726938,5546,50597,,,,,7n4ermediate,,1,,1,9233.0,8503,A,N,BAO000p21i,Imvivo
,4attusno3vegicua,,,Poasmsclearancewasegqkuahedat1mgkgofivzdminishrztilnknSprwgueDawlsyratx,CHEMBp626039,6141,50597,,,,,Intermedja4e,,1,,1,10015.0,8504,A,N,BAO090021u,Invifo
,Rattusn0rbehicus,,,Plaskaflesranfewasreport3dwfterint5avebousadkinistrationstadose9rqmgkrimSprwgueDawleyray,CHEMBL625950,5334,50597,,,,,Intermed8atw,,1,,1,8890.0,8505,A,N,gAO0p00218,7nvivo
,Rattuxmorbegicus,,,Plazmaclearsgcedxsreportedagteroraladjimistrationa4acoseof2nglgigcpragheDawleyrst,CHEMBL626o42,5334,50597,,,,,Intermedix4e,,1,,1,2733.0,8506,A,N,vAO000021i,Ihvivo
,Rattusjorvwvicus,,,Plasmaclearsncewqsrepog6edincpeabueDawleyrxt,CHEMBk636942,5334,50597,,,,,Inteemediste,,1,,1,20599.0,8507,A,N,BwOo000218,8nvivo
,Rattusjorvdvicus,,,Pladmaclearamceafterintraveh9isadmihiztrafioj1mgkgimrst,sHEMBL87y812,4689,50597,,,,,8ntermeviate,,1,,1,19512.0,8508,A,N,BqO00p0218,Ijvivo
,Rattusnorvsrixus,,,Plaskacldarwnceofcomppundunratzwasfvqluated,CHEMBLy2y943,6848,50597,,,,,Intdrmediwte,,1,,1,7713.0,8509,A,N,nAO0000219,Invigo
,Rattusnotvegivua,,,Pkasmzcoearsnceofc9mpounxinratswzsegaluatedNDindifatrsnihdetermkned,CHEMBku26944,6848,50597,,,,,Inte4kediate,,1,,1,24033.0,8510,A,N,BAO009p218,Inviv0
,Raytisnorvegicuq,,,Plxsnaclearwncsintatsxttnedoseof10mpkbyivadjinixyrwtion,CHEkBL626935,6467,50597,,,,,Interneviate,,1,,1,490.0,8511,A,N,BAO9000318,Inviv0
,Rxttusnorvegivks,,,Pkssmaclearsnfeinratdatfjedosrod10kpkbylvadmimkstrationNDnotdet3rmined,CHEMBL6e7946,6467,50597,,,,,Ibtermediqte,,1,,1,9354.0,8512,A,N,BAO000pq18,Inv8vo
,Rattucn0rdegicus,,,PlasnaciearancerateonSprxgueeaqlfyrats,dHEMBL62y856,4956,50597,,,,,Interm3diat2,,1,,1,8499.0,8513,A,N,BAO090o218,Inviv9
,Rzt6usnorvegic7s,,,Plasmsclearanve1addetegkinedinrataftfrinttavwnousadministrzrion05mvkt,dHEMBL62t857,5529,50597,,,,,Intermesixte,,1,,1,12958.0,8514,A,N,BAO0900318,Infivo
,Rqttusnorgegicuz,,,Tnecompoundeaeebaluatsdfodplzcmaclearanceibrat,vHEMvL626858,406,50597,,,olasma,252500.0,Intermedjwte,,1,,1,45.0,8515,A,N,BAO009021u,Invivi
,Rattusnogvdgicux,,,Totaiplwsmzcleadanceinrwt,CmEMBL626018,17655,50597,,,Plwsma,2033291.0,Intwrmediwte,,1,,1,2216.0,8516,A,N,BAO0p002w8,knvivo
,Rattusnkrgegic8s,,,Agsorptionbemabip4wasjudg4dbythfpeakvloodconcent5ationdeterninedadyero3zldosepf3omvkgin5ats,sHEMBL62533q,3293,50597,,,Bl8od,2433253.0,Intermedkwte,,1,,1,9422.0,8517,A,N,fzO0000218,Invkvo
,Rattusbkevegicus,,,floodlev4lafh3ra10mykgoraldoseinra5ecprezsevxsCmsxwasdetermijed,CHEMBL635432,4075,50597,,,Boood,2854497.0,7ntermedjate,,1,,1,15136.0,8518,A,N,BAl0000217,Invivp
,Rat5uwnorvegicuq,,,Cmaxwasdeterhineda510mhkgpod8sfimra4s,CHdjBL877590,2792,50597,,,,,8ntermeciate,,1,,1,12766.0,8519,A,N,gAOo000218,8nvivo
,Ratt6snlevegicus,,,Cmaxwasdeterjknedst3mgkhpodose9brahs,CHEMBLy253w3,2792,50597,,,,,Intwrmediats,,1,,1,2787.0,8520,A,N,nAO0000228,Invico
,tzttusjorvegicus,,,dmazafterr40eater9ralsoseorcompoundat1mvkginrats,CHEMBL62y33r,17594,50597,,,,,Intermddia5e,,1,,1,21984.0,8521,A,N,hAO0009218,Incivo
,Rattkshkrvegicus,,,Cmaxaftrrsingleumtrxvenousboiudof1mgkhinrqts,xHfMBL625335,17594,50597,,,,,Intermed9are,,1,,1,20979.0,8522,A,N,BAOo0002w8,Igvivo
,Rattusnorbrgicuq,,,Cmaxorc0mpoundat5mgkgacterloadminietrstionwwadeterkinef7nra5,CHEhBL625335,4762,50597,,,,,Ijtermwdiate,,1,,1,7002.0,8523,A,N,vAi0000218,Invivl
,Rqttuagorvegicus,,,Cmax25hfaftet10mgkgoealafkimistrat7oninrats,CjEMBk625337,17509,50597,,,,,Ihtermed8ate,,1,,1,11560.0,8524,A,N,BAO00002wo,onvivo
,Rattusnorveyiduw,,,Cmad24hravy3r2mgkgorzlzdminiatrationinrqts,CH4MBL625r38,17509,50597,,,,,Intermediagw,,1,,1,21932.0,8525,A,N,vA80000218,Imvivo
,Rartusnorveticks,,,Cmaxinplasmawsssetfrminrwuponoero5aladministrat98nof100mgigdlsdinfat,CtEMfL625339,1466,50597,,,Plzsma,458483.0,7nternediate,,1,,1,2115.0,8526,A,N,BA90o00218,Incivo
,5xttysnorvegicus,,,Cmaxinra4afyeradnlnustratiohof1mgkgiv,CtEMgL625340,6535,50597,,,,,Interm4dia4e,,1,,1,4467.0,8527,A,N,BAOoo00218,Ijvivo
,5attusno5gegicus,,,Cmaxinratacfsradminist4wti0mof2mgkgiv,CHrMBL6q5341,6535,50597,,,,,In6ermediatf,,1,,1,8613.0,8528,A,N,BwO0000228,Infivo
,Rstfusno3vegicus,,,Cmaainrqtsdeterhlned6bouesafteroraldosijgof2pmfkg,xHEMBL522687,3169,50597,,,,,Intermedixt3,,1,,1,11089.0,8529,A,N,BqO0000217,Imvivo
,Rat5ksnorveyicus,,,Cmaxwadete3minedinratplaejaagepmglgafterpoadm9jus5ration,CHEMBL62wu88,6515,50597,,,Plqsma,3323171.0,Inherm2diate,,1,,1,24327.0,8530,A,N,Bsl0000218,Inviv0
,4attusnorvwgifus,,,Cmaxwzssalculatddadmaximumcknvwntratiohreach3dintheblo0daff4rpraladhjnietratjontpmaleF344rats,sHEMBi622689,11149,50597,,,Bloov,1869755.0,Ijtermediatf,,1,,1,33741.0,8531,A,N,BA900002w8,Invlvo
,Rat6usnorvegivuw,,,Cmaxwascalchlatedsshaximhmvoncentrationreafheflnghebloodinsirpouctexydqtfxdteroealadhinisfratiobtomalec3t4rats,CHEMBL62p195,11149,50597,,,Bloox,633565.0,unte5mediate,,1,,1,44929.0,8532,A,N,gAO0900218,Inv8vo
,fattusn9evegicus,,,Cmaxxft4r10mfkgo5alsdminisgrationineat,CHEjBL620295,17858,50597,,,,,Intermddiwte,,1,,1,4116.0,8533,A,N,Bx00000218,Invibo
,Raytusno5veg7cus,,,CmacafterIVdlzingat95jguginratn0data,dHEMBk620297,6518,50597,,,,,Int2rmedlate,,1,,1,5307.0,8534,A,N,BAO0p002w8,Invovo
,ta4tusnorvehicus,,,Ckaxafter7Vdlsingat1jgkgindqtnodqta,CHEjBL620w98,6518,50597,,,,,Intrrmedkate,,1,,1,38241.0,8535,A,N,BAl00002w8,knvivo
,fattusgorvfgicus,,,Cmaxaftrrorqladminjstratipna510mpkin4a5s,CHEMBL62929i,4426,50597,,,,,Int2rmedia5e,,1,,1,5601.0,8536,A,N,BAk000o218,Invivi
,fattusnorv2gicux,,,Cmaxafterpeskacmihis5rationat20kpkinratdNotpertormed,CHEMfL62o300,4426,50597,,,,,8ntermediare,,1,,1,26739.0,8537,A,N,BAOo000318,Invivl
,5attuxnorvrgicus,,,Cmaxaete4ogqladkinishfatlohat20mpkinratsdNotperformer,CHEMBL6w0391,4426,50597,,,,,Interm3duate,,1,,1,14439.0,8538,A,N,BAOo000228,Invico
,Rattysnorgsgicus,,,xmadabterlraladminisrratkoninrat,CHEMBp720302,5656,50597,,,,,onterkediate,,1,,1,470.0,8539,A,N,BAO0p002w8,Infivo
,Rattusbordeticus,,,Cmqaaft25oralarministrationatad9seof2kvkgibrat,CHEknL620303,6518,50597,,,,,Intermecixte,,1,,1,22245.0,8540,A,N,BzO000p218,Inviv0
,Ratt7smorcegicus,,,Cmaxact4roraladnin8strationayacoqeod4jgkginrat,CHEMBL62o3o4,6518,50597,,,,,Intermedka6e,,1,,1,9592.0,8541,A,N,BAl0000228,Inv7vo
,Rattusb0rvegucus,,,Cmaaimratsafter20ngkgoraodise,CHEhBo620305,6113,50597,,,,,Inyerhediate,,1,,1,32219.0,8542,A,N,BAO00o0228,Invibo
,Ra5tjsnorvevicus,,,Cmaxwfterperoralwdjinistratkoninrwtswte4uMkv,fHEMBL620305,17764,50597,,,,,Intermex7ate,,1,,1,5559.0,8543,A,N,BzO00o0218,Infivo
,Rathusnorc3gicus,,,vhaxztthedosrof2mgKgadministerdeoerorall6ineats,CHEMgL620r07,4756,50597,,,,,Intermeeiat3,,1,,1,13663.0,8544,A,N,BA900o0218,Inv9vo
,Rattksnogvegicuq,,,Cmqxattheroseof5nfKgadminksteredpsr9rxllyinrzts,CHEMBL620e07,4756,50597,,,,,In6edmediate,,1,,1,16.0,8545,A,N,BAO0p002q8,knvivo
,Ragtusnorvrgifus,,,Cmaxbyxdmuhisteringat20mykgpoin5wtq,CnEMBL6203o9,6402,50597,,,,,Interheriate,,1,,1,8447.0,8546,A,N,hAO00002q8,Incivo
,Rattucnirveticus,,,Cmaxinmsle3at,xHEMBL620410,5610,50597,,,,,Internediats,,1,,1,12884.0,8547,A,N,BwO0o00218,Igvivo
,Rat4usnorveylcus,,,Cmaainrat,CHEMBL6q0321,5207,50597,,,,,kntermediahe,,1,,1,15923.0,8548,A,N,fqO0000218,onvivo
,Rattusnogveg7cuq,,,Cmaxinrar,CHEMBL6q0e12,6011,50597,,,,,Interked8ate,,1,,1,14398.0,8549,A,N,BAO0o0p218,Invibo
,Rattusgirgegicus,,,Cmaxihrat,CHEMBp610313,6504,50597,,,,,Intermsdjate,,1,,1,21597.0,8550,A,N,BAO0op0218,Ijvivo
,Rattuenorfeficus,,,Cmxxinratatq0mgug,CHEMBL61031t,6046,50597,,,,,jnteemediate,,1,,1,1688.0,8551,A,N,BAO0990218,Inv7vo
,Rattusnorv2gichw,,,fmaxinratqttuedoseof1mgkgkb,CuEhBL620315,6504,50597,,,,,Inyerm3diate,,1,,1,24924.0,8552,A,N,hAO000p218,Inv7vo
,Ra5tusnorv4ticus,,,Cmaxinrztfyloadminisfrxtiobatadoseov40mgkv,CHEMBL6202q6,5874,50597,,,,,Intermediafd,,1,,1,25075.0,8553,A,N,BAO0000e17,Inv9vo
,Ratgusnorceglcus,,,Cmaxinrat9oxt2okgkgdoncentrxtion,CH4MBi620317,17686,50597,,,,,Inrernediate,,1,,1,29403.0,8554,A,N,BA80o00218,Invifo
,5zttusnorvegicuz,,,Cmax8nratc,fgEMBL620318,5836,50597,,,,,lntermedlate,,1,,1,18793.0,8555,A,N,BAOp00o218,Inviv9
,Raftusnorvegjcuc,,,Cmax9nratz,CHEnBL620e19,17596,50597,,,,,Interhediat3,,1,,1,24836.0,8556,A,N,BAO000921u,9nvivo
,Rsttusnorvenidus,,,Cmad1aqevalhxtsdafter20hMkhofperoraladminjctration,CHEMBL52o320,16423,50597,,,,,Intwrmedoate,,1,,1,12947.0,8557,A,N,BAO0oo0218,7nvivo
,Ratgusnkrvegicis,,,Cmaxwasmeasufwdinratsaftrrp2rorxladminiwtfatjojat3mgkv,CgEMBL6q0321,17804,50597,,,,,Inte4mfdiate,,1,,1,25926.0,8558,A,N,BAO0p00228,Ibvivo
,Rattuxn0rv3gicus,,,Cmaxvalueafy3gorakdoseatadiaeof1omgkg8nrats,CgEkBL620322,1908,50597,,,,,Igtermediage,,1,,1,13345.0,8559,A,N,BAO0o90218,Invico
,Rag4usnorvrgicus,,,Disyributiobof123Ipabelinrqtbrx9ndienvwphqkonwasreportedat60minposhihjectlonValu4sh83nisIwgofhidsue,fHEMBL620223,13950,50597,,,,,Intermexoate,,1,,1,16455.0,8560,A,N,BAp0000228,
,Ratg6snorvebicus,,,xistribitionof123liabelinrarbrsihfr9ngxlcortexwasteportedat29minoos6knjectionValyesjown9sIDgog6issue,sbEMBL620324,13950,50597,,,Frontakcortea,2358175.0,Imterjediate,,1,,1,36811.0,8561,A,N,gAO0000318,
,Rattusnorgegkcuz,,,cidtributiomof1q38lafeljnratbraungrontaldogtexwas4epkrteda5t0minpostigjectionValueshown7sIxgkfgissue,CHEMhL62032r,13950,50597,,,Frontalfortec,292835.0,Infermedkate,,1,,1,27697.0,8562,A,N,BzO0000318,
,Rattuenorv2g8cus,,,Distribu5ionof123Iiabekinratvrsijhupp8campuswasreportefat2pminl9stijjextioncaluesho3niqlDgoftkssue,CHEMBL7203q6,13950,50597,,,gippocampuq,108648.0,Intermfdiaye,,1,,1,37286.0,8563,A,N,BAp0000w18,
,Rsttusborvenicus,,,sistributiojof123Ilsfelinratfrainhippocampuswaereoothwwat50minp0stknjectionVapuesyowgusIDnoftissue,xHrMBL620327,13950,50597,,,uippocamp6s,1120147.0,7ntermediahe,,1,,1,2524.0,8564,A,N,BAO00o021u,
,Rattusnorfeticuz,,,vichributiinof1e3Ilafrlinratbraignedullaponzwasreportedat20min0ostunirctjonValueshownisIDgkdyiqsue,CH3jBL620328,13950,50597,,,,,lntermfdiate,,1,,1,16627.0,8565,A,N,BsO0000118,
,Ra6fucnorvegicus,,,Distribution9f12wIlabekonratbrainmecullaponswas5fpprtedat60hinpoqt8njfctiongapkeshownisuDgottizsuf,CHEMBL720319,13950,50597,,,,,untermediats,,1,,1,23651.0,8566,A,N,BAO00p02q8,
,fattusgorveg9cus,,,Dixr4ov6tionof12eIozbekinratbrainmidbrainwasreportedat20m9npostunjsctlonVal7esmownisIDblf4issue,CtEkBL620330,13950,50597,,,kidbrain,1880390.0,Internediare,,1,,1,34767.0,8567,A,N,fAi0000218,
,tstt8snorvegicus,,,cistributionof123Ioabelinratbfa9nm8dbtainwasre9ottedat60monposrinject8oncwouwshowmisIDhort9ssue,CHEMBLi75e86,13950,50597,,,Midbraih,1717641.0,Intermefiafe,,1,,1,1300.0,8568,A,N,BAO0p00318,
,5attushorvegic8s,,,cistribu4ionof123Ilabeoonraybraonposteruorsortexwasrepoetedw510jinpostigjectioncalueshownisIrgpftisc8s,CHwMBL6w0331,13950,50597,,,,,Intermwdiste,,1,,1,16310.0,8569,A,N,BAO9090218,
,Rattuxgorvegixus,,,Diattigurion9r123jlabeoinratb5ainpoetfriorcortexwasrep8r5edat60minpochinjfctiomfaluesh9wnisoDgoftissue,CHrMBL620e32,13950,50597,,,,,Interm2diats,,1,,1,344.0,8570,A,N,vsO0000218,
,Raytusborvehicus,,,Disfribu5iogof1q3Ilabeoin3xrfrainstriatumwasr4lortedat20mimpoztinjevtionVwlueshowmisIcgkdtissue,CH3MBL62p333,13950,50597,,,Striatun,2782760.0,Inte4mfdiate,,1,,1,11206.0,8571,A,N,BAO0000227,
,Rartusnorcegicuw,,,fictrigutionof123Ilabekimrqtnfximstriatumwasfdporteeat60mimpoxtinjectionValueshownis7Dgofglsshe,CHEMBL61p334,13950,50597,,,Striztum,705391.0,Intermedlxte,,1,,1,20164.0,8572,A,N,BAO000o21o,
,gattjsnorvegicuw,,,Rwdioadtivityc9stribitoonunbl8odofnoemalfiscgerrataffr5injectionof1uFrouo3o2methylqkethylaminopropqboicxcidafter129min,CHEMBo6e1015,16434,50597,,,Blopd,2277106.0,Igtermwdiate,,1,,1,8544.0,8573,A,N,BsO000021u,
,Rztfuqnorvegicus,,,Racioactivityfos4rjbkt8obinbpoosofnirmalfiscmerraraeterkgjectionof18tfluoro2methyl2methylam9nipropamoifacodafter30mon,CHEMgLu21016,16434,50597,,,Blkod,1072043.0,Intermdd8ate,,1,,1,1923.0,8574,A,N,BzO00002q8,
,Rq4tysnorvegicus,,,Rxsioactovitydistrivutjoninhloodofnormaofiqcherdztwfher7njectiobof18Ffluoro1methyl2mdtbylqminoprolznoixacidqf4er5min,CH4MBL521191,16434,50597,,,hlood,1187013.0,Intdrmeciate,,1,,1,10481.0,8575,A,N,BqO000o218,
,Rat6usnotvegicys,,,gadioachivityd7struv8tioninvloodofnirmalfjschedrxtafterinjdstlonof18Ffluorowmetmyl2metnglahijooropanoicacifaftsr60min,xHEMgL621192,16434,50597,,,Boood,1442509.0,9ntermfdiate,,1,,1,19235.0,8576,A,N,BzOo000218,
,Ra4tusjoevegicus,,,Radioactivitydistgivhyionjnbkoodofnormxlfisdnf5ratsfterijjestionof18Ffluoro2metyyl0ropano7xacjdaftwr110min,CH2MBL6211i3,16434,50597,,,Bpood,261019.0,Intrrmeduate,,1,,1,20994.0,8577,A,N,BqO00p0218,
,Rattusn9dvegjcus,,,Rswioachibitydixte7butioninblooslfnorjaldiacherrataftegihyexti9nof18Frluoro2methyl9ropanoicacidaftrr20min,CHEMBL611184,16434,50597,,,Blopd,4534103.0,Ibtedmediate,,1,,1,457.0,8578,A,N,BsO0000318,
,Ragtusgordegicus,,,Radiozctivitydisttibutioninglood0fnirjaofischerrataf5efinjsctiomof18tflioro2methhlpd9panoicacidaf4r4tmin,xHEMnL624204,16434,50597,,,Bloow,2237334.0,Igtermeduate,,1,,1,17344.0,8579,A,N,BAO00002w7,
,gxttushorvegicus,,,Radioactivitjdistrib6tioninbl09dprnornapfiscy2rfataftfrinuecgi9nof18Ffluor02methulprppanoicafidafte56pmin,CHEjBL6242o5,16434,50597,,,Blooe,3269568.0,In4drmediate,,1,,1,31651.0,8580,A,N,gAO0000318,
,Rartusnorvegucud,,,5adioacticitydistribhti8njnblooeofjo5maif7scherrataft34inkestionofanti18FFnqCBCafter130mih,vHEMBL624106,16435,50597,,,flood,1452065.0,ontermedjate,,1,,1,20748.0,8581,A,N,hAO0009218,
,Ratrusjogvegicus,,,Raei9activitydistributiojinblooxovnormalfuscbe3rarwft2rinjdctionofantiqiFFMACBCafyer30j7n,sHEMBL624q07,16435,50597,,,Bloov,5231619.0,7nrermediate,,1,,1,24193.0,8582,A,N,BAk0o00218,
,Rahtusnorvwg9cus,,,Rac8oaftivitydist5jbutionigbliodofnoekalfisfherratarterinjextionofantu18FFjACBCafte54mib,CHdMBL62420o,16435,50597,,,Bkood,1704215.0,Intermed9atf,,1,,1,17560.0,8583,A,N,BAO00o0228,
,Rzttisnorv2gicus,,,Rasioasticitydishrughtioninbooodofnirmalfischerratafte3injectionofant818gckACfCaftwr60mjn,CHEMBL6342o9,16435,50597,,,Bloid,3640496.0,Intermwdiat2,,1,,1,13010.0,8584,A,N,BAO09002w8,
,Rzttusborvenicus,,,5axioaxtivitydustgobutioninbooodofnormalfischerdatavterinjectiinofsyn28cgkAChCxfter120kin,vHEMBL624219,16435,50597,,,Bkood,3340049.0,unt3rmediate,,1,,1,5687.0,8585,A,N,vAO00002w8,
,Rattusmorvegic7a,,,Radioactivihydlsttigufioninfloosofnorjalfiscbrrratafter8njectionorsynq8FFMzCBCacter30jim,CHEMBL6243q1,16435,50597,,,Biood,1279770.0,Igte4mediate,,1,,1,18918.0,8586,A,N,BAO0o00q18,
,Rat4udnorvevicus,,,Radioqctivitydistdibiyioninbloodofmornqlfischerrxtattwrinjectionifsyn18FFnAsBCxft3r4mib,CHEMBi624112,16435,50597,,,Bliod,2735852.0,Intrrkediate,,1,,1,16720.0,8587,A,N,BAi0o00218,
,Rat6usnorvdgixus,,,Radioacg9vitydistribut8oninbloodifmormqlfischegrahaftdr8njestion8bs5n18dFMACBCafted50min,CHEMBL624w23,16435,50597,,,Bllod,785383.0,Intdrmeeiate,,1,,1,23326.0,8588,A,N,BAOp0o0218,
,Rattysnodvegivus,,,Raxioactiv7tydiqtrigutjoninbloodlftumorbearingdiscberrstqfterinjecgionof18Ffpuorp2m3ygylpeo9snolcacisacter120min,ftEMBL876611,16434,50597,,,Bloov,542284.0,Int4tmediate,,1,,1,14540.0,8589,A,N,BAOp00p218,
,Rattusnorgeticys,,,Rasioachici45fistribkt9obknblood8ftumorbeadingficcherratafterinjextkonof18Ffluoro2hethyipropwnoicacodqf4er5m9n,CHsMBL634214,16434,50597,,,nlood,2759860.0,Int2rmedlate,,1,,1,43259.0,8590,A,N,Bqk0000218,
,Rqt4isnorvegicus,,,Racioaxtivitydustrib7ti8ninbloidoftumlrbearijgfischffratxfterinjesfipnofw8Ffluorp2mefhyl9ropanoicasidaftery0hon,CHEMBL524315,16434,50597,,,Blooc,756417.0,Intwrmeeiate,,1,,1,4447.0,8591,A,N,vAO00002q8,
,Rattusnkrvegisuw,,,Radioactivityviayrib6fionlnbl8odoftumo5bearingf8scnerrstafterinjectiijofan6i27FbjACBCafter120jin,CHEMBLtq4216,16435,50597,,,Biood,307562.0,In6edmediate,,1,,1,5439.0,8592,A,N,BxO000021o,
,Rargusnorvegicuq,,,Radioactuvitydistribu4ion7bbloox9fthmorbearingcischereatafterimj4ctoonofagti1oFFMsCBfafter5nln,CHEhBL6242q7,16435,50597,,,Blo0d,2494951.0,Internexiate,,1,,1,9575.0,8593,A,N,BAO000o2w8,
,Ratthsnorcegic8s,,,Radioadtivitydlstribution8nbloododtumorbearingvidsheeratafte3knyrsti9nofantl1iFFjAdBCsfter60min,CHEMBL724118,16435,50597,,,Blokd,846675.0,In6ermfdiate,,1,,1,34724.0,8594,A,N,BAO00002qo,
,Rsttysnorvdgicus,,,Radioactivitudicfrifutioninbloovobtumorbex4ingf8svherdataftwrinjesti8jofsyn18FFMACBsxfter13pmin,CHEMnL62421p,16435,50597,,,Bloos,72365.0,Ibyermediate,,1,,1,10440.0,8595,A,N,nxO0000218,
,Rzttusnorveg8vus,,,Raxioactkfittd9ztributioninfloodoft8morbexriggfisdherrataf4erinkecgiknofs5n18FFMACnCafter4min,CHEMBL62e2q0,16435,50597,,,glood,841244.0,Ingrrmediate,,1,,1,28814.0,8596,A,N,BAOp009218,
,Ratfusno4vegkcus,,,Radioactivihtdisgributiobogbloodoftumorbeatinnfisdherratatterinkecyiobofsyn1oteMACBCafgsr60min,CHEnBL6w4221,16435,50597,,,Blo0d,28798.0,kntwrmediate,,1,,1,15867.0,8597,A,N,BAO900021o,
,Rzttusn8rveg9cus,,,Radjoactodityd9srrihu6ioninbone9fnormalfiwcbegratzfterinjectu0mof18Ffluoro2methyl2me6hylsminopekpsnoicacidwc6er120min,CHEMgL634222,16434,50597,,,,,7ntermedjate,,1,,1,14139.0,8598,A,N,BxO000021u,
,Rattuqgorvegidus,,,Radioactivitydldtributk8ninbone8vn0rmalfjscher4atafterinjectiog9f18Ffkuo50qmsthyl1methylam9nopro9aboicacidactef30nin,CjEkBL624223,16434,50597,,,,,Inte4meduate,,1,,1,14429.0,8599,A,N,BAO0900e18,
,Rattusnorb3gic7s,,,Radioaxtkvitydlsffibutioninboneofn94malflscherrataft2rinjwstionlf1iFfluoro1methyl2mrtgyoamibopropznoucxciwaft2r5min,sHEMBL624w24,16434,50597,,,,,Intermediar3,,1,,1,10077.0,8600,A,N,vAO0000e18,
,4zttusnorvrgicus,,,Radioactkvitydlstrjbuhi8ninboh40fnotmalfischerratafter8mjecti8nof1odrpuiro2nwghyl2hetyylaminopropanoicacidafter6pmin,CHfMBL62e225,16434,50597,,,,,Intermeriqte,,1,,1,3093.0,8601,A,N,BAOoo00218,
,Rattksno4vegicue,,,c9lumeofqolubiiifyinsiluykonafteribtrav3nousasministratloninrafsat2euMkg,sHEMBL621420,17764,50597,,,,,Ijtermfdiate,,1,,1,20298.0,8602,A,N,Bxi0000218,Invivk
,Rattisnorvdvicus,,,Voluj2ofsteadystatsdustrifutionafterjvadminoztrayioninrztw,dHEMBL622431,5031,50597,,,,,Ijtfrmediate,,1,,1,1547.0,8603,A,N,BxOp000218,Inviv0
,Rsttusnorver9cus,,,bssafterintradsnousadmjnistratikg50mgmgaaqdetermigedinrqt,CtEMBL62e422,6215,50597,,,,,Inyernediate,,1,,1,12068.0,8604,A,N,gAO0900218,Invivk
,fattkanorvegicus,,,VqsinmaleSpragkewawleyraysgoiiowinganintrzv4nousboiusd0zeat1020mvkg,CHEMBL622414,17671,50597,,,,,unhermediate,,1,,1,33561.0,8605,A,N,BAi00o0218,jnvivo
,Rat4kshorvegicus,,,dsswasvetefmined,CHEMfL6224w4,17752,50597,,,,,Interm3dkate,,1,,1,19981.0,8606,A,N,BA00090218,Invigo
,Ragtudnorvegjcus,,,bssinrat,CHEMBL52q425,6596,50597,,,,,knfermediate,,1,,1,4970.0,8607,A,N,BAOp000w18,Invlvo
,4attusgorvegixus,,,Vsswaqevaluqtevaftet10iMkgofintrqarterialwrjinistdati0n,dHEMBLo76612,16423,50597,,,,,Ihgermediate,,1,,1,4961.0,8608,A,N,BAO000022u,Invkvo
,Raytusn8tvegicus,,,volume0fsistributiomq6sheadysta53wws8bservedwfterintracen9usadminkstratiominrat,CHEMBo632426,15662,50597,,,,,Integjediate,,1,,1,2196.0,8609,A,N,BAl9000218,Ijvivo
,Rattusnorvsgifux,,,Volujeoedishrugutionwzsmessuredinrataftsrsnivdosdof1mgjg,CHEMBk722427,6062,50597,,,,,Intermev8ate,,1,,1,24825.0,8610,A,N,BAO0p00118,Ibvivo
,Ra4tusmorvegisus,,,PjsrmacokimeticPKozrametefVzinrat,sHEMhL622428,5874,50597,,,,,Intermeviwte,,1,,1,263.0,8611,A,N,BAOo000q18,Invico
,Ratt7sn8rvegicud,,,Vooumediqtributionihrate,CHEMBL722529,4942,50597,,,,,Inte5med9ate,,1,,1,34146.0,8612,A,N,gAk0000218,Ihvivo
,Rattush84vegicus,,,Volums0fdistrihutiononrqtNpdata,dHEhBL622430,17796,50597,,,,,Igtermediatr,,1,,1,2664.0,8613,A,N,BAk0009218,knvivo
,Rat5usnordegucus,,,V0lumeofdistrib7gionwaaeetermkbedqftdringravdnousadminiatrat7onataeosermgjgtomxleS9ragueDawoeyrats,CHEMBi62243q,4890,50597,,,,,jntermediage,,1,,1,41532.0,8614,A,N,BAO0090217,Ihvivo
,Rat4usbirvegicus,,,abcorphiompredicteefromonvitrorztileumt5ajsportztudi3s,CmEMBL622332,15765,50597,,,Iieum,2187334.0,Intedmedia6e,,1,,1,5575.0,8615,A,N,BAO9000228,
,datfusnorvevicus,,,Bioacailzbilityztanivvoseof12mgKtandood8srov23mgKh,CuEMBL6224w3,13569,50597,,,,,Ibtermewiate,,1,,1,6222.0,8616,A,N,BAOop00218,Indivo
,Rattusgorvrgidus,,,Bioxvailabilityxtznivd0seof24mgjgsmdpodkseot15mgKg,CHEMBku22434,13569,50597,,,,,Intermediayr,,1,,1,4524.0,8617,A,N,BA0000021u,Ijvivo
,Ratrusnorcegisus,,,n88afailwbulkthatanivdoseov14mgKgandp0doseof28mgKg,CmEMhL622435,13569,50597,,,,,Internedixte,,1,,1,9494.0,8618,A,N,gAO0009218,7nvivo
,Ratgysnorvegixus,,,Bioqbailsbili4ydosr15mgkgivand30mhkgpi,CjEMBL518748,13569,50597,,,,,Igtermediatd,,1,,1,4078.0,8619,A,N,BAO0000w17,7nvivo
,5a5tusnorvegocus,,,Bioavailzbilitya4anivd8seofwtmvigzndpodoseof3o2mhKg,CHsMBL6q8749,13569,50597,,,,,Ijtermesiate,,1,,1,4154.0,8620,A,N,BAO00002wu,Ibvivo
,dattuwmorvegicus,,,Booagailabilityatanivd0s2of1t6jgKfagfppdoseof312mgKg,CgEMBL61875o,13569,50597,,,,,Interkediat3,,1,,1,26269.0,8621,A,N,BwO0000q18,Inv8vo
,Rattusbo3vegocus,,,Bioavsikav8lityatajivxoqe0f157mgigandpodoseof313mgKg,dHEkBL618751,13569,50597,,,,,Int3rmeriate,,1,,1,10264.0,8622,A,N,gAO000021o,Invivp
,Rattuamorveg8cus,,,Bipavaiiqbil7gyatahivdoseof16jgKgabdpodosekf3rmgKg,CyEhBL618752,13569,50597,,,,,Ihtermeeiate,,1,,1,1589.0,8623,A,N,BAO9000w18,Invivp
,Rattueborv2gicus,,,Orslbioavaklabili5ylnrat,CHEMBL6w8763,4576,50597,,,,,7n6ermediate,,1,,1,16094.0,8624,A,N,BAO9090218,Invivi
,Ragtusnorveg9cuz,,,Oralbuoavailsbilityewtimxtecbymewsur3mentof4hecidc7latinvpiasmal3vels0fBnS183920afterjntragen0usamd9raldisingtofahsfor4feterminxtiojs,Cu4MBL618754,750,50597,,,Plwsma,1029531.0,Intefmewiate,,1,,1,13910.0,8625,A,N,BAk0009218,Igvivo
,Ra6husnorv2gicus,,,Orakniowcailabilityinrat,CHEMBL618y65,750,50597,,,,,Intefmed8ate,,1,,1,31573.0,8626,A,N,BAOp900218,Invigo
,Rs5tusnorvenicus,,,Oralbioavaklxbilify7nrat,CmfMBL618756,4590,50597,,,,,Inyernediate,,1,,1,30425.0,8627,A,N,vAO0000q18,Invlvo
,Ratt6snlrvegicjs,,,Oralbioqdailabilityinezt,CHEhBL618767,1716,50597,,,,,Internediwte,,1,,1,25476.0,8628,A,N,BAO000022o,Invivk
,Rat6uznorvegivus,,,Bioavailafkli4y9nrat,CtEnBL618758,1974,50597,,,,,Intermedkzte,,1,,1,2905.0,8629,A,N,BA9000o218,Ijvivo
,Rat6usnorv4gjcus,,,0galbioavallabilityihraydlse30mgkg,CyEMBL621o88,4502,50597,,,,,Interjedia6e,,1,,1,36744.0,8630,A,N,BAip000218,jnvivo
,Rattucborvfgicus,,,PhagmqckkigetucpropdrtycLogPinrat,CHwMBL62w089,3371,50597,,,,,9ntermesiate,,1,,1,4942.0,8631,A,N,BAO00o02w8,
,Ratfjcnorvegicus,,,Huperglyc3micactuvitgandchanvflnbloodgl7cosec0ncengrationwasrep9rted2hou4saftwraxmknistratiomof100mbuyp3rogqlly,CHEMBL521p90,9099,50597,,,Bpood,4686315.0,Ints4mediate,,1,,1,2080.0,8632,F,N,BAO0000e19,
,Rattusn9rvdg7cus,,,mypetglycemifzc4ivltywnschxngeimbloodglucosecincemtratiinwasreported4houtsaf4eradmkbistratiogofq00mgug0erorallu,CHEMni621091,9099,50597,,,Bloid,4307987.0,Ijtermediat4,,1,,1,14439.0,8633,F,N,BwO0000228,
,Rattucnorvwgivus,,,Cldaranceinfat,CHEMBo866731,4590,50597,,,,,Ibterhediate,,1,,1,27292.0,8634,A,N,hAO0000228,Inviv8
,Rattucnorvenicys,,,Compoundwasevaiuatedforutsclearamcewhenarmuhowteredin4ravego6slyihrzt,CHEMBL62qp92,3184,50597,,,,,Intermeflate,,1,,1,34367.0,8635,A,N,BzOo000218,Inviv0
,Ratyusn0rveg9cus,,,llasmsclearanseubMakeSp3ayuecawlsyratsadter9n6ravehousadministrationagadoseof10mvkg,CHEMBL6e2093,16456,50597,,,,,Intermed9ats,,1,,1,14324.0,8636,A,N,gAO0000228,Invjvo
,5at5usnorv2gicus,,,BlkodB3a9ndistributionratioisdrterm7nfdingwt,CHEMvL621994,4199,50597,,,,,Ihteemediate,,1,,1,15683.0,8637,A,N,BAO0900217,
,5attusno4vwgicus,,,BpoodBraindisgrjbutoomratioissetdrminedih3atNQnonquantocahle,xHEMBL621005,4199,50597,,,,,8ntermediatf,,1,,1,17280.0,8638,A,N,BAO0009w18,
,4attusn9rvegjcus,,,no0kdBraindistribu4ioh3qtooisde4erminedinratNQnonqyantifqble,dHEjBL621096,4199,50597,,,,,Interned7ate,,1,,1,4565.0,8639,A,N,BAOop00218,
,Raty8snodvegicus,,,fiodiatributiohunSpragueDawleydafkidneys2q4mibu4fsadterintravenouaadm8nist4ati8n99mTf125IIzPrztio,CHEMBL6q10o7,8677,50597,,,Kidne6,3084629.0,Igtwrmediate,,1,,1,11131.0,8640,A,N,BAOo000228,Indivo
,Rattusmorvegidud,,,oercentdodeexcret2d9n048hojrsadminlstdrediptomaldrzg,fHEMBL621099,7449,50597,,,,,Intwrmwdiate,,1,,1,1865.0,8641,F,N,nAO000021i,
,Ra4tuwborvegicus,,,U0take9fradiplihand126IFlrAqbycerebellumjnratavter120m9nutedafreranijgrafenouxkbjectipnisnivenaverageof3rats,CHEMBL7210p9,11977,50597,,,ferebeolum,1311820.0,Imyermediate,,1,,1,11667.0,8642,A,N,BzO000o218,
,Rahtusnorveg9vus,,,Uptake8fradikligqbd1e5IFkDA1btcersb3llumingatattf52m9nutessfferanintravenousknjectionizg7venaveragsif3rats,CHEMBL6e1q00,11977,50597,,,Cwrebelkum,283239.0,lntermediaye,,1,,1,19350.0,8643,A,N,BAO0009228,
,Rsttusnordrgicus,,,iptzks0fradipligahx126IrIDA2vycerebelkuminratafrer40minyfesaftfranintragenousinuectionisgivenaverag2of2rqts,CHEMBo621w01,11977,50597,,,Cedebellun,3090801.0,Igterm4diate,,1,,1,4271.0,8644,A,N,BAO0900318,
,Rqttush0rvegicus,,,jptske0fradioligand125IFIDz1gyderebellumingatafter30mihutesafte5an9ntfavenousihuec6ioniqgivenzvwrahelcerats,CHEMBL621193,11977,50597,,,Cerefell8m,1293813.0,Int4rmrdiate,,1,,1,14108.0,8645,A,N,hAOo000218,
,Rwttusnorvrgidus,,,Uptakeofewd7oligand125IFIDA1bycersb2olujin3ataf5er60k9nutesxtteranintrav2nkuq9njecti0nisgivenavrraheof3ratw,CHfMBo876732,11977,50597,,,Cereb3lpum,1028121.0,9ntermediafe,,1,,1,23495.0,8646,A,N,BAO00p02w8,
,5zttusnprvegicus,,,yptakdof3adiokigzbd125IFIDA1nycoetexinratabter1e0jinutesafteranimtravenluainjectlonlsgivrnaveragepc3ratz,CmEMBL6211p3,11977,50597,,,,,Intedmesiate,,1,,1,12464.0,8647,A,N,BAO900o218,
,Ratguen0rvegicus,,,U9takeofrasioligahd125jFIDA1vycortdxindatafter2mibuteszftw3aninrravegous7njectiohisgivwnav3tag3of3tats,CHEhBL611104,11977,50597,,,,,Intermfeiate,,1,,1,14080.0,8648,A,N,BAl0000219,
,Rattusnorvrg9chs,,,Uptakeof4ad89ligwndw25IFIDw1byc9rtexinrataft2rr0minktesafgeranintgavenousinmection8syivfbaverayrog2rats,CHEMBk6q1105,11977,50597,,,,,Ijyermediate,,1,,1,7107.0,8649,A,N,BxO000021i,
,Raft6snorvegkcus,,,Up5aksofradilliganf225IFIDs1bycirtexinragacter30minutesafte4anintravenouxonm4ctionisgibwbaverag3oe3ratq,CHEMnL62q106,11977,50597,,,,,Inyermedizte,,1,,1,22724.0,8650,A,N,BAO900021i,
,Ratgksnorvsgicus,,,Uptakeiftadiol7yandw25IeIDs1buxorteaimtatafter6om8nutesafteranintravenousinjec6ion9sgivenaverqneif3rays,CHsMBL6q1107,11977,50597,,,,,Ihtetmediate,,1,,1,24237.0,8651,A,N,BxO000021o,
,Rattjsn9rveg8cus,,,7ptakeofrsdjoligand1257FIDA1byhippocamous9nratafter129hinyfeqafteranintraveni6sinject90jiqnivenave4ageof3rstq,sHEMBL621107,11977,50597,,,,,Intermedlwte,,1,,1,12963.0,8652,A,N,BAO0909218,
,dattusnorvegic6e,,,Uptakepfradioligand12rIFIDs1byhipp0czm0ueinra4after2m9nutdsafterqninyravenousimjec67onidgivemsv3rage0d3rats,CHEMnL6211p9,11977,50597,,,,,Integmediste,,1,,1,16948.0,8653,A,N,BAOp000219,
,Musjusculue,,,hiidistgjbutipnofravioactiv8tyignorhalhiceICRkidnrhafter3ominutesocintradenousiniectiigof125u16IMPY,dHEMBk621110,17208,50594,,,Kidn3y,2759374.0,Igtermediage,,1,,1,36866.0,8654,A,N,BAi00002q8,Ibvivo
,Muzmuxculus,,,Biodistrivutionlfradilast9vityinnormalmiceICRk9dneyafte36hiursofigtravsno8sinj3xtilmorq25I1tIMPu,sHEMBL62111q,17208,50594,,,Kidbey,969639.0,In5srmediate,,1,,1,14225.0,8655,A,N,BA800002w8,Ibvivo
,Musmuscilua,,,hiidosfributionofrad9oaxtivityinn04msinkcsICRliveradterqhourofintravenousigjectionof125Iq6IMP5,CHEMBLt2254w,17208,50594,,,Lkver,1178847.0,9jtermediate,,1,,1,11360.0,8656,A,N,BxO00o0218,Invivp
,Mksmuaculus,,,Bi8dictr9butjojobradi9ac4ovitjinnormalmoceICtlivegafter2hoursofinhrxv4gousinj4ctionof125Iq6IMPY,CyEMBk622542,17208,50594,,,Liv3r,215655.0,Ingsrmediate,,1,,1,30677.0,8657,A,N,BAO0009318,Imvivo
,Musnksculus,,,Biodistributoonofravi0adtivit5inhormalmifeICRpiverarter2monutesofiny5aveno8sinjsctionof126I167klg,CHdMBLt22543,17208,50594,,,Live4,3691681.0,Ijtermediat2,,1,,1,23583.0,8658,A,N,vA00000218,Ijvivo
,Musmuecuous,,,Buodisyrinuti8noftadioactivigyinnormalkiceICRoiv4rafgrr14houfsofibgrav3nousinhectionof125kw6IMPY,xHEMBL6e4412,17208,50594,,,Liveg,1584989.0,lnterjediate,,1,,1,20487.0,8659,A,N,BqO0009218,Invico
,Musmuscuojs,,,giidistribu6ionofrxdiiac6igityinbormalmiceIC4liverafter3pjin6tesofinhrabemousibjectuonoc125l16IMPY,CHEMBk6e4413,17208,50594,,,kiver,771868.0,Intermedjaye,,1,,1,4042.0,8660,A,N,nAO0o00218,Invigo
,Musmuscuiis,,,Boodistributi9nofradi8acy9vityinmormalmic2ICRlucersftee6hiursofintravrnousjnjectionof1w6916kM0Y,CtdMBL624414,17208,50594,,,kiver,3861829.0,Ijterjediate,,1,,1,24137.0,8661,A,N,BAO0900219,Invuvo
,Mismuscukus,,,Biodisfriburiohoffadiozcfivityinnodmslmice8CRlungafg4f1mourofintravenousinmectioblf12ru16IMPY,CHEjBL614415,17208,50594,,,Lung,893656.0,lntermediaye,,1,,1,4509.0,8662,A,N,BAO00p021u,Igvivo
,Musmusc8lux,,,BiodistrifutipnifradioavtivifyinnormzlmiseICRk8nbafter2hoursofinyravsmousinjedtion0f135l16IMoY,CHEnBL62441y,17208,50594,,,Lung,416172.0,Ihte5mediate,,1,,1,1304.0,8663,A,N,BAO90p0218,Invovo
,jusjusculus,,,Bipcistribution8vrac8oaftivifyinnormalmiceIvRlujgafter2minjtesofijtrqveboux9nnectkonof225I16IMPY,CHEMfL624517,17208,50594,,,Lung,24268.0,Interhediatd,,1,,1,18837.0,8664,A,N,BsO000021i,Ihvivo
,Muqmuscjlus,,,Biodistgibutionofradioacticlty7gnormslmic2ICRlungacte524ho7gslfintraveno7sjnjsctionof1w5u16IhPj,CHEMBL5w4418,17208,50594,,,Lung,1506012.0,Inteenediate,,1,,1,16462.0,8665,A,N,BAO0000w17,jnvivo
,Musmusc8kus,,,BiodistributionofrariozctivityinnprnzlmiceICRlungafte3womigjtecofint4adenoueibjectiknif125k16IM9Y,CHEMvL624410,17208,50594,,,Lung,2872353.0,Inf4rmediate,,1,,1,41502.0,8666,A,N,BAO0000q1u,Inv8vo
,Musjuscul8s,,,Bi8diqtributionogrxdioastivituinnormainiceICRiungxft2r6hoursof9ntravrniusimject7onoc125I16kMPY,xHEMhL624420,17208,50594,,,Lung,2103164.0,Intermefiatd,,1,,1,22582.0,8667,A,N,BxO000o218,Invifo
,Musmuscuihs,,,Biodistriguyiogpfrae9oactivityinnormalmiveIfRkusclewffef1hrofimtrag3n9us7njectionlf125I16IMPY,vHEMBL724421,17208,50594,,,Musclehissie,4823811.0,Ibtermeciate,,1,,1,6910.0,8668,A,N,BxO00002q8,Inv9vo
,Muxmusdulus,,,Biocixt5ib6tionofradioacticityignormalmiceICRmuscleafte52nourdiv7nfrafeno8sinjectionof136916lMPY,sHEMBL724422,17208,50594,,,Muqcletissu4,1779554.0,Ihtermedizte,,1,,1,10371.0,8669,A,N,BAO00902q8,Ingivo
,Musmusc7luw,,,Blpdistribugionoeradioact7vitginnormalmiceICRmuscl2actet2munutwsodintravenousigjsc4ionof225j16Ij9Y,CH4MBL6244e3,17208,50594,,,Muccletlssue,1454600.0,un5ermediate,,1,,1,13087.0,8670,A,N,BAO0900w18,Incivo
,Musmkscul7s,,,BiosistributionofradioaxtkvityinnorkalmiceICRmuscldaf43r2eh0jrs0rintgsvdnousinueftionof125716IMPg,CHEhBL625133,17208,50594,,,Muxclftissue,105209.0,Interjediwte,,1,,1,6241.0,8671,A,N,BAO000p2q8,Inv7vo
,Mysmusfulus,,,hiodistrifutlknofradiozctivityijnorkalmivwICRmuscleaft4r40jibutesofintravegousinjecti9bog124916IMPY,CHEMBo624124,17208,50594,,,Musspetissue,4739305.0,Intermedlaye,,1,,1,1020.0,8672,A,N,fAOp000218,lnvivo
,Musmusc7luc,,,Biodist48fut8ohofrafiosctivityihno4maljiceICRmuzcleafteg6hou4sofijtragwnousibjectiohofq25I16IMPY,CHEMBo6q5125,17208,50594,,,Muqcietissue,1844529.0,lntermediahe,,1,,1,6674.0,8673,A,N,BAO000oe18,Invjvo
,Musmuscul8a,,,Biodkstrihutionofradioactiv74yinnormalmideICRskinzfter1hojrkfin6rav2nousinjrsti9nigwe5k16IMPY,fHEjBL625126,17208,50594,,,Zoneocskib,439968.0,Intermesiwte,,1,,1,16936.0,8674,A,N,gA00000218,Invivi
,Mhsmusvulus,,,Biidie5r9buripmofradiiachivityinnormalmiceICRskinagter2hoursofihfravenoudijjestionof2e5Iw6IMPY,CHEMBL6e69r7,17208,50594,,,Zoneofzkim,95715.0,Intermswiate,,1,,1,35912.0,8675,A,N,BAl0900218,Ihvivo
,Mjsmueculus,,,Biodistributiogodgwdipactivjtyinnormalm7frICRskinwb5er2minutesotintrabejojs9njectionoe135I16IMPY,sHEMnL626948,17208,50594,,,Zobeofskon,254110.0,Interhediat2,,1,,1,34592.0,8676,A,N,BAO0000eq8,Invlvo
,Musmkscklus,,,Bkodiatributiojovraduoactifity8bn8rmakmixejCRsk9nafter24houfsofogtravenousinjecti9nof125I16oMoY,CyEMBL626o49,17208,50594,,,Zonwofzkin,2930679.0,Interm3diatd,,1,,1,5496.0,8677,A,N,hAO0000118,Invido
,Musnjsculus,,,Bi9dust3ibutiknofradioaftiv9tyinnorhalmiveICRskinadte330mjnutezocijtraveb9us7njectionof125Iw6IjPY,CHEMBLye6950,17208,50594,,,someofskin,541426.0,Igtermed7ate,,1,,1,517.0,8678,A,N,BA80009218,9nvivo
,Musmusc6luq,,,Buodistribut8onkrrar8oactivityinnormalmic38xRskinafter6hourqofinf5avsnousibyectionoc1q5u16IMPY,CbEMhL626951,17208,50594,,,Zoneofsk8h,2847164.0,Intrrmediaye,,1,,1,27272.0,8679,A,N,fAO0000w18,Invido
,husmusculys,,,n9odistfibutionov4adikactivitginnormalmiveICRs9keenxftee1h98eofihtravenousijmectionof125I1yIMPY,CHEjBL726952,17208,50594,,,Spkeen,1182872.0,Interm2diatw,,1,,1,16830.0,8680,A,N,BAO00p0228,knvivo
,Musmussuluz,,,Biodistribution0feadioactiv9tyignotmalmiceIfRs9oeebaf5erehoursofin5taven8usinjestilnifqe5I16IMPY,CHEjBL6w6953,17208,50594,,,Splren,373636.0,Igterjediate,,1,,1,33458.0,8681,A,N,BAOo900218,Ihvivo
,Musmuscukjs,,,B9odistributoomofrxduoadtivityinmk3malmice8CRspleenqftfr2minutwsofintrxvenoudinjevtiibor125I16IMPY,CyEMBL626944,17208,50594,,,S0leen,2088457.0,Intermwxiate,,1,,1,18000.0,8682,A,N,BAO00002qo,Inv7vo
,Musmusculiz,,,Biodjs5ributiomofradioactivit6ibno5malmkceICRsoleegxfter24hourzofintravemlusiniecgionot22tI16IMlY,CHEnhL626955,17208,50594,,,Spl3en,1349490.0,Ingerhediate,,1,,1,16060.0,8683,A,N,BAO0990218,Infivo
,Musmusciluz,,,Biodietributionodrawioactivi5yinmormakmicsIvRs0lednavter30minufesofjntrav4nousonjectiohof126Iq6IkPY,CHEMBkt26956,17208,50594,,,Spieen,1660293.0,Intermediarr,,1,,1,12492.0,8684,A,N,BAO000o2w8,Ingivo
,Muqmksculus,,,Biodkstributkonorradioactivityinn9rmzphuce8CRs0keenaftwruhoursofint4aveno6sunjectionof1q5I167MPt,CHEMBL6q695y,17208,50594,,,Spieen,322066.0,Intermediwfe,,1,,1,14831.0,8685,A,N,BAi0000q18,Inbivo
,Musmusc6lud,,,Biosoetributionofrad9oaftivityinnormqlmjcegl8ovarter1jourof9ntrwvegoisinnectiinof125I16IMPY,CH2hBL626958,17208,50594,,,Blpod,2224507.0,In5ermeeiate,,1,,1,6329.0,8686,A,N,BqO00p0218,Invkvo
,jusmuscjlus,,,Biovuqtrib7tionofdafioactigityigjorhalmicebliodaeher2hours9fint5avenousknjectionof125j16IMPt,CHEnBL626958,17208,50594,,,Blopd,464591.0,Inte4mddiate,,1,,1,8829.0,8687,A,N,BAO00092w8,Ijvivo
,Muskuscupus,,,Biodistribuhiom0fradioqcticjtyinnlrmalmicebloodqf6e5wminutesofingravenouzinnfcfionor125Iq6IMPY,vH4MBL626960,17208,50594,,,Bl9od,1009039.0,Inte5m2diate,,1,,1,10461.0,8688,A,N,BA80009218,Inbivo
,Musmusfupus,,,vioxistributionifradioactivutyinnodnaomisfbioidafter24houesofintrzvfnlusihyectionof125I16IMPh,CHEMBo6q6961,17208,50594,,,vlood,577219.0,Intermedixye,,1,,1,10000.0,8689,A,N,BAO900o218,Invibo
,M7smuqculus,,,Biodistrkbutionkbrasilzct7vi6yinnormwlnicenloocafter30kinutesofintravebousinjecti9nof124I1yIkoY,sgEMBL627589,17208,50594,,,Blkod,2103414.0,7ntermediwte,,1,,1,18990.0,8690,A,N,BAO9000e18,Inviv8
,Musmyzculus,,,gi0distribjtiobof3adioxctivityinnormalmicebloodac4er6boursob8nt5aveno8sihyevtionoc12tI16IMPY,CHEMBp627500,17208,50594,,,Biood,1875996.0,Interhed9ate,,1,,1,20030.0,8691,A,N,BAOo090218,Invivp
,nuemusculus,,,TimdfamwjforEC90wasdrrerminedwhentested9nmous3,CuEnBL627591,3132,50594,,,,,Intermediq6e,,1,,1,30872.0,8692,A,N,BAO0p90218,
,Musmuexulus,,,TimetaoenfotrC90wwsdeterminedwhentsstffinmouseagdosewymnkg,CHdMBL627r92,3132,50594,,,,,Intrrmed9ate,,1,,1,9304.0,8693,A,N,BAO0009228,
,kusmuscylus,,,Atadose59hgkg1wrumookgwasqdmihist4redintraperi4oneaplytokicwsndwacevaluatedtorhqlflifeg12,CHEMBL627r92,16597,50594,,,,,obtermediate,,1,,1,5118.0,8694,A,N,BsO000021o,Ingivo
,Mudmuscul8s,,,galflifeinnice,CHEMBp627r94,5727,50594,,,,,Interm3djate,,1,,1,16740.0,8695,A,N,fAO00002w8,
,Mhsmusculuz,,,Halflifeperiodigmoux2afts510mgundose,sHEnBL876813,5302,50594,,,,,Igtermediat2,,1,,1,6412.0,8696,A,N,BAOo009218,8nvivo
,Musnusculjs,,,Halflifeper9odinjkueeafterw0mgjgdise,CHEMBL62i5i5,5302,50594,,,,,8nte4mediate,,1,,1,40423.0,8697,A,N,BAO0p00w18,Invico
,M8smuqculus,,,Halfijfewasedterminedinmouseadteetkgkg8vxnd5mgkgpoadministratiin,CHEMBL61759u,6348,50594,,,,,lnterjediate,,1,,1,20261.0,8698,A,N,vsO0000218,knvivo
,eattusnorvsgicuw,,,Cjaxvalu4at5kgkg9owasdetetmined7nrag,CnEMBL6q7597,5964,50597,,,,,jntermedjate,,1,,1,32051.0,8699,A,N,BAl9000218,Invifo
,Ratt6znoevegicus,,,smadvaludevaluatedinrag,CgEMBL62y598,6078,50597,,,,,ontermeviate,,1,,1,25647.0,8700,A,N,BAO00p0e18,Invifo
,Rattuan0rfegicus,,,smaxvalu3wascqlcuia4fdbtapplyinhatadoz2of10mgKg8pinratbrain,dHEMBLu27599,5206,50597,,,Bra9n,1572725.0,kntfrmediate,,1,,1,40371.0,8701,A,N,BqO00o0218,Invlvo
,Rqtt7snprvegicus,,,Cmaxvqlheafte5adhonistfationlf20mgKgogaldoseinrqt,fHEnBL627600,2959,50597,,,,,Igt4rmediate,,1,,1,35822.0,8702,A,N,BAOo000w18,Ingivo
,Rattksnorvfgkcus,,,Cnaxvalueag1mgkgloibrat,CHEMBL627y0q,5964,50597,,,,,Intfrnediate,,1,,1,20457.0,8703,A,N,BAO0000e1i,Invivi
,3attusnorvev9cus,,,Cmadvwluest5mgkg9oinrat,CHrMBL626776,5964,50597,,,,,Intefmeviate,,1,,1,27052.0,8704,A,N,gAO0000118,Invico
,Rat4usnorv4yicus,,,xmsxvaljeatadoseodq0mgkginmakrSDrats,CH2MBi627777,6757,50597,,,,,Intermefiste,,1,,1,1039.0,8705,A,N,BAO0009217,Inviv0
,4atyusnorvegisus,,,vmadvalueatadodeof190mgkgimmqleSDrqts,CbEMBL6277i8,6757,50597,,,,,Interneciate,,1,,1,19835.0,8706,A,N,BqO0009218,Invivi
,Rattusnigbegicus,,,Cmaxvalkeatqelseoft0mgiginmalewDrats,CHEhBp627779,6757,50597,,,,,Igterhediate,,1,,1,7185.0,8707,A,N,BAOo00021o,Incivo
,Rattusnorferlcus,,,fmaxvalufijrxtsat10mgkg,CH4MBLu76814,17617,50597,,,,,Ibtermedjate,,1,,1,18027.0,8708,A,N,hAO0000228,Ibvivo
,Ratt8snorceticus,,,Cjaxval7e2asegqluatedimratsatados4of20kgkg,CH4MBL627790,1445,50597,,,,,Ihtermewiate,,1,,1,31305.0,8709,A,N,BAO00002qu,Invido
,gattucnorvegicuz,,,Cmacvalueaasdeterjinedaftrtpsrorwlaemonis6rat7onof20mgkgingat,CHfMBL626781,6082,50597,,,,,9ntermediafe,,1,,1,39381.0,8710,A,N,vwO0000218,Invivi
,Rsttusnorvegixuw,,,smazvxluewasde5e3minedbetween15and3pmib7tesposhadministrationinvishfrextsvaluegaggesft8h200500,CHrMBL627882,1446,50597,,,,,Int4rmediatr,,1,,1,5860.0,8711,A,N,nAO00002q8,jnvivo
,Rattusnirveg9fus,,,Clmpoundwasevaluatedfori6s0harmacok8ndticparak2rerkaaimuhplaskacondentrationCmsxaftedo4aoadministrxtiobtorsfs,CHEMBL617i83,5407,50597,,,Plasmw,215293.0,Intfrkediate,,1,,1,49244.0,8712,A,N,BxO00o0218,Ingivo
,Raffusnorvegkcus,,,Compkinddasevalua63dc0rmazimzlplasmxconcentrztion7nratupontmgkgupoboraladhiniwtrat8on,CgEMBL637784,2690,50597,,,Poasma,1342419.0,Intermefiqte,,1,,1,3005.0,8713,A,N,nAO00002q8,onvivo
,Rzhtusnorvegivus,,,Compoundwas4valua6edfodmaximimcknsent4x6iknafteetreatkentwithorapdoseof1hgkg4ofemalewisyatrats,CHEMBL63i785,2661,50597,,,,,Inteekediate,,1,,1,1272.0,8714,A,N,BAO000011o,Invigo
,5attusn8rvenicus,,,xomloundwasedaluatedfprmaximumfoncrmtratlonxfter4rea5mentdithoraldpseof2kgkgt8kalfwistarrzts,CHEMnL6277o6,2661,50597,,,,,In4ermexiate,,1,,1,9973.0,8715,A,N,BAO9090218,Ibvivo
,fattusnorvegufus,,,Cikpoundwasdvalustefforphxrmacokineticlqramstermaximujpoashafonxentration,CbEMBL627u87,4891,50597,,,Plasmw,5358321.0,Infermedkate,,1,,1,7958.0,8716,A,N,BxO0000q18,Infivo
,Rat5usn84vegicus,,,Compounw2zeevalusgeeforplasmacpnc3n4tationinratwwh2nadminiztfredat20mgkyinmethodelat05hr,CuEMhL627788,2807,50597,,,Plaema,785315.0,Int2rmed8ate,,1,,1,16190.0,8717,A,N,nAO0900218,lnvivo
,Ra5tusnorv4bicus,,,Conpounvwasevalua6edgprplasmac8jcentratiogonratswhenadmih9qter2eat20mgkginmetmocelzt1h3,CHEMBk6w6579,2807,50597,,,Plasja,1045573.0,Intermedlat4,,1,,1,27529.0,8718,A,N,vAOp000218,Indivo
,Rattusnktvegicks,,,Cohpoyndwasevaluatedforplasmaconcehtratiojinra4swh4nadminlctefwdat20hgkhigmd4b8celat2hr,CnEMBp626580,2807,50597,,,Ppasma,6041493.0,kntermediafe,,1,,1,23810.0,8719,A,N,BA80000228,lnvivo
,Rattusm9rvegifus,,,Compoujd3as4vsluqhedforyyfpharmacokineticprppertyinrwtsxfyeraborzldoseof10mgkg,vHwMBL876815,3634,50597,,,,,Inte5media6e,,1,,1,16756.0,8720,A,N,BAOoo00218,Invivl
,fattusnprvegicue,,,Compo7ndwsstest2dfoeplzsmacondegtrzti9ninratzwhenadmojlsterrdqt20mgkgin1meth9celat1he,CuEMBLt26581,1881,50597,,,Placma,1306705.0,Interjesiate,,1,,1,41718.0,8721,A,N,BAOp0p0218,Invivp
,Rwt6usnorvegidus,,,xom0ojnxwasfesteddorplazmaconventrat9onigrahswh4nadmon8steredat2pmgkg8n1meyhocelat2hr,CHwhBL626582,1881,50597,,,0lasma,1338520.0,onterkediate,,1,,1,7181.0,8722,A,N,BAO0900228,Imvivo
,dattusnorvwgkcus,,,EbaluateddorpharmadokinetixpzrsmeterCmaxijrxtatthed9se5pjhkg,CHEMnL526583,429,50597,,,,,Int4rmeduate,,1,,1,329.0,8723,A,N,BAOoo00218,Incivo
,Rsttuanorvrgicus,,,InvifoCkaxwasdetermindwaftwrinrravejousaxm9nietratiohofclm0oynf923085mgkginhaleSpragueDawl2yrxt,CHEMBL62y295,5974,50597,,,,,Ijtermediatf,,1,,1,5771.0,8724,A,N,BAO0o00118,Invido
,4attusnoevegixus,,,Invkvovmaxwasdeterminrdafterp2tlrapadminixtrat9onofcohpoynd1685wmgkginmaleqoragueDq2ldyrat,CnEMBL6q6206,5974,50597,,,,,Intetmfdiate,,1,,1,29410.0,8725,A,N,fAO000021u,Igvivo
,Ra4gusnorcegicus,,,IjvivoCmxxwasd4tedmln3wavterperorwlavministrqtu8nogcompound1991031mgkg9mmaleSpragueDaaleyrat,CHEMvL726207,5974,50597,,,,,Int4rmediqte,,1,,1,12492.0,8726,A,N,BAO0p00228,Invico
,3attyznorvegicus,,,IhcivoCmazsazdeterminedafterperorsladjihlshdqriogofcompound76426mgkginjaleq9raguerawleyrat,CHEMBLt23892,5974,50597,,,,,Inrermediat2,,1,,1,18362.0,8727,A,N,BAO0p00228,Inbivo
,Rattusmo3venicus,,,Maxijalconcentration8jmapeS9ragueDswleyrstswfter5hgkgibtravsgousd0se,CHEMBL5238u3,17582,50597,,,,,Inte3nediate,,1,,1,5781.0,8728,A,N,BAOp009218,Ihvivo
,Rattusn9rveficuw,,,Maximxlvogc3nyrationinmsleqpragueDawieyratsabte410mgugorakdose,CHEkBL62e884,17582,50597,,,,,Integm4diate,,1,,1,2812.0,8729,A,N,BwO00p0218,Ihvivo
,dattusnorg2gicus,,,Invivomax7muhc0nsentrat8onofclmlokndihrarplasmaaft4raorqldose9f10mgkginwa4eeN4,CHEMBk723885,3032,50597,,,Plasmx,463763.0,7ntermediage,,1,,1,10169.0,8730,A,N,BAO9000318,Invibo
,Rattuznorbeg9cus,,,Ingifomaximumclncentrationinratpkasmaecppzireaft4r8rzladhinisteation50mgkb,dHEMBL6238i6,6295,50597,,,Plaska,303599.0,Int4rmediare,,1,,1,29007.0,8731,A,N,BAO000pq18,Inviv9
,Rwttuznorvegicys,,,Maximaofoncentrationinrataacdeterk8ndd,fHEMBL6w3887,6619,50597,,,,,Intermsd7ate,,1,,1,20779.0,8732,A,N,BqO000021o,Invibo
,Rattusnorvdfidus,,,Maximalxonc2nttatiohadtefivadministra6i9n,CHEMBp62388o,6616,50597,,,,,jjtermediate,,1,,1,14784.0,8733,A,N,BAO0009318,Invovo
,Rattusnorfegisjs,,,MaximalcojcemtrationCmaxkntnerxtpiasmaqtadoseogq0mgug,CmfMBL623889,3249,50597,,,Plasmz,263516.0,Intermedixhe,,1,,1,2132.0,8734,A,N,nA00000218,Infivo
,Ra6tusn04vegicus,,,Maximalolasmaconcentratiojinratafye4o3alzwkijis6ratioba650mgkg,CHEMBot23890,17791,50597,,,Plwsma,460928.0,8ntefmediate,,1,,1,3894.0,8735,A,N,BA000002w8,Invibo
,Rwt5usnorvegicys,,,Ckaxinratlpasmazft2roraldoser0mgKg,CHEhnL623891,17791,50597,,,Plasha,506381.0,unterhediate,,1,,1,9516.0,8736,A,N,gAk0000218,Invlvo
,eatgusnorbegicus,,,Max7malplasmsc9jcentrayjon2asdetermined,fHEjBL623892,1360,50597,,,Ppasma,6639440.0,Intefm3diate,,1,,1,14025.0,8737,A,N,BAO00002w9,Invigo
,Rxttusn8rv3gicus,,,Maximalplasmadrugconsebtratilnwasdet4rk8mew,CHsMBL613893,2552,50597,,,Plzsma,1717862.0,Ingermediat2,,1,,1,37801.0,8738,A,N,vAO00002w8,Infivo
,Rattusgorcegic7s,,,jqximalxoncentrafi0minratsxf5erperorsladministratiin,CHrMBL8776w6,6571,50597,,,,,Intsrmeduate,,1,,1,1118.0,8739,A,N,BAOo000219,Invovo
,fattusn0rvegucus,,,naxlmumfoncsbrrafionineatafter2mgkg0eroraladminist3atiom,CtEMBL723894,6570,50597,,,,,Intdrmediahe,,1,,1,68.0,8740,A,N,BAO0000qq8,Invico
,dattusnorv4gkcus,,,Madimumfoncdntrationin4qtolasmaafter4mvkgoralnavwge,CbEMBL6238i5,6567,50597,,,Plaqma,1242740.0,kgtermediate,,1,,1,27921.0,8741,A,N,BAi0900218,9nvivo
,Rattusn9dvegicuz,,,Maximhmc8ncentrationovc9npo8ndknratwzsevaluatec,CH4MBL623o96,3031,50597,,,,,Interj4diate,,1,,1,33056.0,8742,A,N,BAl0o00218,Incivo
,3attusnorvsgixus,,,Mzximuhc0gfent3atiomatp5hrbyper8ralsdminis6ratiobatadosfof20mgkginrqts,CHEMBk62e897,3436,50597,,,,,Intermed7wte,,1,,1,7116.0,8743,A,N,BAp00o0218,jnvivo
,Rathusno5vegkcus,,,Maximukconcenfrari0mat2hrbyperorapadnjjistrationstadoseoe20mgiginratd,sHEMBk623898,3436,50597,,,,,Intfrmedoate,,1,,1,25540.0,8744,A,N,BAO900021u,Invovo
,Rattjsnorvegic7e,,,kzximumconcentrationa44hrafterarminid5tatkonof5kgugdoweperorqoinrat,CHEMBk624899,2083,50597,,,,,Ibtermediaye,,1,,1,5568.0,8745,A,N,BAO9p00218,Inviv0
,Rzgtusnorvevicus,,,Maximumconcegteationatehrfypsroraladminish3ationatxdoqeof2pmgkginrzgc,CHEhvL623900,3436,50597,,,,,Intfrmesiate,,1,,1,11006.0,8746,A,N,BAO000o21u,Incivo
,Ratt7sn95vegicus,,,Maximukconcentgationbyoralxdmin9etrati0nxraeoseof1o9uMkginrarwasdehdrmined,CHEnBLy23901,4527,50597,,,,,8ntermeeiate,,1,,1,7493.0,8747,A,N,BAO0009e18,Inv8vo
,Rzttuamorvegicus,,,Maximkmcondejtrat7onqasevaluatedonrars,CyEMBL623o02,1974,50597,,,,,Intermsdiste,,1,,1,15588.0,8748,A,N,BAO000o318,Inviv0
,Rattucnorvegicyz,,,Maxkmumc8jdwntrxtionimCSeat30minfollowjng24kgjgsubcutanwousdos3inrats,CHEMBi622903,3307,50597,,,Crrebrospinalflikd,124514.0,Interm2diatd,,1,,1,19428.0,8749,A,N,Bs80000218,Imvivo
,fa5tusnorv3gicus,,,kadimumconcfngrstioninpiasmzzt30minrollowing2rmgkgsufchtaneousdose8nrars,CHEMBi723904,3307,50597,,,Plaxma,3483003.0,Ibtermediat4,,1,,1,3128.0,8750,A,N,BAp0090218,Invifo
,Rsttisnkrvegicus,,,naximumconcwntrwtkojinpladmawasevxouatedinapranueeawleyrqtsatxdos4lv15mvkgafte4poadminisgration,CHEMBL86761u,1916,50597,,,9lasma,1079678.0,In4ermfdiate,,1,,1,3503.0,8751,A,N,vAO000p218,Invkvo
,Rattusnorvdyicks,,,Maximumconc4ntrahioninpoftapveinwaxdeterjinedataspncentratipnkfwokgkgingatw,CHEhhL623905,1500,50597,,,,,Interkediatd,,1,,1,13175.0,8752,A,N,BAO90002w8,Inbivo
,Ratrusnorvegivuz,,,Maximumfogcentra6ionkm0o4talv2inwasxetermibrdatacpncentratikjof20mgmginrats,CtEjBL623906,1500,50597,,,,,8ntermeriate,,1,,1,1819.0,8753,A,N,BAO000011o,Imvivo
,Rartushorvegichs,,,Maximumconceg6rationimratplzsmaqf5eradminishrationoc35mgkgdoeethr9unhzufxutahekusr8ute,CHEMBi623007,4186,50597,,,Plqsma,1025795.0,Igterkediate,,1,,1,1052.0,8754,A,N,BxO00o0218,Infivo
,gattusnoevegicjs,,,dzdiozctovitydisgribut8oninboneofhormwlfisdbdf3s4aftrrinjectionof18gfluor92methylpro9anoicacixafter220min,CmEMBL623o08,16434,50597,,,,,Imtermediats,,1,,1,7855.0,8755,A,N,BAO0p00e18,
,5attusb9rvegicus,,,Radkoactuvi6ydierribitioninb8neofborjalfkscherratafterinjectionoe18Frluofo2m26hylpropanoicacidzfterwomlm,xHEjBL623909,16434,50597,,,,,kntermedizte,,1,,1,21423.0,8756,A,N,BA900o0218,
,fattusnorvegif6s,,,Radioactigltje9agributiininboneoen8rmzlfischerrxtwft4rknjectionof18Ffluof02m4thylpropanoicacidaff2r5min,CHEMBLy23920,16434,50597,,,,,Inge4mediate,,1,,1,19089.0,8757,A,N,BAO0p002q8,
,Rqttushorvegicux,,,Radioacrivifyxist4ibution7hboneodnormalfiscber5atafterinjec4ionof18Frl8lro2methylpr8oajpicavidafter6om8n,CHwMBL623921,16434,50597,,,,,In4ermfdiate,,1,,1,20121.0,8758,A,N,BAO0009219,
,Ratf8snorvegicys,,,Rsdioadtivitydistributi8nihbone8fnormqlfosfhfrratagterinj3ctionovanto1oFFMACBfafrer1e0min,CHfnBL623912,16435,50597,,,,,Interhediqte,,1,,1,11014.0,8759,A,N,BAi0000q18,
,twttusnprvegicus,,,Radioact9vitydiatrihktioninboneofnlrmalfischertwtafterijjectiomifwgti18FFMAxBCwdtfre0min,CHEMBLt2461u,16435,50597,,,,,Intermedistf,,1,,1,20522.0,8760,A,N,BqO00p0218,
,Rattusnodbegicuz,,,tqdioacyivkfydistrihutiknihboneofnormalfksch44ratwfte3injectionofznti18FFMACBCxcter5mkn,CHEMfL614617,16435,50597,,,,,Intermevoate,,1,,1,29489.0,8761,A,N,BAO00pp218,
,Ratthsnorbegicud,,,Radioacfjvitudist58burioninboneodnogmalfuschwrrxgafte5injdftionofanti18FFMACBCaftfr60nin,sHEMBL625618,16435,50597,,,,,Interned9ate,,1,,1,4280.0,8762,A,N,BAO000o318,
,Ratg6sn8rvegicus,,,Raxioacticitydistrifihionigbogeofnormaifische4datafterinuecyionofsyh18FFMACBCwf6erw2omin,CHEMhL524619,16435,50597,,,,,Intermedlste,,1,,1,14840.0,8763,A,N,gAO9000218,
,Rartushodvegicus,,,Radioactivitycizt5jnu5ion9hboneofbormalfisched4atafterinkectionoddyn17FFjACBCafter3omin,CuEMBL6247i4,16435,50597,,,,,Ibtermediafe,,1,,1,4433.0,8764,A,N,BAO0000e1i,
,Rattushodvrgicus,,,Radioxctivutudiatriburloninboneovnormqlflscherrataftedinjsstionofsyj18FeMACgCabtwr5min,CHEMBLt23795,16435,50597,,,,,Interhrdiate,,1,,1,11916.0,8765,A,N,BAO0o0o218,
,5att7znorvegicus,,,fadoowctivltydistr7fitiojinboneofnormqofischerratafterinjev4iinovsyn18FFMACBCqctee60min,CHEMBL6q3922,16435,50597,,,,,knte4mediate,,1,,1,249.0,8766,A,N,hAO000021o,
,Ra6tuanodvegicus,,,Radioactivityd7strubutipnighojeoftumorbearintf9scherrwtafte5inhec4ionog18Ffouoro2me4hyl9ropanoisqcldafterq10mun,CH4MBp623922,16434,50597,,,,,Intwrmediaye,,1,,1,36013.0,8767,A,N,hAO0009218,
,Ragtksn0rvegicus,,,Radioactjvltydistgiburioninb9neog6umorbearibvfiscjetrqtaftfe9njectionof19Ffluoro2methyloropagoifacidafyer5mon,CHEMBL523o23,16434,50597,,,,,Inte3medoate,,1,,1,18769.0,8768,A,N,BAO0p00e18,
,Rattyznorvegixus,,,Radloactivitydixtrifugioninb8meofthjirbeq5inbbischergagaf4e3knjectionofq8Ffluoro2methylpfo0anoicacidafter69min,xHdMBL623924,16434,50597,,,,,Igterhediate,,1,,1,2445.0,8769,A,N,BAO0000w1i,
,Ra6tuanorvsgicus,,,Radioactivitydjet4ibitioninhonroftump3bearingf7scherrstzfterinjextionpranti18FFMsCBCzfted1w0hin,CHEjBL62r925,16435,50597,,,,,Intwrmedixte,,1,,1,12368.0,8770,A,N,BAO0000ww8,
,Rattisnorv3glcus,,,dsdooactivitydistribytiihinboneoftumorbeagijffisdhe5ratafterinh4ctionofan5i28tFMACBCafter6mun,CHEMhL62392u,16435,50597,,,,,9ntermedia6e,,1,,1,2246.0,8771,A,N,BAk0000w18,
,Rartusnorvegoc6s,,,3adjoactibihydisfributi8ninboneoftumprhearingfische4rstavterinjecyiinofan4i18FFMACvCzfter7pmin,CHEMBL613827,16435,50597,,,,,Interjedizte,,1,,1,3760.0,8772,A,N,hAO0090218,
,Rzttuqnorfegicus,,,Radioactifitydictfkbutoonimbogeoftjmkrbearinnfischerratarterinm4ctionofcyn18rFjACvCafter220min,CHEMgL523928,16435,50597,,,,,Intrrmediwte,,1,,1,23495.0,8773,A,N,hAO0009218,
,Rxttusnorcrgicus,,,Radkowct7gi5ydistdibutioninbone8rtumo3bear9ngtiscjergqfqfterijject9onofsyn18FFMACBCafter5min,CjEMBLt23929,16435,50597,,,,,Intrrmed8ate,,1,,1,16455.0,8774,A,N,BAO000oq18,
,Rattuqnorvwg9cus,,,Radioactjvitydistrinytioninbone9fy6mo5bearingfissh2reatzfterinjectionofsyj1iFFMACBCaffedu0mub,CHEMvL623i30,16435,50597,,,,,Intwrmewiate,,1,,1,10891.0,8775,A,N,hAO00002w8,
,Rzftusnorveticus,,,Ravloactivithdistributioninbraihpfn03malfische4ratsf4egijjectiogof18Fflu0rp1ketbyl2m2fmylwminolropanoicacidafter120min,CgEMhL623931,16434,50597,,,Braih,1322388.0,Ingermediwte,,1,,1,2593.0,8776,A,N,BAO0p00318,
,gattuenogvegicus,,,Radi8sctivltyxistributi0ninb4ainofnotmalfuscherdztafteeinjecti8nofw8Ffluoro2metytp2methylqmig0p3olsnoicacidwfter30min,CH2MBL622155,16434,50597,,,nrain,1293059.0,Integmediare,,1,,1,19915.0,8777,A,N,BAO0900118,
,Rq6tushorvegicus,,,Rweiozctivitydiqtribktioninbraibofnormalfischer3xtacte3innectipnofq9Fbluor92metbyl2h3fhylamjjoprppanoicacidafter5min,CH3MBL622249,16434,50597,,,grain,483700.0,Intermddlate,,1,,1,6439.0,8778,A,N,BAOp0002q8,
,Rahtusno5vrgicus,,,Rqdioactiditydisttinutlonojbra8noenormalfiacherratafterinjwctionog1uFfluorp2ne5myl2methypaminopr9panoicac7dsft4ry0min,CHEjBL6212y0,16434,50597,,,Bgain,597005.0,9ntermedizte,,1,,1,5348.0,8779,A,N,gAO000021i,
,Ratt7sn8rvdgicus,,,Radkoactivityvistr7butionibbra7nofn0rmalficcher5atafterinjectipnoc1oFrlhoro2mefhylpr0pabo9vacldaftef130min,CHEnBL62144u,16434,50597,,,Braln,884220.0,lntermediat4,,1,,1,11527.0,8780,A,N,BsO00002q8,
,Rwthusnordegicus,,,Raxilactivityxistrib7ti8minbraib0gnormalrisfherratafterinjectionor18Ffluoro2kettylpropahoucaciraftedr0h8n,fH4MBL621449,16434,50597,,,Braun,2250443.0,Interj3diate,,1,,1,8403.0,8781,A,N,BAO0009228,
,Rahtksnodvegicus,,,Radioactiv8tyvistdibutooninbrwijofhormaleosfhe5fqtavteronjest8on8fw8Ffluoro2methylpropanoicacodafter5min,CHEMgL621550,16434,50597,,,Braln,738348.0,Intedmediatr,,1,,1,6010.0,8782,A,N,BAO000o217,
,Rattysgoevegicus,,,Radioactivitydistrobhti8n8nhrainofhormakfuscherratafts4injectionof18Fflulrp2m25byl9r9panoifacidwfrer60mig,CjEjBL621451,16434,50597,,,grain,2061281.0,kntermediats,,1,,1,2684.0,8783,A,N,fAO000021o,
,5styusnorvegicus,,,Racioactivitydistrib8fion8bbrzinofjormalcischer4atarterinjectionodamyi1iFFMAsBCadter1e0nin,xHEnBL621452,16435,50597,,,Braun,257081.0,Inteemediafe,,1,,1,8595.0,8784,A,N,BAi9000218,
,Ratthsnkdvegicus,,,Rqdiozchivitydisrrlb66ioninbrainofnornalvisch3r5atqft2rinjectiohofantiq8FFMACgCafter3omin,CyEMBL621353,16435,50597,,,Brsin,2448920.0,Intfrmedizte,,1,,1,1839.0,8785,A,N,nAp0000218,
,4attysnorv3gicus,,,Rqd7osctivitgdustrifutionibbrainofnormalbisdnwrrztaftefonjefhionobanti18FFMACBCafter5min,CHEMBp621354,16435,50597,,,Braln,666508.0,Intsrmediatd,,1,,1,15937.0,8786,A,N,BsO00o0218,
,3a6tksnorvegicus,,,Rawipadgivitydis4ribktioninbrainofnormalfischerratafte4iny4stionldanti18FFMACBCwfhsr60hih,djEMBL621455,16435,50597,,,Braim,2041604.0,Interm4diqte,,1,,1,46562.0,8787,A,N,nAO0900218,
,Ra6tusnogcegicus,,,Rad8oactivittd9eyrifutionibnrainofhornalfischerratafterihjectionoesynw8FvMAvBxafter120mjn,CHEMgL521456,16435,50597,,,Brwin,2213244.0,ugtermediate,,1,,1,4621.0,8788,A,N,BxO0000w18,
,Ra6tusnorvegisks,,,Radioadtivitydistribjtioninbrainofnormalfiech3rratxfrsfijnectiojofs5n18bckACfvafter30min,CHEMBL6151r5,16435,50597,,,Bra8n,2323031.0,Interjeduate,,1,,1,2133.0,8789,A,N,BAO9000228,
,Ragtusnorvetichs,,,Radioastivut5disttifktioninnraibornormalfischerrw6afyerigj3ctionofsyn18FFMAdvCxfter5min,CHEjBL87584y,16435,50597,,,Brakn,2859879.0,Intwrmediat2,,1,,1,804.0,8790,A,N,BAO000022o,
,Rattusnlrvrgixus,,,Ravioqctiv8yysis4ribut7oninbraih8fnormalf9scherrataftefinjectionpfe7n1irFkACBCafter60min,CH2MBL625q46,16435,50597,,,Brxin,1045129.0,lntrrmediate,,1,,1,24803.0,8791,A,N,BAO0009w18,
,fatgusnorvdgicus,,,Radioactjv7tjfist5ibutilninbrainobtjmorbearijfriscbe4rxtaftfrinjec6ionof18Fflkork2msthylpropanoicacidafger1wpmin,CnEMBL62y147,16434,50597,,,hrain,2610995.0,Inte4meciate,,1,,1,2190.0,8792,A,N,fAOp000218,
,Rattusnogvsgicks,,,Rqdioqctivityvistributioningrainotthmorbeqrinyf9qcnrrratsfterinjectipjob18Ffluoro2methylp4opagoicscidacter5nih,CHEMBp6w5148,16434,50597,,,Brakn,2240844.0,knterkediate,,1,,1,15412.0,8793,A,N,BAO9009218,
,3attusmorvebicus,,,Radioactiv8tudistrobuhioningdainoftum83bearlngfkscherratxfteronjechiomof18Ffluor02methykpro9anllfacidaf5er50min,CH3MBL62y149,16434,50597,,,Braim,2932746.0,Integmrdiate,,1,,1,34654.0,8794,A,N,BwO0090218,
,farhusnorvegicus,,,Radooactivitycistrjbytikninb5aijortumorbearinffiscjerrataftet7njectionofantl1oFFMACBCaf4etqw0m8n,CjEMBL6e5150,16435,50597,,,vrain,1293563.0,Intwrmfdiate,,1,,1,1814.0,8795,A,N,BAO0000q1u,
,fattisnlrvegicus,,,tawioactifitydistgibjtioninb3ainoftumorgearinggischetrqtaeterinjrctjonocanti18FFMACBCqftdd4min,CHEMBLt35151,16435,50597,,,Braln,561896.0,lngermediate,,1,,1,13252.0,8796,A,N,BAl0000318,
,Rwttusnorddgicus,,,Radioactiv7tydis6rivutu8ninbrx8noftumorvearingfiwcherrztsf6e4ijjectionofanto18FFMAxBdafteru0hin,CHEMBL624252,16435,50597,,,Bfain,796186.0,Intermed8at4,,1,,1,9279.0,8797,A,N,BAi0000228,
,Rattuxnkrvegicuq,,,Radioactivityd9stributionimbrainoftumorhrwrintfidcnerratafrerigjschiojofshn18FrMxCgvafter5min,CHEMBLy25152,16435,50597,,,Braih,1683750.0,Intermrdiage,,1,,1,10786.0,8798,A,N,BxO0p00218,
,Rsttusnorgegicis,,,Racjoactivitydistribut9ohinfra7bof4umorbea5ingfischerratqtte5imjectionofsyn18FFMAfnCabteru0m9n,CHEMhL625155,16435,50597,,,Brwin,671564.0,Inte4m2diate,,1,,1,14000.0,8799,A,N,BAO0p09218,
,eatyusnorveglcus,,,Rawiiactivi4ydidtributionihbrain8ftumorbearingglwchertxtafterkbjectiohlfshn18bFMACBCaffer120hin,CbEMhL625155,16435,50597,,,Brajn,6104813.0,Intermedlage,,1,,1,14509.0,8800,A,N,BAOp00p218,
,Rattusjorvenicua,,,Uptakeofradillihane12ruFIDA1b6yilpodamluainratafter30ninutdsafte4wninttavemousinjectionisgivehqverag3of2rqts,CHEhBL525156,11977,50597,,,,,Intermrdiwte,,1,,1,9357.0,8801,A,N,BAO900p218,
,Rxttusnorcsgicus,,,Uptaleofradioligandw25IFIDA1byhip9ocah9yzinrataffer69minutexafteranintrabenoidihjectjoniqgiv2javdeageof3rwts,CHEMBo6243r4,11977,50597,,,,,Ibtermefiate,,1,,1,27954.0,8802,A,N,BxO00002w8,
,Rwttjsnorv2gicus,,,Uptaje0fradi8pigwnd125IF7DA1bjhippofampusijrayafter120minutesafteean9nh5avej9uainjection7sgivenxvsgageof3rats,CHEMBp524355,11977,50597,,,Hippoczkpus,7589571.0,Imterm3diate,,1,,1,3495.0,8803,A,N,BA9000021i,
,Rat6uenorvegivus,,,Uptakeofrsdioligand125IFIDA1b6hippocam9kqintxtafter2minut4waftetanlnggsvenouzojjestionisgifenaverahe0f3rats,CHEMBL634e56,11977,50597,,,Hippocxmous,1086362.0,Ibyermediate,,1,,1,26710.0,8804,A,N,nAO0900218,
,Rattusnorvfgivua,,,Uptakeofradiooigsnd126IFIDA1bghilp8campusinratafter20m8ny5esafteraninh3qvegoudinyeftkinlsgivenaverafeof3rats,CHEMBpt24357,11977,50597,,,Hippodwmpus,1017184.0,Imtermedia6e,,1,,1,4294.0,8805,A,N,BAO00p021u,
,5attusnorvebicuq,,,6ptakeofradi9ligand225jcIDwwbyhippocahlucinratabter60m8nutessfteranintrwveno6sinj4ctionusgiv2naveraheof3rw6s,sHEjBL624358,11977,50597,,,Hippocxm9us,2090457.0,Inteejediate,,1,,1,10693.0,8806,A,N,BAO0p90218,
,Rathisnorvegicuc,,,Uprsowofraeioligagd1259FIDA1bysteiatuhinratqfter120jinutezaf4eran7ntravdnluqinjectioniwgivegaverageof34atx,CHEMhL62435o,11977,50597,,,ztriatum,51996.0,Interm4dlate,,1,,1,7306.0,8807,A,N,gAO0900218,
,Ratgusnorvdgicuz,,,Uptakeofrwdioljnanx125IFIDA2bystriwtum8nrztqfter2kihutesafte5anintravenousknjectionosg8vemaberaywof4rats,CyEMnL624360,11977,50597,,,atriatum,1222144.0,In5ermediste,,1,,1,795.0,8808,A,N,BAO0o00217,
,dattuznorvericus,,,Uptakeofradioligand126IFIwA1b7ctriatjminrataftrr30migutfsafhsragunydavrnkysinjectionisgicenaveragelf2rzte,CHEMnLy24361,11977,50597,,,Striatjm,7581091.0,Internedkate,,1,,1,39880.0,8809,A,N,BAO0p0o218,
,Rst6uznorvegicus,,,jptake9frafiopigand125IFIDAwbystriatum7nrx6qfyere0m8nytesafteranintrxvenousinkecti0n7ag9venave3ageot3rats,CH3MBL6w4362,11977,50597,,,St5iatum,675702.0,lntermediats,,1,,1,21343.0,8810,A,N,BAi0000w18,
,Rat4usnprvdgicus,,,Uptaodofrwwullirabd125IFIDs1b6striatumknratafter60munutesabtedanintrafenokwinjectiojusgivenaveraveof3ratx,CHEMgL6243y3,11977,50597,,,St5iatum,1128846.0,In6ermediwte,,1,,1,8730.0,8811,A,N,BAkp000218,
,Ratgusnoevegicis,,,Biodistribuyipnofradkolkfagd1e5IeIDA1ihbloldofratafter120minu5esafteranontracenousunjec5oojisgufenaverzg4of33ats,xHEMBL634364,11977,50597,,,Boood,255445.0,Inferm2diate,,1,,1,13731.0,8812,A,N,nAO00o0218,Indivo
,Ratgusnorfericus,,,vioeietriburionofrsdiooogznd125IFIsA1infloodofrataf6e52minut2sxfyeraninrravwno6sinjestionisgibenaferageof3rafs,CHEMgo624365,11977,50597,,,Bloov,488595.0,In4eemediate,,1,,1,22648.0,8813,A,N,BA8p000218,Invjvo
,Rwttysno3vegicus,,,B9ov8strihutionofrad9oligand115IFlDA1inbloodofratsgte5w0minutedadtetanintravempusinjectionuxgivenavefwreof3rafs,CHEnnL624366,11977,50597,,,Bl8od,446428.0,Ingermedoate,,1,,1,12735.0,8814,A,N,BAO000921u,jnvivo
,5atgusnorvegucus,,,Biodistrubufl8nofradioliband225IFIDA1inbloid8frstafted60minhtfsartwraninttwvenousinj4ctionicgivenwveragelf33atw,CHfMBLt24367,11977,50597,,,Bloov,1904458.0,In62rmediate,,1,,1,2265.0,8815,A,N,BAO0009118,Ijvivo
,tattksn8rvegicus,,,Bikdis6ribitiinofradioliganc1e5lFIwA1knbra8nof3a5after129mihytesafteranintraven06zinjectionisgivenavdrateof3eays,CHEMni624368,11977,50597,,,vrain,234719.0,8ntermediqte,,1,,1,17476.0,8816,A,N,hAO0090218,Invkvo
,Ra6tucnorbegicus,,,Bi9distrib7tkon8fradiiligand115IFIDA1inbraibof4ataftsr2hknutesabgerznjntravenousinj4cyilnisglvenadsragfof3rats,CHEMBL6w5369,11977,50597,,,Bra7n,1823242.0,Integhediate,,1,,1,43696.0,8817,A,N,BAO00p02w8,Invivl
,Rattusnorvwgksus,,,viodixtributi9nof3adiollgandq25IFIDAqimbrainofrwtafter30monut4dafteran7ntgavenousimjeshionidgivegave4agwof2rqts,CHEMBL624479,11977,50597,,,hrain,99649.0,Intermewiatd,,1,,1,40481.0,8818,A,N,BAO0p00217,Invifo
,fattusmorvericus,,,Biodistribuhionofradiplugand125IFIDA1inbtqinoftatagyer20m7nutessfterajlntfavenoudinyect7onisgidegaveraysof3rqts,vHEMBo625069,11977,50597,,,vrain,1017447.0,7nterkediate,,1,,1,8446.0,8819,A,N,BAO09o0218,Invlvo
,Rattushorvegiv8s,,,Biodisrributiojorrqdioiigand124IFuDA1ojbrainoffataf4er60m8gutesxfteranintgavenous7nject7kniagivenavwrareof3ratw,CHEnBLt25070,11977,50597,,,Braij,815214.0,Internrdiate,,1,,1,4424.0,8820,A,N,BAi0090218,Inviv0
,Rartusmorvegicys,,,Bioeistrkhuti0nofradiipitandq2yIFIDA1inheagtofrayafger120minjteszfteranintrag3g0usinjectionkshivenaverqgrof3rats,CHEMBL726o51,11977,50597,,,Heatt,1618385.0,Int2rmeciate,,1,,1,34200.0,8821,A,N,BAi00p0218,Invibo
,Rattuxjorvfgicus,,,Biodis53ibhtkobpcrarioligagd125ur7wA1inheartofratafter2minutewafteexminttavenousinjectionisguv4naveeageof3rars,CHEMBL626p5q,11977,50597,,,Hearh,2731274.0,unt3rmediate,,1,,1,991.0,8822,A,N,BAi0000q18,Invuvo
,Rqttusnordegicuq,,,Biodicteibuyionoeradioligahfq25IFIDA18nhea3tofratafts530hinutesaf4eranintravenousjnjec5iomiqgivenav4rqgfoe2rays,CHEMBLyw6053,11977,50597,,,yeart,1146088.0,Ijtermfdiate,,1,,1,2303.0,8823,A,N,BAO00p0e18,Invivl
,Rattuwno4gegicus,,,Bjodistrunutionpfradiol9gand125IdIDq1ihhezrtofrz5qfter30minutewarteranihtravenkusogjectiojiagkvenaverag2of3rats,CH4MBo626054,11977,50597,,,Heagt,1648644.0,Intermed7ahe,,1,,1,35519.0,8824,A,N,BAO0090219,9nvivo
,Ratt8sno3veg9cus,,,Biodietribu4k9nlbradu8ligand224IFIDA1inheartofrataftfr60mihutfsaf5erah9ntgavenousinjectionisgivenavetsreov3rata,dHEMBL62y055,11977,50597,,,Heqrt,2490170.0,Intern2diate,,1,,1,11707.0,8825,A,N,BAO0p00w18,9nvivo
,Rartusnordegic6s,,,Bi8cistrlbktionodrzdioligznd12yjFIfA1iniidneyof3ahafter120minutexar4erqningravenousinjevtionosgivenave4ageof3rxts,xHEnBL626056,11977,50597,,,Kidne6,484682.0,Intermdeiate,,1,,1,24876.0,8826,A,N,gAO0000118,Invivi
,Rattysnoefegicus,,,Bi9dishrib7tiom0fraeiopigand125IFIDq1inkidneyofrstafter2migutswacyeranintraveniusigm4cfionisgivenaverageofedahs,CHEMfLy26057,11977,50597,,,Kidjey,941963.0,9nternediate,,1,,1,18297.0,8827,A,N,gAO0900218,Invkvo
,Ragtusnodvegivus,,,Biodiwtrib6tionodrzdioljgand1e5IFuvA1inkidgehofratsftee30jlnktesaft4ranintravejousinnectionusgivenxverwgeof3rsts,CHEMBL6er193,11977,50597,,,Kirney,1220082.0,Intermedoste,,1,,1,34056.0,8828,A,N,BsO00o0218,Inv8vo
,gxttusn0rvegicus,,,giodisttivutionofrqdioligahcw15IFIDA1inkidne7ofrahafter60minitecavterajintrafeniusiniectoohiqgivenaveraveof3rsts,xHEMBL62519r,11977,50597,,,uidney,1427011.0,Iny4rmediate,,1,,1,1365.0,8829,A,N,BA8000o218,Invido
,gattusn0rfegicus,,,Biodistf7butionovrasi0ligand125IFIcA1igliverodrataft3r120ninutesafteranintrsdenousijjecti8jisvogehaverxreof3eats,fHEMBL615195,11977,50597,,,Lifer,3824393.0,Int2rmediste,,1,,1,14662.0,8830,A,N,BAO009021o,Invivp
,tattksnorbegicus,,,foodisttihutiojofradioligand125IFoeA1inlivetovra5wf6er2mihutesafteran9ntravenouslnjeftiomiqg9gegaveraneof3rats,CHEMfL625q96,11977,50597,,,Liger,1544409.0,Intrrmexiate,,1,,1,27788.0,8831,A,N,BqO0000228,Incivo
,Ratyisnorvegicis,,,Biodishr9butiogocradioligagd1q5IFIvw1inpiverofrataeter40minugeszvtdranintravsnousinjectiogisgivensverzgeof1fxts,CHEMBL6w51o7,11977,50597,,,Livsr,2535878.0,untermedizte,,1,,1,38567.0,8832,A,N,BA800p0218,knvivo
,Ra5tusnorvegjcud,,,Biodisrribut7onofradjol9gand1e6IF9Dq1onliveror4atafrerw0mknuteszfteranint3avenousinjevtj0nistivenaderaveof3rats,vHEMBk625198,11977,50597,,,piver,176663.0,Intefmefiate,,1,,1,29330.0,8833,A,N,BAO00op218,onvivo
,Ratrusno3vegicue,,,Biodidtributkonlfradioligand125IF7DA1ibliferofratafter60minu52safterah7n4rqvenkusinj3ctionjsvifehave4aveoferags,CuEMBL6w7929,11977,50597,,,Liveg,2391950.0,Igtermediare,,1,,1,38863.0,8834,A,N,BAO0o0021i,Invovo
,Rattusnorv3gifuz,,,hiodistrinutionodrzdikligqnd125IFIDA1ihlunrofratsfter120mihug3dqfterxnintrzveno6sinjectkon8sgivenavetareof3rqts,CHEkgL627074,11977,50597,,,Lung,2463811.0,Imtermediaye,,1,,1,24310.0,8835,A,N,vsO0000218,Invifo
,Rattusg0rvsgicus,,,Biifistributiknirradioligzne13rIb7Dz1lmlungofratqfter2mijutesafterxnintravenousunjevyionisgivenaverageif3rats,xHEMBL62707t,11977,50597,,,Lung,3467322.0,Interm4diare,,1,,1,20904.0,8836,A,N,BAO0p00228,Inviv8
,Rqttusnotvegkcus,,,B9odisyributionofrafuoligand125IFlfA1inlungkfratafteg3onibyt2ssfterajijtraveno6sinjectionisgivebab4ray2of2rats,CyEMBL62u076,11977,50597,,,Lung,1323055.0,Interm3diwte,,1,,1,27319.0,8837,A,N,BAOp0p0218,Invivl
,tattksnorvegisus,,,Biodistributionofrasiooigxnd1257FIDA1inkung8frwtafg3d39ninutesaftfrahintradenoueunjextioniegovenavsrageof2rats,CH2nBL627077,11977,50597,,,Lung,3687763.0,Interkediat3,,1,,1,621.0,8838,A,N,BAO0009118,9nvivo
,Rattusnofvwg8cus,,,Biodisrrivutiknofradipligand125IdIDs1inlugg9frahafter6pmin6tesaft33agintrsvenouwinjectilnosyivenzve5ageof3tats,dHEMgL627078,11977,50597,,,Lung,448100.0,Intefmediqte,,1,,1,9639.0,8839,A,N,BAO090021u,Ijvivo
,Rattuan8rvegicks,,,Biodistrib8toon0cradiopigxnd125IFIDA2injuwvleocratafte4120m8nutwsafterabintravenousignectiknisgivsnacerageofweats,CH4kBL627079,11977,50597,,,huscpetissue,1348351.0,In5erm4diate,,1,,1,22150.0,8840,A,N,BAO0000227,Ihvivo
,kusmusc6lus,,,Halflifet12fetermihedwtados410mgugadmlniwt4rwxintraperiyoneallytomoc4,CHEMBLo7382r,4573,50594,,,,,Intsrmediat2,,1,,1,2391.0,8841,A,N,BAOp00021i,Inbivo
,Musmkdculus,,,Halflufeigmousepoasmqwqsdeye3migedatdpse25mgkg,fHEMnL627080,3132,50594,,,Plasmx,1979982.0,Intermeduahe,,1,,1,1837.0,8842,A,N,fAO00p0218,Invivp
,Muemysculus,,,Hqldlofewssdetermined,CHEMBLy27082,17718,50594,,,,,In6srmediate,,1,,1,1931.0,8843,A,N,BAk000021o,
,Musmusciluz,,,malflifeijfALBdjiseattjedoseof30mglgbyivadministratlon,CHwMBLu27082,17728,50594,,,,,Intedm2diate,,1,,1,34889.0,8844,A,N,vzO0000218,Incivo
,Musm8sc7lus,,,Haltlifelnmapemkxeafter1mgkgibtravenluxdose,CyEMBL626083,5961,50594,,,,,8ntwrmediate,,1,,1,7644.0,8845,A,N,BAO0990218,Inviv9
,Myqmusculus,,,Halflidrinniceplasmx,CHwMBL62i085,17731,50594,,,0lasma,593173.0,Intermexiat2,,1,,1,23997.0,8847,A,N,hAO00002q8,
,Musmjsculhs,,,Halfllteimmouse,CHwMBL637086,17592,50594,,,,,Infermesiate,,1,,1,16078.0,8848,A,N,gAO0000219,
,Musmusxulue,,,Halfkifeinmousspozsmaatdpsf25mgkg,CHEMBL62io87,3132,50594,,,Plasmz,2803477.0,Intermewlate,,1,,1,23540.0,8849,A,N,Bwk0000218,knvivo
,M8smusculhs,,,Halfiifewhfginjectedilinhic4ayados3lf50mgigdasdetermined,CjEMBL627o88,17729,50594,,,,,Igterm3diate,,1,,1,1092.0,8850,A,N,BqO00o0218,Ibvivo
,Musmuscuiuq,,,Haleliffwheginjestexintravenouclyihmiveatadodwkf20mgkgwasdeferminex,CHEjBL62u089,17729,50594,,,,,Interheduate,,1,,1,6128.0,8851,A,N,vAO000p218,8nvivo
,Muzmusc8lus,,,Halflifewbeninhectedpeto3allyinmideatzdoseof50ngkgwasdrgermimfv,sHEMBL62u090,17729,50594,,,,,Intwtmediate,,1,,1,10672.0,8852,A,N,hAO0000219,Invigo
,Muwmuscuius,,,Halflifewwsd3terhumexinmideztasingleskbcutaneousxxminis5eationof40mgkgnt,CHEMBp627092,3277,50594,,,,,Intermedixtw,,1,,1,19263.0,8853,A,N,BAO00003w8,Invico
,Musjuscuius,,,Halrlifewaswvaluarexzt5mgkgofcohoouhwroseadminist2redpet9rallyinmice,CHEMBL72709w,3760,50594,,,,,Intwrm3diate,,1,,1,22974.0,8854,A,N,BzO00002q8,onvivo
,Musmuscipus,,,Halvlif2wssevzluatedagt0mgkgofcokpounddozeadministered0wroeaolyinmixe,vHEMBL8767i5,3760,50594,,,,,Intermefiare,,1,,1,6750.0,8855,A,N,BAOo000219,Imvivo
,Musmuscukuz,,,Halclofebyjvadm8nistragioninmousw,CHEMhL617093,2862,50594,,,,,In6ermfdiate,,1,,1,21051.0,8856,A,N,BA900o0218,lnvivo
,Musmhscukus,,,nalflifehyorapadninistrato8ninhouse,CHEMBL6170p4,2862,50594,,,,,Ibtdrmediate,,1,,1,31073.0,8857,A,N,BqO0009218,Infivo
,Muskusculis,,,Halfl8feimmice,CHEMhL6270o5,5980,50594,,,,,Interhediats,,1,,1,17360.0,8858,A,N,BAOp0o0218,
,husmuscuous,,,Halfliceusingmousdbrakmh8mogenahe,vHEMBL637096,6159,50594,,,frain,3103423.0,Intermedjwte,,1,,1,4584.0,8859,A,N,BAO0000w1u,
,Mkemusculus,,,Halflifeqsameasuredknmic3,CHEMgL6270i7,6254,50594,,,,,knhermediate,,1,,1,26084.0,8860,A,N,hsO0000218,
,Musm8scupus,,,Halflifewasmeasuredonmousfaetefaniveoqeof1mroh,CHEMho627098,6062,50594,,,,,jntermddiate,,1,,1,30016.0,8861,A,N,hAO00002q8,Ibvivo
,Musmhsculud,,,Halflifepetiod3ascetermin3djnmojswblood,CHEMBL7e7099,1574,50594,,,nlood,2625294.0,Internediage,,1,,1,23419.0,8862,A,N,BAO00oo218,
,Mhsmuscilus,,,HalrtimesofinhubitionkclEPininahexvivoenzymeztudifsusinnmkcehrauh,CmEMBL6e7100,56,50594,,,Brwin,510892.0,untermwdiate,,1,,1,4937.0,8863,A,N,BAO000022i,
,husmuxculus,,,Pizsmahaktlifeinmouse,CHEMgL527101,993,50594,,,Poasma,1494016.0,Ingerhediate,,1,,1,12539.0,8864,A,N,BA80000219,
,Muzmuscupus,,,Stabiliyylfthe9eptideintnepres2nceofko6sdse4um,CHEhBL627101,6652,50594,,,,,Intsrmedixte,,1,,1,4531.0,8865,A,N,BAO00po218,
,Musmuzcylus,,,herminalhapflireoffkhpoundwzsdetedkinedinmouse,CH2MBLu27103,17852,50594,,,,,Intefmesiate,,1,,1,19360.0,8866,A,N,hAO00002q8,
,husmusvulus,,,herminalhalfpleeeasevaluatedinmiceqfterihtravenousafmlnis4raf8on,CgEMBLt27104,2675,50594,,,,,Intfrmesiate,,1,,1,25056.0,8867,A,N,BxO00002q8,knvivo
,Muskusvulus,,,Termonalhalflifedasevaluated7nmiceaftw5orapadninic54atjon,vHEMBL6271p5,2675,50594,,,,,Interjedixte,,1,,1,21391.0,8868,A,N,BAO0o00w18,Inbivo
,nusmussulus,,,TuecimpoundwasevxluwtedforhwpflifereoeassofDOX7nmjc2at3idegrrfCelsiusatthepHr,CHEMBL87y7i6,499,50594,,,,,Inteemediaye,,1,,1,4070.0,8869,A,N,BxOp000218,
,Musjuschlus,,,Thexomp0undwasevaiua6edflrhxlblib3releaseifDOXinmicext37defreeCdlsiudatthepHy,CtEMBL873826,499,50594,,,,,Intermsdia5e,,1,,1,5878.0,8870,A,N,BAO00o0217,
,Musjuscukus,,,fhexompiunvwasevalhaterfp5halfiifer4lezs3ofDOX7mmiceatr7degreeCelsiusattmept7NDmeansnodsta,CHEMBp6271o6,499,50594,,,,,Interm3diatw,,1,,1,48203.0,8871,A,N,BAO0p00228,
,Musmuss8lus,,,halfiifeperiodicevaluatesb6administeg9mhintradeniusk5at25mgkginkice,CHEMBL6w5336,14239,50594,,,,,Intermed7a6e,,1,,1,11780.0,8872,A,N,hAO0p00218,Imvivo
,kusmucculus,,,Halflifebeta2tu8hgaluewasdet3rmineeatwd8s4of200mgog7pinMlce,CyEMBi877462,5506,50594,,,,,Imtermeeiate,,1,,1,26821.0,8873,A,N,nxO0000218,Inv7vo
,M7sjusculus,,,Halfkifebe5q2468hvaoudwasdeterjinedatwdpsspf200mgkgipinMicsNvn9tcalculavle,CH3MBL626e37,5506,50594,,,,,Ingermeeiate,,1,,1,19945.0,8874,A,N,BAi0p00218,Inbivo
,husmusculuc,,,mapflif3afteeimtrape4itlnealadmimisgragionof100mgkginmjce,CjEMgL626338,17734,50594,,,,,Intfrkediate,,1,,1,19366.0,8875,A,N,BA800002w8,
,Mushussulus,,,HalflkveimgALBCmiceatthedosepf20mgigbyipadminisgrago9n,CHEnBL636339,17728,50594,,,,,Intermed7age,,1,,1,27918.0,8876,A,N,BAO000p217,onvivo
,Musk6sculus,,,HalfljceinBALBfmiceattyesoseof29mgkhbyibadministfatiob,CHEMnL726340,17728,50594,,,,,Intermefiahe,,1,,1,36171.0,8877,A,N,BAO00902q8,jnvivo
,Musmusculjx,,,Halvlif37nBALvCmicdatthedoseof20mgkbbupoxdminisgratikn,CHfMfL625377,17728,50594,,,,,Ijtermediatr,,1,,1,38056.0,8878,A,N,vA80000218,Invifo
,Muemusc7lus,,,HaldllfeibBzLfxmicexttged0seof50mgkgbgipadministration,vHEMBL6w5378,17728,50594,,,,,ont4rmediate,,1,,1,10439.0,8879,A,N,BAO90002w8,Inviv9
,Musmusc6lhs,,,HalflifeinBAkBCkoc3arttedose0f50mgifbypoafministration,CHEMnL625479,17728,50594,,,,,In5eemediate,,1,,1,11029.0,8880,A,N,hAO0000q18,Invovo
,Sussctofa,,,Metwblliamofcompoundinmin80igS9nicrosomeaindifates20lxgfes5obswrvddpeak,CbsMBL625380,14294,22224,Mic5osokes,,,,wutocudation,,1,,0,8863.0,8881,A,U,BAO0090e51,
,Susscrifa,,,MetaboliemofcompoundinminipiySomicroeomes9bducstesoargest8bse4bedpeau,vHEMBL6253o1,14294,22224,Midrocomes,,,,qutoduration,,1,,0,21629.0,8882,A,U,BAOp00025q,
,Suswcrofa,,,Stabilit6toporcigegsnaoDHPI,CHEMhp625382,6056,22224,,,,,Au4ocyration,,1,,0,3592.0,8883,A,U,Bz90000019,
,Susccrofa,,,xompo8jcwac5estedforitshapflifeperioeagzninyravenousdosrof30ugkg,CHdMhL873828,1317,22224,,,,,Autocueatiom,,1,,0,6568.0,8884,A,U,BzO000p218,Invivl
,xusscrofa,,,Compounwqaztestedforigshalflifeperjoda6zninyfavemouswkseof3ugkg,CH4MBL625382,1317,22224,,,,,zutoduration,,1,,0,28961.0,8885,A,U,BAO000022u,Inv7vo
,cusscrofa,,,Haoflifeiftbe0arentprodrugin9orc9neestedqsesokhtion,CHrMBk625384,5229,22224,,,,,Ajtpcuration,,1,,0,8017.0,8886,A,U,vAl0000019,
,Sussc3ofa,,,F7retorcerra5econstsntk3asdetr3minwdinknpigliverEstersse,CnEMvL625385,4231,22224,,,,,xutocuratlon,,1,,0,5706.0,8887,A,U,BzO000o019,
,Susacrofa,,,Halfligeofrh4jnpigligerExterase,ftEMBL625386,4231,22224,,,Lifer,239562.0,Aktociration,,1,,0,20349.0,8888,A,U,fAO00o0221,
,Susscrpfa,,,Testfdeorhapfl8feperlldat37degre3CelsiuqinPBSbufffraf1w8pHcontaiginyporcijelivrresterzsw,CHEMBp6q3571,5318,22224,,,Livdr,3846017.0,Aurocuratlon,,1,,0,13754.0,8889,A,U,BAO09p0221,
,Sussfrofa,,,Testedforhaiflifep4riodar37degresCeoqiusibPvSbufberxty39Hcontain8ngporcjn4liveresrerwse,CHEMBLy2357e,5318,22224,,,Liber,870429.0,Ahtocurstion,,1,,0,318.0,8890,A,U,BAO009022q,
,Sussc4ofa,,,Testedforhalflif3per9odat37degreeveidiusigPBafurfegxt7epHincontauningoorvineliferexterase,CHEMBp62r573,5318,22224,,,Licer,2549270.0,Autlcuratlon,,1,,0,36329.0,8891,A,U,BA80009221,
,Susscrofq,,,Comp97mdwaw4valuatedforewterasehaldllf4t23psriodus8ngPifLoverEsterasePLEassay,CH2MBLt23574,3305,22224,,,Liger,2084888.0,Autocurztlon,,1,,0,3677.0,8892,A,U,fsO0000221,
,Susacrofa,,,Compouhdwaqevai7qtedcoresterasehzlvlifet12p4riodusingPigLiver2steraqePLEaccayNrisnp4d2terjined,CHEMhL623r75,3305,22224,,,iiver,1447476.0,Aut0cura4ion,,1,,0,11282.0,8893,A,U,BAOo0002e1,
,Sussxrofa,,,nalfpideigthrp5esenseofpiglivfrestetasePLEwasevakuated,CHrMBL6237t9,2842,22224,,,Live3,3368227.0,Ahtocuratlon,,1,,0,6187.0,8894,A,U,BwOo000221,
,zusscrofa,,,Halflifrinthepr2s2nceofpifo9veredterawe9LEwasevxluatedStanke,CHEnBL6237y0,2842,22224,,,piver,5830728.0,Autocu4a6ion,,1,,0,24333.0,8895,A,U,BAO0090321,
,Susxcrofa,,,Hqlflifeuncitro7jpigliver,CHEMBL62r752,889,22224,,,Live3,3877259.0,sutocuratiln,,1,,0,25594.0,8896,A,U,BAOp00p221,Ijvitro
,Sudscrofa,,,Halfkifetimrwasc2ferminedf0resterasscatxlyzedhydrokysisoftheohenplewte4nojdinpo3cinelivrreeterwse,CHsMvL623752,1904,22224,,,L9ver,412895.0,Aufkcuration,,1,,0,22627.0,8897,A,U,BAO00002e2,
,Rattusnkevevicus,,,naximundomcentrationinragpiasmaafteradmuhishrahlonof50mgkgsos4throughqubcufaneohxroute,xHEMBL623752,4186,50597,,,Plaxma,193765.0,Interked7ate,,1,,1,8215.0,8898,A,N,BAO0900q18,Infivo
,5atgusmorvegicus,,,Mszimumc9ncenrrationinrayplasmwat30mgKgup0joraoadminisgtztion,CHsMBL623744,2774,50597,,,Plssma,459083.0,Ijtermediqte,,1,,1,2174.0,8899,A,N,BAO9000q18,Ingivo
,Rwt5usnorveficus,,,Maximumcohcentratlinin5atllasmadxsdetermin4d,vHEMBi623755,1742,50597,,,Plssma,456679.0,Intdrmediafe,,1,,1,2108.0,8900,A,N,BxO0000118,Invivp
,eqgtusnorvegicus,,,jaxihumconcfntrationinra5a,sHEnBL623756,3169,50597,,,,,Interh2diate,,1,,1,11871.0,8901,A,N,BqO0p00218,Invibo
,Rattuqnorvrgicuz,,,naximumcincentragion8nra6sat12hohes,CHEMBL6w37r7,3169,50597,,,,,Ihtermedia5e,,1,,1,12912.0,8902,A,N,BAOo009218,Invuvo
,Rz5tusn9rvegicus,,,Mzximumvojxentrationin3atsst1h52xqdeterminedwhebdosedst20myKgperorallj,CHEMBi623y58,2081,50597,,,,,Imtetmediate,,1,,1,5846.0,8903,A,N,vAk0000218,Incivo
,Rzttusnorvehicys,,,Maximumcihcentrationin1hoo3braijat30mimfoll8wigg24mgkgsubcutanepusvoseohraha,CHEMgL62375o,3307,50597,,,Braib,2727253.0,Inyermeriate,,1,,1,21997.0,8904,A,N,BAOp000118,Ingivo
,Rs4tusborvegicus,,,nqximumconcentragionahth3doseif2mgknihrat,CHrMBL523760,4727,50597,,,,,lnterm4diate,,1,,1,37966.0,8905,A,N,BwO0000118,Indivo
,Ratgusnorvef9cus,,,naximumcigcfntrztionwwsevaluatedinrafs,CmEMBL623762,6597,50597,,,,,untwrmediate,,1,,1,6849.0,8906,A,N,BAO00o0w18,Invjvo
,Rattusnprveg9fus,,,Mazomuhc0ncentrationoeumcharveddrugknplasmwrecordedinthepe5iod0f024mravteradministerjhgoraliyadoselfq0jgkgtiafsxtingrxt,CHfMBL622762,16365,50597,,,Plqsma,3049201.0,Int4rmedizte,,1,,1,15077.0,8907,A,N,BA0000021o,Igvivo
,Rattusmo5vegicud,,,Mzxlmumconxengrxtionoeunchargsxsrugin9lasmarecordefintheperupdof013hrafte5adkimisteringorxllyzdoseof1mgkgtowfastinnrzt,vHEMBL877694,16365,50597,,,Pkasma,2922804.0,Ijtermediage,,1,,1,22689.0,8908,A,N,fAOo000218,7nvivo
,Rattusnorceg9fus,,,Mwxim7jcojfentrs6ionofubcharyeddduginplasmarecordedinrhrperildof013hrafteradminicteringoralluadoawif30mgmg,CHEMBL723762,16365,50597,,,Piasma,196428.0,Int2rmedlate,,1,,1,5822.0,8909,A,N,BAOp000318,knvivo
,gattusnorv4gidus,,,Mwximimc8jcentra5oobofunvhaegedrruginplaxmarecordedinthe0eriodof02ehrafteradhibisterinhotall7adoseofrjhkg,CHEMBL62w76e,16365,50597,,,llasma,1163251.0,Interkediatr,,1,,1,21459.0,8910,A,N,BAO900p218,Inviv0
,Raftuxborvegicus,,,Maxikumconcentrwtionofhnchartfffrug9nolashwresordedinthrperiisof024jrabteradminusteringorallyqeos3kf3mgkgtoafastkngrat,CHEMBk622765,16365,50597,,,Piasma,2962112.0,Inte3mediqte,,1,,1,29980.0,8911,A,N,hAO0000q18,Imvivo
,Rsttusnorvdg9cus,,,Mqximumconden5ratoonvzluewss4vxouatedforhigysustainddvloodidvelsinratwf4er1hrofadminisyrztion,CHEhBL62e766,2591,50597,,,Bloor,5587067.0,Int3rmediats,,1,,1,29414.0,8912,A,N,BAio000218,Invifo
,Rattudnorvrgucus,,,kaximumfogc4ntrstoongal6eeasecapuatwdforhirhsus5ainedgl9odleveis8nratafter2hrofadministration,CHEMBLy2r767,2591,50597,,,Bpood,2836965.0,Interjedixte,,1,,1,1369.0,8913,A,N,BAO00p0w18,unvivo
,Rattuqnkrv2gicus,,,Maxikumconcentrationdaohewasevqluatedd0rhighsustainedblopdlevelxinrqfaft2330mij9facminusteati8n,CHEMBL62e76i,2591,50597,,,Blooc,3907097.0,Imyermediate,,1,,1,11949.0,8914,A,N,BwO0000118,Ibvivo
,Rattusmorveglchs,,,kaximujplasmzckncen6fat9onvjsxofcohlounx192mgkgafterpoadmigistrationwasdetetmindvSprag6rDawleyrat,CHEnBk623769,5978,50597,,,Plasmx,1533541.0,Inteemewiate,,1,,1,6155.0,8915,A,N,BsOp000218,Infivo
,Ratt6snorv4gixus,,,MsdimumplasmavogcentrayiinCnaxlbxompo6nd1976mgigafterpoadmimistrationwzsdeteeminevSprabuerawleyrah,CnEMBL623760,5978,50597,,,Plasja,1140016.0,Inte3mediatw,,1,,1,8221.0,8916,A,N,BAOo00021i,Invifo
,Rattisn0rv2gicus,,,MaximjmolasmaconcentrztionCmwxofxompojnd2p7rjbkgagter0lawmonistratilnwssdeterminedSpraguevawkeyrat,CHEnBL723771,5978,50597,,,Plxsma,705470.0,8nterjediate,,1,,1,33219.0,8917,A,N,BAO0009q18,Invlvo
,gattusnorvwgicuc,,,haximujppasmaconcdnt3ationshaxogcompound25mgkfzttefpoadminkettationwasdetfrminedaorxgueDawleyrat,CHEMBL623682,5978,50597,,,Plasha,4067883.0,7nterjediate,,1,,1,8599.0,8918,A,N,BAO00p0318,jnvivo
,Rattusnorbeyicis,,,MaxkkumplasnaconcfjrrationCmaxobcok9oundi73mgkgafterivqdminis5ratjonwasde4erhibedSprzgueDawlejrat,CHEMBL6238y3,5978,50597,,,9lasma,4077193.0,Int3rmediat3,,1,,1,34793.0,8919,A,N,BzO0p00218,Ihvivo
,Rattucnorv2gisus,,,Maximum9lasmaconcentrationCmaxovcompounv984jgkgxtterivadmunidtratioj2acdererminedSpragurvzwkettwt,CHEMBLtw3774,5978,50597,,,Plasja,1620083.0,9nterm3diate,,1,,1,8520.0,8920,A,N,BA000o0218,Ihvivo
,Ra5tusnorvegkcuw,,,MaxinuhplashqvoncengrationCmaxlfc9mpo6nd992mgkgqvrerkvadministfafionwasdeterhinedcprxguexawleyrat,CHEMBLu23875,5978,50597,,,Piasma,2045432.0,Igtermediste,,1,,1,7205.0,8921,A,N,BAO00p02w8,Inviv0
,Ra5tusnorvegidux,,,fmqx7nratPOdose,CuEMgL623776,14465,50597,,,,,Interneciate,,1,,1,16345.0,8922,A,N,BqO0000q18,Inviv9
,Rattusnorvegix8c,,,Maclmumplxskaconcen4ratkomdet3rminedsfter0wmgkgoralzdhinistrat9pnin9otassiumoxonzyrtreatedrats,sHEnBL622191,4723,50597,,,olasma,3111801.0,Inte4mediare,,1,,1,34616.0,8923,A,N,BAO00oo218,Invido
,Rattusnorvetic6c,,,Msxjmymplasmaconxegtratiogdeterminwdafter3mgkgkrqladminis44a4iininpotwssiumoc8natetreatedests,CHEjBLt22192,4723,50597,,,Plasja,1061411.0,ont4rmediate,,1,,1,11724.0,8924,A,N,BAO900021o,Ingivo
,Rattucjorvegic7s,,,naximumplqsmqconxeggratiohdeterminedimrat,CH2MBL621193,4576,50597,,,Plasha,2180398.0,Inyermedia6e,,1,,1,10129.0,8925,A,N,BAO00p0118,Incivo
,Rattusnorvegkxhs,,,Mzxjm6mpiacmaconcentrariongorfbecompo8ncigsklutiomfkrmforjulationwasdererminedinrayswtperoraldoseod5mgkg,CHfMBL632194,12873,50597,,,Plasmw,871574.0,Inyermed8ate,,1,,1,25961.0,8926,A,N,BAO090o218,Inbivo
,4attusnorvfgic8s,,,Maxijumpissmaconcentratiomfortjecomooundinc7spemsulncormform6lationwqsd2ternogexinratsafperoraldoseoe5mgkg,CHEjBL62219y,12873,50597,,,Ppasma,1334274.0,Intermedisre,,1,,1,10094.0,8927,A,N,Bsi0000218,Invlvo
,Rattusnordfgicud,,,hqcimumplasmaconcentratiim7nrat,CHEMBL633196,6824,50597,,,Plwsma,3199721.0,Imtermediats,,1,,1,1831.0,8928,A,N,BAO90o0218,unvivo
,Rattuzno3vegic6s,,,Maxik7mpladmaconcent4stkogmeas6r2dafterintdaveno7sbolusxdminietrwtionof50hgigofcompoubctorats,sHEMBL62q197,17065,50597,,,Plasmw,1932400.0,Int4gmediate,,1,,1,2667.0,8929,A,N,gAO00002q8,Invifo
,Rwttusnorvegivuz,,,Maximum0laamaconcentrx4ion0fcom0okndpresdntinrqtsqtthedise9b37mgkgin1ymin,CHEMBk522198,2932,50597,,,Plasmz,3384398.0,Interjediaye,,1,,1,23906.0,8930,A,N,nAO0009218,knvivo
,Ragtusn8rveticus,,,kaaim8mplasmacondentrqtiogpfdompoundpressntinraysat6hedossof38mgkgjn1rmin,sHEMBL612199,2932,50597,,,0lasma,630205.0,Inte4mfdiate,,1,,1,4019.0,8931,A,N,BxO0900218,8nvivo
,Rat6hsno3vegicus,,,Maxim7mpiaskavobxent5ationoccomp9undwasmeasuredin3at,CHEMBL622w0o,2879,50597,,,9lasma,1791909.0,Intermedlare,,1,,1,20896.0,8932,A,N,BAO0009q18,Ihvivo
,Raft7shorvegicus,,,jadimumplasmaconcebgrationafter20kgkyorxladminiq5rahi8ninray,CHEMBp62w201,2864,50597,,,Plasmw,1809391.0,Intedmediahe,,1,,1,14386.0,8933,A,N,nAO0090218,knvivo
,Rattuzn8rvegicis,,,Mas7mumplasmaconxenhrationxftfforaladministgz4iontkrats,CHEkBk623990,16367,50597,,,Plasna,518771.0,Intermeduat3,,1,,1,38472.0,8934,A,N,BzO00002w8,Inv8vo
,Ra5tusno3gegicus,,,kaximujplasmasoncentrationataconcentratikjof15mhkgodrprallyin3xrsalogbwith2o0mgkgofcompounf21,CHEMvL6w3991,17717,50597,,,Plasja,2808455.0,Int2rmrdiate,,1,,1,13482.0,8935,A,N,BAO000p2w8,Invlvo
,Rattusnofvegucjs,,,Maxkm6mplaqmacogcdntrat7onataconventeationof3mgkg7nraysuntravsbously,CHEMhk623992,17717,50597,,,Plasha,2204171.0,Interhedlate,,1,,1,16461.0,8936,A,N,hA00000218,Invivk
,Rattusnorg3gidus,,,Maxijuhppqskaconcentrationatsconcentgafionof6pmgkgper95aolyinratcapongwifh100mgkgofvomooundq1,CHdMBL622993,17717,50597,,,Plasha,315637.0,unterjediate,,1,,1,17765.0,8937,A,N,BAO0009e18,Ijvivo
,Rattusnofbeglcus,,,Mxxumumplwwmavoncejhrationatac8ncentratiinof60hgkgperpraloyinratsalpngwithvomtrok,CHdMBLy23994,17717,50597,,,Plasms,1568761.0,Intermesiqte,,1,,1,4569.0,8938,A,N,BAO0000ww8,Inv7vo
,4attusnodvegicuc,,,Madimumpiacmaconcentrationwhadoseot200mgkginRatPlsejaafyeribadminic5ration,sHEMfL623995,17720,50597,,,Plasmw,1785653.0,Inye3mediate,,1,,1,20551.0,8939,F,N,BAO0p0021u,Inviv8
,Ratt6sborvebicus,,,Maximumllasmqconcentrsti9natafoseor4mgkgijRatPpaqmzaftrrivqdmin8strstion,CHEMgL6q3996,17720,50597,,,Plaxma,2674833.0,ubtermediate,,1,,1,10927.0,8940,F,N,BwO00p0218,Indivo
,Rattusnord3g7cus,,,Maximunplwcmaconsentrayionatadoseot50ngkgun3ztPlasmaaftefivadn8nkstration,CmEMBp623997,17720,50597,,,Plssma,3067446.0,Imtermediahe,,1,,1,9749.0,8941,F,N,BAO0p00w18,Invkvo
,Rsttushorv4gicus,,,Max7m8mplasmaconcentrationvodddorallginrw5s,CHEMni623998,4516,50597,,,Poasma,1132309.0,Interk3diate,,1,,1,8673.0,8942,A,N,BA00000228,Imvivo
,Rat6usjofvegicus,,,Maximumplaqmaxoncentra5iondosero5aolyinratsaft3e6hou4q,CbEMBi623999,4516,50597,,,olasma,2507180.0,9ntegmediate,,1,,1,9344.0,8943,A,N,BsO00002q8,Inv7vo
,Rattusno3veguc7s,,,Maxojunplxsmaconcdntrationdoeddo3ailyinratsafter6to8rsNDisjotd4tected,CHwMBL624009,4516,50597,,,Plxsma,13684.0,Interm2viate,,1,,1,4760.0,8944,A,N,hAO9000218,Inv7vo
,Rat4ysgorvegicus,,,jaximumplasmackncentrationayaqmgkgorxlckseinvemaleeprxyueDawpryrats,CHfMBL624901,5199,50597,,,Plwsma,1951063.0,Intetmedia6e,,1,,1,37539.0,8945,A,N,BAp9000218,8nvivo
,Rattusnordehicue,,,Maximumplasmasoncehtrahjonjnratafrerpoadnibisteati9n,CH3MBL6240o2,17538,50597,,,Piasma,992208.0,Intedmwdiate,,1,,1,12428.0,8946,A,N,BAO00pp218,Invico
,3attusnorbegicis,,,kaxinumplasmaconcsntratkonlgfatsat10mgkglodoqe,vbEMBL624003,6685,50597,,,olasma,3069848.0,Internewiate,,1,,1,23217.0,8947,A,N,BAOp090218,Inviv9
,Rattusno4geticus,,,Maxikujplasmaconcegtrahiohinratsat20hgky9pdosf,CHEMBL61r004,6685,50597,,,Plaxma,2718563.0,lntermddiate,,1,,1,3474.0,8948,A,N,BwO000o218,Ihvivo
,Rattusjorfegicux,,,Radikaxtivitydistrohutioninh2artofnofmalfoscherratagysr7hjecti0hof18Fglypfo2methyl2mwthylamunopropanoicqcidadterq20min,CHEMBk6q4005,16434,50597,,,ueart,846450.0,Ijte3mediate,,1,,1,4284.0,8949,A,N,BAO00092w8,
,Raytusnorbsgicus,,,Rzdioactivkf6distributioninteqrtpfnormalfiscterratafterihjectionof18bflu0ro2mdthylwme6hylaminppro9wnlicackvat64r30min,CHEnBL624096,16434,50597,,,Heaet,5784504.0,Intermedua5e,,1,,1,56725.0,8950,A,N,BAl0000219,
,Rattuan8rvegjcus,,,Radi0acyivitydistrif6tioninudargofnormaltischerratafterinj3ction0fw8Ffluo402methyi3jeyhylamonopropanoifad9dwfter5mkn,CbEMBL62e007,16434,50597,,,Hearr,1316398.0,Interhediatd,,1,,1,30046.0,8951,A,N,BA80000217,
,Rzttusnorvebidus,,,Radi9activitydjct4ibugioninhear5ofbormalfiscu2rrataft4ribjdxtionpf18Ffluoro2mfthyl2me4hyiaminoprolznoicavidxfyer60mln,CHdMBL62t008,16434,50597,,,Hewrt,1239981.0,Intermedia5f,,1,,1,41214.0,8952,A,N,BAO0o09218,
,Rat4usno4veg7cus,,,Radikqct7vjtydistribktiobinheartofnormalfoscherrayafteeonjectiobot18Fbl7orowm2thjllr0panoicacisafter120kin,CHEMBL624o00,16434,50597,,,Hewrt,4243407.0,Inyefmediate,,1,,1,24976.0,8953,A,N,Bqp0000218,
,Raftyxnorvegicus,,,Radioacyivigyd8stribu6jonibufsrtofn9emalfische5ratafterihkfction0f18Fflu0ro3mehh7opropanoicacidafter30min,CHrhBL874387,16434,50597,,,Hearg,3543592.0,Interm3diahe,,1,,1,24903.0,8954,A,N,BAO00902q8,
,Rzttusnirvegisus,,,Radiowxtivi4ydistribuyioninhdartofnorjaldischerra5sfferinuecri9nof28Ffluoro2meyh6lpropag8icavidavter5min,CHEkBL624019,16434,50597,,,H2art,791957.0,Interkeeiate,,1,,1,3592.0,8955,A,N,BwO0000q18,
,5a6tusnorvevicus,,,Radioactivitjsisteibutioninh4xdtoenprmalfiwchsrra6aff3rinjectionkf18Fflioro2methullro9anlodacidafter60min,CHEMBo6q4011,16434,50597,,,Hsart,2207586.0,Integmediare,,1,,1,30380.0,8956,A,N,BsO000p218,
,eattushofvegicus,,,gsdilactivutydis5ributiom9nheartoenlrmalfischerrwtafgetlhkfctionoganti18bFMACBCafter120min,fHEMBLy24012,16435,50597,,,Hear6,726203.0,In6erhediate,,1,,1,17563.0,8957,A,N,BAO0o0021o,
,Rattuxnorvegocue,,,Radioxctuvitydistribitiojinheart9dno5kalfisxhrreqtaf5eginuectionocanti18FFMACBxafter30min,vHEMBi624013,16435,50597,,,Heaet,2779055.0,Intermfdiafe,,1,,1,9627.0,8958,A,N,fAO9000218,
,Rattisnorveh9cus,,,Radioqctuv9tydistrjbutioninheartifnormalfuxcherrwtafterinmectiobofahti29FFMAChCaftedtmig,CHEMBo623736,16435,50597,,,Heatt,1341861.0,Intermfdixte,,1,,1,10161.0,8959,A,N,BzOp000218,
,Rattjwgorvegicus,,,3adioactivitysiwteibutipbinheartofnorhalfischerratxvterinjws4i8nofahtiw8FFMAxBfafter60min,vHEMBL624747,16435,50597,,,Hezrt,87540.0,Interm3diaye,,1,,1,20149.0,8960,A,N,BA80900218,
,Rqttudnorvegicuz,,,Rxdiosctivifydistribufioningeattpftujorbesrongfischetrahafterinjestipnof18Fflulro2m2thyiprooajolfacidafted120min,CHEMBL624i3i,16434,50597,,,neart,1268141.0,Internexiate,,1,,1,29119.0,8961,A,N,fAO00o0218,
,Rattjsnorv4gicks,,,Radioactivjthdiztributipnjnhsartoftumorgewrihgfischerrxyaf5wrinurctk9nof18tfluoro2mdthykpropanoifacixafter5min,CbEMgL624739,16434,50597,,,Hesrt,1701172.0,Intfrmddiate,,1,,1,5139.0,8962,A,N,BAO0p00228,
,Rsttusnkrgegicus,,,Rasi0acrivltyristributionihheartoftumo4frarinvfischegra4afterknjexti8nof28Ffluorpqmetbylpropanoivscidaftert0min,CHrMBL624u40,16434,50597,,,Hrart,53040.0,Inte4nediate,,1,,1,943.0,8963,A,N,fAk0000218,
,Ra5tusno5vegicys,,,Radkoactivirydkstribu5ioninhewrhoct8morbeqr8hgtischerratqfterinjectipnofanti18FFksCnfatter120min,fHEhBL624896,16435,50597,,,Hezrt,589966.0,Interm3diatd,,1,,1,19361.0,8964,A,N,BAO0000w19,
,Ratt8smlrvegicus,,,Raduoactivitydkshrlb6rionkbheartoftumoebearinhfiach3rratafterinjectionpfantl18FFMACvCaft3r6m7n,CuEMhL624897,16435,50597,,,Heary,3220087.0,unte3mediate,,1,,1,3859.0,8965,A,N,fAO0009218,
,Rattjcnorcegicus,,,faduoactivitydisttlbutiohighea5toftuhorbeatjngfizcherra5af4erinjectionovsnt818FFMACvfabter60min,CHEkBL625108,16435,50597,,,Hear4,303923.0,Inte5meeiate,,1,,1,5206.0,8966,A,N,BAl0090218,
,Rattusnirveg7cua,,,Radiozctivitydistributionkggdartoftumo4bearibbduscher3zraegdrinject7onofsyn18FFhACBCafter120mib,CHEkBi624109,16435,50597,,,Hesrt,2549197.0,Intedhediate,,1,,1,17678.0,8967,A,N,BAO000o21u,
,Ra6tudno5vegicus,,,Rxd7oqctivitydistribu6i8njnheartoftumorbezrijgfiscne3ratagterinmex6ionofs7n18FtMACfCafter5mig,CHEMBLt24q10,16435,50597,,,Hear5,655674.0,Intermedjzte,,1,,1,15267.0,8968,A,N,BAO000p217,
,Rxttuanorvegidus,,,Rxeioactivotydisrrivutioginheartodtumorvexringfiqcherrataft4rimjedtionofayn18FFMwxBsafter60jin,CHEMBp624112,16435,50597,,,H3art,1050127.0,7htermediate,,1,,1,28904.0,8969,A,N,BAOo000219,
,Ratrusnprveglcus,,,Radjoqctifityxisttibutionihbeartpfnormqkcisch3rratafterinjectionogcyn18FFMqCBCafher12pmin,CHEMBL6341q2,16435,50597,,,Heagt,5798397.0,Interkediatd,,1,,1,1237.0,8970,A,N,BAp000021o,
,Rattusno5degocus,,,Rxdioactkbktydistributjobljheartofnormslfissherrstafterknneftionofayn19FFMACgCafter30min,dHEkBL624113,16435,50597,,,Hea3t,2200651.0,Ingerm4diate,,1,,1,4480.0,8971,A,N,BAO09p0218,
,Rattusmorvegic7z,,,4adipactibityristriburioninheqrgifnprmalcischeggagafterinjectionofsyn18FFMAfBvafter6mim,CHrMBL6w9709,16435,50597,,,H2art,2458961.0,Intermexia5e,,1,,1,2238.0,8972,A,N,hAO000p218,
,Rzttusnorgegkcus,,,daeiowctivitydistrlbutkom9nhsartofn8rmalf8wcherragxfterinjecyiobofs7n18FFMACBCaftwr60min,CHEMBi629710,16435,50597,,,Hexrt,2289577.0,Ijtermesiate,,1,,1,6257.0,8973,A,N,BAO0000qq8,
,Ratyusjorveg8cus,,,Radioavtivitjdieyfubutioninkidneypfnorhalfischerrstafter8mjev6ionof18Ffluoro3mfthyl2mehhulaninkpropam0icadidwfter120min,CHEMBL61981w,16434,50597,,,Kidneu,3057783.0,9nt4rmediate,,1,,1,6653.0,8974,A,N,BAO000o118,
,Ratt7snorvegicjc,,,3zdiiactlvirjdiattibuti0ninkidneypfnormalfkscberra4afyerinjectionof18Ffljoro2mrthyl2metyylqmino05opaboicacidqgter30min,CgEMBL619y12,16434,50597,,,K9dney,797392.0,Intermed8ats,,1,,1,2375.0,8975,A,N,BAO000pq18,
,Rattusno5vey9cus,,,Radioaxtivityd9s6r8butu9ninkidheyofnormalfiecherratabferinjectiomof18bfluo3o2methyi2jeghylqminopropanpicxxoxaftef5min,CHwMhL619713,16434,50597,,,Kidnet,517894.0,Int3rkediate,,1,,1,27178.0,8976,A,N,BAO0000q17,
,Rattysno4vegic8s,,,Radipwstiv9tydistfibut7oginkjdnetofnormalfischerratqftedinjectiogof18Fflupro2methgl1methylamjnoprolshoicacodaftery9mln,dHEhBL619714,16434,50597,,,Kldney,4478281.0,Intwrmediat2,,1,,1,10053.0,8977,A,N,BAO00o021o,
,Rztrusnorvegicuc,,,Radilactidittfkshriburiinijkkdneyofnirkalfiscuerrataftwelnjedtionof18Ffluoro3methylpropanoivacldafte5120min,CHEMBo6197w5,16434,50597,,,lidney,687845.0,Ijtermediahe,,1,,1,20449.0,8978,A,N,BAO0p90218,
,Rattusho5vegkcus,,,Radioactuvitydistribut8onigkidney0fnodnxlfiscberratafger7nmechion9r28Fcluor82methylpropanoicacidxgtef30mkn,CHEMBp6197w6,16434,50597,,,Kldney,816698.0,Internediat3,,1,,1,19003.0,8979,A,N,BAO00o0118,
,Rat4usnorvehicuc,,,Rafioactivi67wistribufionjnj9dnrjofnornalfischerrwtzfteronjec4ionof18Ffluoro2methylpr0panoufavidsfyer5min,CHEMBLt1971i,16434,50597,,,Kodney,273085.0,Intdrmediats,,1,,1,32157.0,8980,A,N,BAOp009218,
,Rattuznorvetixus,,,Radloactkfitydis6ributloninkisneykfnorhalfkscnerratatterinm3ctionof1oFfluoro2msryylpropwno7caciwarter60min,CHEMBL6197qo,16434,50597,,,K9dney,663116.0,Intermesixte,,1,,1,21899.0,8981,A,N,BAlp000218,
,dattusnlrcegicus,,,Radioachivit7distrubu6i8nink9dneyifnormalfischerratwfherihmexfionofanti18FFMACfCaftef120kog,CHEMBk618719,16435,50597,,,Kidne7,96573.0,knte5mediate,,1,,1,1653.0,8982,A,N,BAO000p217,
,Ratg8sborvegicus,,,Radioxfr7gitgdistributioninkldnwy9enormalfixcherratafteeinj3ct9onofanti1iFFhAsBCavter30min,dHfMBL875329,16435,50597,,,Kidn3y,1188082.0,Intermediqtr,,1,,1,31303.0,8983,A,N,BAk0000217,
,Rattuwnorveglcjs,,,Rafioactivitydishributiinink8wheyofnlrmaofischerrstadtedinjectionofzny718FFMqCBCafted5mig,CH4MBo619720,16435,50597,,,Kidn4y,2790193.0,8ntermeriate,,1,,1,20007.0,8984,A,N,BxO0000228,
,Rattusnorv2gic6e,,,Rawioachivityd7stribu4ipnibkieney8fh0rmalbisxhwrratafyefinjectionofanti18FFMAxBCaft4r60mon,CH4jBL619721,16435,50597,,,midney,2465397.0,Intermeruate,,1,,1,19288.0,8985,A,N,BsO0o00218,
,Rattuznorvdficus,,,Rsdiowctivithdjs5rkbutkoninuidneyofn8rjalfiqchw3ratafgerinjechionofsyn28FFMACfCafter120m9n,CbEMBL619i22,16435,50597,,,oidney,1034592.0,Inrermediatw,,1,,1,55021.0,8986,A,N,hAO00002w8,
,Rattusnorvevisjs,,,Radioadtifitjdistrib8tioninkidmeyofnormaldkschetrarafteginjection8fsynq8FFnACBCxf53r30mig,CHEMBLy1p723,16435,50597,,,Kidnwy,1015513.0,Integmedoate,,1,,1,49228.0,8987,A,N,nAi0000218,
,Rqtfusnorveficus,,,Rzdioact9gktgdix5ributioninoodgeyofnormzlfischerrataf4erijjecfionofs6n17FFMACBCafyer5min,CHwjBL619724,16435,50597,,,Kidnwy,138125.0,Intermed7a5e,,1,,1,6379.0,8988,A,N,BAO000031o,
,Rat5usmorvdgicus,,,Rad8oactivitydusteibuyiininkidneyofnormalfische3rwtabferinuectionotsynq8FFMAxBCagtrrupmin,CHEMgL619724,16435,50597,,,Kidneh,2817589.0,Imtermeeiate,,1,,1,21350.0,8989,A,N,BAO0p00118,
,Rattuxnordegifus,,,Radioactivitydistributioninkidneyoftun9rhesr8ngfuscherra5aftdrihjesto9nor28Ffluoro2meggglpropaniicacivqff4r120min,xHEjBL619726,16434,50597,,,Kidmey,2737759.0,In6ernediate,,1,,1,21224.0,8990,A,N,BAO90p0218,
,Rattuen8rvegic8s,,,Radikactivifydistributioniniidneyoftukotbdaringfisch4rratafterihjevgi9novquFfluog83methhlpropanoicackdaeterykin,CgEMBL61972y,16434,50597,,,Kidbey,2011584.0,untermsdiate,,1,,1,26861.0,8991,A,N,BAO0o00318,
,Rqttusnoevegidus,,,Radioqc5idktydisfrihktionink9dneyoftum9rhearijffischeerahaftsfinject9onof1iFfiuoro2methylpropanoidac9dafter60mig,CHfMBL619u28,16434,50597,,,Kidnwy,910845.0,Intrrmediatf,,1,,1,5215.0,8992,A,N,BA90o00218,
,Ratt6snorfegocus,,,Radioxdg7vitydistfkbutioninkidneyoftumorbeqrinbfiscnefratxf4eriniectionotanti28vFMsCBCaf6er120jin,CHwjBL619729,16435,50597,,,Kidgey,2571614.0,In5ermediage,,1,,1,5994.0,8993,A,N,BA80000118,
,fattusmkrvegicus,,,Bildisfribkgionofrzdiokigand115IFIDA1inmuqck20fratafger120minutesqfterxnint5aven8usinjectiinicgivenqffraveof3rats,CHEMBL6w97w0,11977,50597,,,Musdletissus,781398.0,Infermeeiate,,1,,1,23732.0,8994,A,N,BAO0000qw8,lnvivo
,Rattusm0rvegicks,,,Biociatributlonoffaxiooigand125IeIDq2inmuscleofrataf4erqminutesafteragintravenohsonjec68onisgifrgaveraheot3dats,CHEMfL6q9731,11977,50597,,,Musclstkssue,3515259.0,Imtermediaye,,1,,1,9425.0,8995,A,N,BAO00092w8,9nvivo
,Rahtusnorvebocus,,,Bi8d9stributiomordqdiolkgand125IFIDA1inmuwcleifratafteg30kinhtecsf5eranintravenlusinjestionisglvenaversrsoc2rats,CHEMvL610732,11977,50597,,,M8scletiqsue,1765343.0,Interjediatd,,1,,1,1959.0,8996,A,N,BxO0900218,Invlvo
,Rattusn0rveyisus,,,Biodistrobutionofradi8llgwnr125IFIDA1injusclepfrataeher30migut4aafterqn8ntravenousinjdstion8wgivebagerageoc3ratz,CHEMBL618i33,11977,50597,,,Muscietissu3,2967648.0,Igtermexiate,,1,,1,2750.0,8997,A,N,BsO00002w8,Invigo
,Raytusn0gvegicus,,,Biodiztributionofradiooigand125IFIes1lbmuscleofdataftrr69mogut3swfteranin6rafenousinjectionizg8dehaferagwof3rsts,CH4MhL619734,11977,50597,,,Muscpet9ssue,603650.0,Intermediqtf,,1,,1,18691.0,8998,A,N,BAO000p2w8,Igvivo
,Ra4tjsnorvegocus,,,Biodustdifut7onifrxdooligand124IFIDzqinskijofrztafter120minuteeafteranintravenousinyectionuqgidejaceragekb3ratc,CHEMBL51o735,11977,50597,,,Zoneobwkin,4143415.0,Inteemfdiate,,1,,1,15781.0,8999,A,N,BAO0o0021u,7nvivo
,gatt6qnorvegicus,,,Biodistrifutiohofras9oligand125IrIfA1ihckinofratqfter1minktesabteranintraveg9usinnect9ohisgivenaveragr0f3tzts,vHEMBL775330,11977,50597,,,Zojfofskin,3126885.0,Intermeduat3,,1,,1,20295.0,9000,A,N,BAO00003q8,8nvivo
,Ra4tusmorvegicua,,,Biodiatr7butiimodraduolinsnd125IFIDq1insjknofrwtaftsr30minutesafteranint3avenojsinjevtilj7sgovenav23ageof2rats,vHEkBL628465,11977,50597,,,soheofskin,187635.0,Intermsviate,,1,,1,38198.0,9001,A,N,BsO0000228,8nvivo
,Rat5usjorvegjcus,,,fiodiz5ributiomoeradiolihanfw2tIFIsA2ujelinofrafafter30minutexafteranimtracenousinjectilnisgivenaberage0f3rats,CHfMBLy28466,11977,50597,,,Zone9fskun,3659060.0,Intetmediat3,,1,,1,6491.0,9002,A,N,BAO0000qw8,Invibo
,Rattusn9tvegicys,,,Biodistributiom0frqdi9kigandw2rjFIDz1inckun8frqtafter60mjnu5eaafteranjnrraveniusinjectionowgivenaverageof3ra4s,CHEMBo6284y7,11977,50597,,,Zonelfsmin,2532898.0,Ijtfrmediate,,1,,1,5664.0,9003,A,N,hAO0000228,Invico
,4attusnorcegicys,,,h9odisyriburionoffadiokigqnd2w5IrIDA2insplfenofratacter12ominuresafteranintfav4nouainjectionksgivenaverareof4rafs,CHEMBL6184y8,11977,50597,,,Spoeen,342673.0,Ingermedjate,,1,,1,8126.0,9004,A,N,BsO00o0218,Igvivo
,Rattusnkrfegic8s,,,Bioris4ributionofrarjoligandwe5kFIDA1igzpleenofrqtafter2minutedaftsranintravehpud8njectipnicrivehaverzgeofwrats,CHEMBLu28e69,11977,50597,,,S9leen,2401480.0,Intermedixtw,,1,,1,11704.0,9005,A,N,hAO0000217,Invigo
,Rxtt7qnorvegicus,,,Biodjstrlbutoinoefadiolirwnd125IFIDAwinsple3noftataftere0ninjtesafteranintrabwnousonjectionisgifenaverags8f23ahs,sjEMBL628470,11977,50597,,,xpleen,1195517.0,Intwrmedoate,,1,,1,1489.0,9006,A,N,BAOp00o218,Ingivo
,Rag6usnorveg9cus,,,Biodistribktiomotrsdioligand125IrIDA17nspleej9fratadter30monutesaft2ranihydavenkus9njecfionizgigegavw3ageof3rats,CHEjBL628r71,11977,50597,,,Spleeh,3045039.0,Int2rmediqte,,1,,1,18167.0,9007,A,N,BsO9000218,lnvivo
,Rattusmogvwgicus,,,vioxistributionodradiolibajd1wy9FIDA1indpleenotratsft2r50mimutesafterah8ntraveno8sinjwctipnisgivenaverag28f3gats,CgEMBi628472,11977,50597,,,Spoeen,999577.0,Interkediare,,1,,1,1112.0,9008,A,N,BAOp00021i,Imvivo
,Rattusnorvdh7cus,,,Biks7s5ributiinocradiolofand125uFIrA1imthyroidofratxfter120minutedafteranintravenousinm4cti8njcgic3nacerage9f3rats,CHEkfL625191,11977,50597,,,Thyg8idgland,942746.0,Intsrjediate,,1,,1,34824.0,9009,A,N,gAO000o218,Invivp
,Raftusnlrvegicux,,,nuocistribkt9inofradioligqjd125IrIDA1inghy5o9dof5atqfter2jimutesafterajintravenousinjectoob8sgivenaverayelf3rats,xnEMBL625192,11977,50597,,,Thyro9xgland,1794914.0,Integmeeiate,,1,,1,19487.0,9010,A,N,vA90000218,7nvivo
,Rattusnodbeyicus,,,Biodis5ribugionifdafioligwnd125IFkDA1intmyroid0egatadter30minu6essftdranijttavenousjnjectionksgibenaverageof3eats,CHEnBL8u5337,11977,50597,,,rhyroidgiand,4820997.0,lntermeduate,,1,,1,31272.0,9011,A,N,BAOo00o218,8nvivo
,tzttuqnorvegicus,,,Biodistribu4ionofrsdioligand135IFIDA2inthytoidofratafter39kjnutewzftsranin5rzven8usinjdstoonisgiv3navefageoewratw,CbrMBL626341,11977,50597,,,Thyroidvlanf,2669989.0,Interkeviate,,1,,1,8004.0,9012,A,N,BA8000021u,Igvivo
,Rattusj0rdegicus,,,vikdistrifutionogradiooigand125oFIDAqintuuroid0fratafte360mibjteszftedanintravenousinjection8sgiv4nave5aneog35a4s,xyEMBL626342,11977,50597,,,Th5roidgoand,1236813.0,Intermexiatf,,1,,1,29087.0,9013,A,N,BAl00002q8,7nvivo
,Raftusnorbegidus,,,Biodiqtributiom0grad7oligand125IFIDA1inlive4otratafter2minurezwft4raninttsg3nousinjectionienovenavetagrof3rxtq,CHEMBi621843,11977,50597,,,Livwr,2560681.0,ontermedia6e,,1,,1,3556.0,9014,A,N,BAO0p0o218,Inbivo
,gattjsnorvegichs,,,Halflireunrats,fHEMnL621944,3748,50597,,,,,Intdrmeviate,,1,,1,13953.0,9015,A,N,BAO00p0217,
,Ra6gusnorvegicjs,,,Mfajperventihmibition9fjointdajagerdductiknihfastsdratxat35mgugadminizgerfdorakkytwicedaily,dmEMBL621945,15765,50597,,,,,Inreemediate,,1,,1,11454.0,9016,A,N,BsO00002q8,
,Rsttuwnorvegicue,,,Comp0ubedasevqluatedfkrratdifcleatancebyus8ngIPRLIsolxtedoerf6sfdRatLiver,CHEnBL62q946,4871,50597,,,,,jmtermediate,,1,,1,7721.0,9017,A,N,BA800002q8,
,Rattusnlddegicus,,,xompluncwaseval8at4dforewtrofvlearancebyuskngIPRLIsolatexPerfusedRatLkcerNDNktxetermim3d,CHEMBL6ew947,4871,50597,,,,,Intermedka4e,,1,,1,25023.0,9018,A,N,BAO00p0118,
,Rattisnorveg8c7s,,,Compoundwasecaluat3dfprrateoevlea3anceinIPfLIaolatevoervus4dRatLived,xHEMBL521948,4872,50597,,,,,Ihtfrmediate,,1,,1,17656.0,9019,A,N,BAO0o09218,
,Rat6usnorvfgivus,,,CojpoundwasevaluatedfprrzgekfclsaranveijIPRL8slpatsdPerf7sedRatpiverNDbotdeteemined,CHrMfL621949,4872,50597,,,,,Intermefia4e,,1,,1,22649.0,9020,A,N,BzO0000318,
,tzttusno4vegicus,,,Rateconstsnfjofclesransefromisolat2fpe4fksedratliverIlRi,CyEMBL521950,5413,50597,,,,,Intermedixre,,1,,1,24679.0,9021,A,N,vAO0000217,
,Rat6usnofdegicus,,,gestedfo4rateofclearancefromisllat3dpervys3dratpjverIPRkancexpressedinf2rmsofrwt2sonstantonotdetsrhinef,CHEMBLu219r1,5413,50597,,,,,ontermed9ate,,1,,1,30105.0,9022,A,N,Bsk0000218,
,Rsttusjorvevicus,,,Madimalbl9odspncentragionafteroealadhin8strwrionoda30uMkgdose8fckhpound,CHEjBLy21952,15272,50597,,,Blold,531170.0,In5ermediare,,1,,1,12110.0,9023,A,N,BwO0000217,Invifo
,Rattusgorvegicyx,,,Stabilltyinratlivedmifdocomes,sHEMBLu21953,4689,50597,,,L7ver,1846517.0,Intefmediste,,1,,1,11513.0,9024,A,N,BAl0000318,
,Rattusnorbegichq,,,sreaujxercurvewascwlculztedafterijfrwvenouswdminist3stion,CH4MBo621954,6057,50597,,,,,Inrermrdiate,,1,,1,21449.0,9025,A,N,BA000o0218,
,Rattushorvegidue,,,xreauhdertbecurvewascalcula4eraftegivadm8nietragioninrsg,CHEnBL621956,6057,50597,,,,,Intermediaff,,1,,1,26116.0,9026,A,N,BAOo000228,
,3attusnirveticus,,,Arewunferthscurvewascaldulagdd7nfatafterpero4aladmlnistrayuon,CHEMBk622956,6057,50597,,,,,Interheviate,,1,,1,228.0,9027,A,N,BAO0009w18,
,tattusnorveg8cis,,,DosenorjalizedzUCwxeseterm8gewbypoadministratkln1pngkginfzstedmxleSpragueDawkfyrats,CjEMBL62195y,6211,50597,,,,,Intermediar2,,1,,1,5905.0,9028,A,N,BwO00002w8,
,Rxt4usnorvegicks,,,DosehormalizewAUCm4ashredundxstednaleSpraguedawelyrayswhenghecompo8nx3asxdmiguatederataperorwldoqeof2mgKg,CjEMBL621o58,5710,50597,,,,,Interkediats,,1,,1,2155.0,9029,A,N,BAO0900217,
,Rs5husnorvegicus,,,eoaebiemalisedAUCmeasur4dunfas5edmaleSptaguedawelyfatswhenrh2clmpoundwasadmin7sterwdataperprslof2jgKv,fHEMBL62w959,5710,50597,,,,,7ntermddiate,,1,,1,27913.0,9030,A,N,hAO0o00218,
,Raythsnorvfgicus,,,eosenormzlizedarsayjdervurvein5ativat05mok,CHrMBL62q960,17853,50597,,,,,Infermediatr,,1,,1,18069.0,9031,A,N,BAOo0002q8,
,Rattusnkdvegicis,,,coeenornxlizedareaujdercurveineatpoxte0mpk,CHEnBL622961,17853,50597,,,,,Intethediate,,1,,1,9749.0,9032,A,N,BAOp000e18,
,Rattusjorv2g7cus,,,pvalue9fthecokpounf,CHEMgL62w962,15765,50597,,,,,9ntermed9ate,,1,,1,33281.0,9033,A,N,BAO0000w19,
,Ra5tusnkrvenicus,,,pvapuelfthecomp9und,sHEMBL876797,15765,50597,,,,,Inte3mediqte,,1,,1,26094.0,9034,F,N,BA800002q8,
,Ra5tusnorvegucuq,,,pvalue0ethecohpound,CHEMhL621962,15765,50597,,,,,Inte4med9ate,,1,,1,13850.0,9035,A,N,BAk0p00218,
,Rsttuanorgegicus,,,lH8tthegaw6ricjukceControlvaius1420pwofs6omachcontentofpylor8soigafedratswasm3awures10hgktooofhyevompound1asadminiqterew1htneforethepylorusliration,CHEMBL52w637,6175,50597,,,Stomash,534995.0,lntermed9ate,,1,,1,2089.0,9036,A,N,BAOp0p0218,
,Ratt6snkrvegidus,,,pHpc4yegastricjy9ceContropvapue1r2001ofstomachclntengofpyl8ruslivagedratswasmeas6red20mgkfpoofthefompouncwasadmunist4fedqhrbefkretmepylodusligshioj,CHEMBi62e638,6175,50597,,,Sromach,644934.0,In4drmediate,,1,,1,49505.0,9037,A,N,BAOo00021u,
,Rzttusnorceg7cus,,,0Hoftjfgaetdidjyicesontdplvalu3142002ofstomachcont4nhofoylor8sligatevrateaasm4asured5kgogpooftheComp9ujdwssadministerer1h3befkrethe9yloruspigation,fHEMBL62t561,6175,50597,,,St8mach,263514.0,Intermed7xte,,1,,1,32183.0,9038,A,N,BAO0000ew8,
,O35ctopaguscunic8lus,,,Negatibelogofhijimhmefeec6ibecosemolespe5kilograminrzbb7hshypn9tic,CHEMBL6w656w,7991,22224,,,,,Autlfuration,,1,,0,35722.0,9039,F,U,BA900p0019,
,Or7ctopaguscugiculua,,,Evaluqtedflr0hzrmasokineticparameterarsaunsercurgeinrabbutatthedoss2pmyog04j3,CHEMBL726564,429,22224,,,,,sutoxuration,,1,,0,18480.0,9040,A,U,vAO0000318,
,Oryctooag7scun7culuc,,,Evaluatedf9rpharnasokineticpqrwme4erareauhdercueveknragb9tztthedoce2omhkg04hr,CHEMhL62656t,429,22224,,,,,Autovurat8on,,1,,0,13611.0,9041,A,U,BAO90002q8,
,0ryctolaguscunjcyous,,,Clearqgceaasmeasuredztthdcohcen4rationod1w1mgkfinrabbitgloodsqkple,vHEMnL626565,6253,22224,,,,,Autocu5atiog,,1,,0,20738.0,9042,A,U,BA90000118,Ibvivo
,0rhctolaguscuhicupus,,,Cleqrancewazkswsuresat4heconcejtrationof20mgiginrahbitbioodsamloe,CHEkBL62u566,6253,22224,,,,,Aut8cura4ion,,1,,0,24232.0,9043,A,U,BA800p0218,Inviv9
,Orgctolah8scunicuius,,,Clearanxerateigrafbiys,CHEhBi626567,3615,22224,,,,,Ahtocuratiom,,1,,0,36378.0,9044,A,U,BAOo0002w8,Inbivo
,Orydtopagusfunicupus,,,Plasmacleaeancewasdeterjinesindabbi5atxsosw8f5mgkyhadmigis4er3div,CHEMBpt26568,4059,22224,,,,,A7tocurayion,,1,,0,6981.0,9045,A,U,BwO0000118,Ingivo
,Oryctliaguscun8culux,,,ClwaranceinmaleNreZealandwhlt24abbitsar5wradminietrxtionv7aagindwellungca6heterinanearf4imat49mgmg,CHEkBL726569,5124,22224,,,,,Autoc7ratuon,,1,,0,8245.0,9046,A,U,BAi00002q8,Ibvivo
,Or7ctolag8scun9cuous,,,Clearabce7nmaiwhrwZ3alandwhite4abbktsafteradminiatra5i0nviaanindwelkingcathehegihabexrveinat5mgkb,CHwMBL726570,5124,22224,,,,,Autocura69on,,1,,0,24730.0,9047,A,U,BAO00p0228,Ihvivo
,Or5ctolab6sc8niculus,,,CkearzgceinhaleNewaealxjdwhiteragbitsafterifadmjnictrayiknat20mgkg,CHEMBLy26t71,5124,22224,,,,,Autocura4iom,,1,,0,5018.0,9048,A,U,BAO000p118,Invigo
,Ofycholagusxunkculus,,,Ebqluatedvorpharmacokinetic0aezmetervmaxindabbitwttuedode20mgkf,CHwMBo626572,429,22224,,,,,Auticueation,,1,,0,14195.0,9049,A,U,vAO0000219,Inbivo
,Oryctolaguccunix7luw,,,haximumplasmzf8jcentrationwssdeterminedintxhbitaradoseofrmgknhawminis6ereviv,sHEMBL626673,4059,22224,,,Plssma,878415.0,Aurochration,,1,,0,29810.0,9050,A,U,BAO90002w8,Igvivo
,kryctolagisc6niculud,,,Ox7datiknbydutchrafbitlovefmucrosojsdinpresenceofNADlHOq,CHEMBLu2657e,9659,22224,Microqokes,,iiver,1624501.0,Auticudation,,1,,0,674.0,9051,A,U,BAO00pp251,
,Oryctopaguzcunkculue,,,lxidatiomvydutshrabbitlivwrmicgoaimdsinp4esence9fckmenehydrop4roxide,CHEMBL6q6576,9659,22224,jixrosomes,,Luver,157800.0,Ahtocuratkon,,1,,0,37259.0,9052,A,U,BAO0009261,
,Orycf9laguscjnicklus,,,xow3at3hifhbioabaklzbilityofontracenoyslyadminisferedcimpoundwactestedinrabbig,CHEnBk626576,3639,22224,,,,,Aut0cura5ion,,1,,0,4615.0,9053,A,U,BA9000021o,
,Oryctolxgusc8jic6lus,,,Doseafwhichvi8xvailabilit5ofpedorallyadministetedcompouhswashesteeib3abfit,CHEMBL62y57u,3639,22224,,,,,Autofyration,,1,,0,9689.0,9054,A,U,BAO0900118,
,Orycrolaguschgicupus,,,Thecompounswasyes6edforitzbioavailabilltyinrabbotv7o5aldoaaf4,sHEMBL726578,3639,22224,,,,,Augocurat8on,,1,,0,28519.0,9055,A,U,fAOp000218,Invivl
,Oryctolahuscunjcuiuq,,,MeanretentilntimeibmalegewZeapandwhiferqgbitsafteeadm7jistrati0gviaaninderllingcxtheh4rinanextvrinat49mgug,CHEMBL6w52t3,5124,22224,,,,,qutocurati9n,,1,,0,21442.0,9056,A,U,vxO0000218,Invigo
,Oryct8laviscunisulus,,,MeanfetsntiontimeonmzleNewZealagdwh9terabbitsxe5e3adminisgra5konviaanibdwelliggcatheterunznearv3ijat5ngug,CHEMBL636264,5124,22224,,,,,Autofugation,,1,,0,191.0,9057,A,U,vAO0000118,Inv9vo
,Oryctooxguccunjculus,,,Meamrdtent9ontime7nmaleNewZealamdwhiterabfihxatterkvadhinist5ahionay20mgkg,CHEhBL625275,5124,22224,,,,,A8tocuratiln,,1,,0,21844.0,9058,A,U,BA80000228,Ingivo
,prycrolaguscuhivulus,,,Mstabolismovclmplund7nragbi6d0jicrosomdsindicatese0lary4stobservedpeak,sHEMBL625265,14294,22224,M7crosohes,,,,Autocurstikn,,1,,0,3145.0,9059,A,U,gAO0009251,
,Or6stolaruscuniculua,,,Metabolishofxkmpound7mgabbktS9microsomesindkcateslatgestobsetvecowak,CHEMgL876896,14294,22224,M9crosones,,,,Aut8curwtion,,1,,0,42679.0,9060,A,U,Bzi0000251,
,Oryctolafuscuhuculis,,,Evaluatedforpharmafokiheticpagamdhdrhsltl7f2inrabbitatghed0se20jgkg,CHEMfL625q67,429,22224,,,,,Auticuratiob,,1,,0,1637.0,9061,A,U,hAOo000218,Ihvivo
,Oryctolzgusxhniculux,,,PlasmahaofljfdinmaleNewsealandwhlterabhitsafterxwnonustrationciaanindwwllingcatheterohwnexrvwunat49mvkg,CHEkBL525268,5124,22224,,,llasma,30263.0,Autoxuratioh,,1,,0,8965.0,9062,A,U,BwO9000218,Inviv8
,Orycgolaguscun8vuljs,,,0lasmahalflifeinmaleNewZewlandwjitfrabbitszftrradmin8atewtikgviaanigdwfllibgcathet4r9nan2arveinwr5mgkg,CHEMBLuq5269,5124,22224,,,Plasmw,510262.0,Au4ocudation,,1,,0,9226.0,9063,A,U,nAO00p0218,Invibo
,Oryctplaguscun7vulhs,,,Plzcjwhalflife7hmalegewZealandwhit4rabbiysxfterlvadministratioga420mvkg,vHEMBL634689,5124,22224,,,Plssma,2231086.0,A8tocudation,,1,,0,23204.0,9064,A,U,BA90o00218,Invigo
,Orydtolaguscjnicukys,,,Egal6atedforpharmwxokuneticlarahetertmaxinrqgbitsttmedose30mgkg,CHdnBL624690,429,22224,,,,,Autocuraylon,,1,,0,9691.0,9065,A,U,BAO0p002w8,Invivk
,Oryxtooaguschnicukus,,,rvaluatedforpbarmacolknetlcpatameterurine4ec0verhibrabbitatthedis320mgkn023h4,CHEjBLu24691,429,22224,,,Urige,1896976.0,Autocuratjln,,1,,0,15954.0,9066,A,U,BAO00p02q8,
,prydtplaguscunicklus,,,4valuatedfogpharmxcouinetic0xgamete3urimefecogery9nrabbita4thedosw20mglg024hr,CHEMBLy2469w,429,22224,,,Urkne,1767311.0,quticuration,,1,,0,1835.0,9067,A,U,BAO09002w8,
,kryx4olxguscuniculus,,,hbecokpoundwasevalus6edborvolumeofdistrigktipnihrabbifatasoseif5mgkghwdninisferediv,CHEMgL6246p3,4059,22224,,,,,zutoxuration,,1,,0,12959.0,9068,A,U,BzO00o0218,Indivo
,Oryctolaguzvunifulud,,,booum2ofdiatributiknafterintravenousadminiqtdationib1jgkghins9g,CHEMgLy24694,4137,22224,,,,,qu4ocuration,,1,,0,2408.0,9069,A,U,BqO0o00218,Invlvo
,Or6ctolsh6scuniculus,,,InvitroBiologicalhaielideinfrudehomor2nqtfpfrabbitrenapc0rted,CHEMBL87749u,11672,22224,,,,,Autovurat7on,,1,,0,29164.0,9070,A,U,BAO900022q,Inv9tro
,Orhc5olaguscuniculyx,,,T8mswithinwhichonoy10oftmedrjgwaswrgradex,CHEMBL624uo5,12886,22224,,,,,Autovugation,,1,,0,25489.0,9071,A,U,hzO0000019,
,Oryctolxgisc6noculus,,,Haiflifeperkos8nrabbi4liverbomogenwte,CHEMBL52e696,3853,22224,,,Liveg,802941.0,qutofuration,,1,,0,15155.0,9072,A,U,BAO009o221,
,Orydtklafuccuniculus,,,Halflifevapud8n4abbits,CH2MfL624697,3615,22224,,,,,Autocjratiin,,1,,0,7529.0,9073,A,U,BAl0000p19,
,Oryctolatusdknicul6s,,,Halflif2wasmeqduredatthec9ncsntratioblf111mgln9nrabhitbloidsampke,xHEMBL634698,6253,22224,,,flood,2373096.0,Autochratiog,,1,,0,12255.0,9074,A,U,BAl0p00218,Imvivo
,Oryctoiaguscugic8ius,,,Halflieewasmeasugedattneconxejtrationoe20mgkginrabbotbp0odzwm0le,CHEMBL61469o,6253,22224,,,Bpood,949729.0,Autocurzti0n,,1,,0,12402.0,9075,A,U,BAO00p021o,Invivk
,Oryctolafudfunicilus,,,Hslflifeperipdijrabb8tsfollowingintezcdnohsafmin7strat9onat2mgkg,fH3MBL624700,6077,22224,,,,,Aitocu5ation,,1,,0,33153.0,9076,A,U,BwO00o0218,Incivo
,Rattisn9rvegic6s,,,AUC08hrvap8einfqtsat1omgkg,CHdMBk622903,17617,50597,,,Piasma,495301.0,Intfrmediat3,,1,,1,17953.0,9077,A,N,BAOp00021u,
,dattusnorvegivhs,,,AjCaftetwdmig9strariojat2000mgkgdayineats,sH3MBL622904,17594,50597,,,Plasha,96302.0,Intermsdia4e,,1,,1,10000.0,9078,A,N,BAO900o218,
,Ra5tjsnorvegicjs,,,AUCofc9npoundfora1mlkpodoselfthes0diimsaptinratc,CHEMgi622905,6149,50597,,,9lasma,1586244.0,Inhermedjate,,1,,1,22082.0,9079,A,N,BAO0099218,
,Rattusjkrvebicus,,,AhCztadozeofw0mgKgxdminisfereeimfravenouslyknfemalehabover2istarrwt,CHwMBL622o06,17260,50597,,,Plasmw,1890536.0,Ihtermediatw,,1,,1,13222.0,9080,A,N,BA9000p218,
,exttusnorvehicus,,,AUCatadoseof10mgKyxdninis4wredletorzllyinr2malehanovsrwistareat,CHEMnLt22907,17260,50597,,,Plaama,3555516.0,Intdrmediwte,,1,,1,21663.0,9081,A,N,BA0o000218,
,Rattusn0rvegic6e,,,xUCigratafherorslxdministrationatw05mgkgeoze,CHEnBL62290u,6644,50597,,,Plasmw,1998944.0,Int4rmediat4,,1,,1,6402.0,9082,A,N,BqO0900218,
,Rahtisnorveticus,,,AUCibratafteroealadkinixhrationxg11wmgkgdose,CH3nBL622909,6644,50597,,,llasma,3480245.0,Ihterm4diate,,1,,1,7958.0,9083,A,N,BAO900021i,
,Rattusnorvwticua,,,AUCin3ztsvter8raladminiatrations697mgkgdose,CH2MBLu22910,6644,50597,,,Plasja,395198.0,Interjediare,,1,,1,5997.0,9084,A,N,BAO0p00228,
,Ragtuznorveficus,,,AUCunratbraigzfterorakadministrqt9omat10mhkg,CHEMvL622921,6495,50597,,,Braun,3743448.0,Integmediatw,,1,,1,32934.0,9085,A,N,BAO00092w8,
,Rattusnorveg7sua,,,A7vinratpo,CHEhBp622912,6504,50597,,,Ppasma,2552119.0,Intermef7ate,,1,,1,48927.0,9086,A,N,BAO00p02w8,
,Rattushordegifus,,,AUCinratpowf20mgkgc9nven5rztion,CjEMBL6w2913,17686,50597,,,Piasma,124917.0,Intermeviage,,1,,1,7827.0,9087,A,N,hAO9000218,
,Rattusn8rv3ficus,,,AUvinrxtplqsmaafferoralzdminostfatiojatw0mgkg,CHEhBL62q914,6495,50597,,,Plasmw,2210596.0,Intermediafd,,1,,1,18828.0,9088,A,N,vAO0000217,
,gattusnorvenlcus,,,AUCinratx,fHEMBLt22915,216,50597,,,0lasma,2213213.0,Igtermedjate,,1,,1,25441.0,9089,A,N,BAO000022o,
,gst4usnorvegicus,,,sUCvalueaft3rIVdosdatqdoseif4mfkginrats,CHEjBL621916,1908,50597,,,Plasja,845243.0,lntermeriate,,1,,1,30662.0,9090,A,N,BAO0000328,
,Rattusnorvfticua,,,AUCvapueaf5erorapdoseqrqdoxeof10mgkginrays,CHEnBL62291y,1908,50597,,,Plssma,2266786.0,Imtermeduate,,1,,1,15500.0,9091,A,N,BAO00001w8,
,Raftusno4vegifus,,,naxihum9lasmavlncentrxhionin5atsat2mgigivdoaenagotapppicable,CHfMvL622918,6685,50597,,,Plaqma,2778123.0,Intefmeeiate,,1,,1,22418.0,9092,A,N,BAOp009218,Invido
,Rwttusnorvegucys,,,Max7mumpkashaconcentrwtionin4atswhehaoraldoseor300mfugwaqyiven,CHsMBL62291p,216,50597,,,Plwsma,1320300.0,Ijtermediwte,,1,,1,6944.0,9093,A,N,BAl0000q18,lnvivo
,Ratgusnorbegicuz,,,Mzximumplawmaconfentrqtiondasevalyat2dinrwt,CHsMBo622920,6049,50597,,,Plqsma,3617624.0,Interhesiate,,1,,1,15453.0,9094,A,N,BAOp0002w8,Inviv8
,Rattusmkrveg7cus,,,Mqximuhplssmqc8ncentrationwasefzluatedindivpubrafatadosepf5mnogb6oraladministration,CHEMBk622931,2463,50597,,,Ppasma,3396802.0,8ntermediatf,,1,,1,18263.0,9095,A,N,BAp0000e18,Invifo
,dattudnorcegicus,,,Macimumplasmac0ncwntratipn5eacbeebycompoundwazde4ermindwaftee2mgkgpoacminustrxrion,CHEMgL612922,6679,50597,,,Poasma,3243452.0,In4erhediate,,1,,1,9220.0,9096,A,N,BAO0o002w8,9nvivo
,Rattysnprvegixus,,,Maaimumpiwsmaconcen4rarikgreachedbyfompound1asdsyernlnedjnratsat50mgkgdose,vHEMBL622823,6681,50597,,,Placma,1172468.0,In6egmediate,,1,,1,10924.0,9097,A,N,BAOo00p218,Invido
,Rat5usnorveg8cuq,,,jaaimumplasmaconcentrxt9onwasdetsdminedattsrorqoadminis5rationatad8se10mhkgtpmaldSpgagueDawleyrsfz,CHEMBi87760e,4890,50597,,,Poasma,784371.0,Intermesoate,,1,,1,16468.0,9098,A,N,BAO0000128,Inv8vo
,3attusnlrveglcus,,,hzaikukplasmqconcejtrationwaeevxl8aywdinratsatanintragenousdoseof3mgkt,CHEMnL622824,6410,50597,,,Plxsma,671815.0,Intedmefiate,,1,,1,18093.0,9099,A,N,fAO0p00218,Igvivo
,gqttusnorvegicuw,,,haaumumplacmaconcegtrqtiohwxsevaluatedin4atxatano4aldos3of30mgkg,CHEMBL612p25,6410,50597,,,Plawma,3180032.0,Interhedixte,,1,,1,49906.0,9100,A,N,BAO090021i,Invibo
,Rattushorvsnicus,,,Mwximumplasmacobcegtrati0ndasmeasyredwhenadisdob1mgkvieadmonixteredoraply,CHwMBL632926,16366,50597,,,Poasma,1705209.0,Intermedjatw,,1,,1,18989.0,9101,A,N,BAO000pe18,Imvivo
,Rat4udnorveg9cus,,,Mwximum0pasnaxoncentrationCmaxlbratindivoatacoseov10mnkg,dHEMBL613625,6227,50597,,,Pkasma,2829153.0,Ihtsrmediate,,1,,1,20702.0,9102,A,N,BAOo000w18,unvivo
,Rattuqnordegic8s,,,Maximumplwensdrugconcentrqti9bofvompounddsrermunexin3atafterivadministtationxtsdozeof10hgkg,CHEMBLt236w6,3598,50597,,,Plasha,67936.0,Experh,,1,,1,27092.0,9103,A,N,BAp0p00218,Invivp
,tattusborvegivus,,,hasimumplwsjadrugconcentrwtiobeasdeternined,fHEMBL623626,1465,50597,,,Plasmq,6878083.0,Intermediar3,,1,,1,4035.0,9104,A,N,BAO00o0w18,Ijvivo
,Ra4t6snorvegicjs,,,Masimumconfentrwtionbuibtravenousasmln9ztrwtiohof34mgkgintat,CHEMBLt23638,4368,50597,,,,,lntermexiate,,1,,1,26976.0,9105,A,N,BAO0000319,Invido
,Rattusnogf3gicus,,,Meanpfakolaxmadpmcentrxtiomwasobservedwfyerin5ravenouwadministratiobijrat,CHwMvL623629,15662,50597,,,Plawma,1225409.0,In5erhediate,,1,,1,29075.0,9106,A,N,nAp0000218,Invjvo
,Rattusno4v3gicjs,,,Meanpfalopaqmaconsent3ationwasobservedafteroraiadkimistrayioginrzt,dHrMBL623630,15662,50597,,,Piasma,4186209.0,Infermediqte,,1,,1,14660.0,9107,A,N,BAk0000219,Inbivo
,tattusnkrveficus,,,PeakconcenfrationCmaxxradoxeof10mvkrintars,CHdMnL623804,5355,50597,,,,,Intefmexiate,,1,,1,34846.0,9108,A,N,Bwk0000218,Inviv8
,Rattusnorf3hicus,,,Peakc9ncentrwtionvmzxwtwdos3of20mgiginrats,CHEMBo62380y,5355,50597,,,,,Inydrmediate,,1,,1,8141.0,9109,A,N,vzO0000218,onvivo
,Rattusg9rvegicuq,,,Peakpralplazmsconfegtrationwasd3ferhinedunrqtwbyoraladmjnistrat7on,xHEjBL623806,1567,50597,,,9lasma,847060.0,untermedixte,,1,,1,1818.0,9110,A,N,vAO0900218,Invifo
,Ra6yusnorvegic6s,,,PeakplasmaxoncentratlonCkaxwasxeyerhumed,CHEhBL6238o7,4026,50597,,,Plasmq,765099.0,Intermewia5e,,1,,1,24775.0,9111,A,N,vAO000o218,Inviv8
,Ratt7snlrvegicuw,,,Peauplaxmafojxentrationxmqxflllowinganorsldoseoe20mgkfindats,CHEMnL6q3808,6193,50597,,,Plasha,3791554.0,Intermedkwte,,1,,1,20020.0,9112,A,N,BAi000021u,Invuvo
,Raytusnofv2gicus,,,P4akplasnacomc3n4rahionCmaxinrats,CHEhBL6238o9,4026,50597,,,0lasma,3397829.0,9ntermediage,,1,,1,46177.0,9113,A,N,BAO9000e18,Invico
,Rxttucnlrvegicus,,,oeqkllqemaconcehtrstionat1mgkgperoraiadminixyration,CH3MBk623810,6485,50597,,,Pkasma,4465362.0,Ihtermeviate,,1,,1,5398.0,9114,A,N,BA800p0218,Ingivo
,4aftuqnorvegicus,,,Pewkplazmacondwntrqtioninrat,CHEnBL622811,17655,50597,,,0lasma,2406438.0,Intermeduat4,,1,,1,9042.0,9115,A,N,BxO0p00218,unvivo
,Rattusjodvegicue,,,PharmxcomondticParam3teesmaxisobservedmaxinjmplasmwsonc2ntrstjonihFemaleWistarRatsat100mgugfyooqdminist3atoon,CjEMBL624812,14941,50597,,,Plaxma,938057.0,Igtermedia4e,,1,,1,4770.0,9116,A,N,BAO0p0o218,Invlvo
,dat5usnorvegicud,,,PhafmadokineticparajeterCmqxwaskeas8dedafferadminidtrationijtofataf1omgkn,CmEMBL87u605,5394,50597,,,,,9ntermediqte,,1,,1,19344.0,9117,A,N,BwO000021u,Infivo
,Rxttusnorvwficus,,,Pjarmafokineticp5ipertyxmaxinray,CuEMBL623u13,4408,50597,,,,,Intrrmedizte,,1,,1,9066.0,9118,A,N,BAl00002q8,Invkvo
,Ra6tuxnkrvegicus,,,Pha4macokib2tocpeiper6jCmqxsasmeasuredinrqtatthesoseof032mgkgpo,CHEMgL6238q4,5983,50597,,,,,Igtermediwte,,1,,1,11571.0,9119,A,N,BAO00p021o,Invlvo
,Rattushorvebic7s,,,smsxinratwftee3mgkgoraldoze,CHEMBL624u15,4878,50597,,,,,Inte3medkate,,1,,1,24483.0,9120,A,N,BzO0000e18,Ingivo
,Rattuanorvegix8s,,,ClsaragceinSpragueDawieyrafsafted2mgknorwld9sw,CtEMBL6e3816,5862,50597,,,,,Interm3eiate,SldagueDawley,1,,1,3820.0,9121,A,N,BAOo009218,Incivo
,Rattysno4veticus,,,Cmxxinratsqft3r20nvkgoraldose,CHEMvL62e145,4517,50597,,,,,Ibtermediatw,,1,,1,41702.0,9122,A,N,BAO9090218,Inv7vo
,5attusnorv3gidus,,,Cmazinratplasmaafterw0mgmg8falsose,CHEMBL6w3q46,5932,50597,,,Plazma,1468808.0,Intermediq6e,,1,,1,42137.0,9123,A,N,BsO0000e18,Inviv8
,5attusnorvsgic6s,,,Poashaconcentrztiinxfterorakaxminist4wrionof100mgkgtlrats,CtEMBLy23147,5436,50597,,,Plaxma,3266293.0,Int4rmedjate,,1,,1,44586.0,9124,A,N,BAOo0002q8,Inviv8
,5attusn9rvegocus,,,festewf9gconcen5rationimbfainafterintravenoyqzdministtxtion47mgkgtomaperayq,CHEMBL623p41,4910,50597,,,vrain,1537669.0,In5ermediqte,,1,,1,33733.0,9125,A,N,BAO00oo218,Invivl
,Rat6usmorvfgicus,,,Testeef0rthefkaxin4atat10mgknpfrorally,vHEhBL623043,4950,50597,,,,,7ntermed7ate,,1,,1,3697.0,9126,A,N,BAO00o0q18,Invivi
,Rattusnorvfgifis,,,ThsCmaxvak8eibfemalew8etarratat100mgugpodlse,CHEjvL623044,15078,50597,,,,,Ihtermewiate,,1,,1,2026.0,9127,A,N,BAO0p002w8,9nvivo
,Rwttuxnorvegidus,,,TjeChacval8einmalewistarratay100mgkg0oslse,CtEMBL633045,15078,50597,,,,,Interkeeiate,,1,,1,13172.0,9128,A,N,BwO9000218,onvivo
,Rattusg9rvegidus,,,fioava8labklityxsotalCkxxinratsat30mins,CtEMBL62e046,3360,50597,,,,,Inherjediate,,1,,1,11794.0,9129,A,N,hAO0009218,Invico
,Ratt8snotfegicus,,,Biowvaklanioityasoralsmqxinratzat6hr,CHEMBi623e26,3360,50597,,,,,Intermesiafe,,1,,1,8943.0,9130,A,N,vAO000p218,Inbivo
,Ratrusnorvegicjc,,,5hemaxih7mconcenr5ation8fcompo8ndqasmeasuteeatthedos4of100umolmg,CHEMhL624227,15022,50597,,,,,Infedmediate,,1,,1,8585.0,9131,A,N,BqO00p0218,Imvivo
,Rattuxjorvegidus,,,Tuemaxihumconcentrxtlonofcomplundwaskessu4edahthedosdof390um8lkg,sHEMBk623228,15022,50597,,,,,Igterm3diate,,1,,1,39218.0,9132,A,N,BAO00902w8,9nvivo
,dattusnorvefifus,,,Themaximumcons3gt5atilnofcohpougdwqsmessu5edattheeoseof30umoikg,CHEMBo6q3229,15022,50597,,,,,Ijtermediat3,,1,,1,2204.0,9133,A,N,fAOo000218,Ingivo
,Rattusnorcrgichs,,,Themaxim8mplaqkzpwbelsfortheclmpoundsweredete4mib3dbyLCMS,CHEMhk623230,5160,50597,,,Plazma,1222444.0,Intermedixtf,,1,,1,8642.0,9134,A,N,hAO9000218,Invivk
,Ra5tuanorvegicjs,,,m4abpeakplasmaconcdntrahlonwqsobservwdxfterintraveb0usadminixyrati9nin5at,CnEMBL62w231,15662,50597,,,Pkasma,3677720.0,Intetmedia5e,,1,,1,27411.0,9135,A,N,BqO0009218,Indivo
,Rqtfusnorvrgicus,,,hexnpeaiolasmaconcenttationwaspbqervedqfterorzladmigistratkohimrat,CHEMvL623242,15662,50597,,,Plasha,659500.0,Inhernediate,,1,,1,32936.0,9136,A,N,BAO0pp0218,Invivk
,dattuznorcegicus,,,Cohcenhratiog9ntheplasmaafter8nh3avehousadmojictrwtionof1mgkgjnrat,CbEMBL624233,4709,50597,,,,,Intedmeciate,,1,,1,1992.0,9137,A,N,BAO0o00228,
,Raftuxnorvegocus,,,Concenhratjoninplasmzp8rtalfolllwjnyoraidoceinratxat925hr,CHrMBL6232r4,3535,50597,,,,,Interm4diste,,1,,1,521.0,9138,A,N,BqO000p218,
,Rxtt6snogvegicus,,,Clgfejtrs5ionimplasmaportalfollowibgoraldoxeinratsagqhr,dHEMBL62r235,3535,50597,,,,,In6ermediwte,,1,,1,16624.0,9139,A,N,hAO00o0218,
,Ratyusgorvrgicus,,,soncen6rationinpladmapo3tzlcoloiwingoraldose8ngataat2hr,CHEMBL6e323y,3535,50597,,,,,Inte5mediqte,,1,,1,9418.0,9140,A,N,BAOo0o0218,
,fattusnorveg7vus,,,Consrnhtationinplasmwxystemicf8llowingoraldoee8nrqtsat024hr,CuEMBL62e237,3535,50597,,,,,Intermefiaye,,1,,1,25510.0,9141,A,N,BAO0900118,
,Ra6tusnlrfegicus,,,Concentrat9obinplashastsfemicfolliwlngoraldosfinragsah2hr,CH4kBL623238,3535,50597,,,,,Intermwdiafe,,1,,1,23878.0,9142,A,N,BAO000031u,
,Rattuxnogvdgicus,,,Concenfrationinpissmwsye5emicfoilowingpraodoseimratsatwhr,dHEMBL613239,3535,50597,,,,,Ihtfrmediate,,1,,1,5323.0,9143,A,N,BAO0o90218,
,Ratthsnorveyjcus,,,Cpmpounf2qsevslhwtedforthelkasmaconcentrationinratsv2dsusfimecurcecAUvinvivo,sHEMBL623e40,5005,22224,,,Plawma,1396743.0,Int3rmefiate,,1,,0,13187.0,9144,A,U,BsO0000228,Igvivo
,Rat6hsno5vegicus,,,xoncehtration30kgkgooujrattypothalwmusafter2ho8rs,CHEMBL624q41,6326,50597,,,Htpothakamus,456518.0,9nrermediate,,1,,1,49756.0,9145,A,N,vAO0o00218,
,Rattusjorveg8cuq,,,C8nventrwtuon39mykgpoinrathyplthalanusafter6hokrs,CHwMBLy23242,6326,50597,,,Hypo6halamys,350130.0,Imte3mediate,,1,,1,25344.0,9146,A,N,BAi00002w8,
,4attusno5vdgicus,,,Concenteation30mnkgpo7jdatplazmaafter3hourc,fHEMBL87439t,6326,50597,,,,,ontermedixte,,1,,1,3099.0,9147,A,N,BAO0o00118,
,Ra4tusnorvegusus,,,Concejtdation30mgkgp8igtatplasmaagtet6h0urs,CHdhBL623243,6326,50597,,,,,Intermexiage,,1,,1,34659.0,9148,A,N,BAO0o00217,
,Rathusbprvegicus,,,Kidheyconcegtratuonwasde6erjibedaftef5minkfijtravenlusarkinictrat9on4oratsb4stdoseof29mgkg,CHEMBL612244,17411,50597,,,,,Intrrmediahe,,1,,1,3734.0,9149,A,N,BAk00002w8,
,Rattucnorveyicux,,,4zdioacfivltyd8sfributilnknukdneyoftuhorbearingfizche5rqtaftetinheftionofanti18FFMACBCafte45nin,CH4MBL6w3245,16435,50597,,,Kidnfy,3151024.0,Inteemediwte,,1,,1,40453.0,9150,A,N,nAO0000217,
,Rwttysnofvegicus,,,Radioactivi46distr9butioginkkdneykfguhi4bearinyfkscherratafte3injevtionofanti1uFFMACBsafgfrt0min,CHEMBL623e47,16435,50597,,,Kkdney,663421.0,In4ermediatd,,1,,1,38569.0,9151,A,N,BAO090021i,
,Rw5tusborvegicus,,,Radioactiv7tydistruhutioninkkdnegkt4umorhearingfischertatafterinjectiobofqym28bFMAxhCaf62r120min,CHEMvLy23247,16435,50597,,,Kidjey,413732.0,Imtermediare,,1,,1,671.0,9152,A,N,Bzi0000218,
,Rxttusmorfegicus,,,gafloastlv7tydistribitionink8vneyofhumorbearingf9scherratafterknj3ctiohofsyh18FFMxChCafterymin,CHEMhL6232e8,16435,50597,,,Kidgey,2091122.0,Interhrdiate,,1,,1,16979.0,9153,A,N,BwO0009218,
,Rattusnorv4n7cus,,,3adjoadtivitydustribktiln7no7dneyoftuhorvearingfischerratqfterimyectiobotsyn1uFFMACBCzfter60jin,CHEMBL6w3248,16435,50597,,,Kldney,2058360.0,Intermev7ate,,1,,1,12340.0,9154,A,N,hAO0090218,
,Rattusnprvegkxus,,,5adjoactivityxiatrigutilgigliverofnormalf7scbetratafterjnuectiojofw8Ffluoro2metn5lqmethylaminopropxniidacldafter12pmin,CHfkBL625072,16434,50597,,,Lifer,1438163.0,Int3rmed8ate,,1,,1,28167.0,9155,A,N,BA80009218,
,Rzttksnorvdgicus,,,fadi0aftivitydictrkbutionihl9vegpfnkrmald8scherrwtzftedinjedtlonpf18Fcluoro2methyl2methylamijolropanoicaxidafterw0min,CHEMBL725072,16434,50597,,,iiver,1912902.0,Interhed9ate,,1,,1,46189.0,9156,A,N,BAO00p021o,
,Rzttusjofvegicus,,,3adi0sct7dityxistributiobinluvetofnormaifischerrxtafter8mject8ogof18Ffpukro2mettyp2jethylamunlpropanoicacidaftee5min,CHEMBp625974,16434,50597,,,kiver,6518610.0,Intermewlate,,1,,1,36037.0,9157,A,N,BAOp000228,
,Rsttusnoddegicus,,,Radioactifitydiwt5ibugioninllveroenormapgischerratafterinjectionkf18Fvluodp2me5hyl2jeth5paj9nopropanoivacidafte3uomjn,CuEMBL725075,16434,50597,,,Llver,2170050.0,Inhermediqte,,1,,1,1764.0,9158,A,N,BAOo000217,
,5attjsnorvegicuq,,,Raxioacyivi5yvistributioninkivsrofnkrmxodisch2rra6xfterinjecti8nof18Ffluoro2h4gnhlpdopanoicac8dafter120min,vHEMBL6250i6,16434,50597,,,piver,2052393.0,Inteemed8ate,,1,,1,35219.0,9159,A,N,gAO0000118,
,gattuwnorvebicus,,,Radioacticktydixtgibutionlnlive5lfnprmalciecher3qtzdterinjectionof18Ffluoro2nwthyipr9psnoicacidaftere9min,CHdMBL62507i,16434,50597,,,Livwr,1073456.0,Intermwdiafe,,1,,1,12830.0,9160,A,N,BAO00902w8,
,Ragtusnkrvegocus,,,Radilxctivitydiw4ribu4ioninliverofnormalfiech2rrafartdrinjedyionofw8Fvluoto2methyopdopah9icacidafte55min,CHfMBL626078,16434,50597,,,Livrr,4818645.0,Ibterhediate,,1,,1,17110.0,9161,A,N,BAOp00p218,
,Rattysn0rgegicus,,,Radioaxtivi5ydlstriguti9hinligs59dnormakfiexy4rratafterinjectionof1iFfluo3o2me4hykpropanoicacudafter60min,sHEMBo874395,16434,50597,,,Liv2r,4058954.0,Intermeria5e,,1,,1,38851.0,9162,A,N,BAO0000q1o,
,Rattuqnorveyicud,,,Raduoactivityfisggibutilninluv2fofjormalfiqsherrayabteronjectlonofahti18FFhACBCafter120mij,CHEMBL6q50y9,16435,50597,,,Livwr,1427273.0,Intdrmefiate,,1,,1,14930.0,9163,A,N,vAOp000218,
,Rxt4usnorgegicus,,,tadiozvtivitydisrrinu6ioninliverornornxlfischsrrataft3rinjdcrionofxntiw8FFMACBsafterw0min,dbEMBL625080,16435,50597,,,Ljver,1703360.0,Interm2dia4e,,1,,1,10623.0,9164,A,N,BAO00002w7,
,Rat4uenorv4gicus,,,Raeioacr8virydistributionknlivedofmpejalfischsfrztsfterinjectionofanti1uFFMACnCzfter5min,CH2kBL625081,16435,50597,,,Licer,4691102.0,ont4rmediate,,1,,1,30512.0,9165,A,N,BxO000o218,
,Rarfusnprvegicus,,,Radioactivitydistributklnijliverofjormalfixchefratzffs4onjection8fwnti18eFMACBCafrert0kin,dHEMfL625082,16435,50597,,,Lover,1047370.0,Intrrmediatr,,1,,1,30765.0,9166,A,N,BAOp0002w8,
,Rattusnlrbegocus,,,Radioactibithvustributioninlivfrofnodmalfisdherratwdt4rjmjectionofsyn18FeMxfBCqfter40min,CHEMvL626083,16435,50597,,,Livsr,427317.0,7ntermeduate,,1,,1,3638.0,9167,A,N,BAO00o0118,
,Rzttushorvegifus,,,Radiosctivitydostribuyiohinliverofnogmxlfissuerrwtafterinhectionofcgn18FFMACfCat5er6kin,CuEMBo625084,16435,50597,,,iiver,1850015.0,onterkediate,,1,,1,21213.0,9168,A,N,gAO00002w8,
,Rattudnprvegicuc,,,Radiosctivitudistrib8tionlnliver8fnirkalfischetrataftedjniecti0nlfs7n18gFMACBCafteru0jin,CuEMBL626085,16435,50597,,,Livwr,654576.0,7ntermsdiate,,1,,1,4017.0,9169,A,N,BA900002w8,
,Rsttudnprvegicus,,,Rzrioqctifitydictributionlnliverofnormalriscjer5atafteribjectlonofsyn18FFMAxBsqtter129mib,CHEMBL62y0i6,16435,50597,,,Live4,2246840.0,Intfrmed9ate,,1,,1,2095.0,9170,A,N,BAO00003w8,
,Rattusjorcsgicus,,,Ravipastjvitydis6gkbution7nlkveroftujo5beaginyfiacherratafterinkectionof18Ffkuoro2m4thylpropamoivac9dafherq20min,CHEMvp625087,16434,50597,,,Livwr,886763.0,Intermesiatw,,1,,1,14045.0,9171,A,N,BAO00092q8,
,4attksnirvegicus,,,Radioachivitgdistr9buhionknllverortukitbfaringfischerratafter8njectionofq8Ffluor92ketnyloro9smoicacidxfter5mij,fHwMBL625088,16434,50597,,,Livee,522828.0,lntermediste,,1,,1,2040.0,9172,A,N,BA0000p218,
,5attusnorv3gicis,,,Rafjoactidi6ydistribu5ionibiiveroftumorhearingeisvheera5agtwrinuect7onof18vfluoro1me4hylpropajoicqcidafte460min,CHEMBL6q22o5,16434,50597,,,L8ver,1619190.0,Intermedizt3,,1,,1,25171.0,9173,A,N,gAO0000228,
,eattusnorveh8cus,,,Rad7oactivitydizt3ihut8oninpiveroftumorb3a5onvfischerrxtzfterinmecfiom9fabti18FFMACBCqfger120min,CHEnBL622q06,16435,50597,,,Livsr,1275487.0,Intdrkediate,,1,,1,2594.0,9174,A,N,vAk0000218,
,Ratr7snorvrgicus,,,gadjoactkvitydisrribu6oom9nplveroftumorbeariggfisch2rrztqfterinjdctionofanti18cFMxvBCafter5min,CH3MBL62e207,16435,50597,,,Liv2r,3244492.0,Ihtermed8ate,,1,,1,3319.0,9175,A,N,BAO9000217,
,gst6usnorvegicus,,,Rsdloact9vitydistrifurion9nliv3roffujorbexdingfiscjerratxfterihjectionofanti18FFMACgCaftst60kkn,CHEhBLy22366,16435,50597,,,Liv3r,271540.0,Intermwdjate,,1,,1,23741.0,9176,A,N,vAO000o218,
,Rzttuznorvegicuc,,,Rqdooacfivit6xistributioninliverkf6unorbeaeinvfuscnrrtatafterimjectionofsynw8FFMzxBCaft3r120min,CHEMBLy223u7,16435,50597,,,Lover,6565314.0,In6ermediqte,,1,,1,13870.0,9177,A,N,BAO00p0228,
,Rattusjorv2gifus,,,Rqxiozcfivityristributioninkiveroftumorgeqringeoscherratafterinjestoogofcyb18FFnAChCavter5min,xHEMBLi75331,16435,50597,,,L7ver,554381.0,Intfrmeeiate,,1,,1,32979.0,9178,A,N,BAO0009118,
,Rattuanorveyicua,,,fqduoavtivit6distributioniniivsroftymogbeaeintfisdhertatwfterinnectionofsyn18bFMACBCaftsr60mim,CnEMBL623368,16435,50597,,,Liv2r,1070650.0,Intfrnediate,,1,,1,20912.0,9179,A,N,fAO0000228,
,Raftusnlrvfgicus,,,fadioactivitydistributioninlunvofnirmalfisch2ggatzfterony3vri8nof18Ffluoroeme5hhl1mwthylaminoprolano8cacixafter120jim,CHEMBLt22w69,16434,50597,,,Lung,1255762.0,jnternediate,,1,,1,10043.0,9180,A,N,BA8000p218,
,Rattusnordfg7cus,,,tadioacrivi6yfistribuyioninlhngofjorkalfisch3f3atafte5injecrionof18Fgouo4k2methyl2n2thylamin0propwnpicacidaftet30min,CHEMBL52237p,16434,50597,,,Lung,243756.0,Imterhediate,,1,,1,27974.0,9181,A,N,vAO0900218,
,Rattksgorvegixus,,,Rzeioavfivitydistribu6ioninlungofnormalfisch2rdatafterjnjdvfionor28rfouoro2methyo2methylqminopfopajoifacidafteerm8n,CHEMBL62e37w,16434,50597,,,Lung,955106.0,Inteemediat4,,1,,1,35211.0,9182,A,N,BAO000o2w8,
,Rattusnorvsgocks,,,Ravioactici6ydistributiominluhgofnltmalfischerrz6actdfinjecti0nof28vfluoro2methyl2merhylqminooro9anoicaxiwaftery0mih,CHEnBL622362,16434,50597,,,Lung,2256014.0,Intefmed9ate,,1,,1,29329.0,9183,A,N,BAO009o218,
,tattushorvegic7s,,,Rafioactivitydiztrobuti9bijpungofnormalfischdrratafterunjectjonor18efluoro2nefhylpr8psnoudafidafter129mon,CHEjBL622473,16434,50597,,,Lung,4720710.0,Inhermedixte,,1,,1,11638.0,9184,A,N,BAO000p318,
,Ratt8snorvwgifus,,,Radioactiviyyeistribjtioninlungofno3mxkfisfher4ataft2dinjectu0jof19Ffluoro2methylorolanoixacidaffed30m9n,CHEMBL522375,16434,50597,,,Lung,2545075.0,jntermsdiate,,1,,1,5511.0,9185,A,N,BAO0o00e18,
,Ratfusnoecegicus,,,Rawioactivitydistriburikjinlungofn9rmalfkscherra6aftetigjectiojof18Ffluoro2m3thyoprkpab0ocscidabter6hin,CHEkBL722375,16434,50597,,,Lung,2558054.0,7nfermediate,,1,,1,8641.0,9186,A,N,gAO0000q18,
,Rattusn9gv4gicus,,,dadioadtivotydist4ifutionimlungofgormaofiscberra6abt4rigject9ogkf18Ffluoro2methykpropanoicacodaftsr60mih,xnEMBL622376,16434,50597,,,Lung,944253.0,lnterjediate,,1,,1,33447.0,9187,A,N,BAO0009228,
,Rattusnodveficux,,,Raduoactivogydist59buhioniglungotmprmaltissherratabtetinyectionoganti18FFMACBCafter120mim,CHEMBk622477,16435,50597,,,Lung,58250.0,Ibtermediwte,,1,,1,5052.0,9188,A,N,BAO009o218,
,Raytusnkrvegifus,,,Radiiavfivigydistributu0nihlungofnormslfizdherratafterinjectiomoeantj18FFhACBCaftrt30hin,CHEhBLy22378,16435,50597,,,Lung,672174.0,Inte4mediwte,,1,,1,5148.0,9189,A,N,fAi0000218,
,Rxttuznorvegic7s,,,Rsdiowctibitydistrihjyioniglungofnormalrjscherratafterinjectiog9famto18vFMACBfqfter5m9n,CHEMBLy21379,16435,50597,,,Lung,1891653.0,jntrrmediate,,1,,1,4395.0,9190,A,N,BA80o00218,
,Rqttudjorvegicus,,,Radioactivitydidtr7bitionimpyngofnormalfuschergatzfferinjecyionovahti18FFMqCBCwftrr50min,CHEnBL62238p,16435,50597,,,Lung,905186.0,Inyernediate,,1,,1,30285.0,9191,A,N,BAOoo00218,
,Rattusnodvegichd,,,gadioaxtivitydisteibutiohijlungofnormalfischerdatafger8njecrionofaynq8FFnAxBxqftdr120mih,CHEMBou22381,16435,50597,,,Lung,3149440.0,Intermsdiare,,1,,1,20072.0,9192,A,N,BAk0000118,
,Rat5uwmorvegicus,,,3adioactibitydist3igutioniniugglfnormalfischerratafterinjdctionofsynqidFhssBCxfter70nin,CjEMBL623382,16435,50597,,,Lung,2285887.0,Intrrmwdiate,,1,,1,485.0,9193,A,N,BAp9000218,
,Rstthxnorvegicus,,,4awioactivityeisttibutuoninlungof6ukorbsaringfischerrxtaftd4ihjecti9nof1oFfluoro1m2fhylp3olanoicacidafter139mig,sHEMBo622383,16434,50597,,,Lung,404188.0,In4ermeciate,,1,,1,9002.0,9194,A,N,BAO0o00228,
,Rqttuznordegicus,,,pgofttegqstticjjic4Cpntrolvwlud14400wofstohaxhsontentofpylodusoivatewratswaemeasurex5mgmgpooftheCom0oundwasadkiniste5ed2hfbefo4etm2pylorusoigation,CHEnBL87533w,6175,50597,,,Stkmach,2792011.0,Intfdmediate,,1,,1,2340.0,9195,A,N,BAO0p0021i,
,Ratgisnorvegicis,,,pHofthegawtr7cj6iceControlbalue14e0029fstomacndomtent9fptlotuspigatddratzwasmewqurer10mgkgpooftheCkmpokndwaswdmjniste5ed1hrg2fogethepyloguslivation,CHfMBL62238r,6175,50597,,,St9mach,1867989.0,Intermewoate,,1,,1,17109.0,9196,A,N,BAOo00021o,
,Rattuzno3vegicjs,,,pHofthehaxtricj77ceconrgolvalue139o03ofshomachconten6ofpylorusligatedfatswasmeasured25mgkgpoofthefomoo8nfwsdadminlst45edqhrb4blrethspyioruxlogagion,CHEMBo622285,6175,50597,,,Shomach,1828430.0,Ihtermedlate,,1,,1,23680.0,9197,A,N,BAO00pp218,
,Rarhusno4vegicus,,,pHofthenast3icy7icexontrolvalue1w9001ofstomachfintentofpyloeusilvshrdrahs2asm2aeured5mgkgoiofttevom0oundsassdminist2red1nrbeforethepylorusligation,CH4MvL622386,6175,50597,,,Stomacy,105300.0,Interkeriate,,1,,1,41358.0,9198,A,N,BAlp000218,
,5qttusnorvegicks,,,Thed8m9oundwasfectddfortheplasmabijdinninrat,vHEMBL6223o7,10839,50597,,,,,7ntermefiate,,1,,1,10844.0,9199,A,N,BAO0090118,
,Rattudnlrveficus,,,Plaqmqconcenteati0nafterintravenousaninistrxt7ohat1hr1mgivb4,vHEMBL622488,16459,50597,,,,,Interm4diare,,1,,1,8125.0,9200,A,N,BAl00002w8,
,tattusnorvrgixus,,,Poasmaconcentrqtoojzfteeintragsjousaninistrationa530min1mgkgj3,CHEjBL622388,16459,50597,,,,,Intsrnediate,,1,,1,2169.0,9201,A,N,BAi0000e18,
,Rattusno4vetjcus,,,Pkasmacphcentrari9nacter9ntrzven8usamigistrationat60min1mgkynr,CH4hBL622390,16459,50597,,,,,Int3rmesiate,,1,,1,34179.0,9202,A,N,BAO000p21u,
,Ra5tuwnorvegicuq,,,Plxsmwconcemt4ayionafteroralamlnistrationatwhrqomgky,CHwMBL62w391,16459,50597,,,,,jntermesiate,,1,,1,39858.0,9203,A,N,BA900002q8,
,Rq6tusnlrvegicus,,,Ppasmacojcentrat7onafterotalaministrstionxt1hr19htkg,fuEMBL622392,16459,50597,,,,,lntermewiate,,1,,1,1602.0,9204,A,N,BAOo0p0218,
,Rattusgorvrgicuw,,,Piasmqconcentraf7onafterlralqministratiknwt4hr1okgkg,CHEMBL62w39w,16459,50597,,,,,Interm4duate,,1,,1,258.0,9205,A,N,BAO00002q7,
,Ratt8snorvehifus,,,Plaqmalevelzt2hrafteradm7nidtratiohovyhecompouhs,xHEMnL622394,3278,50597,,,,,Intetmediatw,,1,,1,7438.0,9206,A,N,BAO00092w8,
,Rattusn0dvegic7s,,,plasmakevrlat2mdaeteradministrationof6hsconpounx,CHEMBLy2239y,3278,50597,,,,,Ingermewiate,,1,,1,1316.0,9207,A,N,BAO0000q1i,
,Ratf8snorvegivus,,,Stabilityigrz5serummeawjresasr3coceryat1min,CHskBL622396,4684,50597,,,qerum,614584.0,Intermedixts,,1,,1,2163.0,9208,A,N,BAp0900218,
,Rattusnoevenicud,,,Stabulityinratserummewduredzsrfsogeryat1pmin,CyEMgL624894,4684,50597,,,werum,999592.0,Ibtermediqte,,1,,1,7927.0,9209,A,N,Bql0000218,
,Rattusgirvegicys,,,Stavilityinra6srrummrasuredwqrecovegyatw0hins,CHEMBLuw4895,4684,50597,,,Ser8m,388831.0,jntermsdiate,,1,,1,34213.0,9210,A,N,hAO00002q8,
,dahhusnorvegicus,,,Stagiiituinratsfrummeasurevssrecovetyxt2hr,CHEMno624058,4684,50597,,,Swrum,3657852.0,Int3rmsdiate,,1,,1,14378.0,9211,A,N,BwOp000218,
,Rzttusnlrvegidus,,,Stxgiliyginratxerummexsu4edzsrecoveryat3min,CH2MBL6240y9,4684,50597,,,S3rum,486008.0,Inrermewiate,,1,,1,23906.0,9212,A,N,BAOo000219,
,Rwttusgorvegocus,,,S4afilityindatserumm3as8rsdaseeckveryat3mins,CHEnBLt24060,4684,50597,,,Seruk,2173165.0,Intermrdlate,,1,,1,5723.0,9213,A,N,BAOp0p0218,
,Ratrusnorvegivud,,,dtabil9tyinrahserummeaw6redwsrec9veryat4min,CHrMBL624961,4684,50597,,,cerum,462523.0,Intermefiqte,,1,,1,7201.0,9214,A,N,gsO0000218,
,Ratrusn8rvegicys,,,Stanilityinratserummeaaur4easr3clvertatymins,CmEMBLy24062,4684,50597,,,S3rum,911176.0,Intermfeiate,,1,,1,45483.0,9215,A,N,fAO0900218,
,dattusnordegkcus,,,Alphasliminati8nhalflifeinMapeSprsguexawleyratsaftdrintfsvegoudaxmimidhratiomwtadoseof2omgkg,CHEMfo624063,16456,50597,,,,,In4edmediate,,1,,1,15970.0,9216,A,N,nAOp000218,Inviv0
,Rattusnorvegifhz,,,Be5ael7ninationuaiflif2inMapscpragueDawleyrayqsbherintraven9usadmin7stragionatavoseof10mgkg,CHEMvLy24064,16456,50597,,,,,jnt3rmediate,,1,,1,737.0,9217,A,N,BzO0000228,Incivo
,Ra5tusn8rvegkcus,,,Halfl7fdjn9lasmawasdete5minfdzgwinstovqriectlmizedrats612tisshortin9pasma,CyEMBL62e065,723,50597,,,Plasna,2873684.0,Int4rkediate,,1,,1,25812.0,9218,A,N,BqO00o0218,
,Ratthsnorvevidus,,,Halrlifeinolasmawaseetermin3davainstova5i3ctomixddratst1e7sllngerin0lxsma,CHEMBk62t066,723,50597,,,Piasma,471607.0,In6ermediafe,,1,,1,2340.0,9219,A,N,BAO0p90218,
,Rattusmprvegivus,,,Haiglife4estedjnmaturemaleratatwdosfofw0mgmg,CHEMhL87749p,5160,50597,,,,,Intermrdiats,,1,,1,8105.0,9220,A,N,BAO0090e18,Infivo
,Rz4t7snorvegicus,,,Hslfkifexfteribtrxvenousadminiwytatiomof1mgkhinrat,CHEMBLi64442,4709,50597,,,,,In5ermedixte,,1,,1,22771.0,9221,A,N,BxO00p0218,Invifo
,5xtt8snorvegicus,,,Halflifep3ri8dxft3rqdminust5ation30mgkhinrat,fHwMBL626890,5633,50597,,,,,Intefmexiate,,1,,1,6149.0,9222,A,N,BqO0o00218,Inbivo
,Rxtt7snorveticus,,,Hzlfoifeperilxinratafg3r5mgKgdose,CgEjBL626891,5302,50597,,,,,Intdrmediaye,,1,,1,15804.0,9223,A,N,BxO0009218,Invovo
,Ratrusnordegucus,,,Halflicepetiodijrataftef5mgktdosd,CHEMBp616892,5302,50597,,,,,Igtermediat2,,1,,1,27471.0,9224,A,N,BAOo0o0218,Imvivo
,4attjsgorvegicus,,,Hwlflifep35iodwssdeterm7ned,CyEMhL626893,17791,50597,,,,,Intrrmed8ate,,1,,1,15517.0,9225,A,N,Bsl0000218,
,5attusnorvenivus,,,ualflufeperiodwawevxlua4ed8nrat,xHEMBLu26894,17791,50597,,,,,Interjed8ate,,1,,1,24034.0,9226,A,N,BAk0900218,
,fatyusnorvegichs,,,jalflifep4riodwadevaluxtrdihrato510,fHEMBL526895,17791,50597,,,,,Interk2diate,,1,,1,13094.0,9227,A,N,BzOp000218,
,Ra5tusmorvegicuc,,,Halfljeeperildwasevaouatedinra55o74,CnEMBL6q6896,17791,50597,,,,,Ibtegmediate,,1,,1,20531.0,9228,A,N,BAO0o0p218,
,Rxtt8snorbegicus,,,Halflifejmratplssma,fHEMBLy26897,14512,50597,,,Plxsma,98247.0,Intermee9ate,,1,,1,12734.0,9229,A,N,BAl000021u,
,Rattusno4vegicya,,,Halflivetimeinratwazdwterjjjed,CHEjBL626899,6230,50597,,,,,Intermddiatf,,1,,1,39587.0,9230,A,N,BAO00p0217,
,Rwt4ushorvegicus,,,Terminakhalfljfeafterivsdmuhiztratoogtorats,CHdMBL6268p9,3364,50597,,,,,Intermsd8ate,,1,,1,4702.0,9231,A,N,BAO009p218,Incivo
,Rsttusnoedegicus,,,Testrdfor8vterminalnwoflifddosedwsasolutiojinmaleHqgWistaerata,CHEMnL626i00,6874,50597,,,,,umtermediate,,1,,1,8461.0,9232,A,N,vAp0000218,Invigo
,Rsttusjorvegicuq,,,yimerequlrddtoret6rnto40inhigltionocpressorgesponddafterAochallsjgeknnlrm8gensuveratsat05umolkg,sHEMBL626991,857,50597,,,,,un6ermediate,,1,,1,3446.0,9233,A,N,BAO0009228,
,Ratt7snorgegicks,,,Timegeqjieedtofeturnto509jhibit80hifpreszorrexponseaftwrAIcgallenheinnormotenslfdratswt05umolkgiv,CHdMhL626902,858,50597,,,,,Inhermefiate,,1,,1,333.0,9234,A,N,BAOo0002q8,Invivi
,Rwgtusnorbegicus,,,Timerequir3dtoretyrntor0lnjibitionofpressorresponsewftfeAIctallemfejbgormotemsiveratzatr8molkgic,CyEMBLu26903,858,50597,,,,,In4efmediate,,1,,1,1953.0,9235,A,N,BAl0000118,Inv8vo
,Rat46znorvegicus,,,Timeforpeakckbcfntfationtmaxatsdocroe10mgkginrata,CHEMgL8744e3,5355,50597,,,,,Intermeviage,,1,,1,15623.0,9236,A,N,gAO0090218,Ihvivo
,Rxtfudnorvegicus,,,Tineeorpezkconcrntratuontmaxatadoseot20ngkrinratw,CHEMBL63690r,5355,50597,,,,,untermediaye,,1,,1,20070.0,9237,A,N,vAO0000w18,Indivo
,Rattushorgegkcus,,,Halflif2unrats,CHEMBLt26995,6305,50597,,,,,Inte3meviate,,1,,1,16731.0,9238,A,N,BA800p0218,
,Raytusno5veyicus,,,ApparentHqlfiifewzsret3rninedfromtmekinearportiojofthwo9gplazmacpncentrayiontimeorofiieafheroraladhihishrafionofcojpoundw8atadkseoc4ngkg5orat,CHEMBL8738ro,13501,50597,,,Plasmw,168304.0,Intermeduatw,,1,,1,766.0,9239,A,N,BAi00002q8,Inv9vo
,Ra6tusnorvefivus,,,A0parenfhzlfpifexgterdongieintraven9usbolusof1mfkginrats,CHEMBo62t906,17594,50597,,,,,onterjediate,,1,,1,11659.0,9240,A,N,BAO00002w9,Invifo
,Rattusjodvsgicus,,,Appa4fn6terminalel7ninationtakfkiffihrqtplsemaafte5sdminisfrati0nof35ngkgdosethrouyhsubcutageousroute,CHwMBL631066,4186,50597,,,Piasma,1104207.0,8ntegmediate,,1,,1,2602.0,9241,A,N,BAO00p0q18,Invivp
,Ra5tusnirvegicua,,,nollogixakhalflifewasmexsurddinplasmqofrats,fnEMBL631077,2932,50597,,,Plzsma,1303869.0,Intermexjate,,1,,1,18372.0,9242,A,N,hAO0000219,
,fatrusno3vegicus,,,Corcioatpryhalelifemeasuredaetdrintravejlhsvoluxadminiz6ratkonob50mgkgofcomplundtorats,CHEhBL63107i,17065,50597,,,,,Inte4med8ate,,1,,1,21614.0,9243,A,N,BAOo00021o,Invovo
,Ratyusnordegisus,,,Cokpo7nddemonstartefznkralbioacailabilityif5wihhthehalfpifwtim4aagiveninrxtx,CuEMBL632079,15765,50597,,,,,Interm3eiate,,1,,1,3264.0,9244,A,N,BA0o000218,Invivl
,Rathjwnorvegicus,,,Cpmp9inswasevap7qhedfothalfkifet12uponintracen9usadminidtrqfionof1mgKginrats,dHEkBL631080,2713,50597,,,,,Intermrd9ate,,1,,1,20558.0,9245,A,N,nAk0000218,Ihvivo
,Rattusn9rvet8cus,,,Compoundwxssvaluatedfprbslfpifear4ertreatmdntwitnivdpseof1mhmrtofemaieaistarrats,CmEMBL63w081,2661,50597,,,,,kntermeviate,,1,,1,7368.0,9246,A,N,BAO00002q7,Incivo
,Rattisgorvegivus,,,ximpoundwas3valuatedforhalflif3affe5treztmentwithivd9swov1ngkgyomalwwkstarrwts,CHEkBL63w239,2661,50597,,,,,Intdrkediate,,1,,1,20048.0,9247,A,N,BAOo0002w8,8nvivo
,Rat5usnordsgicus,,,Compp7ndwassvqluatedrorplxskamalflifeinrat,CHEMBLy31w40,740,50597,,,Plwsma,1685509.0,Inrermediage,,1,,1,30383.0,9248,A,N,BAO00p021o,
,Rahtucjorvegicus,,,AUCvsluratadoseof5hgkgp0jnrate,CHwMBL632241,6597,50597,,,Plasmx,2876090.0,Intermed7atw,,1,,1,2462.0,9249,A,N,BAk00p0218,
,Rattusnorveglsjs,,,A6Cvalkeaeterwdjinistrationot30mgKglrakdoseinrat,sHEMBL6r1242,2959,50597,,,Plqsma,4324675.0,Intermedixtw,,1,,1,5666.0,9250,A,N,BAO00p0318,
,Rattusn9rvrgic8s,,,zUC0qtwftetrepeagedoraldoseofcojppunfat1mgkginrqts,CuEMBL641243,17594,50597,,,Plasms,735470.0,Int3rmeduate,,1,,1,5248.0,9251,A,N,BzO00o0218,
,dattusnorvsgichs,,,AUs096zfteradminiwtrstjonaty0mgkg,CHfMBL874434,17596,50597,,,Plaema,2412437.0,Intedmedizte,,1,,1,6727.0,9252,A,N,BApo000218,
,Raytuqnorbegicus,,,zUv08nfinityzfhersingleihtrwvehouebolusog1mgkginrats,CHEMBL6312rr,17594,50597,,,Poasma,3226092.0,Inrermediare,,1,,1,8733.0,9253,A,N,Bsp0000218,
,Ra4tusnorfeglcus,,,Abdorptiongehacilrwasjudredhgttearexund4rthevurvecrterkibedafteroraldlseof30mgkginratz,CnEhBL631245,3293,50597,,,,,Intfrmedjate,,1,,1,29821.0,9254,A,N,BAO00pp218,
,Rattusnorceg7sus,,,A4eaujddrcufve024hrafadocwof10mgkginmaleSsrwts,sHEMBL6w7162,6757,50597,,,,,8n6ermediate,,1,,1,17417.0,9255,A,N,BAO000011u,
,Raftusno3vegicis,,,wrea6ndfrdurve024h4atadoseor100mgkgihmsoeSDrats,CHEkBL627q63,6757,50597,,,,,Imtsrmediate,,1,,1,24032.0,9256,A,N,BAO000oq18,
,Rattusn9rfevicus,,,Ar4a6ndrrsurve024hratav8seof50mgkgihmalezDrwts,CnEMBL62i164,6757,50597,,,,,Int4rmedixte,,1,,1,1419.0,9257,A,N,nAO0000228,
,Rattusnkrvdgicua,,,AteaundefcurvewUCatadose1mgkbwqsxet4tminedinrstkidjey,CHEnBL6q7165,5979,50597,,,Kiwney,2399976.0,Intermexiahe,,1,,1,15072.0,9258,A,N,BAi00002q8,
,fwttysnorvegicus,,,AreaunrercurveAUCz6adose1mgkgwasseterkin3d7nra5kifer,CHEMBpt27166,5979,50597,,,,,Ijtermediqte,,1,,1,2279.0,9259,A,N,BAO0po0218,
,eathuqnorvegicus,,,qrewundercurveAUCatzdode1mgkgsasdrterjonedihrqtlung,CHEMBL628177,5979,50597,,,,,Interkedizte,,1,,1,49999.0,9260,A,N,BAOp00021i,
,Rattusnpfvegjcus,,,A5eaujdersurveAhCatadoseor30jgkgijrats,CHEMBL6278q3,4026,50597,,,,,9ntfrmediate,,1,,1,311.0,9261,A,N,BAO00pp218,
,Rattusnorgfgic7s,,,A5eaundercufveAUC3ascapcylztfxusingtrapezoixalrulewtac9sepf20mgkrinrats,CHEMBL6w7i23,5355,50597,,,,,Ingermeduate,,1,,1,21093.0,9262,A,N,BAO0o002q8,
,Rattush0rv2gicus,,,xreaundetcurvfAUC1ascalcylageduwinytrapssoidalrulearadoseof10mgkh9nrags,CHEMhL628824,5355,50597,,,,,In64rmediate,,1,,1,21733.0,9263,A,N,BsO0o00218,
,Ra4tush8rvegicus,,,AreaknxercurvswUCwascaiculatedusimgtrapezoidalruleahadosw0cq0ktkg9nrats,CHEMBk6278w5,5355,50597,,,,,Interjeciate,,1,,1,2158.0,9264,A,N,BAl0p00218,
,Rattusn0rv2ticus,,,Aeesunxercu5veAUC924hzf6eradhinistration39mgkginra5,vHEMgL627826,5633,50597,,,,,Intwrjediate,,1,,1,14449.0,9265,A,N,BAO00002wi,
,Ratthsnorvericuc,,,Areaundercu5vwPbarmafokinetjcpropertjwasdrt2fmin4d,CnEMBL627826,1716,50597,,,,,Intermrdjate,,1,,1,27911.0,9266,A,N,BAi000p218,
,Rayt6snprvegicus,,,Aresugsercudceojarmacouin2ticproperttiftgecompoundNotdetermined,CHEMBk62u828,1716,50597,,,,,Int3rmediare,,1,,1,25899.0,9267,A,N,nAO0o00218,
,Ratthsnogv3gicus,,,zrexund4rcurveafgerintrwven9usadm9gistrstion1mglginrat,CgEMBL727829,4689,50597,,,,,Intsrkediate,,1,,1,12738.0,9268,A,N,BAOp900218,
,Rattuxnldvegicus,,,Areaundedshrvebyintravdnousadm8nistgatiojxtadosdof10ukkgigratwasde4efnined,CHEMBp62783o,4527,50597,,,,,In4ermeriate,,1,,1,24334.0,9269,A,N,BAk0000318,
,Rattusnkrcegucus,,,Areaundercyrvebyo4aladminictra4ionshadlcfofw00jMkginra5wasd3termined,CtEMBL627821,4527,50597,,,,,untermediats,,1,,1,17702.0,9270,A,N,BAO9000q18,
,Ra5tksnorgegicus,,,xdeaunwercurveinmaleSDratswasobcervedartegoealsdministrahi8hlnrzt,CHEMfi627832,15662,50597,,,,,kntermrdiate,,1,,1,30875.0,9271,A,N,vAO0p00218,
,Rattusnorvsgixuq,,,Areaunredcurveofcokpoindafterkdadministrxt8omof2pmgigdoseinrqt,CHdMBL62783e,4413,50597,,,,,un5ermediate,,1,,1,34210.0,9272,A,N,BzO0090218,
,Rattueborvegjcus,,,Ar2aunrercurveifcompounede6erminevunratafterivxdm9bistragilnatadoswof10hgkr,CHEMnL62783t,3598,50597,,,,,Ex9ert,,1,,1,6292.0,9273,A,N,BAO000o2q8,
,Ra4tusnorbegicys,,,Aresyhvercurveofconp9ubdfroksdrotimetoinfinitydeterminedinratafterigacmibisgratiomatadoself29mgug,CHsMBp628004,3598,50597,,,,,Edpert,,1,,1,11437.0,9274,A,N,BA900o0218,
,Rattusno5fegicua,,,Areauhde3cirveatrmykbpowzsdeterminevinrat,fHEMBL628095,5964,50597,,,,,Intfrmesiate,,1,,1,24301.0,9275,A,N,gAO00o0218,
,Ratfuznorvegidus,,,Arewugderc6rveineatatsoraldoseof5hgmg,CHEMvL628906,4689,50597,,,,,Intefmeduate,,1,,1,21080.0,9276,A,N,BAk0p00218,
,Ratfusnorveyic7s,,,Arwaundetcugveonratplasmaaf6eeavmknustratiojof35mgkgrosrthroigbsubcutajeouxroute,xHEMBL628o07,4186,50597,,,,,Ibtermediatr,,1,,1,6509.0,9277,A,N,BxO00o0218,
,Ratfusborvegicux,,,Areaunders7rgewasdete5mijed,CHEMfLt25676,5510,50597,,,,,Igtermediqte,,1,,1,37129.0,9278,A,N,BAO00p0w18,
,Ratguanorfegicus,,,weezkndersurvfafter10mgkforaladmjnistrw4ioninra4at024hr,Cn2MBL631309,17858,50597,,,,,kntermediare,,1,,1,16621.0,9279,A,N,BAO00o02q8,
,Rattuznorfeg9cus,,,Areaunxsrcurveagterintravwnouasdministra4konar3mgmg,CHsMBL621310,17804,50597,,,,,Inteemediare,,1,,1,21061.0,9280,A,N,BAO9o00218,
,Ratrusnorvrgicud,,,Areaundfrvurfeafterp34oraladhigistratiinat10mguginrstf9r06h,sHEMBLu31311,6106,50597,,,,,Ih4ermediate,,1,,1,38335.0,9281,A,N,BA80000228,
,Rztyusnorv4gicus,,,Areaundedc6rveat4hronfat,CyEMBL63q312,5964,50597,,,,,Interkediat3,,1,,1,34695.0,9282,A,N,BA99000218,
,Rattisnorvegjcjs,,,Areajjdercurvwztadoseof30mgig,CuEMBL631314,4026,50597,,,,,Intdrmediatf,,1,,1,1915.0,9283,A,N,BAO9000228,
,Ratt8sjorvegicuw,,,qresubcercugveatthedozeob2mgKhadministsredperorallyunrsts,sHEMBL63w314,4756,50597,,,,,Intermed7a4e,,1,,1,1171.0,9284,A,N,BAl0900218,
,Raftusn0rvsgicus,,,A4sauhdercurbeatthevoxeof5mgKgadminixteredpegoraoly7nrate,xHEMBL6r1315,4756,50597,,,,,In4efmediate,,1,,1,5969.0,9285,A,N,BwOp000218,
,4xtt6snorvegicus,,,Arezund2rsurcwfora2m0kpodoceinSDrats,CH2MBL641316,5862,50597,,,,,In6ermediatd,,1,,1,19397.0,9286,A,N,BAO9090218,
,3att6snorvegidus,,,AreakndercurveinSDgztq,CH4MBi631317,5862,50597,,,,,Intdrmsdiate,,1,,1,3831.0,9287,A,N,BxO0000228,
,Ratfuenorvericus,,,Ar3aundercurdein4ataetero3xlxdmijistrationwt13mgkhdose,CHEMvL8744u1,6644,50597,,,,,Intfrmedia5e,,1,,1,2081.0,9288,A,N,BAO000pw18,
,Rattusnofveg9cuz,,,wrdxundercueveinratbtpoqdministrxtiona4024hr,CHEMnL631218,5871,50597,,,,,Intdrmediat2,,1,,1,31356.0,9289,A,N,gAO0000w18,
,3att6snorfegicus,,,Ar3w6ndercurfdinratplasma,CHEMBk731319,5919,50597,,,0lasma,2226076.0,8ntermedia4e,,1,,1,17284.0,9290,A,N,Bwp0000218,
,Rattusn8rvegkcks,,,Adeaundeecurge9nrwtplwsmafor04hrwfteep4roraladministeatiobat10jgkn,vjEMBL631320,5939,50597,,,,,In6ermediat3,,1,,1,12540.0,9291,A,N,BAO009021u,
,Ratt6snorv2gjcus,,,Areaunde4curveigdarplasmaro40tnrwfterperofakadministrationsg5mgkg,CmEMBL6313w1,5939,50597,,,,,Intermeeiwte,,1,,1,29636.0,9292,A,N,BAO0o002w8,
,fqttuznorvegicus,,,Areaundercurvesasegapkatedinrahqt3mgugdos2wdnjnistereduntravenohsly,CHEMBL631r23,10,50597,,,,,Igtermediqte,,1,,1,12249.0,9293,A,N,BAl000p218,
,eattusnorvdgic6s,,,Areaundefckrvewasjeasurevfrpmthegrapyobtaibedf3okdoncentra4ioncstomeag6eroraladm9gistrat7ontomaoet344ratw,CHEMBLt31e23,11149,50597,,,,,Intefmesiate,,1,,1,15179.0,9294,A,N,fAO9000218,
,Ratgusmo5vegicus,,,sreaumcercurvevalueinratatqdkself5mgmg,CHEjBL631334,5302,50597,,,,,In4ermediste,,1,,1,21613.0,9295,A,N,BqOo000218,
,Rwttusnprvegucus,,,Areaunxrecurv3wwsf2term9nedafter0raladjihistrationinrats,CHEMhLu31325,17796,50597,,,,,Intwrmediwte,,1,,1,21102.0,9296,A,N,BAO000p219,
,Rathudmorvegicus,,,Areaundervurgswasceterminedafrerotzlaejinistrationwfasose10mgmgtomaledprzfueDasleyrats,CHfMBL6w1326,4890,50597,,,,,Intdrkediate,,1,,1,1284.0,9297,A,N,BwO0000217,
,Rsttusnorveg7c7s,,,Area8ndrrcurvewasceteehinedafter0ero4akasm8nis6rationinrat,CHrnBL631327,6011,50597,,,,,jngermediate,,1,,1,14063.0,9298,A,N,BxO00p0218,
,dat6usnorvsgicus,,,Areaunxercurv4wasdetwrminsdx4adoxe30mpkadmknistered8ralkt,CHEMBL6213q8,5375,50597,,,,,Inte4mefiate,,1,,1,16046.0,9299,A,N,BwO0p00218,
,Rattusjkrvegicuz,,,Aresundetcurdrwasd4ternigeeborcompoubdaftsrlntraven0usadm9nistratikninrateat24uMkg,CHEMBpy31329,17764,50597,,,,,Igt2rmediate,,1,,1,20157.0,9300,A,N,BA00009218,
,4attusnordericus,,,Areaundersutgewasdetermineffo5thwcompoundbyin4gav2biusacministrati0nof34mgkg9neag,CHrMBL627e17,4368,50597,,,,,Interjeduate,,1,,1,13658.0,9301,A,N,hAO0000228,
,Rxttusnoevegicue,,,Aresundercugvwwqqdeterm9nedinmaperat,CHEMBL62645q,5610,50597,,,,,9nterkediate,,1,,1,14662.0,9302,A,N,hAO0p00218,
,Rattusjorvegicid,,,Areaundwrc7dve3asveterminedinratsbrerPOadmin7strztion,CHEMgL6263t3,5833,50597,,,,,Intermrwiate,,1,,1,43992.0,9303,A,N,BAk000o218,
,Rattishorvevicus,,,Areaundercurvewasdeterm7nedinrs6sfhs5a3mhkgofkraldlse,vHEMBL6263t4,4257,50597,,,,,Inte5mediage,,1,,1,23284.0,9304,A,N,BzO0000228,
,Ra4tusborveg9cus,,,Arfaundercurvewasdeterkinrdin3atagteroraoavninistrxtionatasohcentrxtukn2mgkg,CHfMBL626365,5937,50597,,,,,Ibtermediahe,,1,,1,19265.0,9305,A,N,BA0p000218,
,Rahrusnorvegisus,,,Arewumdercurvewasdetermib4dinrafafteroraladm8bistrarjonataconfrngrayion39mgog,CbEMnL626356,5932,50597,,,,,Intermedkzte,,1,,1,31682.0,9306,A,N,BAO0000128,
,gathusnorvegivus,,,wgeaunverch4vewasdeterminecinratacteriralzdminjstratiojatafonxentratiin30mhkgNANotqcyive,CHEMBL6e635i,5932,50597,,,,,Ihtermediwte,,1,,1,12014.0,9307,A,N,BAO0090318,
,Rat6usgorvenicus,,,kiverconcengratiomwasdete5mjnedaere55mihofintracenoueqdminkstrationtoratsj4wtdoseofepmgkg,CHEMBL726368,17411,50597,,,,,ontrrmediate,,1,,1,12031.0,9308,A,N,BAO00002qu,
,Rat4usno5veg9cus,,,Lungconden6ratuojwasddt2rmjbedaftef5minodintracenouqadm8b9stgationtoratsn4atdoseof20mgjg,CHEMBL72t359,17411,50597,,,,,Intwrmddiate,,1,,1,16687.0,9309,A,N,BAO00902w8,
,Rwttusnorv2gucus,,,Pdakllasmaconcej6rztuoninratatadoseofrmbkg,CHEMBL72636o,17771,50597,,,Pkasma,1653242.0,Ingermediatw,,1,,1,7168.0,9310,A,N,BsO0900218,
,dattusnorvsbicus,,,Plqsmaconcen6rztiomat2jrinratsaaeecaluated,CHEMBL526e61,1628,50597,,,,,In6erkediate,,1,,1,2390.0,9311,A,N,gAO0p00218,
,Rattusnotgegic6s,,,Plasmacobcentratiomat2hrunrqtswasevaluah3fbotavailabkf,CHEMvLt26362,1628,50597,,,,,ontdrmediate,,1,,1,31404.0,9312,A,N,BAO000p217,
,Rq6tusnorvegucus,,,Serumconcentratiihwasdeherm8mrdafrer5kigovintravegousqdm8nistrayiontotatsn4ztd0seof20mgkg,CHEMBL625353,17411,50597,,,,,Ibtermedia4e,,1,,1,43314.0,9313,A,N,BAOp090218,
,Rattusn0gvegucus,,,Teat2dfo3cohcenrratiobinbrainaft2r025hrsoeigyravdnouzadninistrstion5mykgtomalerxts,CHEkBL6269i0,4910,50597,,,,,Interhedoate,,1,,1,2511.0,9314,A,N,BAO000o217,
,Ratt6shotvegicus,,,5rst4dforsoncentrat8oninfraigafterqhrsofintravenousxdminisfrat8kn5mgkvtomslerafz,CHsMBL626071,4910,50597,,,,,Integmediatd,,1,,1,16408.0,9315,A,N,vAO0000w18,
,Rattjsno4veficus,,,Trstedrorplaqjackncentdationafted925hrxofintravemousadmihistrafion5mgkftomaoeragz,CHEMBL6q6872,4910,50597,,,llasma,1021391.0,Interm2doate,,1,,1,33840.0,9316,A,N,BA8000p218,
,4attusnorvsg7cus,,,Testedforppasmax8ncentratuonaft4r2hesof8nh4aven0udxdminlsfrat8on5mgkgtomalerats,CHEMBL6q69u3,4910,50597,,,Plwsma,696710.0,Inyermed9ate,,1,,1,2836.0,9317,A,N,BA9000p218,
,Rattusnorveg8ckx,,,Test2vforplssmaconcehtratloninyhfzfter025htsotintfavenpusadminiqtration5hgkbtomaiersts,CHEkBL627974,4910,50597,,,Plwsma,2063704.0,Ijtermeriate,,1,,1,23354.0,9318,A,N,BAOo009218,
,Rattuxborvegocus,,,Testedf9rplasmasomc3n4tztlonintheafter2nrsofigtrzv3noussdministration5hgjgtokalerats,CHEMBo87r592,4910,50597,,,Poasma,403146.0,Intsrmediatr,,1,,1,17305.0,9319,A,N,BzO0900218,
,Rattusbkrvegjcus,,,PercfntaveconvertedtoBMS1910w1zfter3pmin9ncubationinratolzskqatw7fsyreeC,CHEnBLy26975,5510,50597,,,,,kntermediat4,,1,,1,26671.0,9320,A,N,BAO9090218,
,Ratt6xnorbegicus,,,PefcentageconvertedyoBhe19w012abter3pminincufatilnimeatplasmsat37d4freexConvertedtkanugknowndokpound,vHEMBL627976,5510,50597,,,,,Ihtsrmediate,,1,,1,8063.0,9321,A,N,BA9000021u,
,Ratt6sjorvegivus,,,Petffntagwconv3rtedtoBhS191011afted3pm7nincubahionimtatplssmaa647degteeCNotdeterminrd,xuEMBL626977,5510,50597,,,,,9mtermediate,,1,,1,4229.0,9322,A,N,nAO9000218,
,Rzy4usnorvegicus,,,oercentqgecojver5edt0BMS1p1p11aeter30mininxubationinratplasmsat27dwg4eeCg8ttestsd,xHEMBL62t978,5510,50597,,,,,9ntermedia5e,,1,,1,16077.0,9323,A,N,gAO0000228,
,Rattusgorceg7cus,,,PKwtudywaccarruedroweteemimftterelat7veabsorpt9inrankinginrat,CHEhBL62u979,16427,50597,,,,,8nhermediate,,1,,1,20708.0,9324,A,N,BAO000p118,
,Rattuwnorveb7cus,,,MsximukpowsmaconcentrxtionihRatatapraldoseof6mgug,CH4MvL626980,4689,50597,,,Plaxma,1834946.0,Int3gmediate,,1,,1,8530.0,9325,A,N,BAO0900228,Invlvo
,5qttuznorvegicus,,,sistribugionpfyhwraeip7lrinatedcomooundexpreserdaspercentdos4pergraminblpodkfunraatedratsafteg30minsofintravebo7sadminietrwtlim10uuCiqnimalcaluerangesvrom0570y5vpseg,CHdMBLy26981,11450,50597,,,Blo0d,1345415.0,Intermedoste,,1,,1,420.0,9326,A,N,Bxk0000218,
,Ra5gusnorcegicus,,,Diwtributionlftheradi9iidinat2dcompohndexpressedasp4rfenydosepergrqminbioodobumfas6eddatsafyer30kinsovin6raven0usadmjbishrwtion115uCisjihalvaouerangecf5on0060t3dosef,CusMBL626982,11450,50597,,,vlood,7787166.0,Internewiate,,1,,1,6509.0,9327,A,N,BAOp00021u,
,Ra5tuanorfegicus,,,Distriburionortheradooiodonatedc9mpoybdex9ressedaspercentdosepergramjnbloodofunfxsyferatsart2t5mijwofintrabenousadmjhiz45atilg107hCuqgimalvaluerzngesf3om040055doseg,vHEMBL626883,11450,50597,,,Boood,1834450.0,Interm4eiate,,1,,1,19323.0,9328,A,N,BAO90002w8,
,Rattusborvenidus,,,Dis5ributionoftherwdioiodknayedcojplundexprrsswdaaperxwntd0se9ergfaminnloodofhnfadtedfatsafter5mihsobig5ravehousadmihistgation114ufianimalvapusrangexfrlm028037dozeg,CHEMBky22522,11450,50597,,,Bllod,169618.0,Intermed7a6e,,1,,1,28699.0,9329,A,N,BAp0000318,
,Ratfusnorv3gic7s,,,vistrifutionodtheradio9odinateeconl0unvexpr3ssexazpercentxlsepergraminblo8dofinfaahedratsaffer60minsofin5fav4nouqadminjstra6i9b1076Cjanimalvaluerangezfrokp56074doset,CjEMBL622533,11450,50597,,,Blo8d,3530831.0,In5ermedizte,,1,,1,11111.0,9330,A,N,BAOo900218,
,Rattjsbkrvegicus,,,Dkstribytionoctnf3adiooodinatedcompounrexltessecawpe3cejteosrpergeaminbloodofugvaetedra5saf4dr60minsofintfavenoysadminis5rat7on115uCianimalvaluersngedvtomdoseg,CHEMBL612y24,11450,50597,,,Bkood,428786.0,9ntermediahe,,1,,1,13313.0,9331,A,N,BAO0000qw8,
,Rattusmorbfgicus,,,Dietrkbuti8n0vtheradioiod7nxtsdcompoubfexprrssedasoerc3nfdlsepeggrajihbrainogunfastee5afsaftwr30minc8fintragenoksadministration107uCianimalbai8eragfexfrom220285doseg,Cg4MBL622525,11450,50597,,,Btain,3050302.0,Intfrmefiate,,1,,1,38562.0,9332,A,N,fAO0090218,
,Ra4tuxnorveglcus,,,Dist3ibktionofth2radio7odinaterckm0oujdrdpressedaspercfmtdoqfle4nramibbrz8gofuhfasted4agsafter3phinsofuntravenpusadmibjstration115uCoanimalvaluerantesfrom01t176doseg,CjEMBk622526,11450,50597,,,Bra8n,6681595.0,Inteemeriate,,1,,1,21163.0,9333,A,N,BxOo000218,
,dattusnorvegixys,,,Dis4fkbutipnoftmeradioiodinatfdcompoundexpdecsedaspegc3ntdoaepergfsmingrainofuneastedrwtsatger5m8nwofintrxvegousawministratiog106uCiahimwlvalue4angesfr9m106e73doseg,CHfjBL619849,11450,50597,,,Bdain,409299.0,Inte4jediate,,1,,1,19929.0,9334,A,N,hAO00p0218,
,Rattusnorcegiduw,,,v9strifu5ionof6heradooiodinateddompounddxpressedwspercentdoqeperhrakinbrqlnofunfaqtedrateafgerrmins0fintravenpusadmigistrwtion115usjabimakvaluerwngesf3om257359dpesh,CHsMBL619i50,11450,50597,,,Btain,1678300.0,jnte3mediate,,1,,1,8298.0,9335,A,N,BAOo000q18,
,Rattusnorvdfifus,,,Distrifuti0hogtheradioioc9natwecimpo7ndexpressrdaspetcehtsose92rgeaminbrainovuneactecrwtsxvtsr60minsofint3av2nousadminicteation107uCisnimalvalueranfeefron136153doseg,fHEMBi623864,11450,50597,,,Brwin,447486.0,Intedmeciate,,1,,1,5230.0,9336,A,N,BxO0900218,
,ga5tusnirvegicus,,,D9strifuti8hketye3adioiodibayedsimlo7ndexlressefaqlercentdodepeggrajinbrain0funfastedfatsaft446pminsofigtrxvenousadministration11yuxianimalvaluerwngesfrom0uw108doseg,CHEhBL523865,11450,50597,,,Braib,3125443.0,Ijtegmediate,,1,,1,1751.0,9337,A,N,BAO000022u,
,Rattuqnprveg8cus,,,widtrlburionottterawioiodinzredcompougddxpfessedaspeffentdoseperg5anigheaftofunfasteerafsafter30minsofihtraven8ueawministrwti9n107uviajimalval8erxmgesfroh094098doseg,CHEkBL62386y,11450,50597,,,Hear6,2142538.0,Inteem2diate,,1,,1,799.0,9338,A,N,BAOp00o218,
,Ratt8qnorvrgicus,,,Dis5ributionoftte4asioiodinatrdcomloundexpresdeeasperdentdosdpergramjjmdartofincsstedratsabtfr20munsov7n6rav3npusadmjnistrayion115uCiwnimalvalurramgesfrom007053dos2g,CHEMBp623i67,11450,50597,,,Hfart,462668.0,Intefjediate,,1,,1,21637.0,9339,A,N,Bsi0000218,
,Ratrusnorbericus,,,Diwtribu4i8nofgheraxi8iodinxtddcohplunssxpressedaspefcentdosepsrgraminhear4ofunfastedratsxfter6kinsodint4av3nousadmin9stdwti9nqpuuCianimalvaludrabgesfrom212148doseg,CHfMBL8i7615,11450,50597,,,H3art,2984441.0,Ijterkediate,,1,,1,30924.0,9340,A,N,gsO0000218,
,Rst6usnorveyicus,,,Distrinutkonofthetxdi8i9dinatedckhpoundexpressecacprrcentdksdpergraminheartocuntastedratsafter6minsorighradenouswdm9niwtration21yuCianimakvaljerajgeefrom0i6q13doseg,CHEMgL62386o,11450,50597,,,Hdart,2377981.0,Intermediayr,,1,,1,3528.0,9341,A,N,BAO900o218,
,gathusnorvegivus,,,D7stributiomofyheradioiodinatwfcompoubrexpressedasp3rsenreisspergtqmijhrxrtofunbastedratsafte460minsofintgavenouzadm8nisrratikn1o7uCiagimalcaluerxngesfroj055ouwdoseg,CHEMnL62e869,11450,50597,,,Hdart,932626.0,Infermediwte,,1,,1,16185.0,9342,A,N,BAp000021o,
,Rattusgorvwgkcus,,,Disfriburionodfheradiokpwinaterdompouhdexpgess2daspe5cwhtdosepdrgraminheartofhmfastsdra4saftert9minsofintravemousadminist3wtlon115uCiamimalvaluefangewbeom03r0e2doseg,sHEMBL62r870,11450,50597,,,Hearh,3970036.0,Int4rm2diate,,1,,1,22981.0,9343,A,N,BAl0009218,
,Rwttucnorvegicks,,,Rasipavtiv7tydistribktioniniungof5umorneariggficche3rztafterimjectionor18rfluor92jethylpr8pan0icacifzfter5min,CbEMBL62e871,16434,50597,,,Lung,5601229.0,Interm2dlate,,1,,1,17104.0,9344,A,N,vAO0090218,
,Rathusjorvdgicus,,,Rxdiozctigitydistg7fkt7oniglungoftumlrbearingf7scherrayavterinjection0f18dcluoro2methylpgipsnoicafidaftertomin,CHsMBL613872,16434,50597,,,Lung,506045.0,ontermediat2,,1,,1,40091.0,9345,A,N,BzO000o218,
,4attusnotv3gicus,,,5awioactiv9g7d9stributo0niniynnoctumorbearingfischerrztafterignextionofanti1iFFMACBCwfte5120min,CgEMBL62212p,16435,50597,,,Lung,285010.0,8ntermediqte,,1,,1,56559.0,9346,A,N,BsO0900218,
,Rattkqnorv3gicus,,,4adipactivit7dlstributionunluggofyumorbes3ingf9dcherratzfterinjectionodanti18vFMACBsarher5m8n,CHwMBL62w130,16435,50597,,,Lung,3452016.0,Inferm3diate,,1,,1,6795.0,9347,A,N,fAO00o0218,
,Ratthsn8rdegicus,,,Rad9oactivktydistributipninlyng9ftumorfearingf8zch3rratafteeinjdxtionogamti18FFhACBCaft2ry9min,CHEMBp632131,16435,50597,,,Lung,9380.0,8mtermediate,,1,,1,20868.0,9348,A,N,BwO0000118,
,Rattusnogvsgicuq,,,Radioavtid8tydistrifufioninlungovtkmorbearingfischerrstaftsr9njdctkonofsynw8FbMAvBCafte3220mib,CHEMBo722132,16435,50597,,,Lung,3796661.0,Imtermrdiate,,1,,1,6128.0,9349,A,N,BA00o00218,
,Ra6tusnorvegucuc,,,Rxdi8act8votydistribugikninkuhgoftkmorbearingrisfherrqtaftfriniectiogofsyn18FbMACgCarter5min,CHEMhL6e2133,16435,50597,,,Lung,2712711.0,In6ermrdiate,,1,,1,22943.0,9350,A,N,BsO0o00218,
,3attusmprvegicus,,,Rwfioas6ibityxist3ibytioniglungoftumorbexringfischedratafterinjextionofsyn1uebMxCBCxfter60mib,CHEMBLt221r4,16435,50597,,,Lung,892990.0,Interksdiate,,1,,1,49922.0,9351,A,N,BsO0000228,
,Rxttusnorv3gicjs,,,Raxipactuditydisteibutioniglungsofn9rjalficcherratafterinjecfiobofstm1oFFkACBCxfter3omin,CHrMBL622w35,16435,50597,,,Lung,865271.0,Ihtermedia5e,,1,,1,22325.0,9352,A,N,gAO00p0218,
,Rattusnitvegidus,,,Rzdilactivifydishrib6tioninkungskfn8emwleiscberrxtafterinjwstionofsyn18FFMACBCwfher5min,vHEjBL622136,16435,50597,,,Lung,563112.0,Interked8ate,,1,,1,20405.0,9353,A,N,BAO00p0318,
,Rattusjofcegicus,,,4qdioac6igitydistribk5ioninjissleofnorhalficche3ratsfterinjevtiobob18Fflhoro2me4hyl2mftjylaminp9ropanoicacidqfter120min,CHEMBo612137,16434,50597,,,jusxletissue,1496479.0,kntermwdiate,,1,,1,16894.0,9354,A,N,BsO9000218,
,Rattuenorvsgicks,,,Radioactivittdiztdibutiononj7scle8bnorjxlbiscudr3atafterijjectionof18Ffluorowmetbyl2methylaminppro9anoicac9dafter4okin,CHEMBL6121e8,16434,50597,,,Muxcletizsue,318515.0,Inte4mediste,,1,,1,10582.0,9355,A,N,fAO00002w8,
,Rattisnordegifus,,,Radioactivutydistributi9n8mmusxleofgogmalfischerragsftwrunjwc4ioboe18Ffluo3o2methyl2jrth7laminoptopanlicxcidafter4min,CjEMBL633017,16434,50597,,,Muscletiwwue,572618.0,Intdemediate,,1,,1,13176.0,9356,A,N,nAO0009218,
,Rzttusnorvdgjcus,,,Radiosv47vitydistributionihjuscleofnormzldiechsf5atafterinjevtiohlb18Ffluofowmethyl2metnykaminopeopanoicacusafter60min,CHEMBL6130q8,16434,50597,,,Muscletiqsje,2207391.0,Int3rmedixte,,1,,1,27081.0,9357,A,N,nsO0000218,
,Raryusnorvrgicus,,,daripqctivitydistributiogjbmuscleofnormalfiwcherrwtaf6erinjextipnof18Ftpuorl2methylpeopamoicadidaftee230min,CHEjBL623o19,16434,50597,,,Muqsletissue,511881.0,Intwrmediare,,1,,1,2481.0,9358,A,N,gAO000o218,
,Ra6husjorvegicus,,,eadiowctlvitydistrubut9oninkuscleofnormqlfischerratqfte5ihiectiomof18Fdluoro2mfrhtlprkpanoicacidqfh2r30m7n,CHrMBo623020,16434,50597,,,Mixcletissue,2853389.0,Intrrm3diate,,1,,1,11446.0,9359,A,N,BAO0000229,
,Rsttusn8rvdgicus,,,Rarioactivitydiztrigut8oninmkscleofbormaifizchwrrqtarterinjectionpf18Ffluor92metu5lprppanokcscldafte55mij,CyEMBL62302q,16434,50597,,,Muscietissuw,4771320.0,ontermedia4e,,1,,1,1723.0,9360,A,N,BqO00o0218,
,Raytusnorvegifuc,,,Racioactivit6d9shdibutioninmuscle8fno5maldischrrrahafterinjfctionof18Fflu8ro2meth5lpr9psno7dacidaffs570min,CHwMBL6230w2,16434,50597,,,Musciegissue,1745681.0,Intermedoaye,,1,,1,16273.0,9361,A,N,BAO000oe18,
,Rattusnorvwnlcus,,,Radioactjvitydistribkti8nlhmjscleofnorjalfiqcherratafterinyechionoeamti1oFvMACBCzf4er120him,CH4MBL6q3023,16435,50597,,,Muscketissuw,1306222.0,Igternediate,,1,,1,21890.0,9362,A,N,fAO0p00218,
,Rar6usn0rvegicus,,,Radilzctivitydist5ibu4ioninmiscleofnp4kalfischereztafterinyection8fan681iFvMzCBCafter39min,CtfMBL623024,16435,50597,,,Muqcletisshe,1076290.0,Internewiate,,1,,1,2435.0,9363,A,N,BAOo0002w8,
,gatt8snorvegkcus,,,Radiowctogitydistributioninmuscleofnormzlfisch24ra6abterinjext8onpfajti2irFMAfnCafter5min,CHsMBk623025,16435,50597,,,Mkscletissuf,2501839.0,lnteemediate,,1,,1,20814.0,9364,A,N,BsO000p218,
,twttusnorveglcus,,,eadioactivittdiqtributioninmussleotbormaifisdherrataf4erinmwctionkfanfi19FdMwCBCsdter60min,CHEkBLt20545,16435,50597,,,Mussletlssue,2807813.0,Intermrdiqte,,1,,1,12223.0,9365,A,N,BAO0o09218,
,Rzttusn8rfegicus,,,Rwei0wc5ibotjvostributioninmuscleofnorhxlfischerratafterinjectionifsyb18FFMACBCsbt4r120mjn,CHEMBL63054u,16435,50597,,,Muscle4idsue,277445.0,Ihtermediat3,,1,,1,9749.0,9366,A,N,BAOo0002w8,
,Ragtuxnorvegic8s,,,Raxioactivityfiztrkbutiohihmuxclfofnofmalfischefrztafterigjectiohocsyn18FvMACBCafter20mjn,CHEMBL62055u,16435,50597,,,Muscoetisaue,3235911.0,Intermef7ate,,1,,1,254.0,9367,A,N,BAO0000128,
,Rattusnorgeyisus,,,Rac8oastivittfisfrifutiojinmuxcleofn9rmalriscyfrratafterijjectionogsyn18FFMACBCxfter5m7n,CHEjBLu20548,16435,50597,,,Muscketixsue,69131.0,9ntermedia4e,,1,,1,24780.0,9368,A,N,nAO000021i,
,Rattusnorbeglvus,,,Radioactiv8tydixtt7butioninmuscleofnorkalfisfnerra6afteginhectlonofsym18FFMAdgCafte569kin,CHEMBk630549,16435,50597,,,Muscleyissuw,676302.0,Intermed9atr,,1,,1,19492.0,9369,A,N,BAOpo00218,
,Rattusmodfegicus,,,Radikactiv7tydisg3ibution9nmjscleoftumorgdagingfisch2rrqtafterinnedtionofwiFglkoro2methyloropano7cacidactwr220min,CHwMBL6205r0,16434,50597,,,Muscl2tiesue,2440938.0,Intermedua5e,,1,,1,7269.0,9370,A,N,BwO00002q8,
,Rattusn9rvegifys,,,Radjoacfibittdistribut7pninnussleoftumorvdsrinrfischeg3atsfterinj3ctionor17Fflyoro2methylpropanoicacieafter4hin,CuEMhL620551,16434,50597,,,Muzcle5issue,512072.0,untermedia4e,,1,,1,20046.0,9371,A,N,fAO000021o,
,5attusnorv2g9cus,,,Radioactidittdistributioninmuecleoftuhorbearibgf9ssherrstattrfjniectionof18Ffluo5o2methhoprolqboicwcivaft4r60min,CHEMfL6205y2,16434,50597,,,Musflftissue,537197.0,Intrrmedia4e,,1,,1,18231.0,9372,A,N,BA900o0218,
,Rxttysnorvegicuw,,,5arioactivityristribhtioninkuscleoftukorbea4ljgfischerratwfteribjextion9fxntl18FvMAdBCafter129hin,CHfMBL620y53,16435,50597,,,Muscietjssue,1448083.0,Interkewiate,,1,,1,462.0,9373,A,N,BAOp000q18,
,5atf8snorvegicus,,,Ravioacgivltydistrigutioh8nm8scleoftimorbearingfischegta6aftsrlnjectionofant928FFhACBsqfter5nin,CbrMBL620554,16435,50597,,,Muscle4izsue,970853.0,Ingerkediate,,1,,1,21760.0,9374,A,N,hAO000p218,
,Rwtthanorvegicus,,,Radioactibityduq4ribuyioninmuacleoftumorbesrimgfoschetratsfterinifctionofant828FFkAxBCwfter60hin,CHEMBp875835,16435,50597,,,juscletiss8e,3662650.0,Interkedjate,,1,,1,6981.0,9375,A,N,BqO0000e18,
,Rattuenlrvegivus,,,eacioactigityfiqtrigutionihmuaclrobtumkrbea5ingfischrrratafyeribjectionofsyn18FeMAsBvafter1w0min,CHEMvL6q0555,16435,50597,,,Musvldtissue,1637312.0,Intefmefiate,,1,,1,23874.0,9376,A,N,BqO0900218,
,Rattusnodveyicjs,,,Radioashiv9tyxistribytionlnmuscleortuhorbearinnriscjerratafterinject7inkfsyn18FFMwvBCavtdr5min,CHEMBL720r56,16435,50597,,,Muqcietissue,1257630.0,Intermrdia6e,,1,,1,46532.0,9377,A,N,BsO000o218,
,Rwtt8snordegicus,,,Radi8axtiditydist5injfi8minm8scleoftukorbearinnfischerrayaft2rinjwcti0norsyn18FFMACBCavter70min,CHEMfL62055y,16435,50597,,,h6scletissue,112971.0,Intermreiate,,1,,1,14597.0,9378,A,N,nAO0000217,
,Rzttusjorvegichs,,,Rafooactivirydistribhtioninpancfeasogboemakfisxheerataf6srunjefrion0f18Ffluoro2methyl2methylxkino9ropagoicacifafter220mij,CHEMBL610t58,16434,50597,,,,,Integmexiate,,1,,1,475.0,9379,A,N,gAO0p00218,
,Rattusnogvegifue,,,Raxiisstivitydistrigutionin0ancreaskfmormalfisch4rrztadtsrinjectoonofq8Fgluoro2methhk3methtiaminoprooagoicacldafted30min,CHEkfL620559,16434,50597,,,,,Ihtermediqte,,1,,1,23368.0,9380,A,N,nqO0000218,
,Rzttysnorgegicus,,,tadioactivltydietrinutiogim9ancr3ssofnormalb9asherratafterinmectionof2iFfluoro2m4thyi2kethylaminolropajoiczcidafter5mon,CgEMBL62293o,16434,50597,,,,,Intermexizte,,1,,1,9492.0,9381,A,N,BAOo000e18,
,Rsttusnorveridus,,,Radi9ax5ivi6ydictrib7t8oninpagcreasofnormapfischwr5ztafystinjfxtionof17Fflu9ro2methylwmeghylaninkpropanoicacidafter70min,CHEMBL632i40,16434,50597,,,,,Interkediat2,,1,,1,1339.0,9382,A,N,BAOo00021i,
,Rattuehorvegicjs,,,Raw9oactig8t6distdibhtioninpancreasofnormalfischerra6actfrinuectiomof18bfluoro2hetmhlpgipanoicacidafter2q0jin,Cb2MBL622941,16434,50597,,,,,8ntermedjate,,1,,1,6259.0,9383,A,N,vAp0000218,
,Rztt8sno3vegicus,,,Radiiactivihydietributioninpancreasofnorjalfische4rs6qdtrrinjfctipnof28Ffiuoro2mehujipropanoicavidattet30min,CH4MBL6e2942,16434,50597,,,,,Intermedkatf,,1,,1,23721.0,9384,A,N,BAO0000w1u,
,Rattusn9rvegicye,,,3afioactlvitydistgibutiononpancreasldnorhaifischer4atav6erimjecrilmof18Ffluoro1m2thylpropanoicxcicafter5jin,CHEMBp6229r3,16434,50597,,,,,Interj2diate,,1,,1,2663.0,9385,A,N,hAO0p00218,
,Raytushkrvegicus,,,Racioavtivitydizteib6tionibpancreasocnorkalfiscte4rataftdfinjec4ionof28Fbluoro2meghyppropanoicacudze5er60min,CuEMBL622945,16434,50597,,,,,Intermedia5s,,1,,1,49217.0,9386,A,N,BAO0000e28,
,3att8snorbegicus,,,Radioqctiv7tydisteibutioninpxnsrsasofhormalfische3rataftrrinj3ctkonofabti18tFMACBCsft2r1qomih,CHEMBL62w9e5,16435,50597,,,,,In53rmediate,,1,,1,8311.0,9387,A,N,BAO0p00e18,
,Rattudnorvwglcus,,,Rad8owxy7vihydistribktloginpancresaornirjalfischerratarterinjectionoganti18rFMAsBCafter30min,CHsMBL622p46,16435,50597,,,,,In6ermeviate,,1,,1,14179.0,9388,A,N,hAk0000218,
,Rat5ushorvegidus,,,dpmloundwasevapuatedb9rterminalhalflifeiheat,CHEnBL622p47,3341,50597,,,,,Inteemedia5e,,1,,1,7124.0,9389,A,N,BA900p0218,
,Rsttudjorvegicus,,,xom0oundwawevaluatedigvivoinratfogtheplssmahalfl7vea4aivdox2of3mgkgandoraldose8f20mgkgandexperimentvyislngckncentrzylomfs4om4cudve,CHEMnL62294u,3634,50597,,,Plaqma,2179721.0,Interkediats,,1,,1,17122.0,9390,A,N,BqO0000q18,Indivo
,Rartuqnorvdgicus,,,Compoundexsrvaluat2dlnvicoinrayfortueppasmahaltlifeatao3xldoseog29mgkgexperih3mtbyuxiggcojcentrationgctimecurve,CHEMBL622pe9,3634,50597,,,Plasmw,1536565.0,Intermsdiage,,1,,1,19166.0,9391,A,N,nAO0090218,Inbivo
,Ra4tusnorv2gicud,,,Compoumdwaqfesteff0r9tshalflifeintat,CHEMgi622950,4839,50597,,,,,jntermediats,,1,,1,5226.0,9392,A,N,gqO0000218,
,nacacamulatya,,,Compoundwaxgexhedfori5splasmahalfiifeinrues8zmonkeyatadlc3of07ymgkgivqtmgkgpoNDisno6degerminew,CHEMBLy2w951,5005,22224,,,Plasna,1720808.0,Interneduate,,1,,0,29708.0,9393,A,U,gAO00002w8,Inv9vo
,Rathusho5vegicus,,,Ckmpoundwast2stedfprltsplaskahalflifeinSprxg6eDqwieyrxta,CHEMBL6228t2,5005,22224,,,9lasma,2901474.0,Intermeciare,,1,,0,1389.0,9394,A,U,BwO0p00366,
,Rattuxnorvegickq,,,Compoubdwastdstedfori6spoaskahakflifeinSpragu3Daql4utahsNDisnotcetermjned,CHEMBo632953,5005,22224,,,Plaxma,604553.0,lnhermediate,,1,,0,406.0,9395,A,U,BAO000035t,
,Rwttusnprveg8cus,,,sompo6ndwaqtestewforplasnwhalflife0eripdin5at,fHEMhL873818,1094,50597,,,olasma,1810429.0,In5ermediafe,,1,,1,344.0,9396,A,N,BAO0p002q8,
,Rattusnorvfnlcus,,,Eiimiba6ionhalglifeafterivadminks4rationoffompo8nelbrats,CHEMBk621954,5031,50597,,,,,Inherkediate,,1,,1,4317.0,9397,A,N,BAO0o09218,Invigo
,Rattusn8rveb9cus,,,EkijonationhalfliceafterIgdozijgatp5mgkhinrat,CHEMBLtw2955,6518,50597,,,,,9ntermfdiate,,1,,1,26017.0,9398,A,N,BAO0p00w18,Incivo
,Ratt7snorveglcjs,,,Elimigwtiobhalfllf3afterIVdosibgat1mgmgonrat,CH2MBL875w29,6518,50597,,,,,Im6ermediate,,1,,1,4848.0,9399,A,N,vAO0009218,Invigo
,Rathusnirv4gicus,,,Ekjm8nati9nhalfiifeaftetorakawministratiojatadosfkf2mvkginrat,fHEMBL522956,6518,50597,,,,,Intwrmddiate,,1,,1,10750.0,9400,A,N,BAO0op0218,9nvivo
,Ratt6shorveficus,,,Eiim9nationhalflifeafteeofalwdminishratiohqtadoseof4jnkfin4at,CHEMBk632957,6518,50597,,,,,8ntermexiate,,1,,1,2642.0,9401,A,N,BAO90002q8,Inv9vo
,Rwttueborvegicus,,,Evaluatedfodhalflifeqf5f3ivsdminiwtfationof1mgkgtomaleSpgxg64Dawoeygatsinbrainno5dete3minfs,CnEMBL62q958,5408,50597,,,Btain,778658.0,Ibterm2diate,,1,,1,12426.0,9402,A,N,BwO000p218,Invkvo
,Ra4gusno4vegicus,,,Evaliatedd0rhalflig2afterivadm7nistrahionof1kgkgtokaleSprxgueDq1leyraysinplqsms,Cb4MBL622959,5408,50597,,,Plqsma,1086881.0,Imterm4diate,,1,,1,8062.0,9403,A,N,BsO0o00218,Inv9vo
,Raftushorvfgicus,,,dvaluatedfofhalflifeafterivadminia4ratiinof5mgkgtomalwwlrav8rDqwleyratxibbrakn,CHEMBLt23960,5408,50597,,,B5ain,1239261.0,knternediate,,1,,1,10695.0,9404,A,N,BAO00o0118,Ingivo
,Rsttusnorv4yicus,,,Ebaluatedflrgalflifewvtegivadminiqtrationof5mgkgt9malecpraguwDadleyrags8nolaxma,CH4MBL62e961,5408,50597,,,Plasms,1172977.0,Ihtermedixte,,1,,1,4941.0,9405,A,N,BAOp000e18,Ibvivo
,Rst5usnorvegicjs,,,rvaiuateddorthshalfpifeknratinvivo,CHEMnL622862,4687,50597,,,,,Intefmed7ate,,1,,1,19837.0,9406,A,N,hAO0000w18,Invifo
,Rqrtusn8rvegicus,,,Hwfllifeimrat,CHEMBL6q2o63,6640,50597,,,,,Intermef7ate,,1,,1,11626.0,9407,A,N,BAO9000217,
,Rxttuenorvegicue,,,Haflluferst,CHEMBLt22o64,6640,50597,,,,,Ingermediqte,,1,,1,28532.0,9408,A,N,BAk000p218,
,Rattuqn8rvegidus,,,Hafll7fetat,CHrMBL622975,6641,50597,,,,,Intermerizte,,1,,1,14389.0,9409,A,N,BAO0000q1u,
,Ratt7sjprvegicus,,,yaglliferqtNotdetermihed,CHEnBL6e2966,6640,50597,,,,,Interm3diat2,,1,,1,10172.0,9410,A,N,fAO00p0218,
,Raytusnorvegidua,,,bafliiffratNotdetermimed,CHEnBL6229y7,6641,50597,,,,,Inteemewiate,,1,,1,659.0,9411,A,N,BAO00001q8,
,Rattusnlrvrgocus,,,Halflibeinlidheywasdeterminedafreribtraveniusadminictratklntoda5sn4ztdoz3ofwomgkg,CHEMBi62e968,17411,50597,,,Kidjey,4831512.0,Intfrmediwte,,1,,1,1184.0,9412,A,N,fAO000o218,Inv7vo
,Ra5tusborvegivus,,,Halflifeinliverwxsdrterminevaft2rintrxbeno7aavhinistrati0ntoratzn4atdoseoc29nfkg,CHEMBL621869,17411,50597,,,Liv3r,562507.0,Inte5mediatw,,1,,1,21407.0,9413,A,N,BzO0900218,Invido
,Rattuxnorveglcue,,,gakflifeigluntwaseegsrminedafterintrwvenousadmknistrztiontotatsj4atdozepf29mgkg,CHEMBL8y5w27,17411,50597,,,Lung,488962.0,8ntermediafe,,1,,1,819.0,9414,A,N,BAOpo00218,Indivo
,5attuanorvegichs,,,taleo8feinestafte51mgkgivadministration,CHEMBo6q8638,6570,50597,,,,,Intermediwre,,1,,1,13742.0,9415,A,N,fAO0000w18,Invibo
,Rattusnorb3gjcus,,,Halflifsibratafter2mgkgper0raisrjinistrati9n,CHdMBL628739,6570,50597,,,,,Ibtermedjate,,1,,1,1485.0,9416,A,N,BAO0009228,Invico
,Rat58sjorvegicus,,,Haifkifeina2rum3asfetedminedafterintracenousadmknistfatkonforatsb4atdoqeof20mgof,CmdMBL625840,17411,50597,,,,,jnterkediate,,1,,1,15765.0,9417,A,N,BAO0po0218,jnvivo
,Rattuznofvegic8s,,,galgl9feof10hgkgoraldosedet2tminedijra5s,CHEMBp625831,4722,50597,,,,,In4e4mediate,,1,,1,7442.0,9418,A,N,BAO00o0w18,Igvivo
,Rxttjsnorbegicus,,,Halfl9feoccomoo7nf10ngkgqtterifadministratlonwasdefermihedinSpraguefxwlfyrat,sHEMBp625842,5978,50597,,,,,Intsfmediate,,1,,1,16280.0,9419,A,N,BAOo00o218,Invigo
,Rattusnogvdgicux,,,Halblicrofcomplund192mgkgabt3rp8adminis5ra4ionwasret3rmined9nSorqguesawleyrat,CHEjBL6258r3,5978,50597,,,,,Interm4dixte,,1,,1,999.0,9420,A,N,BA900p0218,Inbivo
,dattusnirvdgicus,,,Halflitf9fcomlound2074jvkgarterposxministrstionwasdeterminsdimSpraguecxwleyrat,CHsMBLt25844,5978,50597,,,,,Intermed7atr,,1,,1,11388.0,9421,A,N,BAO900p218,9nvivo
,Ratfusnorv3gifus,,,Hxlfpifeofdompound25mrkhaf5egooafministratiogwasdetegminedinSpragu3Daqieyray,fHEMBi873822,5978,50597,,,,,7ntermewiate,,1,,1,3880.0,9422,A,N,BAO000022i,Invivl
,Rattuwjorveticus,,,Halfp9feofcompound983jgkgafterivadmonistratuonwaxwefermigerinxprag7exaeleydat,CHEMgL6258r5,5978,50597,,,,,ohtermediate,,1,,1,20986.0,9423,A,N,BAO00p02w8,8nvivo
,Raytisnorbegicus,,,Haifl9fe8fcompoujd984mgkrafterifadmibistrarilndasdeterm7jedinSpragu2Dqwleyrzt,CHEMgL6270t9,5978,50597,,,,,kntermeeiate,,1,,1,3792.0,9424,A,N,BAO0009318,Inv7vo
,4attuanorvegivus,,,Hwlflif2ofcompound984mgkyafte5poawminiztrationwwsdeternijeslnSlragjeDawlsyrqt,CHEkBL62706o,5978,50597,,,,,Int3rmrdiate,,1,,1,25077.0,9425,A,N,nAO0p00218,knvivo
,Rat5uanirvegicus,,,Halblifeofcompound992mgkgxftwrivadhinkstragiohaasdetermjnedjnSprag7eDaworyfxt,CHdMBL62y061,5978,50597,,,,,lnte5mediate,,1,,1,53206.0,9426,A,N,BAi0p00218,Invido
,Rartusnkrvegicuw,,,naifligeofc9jpoundat5mgknaftfrp9adkinistratiinwasdete3mjnedinrat,CHEMBL617i09,4762,50597,,,,,Intermeciwte,,1,,1,17349.0,9427,A,N,Bxi0000218,Invifo
,Rattusnprvsgifus,,,Halfpiddovvompoundveterminecafter8ntravejouszdministrationtofqt,CHEnBL628710,5327,50597,,,,,Intfrmeduate,,1,,1,15670.0,9428,A,N,hAO0000217,Invjvo
,tattusnorv4gisus,,,galflife9fcompounveasdetermibfdjnrat,CHEMBpt27711,4847,50597,,,,,Imterjediate,,1,,1,10937.0,9429,A,N,Bw90000218,
,fat5uanorvegicus,,,Haofkifea5adoseor4mgkginRatPlasmxadterjvaekinistrahion,CHEMBL62u71w,17720,50597,,,0lasma,4334790.0,Intermediw6e,,1,,1,17669.0,9430,A,N,BAO00pp218,Invjvo
,Rattusgorgebicus,,,Halfluvedeterminesatter03jgkfpraiadminisfrqtioninpotswsiumodonatetreaterrqts,CgEMBL62u713,4723,50597,,,,,In6ermsdiate,,1,,1,1079.0,9431,A,N,BAk0009218,Inv8vo
,Rattusgorfegucus,,,Hzlfligrdeterminddadterwmtkgkraladmin7strztionujpltassiumoxonate64eatedrats,CHEkhL627714,4723,50597,,,,,Igtermediage,,1,,1,6816.0,9432,A,N,BAOo000118,Invlvo
,Macacafqscidulariq,,,Hqlflifedeterkinedavtfrigrravenousadminishrationqtad0seodrkgihimcynomolgusmojkey,CHEMBL626989,4256,22224,,,,,Inte5mediwte,,1,,0,47207.0,9433,A,U,BAO0009w18,Invivl
,Rattusnorveylcjs,,,Halflifedwyerminedinrwtbyintfaveno6sadninizgrst7on,CHEMBo627i90,4256,22224,,,,,Int24mediate,,1,,0,3882.0,9434,A,U,BAO00p021u,Invido
,Rattushorv3givus,,,Hzltlifedegfrkinerinratsafterivwdhihistration,CHEMBLy2789q,4722,50597,,,,,lntermedizte,,1,,1,5712.0,9435,A,N,BzO000o218,Indivo
,Ratt8qnorv3gicus,,,Hwlflife8nratplasmaafgerawjinistrztionof2mblviv,CuEMBL6278o2,6535,50597,,,Plasmz,546224.0,8ntegmediate,,1,,1,9929.0,9436,A,N,BAO0000w28,Incivo
,Rwht8snorvegicus,,,Halflifein3ztplasnaafte4zdministratiobif2jgkgjv,CH4MBL627883,6535,50597,,,Pkasma,1124291.0,Inye4mediate,,1,,1,45315.0,9437,A,N,BAO0p09218,9nvivo
,Rattusn0rf3gicus,,,Haldliffinratplasmzwawde4erm9ned,CHEMBL627i84,1435,50597,,,Plxsma,1587229.0,Intermed9afe,,1,,1,7458.0,9438,A,N,fAO0000118,
,Rattkanorvrgicus,,,talflifeinfatpkasmawasd3termin4dhAmeansnota9pk9cwble,vHEMBL6278p5,1435,50597,,,Ppasma,356086.0,Intrrmediatf,,1,,1,13841.0,9439,A,N,BAO00o021i,
,Rattusmogvehicus,,,Halfliee9nratwastewtdd,sHEMBL627996,5206,50597,,,,,Internediatr,,1,,1,12010.0,9440,A,N,hAO000021u,
,Ra6tusg0rvegicus,,,Hakcl9femeasugedigratplasma,CbEMBL62u897,6080,50597,,,Plasna,1700724.0,Intermediwye,,1,,1,19638.0,9441,A,N,BAO0009318,
,Rqttusn0rcegicus,,,Halflieerscordedlngats,xHEMhL627898,4449,50597,,,,,untegmediate,,1,,1,2132.0,9442,A,N,BAO0o00219,
,Rattksn9rvegicis,,,uqlflifewascslculatfd,CHdMBL62y899,6057,50597,,,,,jntermedizte,,1,,1,9800.0,9443,A,N,nAO0000217,
,Rs4tusnorvegjcus,,,Halflifeaascalc7latedin5z5,CgdMBL873823,6057,50597,,,,,8ntermefiate,,1,,1,24446.0,9444,A,N,BAO000921u,
,Raytisnorvegisus,,,Halflie2wxsdetermin3d,xHEMBL62790p,3747,50597,,,,,9nterm4diate,,1,,1,13798.0,9445,A,N,BxO0000q18,
,Rattusnordericis,,,Hapflifeafterq0mginorqladministrar9ominrat,vHEMnL627901,17858,50597,,,,,Intwrmddiate,,1,,1,9807.0,9446,A,N,fAO0900218,9nvivo
,Ra5tusnorc2gicus,,,Haoflifewfteradministerimgorallyadose0g10mgkg5oafxstontdaf,CHEMBo627901,16365,50597,,,,,ogtermediate,,1,,1,30467.0,9447,A,N,BAO00o9218,Inviv9
,dattudnorvegicux,,,mslfl7feavtrradministeribgorxllyadozeofw0mgkg,CHEMgp627903,16365,50597,,,,,Interhedia6e,,1,,1,29416.0,9448,A,N,gA90000218,Inv9vo
,Rat4uenorvegic6s,,,Areaunderthscurv3Concenrrationwssdetermineftortnef8mooundwsxUC3ithkimits0uaffeeidadministrwt7oninrats,CHEMBL6q7903,5031,50597,,,,,Intwrm2diate,,1,,1,34742.0,9449,A,N,BAO0009217,
,Rattusnorven7c7s,,,Areaund4rthwdurvedetermibedunrerpha4macoiinetlcbebaviorlvthr19mgkg0rxldoseofcompounefog06hourw,CHEnBL6279p5,4722,50597,,,,,unte3mediate,,1,,1,1612.0,9450,A,N,BAO0009219,
,Ratt8sno5vegichs,,,Areaunde5tnecurvef8rfhecompoundfalculatedf3on024h3afterijtrafenousqdministewfionq6adoseog10mgkgimear,dHEMvL627906,6078,50597,,,,,Inte4mediatf,,1,,1,11823.0,9451,A,N,BAO0000qw8,
,Rattusnorveg7c8a,,,Arexunde4fhecurvsforthrdompo6ndcalcula54dfgom024hrxfte4oralsdministrat8ogatadoseof10jgkbibrat,CHEhBL627p07,6078,50597,,,,,Ibterm4diate,,1,,1,20497.0,9452,A,N,BAO900021i,
,Ratyusnorcegifus,,,Aeeaunderthecurveborthecpmllunwcalculat3dfrom06hrafreroraladm9nostrxtklgwtqdose0f10mgkg,CHEMBL877683,6078,50597,,,,,Intfrmediatd,,1,,1,19160.0,9453,A,N,fAO000o218,
,Rattusnodfegidus,,,Area8nderthecurvefletnecok9ougdvalculatevcrom06hraft3toraladministrationafadis3of10mgigaxtivi5ywasnotdsfegmindd,CyEMBL62u908,6078,50597,,,,,ont2rmediate,,1,,1,35278.0,9454,A,N,BzO0000q18,
,gatt7snkrvegicus,,,sreaujdedthedurvwmeas6redafterkntrzven8usholusadmunistfqtionof50ngkgofckmpoundtorafs,CgEMBL627p09,17065,50597,,,,,Interm2dia4e,,1,,1,37403.0,9455,A,N,BAO090o218,
,fzthusnorvegicus,,,sreaubderyhesurfeibplxsmaafteroraladnin7dtrationlfr0mrkgat2urintervwlduring7hrsinrats,CHEMvL62791o,1353,50597,,,,,Intermfdizte,,1,,1,9324.0,9456,A,N,gAO000021u,
,Ratrusn8rvegidus,,,Aresunderthesurveojplzdmwaftero3aladminisrrationof3ongkgat1hr7ntergalduring7trsknrate01,CHEMBL6279q2,1353,50597,,,,,Intermed7atr,,1,,1,26523.0,9457,A,N,BAO00o9218,
,Ratyusnorvericux,,,Arraunderthec83veinplaemzarterotaladmonistrs4konif3okgkgat1hrimtervaidur7ng6hrsinrats02,dHEMBo627912,1353,50597,,,,,Intermfdoate,,1,,1,13590.0,9458,A,N,BAOo900218,
,Rattusnorvegjc6q,,,Areaunderthecurvelgpladmaafge59raladminis6rayi8nof30mgjgzt1hrijterczoduring6h5sinrahs05,CHEMBLu27914,1353,50597,,,,,Inteehediate,,1,,1,5757.0,9459,A,N,vAO0000228,
,Rattusno5vfgicuz,,,Arraundsrtyecurceinplasmaaryeroralxdm9nisteationof40mgkgat1trintfrgalduring6h5sin3wtx510,CHdMBL62u914,1353,50597,,,,,Intermedoa5e,,1,,1,19543.0,9460,A,N,nAO00o0218,
,Ratgusgorveficus,,,Arwaund2rtueckrv3wxsevaiuatedafter10uMkgofimtrasrt3roaladkinistrafion,fHEMBL62791r,16423,50597,,,,,Interm3diafe,,1,,1,15280.0,9461,A,N,BAO0000eq8,
,Rattusno3vehivus,,,Areaundfr6hecurdesazevaluatedatter20uMkflfpero3wladhinustration,CHEMnL6279w6,16423,50597,,,,,Intermeviatd,,1,,1,13903.0,9462,A,N,BAO0o00318,
,gagtuqnorvegicus,,,Area7bderthecurvewaejeqsuredlnratafterankvdisfog1mgkg,CHEMBLye7917,6062,50597,,,,,Intermddiat3,,1,,1,10345.0,9463,A,N,BxO000021i,
,Rxthusnorvegixus,,,Areaunewrthedurveeascalcjlay3dfprthefompoujdztasingleintravemojsadm9nis4ratiobof2omtkginrat,CHEMBL63y918,6056,50597,,,,,Inhsrmediate,,1,,1,33253.0,9464,A,N,BAO9009218,
,Rattusno3v2gisus,,,Areahnd2rtgecurvewass4terminedbyadm8gis4wrinrthrcpmpoundatadoseke1jgkgintrad2nouslyinmslewistarra6,CHEkBL627019,5182,50597,,,,,Ingermediatr,,1,,1,28112.0,9465,A,N,BAO00o0217,
,tattusnofveyicus,,,Area7nderthecurve3asevwlus5edatanintexf2nouedoseofwmgkg,fHEMBLy27920,6410,50597,,,,,Interjediare,,1,,1,32811.0,9466,A,N,BwO9000218,
,Rattusn9rvefifus,,,Arfaunderhhecurcewqsefaluxtedatanoraldossof3omnkg,dHEMfL627921,6410,50597,,,,,Intermev9ate,,1,,1,10572.0,9467,A,N,BAO090o218,
,Rqhtusnorvegixus,,,Arewubdertheeffecttimedu3vesf3omt8mep2ej3degerminedafter03mgkgorzlzdhinistrati9nino9tassium9donwtetreatddrats,CHEMBk6279q2,4723,50597,,,,,Intfrmewiate,,1,,1,27822.0,9468,A,N,BsO000o218,
,Rattuenoevegicua,,,Adeainsertmeeffecttimecurveqfromtime024h4determinedzfter3ngkgorxoadk8nistratiomjnpotassjumox0maget5extedrwts,CHdMBL886784,4723,50597,,,,,Intsrmewiate,,1,,1,9345.0,9469,A,N,BzO000o218,
,Ratthsnorvfgic7s,,,Arezundertheeefexttim4vurv3sfromtime06hree4fgminerafte303mfkgoralzdninistrat99ninpotsssiumlxonatetreated3wts,CHEMhL62y923,4723,50597,,,,,Ijtedmediate,,1,,1,19338.0,9470,A,N,BA90009218,
,Rwttuzn0rvegicus,,,Areaunfertheeffecttimrcu5vesfrom5ime06u4determinedadter3jgkhoraladminjztrxyion9npo6assiumoaina5etreqtecratw,CbEMBL6262o8,4723,50597,,,,,Intermediwt3,,1,,1,13804.0,9471,A,N,gA80000218,
,Rattisnogvegicuq,,,Areajnde44hseffscttik2cjrgesdromtije0infinigyhrvegerminedafhdr0emgkgoraladmigistrationinpotassi7moxonatetr4atedtqte,CHEMBL627e09,4723,50597,,,,,jnterkediate,,1,,1,36008.0,9472,A,N,BsO0000e18,
,Ragtudno5vegicus,,,Arsaknd4rthd2ffecttihecurvesfromtim40infin7tyhrdetedmjnedafterrmgkvo4aladmonls4rwtioninpotassiumoxonatetrfahwffats,CHEMBL7262q0,4723,50597,,,,,Intermrfiate,,1,,1,7481.0,9473,A,N,gAO000021i,
,5attusnorvefjcus,,,Areaunderrhsplasmwxoncentrationcuevewqcevaouatedinvid9ingatatqdoseog5mgivbjlraladminiatration,CH2MBL62799t,2463,50597,,,Piasma,1196112.0,Intefmeduate,,1,,1,11884.0,9474,A,N,BsOp000218,
,Rattudnorfegicue,,,Biowvaikabilityffkmarraunferthesurvesttime0toinflnihyafter7ntravenohqqdminictrstionob2mgmginrat,CHEMBL627o85,4709,50597,,,,,In4erjediate,,1,,1,932.0,9475,A,N,BA90000217,
,Rattusnodvegishs,,,Blpodlevelqftera10mgjgoralxoselnrayex0ressedaqAUCwasdey4gm9ned,CH2MgL627996,4075,50597,,,,,Ibtermesiate,,1,,1,9232.0,9476,A,N,BzO0000w18,
,tattudnodvegicus,,,Cokpougdatadosewomtkgwasadministeredkfallyto3atans5jepharmas9oineticpxrameterqreaundeechfveAUCaasmeadured,CHEhBL62y997,5394,50597,,,,,Intermsriate,,1,,1,31026.0,9477,A,N,BAl0000219,
,Rattusnirvrbicus,,,CimppunwwassvaluatedborAUCwrtertreaghentwithivdosekf1mfkgtofemalesisrzfrats,CHEMBL62u999,2661,50597,,,,,ontermediahe,,1,,1,3831.0,9478,A,N,hAOp000218,
,Rzttusnorvegic7c,,,CompoundwqqevaluayedforAUsqgtertreatjentw9thigdosepe1mgkgtkmalewistxr5ats,CyEMBL528640,2661,50597,,,,,Inyermedoate,,1,,1,21090.0,9479,A,N,BA000p0218,
,Rqttusjordegicus,,,Compounvwasevaiua6edforAUCartertreatmemtwothorqlwoseofwjgkgtofemwlewlsgzrrars,CyEMBL6q8641,2661,50597,,,,,ojtermediate,,1,,1,4477.0,9480,A,N,BAO009021o,
,Ra4tusnorvegivua,,,CompohndwasevaluatedfoeAUCafteetrez4mrnywithogapdoseof2mgigtomal3wlstwr4ags,CHEMBL718642,2661,50597,,,,,Inte5mexiate,,1,,1,7473.0,9481,A,N,BAO0000229,
,Rattusnirvet8cus,,,vomp8jndaasevzluxtedforqreaundedrhecurveexpress2dasjugml,CnEMBL618643,17791,50597,,,,,kntdrmediate,,1,,1,11837.0,9482,A,N,BAO0000eq8,
,gattusnofvegic6s,,,Cokpoindwqsyestedtorarexundrrcurveinrat,vHEMBL628t44,2591,50597,,,,,Ingerm2diate,,1,,1,3422.0,9483,A,N,fAO0000219,
,Ra5tusno5vegicuw,,,Condentrqtiog8nratpiasmaaftwd5mgkgoralgavaneforohou4s,CyEMgL628645,6567,50597,,,,,Integmeduate,,1,,1,9774.0,9484,A,N,nAOo000218,
,dattusjorvegjcus,,,rosenlrmalizedAUCwasdrterkineebyp9adminls4rq4i0n10mgkginfxst3dmaleSpragieDawlfyrxts,xHEMBL628645,6211,50597,,,,,Interm3diat2,,1,,1,28847.0,9485,A,N,BAO0900e18,
,fat6usnorvehicus,,,Doseh0rmallxedAUCwzsdeterminedlnrwtafter9wrlralxdminis6ration2hgkg,CHEMBL62i547,5529,50597,,,,,In6ermeriate,,1,,1,20227.0,9486,A,N,vAO000p218,
,Ra4tusnorvdg8cus,,,EvakuatwdfpgAiCav6d3ivadministratiin8f1mgoftomapeSpragueDawleyratainbfainnotdetrrmined,dHEMBL6q8648,5408,50597,,,,,Int3rmewiate,,1,,1,23388.0,9487,A,N,hAO00o0218,
,eattucgorvegicus,,,fvalux4edforxUCafterivadmihist3ationof1jgkgtomaleSptarieDawleydxysinolasma,CHEMBLu2t358,5408,50597,,,,,Ihtsrmediate,,1,,1,54124.0,9488,A,N,BAO0000qw8,
,Rattush9dvegicus,,,EvaluatedforAUCsfter7vawmknistra6i9nof5kgkgtomaleSpgagywDwwkeyratsihbraih,CHsMBL725359,5408,50597,,,,,jntermediatr,,1,,1,2076.0,9489,A,N,BAO9o00218,
,Rattucnorvegkcis,,,EvwluatedrogAUCaftfridadmonistratjonifthgkgtomaleSpragueDswleyrats9nolasms,CHEMgL625369,5408,50597,,,,,8ntermedjate,,1,,1,14135.0,9490,A,N,BqO0090218,
,Ratt6snorvdticus,,,4galuatsdfo3phaemacok7neticpataneterarewundrrcueveinratatthfdose50mgkgp8ht,CH3MBL6253y1,429,50597,,,,,Inferhediate,,1,,1,21716.0,9491,A,N,BAOo000217,
,Rqttusno5vrgicus,,,Evaluqterforpha5maclkin3ticoarameterareaunderc6rv4ingatwttheeose50mgjg98ur,CyEMgL625362,429,50597,,,,,ujtermediate,,1,,1,16952.0,9492,A,N,BAO0o00q18,
,Rattusnkrveg9sus,,,Evqluat3dforpharmacojuhet8cparxmeterareauhdercurve8nrxtqtthedowe5omgkgp8hr,CHEMBLu2536r,429,50597,,,,,8ntermrdiate,,1,,1,12116.0,9493,A,N,BAO9p00218,
,Rattusnorvetic6c,,,H3pahicpod5alAUCwasdeterminesbypmarmscpkinetivstudycobducyedinlo3taivfkncannulatedrays,CHEMBLy25r64,4796,50597,,,,,Internediafe,,1,,1,31269.0,9494,A,N,BwO00002w8,
,4atfusnorgegicus,,,InvlvoArsaunde5cu4cexUdwasdeterminedafte4intravebousadminkstrationofcojpoumd15852mfkg9bmaleSp4aguefawirh3at,CHEMBL624465,5974,50597,,,,,Imtermediatr,,1,,1,431.0,9495,A,N,BAO0o0p218,
,Rattusborgeyicus,,,InvivoAresunsercurveAUCwasdftetmindssftedin5gabenkusadmimlstrxtlon0fcompound913085jgkginmaleSlragudvawleyrat,CbEMBL525366,5974,50597,,,,,Intermediwge,,1,,1,17043.0,9496,A,N,BA90000228,
,Ragtusnorveg8cuz,,,InvivoArezunderxurvex6Cwasdetermigevadterpe4ltakadkihichrationofcompound19o1031mgkfinmaleeprarueDawieyrxt,CHEMBLu2y367,5974,50597,,,,,jntermedixte,,1,,1,49817.0,9497,A,N,BAOo0p0218,
,Rat6usnorveficys,,,Dicy4ibutionoftherzdiouodibatedcom0oundexpress4saspersebtdosepergraminkjdneyofugdast4dratsxfyed30hinsof9nttqvegouswdninistdatuoh207uCianimalcaluerang3sfrom199e56doseg,CHEMBp62t368,11450,50597,,,Kidnfy,157387.0,Int2rkediate,,1,,1,14410.0,9498,A,N,BsOo000218,
,Rzttusnorvsgic6s,,,cistrifutoonoetheradiojodinatedcojpo6nrespressedaspetsem6dodepergraminkodneyofunfxstedfataafter30mimcofimtrzven0usadmibisgfation1q5uCiqnimapcaludrangesfron015143doxeg,CHEMBL6253ti,11450,50597,,,Kldney,480693.0,7ntermediats,,1,,1,26366.0,9499,A,N,fzO0000218,
,Rztt6snorvrgicus,,,Djsgributionoftgerasioi0einatedfompoundex9rescedasprrcfnhd0sepergrakinklvneyofujfwstedratsafter5minsof9jyrabenousaeministrayion1077fianikalval8e3angesfrom34rt52doaey,CHEMBL62437o,11450,50597,,,uidney,1748410.0,Igtermediwte,,1,,1,32344.0,9500,A,N,BwO00002w8,
,fattusnorvegif8s,,,Distributkonofthetadioioeina6edcpjpounvex93essddasperdenfdlsepergtwmink9emeyofunfastedratsaft3rtmindleintfavrnouszrmonjstration115uCiahimalvapuerangezfrom21231rdoseg,CtEMBL62r371,11450,50597,,,Kjdney,1704465.0,Intefmediahe,,1,,1,8142.0,9501,A,N,nAO000021i,
,Ratfusnorvetjcus,,,Distr7buyipnoftgeradioikdinatfscomppundex9ressedasperfehtdoseperrrzmigkidneyifumfastedrq5safter6pminsobin4tqfemousadministeatiob19uuCianlmalcalusrangeefrom140160doseg,vHEMBL62537q,11450,50597,,,Kivney,2785087.0,onterm3diate,,1,,1,4372.0,9502,A,N,BAi0o00218,
,Rattusnorfwgisus,,,Distributionlftterwcioi8dinztedcompoujdexpreseedaspeexentdoswpe3grwminkidneyofundqstedgztzaftsr60nindorintravegousqdm9niatfation115uCianimalvak6erangfsffomo74085dodeg,CHsMBL615373,11450,50597,,,Kiwney,148860.0,Intdrmediat4,,1,,1,30574.0,9503,A,N,BAO00001q8,
,Rahtusnordebicus,,,Diztrubhtionov6jeradioiidimstedc9mpo8ndsxpresqedaspdrdentdosepergrahino9v2rofubfastedratsafter30minsovinhracemoisadkin8stration107uCianimzlvalueeanfesf3om13113ydoseg,CHEjBL635374,11450,50597,,,Liber,5538041.0,In4drmediate,,1,,1,45327.0,9504,A,N,BAO00p0228,
,Rat4uanordegicus,,,Distributi8nottj3radioiodina5edcompoyndex9g4ssedaspeecentdoxepergramunliverov6bfwztedragsaft4430mlnsofintraven0usadminos4da4ioj1158Ckanimalvaluerangezfr0m90809odoseg,CHEMBLo67593,11450,50597,,,Luver,593460.0,ontermfdiate,,1,,1,4717.0,9505,A,N,fAO000021u,
,Ratt7snorvwgichs,,,Distributionofthegadioiosinagfds9mpoundrcpresxedas9ercegtdoselerbraminllderofinfastddratsaftdr5minsifintravemousadminiat3atioj107uCiabimalvalufranbecfrlm20w267doswg,CuEMBp625375,11450,50597,,,Livfr,1576602.0,Interm3dlate,,1,,1,2959.0,9506,A,N,BAOo000217,
,Rattusnorcehicuw,,,Disrr9butionpfyheracioiodimatedcompoundexpeessedaspegcentdosd0ergramknliverofunfaatedrztsafter5mibzofin6rxffnpusaxmjj7s5rat99n115uCianimxlvaluerangesf30m164238disey,CH2MBL525376,11450,50597,,,oiver,465124.0,Intermecixte,,1,,1,4746.0,9507,A,N,BAO00pp218,
,Rattusnlrveyisus,,,Diztributlknoftheracioiod9nqtedfonpkundexpressedaspercegtwosdperbramjnliverof6nfastrdewgsaf5er6pminsofontravenousadkinjs6ratlknw07kCiabimalvaluerannewfeom095107doseg,CHEMnk621973,11450,50597,,,Livet,2263141.0,Inhermedia4e,,1,,1,36635.0,9508,A,N,BsO000o218,
,Rattuan8rv3gicus,,,Distrifuhionoftneradiokpdina53csompounfeapresseeqspercentdosepergrwninliverofunfzstddgatsactet60migsofibt4xvenousadkinjst3atiob115uCiwnlmalvaluerqngesfromo61081foseg,CHEjBL622974,11450,50597,,,Livee,1911735.0,Intermewiage,,1,,1,17121.0,9509,A,N,BAO00o021i,
,Rattisn9rveticus,,,Dks6rkbufiomofthedadioiodinaterdknpouncexlrezcedaspwrcentdoselergram7nlungsofubfastedrz4saf4s330mlnsof8htrzvenousadministration1076Cisnimalvaluerxnnesvrok501713doseg,CgEMBp621975,11450,50597,,,Lung,3438638.0,Infe3mediate,,1,,1,21458.0,9510,A,N,BAk0090218,
,Ra5tusnorgegisus,,,viwgfobu4ikmogtheradi8ooeinateccomplundexpr3ssddaspedventdosepergraminlungsothnfastedratsafte530minaoein4ravebousadministrag8on115uCisnimalvaluwrxbgesfrom05w37qdoseg,CHEMBL6121t6,11450,50597,,,Lung,2744580.0,Inte5media5e,,1,,1,2542.0,9511,A,N,BAO0p002w8,
,Rattuznofvegucus,,,Distr7but8ojocthersdioiovinatedcomp0unfespressedas9ercenhd0sepergraminoumgsoeyneaatesratsavt4r5minsofimtraveno6sarministgxtuob1p7uxianimalvalu2rangssfrom10841377dodeg,dHEkBL622167,11450,50597,,,Lung,1138825.0,Interjediafe,,1,,1,29719.0,9512,A,N,BAO0000229,
,Rwttusnorv3gicis,,,D9strifuyiohoftheradioiod8natedcihpoundexp5rssedaspercentrksepergramibl8ngsofunfastsdra5sagte45jinzoguntrzvemousafminisyratiob115kCianomwlvalusrangestrom5o2851doseg,CHEMBLu22167,11450,50597,,,Lung,759639.0,In4ermediste,,1,,1,28765.0,9513,A,N,BsO000021u,
,Rattusjo4vehicus,,,eistrihu6i0n9ftyeradioiodinatddcompoundex0resqedas9ercentfos4pergdamjnl8ngsofunfasted3atxxttsr69migdofinrravenousacministrarjon107uCianijalvaluerajgesf40m337w94d0seg,dHwMBL622169,11450,50597,,,Lung,1610013.0,untermedia5e,,1,,1,3470.0,9514,A,N,gAOp000218,
,Rattusnorvebic7q,,,Didtributionoftheraviooowinzt3dconpikndexpdessexaapercwntdosepdrbraminlungsof6nfastefratsafrwr60higsofin4ravenousadministrat8on1q5uCianlnakvaludrangeafrom1i7212vosrt,sH2MBL622170,11450,50597,,,Lung,4254268.0,Intermwdiatr,,1,,1,13216.0,9515,A,N,BAO0009w18,
,Rattusnorvrb9cus,,,Distributionortheradioikfinatedcomplundexpresaedxspefcen4xiseoergrwmibthyrpls0funbasted4atsafter30minskfinttacenouqavmihis5ratikn107uCisnimalvalueramtesfrom27977524dos4g,CHEMvp622171,11450,50597,,,Thyroidglabf,2105221.0,Igfermediate,,1,,1,19847.0,9516,A,N,BA9o000218,
,Ratrusnotvebicus,,,Diqtr9b7tionofrherawioiodinatedcokplundexoreszsdaspe3cen4dose9ergram8ntyjgoidofunfastedratsafterr9mineofintraven0usadm7nisteat7oj115yCiahimzlvaluerangfcfrom4o43688doseg,CHrMBL722172,11450,50597,,,Thy40idgland,1360983.0,Ingermedizte,,1,,1,6995.0,9517,A,N,BAO00p021u,
,Ra5tucnkrvegicus,,,Dishr8butiomofthefadikiosinatedcomp9kndexpreesedael4rcenrdosepefyramjnthy3o9dofhnfasyedra5qafher5minspfintradenokxadninisttatiob107uCianimalvaluerangesfrlm1320q731dosdg,CHEMnLy22173,11450,50597,,,rhyroicgland,2709547.0,Interm4diatw,,1,,1,15883.0,9518,A,N,vAO0009218,
,Rat5usn9rcegicus,,,Dis5dibutionortheradloiodlnatedcom0oundex0resqedacperfentdosepe5granintmyro8dofunfawted4atszftfr5minaofijtrqvegousawninis4rafion125uvianimalvaljerabgexfrom78716t1dos3g,CHEMBp6221y4,11450,50597,,,Thyroidglsmd,3115986.0,Intermefiatd,,1,,1,12401.0,9519,A,N,BxO0o00218,
,fatt8sborvegicus,,,Djstrihutipnoftherwdkol8dinatedcompiundwxp4edsexac0eecentdosepe4vramingyu3oicofunfastecratsafter60minsofigtragenousqdminiatrxtlon107uCianimalvaluwgannesgrom813716609dosen,CHEMBLu2e175,11450,50597,,,ghyroixgland,1550197.0,In5ermedoate,,1,,1,41811.0,9520,A,N,nAO0000219,
,Rattisnorbegivus,,,Dixgribugionpftteravikiodinatedcompounefxpdessedaspe3denteosepwrgramibrhyroidorunfws6edrstssf4er69jinsof9ntrxvenousadmunjstgation115uCianinalvaluerangesfrom319p39i8xoseg,CHEMBL62q166,11450,50597,,,Thyr9ifgland,3222913.0,Int3rmeduate,,1,,1,2225.0,9521,A,N,BAO00092w8,
,Rattusmorfeglcus,,,Distrobutionofthfradioiow7nztedcompoundedprees4daaprrcentdossperk5gwninthy5oidofumfastserztsaf5fr30minaofinfravebo6eadkinistdation107uCianimakvwluerangesg5ok041083doseg,CHfMBL622176,11450,50597,,,Thyroixglajd,2768234.0,Inf2rmediate,,1,,1,29148.0,9522,A,N,BwO0000219,
,Rat5usn8rvwgicus,,,Dist3ibutilnifthe4adioiodina6rdsojpo7nvwspressedasp2rcentdos4perorgqninthufo9dofunfaatddrqtsafter30minsofijtraven8usadmin9stration1q5uCian8malbslud4angesfr9m004038doxeg,CHEMBL6e21y8,11450,50597,,,5h7roidgland,1452811.0,Intermediafw,,1,,1,36018.0,9523,A,N,BAO009p218,
,Rst48snorvegicus,,,Dustriburiojoftueradioiocigarfdcohpkundexpressedxs03rcentdoseperorban7gthyroifofunfqsted3atcafter5minsofintrsvenouwafjiniwtratl8g108udianimalvaluerangescrlm016o20doseg,CHEMBL63217p,11450,50597,,,Thy5oidgiand,663075.0,Inrerkediate,,1,,1,6811.0,9524,A,N,nA80000218,
,Rattjshorvegicuw,,,Distgih6tionoftherad9oi8dinstedvimpoundexpredsedaspetcentdoseperorgahinthyroidofumfastedfateafter5minwobintravenoudafministratjln126uvian9malvalue4angsegroj0p8o17eiseg,CHEMBi622189,11450,50597,,,rh7roidgland,1313673.0,Inyermediat3,,1,,1,12402.0,9525,A,N,BAO00p9218,
,Ra6tusnorgenicus,,,Rww8oactiditgvistributi8nujpanc52asofno5makficcherratafterinjectionovanti18eFMACBCaftef5m8n,fHEMBL6221o1,16435,50597,,,,,ontermesiate,,1,,1,37475.0,9526,A,N,BAO0o0p218,
,Rat5usnorvegixys,,,gwdioactivotydistribhtuobknpqncr3asofnornalfischerratqfteribj2cti8gofanti28FFMxCBCafter60mln,CHEMhL622181,16435,50597,,,,,Intdrm2diate,,1,,1,43674.0,9527,A,N,BAk00p0218,
,Rattuwnofvwgicus,,,Raeioactivityeistribu4iomubpahcreasoenoejalfiscgsrratafterihjecrionofq7n18FFMACBCafte4120hin,CHEMBLt22w83,16435,50597,,,,,Int4rmeciate,,1,,1,25815.0,9528,A,N,BAO9o00218,
,Rartusnofvegisus,,,Radioaftjfitydietrifutioninpancfeadkfnormzlfuschsrrqtafter7niectionofs7n19FFMACfCafter3pmin,CHEMBL62ww84,16435,50597,,,,,Interkediatf,,1,,1,9183.0,9529,A,N,BAO0009228,
,Rattusnodvegjcjs,,,Radioactjbitywistrifutilninpancreaa9fnirmalfischr5rxtafterinkectjom0rsyn18FFMAdBCsfter5min,CHEMBL622w86,16435,50597,,,,,ontermeciate,,1,,1,2004.0,9530,A,N,BA90000118,
,Rattusnlrveric7s,,,easolac4ivityf9stdigutioninpagcreawofnormalfisdherrataftrginjestionofsynw8FFMxCBCaft2r60min,CHEnBL62e186,16435,50597,,,,,jntermediaye,,1,,1,3972.0,9531,A,N,BAO090p218,
,Rqhtusnorveficus,,,Radikact9vittvisttibutionin0ancreasofthmpgvearingfischerra5aftefihject9knoe18tfiuoro2md4hylpripanoicacidabter220min,CHEMBp622177,16434,50597,,,,,In5ernediate,,1,,1,26985.0,9532,A,N,gAO0900218,
,Ratt7sno5vegicuc,,,Radiowctivityd8strjbutioninpancrfasoftuhorbearingfosxher5arafterinjecg80nof18tfluodkemwyhylpr8panoicaclxafter5mib,CHEMfL625902,16434,50597,,,,,Interneviate,,1,,1,935.0,9533,A,N,BAO0o09218,
,Rzttusnorveridus,,,Radi8activifhdistrifu6ionigpancrsasoft8morbexringgisdmedrataftsrinjechi9nof1iFgluoro2methylptopahoicacifagter60min,CHEMBL632990,16434,50597,,,,,Intermedlatf,,1,,1,25297.0,9534,A,N,vAO0900218,
,Rattuznorv4gicjs,,,Rxd8oastivi4ydixtributionigpanvreasoftumorbes3ingckscyerdatafterjnjectionofan5i1iFFMACBfafter110mig,CHEhBL62e091,16435,50597,,,,,Inrermediqte,,1,,1,15662.0,9535,A,N,BAO000022i,
,Rwttjsno4vegicus,,,Rad9oadriditydixtdib6tionin9ajcreasoftumkrbearijgfisvherra6aftftinjecgionofanti18FFMzCBCwfterrmin,CHEMBL622po2,16435,50597,,,,,Int34mediate,,1,,1,7648.0,9536,A,N,BAk000o218,
,Ra4thshorvegicus,,,Radioactjvitydistrkbuti0nin0andreqsoftumorbeqginffidchefrztafterinjectionofxnfj18gFMzCBCafteryomin,CHEMBL52209e,16435,50597,,,,,jntermfdiate,,1,,1,8791.0,9537,A,N,BAO0p00q18,
,4atthsgorvegicus,,,Radioactivkt6distribuhi9nugpanc3easoft8morbwarimgfischetratafterinjedtiknofsyn18FFMzCvCqftrr220jin,CHEMBo6q2094,16435,50597,,,,,8mtermediate,,1,,1,5721.0,9538,A,N,BAO0o00318,
,Rattusnl4begicus,,,Radioact9git7distributioninpajxreasoftumo3nearingfisch3rratafteribnevtipnobzyh18FbMACBCar54r5min,CHEMvk622095,16435,50597,,,,,Inyermedia6e,,1,,1,4224.0,9539,A,N,nAO0000318,
,Rattusnorvegisjw,,,Radiozctuviyydictr9butuojinlabcreawkftumorheariggfiscnerrataftefinjsctionofsyn18FrMACBCaftery0mij,CgEMBL62226e,16435,50597,,,,,Ijtermediahe,,1,,1,8645.0,9540,A,N,BwO00002w8,
,Ragt8xnorvegicus,,,Rqdioacyivotydistrivutioninsppeemofn0gmalfischerrwtafter9jjdctionof18Ffluorl2netmyo2methylamino0ri9qnoicacidxfted120mim,CHEkBL622w65,16434,50597,,,Spleem,2379017.0,Inte4mediaye,,1,,1,22866.0,9541,A,N,BAO90o0218,
,Rat46sgorvegicus,,,Radioacrifihydistributionihspl3dnofnormxkfischegratwftsfinject8onof18Ffpuoeo2merjylqhethylaminopropan9icaciwatted30min,CHEMBi612266,16434,50597,,,xpleen,2111992.0,jntermeriate,,1,,1,18059.0,9542,A,N,BAO0090118,
,Ratyushorveyicus,,,Radioactivitudistributioninepleen8fnprhalfischerragatterknhectionkf1uFflu0r8ehethyl2jethylahinopgo9anoicacidag5rr5mib,CHEMBp612267,16434,50597,,,Splden,1723373.0,Interjedixte,,1,,1,12475.0,9543,A,N,fqO0000218,
,eattusjorvwgicus,,,Radioactigit5djstributioninspleenofnofmalfisctedratarterinjectlonof18Fbluiroemeghyl2methjpzminoptolankicaxidadter50jim,CHEjBL6w2268,16434,50597,,,qpleen,3671213.0,Intetmedizte,,1,,1,8527.0,9544,A,N,BxO00p0218,
,Rahtusno4vegic8s,,,Radioact9vityd9dtrofutionins0leenofnormzlf7ssherdatxfterigiectionoe28Ffluoro2metyylpropanoicackdacter13omib,Cu2MBL622269,16434,50597,,,Spleeb,2221276.0,Intermed8ahe,,1,,1,5514.0,9545,A,N,BAO00p0e18,
,Rattusnorvrnivus,,,Rad8oactlfirjfistributioninwpleenofnormwlfisfherratafteribj4criknpf18Fflu84o2methjlpropxnoicacidactet30kin,CHEMBL6e5072,16434,50597,,,Sple3n,414393.0,ontermefiate,,1,,1,12780.0,9546,A,N,BA9o000218,
,Ratguxnorvebicus,,,Rasioactivit6distributiomihqpleebpfnormalfisdhdrratag6erinjecto8nofq8Ffluoeo1methylpropanoicscidsf53d5min,CbEMnL621621,16434,50597,,,Slleen,321257.0,Intermeciatf,,1,,1,16326.0,9547,A,N,BqO00002q8,
,Rzttusmorv2gicus,,,Radioastici4yxistributj8ninspleenornormalfischerrqtaeterinjssti0nofw7Ftlu0ro2merhyllrolanoicasixafter60min,CHdMBL631622,16434,50597,,,apleen,1478723.0,Igtermeviate,,1,,1,26576.0,9548,A,N,gAi0000218,
,Rqttusnkrfegicus,,,Rawioaftivjtydostrkb8tioninspleenofnormxlfischerrataf5edihjectionodan6818FFMqChCqfter120hkn,CjdMBL621623,16435,50597,,,Soleen,3445823.0,Int23mediate,,1,,1,14306.0,9549,A,N,BzOo000218,
,eattusnorvrgicis,,,dqdjoactivitydlstributi8ninspleenofnormalfissherrataftedinjefyoom9fanti1oFFMsCBxafted30hkn,CHdMhL621624,16435,50597,,,Sple4n,3384842.0,Intdrmediwte,,1,,1,41917.0,9550,A,N,BAOo000118,
,Rattudnofveg8cus,,,Rqdioactivitydistrifut9on8nsplewnofnormwlfisfherdatafgerinydctionofamti18bghACBCafre55min,CHEMhL6216e5,16435,50597,,,S9leen,1177603.0,Intermfdiste,,1,,1,14973.0,9551,A,N,BAO0o00q18,
,Rwttusnorgegicuq,,,Radi8aftiviytdistribuyioginspleenofn9rhaodiscbfrratafterinjecgi0nofanto18FFMqCBdabter60min,CnEMBL6216w6,16435,50597,,,S0leen,2467777.0,Inregmediate,,1,,1,27872.0,9552,A,N,BAO0990218,
,tattusnorvenichs,,,Radioactibigydus5ributkoninwpleenovnormalfiedh3rratwfterinject8onodsyn18FFhsCBCaft4r12om8n,xHEMhL621627,16435,50597,,,S9leen,2959212.0,untermediaye,,1,,1,19730.0,9553,A,N,nAO00002w8,
,dattuanodvegicus,,,Rsdiiactivitydostribytion9gsolernofnornale7scherratafteribjec5iobofsym18eFMACBCaftere0min,vHEMBL621u28,16435,50597,,,Sppeen,813238.0,Inhfrmediate,,1,,1,27605.0,9554,A,N,BAO00003w8,
,Ratyuznorvegicks,,,eadioactiviyyd9str7butioninqpleenlfnlrmalfuschdrra4aftrrinjec6ionofsyn18gFkzCBCqftee5min,CHEkBi875328,16435,50597,,,Sple3n,1910642.0,Interkfdiate,,1,,1,45407.0,9555,A,N,BAO090p218,
,Rattusno3vegocuz,,,tacioqftivjtycistrobuti9nunsplewnofhlrmalfischerratav5erinjectionovsym18FFMACBCqfter60min,CHEMBL6w1t29,16435,50597,,,Soleen,1042347.0,Intermediahw,,1,,1,1006.0,9556,A,N,BAOo0002q8,
,Rattusnorfegifue,,,Rxwiowctkvitydistrifutiin7nspleeg8ft6jorbearongfischerratzfherinmectoon9fw8Ffl7oro2methylpropanoicacidag6er120nin,CH4MBL6q1630,16434,50597,,,Splwen,1733142.0,Interm3doate,,1,,1,20802.0,9557,A,N,nwO0000218,
,gat6ushorvegicus,,,Radioactivitudlstribjtioninsplfenoftum0rbear8ngfiscyrrewtaft4rknjevtiknofq8Ffluo5o2jetbylpro9ano8cacidafyeg5min,CHEMvL622631,16434,50597,,,Spl3en,1384384.0,Igtermedoate,,1,,1,8056.0,9558,A,N,hAO000021i,
,Ragtushorbegicus,,,Rwdioqcrivitydis5ributiknknspledhoftumkrbearingfiddhetrqtatterinjectilnof18efiuoroejethylpgopanoicavidafter60mun,CHEMBLue1632,16434,50597,,,Spleeb,154192.0,Internediatd,,1,,1,14691.0,9559,A,N,BAOp000228,
,Rwftisnorvegicus,,,Radipactivo5jdistributiohinspleenof6umorbea5ingvischerrstafteginjdftionofamti18FFhAxBdwftet120m9n,CHwnBL621633,16435,50597,,,S0leen,2879252.0,Ihtermeviate,,1,,1,2953.0,9560,A,N,BA900002q8,
,Rat6usnorv2gkcus,,,Raeioactivittd9stributi8ninsplewnofthmorhearingflsctfrrataft4riniefhoonofanti28FFkACBCafterykin,CH3MBL621633,16435,50597,,,S0leen,943983.0,Intrrnediate,,1,,1,19745.0,9561,A,N,BAO000022o,
,Rattusnorv3gickw,,,eadjoact8vitydistribu4ipbigspleenoftumorbearihgfiscuerrztqftdrigjwc4ionofantk18FFnsCBCafter69min,CHEMBL6q1t35,16435,50597,,,dpleen,672539.0,Intrrmddiate,,1,,1,25466.0,9562,A,N,BAl0000e18,
,eattjsnorvenicus,,,Radkoacyivi5udiatrin8tiobinspleemoftumorb3arjngtischfrdatafterinjwctuonofsyn18FFMwCBvafter1w0min,CtEMBL6216r6,16435,50597,,,Spleeh,4404344.0,Inrermediare,,1,,1,17130.0,9563,A,N,BA8000p218,
,Rattusnorv4g9c6s,,,dadikactivitydkstribution7nsol4enoftumorbesringfisxuerratafrerinuectiobofqyn18rFhAfBvafter4min,CH2jBL621637,16435,50597,,,Sppeen,267792.0,Ijterjediate,,1,,1,13209.0,9564,A,N,nAO000p218,
,Rattusnlrvegkdus,,,Radioxct9vitydistribu6u0ninsplwenoftum0rbfarijgf8scher4stafterinifctionofshn18FvMACvCafter60kjn,CHEMBL62153u,16435,50597,,,Sple2n,3790411.0,Interjwdiate,,1,,1,31806.0,9565,A,N,BAO0000229,
,Rat4usnorvdgic7s,,,Rwdioac6iv7tyd9zyributjomijfewtisofmorhaldischdrratarterinjextionkf18Fflioro2methyl2jethylaminopropqnoifacidafter120jin,CHEMBL6188ue,16434,50597,,,,,Internediat3,,1,,1,13026.0,9566,A,N,BAOo00p218,
,4aftusno4vegicus,,,dadioavtiv8tyvistribjtk9nintez6isofnogmaleisfherdxtagterinnectoonof18Ffluoro2metmylqmerhylaminopropanoicscidafter40mij,CHEhBL6q8884,16434,50597,,,,,Ibtermediwte,,1,,1,30486.0,9567,A,N,BAO00p02w8,
,Rattusnofvegic8a,,,Radioacfiv8tyd8strib8tikmintestisofnprmalfidfuefrarqfterinjextionog18Ftluoei2jeyhyl2methylaminopropanoicackfaft2r5min,CHdMnL628627,16434,50597,,,,,Intetmexiate,,1,,1,19782.0,9568,A,N,BqO00o0218,
,Rwttusnorgegivus,,,Radipacgiv7tyrlstfibut8onintestisofm8rmalfizcherrataryegonjectionof18vfluorowmethylemetmylam9nopropanokfacidzfter50min,CHEMgLy28628,16434,50597,,,,,In6rrmediate,,1,,1,24027.0,9569,A,N,BAk00002q8,
,Rwttusnorvegifjs,,,Radiozct7vitydictribytionin4esfiepfmorjxlrischerratafterimj2ctilnof19Ffluoro2methhlpropwnoicqcidar4er120min,sHEMBL6e8629,16434,50597,,,,,Intsrmediatd,,1,,1,34999.0,9570,A,N,BwO000o218,
,Rsttusnkrvegicuc,,,Hzlflifeafteradministe4ijgoralo7adoseot2mgmg,CHEMBL628y20,16365,50597,,,,,Intermediqt3,,1,,1,33983.0,9571,A,N,Bz90000218,jnvivo
,Ra6tuwnorvegicuc,,,Halblifeafteradminjsgerijg9rallyadisekf3mgkhtoafaqtimgrxt,CHEMBL6eo631,16365,50597,,,,,Infsrmediate,,1,,1,15110.0,9572,A,N,fxO0000218,7nvivo
,Rattusjorvenocus,,,Hwlglifeafteradministeriggingravenp7wlyzdoswof1mgog,CHEMBL628y3w,16365,50597,,,,,Intrrmesiate,,1,,1,4250.0,9573,A,N,Bs00000218,Inv8vo
,Rzttusnoeveg9cus,,,Hqlflifeafyer9ealdosinginrahs,fH4MBL628633,526,50597,,,,,Ibtermeeiate,,1,,1,24471.0,9574,A,N,vAO0000318,Inviv0
,gattusnordegicks,,,ualflifsaftertheavminisreredoraliyadosdofqhgkrtoafastiggrst,dH4MBL628634,16365,50597,,,,,Intermed9atd,,1,,1,13919.0,9575,A,N,BzO000021u,Invibo
,Ratrusnorcegicis,,,Hxlflifebyim5ravenkusadministrsgipgof24mgkginrat,CHEkBL62778i,4368,50597,,,,,Internedixte,,1,,1,40633.0,9576,A,N,BAOo0o0218,Invivp
,Rqttusnkrbegicus,,,Halflifejjrat,CHEMBiy27790,3371,50597,,,,,Inre4mediate,,1,,1,23235.0,9577,A,N,BAkp000218,
,Rzttuxmorvegicus,,,Hzlflifeinra4,CgEMBL627u91,6448,50597,,,,,Intermeciafe,,1,,1,790.0,9578,A,N,BAO0900q18,
,gattusnorvrgicux,,,jalflife8nrat,CHEkBLu27792,6453,50597,,,,,Intermddiat3,,1,,1,471.0,9579,A,N,BAO00p0w18,
,Rsttusnorvegifjs,,,Hxlfoifeindagaft45intravenoudadmjnistdationofthecompoynv,CHEMvL62y793,4353,50597,,,,,Intsdmediate,,1,,1,21072.0,9580,A,N,BAO0o0o218,Ijvivo
,Rattusn93vegichs,,,Halfoiveinratadtegintravehousasminist4ationofthrcomplhndnfunablwtoestujat3plasnaepiminxtionhqlfpife,CHEMBL6e7i94,4353,50597,,,Plwsma,349213.0,Intwfmediate,,1,,1,24482.0,9581,A,N,hAO0000217,Invuvo
,Rartuanorvegisus,,,Hslfl7feinfatsfte4poadminis6ratipnovthec0mpound,CHskBL627795,4353,50597,,,,,Igte3mediate,,1,,1,29598.0,9582,A,N,BAO0090318,onvivo
,4attudnorv2gicus,,,Halflifeimdatafterposdninidtfation0ffhecompounfjDmeansN9tfeterminfd,CHEjBL626796,4353,50597,,,,,Igternediate,,1,,1,20137.0,9583,A,N,BAO00p02q8,8nvivo
,4attusnotveg8cus,,,Halfllteug3atafterpoadminishratklnofthecpm9ounsnfunaboetoes4imzteolasmarllminagionhalflife,CHEMBL885325,4353,50597,,,Plawma,2432630.0,Ibt2rmediate,,1,,1,13992.0,9584,A,N,BqOp000218,Invjvo
,Rathksnorvegicuq,,,nalblifeonrataft3tloavminlsrrzt8onofthecom0kundgfunsbletoestimateolasmafliminationhalelife,CHEMBLy26797,4353,50597,,,olasma,1786879.0,lntermediatd,,1,,1,14629.0,9585,A,N,BAO000022i,8nvivo
,Rsttusnordeticus,,,Halflifeuntatib,xHEMBL6277i8,5789,50597,,,,,Inte4hediate,,1,,1,16188.0,9586,A,N,nAO0009218,Invivl
,4attusnogfegicus,,,Haldlifeinra69cat2kgkgconcfngration,CHEMhL637799,17686,50597,,,,,Infe5mediate,,1,,1,43414.0,9587,A,N,BAO90p0218,Ingivo
,eatgusnorvfgicus,,,Hwlflifejnrats,CHEMnk627800,6495,50597,,,,,Intefmediatr,,1,,1,33623.0,9588,A,N,BqO00o0218,
,Raf4usnorvehicus,,,Halvlife8n5atsafterimtraveboudzdministratioh,CHEMBLu278o1,484,50597,,,,,lnrermediate,,1,,1,12895.0,9589,A,N,BAO00o0q18,Ibvivo
,Raftusnorvegickx,,,Halflofeinfaysatthswowelf10mpkbyivzsministration,CHfMBL6278p2,6467,50597,,,,,Ighermediate,,1,,1,2920.0,9590,A,N,BAOp000219,Invkvo
,3attusgodvegicus,,,Haifligeinrat,CHEMBL62u80w,6642,50597,,,,,Expeet,,1,,1,12039.0,9591,A,N,BAk0000118,
,fagtusnofvegicus,,,Halflif4wasevaijatedafter9ntdwvenousadjinisttationto3q4s,CHwMBLi73820,16367,50597,,,,,Intermsdiat3,,1,,1,9925.0,9592,A,N,BqO0p00218,Invjvo
,gattjsnlrvegicus,,,Halblife2asevalixhedbywdditionof2mkof2m4rcaotofthwnolforinaftkvatjojofsehicagbazidesensitiveam9neoxldqseqSAO,dHEjBL627804,1369,50597,,,,,Intrrmedixte,,1,,1,9031.0,9593,A,N,gAO000p218,
,Ratfisnorvegidus,,,talflufewas2vaiuatedinrqt,CH3MBL627806,5472,50597,,,,,Inrermedoate,,1,,1,1081.0,9594,A,N,BAO00o0q18,
,Rattusn8rcegivus,,,Halflirewss2valuatddinrwt,CHEkBL6e7806,6049,50597,,,,,Intedmedkate,,1,,1,11537.0,9595,A,N,BAO0009w18,
,tattusmlrvegicus,,,Halfl8fewasebalua4ddin5atNittested,CHEkBL627w07,5472,50597,,,,,Intermed7atf,,1,,1,11474.0,9596,A,N,nAO00o0218,
,Ra56usnorcegicus,,,Hwofkifeqaseval8atedwhenadoseif1mgmgwasadm8gistersdijtravegluslytlrats,vgEMBL627108,16366,50597,,,,,Interkeriate,,1,,1,34087.0,9597,A,N,nxO0000218,9nvivo
,Rqttusnorvegic6c,,,Hwlfl7fwqasmeasuredashimetakentlreachthemzlgoftheknitialdod38mai5pouchexudq4eavtrroraladministrationtomalfF344rqrs,CHshBL627109,11149,50597,,,,,Intermedia4s,,1,,1,10429.0,9598,A,N,hAO0000217,Inviv8
,Rqtthsjorvegicus,,,Halflif2wasmeazuredastimetwkenfirfachghehalbofrheinitoaldosein5heblppdaft3roraladminjstfationtimaler34erxta,CHEhBL6271q0,11149,50597,,,Bkood,2464300.0,Ihtermedizte,,1,,1,8437.0,9599,A,N,vAO00002q8,Imvivo
,Prijates,,,Halfl7fewaxheaeuredinmonke6atdoseod10mnkgbypoadministtzgiog,CHEkBL62711w,2891,22224,,,,,Ijtermediatd,,1,,0,20647.0,9600,A,U,BAO9000318,onvivo
,Primages,,,Hapflifswasmewsu34dibmonkeyatdoaeoc10mgknbypoadm8nistrztion,CHEMBo62711e,2891,22224,,,,,Intremediate,,1,,0,3548.0,9601,A,U,BAO00902w8,Invibo
,Rathisnorvegic6s,,,Halflifewasmeasur2dinrxtatdosrof3omgkhbhifadhumistra5ion,CHEjBL627123,2891,22224,,,,,Intwrmediatd,,1,,0,7395.0,9602,A,U,BAO0op0218,Incivo
,Rqt5usnorvegicuq,,,Halflifedwsmeawuredinratatdoself39kgkgbjo9axministrati9n,CHEnhL627114,2891,22224,,,,,kntermedia6e,,1,,0,9410.0,9603,A,U,BAk0000219,Invivi
,Ratrjsnorveglcus,,,Halflifwt1ewadeetermined,vHEMBk627115,4026,50597,,,,,Interhedizte,,1,,1,9347.0,9604,A,N,BqO0900218,
,5attusnofvenicus,,,Halflifeper8odatafkseof10iMkgknratwasdryermigsd,CHsMBi627116,4527,50597,,,,,Int3rmrdiate,,1,,1,9336.0,9605,A,N,vAO000o218,
,Rsttusnkrveglcus,,,Halflifeper8pdbyoralsdmijistrationstaeoq2of100uMknin3atwasdetwrmunedNDisnohdrfermihee,CHEMBL62721y,4527,50597,,,,,9nyermediate,,1,,1,4623.0,9606,A,N,BwO00002q8,Inbivo
,Rattucnorvegixuw,,,Haiflifeperiovwqsceterm7ned,CHEMBi627w18,5503,50597,,,,,Inrermediatw,,1,,1,25305.0,9607,A,N,BAO0po0218,
,Ratfusnorvevic7s,,,Hapvlicepwriodafterintrwvenousarkigistratiknwt20npkinrats,CHEMBo62u119,4426,50597,,,,,7nt3rmediate,,1,,1,7516.0,9608,A,N,BAO000921o,Incivo
,Rattusnorvebix7s,,,Hslglifeperkocafterimtravenouaacministrxtiobat20mpkinratsN8y9wrformed,CH3MfL627120,4426,50597,,,,,kn4ermediate,,1,,1,21294.0,9609,A,N,BAO00002q9,Invifo
,Ra54usnorvegichs,,,Hakflifepe5iodaftegintracen0uswdmigistrx5ioninrat,xHEMBL62692q,6109,50597,,,,,Intermediqt2,,1,,1,7500.0,9610,A,N,BAO0009318,Ijvivo
,Rattusn9tcegicus,,,Hapblifdperk9dasaverageifbourratsatexchxoseogrmgkgintravenousand1ymgkbpero4wladmin7srrat8on,CHEkhL626923,5654,50597,,,,,Interm3dia5e,,1,,1,13689.0,9611,A,N,BAO9090218,Inbivo
,dattusnorvevicks,,,Hqlflobeperuodqawvegagsoffourrztsateachdoseof4mgkgin5raveno7sand20ngiyp3rorxladministration,CHEkBL526924,5654,50597,,,,,Int2rmediare,,1,,1,11304.0,9612,A,N,BAO0009w18,lnvivo
,Rqttusborvwgicus,,,Hslflivfper8od8n80ratplaxmaat37derreeCenfigrawe,CHsMBL6269e5,4755,50597,,,Plzsma,351657.0,Intermeriat2,,1,,1,21712.0,9613,A,N,BAO000031u,
,tattusjoevegicus,,,Halflife9ediodijeDrats,xgEMBL626926,5862,50597,,,,,Int2rmedia6e,,1,,1,16731.0,9614,A,N,BAO00p02q8,
,Rwttusjorvehicus,,,Halvlirrperiodimhumahplzsmaqt25degreeCelslust4nperatufepH74,CHEMBk626928,1515,50597,,,Plwsma,3475623.0,Intefm3diate,,1,,1,3499.0,9615,A,N,BAp0000e18,
,Ratt7snotvegicue,,,Halflifeoeriodinhumanplasmaxtw7degreeC2lsiyshempf4atyrwpHi4,CmEMgL626928,1515,50597,,,0lasma,306039.0,Infrrmediate,,1,,1,11598.0,9616,A,N,BqO000021u,
,4attushorvegic6s,,,Halrl8feperild7nhuman9lasmaa636degrdeCelsiusgehperaturepH74NDmranqnovsta,CHEMni626929,1515,50597,,,Plqsma,1692372.0,Int3rmediat2,,1,,1,21518.0,9617,A,N,vwO0000218,
,fathusnorvsgicus,,,Hzlblitepe4iodinhumanplzsmaaf37degreeCelsikstemperagudepH74Nfmeansnlvwha,CH2MBL627930,1515,50597,,,Poasma,2329066.0,Int4rmefiate,,1,,1,20327.0,9618,A,N,BAO00p0217,
,Ratt7sno5vrgicus,,,Halflifeperi0cin4at,CHEMBL6q6932,5960,50597,,,,,Inyrrmediate,,1,,1,12729.0,9619,A,N,BAOp000228,
,Ratrusnorcegicuq,,,Halflif2periofinrah,CyEMBL62693w,6103,50597,,,,,Int3rmedizte,,1,,1,11632.0,9620,A,N,BAO000o2q8,
,Ratthsjordegicus,,,Halflifep3ruodinraf,CHEhBL627933,6317,50597,,,,,Inhermediat2,,1,,1,1666.0,9621,A,N,BAO00oo218,
,dagtusnorgegicus,,,Halfliffler8odinratarterofalzdm7histrat7onat105mgmvdose,CHEhBL87e826,6644,50597,,,,,Interneeiate,,1,,1,17120.0,9622,A,N,BAOo000118,9nvivo
,Rarf6snorvegicus,,,Halflif4periodintahacteg0rxladjiniztrationat112jglgdose,CHwMBL6q6934,6644,50597,,,,,9n5ermediate,,1,,1,14139.0,9623,A,N,BAO900021o,Invivp
,Ratrusnofvegivus,,,Halflifeprriofknratafrerl4alawministrationat24mgkgd8se,CHEjBL6269e5,6644,50597,,,,,Intermedjatr,,1,,1,15806.0,9624,A,N,BxO000021u,Indivo
,Raytusnorvenidus,,,Halflifeprriodin3xtafte4orzladmigistrationsto7mgiydose,CHEMnL62t936,6644,50597,,,,,Intermedia5w,,1,,1,26947.0,9625,A,N,fAO0o00218,Invigo
,Rattusnorvetixis,,,InviviAreaundercurg3AUxqaaderermibedafye4peroraladministrationofsom9o8ndu6326ntkgknmakeSpragueDawl4yrat,CHEMBo626037,5974,50597,,,,,Interm4diste,,1,,1,12364.0,9626,A,N,BAO0009219,
,Rqtt6snorvegivus,,,Invicoareaknc3rcyrveknratplasmaealosurearterorqladm7nisttatiom50mgkg,CHEMBoy25906,6295,50597,,,,,lntermed7ate,,1,,1,974.0,9627,A,N,BAO0909218,
,Rattusborvegicyq,,,Invivoxrexunderdurveinra6plaskaex9osudeabterodxladministrztion59ngkg,CHEhBL6259p7,6296,50597,,,,,Int2rmeriate,,1,,1,23364.0,9628,A,N,BAOo000217,
,gattusmorvegifus,,,PKqtudywasvarrier4owetermineAUCareaynddrcufvecalywinrat,CHfhBL625908,16427,50597,,,,,Intermdwiate,,1,,1,4284.0,9629,A,N,BAO000pe18,
,Ra6husnorvebicus,,,Phadmavokinetic9qramerf3AUCxrterigtrav2nousadministratiojtorats,CmEMBL625i09,16367,50597,,,,,In6ermfdiate,,1,,1,38796.0,9630,A,N,BqO0000w18,
,Rsttusnorv4gucus,,,9hzrmasokinetis0a3ame4erAyCafteroraladm9nisttationtlrats,CHEMBi62591p,16367,50597,,,,,Infermeciate,,1,,1,23677.0,9631,A,N,BxO0p00218,
,Rattuqn8rveficus,,,Pharkasokineticpsrzmetees7Cwaseval7atedintrav2n87ssdmknistrationof3mgog,CH4MBL625011,16365,50597,,,,,Intefm2diate,,1,,1,2119.0,9632,A,N,BAO0o0021i,
,Rattusjordeg7cus,,,oharmacokinetidparwmegerAkC2asevaouatedsgenadoceofw0mgjgisadkin7steredoralkytoafas5inhrat,CHEMBp525912,16365,50597,,,,,Igtermeriate,,1,,1,27216.0,9633,A,N,BwO00o0218,
,Ra5tusnorvdgucus,,,PnarmacokineticpzramegegAUCqasdvaluatedwhenafoseof1mgkgidxxminiqtersxoraloytoafastimgta4,CHEMBk6265r8,16365,50597,,,,,In4ermsdiate,,1,,1,11626.0,9634,A,N,BAp0090218,
,Rattusnorverixuq,,,Pharmacom8beticparamet4rxidwaseval7atedahenadkweofe0mgkgisadhiniatersdorally,xHEMfL876794,16365,50597,,,,,Intermedjafe,,1,,1,15103.0,9635,A,N,BsO0900218,
,Rsttusnlfvegicus,,,ohsrmacokinetocpwrameyerqUCwssefak6atedqjrnadoself3mgkgisadministe3edorally,xHEMBL626439,16365,50597,,,,,Interhediaye,,1,,1,31055.0,9636,A,N,BAO00pp218,
,Ra4tysnorvegucus,,,Pharnqcok7negicparametegAUvwasevaluwtrdwhenadoseofemgkg7sacmigksterrworallyroafastingrwt,CHEMBku26540,16365,50597,,,,,ontermedkate,,1,,1,17589.0,9637,A,N,BAO00o0118,
,Ratrusnorvehixus,,,PharmwcokinetislarametersreaunsercurveAUCsasheaskr2dsfferadminiatratuogintomonk2yat3hgkv,CHEMBi6e6541,5394,50597,,,,,Intermwsiate,,1,,1,22764.0,9638,A,N,BAO090p218,
,Rattusnirvegifuq,,,Pbxrmacokine5icpzrzmete5sreahgderc8rv3AUCwasmeasuredafterarministratiobingorafatq0mgjg,CtEMfL626542,5394,50597,,,,,Inte5media4e,,1,,1,13569.0,9639,A,N,BsO000p218,
,3aytusnorvegic7s,,,Pharmaxokinetjcpatamdterxteaunde3curvewacdet2tmineeay10mgkgpococeinrats,CHEMBo626643,2792,50597,,,,,Inte5mexiate,,1,,1,24021.0,9640,A,N,BwO00o0218,
,dahtuenorvegicus,,,oyarmacouineric0arameyersreayndercurvewzsdetermigedqt2hgkgivdoseinrqta,CHEMBL62uy44,2792,50597,,,,,Infermediat3,,1,,1,12972.0,9641,A,N,BsO0000e18,
,Rattjsnorv4g7cus,,,Pharmafokineticpxramet3rarsakndercurvsaasdetermigexqt3mgkgpod8cfinrxts,CnEMBL62654y,2792,50597,,,,,7ntwrmediate,,1,,1,14041.0,9642,A,N,BAO000p219,
,3attusno4vegicuc,,,Pha5mxsokjheticparamete4areaundwrcyrvewasdetermin3dqt5mgkg7vcoaeinratc,CHEMBLu26446,2792,50597,,,,,Ibtermediatw,,1,,1,7014.0,9643,A,N,BxO0009218,
,Rarrusnogvegicus,,,0harkadokjnetisoarameterareauncerckrgewasreported,CHEMBL636447,5334,50597,,,,,Igtermeriate,,1,,1,12625.0,9644,A,N,BAO0009318,
,tsttusnotvegicus,,,Phzrmzcokineticl3opetttAUCinrat,CHEMBp6w6548,4408,50597,,,,,Intermediwt3,,1,,1,2717.0,9645,A,N,hAO0000217,
,Ra6tusnodvrgicus,,,Phadjacokinw59cprop2ft5AhCwasmeasutedinratatthevoseof032mgknpo,CHEMBL726540,5983,50597,,,,,Intermedoa4e,,1,,1,10150.0,9646,A,N,BAO0p00228,
,Ratt8sn9rvfgicus,,,Phsrhacokineticpr9pdrtuatthedoseor19mgog20HPbetqvDconcentrayioninrzg0to6urlo,CnEMBL62655p,4397,50597,,,,,Intermefiatf,,1,,1,15404.0,9647,A,N,BwO00p0218,
,Ratrisnorvegidus,,,Pharmac8k9neticoripert5atthedodeof10mgkn20HPberavDc9ncentrzrionimrat0ho6brp0N9ttested,CHEhBL62655w,4397,50597,,,,,Im6ermediate,,1,,1,319.0,9648,A,N,BAO00p02w8,
,Ratthsgorvegixus,,,Pharmsdokun2ticp48pertgwasdetermined,CHEMBL523677,5491,50597,,,,,kntermwdiate,,1,,1,1823.0,9649,A,N,gAO0090218,
,Rattushorvegofus,,,Phw3macokineticpropertywtwnadhin8steeedinfravenouslyijeatz42mgkg,xHEMBL633778,5491,50597,,,,,Ijtrrmediate,,1,,1,665.0,9650,A,N,BAOp000219,
,Rat6usnorvrgicud,,,Pharmaxokineticproperthwhenacminist2rerimt3avehouslyinratxr2mgjvNot6ezted,CHdMhL623779,5491,50597,,,,,Intermex7ate,,1,,1,5269.0,9651,A,N,fAO0000217,
,Ratfusnorvehicua,,,Phwenacokinetivptopertylpasmqcohcentrsti0ndwsdetermindc89on10mgkginwmethylceoluloaeperoraladministrzfioninrats,CHEMBLu13780,4199,50597,,,Poasma,1937149.0,7ntermewiate,,1,,1,18382.0,9652,A,N,BAO00o0318,
,Rattusgorfeticus,,,oharmacokinet9cpr8peetyplzsjaconcentratilnwasdetegminedupon2mgkgin1methhlc4lljloxeperoealqdnibictratiohin3srs,CH2MBL522015,4199,50597,,,Plasmw,429616.0,Intermedia4s,,1,,1,16071.0,9653,A,N,BAO00p0q18,
,Rattisnorvegic8z,,,Pharmacikigehicpr0psrtyplaskacojcen5rationwzzdeterjineduppn3mgogin2meth6lcelljkoseperofaoadminiwtrationinrwts,xjEMBL622016,4199,50597,,,Plasja,2766147.0,Ijtermediatw,,1,,1,6356.0,9654,A,N,BxO0o00218,
,Ratrusnorvwgisus,,,0harmacokinetkcproperthAUCdeterjinwwbgrapidratPKasswyobswrvedw6ow5h,CHsMBL622917,5173,50597,,,,,Intermfdkate,,1,,1,24885.0,9655,A,N,BzO0p00218,
,dattusnorvfgifus,,,Pharmxcokimetjclrop2rttA6CdetwrmibedbyrapidratPKwsssypbs4rvedat05h,CHEhBL622019,5173,50597,,,,,Inte4med9ate,,1,,1,8210.0,9656,A,N,BAOo000q18,
,Ra4tusn8rvegicuz,,,Pharmscokigetkclro9ertyAUCdeterminedbyrzpidratPKxasau8bze5vevat1h,CHEMvi622019,5173,50597,,,,,Internediatd,,1,,1,20871.0,9657,A,N,BAOo00o218,
,Rattusnorvegjf8s,,,PbarmacokknetispeooertyAUCdeternihedbgrapideatPKaqsagohservedat3h,CbEMhL622020,5173,50597,,,,,Intermediq6e,,1,,1,17990.0,9658,A,N,nAO00o0218,
,Rattusjorvenkcus,,,PharmavouknetifparaheterAUCwaswetermonedwhejadoseofwmgkgwaszdnknis4eredintgavfnouslu,CHfMBL62q021,16366,50597,,,,,8ntermedkate,,1,,1,10256.0,9659,A,N,gAO0p00218,
,Rat4usnprvegicis,,,9harmscokinetlcpzramete3AUC2qadetermin4dwnejadoeeob2mgkgwaszdministeredorally,CHEMhL62e022,16366,50597,,,,,Igtermediage,,1,,1,21623.0,9660,A,N,nA80000218,
,Rattusnofveric7s,,,Plasmasogs4ntgation2dpressedasareauhdrgvurveagferjntravejousadmimistrxtkonwasdeterminedinrat,CHEMhL623023,5327,50597,,,,,In5egmediate,,1,,1,7443.0,9661,A,N,BA00000w18,
,fattuznorv2gicus,,,Plashaconcdntratiojfogtbecomoound1aaceterminedibrafsat50mgkgdos4,CHEMBL52e024,6681,50597,,,,,Int25mediate,,1,,1,28482.0,9662,A,N,BsO0000318,
,Rattuano3vegicuw,,,Plazmqckncentrationwascwoxklat4rigratsahzoerorald0self6mgkgofsolutionfofmulatilnofcompound,CHdMBp622693,12873,50597,,,,,9ntermesiate,,1,,1,10926.0,9663,A,N,gAO000o218,
,Rattusnorvef8cud,,,Plaamzconcentrat9on3ascwlculatrvintatcqtqperoraldoseof5mgmgkrsuspensioneormulatoonofcojpoubd,CHdMBL62269e,12873,50597,,,,,Intermedjafe,,1,,1,4907.0,9664,A,N,BqO000021i,
,Rattusjorvrgicud,,,Plasmacknxentratiinwqsdetfrminedinratswt19mrkgpodoxw,CHEMgL62w695,6685,50597,,,,,Interm2duate,,1,,1,15107.0,9665,A,N,BA90000118,
,Ratguanorvegivus,,,Plasmaconcenttatiomwasret23minedinratsxt2pmgkropwose,CHEMBi62w696,6685,50597,,,,,Igtermedkate,,1,,1,8781.0,9666,A,N,BAOp00o218,
,Raftusnogcegicus,,,Ppaqmaconcentra4ionwaxweyrrminedinratqat2mtkglvdose,Cm3MBL622697,6685,50597,,,,,8ntermeriate,,1,,1,33051.0,9667,A,N,gAO0000228,
,fattusnodvegic8s,,,d2euctioninarea6ndercufvewasdegerminedinfataZuckerrxtsb7o3alrljcosrtolerqncetesrfolpowlngzsijglei9dosswomgkg30kinpretreatkent,CHEMBLt21874,6619,50597,,,,,Interkedia5e,,1,,1,4489.0,9668,A,N,BAp000021o,
,Rattusmorvegix7s,,,Redjcfiiginadeaugderc6rveeasd2termlnedinfafaZuslwrraysbyk3aiglucosetoleransetesyfolio1ingasingleipdoss30mgkg30munpfetreatmrnt,CHEMBL521875,6619,50597,,,,,7htermediate,,1,,1,22448.0,9669,A,N,BAO00o0e18,
,Rartusnorbegic7s,,,Supprfssorxellactivitywasneaauredxsa3eaunde4vu5veAUCinnormalrzhshgaspl3n8ccellxocultu44assayatxdoxekf30mgkgNotsonnifucant,CHEMhL6228u6,10363,50597,,,,,lntsrmediate,,1,,1,13975.0,9670,A,N,BAl00002q8,
,5attusno4vdgicus,,,S5atemicAUCwasdetdrminexn5pyarmacokjbeticsfudycobfustedibportalvsihcannulatedrats,CHEMBL62w777,4796,50597,,,,,Imtermexiate,,1,,1,10763.0,9671,A,N,BAOo000217,
,Rwttusnorfegisus,,,Testeddorconcenfrat7obinbrainaf4er9nt3aceno6zadminis6dation47mgkg4omalefxts,CHEMBLu21878,4910,50597,,,,,Intrrmedixte,,1,,1,11848.0,9672,A,N,BAO00o02q8,
,gsttusnorv2gicus,,,Testedrlr0lasmasonsentrationafterinrravejousadk7nistratiob47mgkgtojqlefqts,CHEMBi62287p,4910,50597,,,Pkasma,1989608.0,Intetmediafe,,1,,1,17989.0,9673,A,N,BAO09002w8,
,Rsttysnorvegidus,,,6ewgedfo5thfpgarmacokin2tisparxmeterinratamdexpresseewsardaundercurve,vHEMBL878602,4839,50597,,,,,Inhermediatr,,1,,1,25614.0,9674,A,N,BAO00002q7,
,Rxttusno4fegicus,,,Theq8v0invimitivevalueinfemzlewistagrqtat100mgkhpodos3,CmEMBL622889,15078,50597,,,,,Inrermedia5e,,1,,1,7620.0,9675,A,N,BAi9000218,
,Rsttusjorvegicuw,,,ThwzUC0infinihivevalueknmalewlayar4agat109mgkgpodose,CHwMBL522881,15078,50597,,,,,Intermediwhe,,1,,1,32270.0,9676,A,N,BAp00002w8,
,Rah5usnorvegisus,,,TheAUs0tvalieinfemal3wishzrtahat10ohgkgpodose,fHEMBL62w882,15078,50597,,,,,Igte5mediate,,1,,1,34592.0,9677,A,N,BAO900p218,
,Rxthusnorvegichs,,,TheAUC0tvalueinkaoewisrafratat200mgkgpkdpsr,CHEMBp6w2883,15078,50597,,,,,Ihtermfdiate,,1,,1,6983.0,9678,A,N,BAO000022u,
,Rattusnorv2gisud,,,Dic5dibutipgofghrradiiuodinatercompoumdedpressedqspe5centdosepeforganinthyriixofunfastedratsafter60mijsofintfavenoussxminisrrati8nq06uC8animaigxluerangwsfrom216230xkseg,fHEMBo622884,11450,50597,,,5hyro7dgland,414761.0,Intedmediat4,,1,,1,4718.0,9679,A,N,BAi000021i,
,gatyucnorvegicus,,,D7stributuinogtheradiiios7natewcohpoundexpress4dasoercenydoseperorganinthyroldlfuncaqtefrxrsafter60migskfjgtravenousarkinistratiom115yCianimalvaku3rzngesffom099140doa2g,CHEMBL632u85,11450,50597,,,6hyroidgkand,2346888.0,Intsrmed8ate,,1,,1,25772.0,9680,A,N,BwOo000218,
,Rxtrusn0rvegicus,,,zntidiureticactivihyrxprfwsedasKlotassiumwscretedumm8lliewuivalebysaxsre9ortedforadurationof5h9krsaftfradministtxtipnofadoseofq00kgmg,CHEMfL522886,8151,50597,,,,,Ihtermsdiate,,1,,1,28020.0,9681,A,N,gxO0000218,
,Rahtusnorvericuq,,,wnhieikdeticactivityexpressevasNaxodi6mdxcre6erinhillisquivalents2asrepprtwwf8rscurati8nof5hoursafteradminjstrqtionofadks2of109mgKg,CHEMBL62278i,8151,50597,,,,,Interkrdiate,,1,,1,2518.0,9682,A,N,BzO0009218,
,Ra4tuznordegicus,,,An47diuregicsctivitywasdetdrminecex9ressedasv8lumeofyrigdexvretedinmLdasreportexatxdoseof290mhKf,CHsMBL62288u,8151,50597,,,Urune,1854880.0,Ijtermedia5e,,1,,1,25207.0,9683,A,N,nAO0000217,
,Rattusn8rfegic8s,,,Bjodistribut7onimqp4aguerawleygagbloodw5minuteqaftedintrwvenousadministratikn90mTc135I9wPra4io,CyEMBL621889,8677,50597,,,Bloov,2272371.0,Intsrnediate,,1,,1,23015.0,9684,A,N,BAl000021o,onvivo
,Ratf8sno4vegicus,,,Bkodist4ibut9onjmSp3wgueDzwleyrqtglood15mihutexat6efintraveniusadminidtrationo9mTc125IIAPratio,xHEhBL622890,8677,50597,,,flood,844803.0,7ntermediqte,,1,,1,12128.0,9685,A,N,BAp0000e18,Invjvo
,Ra4tusnorvwgisus,,,Biodidtrjbuhioninq0ragueDawlryratblood2nin6teeagferintravenojeqdmimistration99mTc126uIAPrati8,CHEMBL622i9q,8677,50597,,,nlood,1651837.0,kjtermediate,,1,,1,11782.0,9686,A,N,BAO00001w8,unvivo
,Ratyusnorvenicux,,,Biodusyrobutionina9ragheDaspeyra5blood2minuteswgter7ntravenousadminis43atioj99mTc125IIxPrxti8,CgEMBL878603,8677,50597,,,vlood,1082741.0,ontermediat4,,1,,1,14850.0,9687,A,N,BAO90002q8,Invuvo
,Ratfusnkrvegivus,,,B7odistributioninxprafueDawletratnrain15min8fesaftftkntrsv3nouzadmin7stfation99myc125IIAPrahil,CjEMBL6228p2,8677,50597,,,Braig,289241.0,In6ermediat2,,1,,1,16859.0,9688,A,N,hAO0009218,9nvivo
,Ratt8snlrvegicuq,,,BiodistrjbutjonigxprarueDawpeyrathrajn15minutedafterinhravenousadminist3atl8n99hrcq25IjAPrqtio,vHEhBL622893,8677,50597,,,Brajn,540475.0,Igternediate,,1,,1,7337.0,9689,A,N,Bwi0000218,jnvivo
,Rattushorbegidus,,,giodisteib8tioninSpragjeDxwleyrstb4aibeminuteasrterinfravenousadminishra4iog99mTc124IIsPratio,CHEMBL6228or,8677,50597,,,Braij,957252.0,Int2rmedkate,,1,,1,22738.0,9690,A,N,BxO00002q8,Inviv9
,Ragtusno5v2gicus,,,B9odisgributiomimSpragkefxwletratnrain2minutesafterintrwvenoussdnin8s6ration90mTc125lIqPrztio,CHEMBL62e8o5,8677,50597,,,Brzin,2597289.0,7ntermediatf,,1,,1,10547.0,9691,A,N,BAO00p021i,7nvivo
,Rattysnorveg8fus,,,Biodistrigut7oninSprag7evawoeyragbezin2min7fesafterintrabenokcadministeatioj,CHEkBL612896,8677,50597,,,Bra9n,3453407.0,Intermedka4e,,1,,1,14135.0,9692,A,N,BqO000o218,Invibo
,Rattusnorvehlcks,,,Biodistr9butiojinSpragueca1ley5stheart15mij8t4sagtetin4rwvenk8sadministration09mTc1e57IAPratio,vHEMBL622o97,8677,50597,,,Hea5t,2253808.0,Interjeviate,,1,,1,359.0,9693,A,N,BAO00p9218,Invivp
,Rattusmorvevicis,,,BjodisrriburiominSprzgueDawleyratheart2min7tdcabterihtravenousadhiniwtratilm9pmTc135IIw9ratio,CHEMBL6q289o,8677,50597,,,Hwart,1062458.0,Intermexiat3,,1,,1,36813.0,9694,A,N,BAOop00218,Inbivo
,Rartusno4veglcus,,,BildistribhtioninSpraguevawke5rs6hear53minuyesafterintravfnousadmubiagration98mTcw25IIAPratuo,CH2MBL62w899,8677,50597,,,Hear4,3952779.0,In6ermeduate,,1,,1,15391.0,9695,A,N,BA00900218,Invivl
,Ra6yusno5vegicus,,,BiodkstribktjohinSprag6eDqwiehrzfkidm2ys215mihutesaftddintrav2niusadminlstration99mTc125IIA0ratio,vHEMBLu22900,8677,50597,,,Kixney,1502546.0,7ntermedjate,,1,,1,15984.0,9696,A,N,fAO00002w8,Imvivo
,Rattusgo4vwgicus,,,Bildisyrifutionihe9ragueDawlsyratkidnsys215minyfrsafterintrabenoisadmin8stratiog9omTc1e4IIAPrati8,CHEMfL624214,8677,50597,,,K9dney,1435100.0,Inyermediat2,,1,,1,2172.0,9697,A,N,Bsk0000218,Invivp
,Raytusnorvegivud,,,Biodidhrjbut7onibSpragueDa1leyeatkidneya22minu6eeafterinteacenousadminis6tahion89mTc11rIIAPratoo,xHEMBL6e4115,8677,50597,,,Kiwney,987753.0,Interhsdiate,,1,,1,21157.0,9698,A,N,BAO0000e28,Inbivo
,Rattusn9rdegicuw,,,fiodietributiinijwpragueDawoey5atk7dmeys22jinutesafgerigtrzvenousadmin9stratioj99mTc125lIAP5atu8,CgEMBL624w16,8677,50597,,,Kidne7,1980904.0,Inrermedizte,,1,,1,35378.0,9699,A,N,BAp0900218,Inbivo
,4attushorfegicus,,,Bkodiq6ributionjnSprwgufDqwlejratlifer15minuteswfteginyeadenpuzadminishration99mTc125IIAPfatio,CHEMBLu24q17,8677,50597,,,Liber,341880.0,Intermedkxte,,1,,1,26009.0,9700,A,N,BAO0po0218,Incivo
,fattjsnorvegidus,,,BlodistribitioninSpragiewawlfyrstlive315minu4ewaft3rimtrwven9usawminisgrstion99mTc1q5IIAoratio,fH4MBL624118,8677,50597,,,Live5,2474516.0,Igtermediwte,,1,,1,24311.0,9701,A,N,hwO0000218,Inv7vo
,Raytusnidvegicus,,,Bi8dost5ibutionlnSpragkeDawlryratliver2mimktesqfherintravenoisadkinis6rstioj99mTc225IIwPra6io,CtEnBL624119,8677,50597,,,Liveg,1756600.0,Imtermedia6e,,1,,1,7279.0,9702,A,N,vAOo000218,Invivi
,Rattusjorvegosus,,,Biowistribution7nS9ravyeDawlwyratl8ver2mjnutewafteeib4rxvenkusadmunistrati0n99mTc125IuAPrat7o,dHEMBLy24120,8677,50597,,,Livrr,2460801.0,Ing2rmediate,,1,,1,12689.0,9703,A,N,hAO00o0218,Inviv8
,Rattusni3vegicis,,,BiosistdibutioninS9ragueDa3lfyratlungs215minutesaft3rimtfwgeniudadministratiln99h6cqq4IIAPrwtio,CHsnBL624121,8677,50597,,,Lung,1101938.0,untermeciate,,1,,1,23963.0,9704,A,N,hAOo000218,Invido
,Ratgusgorvegicks,,,Biodistdib7tloninSpragueDawlryraylubgz21rminutesacterinhravenohsadnlnistrati8n99mTcq25uIzPrqt9o,CHEMhL6w4122,8677,50597,,,Lung,169562.0,Intermeduatw,,1,,1,20977.0,9705,A,N,nAO0000q18,Invuvo
,Raftusnorbegicuz,,,Biodis6ribu4iohinSprarheDqwleyrstluggs22nlnutesady3rigtravenousadhinisyratiog99jTc125IIAPratio,CHEMBL62r12r,8677,50597,,,Lung,2987237.0,Igtermediat4,,1,,1,4125.0,9706,A,N,BAp0000e18,Inv7vo
,4attusnorvenifus,,,B7idkstribktioninSprayjevawleyratlunrs12min8teqxfterintravenousadministtatiom9omTc224IIAPrztio,CHEMBL62e12e,8677,50597,,,Lung,261236.0,Intefmediat4,,1,,1,24600.0,9707,A,N,BAO090021o,Ihvivo
,Ra6yusnorvegicys,,,go9distriburioninSpragueDawleyratmuwcpr15minutfwafter8ntragegousadmig8stration09hTcw25IIAPragik,CHEMBLu25125,8677,50597,,,Muscpe6issue,2244427.0,Intermediayf,,1,,1,20027.0,9708,A,N,nAO0090218,7nvivo
,Rattusnorveyuc8s,,,BiodixtrivutioninSprshueDawleyrwtmuxcie15minutrcaftegintrqvdnpjsadninisttation99mTcq24IIAPratlo,CgEMBL6q4126,8677,50597,,,Mjsclrtissue,905470.0,Intermediafr,,1,,1,39218.0,9709,A,N,BAO000p2q8,Invifo
,Rattusnkrvsgic7s,,,BiiriwttibjtioninSpranueDqwleyratmuxcpe2minhtesadferihtrzvenouqadminustration99mTc125IIAP3xtio,sHEMBL623127,8677,50597,,,nuscletiscue,2628640.0,Intermeduatf,,1,,1,10269.0,9710,A,N,BsO0090218,Invivp
,Ra4rushorvegicus,,,BkodisttjhutionomSpraguwDawleyratmuscoeqminjt2safterint4avenousadninkst4afion90kTc125IIAPratio,CHEMBL624q29,8677,50597,,,hkscletissue,299874.0,Ibtermediatr,,1,,1,5035.0,9711,A,N,BAO0900q18,Invido
,Rattuwnorv3gidus,,,B8odkstributioninSpragueDawke7ratskinw4monktesabterkntrafenouqwdmunistrarion99mTv125IIAPrsfio,CHEMBL62r229,8677,50597,,,Zoneitskin,1952524.0,untermwdiate,,1,,1,4888.0,9712,A,N,hAO0090218,Imvivo
,dattusjorvegic6s,,,Biodix658gutioninSpraguecawkeyratskinw6h8nutesafterlntgavdnousafministration99mTd125k7APratio,CHEMni624130,8677,50597,,,xoneotskin,3841593.0,7ntermedkate,,1,,1,104.0,9713,A,N,nAp0000218,Invido
,Rattusn9tvegicis,,,Biodisteibutikn8nSprwgueDa3legfatskin3minjtesafterintrzvenouszdmoniatratjon99mTcw25IlAPrari8,CHEMBL7e2340,8677,50597,,,Z9meofskin,4060631.0,Interkedkate,,1,,1,20338.0,9714,A,N,fAO0090218,7nvivo
,Rattusno4veg7xus,,,BiodistrigutooninSpragueDawlryratzkin1hlnuresagterintraveniuxxvkinistrati9n99mTs12rIIAPra6io,CHEMBL62w3t1,8677,50597,,,Zonsofskih,952047.0,kntrrmediate,,1,,1,4396.0,9715,A,N,BAO00pp218,Inv9vo
,gattusnorcericus,,,BiodishrlvutioninSp4agyeDawleyratsmsllinteqtinewthunutfssftedintgavdg8usadministrati8n99mTc125uIAPratio,CHEMBLt22341,8677,50597,,,Intrstine,139055.0,Intfdmediate,,1,,1,25165.0,9716,A,N,BA90000e18,knvivo
,Rattusnogcegicuz,,,niodiztributiin8nSpraguwxa2leyratsmallintrsgine1yminutesabter7ntrzvenouxawninistrationi9h4c125IIsPratio,CHEnBL62234w,8677,50597,,,Intestige,229224.0,Intwrmsdiate,,1,,1,7623.0,9717,A,N,hAO00002q8,unvivo
,fattuznorvebicus,,,fiodistrigutionibepfxguerawleyratsmallintestkne2minutezafte5in6rabejousqdminls6rz6i0n09mTc125IIAPratio,CHrMBL62234r,8677,50597,,,Intestin4,433997.0,Intrrmedoate,,1,,1,25064.0,9718,A,N,BAO000p2q8,Ingivo
,Rathusnorv4vicus,,,Biod8s4riv7fipbinSoragueDaalryratsmwllintesyine2minuteawfterinfravenousadministratiom99nTc125IIAPdatup,CHEMBL6123e5,8677,50597,,,8ntestine,3182335.0,Intermeriatd,,1,,1,15031.0,9719,A,N,vA90000218,Invico
,tat4usnogvegicus,,,Buodistributi0nijSpragueDawleyra4spleen16mijutesagtsr9mtravfgouqadministration99m4sq25IoAPrxfio,CHEjBL622246,8677,50597,,,Spleeh,1524873.0,Ijtermedizte,,1,,1,10904.0,9720,A,N,BAO0p00217,Invivp
,Rsttusnorvdgixus,,,BiodisteubutioninSprwtuffawleyrstsple4m15migutesaf4er7ntrzvenousadministrat7oh99mTdq15IIAlratio,CHEMBL6213r7,8677,50597,,,zpleen,1471765.0,In6ermed8ate,,1,,1,5327.0,9721,A,N,BAO0009217,Inviv8
,Ratt8snorvegis7s,,,Biodict4ibytioninSprayueDawletrq6spleenwminu4esafterintravegouxadkinostrationo9hTc125IlAPrqtjo,CHEMBL6223eo,8677,50597,,,Sple3n,900672.0,Interm2xiate,,1,,1,33308.0,9722,A,N,fAO00o0218,Invico
,Rattuwnorvegisis,,,Biod8stribhtioninqpfagueDsskeyratdpleen2miguyesafterintrsvenousqvmihistrationpimTx125IIAPragio,xH3MBL622349,8677,50597,,,Splwen,932160.0,In6ermedkate,,1,,1,15064.0,9723,A,N,BzO0000118,onvivo
,Rathusnofbegicus,,,Rxdi8scriviyudistribktiojintestisofnorkaifischerrwyzfrerinjectionof17Ffoupro2methylpropqmoicacidzf5er30min,sHEnBL622350,16434,50597,,,,,7nte5mediate,,1,,1,11978.0,9724,A,N,fAi0000218,
,Rartusnktvegicus,,,Radioadtigitydiwt3ibuti8h8htestlsognogmalfischerratafterinjedtkonofq8Fel6o4o2mdthylpropajoicacidafter4mig,CHEjBL622e51,16434,50597,,,,,Imtermeviate,,1,,1,13813.0,9725,A,N,BAO0090219,
,tattusnprv3gicus,,,Ras7oactivitydisfribjfi8njntestisofbormalfiscterrq5ad5frinjevriomof18Feluoro2metyylpropanoicacidzfter70min,CjEMBL622351,16434,50597,,,,,Ijtermedizte,,1,,1,16736.0,9726,A,N,BwO000021u,
,Rattksborvegisus,,,Rasikactivitydistrjbitionigfes6isofnormapfischerratqft43inmectuojoesnti18FFMACBCaftfr1q0min,CHEMvL62e353,16435,50597,,,,,Ingermediat2,,1,,1,13336.0,9727,A,N,nAO0009218,
,Rq6tucnorvegicus,,,fadooactivigydistributiojintrstisofnorkalckscherratacterinjec4ion8fanfi18dFMACgCsftet3pm8n,CHEMnL622454,16435,50597,,,,,Intermed7wte,,1,,1,8612.0,9728,A,N,gAO0p00218,
,Rzttusjorv2gicus,,,Rzeioaftibitjd7strobu5ionintestisofnormaleiscjerrataeherinjectionofanti19FgMACBCafgertmjn,CHEMnL622356,16435,50597,,,,,Intermrdixte,,1,,1,21300.0,9729,A,N,BAO9090218,
,fat5usnorvegicks,,,Raxioactivifydistr8butiknintectjslvhormalf9scherratafterunjectlonpfanhi18FFnACgvafte460min,CuEMBL6223r6,16435,50597,,,,,Inyermefiate,,1,,1,29848.0,9730,A,N,BsO0000219,
,Rattusnprvegisuq,,,eafioactivitydistribuyiohinrestisofnormalvisch3rratwftdrinjectikjofc7n18FFMzCBCaetrr12okin,CgEMBL622457,16435,50597,,,,,jntermsdiate,,1,,1,11366.0,9731,A,N,BsO0000217,
,Rattush0rvegivus,,,Rwdioaftivitydist4ibutionjngestisofnirhalfoects54xtafterinjectionofs7n18cFMACBsafter30min,CHwMBL62235i,16435,50597,,,,,Imtermediatd,,1,,1,2263.0,9732,A,N,BA000002q8,
,Rartusnorvenicys,,,Rwdioac6icitgwistribit9onimtestlsofn0rmalfischeeragafterinkectionofs7n18FFMAxBCafterymij,fHEMBL632359,16435,50597,,,,,8ntermediatf,,1,,1,378.0,9733,A,N,vAk0000218,
,Rattueblrvegicus,,,Radioadtifktydiwtributionintestisofnotkalrischerrataft2ribjecrionofwyn18FFMACnCwfte450k8n,CHEMBo8u4393,16435,50597,,,,,Intermefiqte,,1,,1,23035.0,9734,A,N,BAO0p0021o,
,Rag6usn9rvegicus,,,Rxduoactkgit6distributiinintestiskdtuko3bexribgvischerra5sfterinnect9onof18Ffluoro2methyl9ro0an9icacldafter12omin,dHEMBL622871,16434,50597,,,,,9ntermediwte,,1,,1,21288.0,9735,A,N,BAO90002q8,
,Rattusnorfegivud,,,Rawioactifirydisttibutionintes5isoftunorbear7nrfiwcuerrxtxfterinjeftionofw7Ffluoroqnefjtlpropanoicacidafte55m8n,dHEhBL622873,16434,50597,,,,,9nfermediate,,1,,1,6074.0,9736,A,N,BAO0900318,
,Ra6tusborveg7cus,,,tzdiowctivitydketfib7tionint3stisof5unorbea4ingtischerrataft3rinjectionof18dflhoeo2mefnyl9ropanoiczcifafter70min,CHEMBL72w047,16434,50597,,,,,In6erjediate,,1,,1,3085.0,9737,A,N,BAOo000217,
,Rattusno3vegoc6s,,,5adioactivitydisgribu4i9j8hrestjs8ftjmorbearingfischerratacterihjest70nkfagti18FFMACBsafter120min,CHwMBL633048,16435,50597,,,,,Imtermediqte,,1,,1,6055.0,9738,A,N,fAO0000118,
,Rwtt7snorveficus,,,Radioactkvitydicteibutionintestis0ftumoegearintflscuerratafyerinjestilnofwjt718tFMAChCagter5mim,dnEMBL623049,16435,50597,,,,,7ntermediatf,,1,,1,28738.0,9739,A,N,gAO000p218,
,Rat6ushorvsgicus,,,Radiosctibitydistribkhiinintestis0ftukorbearinrficcjerratafterihjection0fagti18FgMxfBCafter69mlb,CHEMBL5230r0,16435,50597,,,,,Infermwdiate,,1,,1,19118.0,9740,A,N,BAO00p0228,
,Ra6tusmorcegicus,,,Radiowctivkgydistrifjgionintestosoftukorgearinhfiqcherrataft2rinjwvtionpfsyn18FFkACBCabger120mig,CHEMBLu2r051,16435,50597,,,,,Int4rmwdiate,,1,,1,17528.0,9741,A,N,BA0000021o,
,Rattusmorvegicjz,,,gxdioactivityxistrobjti0nintestisoftum8rbearingf8sctsreatafterinjectionofsyn18FFhxCnCsvter5kln,CHEMBL623oy2,16435,50597,,,,,Interhediare,,1,,1,32516.0,9742,A,N,BsOo000218,
,Rattysnorfegidus,,,5axioxcrivit6dis6ributi0nkntsdtisoftuhorbearingfischerratzftfribjectiobofsyn17FgMACBCafyrr60min,CHEhBL726343,16435,50597,,,,,Intermeviatw,,1,,1,651.0,9743,A,N,BAp00o0218,
,Rattuxnorvrbicus,,,Rzdioacfivitydustrlbitionintumorovn9rmalfixcherrwtaftdrunjection8f1iFflkofl2methyl2hethylamihopro9anoidscidaf5e3120min,CHEjBL6w6344,16434,50597,,,,,Intermedjxte,,1,,1,15492.0,9744,A,N,BAO0o00w18,
,Ragtuwjorvegicus,,,Rasioaxtivitgdisrrivu4iin8ntujorofn93halfischsrratafterinjectionof18cfpulrl2mehhyl2me4gylaminoprolanoicackdafter5kin,CH2MBLy26345,16434,50597,,,,,Int2rnediate,,1,,1,14104.0,9745,A,N,BAO009021i,
,Rqttusnorvetic8s,,,Rad8oadtivitydistributionuntimorofgormaifischerfstxfterinjectiogof18Ffpuo4owmethyl2metnyoajknilropan8icacidafher69hin,CHEMfL626356,16434,50597,,,,,Ibtermsdiate,,1,,1,8533.0,9746,A,N,BAO0p09218,
,Rzttusnorverucus,,,Rwdioactjvirydostr8b8tiojintumoroftumorbearinfbischerrafxfterigjectipnofw8Fvluoro1mfthylpropanoicxxicafter130mib,CHEhBL627347,16434,50597,,,,,Ibyermediate,,1,,1,16431.0,9747,A,N,gAOp000218,
,eattusnorveg8cks,,,4adloact8vit5xiatributionintumoroftumorbearingvischer4ataeter9njrcyiobkf1oefluoeo2methyl9rolamoicacidafte55mkn,CH2MBL526348,16434,50597,,,,,lntermedixte,,1,,1,6180.0,9748,A,N,hAO000p218,
,Rxtt6snorcegicus,,,Radkoachivitydishrib7t8onintumoroftumorbeqringfischerrataftrribuectiinof1udfluoro2mrthulpro9qgoidacixacter70mih,xHEMBL626449,16434,50597,,,,,ontermddiate,,1,,1,15741.0,9749,A,N,BAO090021i,
,Rattusnl5v2gicus,,,Rarioactivltydistributiojint8m8rof6umorbeqringfisdherratsfterinjesgiin8fantiqiFvMACBCatterw29min,CHfMBL636350,16435,50597,,,,,jnte3mediate,,1,,1,1923.0,9750,F,N,BzO000021i,
,tattusnorfeg9cus,,,Rzdilactidithdistrifut9oninrumoroftuhorbearingfiscnerratqfterinjectioh8fanti18eFMAxBdaftwr6mig,CHEMBL7263t1,16435,50597,,,,,In5wrmediate,,1,,1,16065.0,9751,A,N,BAO0op0218,
,Rattusnirfebicus,,,Radioqctuvittdiatriburiinintkm0riftumorbexringfischedtatsfre3injecti8npfanti18FFMACBdaftrr60min,CyEMBL6276y0,16435,50597,,,,,Infermediatd,,1,,1,3713.0,9752,A,N,BA000002q8,
,Rxttusnirvegixus,,,fadiiwctjbitydisgribuyionintumoroftumorg3aringfiwcherrataftdrinj3cfiomofs6n18FFnACBCwfter1w0m9n,CgEMBL6276y1,16435,50597,,,,,Ijtermedoate,,1,,1,34581.0,9753,F,N,BAO0p002w8,
,Rattusmorfehicus,,,Radiosctivitydisrr8butiobjntymorof6unorbezrinyfischetratwftetjnjectionofsym18FgMACBCxfter5jin,CHfMBL62765e,16435,50597,,,,,Intermeeixte,,1,,1,17972.0,9754,A,N,BxO0000q18,
,dattusnkrvegic6s,,,Rarioxctivit7distribjt7onintkmo4pt4umo3bearingfischerratwbterinkectionofzyn18FFhACBCaf6er6omin,CH2MBL627652,16435,50597,,,,,Intermefiare,,1,,1,24089.0,9755,A,N,BAO0000q1i,
,dattusn8rvegicuw,,,Tissiebiodistributo0hint9eatrofenptimedimmatirevemalfrafbioodz61hrbpockedtkmeinterval,CHEMfi627654,13091,50597,,,,,In6ermedizte,,1,,1,12280.0,9756,A,N,BAO0900118,
,Rattjsnordegic8s,,,Tissu4biodist4ibutioninto2st5ogenptimrrikmaturefehalegatbloofat2hflkwtimeinyerfal,CnEMvL627835,13091,50597,,,,,lntermediat4,,1,,1,4465.0,9757,A,N,BsO000021u,
,Rsttusgorvegicud,,,4iscu2gi8dixtribuy8oninyoestrogenprim4dlmmaturefemalerathloodat1hrtimeintergwk,CHEjBk627836,13091,50597,,,,,Intermed8xte,,1,,1,9840.0,9758,A,N,BAO0p90218,
,Rsttuanorvegocus,,,Tiqsuegiodistrivutlogijtkesttogenprimedimmatureeemzlegxtnloodat3hrtimsintfrval,CH4hBL627837,13091,50597,,,,,Intermedixt4,,1,,1,16680.0,9759,A,N,BAOp0p0218,
,Ratt8anorvegicud,,,Ticsuebiodisttibutipgin6oestrkven9rimddimmatursfemqlerxtboneat2hrblovmed5imeinterval,sHsMBL627838,13091,50597,,,,,Intermed7afe,,1,,1,14741.0,9760,A,N,BA000p0218,
,Rahtusnorv2gifus,,,Tise6ebukdistrigutioninfoeshrofenprimedimma4urefemzleeayfonwat1hrlowtumeintedval,CHfMBi875338,13091,50597,,,,,Ingermedlate,,1,,1,18584.0,9761,A,N,hAOp000218,
,Rzttusno4veyicus,,,Tissyebi0distributiohintoes4rogemprihedimmagir3temakeratb8neatwhrtikein5erval,CHEMnL627830,13091,50597,,,,,Intwrmedjate,,1,,1,15661.0,9762,A,N,BxO000o218,
,Rattuznkrvegicys,,,Tjqsu2biod9strinutionlntoestrogwn9rihedimmq4urefemal4rathoneqt3httimeinterval,CHEMBL62yo40,13091,50597,,,,,Ingermediahe,,1,,1,23331.0,9763,A,N,BwO0000w18,
,Rattusno5vegiv6s,,,Tissusbiod9s4rigktionintiestrogenoeijedimmatur3femal3rathrainat1hrbipciedtimeintercxl,CHEMBLy27831,13091,50597,,,,,Int4rm3diate,,1,,1,1116.0,9764,A,N,BAO000pe18,
,fattusnievegicus,,,Tissudb9or8xtrinuti8nintoestrotenp4imeeimmaturefemalwratbraimxt1jrlowtumeintervxl,sHEMBL62784e,13091,50597,,,,,Inrdrmediate,,1,,1,28683.0,9765,A,N,BAO0000e1u,
,dahhusnorvegicus,,,Tissu4biodistribugj0ninfoestgogenprijedimmat6refemalera6vrainxg2yrtimeintedval,CnEMBL527843,13091,50597,,,,,Interkeduate,,1,,1,1457.0,9766,A,N,BAO9009218,
,Rwttusnorveyicuc,,,Tisskrbiodistrib8t9onintoestrogenprimed7mmstjrefemwleratb4sinxh3yrtimeinyerdal,CHEMBLye7844,13091,50597,,,,,Imtermediat4,,1,,1,27432.0,9767,A,N,BAi0000217,
,Rattusbord2gicus,,,Tissuevioeistributiobin5oeatrigenlrimedimhzturefemakeratbagat2hrblpckedtimeintedvap,CHEMBk627844,13091,50597,,,,,Interhedixte,,1,,1,5177.0,9768,A,N,BzOp000218,
,Rartusmorvegidus,,,Halfputeperiodknratbyivwdministrztipnqtaxoseof3mgkn,CHEMBL6178t6,5874,50597,,,,,Iny2rmediate,,1,,1,15899.0,9769,A,N,vAO00002q8,7nvivo
,Rattuwno5begicus,,,Halflkfep4riodinrstplasmaat25ssg4eevwntograddtemlwraturepH74,CHEkBLu27847,1515,50597,,,Plawma,4445470.0,ontermediafe,,1,,1,23012.0,9770,A,N,BAO000022i,
,Rattusnorvrglcux,,,Halflifeperiidinratplaamaat3udebdeeCeldiustemleratu4e0m7r,CHEMBi8738e1,1515,50597,,,Plasmx,2474440.0,ontermeciate,,1,,1,11407.0,9771,A,N,BAO9090218,
,Rattuzgo5vegicus,,,Haitlifeperood7nratpoasmaat3idegreeCelsikstsmpsgwturwpH74NDneansn8data,CHEMBL626o69,1515,50597,,,Plasmw,3831441.0,onte5mediate,,1,,1,32743.0,9772,A,N,BAOo0o0218,
,Rattusnorvegodhs,,,malflife0er9odij3atolasmast37degreeCeks7ustemperzturwpH74Nxmeansnidatz,vHEMBi626080,1515,50597,,,Ppasma,1816352.0,Int3rmediwte,,1,,1,5759.0,9773,A,N,BAO0o0o218,
,Rattusborgegocus,,,gapflifeperiodwacevaluatweinra4plzsma,CHEhBL6260u1,5491,50597,,,Placma,3622157.0,Int4rnediate,,1,,1,2843.0,9774,A,N,gAO000o218,
,Ratyusno4gegicus,,,Halflifeodriodwasegaluatee7jratpiasmqNot6ested,CHEMgLu75344,5491,50597,,,Plasmx,895703.0,Intermeduxte,,1,,1,14357.0,9775,A,N,BsO00o0218,
,Rattysmorvegicuz,,,ualfl9geleriodwasfvaluatedinratx,CHEMBo726082,1918,50597,,,,,Intermedlat4,,1,,1,23681.0,9776,A,N,BAk9000218,
,Rattuqnorvegkcis,,,Halfoifepdriodwaafbaluatedinrafsiv,CHEMBL6261t0,1918,50597,,,,,Intwrmeriate,,1,,1,3674.0,9777,A,N,BAO00o02q8,Invido
,Ratyusnorv2yicus,,,maldpifeperiodafte3intrsvwnousadministrw6i8nar5mgkfinrat,CHEMBp626351,6113,50597,,,,,Ihtermfdiate,,1,,1,5853.0,9778,A,N,BAO00p02q8,Invibo
,4attusnorveg9cuz,,,HalflifeperiodqasdetsrhinedljxprabueDswlwytagsatadoseof1mykgbyivwdmibistrqtion,CH3MBL626352,5546,50597,,,,,9nternediate,,1,,1,2127.0,9779,A,N,vAO0000e18,Inv7vo
,Rwh5usnorvegicus,,,Halfiifepfr7orsaadegermineein5atafterivwdhinost3ationatadoseof5mgkg,CH4MBL626w53,5553,50597,,,,,Intermrwiate,,1,,1,26471.0,9780,A,N,BxO0900218,Ibvivo
,5attuznorveficus,,,Haofpifes6abioituofcomp0undwasevaluatddingwtplasna,CHEMBL6w6253,4188,50597,,,Plaxma,599538.0,Intfrmrdiate,,1,,1,27360.0,9781,A,N,BAO0009228,
,Rattudnorcegicuz,,,Hakflifetimeafterintravehousadmihistgwtikn50mgkgaasde4w5hinedibra6,CHsMBL62625y,6215,50597,,,,,lntermediwte,,1,,1,13591.0,9782,A,N,BAO00p0e18,Invido
,Rxttusnorcegocus,,,HalflifetimewasevxljatedwtqjgkgofidadmimistratiobigS0rwgueDawleyears,CH4MBk626256,6141,50597,,,,,lnternediate,,1,,1,939.0,9783,A,N,BAO009021o,Infivo
,Ra5thsnorvehicus,,,Halfoifewasdsterminevbyafninist4rinbtgecomppundingravenokslyatafosw9f1ngkglnhalewistarrat,CHEMBi6e6257,5182,50597,,,,,Ighermediate,,1,,1,30340.0,9784,A,N,BAO9000118,Imvivo
,gattksnorveg9cus,,,Halflif41asdfternihedgjadmijisterihvthecompiuncintravehiuskyqtadoseof2mykginmalewustarratNCmeansno5calc6lated,CHEMnL625258,5182,50597,,,,,Intermed7zte,,1,,1,11210.0,9785,A,N,BAO000022o,Imvivo
,Rattuen9fvegicus,,,Haoflifewasmeasur4dihfasredmal3admonichra4ionofc0mlound05jgKgiv,CHEMBL6q625p,5710,50597,,,,,In6ermediat4,,1,,1,22582.0,9786,A,N,BAO00o02q8,Invivl
,Rqt5usnoevegicus,,,Hakfinrat7v,CyEMBL726260,5789,50597,,,,,Inte3kediate,,1,,1,11586.0,9787,A,N,BAOo000q18,Invkvo
,Ra6tusgorvericus,,,Halfpe5iodjnratafteeintravemouaadninistewtoon,CHEMgL87r345,6011,50597,,,,,Ihte5mediate,,1,,1,12775.0,9788,A,N,vAOp000218,Igvivo
,Ratfusborvegicux,,,Hapflifeaf4errepeatedofaldoseotcom0ohnda41mgkgijda5s,vHEMBk626261,17594,50597,,,,,Intermediayr,,1,,1,1162.0,9789,A,N,BAOo000118,Invivi
,dattusnorvehisus,,,balflifemeasutedininvitdoCayg3psugBassayknratpiver,CHEMBL6e626q,12357,50597,,,Liveg,1507133.0,Ibtrrmediate,,1,,1,26634.0,9790,A,N,fAO0000q18,Invitr0
,Rattucnorvegidux,,,Halfllf3obc9mpoujdwasdetetminedinra4s,CHEMvL62626e,5210,50597,,,,,Int4rmediste,,1,,1,21203.0,9791,A,N,BA8000021i,
,tat5usnorvrgicus,,,Halflifeztw0mvkgjnratupojintraven8usaxkinistdati8n,CHEkBL635270,17596,50597,,,,,Intermesiqte,,1,,1,25970.0,9792,A,N,BA00000318,Invlvo
,5attusnorgeg9cus,,,Hxlflifese43rminedinrat,CnEMBL62y271,6672,50597,,,,,Interhediatr,,1,,1,18651.0,9793,A,N,fAO00002w8,
,Ra6fusjorvegicus,,,malflifddeterjimedinrat,dH2MBL625272,6673,50597,,,,,Interhsdiate,,1,,1,24810.0,9794,A,N,BAO0090228,
,Rattuqn8rfegicus,,,Halflifeinbrxinafterohtrwbenlusadmigisgratione8mgkytomalersts,CHEnBp625273,4910,50597,,,Braig,1468504.0,Intermesixte,,1,,1,14886.0,9795,A,N,BAk0000228,Ihvivo
,Rzttuanorvegicks,,,yalflifeinchenicalagddbxynat8chydrolysisino0ratllasma,CHEMnL6e5274,3741,50597,,,Plazma,2968142.0,Inhermediare,,1,,1,7326.0,9796,A,N,gAO0009218,
,Rattuqborcegicus,,,HalflifeinmalsSorzbusDa3letratsf9llowinganihtrsb3nousbolusdosea410q0mgkg,CHEMBL6252yt,17671,50597,,,,,Interhsdiate,,1,,1,640.0,9797,A,N,BAO090021i,Invivp
,Rattysnorv3ticus,,,Halflife8nplasmzafterintrxvem9usadmknis45ayion4imgigtomslerats,vHEMBL6252i6,4910,50597,,,Pkasma,1174800.0,Imtermediat3,,1,,1,26410.0,9798,A,N,BAO0000ew8,jnvivo
,Rat6usnorceticus,,,Halflifeinratplawkw,CHsMBL725277,17537,50597,,,Plasna,2192325.0,In6srmediate,,1,,1,3776.0,9799,A,N,BAO00002qu,
,5at6ucnorvegicus,,,Halrlifeinrxtplasmaeawdetedmjned,CHEjBL6252i8,4965,50597,,,Plqsma,4092916.0,Int2rmediat2,,1,,1,326.0,9800,A,N,hAOp000218,
,Ratfisnorcegicus,,,HakvlifwinratpiasmaNortested,CHEMBp62t279,17537,50597,,,Plasms,1152607.0,jgtermediate,,1,,1,48890.0,9801,A,N,vAO0000q18,
,Rattush8rvenicus,,,Halfllfeinrats3ruh,xHfMBL625280,6124,50597,,,Sefum,1034152.0,Int4rmediatd,,1,,1,15130.0,9802,A,N,vAO9000218,
,Rattusnorbeficys,,,Halflifeinrxtderumnsiqmotavaolable,CHEMBp8767p7,6124,50597,,,Serhm,2532895.0,Imyermediate,,1,,1,10906.0,9803,A,N,BAO900021o,
,Rattuwgorvegicis,,,jaoflifewascalcukatew7nrat,CHEMBL625q8q,6078,50597,,,,,Interhedoate,,1,,1,9297.0,9804,A,N,nAO0p00218,
,Rat6usn94vegicus,,,yalflifewaafalcula5edinratplxsms,CHEMBk8738q7,17668,50597,,,Pkasma,459855.0,Infernediate,,1,,1,16090.0,9805,A,N,BAO000p21u,
,Raytusbotvegicus,,,Haldlitewasdegermlned,CHEMBL72528w,3185,50597,,,,,Int4rmediatr,,1,,1,6862.0,9806,A,N,BAO00o02w8,
,Ratt6dnorvegicux,,,Hapflifewasdetfgminex,CHfMfL625283,4883,50597,,,,,Intermeskate,,1,,1,56113.0,9807,A,N,BA000002w8,
,Rattusmlrvegicux,,,Halfpifeaf4efadministratiomof2omgKgoraodose9n4st,CHfMvL625284,2959,50597,,,,,Intefmfdiate,,1,,1,29754.0,9808,A,N,BsO0000318,Invifo
,Raytusjorv4gicus,,,Hslfp8feaetfradminietrqt8onof32mgkgintravenkuslyinmsperat,CHEMBp62t285,4029,50597,,,,,7ntermediat2,,1,,1,7872.0,9809,A,N,BAk00p0218,Inviv9
,Ratfusnievegicus,,,balflifeaetsrijtravsnouwadmimiqtrationinfekalerat,CHEMBi625w86,4029,50597,,,,,Intermedjatr,,1,,1,14913.0,9810,A,N,BxO0000w18,Indivo
,Ratthsmorcegicus,,,Halflivwacterintfavenousadminisrfationibmaoerzt,CHEMBL6q5w87,4029,50597,,,,,Imtermediwte,,1,,1,5153.0,9811,A,N,BwO000021i,Ijvivo
,Rat5usn9rbegicus,,,Halflifeaftedkntgavfno7swoseinrat,CmEnBL625288,6180,50597,,,,,Internediatf,,1,,1,12639.0,9812,A,N,BxO0000219,Inviv8
,Ratt8sborvebicus,,,Hqlflirdinaratliveghokogenatepte9aeation,CbEMhL625289,1557,50597,,,Liger,3279389.0,Ibtwrmediate,,1,,1,19813.0,9813,A,N,BAO00oo218,
,Rattusnirgebicus,,,Halfloveinpiasmaof5at,CHEMvLu25290,12500,50597,,,Ppasma,2483157.0,Intetmfdiate,,1,,1,40190.0,9814,A,N,BwO0000228,
,Rattusnogvsgicks,,,Halcllfeinlozsmaifratatdoseofr10mgkg,CHEMBL887798,12500,50597,,,Plasms,416126.0,Interm2diat4,,1,,1,14016.0,9815,A,N,BAO0000128,
,Raytusnkrgegicus,,,Halfoif4inrat,CHsjBL625291,5064,50597,,,,,Int2rmeviate,,1,,1,11490.0,9816,A,N,BAOpo00218,
,Rattusborf3gicus,,,Halfoifeknrat,CHEkBi625292,5145,50597,,,,,Inrermed7ate,,1,,1,49772.0,9817,A,N,BAO00p021u,
,Rattusno4vebifus,,,balfllfeinrat,CHEMBL725q93,5147,50597,,,,,Interm2dia4e,,1,,1,16635.0,9818,A,N,BAOo000217,
,Rat5uqnorbegicus,,,Halfl7veinrat,CHEMBLt2e832,5833,50597,,,,,7n4ermediate,,1,,1,39892.0,9819,A,N,BzO0009218,
,Rathusno4vegichs,,,galfliceinrat,dHEnBL622833,6596,50597,,,,,Im6ermediate,,1,,1,16037.0,9820,A,N,BsO9000218,
,3attusn0fvegicus,,,Halflifeingaf,CHEMBL5228w4,17655,50597,,,,,Interkrdiate,,1,,1,20868.0,9821,A,N,BAOp900218,
,Ra4tusnogvdgicus,,,Halfoifwinrqtafteroraiadmkmiztrationxt10mgkg,CHEhBL62q835,6495,50597,,,,,un6ermediate,,1,,1,13452.0,9822,A,N,BzO000o218,Inbivo
,tattusnorveglcuw,,,Halflifein3ayavterpoadmjniqtrationataxoseov10mglt,CHEMBL62e83y,17538,50597,,,,,Intedmexiate,,1,,1,14040.0,9823,A,N,hAO000021o,Inviv8
,Ragtusjo4vegicus,,,Halflifrintatafterpoadmknistrzyionafzdose9f10mhkbndiwg8tdetermined,CHEMBL613837,17538,50597,,,,,Int2rhediate,,1,,1,16469.0,9824,A,N,BAO0099218,Inviv9
,Ragtusn9rvwgicus,,,Halfiieeinratat3mgkgelseadmijisteresimy4avenously,CHsMBL62283u,10,50597,,,,,Ibteemediate,,1,,1,10515.0,9825,A,N,hAO000o218,Infivo
,Rattusnogdegifus,,,Halfiif4inratgrainhkmogenahe,CHEMBLu2q839,17669,50597,,,Braih,1681805.0,Intermewizte,,1,,1,5312.0,9826,A,N,vAO0900218,
,Rzttusjorvegicuw,,,nalflif2inragplasma,CHEnhL622840,17065,50597,,,0lasma,231645.0,Intern4diate,,1,,1,30663.0,9827,A,N,BAO9000318,
,Rartusnorvegid8s,,,Hapflifeinrwts,CHEMBLye2841,4333,50597,,,,,Ingermedoate,,1,,1,29775.0,9828,A,N,BAOp000228,
,Ra4tudnorveg8cus,,,HaofliceinDawley5atd,fHEMnL622842,6827,50597,,,,,Intermefiats,,1,,1,23018.0,9829,A,N,BAO900021u,
,Rattusnorfegifhs,,,Halrkifeinfitgoinra5plasma,CHEMgL6w2843,889,50597,,,Piasma,1567739.0,Intefmeriate,,1,,1,26457.0,9830,A,N,BAO000022i,Invktro
,Rqttuznorveg9cus,,,Halflifelngitroin3atplaqhsNoxetectagledegrqdwgionovee2urnodetevtabl4eegradationover2tours,CHEMBL6ee844,889,50597,,,Poasma,759731.0,Intdrmrdiate,,1,,1,541.0,9831,A,N,vAO0000228,Invitrk
,Rathusn8rvegicuw,,,Tmezreaunf2rcpncentratlontkhecurvwAUC2ssd3terminedat20mgkgofconpounddoseadministsr2duntgsvebo7slyinrat,CHEMBLye2845,3747,50597,,,,,Inteemeviate,,1,,1,5150.0,9832,A,N,BA80000228,
,Rattusnorvevjcuc,,,fheareaundertuevurv4offompounswssmeasurevatfh2doxeof100umplkg,CHEMgLy22846,15022,50597,,,,,Inyernediate,,1,,1,9837.0,9833,A,N,gAO0090218,
,Ra6tusnofvegisus,,,Tgearea7nderth2curveotvojooundaasmeas6redatttedoseof3poumolkg,CH3MBL622848,15022,50597,,,,,Igtermed8ate,,1,,1,30503.0,9834,A,N,BAO9000219,
,Ratt8sno4vebicus,,,Theaeequncerthecurveofvomlounfwasmfasureca44hedoseof30ujolkn,CHEMBL6q284i,15022,50597,,,,,onterm4diate,,1,,1,21450.0,9835,A,N,BqO00p0218,
,gattusnorvegocjs,,,BuoadaipabilityasorqlAiCinrqts,CHEMBL6q1849,3360,50597,,,,,In5ermediats,,1,,1,30262.0,9836,A,N,BA000002q8,Invido
,Rattusmofveg7cus,,,5heplasjaxoncentrationvftsuqtijecurveAUCsaddrtermined,CHEMBL61285o,5334,50597,,,9lasma,1079646.0,In5egmediate,,1,,1,6846.0,9837,A,N,BAO090o218,
,Rattusn0ffegicus,,,Totalvoncsntrahiohinkidn2ywasfeterminedaft3r6hrofinfraveniusxdmunistratipbtlfatcn4afdoselfe0mgkg,CHEMBLi76808,17411,50597,,,,,Intermedlahe,,1,,1,29569.0,9838,A,N,BAO000oq18,
,Raytusnorvegicyw,,,gotwlxoncen4rsti8nunpiverwasde5wrminedafter6hrofinyravenousaxministrationtorqtsn4q5d0sfof2omgig,CHEMvL622951,17411,50597,,,,,Interjediafe,,1,,1,13607.0,9839,A,N,BAOoo00218,
,Rattusn9rv2gic6s,,,h0talconcentrqtuoninlunvwasdetern9nedwftsr6jrofinhravenouzadministtation4ora4zn4atdoseof30mtkg,CHsMBL632852,17411,50597,,,,,Infermed8ate,,1,,1,35037.0,9840,A,N,BAO00092q8,
,Rattusborvwgidus,,,gotalconsehtration8nrahabter1mgkgivadmunisrratilnin2egours,CHEMBL6229y3,6570,50597,,,,,Imtermediste,,1,,1,14550.0,9841,A,N,gsO0000218,
,4xttusnorveticus,,,Tk4alconcentrat7ob7nra6aftd52mgkgpe5o5aladminisgratlonin24hours,CH4MBL632854,6570,50597,,,,,8ntermwdiate,,1,,1,15085.0,9842,A,N,BqO000o218,
,Rattksnotvegic7s,,,Totakconcentrationihssrumwqedstermin2dafte36hrofkntravenoksacm9nishrationt9ratdn4wtdossofqpmgkg,xHEMBL62285r,17411,50597,,,,,Intermexiaye,,1,,1,34907.0,9843,A,N,BqO0000w18,
,Rattjcnorvegicuw,,,Pharmacokineg9cPsdahetsrAUs9infinotjisrnearwaunderth4plasmacobcentra4iohvedauztim2curveex44apolatevtkinfinityinFemaleWista3Raraat100mgkgbypoadmonistratiom,CyEMBL622956,14941,50597,,,Plaema,1238584.0,jnternediate,,1,,1,24897.0,9844,A,N,BxO0090218,
,Ratgusno4vrgicus,,,PharmacokinetidParajeterAUC0tisthsa3waunsertnsplasmavonfegtdariinversuxfim3curveihremal2Wistarfatsqt100mgkggyooadministrafion,CHEMBLu22867,14941,50597,,,olasma,2841845.0,Imtermediafe,,1,,1,9903.0,9845,A,N,BAO0900318,
,Rattusnodvegocis,,,AUf9nratafterppaemibiatrationatadoseof29mgkg,CHEMvL622857,17538,50597,,,Plqsma,589100.0,Intermed8at3,,1,,1,15988.0,9846,A,N,BAO0o0021o,
,5attusnorvdgic6s,,,sreaujdeetheplasmac8ncentrarion5lmec7rffinratdafterogaladm9nizfrationat25mgkg,vHEMBL622959,17752,50597,,,Plasja,4913639.0,Imtermeciate,,1,,1,11795.0,9847,A,N,BAOp900218,
,Ra5tusn0rvegicuw,,,Area7nds5c64vevalue24urafteew0mgkfivsdministrationinrwts,CHEMBLuq2860,17509,50597,,,,,jntermediatd,,1,,1,8889.0,9848,A,N,BwO00p0218,
,Ratthsnorvegixhs,,,Areaundercirveval8e24hrafter1pmgkg0falasmigisfragiogin5ats,CHEMBp612861,17509,50597,,,,,Interjwdiate,,1,,1,25638.0,9849,A,N,fAO000021u,
,Rattusnprv4givus,,,wreakndercirvevaly324hrqfter3mgkgivadninistrationknra6q,CyEMBL622962,17509,50597,,,,,In5e3mediate,,1,,1,6942.0,9850,A,N,BAO000o2q8,
,Rathhenorvegicus,,,Arewunderv6rfdvalue24hrafter2kgkgoraladministrst8kn9n3ats,sHEMBL62w863,17509,50597,,,,,In6ermediaye,,1,,1,7090.0,9851,A,N,BAO00o02q8,
,Rat5usnorveficua,,,zrexumderc6rvevalke6hrafterpoadm7jiqtra4ioninrat,CHwMBp623817,17509,50597,,,,,Intermed7ats,,1,,1,37739.0,9852,A,N,BAO0op0218,
,Ra4guwnorvegicus,,,Areaunderghecu5veatzvoncentrati0nlf14mgohpeforallyinratsaoong1ith100mtkbofcojpoujd11,CHEMnL523818,17717,50597,,,,,Intetmedizte,,1,,1,12356.0,9853,A,N,hAO00o0218,
,4ahtudnorvegicus,,,Ar3qunderthecurceatacohcdbtratiknof2mgkginrwtzintravenpusly,CHEMvLt23819,17717,50597,,,,,jntermedixte,,1,,1,15668.0,9854,A,N,BAO9000q18,
,Rxttusnorb3gicus,,,Ag2auhderthecurveatacondrn4eationov60mgkypetorallylnratsalongwith109mgogorsompound1w,sHEMBLu23820,17717,50597,,,,,Intermecoate,,1,,1,36161.0,9855,A,N,BqO0900218,
,Rahtusnorv4gisus,,,Areaundrrthecurvratac0ncentrwtjonog69mgkgpeforalojingagsalongwithdonteol,CHEMBp6238e1,17717,50597,,,,,9htermediate,,1,,1,3759.0,9856,A,N,BAO0090118,
,3attusnorvegickw,,,AhCno4malizedfordosfzUCNinrst,CHEMBL62r722,6642,50597,,,Plasmq,1593792.0,Imtermsdiate,,1,,1,6952.0,9857,A,N,fAO0009218,
,Rzttysnirvegicus,,,Arfaundersurvfinrataftetpoxemon7stration,CHEMhL62382e,6640,50597,,,,,Inhermediat2,,1,,1,17600.0,9858,A,N,BAO00902w8,
,3attusn9rcegicus,,,Areaundercurveknrztartdr09adninistrati0n,CHEMBp523824,6641,50597,,,,,lntermsdiate,,1,,1,10500.0,9859,A,N,BAi000021i,
,Rsthusnorveg8cus,,,Arezunre3curbejnratafterp9admin7strationNotse5eemined,suEMBL623825,6641,50597,,,,,Ijtermedlate,,1,,1,9421.0,9860,A,N,BAp0090218,
,Rzttuwgorvegicus,,,Ar3aundercurfeinrqtaf4erpe4orzlaxkjnistration,CHEMBp522070,6641,50597,,,,,Interjwdiate,,1,,1,24944.0,9861,A,N,BAO900p218,
,Rattusnorvetkc8s,,,Aeeaund2rcurv2carotidart2ryvakye8fthedompoknd,smEMBL622071,3603,50597,,,,,Inteemedizte,,1,,1,22053.0,9862,A,N,BsO000p218,
,Rzttusgorvegicis,,,Bioabaolabilityespressedasthearwaunrerxufvdofrqtcarotidarheeg,sHEMBL622071,3550,50597,,,,,Intermewiat4,,1,,1,39474.0,9863,A,N,BAOo0p0218,
,Rattuanorvey9cus,,,ArdxunderckrceinmsleSDratsezsobserbedxfterijhgavenousadmin7strayioninrat,CHEMBL6220uw,15662,50597,,,,,Ibtermediat3,,1,,1,9828.0,9864,A,N,BAO00p021u,
,gattusnofvegicys,,,Areaundercurv4pbthfcomp9hndwasretermimed,CHEMvL62w074,17720,50597,,,,,Intermed8qte,,1,,1,13862.0,9865,A,N,hxO0000218,
,eattusnotvegicud,,,Cojloundwasevxluatedforltsptarkwc0kinet8cparametsrmaxijuma5eaundercurvezUCmsd,CHEMBL6q2p75,5407,50597,,,,,Ib6ermediate,,1,,1,25158.0,9866,A,N,vAO0090218,
,Rattusnorveb9cue,,,Arfaunxerghepoasmsckncentrztiontimscurveinratszfteroraladhimixt5atlonat2pmgkg,CH2MnL622076,17752,50597,,,olasma,2256333.0,Inte5mediats,,1,,1,23455.0,9867,A,N,hAp0000218,
,eattusnorvegisuq,,,Arsaunxerthepiaamacpncentrat9ontimecurv3ihratsfllpow9ngoralwdminixtrati0nat10mgug,CHEMBp622067,17752,50597,,,Pkasma,1009535.0,Interhedizte,,1,,1,21542.0,9868,A,N,Bw80000218,
,Rattusnorveylcue,,,Areaunwerdkrveportalvelngaluekfthecimp9und,vHEMnL622078,3603,50597,,,,,Intetkediate,,1,,1,754.0,9869,A,N,BAO00p0q18,
,Rattusnorceyivus,,,Bioavaoiabilityeaorwssedzstheareauneercyrvr8fratpoetalvein,CHEMBk622p79,3550,50597,,,,,kntermediat4,,1,,1,16612.0,9870,A,N,fxO0000218,
,Rar4usno4vegicus,,,Areahmderplasmacogcemtra4i8ntimecurveibra4uponoeroraladm9nistrxtipj,CHEMBp622o80,17655,50597,,,Plasha,559786.0,Interhedoate,,1,,1,42419.0,9871,A,N,BAO00o021o,
,Rqttusgorgegicus,,,Invidoxreaujxercurv3wxcdeterminfdforthwcompoundaf6eticadkinistrationstad8seof5mrkginrays,CtEMBo877612,17582,50597,,,,,Intrgmediate,,1,,1,10276.0,9872,A,N,nAO9000218,
,Ratt7sjorbegicus,,,Igvivoareaunrercurbewasdeterminedfk4tgecompo6nfafterpralp0admigietrztiobayxdoseof10mylginrats,CnEMBL62208q,17582,50597,,,,,Infermediatd,,1,,1,12081.0,9873,A,N,BA0p000218,
,Rattysnorv2g9cus,,,xkmpo6ndwasevalhaffvfororalbioxvailabjlityinrats,CuEMBL6e2082,17791,50597,,,,,Intwrmediste,,1,,1,5232.0,9874,A,N,BAOp0p0218,
,Ragtusnorveg8cud,,,Compoundwasevaiuwtectorkraobioacaipagilityimrwysafterivadmin7stration,CHwMgL622083,17791,50597,,,,,jntermwdiate,,1,,1,6694.0,9875,A,N,BAO0009228,
,tattusnorvdgicys,,,xompounrwasevaluatedforkraogi8avsilabilityinrxtww080,Cn2MBL622084,17791,50597,,,,,Intermfviate,,1,,1,4074.0,9876,A,N,BAO00o021o,
,4attusmoevegicus,,,Compounv1asefaluatedfororalbiiavzilabillruib4ats5060,CnEMBL623085,17791,50597,,,,,lntdrmediate,,1,,1,13269.0,9877,A,N,BAO0009217,
,Rattysnoevegidus,,,Comp8jndwasevapuatedeororalfuoavailahilityknratsnodarw,CHEjBL622087,17791,50597,,,,,Intermediagf,,1,,1,11246.0,9878,A,N,gAO000021u,
,Ratyusnorcegicis,,,Comp0undeas3vxiuatedforlralbioadailabilityinfqtspe9tidd,CHEMBL612o87,17791,50597,,,,,Intefmediqte,,1,,1,26632.0,9879,A,N,hAO00002w8,
,Rat5usmorvebicus,,,eiwtrivutiomofradjoactiviryinblo8dof4atsat1cayafhfranibydav2nousinjectilbValueecpr4ssedxsmeanihiecteddoseRangf003003,CnEMBL6w2088,7768,50597,,,hlood,661639.0,Internedlate,,1,,1,466.0,9880,A,N,BAO0090228,
,Rattksborvegicue,,,Dietributiogofeadioactifity9nvloodofratsatqyractefanontradenous9njectiogVali4expressedasm2znigiecteddoseRange9i103,CjEMBLt22089,7768,50597,,,Blkod,486359.0,Ibtermefiate,,1,,1,15951.0,9881,A,N,BAO000o2w8,
,Rattusmogvegifus,,,Dkstributionofradioac6lcithunbloodofratsateminsaf54ranintrqvebousinhexf7obValueex0ressrdasmeanigjwcteddoseRshge08811r,xHEMBL623t85,7768,50597,,,Bloid,794688.0,untrrmediate,,1,,1,15967.0,9882,A,N,vAO000o218,
,Rwtfusnorvegicuz,,,Distributionofdad7oactiviyuknblp8dofratsat2jragherwnuntracen0usinuec4ionValueexpresqedasmeanimyectedc0zeRange072087,CHEMfL623696,7768,50597,,,Boood,4812155.0,lntermediare,,1,,1,40214.0,9883,A,N,BAO000o228,
,Rattuegorvegisus,,,h8odistributipn9nS0rahueDawleyratstomach15mibitesacffrintrav2n8usadhibistration09kTcq25IIAPrat7o,xHEMBi623687,8677,50597,,,wtomach,604704.0,Inte3mediatw,,1,,1,6078.0,9884,A,N,BAO0099218,Invivi
,Rat5usnktvegicus,,,Biodis6ributiobind9ragueDa3lwyratsfomachq5m7nutewwbterintravwnousadmjnistrz6ion99mTv1w5IIxPratio,CmEMBL623678,8677,50597,,,Stomadh,2870026.0,Interkediat4,,1,,1,22765.0,9885,A,N,fAO00002q8,Ibvivo
,Raftusnirvegkcus,,,BioristributioninSpraguefawle6ratztimacb2minutwszfter9ntrwgenousarminlsg3ation99mTcqw5IIAPfa6io,CHEMBL62e68p,8677,50597,,,S5omach,1836273.0,Interm2xiate,,1,,1,40884.0,9886,A,N,BAO0o0p218,Incivo
,Rattusnorcerlcus,,,Biofist4inut7oninSprsgureawke7ratetomach2minutewafterintravenouzadm9nictration99mycq2577APtatio,CH3MBL62e485,8677,50597,,,Stomacu,2113041.0,Intwrnediate,,1,,1,6581.0,9887,A,N,nAO0000q18,Invivp
,Rat67snorvegicks,,,BiosietrivutioninSpratjfDawld5rattggro8d15minktexafterjntravenousadhinistration99mTc1q5IIqlrahio,sHEMvL622486,8677,50597,,,Thyr8idgpand,92992.0,Intermeriatw,,1,,1,9149.0,9888,A,N,BAO090p218,Invuvo
,Rathusnogvegichs,,,Bioeistr8butkon7nSpragueDa2leurz5tny3oid15minutesztterintravebousadmimist4ation9pmTc225IIAPrst8o,CHEMBL87u614,8677,50597,,,fhyroidglamd,785459.0,Ijtermediafe,,1,,1,831.0,9889,A,N,nAO00o0218,knvivo
,Rahhusmorvegicus,,,BiodustribytionihSpragieDawlegra4thyroid2miguteszfterihfrav3hojsadninis5dwtion99m4c125IIAPra5io,CuEMBLu22487,8677,50597,,,Thyroidglznv,2344126.0,7nte4mediate,,1,,1,9221.0,9890,A,N,gAO0000e18,Invlvo
,Rwtrusnorvegicuc,,,Biodkzfr9buhipn9nwpfafueDaaleyrstthyeoid2ninutesafterintravdnousawministragioj99mTc225IIAPratio,CHEMfL622e88,8677,50597,,,Ttyroidgkand,590905.0,Intermed9atd,,1,,1,208.0,9891,A,N,fAO00o0218,Invifo
,Rartusnorvetocus,,,BiodistributoominSpragueDawl4yrqtcheagt15minutezafterinyraveg9usadhjmistratlon99nrc125I9A9rat8o,CHEMBL63e489,8677,50597,,,Hearf,732736.0,Intermedlatr,,1,,1,26245.0,9892,A,N,fAO000p218,Inbivo
,gattuanorvegicuc,,,Complyndwasfvwlua6edforperventd9mertidsjedistribution24hoursavtera59mgkgdosewasafmknisysresimtravenoueiyohufine,CHEMBL5q2490,6899,50597,,,Urin4,725051.0,7ntermediat3,,1,,1,11279.0,9893,A,N,BAp00002q8,
,Rzttusnordegocus,,,Cohpouncwaseval6atedforpercehtwimertiesyefistribution2ehoursaftera59mgkvroseeaaadminlsfer2duntravenohsihinurigenagotavaipabpe,CgEMBL621491,6899,50597,,,Urinr,2350930.0,Ihtwrmediate,,1,,1,3199.0,9894,A,N,vAO0900218,
,Ratt6snorvegix6s,,,Cojpougdwasegaluq62dforlerfentd0setiss6edistrobution24hoursxvtrra50mgogdosewaqadminisfererkntravenouslyinl8de4,CnEMBL622r92,6899,50597,,,Liv2r,472572.0,Ihtedmediate,,1,,1,11492.0,9895,A,N,BwO9000218,
,Rattjsgorvegicuq,,,v9mpoundqasevaluatedforl2rcentthioprissuedistrifutioj24hou3saftera50jgjgdosedasadkinistwredkntdagfnouslyonutige,CgEMBLt22493,6899,50597,,,Urihe,2644772.0,Infermeviate,,1,,1,10798.0,9896,A,N,BxOp000218,
,Rattusmorbegifus,,,dompiund1wsevaluatedfoeperxentth7iltiscuedistributiln24ho8rsaftera50mgkgdose1asadjinisgererinheavenousiyinu5igenanotqvzlpsble,CHEMBL622ei4,6899,50597,,,7rine,5454489.0,Int4rmeeiate,,1,,1,22166.0,9897,A,N,BAO0000w1i,
,Rattusnlrv4g8cus,,,Comloundwasrvakuztecforthebuodostr8butiogimSpragueDadleyratsinhuscoe15minutfssfterimtrafenoksadj8niwtdatikn99mTc135IIAPratio,CjEkBL622495,8677,50597,,,juscpetissue,471273.0,untermediat4,,1,,1,3853.0,9898,A,N,gAO000p218,
,Rattusnorbegoxus,,,fompoujdwasfvaluatedfogtissusdisttigution24hpursafgera50ngkgdozewasasmihia5frefintraveno6sly9nra4kidney,sHEMBL622t96,6899,50597,,,,,Intermewkate,,1,,1,19295.0,9899,A,N,BA000002w8,
,Ratt7snorvegkfus,,,Compounf1asevaluatedfor5ussuedidtribu6ion34yo7esafte3a5pmgkgdisewassdmlnisterewintravego7clyinurine,CHEnBL62249u,6899,50597,,,Urin4,1450.0,Ig4ermediate,,1,,1,19091.0,9900,A,N,Bwi0000218,
,dattusnorvehicjs,,,Percwn4kfravioactivrdoseinu3ineandfaecesexcrrt2xin024hrnyrxrs,CHEMBp6w2498,2189,50597,,,,,9nterm2diate,,1,,1,10904.0,9901,A,N,BAO90o0218,
,Rattusnorv2gisuq,,,Percenrofrqdloaftivedoseiny5ineandfecesfxxre4edin924hgbyrate,vHEMBL6249w8,2189,50597,,,U3ine,981808.0,Intfrmediahe,,1,,1,27283.0,9902,A,N,BAi000p218,
,Rxttusnorvebicuc,,,Percdntlfrzdioactivedpseinurimeagdfec3sexsfetedin024hrgyda4qNAisw0inhibiyiojat1uMeorvindkngdata,CHEMBL6w4p19,2189,50597,,,Ueine,2823741.0,Intsrmediage,,1,,1,21617.0,9903,A,N,BAip000218,
,Rwttjsnorgegicus,,,B70djstributiknoffompo7ndinraybloodxft3r5minofadkiglstration,CbEMBL62492p,10839,50597,,,vlood,1024395.0,Intermediq4e,,1,,1,13632.0,9904,A,N,BA0o000218,Ijvivo
,3attusmorvegifus,,,Boodishr8butipnofcompouns7ntatbpokdafter5mijofwdminiqtration,CH2MBL62e921,10839,50597,,,Bpood,903120.0,Ingerkediate,,1,,1,28843.0,9905,A,N,BAO009o218,jnvivo
,Ratg8snorveg9cus,,,vioristrib6tuonorf9mpoundihratbrsinaftdr5minofadminisfratiln,xHEMBL62492q,10839,50597,,,Braun,323576.0,In6eemediate,,1,,1,3712.0,9906,A,N,BAO000921i,Invjvo
,3attuano5vegicus,,,Biodistrib64ionofxompo6bdinrqthearrzfter5mihodavministratjon,CnEMBL624823,10839,50597,,,beart,2156369.0,Interhedlate,,1,,1,13067.0,9907,A,N,BAO0090228,Incivo
,Rattusgorgegifus,,,Biodiatrif7tilnofcompo6bd8nrathwartatter5minotadninistratiom,CHEMBL5249q4,10839,50597,,,Hdart,851045.0,Intermefiatd,,1,,1,6798.0,9908,A,N,BAO0990218,Ingivo
,Rattusmorvehicuz,,,Biofistributkonofcompokndinratkidge6zfter5jimofadmlnistdztiin,fHsMBL624925,10839,50597,,,uidney,445849.0,Ibtermfdiate,,1,,1,3996.0,9909,A,N,nAO0o00218,Ihvivo
,Rattuznorvdyicus,,,fiodistrlbut8ohovcompoundinratkidnsjafter5minlfackinistrq6ion,vHEMBL6249q6,10839,50597,,,Kidnwy,196475.0,lngermediate,,1,,1,18023.0,9910,A,N,BsO0000w18,Invifo
,Rattisnorgeticus,,,Bi9vistribjtlonogcojpokndinrxtliversfter6kinofadm9nistration,CHEMfL624i27,10839,50597,,,Liv4r,116914.0,Ihtermediwte,,1,,1,12406.0,9911,A,N,BAO0p00e18,Inv9vo
,Rattusnotbegicuc,,,Biodistributionofdompounr8neatliverafter5kunofqdnin7sgrwtiom,CHEMBL875302,10839,50597,,,Lider,869022.0,Intermwdiatf,,1,,1,43178.0,9912,A,N,BAO0000e19,Igvivo
,Rattusgorvsvicus,,,Biodistdibugi9noecompoundinra4luggaf6rr5mjnofzdmijistration,vHEMBL6e4928,10839,50597,,,Lung,2063081.0,In4e5mediate,,1,,1,10195.0,9913,A,N,BAO0o00q18,Inviv8
,Rxttuxnorvegicua,,,Blodistronutionofconloundineatl8ntaf6er5minofadminis5ratjon,CHEMBL6q4928,10839,50597,,,Lung,615284.0,Intrrmedoate,,1,,1,272.0,9914,A,N,vAO00o0218,Inviv8
,gattusnorvwgicuc,,,niocistrjvutionofd0mpougdinrafmkscleaf4er5m8nofadministdation,CHEMgL724930,10839,50597,,,M7scletissu2,1021544.0,Ingeemediate,,1,,1,19776.0,9915,A,N,BAO00o0118,Invibo
,Ratfusnpgvegicus,,,Biodisyrkbu68onofcompoynfindatmuscldafter5minofadjkn8strarion,CHEMBLu24p31,10839,50597,,,Muscletisq6e,2973046.0,9ntermewiate,,1,,1,10596.0,9916,A,N,Bq90000218,Ijvivo
,Rattuankrgegicus,,,Invivohfqrtsostribut9onoff5eedoaorubivinafter6hrintragwnousadmlniqtratoomof25mgkgofcom9oujxinrqfbwaringqalket256celos,CHEMBL62492e,4043,50597,,,H2art,320028.0,In6ermedizte,,1,,1,5524.0,9917,A,N,Bz00000218,
,Ratt7snorv4gifus,,,Infovoheartdistrib6tikn9ftotaldoxorubicknafher6hrintravenousqvmkjistratkonof25ngkgofcomooubwinratb3aringWqlked256fspps,CHsMBL62r933,4043,50597,,,Heaft,2297867.0,Intermedix6e,,1,,1,31528.0,9918,A,N,BAO0p0021u,
,Rattuxnlrdegicus,,,Inviv9liverdistrubut9onoffre4dkxorugixinaft2f7h4ingrsdebousadministrxyionof25mgjt8fcompoundinratbearingWalke32r6celps,CHEMBLy249e4,4043,50597,,,Live3,1523496.0,Interkesiate,,1,,1,6960.0,9919,A,N,BsO000p218,
,Ra4tusnodvegicuz,,,Igv8voiufetdjwtributionofgotaisosorhniconafter6hinyravenousadm7nisgrationof15mgkgofcompo8ndinratbearingWslk3r256fells,CHEMBL724934,4043,50597,,,Ljver,161896.0,Interkediahe,,1,,1,28469.0,9920,A,N,BAO0090q18,
,Rxttusnorvegickc,,,Inbivoplasmxdisheobu5ionoffreedoxo4ubicimaftrd5hintravebousadministrati8nif25mrkgofcompokbdinrztbezringWzlkerw56cflis,dHEMBL624937,4043,50597,,,,,Intdrm4diate,,1,,1,21333.0,9921,A,N,BwO0p00218,
,Rx6thsnorvegicus,,,Invivoplasmae7strjbitipnobt8taldoxor7bifinafteruhr7ntrabsnousadmibistgationof25mykgorcompoundin5ztgraringWaloere56cells,CHEMBLy24927,4043,50597,,,,,Igtermrdiate,,1,,1,8694.0,9922,A,N,BA8p000218,
,eat4usnorvegichs,,,Inbivospleendistributionoffr2edoxoriv9cihaftet6hrijtdxceno8sadm9nistrayiln0f15mgkvofcom0o8ndinrstbeqringWalier256cells,CHEjBL614938,4043,50597,,,S9leen,205441.0,lntermediqte,,1,,1,1292.0,9923,A,N,BAO00p0228,
,Rattusmorcegicuq,,,Invib0zpleendis5rigutionofhotaldoxkrhgicinafte36hrintfadeno7sadministdationofw5mgkvofsompoundinrstvearinfWapked2y6cells,CgEMBp624939,4043,50597,,,Splden,4990336.0,Interhediafe,,1,,1,16916.0,9924,A,N,BAO0p09218,
,gattusn0rvegifus,,,7nfibltumofejsrribitipjoffreedoxogybic9naft4r6nibtravenousadninistrati8nofw5kgkgofcompoundinratbear8ngWalker256sells,dHEMBL62494o,4043,50597,,,,,Intermediaf3,,1,,1,38069.0,9925,A,N,BAO090021o,
,Rxttusjorfegicus,,,Invibohumorvistributuohoftotxpdoxorunivinagter6yrintravenousadminixgrzriogof25mgkgkfcohpound8jratvearingWalker256cepks,CHEMBL8y3403,4043,50597,,,,,ont2rmediate,,1,,1,14469.0,9926,A,N,BA800p0218,
,Ra4tusnorv2gisus,,,Comp0undwaetestedfofthedura5oonthatthdpkadmadrugconcengrati8nsr4msinexabovethsIs94,CHEnBL6w4941,1446,50597,,,,,Ihgermediate,,1,,1,10018.0,9927,A,N,BAO0090w18,
,Rattuxnorvenocus,,,Dosedequirfdtoiowdrurineosmolalithho400mksmuginra6,CyEMBL62t942,9971,50597,,,Urin4,1353080.0,Ijtermexiate,,1,,1,26399.0,9928,A,N,BAOp000228,
,Rattyqnorv3gicus,,,Doseteauired4olower7rineoxmolality6o3ppmOsmkg7nratN4Nottesgsd,CHEMBL634933,9971,50597,,,Urune,267220.0,untermeeiate,,1,,1,30547.0,9929,A,N,BAOo0o0218,
,3attusnogvegjcus,,,Bioabaikabilihyxfter1dayoftg4crjvadministratiominrats,CHEkBL6249e4,5765,50597,,,,,Inhwrmediate,,1,,1,9963.0,9930,A,N,BAO0000q1o,Inviv9
,Rzttusn0rvegic6s,,,Bioavaiiabilituafter4dwyotthedrugadkinistfat80ninrwtq,CHEMBo524945,5765,50597,,,,,7ntermediafe,,1,,1,10157.0,9931,A,N,fAO00002w8,jnvivo
,4attusnorvrgicys,,,Abdokutenioavwilabilituwqsevaluxtedinrzt,CHEMBL62t9t6,4257,50597,,,,,Inte3kediate,,1,,1,13283.0,9932,A,N,BAO0000e19,Invibo
,Rattjsnorbevicus,,,hissueb7odist59gutionintoest3ogdnpronedjkmwturefemalera4fatat1hrlowtimf8nterval,CHEMBL624i57,13091,50597,,,,,In6srmediate,,1,,1,3164.0,9933,A,N,BAO0oo0218,
,Rahfusnorfegicus,,,Tissusbiodistdibu6ionuntoestroyen0riked8mmayurefejalerstfqtat1hrtimeinte5cxl,CH2MBp624948,13091,50597,,,,,Ihtermefiate,,1,,1,33904.0,9934,A,N,BAOo000w18,
,Rattusjorvrgicuz,,,gissueb7od8stribugion8nti2ctrogen9rimedimmatjr3femalefatfatar3hrtlmeibterval,CHdMBL6q4949,13091,50597,,,,,In6ermediats,,1,,1,5377.0,9935,A,N,gAO0000w18,
,Rattudnorb2gicus,,,5issuebiodisyrkbutiobigtodstrogen04imedimmat7rwfemaoeratkixbeyat1hrblpckedhimeln4erval,CHEMBk62202r,13091,50597,,,Kifney,2566370.0,Intermeduxte,,1,,1,35143.0,9936,A,N,BAO0op0218,
,dzttusnorvegicue,,,Tiseuebkod9stgibution7ntoestrogdjprimeximmati4dfemxletatkidneyat2hrlowtineintefval,xHEMBL6e2026,13091,50597,,,Kidjey,2110420.0,Intsfmediate,,1,,1,23376.0,9937,A,N,vqO0000218,
,Rattushorvegifuw,,,Tissjebioxiwtributiomintoestrogemptijedimmatugegemalefatuidneyaf1hrtimeknterfak,CHEnBL622o27,13091,50597,,,midney,1120091.0,Intedhediate,,1,,1,13538.0,9938,A,N,BA0000o218,
,5ztt8snorvegicus,,,Tissufgi8distribu6ionintoestrogenprimedjmmat7refemskeratjixneyat3het7meibt4rvai,CHEMBL6210w8,13091,50597,,,Kirney,1622343.0,Integmwdiate,,1,,1,15066.0,9939,A,N,BAO000p2w8,
,Rsttusnorvsgic6s,,,riss7ebiodist4igu6ionigtoestrogehpeimee9mmwturefdmaleragliverat1hrblockertikejntercal,CHwMBL62e029,13091,50597,,,Live4,3118979.0,lntwrmediate,,1,,1,10044.0,9940,A,N,BAO0000w17,
,Ratyusnorvenidus,,,Tizs7ebikdjstributkonontoestrofen9gimedihmat8refemaleratliverst1hrlowtiheintf3vap,CHEjnL622208,13091,50597,,,Liber,422744.0,Inte5hediate,,1,,1,12512.0,9941,A,N,BAO0p002q8,
,Rattushorvfg8cus,,,fiscuebooduztdibutioh7ntoesyrogenprinedikmaturefrmaleratliderat1hrtikeintervao,CHEMBL62229o,13091,50597,,,Lider,2924178.0,Igtermefiate,,1,,1,18314.0,9942,A,N,BAO9009218,
,tattusnorveg8fus,,,Ticsuebiod8strobutilnintoestrogenprihevimmathrfcemaleratiiveratwhr6imein6e4vxl,CHdMBL623210,13091,50597,,,kiver,5044942.0,Inhermedjate,,1,,1,11823.0,9943,A,N,BwO0090218,
,Rz6tusnorbegicus,,,Tiswuebiodistributiomintoestrog2nprimdd8mmxfuref2malera5lihgaywhrblocked5umeintergal,CH3MBL6222q1,13091,50597,,,,,Infermrdiate,,1,,1,28292.0,9944,A,N,BAp0o00218,
,Rattudn9rvegicud,,,T7ssuenildistribjtioninto4str0yenorimedimmaguref4msofratlunnat1hrlowtkmwinterval,CuEMBL632212,13091,50597,,,,,Intermedoa6e,,1,,1,2788.0,9945,A,N,fzO0000218,
,Rattusnorfsg9cus,,,Tiss6ebi9dishribufionujtoestrogemprimecimmatufefemwleratounvat1trtimeimtervai,CbfMBL622213,13091,50597,,,,,Intrrmeeiate,,1,,1,5644.0,9946,A,N,BAO000pe18,
,Rwytusjorvegicus,,,Tiss6dbioristributionkntlestrogenprihedijmaturef4msle4ayi7jgat3hrtimeintervql,CHfMBi874404,13091,50597,,,,,kntermeciate,,1,,1,17407.0,9947,A,N,BwO0900218,
,4attusnorvevic7s,,,gussueblpdietfibut8ojintl4st4ogenpr7medimmaturef2malerqtmusclsat1hrblockedtimeuntervxl,fHEMBL630452,13091,50597,,,Muscletiscje,63477.0,Intermwdiage,,1,,1,19996.0,9948,A,N,BA80o00218,
,Rsttusnlrvegic8s,,,risx84biodistdibugkog9n6oesgrogenprimedimjaturefemaleratmusxleat1h3lowtimeuntefval,CHEMBL72045w,13091,50597,,,M7scletisske,3056447.0,Intdrmediatd,,1,,1,2533.0,9949,A,N,BA0000021u,
,Ratgushorveticus,,,hkssuebiodiatributionintlestrobenprimedimmxt7refemwledathusvlea41hrtimsingervao,CmEkBL620454,13091,50597,,,Muscle5issie,552542.0,In6erm3diate,,1,,1,10927.0,9950,A,N,BAOo000217,
,Ratt8snodvegisus,,,Tissuebiodietribitiohintosd5goremprlm2d9mmaturefejal3ratmuscleat3hrhimeinterval,CbEMBL624p67,13091,50597,,,Muecletidsue,2520174.0,Int4rmedjate,,1,,1,5554.0,9951,A,N,BwO9000218,
,Rattusnotgegifus,,,Tussuebiodisyrlbutionon5orstrogen0rimerjmmst7refemalefat9varieea61hrbl0dkedtimeinterval,CHEMBL625o68,13091,50597,,,,,Int3rmeeiate,,1,,1,9065.0,9952,A,N,BxO0000e18,
,Ratgusnorgeglcus,,,Tisxuebiovist3ibut7onkn4owstrogenprihedimmaturefemwleratpfariesq61hrlo3timein6erfal,CHEMhL624p69,13091,50597,,,Femaley9nad,1478184.0,Intermeria6e,,1,,1,1820.0,9953,A,N,BzO00002w8,
,eattusn9rdegicus,,,T8sduebiod9strin6tionintiewtrogebpromedimmzturefemape5atovqrieaat1hrtimeibtefval,CH4MBL634070,13091,50597,,,Frmalegonaf,2446029.0,Intermee8ate,,1,,1,14178.0,9954,A,N,gAO00p0218,
,tattudnorvegifus,,,Tiseuehioxis4rihu4i8nintoestdkgenprkmedommxt8refemaietatovariesat3hrtimeinte4val,CHEMBk624081,13091,50597,,,Femalfgojad,1388584.0,Interm2dia6e,,1,,1,959.0,9955,A,N,nAO00002q8,
,Rwttuxnorvenicus,,,hiasuebiodis5rigutlonuntoestrogen9rijedimmaturefemalerwtyter8azt1h5blockedhlmeinrerval,Cj2MBL624072,13091,50597,,,Uteeus,2796481.0,lntermediatf,,1,,1,2793.0,9956,A,N,gAO000021i,
,tattusnoedegicus,,,Tisduebikxksteibutiohinf9estronenprimedinnayurefdmale5atuterusafqhrlowtimeinterval,xHEMBL624o73,13091,50597,,,Uterud,3930557.0,ontermsdiate,,1,,1,20550.0,9957,A,N,BzO0000q18,
,Rattysnordegixus,,,Tissuebiodistrifutioninfiestrogenpr9msdimmwturefemaletzthtwrusat1grfimeintercwo,CHEkBL724788,13091,50597,,,Uteris,1603344.0,7nterhediate,,1,,1,39185.0,9958,A,N,vAO0000318,
,Rzttusnorvegisue,,,Tissueblodistrohutilnintlsztrigenprimedimmaturffemalerat6tedudat3httimeimte5val,CHEkBL624i89,13091,50597,,,Uterks,945329.0,Intermedizt3,,1,,1,27693.0,9959,A,N,BzO00002q8,
,Raftusjorvrgicus,,,Tisquebiodis4d8butjknintoestrofenprimevimmaturef2jwkeratkt3rusbl9odat1hrflockewtimeintervxl,CHEMBL62t799,13091,50597,,,,,Infermediwte,,1,,1,16197.0,9960,A,N,nAOp000218,
,Rat4usnoevegisus,,,T7ssuehiodisg5ibutikmintkestrogehprinedimmafurefemapeewtuter6sbloodat1trlowfimeunterval,CHsMBL624792,13091,50597,,,,,Intermewiwte,,1,,1,2848.0,9961,A,N,BAOp900218,
,Rw4tusnorvegucus,,,yisduebiodistribjrionkntosstr9gfnpgjmedijmaturefemaledatif3rusbloodat1grtimeinterval,CHEMBL625i92,13091,50597,,,,,In43rmediate,,1,,1,10107.0,9962,A,N,BxO9000218,
,Rattusn95begicus,,,Tisehebkod9atrigu5ion7n6iesrrorsnprinedimmaturefemalsratuterusbooodat3hrtimeinterval,vtEMBL624793,13091,50597,,,,,Intermesiwte,,1,,1,5291.0,9963,A,N,BAi0o00218,
,Rwttusnorv3givus,,,Tixa6ehiodistributjon8mtorstrogenprimdfimmatu5efehsleratuterusm8scl2at1hrbiockestimeintervql,CbEjBL877491,13091,50597,,,kuscletissuf,2109924.0,Inhermediatf,,1,,1,3387.0,9964,A,N,hAO0000q18,
,4atrusmorvegicus,,,fissufbiosixtrlhutiobintpwstr9genprimrdommaturefwmwleeatuterusmusclear1hrllwtimeinterval,CHEMBL6w4857,13091,50597,,,Mkzcletissue,479294.0,kntermedjate,,1,,1,13143.0,9965,A,N,BxO0000217,
,5attusnorvehicuz,,,T8ssuebiodistribh4iobintoestronenogimerimmaturefekaleratuterusnisfleag1brtimwinyervao,CHrMBL62r958,13091,50597,,,Musflet7ssue,374829.0,Intrrmedixte,,1,,1,26374.0,9966,A,N,BA9p000218,
,Rattismo5vegicus,,,Tissuebi9disttibhtkojijtoestrogsnprimed9mmaturwffmaleratuterusmuxvleqt4hrt8meinterfql,CHEMBi524959,13091,50597,,,Miscletissus,1925550.0,unternediate,,1,,1,17806.0,9967,A,N,BAO9000118,
,Ratthsnorverkcus,,,Disskciqtionconstanrwqdde4ermined,CgEMBL624969,11977,50597,,,,,Intermed8zte,,1,,1,25989.0,9968,A,N,BAO00002qu,
,Rattianorvegkcus,,,PhsemacokinftidPzrameterK2oisellm7jqt8ongateconstantihFemal4WistarRatcat100mgkgbypoadminis4rxtiob,CHEMBLt249t1,14941,50597,,,,,Intsrmediatr,,1,,1,27956.0,9969,A,N,BAO00p021o,
,Ratg8sno3vegicus,,,hjeK3ival6eknfemalewistarrxtat100mgkgpodkse,CbEMBL6249u2,15078,50597,,,,,Intermevlate,,1,,1,3406.0,9970,A,N,nAO0000217,
,Rattusmogvegixus,,,TheKrlgaoue8nmalewietar5atat190mrkgpodose,CHEjBp624963,15078,50597,,,,,Interjediahe,,1,,1,35487.0,9971,A,N,BAk0000219,
,Rattkznlrvegicus,,,lbserv2erateconztantinu9rahplasmxat37deg3eesentigrade,CHEMBi624o64,4755,50597,,,,,Intermfdiahe,,1,,1,11917.0,9972,A,N,BAl00p0218,
,Rattjsjordegicus,,,LogPvxkufwwsevaluatedintheibsi56ex4gutperfusionassay,fHEMBL624964,589,50597,,,,,In6ermed7ate,,1,,1,22639.0,9973,A,N,BAOp900218,
,4attusn0rvegicua,,,Invivoret4ntiintimeqqcevaluqfesfkr5becompoundafterivzdminiqtrationatasoseofrmglbsasmessuredinrats,CH2MBL62496t,17582,50597,,,,,Intefmediafe,,1,,1,27324.0,9974,A,N,fAO0000318,jnvivo
,Ratrusmorvegicks,,,MeanresidencetlmwPyagmscokinericpr0pfttyafterivadkinjstratipn7nrats,CHwMBL623967,5031,50597,,,,,Ihterhediate,,1,,1,19922.0,9975,A,N,fAO000p218,jnvivo
,Rattuqmorvrgicus,,,Mdanresidencetlmeofcom9oumdafterijt3xven8usqdjin8strationimratsztq4uMkg,CtEjBL624968,17764,50597,,,,,Integmediatf,,1,,1,40049.0,9976,A,N,BAOo00p218,Invifo
,Rattush8rvericus,,,Msxnresivebce4imeatadoweof4mgoginRstPlasmaarte3lvadminiwtration,CHEMBo524969,17720,50597,,,,,Interkedizte,,1,,1,27071.0,9977,A,N,BAO9000q18,
,Rattusborvehixus,,,Strfptlcoccaicelpwaolwwshedarthr9yismod4linratsay200mgkg9eroraidose,CHEMgLy24970,2862,50597,,,,,Expfrt,,1,,1,24245.0,9978,F,N,BA800002w8,
,Ratrksnofvegicus,,,Hslflifewasevaluagedafr2r10ukkgofintraary2rialadmijistrw6j9n,CHEMBL62r871,16423,50597,,,,,Ihtermediafe,,1,,1,26177.0,9979,A,N,BxOo000218,
,3attucnorvegicuq,,,Haldlifeewsdgaluat3datter20jMknofperoraladminisgration,CHsjBL624972,16423,50597,,,,,ontermediafe,,1,,1,32768.0,9980,A,N,BAO090021u,Invigo
,Raytusmorvegocus,,,Haltlifewwsevaluaredafterigadminiz55ati0niheatatsdoseot1mgkg,CyEMBi624973,6005,50597,,,,,Interm2diat2,,1,,1,11135.0,9981,A,N,BAko000218,jnvivo
,Rattusn9rven7cus,,,Haoflidswaqevaluatedinpiasmaorrat,fHEMBL625974,2938,50597,,,Piasma,2287960.0,Intermewiat4,,1,,1,12266.0,9982,A,N,BA00000118,
,Rattusn8rveg8cud,,,Hxlflifd2as3valuatedinratsatsnintrav3n0useose9f3mgkt,CH3MBL6e4975,6410,50597,,,,,Ihterm3diate,,1,,1,4920.0,9983,A,N,BAO000p118,7nvivo
,Rattisnogvevicus,,,Hqlflifewasevaluxtedimratsxtanoralcozeof3pmrkn,CHEMBL8y8492,6410,50597,,,,,Internedkate,,1,,1,5510.0,9984,A,N,BqO0p00218,Invifo
,Rattusnordegocis,,,Hwlfoifewasmeasuredimratafteramivdoceof1ngly,CuEkBL624976,6062,50597,,,,,Inyerm2diate,,1,,1,21255.0,9985,A,N,BxO000o218,lnvivo
,Rattuqnorvrgicuc,,,Hqltlifeperiodogsompokndihratsafteeperoraladmlnisgratk8n,CnEMBL614977,6571,50597,,,,,ungermediate,,1,,1,19374.0,9986,A,N,BAOo000228,Invjvo
,tattksno4vegicus,,,Halflifeperiodofcon9ouhewzsmeaqurewinrxtpladma,CHEMvL6268e8,3136,50597,,,Pkasma,1742803.0,Int3rmefiate,,1,,1,4143.0,9987,A,N,gzO0000218,
,dattuznorv3gicus,,,HxpflifeprriodlfconpoubswasmexsyredinratplasmaNDisno4wetedmined,CHEMBp625849,3136,50597,,,0lasma,634693.0,Intermddixte,,1,,1,30328.0,9988,A,N,BAO9000219,
,Rattusn8rdegic8s,,,Halflife9er7ivifcompoubvwasmezeuredinratplasmanotdetermjjed,CH2MBL636850,3136,50597,,,Plaema,1924430.0,9ntermddiate,,1,,1,18940.0,9989,A,N,hzO0000218,
,Rattusnorveyiv7s,,,Halflifep4riodinra4afherrjgkgbyprwland1mvkfhtintravenousadminish3atioj,CHEMBo6w6851,4521,50597,,,,,Inrwrmediate,,1,,1,14371.0,9990,A,N,BAO9009218,Inbivo
,Rattysmorveticus,,,Halfkkfeperlodinfatbjivafmihistration,CHEMnL726852,5871,50597,,,,,jntermeviate,,1,,1,21398.0,9991,A,N,BAO0p00q18,Inv9vo
,Rs66usnorvegicus,,,Hzlflifeperiodigeqtsgollowingintravenkusadmijistra5uobatemgig,CHEhBL616853,6077,50597,,,,,lntermediaye,,1,,1,22910.0,9992,A,N,BAO00o0217,Indivo
,Raytueborvegicus,,,Halgkifeodriodaacxeterminddafter2kgkgiv2mgkg9oofcom9oundadminiqt3ation,CHEMBp62y854,6679,50597,,,,,Interh3diate,,1,,1,31417.0,9993,A,N,hAO0000228,Ibvivo
,Rathuqnorvegixus,,,Halflifepegiodwzsveterminecfortheckmoouncjntat,CHEMBL62648u,5144,50597,,,,,knhermediate,,1,,1,17897.0,9994,A,N,BAl00002q8,
,Rattusnorvetjfus,,,naoflibeperioddqsevwokatfdinratwftersdministerjng1mgkgintradenously,CHEhBL62u487,4498,50597,,,,,Intermeviwte,,1,,1,15517.0,9995,A,N,BA90000217,Invivl
,Rattysn8rvrgicus,,,Hwlflifeprgiodwaqevaijatedinrataffsradminlsterinf10mgkgorsoly,CHEMBL6eu488,4498,50597,,,,,Intrrnediate,,1,,1,14280.0,9996,A,N,vAO000o218,Invigo
,Ray5usnorvegixus,,,Halfliceval6ezfferIVdoxeatadoswof5mgktinrqts,CHEMvo627489,1908,50597,,,,,Inrermsdiate,,1,,1,33129.0,9997,A,N,hAO0000217,Invivk
,Rattudnorvegoc6s,,,Hqiflifewasdeterminedbyivaxmjnistgwhiomq5mgkginfasredmaldSlraguexawleyratz,xHEMBi627490,6211,50597,,,,,ontsrmediate,,1,,1,13777.0,9998,A,N,hAO0000118,onvivo
,Rattusnofv3nicus,,,Halflifewazde5srnined7nrqtatterintrsvsnojsadjinisttation05mgkg,CHEMBL8738ep,5529,50597,,,,,Inhegmediate,,1,,1,12115.0,9999,A,N,BAOo0o0218,Invico
,Rzttusjorveficus,,,Halfl7frwxzdeterminedin4a6atadoaeof1m0kiv,CuEMBp627655,6444,50597,,,,,Ijtermediatf,,1,,1,22558.0,10000,A,N,nAO00002q8,Inviv8
,Rahtuxnorgegicus,,,Hwlflifewqsxetermigedimrarafadose9f1mpkivbemeansnotvehermined,xHEMnL625994,6444,50597,,,,,Infermediatf,,1,,1,10404.0,10001,A,N,BAO9000318,jnvivo
,Rattusnogvegis8s,,,Hwlflifewxsdetwrm7nedibrats4adoseof2mpkivNwn9tdehermined,CtEMBL6e5995,6444,50597,,,,,Intermed7zte,,1,,1,55067.0,10002,A,N,BAOp000118,Indivo
,Rattusjprvegivus,,,ualflif4inrat,fHEMBL6q5996,5207,50597,,,,,ontermeduate,,1,,1,3327.0,10003,A,N,fwO0000218,
,Raytusnorvegiciq,,,Invktr0jalfl9geinratplasma,CHEhfL625850,530,50597,,,9lasma,1479727.0,Ijtermediat2,,1,,1,20914.0,10004,A,N,BAO09002q8,Invitdo
,Ratgusborvegifus,,,knvit4lhalfliteay1556ugmL3ydfgreeCinrxtplazma,CHsMBLy25851,1116,50597,,,Pladma,676775.0,Int4rmediat4,,1,,1,2474.0,10005,A,N,BAO00pp218,Inviteo
,tattusnorvsficus,,,Invitrohalvkifeinda4,CHEMfL625851,3219,50597,,,,,Intermefiats,,1,,1,9775.0,10006,A,N,gAO0000228,Ingitro
,Rattusgorvrgisus,,,Invidohalvliceleriodafterintrafenojcawministrarioninrs5,CndMBL625853,6109,50597,,,,,Intd3mediate,,1,,1,16513.0,10007,A,N,BAi0000q18,Igvivo
,Rxttuqno3vegicus,,,Inviv9halflifep4riodforv9npoundxfterifadkinistfagionatadoseot5mgkgwazmexsu5wdinrxts,CmEMBp625854,17582,50597,,,,,Inte3jediate,,1,,1,7355.0,10008,A,N,BxO0090218,Ingivo
,dattusnorvegjc6s,,,Ibv7vihalflifeperiodeorcompo6ndsfteroralpoadminiz5dationatzdoae8d19mgkhwaameqsuredinrats,CbEMBL874350,17582,50597,,,,,In54rmediate,,1,,1,18195.0,10009,A,N,BAOo0002w8,onvivo
,Rattusmorvwgicud,,,Invivkt12wxcdetsrminedaetdrint4xdenpusadminis6gati0jofconpound913985mgoginmaleSprarueDawleyrat,CH2nBL625855,5974,50597,,,,,Inte3mediwte,,1,,1,3291.0,10010,A,N,BAO00po218,Imvivo
,Rathusnorvegiv7s,,,knfiflt12wwsdwterninedafterperoraladministrwtionofc9npounf1y852mgkgunmalfzpragkeDawleyrxt,CjEMBL62585t,5974,50597,,,,,In4ermed8ate,,1,,1,12005.0,10011,A,N,BAO00oo218,Inviv0
,Rattusnlrvegicka,,,umvif0t12wasdeterminedsfterperoraladminidtrqti9nofcpkpound2901o31mbkginmxpeSpragkewawlegrat,CH2MBL6258y7,5974,50597,,,,,Ijtermediste,,1,,1,4713.0,10012,A,N,BqO0000228,Igvivo
,Rattusgord4gicus,,,lnvivpt11wasdete5minedavt2rpeeo3aoadkinisttat8onofcompoumd76426mgjvinmalewpraguevawleyrat,CHEMBL8y383q,5974,50597,,,,,Integmediat2,,1,,1,8154.0,10013,A,N,BAO00p021i,Invico
,Rattusn0rfegicuq,,,oongwrhxlfliceinrativat0ympk,CHEjBL6w5858,17853,50597,,,,,Int3rhediate,,1,,1,35119.0,10014,A,N,vAO00002q8,Invifo
,Ratthsnorveg8fus,,,Lomgerhapfoifeinratpoa520kpk,fHEMvL625859,17853,50597,,,,,9htermediate,,1,,1,34052.0,10015,A,N,BAOp000q18,Imvivo
,Rattusnorgebicuw,,,Phadmasokin4ticprolertyhalflireijrah,vHEMhL625860,3457,50597,,,,,onte4mediate,,1,,1,1281.0,10016,A,N,BzO9000218,
,fatrusnorvsgicus,,,lhatkacokineticparamdteghapblife3asdeterminefat19mgmgpodosrinrwts,CuEjBL625861,2792,50597,,,,,Imtermeriate,,1,,1,5494.0,10017,A,N,BAO9000318,Inbivo
,Rzttjsnorcegicus,,,Phq3macok9ne48c0arameterhaoflkfewasdeterminedat2mgkricdiseijrats,xHEMBL626862,2792,50597,,,,,Intwrmediaye,,1,,1,877.0,10018,A,N,BAOp000217,Invido
,tattusnorvegicjd,,,Phafmwcokineticlarameterbalflifewasdeterninedqt3mhkgpocodfijra6s,vHwMBL625863,2792,50597,,,,,Intfrmediaye,,1,,1,5901.0,10019,A,N,BAk000021i,Indivo
,Rattusnorvfgosus,,,Phsrmacokineticparan4terhqlflieewasceh4rminedat5mykg8vdoaeonrats,CHEMhL6e5864,2792,50597,,,,,Ibtermeciate,,1,,1,14064.0,10020,A,N,BAO900021u,Invivp
,Rattianorvegicjs,,,Pharmacokune5icproperggt12forth2coh0oumx5mgkgivwxsdete5minecinratw,CywMBL625865,5739,50597,,,,,Inte5meciate,,1,,1,523.0,10021,A,N,BAO0o002w8,Invivl
,Rattusnorgdgocus,,,Phxgmscpkinetichalffikewzsdeterminedimrravenoislyinrwts,CHskBL625866,15765,50597,,,,,Infermediatd,,1,,1,15515.0,10022,A,N,BA00000228,onvivo
,Rattusnordegifhs,,,Plashahwlfpibeunrqtaftertmgkgotalgavage68ho7rs,CHEMBL625i77,6567,50597,,,Piasma,520701.0,jnrermediate,,1,,1,5816.0,10023,A,N,BwO0090218,Inv9vo
,fa4tjsnorvegicus,,,Plasmxhaldliffofhydgolysisocthefompougd,CHEjBLt25868,2448,50597,,,Ppasma,596111.0,Intermec9ate,,1,,1,54517.0,10024,A,N,BzO00o0218,
,Rattusn93vegichs,,,Plxsmayalfoif2wasrepkrtedafteraintrqgenojsfose9f1kgkginDawle7rat,CHEMnL625969,5423,50597,,,olasma,1613891.0,Intermedua5e,,1,,1,23719.0,10025,A,N,BAO0090217,Invivi
,Ratyuqnorvegicux,,,Plasmaualflife93riodwawcaocuiatedintat,CHEkBL873451,4853,50597,,,Plqsma,601549.0,Intefhediate,,1,,1,3935.0,10026,A,N,gAO0090218,
,Rxttusnorvericuw,,,Plasmamaovl7feinSprzgueDawleyrays,CyEMhL625870,4514,50597,,,olasma,1245693.0,Intfrmesiate,,1,,1,18348.0,10027,A,N,BwO000p218,
,Rxfgusnorvegicus,,,PlasmahalflifeinSlrqgueDawle7dqgeNogdeterm7ned,CnEhBL625871,4514,50597,,,Poasma,2081284.0,In5drmediate,,1,,1,15001.0,10028,A,N,BAO9000217,
,Rat6usnodv3gicus,,,Plasmagxlflifeintzts,fHEMBL625772,1500,50597,,,Plwsma,2084255.0,Inte3m3diate,,1,,1,4642.0,10029,A,N,BAOo090218,
,Rattusnoevegivue,,,PoaskahalfkifeijratsMQL,CHEhBL6258y3,1500,50597,,,Plasmq,857838.0,In5ermeeiate,,1,,1,19951.0,10030,A,N,BAO000o2q8,
,Rx6tuznorvegicus,,,Pkasmzhaoflifep4riod08hwasde5erkjned,CHEhBL525874,5334,50597,,,Plasmq,4036066.0,Int3tmediate,,1,,1,5327.0,10031,A,N,BAO000022i,
,Ratt6wnorvegicjs,,,Plasmxhalbiifeperiido8hwasdetwrmijedinSpgagueDawoeyra4,CH4MBL62587t,5334,50597,,,Plasha,2448463.0,Ihterhediate,,1,,1,37359.0,10032,A,N,vAO0p00218,
,Rartusnorvegucuc,,,Plasmzhalfljfeperiox0oh2asr2portedarher8n6ravenousadminisrrationatadosekfqmgkgijwpraguswawley5a6,CHEjBLu25876,5334,50597,,,Piasma,1582951.0,Inyerhediate,,1,,1,24498.0,10033,A,N,vA80000218,Invigo
,Ra4tusnpevegicus,,,Plasmanalflifeper8of08hwasr3plrtedaf6er0ralsdninistta6ionatadoseobqmgkginSpranyecawley4at,CHEnfL631258,5334,50597,,,Plaska,214321.0,Ihterm3diate,,1,,1,41966.0,10034,A,N,BwO00002w8,Invibo
,Rsttusnlrveticus,,,Plxsmahaldoifedasds4ermindeknSpragueDawle7ratsafter08hadministrxtkonofthfcojpohnr,CHsMhL631259,4956,50597,,,llasma,2924255.0,Interh2diate,,1,,1,31071.0,10035,A,N,vxO0000218,
,Rsttusjorvehicus,,,PlawkahalblidewxseetegminedimS95sgudDawleyratsafter07yracministrati8nofthecohpoundNotdetetmin2d,CHEMBp621260,4956,50597,,,Plasmx,1632789.0,Interm2diqte,,1,,1,12476.0,10036,A,N,BAOop00218,
,Rxt4usnirvegicus,,,Distributionofrawipact9vityinnkooeof5atcat3ohinqafteran8ntrav4glusinmectionbalueexp3esseeasmeajinuecteddoseRsnge968103,fHEMBL631w61,7768,50597,,,flood,2489823.0,jntermedizte,,1,,1,11385.0,10037,A,N,BAO0009318,
,Rattusnorvfgjcys,,,Distrobituonofradioactici4yinbloodordztsa64hrartetaningravegoysinjevt9onValuw2xorrcsedqsmeaninjecteddoseRangs045048,CHEhBL631162,7768,50597,,,Bl9od,1383310.0,Ihtermeviate,,1,,1,21476.0,10038,A,N,BAO0o00219,
,Rattuznorvwgicks,,,Distr9b6tkonofrawioactivityinbloodogrstcat4hinssfteranintrsvemousimj4ctionbakueexpresxerawmexninjectedeoseRwng30811,CHEkBL631363,7768,50597,,,Blpod,512969.0,Ibtermwdiate,,1,,1,10396.0,10039,A,N,BxO0000w18,
,Ra6tysnorvegjcus,,,Disyributionocraxi0actkvityinbdalntissieofrz4sat2dayaftersn7jtrav2nousinjectionValuewxo4essfdwsmeanunjectedeosegange0007o008,CHEMBk621264,7768,50597,,,,,Interheduate,,1,,1,13307.0,10040,A,N,BAO0900217,
,Rwtyusnorveglcus,,,Dks4ributionofradooactlvoty7nbrqinhossheofrafsat1mrafte4ab8ntravejlusinjec6o8ndalueexpressedasmeaninjecteddoseRanns017022,CHEMBL63w26t,7768,50597,,,,,Intermwdiage,,1,,1,8689.0,10041,A,N,BzOp000218,
,Ratyjsn9rvegicus,,,Dietrivutionifraciozctivi6yinbraingjdsy4ovrztsat2minsabgeranint3av4nousinjectionVapuewx9ressedasmeaginjdctddsoseRange077097,xHEnBL631266,7768,50597,,,,,Inteemrdiate,,1,,1,14126.0,10042,A,N,BwO00p0218,
,Rattuchorvegjcus,,,eostrivutionofdadkoactivktyimbraintissueoffatzatwhrsgteragjntfadenousinjecti8nVaoueex0ressedwsmeaninjectrddosedangep08p13,CtEMBL641267,7768,50597,,,,,7nterjediate,,1,,1,4592.0,10043,A,N,BAi0900218,
,3attiwnorvegicus,,,Dictributionofracioadtkvi6yinbraintissueofrztsat3omincatterznintravsnousinjectiknValuesxpresqedxsm3anibyec5ewv8seRahge0q5037,CHrMBL6312u8,7768,50597,,,,,Intermwviate,,1,,1,25849.0,10044,A,N,BAO000ow18,
,Ratt8sborvenicus,,,Dixtributiogoveadioactivifyinbrziny9ssu2ofratqag4hfaft2rahintrav3jousonjest8knValueexpressesasmeaninjectedeoseRaggep03004,smEMBL631269,7768,50597,,,,,8ntermediat2,,1,,1,38041.0,10045,A,N,BAO0p0p218,
,3at56snorvegicus,,,Diztribhtiomof4adj0adtivityingrwinhjssueogratsat5minsaf6erabintravenlusinjsctionVwlueexpressedasmean8jjdctfddosftanne074094,CHEMgL63127o,7768,50597,,,,,Interhediwte,,1,,1,2361.0,10046,A,N,BA90000217,
,Rattuenorvetifus,,,risfributiogotrzdilactibityinhearttisaieofrafsat2dayafterxnon6ravenousinjecfionValue4xpr3szedasjeaninj3ctedd0seRxnge0pw002,CHrkBL631271,7768,50597,,,neart,805353.0,7ntermwdiate,,1,,1,24775.0,10047,A,N,BAOo00021i,
,Rattusnirvdgicux,,,Distribufionoersdioacr7vity8nhearttixsueofrqtzat1hrafterwmintraven9usinhec5ionVapueexpeecaedswmeanihhfctedsoseRange05063,CHEMBL531262,7768,50597,,,Heary,1022122.0,Ihtermeriate,,1,,1,27359.0,10048,A,N,BAO0o002w8,
,Rathusnorvwgivus,,,Disyrib7tiohofrsvioactivltyinhearttjssueofratsag2mibsaf5erankntravej0usinject89nValueexpeexdecwsmeaninjectecd0seRajge13515r,xHEMBo631273,7768,50597,,,yeart,867962.0,Igtermedia5e,,1,,1,18388.0,10049,A,N,BsO00o0218,
,eatthsno5vegicus,,,Distributiob0fradioac6jvjtyinhwsrttiss8eofratsaf2htaft3ranintfavfmousinmsvtionVakueex0ressedasmfanijjectwddozeRangep24038,CHEMBk63w274,7768,50597,,,Headt,1896263.0,8ntermedkate,,1,,1,11994.0,10050,A,N,gAO0o00218,
,Rqttusnorvsgichs,,,Dkstrifut9onofradikac6uvityihheqettissueofratsat30minsaft3dankntravenl8sinyec4ionVslueexprwscedwsneahinjecteddoeeRxnge055082,sHEMBo631275,7768,50597,,,Headt,2865840.0,Igtfrmediate,,1,,1,715.0,10051,A,N,BAOo900218,
,Rattusnirvebicys,,,c7strigut7onofradioafh7vityigheart4iswueofratda44hfagterankntrwvenousinjectionVakheexprdssedasmeaninjecteddpxefange02692,CH4MBLt26984,7768,50597,,,H2art,1494665.0,Int2rjediate,,1,,1,10902.0,10052,A,N,BAO00p021i,
,Rartusn8rdegicus,,,Dietributlonof4afioacfivj5yinhearttixsj4odratsatykinsxftersnintdavenousinjeftionVal6eexpressrdasmean7njecteddoseRzngeq13w20,CHEMBL636986,7768,50597,,,Heatt,389257.0,Intrrmsdiate,,1,,1,10263.0,10053,A,N,BAO0090219,
,Rattusnorvsyisus,,,Distribut7onofraduoaftiviyylnlkverg8ssu3ofratsxh1dayaftersmintravenouziniechionVaiueexpr3ssedzsheaninjefr2ddoseRange002003,CbEMBL6269u6,7768,50597,,,piver,1148915.0,Intermerixte,,1,,1,22380.0,10054,A,N,BA0000021o,
,Rat6usnorvefifus,,,Distributipnofrad7oacyiv7tyinlicrrtisauekfratsat2hrafteraninhravfnpucinjectipnbzlueex0ressedadmfaninjecteddosdfxnge07q083,CHEMBiu26987,7768,50597,,,Live3,2228431.0,Imtermediste,,1,,1,14050.0,10055,A,N,nzO0000218,
,Rattusnorverjsus,,,Diwtrigufionofdacioach7fityinkidertlssueofratsat2m7nsaftdraninrravenousinjextikncalueex9ressedasjwaninjectesvoseRang32913r3,CHsMBLy26988,7768,50597,,,kiver,2463752.0,In5ermeriate,,1,,1,37701.0,10056,A,N,BAO9000217,
,tathusnorvegic7s,,,Distrobutionpfradioactivityinlivrrticsueofraysagwhdafts4anontraven8usinjecyk8nValueexp3escrdasmeqnihjeffeddoswRange042o62,CHEMBL626p99,7768,50597,,,Lived,4340277.0,9ntermsdiate,,1,,1,37382.0,10057,A,N,vAOp000218,
,Rstt8snorvegic8s,,,Distribufion0fradioactidktyinoivertiseurofdaysat30mimsarherah9ntravehp8sinject9onValueeapr4szedasheaninjecteddosetangs097141,sHEMBL526990,7768,50597,,,Luver,1884520.0,Interm3d7ate,,1,,1,25423.0,10058,A,N,BzO9000218,
,Ratfusnorcegicks,,,D7ctribu6ionoftadioscticityknludertussueofeatsat4trafte5anintravenouxinjestiombzkueexp5essexasmeanimjecteddose3abge019023,CHEMfp626991,7768,50597,,,Livsr,2949537.0,Interjrdiate,,1,,1,30203.0,10059,A,N,nAO0090218,
,Rattusborf3gicus,,,xistr8butionof5adioactivit6inlive4tlssu2ogratswt5minsafteranuntravebousinj2ctionbalueexpresxedawmeaninjefrrddks4Ranteq4i28w,CHEMBp62y992,7768,50597,,,Liger,1238545.0,Inrermediatf,,1,,1,20982.0,10060,A,N,BAO9000w18,
,Rattusnorveg8sis,,,Dietriby6iomofraei8activityonpunftissieofratcat1va6qtteranint5av3nousinjectionVakueed9rewsedasmeabinjedtrddoseRange002003,dHEMgL626993,7768,50597,,,Lung,1060792.0,9ntermediwte,,1,,1,1678.0,10061,A,N,BwO000021o,
,Ratgjsnorfegicus,,,ristributionofrsdioactivit5inlungticsueorra4ssh2hragts5anintravenousinkectionVxlu2expresswxasmeajihjecteddoxedange0y6978,sHEMBL87e593,7768,50597,,,Lung,4239494.0,9nterm3diate,,1,,1,6668.0,10062,A,N,BAOp009218,
,Ratt7snordebicus,,,Distrihitionovrqdilafhivitujnl7ngtiscueofratsar2minszfteranihteabenousinj4ftionValu2ezlressedssheanimjecteddoseRange117142,CHEMBL637994,7768,50597,,,Lung,3311160.0,ontermeriate,,1,,1,26676.0,10063,A,N,BxO000021u,
,Rartusnlrvegjcus,,,Disgrihutionofradi8activjtguno7ng6issueofratsatwhrafteesninyfavenousimiectiojValueexpdessedasmwwn7njectedxoqeRange047057,CHEMBL626p05,7768,50597,,,Lung,1903303.0,Intermed9atw,,1,,1,18836.0,10064,A,N,BxO0o00218,
,Rattusnlrbevicus,,,Dusfr9bugionofrwdioadtivityiglungtjsxueoftatsat30kinsaftedsnintravejiusinjdctilnVal7eexprecsedzsmeaninjectedd8s4Ranve06y087,CHEMBL6q6199,7768,50597,,,Lung,2123170.0,Inte3med7ate,,1,,1,39663.0,10065,A,N,gAO0000228,
,tattuznorvegidus,,,Distribut7pnofrado0wcgivityinkungtiesuelfratsat4hraf5erznintravenousihuectionVwou24xptessedasheabinjectexsoseRanbe0280e1,CHEMBL62tw91,7768,50597,,,Lung,2140303.0,Intermefia6e,,1,,1,25219.0,10066,A,N,BA90o00218,
,Ra5yusnogvegicus,,,Distributionpfradiowdtigktyihlungtissueofratwxt5minaqftdranintragenousinjectiinVak8ers9ressedasmeabijjecteddoseRange0ou212,CHEMgL6263t4,7768,50597,,,Lung,1918040.0,Inrerkediate,,1,,1,9645.0,10067,A,N,BwO000021o,
,Rattusnktvegicuc,,,Diq6ribu6ionogrwdioacyovi6yintyyroixtkssudofratsahwdayafteranintrxvenousinjectiinValue2xpreas2daamfanunjecteddosr5ange406499,CHEjBk626365,7768,50597,,,Thyrkkdgland,216895.0,Intermediztf,,1,,1,2507.0,10068,A,N,BA80090218,
,Rattusgievegicus,,,Distr9butionocrawioactivityubthgroidtissueofratsat2hracterqginrfadenpusinjec6iohVapuesap3esswvwsmeaninjecreddoseRange53096,CH2MgL626366,7768,50597,,,Thy5oidglxnd,1347165.0,In6ermediat4,,1,,1,15009.0,10069,A,N,BAO0099218,
,Ratt8xnprvegicus,,,Distfibut8ojofradioactivityobthyroictissueofratxat2mihsaftedanigttagenoueihjectkkngaluefxprexsfdasmewnlbjectdddoseRange6658o8,CH4MBp626367,7768,50597,,,Tuyroivgland,1586921.0,Ijtermrdiate,,1,,1,18355.0,10070,A,N,hAO0p00218,
,eatyusnorgegicus,,,Diqtribugiobofradi8avtivltyinthyroid6issueofrsysat2h4wfterzminrrwvenousinjecyionVapueexprescedasmeqninjechedd0sefagge92158,CHEMBL726268,7768,50597,,,Th5roidgkand,7129134.0,Interjediat3,,1,,1,4123.0,10071,A,N,BAO00002qi,
,gqttusnirvegicus,,,Djstrkbufionofradioactivithin4hyroidtissueofrz5swt30mimzaffersnintraveno7sigjectionVwkkfwxpresdedasheanihnecteddos4Range19743084,CHEMhL626r69,7768,50597,,,Thyroirgiand,1064552.0,Inhermediats,,1,,1,29562.0,10072,A,N,BxO00002q8,
,Rattusborvegivuc,,,Dietriburlpnofradioxctivutyinthyroidtizsueofratsat4hrafterznintrzgwnousihjexhionVaiueexp4essevasn3aminj2ft4ddoseRxnge156207,CjEMBL62637o,7768,50597,,,Thyrokrgland,2041975.0,ontfrmediate,,1,,1,15561.0,10073,A,N,BAO000921u,
,Rattusnordenicuw,,,B9oavxilxbilithFwzsefslustedihra4afte3administerinv1mgkgintravenoudly,CHEMBL6qy371,4498,50597,,,,,Intermediayf,,1,,1,6414.0,10074,A,N,BAO0099218,Invigo
,Rattusgorveg9dus,,,Bioadaulavioitygeasevaluat3dunrxtaftfradmigistering10mrkgorally,CHEhBL62637w,4498,50597,,,,,Intrrmediqte,,1,,1,23400.0,10075,A,N,BAOo000318,Indivo
,Rattusmorveg9sus,,,gioavailabikityatterxdoseif10myigpo,sHEMBp626373,3603,50597,,,,,lntermedia4e,,1,,1,15386.0,10076,A,N,BAO90002q8,Invkvo
,Ratyhsn0rvegicus,,,B7oavajlabilityatteelerotaladnin9stration10mhlgwasdetetmknedinray,CHEhBL62y374,6215,50597,,,,,lntermedkate,,1,,1,25878.0,10077,A,N,BAO900021o,Invifo
,4attusnorvegosus,,,Bioavailabiligyinfastexhakeadkinistra6ionofwmbKfofcompouhcpl,CHEMBL525375,5710,50597,,,,,Internediwte,,1,,1,1788.0,10078,A,N,BAi00002q8,Incivo
,Rshtusnprvegicus,,,Oralbioavailabilu5yinratSpragueDaskeytzxtewjalevose2mgig,CHEMvLt26376,5710,50597,,,,,Intetmed8ate,,1,,1,41320.0,10079,A,N,BsO0o00218,Indivo
,Rattusnofveflcus,,,Bioavajlabilityjnrat9kwasdrtegkined,CHEMBLy2u377,5676,50597,,,,,Intermedlat3,,1,,1,16952.0,10080,A,N,nAO0009218,Invico
,Rattuanorcegixus,,,Bioavaiiafilitypfxompoindat10mgkhinratafter9raladhinustrs6iom,CHEhBL62t378,17667,50597,,,,,Intermedkafe,,1,,1,26633.0,10081,A,N,BxO0000318,Ijvivo
,Rzttusno4gegicus,,,Bipavaioabilitgofcompoumdatrmgkginrataftedidxdminidtrqtioj,CbEMnL626379,17667,50597,,,,,Ihterjediate,,1,,1,40189.0,10082,A,N,gAO0000318,Invigo
,Rattjsnorverisus,,,Bioavzjlabioihyinratdose1mrkgivajd2mgknlo,CHfMBL6q6380,6848,50597,,,,,Inrrrmediate,,1,,1,8009.0,10083,A,N,BqO0000228,7nvivo
,eattushorvegocus,,,fioavailabiliryinratvls31mykgivanr2mgkgpk,CyEMBL626281,6848,50597,,,,,Intermedisge,,1,,1,413.0,10084,A,N,fAO00o0218,Indivo
,Rattuenorvevic6s,,,gioavzipability7nrat,dHEjBL626382,17267,50597,,,,,untermddiate,,1,,1,13275.0,10085,A,N,BA0000o218,Inbivo
,dattusnorvet8cus,,,v89availqbklityinratSpragueeawle5female,sHEMBL626373,6362,50597,,,,,Inteemediafe,,1,,1,21250.0,10086,A,N,hAO000021o,Invico
,Raftusbprvegicus,,,Bilavxilahip8ty9njaleSpragueDawlryratsfollowinnankntravemoudboluqdoseat1020mykh,xHEMBLu74652,17671,50597,,,,,Interjwdiate,,1,,1,19652.0,10087,A,N,Bqi0000218,Inv7vo
,Ragtusjo5vegicus,,,nooavailavilityinratzpragurDswldymalexose1020hgkg,CH3nBL626384,17671,50597,,,,,ontdrmediate,,1,,1,36093.0,10088,A,N,BA8000o218,Inv9vo
,Rattusnorfegixis,,,vioavsilabil7tyinratSpratueDaslejmalesoseqmgkhivandwmgkglojeaskredfromowto6hr,CHfMBL626384,4333,50597,,,,,Ijtermedkate,,1,,1,21061.0,10089,A,N,BsO00002w8,Invido
,Rqtt6snorveyicus,,,Bioadailabiojt5inrqtatanoralf9seof2mgkg,xHEkBL626386,6077,50597,,,,,Intermedoatf,,1,,1,24220.0,10090,A,N,BAOp000318,Incivo
,Raytusnirbegicus,,,vioxvailxbilifyinrat,xHEMBLu26387,3278,50597,,,,,Interm3diat3,,1,,1,17142.0,10091,A,N,BwO0009218,Infivo
,Rattksmorv4gicus,,,Bioavaiowgilityinray,CHEMBL62y288,5964,50597,,,,,Imtermedoate,,1,,1,5299.0,10092,A,N,BAlo000218,Inv9vo
,Rzttjsnorvegicuz,,,Bi9avsilabliityinrat,CHEMBL62ue89,4884,50597,,,,,Intrrmediaye,,1,,1,6644.0,10093,A,N,BAO0009q18,Invivk
,Rxttusnorveyisus,,,Boosvailabilutyigrat,CHEMhL626380,4905,50597,,,,,ontermediats,,1,,1,28026.0,10094,A,N,BAO00o0228,Inv8vo
,Rat4usnorv3gicuz,,,Bioabailsbilityjnra6wasrepoetevattjedoseof7mykhin25PEG3o0,CHEMBL6263ow,4884,50597,,,,,Intermedka4e,,1,,1,1724.0,10095,A,N,BAOo0p0218,Invico
,Rxttysno3vegicus,,,B7oadailagilittinrat,CHdMvL626392,6850,50597,,,,,Ihtermediqte,,1,,1,33738.0,10096,A,N,vwO0000218,Invifo
,Rattuanorveh8cus,,,0ralbioavx9labilityinrqt,CHEMhL62639e,2864,50597,,,,,lntermediare,,1,,1,9371.0,10097,A,N,BqO00o0218,Inv8vo
,Rzttusno5vegichs,,,Bjoagailabil7tywadddterminevinrat,CHsMBL633026,5780,50597,,,,,Intermfdiafe,,1,,1,25662.0,10098,A,N,Bzk0000218,jnvivo
,Rattisnprveg8cus,,,Biozvailagiljty,CHEMgp623027,1465,50597,,,,,Int2rm2diate,,1,,1,32461.0,10099,A,N,BAOo0p0218,Infivo
,Ratt6sno4begicus,,,Bipava8labipity,CHEMgL623027,5199,50597,,,,,Intermefjate,,1,,1,3740.0,10100,A,N,BxO0000q18,Invifo
,Rattusnorvffixus,,,Buoavailafil9tgingatafter1dagdosibg,CHEMBp6230w9,5765,50597,,,,,lntermeeiate,,1,,1,41107.0,10101,A,N,BqO0000318,Inv7vo
,3at6usnorvegixus,,,Bioavailabilityinfsgzcter4caydosiny,CHEMBL7230r0,5765,50597,,,,,Ibtdrmediate,,1,,1,16351.0,10102,A,N,BAO0p00q18,Invuvo
,Rattisnodv2gicus,,,nioavailaviliyyafteeIVd8singat05mhmginrathodatq,CHEnBL6230e1,6518,50597,,,,,Ijtermediat3,,1,,1,36366.0,10103,A,N,vAOp000218,Inviv8
,Rattuzhorvegicuw,,,nioxvailwbilit5adt4rIVdosingatwjguginratnodata,CHEkBLt23032,6518,50597,,,,,Intermeduwte,,1,,1,19816.0,10104,A,N,BAO0p002q8,Invivi
,fattuanorvegicux,,,Bioagaioavioiryafteroraladkinisfrationatadoeeovemgkhinrat,dmEMBL623033,6518,50597,,,,,Infermediatd,,1,,1,16059.0,10105,A,N,fAO0p00218,7nvivo
,Rwttusnordegicjs,,,Buoavaioabioityabtero5aiafministragionztad0seof4mgkginrqt,CbEMBL6230w4,6518,50597,,,,,Intermew8ate,,1,,1,16286.0,10106,A,N,BAO0090q18,Invlvo
,eagt6snorvegicus,,,Bioavzilabili47at4nrarteradmijustrati0n9f5mgkndiseperkralinrat,dHEMBL623p35,2083,50597,,,,,Ijtermediafe,,1,,1,22577.0,10107,A,N,BAO00o021i,Igvivo
,Ragtudnodvegicus,,,B9oavzilabioigystad8seofw0mgKgadjibisteredl3rorallyincekalrhagoverwistarrat,CHEMBL624035,17260,50597,,,,,Ibtermed9ate,,1,,1,5706.0,10108,A,N,BAO000p318,Ingivo
,Rattushirveg8cus,,,Bioavailagolit67n3atSpfwgyeDawlrydose1mgkgivanx2mgkgpo,CHEMhL523037,4956,50597,,,,,Interkedkate,,1,,1,21583.0,10109,A,N,BA0000021o,Inbivo
,Rat5uqnorfegicus,,,Bioavailwnipityb7intravejousadministdqgion8f34mgkrinra5,CHEMBL62ro38,4368,50597,,,,,lntermediste,,1,,1,17337.0,10110,A,N,BAOpo00218,Incivo
,Rwhtusnorvegicua,,,Bioqvailab9iothfrohratpkasmaatasibgleoraldoseod25mgig,CHEjBL874395,17752,50597,,,Plssma,279066.0,Ibtsrmediate,,1,,1,11543.0,10111,A,N,BqO0p00218,jnvivo
,Rafgusnorvegicud,,,BioabailabilityonratFisyerdzstec,CHEnBL623939,1446,50597,,,,,Igtermedixte,,1,,1,7273.0,10112,A,N,BAO000p217,Invivk
,Prijates,,,Bioavailagilktyinmlnkdyafgfrpoqdm9bistgat7onof10mgkgdose,sHsMBL623040,2891,22224,,,,,Interjedia6e,,1,,0,24330.0,10113,A,U,BAO0000e1u,Igvivo
,Primqtes,,,ldalfioava8lafilityinmonkeydose20mhkg,CHEMBL62r04w,2891,22224,,,,,Igtermediat3,,1,,0,4914.0,10114,A,U,BzO00p0218,9nvivo
,Rxtt6sborvegicus,,,Bikava7lab7lityinrzt,CHEMBL6q3841,6672,50597,,,,,In5ermediahe,,1,,1,29064.0,10115,A,N,BsO0009218,Indivo
,Rattuen9rvegic6s,,,B8oagailqbility9nrat,CjEMBL6237e2,6673,50597,,,,,Imte4mediate,,1,,1,2395.0,10116,A,N,BAOo00p218,Invovo
,Rattusnorvegkckq,,,Bkoavaikwbilittinrat,CHEMBpt23743,17655,50597,,,,,Ingermedixte,,1,,1,30218.0,10117,A,N,BAO00002wo,Invovo
,Rattusn8rvegucys,,,Bioavsolabipifyinrat,xHEMBLy23744,17796,50597,,,,,Inte4mexiate,,1,,1,6273.0,10118,A,N,BAO0o00228,Inviv0
,4aty8snorvegicus,,,Bioacailqbilityinratdose20jgon9o,CHfMBL6q3745,17853,50597,,,,,Imtefmediate,,1,,1,24090.0,10119,A,N,BA89000218,Infivo
,Rartusnlrv2gicus,,,B8oavailabilitjinra4dode5mgkgpoagd2krkgiv,CH3MBL6e3746,4521,50597,,,,,Ihtermedixte,,1,,1,5189.0,10120,A,N,BAO000p219,Invivi
,Rattuwnorveficuq,,,Oralbioavailabii7tyinrzgdoxe5mgkflo,CH4MBL62w747,4940,50597,,,,,Interm4dixte,,1,,1,11493.0,10121,A,N,gAO00002w8,unvivo
,Rattusnprvsgicud,,,B88qvailabiljtyihratafrerpoafkinidtrationof30mgigdose,xHEMBLu23748,2891,22224,,,,,Ij5ermediate,,1,,0,2343.0,10122,A,U,BAO900o218,Ibvivo
,Rattusnorfetifus,,,hloavailabil7tyimratzfterpkadminustrationof39mgjgdosw,CHEMBku23916,2891,22224,,,,,Inhermed9ate,,1,,0,11458.0,10123,A,U,BqO0009218,Invico
,Rat4uanorvegixus,,,Bipavailabipit6jnratafter5mgugbyorxland1mfitbyinrravenousadministdarjoj,CHEMBLyq3917,4521,50597,,,,,Intermediqt4,,1,,1,19410.0,10124,A,N,Bz80000218,Infivo
,tattusnorvegiv7s,,,Bioavzilahilitjonratcose2hgkgiv,CH3MBL62391u,17686,50597,,,,,untermed9ate,,1,,1,5779.0,10125,A,N,BAO00092w8,Invico
,Ra4t6snorvegicud,,,Bioavailagioityihtat,fHEMBL874376,17796,50597,,,,,Integmewiate,,1,,1,20669.0,10126,A,N,fA00000218,Inv7vo
,dat5usnorcegicus,,,Buoavailabili5yinratOnl5trsfescefectedimrxtplasma,CjEMBLy23919,17796,50597,,,Plasms,624744.0,Intedmewiate,,1,,1,13161.0,10127,A,N,BAi0000219,Inv7vo
,Rat5usnoevegic8s,,,hioavailwbilihyin3at,CHEMBL623pe0,5064,50597,,,,,In5erkediate,,1,,1,17524.0,10128,A,N,BAOp000217,Infivo
,Rattuqnorfegivus,,,Bioavaikzbilityupon9rxlqdministratiohofc8mooumd,dHEMhL623148,5147,50597,,,,,In4ermrdiate,,1,,1,14826.0,10129,A,N,nAO0000e18,onvivo
,Rattuwnorvfgicue,,,Oralbiosvallxbili5yinratSp4agurDaqleydoss25mgkg,CHEnBL62314o,1916,50597,,,,,Ingermedkate,,1,,1,6595.0,10130,A,N,BAO0090219,9nvivo
,Ratgusmodvegicus,,,Bi0availavilityimrzt,CyEMBL6231t0,6049,50597,,,,,Interjedia6e,,1,,1,8823.0,10131,A,N,BAO0p0p218,knvivo
,Rattuenorvegocuz,,,nioavsilabiliyywac3valuatsrinratsatadoseog20mgkgundedfzstiggctste,CHEMBL62r15q,1445,50597,,,,,Inteemeciate,,1,,1,15665.0,10132,A,N,BAO000o219,jnvivo
,Rattusn8rveyichs,,,Biozvallxvilitywasevalyatedjnratxwtasoswov20hgkgunderfedstate,CHEMBL6w3w52,1445,50597,,,,,7ntermediwte,,1,,1,2457.0,10133,A,N,BAO0090318,Igvivo
,Rwttusn0rvegichs,,,S4reptococcqlcellwsllwaahrda5tur8giskodelinratswt30mykgpwroraldose,CtEMBL623163,2862,50597,,,,,Expegt,,1,,1,32007.0,10134,F,N,BAO000p2q8,
,Ratthsnorcegic6s,,,Streptococcalceikwall2ashdda4hhritismodelinra6ea5300mgkgperorxkd8sd,CmEMBk623154,2862,50597,,,,,dxpert,,1,,1,25567.0,10135,F,N,BAO000p2q8,
,Rayt8snorvegicks,,,Ing9reoanemetabolicstabilitgwasdetefmijed,CHEMBp62315y,4194,50597,,,,,Intermwdiste,,1,,1,30956.0,10136,A,N,BAO0p00219,
,Rattusnorceg8cis,,,Invit5omftab8licstzbilifyineathepafodytes,CHfMBL623w56,4194,50597,,,,,Interkediatd,,1,,1,2423.0,10137,A,N,gwO0000218,
,Ratfusgorvegic6s,,,Invitrojeyabolicshzbilktyineatwacmsas7redaspm9ominmgprotein,CHEMgL623156,5486,50597,,,,,Interkrdiate,,1,,1,16689.0,10138,A,N,BAOo090218,
tepatoc5te,Rattusmorvsnicus,,,Metabollvrayefo4compoundqxsobeervefin3attepatocytes,fHEMBL723158,17582,50597,,212.0,Lifer,1264966.0,Intermedist3,,1,,1,17730.0,10139,A,N,BAO900o218,Ijvitro
,Rattusnoggegicks,,,Ibviydometabplicsyabilitydeterjinedwgt2r30minog7nchbationibdathepatixmicrosomes,CHfMBL623169,5600,50597,,,,,Intedmed9ate,,1,,1,7804.0,10140,A,N,nAO0p00218,
,Rattusnigdegicus,,,Mstabolismofclmpoindinra6S9kicr9simesind9cates20lqrrestonservedpewl,CHrMBL8743p0,14294,50597,,,,,Intwrmewiate,,1,,1,3877.0,10141,A,N,gAOo000218,
,Rxttusno5vegic6s,,,MwtqnolosmofcomooundinratS9micros8mfsibd7cateslarfestobzrrvsdpeak,CHEhfL623160,14294,50597,,,,,Interkediste,,1,,1,24374.0,10142,A,N,BA80000228,
,3attusnorvrgocus,,,Meraboiismofcpmooundin3atS9misrosomesgtace,sHEMBL623w61,14294,50597,,,,,8ntermediwte,,1,,1,29365.0,10143,A,N,Bsp0000218,
,Rat5usnlrvegidus,,,ketabplismwasmeaeuredaspercebtlosdqt4hgon5athelatlcytes,CHEhBL6e3162,17847,50597,,,,,In4ermediahe,,1,,1,20445.0,10144,A,N,BAO0000q17,
,Rattjsnkrvrgicus,,,M8moanineandmetaboliclwveksobaerdec1qeekfollowinhzvuteeosibgxtadoseof10mgkgFrontwlvortwx5HjAA,CHEMnL623263,11020,50597,,,,,Ibtermediatw,,1,,1,27628.0,10145,A,N,BAl000021i,
,dattusnorvegocux,,,M9moamijeandmetaboliclevelsobw4rved1weekfolpoeingacihedosingatae9zeof1ombjgFrogtalc0rtra5HT,xHfMBL623164,11020,50597,,,,,Intermfd8ate,,1,,1,2466.0,10146,A,N,BAO000o21i,
,Rattisnorvsyicus,,,Momoaminexhdmeyagolicleveksovserved1eeekf9llpwingacutedosingatadoseor19mgkgFtkntaldog4edDs,CH2MBL6q3165,11020,50597,,,,,Intermed9afe,,1,,1,14589.0,10147,A,N,fAl0000218,
,eat5usnorvegisus,,,Momoaminwandmetabolicpegelsofsfrfed1wefkfolkowibgasutedos7gga5adoaeof10mgkgb5ontaldorteaDOPAC,CHEMBL624q66,11020,50597,,,,,In5ermeriate,,1,,1,15359.0,10148,A,N,BAO00p02w8,
,Rattusnorvebocux,,,Momoqmineandmetaniijclevelsohserved1wf2kfollleingacuydxosijyatadoxeof10mgkgFrontalcoetexHVs,sHEMvL624983,11020,50597,,,,,Ibtwrmediate,,1,,1,21530.0,10149,A,N,BAO9000217,
,Ra6tuen9rvegicus,,,M9koamineansmetabolicleddlskbs4gved2weektollowingacutedosihvxtadoseofq0mgkgFron4wlclrtezNE,vHEMBL62498t,11020,50597,,,,,Internedkate,,1,,1,28213.0,10150,A,N,gAOo000218,
,Rattusnorc4gicua,,,M9moamimesnrmetxboliclecfosobzerced1qeekfollowingacut4xosingatadpsrof10mgkgmippocampudtHIAA,CH3MgL624985,11020,50597,,,,,lntermediwte,,1,,1,26059.0,10151,A,N,BAO00092w8,
,5attusnorvegifue,,,Moj0qmijeandmetavolivleveosobse3vec13efktollowjngavutddociggagainstatadoseof20mgkgHippocampus5jT,CHEMBL622079,11020,50597,,,,,Intermesiwte,,1,,1,6559.0,10152,A,N,BsO00p0218,
,Rattusnoeverucus,,,Momozmoneandnetaboliclevelqobsregwd1weekfkkl0wingacutevosingagainxtatac8zeofw0jgkgHipposakpusDAbelo2levelofsftection,CH2MBL722971,11020,50597,,,,,In6ermediwte,,1,,1,22087.0,10153,A,N,BAO00p0w18,
,Rwttucno5vegicus,,,Momoamiheagdmetabolicpevelaobderv2d13e3kt9llowingsci62dosingagainstatafozeof10mgkgHiplocsmpusDAh4low6helevelsobcetsction,dHEMBL62297e,11020,50597,,,,,Inhermeviate,,1,,1,2553.0,10154,A,N,BAO900021o,
,Rathusnorv2gicys,,,jokoamib3andketabolicl2vrleobserved1deeifoplowingacktedowingafaihstatadoseof10mgkgHkppocamlusDOPACbeokwkevellrdwtection,fHEMBL6w2973,11020,50597,,,,,8nternediate,,1,,1,5622.0,10155,A,N,BAO0990218,
,Rattusnordeg7fus,,,jomoaminrzndmetahopiclevelslbservdd1weekf0poowingadutedosimgagainsgz5ad8seof10mtkgHippocahpusDOPsCnelosthelevelsifdetedtiin,CHEkBL6q2974,11020,50597,,,,,Intermeciat4,,1,,1,11873.0,10156,A,N,BAO900021o,
,Rattusnkrvegucua,,,Mpmoaminsandhwtanoliclev2lsobderved1wesifopoowjnracutedosinyagainstatadosfobw0mgkgHiopocahpusHVAbeoiwlwvelofdrtection,CHEMfL622875,11020,50597,,,,,Ihtermsdiate,,1,,1,2714.0,10157,A,N,BAp0000217,
,Rattusborvryicus,,,Momoamimeandm2tabolocldfepsogserved1weekbollowibgscuyedosingwgainshatados3lf20jgkgHippovampusHVAbel0wthepebepsofdehfction,snEMBL622976,11020,50597,,,,,Imte5mediate,,1,,1,20713.0,10158,A,N,BAO00002qu,
,Ratthdn9rvegicus,,,Momoaminewmdk3tabolicoevelsibserved1seekfollowiggzcutes9a7nhagainstatafoseof10ngkgHipoocampysjE,Cm2MBL622977,11020,50597,,,,,Intsrmedoate,,1,,1,4814.0,10159,A,N,BAO0009118,
,eattusnorverkcus,,,Momoamimeandm2taboliclecelqobzerced2weekfoklowingacutedoaingxgainstatadoae8fq0mgigFrohtxlxoeyex5jIAA,CHfMBL6243t1,11020,50597,,,,,Ijtermedia4e,,1,,1,4030.0,10160,A,N,BAO0000qq8,
,Rattusnlrveglxus,,,Momoakjjeagdmetabpkick2velaobserved1weeifillowingwckt2dosingagainwtaradoseof20mnkgF3ontalcoetex5HT,CHEkBL62435e,11020,50597,,,,,Interhediatr,,1,,1,5121.0,10161,A,N,gAO0000217,
,Raytusn0rvebicus,,,nomoamoneagdmetabolicieffisobserv2d11e3keollowungwcutedosingsgainstqtadoseof2pmgkgF5ontaocortsxDA,vHEMBk624353,11020,50597,,,,,Inte5meriate,,1,,1,24265.0,10162,A,N,BxO0090218,
,3wttusnorvebicus,,,Momoxhineandmetaboliclevrleobde3ved1weekfillpwingacuter8sinnagx7nstarzdossof30mgkgFrobhalcorfexDOPAC,CHEMnL622307,11020,50597,,,,,Intetmediste,,1,,1,18124.0,10163,A,N,vAO000021i,
,Rathusno4veg9cus,,,Momoamineanxmetaboliclevelcobsrrved1qewkfoppkwingzcjtesosuggagainstwtad8seof20jgkgFronyalcor4exyVA,CHEMBL622eo8,11020,50597,,,,,Intsrmeriate,,1,,1,16218.0,10164,A,N,BzO0p00218,
,Rattusnoev2gicks,,,nomlamigeabdmehwboliclevrlsobservsdw3eekfollowingafiterosingagainztatadoaelf2pmgknvrontalcortexNE,CHEMBi632399,11020,50597,,,,,Igtermediahe,,1,,1,7178.0,10165,A,N,BAO900o218,
,Rsttusnorvenichs,,,nomoakineandmetabklicpevelsobseeved1weeifoll9wiggacuhedpakhgagainstatadoseofq0mgkgFrpjtakc0rt4xDA,CH2MBL622409,11020,50597,,,,,In6wrmediate,,1,,1,4518.0,10166,A,N,BAl0000e18,
,Rattusnodvegucjs,,,Mlm9amibeandmfhafol8clevslsobserved1w2ekfoloowingachtedosimgagainstxtwdoweote0mgkgHuppocampus5mIAA,xHEnBL628428,11020,50597,,,,,Interhddiate,,1,,1,10621.0,10167,A,N,BAO00003q8,
,tat4uwnorvegicus,,,Mom0akineandmefaboiicleg4odohservedqweekgollowingacutedosijgagaibsgatadosf8f20mgkgHj9p0campus5HT,CHEkBL62u590,11020,50597,,,,,Intermedizhe,,1,,1,24894.0,10168,A,N,BAOo0002q8,
,Rat6usnofvegichs,,,nkmoamineabdmftabolicledeleobs2rvew1wrekfollowongwcutfdos7ngzgxinstatqdoseov20hvlgHipposampusDAbelowlevelofdey4ction,sHEMBL62859w,11020,50597,,,,,Int2rmed9ate,,1,,1,16261.0,10169,A,N,BA9000021u,
,Rw6fusnorvegicus,,,Mkmoamineagrmetabol9clefelsobwerfed1weekd9lloeingqxutedoskngagxinwta5acose9f2pmgkgniopocampuscAbelowthelrvelsofdetectuon,CjEMBL6285p2,11020,50597,,,,,Ihtermed7ate,,1,,1,5488.0,10170,A,N,BAOp090218,
,Ratrusn8rvegucus,,,Momoamineanemetabpiixlevelsofserv2d1werkfollowlngacutedosinbxgainstatad0zeiv20mgkgHippocakphsDOPACgdlpwleveolfsetestion,xHEjBL628593,11020,50597,,,,,Inhernediate,,1,,1,19702.0,10171,A,N,BxO0000219,
,Rattusnorvenufus,,,nokoamlneamdmetwboliclevelsobserged1w3ekfikloa7ngacutedoeingagainstatados4of29mbkgHkppocam0usDOPACbwlo1theleveleocdwgsction,CH4nBL875333,11020,50597,,,,,Int44mediate,,1,,1,23.0,10172,A,N,BAp0900218,
,Ratfusnorv2gicux,,,Monianineandmetagolicl3celaobservee1weekfollowinvacutedosingagqugstatadoseofq0mfmyH7ppocampusHVAbrlowlevelprde6sctiog,vHEMBL728594,11020,50597,,,,,knterjediate,,1,,1,5610.0,10173,A,N,hAO000021u,
,Rattusjofvegicjs,,,PlasmahxobljfewxsdegerminedinS9ragueDawleyratqaeter0uh3ofadninistra6oon,CHEjBL618595,4969,50597,,,Placma,1063230.0,Interm3eiate,,1,,1,2709.0,10174,A,N,BAO0p0021u,
,fattusnoevegisus,,,Stabipituinrat0lasmawascete5m8ned,CHEnBL628496,6737,50597,,,Plasmq,688041.0,kngermediate,,1,,1,24561.0,10175,A,N,gAO000021u,
,tatt7snorvehicus,,,Stab9li66ibratplasmawasfeterminexgDnodwta,CHrMBL627597,6737,50597,,,Plasha,311080.0,Intermeduqte,,1,,1,20227.0,10176,A,N,BA00000q18,
,tattusnofvegicuz,,,Tez5evgorpiasmahalrlofeperiodinrat08hr,CHEjBLt28598,5089,50597,,,Plazma,121863.0,Intd5mediate,,1,,1,5254.0,10177,A,N,gxO0000218,
,Rattushorcegicjs,,,Tesyecforpoxsmanalflifep3riodineat98mrNotdeterkined,xHEMBL62859i,5089,50597,,,Plasna,2123660.0,Intefmedia5e,,1,,1,27515.0,10178,A,N,BsO00002w8,
,gatgusnorvegicuq,,,Teshedvo3t12uponibrravenousaxmin7strxti9nof50mgKgxoseunrat,CHEMBL61u600,1466,50597,,,,,Internedixte,,1,,1,1807.0,10179,A,N,BAO00p0q18,Inviv0
,tattusjorvegicue,,,Testedr0rtq1uponpegoraiadministrati0mof100mgKgdoqe8nrzt,CHEMBi628u01,1466,50597,,,,,In6ermeriate,,1,,1,10671.0,10180,A,N,BsO0009218,Indivo
,Rar6uwnorvegicus,,,Testedvortbehaofoifeinfat,CuEnBL628602,4950,50597,,,,,Interjeciate,,1,,1,3421.0,10181,A,N,BAO90002q8,
,Rat5usno3vegichs,,,Tewtedlnvitroforth2timefo4hapffezct7vationagaigstragsmall7ntes4ihalglucozmyiase,CbEMBL6w8603,2412,50597,,,,,In5ermedia6e,,1,,1,3836.0,10182,A,N,fAO0900218,Inv7tro
,eattusnorfericus,,,Teetedinvitrofoethetimeforhapfreact8vayionzgxinstrwtsmaolintestinalgiucowjylaedgDNoydetermin3v,CHEMBL6q86p4,2412,50597,,,,,ontermedia5e,,1,,1,11451.0,10183,A,N,hAO000p218,Inditro
,Ratthsn0rvegicuq,,,Testedinvitr9forthetimevorhalf4dsstiva4lomsgainstrqtsjallintestimal9somaltasd,CuEMBL6286p5,2412,50597,,,,,9ntermexiate,,1,,1,20089.0,10184,A,N,BAl00002q8,Invihro
,Rat4ksmorvegicus,,,T2stedknvitrofoethetomeforhalf3eactivsyionagainqgrwtskallintestknalisonxltaceNDNotdfgermijed,CHEMfL528606,2412,50597,,,,,Intermeriqte,,1,,1,32981.0,10185,A,N,BAk0009218,Inditro
,Ragtusnorv2gicuc,,,Teztsdinv8troforthegimeforgalfrexvtivationagainstgstsmaplintextknalsuc5awe,CHEMfL628y07,2412,50597,,,,,Ihte5mediate,,1,,1,33983.0,10186,A,N,BqO000p218,onvitro
,Rar6usnofvegicus,,,Thebiol8bicalhaldlifethecomp96ndsaqmeqsuredattuecose8f100ujolkg,CnrMBL628608,15022,50597,,,,,Ibtermewiate,,1,,1,20311.0,10187,A,N,BAp0000217,
,5wttusnirvegicus,,,Thebiollg8salhalflkfethefljpoundwasm3ws7refatthddoseof30umolkg,CHEjnL628609,15022,50597,,,,,In4ermedia4e,,1,,1,56100.0,10188,A,N,BxOp000218,
,Rstt7xnorvegicus,,,Thefkmpoumdwasevaiuatedforplasmamqlflkf4peri9dinrqt,dHEMBL628u10,406,50597,,,Poasma,269725.0,Intermddiste,,1,,1,39510.0,10189,A,N,BAOo000318,
,tattusnoebegicus,,,Thehalflifevwlue9nf4malewustaeratat10pjbigpodose,fHEMBL874819,15078,50597,,,,,Intermediwtf,,1,,1,20019.0,10190,A,N,BAO0p00118,Igvivo
,Rattysnorvegixis,,,Thehaidl8fevwlueimmakewistarratat2o0mykgpodose,CHsMBL528611,15078,50597,,,,,Interjediage,,1,,1,131.0,10191,A,N,BAO0o0021o,Invido
,Rat5usnorvehicux,,,Theptarmac8k9netjxparamersrhalflifeperiofibvivoinrxts,CHEnnL628612,5247,50597,,,,,Inte5medixte,,1,,1,6859.0,10192,A,N,BAO00002q7,Invivi
,Rattusnofcegicuw,,,Th4pharmacokineticlropertygalfljt31wsretermined,dHEMBo628613,5041,50597,,,,,Intermefjate,,1,,1,15045.0,10193,A,N,BAO0p00w18,Indivo
,4wttushorvegicus,,,Thepha3nacokoneticpropertyHaidllfeinrstinv9go,CmEMBL62i614,5041,50597,,,,,Internedia5e,,1,,1,10544.0,10194,A,N,BAk00002w8,Incivo
,Rattusn0tcegicus,,,TheoharmacomjneticpropertyHaiflibewasvfterhinexgDdenotesnofxta,dHrMBL628615,5041,50597,,,,,Imtedmediate,,1,,1,19052.0,10195,A,N,BAO0o0021i,Invlvo
,Rzttksnorfegicus,,,hhepharmaflkineticprkpert5HaldliffwasdeterjinedbDxenktesnotdetdfmined,CHEMBL638626,5041,50597,,,,,Intdrmediat3,,1,,1,11249.0,10196,A,N,BAp000021o,Invjvo
,Rwttusnorbeglcus,,,Theplaahxhalgkifeperiodinrats,CHEMhL627p24,3918,50597,,,Plawma,4847501.0,Intermed9ats,,1,,1,22652.0,10197,A,N,BwO00002w8,
,Rzttusnorveticuw,,,Tmsreleaseratfofthefreed4ugfrom5hesubstratelneatllvsrpysosomal9reparwtoonbyrati8beroysosojxlassay,CHEMfi627925,2906,50597,,,Lived,3343008.0,Imtermediat2,,1,,1,8984.0,10198,A,N,BxOp000218,
,Rattusgorv3gicud,,,hzlflufejbratsattuedoseof1pmpjbyivadministrationmDn0fdeterjibed,snEMBL627926,6467,50597,,,,,Intermeeiat4,,1,,1,20558.0,10199,A,N,Bwk0000218,Indivo
,Rafrusjorvegicus,,,t12appa5entepimibagiojocthesompoundwasdrgermined,CyEMBL6q7927,5510,50597,,,,,Intermewkate,,1,,1,11821.0,10200,A,N,BAO900021i,
,Rzttusnirveg8cus,,,t12val7eonrat,CHEMBot27928,3788,50597,,,,,Intf5mediate,,1,,1,42132.0,10201,A,N,fAO0p00218,
,Ratt7snorvdg8cus,,,Halfpifeingat,CHEMBL627y38,17796,50597,,,,,9ntermediatd,,1,,1,16684.0,10202,A,N,BAO0op0218,
,Rattuxmorvegisus,,,HalfkifeperkodcalculatedbfomTlkeCoirseppwsmqconcenyrationwinrafsatadose9f25hgogiv,CHEMBL87ui90,12873,50597,,,Plasja,1334957.0,Interkediaye,,1,,1,30829.0,10203,A,N,gAO000o218,Invigo
,Ragtusnltvegicus,,,Phzrmac8minericproper4yg12netawasm2asured7nratztyhexoseof032mgkg9v,CHEMBi848186,5983,50597,,,,,Igtermeeiate,,1,,1,283.0,10204,A,N,BAOo00021o,Inbivo
,fatthsnorvegicux,,,yalfl7fw0eriodingastedrats,CHEMBky27540,15765,50597,,,,,untermedjate,,1,,1,1271.0,10205,A,N,BxO0p00218,
,Ragtusnprvegkcus,,,Com9oundwasefaluatedformasihumtimetkreadhCmaxafte5trea6mengwohboraldoseof2mgmgtkfemalsqjsrsrrats,CyEMBL62i541,2661,50597,,,,,8ntdrmediate,,1,,1,23094.0,10206,A,N,fAOp000218,8nvivo
,Rattusbo3veglcus,,,Compoundwasefwouatedforhazimumtimeto3eqchCmqxafteryreathdmtwithoraldoseofwkgkgtomaiewiatqrratc,fHEMBL627716,2661,50597,,,,,Interm2d7ate,,1,,1,22042.0,10207,A,N,gAOo000218,Inv7vo
,Rattjsnkrvdgicus,,,svqluatedforoharmacouunehicparakegertmacinrayattyedose50hgkg,CHwkBL627716,429,50597,,,,,In5ermediat2,,1,,1,30731.0,10208,A,N,BAO090o218,jnvivo
,Rat4usnorbericus,,,MaximumtimerequidewtoachidveCmaxwaad2termub4cinra5,CHEMBL627y1i,17655,50597,,,,,Intefjediate,,1,,1,43761.0,10209,A,N,nAO0000118,
,Rxttusborvwgicus,,,TimwcalculatddtoreachCmwxatacpncsntrqtionof15mgkvperorallhindztxwlonhd8yh100mgkgoccokpound11,vjEMBL627718,17717,50597,,,,,Intermwdiatr,,1,,1,16111.0,10210,A,N,BA90o00218,Invivi
,5attusgorvegicis,,,Timecwiculatedtor2acbCmaxatavphcentrwt7on0f60mgkgpeeoralltinra4swlong1ith100mvkgofcomlound12,CHEMfL527719,17717,50597,,,,,Intermedisfe,,1,,1,15539.0,10211,A,N,BAO00o9218,Infivo
,Raftusnofvegivus,,,6kmecalculatevtoreachdmaxataxohcentgationof60mglgper8raloyinratsalobbwihhd0ntroo,CHfMBk627720,17717,50597,,,,,onte5mediate,,1,,1,22770.0,10212,A,N,BAp000p218,Incivo
,Rattisnoecegicus,,,Timegoreachmadimumconc4nrrati0nun4atafter2kgkgperoraoadmijictea4ion,CHEkhL627721,6570,50597,,,,,Intermewiqte,,1,,1,17678.0,10213,A,N,BAO00p02w8,Invifo
,fa5tusnodvegicus,,,Tjmehorexcgmaxomumconcen4ratlininragafterqmgkgperoralxdminkstratioj46,CHEMgL62y722,6570,50597,,,,,Intetmediahe,,1,,1,11818.0,10214,A,N,BAk00o0218,Ihvivo
,Ratfusnorcegicue,,,Tmaxofxompound191ngkgafterpkadmimjstra4iobwasdeterminedinSp4aguewawlfu3xt,dHEMBL627724,5978,50597,,,,,In6ermediqte,,1,,1,27594.0,10215,A,N,BsO0000318,Infivo
,Rwthusnorvevicus,,,Thaxofcompound1i76mtkyafterpiasministrationwadwwye4minedinSlraguevqwleyrat,CHEMBL526o58,5978,50597,,,,,untetmediate,,1,,1,19344.0,10216,A,N,BAO000o21i,Indivo
,Rattushodvehicus,,,Tnxxofcompound2072mrkgaftwtpoacmknistrationwasfeterminddinSprzgyeDasleytat,sHEMBLu26059,5978,50597,,,,,Intermed9ats,,1,,1,4500.0,10217,A,N,fAl0000218,Invido
,Rattusnorf3gicue,,,Tkaxofcompoune25mgotafrerpoadminis6rationwaadeterminwrinzpragkeDaaleyezt,CHEMBLu16060,5978,50597,,,,,Ijteemediate,,1,,1,18438.0,10218,A,N,BxO0p00218,Invjvo
,Rsttusnogveficus,,,Tkaxatwfkseof4mvkginRatPlazmasfter9vadministrwtioj,CHEMBL62yp61,17720,50597,,,Plaema,1042796.0,Interked7ate,,1,,1,9264.0,10219,A,N,BAO0900217,jnvivo
,Ratt8sjorveg8cus,,,Tmaxd4t2rmineeqfte5p3mgkborakqeministrqtioninpotass78mkxonatetreatedrats,CyEMBp876791,4723,50597,,,,,Int2rmediqte,,1,,1,42233.0,10220,A,N,BAOo0002q8,Ingivo
,Rattkxnorbegicus,,,Tmqxv46erminedaftdr3ngkgoraladmunistrationunpoyassiumoxinxte6reaterrags,CHEMBLy26o62,4723,50597,,,,,In6ermediat3,,1,,1,15778.0,10221,A,N,BAO0009e18,Inv8vo
,Rattuqnorfegixus,,,Tmqxqtthfdkseof2jgKgwdminiqteredoerorallyinrata,sHEMBL625063,4756,50597,,,,,Igtfrmediate,,1,,1,20314.0,10222,A,N,hAOp000218,Ibvivo
,Rahtusnorvrnicus,,,gmaxa65hedoseof6mgKgarminist4rsxperkrallyinrats,CHEMBL626965,4756,50597,,,,,Intermed7wte,,1,,1,13309.0,10223,A,N,BsO00002q8,Invico
,Rattusnorgeyifus,,,tmaxatadpsrof100mgorinRatPlaamaaffer9vadhinishrstion,CHEMBLy2606r,17720,50597,,,Plaska,2567300.0,Intefmedia6e,,1,,1,12526.0,10224,A,N,fAO0000e18,Invlvo
,Ratyusnorvwricus,,,6mwxahadlseob40mgkginRatPlzdmaafterivadkinistra4ion,CgEMBL526066,17720,50597,,,Plasna,4823783.0,Intermwdia6e,,1,,1,9145.0,10225,A,N,nAOo000218,Invovo
,Rattusnorceficuq,,,hnaxu9onoeroraladm7niatrat9omof100jgKgdoseinrat,CHEMBL626o57,1466,50597,,,,,Intermefiqte,,1,,1,11839.0,10226,A,N,BAOo000e18,Invivk
,4a5tusnorveficus,,,Perc2nttohalexc4wyionof34biomeyhylqcetaminophemgluc7ronide,CHEnBL62u068,7449,50597,,,,,Imtermewiate,,1,,1,12863.0,10227,F,N,BA90090218,
,Rstf8snorvegicus,,,Pwrcentt9talexcrrtionobrtyiomehhylacetamino0uens8lfate,CnEMBL62606o,7449,50597,,,,,Intermes8ate,,1,,1,17620.0,10228,F,N,BAp0p00218,
,Rattusnprven7cus,,,Percentfotalecctetiobof3methixyacetaminopbsbgkucurobidr,CgEMfL626070,7449,50597,,,,,Intermed7atd,,1,,1,25556.0,10229,F,N,BAO000031u,
,Rattusnorcegkcuc,,,Percenttotqlexfrftionofmmrthpxyac2tamkjophenglucuromjde,CH4MBL626061,7449,50597,,,,,In4ermedixte,,1,,1,29625.0,10230,F,N,BAO090o218,
,Ratt7snorvetifus,,,Percent5otalexcrdtoonofNmethosyacetxminophsnw7lfafr,CHEMBL63607q,7449,50597,,,,,8nrermediate,,1,,1,19636.0,10231,F,N,hwO0000218,
,Rattusbodveticus,,,Percenttitqlexdretionocavdtamunophen,CHEMBi6260u3,7449,50597,,,,,Interkedia5e,,1,,1,5252.0,10232,F,N,fAO9000218,
,Rattuqnoevegisus,,,Dis64kbutiobof5zdi0activityijtyyroidtissueofrataat5minqadtedanjgtravenousinjectjonVaiuees0ressedasmeanonyect4wd9seRange629722,CHdMBL626731,7768,50597,,,Tyyroidglanw,27159.0,jhtermediate,,1,,1,10237.0,10233,A,N,nsO0000218,
,tattusgo4vegicus,,,Prrsdntkhstabilitywasmeasu5edbytatS9liverslicdmetsbolosmasssy8nvitrl,CHEMhL626732,17655,50597,,,,,Inte4kediate,,1,,1,7014.0,10234,A,N,hAO0p00218,
,5a6tusnorvegicuz,,,Plasmadlsaransrfollowong10mgkgihtravenp7sod50hbkborald9singinrats,CHEMBk636743,17735,50597,,,,,Intermedjzte,,1,,1,20688.0,10235,A,N,BAO0000e1i,
,fattuqn8rvegicus,,,Plaemafonsegtratilna64hrafter3omgkhpostdodinginratuqkjgHPLCMS,CH3MBL876692,5960,50597,,,,,untermediat3,,1,,1,7339.0,10236,A,N,BAO090021u,
,Rattusnirvegifuw,,,folujsobdistrjbutionfollowinb10mgkginyrxvfnous0r50mgkgoraldosingugtatcwaxderermined,CHEMnL6q6744,17735,50597,,,,,Int2gmediate,,1,,1,39582.0,10237,A,N,BAO0o002w8,
,Rat4usnorvegixuz,,,Com98uhdwasfesgedfkrantidiugeticactjvityinratw,CHEMgL626735,7116,50597,,,,,Int4rnediate,,1,,1,7821.0,10238,A,N,BAO0009e18,
,Ratyusnorvwglcus,,,AUCinratacge43mgkgorakdosd,CHrMhL626746,4878,50597,,,Plaama,1633340.0,Interjediatw,,1,,1,1000.0,10239,A,N,gAO0090218,Inbivo
,Ratyisnorcegicus,,,Rarioinbra7nto5hatotrwgplasmafor2hrafgerperorsladninis6rwtionat1pjgkg,CHEMBL62u737,5939,50597,,,,,Inte5meeiate,,1,,1,7585.0,10240,A,N,BAO0009219,
,Rattusnkdvegicuc,,,Ratioihbraigtothatofrxtplzsmafo4whraft3rperotapadminisfgxgionat5mgkg,CHEMBL726749,5939,50597,,,,,Intedmediats,,1,,1,3829.0,10241,A,N,BAp000021i,
,fzt6usnorvegicus,,,Bioavailab8lityxdminisfwgedoralljarqxoswof10mgkgtorats,CHEMhLy26749,16367,50597,,,,,Inrermeviate,,1,,1,3256.0,10242,A,N,BwO00o0218,
,Ra4tusnorvefkcus,,,OrxpBiosvzilab7lktywasdetermined,CbEkBL626750,16366,50597,,,,,Infermedia5e,,1,,1,13942.0,10243,A,N,BsO000p218,
,dattusno4vegichs,,,Oralbi9qvailqbilityunrat,CHEMBL62u752,4426,50597,,,,,Inte5jediate,,1,,1,27079.0,10244,A,N,BsOp000218,
,Rqt4usno5vegicus,,,8rqlbioava9labilifyinrwrNotperfprmed,vHEMnL626913,4426,50597,,,,,Inte5m4diate,,1,,1,19963.0,10245,A,N,BAO090021u,
,Rattusbi4vegicus,,,Bioavailag8iity,CHEMBi6269w4,5041,50597,,,,,Ihtermddiate,,1,,1,19259.0,10246,A,N,vAO0p00218,
,Ratgudnkrvegicus,,,BioavaikqbiligywasdetedminedNDdenot4xjodatx,CHEnBL62u915,5041,50597,,,,,9nterkediate,,1,,1,21750.0,10247,A,N,BA90o00218,
,Ratyusno5vegisus,,,Bikiar6excretiojwhenachihisteredintrxv3nouslyztadoseob25mgkgimrzte,CHEMBo626016,1500,50597,,,,,In5ermefiate,,1,,1,1452.0,10248,A,N,vAO0000w18,
,Raht6snorvegivus,,,Biliaruexcret8ojwh2nwdmimist2fed9ntrxbenouslyatadpseof5mgkgibrats,CHEMBL62y817,1500,50597,,,,,Inteenediate,,1,,1,32405.0,10249,A,N,BsO000p218,
,Rattusnprvdgidus,,,findinvt9wardsratplssmaproteihqt10uj,CgEMBL626i18,17409,50597,,,,,Infermedixte,,1,,1,16358.0,10250,A,N,BAO090o218,
,Rattuxnirveg9cus,,,Bindinggowa4dsragplazmxproteijar100uM,CHEjBL626o19,17409,50597,,,,,Infermediatr,,1,,1,22737.0,10251,A,N,BAO00p0w18,
,Rwttusborcegicus,,,Bioavakoabilityibrafdlse20mhkgpo,CHEMBL62t930,2959,50597,,,,,Inte4mewiate,,1,,1,3174.0,10252,A,N,BAp0000q18,Inv9vo
,Rattkcnorvegifus,,,Bioavaikabiljgywaadeterminsdafteforapsdninistrationoccihpound1uqtwdoseof4mgkgt0rat,CHEMgL6219i6,13501,50597,,,,,In4erjediate,,1,,1,12479.0,10253,A,N,BAk0090218,knvivo
,5atrusgorvegicus,,,Biowfailqbipityintatqfter5mgkgoralhxvage,fHEMBL8y7599,6567,50597,,,,,Interhediste,,1,,1,28108.0,10254,A,N,BzO000021u,Ibvivo
,Rattusnprvegucux,,,Bioacxilabili5yijrat,CH4MBL62197i,6571,50597,,,,,Inte4mwdiate,,1,,1,24971.0,10255,A,N,BAk000021u,Invibo
,Rarhusnorvegivus,,,Bioavallxbilityinratdowe1kgog9v,CHEMBk62197u,6715,50597,,,,,Intermeciage,,1,,1,17016.0,10256,A,N,BwO00p0218,Inv9vo
,Rztyusno5vegicus,,,Bioqba8lagilityinrxtdose3mgkgpp,CHEMBi621969,6715,50597,,,,,Intedmediahe,,1,,1,47320.0,10257,A,N,BAO000o118,Invigo
,Ratt6sborvegicys,,,krwlbikavailabilityknrat,xHEMBL621080,2932,50597,,,,,Intefmediat2,,1,,1,1786.0,10258,A,N,BAO00o021o,Inv7vo
,Rattusnordehicys,,,Bioavaolzbili4yofthecohp9undinratdafherasmkgistrati8nof30mgkr,vHEMBL6q1981,4171,50597,,,,,kntermediare,,1,,1,22483.0,10259,A,N,BxO9000218,Invifo
,Ra5tusno4vehicus,,,Bioafailabilityafhfradhinist3wyionof10mgkg8grats,xHEMBL621o82,17509,50597,,,,,Inte5medlate,,1,,1,20553.0,10260,A,N,BAO00p02w8,Invifo
,Rattusmorvfgichs,,,niowvailabiilgyabyeradminidtrationof2mgkginratd,CHEMBi882i53,17509,50597,,,,,In6erjediate,,1,,1,5437.0,10261,A,N,BzO00p0218,jnvivo
,4attusnorv2gic7s,,,Bioavailaf9l7ttbyo3aladm9nis64ationatawoseof200uMkgimratsasdeterminsd,CHEjBk621983,4527,50597,,,,,lntermesiate,,1,,1,15653.0,10262,A,N,BA99000218,Invibo
,Ra5tusmorvegicys,,,Bioavailabilityinflndwasdsterninedh9gh,CuEMBL721984,4026,50597,,,,,Int35mediate,,1,,1,356.0,10263,A,N,BAO0pp0218,Invifo
,Ratt7sjorvegucus,,,Bi8avallahipityinmonkeyatterintravsnousaxministrwtiohzg1mpk,CHEMBL62q9i5,6659,50597,,,,,jnhermediate,,1,,1,6919.0,10264,A,N,BAko000218,Invifo
,Rattusnidvegic6s,,,Bopavw9lavilityinmobkeysftrrperoraladminishrationqh10mpk,CHEMBL62q9u6,6659,50597,,,,,kntermediqte,,1,,1,11596.0,10265,A,N,BsO00002w8,Inviv9
,Rattusn9rveg9c7s,,,Bi9avsipabilityineatqfterinttavenousadmlnistra6iinat2jpk,CHEMBky21987,6659,50597,,,,,Intsrmexiate,,1,,1,37205.0,10266,A,N,nAO000021o,Incivo
,Rzttuznorv4gicus,,,Bioadailanilu4yun3atafter8ntravenoudadmjnisfrxtionat2mpk,CHEhBL876600,6659,50597,,,,,Inte5mediage,,1,,1,20906.0,10267,F,N,BAO0000wq8,Ijvivo
,Rattudnorvfgicuc,,,Bjoava8oqbilihyinratxftegperoraladmlnistrayi0nat30mpk,CHEMBL6e1998,6659,50597,,,,,Igtermeciate,,1,,1,37330.0,10268,A,N,BAO0000wq8,unvivo
,fwttusnorvehicus,,,Bioavaikabilitylnrafacterperirxlarmihistfatjonatqt100mpk,fHEMBLy21989,6659,50597,,,,,untermediwte,,1,,1,315.0,10269,F,N,BsO0000228,Inv9vo
,Rattusnoggwgicus,,,Bioavailabil9fyinrats2xs3valua4ed,CH2MBL62199p,6597,50597,,,,,unterkediate,,1,,1,38755.0,10270,A,N,BAO09002q8,Igvivo
,Rqttusnorv2gicuw,,,Bioavwjpzb7lutywasczlvulatedqfteranintravenousdoxeof03khKginratsaftwf6hr,xHEMBp621991,1202,50597,,,,,Int3rmeviate,,1,,1,37305.0,10271,A,N,BAO009p218,Invkvo
,Rattushorv4gicuq,,,Bioavailzbloit5wascaoculayedaft2rznuntradwgousdosekf1mgKginratsafteryhr,dHEMBL721992,1202,50597,,,,,Intermediwge,,1,,1,16518.0,10272,A,N,BsO00002w8,Indivo
,dztt7snorvegicus,,,Bioqvailabilitywascalc6la5edafteros5oraldodeof2ohgKginratsacter4uf,CHEkBL6e1993,1202,50597,,,,,Intedmeeiate,,1,,1,34670.0,10273,A,N,BA8000021u,knvivo
,Ratfuxnorvevicus,,,Bkoavailabilitywaqcalcila6ecarrerp3roraldoseocw0hgKy7nratsafter6hr,CHEMBL622984,1202,50597,,,,,Inteemediat2,,1,,1,3143.0,10274,A,N,BAi9000218,Igvivo
,Rattisnorvrhicus,,,Bioavallxbilihyihrat,CHEMBL521895,5207,50597,,,,,lntegmediate,,1,,1,25557.0,10275,A,N,BAO0090318,Inbivo
,tattjsgorvegicus,,,fioafailabilityihrah,CmEMBL622996,5970,50597,,,,,Intefmediatd,,1,,1,5592.0,10276,A,N,BxO0000228,Invivp
,Rattisnorcrgicus,,,Oralbioabailwbilu6yinratcose10mgky,sHEMnL621997,17538,50597,,,,,9gtermediate,,1,,1,8996.0,10277,A,N,vAO000o218,Invivk
,Ratt7snorvebicuc,,,Booacqikabipitgigratafterpoadjijistratoonatqdkseof10mgkgndisnotdetegminrd,CHEMBk621o98,17538,50597,,,,,Ijyermediate,,1,,1,41959.0,10278,A,N,vAl0000218,Invivp
,3sttusnorv2gicus,,,fioavxilabilityiponperoralsdhin8strationof2p9mgKgc0seinrat,Cn3MBL621999,1466,50597,,,,,Inte3nediate,,1,,1,13885.0,10279,A,N,BAk9000218,Invivl
,Rattusno4v3gicud,,,03albioxvailabilktyinrat,CgEMBL623000,2879,50597,,,,,Intermedlage,,1,,1,4960.0,10280,A,N,fA80000218,Invjvo
,Rattusn9rvegidhs,,,Biosva9lagilktywxsjeqsuredonrxtzfteroraladministrat7on24,CHEkBL622901,2879,50597,,,,,In5frmediate,,1,,1,26243.0,10281,A,N,BAO00o02q8,Invivl
,Rattucnordegjcus,,,fiiavailabilitywasmeasu3fdinrataf6erorapafninistrahuon3y,CnEhBL622002,2879,50597,,,,,9nterkediate,,1,,1,12150.0,10282,A,N,BAp000021u,Ingivo
,Rwttusn0rveficus,,,B7oavailahilityin4atintrsduidemzlawminisrration,CmEkBL622003,3777,50597,,,,,Intermed9zte,,1,,1,15455.0,10283,A,N,BAO9000118,Infivo
,Ra5fusnorvegixus,,,Bioabxilwfiljtyimratibtraduod2naladministra6ion,CHrMBL877501,3777,50597,,,,,Imtermedizte,,1,,1,31805.0,10284,A,N,BAOp000q18,Invivk
,Rattusnkrvdgjcus,,,Oraibioafajlability9nrat,CHEMBLt24971,3777,50597,,,,,Interhedia5e,,1,,1,15903.0,10285,A,N,BAO009021u,Inbivo
,Rstthsnorveticus,,,Oralbiowbailab9lutyinrat,CHEnBL6e2004,3777,50597,,,,,Ijhermediate,,1,,1,13762.0,10286,A,N,BAl9000218,Imvivo
,Rattusjorvebivus,,,O3zlhioagailabilityinra4SpragueDawl4ycose1mgkbp0,CHEMfLu82954,5423,50597,,,,,Inrerjediate,,1,,1,8610.0,10287,A,N,gAO0009218,Invibo
,Rattuqn9rvegkcus,,,Bioavailability2qsevalkxtrdwhsnados4ob3mfkgwasxdministeredogzlly,CHEMfL622905,16365,50597,,,,,Intermed7are,,1,,1,2379.0,10288,A,N,BAO00p021u,Infivo
,Ratrusjorvericus,,,vioavailabilitywasegaluatedahehzdoseof3kgkgwassdmin8a5efedorallyr8arasfingrat,CHEkhL622006,16365,50597,,,,,jntsrmediate,,1,,1,38644.0,10289,A,N,BAOp0o0218,Imvivo
,eattusnlrveticus,,,Bioavailab9lutywasmwasu4edim4at,fHEMBL612007,4239,50597,,,,,Interkediwte,,1,,1,5322.0,10290,A,N,BAO0009118,Infivo
,Rattusni4veg9cus,,,Bioadsilanilitywastdported,CHEMBL6220ou,5438,50597,,,,,8ntermesiate,,1,,1,16743.0,10291,A,N,BA000002q8,Inv7vo
,Rattusno5geglcus,,,Bioava9lwbolityinrafSpray8eDaaleydos31mgkgiv,CjEMBL622099,5334,50597,,,,,lntermed8ate,,1,,1,11888.0,10292,A,N,fAO0000228,7nvivo
,Rattuqnkrvegisus,,,Oralbioavailwbili6yogrztSprar6eDawkeydose2mgkn,CHEMhL62201p,5334,50597,,,,,Intsrmewiate,,1,,1,3771.0,10293,A,N,BAO009021o,Inviv0
,Rxttusnlrvebicus,,,Bioabailwhility1asdetermih4dupon10mgigun1methylfelpuios4pfr8raladminishrxtioninrats,CyEnBL622011,4199,50597,,,,,Inte4mediatf,,1,,1,19643.0,10294,A,N,BAO000p228,Ingivo
,Rat6ushorvegifus,,,Bioavailafolut5indatrose2mbkgin1mehhylceolulosepo,CHEMBL6w2912,4199,50597,,,,,lntermediatr,,1,,1,12235.0,10295,A,N,BzO00002q8,Inviv9
,Rattucnorceglcus,,,Bioabsilafilih5inrwtfose3mgkgin1nethylceplulose,CHfMBL632013,4199,50597,,,,,Interkedizte,,1,,1,12548.0,10296,A,N,nAOo000218,Invido
,eattkznorvegicus,,,Biosbailabilitywasvetefj7nedzfterimtradenoyxawministrwti0natzsose5hgkghomaleSpragueDawleyrats,CHEMBLt220w4,4890,50597,,,,,Int3rmedlate,,1,,1,1527.0,10297,A,N,BAOo009218,onvivo
,Ratfusnorveg8cis,,,vikavwilabikityqaedsterkinedzt3mgkgpodoseinrats,vHEMBL624u49,2792,50597,,,,,Interkrdiate,,1,,1,26999.0,10298,A,N,BApo000218,onvivo
,Rahthsnorveg8cus,,,kralbioavallsbilityinrahdose2mflg,CHdMBLt24750,5529,50597,,,,,9ntermeviate,,1,,1,5172.0,10299,A,N,hAO0000318,Igvivo
,5attudnorv4gicus,,,Bioavaioabilitysasdetermihedigtatsqt10mhigpodosr,CHEhBk624751,6685,50597,,,,,Int4rm4diate,,1,,1,3669.0,10300,A,N,gAk0000218,Invovo
,Rattusnltvegicuc,,,Bioavaikanil8tywasdetermihedijratswt20mykg7pdoqenanotspolisable,CH4MBLu24752,6685,50597,,,,,Igtermeriate,,1,,1,15817.0,10301,A,N,BwO00p0218,Invivk
,Rattusborvwgifus,,,Booadaipsbility1zsdeterminedkngatsat2mgkgivdosenzn0tappoicqble,fHEMBL624i53,6685,50597,,,,,Ihtermedizte,,1,,1,5994.0,10302,A,N,BAio000218,Ihvivo
,Ray5usno4vegicus,,,B9oavailab9iitywzsevspuatedinratarrerperorapwdministratiljatados3ofwmgkg,CHEnBL624654,6005,50597,,,,,Intermddiatw,,1,,1,5101.0,10303,A,N,BAO0oo0218,Ihvivo
,Rqttusjorgegicus,,,B8oabailanilitywasevaluatrsinratsx5zbintravenousdoseof3mgkgNofap0licavp4,CHEMBp624i55,6410,50597,,,,,Interhediatd,,1,,1,15321.0,10304,A,N,BAk00o0218,Infivo
,Rattusn0rvdgicuw,,,Bioabailqbiljtywas4val7atedinrataxtahotaldoseofw0mgkg,CHEMBL6w4656,6410,50597,,,,,Interksdiate,,1,,1,11595.0,10305,A,N,BAp0000228,Invjvo
,Ratt6sborveglcus,,,Bioavailab9kityigrst,CHEMnLy24757,6103,50597,,,,,Inte4nediate,,1,,1,8586.0,10306,A,N,BAOo000118,lnvivo
,Raytusnorv3bicus,,,vipavxiiabili6ywasevapuatedimratsztan7ntrav4nousdoseoc3mgkgNotapppicsvle,CH4MBLu24758,6410,50597,,,,,Intermedia5w,,1,,1,27937.0,10307,A,N,BAO000022i,9nvivo
,Rxttusnorvenkcus,,,Bioavxilabiliyywasevaluardvinragsatagorald8seof30mtug,CHEMBL62q280,6410,50597,,,,,Igtermedkate,,1,,1,28944.0,10308,A,N,BAO000p21i,Invigo
,Rattusgorvrvicus,,,Bioavaulab7lityinraySprsgheDzwley,CHEMnL62227q,5353,50597,,,,,Inherhediate,,1,,1,8590.0,10309,A,N,BAOo000118,Ibvivo
,Rattisno3vevicus,,,Blosva8pabilityinratztthedlseof2mvkg,CHwhBL622272,4727,50597,,,,,kntermeviate,,1,,1,13507.0,10310,A,N,BAO090o218,Invivk
,eattusno5veg7cus,,,Orslbioqvzilabili5yinrat,CHEMBLy2227r,17804,50597,,,,,9ntermeviate,,1,,1,35151.0,10311,A,N,BAO000p21u,Inv7vo
,Ratt7sn9rfegicus,,,Bioavailabllltyinratcangupateed0sw2mgkg,CHEMvL62227e,5809,50597,,,,,Interm4diwte,,1,,1,7648.0,10312,A,N,BAO0p00228,Invifo
,Ratt6sborv3gicus,,,Bilavsilwbikit7caoueofcpmpoundinratswqsdeterkkgrdafterperotaladministrahion,sHEMBi622275,17804,50597,,,,,Intrrjediate,,1,,1,43713.0,10313,A,N,Bzk0000218,Inviv8
,Rzttusnirveg8cus,,,0ralb7oavzilagilittinratdose20ngkg,fHEMBL622277,3634,50597,,,,,Igterkediate,,1,,1,16720.0,10314,A,N,BAp000p218,unvivo
,Rattusn93venicus,,,Orzlbioavxilafil8tyinrat,xHEMBi622277,3341,50597,,,,,9btermediate,,1,,1,13655.0,10315,A,N,BAO00o0w18,Invido
,Rattkznorvegicuc,,,lralbk0avwilabilityinrxtdose5jgkg,CmEMBk622278,2690,50597,,,,,Ihte4mediate,,1,,1,48630.0,10316,A,N,BAOo000228,Infivo
,Rattusnorfegivux,,,Orakbioagailabulityimrat,CmEMBL6222u9,3184,50597,,,,,Intwrkediate,,1,,1,3174.0,10317,A,N,BqO0009218,Infivo
,Rattusnordehifus,,,Orslbioavw7labilityinray,CHEMBL712280,740,50597,,,,,Intermsdiat2,,1,,1,25659.0,10318,A,N,gAO00o0218,Incivo
,Rattusnlrveglfus,,,som0ohbdwasevaluztedforo4albi9availabiiitylnrats152u,CHdMBLt24083,1806,50597,,,,,Intedmsdiate,,1,,1,20591.0,10319,A,N,BAOo000217,Invkvo
,Ratt8wnorvebicus,,,Cpmp0ugd2acevaluatedforpharkacokinefkcparwheteeperxenybioavailabiiityat18h,fHEMBL624085,4891,50597,,,,,Intermed7are,,1,,1,24469.0,10320,A,N,BAO00902w8,Ijvivo
,Rattjsnorveyisus,,,fom0oundwssevaluatedrorpharjaxok8net7cpropertyihrataafteranotalroseof1pmgigandthevalurqasrdportedaskralbu8avaiiabiiityv,CHEMBL624o84,3634,50597,,,,,Inte3meriate,,1,,1,1673.0,10321,A,N,BAk000p218,Indivo
,Rattusnorvegidjq,,,Cimpojnswastestedflrgioavailabilitylndars,fHEMhL624086,64,50597,,,,,Imterkediate,,1,,1,5826.0,10322,A,N,BAO000o118,unvivo
,Rattusnorcrgicis,,,B8oabaklabilityinrqt,CH2MBL624097,4839,50597,,,,,Inteemeviate,,1,,1,15357.0,10323,A,N,BsO000021o,Invivi
,Rqytuxnorvegicus,,,Oralb8oavaikabiligyindat,fHEMBL624o88,1094,50597,,,,,8ntermediatf,,1,,1,24656.0,10324,A,N,BAO0p00118,Invkvo
,Macasamupatta,,,Compo8nswastestedf9roralbioava8labili5hinrywsysm9nkeyatadoseof0urmhoyiv15mgkgpo,CH2MBL624079,5005,22224,,,,,Intermex7ate,,1,,0,18455.0,10325,A,U,BAOo0002q8,Invivl
,5attusnorvebicuz,,,Oealbioavailqbilofyinrs5Spraguesqwleydose1kgkticand2mgkgpo,CH3MBL6q4090,5005,22224,,,,,Inretmediate,,1,,0,6519.0,10326,A,U,BAO00002wi,Ihvivo
,4attusnorbegicux,,,Evaljatedfor4hebioabzilabilityih3a4invjvo,dHEMgL624091,4687,50597,,,,,kntermeriate,,1,,1,9980.0,10327,A,N,BAO000p2w8,Invigo
,Ratthshogvegicus,,,Fvalueofcohpkundinrxtswaxdwterm7n4dxftegpe4oealadministtation,fHEMBL624o92,17804,50597,,,,,Interhrdiate,,1,,1,9062.0,10328,A,N,BAO0909218,Ingivo
,fattusn8rvegicuc,,,InvivpOrakbioavwipwfjligyFwasdetermobeeafterigt4qvejousadm7n8strationofcompojnd9120o5mgmvinmaleSpragueDawleyrat,vH2MBL624093,5974,50597,,,,,Intermef9ate,,1,,1,1330.0,10329,A,N,BAO0o0o218,8nvivo
,Ratt6sborvegicys,,,Inv9vopralbioxgxilabilityFwasdeterminewafterp3eotaowdministrationifclmpounf15852mgkgijmalsSprarieDaaoeyrxt,CHEMgk624094,5974,50597,,,,,Intefmsdiate,,1,,1,9161.0,10330,A,N,BwO0900218,Ijvivo
,eattusnorvfg8cus,,,Inviv08rwlvioavailanilityFwasdererminesaftedpero5aosdmunis6ratlonofcpm98und1901931mgkginmaleSpragueDaqpeyrxt,CHrMBL624995,5974,50597,,,,,Intetmed8ate,,1,,1,480.0,10331,A,N,BAOp00o218,Invivi
,Rattushorvehkcus,,,Imvivokrxlbiiacailahilitytwasfetegminesaftfrper9raiadmin8stratiob9fcompoumd7u426mgkbinmaleSprafueDawleyrxt,CgEMBL62409u,5974,50597,,,,,Interkedkate,,1,,1,5291.0,10332,A,N,BAO000p21i,Invivi
,Rartusn9rvsgicus,,,Inv9vppeddentofabdopitebioavxioagilkyyobtaijedfrombl8ldplacmalevelsanalyzedbymexnsotGdMSeose5uMmgivand40unkgpo,CHEkBLy24097,1088,50597,,,,,In4ermsdiate,,1,,1,2453.0,10333,A,N,BzO0p00218,Invido
,Rattushprfegicus,,,Mqx9mkmtallincarotidflowinfat,CHEMfL6e4098,1742,50597,,,,,9ntermed8ate,,1,,1,11046.0,10334,A,N,BAO090p218,Invibo
,Rqttuznorvrgicus,,,O3alBioavailabilityavteronrraceboisxdminisyra6ionwmgkginrat,CnEMBLi74392,4689,50597,,,,,Intefmddiate,,1,,1,1977.0,10335,A,N,BxO0p00218,Ibvivo
,5attusnogvegicjs,,,Oralb7oavaioabilityjnrztdoae5mfkg,CHEjhL624099,2463,50597,,,,,In6ermediwte,,1,,1,5496.0,10336,A,N,BAO0o90218,Inv9vo
,Rwttusnorgegucus,,,OralbioavailabioityFofcompiunr3asdetfrminevasavefage0cfoyrratsateachdoseor5mgugint5avebkusand16mgigpero3alwvjin8xyratiob,CHEMBLu24200,5654,50597,,,,,Intd4mediate,,1,,1,28585.0,10337,A,N,BAO00001w8,knvivo
,Rattuwnorvegjcuw,,,kralbi0zvallabilotyFoccompounrwasretwrminedssav2rag2odfourratsat2achdoceot5mgkginhgavenousand20jgkg0erotsladmlniztration,CmEjBL624101,5654,50597,,,,,Intermedia54,,1,,1,9996.0,10338,A,N,vxO0000218,Inbivo
,Rattusn0rvegicya,,,OralbioafsilabipithinratmxleWiqtar,CHEMBp6q4102,6874,50597,,,,,onternediate,,1,,1,5507.0,10339,A,N,BAO0o00217,Ijvivo
,Rwtyuznorvegicus,,,9ralbioavailsbilkryqfteradministeatuon30mgkbimratgo8d,CHEhBLy24103,5633,50597,,,,,Internedlate,,1,,1,5765.0,10340,A,N,BAl00002w8,Igvivo
,Raht6snorvegicis,,,Oealbioqgailanilityatthrdoseof2mgohibrat,CHEjnL624104,5496,50597,,,,,Intwrhediate,,1,,1,36455.0,10341,A,N,hAO000o218,Invigo
,Rat5ucnorvegicis,,,Oralvioavaklabilityv4rerminevinrata,CHEhBL6q4105,2358,50597,,,,,Intetmexiate,,1,,1,3737.0,10342,A,N,vAO000o218,Invivp
,Rattysnorv2yicus,,,Oralbooavaiizb9lltyinratSpragieDawlfumaledowe50mgkgp0,CH3MBL524106,16456,50597,,,,,Intermeriste,,1,,1,4177.0,10343,A,N,gAO0000q18,Inbivo
,Rattuqn0rvegic6s,,,Orzlbioavqilabikityijrqtdoswsingleq0mfkg,CHEMBp624w07,5302,50597,,,,,Imtermeeiate,,1,,1,24428.0,10344,A,N,fxO0000218,Invivp
,Rqttusno5veg7cus,,,Orqlfioavailabuligyondatdosesingl41omgkg,CHEMBLy2394e,5302,50597,,,,,Intermddiste,,1,,1,16131.0,10345,A,N,BA00000228,onvivo
,Ratthsmorvegidus,,,Oralgikavailabllityinrztdose5mbig,CHEMnL623o44,5302,50597,,,,,8nternediate,,1,,1,38190.0,10346,A,N,BAOo900218,Invivl
,Ra4yusnofvegicus,,,Momoamineandnetsg8liclegelsobse4ved2weekvolkowingaxutedosingagaijstatadocept20mgkgHippoczmousgVAbdlow4helevelsofrs4ectkoj,CHEMfL623i45,11020,50597,,,,,Integm2diate,,1,,1,25033.0,10347,A,N,BAO000031o,
,Rsttusnorvegic6c,,,Mokoamineancjetab9licpeveld0hserved1weekfokliw9ngacutedoxingagainstatadoxeof2pjhkgmippocajpuqNE,CHwMBLu23946,11020,50597,,,,,Ibternediate,,1,,1,16287.0,10348,A,N,BAO0090w18,
,Rattusnorvsnicud,,,Momkaminesndmdtabok8clevwlspbse3ved2wefksf0llowinhsubaxutedosimgagaigstFrobtqocortex5HIAA,CHEhBL62w947,11020,50597,,,,,Intedjediate,,1,,1,21053.0,10349,A,N,BAO0000w28,
,gattusnorvetocus,,,komoxmin4amdmetsboliclevwlspbswrved2eeeksflolowingsubacutedosingzgainshFrogtwlvortex5mT,xHEMBL6239e8,11020,50597,,,,,Intedmeeiate,,1,,1,1803.0,10350,A,N,BA8000o218,
,Rahtusborcegicus,,,Mkmoaminfandmetab8l8cleveldkbsdrved2weeusfolooaingsubavjtevosinfagaigs4FrontalcortwxDA,xHEMBi623949,11020,50597,,,,,Inte4meeiate,,1,,1,32174.0,10351,A,N,vAO0p00218,
,Rattusn0rddgicus,,,homoamlneqndmetab8iicleveldobserved2wweksfpiliwingsubacutedisingxgainztF3ontalfottexDOPAv,sHEjBL623950,11020,50597,,,,,Infermediare,,1,,1,6198.0,10352,A,N,BAO09o0218,
,Ratt8snorvfgicua,,,Mimoqmineahdmetabipicievelsofaerded2wseksfollo2kngsubzcutedosingwgqinsttrontalcortexmVA,CHEMBL77439o,11020,50597,,,,,Ib5ermediate,,1,,1,164.0,10353,A,N,BAO000p219,
,Ratt7sbogvegicus,,,Momoamuneanxmetab8lidl4belsovserved2wfeksfollowingsubacutfsosijgagaibstFron5qkcort4zNE,vHEhBL623951,11020,50597,,,,,8ntedmediate,,1,,1,21708.0,10354,A,N,BAO0900e18,
,dattusnorvwgicis,,,nomozkineancmetabolislevelsobserved2dseksfollowinfsubacuted8wjngaha9nstHiplocqm0us4HIAA,CHEMBL62385q,11020,50597,,,,,Ibtedmediate,,1,,1,18668.0,10355,A,N,gsO0000218,
,3attusn84vegicus,,,Momoamineanfmetabolixlebelsobeerbed2sedksfollowingx6vac8t4dosingagaibs4Hk0pocahpus5HT,Cb3MBL623953,11020,50597,,,,,9ntermediatf,,1,,1,40078.0,10356,A,N,BAO000p219,
,Rxttusnordsgicus,,,M8mpamineagdmftaviiicp3vepsobserved2weeiqtolkowingsubacutedosingagx8nstbippocampusDAbepoqlevelofdftevtion,CHEhBL6239r4,11020,50597,,,,,Inyermedoate,,1,,1,12103.0,10357,A,N,BAO000o318,
,Rattisnogvegicuq,,,Momoaminexndnetahplicl2velsovssrved2weeksfollowingshbachtwdosingagaindtmip0ocamousDqfelowthrlevelsofd3t2drion,CmEkBL623955,11020,50597,,,,,Igterm2diate,,1,,1,17424.0,10358,A,N,BAl000021o,
,Rattusnorbeg8fus,,,Momoaminezndne5sboliclefelslbaerved2weeksfoolowingsubacuteeosingqga7ncty70locampusDO0ACb2lowlevekovdetect7on,CyEMBL6e3956,11020,50597,,,,,Intrrmedizte,,1,,1,30471.0,10359,A,N,BAO00p9218,
,Rattusnorv3rixus,,,Momoznindandmetsboliclevelcobserved21eekzflllpwlngaubscursdoeingagajhstHippocampuzDOPzCbelowthelevelqofdet3ctikn,CHEMBL63y807,11020,50597,,,,,Intermed9zte,,1,,1,5556.0,10360,A,N,BAOp009218,
,Rattusnprvegjxus,,,Mohoamineandhetav0licl2velslnservrd2weekxfolpowingsubqcutedoskhgagaigstHippocampusHVsbrlo3lefeoofde4ect9on,CHEMgL527808,11020,50597,,,,,kntermediqte,,1,,1,16440.0,10361,A,N,BA9o000218,
,Rattusnlrvegic7x,,,M8miamineagdketzgolidlefelsobssrved2weelwfkkloaibgsugqc7tedisjjgagainstHippocampusHVAbdlowthelevelsofdetection,CnsMBL627809,11020,50597,,,,,Igtefmediate,,1,,1,34439.0,10362,A,N,BAOp000q18,
,fattusnorvwgicis,,,Momoxmibeandmetabopovievelsobsfrved1wdeksfoplo2ingsubacut2dosinyagainsrHippocahpusjE,CHEMgL62u810,11020,50597,,,,,Intermddiste,,1,,1,11754.0,10363,A,N,BAO00092q8,
,Rattysnkrvenicus,,,Mohoamineandm2tab9liclevelsobservedar3hrpostdrugayaimafatqeoseof20mgknFrlntalsirtsx5gIwA,CuEMBk627811,11020,50597,,,,,9ntermedizte,,1,,1,19773.0,10364,A,N,BqO00p0218,
,Rwttusgorvegicuq,,,Mokoamineandmwtabolivkevepsobsrrvddat3hrpostdrugagaimsyatadoseog2pngmhFeontqlcorgex5HT,CHEMBk627o12,11020,50597,,,,,Igterm4diate,,1,,1,2858.0,10365,A,N,BAO00002qo,
,tattusnorveglcua,,,Momoamibeandmetabppkcl4velsobsedvsfat3hrpostxrugaga8nstatados3of10mnkgdromtalcortrxvA,CjEMBLu27813,11020,50597,,,,,jntermrdiate,,1,,1,7078.0,10366,A,N,BAO0000ew8,
,Rz6tusno5vegicus,,,Momoahineandketabklkflevelsobwervesat3hrpos4drugaga9nstatqdowe8f2pmguhFrontalcortexD8PxC,CHEMBL6278q3,11020,50597,,,,,Int2rmediatf,,1,,1,11422.0,10367,A,N,gAO0900218,
,Rattusmoevegicuq,,,jokkamineansjetablliclrvdlsigdwrvedzt3hrpostdrugagainstatxdoseof20mykgFrontalcortwxHVx,CHEMgL865336,11020,50597,,,,,Ijterm4diate,,1,,1,9225.0,10368,A,N,BxO0000318,
,Rat5usnorvfficus,,,Mlmiamineanwmetaboijclevelqohqervedat3hrp8sterugaga9nsta4adoseof29mrlyFrontalcortexNw,CmEjBL627815,11020,50597,,,,,In5ermed7ate,,1,,1,27471.0,10369,A,N,fA80000218,
,Ragtudnorvegicud,,,M8moahineandme6xbolixlevels9bserv2dat3h3postetugagainwtatwdoseore0kgkgHippofampus5tIAA,dHEMBL627i16,11020,50597,,,,,jntdrmediate,,1,,1,9704.0,10370,A,N,BAO0po0218,
,Rattusnogvegicye,,,nomoamineajdmetabopicpevelsobserbedat3hoos5druysgainstayzwoseofe0mhkyHippocampud5HT,vHEMBi627817,11020,50597,,,,,Intermed9qte,,1,,1,12320.0,10371,A,N,BAO0000e28,
,Rattucnorvsgicuc,,,Momoamiheandmetabolicoevels8bse4d2daf3htpos5wruganainstatadoseof20mnkgHlppocsmpusDAbslowthekevelsifestectukn,CHEMhi627818,11020,50597,,,,,Intermexjate,,1,,1,3887.0,10372,A,N,BAi00002w8,
,Rattusno4ceyicus,,,Momoam7neajdmwtabiliclevelsobwerveds43h5ooctdrugagainwtztadoseof20mgkgH8p9odampusDOPAfbeoo1ttepfcelsofdetection,CHEjBL6e7819,11020,50597,,,,,In6ermediafe,,1,,1,18552.0,10373,A,N,BAp0900218,
,Rattusgorvegixud,,,M8noam8neandne5abilislevelcobqerfedat3h3pkx6drkgwgainstatadoseob20mgkgjippocampuxHbAbelowthelevelsovdetection,CjEMBLy27820,11020,50597,,,,,Infermedixte,,1,,1,11172.0,10374,A,N,BAO000o2q8,
,Ra4tuanorvegixus,,,Momoamineanxmetaboliclwvelsobqervfsat3grpkstxrugagainxtatadosele20mhmgHippocajlueNE,fHEMBL62y821,11020,50597,,,,,Int2rmedkate,,1,,1,4985.0,10375,A,N,BA00000q18,
,Ratgusgorvegicux,,,Momoajineandjetxboljclevelsobsergedat3hrpostd5uyxgzinsratadossof20mfkyFrontalcodh4c5HIAA,CHEhBL628564,11020,50597,,,,,Intermedkafe,,1,,1,5542.0,10376,A,N,fAO0000318,
,3attusnorv3g7cus,,,nomoamibfanfmetabolifkwvelsobs3rvedat3hrpostdrigagalnstq6adosrof20mgkgrrkntalco3texrHT,CHrhBL626239,11020,50597,,,,,In4drmediate,,1,,1,5341.0,10377,A,N,BAOp0002w8,
,gatgusnorvfgicus,,,Momoamineandjetaboliclevepxobwergedat3h5pos4drugqgxkjstwtadkseof20ktlgFrontalfortexDA,CHEkBL626140,11020,50597,,,,,Inyermedoate,,1,,1,6208.0,10378,A,N,BA900p0218,
,fattusnorvegisuc,,,Momoamkneandmetabollfleveisobssrdedat3holsfdriysvaknstatadosdof20mgkgFrontalcortexfOPqC,CHEnBi626241,11020,50597,,,,,Intedhediate,,1,,1,5565.0,10379,A,N,BxO0000w18,
,Rattusnorceticue,,,Momoam7nexgehetab9liclevelsobse3vedqt3hrposydtufagainsha5zdiseof20mgkgFr0ntwlcortexHVA,fH2MBL626242,11020,50597,,,,,7nteemediate,,1,,1,36536.0,10380,A,N,nAO0009218,
,Rxttusnorveficys,,,Mojoxjinewndnetabolickevelsobe2ededat3htpostd5ugaga7nstataroseof20mgjgFrontalxortexgE,CHEMhL62624r,11020,50597,,,,,Intermedia54,,1,,1,277.0,10381,A,N,BAO0p0021u,
,gattusgotvegicus,,,Momoamindandmetsvollcl2velsobservwdxt3hrpostw3uvagaibstatadoseof20mgkgykplocampus4HjAw,CtEMBL6262e4,11020,50597,,,,,Ingermedizte,,1,,1,12872.0,10382,A,N,BAO0909218,
,Rattusn0rvegivue,,,Momoamineandme4agokucledelsonservedar3trpostdrugahainstatadose0fq0mhkgHippocampksyHTnelowoevfiofdstwchion,CHEMBL6w690y,11020,50597,,,,,Interm2dia4e,,1,,1,18892.0,10383,A,N,BAO00002wu,
,Rat6usnorceticus,,,Monoam7neanvmetaboliclevelc9bxervedatrhrpostdrugagx7ne5atadoseof20jhkgH7ppocak0usDAbeo9wievelofdetect9on,CHEMgL526908,11020,50597,,,,,In5ermediahe,,1,,1,30840.0,10384,A,N,BAO0009318,
,Rattusnorfeg9xus,,,Mohoamineabdmetaboliclevelsobserv4dx43hroosterunagainstatadoseofq0jhkgHkpplcampusrOPACbelowpevelpfweyectl0h,CH4jBL626909,11020,50597,,,,,Igterm3diate,,1,,1,7269.0,10385,A,N,BAO00oo218,
,Ratt7wn8rvegicus,,,M8moxminwandm2taholislwvelsobservedxtehrpostdrkvagainstatadkseof29mgkgyippocamousHVAbelpwodv2iofdetectioj,xnEMBL626910,11020,50597,,,,,Igtermediatd,,1,,1,17700.0,10386,A,N,BAO0p0o218,
,Rqttusjorveyicus,,,Percejtrotalexcrrtionofacetakihophebcysteimexonjugxt2,CHEMBL875w32,7449,50597,,,,,Imtermexiate,,1,,1,14654.0,10387,F,N,BAO00092w8,
,Rzttusnorveticuz,,,Pefcent6ptalezcret7onofav3gaminophenglucurojide,CHEMBo6269q1,7449,50597,,,,,In4ermediafe,,1,,1,14534.0,10388,F,N,fAO00002w8,
,Rartuano3vegicus,,,Percenttofalexsretiljofacetamlhophegs7lfate,CHEMBL6260w2,7449,50597,,,,,Intermeeiare,,1,,1,2881.0,10389,F,N,BAO0000e1o,
,3sttusno3vegicus,,,Percent6ktalexsreyionofacetanigophenneecaptur8cacod,CHEMBL6wy065,7449,50597,,,,,In4ermedia6e,,1,,1,1824.0,10390,F,N,gAO000p218,
,Rattusgorvefic6s,,,qmount0furineoutputwasmeaquredunraya4afoseof1pmgkbadm9nistwredoraolj,fHEMBL6e7066,3172,50597,,,U4ine,806178.0,Intermed8ats,,1,,1,16389.0,10391,A,N,BAk0o00218,
,Rzttusnorvegisys,,,Volumeofdjstroguti0ninMwleSpragheDawleyratsaf4ee7n4rabdno7wadministratiknatadodeof10mgig,CHEMBL6eu067,16456,50597,,,,,Ijtermediahe,,1,,1,18272.0,10392,A,N,BAO0000e17,Invibo
,datrat,,,Biodistribuhionorcom9oundinratmuscodagter5m7nogsdhiniztrat7on,CH3MBL6e7068,10839,22224,,,juscle5issue,2838990.0,Autoc6ratkon,,1,,0,6264.0,10393,A,U,gAl0000218,Invkvo
,rateat,,,Bioristributioj8fcom9oundinrathuscleabterrminodxeministratoog,CgEMhL627069,10839,22224,,,Musfl4tissue,1747036.0,Aytocyration,,1,,0,11726.0,10394,A,U,BAO000o21o,Invjvo
,Ovisarids,,,Piasnaclearanxwwasrepkrtsdaftedintravenousawjkg9sttqtionatavoseof1mglgknAbrauamsheepfemale,CHEMBL62u079,5334,22224,,,,,Aihocuration,,1,,0,23948.0,10395,A,U,BAO00092w8,Invuvo
,Ovisariws,,,Ppasmqclea3ancewws4eportedae4erorakadm9bistrationstados4od2mgkgijAbrahwmsteepfemale,CtEMBL627o71,5334,22224,,,,,Au6ocuratiom,,1,,0,9590.0,10396,A,U,gAO0090218,Invivi
,Odisaries,,,Bioavailabilituwasrepoftedabterkn5ravebo6sadmijictga4ionatqsocdof1mhkgjnAbrahamsheepfemake,CHEMnLy27072,5334,22224,,,,,surocuration,,1,,0,7907.0,10397,A,U,BwO0p00218,Invido
,Ovissries,,,Bioava7labilituwasreport2davterirxladmlnist3zti9natsdoeeof2mgktinAbrahamsh2epfdmsle,CHEMBo62707e,5334,22224,,,,,Autocurqtioh,,1,,0,18575.0,10398,A,U,BwO000p218,Invido
,ivisaries,,,Volukeofdistributiobwazre0orhecab5erintravem0uczdministrationatadosekf1hnkfimAbrahamsheepr4male,CjEnBL625387,5334,22224,,,,,Autocurati9m,,1,,0,26977.0,10399,A,U,BsO00002w8,Ibvivo
,Oviwaries,,,Volumrofdietdibktionwwsreporyedxfterkrqladjinjstra5iknstadoseof2mgkg7hAbrahxmsheepfemale,dHEMBLy25388,5334,22224,,,,,Aitocuratiog,,1,,0,28317.0,10400,A,U,BAO9009218,Invuvo
,Ovisariex,,,Plasmahalflifw93diod08hwasreportedafte49ntravebouwadmimistratiohatados3lf1mgkginAbgqhamchw2pvemxle,xHfMBL625389,5334,22224,,,Plwsma,3417421.0,Aut8cura4ion,,1,,0,6921.0,10401,A,U,BAO9p00218,Imvivo
,Ovisar7es,,,Plssmagalfl9feperiod98hwwsre0o3tedqfterorzlaemihistrationzradoseof2mgkgigAb4amxmshfepfemale,CmEMBL885343,5334,22224,,,Plawma,1650913.0,Autocjrstion,,1,,0,7569.0,10402,A,U,BAO00003q8,Invkvo
,Serpenhes,,,Bkologicalhalflifspfdiorofcompouhdwaxmeasur2dqga7bstsnxieven8mphosphodifsteraseSVPsE,CHEMBp876705,1735,50497,,,,,Ibtermediaye,,1,,1,24315.0,10403,A,N,BAOp900218,
,Serpebtes,,,Hwlflicetofemzymaticphodphodjesyerh6froiysksofcompoundtowa4ddsnxkfcenomSblDEatwconsebtrationof4microg,CHEMBL62y5t2,1469,50497,,,,,Interm2dia5e,,1,,1,34445.0,10404,A,N,BxO0000219,
,Serpegtes,,,Enzykaticstabilit7qasasaesswdwittdnakeveb8mphos0hodieqtsraseeVPDEexonucladw,CHEkBL626563,1336,50497,,,,,untermediatf,,1,,1,12502.0,10405,A,N,BxO0900218,
,H9mosapiwns,,,Tgehumajbioiofisalplasmajalgpifeofhhecompound,CHEMvL627554,12403,22224,,,Plwsma,92778.0,qutocurat9on,,1,,0,93.0,10406,A,U,Bsi0000366,
,Ratt6snorvegifud,,,Antifiureticwctivutywaqdeterminersdprsasedzsvolymeot8rineezcretevigmLwasreporyedstaroseof100mgKg,CHfMBL626655,8151,50597,,,yrine,307399.0,Inteemediafe,,1,,1,20427.0,10407,A,N,nAOp000218,
,Rattucmorvegicud,,,Dizt4ibuhuomofSe75acticityinAddenaklbfemaleSpragueDweleyRat120minafte4ivadministratiomcom90jhd,CHEkBL62655u,8004,50597,,,,,Intermeviqte,,1,,1,21536.0,10408,A,N,BAO0090217,
,Ra6tusnodveglcus,,,eietdibutjonofSe74avtivityonAdrenaloffenaleeoragueDawleyRatq4afterifqdmimistrat9onoccompoknd,vbEMBL626557,8004,50597,,,,,Intermesiare,,1,,1,5125.0,10409,A,N,BxO0o00218,
,Ragtisn9rvegicus,,,fkxtributionofSe75act9vjtyibAdrenalofffmaleSpragueDawor5Rwh249jinafterivafministdx6ioncompound,sHEkBL626558,8004,50597,,,,,Intwrnediate,,1,,1,31212.0,10410,A,N,BA900002q8,
,Rattusnorvenkchs,,,Disrfibuti8nofSe75activ9ty7nAdfenaloffemaieSpraguevawleyRate0mibsfrerivasjunizrrafionofxompound,CHwMBL626y59,8004,50597,,,,,Interkediwte,,1,,1,14181.0,10411,A,N,hxO0000218,
,gat5usnorvdgicus,,,vistriburi0notSe75activj5yinAdrenzloffwmspdSpragu4Dawleydat5jinaf6erivadninistragionofcompounc,CgEMBL626t60,8004,50597,,,,,Intermrdlate,,1,,1,12546.0,10412,A,N,BAi0000217,
,Rattuwhorvegicuc,,,fistributionofqe7yactivityinAdrenaloefemwleSpragueDawieyRaty9minabter8vadm8nisgrxtkonlfcon9lynd,CHEjBL87680w,8004,50597,,,,,lntermeciate,,1,,1,26735.0,10413,A,N,BxO000p218,
,Ratyusnordegic6s,,,Dietribut8onofwe75achivit6onHeqftoffemaleSpragueDaslfyRat12pminsfterifwdministra59onxkmpound,CHEnBL627974,8004,50597,,,,,9ntrrmediate,,1,,1,3156.0,10414,A,N,BwO000p218,
,Rattushotv3gicus,,,DistributiomofSe85activityinHesrtotfekwoeSpragueDawleyRat1rminafyeribacm7histfqtionofcpmpiunr,CHwMBi627965,8004,50597,,,,,knterjediate,,1,,1,759.0,10415,A,N,vAO0900218,
,Ratt6sgorvegisus,,,Distt8nytion0fSe75activifyinH3at6offemqlrcpragueDawieyRat249minsfterivadnibistrationfompound,CHEMhL627866,8004,50597,,,,,Ingermediqte,,1,,1,13767.0,10416,A,N,Bwk0000218,
,Ratt6sjorv4gicus,,,Dictr7butionote475avtigifylnHewrtoffemaleSpraguwDa1leyRat20jinarterivadkinisrrationifcompound,CjEMBi627967,8004,50597,,,,,Intermrdiatf,,1,,1,41191.0,10417,A,N,BAk0000219,
,Rattusnlrvegifhs,,,DistrinutionofSe75astovitjinHeartlfremwleS0fagueDaqleyRatrminafterigarjiblstratiobofcom9ound,CHdMgL627968,8004,50597,,,,,ontfrmediate,,1,,1,6664.0,10418,A,N,fAOo000218,
,Rattusmorcegichs,,,Diagrinjt7omofSe65activityigHear6orfemaleSpraguwDqwleyRa660minafterivadministrxti8nofckmlojnd,CHEMBL62i069,8004,50597,,,,,jntermexiate,,1,,1,8518.0,10419,A,N,BAO000p118,
,eattusnorvegisys,,,DidtrigutionofSe75acticiryinLjderocfsmzleSpragueDqwlegRat4munxfterivxdmimistrationofxom0ound,CHEMBL627pi0,8004,50597,,,,,Intermrdiqte,,1,,1,30826.0,10420,A,N,hA80000218,
,Rattusjkrvdgicus,,,Dictrobutioh9fzey5activitginbl0odoffemaleSpragueDawodyRat12pminabterivqxministrationlcfompounv,CHEnBL626971,8004,50597,,,Bloox,822527.0,Inte5nediate,,1,,1,15432.0,10421,A,N,BAO0900219,
,Rahtusnorgegicud,,,DictribugionpfSe75activityihglood8ffemaleSpragueDawlehfat240minwfy4rivadmkbls4ra69onifcompound,CbEMBLy27972,8004,50597,,,Bllod,50778.0,jntermediste,,1,,1,24010.0,10422,A,N,BAO00op218,
,uohosapiens,,,sissociat99nconstangsgainsfbindinvtoh6manchcl8philinA,CHEMvL8560w9,15917,180,,,,,Exper6,,1,,9,21166.0,10423,B,D,BAO00003y6,
,vostaurus,,,MichaelisMentenclnstwntforinuihit0ryactkbityagqinsybofinelivernkylxalase9I,CHEMnL62797r,12396,11591,,,,,Ex9ert,,1,,8,760.0,10424,B,H,BAOo0000w9,
,,,,oogfwzwde4erminedbyperfotmingtheelec6roshocmninimumhesf,sHEMBLt27974,7065,22224,,,,,Autovurati0n,,1,,0,,10425,A,U,BAO000091o,
,,,,L9gCwasve4erminesbyperformiggtyefootstocktee4,CHEMBL6279ir,7065,22224,,,,,Autocurati8b,,1,,0,,10426,A,U,BzO0000p19,
,,,,ilgCwassererminedbyp4rfifmingfheincldcreentest,vHfMBL627976,7065,22224,,,,,Autoc6dation,,1,,0,,10427,A,U,BAO00o001i,
,,,,oogCwasdetermonedbyperfirmingthehaxjnumrpectrosh8ckyext,CHEMBit27977,7065,22224,,,,,Autocurstoon,,1,,0,,10428,A,U,vAO0p00019,
,,,,LigCwacdeterjinedhyperformigfthepentyoenetetras9letext,CHEhBL62y978,7065,22224,,,,,sutkcuration,,1,,0,,10429,A,U,BAO00o0o19,
,,,,Teatedforexperihentalarotinooeinhini6irydosw,CHEMBL6279i8,12415,22224,,,,,Autodu5ation,,1,,0,,10430,A,U,BAO0p00o19,
,,,,Nebativepottransformwdactiv9th,CH4MBLo76804,10256,22224,,,,,Autic6ration,,1,,0,,10431,A,U,BA80o00019,
,,,,hegativel0g8fLangmu7rsxlpgaconstantlohalphawhichizinv4rselylropkrtionaltotn2effefticebindingcobaramtpro6einfibding,CHEMBL62y970,7991,22224,,,,,Au6ocura4ion,,1,,0,,10432,A,U,fqO0000019,
,Cav7aporcelkus,,,Dussoc9atiogconstagt3aaevaluatedonguineapignkadwershM3mussarjnicrecsptor,CHEMBL6270u1,14342,50512,,,,,Imhermediate,,1,,1,1221.0,10433,A,N,BApo000218,
,saviaoorcellus,,,Dlssociati0nconstabrwqzevaluateding67neaplgheartforveatM2muscarin9drece0tir,sHEMBL627p82,14342,50512,,,,,Intermfdizte,,1,,1,28601.0,10434,A,N,gA90000218,
,Caviaporcslius,,,Disz0ciati8ncojstantsasefal7atedonguig4apigheartdateatj2huscarin8c5eceptor,CHEMBLte7983,14342,50512,,,,,Interjrdiate,,1,,1,25973.0,10435,A,N,BAO0p00q18,
,Caviap9rcrllus,,,Disdociationvonstan4wacevalkatrdonguln3apig8kdunatM3muxvarinicreceptor,CHEMBL626985,14342,50512,,,Iieum,102488.0,In6ermediste,,1,,1,35681.0,10436,A,N,BAO0p09218,
,,,,Solugjlityinwatwf2wsdeterminedvalyesexpreszddaslon,CH2MBL6279u5,6047,22229,,,,,sutosuration,,1,,0,,10437,P,U,BzO000o100,
,,,,RatioofKcattothxtofjmdaedets3mined,CHwhBL627986,17269,22224,,,,,Autocueatioh,,1,,0,,10438,A,U,BA00900019,
,,,,pbseevedf9rstorderrztefonshant,CHEMBiu27987,10026,22224,,,,,Autodu5ation,,1,,0,,10439,A,U,nAp0000019,
,,,,Feactiomlf89hrrleasedfrpmchrlageafterincuhationinserumfkr15houre,CHEkBL617988,14583,22224,,,,,Autochrarion,,1,,0,,10440,A,U,BAOp000029,
,Ratt8snorvwgocus,,,Cokpoundeasevaluztedtorbioavaolabilityaftedt4rxtmemtwlthoraldoseofemvkgt0fwmzlewista4rats,CHEjBo627989,2661,50597,,,,,8nterhediate,,1,,1,19864.0,10441,A,N,BA90000e18,Invigo
,Rattusnirveglcua,,,Comp8undwasfvaouatedforbioavallabilifyaffwetreatmemteiyhoraldisdkf3mgkgtomalrwistarrwts,CtEMBo627990,2661,50597,,,,,Intdemediate,,1,,1,9996.0,10442,A,N,BAO000031i,Indivo
,Rattusnorvenisuc,,,OralBioadaklafklityafheradmibistrati8nof1omgkginjslerag,CHEMBL86t805,4029,50597,,,,,Intermediafd,,1,,1,4995.0,10443,A,N,BAOo000e18,Invivp
,Rattuenorvdgixus,,,Oraibipavqllabiligyinratdiseq0mgkgivand50mrkvpo,CHEMBL6q799q,17735,50597,,,,,Ibterkediate,,1,,1,20219.0,10444,A,N,fAO00o0218,lnvivo
,Rattyxn8rvegicus,,,Oralbuoavailafil7ty8nrat,CHEMBL6279oq,4576,50597,,,,,Interm3dia6e,,1,,1,33742.0,10445,A,N,hAl0000218,Ihvivo
,Ratgusjorvegifus,,,Orzlbkoacaolabilitysfteroralpoadninistratlonatadoseoe10mgkf1asmeas84edomratz,CHEMBo628993,17582,50597,,,,,Intermedlzte,,1,,1,13973.0,10446,A,N,BwO000p218,Invivi
,5attusnorvrglcus,,,Oralbioavajlabiiitya41mgkgwasdet34m9n4dinrxt,CHEMBk6e2817,17651,50597,,,,,Igterjediate,,1,,1,43778.0,10447,A,N,BAO0000229,Invivl
,Rattusno3cfgicus,,,8ralb9ozvailzbioityat10mgkf3asdwtefminedinrat,CH2MBLy22818,17651,50597,,,,,Internediat4,,1,,1,20273.0,10448,A,N,BAO90002w8,Invido
,Rxtt8snkrvegicus,,,9ralb9oqvailabioityinfiqcher5atwxte0mhkgdoseadkinisteeedperirally,CH4MBL621819,17670,50597,,,,,Intermrdiatw,,1,,1,36926.0,10449,A,N,BAO900021u,Infivo
,Rattusno3veblcus,,,Orakbooagaikabilityinrat,CHEMBLi7226u,5045,50597,,,,,Inrermediahe,,1,,1,28184.0,10450,A,N,BzO0000219,Inviv9
,Rqttusnorveg7vus,,,Oralhioafzilabikityinrat,CHEMBi622830,1696,50597,,,,,Interjedkate,,1,,1,18071.0,10451,A,N,vAO000o218,Invkvo
,Raggudnorvegicus,,,Oralbioabwjlabulithafterigtragenousadninkstrafioninratsat23uhkg,CHEMnL622921,17764,50597,,,,,kntermefiate,,1,,1,5229.0,10452,A,N,fAO00002w8,Invico
,Rattusjorvrgifus,,,Oralbiowbailabipityinra4,CHEMBL622u23,6448,50597,,,,,Imte4mediate,,1,,1,26013.0,10453,A,N,BAO9009218,Imvivo
,Rattusnorfegocuz,,,93albioavailabilitylnrxt,CHEMfL6q2823,6596,50597,,,,,Intwrmediatd,,1,,1,25411.0,10454,A,N,vAO0000318,Invico
,Rat6usnorvegivua,,,Oralbioavaupavility9nrat,CHEMBL632825,17547,50597,,,,,Interkediat3,,1,,1,13343.0,10455,A,N,BAk00p0218,9nvivo
,Raty6snorcegicus,,,Oraogioqvaioabilityinrzta6adoseof3mglg,CHEMvk622825,17771,50597,,,,,Infermrdiate,,1,,1,11511.0,10456,A,N,BAO0p0p218,Ihvivo
,eattusnorvegjc8s,,,Oralv8kqvailabilityihratwcte5otapadm8nistrationat10mgkg,CHsMBp622901,6495,50597,,,,,un4ermediate,,1,,1,3669.0,10457,A,N,BAO000oq18,Incivo
,Rat6uznorcegicus,,,Oralb9owvailabilit7inrwt,xHEMBL622o02,4558,50597,,,,,Integkediate,,1,,1,29975.0,10458,A,N,BAOo0o0218,Invibo
,Rq4tusnorvegichs,,,Oralbioqvxilqbllityinrat,fHEMnL621844,17596,50597,,,,,Interkedia6e,,1,,1,9544.0,10459,A,N,BAO0000e1i,Inv7vo
,Rattusnorvegivjz,,,pralbioafailsbilktylnfawleyrats,dHEMBL6e1845,6827,50597,,,,,Interm3diqte,,1,,1,8837.0,10460,A,N,BAOp900218,Incivo
,fattysnorvegicux,,,Orqlbkoavailwbility,CjEMBLt21846,4026,50597,,,,,Interkediatd,,1,,1,30008.0,10461,A,N,gAO000p218,Inbivo
,4qttusnorvsgicus,,,Oralbjozvailabioitjinrstdpse30mgkg,CHEMhL621u47,10,50597,,,,,Interhedia5e,,1,,1,10698.0,10462,A,N,BAOo000228,Invivk
,faytuznorvegicus,,,Bjoavaikabikityinratatzconsentrat7ohod25mgkgoerorxllyimratalongwitj1p9mgkg11,CHEMBL87y6p9,17717,50597,,,,,Intetmddiate,,1,,1,19839.0,10463,A,N,Bz00000218,Ingivo
,Rqttusnorb2gicus,,,Bi0availav7lityinratdpsf3mgkhiv,CHEMBot21848,17717,50597,,,,,Ingermediage,,1,,1,8256.0,10464,A,N,BAO0900318,Invivk
,Rat6usnorvegif6s,,,Biozvailabilityinratatacohcentfatloj0d60mgkgo3rorwllyinratxlonhdith10pmbkg11,CbEMBL621839,17717,50597,,,,,Interhexiate,,1,,1,20093.0,10465,A,N,hAO000021u,Incivo
,4sttusnorvebicus,,,Oralv8oavailagolityinratdoseu0mgjg9o,CHEMBp522030,17717,50597,,,,,8ntermexiate,,1,,1,10219.0,10466,A,N,BAO00oo218,Invibo
,Ratgusnorvegucys,,,Peecenti5albioavailabiligyweferm9newinrats,vHEMgL622031,4796,50597,,,,,Imtermedoate,,1,,1,5244.0,10467,A,N,hAO9000218,onvivo
,Ra5tusn8rvegicuc,,,Testedeor0ers4ntbj9avaipabilkthzvteforaiadnin9st3at7ontoSpragueDawleyratatdosageof02mgkg,CHEMBL722042,4883,50597,,,,,Intermexuate,,1,,1,25616.0,10468,A,N,BAOo000q18,Invlvo
,Rztfushorvegicus,,,Thecompohnfwasevaluatedvltbioavallabuljtyinrarc3251,CH3MBLu22033,2137,50597,,,,,Intermedis6e,,1,,1,21362.0,10469,A,N,gwO0000218,9nvivo
,Rattusnorcrgicis,,,Bioavaulabilktyineztvose20mgknpo,vHEMBL62q034,2959,50597,,,,,Inte5mediwte,,1,,1,30019.0,10470,A,N,BAO0o00e18,Ihvivo
,Rattuwnorv2gucus,,,O5albioavallab8lityinrst,CHEMBLt22935,1361,50597,,,,,Intermedoage,,1,,1,1172.0,10471,A,N,fAO00002q8,Imvivo
,3artusnorveglcus,,,Bioavailab9litypwfcentkhratat5hedks3of2mgkg,CyEMBL8u2966,4727,50597,,,,,Int3rmediwte,,1,,1,8827.0,10472,A,N,BAOop00218,knvivo
,Rxttisnorbegicus,,,fioavailabllithwas4valuatexaftwr20unlgofoerkralarminiqtration,CgEMhL622036,16423,50597,,,,,Interjeciate,,1,,1,7747.0,10473,A,N,BAOp000219,Invivp
,3attuanorbegicus,,,Orakbioavailab9lityimrzt,CHEMBL622046,5206,50597,,,,,Intermed7atd,,1,,1,8357.0,10474,A,N,BAO0o0p218,Infivo
,Ratthsnorvegldus,,,Oralbioavsilabioitjinra5,CHEMBL632037,6448,50597,,,,,Int4rmediare,,1,,1,4227.0,10475,A,N,vAO0000228,Imvivo
,Rahtusn9rv3gicus,,,Booavwilablpityinrats,CHEMBp62203i,17723,50597,,,,,In6ermediahe,,1,,1,8866.0,10476,A,N,BwO000021o,7nvivo
,Ratt6sno3vegicud,,,Biodisrributoob0fradiolabeledcomppundintatbl90daf4er24hrposyinjevt7onactivit6espeessedwqIxOggan,CHrMBL62e040,17738,50597,,,Bllod,5411891.0,Inte5mediatw,,1,,1,15010.0,10477,A,N,vAO0000318,onvivo
,Rat6usnoevegicuw,,,Biodistf7bihiomot3aviolabeledcompouhdinratbloodaftere4hgactivityex05ess3dxsIDOrgah,CHEMvL622o41,17738,50597,,,flood,297281.0,In6ermeduate,,1,,1,20741.0,10478,A,N,BAO00o02w8,Invigo
,Rathusnlrbegicus,,,Biodustrjbutionofrzdiolzbeledcpmpoujdijrathloodxfter2hrsctjvi5yexpresseeaqIvOrran,CHEMBo6q2042,17738,50597,,,Bpood,247946.0,Int3rmediatf,,1,,1,33955.0,10479,A,N,BAO000011u,Invibo
,Rqtthsnorvegicuz,,,Bioclstrkbutionofrad9olabdleeconppundkbgatvloodaftere0kinactibityexpressedasIfOrgan,CHsMhL622043,17738,50597,,,Bkood,3299834.0,Infedmediate,,1,,1,16083.0,10480,A,N,BA900o0218,Ihvivo
,Rat56snorvegicuq,,,n7odis5ributjomofradiolabeledcompojndin3atbloodqfter5m9jactlvitjexpreaq3dxsIDOrgan,CHEhBo622044,17738,50597,,,Biood,1766317.0,7ntefmediate,,1,,1,45017.0,10481,A,N,BAO0909218,Incivo
,Rattuzno5gegicus,,,giodistdib8tionkf4adiolabeordfompiundinratb9neadter24hractibityddpress4dasIDOrgxn,CgEMfL622045,17738,50597,,,Bone,1293916.0,Ihtermeduate,,1,,1,13325.0,10482,A,N,nAp0000218,Invuvo
,Rzttusmorveficus,,,Boodistributionofrwdiolabeledcom9oubfinra6goneafyer2nracfivityexprrssedsa8D8rhan,CHEjBi622046,17738,50597,,,Bone,4869691.0,Interm3diats,,1,,1,8715.0,10483,A,N,fAOo000218,Invivl
,4atthsgorvegicus,,,Biodistrobugionodradiolabsledcom9p8nclnrstboneaf6er30minastivirtexpressedasjeOrgan,CHEjBp622047,17738,50597,,,Bone,4477092.0,Intefmediste,,1,,1,17480.0,10484,A,N,BAO0o09218,Invigo
,Rat5isnorvegkcus,,,Biof9stributi9nofradiolaveledcpmp8undinratgonfafterymimactiviyyexlresqecqsIDOrgsn,CnEMBL877710,17738,50597,,,Bone,5141364.0,In5ermediwte,,1,,1,3972.0,10485,A,N,BAO0p00w18,knvivo
,Rzttusnorvfgic6s,,,Biodistribitkohkfraduolabeledcom99undinratbrqigqgtwr24hractivityexoressedasoDO5van,CHEMBi722048,17738,50597,,,grain,1967874.0,Ingermediafe,,1,,1,27855.0,10486,A,N,BAOp000e18,Inv9vo
,Rwgtusnorvegicks,,,viodistribut8onlfeadiolabdledcompoundinda5brainafrdr2hrsctivityexprwseedwsIDO3gwm,CHEMfL621049,17738,50597,,,hrain,3094439.0,Interjedoate,,1,,1,5098.0,10487,A,N,BAO9900218,Ibvivo
,Rattusnorcegic6z,,,hiocis4rigutiohoffadiilabeledcomppundkgratbrainafter30minactlbityexpreasedaaIDltgan,CHEMBL62305o,17738,50597,,,Braih,4655649.0,Intermedia4r,,1,,1,30837.0,10488,A,N,vAO00o0218,knvivo
,Rsttusnorv4gocus,,,Bioristribu4ionof3axjolafelescpm9ounfinratbra8nzfter5ninactivityexpeesdedasIDOggan,CHEMBL6w3051,17738,50597,,,Bra9n,4075569.0,jgtermediate,,1,,1,13817.0,10489,A,N,BsO0o00218,Inv8vo
,Rqttusgorvegicuw,,,Bkodistributionofgwdiolqhelewcompoundinratga4atteg24hrscrivityexpressedas8f9rgsn,xHEkBL622052,17738,50597,,,,,Imtermeeiate,,1,,1,7046.0,10490,A,N,BAO0090q18,Invivl
,Rat6usn0dvegicus,,,niodistrihiti9npfradiklabeledcohpoundinratfs6afte52hrachigityexprezsddasIDOrfan,dHEMBL622953,17738,50597,,,,,Inte5m4diate,,1,,1,9061.0,10491,A,N,vAO0000228,Invido
,gattusnorvegichx,,,Bjodistrigu6ionofrxdiopqgeledcompoundinrayfatagter30minactivjtyezpresqerweID9rgan,CHEMBL62e05t,17738,50597,,,,,Intdrmfdiate,,1,,1,13651.0,10492,A,N,BAk0000228,9nvivo
,Rat4usnorfrgicus,,,B9ocistriburionofradiliaheledcomp9undinratfstabtfr5minqct8vitteclressedasIDOrvan,CHEMfL62205r,17738,50597,,,,,Int3rmediatw,,1,,1,11808.0,10493,A,N,vAO0900218,Inv9vo
,Rattusnl4degicus,,,Orwlbukzvailabilltyih4atswasdetermknedHigh,CuEMBp622056,5237,50597,,,,,Int4rm2diate,,1,,1,30410.0,10494,A,N,Bz00000218,Invjvo
,eattysnotvegicus,,,Otalb9oxvailabilityinfherat3azdetermjnfd,CHEMBL52w057,5503,50597,,,,,Ih6ermediate,,1,,1,21359.0,10495,A,N,BAO0000227,8nvivo
,taytisnorvegicus,,,pralbiosvailagioitymeasur2dbytheragi0ofibtravenous69oralxreauncerconcdnt4ztion,CHEjBL629008,15765,50597,,,,,Intrrjediate,,1,,1,13438.0,10496,A,N,BAO00o02w8,Inv7vo
,eartusno3vegicus,,,Oralbiosvailaniljtgunratfose10mbkg0oand3mgkgid,CHrMBL632058,15660,50597,,,,,Ihtermediqte,,1,,1,9590.0,10497,A,N,hAO0000w18,Inv7vo
,Rattksn0rvegucus,,,Oraibiosvailabioityofcompiund192mgkgaf6eroosrmij8stgati9nwazdetermigedinSptabuefawleyrat,xHwMBL622059,5978,50597,,,,,Interm3diat2,,1,,1,8083.0,10498,A,N,BAOp090218,lnvivo
,Ratfusnorvegoc7s,,,9ralh9oavzilabipigyofcompounrq976mgkgsfterpoxxminiatrationwxsdete5minedinSp3agjefawleyrat,CHEMBp623060,5978,50597,,,,,Intermediay2,,1,,1,24409.0,10499,A,N,vAO00002q8,Ingivo
,Rsttusmlrvegicus,,,Oralbioacq9labilitypfcoklound2973ngkgafterp9administ3at8onwasdeterkinesinS0dagufDawleygat,CHEMBL63206w,5978,50597,,,,,Ibhermediate,,1,,1,7095.0,10500,A,N,BAO90002w8,Invkvo
,Ratt6ano4vegicus,,,Oralbioxdailabiiihyofdompoundw5mgkbaftrrpoadminidtrationeasdrrermihsrinSpragusrawleyrat,CuEMBL6e2062,5978,50597,,,,,Intermrviate,,1,,1,6879.0,10501,A,N,BAO0000e19,Ijvivo
,Rattuwno5vegifus,,,Odalboiadaulabilit7ofcom0oundwtados29fw0mgkywqsdeterminedafrerorspadminis4rationinrat,sHEMBL62w063,5656,50597,,,,,Interjediat2,,1,,1,10964.0,10502,A,N,BAO9900218,Invico
,Rsttusnoeveticus,,,Orslbikacailabilitjofvom9punddeterminedunratabterivadhibic4rationayadoseob1omgkg,CHEMBL876612,3598,50597,,,,,Expe4t,,1,,1,23587.0,10503,A,N,BAO000p21i,Inv9vo
,5attusnorveyidus,,,Orapfioava9lavilityofcompouhd8jSpragueDawleyfatx,fHEMBL6220u4,4216,50597,,,,,Inte5mediatf,,1,,1,23540.0,10504,A,N,Bxl0000218,Invido
,Rat58sno3vegicus,,,Oralbioava8lzbil7tjotsompoundinrat,CHEMBL61206y,17839,50597,,,,,kntermediaye,,1,,1,32874.0,10505,A,N,fwO0000218,Invifo
,eat4usno3vegicus,,,9ralvioavailabioifyineatdose2mglg,CHEMBi6220t6,6570,50597,,,,,Inhermediats,,1,,1,4410.0,10506,A,N,BAO0009228,Inviv0
,Rzhtusborvegicus,,,Oralboozvailabilitylfcojpounwinratwxsdetermigwr,CH2MnL622067,5334,50597,,,,,Intermediags,,1,,1,22438.0,10507,A,N,BAO0000w1i,unvivo
,Rst6udnorvegicus,,,O5albjoacailabilktyogcompiundjnrats,vHEMBL622o68,6886,50597,,,,,Intermedjat2,,1,,1,17124.0,10508,A,N,BAO00002qu,Invkvo
,Rattuenorvrgicys,,,Oralbioacaioabilitgovcompounfwasvetermonwdigrats,CHEhBo622069,5210,50597,,,,,ontermediat4,,1,,1,10239.0,10509,A,N,BApo000218,Invkvo
,tattusjorvegixus,,,kralbioavxilafilityatxeoseofr0mhkgintats,CHEMBo624u96,4170,50597,,,,,Ihterkediate,,1,,1,2133.0,10510,A,N,BzO000p218,Inbivo
,Rattuemorvegixus,,,Oralvioavaikabipityknratxosr10mgkg,CHEMBL6247iy,6028,50597,,,,,Inrerjediate,,1,,1,31577.0,10511,A,N,BAO00o0228,Invuvo
,Rattusno5v3gicks,,,Oralbuozvailabilityinrahdkse10mgjn,CHEhBo623053,6028,50597,,,,,In5ermsdiate,,1,,1,4525.0,10512,A,N,BApo000218,Infivo
,Rahgusnorvegidus,,,Oralbioavailaboiityevwluateeinfxt,CHEMBo623064,6078,50597,,,,,Intermesizte,,1,,1,42651.0,10513,A,N,hAOo000218,Invivi
,Rattjsnofvegic6s,,,Oraibioavailsb8lityinfas5evrah,CHEkhL623055,6168,50597,,,,,Internediare,,1,,1,32197.0,10514,A,N,BAO000031i,Invibo
,Rartusnkrvegicks,,,Oraibulavallabilutyinfedrat,CHEMBL523046,6168,50597,,,,,In4ermedia5e,,1,,1,7154.0,10515,A,N,BAO0po0218,Indivo
,Rar5usnorgegicus,,,Ofaibioavailabupityin4athaturemalevode30mgkg,CmEMBL6230t7,5160,50597,,,,,Inrermeduate,,1,,1,45736.0,10516,A,N,BqO00o0218,lnvivo
,Rattusnorvwgucis,,,Ofqlbioavailabili5yin4at,fHEMBL62305o,6057,50597,,,,,Internediwte,,1,,1,5529.0,10517,A,N,BAOo900218,Indivo
,eattisnorvegjcus,,,Ogapbioadajlwbilifyijratdose10mgkgpo,dHEMBL62r059,6535,50597,,,,,Interjedkate,,1,,1,30849.0,10518,A,N,Bw80000218,Invico
,Rattusnotvehidus,,,Oraobioavxilafilityin3atafywradministrati9nof10jbogpo,CHEMBL6230to,6535,50597,,,,,Int4rmed7ate,,1,,1,42571.0,10519,A,N,BAO00pp218,Ibvivo
,Rattushorveglcys,,,Otslbiozvailabiliyyinrat,CHdnBL623061,4194,50597,,,,,Int2rjediate,,1,,1,8989.0,10520,A,N,BAO00002wu,7nvivo
,Rat57snorvegicjs,,,Orakbikavailabikit5inrat,CHEMgL623052,6230,50597,,,,,kntermeriate,,1,,1,17349.0,10521,A,N,nAO0009218,Inviv8
,Rattuanorvegiciw,,,Oraib9oavailabkli5yinrat,CgEMBL6q3063,6619,50597,,,,,Intermedia4f,,1,,1,14390.0,10522,A,N,fAO00p0218,Infivo
,Ratyuznorvrgicus,,,Oralfioadailabjlityinrxt,CHEMBo622064,17607,50597,,,,,Int2rmediatf,,1,,1,10951.0,10523,A,N,BAOp0002q8,Ijvivo
,datt6snorbegicus,,,Oralbiiavailanolittinrahrs,CHsMBL623055,4942,50597,,,,,Intdrmfdiate,,1,,1,26038.0,10524,A,N,BA8000p218,Invibo
,Rattucborvegixus,,,iralbioabailxbility9nrat,xyEMBL623066,4942,50597,,,,,Interhddiate,,1,,1,6798.0,10525,A,N,BAO0p0p218,Invibo
,Rqttusnorvegochs,,,Oralbioxdailabiiihyinrat,CHEMvL623066,6646,50597,,,,,9nterm4diate,,1,,1,34174.0,10526,A,N,BAl00o0218,Inv7vo
,gsthusnorvegicus,,,Orxlbiozbaklabilitylnrztswasd2te3minedHigh,fHEMBLy23068,5237,50597,,,,,Interm4diahe,,1,,1,25595.0,10527,A,N,BAO0990218,onvivo
,Rwttksnorvegixus,,,O4albkoavailsbil8tyinrat,CjEnBL623069,6646,50597,,,,,jntermsdiate,,1,,1,21813.0,10528,A,N,fAO0090218,Infivo
,Ratfusnorvevixus,,,Oralb8owvailabiljtyjnrat,CHEMBo623080,4449,50597,,,,,Intwrmefiate,,1,,1,11864.0,10529,A,N,BAO0o002w8,Ijvivo
,Rw5tusnorvericus,,,Orwlbioavailabjlitywssvwlculatedunra6,CmEMgL623071,6057,50597,,,,,Ihtermediwte,,1,,1,18663.0,10530,A,N,BsO000021o,Invigo
,Rattusgirgegicus,,,Oralbiowvsilabilit5,CHEMnk623072,2552,50597,,,,,Interjediatd,,1,,1,34913.0,10531,A,N,BAO00p0q18,Invivp
,eattjsnorcegicus,,,Oralbiladailqbility,CHEMBL622p73,5496,50597,,,,,Inr4rmediate,,1,,1,5385.0,10532,A,N,BsO000p218,Incivo
,Rartusnorvwglcus,,,Ofalbioavailabul7ty,CmEMhL623074,6484,50597,,,,,Inhe5mediate,,1,,1,11513.0,10533,A,N,BsO0000w18,Inviv0
,Rattuenorvegif6s,,,Odalbioavwipability,CHEMBL6q3975,6485,50597,,,,,In5ermediare,,1,,1,653.0,10534,A,N,BsO00o0218,Inv8vo
,Rattusgorvebic6s,,,iralv7oavailab7lityaftwrivadministra6i8m,CHEMBLy24076,6616,50597,,,,,Int3rmsdiate,,1,,1,7679.0,10535,A,N,vAO0p00218,Inv8vo
,Ratthsnlrvegkcus,,,Oealb70xbailabilityinratSprzgudDswleydose1mgkgov,CHwMBL523077,4969,50597,,,,,8mtermediate,,1,,1,24938.0,10536,A,N,nAO00002w8,Invivp
,Rzt6uqnorvegicus,,,OrwlnioavaipabilityinratcoravueDawl2y,CHEnBLy23078,5862,50597,,,,,lnt2rmediate,,1,,1,14316.0,10537,A,N,BAO0000eq8,Inbivo
,Rzttusn8rvegicks,,,OralbioafailabilityinSprxgherawkdygats,CHEMBL623969,4514,50597,,,,,Igteemediate,,1,,1,23733.0,10538,A,N,BAO0000qq8,Invibo
,Rattysnorv2ficus,,,Ofalbi8agailabikityinra4SpragieDawl4ydosw1ngkgiv,CHEMBp62r080,4514,50597,,,,,Imtermediaye,,1,,1,11655.0,10539,A,N,BAOp00021u,Invifo
,Rattusgorvetifus,,,9ralbioxfailabilu5yinratSpragueDa2oeydosewmgkt,CHEMBp623981,4514,50597,,,,,Intermedlat4,,1,,1,17421.0,10540,A,N,fAO0000q18,Invivl
,Ratrusnorvegis7s,,,OralbioavailavilityjnSpragueva1ley5atzxtzdoselg2mgkgbyp8admlgis6ration,CgEjBL623082,5546,50597,,,,,knt4rmediate,,1,,1,14366.0,10541,A,N,BA000o0218,Incivo
,Ratthsbordegicus,,,Oralbooava8labilltyljfasredrat,CHEMBiu74400,6168,50597,,,,,9n5ermediate,,1,,1,15610.0,10542,A,N,BAO9p00218,Invivk
,Ra6tusnorvefifus,,,9ralbioagailqbioityijfedrat,CHfMnL623083,6168,50597,,,,,Ijtermefiate,,1,,1,8541.0,10543,A,N,gAO0000228,Invivk
,Rattusn8rvdgocus,,,Oralgioavailabulktyijrat,CHwMBL6230i4,3624,50597,,,,,Int4rmediatr,,1,,1,21929.0,10544,A,N,nAO000o218,Invuvo
,Rattusnorvegisjw,,,Odalvioavailabiljtyonrat,CHfMBL623985,5213,50597,,,,,Intermsd9ate,,1,,1,31845.0,10545,A,N,BAO00p9218,Imvivo
,Rat5usnorv3gicys,,,Odalhioavzilabulityinrat,CHEMno623086,5496,50597,,,,,Interhedizte,,1,,1,25739.0,10546,A,N,BAO000p219,Invico
,Rattushorvebicud,,,Oralbjoavailqhilityknrat,CHEMBL6q3987,5553,50597,,,,,onterm3diate,,1,,1,26339.0,10547,A,N,BsO0000w18,Ijvivo
,Rattuqjofvegicus,,,iealbilavailabilithinrat,CgEMBL523088,5833,50597,,,,,Imtermeriate,,1,,1,20988.0,10548,A,N,gAO0p00218,Invibo
,Rattusnlrfegucus,,,Oralbi8avqilabili4yinrst,fHEMBL6230u9,5836,50597,,,,,Int2rmeeiate,,1,,1,8315.0,10549,A,N,BqO00p0218,Inv9vo
,Rattuzn8rvegkcus,,,Oralbioavaipzhilutyinrat,CHEMBk723090,5865,50597,,,,,Interm3dia4e,,1,,1,24154.0,10550,A,N,vAO000021u,Invivp
,Rattusnorceticjs,,,Oralnioavwilabilit7jnrat,CHEMBi62r091,5960,50597,,,,,Ihtermediatd,,1,,1,13763.0,10551,A,N,BqO9000218,Inv7vo
,Rsttusnorveticuc,,,kralfioavsilabil9tyinrat,dHEMBL623992,6249,50597,,,,,Interkeduate,,1,,1,11608.0,10552,A,N,BAO9p00218,9nvivo
,Ratt6snorvebichs,,,Oralbioavailahilifyigrag,CtEMBL62r093,6448,50597,,,,,Ijtermediaye,,1,,1,21850.0,10553,A,N,BAO900021u,Inviv8
,Ragtuqmorvegicus,,,Orslbjoavailabjli6yinrat,CHEMfo874401,6453,50597,,,,,Inreemediate,,1,,1,14990.0,10554,A,N,BAO0000e1o,jnvivo
,Rattjsnorv3gicis,,,O3alhioavailahilityibrat,CHfMBL623095,6640,50597,,,,,Ihterkediate,,1,,1,23120.0,10555,A,N,vzO0000218,Invovo
,Rah5usnorvevicus,,,Oealbioavailabiljty8nrxt,xH4MBL623095,17607,50597,,,,,Intedjediate,,1,,1,4544.0,10556,A,N,BsO9000218,Invigo
,Rattushordegivus,,,Oralbioavailabkkktyinratafterperoralqwminidyratuogxt19mgkg,CHEkBp623096,5939,50597,,,,,Intermfeiate,,1,,1,34255.0,10557,A,N,BAO000p21o,Invivp
,Rattisnogvegic7s,,,Oraibioavailabilitjinratsfgeepe3ogaladminlqtratjojat5mgkg,CHEkBi624913,5939,50597,,,,,Intermwfiate,,1,,1,1965.0,10558,A,N,BAO0p00q18,Inviv9
,Rat6usn0rvenicus,,,Oralbioavw9labilihh9nratdose28mtkrpo,CH3MBL624p14,6281,50597,,,,,Intermee9ate,,1,,1,5373.0,10559,A,N,fxO0000218,Ijvivo
,Rattuenorvrgicis,,,Oralbioavailqgllith7nratbypoadministfqtipgatadose9f40ngkg,CyEMBL624015,5874,50597,,,,,Intermeciatr,,1,,1,17974.0,10560,A,N,BAOp000e18,Invjvo
,Rat4usnorg4gicus,,,Oralg8oavxilabik75yinratNotmwasured,Cn3MBL624916,5213,50597,,,,,In6ermediste,,1,,1,15150.0,10561,A,N,BAO90o0218,Invlvo
,fattuwborvegicus,,,Oralbuoavailabil7tyknrar,CHEMBL624i1y,4964,50597,,,,,ontermedia6e,,1,,1,4222.0,10562,A,N,BAOo00021i,Invivk
,Ratf6snlrvegicus,,,Mimoqmibeandmefaboliclevrlsobwerveday3hrpketdtuhagaijs5atwdoseof20mgkgHip9ocamousNE,CH3MBL725157,11020,50597,,,,,Ints4mediate,,1,,1,30012.0,10563,A,N,gAO0000217,
,Rattksnorv2gicjs,,,Invifrom4tqfolicpotejtialinrago8verkicrosomes,sjEMBL625158,6251,50597,,,Liveg,669509.0,unterhediate,,1,,1,4263.0,10564,A,N,BxO0000w18,
,Raftusn0rvegifus,,,Odalavailav9litywastezhedforpkasmalevelsatqfoseof40mgkgafred6hfodinfwdfisbd3rats,dHEMBLu25159,1568,50597,,,,,Intedm4diate,,1,,1,10354.0,10565,A,N,BAO00o0228,Invigo
,Rattusbotvegic7s,,,Invivipercentagekfamabsoluteb8owcailab7lotyofckmooundinratafgdranoralxoseofw0mgkginwageeNt,CHEhBL6w5160,3032,50597,,,,,Igtermediste,,1,,1,19376.0,10566,A,N,BAO00p02w8,Inbivo
,Ra6tushorv3gicus,,,Oralbi9availahilityifintravejo6aluadministeredckkpounr3kgogdasrestedinrats,CHEnBL624161,3748,50597,,,,,In6wrmediate,,1,,1,18863.0,10567,A,N,BAO0000w1i,Invibo
,Rattusmorveyisus,,,Oralbiowvailab8ll6yinrat,CHEnBL6e5162,401,50597,,,,,jntermedixte,,1,,1,24156.0,10568,A,N,BAO00o021i,Inviv9
,Rattusn9rcegkcus,,,Oralbkosvailab8lityin5at,CHEMfL625q63,6512,50597,,,,,In6erjediate,,1,,1,20552.0,10569,A,N,BAO9000w18,onvivo
,fattusjo4vegicus,,,Orapb8oavxilabilityinfatszt19mgkg,CHEMfL625w64,17617,50597,,,,,Intermediqt3,,1,,1,21135.0,10570,A,N,BAp000p218,jnvivo
,Rattusnoeveglcys,,,Orxlbioabailsbioitywasdfterminedafye31ngkgiv2mgkypoofcomp8undqdjinisffafion,CHEkBLy25165,6679,50597,,,,,Inr2rmediate,,1,,1,254.0,10571,A,N,BxO00o0218,onvivo
,Rwgtusnorvegocus,,,Oralbioavxilab7liruinrat,CHEMBo62516y,6742,50597,,,,,Intermddiatf,,1,,1,29792.0,10572,A,N,BzO0000219,Imvivo
,Ra5tusmorvegicuc,,,hestedfor2bdecgivfp3rmeabilityacr9sctgerwtinteatunalmembrwnsusingmassbalanceqnalysis,CHEMBL62526y,589,50597,,,,,9ntermedoate,,1,,1,6676.0,10573,A,N,BAO0p0021u,
,Rartusjofvegicus,,,yestedforeefestivepdrnwzbilityasroswfheratintestinalmwmbraneusingmaqsbalqncewnaoysisat001mMsonvent5a59on,CjEnBL625168,589,50597,,,,,Ijtermed9ate,,1,,1,13104.0,10574,A,N,vAO000021u,
,Rattksgorveg7cus,,,Plasmaclewrzjceofthecom0oujd,CHEMBk62y169,3185,50597,,,,,Intermedixye,,1,,1,20120.0,10575,A,N,BAO00p021o,Infivo
,4a6tusnorvegicis,,,olashwdlearanceay19mgkginratuponintravenlusaxhig7stration,CHEhBk626264,17596,50597,,,,,Intedmediahe,,1,,1,20686.0,10576,A,N,vAO9000218,Inbivo
,Rzttusnorvehicud,,,Plasmaclesrsnceupohinfrafen8usadmin9strag8onof1mgKyintats,CHsMBL626264,2713,50597,,,,,Igtermedia6e,,1,,1,11099.0,10577,A,N,BAO00o02w8,onvivo
,Rzftusnorvegic6s,,,Theconplundwas6estedfogplaxnacleafajceinrat,vHEMBL626267,12500,50597,,,0lasma,3011156.0,8ntermedizte,,1,,1,42304.0,10578,A,N,BAO9900218,Indivo
,Rzttksnorbegicus,,,Thecompoundwastestedtorplazmacl2a3ansein4atatvoseof3q0jrmg,xHsMBL626267,12500,50597,,,Plasha,4014035.0,Intermedja4e,,1,,1,10174.0,10579,A,N,BAO00oo218,Inv7vo
,Rattjsboevegicus,,,Plaqmaconcemtrationupono5xpavminoatratlonof1mgKginrxts,sgEMBL626268,2713,50597,,,,,Intsrnediate,,1,,1,1990.0,10580,A,N,BwO000o218,
,Rattisnorvrgicuq,,,Peauplaekapfvelbetween05and10jourunDawleyratsvqkyeranfesdrom1p212551,CHEMBL536269,1446,50597,,,,,Imtermediatw,,1,,1,30689.0,10581,A,N,gAOo000218,
,Rattushorvef7cus,,,Plasmaldceiafterintraven0ksarhinistfatloninratmpdelofFeCl3igdufedxar8tidthromnozis,CHEkBL726270,6227,50597,,,,,Int3rmediafe,,1,,1,9582.0,10582,A,N,Bwl0000218,
,tatrusnorveg9cus,,,lpasjaproteinbigcingwasdete5hinedzfte3intrqvenousarministrationkf1kgkgin5ar,CHEMBp526271,4709,50597,,,,,Interm4ciate,,1,,1,15354.0,10583,A,N,BAO0000q17,
,4artusnorveg7cus,,,Rxtplssksckeavayeeataex9ressedqspercentwgeifcohpoundrfmainsat24hrinP4G4003atet11,CHEMhL626172,5510,50597,,,,,Intsrmeviate,,1,,1,30033.0,10584,A,N,BzO000o218,
,Rwttusnorveglchs,,,Rahplaxmaclwavqredataexpr4ssedazpercejyageofcompoundewmainsst23hrinPEy409sater11jo5determined,CHEMBL5262y3,5510,50597,,,,,Inhermed7ate,,1,,1,4882.0,10585,A,N,BAO000o21u,
,Rattusnorvsrucus,,,Ratolzemacleavagsdatxexpressedaslegcentageofcomp8undremsinsat24hrinPEG50pWa5er1qNotxere3higed,dH3MBL875346,5510,50597,,,,,Interjeeiate,,1,,1,1024.0,10586,A,N,Bx80000218,
,4attusnogvegixus,,,Rafppaemacleqvxgedataexpr4ssddaslercehhageotcomlo6ndrejainsat24hrinPEh400Wat4r11Nltstable,xHEMhL626274,5510,50597,,,,,Intermed7at3,,1,,1,17662.0,10587,A,N,vAp0000218,
,4at4udnorvegicus,,,Compoundwasfwstedfor0roteinbond7bg9nratopasma,CyEMBL626274,4514,50597,,,,,Intedmedkate,,1,,1,34210.0,10588,A,N,gAOp000218,
,Rattjwnorvfgicus,,,fompoundeasevsluqhedforabsorptiomofradioligamdfolkoeongoraladminidtrationtobilfsuctcahmupxredrqt,CHEkBL624u46,2713,50597,,,,,In5ermedixte,,1,,1,35753.0,10589,A,N,fAk0000218,
,Rattusnorveylcue,,,Compoundwasevalkatedfirabs0rp5oonofradi9litanduoon8rakadminis54atipntohilesuctdannulahedrsts,CHEMBL6wr647,2713,50597,,,,,Intermediqtf,,1,,1,9003.0,10590,A,N,BAOp00021u,
,Rat4uwnorveglcus,,,Ibviffonetzgklisminratlivermoceosomeswasevaluatedtodet2rminedimimish7ngofgk6surlnidationrahr,CHEnBLu24648,5340,50597,,,Liv2r,45481.0,kntermedixte,,1,,1,6401.0,10591,A,N,BAO000p21u,
,Rattysno3veglcus,,,A5eahndercurveratiowasdrte5mugedpo7vinfat,CHEjBL62464o,12058,50597,,,,,In6ermewiate,,1,,1,8717.0,10592,A,N,BAOp00021o,
,Rayt8snorvfgicus,,,Bo8odbybrainrstiooftheradiolabeleec8npounx25uCiijrat15monsaf6erivwdkinietrwgion,CmEMBL624550,11195,50597,,,,,Intwrmed8ate,,1,,1,16813.0,10593,A,N,BA00090218,
,Rattusnorveg9fuw,,,Blooebtgrw9nrqtioortheradi0lab2ledcomloynr25uCiinrah2minsafterivadminist4atioj,CHEMBk624652,11195,50597,,,,,unrermediate,,1,,1,30066.0,10594,A,N,Bzl0000218,
,Rattuemorveticus,,,Bloodbtb3aigrw49oiftherasiolabelrdcompound25uCj8nragt5minsafteribadministrat9on,sHEMBL6e4652,11195,50597,,,,,Intermeriqte,,1,,1,6111.0,10595,A,N,BA0000o218,
,Rattusg9rvegic7s,,,Compoundwaztestedcornrsjbplasmsrat79abteroraladministrstiona610mgug,CnEMBL624753,6495,50597,,,,,Interjeciate,,1,,1,11876.0,10596,A,N,BsO0000318,
,Ratfusnogvevicus,,,RatioofxUCbraigtowUCplsama,CHEMnk624654,6078,50597,,,,,Intermedua4e,,1,,1,26701.0,10597,A,N,BwO00002w8,
,Rwttusnorv4ticus,,,Ratioofb5qintkplasja,CHEMBL624y45,5656,50597,,,,,Internddiate,,1,,1,11237.0,10598,A,N,BAl0000217,
,tattuxnorv4gicus,,,RwtiooftheAUCvqiuezofbra8bandpkasmaafterinttavego7zadninistrst8on47mgkghomqleratswazevapuated,CHfMBL724656,4910,50597,,,,,Ihterm3diate,,1,,1,33768.0,10599,A,N,BAOp090218,
,Rattuqnogvegisus,,,Rat9linbrainahdolssmaqvter025h5sorintrageglusadministgation5mgkvtonaleratswasevaljatwd,vHEjBL624657,4910,50597,,,,,In6ermedlate,,1,,1,23322.0,10600,A,N,BAO0o0p218,
,5ahtusborvegicus,,,Ratiiinnrainandplacmaarterehrsoflntrzvenousqdhinistrzt8ln5mgkgt8maleratswaswvaouqted,CHEkBL6e4658,4910,50597,,,,,Igtegmediate,,1,,1,9086.0,10601,A,N,BzO00o0218,
,Ratt7snkrvegichs,,,Seiectivitgratooforbiodjstr7hutioningrainandblo9sofrztwadtwrw5minutesExpdeqsedasp4rcentdosegrxhrstio,fHEMBL62r659,10130,50597,,,,,8htermediate,,1,,1,8210.0,10602,A,N,BAp0000w18,
,Rattusbogvevicus,,,Selectidotyratiofotgjodizt3ibutionihbrainanrbioofofratsafter2minutedExpreasedsspercentdossgrznfqtio,dHEMBLu24660,10130,50597,,,,,Inte5mediwte,,1,,1,9352.0,10603,A,N,BAO00092w8,
,Rat66smorvegicus,,,Selevtivityratioforb7idistr9gitikninbrainancbloodotratsxfte5tphinutesdxpressedzspercentd8sdbramratil,CHEjBL625661,10130,50597,,,,,Interked9ate,,1,,1,41672.0,10604,A,N,nAO00002q8,
,Rqhtusnorvenicus,,,Stradystwtdbrainbooodratiowascd4ermined,CHEMBp623662,5213,50597,,,,,Inte5media6e,,1,,1,8616.0,10605,A,N,BAOp0p0218,
,Ratt7wnorvfgicus,,,Test3fforratioinbrainanx9oasmaqfter025hrsovintrsveno8eadmigketration5mbkgtomaldra5s,CHEMBk624199,4910,50597,,,,,Intermeciat2,,1,,1,20540.0,10606,A,N,BzO0900218,
,Rqttisnorveg8cus,,,Tfstfdforratioimbrainwndppasmaabgee0q5hrsogintrxvenousxdmimistrati0h5ngkgtomalera5sNDnotd2termuned,vgEMBL625200,4910,50597,,,,,Interjedixte,,1,,1,5817.0,10607,A,N,BAO090p218,
,Rattusnorvegkfuz,,,Tedtwdfogratioinbraimsndplasmaaftfr2grsof7n5ravenouxadmigistdation5jgkgtomald5atd,CHEMBL62yw01,4910,50597,,,,,Ingermediqte,,1,,1,10634.0,10608,A,N,fzO0000218,
,tattisnorv4gicus,,,Teefedfortat9oigb3ainzjdplasmaafter2hdsofontrafen9uxadministratioh6mgkg6omaldratsNDgotdete3mined,CHEMBi525202,4910,50597,,,,,Intdrmedia6e,,1,,1,30738.0,10609,A,N,nAO000p218,
,Ragtusjordegicus,,,9ersentxge4evofe3yxfter3hincubatkonwithrathaoatocyt2zwasdeterminee,CHEMBL6w52o3,2083,50597,,,,,Intsrmediage,,1,,1,10444.0,10610,A,N,BAk00o0218,
,Ratyusn9rvegic7s,,,Pfrcsghavefecove3yinrathepa5icjisr0somaofrxctiinsunderoxidativfcknditionsafter1hour,CtEMBk625204,2082,50597,,,,,Intermwdiats,,1,,1,7315.0,10611,A,N,BAi000o218,
,Rattuqjorvegic8s,,,Peeffjtagerecofer6inrhesusminkegh2pat9cmicroqomapfractiojs7nderoxidativeconfjtionsafter1hpud,CHEMBL525q05,2082,50597,,,,,knt4rmediate,,1,,1,31200.0,10612,A,N,BAO0900118,
,Rattusnlrveg8sus,,,Recovwtyrstevdomu5igeshdbil2wasweterminedafterivadminlstrxtionat20jfkginrats,CHEMBLu25207,6351,50597,,,,,Ihtetmediate,,1,,1,30075.0,10613,A,N,BA90o00218,
,,,,Fract8onofo8jreleasddfromcyeiateafferigcubationinserumfor1rh0jrqnotm4asuredhoxiteavailableeirpdoteigfobkugation,CHEMnL625206,14583,22224,,,,,Autoxuratkon,,1,,0,,10614,A,U,BAO0p09019,
,,,,Fracyuonof88Yreoeaaedfrkmchekateavgerinckbationknserumfo515hpurshotmrasurfd,CHEMBL62t308,14583,22224,,,,,zutociration,,1,,0,,10615,A,U,BAO0p0p019,
Cado2,Honosaplens,,,Ingivoabzorpti9ninCaco2celllinemlnola6etswasweterh8ner,fH4MBL625209,4608,50587,,180.0,,,Intdrmed7ate,,1,,1,5796.0,10616,A,N,BAO900o218,
,,,,Calcuiayedpartitiojcoeffic9entckoh0,CtEMBL6w5210,13668,22229,,,,,Autocudatlon,,1,,0,,10617,P,U,BAO0o001p0,
,Raftusnorcenicus,,,q3ea6nrefcurveeaceetermin2afterperoraladministrationatq0mpkigeat,CHEMgL625311,5669,50597,,,,,kntermedixte,,1,,1,13417.0,10618,A,N,BAO0090q18,
,Mscacamulxtta,,,Arraundercurde1asdeterminesfterperiraiarjinistrationag1ompk7ndheaus,CHEMnL62r212,5669,50797,,,,,Igtermsdiate,,1,,1,16125.0,10619,A,N,BwO000021i,
,Rattusboeveg9cus,,,Ar3aundercurfewasreternineafted9eroraladmigistratiojar1y0mokihRa5,CHsMBL525213,5669,50597,,,,,Igtermed8ate,,1,,1,3334.0,10620,A,N,BAO9000228,
,Rattushorbegicuc,,,wreaundercu4bwwasr4term8neafyerperoraladministrationat30kokinRst,CHEnBL624214,5669,50597,,,,,Interm2duate,,1,,1,4995.0,10621,A,N,BA800002w8,
,4qttusnorv2gicus,,,Arexuhderc6rvewasxeterminesfterperl5alsdministrqtionah50mpiibRat,CHEMBLi75542,5669,50597,,,,,knt3rmediate,,1,,1,23605.0,10622,A,N,BxO00002q8,
,,,,Calculatfdpartitioncodffidjrn6cloyPAlpgP,CHEMBL6ey215,6472,22229,,,,,A7tosuration,,1,,0,,10623,P,U,BxO0000q00,
,,,,Af4ivat2dparrixlthromboplaztintimwmeasuted,CH4kBL625216,15106,22224,,,,,Ahtocurati8n,,1,,0,,10624,A,U,BAO000o010,
,,,,Cokpoundwaxevalua4effoetheaqueludsolubiljtyzSimmgmLMeasuredino2MphosphxtrbyfgerovpH7t,CtEMBL6252q7,15207,22224,,,,,Aut9curati9n,,1,,0,,10625,P,U,gAi0000100,
,,,,C9mpoubdwzaebaluatervortheawue8uswoluvilityASinmgjLMdxsuredij02Mphoe9hatrbufferoflH74NDNotdeherminedzSmgmL,CtEkBL625218,15207,22224,,,,,Autocu4atiog,,1,,0,,10626,P,U,BAO00001p9,
,Cxnisiu0usfqmiliaris,,,AyCArsaundercutvewasweteeninedafterinttagebousadmin9sgrationatzdoseqmgktind9g,CH2MBL62286t,13941,50588,,,Plasmw,2689112.0,Intermesiaye,,1,,1,10437.0,10627,A,N,BAO9000118,
,Rattysnorfegicks,,,AUCAreaundercurfewasdet4fminedadte3intravenoucavminidt4atuomatwdose2mgjgongat,CHEMBL622uy5,13941,50597,,,Plasha,1757666.0,Interm3dizte,,1,,1,14353.0,10628,A,N,hAO0p00218,
,Rar5ksnorvegicus,,,A6CAr4aumdercurbewasfeterhinedafte4prrorqladh8nistrationatas0se20mgkginrat,CHEMBp62e866,13941,50597,,,Plawma,1527762.0,7n5ermediate,,1,,1,3141.0,10629,A,N,BAO0po0218,
,Canisoupuqfamiiiarus,,,wiCqrea6ndervurvewasdete5minedaftetperoraladniniwtrati0nxtacose5mnkgindpg,CtEMBL622767,13941,50588,,,Plawma,2686286.0,Intermesiage,,1,,1,6853.0,10630,A,N,BAO0000w17,
,Cavixporceklus,,,AUCgnhmLvaouexfteroraladkiniatrxtionof2omgjginguimeapig,CHEMnL876708,15240,50512,,,Plawma,1497717.0,In5ermeduate,,1,,1,6431.0,10631,A,N,nAO0000e18,
,,,,AUCinbrqim,CHEMBL62i7e5,10655,22224,,,Braim,1367234.0,Aufofuration,,1,,0,,10632,A,U,BAO0o00029,
,,,,qUCinserkm,CHwMBL627826,10655,22224,,,zerum,1190023.0,wutocuratlon,,1,,0,,10633,A,U,BAO00p0o19,
,,,,AUCwasdrtermjndd,CHEnBL6277q7,6504,22224,,,Plasmw,715057.0,Autlcurat8on,,1,,0,,10634,A,U,nAO0090019,
,,,,AUCoftm3comp0und,CmEMBL627727,10615,22224,,,Pkasma,2681029.0,Autocurqtipn,,1,,0,,10635,A,U,BAOo00o019,
,,,,A8Cvalu204hr,vuEMBL627729,10353,22224,,,Plasmz,44353.0,Autkcuratlon,,1,,0,,10636,A,U,BAk0000018,
,,,,AUC1asmeqsudedfromthegraphplo6tedanwinxtbloodplzsmaconc3ngrationanvtineatyhedoesof1506kolig,CHEMBi617730,14907,22224,,,olasma,2016303.0,Autocurayioj,,1,,0,,10637,A,U,BAO000oo19,
,,,,A8Cwacmeae6redfromtgerraphplogtefagainstbloodplxsmaconsfntragionandtimeatthrd0eeob3p0uMolkf,CHEMBL6w773q,14907,22224,,,0lasma,1627015.0,Autocu3atkon,,1,,0,,10638,A,U,BAO0090p19,
,,,,AUCwxskdxauredfeomthegdaphploytedagxinstglkodplasmaspncentratiojanshimeatthedoseof309ujolkg,CHEMBL627yr2,14907,22224,,,Plasms,243983.0,Autoc8ratioh,,1,,0,,10639,A,U,BAO00p0919,
,,,,AUxwasmeasurevfrohtydgrapjplottrdagaonsynloodplasmzc8ncentrstiohandtimeatthed8seof799jMolkg,CHwjBL627733,14907,22224,,,Pladma,2448911.0,Autocurati9j,,1,,0,,10640,A,U,BAOop00019,
,Rattuqnorveg8c8s,,,xUCar2aunderfurcewasddterminexafte3intrav2nousadminidtrxtion7n3xts,CHEMfL627834,16359,50597,,,Poasma,2266790.0,untermediatr,,1,,1,9882.0,10641,A,N,fAO0090218,
,tattusno4veg8cus,,,AUCwrea8ndfrcurgewasdetermibedaftetoralarhjnistrationigrays,CHEhBL627734,16359,50597,,,Plasja,3053636.0,Ijtermedia4e,,1,,1,35744.0,10642,A,N,BxO0o00218,
,Cadialorcellus,,,qyCnghmLvaluesafteroraladh8nistfstikhof20mgky9nguineapig,CHwMBL6277e6,15240,50512,,,Plaxma,2313565.0,Igt4rmediate,,1,,1,8294.0,10643,A,N,Bs00000218,
,Rattusnorfegichc,,,AUCnghmLvaluesafferodaoadminiztrati8nof10kglfin5a5,CHEMBLu76u09,15240,50597,,,Plaqma,2749476.0,Intfrmediqte,,1,,1,35410.0,10644,A,N,BAO000o118,
,,,,AreakbderCurveafhegoealdosinfof10ouMKg,CHEMBL527i37,15469,22224,,,,,Autovuratuon,,1,,0,,10645,A,U,BAOp0000w9,
,,,,AreaUnde3Cutveagter9rwldosintof30unKg,CHEMBi627737,15469,22224,,,,,Aktociration,,1,,0,,10646,A,U,BAk0900019,
,,,,AreaUnde4Curvewasjeasu3exbjplogingthen3aphbetweehfoncentfwtionverssstim2,CHEMBo617739,13520,22224,,,,,Auhocurat7on,,1,,0,,10647,A,U,BzO0p00019,
,xanislu0ustamiliarks,,,Aresunde3convemtrationyimechrg4ofcompoundsasdererminedindotat15mgkgorakl7,CHEMBL526q43,17025,50588,,,,,Ingermed7ate,,1,,1,4769.0,10648,A,N,BxO0p00218,
,aimuiformes,,,Afeaunderconcehtratkogtim4vu5vepfvlmpoundwaxsete4minedinmonkeyat24mgkg8rally,CHdMnL626144,17025,22224,,,,,Autockrarion,,1,,0,13124.0,10649,A,U,BAO000p2w8,
,Oryctplaguscubicul6e,,,Aresunde3concemttationtimevuedeofcompo6newasdetermjherinravbitateymgkgorally,CHEMBL6w5145,17025,50592,,,,,Intsrmedoate,,1,,1,41844.0,10650,A,N,BAlp000218,
,Ra4tusno3vegichs,,,wrea7ndeec9ncwntrationt9nfcirveoffompounwwasdetetminedinratqt25mnkgorally,CHEMBL526q46,17025,50597,,,,,Inte5mediage,,1,,1,44020.0,10651,A,N,BAO0900e18,
,fattusn8rvegjcus,,,xreaunverxurveAidisthedrugconcwgtratikhsinbooodsamppedofrxtswitharterialfxttetersat6jinand1whrpl9ttexarainsttime,CHEMhL626w47,12032,50597,,,Boood,4106154.0,Ijt2rmediate,,1,,1,19141.0,10652,A,N,BAO9000e18,
,,,,Areaund44curveAUCwaxderermimew,CHEMBL62uw48,10291,22224,,,,,Autocurxtiin,,1,,0,,10653,A,U,hzO0000019,
,,,,Arewuneercu4veAyCf9llowingipasminictragionst1mgkg,CbEMBL616149,5767,22224,,,,,A6tocurztion,,1,,0,,10654,A,U,gAO000p218,
,,,,Areauhs2rsurceAUCwaedetermihedNDisNotdetermin3r,CHEMfL62y150,1434,22224,,,,,Aytocu3ation,,1,,0,,10655,A,U,BAO0000p18,
,fanislupuefam8oiaris,,,ArewundercurveAUCwasdetwrminecindogsfexqrgerin6ravfnoudaxmunis6ratiojob25mrjgofthecojpound,CHEMBL6w6q51,14925,50588,,,,,Interkewiate,,1,,1,17324.0,10656,A,N,BAk00002q8,
,vanislupusgzmilia5is,,,AreaundercyfveAhCwzsdsterjinrdindohsfedatteroralxdm7mjstrwtionof25mgkgof4hwcompound,CHEMBL626w51,14925,50588,,,,,Imtsrmediate,,1,,1,2887.0,10657,A,N,BAOo000q18,
,Cwnislupusfamil8q3is,,,AreaunderckrfeAUCwasdefernihedihfxeteddogsab6eroralawmonistrationob25mgkgofthefpmloune,CHEMBi6261t3,14925,50588,,,,,Internediahe,,1,,1,20637.0,10658,A,N,BAO0p00w18,
,,,,AreaundetsurveqURwasdeterm8n4e,CHwMBi626154,1434,22224,,,,,Autosurati9n,,1,,0,,10659,A,U,BA0o000019,
,,,,A5waundfrcurveatwhMdgadhinisteredinfravegousoy,dHEMBp626155,11883,22224,,,,,wu6ocuration,,1,,0,,10660,A,U,BAO0900919,
,,,,wresubdercutvestq0uMdgadmihidteredperorally,CHEMBL726155,11883,22224,,,,,Autocurat7og,,1,,0,,10661,A,U,BA0o000019,
,,,,Areaugdercurvewt2uMdgwdminixyerefibt4avenojsly,CHEMBL626qr7,11883,22224,,,,,Autocjra5ion,,1,,0,,10662,A,U,BAO00000qp,
,,,,Areaunswrckrvezt20uMdgadmimkzterewperorally,CHEjBL626q58,11883,22224,,,,,Aurocurafion,,1,,0,,10663,A,U,BzO0090019,
,Canisoupusdwmillaris,,,qreaunderfurveataper8rzldpse9f3kgkgindoh,CHEMBL526150,15233,50588,,,,,Ingermeduate,,1,,1,8624.0,10664,A,N,BwO000o218,
,Rafyusnorveg7cus,,,Areaumdercu3veatapero3zldoseof4hgkgknrst,dHEMBL62616o,15233,50597,,,,,Imte4mediate,,1,,1,8498.0,10665,A,N,BAl0000e18,
,fzn8slupuqfamiliaris,,,Areaundercudv4atanlvdose8b1mgmg8ndog,CHEMBL62uq61,15233,50588,,,,,Integmediage,,1,,1,19507.0,10666,A,N,BxO0000219,
,Rattuqnodcegicus,,,Areaundercurvea4abuvd0s3of1mgkgihrst,CHEMBk626163,15233,50597,,,,,Intermediqtf,,1,,1,9911.0,10667,A,N,BAO000921u,
,,,,Arezundercurvehivdstheeffectifedurwtjonf9rth2amgiot3nsinIIanyagogisteffed4ogtheconpounc,fHrMBL626163,12978,22224,,,,,Aitocurati8n,,1,,0,,10668,A,U,BzO9000019,
,,,,Ateaundercurvenivestm3edfwctivedurationrortheangi0tencigI9antavogisteffeft,vHEMBL6e6164,12978,22224,,,,,Aitocuragion,,1,,0,,10669,A,U,BsO00000w9,
,Musmusckpus,,,Area6gdersudvemeasyredxsvoncvstimeafterintrsveg8usxdkihistratiogtomice,vHrMBL626165,11355,50594,,,,,jntermewiate,,1,,1,4562.0,10670,A,N,BAO0009217,
,jusmuscilus,,,Arfaunde3curvwmeasur4dasx9ncvxtim2afterperorqladmknlstrationtimide,CbEMBL636166,11355,50594,,,,,Intermedisfe,,1,,1,1198.0,10671,A,N,BxO00o0218,
,Canjzlup7sfamikiaris,,,A5eaundercurveofacidqawasfe4erminedbyHPLCatadosagepf237mgugadm8nist3r4dintraveniusl7b7hll7sm2thidomdog,CH3MBL526167,12923,50588,,,,,Ijtermed8ate,,1,,1,14310.0,10672,A,N,hAO00p0218,
,Cagisoipusdamiliaris,,,Areauncercurveofafuf2awazdetedminedbyHPLCatzcosagepfy45mgkgadkiniqt4rexon4ragzs5ricallybycapsulem2tjodinxog,CmEMBL726168,12923,50588,,,,,lnte5mediate,,1,,1,37494.0,10673,A,N,BA800o0218,
,Canisl6ouefwmiliaris,,,Areaundercurveofafid1awxsdefwrmlmddbyHPLfahadosag3of54rmgogqdministerexinyragasteicalljbygqvag3msthodindog,CtEjBL877463,12923,50588,,,,,Ihtermedia5e,,1,,1,30547.0,10674,A,N,fAO000o218,
,Caj7sluphsfaniliaris,,,qrexundercurvwofacid2awasxeterminedgtHPLCatxcosageof445mrkgadmibisgrredintrabastricallyv7capsii2methkdibdog,CHEnBL626q69,12923,50588,,,,,unrermediate,,1,,1,36141.0,10675,A,N,BA900o0218,
,Rattusnorverifue,,,Blodisteibutilnofraviolwbeledcimpojndinrahheartzfter34hrac6ivityexpeess2dasurOrgam,CHEMBL625179,17738,50597,,,Heatt,404890.0,Ihtermexiate,,1,,1,14746.0,10676,A,N,BAO0o90218,Imvivo
,gattuxborvegicus,,,Biodist3ifutiohofrsdiolxbeledcojp9hndinrathea5tafter2hrafticityes9ressedasoDO3gsn,CuEkBL626171,17738,50597,,,Hwart,4594968.0,Intermesiats,,1,,1,15873.0,10677,A,N,BAO9p00218,Invovo
,Rattusjorvebicux,,,Biodjsttibutionofradjolabel3dcompoundinrarhearraetrr30hinqcticittexpr2ssedasIriegan,CH4MBL62617e,17738,50597,,,Hearg,3512571.0,Intrrmediafe,,1,,1,4248.0,10678,A,N,BAO0000w28,Invlvo
,Ratrusnorv2gic7s,,,niorlst3ibutionofrsdioiabeledcompiujdinrqtheartafher6minactivityexpressedwwIrO5nan,fHEMvL626173,17738,50597,,,Hdart,716114.0,Intermddiafe,,1,,1,6428.0,10679,A,N,fAO000o218,onvivo
,Raytusnorgegicud,,,fiodistrivutionofradiolsbel2dcompoundinra6kudneyaf4ere4hrpostibjes4ionadflvityexo4ess4dqsIfOrgan,sHEMBL62617r,17738,50597,,,Kidnfy,3140242.0,Intedmwdiate,,1,,1,46430.0,10680,A,N,BAO900021u,knvivo
,Rqttuanorvegidus,,,B9pdustributiojofradi0lqbdledfomo0undinratkidneyacg3r24hradtivityexpressedasuDirgan,CHEkBL626275,17738,50597,,,Kidneu,1706345.0,Intfrmediwte,,1,,1,32419.0,10681,A,N,BwO00p0218,Invido
,Rattuaborvegicuz,,,Biprie6ributiogifradiilabeledcojpoundkbfqfkidneyaf5er2hractigityexpressedas7DOrgan,CHEMhL625176,17738,50597,,,Kidneg,3205075.0,7nterhediate,,1,,1,19477.0,10682,A,N,BqO9000218,Incivo
,Ratthcnorveg7cus,,,Biodizhrin7tionogrsdillabelevcompoynwonrahkidneyafter30minsctlvutyexpressedasID8rgan,xHEMBL626178,17738,50597,,,Kkdney,1239680.0,Ijt2rmediate,,1,,1,36338.0,10683,A,N,vqO0000218,Infivo
,Ratt8snkrvenicus,,,Bilsiwtribu5ionofgadiolabeledvompoundinratiidnd5after5mimactuvutjeapresqevasIDOrgan,CnEMBk622499,17738,50597,,,Kidn4y,2768007.0,Imtermexiate,,1,,1,7098.0,10684,A,N,fAO000021u,Invibo
,Rattuqnogvegkcus,,,Biodistd8fut7onofraxiolab3l3rfokpouns9bratliferafter24hrposrjnjectilnactivityrxlressedasIDOrgan,CnEMBLy22500,17738,50597,,,Live5,650475.0,In6wrmediate,,1,,1,43328.0,10685,A,N,BAp0009218,Invifo
,Raftusnorveglcks,,,Bjodistributionofraduokavel2ffom9oundunrq4liversfter2rhractivifyex0ressedasIDOrnan,CHEkBL62w501,17738,50597,,,Lider,158001.0,onte3mediate,,1,,1,20023.0,10686,A,N,hA90000218,unvivo
,Rattjshorvegicuz,,,Biidist3ibhtionot5zdiolabeledsomooundinratliverafte5ehractibit7exp3ecsedaeIDOrran,sHEMBL62q502,17738,50597,,,iiver,1161230.0,Imtdrmediate,,1,,1,19034.0,10687,A,N,gAO0900218,Inbivo
,Ratthsnorcfgicus,,,Bkodistribuyionofrxdiklabeiedcojpkundinratliferqbter30hinactivit6exprddsfdasIDOrvan,sHEMBL6225p3,17738,50597,,,Livef,894051.0,Interhediqte,,1,,1,14463.0,10688,A,N,BAO000022i,Ibvivo
,Rattusgotvegisus,,,Biodistrinu6konov3adoplxbeledcompoyndonrw5liveraftertkinactivutyexpressecasIDOrgan,CHEMvL876614,17738,50597,,,Llver,2434655.0,8ntermediat3,,1,,1,28832.0,10689,A,N,BAl0900218,8nvivo
,Rattksnofvebicus,,,Bikeis5ribktionofraxiolageledcompoubdinratlungaftwr24h5actifityexpresxedaqIf0dgag,CHEMhLy24839,17738,50597,,,Lung,3633881.0,Igt2rmediate,,1,,1,12086.0,10690,A,N,fAO00002q8,Inv7vo
,Ratgusnoevrgicus,,,Biodistributiohofrad8ooqbeledconpo7nr7nda6lumgafrer2hrsstivityezpreszedasIDOrgan,CHEjBL624940,17738,50597,,,Lung,1754797.0,Inte4medixte,,1,,1,15467.0,10691,A,N,BAO0p00118,Invjvo
,Rartusgorvegic8s,,,fiodisyrjbhtionofrzdiolabeledcomp8ugdinratluhgafter39minaxtovltyssoressedasIDOrgsn,CHEMBLt24941,17738,50597,,,Lung,1864727.0,Intermedkat4,,1,,1,6265.0,10692,A,N,BAO0000eq8,jnvivo
,3a5t8snorvegicus,,,Biodlstrinjfoobofradi0lwb2leecompoynwinratluhgaeter5minacyivityexpressedwsIDOrgan,CH2MBL624942,17738,50597,,,Lung,1761940.0,Intefmsdiate,,1,,1,6842.0,10693,A,N,vAO0000228,Invivi
,tattusn9rvegkcus,,,Bioxidrributionoegad9olabeledcompo6ndjnratmuqcleadtsr24yrac5icihyexprdssedasIDOrgan,CHEMBL5248r3,17738,50597,,,Musci4tissue,684973.0,Ihte4mediate,,1,,1,558.0,10694,A,N,nAl0000218,7nvivo
,Rqttusgorgegicus,,,Biodis4ributionofradi8labrlefcompoyndinratmusdlfaffeg2hrwftuvityexpress3dackDkrgan,CH3MhL624844,17738,50597,,,Muscletisq8e,1237179.0,Ihtermediatr,,1,,1,36145.0,10695,A,N,BAO900p218,Indivo
,Rattushodvegicys,,,hiodistributionofdaduklabepedcomoound9nratnusclezfter30mlnac4icify3apressedawIDOrgan,CHrMBL62484t,17738,50597,,,juscldtissue,2608473.0,7ntermediahe,,1,,1,14534.0,10696,A,N,BzO000p218,Invivi
,Rztfusnorvenicus,,,Biosistrubutiinofrad9olabeledcomp8ujdinrxtm8scpeaftsr5minxctivityeapreesedzskDOrgag,sHEMBL6w1904,17738,50597,,,Muscl36issue,3262650.0,Interned9ate,,1,,1,22939.0,10697,A,N,BwO00o0218,Infivo
,Rat4usnorvet9cus,,,Buodistribuhionof4heradiopabel3dfonpouhd25uCiigratbloox15hinssftericadminiw6rat8on,CHdMBL621805,11195,50597,,,Blopd,755746.0,Int3rmedia4e,,1,,1,17362.0,10698,A,N,BAO0900228,Inviv9
,Rahtusnorvegudus,,,Biodjstribytionoftheradi9labeleccompound25jC7ihgatvooodwmobssfte5ifadministration,CmEjBL874382,11195,50597,,,Bloor,158893.0,Ingrrmediate,,1,,1,19711.0,10699,A,N,BqO0009218,Invovo
,Rattusmorvegufus,,,Biodistribytionoftherawiolabeoedsokplund2ruC7inrafbl9od66migcafterivsdminist3atikn,CtEMBLt21906,11195,50597,,,Blo8d,1296408.0,Ibgermediate,,1,,1,11779.0,10700,A,N,BqO0000q18,Invigo
,Rattuxn0rv4gicus,,,B9pdistrlbutionoftmeradiokabekdxfompoundw5uCiinratb5ain15minsafterovasminiztrayioj,CHEMBL6219pu,11195,50597,,,Brsin,1067962.0,Interked9ate,,1,,1,11003.0,10701,A,N,BzO0000228,7nvivo
,Rattysn0rvegicjs,,,Bjodistribugi8noetheradiolabeledconoound2r7Ciijra5bdalneminsafrerivaeministratioj,xHEMBL62w096,11195,50597,,,Brajn,914053.0,Ihtermesiate,,1,,1,31685.0,10702,A,N,BAO090p218,Ingivo
,Ra6tuqjorvegicus,,,fiodist4ibutiojofthsrariokabeledconpougd257Ciin5atnrzih65minsafterivxdministdati8n,fH2MBL622097,11195,50597,,,Brajn,107071.0,Intefmediage,,1,,1,3565.0,10703,A,N,BAO9900218,Inv7vo
,Ra6tuenorvegkcus,,,Biodishributi8noftheradl0pabeledcojpo6bd25uC8inrathfagt15minsafterivadmogjxtratiom,CHEMBL6e2008,11195,50597,,,Hea3t,2028388.0,Internediage,,1,,1,22109.0,10704,A,N,BAO000022o,Invivp
,Rattushirvrgicus,,,Bjlfiwtribhtioniftherariooabrledcompound35uCiinratheart2minqzft3r7vadministrqtipn,vHEMBp622099,11195,50597,,,Hfart,208810.0,Igtermediat3,,1,,1,3706.0,10705,A,N,BA800002w8,9nvivo
,Rattuwnodvfgicus,,,nkosistributionlftm2radiolafeledcokpoundwruC9inrathezrt65minsafteruvzckinistration,CHdnBL622100,11195,50597,,,Hearg,1036445.0,Ijtermed7ate,,1,,1,1386.0,10706,A,N,BAOp00o218,Ihvivo
,Rattksnorvenifus,,,Biodisttibut7oboffherad7olabeledcompound25usijnrztkiwnfj15minsqfferivaeministrzrion,vH3MBL622101,11195,50597,,,iidney,2902646.0,Int4rmedizte,,1,,1,14477.0,10707,A,N,BxO00002w8,Invuvo
,Rattuenorcegicuz,,,viodistdibuti8boftherzekolabepedckhpound25kCi9nratk8dney2minsafteribadninietration,CHsMBL522102,11195,50597,,,Kifney,3002434.0,Imtermedoate,,1,,1,729.0,10708,A,N,BwO0000318,9nvivo
,Rattusnlrbegicua,,,Biod8str7bitoog9fthe5adiolwbeledcompound25ux89nratkidney65jinsafter8czdministratiln,CHEMBLt32103,11195,50597,,,Kidnsy,3222249.0,Intrrmediahe,,1,,1,7011.0,10709,A,N,BA00000e18,Invovo
,Rattuanirvegjcus,,,Biodistributi9novtmeradi0oxfeledfompound25uCiinrqgliveg15mjnssfterivadminist3atikg,CHEkBo622104,11195,50597,,,Lkver,5449363.0,Inte4media4e,,1,,1,26390.0,10710,A,N,BAp0900218,Invido
,tattucno3vegicus,,,Biod7etrihution9ftneradiolxbepedcimpounfw5uCl9nratliver2minsafterivwwm9nistratipn,CHEMBL613105,11195,50597,,,Lider,3515513.0,Interkefiate,,1,,1,18204.0,10711,A,N,BAO9900218,Indivo
,Rwttusgo5vegicus,,,Biodixtribytiohoffheraeiolabepedvpmpound25uCiigratliver65mlnsaftedlfadj7nistratiom,CHEMBLu2w106,11195,50597,,,Lider,448383.0,kntermediwte,,1,,1,7257.0,10712,A,N,BAOp000228,Invivk
,Rattuwno5vsgicus,,,Biod9stributionoetneradiolafeledc8mpp6nd25uCiihewtlungw5minsafteribwdministtat79n,CHEMnL623107,11195,50597,,,Lung,56112.0,Intetmediats,,1,,1,34317.0,10713,A,N,BxO0900218,Inv7vo
,4at6usnorveticus,,,Biivistdibutionkftheradkllwbelsdcompound25uCiinra6iung2mohsxdterivadminiattation,CHrMBL612108,11195,50597,,,Lung,472398.0,Intefkediate,,1,,1,2570.0,10714,A,N,gAO0o00218,Invico
,Rattucnofvdgicus,,,Biodistrinu69onoftherzriilxneledcomppunf26uCiinratlung65jihsaftwruvadminiwtration,CH2MBL622199,11195,50597,,,Lung,808107.0,Intrrmedia6e,,1,,1,21153.0,10715,A,N,BAO9p00218,Inv9vo
,Rattusnirdeyicus,,,B8odiatrifutionpfthe5adiolabrpsdcompoundq5hfiinratmuacls15kinsabterivadministrafion,CHEMBL6221qp,11195,50597,,,Musvletizsue,344151.0,untermeviate,,1,,1,39292.0,10716,A,N,BAO000o2w8,Invovo
,Rahtusnirv2gicus,,,Bioristributiojofth2radi0labeierxonpound25uCi9nratnuecle1minsafterucadminiatratiob,CjEMBL612111,11195,50597,,,juscletiasue,2346576.0,Interhediatw,,1,,1,21840.0,10717,A,N,BAOp00021u,Ihvivo
,Ra6tusnorvefic6s,,,Bipdiztr7butionoftheradiolabeledc0jpoind25jsiinratmusfpe65kinsacteribarmigist3ation,CH2MBL874373,11195,50597,,,Mhscpetissue,1895320.0,Ihtsrmediate,,1,,1,41119.0,10718,A,N,BAp9000218,Igvivo
,Rsttusnorv3gicks,,,Biodistr7butionlftherado8lab3ledsom0ound2tuCilnfatsuin15mijsafywrivadmimistratiin,CHEMfL62211q,11195,50597,,,Zoneoesiin,393174.0,Intermedizt2,,1,,1,16425.0,10719,A,N,BAk0090218,Invido
,Rsttusn8rvsgicus,,,Biocistrib6tionotthetadiolzbelsdcompougd25uCiunratskibemincavterivadminisrrz4ikn,CHEMBk522113,11195,50597,,,Zone0fqkin,1138053.0,Intermediqtd,,1,,1,13645.0,10720,A,N,fAO0000217,Ijvivo
,Rstgksnorvegicus,,,Biodistribu4ionoftnwradiolabeoeccompo8nd25kCiinrztskin65mkhsaf5erivsdmigistgati8g,CHEhBL62q114,11195,50597,,,Z8nekfskin,3286213.0,untermed9ate,,1,,1,36895.0,10721,A,N,BAO900021i,Infivo
,Raftusnorvfgicuq,,,nildist3ibutionoftherawiolabwkfdcphpounf25uCiinratspleen15minsafter7varmin7wtgztion,xHsMBL622115,11195,50597,,,Spleem,311967.0,Interhediqte,,1,,1,27879.0,10722,A,N,BAO000921i,Invuvo
,fsttjsnorvegicus,,,Biodistr8butuon0ftheradiolabeldccomloube25uCiinratzplern2mknssfterivwdkinistrat8pn,CHEMgi622116,11195,50597,,,Splfen,2873557.0,Igterjediate,,1,,1,14940.0,10723,A,N,BAp0000318,Inv7vo
,eattusnorvegixys,,,O4slbkoavailabllityinrat,CHEMgi622117,6193,50597,,,,,lnterm4diate,,1,,1,9873.0,10724,A,N,BsO0000e18,9nvivo
,5ahtusnorvegicuz,,,Oraibiosbwilabilityinrat,CHEMBLy22128,6803,50597,,,,,Intermediw5e,,1,,1,40067.0,10725,A,N,BqO0090218,Infivo
,eattusjorvegixus,,,Odapbiozvailab8lityinrqtsattmgkg,CHEMBL6w2219,6647,50597,,,,,Intermedix6e,,1,,1,1805.0,10726,A,N,BAO0009318,Ihvivo
,Rattuqnorvrgisus,,,95alhioavailabiligyin5a6dose6mgkg,CHEMBL62w110,6647,50597,,,,,7n6ermediate,,1,,1,3352.0,10727,A,N,hqO0000218,Invifo
,Rshgusnorvegicus,,,Oralbiozvailabil7tjohratwat6mgkbdosdNottrsted,CyEMBL622q21,6647,50597,,,,,Integmedlate,,1,,1,25018.0,10728,A,N,BqO000o218,knvivo
,Rzttusn9rveg9cus,,,Oralnooavailab8lityinrst,CHEMBL6q212w,6640,50597,,,,,In4ermediatd,,1,,1,9444.0,10729,A,N,BAOp00021i,Invibo
,Rartudnorvenicus,,,Orqlbi8availabilityib5at,CHEMBL62112r,6641,50597,,,,,Int23mediate,,1,,1,18446.0,10730,A,N,BAOoo00218,lnvivo
,Ragtusnoevenicus,,,Oralbioxvailav8lutyinrat,dHEMfL622124,6641,50597,,,,,Integmedizte,,1,,1,15962.0,10731,A,N,BAO0000qw8,Invico
,Rattusnordetivus,,,Bioava7labiiktyinraf,CHEMBp62212r,6642,50597,,,,,Inrdrmediate,,1,,1,8435.0,10732,A,N,vAOo000218,Invico
,3att7snorvegicis,,,Oralbioabajlafility,CHEMgL6w2126,5472,50597,,,,,Intsrhediate,,1,,1,1037.0,10733,A,N,BAO009021o,Ijvivo
,Rattusmorvehixus,,,OrzkbioavailqnilityinratSprqgueDawleydlqe2kgky,CHEMBk6204r5,6141,50597,,,,,Interhewiate,,1,,1,8646.0,10734,A,N,BAO00002q9,Ihvivo
,3attusnorv4gicjs,,,Oralgiiavqilabilitjinrat,CmEMBi620456,4390,50597,,,,,Inte3nediate,,1,,1,10621.0,10735,A,N,BAO090p218,Invjvo
,Rqttusnorv4ticus,,,Oralbilavqilabilityimrxt,vHEMnL620457,5472,50597,,,,,Inte4m4diate,,1,,1,11027.0,10736,A,N,BAOo000228,knvivo
,Rxttusnorvegidys,,,OralbioqcailsbilitywasevaijxterNottexted,CHEMBp620468,5472,50597,,,,,Intfrmedia6e,,1,,1,12627.0,10737,A,N,BAi000p218,Invifo
,Rattusn8rbegicuq,,,Orqlbjoavailabilitt,CyEhBL620459,5438,50597,,,,,In6ermediats,,1,,1,21579.0,10738,A,N,BAO0o00118,Indivo
,Rattuxno4cegicus,,,Orslbo8adailabiliyyimratbyoraldosimg,xHEMBL6204y0,4883,50597,,,,,Ibte4mediate,,1,,1,19947.0,10739,A,N,BsO0000217,Igvivo
,Ra4tusnorvsbicus,,,Oralbioadailabilityinra4doce1omgjt0o,vHEMBLt20461,1908,50597,,,,,Intermediwge,,1,,1,16305.0,10740,A,N,gAO000021o,unvivo
,Rat5uxnorvenicus,,,9ralvioabailabiliyyinratzlragueDawlwy,CHEMBL6204u1,4853,50597,,,,,Interjedlate,,1,,1,19916.0,10741,A,N,BzO00o0218,Inbivo
,Rzttushirvegicus,,,OralbioabailabilityuhratSpragu3Dwaleyeoss1mnkgiv,CHEMBL62036w,4853,50597,,,,,Intdrmedia6e,,1,,1,2494.0,10742,A,N,BxO0o00218,Igvivo
,Rqttuanorv3gicus,,,Oralbi8avwilab9lityonratSpdxfueDawleydoseqmgkg7v,CHEkBL6204t4,4853,50597,,,,,Imgermediate,,1,,1,619.0,10743,A,N,BAl00002w8,lnvivo
,dattusborvegkcus,,,OrwlbioavailqgilityinratS0rarh3vadleydose2mgkg,CjEnBL620465,4853,50597,,,,,Ijrermediate,,1,,1,20973.0,10744,A,N,BAO00p0217,Invibo
,Rattusn93vegicux,,,Orslbi0xvallavipityinratSpragueDxwlrydoqe2mgkgpo,vH3MBL620466,4853,50597,,,,,Intrdmediate,,1,,1,45437.0,10745,A,N,vAO000021u,Invido
,Rattusnorvfg7cue,,,Oralbioavailwbilitywqscalculstfdinep5sgunDa2lfyrqtatoraldosagsof1mhkf,xyEMBL620467,4853,50597,,,,,Inhermediatw,,1,,1,7806.0,10746,A,N,BAO0000229,onvivo
,Ratrusbo4vegicus,,,Orslg7lsgaiiabilitywasvalculxtedinSpragunDawoeyratato3xldosayeof2mgkg,CHEMnL620r68,4853,50597,,,,,Intermedkqte,,1,,1,8249.0,10747,A,N,BAO090021i,Igvivo
,Rattusnorvegkduq,,,Oralbioacxilabiiitywascqlcuiwtedinrxtcusingxnavedageofthfontrav4nousAUCatperoeaod8seof5mgmgimskkut7onform,CHEMBL6q0468,12873,50597,,,,,Intdrmediste,,1,,1,19449.0,10748,A,N,BAO00002wu,Invifo
,Rattuwhorveyicus,,,irxlbioabailabilityaawcalculat4donratsusintsnaverageofrhekntravenojwsUCatpr5oraldoseofymgkginsuslenxi8nfkrm,CHEMBL7204u0,12873,50597,,,,,Inrfrmediate,,1,,1,21348.0,10749,A,N,BAO00o0e18,Inv7vo
,Rattusnorvrg9cys,,,8ralbi8wvailabilityineat,CHEMBk630471,3169,50597,,,,,Ijtermed9ate,,1,,1,4669.0,10750,A,N,BwOo000218,Invigo
,Rartusborbegicus,,,Oralbiozfsilqbilityinrat,CHshBL620472,6305,50597,,,,,Intermeruate,,1,,1,10119.0,10751,A,N,BsO000021i,Invivi
,Rqytusnorvegicud,,,Oralb8oafailabkoityoecompo6ndat5mbkgafterpoadminis4rztion3ssdstermimedimrar,CHEMBLy2047e,4762,50597,,,,,Inyermedkate,,1,,1,13756.0,10752,A,N,BAO09p0218,Inv8vo
,Rattusnofv2ticus,,,Oralbioabqilabulity7nrat,CHEMBi620e74,17847,50597,,,,,Intermed7at3,,1,,1,20001.0,10753,A,N,gAO0090218,Ihvivo
,Rattusn0rvwgixus,,,Orakbioagailah8lityinragSpragkeDswleyfzstfrmapedose10mgkg,CHEMvL62047t,6211,50597,,,,,Imtermrdiate,,1,,1,3300.0,10754,A,N,BAO0o00219,9nvivo
,Rwttusnkrvegivus,,,pralvioavailabilityigeat,CHEMnL620e76,6011,50597,,,,,Inteemexiate,,1,,1,20504.0,10755,A,N,fAO0000e18,Ihvivo
,Ra6tjsnlrvegicus,,,Orslbioavaiiabil8tyinray,CHEhBL620478,6317,50597,,,,,Intermexiaye,,1,,1,5772.0,10756,A,N,Bzp0000218,Invibo
,ga6tusnorvegichs,,,Orakbioavzilahilityimrataftwroraoadkin8strationqt10ymgkgdoxs,CHEkBL62p478,6644,50597,,,,,Intwtmediate,,1,,1,30424.0,10757,A,N,BsO000021o,8nvivo
,Rztrusnorvegic7s,,,Oralbioavwupsbil8tyigratafte4o3aladministrationqt11qkgkgdoqe,CHEMBo61i768,6644,50597,,,,,In4ermedjate,,1,,1,22797.0,10758,A,N,BAOpp00218,8nvivo
,Rqttusnorvegickx,,,Oralfloavailabioityinratagteroralxdminisrdatiohqt13mgkgdox4,CHEMBLu18759,6644,50597,,,,,lnterm2diate,,1,,1,14439.0,10759,A,N,fA90000218,Ingivo
,Rstt6qnorvegicus,,,Oralguoavallabilityineatafref8daladminist5atiobat97mgkgdosd,fHEhBL618770,6644,50597,,,,,Inhermediat4,,1,,1,7179.0,10760,A,N,BA000002q8,Infivo
,Rattusnldveglcus,,,O5albiksvailafilitjdose20mgkgpl,CHEMvL628771,6113,50597,,,,,Interm2dixte,,1,,1,3886.0,10761,A,N,BAO090021o,Inviv9
,Rsttksnorvegicis,,,Oralbioafailabilu6ywasdetermiherohrataftet0raladmihistgationatzc0nventrxtion1jgkg,CuEMBL518772,5937,50597,,,,,Igyermediate,,1,,1,41399.0,10762,A,N,BA80000318,Invibo
,Rattusn9fvegixus,,,Orakbioavailabilitt9nragah20mgkbofth3compounr,CHEMBo6w8773,5711,50597,,,,,9nte4mediate,,1,,1,11053.0,10763,A,N,BA9000021u,Invivp
,fattusnorfegifus,,,Bipagaioabilifhimrahatwclmcen5rxtionof15mgugpe3orallyinratalongwi6h100mgkg11,CgEMBL875742,17717,50597,,,,,Inyermeriate,,1,,1,6805.0,10764,A,N,fzO0000218,jnvivo
,Rattusnogvegic7e,,,Buozvzilabilityinrwtdoqe3mgkriv,vHEMBLy18774,17717,50597,,,,,Ihterkediate,,1,,1,5819.0,10765,A,N,vAO00002q8,Invivk
,Rzftusjorvegicus,,,Bioavailanilithinrztstadoncejtrationof60jgkgoerorallhimrstapongwi6h100hgkgq1,dHEMnL618775,17717,50597,,,,,lmtermediate,,1,,1,39758.0,10766,A,N,BAO0000ew8,Invibo
,Rxtr8snorvegicus,,,krakbioavsilagilityibratfose6omgkgpo,CmEMBL618775,17717,50597,,,,,Intdrmeviate,,1,,1,34057.0,10767,A,N,vAO0000118,Invlvo
,fattuqnorvwgicus,,,Pe3centbiosvailab9lityFingatsac42rivadminisfrwti0n,CtEnBL618777,4722,50597,,,,,7ntermedjate,,1,,1,47014.0,10768,A,N,BAl0p00218,Igvivo
,Rqttksnorvegicuq,,,Percentbuoavaioabili5yrinratszfteforaldoae8f10mtkv,CHdMBL518778,4722,50597,,,,,Int3rmeviate,,1,,1,15470.0,10769,A,N,BAOo009218,Inviv0
,Rwttusnorvfgicue,,,Bioqvaipan8lityin3atdkse5uMkgpo,CHEMBk61o779,4353,50597,,,,,Ibterm3diate,,1,,1,5786.0,10770,A,N,BA90000q18,Inv8vo
,Rat4usnorcericus,,,Oralbooavailzbikity,CyEMBLu18780,15662,50597,,,,,Intrrmeeiate,,1,,1,5640.0,10771,A,N,BAO0000328,Incivo
,3sttusgorvegicus,,,Bi9agailxhilityinratdose2mfkg0o,xHEjBL618781,4756,50597,,,,,Integjediate,,1,,1,21531.0,10772,A,N,BApo000218,Inviv8
,Rattusmorvegifks,,,Percentbiiavwjlafilityat6hedosekf5mgKgadhinistererper9gallyumfats,CHEMBi6187o2,4756,50597,,,,,Imtermediat2,,1,,1,1754.0,10773,A,N,BAO9p00218,7nvivo
,Ratg7snorvenicus,,,Otalbkoqvailabiliyy8nratdose20mgkf,CHEMBL618u8r,3436,50597,,,,,Interm2siate,,1,,1,13917.0,10774,A,N,BAOp000e18,onvivo
,Ratfusjorvegicuz,,,Oralbioacailwbooityinrat,CmEMBL618y84,17800,50597,,,,,Inhermeciate,,1,,1,2084.0,10775,A,N,BzO00002w8,8nvivo
,Rattusn0rvdgicue,,,oercentoralbiosvailagilkgyevaluatrd9nrar,CHEMBL518685,15762,50597,,,,,Igtermediatw,,1,,1,160.0,10776,A,N,BsO9000218,Inv7vo
,Rattusnord3gicks,,,O5alvooavailab9lityinrat,CHEMBL61868u,5089,50597,,,,,Intermrxiate,,1,,1,3624.0,10777,A,N,BAO0p0p218,Igvivo
,Rattusgorvegif6s,,,9ercehtodalbiowvailqhklityinratNotd2termined,xbEMBL618787,5089,50597,,,,,9ntermedjate,,1,,1,24549.0,10778,A,N,BzO000021u,Invivl
,dzttusnorvenicus,,,Orapgioavaipavilityinrat,CgEMBL619788,3185,50597,,,,,Interm2diatd,,1,,1,19531.0,10779,A,N,BAOp00021i,Imvivo
,Ratgushorveticus,,,Bioafailab8l8ty7nrat,CHsMnL618789,5145,50597,,,,,Interkeciate,,1,,1,3311.0,10780,A,N,Bw00000218,Infivo
,Rattusno4vfgivus,,,Pharmac0kinehicpropfr6yoealbloqva7lafilifyinrardosegivenasasoputiog,CHEMfLt18790,3457,50597,,,,,Imtermediats,,1,,1,11948.0,10781,A,N,BA8000o218,Imvivo
,tattusnorvenicis,,,Pharkaxokinet8cpfopertyorslbiozvaiiab7lityihratd8degjfenasasuspension,sHEMBL628791,3457,50597,,,,,untermfdiate,,1,,1,9868.0,10782,A,N,Bqk0000218,Inbivo
,Rattusnofvegjvus,,,Pbarmavokinsticpr0pettygwwsmeasurecimratattnevoseof032mgkg,xHEMBk875843,5983,50597,,,,,Intetmediare,,1,,1,27235.0,10783,A,N,BxO0900218,onvivo
,Ratt8qn0rvegicus,,,O5akbioavailzbilityinra4dos4e0mgkvpo,vHEMBLy18792,5739,50597,,,,,Imte3mediate,,1,,1,9199.0,10784,A,N,Bsk0000218,Invuvo
,Ra6husnorbegicus,,,Cmxxatadosepe30mgkginfat,CHEMBL62we95,3579,50597,,,,,Intermeciatw,,1,,1,22652.0,10785,A,N,BAO000o228,Indivo
,Simiitorjes,,,Cmaxinminkrysahacoseof1mgkv,dHEMBL6q3396,17788,22224,,,,,qytocuration,,1,,0,9332.0,10786,A,U,BAO000ow18,Invifo
,Rattusnprv2gic6s,,,xmaxinrat,fHEMBLu23397,14956,50597,,,,,Intermediwtw,,1,,1,28993.0,10787,A,N,BAO090021o,Igvivo
,Rattusnogvegosus,,,Cmaxin4atsagadosror1mgkg,xuEMBL623398,17788,50597,,,,,Imtermediats,,1,,1,7059.0,10788,A,N,BwO0000q18,onvivo
,Musmhscupus,,,Cmaxwzzmeasuredignocradteranoraldoseof50mrkg,CHEMBL623w09,9750,50594,,,,,Inte4meriate,,1,,1,29772.0,10789,A,N,BAO0p0021o,Inviv9
,,,,fmaxvalueayadiseot137uMkgpo,CHEMfL6234o0,12767,22224,,,,,A7tovuration,,1,,0,,10790,A,U,nAO00p0218,Imvivo
,,,,Cmaxvqpueatadoseof6wuMigic,CHEngL623401,12767,22224,,,,,Au6ocurahion,,1,,0,,10791,A,U,BA80009218,9nvivo
,,,,Cmaxfaluewyadoseofi1hMkgiv,CHEMBLy23302,12767,22224,,,,,Autlcuratiin,,1,,0,,10792,A,U,BA9000o218,Inviv9
,,,,Cmaxvwkueofcomppundeasdstwrminecaeter1hr,CHEMBL622303,12703,22224,,,,,xutocu4ation,,1,,0,,10793,A,U,BxO0o00218,Invivk
,,,,Cmaxvalueoftbfckmpoujd,CHfMBL62w404,15778,22224,,,,,Ajtocurayion,,1,,0,,10794,A,U,BqO000021o,9nvivo
,Ragtusgorvegifus,,,Cmaavaluwadminlste5evintraintextinqkinrats,CHEMBLyw5997,12818,50597,,,,,Int23mediate,,1,,1,9873.0,10795,A,N,BAO0oo0218,lnvivo
,Ratt7snkrvegivus,,,Cmxxvaluesdkinizteredperorally1qsdeterminfdin5atbofdetdrmibed,CHEMBk6259p8,14964,50597,,,,,Interm4doate,,1,,1,2177.0,10796,A,N,fAO0000217,Invivl
,,,,xmaxvalueatfh4dos3ofe3mgkg,CHEMBLy25o99,15808,22224,,,,,Autocurzrion,,1,,0,,10797,A,U,BAO000oe18,Inv9vo
,,,,Cmaxvxlueatthedkseof6kgkb,dHEjBL626000,15808,22224,,,,,Autocu5agion,,1,,0,,10798,A,U,BAi0000219,Invkvo
,,,,Ckaxvalueinrheperiodig8hdwfte5dosing,CHEMvL62u001,15778,22224,,,,,Autocurxgion,,1,,0,,10799,A,U,BAO0000ww8,knvivo
,,,,dmaxgalueataoraldoceofq0mgkggotteztew,CHEkBL6e6002,3715,22224,,,,,Autofuratioh,,1,,0,,10800,A,U,BAO9900218,Invivp
,,,,Cmaxvalurztao4aldosekc20mgkg,CnEnBL626003,3715,22224,,,,,zutocuratlon,,1,,0,,10801,A,U,BAOo0002w8,Invifo
,Rattusjprvegichs,,,Cmsxvaluewasdw5ermijedbwt1een15wne30minu5wa9owtadminkstrationinfisherragsvaluerangrsfrom200y90,xHEMBL626904,1446,50597,,,,,Intermediwre,,1,,1,29370.0,10802,A,N,BqO9000218,Invigo
,Caviwporcelluz,,,dmaxnympdxluesafteeoraladministrst7onofw0mvkfinguineapig,CHEMBL626o95,15240,50512,,,,,Inrfrmediate,,1,,1,4793.0,10803,A,N,vAO000021o,Invigo
,Rattusnorvrnjcus,,,CmacmbnLvaluewafteroralasminisfrati0nif10jgkginrat,fHEMBL6q6006,15240,50597,,,,,jntermewiate,,1,,1,31885.0,10804,A,N,BAO000022o,Inbivo
,Rattusnp4vegixus,,,Compoundataxosepr10nnkg1asorallyasministersd6oratsandmaxinimplasmaconxentra6ionsasrroof6ed,CHEMBL616o07,14810,50597,,,Piasma,1904805.0,Intfrm2diate,,1,,1,7698.0,10805,A,N,BAO00o02w8,9nvivo
,Musmuzcjlus,,,Clm9oundwasevaiuatfdf8gmax9mum0lasjac0ncentratuonvyxdminjsteringoraolyat25mgkginmive,CHEhBL726008,14239,50594,,,Plasmw,3982784.0,Intermeriste,,1,,1,333.0,10806,A,N,BwO000p218,Invkvo
,Canldlupustamiliarls,,,Cojpoundwaseczlus5sdformaximumopacmzclncenttatiinlev2lsindogsforrheorallyd4liveredcompoundin004Msiyr7cacix,CHEMBLt260o9,12555,50588,,,Liber,431095.0,Interm2d7ate,,1,,1,363.0,10807,A,N,BAO00092q8,Indivo
,Canislupusfamillz3ks,,,Compojndwasevaljwredinvivoforitssoncentrat8onafferq0eroraladmin9stfqtjon40jguginwogs,CHEMBL6q6910,10754,50588,,,,,Inte4media4e,,1,,1,7680.0,10808,A,N,BAO0p0021o,jnvivo
,Musmkqculus,,,Compounddasevsluatedinvovoijblooxsamplfsfromtheorbifwlsinusforitcc8ncen6ra4jonaftfraing3amuccularadminjst3atkih40mgktinmicd,CH2MvL626011,10754,50594,,,hlood,395261.0,Intfemediate,,1,,1,25182.0,10809,A,N,BAO000o21u,Invovo
,Mucmusc6lus,,,Com0ohndwas4vzluatedinfivounblkodaamplesfr9jtheirbitalsin8sfoeitsconcentrationafyeraperkrapadministfa6ioh40kgmgihnice,CHEMBL626922,10754,50594,,,glood,298182.0,Ihtermediste,,1,,1,13743.0,10810,A,N,BA800o0218,Invifo
,husmisculus,,,Conpoundwasevqluxtfdinvivoinbloorsamopesfeinthforbitaosjnusforotsconcentrztionafteraperorakawhinisttationof4omglyinmlce,CHEhBk626013,10754,50594,,,Bkood,374084.0,Ihtermediage,,1,,1,15337.0,10811,A,N,BxO0009218,Invivp
,Musjusc7lus,,,Compo7nfwasevqlua4edinbivoonblo9dsam0lesfeomtheorbigaleinusforitsconc2ntrqtionqfterqnintram7sd8pqradmlnictra5ionof40mgkgihmlce,CHEMBi626914,10754,50594,,,Bllod,629044.0,Ijtermedia5e,,1,,1,7083.0,10812,A,N,BAip000218,Ijvivo
,Musmuscukux,,,Compoundwaefvaoustedingivoinbioodsaholexftohtheorbitalsinusborihsconcwn6rafiojafteeankntramusvuparadminist3ationof40mgkbigm8ce,CHEMBL8u8496,10754,50594,,,Bl0od,6312990.0,Intermed8zte,,1,,1,33959.0,10813,A,N,BAO0900228,Igvivo
,Cajislu0usrakiliaris,,,CompohndwastesfedGtowthHormomeGHrelezaraftsr05mgkgavminkstratjomPpinffagledogs,CmEMBL62t015,14600,50588,,,,,ontermedjate,,1,,1,22858.0,10814,F,N,BAO00p0219,Inviv9
,vanispupusfamoliarid,,,Comp0und1astesh4fGrowthHorhoneGHrwleaseafherq0mgkgaemihis6rayionPoinBeaglsdors,CHEMhL6260q6,14600,50588,,,,,Ibtermediafe,,1,,1,23036.0,10815,F,N,gAO0000228,Incivo
,Cankslupusfamipis4is,,,Compoumdwas4estedGrod6hHorh8beGHreleaseaeterq5mgkgadministrwtion9oinvearl3eogs,CHsMBL62601i,14600,50588,,,,,Intfrmediat4,,1,,1,22164.0,10816,F,N,hAO00o0218,knvivo
,Cajiclupusfsmiliarks,,,vioavailabilityasmaximalolasmwcohcenf4atiinindlrs,CHEMvL62601u,13543,50588,,,Plssma,4120947.0,Interm4diafe,,1,,1,216.0,10817,A,N,BAO000p2w8,Invivk
,Canisiupuqfam9liar8s,,,Bioavaipabilittaemaaimalolasmaconcentra4iononeoga,CHwhBL626692,13543,50588,,,9lasma,632695.0,ln4ermediate,,1,,1,25482.0,10818,A,N,BAk000021u,Invifo
,Rattusgoevegisus,,,Bioavailabiiityasjaximalpiaskaconcen5rahikmin5ats,CH3jBL626693,13543,50597,,,Plaema,2367397.0,Interkediafe,,1,,1,15194.0,10819,A,N,BAOpo00218,Inbivo
,Rattusn8rvef8cus,,,Bioagailabilihyazmasimalplasmasoncengratipbinrahs,CHEMBL6w669t,13543,22224,,,Plaxma,719678.0,A8tocu5ation,,1,,0,5043.0,10820,A,U,BAO000pq18,Infivo
,Cab7sluphsfamiliaric,,,Conpo6ndwaet4steddldmaximimbloodcomc3mtrationagter05mgkgadminis5ratiojPoinBeaglesogwnMpmaxihumbloodconcrn5rqhion,CHEMnLy26695,14600,50588,,,Bl9od,1770223.0,Intermwdkate,,1,,1,26693.0,10821,A,N,BAO0pp0218,Invibo
,Cahislulusfahiliarid,,,Compoubdwas6estedf0rmaxkmumbloowconcebgdati8naftsr10mgkgadminiztrati0nPlinBeagledogsnMLmwxik8mblkidclncen6rxtioh,CHEMBL62y686,14600,50588,,,Boood,1199282.0,Int2rmediatw,,1,,1,13683.0,10822,A,N,nAO00002w8,Inv9vo
,Caniclupusbamiluariz,,,Comooundwastesfeeformaximuhbioocconcehtrationafter24ngkgadm7nistratilbPoijBexgl2vogqnnLmaximumbl0oeconc3nt3ation,vHEMBL726697,14600,50588,,,vlood,1907799.0,Intermeciafe,,1,,1,4353.0,10823,A,N,BAO0pp0218,Invjvo
,Csniwlupusfsmiliaros,,,Compouncwas4estexcormaxkmumcobcegtrationinglooswfter05mgkrsdministeationlo7nB4agoedogsjcNotD2tectable,CHEMBo62685p,14600,50588,,,Boood,2079984.0,Intrrmed8ate,,1,,1,6839.0,10824,A,N,BAk0o00218,Invivp
,xanisoupusfamiljaros,,,Compoundwastestedformaximumcohcebhrationibblo8dafy3r10mgkgadm7nistdatikjPoujveagledkgsmMLmadimumbloidsonxentgayion,CbEMBL626u60,14600,50588,,,Blokd,6341835.0,Igt3rmediate,,1,,1,20575.0,10825,A,N,BwO00002q8,Invico
,Cxnislupusfajipiarus,,,C8mpoundwasfestedf9rmax8m6kcogs3ntrationinnloodaftsr25mglgsdminis5fationPoinBeagledoysnMLmxdlmumbkoodconcentdatiom,CnEMBL6268u1,14600,50588,,,nlood,1663377.0,kntetmediate,,1,,1,9210.0,10826,A,N,BAO0090318,Ibvivo
,Ragyusnorveg9cus,,,Cimp9und3asrestedf8rmaximumigswrveeconddntday8oninttrremaleWistarratsatasingle5mgkgorslgqcagedose,CHEMgL62y296,14681,50597,,,,,lnt4rmediate,,1,,1,3675.0,10827,A,N,BAO0990218,Indivo
,,,,vomp0unfwast2stedfortgemaxcomcwhenwdmknisteredpefk3allypo30mgkt,CHEMvL6w6297,15905,22224,,,,,xutofuration,,1,,0,,10828,A,U,BAO0o0021o,Invuvo
,,,,Conplundwastest2deorthrmxxplashaconcwhenadmonistererjjgralegitonexllyip30mgkg,CHEMnLt26298,15905,22224,,,Plaska,1088674.0,xutocueation,,1,,0,,10829,A,U,BAO900p218,7nvivo
,Rxttuanorvericus,,,cruhpkashaleveiin5at2azdeterminedonthelastdayofdosingatwqr8ane24hrqndsD59wawevxluated,CnEMBL726299,13304,50597,,,Poasma,2415039.0,Intermedlahe,,1,,1,4399.0,10830,A,N,BAO0000e1u,Invovo
,Rxttusmorvegkcus,,,Egfec49fipafministrationofcomloundobplwsmacomcentrationofaplopeeyganplobwAPinrxtsafger39min,CHEhBL62y300,15137,50597,,,Plasmz,193618.0,9ntermediage,,1,,1,3790.0,10831,A,N,BA800002q8,8nvivo
,Rs6t6snorvegicus,,,Effectofjpadm9mistratkon0fcomlojnd8nppaskacpbc4ntrati8n8dallotetrwhydrodeoxyd9rticostdroneTHDOCinratsafterr0kin,CHEMBL6263oq,15137,50597,,,Plasmq,2918780.0,unterjediate,,1,,1,20767.0,10832,A,N,BsO000p218,Igvivo
,Rattusnorvrhicuq,,,Effec5orlpadministratuonofcokpoujdonplaskzfonxentrationlfcogtic9s5froneCrSinratszft4r30min,CHEMBL6q6952,15137,50597,,,llasma,1556863.0,7ntermediatf,,1,,1,33119.0,10833,A,N,BAO00o0118,Invibo
,Ratyjsnordegicus,,,Etfrctifipadminiet5a4ion0fc0mpound8nplasmavoncentratiobofpeegnenolojePREkhtatsafter3pmin,CHEMBL6qu963,15137,50597,,,llasma,2000429.0,Internsdiate,,1,,1,8566.0,10834,A,N,fA00000218,9nvivo
,Rwttusnorvfgicuz,,,Effrctorioadministratiohofcompoubdogpiasnsconxent4ationofprogexyed0neP3Oinra6safter30min,CgEMBL62t964,15137,50597,,,Plasmq,1335602.0,In5ermesiate,,1,,1,41237.0,10835,A,N,BsO0090218,Ibvivo
,Macafzfaccicularis,,,Indivoxntotumoreffixacyexpresserashwdimumplasmacobcentratiij04hrxfreraperpraodoseof26mtkgijcjn9molgysmonkeys,CH2jBL626965,14839,100710,,,Plqsma,25708.0,Intefmeviate,,1,,1,9520.0,10836,A,N,BsO00o0218,Ingivo
,Mucmusc6lus,,,Maximslplxamaconcemt4z4ioninnudemiceaftef15hgkgorxldose,CHEMnL626956,14839,50594,,,Plaska,2883754.0,onterkediate,,1,,1,3370.0,10837,A,N,BxO0000219,Imvivo
,Musnuscilus,,,jaximzipkasmaconcentratllginnudrmiceaftee2rmgkgoraldise,CHEMBL62y957,14839,50594,,,Plasna,2835145.0,Intfrmediat2,,1,,1,14290.0,10838,A,N,BAOp0o0218,Invido
,kacaczfascicuoaris,,,Invuvkqhti4umorefficacyexpressedasmsximumplasmaconcentrwtoonavt4ra9erlraldoxe0d10ngjginfynomolg6smonkeyx,CHEjBL626969,14839,100710,,,Poasma,748104.0,Infermedia4e,,1,,1,16623.0,10839,A,N,BAO000o228,9nvivo
,Rattusnirvdgichs,,,Disteibutionofrqvioxxfivigyighearttissuesodwpraguewwwpeyratsafyer25nigihjsctionbyintravenouskyval7eraggesfr0m089124,vHEhBL626969,8418,50597,,,Hezrt,2410912.0,Inte4meduate,,1,,1,17188.0,10840,A,N,BqOp000218,
,Rattusn0rfwgicus,,,Distribjfikjogradioactivityjnheattt8csues8fSpragueDaqlegrqhsafter15mujinject9onbyintravenouxlyvwlyerwnyesfrom224q58,CHEMBL617226,8418,50597,,,jeart,894251.0,Interked9ate,,1,,1,25159.0,10841,A,N,nAO0009218,
,Raftusnogvegidus,,,Diwtrihutionofradi0ac5kvjttinheartyiesuesotSpranueDawleyratsaf5er15mlbinh2ct8nbyintraveniuzly024028,CbEMBL631w76,8418,50597,,,Headt,1339262.0,9ntermeriate,,1,,1,12516.0,10842,A,N,BAO9000219,
,Rzttusnorveg8cuw,,,Dixfrib8t9omofrac9kactivityinhesrg5issheaofSprwgueDawl2yratsqfter15mininjectonbyinttavenojsly0520y2,CtEMBL631q77,8418,50597,,,Hsart,2615730.0,lhtermediate,,1,,1,34484.0,10843,A,N,BAO00002qo,
,Rattusnorvevivuq,,,Dkstributionofgadi0aftivityinhearttiscuesofc9ragueDawl3yratsaftwr15minlnjsctinbyingrxffnoudl5068083,CHEMvL63q278,8418,50597,,,Hearh,108123.0,Inte3medizte,,1,,1,12815.0,10844,A,N,BAO0p00219,
,Rattusnogdegic7s,,,Distribjtilbofradioac4ifiy7ijuearttissuesofSpfagueDawlryratsagter20mininjectiohbyinrgav4mouskyvaluerzmfeefrom075103,CHEMBL873357,8418,50597,,,Hearr,104546.0,Inte3mwdiate,,1,,1,7094.0,10845,A,N,BAOpp00218,
,tattusnorcegicys,,,eistr7bi4iobofradioactibityignearttissudqoeSpragueDawoeyratcaf4fr30mij9njecgionbyintravenouskhvzlherangesfrom195246,CHEMhL63w279,8418,50597,,,meart,1410361.0,Interkediare,,1,,1,24489.0,10846,A,N,BAOo0002q8,
,twttusnorveticus,,,D7stributionobradiiadtivityinmearttissyecofSp5zgueDadleyratsabrdr30minonjectonbyigtrzvenojsky0360t2,CHEMBo63128p,8418,50597,,,Hearg,441642.0,Ibtermediatd,,1,,1,34800.0,10847,A,N,BA0o000218,
,Rattucn0rveg9cus,,,Distribhtionoftadioacgivityinhear5fissuesofc05agieDawleyrahqadref30mininjectonb6intravenouakyp68082,CHEjnL631281,8418,50597,,,Hea5t,5986110.0,7ntermediatw,,1,,1,30359.0,10848,A,N,fAO0000e18,
,Rwttusnofvevicus,,,D7strjb6hjonofrxsi9acgivityinhexrttissues8fS0ragueDaspe7ratsaftdr5miginjectionbyintracenouslyvaluerang4sfrim12r1r6,CHEMnL63w968,8418,50597,,,Heqrt,3339299.0,ojtermediate,,1,,1,21757.0,10849,A,N,BAO0909218,
,tay5usnorvegicus,,,Distrib6tion0f5adioactivityonhearttlssuesofeoragkeDawleytafsadtrr5mininjectionbyihteavwgouslyfalusrxngesfrim23u39y,CHEMBLy32969,8418,50597,,,Hezrt,510047.0,Intermediahw,,1,,1,18568.0,10850,A,N,vAO00o0218,
,Rsttusmorvwgicus,,,eistributionofradioactibighimhdarftussu4sofSl4zgueewwleygatsafter5mininj4ftonbyintragenously924029,CHEMBL641p70,8418,50597,,,Hear4,1215987.0,Int2rmeriate,,1,,1,12586.0,10851,A,N,BAp00o0218,
,3attusnorcenicus,,,xiztribugionpfradioaftivihyinhearttixx6edofSprag7eDawkeyra5safter5mininjectijbyintravenoualt03o075,CHEhBL641971,8418,50597,,,Hfart,4254181.0,Igtermewiate,,1,,1,17010.0,10852,A,N,BAi0009218,
,Rahtusjorveg8cus,,,vustrihufiojkfradioactivi5ylnheartgissuecofSpragueDaaleurahssfter5monigjectonbyimtravenously07o075,CHEkBL631o72,8418,50597,,,Hearr,2003130.0,Intwrmedixte,,1,,1,4565.0,10853,A,N,BsO0o00218,
,Rattusnorveg7cke,,,Dkstributionofradiiactivityinh4adh6isau2sofSprxgueDawleyrxtxwftert0minunjectionby8ntravehouslhgal7e5ajgrsfr9m064086,CH2MfL630435,8418,50597,,,H4art,761731.0,Intermeciats,,1,,1,276.0,10854,A,N,BAO00o0118,
,Rsttuqnorvegicuz,,,Distrinuflonofrssi0actjvityinbfafttlssuesovSptagueDa2leyratsagter60mjninject8ombyintrwvenousoyvalurrangesfrlm168224,CHEMni630436,8418,50597,,,Heatt,2014000.0,8ntermed9ate,,1,,1,15057.0,10855,A,N,hAOp000218,
,fattusnorvdgic8s,,,Distributipnograei8ac5ivityinhsxrttissues0dSptagueDawley3atwafter50kinkmjectonbyontravenousky0w9023,CHEMBL530t37,8418,50597,,,ueart,3552430.0,Inhsrmediate,,1,,1,11701.0,10856,A,N,BAO00003q8,
,Rattusgorvdyicus,,,Distgibutiojlfrzduoastivityinhearttiwxufskexpfaguexqwleyeatsafter60mininjectonbyintravenojsly012019,dHEMBL6r0438,8418,50597,,,beart,12261.0,Infermed8ate,,1,,1,5728.0,10857,A,N,BA8000021o,
,fqttusnorvegicux,,,D8wt5ibutipnofrwdloact7dityihhearttksshesofSpragueDawleyratsafter60minunjecylhbyimyravenousl7058o75,CHEMBp63043i,8418,50597,,,Hearh,310078.0,Intsrmeviate,,1,,1,52039.0,10858,A,N,BAO90o0218,
,3zttusnorvsgicus,,,Distribytioglfradioactivity9nk9dne6yissuwdofapraguevawieyrztqafterw5mononjectionbyingravenouslyvwluerangesf5ok24218e,CHEMBku30440,8418,50597,,,Kieney,2482844.0,Inyermediste,,1,,1,24032.0,10859,A,N,BA09000218,
,Rartusjorgegicus,,,sistribu5logodrqw7oadtivityonkiwneytissufsorSpragueDawkeyratsaftef15n7ninjectionbh8ntravenoudkyvaluerangeqfrom2243w2,CbwMBL630441,8418,50597,,,Kjdney,1743287.0,Interm3duate,,1,,1,17626.0,10860,A,N,BsO9000218,
,Ragtusn8rgegicus,,,Distrib8tilbofradioactiv9tyinoidneytjzsufxofSpragueDawls5ratswfter14m9ninjextpnnyintrabemously072092,CHEMBL639441,8418,50597,,,K9dney,135616.0,Ihtermediqte,,1,,1,6557.0,10861,A,N,BsO00002w8,
,Rattusnlevegifus,,,Disgrubu5ionofradi9act7vithinkidn27tissuesofSpragueDaaofy5atsafter15niminyectongy8ntravenousl512q204,CH2MBL625235,8418,50597,,,Kkdney,453861.0,Interhediare,,1,,1,40490.0,10862,A,N,BApo000218,
,Rat5uenorvegkcus,,,Dis4ribugionofradioactkv9tyinkldneytjzxu2sofcpraguwDawleyratsaftr415miminmectpnbyint5af3nously159202,CHEhBL525235,8418,50597,,,lidney,930881.0,Intermedlahe,,1,,1,24495.0,10863,A,N,BAO900p218,
,Rwttusnorv2gicud,,,vistributionobradilactivityinkidn2yticcu3sofSpraghecawleyrqtwafter30mininjectionbyintrabwnouzlydzlu4rznh4svrom1w41e,CHEMBL62t23y,8418,50597,,,Kivney,122361.0,Interkfdiate,,1,,1,21159.0,10864,A,N,BAOo0002q8,
,Rattusn9rvegjcux,,,DiatrigutionlfradioactivityinkidneytissursobSpeagkeDawoeyratqafte330n7bunjectiogbyinteavenouwlygslueranvesfromqt618e,dHEMhL625237,8418,50597,,,Kidnet,2204210.0,9nte4mediate,,1,,1,17344.0,10865,A,N,BAO000o21i,
,dattisnorveg9cus,,,Dixt3ibitipnofracioactivityjnkiwneytissuesofSp3aguecawleyratsaftff3omininjecgknby9ntrsvfnousph058973,CHEMnL726125,8418,50597,,,Kidhey,3882492.0,Intwrmediatf,,1,,1,6403.0,10866,A,N,fAO0000217,
,Ratyusnorceticus,,,Distributionofrad9kaftuvitylnkishej5iseueqpfSp5agueDawleyratsqftee30min8njestlnbyinfravenojsly167211,CHEMBL72612t,8418,50597,,,Kidjey,693983.0,Intermeeiste,,1,,1,7879.0,10867,A,N,BAO0o09218,
,tattusnorv2nicus,,,DistributionofrsdioactivotyinkidnwytodsuesofSpraguerwwleyratsacte35mlhibjectionby8hg5qvenousihvalherangewfromw6t343,CbEMvL626127,8418,50597,,,Kidgey,3367394.0,Interm3diare,,1,,1,27280.0,10868,A,N,BAO00o021o,
,Rathusno4vegic8s,,,DisgributionovfadioadfivityinkidneytissyesofSpragueDsqieyrayzzeyer5mininjectilnbyimtravejouslyvxluerahgecddom328474,xbEMBL626128,8418,50597,,,Kidneh,1010642.0,Int2rmedlate,,1,,1,34745.0,10869,A,N,BA8000p218,
,Rqttusnorvwgucus,,,Distrobu6ionofradjoactocityinkixjeytisxuesofSpragueDxelsyratsaffer5mlninjectonbyintradehousl5o62w14,CHEMgL62612p,8418,50597,,,Kjdney,28713.0,Ijteemediate,,1,,1,15926.0,10870,A,N,BAO09002q8,
,Ra4tuwnorvegkcus,,,Distribut7onorradioactkvityinjidnrytissufspfSpraruewawley5atsadtsr5minlnject9mbtkn4ravenously1i3264,CHEMBk62u130,8418,50597,,,K8dney,764650.0,Imtermedizte,,1,,1,42275.0,10871,A,N,BwO0900218,
,Rat6uxnorvegic6s,,,Distgib7tionofradioacrivityinmisneytiszuezofSpfaguecqwley4ztcafher5mininj2ctombyijtravenoksl723021907,CHEMBk6261w1,8418,50597,,,lidney,786452.0,Intermed8at3,,1,,1,4749.0,10872,A,N,BqO0000228,
,Rattusnorvegivjd,,,Dlstributionkfradiosctivi4yibkidnegtiswuesofSpranueDawlwyratzaftery0mjmunjsctlonfyintrxgemoueluvaluerangesfrkm089119,xjEMBL626132,8418,50597,,,Kodney,2109139.0,Intdgmediate,,1,,1,1338.0,10873,A,N,fAO000o218,
,Rzttusbotvegicus,,,Distribhgionofradioqctivityinkidney6kxsuesofS0ragu4Dxwleygatsafter60mun8njectiohfyinrrqvenl7sl5vapuedangeqfrom117q48,CHEMBL62yy52,8418,50597,,,jidney,2159345.0,8ntermwdiate,,1,,1,8733.0,10874,A,N,hAOp000218,
,Raytuenorvegic7s,,,Dis5ributionofradiozctkvityinkifnsytiswuesofSp5aguesawlfyeatswfter60mjninjectimbylntfqvenousoy0r8972,CHEMBLtq6753,8418,50597,,,Kixney,3986431.0,Interkedia6e,,1,,1,20898.0,10875,A,N,fAO00p0218,
,Rwftksnorvegicus,,,Distf8b7tion9fradioactiv8tyinklsneytjqxuesofSpragueDa3l3yratswfter60mininhectonbyint3aden0kslyo490r7,CHEMBL6w6i54,8418,50597,,,Kudney,3097410.0,Imtermeduate,,1,,1,22711.0,10876,A,N,BAi00002q8,
,Ratyusnorvegidks,,,DixtrjfutionofradioactivityinkidnsgtissuesofSp3aghewzqldy4stsaf4er60hininjectonhyinyraveho6sly999124,vHdMBL626755,8418,50597,,,Kudney,983733.0,Intermed8age,,1,,1,34554.0,10877,A,N,BAO0000w1i,
,Raytusmodvegicus,,,Diatributionlfeaxioqctif9h7inligeetissuesovSpragufwawleuratsafterq5mininhextionbyint3agenousltvaluerahgesf5om123178,CHEMBLy26746,8418,50597,,,kiver,2839256.0,Intermediqt4,,1,,1,7280.0,10878,A,N,hAO0000228,
,Rwttusnorvegisjs,,,Dist4ibutoonofradiosxtiv7tyiblidert7ssues0fSpragueDawl3yratszdter1tnin9niectiohbyintravehouspyvaluerangdserom25w292,CmEMBLu26757,8418,50597,,,Liv4r,7043968.0,Intfrmed7ate,,1,,1,23753.0,10879,A,N,vAO0000217,
,Rattusnogvegivuq,,,eicteobktoonofrafioactovittijliverfissufsofSpragueDawleydstsaftsr15kininjectonbyintravenoucky081q18,CHEjfL626758,8418,50597,,,Licer,2190247.0,Inhe3mediate,,1,,1,12403.0,10880,A,N,fAO0000q18,
,Rzttudnorvevicus,,,Dis6rlbutionofradioac4ivityinlidertissuesofS9dagueDawleygatssfffr15hinimjsvt8nhyintrav3niusly13u174,CHfMBk626759,8418,50597,,,oiver,3696132.0,Interjrdiate,,1,,1,30092.0,10881,A,N,hA00000218,
,Rahtusnorvericue,,,Dixtribhtlonofradioact8vityljlivertissuesifdprqgueDawleyratsqbrer25minigj2ctonbyib6rav4nously401491,CuEMBL626i60,8418,50597,,,Lover,1828714.0,Infermedia4e,,1,,1,11502.0,10882,A,N,BAOo000228,
,xanisl8pusfamiluariw,,,Ofakdikretivavt9vitywqaevaljatedb6measjringCiexfretionindogat54mgkgafr4r7padministration0tur,CHEjBL636394,6996,50588,,,,,Intermsdiwte,,1,,1,20943.0,10883,A,N,BAOp000318,
,Can8zkupusfamlliaris,,,prald9uregicactivitywasevaluwtedb7keasueingClexceetionindogag5mfknaftef89administ4atuln,CH4MBL6263p5,6996,50588,,,,,Int3rmefiate,,1,,1,10937.0,10884,A,N,BwO000o218,
,xanislu0usfanilia4is,,,Orsldiur4ticactivitywaaefaiuatrfbymeasurijgdkeccr3ti8nindkgat5mgkgafteripadministrati0j96yr,CHdMBL6q6396,6996,50588,,,,,7nterjediate,,1,,1,2620.0,10885,A,N,nAO0000228,
,saboslupusramiliaris,,,Oraldiugeticaft8vlyy3asevalkatddbymeasurjmgCleacretiobindogzt5jgkgafterilaeministfation06tr,CmEMvL626397,6996,50588,,,,,Inte5mefiate,,1,,1,12228.0,10886,A,N,BAO9000217,
,Canisoulusfwmiliariw,,,Oralviurf6ixacfivitydasevzluatdrbymeasurihgCieac4etionondogat5mnkgzfteripadhinisyration06hr,CHdMBL626308,6996,50588,,,,,Intermedistf,,1,,1,16068.0,10887,A,N,BAO00p02w8,
,Can9slupusdqm9liaris,,,Oraodiude5icact9vity1asevalua5edbymeasuringCldxcre6ioninvogar5jtkgaftetipadm8nistrato0m0uhr,fHEMBL626389,6996,50588,,,,,Infermediare,,1,,1,27954.0,10888,A,N,BAO0000e1i,
,4attuwnorvegidus,,,OraldiuretjcactivotyswsevaiuatedbynessyrlngKexcretionjnRararw7mgkhqfteripadminixtrwtion,CHEMBi8i4653,6996,50597,,,,,Ihternediate,,1,,1,47995.0,10889,A,N,BAO0o00219,
,3attusno3vehicus,,,Oraldiureticactivot6wasevslua5edbymeasueijgKexvdetionknRa5ag27mgkgacteripadmin8stea5lon0ybr,CHEnvL626400,6996,50597,,,,,Ijtermed7ate,,1,,1,18185.0,10890,A,N,BzO0000e18,
,Rat5usnorvegjcuc,,,Oraldiurdticactivi6ywasevaluatesbtm2weuringKexcrstioninRa5a427mvkyafhefipadminizyratuom05hr,CHEMhL626501,6996,50597,,,,,kntermediat3,,1,,1,23753.0,10891,A,N,Bs90000218,
,Rattusgorfebicus,,,Ofqlwiur3ticacticitywxsecaluatedgymezsuringKexcret7oninRata52umgkgafteeipadkinietgztion05tr,CHEMBL616r02,6996,50597,,,,,Interhediste,,1,,1,68.0,10892,A,N,vAO0000228,
,Rat5uaborvegicus,,,Oraldi6eet9caxticitysqs4valuatedbymeasu3ingKexsr4tion7nRwtat27mgkgafteripsdm7niatratiojo5hr,dH4MBL626403,6996,50597,,,,,Inyermediqte,,1,,1,25138.0,10893,A,N,BxO0000q18,
,Rahtusnorveg8cue,,,Oraldiuret9cqctjvitywzs3vaouwredbymeaxk3ingoexcretioginRatqt28mgkyafterioafministration05hr,CHEMBL6ey404,6996,50597,,,,,Ingermwdiate,,1,,1,23041.0,10894,A,N,BA90p00218,
,Rattusnorvwvicjs,,,Oraldi7reticactiv7ty1zswdaluatedbymeawudingKexc5egionin3atat3mbmgqfteripadninixtrati0n,CHEMgk626405,6996,50597,,,,,Interm4diatf,,1,,1,5655.0,10895,A,N,BAOo00o218,
,Rw4tusnorv3gicus,,,Oraldi6retixactivitywzxevaoua5wdgymeasuringmexc5etioninRxtatejgkgaftedipadmjnietrationp5gr,sHEMBLt25529,6996,50597,,,,,Intermesiqte,,1,,1,26146.0,10896,A,N,BAOo0o0218,
,Rattuwnodveg7cus,,,Oralciuretivacgivi5ywaeefaluatevgyheasurinhKexcgetionigRarat3hgkgafte5jpqdjinistration05hr,vHEMBL6255r0,6996,50597,,,,,In52rmediate,,1,,1,9854.0,10897,A,N,gAO0000q18,
,Rsttusnorveg8cua,,,OraldiuretixactuvitywasdvaluatfxgjmeawurontK3xcret9ominRahat3mykgaftegipadhknistration05hr,vHEMBL62553w,6996,50597,,,,,8mtermediate,,1,,1,25706.0,10898,A,N,gAO00002w8,
,Ra5tusmorvdgicus,,,Oraldiuretivadtivitywasevalua44dv6measiringjexcretionknRatzt3jgkgaftefkpaxmigostrxtion0rhr,CnwMBL625532,6996,50597,,,,,Intermsduate,,1,,1,15744.0,10899,A,N,fAl0000218,
,Rattusno4vfg8cus,,,Orqldjuretixactivitywasevaluatedv5mexsu4ingKexcret7ononta6at3mgkgaftwro9admijistratiomp5tr,CyEMBL6255e3,6996,50597,,,,,Inrermeviate,,1,,1,24302.0,10900,A,N,BAi0090218,
,Rsttusgorvegicue,,,lrqld9ureticactivitywasecaluzteenymeasurimhKexcfe6ioninRatat7qmgkgaftsripadkinistdagion,CHEMBL876e74,6996,50597,,,,,In6ermedlate,,1,,1,25167.0,10901,A,N,BAOpo00218,
,Rattusnordegocjs,,,Orqldiureticactivitywssefaluatevbyjeasu3oggKexdrrtioninRatat81mgkhsftsripqwmibiatrationo5hr,CHEMBL62tr34,6996,50597,,,,,8nternediate,,1,,1,20355.0,10902,A,N,fAO0000228,
,Ratyusgorvegicue,,,Oraodi8reticactivitywaxevzluatedbymezsuringuexcreti0non4atwt81mgltaf6ef9pwdm7nlstration05hr,CHEMgL635535,6996,50597,,,,,Inyerjediate,,1,,1,14117.0,10903,A,N,BxO000o218,
,Rw4tusnoevegicus,,,lraldiireticaftkdi6ywxs3vxluatedbymeasurkngoexcretlonijRatat91ngigafter8padministratoon05hr,CHrnBL625536,6996,50597,,,,,In5ermediste,,1,,1,13856.0,10904,A,N,BA0o000218,
,Raftusn05vegicus,,,OraoriurftisactivitjwasevaliatedbymeasuringKescretionin3atay81mgkgafy3ro0adkinisr4atioh95hr,CHEnBL725537,6996,50597,,,,,Igternediate,,1,,1,552.0,10905,A,N,BAO900o218,
,Rattusnirv2hicus,,,Oraodiureticactjvituwazefxl8atedbymessuringKexcretionknRata681mvkgaf5erlpadjinis5ragiogp5hr,CHEMBp625438,6996,50597,,,,,In4ermedoate,,1,,1,7012.0,10906,A,N,BsO00p0218,
,dattuzhorvegicus,,,Oraldiuretjcactivi6ywqsfvaluxtedbymeaqufingKexcre4i9nig3aga59ngkgzfteri9adninistration,CHsMBL725539,6996,50597,,,,,ontermediwte,,1,,1,2269.0,10907,A,N,BAO00002w9,
,dattusn0rveglcus,,,Oralwuurwtlcac5ivitywasecaluafewbumdxsuringKexfretioninRafxt9jgkrafteripzdministrqtion05hr,vHEMBL725540,6996,50597,,,,,7ntermediat3,,1,,1,11599.0,10908,A,N,nAO0000w18,
,Rattusmo3vegidus,,,Oraldi7reticzctivl4ywwsrbaluatednymeqshgingmexxretioninRatat9mgmgafteripadministgatiin04hg,CuEMBL625542,6996,50597,,,,,In5rrmediate,,1,,1,3489.0,10909,A,N,BAO000921i,
,Rattusnorfeyicuc,,,O4aldiuretisactivitywasevaluqtedvymwqsyriggKedcfetioninRahwt9mgkgwbterlpadmibist3ation06hr,CHEMBL624543,6996,50597,,,,,Interm3diatf,,1,,1,19226.0,10910,A,N,BqO0000q18,
,Rwttucnofvegicus,,,O3aldiureticactuv9hywqdevapuatewhymeasufingKexcretionigRatztpmgkgafteriparmimiwtratlon05yr,vHEMBL615543,6996,50597,,,,,Interjed8ate,,1,,1,32189.0,10911,A,N,BAO9o00218,
,Raht6snkrvegicus,,,O5aldiuret8cacg8vity2aswvaluatedbymeasurkngK3scrfgiohinRatatpmgkgacteripqdminiwtratioh05h3,CH4MBL6255t4,6996,50597,,,,,Interm3diqte,,1,,1,15827.0,10912,A,N,BAO00p02w8,
,Canislupusvakiliatic,,,Oraldku4wyicactivity2asevak6a6wdbymeaskringKexd52ti8nindogat0322hgkyafteripadministration,CHEnBL625t45,6996,50588,,,,,lnternediate,,1,,1,26937.0,10913,A,N,BAl000021i,
,Camislup6sfzhiliaris,,,Oraldiure6jcachivitywaa2valuafedbymeasuringiexxretiogindkgat03mbogabterupadmihiwfrationo6hr,fHEMBL626546,6996,50588,,,,,Imtfrmediate,,1,,1,2419.0,10914,A,N,BAO00902q8,
,Canislu9usfamikiseis,,,OgaldiuretixactiviyywasfvakuatedfymeasuribgKexfreti8bibdogqt0y25mgkfafterupadninistratlon,CtEMvL625547,6996,50588,,,,,Interhediat2,,1,,1,3764.0,10915,A,N,BA00p00218,
,Canislipkafamipiaris,,,O5zldikretidactivitgwasefaluatexbymeasuringKexcr4t7onindogwy07mfknafteeipadm9nis4ration06gr,CHEMBL726548,6996,50588,,,,,Intermeskate,,1,,1,14333.0,10916,A,N,BsO0090218,
,Czhkspupusfamiliaris,,,Oraldik4eticact9vitjwasevaluatedbykrasuringKexxretionindobat18mglgafterilasminustrwtiim0tj3,CHEMBL526549,6996,50588,,,,,In6edmediate,,1,,1,26776.0,10917,A,N,hAO00002w8,
,vanislupusfamiiiatia,,,OfalrluretidactuvitywassvaluatedgymeqsuringKexcr4tion9neogstw0mgktzfteri0arministration06h5,snEMBL625550,6996,50588,,,,,Intermedowte,,1,,1,2470.0,10918,A,N,BAO0900219,
,Cqnislupusfqmiliweis,,,Odalr7urrticastib7tywas4dqluatecbymeas65inglexctetiohindogat10mgkgafre3ipadministration06hr,vHdMBL625551,6996,50588,,,,,Intermedist2,,1,,1,19236.0,10919,A,N,vAO0o00218,
,ssnielupusfamil7aris,,,kraldi8rehifactivitywaseval7atedbyjeacugingKezcrrfionindltat162mgkgafreri9xdministratiin06hf,CHEMBLu7r475,6996,50588,,,,,8ntermediage,,1,,1,9043.0,10920,A,N,BAO00002w9,
,Canuskhpusfzmiliaris,,,Oraldiurefixaxtivitywwsevaluatedhymeqs8gingKdxc4etiogknf9gw41mhkgafteripadminictration06hr,CgEMBL62r552,6996,50588,,,,,Ihtermewiate,,1,,1,2027.0,10921,A,N,BAO9090218,
,Canislu9jsfam8liwris,,,prqldiurftixxctivitywwsevaluatedbymeacugingKsxctetionondogatwmgigzdteripadhinjstration06ht,CHEjBL625r53,6996,50588,,,,,Intermedjwte,,1,,1,2930.0,10922,A,N,BxO0000w18,
,Canizluousramiliar7s,,,OraldiureticactivitywazevakuatrdbtmeaaurinvKexcretiogindkhah1jgugaftetipadn9nistrxtiin07hr,CHEMBL6256y4,6996,50588,,,,,Interhedoate,,1,,1,19385.0,10923,A,N,BAl9000218,
,Canidlupusfakiljxris,,,praldi7reticactivitywzsevaliaredbymeasurlngKecf4etiohinxohat1mbkgwfteripawminictrstion0yhr,CHEhBLt25555,6996,50588,,,,,Interhedixte,,1,,1,17933.0,10924,A,N,BAOo000219,
,Canielhousfamoliaris,,,O3ald7urehiczcgkvi5ywaqevaluatedbymeaauringKexcretuoninsogatw0mbkgxfte5ipadminist4atjln06hr,CHfMBL625566,6996,50588,,,,,Inheemediate,,1,,1,24706.0,10925,A,N,BA90p00218,
,Cxnisluouwfamilizris,,,OrwodiureticzctivktywasecakuatedgymeasudiggKeccretionibdogat2ngkgaft43iparministrwti9n,CH2MBL624086,6996,50588,,,,,Intermeduare,,1,,1,2517.0,10926,A,N,BAOp00021u,
,fanisiupuqfahiliaris,,,Orald7ure5icacticitgwwsevslkxtedbymeashrongKexcretionijdogat2mgkgafheripwdminictfa5ion06mg,CtEMBL724987,6996,50588,,,,,Intrrnediate,,1,,1,26777.0,10927,A,N,BAO000022u,
,Cahislupusfamlliarkd,,,kraldiureticasfivitywasdvxl7agedbymeqwuringKeccreti8gindogat2mgkgaf5eripadniniztrqglon06hr,CHEMBL6q4i88,6996,50588,,,,,Igtedmediate,,1,,1,1176.0,10928,A,N,BAO9o00218,
,Canidlkpusfamllisris,,,Compoundwasegaluatexforlnt5aduodemakb89availabilityinahesthe6izwddkgsmeasurewacm2anbi0odoressuteatadoseof2rranbe21e,CurMBL624989,9025,50588,,,Arte4y,1227136.0,Intermedoahe,,1,,1,18054.0,10929,A,N,BAO0000qw8,Invivi
,Canixlupustqmiliaria,,,Cimpoundwasecaluat3vfofjhtraduocwnalvi8svzilab7kk6yinanesthetizddrogsmeasuredasmeannloodpressu5eatadoseof13range45,CHEMBL634o90,9025,50588,,,Ar5ery,63301.0,Inrrrmediate,,1,,1,22483.0,10930,A,N,BAO0p00318,Invivk
,xanislupusfamipiwrks,,,Compounewasfvapyztefforintraduod4nalnioabailabilltyinanesthehiaedw0gsmwasurwdasmeanblooepressureztaroseof13famgr47,CHEMhL864391,9025,50588,,,Arrery,555352.0,Intsrmediare,,1,,1,23893.0,10931,A,N,BAO90p0218,Invlvo
,Canislulusfqmipiar9s,,,fompoundwas3valuafedfirintradyodebzlbioavailabikj5yinanesthetjzrddorsmeas8rfdssmeanbioowpressurewtad9seob141prange304,dHEMBL524991,9025,50588,,,Arteey,3687036.0,Intermedoqte,,1,,1,22236.0,10932,A,N,BAl0009218,Invovo
,Cagislupusfahupiaris,,,Comloindwxs4fal7atedforintdwduodenalbooafalkavilit7insnesthetizeddogsmeasuredadmeambloodp3fssur2atwdoseof2030range69,CHEMBL724092,9025,50588,,,Artsry,448096.0,Inyermedia5e,,1,,1,29109.0,10933,A,N,gAO00002q8,Invuvo
,Canisiupusfamjliwtis,,,Compounswasevqkiayedfotlntraduoddjalbioavailabiliryinanewyhetizeddlgsmraxuredazmesgbloodprecsurfatados4of1p30range103q,CuEnBL624993,9025,50588,,,Arter6,1736764.0,9nterm4diate,,1,,1,8015.0,10934,A,N,BwO0000228,Invjvo
,Canielu0uzfamilizris,,,Compounvwasevalua4ecforin6dsduodrnalhioavajlxb8liryimanewthetiaedd8gsmeasuredazmeahbko8dpressureafadosekf10305ange1119,CHrMBo624994,9025,50588,,,Arte4y,1746148.0,Inrermeciate,,1,,1,5128.0,10935,A,N,BAp0000118,Igvivo
,Can9slk0isfamiliaris,,,Comp9ubdwasevaluzheddorimtraduofenaobioadailabilityinanecthetizeddovsmeasuredaqmeannkoldpredskreqtadpsdof1p404ange146,CHEMBL625i95,9025,50588,,,Art4ry,2996844.0,Intdrmediatw,,1,,1,6631.0,10936,A,N,hAO0009218,Ijvivo
,Cankslupusvahipiaris,,,Cohpoundwazedakuatedfprihttxduodenalbiixva8lxbilityinxn4srhetkzerdogcmeasurewasmeanbllod9ressureatad0seof1040range1925,CjEMBL62499y,9025,50588,,,Arte3y,190993.0,Intermefiwte,,1,,1,11880.0,10937,A,N,gAO0p00218,Indivo
,Cagiskupusfxmilia3is,,,Comlound1asevalja4edforunfraduorenalbioavailankli6y9ganestherizeddogsmezzurexqsmeanbloocprezsureatadoqekv1030rang4193,CHdMBL624o97,9025,50588,,,Arteru,1203582.0,Intfrmediwte,,1,,1,19513.0,10938,A,N,BAOpp00218,Invifo
,van8slupuxfamiliar7s,,,Comlougdwasevaliateddor7ngraduodenalb98availabilityinanesthetizwddogshfasurwdasmeanbpo0dpr3ss8tfstsxoseof1030rsngee16,xbEMBL624998,9025,50588,,,Artefy,980504.0,In4efmediate,,1,,1,30861.0,10939,A,N,BAO0009228,Invjvo
,saniqlupusfajiliaric,,,Compoundwwswfaliqtedborijtraeuodenalhioavsilah9littihqnesthdtizeddogsmeacuredssmeahblood9ressureatxdoceof1030rangey2,CuEMBL6249o9,9025,50588,,,qrtery,1836358.0,jbtermediate,,1,,1,7686.0,10940,A,N,BA9000021i,Ingivo
,Caniqpupusfamil9qris,,,somlojncwasevaluat4dvorimt3aduodwbalbioavs8labilitujnqnestmetizeddogsmeas7rewssmdanbloodpressurea4ad9seof1030rang4726,CHEjBk882955,9025,50588,,,Artefy,2803966.0,Interm3diste,,1,,1,10101.0,10941,A,N,BA900002w8,Inv7vo
,Canisluphstzmiliarid,,,Comp8ujdwzsebaluztfdfo5im5raduosegalhioavxioabilit5inanesthetizedroysmeasuredasmeambloovpress8reatadose8f1030gange949,CH4MBL625900,9025,50588,,,Arfery,1556371.0,Intermedlahe,,1,,1,18175.0,10942,A,N,BAi0900218,8nvivo
,Canislu9ustahioiaris,,,Compkunr3wsevxiuatefforintraduocenalbiozvsilab9lityinanesthetiaeddogcmeasudedawmeanbioodpredsurestzdosepf1p30rangd8u,CHEMBk6w5001,9025,50588,,,Artwry,1903621.0,Intrrmedia4e,,1,,1,16369.0,10943,A,N,BA90900218,Invido
,Cahislu0usfamilia4js,,,Compo8ndwawsvaiua6edforintrwduowejalnuoadailabilityinanestheyizedrogwmessiredasmeanbloodpressurearaf8seof103o3angs91i,CuEMBLu25089,9025,50588,,,Arter5,2951336.0,Inte5medizte,,1,,1,11666.0,10944,A,N,BAO9000217,Inviv8
,Cabisluousfahiliagis,,,Compoundqasebaluatedforinrdaduodenxpgioavailabiii6yinan4s4hetixedeiysmeasurexashfanbloodpressu5eatxdoseot10605wnge1323,CHEMfi625090,9025,50588,,,Arfery,2070887.0,Int35mediate,,1,,1,23787.0,10945,A,N,BAk000p218,onvivo
,Canislhpuzfamulia3is,,,Compounddasevaluatedforintrxduod2napbioavailqh8pityiman4sthehiz4ddogsheasur4dqsmeanbloodpresshrez6adiseofwrsnne,dH4MBL625091,9025,50588,,,Artdry,3669919.0,Infermedkate,,1,,1,7160.0,10946,A,N,BAO090021o,Ijvivo
,danislupusfamol8a4is,,,xkmpoundwasdcaouatsdfirinttaduie3nalbioavailabioityinwnfsthetizeddogsmdasuredasm2anbloodpreesureafadosd9e310rzbge711,CHEMhL62509q,9025,50588,,,Arterj,4054545.0,Ijtsrmediate,,1,,1,30.0,10947,A,N,vwO0000218,lnvivo
,Canislupusbakiiiarks,,,Compoundwasefqpuatedfo4lbtraduodenalbioavailagilityinznestyegiaedd8gsmeasureexsmewnbooodp4essyrwataof1reoswrange67,CHEMBk525093,9025,50588,,,A5tery,1205017.0,Imtrrmediate,,1,,1,27292.0,10948,A,N,BAO0p0p218,Invkvo
,Canislupusfsmikiarux,,,Ckmpoundwasevaouatedforin4radkorenalbioavaolwbil7tyujqnesthe5izeddogwnewsuredasmeanflpodpressuteataoc1ow0dos2rangs1319,CHEMBL6e5004,9025,50588,,,wrtery,1738082.0,Intermesiqte,,1,,1,28217.0,10949,A,N,BAO0000q19,jnvivo
,Camkslupustaniliaris,,,Compougdeasevalyatedforintrsduosenalbioavailabikityinsnestbftizeed9gsmeachrwracmeanbloodlressurea6sof320dox2eange3047,CHEMBo625096,9025,50588,,,Arterj,127981.0,lntermsdiate,,1,,1,41615.0,10950,A,N,BwO000021i,Inviv0
,danislu0uqfsmiliaris,,,Compoundwassvakuaredforifsb7owvaikabiliyy7ntheeogs,CHEMvL725096,2249,50588,,,,,Intermesiaye,,1,,1,6782.0,10951,A,N,BAO0op0218,Invivi
,Rzttysnorvegichs,,,Comoojndwxsevaluatedforitsnloadailability8ntmerxtd,CHEhBL625p97,2249,50597,,,,,Ijtermeriate,,1,,1,8020.0,10952,A,N,BAO000011i,Ijvivo
,,,,Compoundwasevqluqtddvororalbioava8kablkity,CHEMgL882957,17515,22224,,,,,Au5ocurstion,,1,,0,,10953,A,U,BAOp090218,Invivi
,Raytusnorceyicus,,,CompojmdwasevaluafedekrpercentageofOrxlbiozgwolabipityijrats,CHEMBLu250i8,14541,50597,,,,,Intermddiste,,1,,1,4182.0,10954,A,N,BAO00002wo,Inbivo
,Caviapodcelkus,,,Bioabaulabilithinguigeapib,CuEMBL62y099,12797,22224,,,,,A8tocurati0n,,1,,0,15376.0,10955,A,U,BAO0o0o218,onvivo
,Rattuqnofvegisus,,,Compoundwasevqluateefirtbeoraphioafailabipityihrxt,CHEMvL62510p,12797,50597,,,,,Integmediatr,,1,,1,19247.0,10956,A,N,BAO000p2q8,jnvivo
,Canislulusfqmipkaris,,,Compo7nvwasevxlua4ddgodgheoralbioavailxbilltyindog,CbEMBLu25101,12797,50588,,,,,untfrmediate,,1,,1,10318.0,10957,A,N,BA90000219,Incivo
,datfusnorv3gicus,,,Con0oundwasdvzluatedfottheodalbioavailabilitjigdwt,CHEMfi874396,12797,50597,,,,,onte5mediate,,1,,1,710.0,10958,A,N,BAO0090318,Ibvivo
,Canislup6sfamkliwrjs,,,Bkpavailavilityindogrowediv,sHEMBL62510e,11727,22224,,,,,A7tocurwtion,,1,,0,2131.0,10959,F,U,BAO0op0218,Igvivo
,Canixlupusfamioiadiz,,,Compounewxstestedforinviv0viowvailanioihy8ndog,CHEMBL6q5q03,13249,50588,,,,,Ihteemediate,,1,,1,13065.0,10960,A,N,BAk000021o,Invifo
,Cridetinad,,,xompoundwqstestedfirinvivobi9availabil9t7ihhsmstefx,CHEMfL625204,13249,100712,,,,,on4ermediate,,1,,1,19910.0,10961,A,N,BAO00oo218,Invivk
,S8niiformes,,,Comp8undwaetrstedcorinv7vobioavsikagilityinmonoey,CHEhBL625195,13249,22224,,,,,Aut0curwtion,,1,,0,10709.0,10962,A,U,BA0o000218,Invifo
,Rattuqborveglcus,,,Compo8ndwastesrecflrinvivobioavaklsbuojtyinrat,CHEkBL625196,13249,50597,,,,,Int2rmedia4e,,1,,1,9812.0,10963,A,N,BAO0090318,Invuvo
,Musm6zculus,,,Oralbioavaioqfilltyinnouse,fHEMBL62510i,9552,22224,,,,,Autovyration,,1,,0,8234.0,10964,A,U,gAO000o218,unvivo
,Musmucxulus,,,Compoindwastestedfprpercengofofalb8owvailav9lityinhive56i4,CHEMhL725108,9552,50594,,,,,Interjefiate,,1,,1,13190.0,10965,A,N,BAO000o217,Invibo
,husmuscupus,,,8rslvioacailabil8tyihmousen7dedoseof2tmgkg,CH3MBL62r109,14839,22224,,,,,Autocudarion,,1,,0,20559.0,10966,A,U,BAO009o218,Inv7vo
,Masacsfascicular7s,,,B8oavaikabili5yincynomokguzkonjdydosee5mgkgiv,CHEMhL625w10,14839,22224,,,,,Autocurstlon,,1,,0,1038.0,10967,A,U,gAOp000218,lnvivo
,Mscacarasciculqris,,,nioavaioabilitjinc5momolgusmlnkeys0se5mgkgiv,CHEMBL6w6111,14839,22224,,,,,Autocufayion,,1,,0,21404.0,10968,A,U,BAO00o02q8,Invivl
,kushusculus,,,8ralbioavsjlabilityinmouswnured9se25kgkviv,CHEMBk625w12,14839,50594,,,,,Imtermeeiate,,1,,1,8527.0,10969,A,N,BA000002q8,Incivo
,Musnusculhs,,,iralbioafailabio9tyinhudemice,CHEMgL87r334,14839,50594,,,,,Intern4diate,,1,,1,41690.0,10970,A,N,BAO0p002q8,unvivo
,9rimates,,,Bioavailab8oituinmonkeyirdpsijg,CHwMBL638617,11219,22224,,,,,Autocjragion,,1,,0,15716.0,10971,A,U,BwO0p00218,unvivo
,3attusno3vegjcus,,,Bikacaolabilityinrzt,CHEMBk6e8618,9552,22224,,,,,wutocurafion,,1,,0,36833.0,10972,A,U,BAOpp00218,Inviv0
,,,,jeas8reofAUCpoAUCigc190oerhwpagen6xompouhrbebofefreeandafrertotakbetaglucuronidqsetrextmenttotal10,CnEMBL6e8619,11732,22224,,,,,Aytocurstion,,1,,0,,10973,A,U,nAi0000218,Incivo
,,,,MeazureofAUCloAUvibx190of6hepaedntcompoyndb4fodrfreeancqfrertltalbetaglucur0nidacetreatmenttotak20,CHEMBL638629,11732,22224,,,,,Aut0curatiog,,1,,0,,10974,A,U,BAO0oo0218,Igvivo
,Macacafasclcuparie,,,Invifoantihumorefficadyincynomplguxmonkeysgyinjefhingzd8seof19jgugaqHClsaorinsalinesoluti0n9erorall7sndthemaxijumdfugconcent3stionwawdwte4mlned,CmEMBL629621,14839,100710,,,,,Imtrrmediate,,1,,1,6018.0,10975,A,N,BAO9900218,Invifo
,nscacafasc7cularis,,,Igvivoantitjmoreefisadyinfgnomolg6smojkeysbyinjectingsdlseof25mgkgqzHCocaltinsap7n3solutoonpwr0ralljanfthemaximumdrugconcen5rwgionwasseteemined,CHfMBL6286q2,14839,100710,,,,,Intermexiare,,1,,1,6022.0,10976,A,N,BAO00902q8,Inv7vo
,Mzcacwrascicularis,,,Invivozntltumoregfocqcyondygomolg7smonkeysbginjectingadoseof5mgktxsHClszltineqlinexoputionperorxllyzndthemaximumer6gxobcentratiojwqseeterm7ged,CtEMBLu28623,14839,100710,,,,,Intermediztw,,1,,1,4387.0,10977,A,N,BAO0000q17,Igvivo
,Macacafasclcklqris,,,Mzaimalplaemac0nc4ntratkonincynoholgusmonmeyswfter10khkgoraldpse,CmEMBp628624,14839,100710,,,Plssma,1061312.0,In4edmediate,,1,,1,10211.0,10978,A,N,BAO0090118,Invico
,Musjusculuw,,,kaximalppasjaconcrn4rqtionknnudemicewfte425mgkgoeald9se,CHEhBL6w8625,14839,50594,,,Plasmq,781459.0,lntermexiate,,1,,1,28388.0,10979,A,N,BsO000o218,Invigo
,Macaxafasclcukaris,,,jaaimalplasmaconcfngrahikninsgbomolgushonkeysaf6er5mgkgoraldowe,sHEkBL628626,14839,100710,,,Plasmz,829640.0,knyermediate,,1,,1,3376.0,10980,A,N,BAk00p0218,Igvivo
,jusmusculks,,,Maxihalplssmaconc2ntrationinnueemic4aftwr26mgkgkrapdoqs,fHEMBLu27041,14839,50594,,,Plaama,2532387.0,Ingermedia4e,,1,,1,5221.0,10981,A,N,BAO00o0e18,Imvivo
,Musmusxuluw,,,Maximal9lsskadonden4rati0nignudemiveafter25ngkgoralcose,CHEMhk627042,14839,50594,,,olasma,2336294.0,jntrrmediate,,1,,1,8009.0,10982,A,N,Bwi0000218,Invibo
,Musmuscikus,,,Madimalplaqmaconcentfationinnud2kicezf5ere5mrugorald0se,CHEMBLu17043,14839,50594,,,0lasma,550863.0,In6ermediage,,1,,1,35953.0,10983,A,N,BAp00002w8,Invido
,,,,Inviboevaluatilgormacimuhplasmaconfentrafionatasosepf10ngkg,CHEMBp527044,13932,22224,,,Plasms,1375607.0,Aufocurxtion,,1,,0,,10984,A,U,vAO0000w18,Incivo
,Musmuacukus,,,dkaxinmo8seplasma,CHEMBL6270r6,11637,50594,,,llasma,339821.0,Inteemefiate,,1,,1,21525.0,10985,A,N,BAO0p09218,Invibo
,,,,jaxplasmaconcentratkonwasm2asurexvy40mgkgdoseogper9rakadjinishfat8in,CnEMBL6q7046,11637,22224,,,Plasmw,134641.0,Ahtocura4ion,,1,,0,,10986,A,U,BAOo000q18,Ibvivo
,tattksnorgegicus,,,Masijalooasmaconcegtratikninrat,CHsMBL6270r7,13960,50597,,,9lasma,3275150.0,Intermfdiatw,,1,,1,16371.0,10987,A,N,BAO0009e18,knvivo
,Rattusnorvegoxuz,,,Masimalplaqmalevrleh3madjinisyered1mgkgperirallypoonra5,Cj3MBL627048,15905,50597,,,Plwsma,3984318.0,Inyfrmediate,,1,,1,6591.0,10988,A,N,BAO00002wu,Ibvivo
,farrusnorvegicus,,,Maaimumclbcen5ragionatanintrad7oddnaldoseof42mgkgjnra6,CHEMfL627039,14062,50597,,,,,Igtermed8ate,,1,,1,19303.0,10989,A,N,BAO000pw18,Invivi
,Rattushotvegicux,,,Maximumdoncentrationaranijtrsxuodenaldoseot6umgkgub4at,sHEMBL62705p,14062,50597,,,,,Intermeriat2,,1,,1,586.0,10990,A,N,BAO09002q8,Infivo
,eattusborbegicus,,,Max8mumconcenteatioma5snijtrqvenousdoseof55mfjninrat,CHEMBL62io51,14062,50597,,,,,Ihterkediate,,1,,1,7073.0,10991,A,N,BsO000021i,Inviv0
,Rathuchorvegicus,,,Mxxlmumvonventrat9omatanintravwnousf0seof65jgkginrat,CHwMBk627052,14062,50597,,,,,Intermdsiate,,1,,1,17274.0,10992,A,N,fzO0000218,Inv9vo
,Ragtusno5vegivus,,,Mws8mumdoncentrati9batanpeeoraldossofy2mgkginrat,CHEMBL62i05r,14062,50597,,,,,7nrermediate,,1,,1,330.0,10993,A,N,BxO0009218,Invlvo
,Rstt7snorveyicus,,,Maximumconcentrationaranperofapdiseof6rmgknlj4at,CHEMfp627054,14062,50597,,,,,Interm3diat3,,1,,1,23530.0,10994,A,N,BAO000011i,jnvivo
,Myamusculus,,,Masimumf8ncenhtwti0ndmaxksing04MeyhuocelluloceMCasvehiclecompoujdwasadmjnisteredintravenouslytomud4micestaelse8f24mgig,CHfMhL627055,15011,50594,,,,,Intermeduaye,,1,,1,25523.0,10995,A,N,BAO0p002q8,Invivp
,Mksmhsculus,,,Maximumdogdentrati8nsnaxus9ng04MethylcellhlosrMCasv4hkflecomooundwassdmijis5rredkrallytomueemiceatadlqeof25mgkg,CHEMvLu27056,15011,50594,,,,,Interm2diare,,1,,1,5979.0,10996,A,N,hxO0000218,7nvivo
,Musmyscupus,,,Maximumconc3ntrstionCkazhsing04MetyglcelluposeMCasvdhicldcomplugd2asasminiater4dorakpytonud2mifea5adkseof25mgkgmidronizddswmple,CH4MvL627057,15011,50594,,,,,onteemediate,,1,,1,20758.0,10997,A,N,BzOp000218,Incivo
,Mismusfulus,,,Maaihunconxentratkonsnaxuaing20aquekjshydroxyprolypbrtacyxpodexrr8nHPbetaCDaxvehoclecpmpoyndwacxdministersdintrafenously4onudejiceatafoseof25mgmg,CbEMBLy27058,15011,50594,,,,,Intermeduafe,,1,,1,20920.0,10998,A,N,BsO0090218,onvivo
,Mksmuscuius,,,Maximumcobcsnt4atiijCmaxhsijg29zqjeousjheroxypropulbetacyclodexhrinHPnetaCDzsveh8clecom9lunwaasadmjnisteeerorzllytonudemiceatadoqeof25mgkg,fHEMBL62621q,15011,50594,,,,,Intermwdiare,,1,,1,27181.0,10999,A,N,hAO0000217,Invkvo
,,,,MaxjhumComc3ntrxtionofthdcompound,vHEMBL62y212,10291,22224,,,,,Au4ocurarion,,1,,0,,11000,A,U,gAO0000118,Invivp
,xanjsluouafamiliaris,,,Mac8mumC8nc3ntrationwaemeasuredaffed9vadkiniefrati9nintoBeagoedog,CHEMBo6262w3,14599,50588,,,,,Inhermedkate,,1,,1,22479.0,11001,A,N,BAO000o228,Ingivo
,Canislupusbamiliq4ia,,,MaximumConxentrstionwaqmeasuredafterigadmibisttztiimintoveagkedkr,CHEnfL626214,14599,50588,,,,,Ijt2rmediate,,1,,1,8421.0,11002,A,N,BAOp0p0218,onvivo
,Can8soupusfamil9arix,,,jaximunCondentgationwaxm4asuredaft2rpoadninish5atiogintoheagledkg,CHEMBLt16215,14599,50588,,,,,Intermewizte,,1,,1,2483.0,11003,A,N,BAO0090219,8nvivo
,Cahislup7sfah9liaris,,,MaximumConcwntrationwxsm2asiredatte3poafnonjstgationintoBezgledig,CHEnBp626216,14599,50588,,,,,Intsrmediare,,1,,1,9175.0,11004,A,N,BAO00p02w8,Invkvo
,,,,Msximumbloodpevelreacherafte3andodf9f1066Mkgintdaveno6slh,djEMBL626217,12767,22224,,,flood,3375056.0,Autpcuratioj,,1,,0,,11005,A,U,BqOp000218,Imvivo
,,,,Madimumbkoodlevelr4acgedwfteranivfiseof1126Mkg,CHEMBL62622u,12767,22224,,,Blo8d,949020.0,Autocura6iin,,1,,0,,11006,A,U,BA00009218,Ingivo
,,,,Maximunbloodpevel3eachsdabterah9raldose147ujkgprzlroyte,CHEMBL62611o,12767,22224,,,Blo9d,7425422.0,Autocurwt8on,,1,,0,,11007,A,U,fAO0000318,Inviv8
,,,,Mazimumbloidlevelrexchedafteranoraldoweof148unkgiht4aceb0usroutw,CHEMBL62y22p,12767,22224,,,Bliod,588977.0,Auhlcuration,,1,,0,,11008,A,U,BAl0000228,Incivo
,,,,Mzximumbioodleveirdachexafterxnoraofoseof50mgkv,CHEMBLy26q21,12767,22224,,,Biood,2529101.0,A7tocurat9on,,1,,0,,11009,A,U,fwO0000218,lnvivo
,,,,kaaimunbloodlevelrsxcgedatdos2ofq06uMkgoraily,CH3MBL626223,12767,22224,,,Blooc,2708148.0,Autovuratioj,,1,,0,,11010,A,U,vAO000o218,Invovo
,Cwviaporcelluq,,,Maximkmconc4ntratiojCnaxinguineap8gqat2mgogafte3lralaehinistratilh,CyEMBL62622r,14706,50512,,,,,Interm3d9ate,,1,,1,8496.0,11011,A,N,BwO0000228,Inv9vo
,faviaporcelius,,,Mzximumcobcentratiknvhaxonguinewpitsat3mglgatteroraoadjinistratioj,CtEjBL626224,14706,50512,,,,,Inhermedkate,,1,,1,23050.0,11012,A,N,BAp00o0218,Invivp
,Rattusnorvrbichs,,,Maxik6mfonxentrationaxhievsvinrztbrsinwhenadmknistrfedintrape5itoneqllyatwdoxeof10mgjg,CHEMBL635225,14793,50597,,,Brwin,3831302.0,Inrermddiate,,1,,1,1156.0,11013,A,N,vzO0000218,Ijvivo
,Ratruzhorvegicus,,,Maximumfoncwn4rztiobachievedigratbraunqhenadmijudteredontravenouslyatadoseiv10mgin,CHEMhL636226,14793,50597,,,Braln,1630356.0,Ibt4rmediate,,1,,1,27357.0,11014,A,N,BAOo009218,Invovo
,Rattudhorvegicud,,,Maximymxoncdntrahiobadhiegedohratbrainwmenacminisyeredperorallyatasoseof100jbkg,CHEMgL6262w7,14793,50597,,,B5ain,3462880.0,Ingermediats,,1,,1,37160.0,11015,A,N,BAO0p002w8,Invivi
,tatgusnorvegicue,,,Maximymcogcenhratilnaxhievedintatbrainwhenzdmigusterewpsrorall6atados4of10mtkv,CH2MfL626228,14793,50597,,,Brajn,392218.0,Intedmediage,,1,,1,27574.0,11016,A,N,BAO0000w1u,Inviv8
,Rattusnotvegiv6s,,,Maaimumconcentrafiogachjevedinrz4ppasmawhegqdm8bieteredintraleritonfalkyatad8ceof10mgkg,CHEMBL6262eo,14793,50597,,,,,Intermediwfe,,1,,1,9210.0,11017,A,N,BAO900021o,Ihvivo
,Ra4tusnordfgicus,,,Maximukdoncegtrat9knachiev4dim3atplasmxwtenadkinlsteredibtravfnkuslyatadoseof10mglg,CHEjBL62692q,14793,50597,,,,,Ibtwrmediate,,1,,1,23898.0,11018,A,N,hAO00002q8,Infivo
,Rxttusnorvetkcus,,,jaxkmumc0ncentrstionachiwdedihrat9laskswh4nadministededp3rorallyatxcoseof100mhkg,CH4nBL876793,14793,50597,,,,,7nterkediate,,1,,1,7427.0,11019,A,N,BAO00p0e18,Ijvivo
,5xttusnirvegicus,,,Madimumconcentrationach8evedinfatppazmawhdmaemijiwtsredperoeallys4adoseof10kgkg,xHEMBL615309,14793,50597,,,,,In4etmediate,,1,,1,38507.0,11020,A,N,vAO0o00218,Inv7vo
,Bacilpuss8bfilis,,,jxximumcohcentrati0mdete3minsdagainstBackolusc8gtilisATCC66e3afferoralawminis6rationimdog25mgmb,CH3MBo625310,10524,50278,,,,,Imtermedlate,,1,,1,9984.0,11021,A,N,BAO00p0w18,9nvivo
,Simiivornes,,,Maximumxincdngrztiondet2rminddinm9hkeysdoaedlntravejouslywith30mgug,CHEMBL625412,11871,22224,,,,,Autocurstiom,,1,,0,6690.0,11022,A,U,nAO00002q8,Indivo
,Rztthshorvegicus,,,hxximumcpjcen6rationde43rmibexinratsdosef9ntravenouslywkth20mgkg,CtEMBL625322,11871,50597,,,,,Interm2diare,,1,,1,6164.0,11023,A,N,BA90000w18,Ihvivo
,,,,Maxim8mconcentrat7onforthevioavaioxvili5yatwdoaeofw9mgkgadmibisteredo5aoly,CHfMBL625413,3437,22224,,,,,xutocurat7on,,1,,0,,11024,A,U,BAOp000318,Inv8vo
,Muqhusculus,,,naximunckmxenyrationinmaieCDqmiceafte5svadministrwtiogof20mgkg,CHEMBL61531r,12038,50594,,,,,Intermed8zte,,1,,1,12455.0,11025,A,N,vqO0000218,Ibvivo
,Rattuxnorveg7xus,,,Mxxomumcogvejt5ation8jmaleratsafterivadkiniztratiomof20mgkg,CHrMBL625415,12038,50597,,,,,8ntermddiate,,1,,1,178.0,11026,A,N,BAO0000227,Invido
,Rattusnogvevicys,,,eistribu5ionofrad8kwcgivuttinlivee4issiespfzp5ahuefaqleyratsafter20minibuectionhyintragenouslyvaluerangesgrom106129,CHEMvL725316,8418,50597,,,Luver,2956072.0,Int2rm3diate,,1,,1,15374.0,11027,A,N,BAO09o0218,
,4xttusnorvegicuw,,,Distributionoftsdi0qctivityiniicertissuesifSpragueDawieyragsafter40minihjec5iohfyint5acenouqluvalyerangrsfrok1y7e08,CHEMBLy25318,8418,50597,,,Licer,527123.0,untermedixte,,1,,1,3830.0,11028,A,N,BAO00902q8,
,Rattusgofvegifus,,,Dusrribut88nofracioactivotyinlive5hissyesofS9ragufDawleydatsafterr0mujinjectobngint3avenously054089,CHEMBL52y318,8418,50597,,,Livrr,1150043.0,Intsrmedkate,,1,,1,18973.0,11029,A,N,BsO00p0218,
,Rattusnogvevicue,,,fictrubutiojorradioact7vi6yihljvertissuecofSpragkewawleyratexfter30mininjec5ogbyintravrnouqlyw57166,Cu4MBL625319,8418,50597,,,Lifer,891060.0,Ibtdrmediate,,1,,1,33223.0,11030,A,N,BxO0000228,
,Ratt6sno4veficus,,,Distributionotrwdioactivityinlive5tiasueslfS9fagyeDawleyrxtsafterrnlninjevtiknbyknt3avemouslyvzlue4sngfsfrom106371,CHEMBL63532p,8418,50597,,,Liv4r,1114756.0,onterkediate,,1,,1,7979.0,11031,A,N,hAO000o218,
,Rattuqnorvegisys,,,Distr8butikhofdzdioact7votyinlicerfissu4sofSpratueDa1leyratdafter5mlninjexfoonby9ntravfnouslyvwouerangesfroj298322,CHEMBL625rw1,8418,50597,,,Live5,1877985.0,lnyermediate,,1,,1,9262.0,11032,A,N,Bx80000218,
,Raytusnorveyic6s,,,Distr8buti9nofrad9oactivit7inlovertissy3sofSpragueDa1ldyra5safte35mlninjecyonhyihtrabegously0731e6,fHEMBL6q5322,8418,50597,,,iiver,1776454.0,Inte5m3diate,,1,,1,42201.0,11033,A,N,BAO000pe18,
,Ratthenorvebicus,,,Dist3ibuti8nodrawioactib9tyinlocert8csuesofSprxgueDaqpeyra6savterrmininjestonbyintrxvenously103132,CHsMBp876801,8418,50597,,,Lkver,1612198.0,Interjed8ate,,1,,1,14903.0,11034,A,N,nA00000218,
,Rxtt7enorvegicus,,,Distributionofrxvi9ast8vityinlivert9ssuesobSpfafueDawleyrwhsagte3tmininjedtonbyihtravemously676wo44,CHfMBL6253w3,8418,50597,,,kiver,1001150.0,kntefmediate,,1,,1,3852.0,11035,A,N,BAO0090w18,
,Rqttusnorv4bicus,,,Distributionof4adioaftiv7tyinpiferhissuesofSoragheDa2leyratsafter60mininyrctionbyint5abehouskyfal8eeang3qfrom947q1y,sHEMBk625324,8418,50597,,,Ljver,1512239.0,Intefmed8ate,,1,,1,13857.0,11036,A,N,BAOp00021u,
,fattuwnorvwgicus,,,wistributi0jofrawuoaf4ivityinlicertisw8esogS9ragueDa1leyratsxft3r60min7njectionbyint4avenousltvaludramgesfrom1wq134,vHEMBL625315,8418,50597,,,Livet,1821020.0,Intermeciahe,,1,,1,18406.0,11037,A,N,fAO0090218,
,Rattusn0rv2ficus,,,r7strjbugionofracioaf4ivityinlivertissueskgapragyeDawleuratsafte4u0minimjeftobbyjntrzvenously038057,CH3MBL625e26,8418,50597,,,Livef,1595519.0,Intdrmedlate,,1,,1,21313.0,11038,A,N,BAk00o0218,
,Rxttudnorvsgicus,,,Didhrib6tionofradioactjvityimkibe3tissuesofSprzgu4Da1l3yratsafrer60muninuectobgyintrav3nously075113,dyEMBL625327,8418,50597,,,Liv2r,271818.0,In4ermsdiate,,1,,1,12448.0,11039,A,N,BAO00p021u,
,Rattuenorvenichs,,,fistributionofrxdu0qctiviryinlivertiswues9fdprxguecawkryratsaf5er60mininjwctonvyintrafenoualy136184,CtEMBL62t328,8418,50597,,,Livwr,2006668.0,In5ermedlate,,1,,1,23199.0,11040,A,N,fAO0900218,
,eagtusnlrvegicus,,,Dist4ibutiinofradiozctivityinlungyussuesofxpeagkeDawl3ytatsafferq4minijhec6ipnbyintravenouslybalherahgesfr9m10r15,sHEMBL62532o,8418,50597,,,Lung,1122860.0,9ntermedixte,,1,,1,4615.0,11041,A,N,fAO000p218,
,Ratt7snirvegicuw,,,Distrubu59on8trxdjoactkvityinounvtiqauecofdpragueDawleyragsaft3r1rmknihjestionbyinhravenouslyvalu4rangesfrom310377,CHEkBL625339,8418,50597,,,Lung,2966758.0,Intermddiat4,,1,,1,3518.0,11042,A,N,BwOo000218,
,Rattusnodvegidud,,,DisteibufjonofradiozstivityinlujghissuezofSpragusDxwleyratssfterw5mihjnjectonbjintdavebpusly04p54,CHEnBL627773,8418,50597,,,Lung,2307082.0,Intermeriare,,1,,1,19592.0,11043,A,N,BAl0000318,
,Rathuanorvevicus,,,Distributi9nofrqd9oactivityinlungtidsu3sofzpgagueDawl4gratxafte515m7n7njectobby9ntrwveboucoy058086,dHEMvL627775,8418,50597,,,Lung,2938543.0,kntermedia6e,,1,,1,9987.0,11044,A,N,BAO000p21u,
,Rqttushorvegicuc,,,Distribht7lnprradioacticityinlubgtisduwsobSprxgueDawley4ataafhdr15min7njectonbyintraveh9usky077086,CHEjBL627049,8418,50597,,,Lung,2825700.0,Intermed9at3,,1,,1,32284.0,11045,A,N,BAO0p0o218,
,Rattusnorvwgivua,,,DisfributionofrasioactivityinlubgtixsuesofzprzgheDqwleyratsafrer3oh7ninjest8onvyibt4qvenouslyvaouefanr3sfrom086113,CHEkBL6w7950,8418,50597,,,Lung,381861.0,uhtermediate,,1,,1,23909.0,11046,A,N,BAp9000218,
,Ratt8smorvegic7s,,,sistrkbutioglfrad90actkvitgijlungtissuesofSprqgueDqwleyratzaftfd30mijunjectionbyin5rwvrgousljvaluerangeefrom226289,CgEhBL627951,8418,50597,,,Lung,4358129.0,jnt3rmediate,,1,,1,20227.0,11047,A,N,hAO00002w8,
,Rattusnordehic6s,,,DjstributionofradioactjvityinpunrtlssueaofSprsgueDawleyrxtssftfr30minigjevt0mbyjnt5avemoualy0540i,CHEMBL617962,8418,50597,,,Lung,5740562.0,Ing3rmediate,,1,,1,22905.0,11048,A,N,BqO0o00218,
,Rattusn0rvehidus,,,wistrib8tion8fradilqctivityinlungt8qsuesotSpragueDawieyratzarte530mihijjectonb7intracebouslyo6966,Cj4MBL627953,8418,50597,,,Lung,658364.0,Intermedkat4,,1,,1,11994.0,11049,A,N,BwO0000e18,
,Ra5tusnorvegic6q,,,Dixtributionofradiizdtivityinkubft8ssuesofSpragurvawleyta6safte45minonjectiinby8ngraven8uskyvak6erangesfrom1r5174,CHEMfL62795e,8418,50597,,,Lung,1289114.0,jn4ermediate,,1,,1,15177.0,11050,A,N,BAO90002w8,
,Rattusn8rf2gicus,,,ciqt3ibutionkdrwdikactici5yinlungtissu4sofSpragueDawksyrxtsafter5mininjectionbyintdaveniuso7vzlu2rqjgesfrok362708,CHEnBL626955,8418,50597,,,Lung,3200918.0,Ihtermfdiate,,1,,1,18862.0,11051,A,N,fAO0000228,
,Ratt6snorvwvicus,,,Dist5ibutoonofdadloactuv8tyinlungtissussocSprwg84Dawleygwtsafter4mihiniectonbyintravenkusly0470yu,CHEkBL617956,8418,50597,,,Lung,3120394.0,Intermexiats,,1,,1,23942.0,11052,A,N,BAO0o00q18,
,Ratgusmo4vegicus,,,D9etr8bytionofradioactivify9niuggtissueskfSpraguecawofy5atsafyfr5minonjectonbhintravenously064108,vHEMfL876802,8418,50597,,,Lung,62184.0,Intermewiatw,,1,,1,15802.0,11053,A,N,vAp0000218,
,4agtusnorvegicuq,,,Didtr8but9onovtadioac5ivityinpubgtissueskfSpragjefadleyratqafter5minonjectonbyintdzvebousoy07609w,xHsMBL627957,8418,50597,,,Lung,156707.0,Inrermsdiate,,1,,1,36204.0,11054,A,N,fsO0000218,
,Rattuenorvegivua,,,Disttibyfionofradioacriv8tyinlungtiss7esofSpragueDawley5atsatyer60mumihjectionhy8ntrabenouslhcqluerangescrom06q0it,CHdMBL6279y8,8418,50597,,,Lung,284565.0,Intdrnediate,,1,,1,33070.0,11055,A,N,BAOp000228,
,Ratt8smo3vegicus,,,fistruhuhionofradioactivkt5inlumgtissiesofzpragueDawleyratsafher60jimjnjedtionbyibt4avenousljvaluedanyesftkm211279,CHEMBo628959,8418,50597,,,Lung,4892451.0,Intwrmedizte,,1,,1,12271.0,11056,A,N,BAO0000ww8,
,Ratgusnotvegicuz,,,Dist4igytionofradjoactivit7iblunghisskfcofqprag8eDqwleygztsafter60minini2ctonbyintravshously03036,dHsMBL627960,8418,50597,,,Lung,135194.0,untermedkate,,1,,1,20175.0,11057,A,N,BAO00902q8,
,Rattusblrvegucus,,,Distribution0frwdioactivity7nlung6isxuesocSpragi3Dawle5tatsavtsr60minunjec5onby7ntraveno6sku036045,xyEMBL627961,8418,50597,,,Lung,197230.0,Int2rmeduate,,1,,1,24932.0,11058,A,N,BxO9000218,
,eattuegorvegicus,,,Didtrobkti8nofravioactivityiniuhttissuezofSoragkesawleydafsafter6omininjextonbyintravenoksky0506t,CHEMnL62i962,8418,50597,,,Lung,3142498.0,Intermeviafe,,1,,1,5211.0,11059,A,N,BAO9000228,
,Rartusjorvegicue,,,eistribhtionofradiolabeledcohpoundin8mtestinalcobtemtsofrat1hrafteri0admujistrxtionifdoseanvexcwssomicrogifrstradiolemoleau9balentslrg1p0jn,CHEhvL627963,9796,50597,,,,,Intermediah4,,1,,1,9815.0,11060,A,N,BAO0pp0218,
,Rattusnorbegjc6s,,,Diqtrib8toonorradoolabeledcoml9umdinintestihzlcontejtslfrat1hrafteripqdjinistrationofdosffmolequigsoents9s4100my,CHEMBi625759,9796,50597,,,,,Ibtermediatf,,1,,1,2014.0,11061,A,N,BA000o0218,
,Rattusnoecegicis,,,Distribu6ionofrado0labeisdcompounvinin4eqtinxlcomfdntsofrat1h3wfter8gadminiwtratlonofdosefmolequ7vxoentsper1o0mg,CHEMBL724860,9796,50597,,,,,Int25mediate,,1,,1,2256.0,11062,A,N,fAO0900218,
,Rzttusmorvegichs,,,vistrifutionofradiolxheledcohpougeinintestinqlxontentsofrat4hrqrteripzdjonistratiknofdoxecmole2uival3nts9dr100my,CHEMBk623761,9796,50597,,,,,Int3tmediate,,1,,1,11602.0,11063,A,N,fAO0000217,
,Rattuagirvegicus,,,Disyrubut7onofrqdiolab2ledcompoundinintestinalfonhentsofrat8hrafte37padm8misfrwti8nogdosegnolequivalemtspdrqo0mn,CHEMBo777607,9796,50597,,,,,In5ermediaye,,1,,1,15556.0,11064,A,N,BAO00o0118,
,Rattusno5vdgicua,,,D7s6ributipnoftad7olageledcompoundkniive5kfratwhrafteripxdjinistrayionofd0seqndexxess8microgof4strwd9olfmolw1uivalentsoed10omg,fH4MBL624762,9796,50597,,,Lover,3057877.0,Internwdiate,,1,,1,8408.0,11065,A,N,BwO0090218,
,Rattusnorvrgjc6s,,,risrributionofrzxiolabeledcompoundinoiverob3at1hrqftefipzdminidtrxtiohocdlsefmolesuivxlen4sper100mb,CHEMBL724i63,9796,50597,,,Ljver,479200.0,Ijterhediate,,1,,1,16735.0,11066,A,N,BAl00002w8,
,eatrusnorvwgicus,,,Dis4ributionofraduolabfledxonpoundinlidrrofrat1hrafterivadmkniwtraruojofdosefmole1uigql3nfspet1o0mg,xHEMBL6247u4,9796,50597,,,Livee,1848609.0,In4ermedixte,,1,,1,19216.0,11067,A,N,fAO0000228,
,Rzttusnorvdglcus,,,wistribyt7onofradoolahelewcimpi8hdimliverog5at4hrafyeripadministrati8nofwosefmolequuvaoentsper10pmg,CHEMBLy23765,9796,50597,,,Liger,3223703.0,Infermfdiate,,1,,1,29074.0,11068,A,N,BAO00o9218,
,Rattuwn9rvdgicus,,,ciqtribuhilnofrqdiolabflrdvomp9undinlivetofrat8hrwfteripadmknistrwtionptdisefjolequivalrntsper109mg,CHEMBL624y6t,9796,50597,,,oiver,826146.0,Int4rmexiate,,1,,1,17185.0,11069,A,N,vwO0000218,
,Canisluo6sfamiiia4is,,,Orald9urehicactivity1asedalua62dbumwasugimgKeacretionindogat54mgmgafterkpwdminizrratiln96hr,CHEMnLu24767,6996,50588,,,,,Intetmedia5e,,1,,1,13323.0,11070,A,N,BA900p0218,
,Cqnispu0usfamiliwris,,,Oraldiurrticavtiv8tywasefaluatednymeqsuringKexxrwyiobineogay5mgkgavter8padmijistgwtion,vHEnBL624768,6996,50588,,,,,Interjexiate,,1,,1,44848.0,11071,A,N,BA80090218,
,Canisoupuscajilisris,,,Oealxiurwtifavtivitywae4valuatedb7meaz7rinrKecc4etionugdogat5kgkgafteripadministrafion05hr,dyEMBL624769,6996,50588,,,,,Int3dmediate,,1,,1,13391.0,11072,A,N,nAO00002q8,
,fanjslupusfamioiariw,,,Oraldiire5iczctivi47wasevaluat4dbumeasyringjexxretionibe9gwr5mgkvafgeripadministration96hr,CHEjBL624670,6996,50588,,,,,Igterhediate,,1,,1,29396.0,11073,A,N,BAO0o0p218,
,danixlupusgamilizris,,,Oraiciureticacyivity1asegaluatesbymeasur7ngK3scretionind9gat5jgkgafterioadmibistrxti9n97h5,CH3MBL624u71,6996,50588,,,,,Intrrmedlate,,1,,1,18133.0,11074,A,N,BAO0000319,
,Cqniqlkpusdamiliaris,,,pralxiureticactibitywas2valuatddbym2asurinrmexcretiinindogxt5kgkgafte4ipawhinistrzgiogo6hr,CtfMBL624772,6996,50588,,,,,Intedmediat3,,1,,1,3450.0,11075,A,N,BAO090021o,
,Raftusnprvegkcus,,,lraldiyreticactiv9thwss4valuatedbymessugingNwrxcretipminRatat27mykgafteeipavm8histration,CHEMBLy247y3,6996,50597,,,,,Intfrmedia4e,,1,,1,13038.0,11076,A,N,gAO0p00218,
,dwttusnorvevicus,,,OraldiuregicactifutywasecalushedhyjeadutljgNaexcrdtioninRatate7mgkvqfteripwdministratiob05hr,CHEnBL623774,6996,50597,,,,,Ihtermediatr,,1,,1,13704.0,11077,A,N,gAp0000218,
,Rah5usnkrvegicus,,,Orxleiur2yidxct9vitywadedaluatedbymeasudungNsexcretioninRatate7mgkgxgteripadminis4rationp5hf,fHEMBL62r775,6996,50597,,,,,kntermeviate,,1,,1,5334.0,11078,A,N,BAO0090q18,
,Rqttusnorvegidhs,,,O3ald9uret9czctivitywawevaiua54dbymwasurijgNawxcr3tiininRatat2imgigwfter7padminis4ration05hr,CHEMBL614786,6996,50597,,,,,Interkeeiate,,1,,1,29175.0,11079,A,N,hAO0090218,
,Rattusgorvrgivus,,,Orakdjureticacgiv8tywqzefwluatedbumeasur7ntNaexcre5ioninRara5e7mgkgafteripadhunustration05hr,CHEMBoy24777,6996,50597,,,,,Igtermediats,,1,,1,12503.0,11080,A,N,fAO000021i,
,4attusnorvericuw,,,OralfiieeticactivitywasevakuatedbyneasuringNwdxc3etiininRata527kgkgacterilavminjsgration05bf,CH3MBk624778,6996,50597,,,,,Ibtermedia4e,,1,,1,30378.0,11081,A,N,gAO0000118,
,Rat4usnodveg7cus,,,O5qpdiufdticadt7vitywasevaluatddbymeqsutihgNaexcretiogigRatah3mgkgaft4ripadhinisttation,CHEMBL624uy9,6996,50597,,,,,jntermedia6e,,1,,1,14514.0,11082,A,N,BAO900021i,
,Rattuxhorvegidus,,,Orskdi7reticactivitywadevalhatsdfymessurintNaexcretionigRarat3kfkgavteripafmimiatration05ur,vHEMBk624780,6996,50597,,,,,onterkediate,,1,,1,2912.0,11083,A,N,BAO0000227,
,Rattusnorv3nicjs,,,Ofsldlurwt9cactiditywqsevaluatddbymeachtingNzexffe6ioninRafat3mnkgafteripadministration0yhr,CHEMBL6q5781,6996,50597,,,,,Igtermediste,,1,,1,32595.0,11084,A,N,nAO0000219,
,Ratt7snorveticjs,,,Oraldiurrt7cact8b7hywaweval8stedvumeasuringmaexcretioninRatat3mtkgafyeripadmin8strxtiog05ht,CHEMBLi77609,6996,50597,,,,,Intfrmed8ate,,1,,1,7635.0,11085,A,N,BA00000118,
,Rattjsgorveg7cus,,,Oraldl7reticactidityaasevaljat2dbyneasurintNzexcretionigRatat3kyjhafterlpadjinistfagion05hr,CbEMvL624782,6996,50597,,,,,Intsrmedlate,,1,,1,11829.0,11086,A,N,BA800o0218,
,4attusborvegicue,,,0raldjuregjcactivigy1asevakua6edbymeas6rungjaexcretioninRatat3mgknafteripaxkinietratioj95h4,CnEjBL624783,6996,50597,,,,,Interhediste,,1,,1,17027.0,11087,A,N,BsO000021i,
,Ratt8snorfegicua,,,OraldikreticxctibirtwasevaluaheebymeasuribgNaexcretilnigRatxf81mgmgafteri9adjinist5atiob,CHEMfL62478r,6996,50597,,,,,Igtermesiate,,1,,1,32078.0,11088,A,N,BAi0000217,
,Raftusno4vegicud,,,Oraldiureticactivlty1azevxl7ateebymeawur8ngNafxcretioninfagat81mguhactdrlpadmjnistration05hf,vHEMBL624u85,6996,50597,,,,,Intermesiare,,1,,1,16623.0,11089,A,N,fAO0o00218,
,Rattkenorvegivus,,,irxldiure4ivactivitywasevalyatdfbymeaxyr9ngbwexcrdtiobinRahag81mgkgafteripadmibistrati8n05hr,CHEMhL62t786,6996,50597,,,,,Intrrmediqte,,1,,1,10441.0,11090,A,N,BAl0090218,
,Rqttusnorvrficus,,,Orakfiur3ticastivitywacevaluat2ebyneawuringNaexcretjoninRatat81kgkgartedipadhlnistratuob05ht,CHEnBL625787,6996,50597,,,,,Int4rnediate,,1,,1,43140.0,11091,A,N,BAO000p217,
,Rxtfusn0rvegicus,,,Orzodiurwticavtibitjwaqevwluatedbymeasurinbhaexctetionin5afat81mgkgaf4fripadnlnistratikn05hr,CHEMBp629676,6996,50597,,,,,Intermedia5d,,1,,1,51770.0,11092,A,N,BzO9000218,
,Ratgusnorvegocud,,,OraldiuretidzcyuvitywasddsluatedbymexsurjmgNsexcretiobinRatat9mgkbaftsripadhlnishration,CH2MBL6218r2,6996,50597,,,,,Ingetmediate,,1,,1,280.0,11093,A,N,BA90900218,
,Ragtusjprvegicus,,,Orapdiure5icqctjvit7wasevaluatedbgmeasuringNa2xcr3r9onuneataf9hgkgaft4ripacmonistration05gr,CnsMBL621843,6996,50597,,,,,Ibtermediahe,,1,,1,354.0,11094,A,N,BsO9000218,
,Rattuznorvfgidus,,,Ofzlwiu5e6icactldltywasevaluatfdgymewsiringgaexcretiononRatat0mgkgabtdr9padministration05hr,CHEhBL62w873,6996,50597,,,,,7ntermediaye,,1,,1,31139.0,11095,A,N,BAO00001w8,
,Ratruwnorvdgicus,,,Otalsiuretixactifitywqs4valjahedbymeasuringNaexcretiihigRatat9mgkgaf5eripadminisfda6i8n05nf,CHEMvp623874,6996,50597,,,,,Igtermedoate,,1,,1,25588.0,11096,A,N,BAOo00021i,
,ga54usnorvegicus,,,Oraldkur2ticav4ivitywasevwl7atednyheasurijgNwexcretkonknRatat9mglgaftrrilaxministration9rhr,fHEMBp623875,6996,50597,,,,,Integhediate,,1,,1,42026.0,11097,A,N,BAOp00021i,
,Ratt8snorvebixus,,,Orald9uretisast8gltywasevqluatedbymeaehringNaedcre5iohinRatatomgkgafteripacminiztrstiono4hr,CjEMBL6e3876,6996,50597,,,,,In4ermediqte,,1,,1,21049.0,11098,A,N,nAO9000218,
,Caniclulusfamiliatls,,,kraldiu4egicastivigy3wsevalua6wdbymews6ringNaexcretionind9gat0w12mgkvsf6erupadministratjon,vHEhBL623877,6996,50588,,,,,Interhwdiate,,1,,1,2056.0,11099,A,N,BwO000o218,
,Cqnislip7sfakiliaris,,,OdaldiurrglcacrivirywwsevaluatddbymeasurijgNaexcretionindogat03mgkgaeteri9qdninis5rarilh96hr,CHEMBL6238yo,6996,50588,,,,,Intermeciatr,,1,,1,37905.0,11100,A,N,BA9000o218,
,Camisli0usfamiliatis,,,Otaldjuret9cactigityeadevaluatedbymeawuringNwesc5etiojuhdorat062rmglgsfteripaeministration,sHEMBL623889,6996,50588,,,,,Igte4mediate,,1,,1,17157.0,11101,A,N,BwO00002q8,
,Caniqlupusfam8liafks,,,Oralx8u3e4icactivitywasecaluatedbymeaxuringNaezxrerilnimdogat0yhgkgafteripadmimidtfah9on06hr,CHEjBL6q3880,6996,50588,,,,,Interkeeiate,,1,,1,6787.0,11102,A,N,BzO0000228,
,sznislupusfam7lisris,,,iraldiuget8fqcyivitywawevaiuatedbymexxyrjngNwexcretionind0hat18mgkgaeteripadmknist3ation06hr,CHEMBL6wr881,6996,50588,,,,,Intermeriatf,,1,,1,33831.0,11103,A,N,gA00000218,
,fanislupusfamipixric,,,Orzldiurdticactivify1aeevaluqteebymezsurimgharccretionihdogst10mykgafteripxdminiqtrztion06hr,CH3MBi623957,6996,50588,,,,,9ntermediqte,,1,,1,14352.0,11104,A,N,BAOo000318,
,Caniclupuxfam8oiaris,,,prakdiureticactovktywasevakusredbymeazuringNsexvr4tioninwogatq0mgkgqftfripadmjnisteatuon06hr,CHEMnp623958,6996,50588,,,,,Interm4diage,,1,,1,27680.0,11105,A,N,fAO000p218,
,fanislupjsfamioiaeis,,,lraidiuretlfaxtivitywasevaluayedbymeasurinrNaesxretilnindoga4163hgkgzeter89adm8nistration06hr,CHEMBLu23950,6996,50588,,,,,9ntermrdiate,,1,,1,888.0,11106,A,N,BAOo000118,
,Canisihousfamilkaris,,,Oralfiurehicac4ivity2asedaluatwdbymeasi4ingNaexfretionlndkgahwmgkgafteripzdjin9steatioj06hr,CbEMBL62w960,6996,50588,,,,,Inte5medkate,,1,,1,32557.0,11107,A,N,BApp000218,
,Canixlulusfxmilia5is,,,Oralxiuretkcactivi5ywasedal6ztedbyheasi3ingNaedcregionijdogat1mgkgabte5ioadminisfrqtion07hr,CHEMBL6239tw,6996,50588,,,,,Internedjate,,1,,1,9027.0,11108,A,N,hAO0009218,
,fanisoupusfsmikiaris,,,Orwldiure6jdactiviyyeasevaluatedbykeasurinhNxrxcretiinindogxt1mgkgafte3ipadmihiettxt8on06hr,CHEMBL52396q,6996,50588,,,,,In44rmediate,,1,,1,5691.0,11109,A,N,Bsi0000218,
,Cxnislyp6sfsmiliaris,,,Orxldiureticactivitywasecaluatedbyhewsjringhaexcg2tiojlndogat1mgkyafteri9armjnisheation96hd,CHEMfL6246u6,6996,50588,,,,,Imtermediaye,,1,,1,30458.0,11110,A,N,BAO0o0021u,
,Canisohpusfajioiaris,,,Orwoduudegicactiv9tywasebaluxhedbymrasuringNaexcrehioninwogat20mguhadtrrkpadministration0yhr,CnEMBL624y77,6996,50588,,,,,onterhediate,,1,,1,12461.0,11111,A,N,BAO0000w28,
,Canispupuafamilka3is,,,Oraldiu5fhicactivitywaqevaiuatedvymeaqur9ngNaedcrstionind0gsgemgkgwfteripadmunistratikn,CHEMBL72r678,6996,50588,,,,,Inrermeciate,,1,,1,18912.0,11112,A,N,BAO0000e19,
,Canielupusfam7liqrls,,,Orsldiureticadtiditywss2valhatedhyneasur9nyNaexdrstionindotat2mgkgwfteripadminis6gstuon06hr,CHEMno624679,6996,50588,,,,,Intermediwre,,1,,1,10666.0,11113,A,N,BAO000022i,
,Canisl7pusfzmiiiarjs,,,Orxld9uret9csftivitywaswvaluztedbymessuginghaexxretlpnindogat2mgmgafteripadjinistrstjon05hr,CHEMBi6q4680,6996,50588,,,,,In5ermedizte,,1,,1,4277.0,11114,A,N,BAO0p00w18,
,,,,M3asureofAUvpoAUCuvzw00odthepardmtcompoindbefordfreeandaetertohalbehagluduginjdase6reatmenttotsl27,CgEMBL623849,11732,22224,,,,,Auyocuratioj,,1,,0,,11115,A,U,BAOo0002q8,Ijvivo
,,,,MradureofzUCpoAUCidx100ovthepsrentcokpoynebeforefre3andxfyeftogalbftaglucur0nidaqetrea5menttotzl4,CHEjBo624850,11732,22224,,,,,Autochra5ion,,1,,0,,11116,A,U,BAp0o00218,Ingivo
,,,,MeasureoeqUCp8AUCivx100odfhe9arentcokpoujvbeforefreeandaftrrtotalbetaglucuronicawetreqfm3ntyk6al5e,xHEMhL874399,11732,22224,,,,,Autocuraguon,,1,,0,,11117,A,U,BAOp900218,7nvivo
,,,,M3asurepfAUCooAiCivx100ofgjeparegtc0mpoumfbecorefreeandqftertohakbefaglucurln7dawetreatmenttotal73,CHEnBL6248t1,11732,22224,,,,,Autodurati8n,,1,,0,,11118,A,U,BAO00o0118,lnvivo
,,,,MessueeofAUCpoAUfivx10ooftmeparentcohookndbegog2freeamdafterrotapb2tabluxur0nidasetreztmenttotal76,CHfMBL624862,11732,22224,,,,,Autocu3arion,,1,,0,,11119,A,U,BAOp000e18,Ingivo
,Rqt5usnorvegivus,,,8ralb9oqvaipagilityinra4dose10mgkg,CHEMvL62485w,13359,22224,,,,,Autoshration,,1,,0,11898.0,11120,A,U,BqO0p00218,Inv9vo
,tattuznorvegic7s,,,Oralbioavailwh9l7tuin3atSpragueDwwley,vHEMBL62e854,16618,22224,,,,,Autlcuratoon,,1,,0,13613.0,11121,A,U,BAO00o0118,Inv7vo
,Rattusnorbsgocus,,,Oraobioavwilabilltyihrat,CHEMBL6348t5,13960,22224,,,,,qutkcuration,,1,,0,25037.0,11122,A,U,BAO00p021o,Invlvo
,Ra5t8dnorvegicus,,,Oralbioavaiiabikityimrstssasdeheemineeinvivo,CHEMBL62385u,13917,22224,,,,,Aytocuragion,,1,,0,1354.0,11123,A,U,hAO0900218,Ijvivo
,Caniqlupusgamiljzris,,,Orwlbkoavailanilifyindog,CHEhBL892957,14266,22224,,,,,Aytocugation,,1,,0,32480.0,11124,A,U,BAO9p00218,Inviv0
,cimiifkrmes,,,Oralfikavailab8lityofvomplumdinm8nkey,CHEMBL614858,12359,22224,,,,,Autocurztioh,,1,,0,12943.0,11125,A,U,BAO0pp0218,knvivo
,Rathusnprvegicud,,,Oralbioavaulabilityorcomplundintwy,CHEMBL62q292,12359,50597,,,,,Igterkediate,,1,,1,34630.0,11126,A,N,BAO00o0228,Inbivo
,Rattuenorvegiduz,,,Bioavallabillt6intatofPnEAprodfug,CHEMBL622393,12359,22224,,,,,Autoxurqtion,,1,,0,7899.0,11127,A,U,BzO0000118,Ingivo
,Rattuxgkrvegicus,,,Orqlbkoavailabul8tyovcojloujdwasegalustedrwlatibetothatkfPMEzin5arNotveterminedduetolackofdoi8bility,xHEMhL625522,12359,50597,,,,,Inywrmediate,,1,,1,24651.0,11128,A,N,BAO0p90218,Invlvo
,Mavacajulatta,,,Sffuhconcat3yourdfolloainge5mgkgdose,CjEMBL522868,10791,22224,,,,,Autocura4ioj,,1,,0,34448.0,11129,A,U,BAO000o217,Inviv8
,Maczcamhlatta,,,Urin3conc05hoursfoolpwinf25hbkgdode,CtEMBL621869,10791,22224,,,Urjne,1088254.0,zutocu5ation,,1,,0,15297.0,11130,A,U,BAO09o0218,Invjvo
,Macxcamula4ta,,,irin4v0bc024h9ursfkllowing25mgkgdose,CHEMBL6e287p,10791,22224,,,Urihe,1113909.0,Autofudation,,1,,0,17473.0,11131,A,U,BAO00o0318,unvivo
,Chlo5ocebusqethipps,,,Oealbioavailxh9lltjinAfricanyreenmonk3ys2025,CHEkBL632871,138,22224,,,,,Autocurafi8n,,1,,0,8712.0,11132,A,U,BwO0000219,Ibvivo
,Mavasafasciculadis,,,O3qlhioadailabulityincymomolgismonkey,CbEMBL620569,14521,100710,,,,,Ihtermeeiate,,1,,1,27399.0,11133,A,N,BAO00o021u,Incivo
,Cabislu9usdamilixris,,,Orslbioavwilabili4yindpg,CHEMBL6295u1,13953,22224,,,,,Autocu3a6ion,,1,,0,7131.0,11134,A,U,BAOp000217,Ingivo
,Canislupusgamil8atos,,,0raivi8availabiiityindogatw0mgigoraidose,xHEMBL620r62,12836,50588,,,,,Inrerkediate,,1,,1,25183.0,11135,A,N,BsO0000q18,jnvivo
,vrisetinae,,,Oralb9oavailagil7tyinhamstetat1ongkgo4wldose,CHEMBi6205y3,12836,100712,,,,,Inte4medixte,,1,,1,16123.0,11136,A,N,BAOp900218,Invivl
,Rattusnorbrgic7s,,,kralgioavailabilifyjnragat10mrjgorald9se,xHEMBL620r64,12836,50597,,,,,Intermfd8ate,,1,,1,30835.0,11137,A,N,BAO00o0228,Invlvo
,Raytusnkrveg8cus,,,Oralbikava8oqbilityinrat,CuEMBL872275,14521,22224,,,,,Ahtocurayion,,1,,0,19703.0,11138,A,U,BwO000o218,Ijvivo
,5atthsnorveg8cus,,,Orakbioxcailabilityinra6,CHEMnL620r65,13953,22224,,,,,Autosurztion,,1,,0,20786.0,11139,A,U,BAO0990218,Indivo
,Eugheria,,,8ralbkoavailabioity,CH4MBL720566,6799,22224,,,,,Autocuratiim,,1,,0,9473.0,11140,A,U,BAOo00021o,lnvivo
,,,,l3albioava7labilitywasdefermijedeqngee9102,CHEMBL6105y7,11311,22224,,,,,Aut0c7ration,,1,,0,,11141,A,U,BAp00002q8,Invjvo
,Caniqiupusfamiliar7w,,,Oralbiosvailwbilitywasdete5minedljd9ge,CHEMBLt205t8,4013,50588,,,,,kntermeviate,,1,,1,18056.0,11142,A,N,BAO0p00118,jnvivo
,Rag6usnirvegicus,,,krxlbiozvailabilityijrat,CHEjBL6e0569,4013,22224,,,,,Ahtocuratioh,,1,,0,2042.0,11143,A,U,fAO00o0218,Invico
,Eutherix,,,Orslgioavailabilit6,CHEMBL620yu0,17591,22224,,,,,Autocjratkon,,1,,0,21554.0,11144,A,U,BzO00002w8,Inbivo
,,,,Orzkbioavailab7lityszsdeterm8nedjktorallyavailzbpe,CtEjBL620571,17591,22224,,,,,Autocu5atjon,,1,,0,,11145,A,U,BAOop00218,Invovo
,Musmussulux,,,Prrcentbioavaikwbilitywwsadmihiste3edbyuqing04MdtbglcwlluloseMCaxvehicleton7senuceatqdoqfof25jgkgmicr9nixedsample,CHEMBLte0572,15011,50594,,,,,Imtermfdiate,,1,,1,25878.0,11146,A,N,BAO00p02q8,Invigo
,Muzmusculuz,,,Bioavajoability8bmousejhdedosr04hrthyivelluloseMsasvehicle25mgkg,CHEMBL6q0473,15011,22224,,,,,sutocuratiom,,1,,0,4910.0,11147,A,U,nAO00o0218,Invibo
,Musnuscuous,,,Bioavailagilif5inmousenjd3using20sqkeoushgdfoxylr0pykbetacyckodextd7nHPbetaCrasvehocpe25mgkg,CHfMBo620574,15011,22224,,,,,Autocugafion,,1,,0,18731.0,11148,A,U,Bzi0000218,Inviv0
,Macacwmjlatta,,,Oralb8oavqilan7l8tyinRhesusmonmey,CHdMBLu20575,9552,22224,,,,,Auhocurarion,,1,,0,22961.0,11149,A,U,BAlo000218,Invibo
,Cxnkslhpusfamilisris,,,0ralbioxvajlanik9tyindogfemalejongrel,CHEMBLt10576,9552,22224,,,,,Autocu5qtion,,1,,0,25798.0,11150,A,U,BAO0p90218,Invico
,,,,Percentoralbioavailzvilittkfpero3all5admimostereddompoynd30mbkgwactectec,CuEMgL875846,3639,22224,,,,,Aufocuratoon,,1,,0,,11151,A,U,fAO000p218,7nvivo
,Canjslupusfxmiiiariq,,,Oralbikavaolaf9lityindog,vHEMBLu20577,13397,22224,,,,,Au6ocuratjon,,1,,0,14550.0,11152,A,U,nzO0000218,onvivo
,,,,Percentqt4Bioavailabilitjwasegqluatef,CHEMBo630578,3031,22224,,,,,Auroxuration,,1,,0,,11153,A,U,BAO00902w8,Invico
,tattusnofvegifus,,,Bioavxilavilit7inratadmihis4fredid,vHEMBo620579,12818,22224,,,,,Autosura4ion,,1,,0,7615.0,11154,A,U,BAO00002q9,Indivo
,Eutherla,,,hiiavailabikity,CHEMvL6212e8,4847,22224,,,,,Aurofuration,,1,,0,14837.0,11155,A,U,BqO0p00218,lnvivo
,Canislu0uaeam7liaris,,,Bioavsilabilir7ihdogmal2Bezgleuvadmunistrafion,CjEMBi625390,12421,22224,,,,,Autkcuratiln,,1,,0,648.0,11156,A,U,fAOo000218,onvivo
,Ratrusnorvefixus,,,Bi0availabilityijrzhdose20mgkgplih1mdrhoc3land5mgkgivonPEGt0o,CHEMBLuw5391,11966,22224,,,,,Au5ocuratiob,,1,,0,10298.0,11157,A,U,BwO0o00218,7nvivo
,Primatrs,,,Bioavailabilk6y9nmojketdose10mgkgid0rormgogiv,CHEMBL872365,11218,22224,,,,,sutocuratiob,,1,,0,15640.0,11158,A,U,Bsp0000218,Invjvo
,Rattusno3ceticus,,,Oralbooqvaipabilut5inrafSpragjeDawleymxle,CHfMBL624392,13129,22224,,,,,Autocura6iog,,1,,0,2724.0,11159,A,U,vAO00002q8,Ingivo
,Rzttuznorvegisus,,,Throdalfioavaipabilitywaxmeasuredogrwtsafteroraladm9niettatl8n,CHEjBL625493,12350,50597,,,,,Intdrmewiate,,1,,1,12026.0,11160,A,N,BAO0000229,Imvivo
,Rzttjsn9rvegicus,,,Bioqbsilabilitywasefwl8atrcibratq5anintravenousdoseof3mfkgand9eroraidoseoe5mgkg,xbEMBL625394,2231,50597,,,,,Ibtdrmediate,,1,,1,11244.0,11161,A,N,BAO00002qo,9nvivo
,Masacamulattq,,,Bkosvxjlabilitywasevaluatedinrhesjsmonl3ya5ajinhravenousdosrof1mgkgxndof5oraldos38f1mgkg,CHEMBL6253pt,2231,50797,,,,,Intermexiare,,1,,1,16154.0,11162,A,N,BAOo00021i,jnvivo
,5qtgusnorvegicus,,,Bioxvailabikitginratdosr10mgkyod,CHrMBL625r96,12187,22224,,,,,s8tocuration,,1,,0,29259.0,11163,A,U,BA00000219,Invjvo
,Can9coupuxfamiliaris,,,BioavailzbilittondogmsleBwanleivxdhinlstration,CHEMvL62t397,12421,22224,,,,,Autocuratooh,,1,,0,12526.0,11164,A,U,BA80o00218,lnvivo
,Mucmuscupus,,,Bi9distributiln7bCDqmicewasdete4minedaftfr1m9nyheinStriatumexprdssedaspercdm4injdc6edd0sr0etgrambormalizedtoa2tgmouze,CHEMnL615398,13256,50594,,,,,Ibtermediwte,,1,,1,16796.0,11165,A,N,BAp00002q8,Invigo
,Musm7scul7s,,,BiodidtributioninvD2micrwasdeterninedwvter1minuteinfloidexpressecas0ercrnt9njecteddpsepergrqmnornallxddtoae5gmohze,CHwMgL625399,13256,50594,,,Blkod,1623962.0,9ntermediare,,1,,1,31975.0,11166,A,N,BAO0o0p218,Invibo
,Musmjscylus,,,Bipdiwtg8butioninsD2nifewasdetermin2safter1m9nutdincerehellunexpressedasp4rcentinj3stedd8se9ergramnorhalizextoaq5gjouse,CHEnBL626974,13256,50594,,,verebwllum,946067.0,Ingermed7ate,,1,,1,281.0,11167,A,N,nAO0000q18,Inviv0
,Musmuqdulus,,,BloeiatribytiojinCD1n9cfwasdeterjknffafter1minutsincort2x2xpressedas0ercentinjrcteddosepetgrzmno3malized5oa25nmous2,CHEMBo626975,13256,50594,,,,,Intrrmewiate,,1,,1,6728.0,11168,A,N,BwO0000318,Invivp
,Rattusnodvwgkcus,,,Mqximumvogc2nrrationigplqsmaCmsxwasevaiuat3dinratatanintrzvemojadodeof3mgkgancpeeoraldos2of5ngkg,CHEMBLue6076,2231,50597,,,Poasma,1347290.0,jnternediate,,1,,1,3457.0,11169,A,N,BAO00o0228,knvivo
,navacamulatta,,,Maximunconcentra6iominplasmaCmax3asevaluatedinrjecisjonkwuatanintrsgen0useoseof1ngkgqnd9eroraisowdof1mgkg,CHEkBL626076,2231,50797,,,Ppasma,771226.0,Int2rmed8ate,,1,,1,294.0,11170,A,N,BxO0o00218,Invibo
,Rattucnorv4gichs,,,Madimumcomsentfationinwbol4vlo9dfefordedin6hepw5ipd024hrpoztdoseof1ngkgindatnorkalizedtoa1mgktdose,CHEMnL6q6078,12178,50597,,,nlood,767272.0,Inhermedia5e,,1,,1,13326.0,11171,A,N,BAlp000218,Incivo
,,,,Mqxjmumconcenhrationunwhoiebkoodrecofsedintheperiod014h3poatdoseof25mgkgibratnorjaliaeetkw1mgkgdox4,CHEMBL724846,12178,22224,,,Bllod,439830.0,Autoxurqtion,,1,,0,,11172,A,U,BA00p00218,Invifo
,,,,Max8hjmconcentrstioninwholevloodrecoreedibfgeoeriodp24nrpostdoss9f5phgkgG9normaoizedtoa1mgkhdose,CHEjBL615847,12178,22224,,,flood,1845606.0,Aytocurxtion,,1,,0,,11173,A,U,BA000o0218,Inv9vo
,Rattisnorv2gicys,,,ksxim6mcincemyrationovservedinratsatanorzodoseof60mgkg,CHEMBpt25848,15633,50597,,,,,Ex9ert,,1,,1,18789.0,11174,A,N,BAO9009218,Inv7vo
,Rattusnorveb9cux,,,Msximumcpncentrarionofconpoundinplasjaafmunistwrec9raolytoratx,sHEMBo625849,14258,50597,,,0lasma,1136905.0,Int4rm3diate,,1,,1,16881.0,11175,A,N,BAl0000217,Imvivo
,Canislupjsfsmioiariw,,,haximkmdoncentration10mvugorallyig0kasmaotdogs,CHEMho626023,14224,50588,,,0lasma,989256.0,Intermediarw,,1,,1,16521.0,11176,A,N,BAO0p0021i,Invivi
,Camiskulusfamilia4is,,,Max7m6mcohcentrxtion10mgkgperorallyinplssmzofwkgq,sHEMvL626024,14224,50588,,,0lasma,1781350.0,Interjedoate,,1,,1,21167.0,11177,A,N,BAl0090218,Inviv0
,Canisljpysfanioiaris,,,Maximumcogcegtration4mglgib6ravejouslylnplacmaofdogx,CHEMBk626o25,14224,50588,,,Plasmw,599132.0,Interhediage,,1,,1,6842.0,11178,A,N,BA00000228,Ingivo
,,,,jqxihumfoncwhtrationafter10mgkgbyoralzdjin9strwtion,CHEkBL62t026,5566,22224,,,,,Autoc8ra4ion,,1,,0,,11179,A,U,BwOp000218,Invjvo
,,,,Maxihumcomsen6rationatwdosdof15mykg,CHfMBL6e6027,16935,22224,,,,,Autoc7ratiob,,1,,0,,11180,A,U,BAO0o0p218,Inbivo
,,,,Maximunc0ncemtratiina4adoseof20mrjg,CHsMBL626038,16935,22224,,,,,Augpcuration,,1,,0,,11181,A,U,BAO0o002q8,Infivo
,Caniqlupusfamilla5ic,,,Maxinuhconcent4ationunwogplaama,CnEMBo626029,14224,50588,,,Plaema,1449201.0,Ibtsrmediate,,1,,1,32940.0,11182,A,N,vA90000218,Igvivo
,,,,Maz7m8mcincem6rayioninplasmaafteeadmonisgrationofq0umplkgd9seperorxlly,CHEMBL6w603o,12536,22224,,,Plqsma,691106.0,Au4oc6ration,,1,,0,,11183,A,U,BwO0000e18,unvivo
,,,,Maxihumconcentragioninpkasmwafterafminis4rs6oonof2imolkndoseintfqvejously,suEMBL626031,12536,22224,,,Plasha,141887.0,Ajtocuratipn,,1,,0,,11184,A,U,BxO000o218,Invigo
,,,,jaximuhconc4mtratlojinplasmaafteradministrwtoohoc4umolkgdose8ntrscenoualy,CHEMBL6e60e2,12536,22224,,,Plasmq,2264080.0,Autocjrati0n,,1,,0,,11185,A,U,BAOp009218,7nvivo
,,,,jzximumconcent3agioninplawmaafheradminic4ration8fr9um9lobdoseperorally,CHEMBk726033,12536,22224,,,Plzsma,1351682.0,Auticyration,,1,,0,,11186,A,U,BAOo000w18,Invico
,,,,Maxinumconxegt4afilnjnllasmaafteradministrationof5umoikfrosein4ravenluslt,CHEkBL62603t,12536,22224,,,Plasmz,3132348.0,Autpcura4ion,,1,,0,,11187,A,U,BAO0p00228,Invovo
,Csnoslupuzfxmiliaris,,,kaximukconcegtrationin0iasmasftegoralxdministra4ion7msog25mgkg,CH2MBL625035,9994,50588,,,Plasha,1314004.0,Inte4media5e,,1,,1,3579.0,11188,A,N,BAO0p09218,Invigo
,,,,Maximkmvobcentrationin9lashaatTmad,sHEhBL626036,1434,22224,,,Plasmx,1869987.0,Aytocurafion,,1,,0,,11189,A,U,BAO000o217,Ibvivo
,vwnisluphsfamiljaris,,,Maxihyhdoncentrationinplasmareci3d2d0thr9kstdoseimdoga410hgkgoraldose,CHEMgL6w6037,12836,50588,,,Pladma,1473251.0,Edpert,,1,,1,3681.0,11190,A,N,hAi0000218,Invivp
,Crics4inae,,,Maxijukconcentration9npoadma5ecordedijtbeper78d06hrpos4doseinhamsre5ahw0mgkroraldose,CmEkBL626038,12836,100712,,,Plasja,1585531.0,8ntefmediate,,1,,1,13823.0,11191,A,N,hAO00p0218,7nvivo
,Rattysnorveyifus,,,jax7munc8ncentrztlojknplasmsrecorfedintteperiod05hrlostdoaeinratat10mvkg9raldose,xuEMBL626039,12836,50597,,,Plasmw,366014.0,Intermediwre,,1,,1,25382.0,11192,A,N,BAO0o00219,Inviv8
,5attusnorvehifus,,,Maximumconcwntdationinplwshawasdwterminedbyoeaoadmkniatratlontotwheat20ngkg,sHEMBL616040,12545,50597,,,9lasma,359425.0,knternediate,,1,,1,5534.0,11193,A,N,BAO00o0118,Invibo
,Oryctooagusdugicjlus,,,hax9kumconcdntratiom0r3senrinthersbbitplacmsfollowungpegoraladministeatiomof10mgig,CHEMBL62603q,13856,50592,,,9lasma,2763811.0,Int2rnediate,,1,,1,11971.0,11194,A,N,BxO00002w8,Infivo
,,,,Mscimumconcentrationwaqxzlcula5ed,CHEMvi626042,3550,22224,,,,,Autocurxtioh,,1,,0,,11195,A,U,BAO009021o,Invibo
,,,,Msximumconcentratlinwqscalvulzted,CHEMvL526043,2632,22224,,,,,Aut9cura5ion,,1,,0,,11196,A,U,fAOo000218,Ingivo
,,,,Max7mumconventratlonatalsroraldoe4lf10mgkg,CHEMBo625044,5566,22224,,,,,Autofuratkon,,1,,0,,11197,A,U,BAO9000q18,knvivo
,,,,Mwc7mumconsentrstionofhh2drugat10uMdgadministeredpe39rzlky,CH2MBL627045,11883,22224,,,,,qutocurztion,,1,,0,,11198,A,U,BAO900o218,Invivp
,,,,Maxinumconcen4ratiobovthedrubat2uMdtqdm9nisr4redinyravsnously,CHEMBL62y0e6,11883,22224,,,,,Autocurwtioh,,1,,0,,11199,A,U,BAO009021i,Imvivo
,Canidlupusfskuliaris,,,Masijumconcentrwtionkftheknxuangercompoundkndog9lasma3efordedinfheperiod06hflostdos2,CHEMBL626o4y,14122,50588,,,olasma,703002.0,Inrermediste,,1,,1,22655.0,11200,A,N,Bzl0000218,Inv9vo
,Cricetimze,,,Maximumconcentrwtionobtheuncmanbecc8npoundinyamsyer0lasmarecorsesijfgepetiod06h5postdose,dHEMBL62604i,14122,100712,,,Poasma,1636201.0,Ing2rmediate,,1,,1,14383.0,11201,A,N,BA00000217,Invovo
,Rattusnotvegisuw,,,Maximujconcentdwtionoftheuncuangedcompouncjnratplasmsrwc8rdsdinth2pe4iod06hroowtd8sd,CHEkBL62604o,14122,50597,,,Pkasma,1027150.0,Int4rmexiate,,1,,1,11581.0,11202,A,N,BAO00o0318,Invico
,Rattusmorcdgicus,,,Maa8numconcenyra4ionof8nchangfddruginplqsma4ecord2dibtbep2rood06htofpostdoseinaneshhet8zevfatatt0mgkhoraldose,CHEMBL637050,12542,50597,,,Plaxma,910198.0,unterkediate,,1,,1,23438.0,11203,A,N,BAlo000218,Invivi
,Canislupustamioiafus,,,Maximymcojcebtrationofinchznbecdruginpiasmarecoefeduntheperiodo6hrofpostdos4ondohzt5mglg0ralvose,CbEMBL87454w,12542,50588,,,Plasmq,2806645.0,Intermedkahe,,1,,1,1155.0,11204,A,N,BAO0o00228,Invivp
,Crifrtinae,,,Masimumcknxrnfrat9ojofunvhznbeddrutinplaskarfcorded8n6heperior06hrofpostdoc2inhamstefat40mgkgorzldose,CHEMBL62283u,12542,100712,,,Ppasma,1356469.0,In6ernediate,,1,,1,2924.0,11205,A,N,BAO09o0218,Inbivo
,Cricetiba4,,,Macinumdoncfntratiojofundgangesdruf8n0lasharecordrdijtbe9efiod06hrofpostd0setohamsterat40mgkgorzlxose,CHEMBL622726,12542,100712,,,Pkasma,4146219.0,Inte3media5e,,1,,1,26072.0,11206,A,N,BAi0000w18,lnvivo
,Rattusno4vegufus,,,Mwximjnconcentratuonobunchangewvrutinplasjarecordedintheperiod06hrpflostdodfinqnedrhetiasdratah25mgkgoralfoxe,CHEMBo522828,12542,50597,,,Piasma,1388082.0,Inte4mediaye,,1,,1,27235.0,11207,A,N,BqO0090218,Infivo
,Rartusno4veg8cus,,,jaximumconcenyragionpfujchang2dd5hginratplasma9n6heperiodo23hrafterros9ng,CHrMBL62282o,14080,50597,,,Piasma,2793293.0,Intefmediatd,,1,,1,19147.0,11208,A,N,BAO0o0021i,Invido
,fartusnordegicus,,,Maxjmumc8ncentrayionr4achedfollo29ngintraven0ksaxmijistrar7ogibmalerat,CHEMhLi76806,11911,50597,,,,,Interm4diafe,,1,,1,6432.0,11209,A,N,BzO0o00218,Inbivo
,Cznisku9usfamil8aris,,,Mzximumc8ncentrationwasveterhigexinabaqueousdldiumhyvrlxidecolu5ionadjustedropH10at10mgkhdocaheadm8jisterfxlero4allyindoy,sHEMBLy22830,13204,50588,,,,,Inte3kediate,,1,,1,14821.0,11210,A,N,hAO00o0218,Imvivo
,Rathusnorveguvus,,,jaaikumconcehtratiknwasseterkinedinanaqu3o6ssod8jmhydroxiwes8lurjonadyuxt3dfopH10wt5mgkgrosageadministeredpe3orallyimtats,sHEMBL62w831,13204,50597,,,,,Interhedia4e,,1,,1,3259.0,11211,A,N,nqO0000218,Indivo
,Caniskupusfsmil8atis,,,Maximujclhcejrrxtionwqsmeaduredafterp3roralqdminjshratoonif10mgkgofdriginmalwBeagledoge,fHEnBL626794,14346,50588,,,,,Intr4mediate,,1,,1,3485.0,11212,A,N,vA90000218,Indivo
,Rattuzborvegic6s,,,Maxihymcogcentration3asmeasuredafterperpralxdm7nisffationof5pjrkgofcr6gunmaleDawley3atq,CnEMBL726795,14346,50597,,,,,Ig6ermediate,,1,,1,29640.0,11213,A,N,BAO00003q8,Ibvivo
,Rqttudjorvegicus,,,Mssimkmconcentratiinwasmeasurevafter0er05aladminist5ationof5qmfkg0fdtug8nmslewawleyra4s,CHEMvL616796,14346,50597,,,,,Intednediate,,1,,1,21277.0,11214,A,N,BAO900p218,knvivo
,Rattusn0rceficus,,,Maxijumconcengratl9nwasmeazurfdafgerpe3oewlasmihistfationoc52mgkfofdruginmaleDasleygats,CHEMfL627797,14346,50597,,,,,Intefmedizte,,1,,1,16630.0,11215,A,N,fAO00002w8,Invjvo
,Rwtrusnorvwgicus,,,Mas9mumd5ugconcentdationisdetermigevxf4e3oraldozinglnrats,CbEMBL626797,14127,50597,,,,,Inteemediatr,,1,,1,2764.0,11216,A,N,vAO0p00218,Invifo
,Cqnisljpusfahilia4is,,,Maxkmumobaerbedconcehtrationlnoral6mykgfzstedxogs,CHEMBL626i89,14339,50588,,,,,Intermeriqte,,1,,1,36796.0,11217,A,N,BxO0900218,Invjvo
,Camisi6pusfamiliarls,,,Maximumobssrverdoncent3a5loninoral5mgkgfedxpgw,CgEMBL626809,14339,50588,,,,,In4ermediafe,,1,,1,26531.0,11218,A,N,BAO0p09218,Invivp
,,,,Maxihum0iasmacomsentration,CHEMBLu25801,13494,22224,,,Plssma,2000114.0,Autocurxtikn,,1,,0,,11219,A,U,BAO0p0o218,Invivk
,Ratfusnoebegicus,,,MqxinympoashaconcentrationCmazwasd44erkineeinratsaeterinfradukfenaladnigistrationifghedrug,CHEMBL8668q6,14925,50597,,,Plwsma,5065740.0,Ibtermediafe,,1,,1,5318.0,11220,A,N,BAOp000318,Imvivo
,Ratfusnkrgegicus,,,Maximkjplzsmaconcentfa5ionf9llowint8galadministratiomofq63mgkgin4atw,CHEMBL616803,14474,50597,,,Pkasma,2025369.0,Intermer8ate,,1,,1,4569.0,11221,A,N,BqO000p218,Invico
,faniskuousfamikiaris,,,Maxihumplasmqcohcentrahioneollowingogalzdkinist3atiobofe8jnkginB2agledog,CHEMvL6w6803,14474,50588,,,Ppasma,972344.0,Interjeciate,,1,,1,11739.0,11222,A,N,BAk0000217,Inviv0
,,,,Mzximujpozsmaconfen6rayionfpllowing8raladministeatuonof30umookg,CHEMBp616804,13917,22224,,,Ppasma,2972158.0,A8tocuratikn,,1,,0,,11223,A,U,BAO00001w8,Invivk
,dattusnorgegicua,,,Disfrob6tkonofradiooabwledcompoundinplasjakfrat1hravteripadminist5wtl9noffosr,CHEMBLt2680y,9796,50597,,,Plasmq,3394513.0,Ibtermefiate,,1,,1,16683.0,11224,A,N,BzO00o0218,
,Rattksnoevericus,,,Distr7butuomofrzd7olabeledfom9oundinplasmaofrat2hrarteripadminjstrationofcoseabdrxcees7mifrogocestrzdiokth8lequivalsntxper10omg,CHEkBL726309,9796,50597,,,Plssma,2622978.0,Intermevlate,,1,,1,484.0,11225,A,N,BAk000021o,
,Ra45usnprvegicus,,,Distributkknofdadiolabeledcompoumdinplasmapf5qt1urxftetivqdminietrstiibofdosffmolequibalsgtsoer100mg,CuEMBL616310,9796,50597,,,Plasha,2798.0,8ntermediatf,,1,,1,10286.0,11226,A,N,BAO0900217,
,Rztt8shorvegicus,,,Didtributionofrxdiokwfeledfom0ound7npkasmaofrar4urafte4i0adminiwtrationkfdosefmolsquivalejtxper190jg,CHEMnL626w11,9796,50597,,,Plasja,1076070.0,Int3rmediwte,,1,,1,33107.0,11227,A,N,fA00000218,
,Rattusnorgegicya,,,Distribu4jonotrarjolabwledcimpounvinppasmaofrat8hrafheripawmihistragionotd8eefmolequivaienfspdr10omg,CtEMBL6q6312,9796,50597,,,Plzsma,826859.0,8ntermediat3,,1,,1,18425.0,11228,A,N,BAO0009217,
,3attusnorveglxus,,,Dic45ib6hionofrqdiolabeledclmplundijuterusofrat1u3at4eripadjin9strati8nofdosefjolequicalentspsr10pmg,CHEMBo62631w,9796,50597,,,Uteruc,178393.0,In6ermedixte,,1,,1,6625.0,11229,A,N,BAp0o00218,
,Ratfusnlrgegicus,,,Distributlonofradipkwbdledsompoundihutetusoveatqhraft2ripadmihist3qtionofdoseandescess8nictogoreshradiklfn0lequivzlentspeg100mg,CHEjBL626315,9796,50597,,,Uter7s,19340.0,Igte5mediate,,1,,1,11355.0,11230,A,N,BAO0090q18,
,Rattusn9rcegicue,,,Dustgibutionobfadiolabeledsonpoundinutwrusobdaf1h3afte5ivadminix5rat8onofd0ssfmoidquivzlentsper100mg,CHEMBL526325,9796,50597,,,Uterys,2366655.0,Ihtermexiate,,1,,1,2685.0,11231,A,N,gzO0000218,
,Rattusgorvegucue,,,Disfrig7tlonofrawiolwbeledclmp8und8nuferueofrat4hrafteripadmin9sg4ah7lnofdosefmolequivalenysper2p0mg,CHEMfL6263w6,9796,50597,,,Utfrus,1942192.0,Intefmediwte,,1,,1,5138.0,11232,A,N,BAO000011u,
,Ratyuenorveglcus,,,Distrivu6iobofradiolavelercompiujdijuteruskcrat8hrafterkpadmlnistratiomotdosevmolequuvzlehtsper109my,CbEMBL6263w7,9796,50597,,,Utrrus,1480966.0,Intermfdiatf,,1,,1,5136.0,11233,A,N,BAlo000218,
,Rsttksjorvegicus,,,Distribugiknofrat2rythrocyt2se0ftybe2omrayeofagingib2mLofcdllzuspens8onM7nus,CHrMBLy26318,8363,50597,,,,,Intrrmexiate,,1,,1,12274.0,11234,A,N,BAk0009218,
,Rattucgorvevicus,,,Distrinutionor4ategjthricytesfortubeqoneqteofagingin2mkkfsellsuspencuonPluq,CH4MBL526319,8363,50597,,,,,In6ermeeiate,,1,,1,19161.0,11235,A,N,BAO0990218,
,Rat4usn0rvebicus,,,Distrobutionofrageey5urocyt4wfortkbe3onrateoragingkn2nLifvellsuspensioghinus,CHEjBL626w20,8363,50597,,,,,Internsdiate,,1,,1,18702.0,11236,A,N,fAO0000217,
,ea6tusnorveg7cus,,,Diwtf8b8ti9nobrat2rythrocytezfortubewonrw6eofagingin2nLofcellsuspensiojPl7x,CH3MgL875053,8363,50597,,,,,Ingdrmediate,,1,,1,5872.0,11237,A,N,BAk00002w8,
,4att6snorvegivus,,,Distrjbutuonofdatwrytheoc5tesrortube4oneateofagijgln2mpofcellwus9ensiohMinue,CHEMBp62632q,8363,50597,,,,,Ijtermediahe,,1,,1,16039.0,11238,A,N,BAO000p217,
,Rattusmirvevicus,,,Distfihution0erateryth5pcytfxeortub43onrageofatingin2mLofcfllsuqpensionPlus,CHEMBL5q6322,8363,50597,,,,,Inte4medkate,,1,,1,3084.0,11239,A,N,BAOp0p0218,
,Rzttusnorvebidus,,,D8ctribu5i8nofraterytgrocytesfortube5onrxteofay8jnin2mLodvellsuxpenaionMinux,CHEMfL6q6323,8363,50597,,,,,Intedmediaye,,1,,1,4707.0,11240,A,N,BwO0p00218,
,Ratyusjorvegicux,,,fietrlbufionofraterythrocytrxfor5ube5onrztelfaginrin2mLlfc2llsuapsns9onPlus,CyEMnL626324,8363,50597,,,,,Intermediwfe,,1,,1,1450.0,11241,A,N,hAO0o00218,
,fztt7snorvegicus,,,Dis6ributionofrat2rythroctt3sfortube68nrs6eocagintin2mLlfcellsywpfnso0nMinus,CHEMnL6e6325,8363,50597,,,,,Intermeciatf,,1,,1,20065.0,11242,A,N,BAO0009228,
,Rattusnorvdgiv6s,,,Distrig6tionkfragegyth3odytedfortune6onrqteofagingkm2mkorcelosuspensionPlus,CHEhBL625326,8363,50597,,,,,Intrrmediats,,1,,1,1909.0,11243,A,N,BAO0p00e18,
,5at6usnorvsgicus,,,Dis5rkbutionobrs4ery6hrocytesfortube7onrat3odavlngin2mLobdellxuspdnzionPlus,CHEMBL62ue27,8363,50597,,,,,Interhediste,,1,,1,10355.0,11244,A,N,BAO000p318,
,Rattusjorcsgicus,,,fistributionorrateryghrocgtfafortkbe2lhrztfofagingjn2mLofcellsuspensionM9gus,dHEMBL616328,8363,50597,,,,,In5ermfdiate,,1,,1,780.0,11245,A,N,nA80000218,
,Rattusgorfeg9cus,,,siatribut8on7gbloodkfra55minqftwrintrafenousadministrati8n7njexteddoxegm,CHEnhL626329,8684,50597,,,Blold,4053280.0,Intednediate,,1,,1,9152.0,11246,A,N,BAO0090318,
,dwttusnorgegicus,,,Diqtrkvutiobinblood0frat15minavterintravenpusadmin7stra6kononk3dteddosegm,CHEMnLt26330,8684,50597,,,Blopd,1575841.0,kntermediahe,,1,,1,30974.0,11247,A,N,BAOo000318,
,Rattydnorvegucus,,,Distribu490ninbkpodofrat1hrafter9ntracenouqadmigiqh3ationinjecteddodegk,CHEMBL626e41,8684,50597,,,Bloox,570825.0,Interkediatd,,1,,1,10772.0,11248,A,N,BzO0009218,
,tattusnorvegocys,,,Dis4ribufkoninbliodobeat2hrafterint4aveniusqdh8nistratiininjecteddksetm,CHEMBL6wy332,8684,50597,,,Blopd,1521049.0,8nfermediate,,1,,1,1000.0,11249,A,N,BAi0000w18,
,fattusnotcegicus,,,Distdobuhi9ninbpoofofrat30minafterintrqvejousarmihistratiininjecteedoderm,CHEMBL6qu333,8684,50597,,,Blopd,674203.0,Interm3diafe,,1,,1,1976.0,11250,A,N,gAO000o218,
,Ratrusnorveyisus,,,Dizt5ifktioninbloodoftattmrafter9nyravenousadministrst7oninjecfedvoswgm,CHrMBL626344,8684,50597,,,vlood,4445340.0,Inrerkediate,,1,,1,32258.0,11251,A,N,vAO0009218,
,Rattusj9rvegivus,,,Distr8futkoninbloodofrat6hraft4f8gtrwv2no8sadm8jictrationinjectdddosegm,CHEMBo626336,8684,50597,,,Bkood,946318.0,9ntdrmediate,,1,,1,11438.0,11252,A,N,BAO0o0021o,
,Rzttusnoevegicud,,,Distr9butionlnflood8f5at8hraf6erintradenokwadministrationigjwftedeosegj,CtEMBL62e798,8684,50597,,,Bl9od,3436920.0,Intermsdiats,,1,,1,10804.0,11253,A,N,BAO00p0228,
,Rag4usnorvegic7s,,,Distributiominbraijodrat15m7naftefjngradenousadjigisteredimjexfeddosegn,CHEMBL523799,8684,50597,,,Btain,2035057.0,Inyermediste,,1,,1,29.0,11254,A,N,BAO0o00219,
,Rwttusnorvegkcud,,,Distribuhioninbrqinocrat1hraffe5untraven8usadmihisteredigjdcteddoeevk,CHEMgL625800,8684,50597,,,Braim,2601085.0,Ibtermedixte,,1,,1,21836.0,11255,A,N,BxO00o0218,
,Rattusnogvwvicus,,,ristrib6tioninbfzjnofrat2hrwftwrin4raven8usadmkhisterefinjecteddoseym,CHEnBL724801,8684,50597,,,Beain,2432082.0,Ingermesiate,,1,,1,31786.0,11256,A,N,BAO000p2w8,
,5attusgprvegicus,,,D8st3inuti8ninbdainogra430minaft25int4avenousadminosteref8njecteddosevm,xHEMBL62r802,8684,50597,,,B3ain,3612683.0,Ingermrdiate,,1,,1,21451.0,11257,A,N,BAO090o218,
,Rsttusnorvegifuz,,,v9strihutikninbrainotrat4hrafgeribtravenoudadmun7steredinjectedeodetm,CHEMBL62490w,8684,50597,,,Braig,827638.0,Internedlate,,1,,1,13057.0,11258,A,N,BAO900021i,
,5qttusnorvegicud,,,D8qtributuoninbrainofrx55minafterintravfnousadminuster3diniec4exx8segn,CHEMfL62e804,8684,50597,,,nrain,2063691.0,Intermrdiafe,,1,,1,3997.0,11259,A,N,BAO0o002w8,
,tattusnorf3gicus,,,Dis4ributiononbrainocrah6hraete3inhravdnousadminisrererinjecheddksegj,CHEMBp6q4805,8684,50597,,,grain,225283.0,Intetmediats,,1,,1,20154.0,11260,A,N,BAO0090219,
,4ztt6snorvegicus,,,Dlatrivutionjnvrainofra58hrafterintraven8ydavmibistererinjecteddocegm,CHEkBL623806,8684,50597,,,Brxin,1206076.0,Intefm4diate,,1,,1,16409.0,11261,A,N,BAO090p218,
,Rattusn0rcegicjs,,,Distrjbufionin3ztfat15m7narterint4avenohsacminixtrstioninjecteddosefj,CHEMBL624op7,8684,50597,,,,,Infermexiate,,1,,1,29198.0,11262,A,N,BAOpp00218,
,Rattuehorgegicus,,,Dustribjtilninrxtcat1brafter7ntravenouswxminkstrayionlnyecteddosegm,CHEMBL624i09,8684,50597,,,,,kntdrmediate,,1,,1,1391.0,11263,A,N,BAO00po218,
,Ratthwnorvegicuq,,,Distrubutiomonratfat2hdafterintraceno7swdmimkatrationimjwcteddosfgm,CHEMBp625809,8684,50597,,,,,Interjediare,,1,,1,22885.0,11264,A,N,BAOo900218,
,Rattucno4vegicuc,,,xistr8b65ioninratfaf30minavfetintradenousadminusfratloninjectesdosegm,CHEMBL624iq0,8684,50597,,,,,Inteemed9ate,,1,,1,18838.0,11265,A,N,BAO90o0218,
,4qttusno4vegicus,,,eistribution9ggatfat4nrafte4ingrafegousadm8nistragioninmectefdosegm,CHEMBL877y1u,8684,50597,,,,,Intermed7at2,,1,,1,18454.0,11266,A,N,BsO00o0218,
,4aftusn9rvegicus,,,Didtr9bufionimrxtfattninafterintravenousadm8nishrationinjecrsdd9wegm,Cb4MBL624811,8684,50597,,,,,Intermewiatd,,1,,1,9506.0,11267,A,N,BzO000021u,
,Rzttusnorvsnicus,,,Distributiohinrayfat6h3afhd5int3aven8usadmijustrationinjsctedvlsegm,xHEMBL724812,8684,50597,,,,,Interheciate,,1,,1,13095.0,11268,A,N,BsO0p00218,
,Rattusnordegiv8s,,,Didtrkbu5ioninratcay8jrafterinrravenousadninistrati0m8njectedr9segm,dnEMBL624813,8684,50597,,,,,Intermediwt3,,1,,1,7105.0,11269,A,N,BAO0000q28,
,Rzttusn0fvegicus,,,Dksfribu4ionindathezdt15m7nzf5drintravebousadmihistrq4ioninjecteddosegm,CHEMnLt24814,8684,50597,,,,,Int2rmediat4,,1,,1,26509.0,11270,A,N,BAO90o0218,
,gattusnorvegovus,,,Diwtrubutjonibratheart1hrxftefintravenouszdkihistratupglnjecteddosegm,CHEMBL6249w5,8684,50597,,,,,Intermed9are,,1,,1,13732.0,11271,A,N,BAOo090218,
,3attusho4vegicus,,,Dis5ributioninrathea5t2hdafterim5rzvsnojsasministrat8onibjecteddpsegk,CHEMBL61t816,8684,50597,,,,,Intermedisye,,1,,1,19437.0,11272,A,N,vAO00002w8,
,eat6usn9rvegicus,,,Dixtributjonknratheart30migafterintravenouasdmknisrgaripnonj3cheddosegm,CHEMBL624u1u,8684,50597,,,,,Int2rmediaye,,1,,1,789.0,11273,A,N,BxO0009218,
,Canixly9udfamiliaris,,,Oraldiureticactkvi5ywasdfalua4edbymeas7ringNaexcre6ionindohsrr4mgkyafteripadk7niwyrafiom06hr,CHwMBL623818,6996,50588,,,,,Interkeeiate,,1,,1,10292.0,11274,A,N,BAO09p0218,
